PMID- 36257316 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230119 IS - 1932-7420 (Electronic) IS - 1550-4131 (Linking) VI - 35 IP - 1 DP - 2023 Jan 3 TI - Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. PG - 84-100.e8 LID - S1550-4131(22)00411-9 [pii] LID - 10.1016/j.cmet.2022.09.021 [doi] AB - Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metabolic pathways in regulating ferroptosis will provide new insights into TNBC therapeutic strategies. Here, we integrated the multiomics data of our large TNBC cohort (n = 465) to develop the ferroptosis atlas. We discovered that TNBCs had heterogeneous phenotypes in ferroptosis-related metabolites and metabolic pathways. The luminal androgen receptor (LAR) subtype of TNBC was characterized by the upregulation of oxidized phosphatidylethanolamines and glutathione metabolism (especially GPX4), which allowed the utilization of GPX4 inhibitors to induce ferroptosis. Furthermore, we verified that GPX4 inhibition not only induced tumor ferroptosis but also enhanced antitumor immunity. The combination of GPX4 inhibitors and anti-PD1 possessed greater therapeutic efficacy than monotherapy. Clinically, higher GPX4 expression correlated with lower cytolytic scores and worse prognosis in immunotherapy cohorts. Collectively, this study demonstrated the ferroptosis landscape of TNBC and revealed an innovative immunotherapy combination strategy for refractory LAR tumors. CI - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Yang, Fan AU - Yang F AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. FAU - Xiao, Yi AU - Xiao Y AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: yixiao11@fudan.edu.cn. FAU - Ding, Jia-Han AU - Ding JH AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. FAU - Jin, Xi AU - Jin X AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. FAU - Ma, Ding AU - Ma D AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. FAU - Li, Da-Qiang AU - Li DQ AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China. FAU - Shi, Jin-Xiu AU - Shi JX AD - Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai (CHGC) and Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 201203, China. FAU - Huang, Wei AU - Huang W AD - Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai (CHGC) and Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 201203, China. FAU - Wang, Yi-Ping AU - Wang YP AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China; Shanghai Key Laboratory of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China. FAU - Jiang, Yi-Zhou AU - Jiang YZ AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: yizhoujiang@fudan.edu.cn. FAU - Shao, Zhi-Ming AU - Shao ZM AD - Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: zhimingshao@fudan.edu.cn. LA - eng PT - Journal Article DEP - 20221017 PL - United States TA - Cell Metab JT - Cell metabolism JID - 101233170 SB - IM MH - Humans MH - *Ferroptosis/physiology MH - Immunotherapy/methods MH - *Triple Negative Breast Neoplasms/drug therapy/metabolism/pathology OTO - NOTNLM OT - fatty acid metabolism OT - ferroptosis OT - heterogeneity OT - immunotherapy OT - treatment OT - triple-negative breast cancer COIS- Declaration of interests The authors declare no competing interests. EDAT- 2022/10/19 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/10/18 18:52 PHST- 2022/04/26 00:00 [received] PHST- 2022/07/24 00:00 [revised] PHST- 2022/09/21 00:00 [accepted] PHST- 2022/10/19 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/10/18 18:52 [entrez] AID - S1550-4131(22)00411-9 [pii] AID - 10.1016/j.cmet.2022.09.021 [doi] PST - ppublish SO - Cell Metab. 2023 Jan 3;35(1):84-100.e8. doi: 10.1016/j.cmet.2022.09.021. Epub 2022 Oct 17. PMID- 36074155 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 29 IP - 1 DP - 2023 Jan 4 TI - Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. PG - 174-182 LID - 10.1158/1078-0432.CCR-22-1138 [doi] AB - PURPOSE: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is not well characterized. EXPERIMENTAL DESIGN: We studied how T-DXd affects growth and overall survival in orthotopic patient-derived xenografts (PDX) of HER2-positive and HER2-low breast cancer brain metastases (BCBM). Separately, we evaluated the effects of T-DXd in a retrospective cohort study of 17 patients with stable or active brain metastases. RESULTS: T-DXd inhibited tumor growth and prolonged survival in orthotopic PDX models of HER2-positive (IHC 3+) and HER2-low (IHC 2+/FISH ratio < 2) BCBMs. T-DXd reduced tumor size and prolonged survival in a T-DM1-resistant HER2-positive BCBM PDX model. In a retrospective multi-institutional cohort study of 17 patients with predominantly HER2-positive BCBMs, the CNS objective response rate (ORR) was 73% (11/15) while extracranial response rate was 45% (5/11). In the subset of patients with untreated or progressive BCBM at baseline, the CNS ORR was 70% (7/10). The median time on treatment with T-DXd was 8.9 (1.3-16.2) months, with 42% (7/17) remaining on treatment at data cutoff. CONCLUSIONS: T-DXd demonstrates evidence of CNS activity in HER2-positive and HER2-low PDX models of BCBM and preliminary evidence of clinical efficacy in a multi-institution case series of patients with BCBM. Prospective clinical trials to further evaluate CNS activity of T-DXd in patients with active brain metastases are warranted. See related commentary by Soffietti and Pellerino, p. 8. CI - ©2022 The Authors; Published by the American Association for Cancer Research. FAU - Kabraji, Sheheryar AU - Kabraji S AUID- ORCID: 0000-0002-5315-7103 AD - Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Ni, Jing AU - Ni J AUID- ORCID: 0000-0002-4229-775X AD - Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Sammons, Sarah AU - Sammons S AUID- ORCID: 0000-0003-2589-9422 AD - Duke Cancer Institute, Durham, North Carolina. FAU - Li, Tianyu AU - Li T AUID- ORCID: 0000-0001-9856-9657 AD - Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Van Swearingen, Amanda E D AU - Van Swearingen AED AUID- ORCID: 0000-0002-4287-9741 AD - Duke Cancer Institute, Durham, North Carolina. FAU - Wang, Yanzhi AU - Wang Y AUID- ORCID: 0000-0003-0933-9644 AD - Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Pereslete, Alyssa AU - Pereslete A AUID- ORCID: 0000-0001-7995-7507 AD - Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Hsu, Liangge AU - Hsu L AUID- ORCID: 0000-0002-8806-3334 AD - Brigham and Women's Hospital, Boston, Massachusetts. FAU - DiPiro, Pamela J AU - DiPiro PJ AUID- ORCID: 0000-0002-6702-4467 AD - Brigham and Women's Hospital, Boston, Massachusetts. FAU - Lascola, Chris AU - Lascola C AUID- ORCID: 0000-0002-8031-782X AD - Duke Cancer Institute, Durham, North Carolina. FAU - Moore, Heather AU - Moore H AUID- ORCID: 0000-0002-0619-3267 AD - Duke Cancer Institute, Durham, North Carolina. FAU - Hughes, Melissa AU - Hughes M AUID- ORCID: 0000-0001-6190-9101 AD - Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Raghavendra, Akshara S AU - Raghavendra AS AUID- ORCID: 0000-0002-6425-4400 AD - MD Anderson Cancer Center, Houston, Texas. FAU - Gule-Monroe, Maria AU - Gule-Monroe M AUID- ORCID: 0000-0002-4418-3705 AD - MD Anderson Cancer Center, Houston, Texas. FAU - Murthy, Rashmi K AU - Murthy RK AUID- ORCID: 0000-0002-0103-4718 AD - MD Anderson Cancer Center, Houston, Texas. FAU - Winer, Eric P AU - Winer EP AUID- ORCID: 0000-0002-8819-1723 AD - Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Anders, Carey K AU - Anders CK AUID- ORCID: 0000-0001-9165-4074 AD - Duke Cancer Institute, Durham, North Carolina. FAU - Zhao, Jean J AU - Zhao JJ AUID- ORCID: 0000-0002-4561-5688 AD - Dana-Farber Cancer Institute, Boston, Massachusetts. FAU - Lin, Nancy U AU - Lin NU AUID- ORCID: 0000-0003-2263-5413 AD - Dana-Farber Cancer Institute, Boston, Massachusetts. LA - eng GR - Breast Cancer Research Foundation (BCRF)/ GR - Translating Duke Health/ GR - 1P50CA168504/National Cancer Institute (NCI)/ GR - P50 CA168504/CA/NCI NIH HHS/United States GR - R35 CA210057/CA/NCI NIH HHS/United States PT - Comment PT - Editorial PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 5384HK7574 (trastuzumab deruxtecan) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - P188ANX8CK (Trastuzumab) RN - XT3Z54Z28A (Camptothecin) RN - 0 (Immunoconjugates) SB - IM CIN - Clin Cancer Res. 2023 Jan 4;29(1):8-10. PMID: 36305867 CON - Clin Cancer Res. 2023 Jan 4;29(1):8-10. PMID: 36305867 MH - Humans MH - Female MH - Retrospective Studies MH - Cohort Studies MH - Prospective Studies MH - Receptor, ErbB-2/therapeutic use MH - Trastuzumab/adverse effects MH - *Breast Neoplasms/pathology MH - Camptothecin/therapeutic use MH - *Immunoconjugates/therapeutic use MH - *Brain Neoplasms/mortality MH - Treatment Outcome PMC - PMC9811155 MID - NIHMS1836595 COIS- Authors’ Disclosures of Potential Conflicts of Interest: Jing Ni scientific consultant for Geode Therapeutics Inc. Sarah Sammons Research Funding- Abbvie, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Seagen, Sermonix Consulting- AstraZeneca, Daichii Sankyo, Foundation Medicine, Novartis, Seagen, Sermonix Heather Moore Consulting – AstraZeneca, Daichii Sankyo, Novartis, SeaGen, Lilly, Merck, MacroGenics Carey Anders Research Funding - PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer Consulting: Genentech, Eisai, IPSEN, Seattle Genetics; Astra Zeneca, Novartis, Immunomedics, Elucida, Athenex Royalties - UpToDate, Jones and Bartlett Rashmi K Murthy Research funding: Seattle Genetics, Genentech/Roche, Pfizer, Daiichi/Sankyo, Astra Zeneca, EMD Serono Honoraria: Puma Biotechnology, Seattle Genetics, Genentech, Novartis, Astra Zeneca Consulting: Sanofi, Novartis, Astra Zeneca, Pfizer, Genentech/Roche, Seattle Genetics, Puma Biotechnology Jean J. Zhao Research Funding – Takeda Pharmaceuticals, Prelude Therapeutics Consulting – CLOVES Syndrome Community Co-founder and board director of Crimson Biopharm Inc. and Geode Therapeutics Inc. Nancy U Lin Research funding - Genentech, Seattle Genetics, Merck, and Pfizer Consulting - Daichii Sankyo, AstraZeneca, Seattle Genetics, Prelude Therapeutics, Denali Therapeutics, California Institute for Regenerative Medicine Other authors declare no conflicts of interest EDAT- 2022/09/09 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/09/08 11:14 PHST- 2022/04/24 00:00 [received] PHST- 2022/06/01 00:00 [revised] PHST- 2022/09/06 00:00 [accepted] PHST- 2022/09/09 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/09/08 11:14 [entrez] AID - 709125 [pii] AID - 10.1158/1078-0432.CCR-22-1138 [doi] PST - ppublish SO - Clin Cancer Res. 2023 Jan 4;29(1):174-182. doi: 10.1158/1078-0432.CCR-22-1138. PMID- 36302269 OWN - NLM STAT- MEDLINE DCOM- 20221228 LR - 20221228 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. PG - 169-177 LID - S0960-9776(22)00172-2 [pii] LID - 10.1016/j.breast.2022.10.007 [doi] AB - Antibody drug conjugates (ADCs) combine the potent cytotoxicity of chemotherapy with the antigen -specific targeted approach of antibodies into one single molecule. Trophoblast cell surface antigen 2 (TROP-2) is a transmembrane glycoprotein involved in calcium signal transduction and is expressed in multiple tumor types. TROP-2 expression is higher in HER2-negative breast tumors (HR+/HR-) and is associated with worse survival. Sacituzumab govitecan (SG) is a first-in-class TROP-2-directed ADC with an anti-TROP-2 antibody conjugated to SN-38, a topoisomerase inhibitor via a hydrolysable linker. This hydrolysable linker permits intracellular and extracellular release of the membrane permeable payload enabling the "bystander effect" contributing to the efficacy of this agent. There was significant improvement in progression free survival (PFS) and overall survival (OS) with SG versus chemotherapy in pretreated metastatic triple negative breast cancer (TNBC), resulting in regulatory approval. Common adverse events (AE) reported were neutropenia and diarrhea. SG also demonstrated clinical activity versus chemotherapy in a phase III trial of HR+/HER2-metastatic breast cancer (MBC) and is under evaluation in first-line metastatic and early stage TNBC as well. Datopotamab deruxtecan (Dato-DXd) is a TROP-2 ADC that differs from SG in that it has a cleavable tetrapeptide linker and a more potent topoisomerase inhibitor payload. This construct is highly stable in circulation with a longer half-life than SG, and undergoes cleavage in presence of intracellular lysosomal proteases. Dato-DXd demonstrated preliminary efficacy in unselected metastatic TNBC, with common AEs of low-grade nausea and stomatitis. Dato-DXd is being investigated in phase III studies in metastatic TNBC and HR+/HER2- MBC. These novel TROP-2 ADCs have the potential to deliver enhanced efficacy with reduced toxicity in MBC and possibly in early stage breast cancer (EBC). CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Shastry, Mythili AU - Shastry M AD - Sarah Cannon Research Institute, Nashville, TN, USA. Electronic address: Mythili.Shastry@sarahcannon.com. FAU - Jacob, Saya AU - Jacob S AD - University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: Saya.Jacob@ucsf.edu. FAU - Rugo, Hope S AU - Rugo HS AD - University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: Hope.Rugo@ucsf.edu. FAU - Hamilton, Erika AU - Hamilton E AD - Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USA. Electronic address: Ehamilton@tnonc.com. LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial DEP - 20221018 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Antineoplastic Agents) RN - 0 (Immunoconjugates) RN - 7673326042 (Irinotecan) RN - 0 (Topoisomerase Inhibitors) SB - IM MH - Female MH - Humans MH - *Antineoplastic Agents MH - *Breast Neoplasms/drug therapy/chemically induced MH - *Immunoconjugates/therapeutic use/chemistry/pharmacology MH - Irinotecan/therapeutic use MH - Topoisomerase Inhibitors/therapeutic use MH - *Triple Negative Breast Neoplasms/drug therapy PMC - PMC9614644 OTO - NOTNLM OT - Antibody drug conjugate (ADC) OT - Datopotamab deruxtecan OT - Metastatic breast cancer OT - Sacituzumab govitecan OT - Trophoblast cell surface antigen-2 (TROP-2) COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Erika Hamilton's institution has received research funding from multiple entities (see below). Erika Hamilton's institution has received consulting fees from multiple entities (see below). Hope S Rugo reports the following: Institutional research support from Pfizer, Novartis, Eli Lilly, Genentech/Roche, OBI, Merck, Gilead Sciences, Daiichi Sankyo, Seattle Genetics, Sermonix, AstraZeneca, Astellas, Veru, GSK, Taiho, AMBRX and Pionyr. Travel support to academic meetings from Merck, Astra Zeneca, GE Healthcare and Gilead. Consultancy/advisory support from Puma, NAPO and Blueprint. EDAT- 2022/10/28 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/27 18:12 PHST- 2022/08/30 00:00 [received] PHST- 2022/10/13 00:00 [revised] PHST- 2022/10/17 00:00 [accepted] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/27 18:12 [entrez] AID - S0960-9776(22)00172-2 [pii] AID - 10.1016/j.breast.2022.10.007 [doi] PST - ppublish SO - Breast. 2022 Dec;66:169-177. doi: 10.1016/j.breast.2022.10.007. Epub 2022 Oct 18. PMID- 36493792 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1474-5488 (Electronic) IS - 1470-2045 (Linking) VI - 24 IP - 1 DP - 2023 Jan TI - Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. PG - 77-90 LID - S1470-2045(22)00694-5 [pii] LID - 10.1016/S1470-2045(22)00694-5 [doi] AB - BACKGROUND: Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-negative, node-positive, high-risk, early breast cancer. Here, we report updated results from an interim analysis to assess overall survival as well as invasive disease-free survival and distant relapse-free survival with additional follow-up. METHODS: In monarchE, an open-label, randomised, phase 3 trial, adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence with an Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from 603 sites including hospitals and academic and community centres in 38 countries. Patients were randomly assigned (1:1) by means of an interactive web-based response system (block size of 4), stratified by previous chemotherapy, menopausal status, and region, to receive standard-of-care endocrine therapy of physician's choice for up to 10 years with or without abemaciclib 150 mg orally twice a day for 2 years (treatment period). All therapies were administered in an open-label manner without masking. High-risk disease was defined as either four or more positive axillary lymph nodes, or between one and three positive axillary lymph nodes and either grade 3 disease or tumour size of 5 cm or larger (cohort 1). A smaller group of patients were enrolled with between one and three positive axillary lymph nodes and Ki-67 of at least 20% as an additional risk feature (cohort 2). This was a prespecified overall survival interim analysis planned to occur 2 years after the primary outcome analysis for invasive disease-free survival. Efficacy was assessed in the intention-to-treat population. Safety was assessed in all treated patients. The study is registered with ClinicalTrials.gov, NCT03155997, and is ongoing. FINDINGS: Between July 17, 2017, and Aug 12, 2019, 5637 patients were randomly assigned (5601 [99·4%] were women and 36 [0·6%] were men). 2808 were assigned to receive abemaciclib plus endocrine therapy and 2829 were assigned to receive endocrine therapy alone. At a median follow-up of 42 months (IQR 37-47), median invasive disease-free survival was not reached in either group and the invasive disease-free survival benefit previously reported was sustained: HR 0·664 (95% CI 0·578-0·762, nominal p<0·0001). At 4 years, the absolute difference in invasive disease-free survival between the groups was 6·4% (85·8% [95% CI 84·2-87·3] in the abemaciclib plus endocrine therapy group vs 79·4% [77·5-81·1] in the endocrine therapy alone group). 157 (5·6%) of 2808 patients in the abemaciclib plus endocrine therapy group died compared with 173 (6·1%) of 2829 patients in the endocrine therapy alone group (HR 0·929, 95% CI 0·748-1·153; p=0·50). The most common grade 3-4 adverse events were neutropenia (in 548 [19·6%] of 2791 patients receiving abemaciclib plus endocrine therapy vs 24 [0·9%] of 2800 patients in the endocrine therapy alone group), leukopenia (318 [11·4%] vs 11 [0·4%]), and diarrhoea (218 [7·8%] vs six [0·2%]). Serious adverse events occurred in 433 (15·5%) of 2791 patients receiving abemaciclib plus endocrine therapy versus 256 (9·1%) of 2800 receiving endocrine therapy. There were two treatment-related deaths in the abemaciclib plus endocrine therapy group (diarrhoea and pneumonitis) and none in the endocrine therapy alone group. INTERPRETATION: Adjuvant abemaciclib reduces the risk of recurrence. The benefit is sustained beyond the completion of treatment with an absolute increase at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2-negative early breast cancer. Further follow-up is needed to establish whether overall survival can be improved with abemaciclib plus endocrine therapy in these patients. FUNDING: Eli Lilly. CI - Copyright © 2023 Elsevier Ltd. All rights reserved. FAU - Johnston, Stephen R D AU - Johnston SRD AD - The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: stephen.johnston@rmh.nhs.uk. FAU - Toi, Masakazu AU - Toi M AD - Kyoto University, Kyoto, Japan. FAU - O'Shaughnessy, Joyce AU - O'Shaughnessy J AD - Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA. FAU - Rastogi, Priya AU - Rastogi P AD - University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, PA, USA. FAU - Campone, Mario AU - Campone M AD - Institute de Cancérologie de l'Ouest, Centre Rene Cauducheau, Saint-Herblain, Nantes, France. FAU - Neven, Patrick AU - Neven P AD - Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven, Belgium. FAU - Huang, Chiun-Sheng AU - Huang CS AD - National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Huober, Jens AU - Huober J AD - Cantonal Hospital St Gallen, Breast Centre St Gallen, Switzerland. FAU - Jaliffe, Georgina Garnica AU - Jaliffe GG AD - Grupo Medico Camino SC, Mexico City, Mexico. FAU - Cicin, Irfan AU - Cicin I AD - Trakya University Faculty of Medicine, Edirne, Turkey. FAU - Tolaney, Sara M AU - Tolaney SM AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Goetz, Matthew P AU - Goetz MP AD - Department of Oncology, Mayo Clinic, Rochester, MN, USA. FAU - Rugo, Hope S AU - Rugo HS AD - University of California San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. FAU - Senkus, Elzbieta AU - Senkus E AD - Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland. FAU - Testa, Laura AU - Testa L AD - Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, Brazil. FAU - Del Mastro, Lucia AU - Del Mastro L AD - IRCSS Ospedale Policlinico San Martino, UO Breast Unit, Genoa, Italy; Università di Genova, Department of Internal Medicine and Medical Specialties (DIM), Genoa, Italy. FAU - Shimizu, Chikako AU - Shimizu C AD - National Centre for Global Health and Medicine, Tokyo, Japan. FAU - Wei, Ran AU - Wei R AD - Eli Lilly and Company, Indianapolis, IN, USA. FAU - Shahir, Ashwin AU - Shahir A AD - Loxo@Lilly, Indianapolis, IN, USA. FAU - Munoz, Maria AU - Munoz M AD - Loxo@Lilly, Indianapolis, IN, USA. FAU - San Antonio, Belen AU - San Antonio B AD - Loxo@Lilly, Indianapolis, IN, USA. FAU - André, Valérie AU - André V AD - Eli Lilly and Company, Indianapolis, IN, USA. FAU - Harbeck, Nadia AU - Harbeck N AD - Breast Centre, Department of Gynaecology and Obstetrics, Comprehensive Cancer Centre München, LMU University Hospital, Munich, Germany. FAU - Martin, Miguel AU - Martin M AD - Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain. CN - monarchE Committee Members LA - eng SI - ClinicalTrials.gov/NCT03155997 PT - Clinical Trial, Phase III PT - Journal Article PT - Randomized Controlled Trial DEP - 20221206 PL - England TA - Lancet Oncol JT - The Lancet. Oncology JID - 100957246 RN - 60UAB198HK (abemaciclib) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Adult MH - Male MH - Humans MH - Female MH - Adolescent MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Neoplasm Recurrence, Local/pathology MH - Receptor, ErbB-2/metabolism MH - Diarrhea/etiology COIS- Declaration of interests SRDJ reports grants or contracts from Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, and Roche–Genentech for research funding to institute for laboratory studies and clinical trials; consulting fees from Eli Lilly, AstraZeneca, Puma Biotechnology, Pfizer, Novartis, and Sanofi Genzyme for consulting or an advisory role; and payment or honoraria from Pfizer, Eisai, AstraZeneca, and Roche–Genentech for speaker's bureau. MT reports grants or contracts from Chugai, Takeda, Pfizer, Taiho, JBCRG, KBCRN, Eisai, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, and Sanwa Shurui for research grants to their department; payment or honoraria from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, Merck Sharp and Dohme, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore Medical Japan, and Sysmex for lecture honoraria or honoraria for lecture chair; participation on a data safety monitoring board or advisory board for Daiichi-Sankyo, Eli Lilly, Bristol Myers Squibb, Athenex Oncology, Bertis, Terumo, and Kansai Medical Net; and other financial or non-financial interest from British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, Cancer Science, Frontiers in Women's Cancer, Asian Journal of Surgery, and Asian Journal of Breast Surgery for his role as Associate Editor. JO'S reports consulting fees and payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing or educational events from from AbbVie, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Athenex, Bayer, Bristol Myers Squibb, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Eli Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepsis, Sandoz, Sanofi, Seagen, Syndax Pharmaceuticals, Taiho Oncology, Takeda, Theralink, and Synthon. MC reports personal payment support from Eli Lilly for the present article, advisory board, and speaker's bureau; payment or honoraria to institution from Novartis; support for attending meetings from Eli Lilly, Novartis, AstraZeneca, and Pfizer; and payment to institution from AstraZeneca, Novartis, Sanofi, Pfizer, Seagen, Gilead, Daiichi Sankyo for participation on a data safety monitoring board or advisory board. C-SH reports research grants to institution from Eli Lilly for the present article; research grants to institution or contracts from Daiichi Sankyo, AstraZeneca, EirGenix, Eli Lilly and Company, Merck Sharp and Dohme, OBI Pharma, Pfizer, Roche, and Novartis; payment or honoraria from Daiichi Sankyo, AstraZeneca, Pfizer, Novartis, Roche, and Eli Lilly for speaker's bureau; support for attending meetings or travel from Astra Zeneca, Pfizer, Roche, and Novartis; and participation on advisory boards from Daiichi Sankyo, AstraZeneca, Eli Lilly, Pfizer, Novartis, and Roche. JH reports institutional grants or contracts from Celgene, Novartis, Hexal, and Eli Lilly; consulting fees paid to self from Eli Lilly, Novartis, Roche, Pfizer, Hexal, AstraZeneca, Merck Sharp and Dohme, Celgene, AbbVie, and Daiichi-Sankyo; honoraria or payments to self for lectures, presentation, speaker's bureaus, manuscript writing, or educational events from Eli Lilly, Novartis, Roche, Pfizer, AstraZeneca, Merck Sharp and Dohme, Celgene, Eisai, Abbvie, Seagen, and Gilead; and support for attending meetings or travel paid to self from Roche, Pfizer, Novartis, Celgene, Daiichi-Sankyo, and Gilead. SMT reports institutional funding for study, consulting work to personal (honorariums), and manuscript preparation from Eli Lilly; institutional grants or contracts from AstraZeneca, Merck, Mektar, Novartis, Pfizer, Genentech–Roche, Gilead, Exelixis, Bristol Myers Squibb, Eisai, Nanostring, Cyclacel, Sanofi, and Seagen; and honoraria payments to self for participation in advisory boards or consulting from AstraZeneca, Eli Lilly, Merck, Novartis, Pfizer, Genentech–Roche, Gilead, Bristol Myers Squibb, Eisai, Sanofi, Seagen, Daiichi-Sankyo, Athenex, OncoPep, Kyowa Kirin Pharma, CytomX, Certara, Mersana Therapeutics, Ellipses Pharma, 4D Pharma, OncoSec, Infinity Therapeutics, BeyondSpring Pharma, OncXerna, Zymeworks, Zentalis, ARC Therapeutics, Reveal Genomics, Blueprint Medicines, Myovant, Umoja Biopharma, and Menarini–Stemline. MPG reports institutional grants or contracts from Pfizer, Eli Lilly, and Sermonix; consulting fees to institution from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Pfizer, and ARC Therapeutics; honoraria or payment to self for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Research to Practice, Clinical Education Alliance, Medscape, Total Health Conferencing, Curio Science, and MJH Life Sciences; and support to institution from Eli Lilly, AstraZeneca, Novartis, Biotheranostics, Blueprint Medicines, Sanofi Genzyme, and ARC Therapeutics for participation on a data safety monitoring board or advisory board. HSR reports institutional research support from Pfizer, Novartis, Eli Lilly, Genentech–Roche, OBI, Merck, Gilead Sciences, Daiichi Sankyo, Seattle Genetics, Sermonix, AstraZeneca, and Astellas; travel support to academic meetings from Merck, AstraZeneca, and Gilead; and consulting or advisory support from Puma, NAPO, and Blueprint. ES reports support from Eli Lilly for the present article including investigator fees and medical writing; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from AstraZeneca, Cancérodigest, Curio, Science, Egis, Eli Lilly and Company, Exact Sciences, Gilead, high5md, Merck Sharp and Dohme, Novartis, Pfizer, and Pierre Fabre; support for attending meetings or travel from Egis, Gilead, Novartis, Pfizer, and Roche; participation on a data safety monitoring board or advisory board from AstraZeneca, Egis, Eli Lilly, Exact Sciences, Merck Sharp and Dohme, Novartis, and Pfizer; a leadership or fiduciary role from Stowarzyszenie Różowy Motyl as Chair (unpaid); stock or stock options from AstraZeneca, Eli Lilly, and Pfizer; receipt of equipment, materials, drugs, medical writing, gifts or other services from Astellas, AstraZeneca, and Eli Lilly; and other financial or non-financial interests from Amgen, AstraZeneca, Eli Lilly, Novartis, OBI Pharma, Pfizer, Roche, and Samsung for contracted research. LT reports support from Eli Lilly as the trial sponsor for the study; grants or contracts from Novartis for clinical research; consulting fees from Merck Sharp and Dohme, Eli Lilly, and Novartis for advisory board; payment or honoraria from Merck Sharp and Dohme, Eli Lilly, Pfizer, Daiichi Sankyo, Novartis, and AstraZeneca for medical education; and support for attending meetings or travel from Pfizer and AstraZeneca. LDM reports an institutional research grant from Eli Lilly, Novartis, Roche, Daiichi Sankyo, and Seagen; consulting fees paid to self from Eli Lilly; honoraria or payment to self from Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, Merck Sharp and Dohme, Seagen, Gilead, Pierre Fabre, Eisa, Exact Sciences, and Ipsen for lectures, presentations, speaker's bureaus, manuscript writing or educational events; support for attending meetings or travel from Roche, Pfizer, and Eisai; and fees paid to self for participation on a data safety monitoring board or advisory Board from Novartis, Roche, Eli Lilly, Pfizer, Daiichi-Sankyo, Exact Sciences, Gilead, Pierre Fabre, Eisai, AstraZeneca, and Agendia. CS reports research grants from Eli Lilly, and honoraria for lectures from Pfizer and Eli Lilly. RW, AS, MMu, BSA, VA are employees and stock shareholders of Eli Lilly. NH reports support for the present article (medical writing) from Eli Lilly; consulting fees from Gilead, Sandoz, and Seagen; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Amgen, AsraZeneca, Daiichi-Sankyo, Gilead, Eli Lilly, Merck Sharp and Dohme, Novartis, Pierre-Fabre, Pfizer, Roche, and Seagen; participation on a data safety monitoring board or advisory board from Roche; and a leadership or fiduciary role with the West German Study Group and ESMO. MMa reports institutional grants from Roche, Novartis, and Puma; consulting fees paid to self from Roche, Eli Lilly, Pfizer, Daiichi-Sankyo, AstraZeneca, and Novartis; payment or honoraria to self for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Roche, Eli Lilly, Astrazeneca, and Pfizer; support paid to self for attending meetings or travel from Daiichi-Sankyo and Roche; and support paid to self for participation on a data safety monitoring board or advisory board from Novartis. PR, PN, GGJ, and IC declare no competing interests. EDAT- 2022/12/10 06:00 MHDA- 2023/01/10 06:00 CRDT- 2022/12/09 19:02 PHST- 2022/10/12 00:00 [received] PHST- 2022/11/02 00:00 [revised] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/12/10 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/12/09 19:02 [entrez] AID - S1470-2045(22)00694-5 [pii] AID - 10.1016/S1470-2045(22)00694-5 [doi] PST - ppublish SO - Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. PMID- 35639825 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1523-5866 (Electronic) IS - 1522-8517 (Print) IS - 1522-8517 (Linking) VI - 25 IP - 1 DP - 2023 Jan 5 TI - Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. PG - 157-166 LID - 10.1093/neuonc/noac144 [doi] AB - BACKGROUND: Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active brain metastases (BMs). DEBBRAH aims to assess T-DXd in patients with HER2-positive or HER2-low ABC and central nervous system involvement. METHODS: This ongoing, five-cohort, phase II study (NCT04420598) enrolled patients with pretreated HER2-positive or HER2-low ABC with stable, untreated, or progressing BMs, and/or leptomeningeal carcinomatosis. Here, we report findings from HER2-positive ABC patients with non-progressing BMs after local therapy (n = 8; cohort 1), asymptomatic untreated BMs (n = 4; cohort 2), or progressing BMs after local therapy (n = 9; cohort 3). Patients received 5.4 mg/kg T-DXd intravenously once every 21 days. The primary endpoint was 16-week progression-free survival (PFS) for cohort 1 and intracranial objective response rate (ORR-IC) for cohorts 2 and 3. RESULTS: As of October 20, 2021, 21 patients received T-DXd. In cohort 1, 16-week PFS rate was 87.5% (95%CI, 47.3-99.7; P < .001). ORR-IC was 50.0% (95%CI, 6.7-93.2) in cohort 2 and 44.4% (95%CI, 13.7-78.8; P < .001) in cohort 3. Overall, the ORR-IC in patients with active BMs was 46.2% (95%CI, 19.2-74.9). Among patients with measurable intracranial or extracranial lesions at baseline, the ORR was 66.7% (12 out of 18 patients; 95%CI, 41.0-86.7), 80.0% (95%CI, 28.4-99.5) in cohort 1, 50.0% (95%CI, 6.7-93.2) in cohort 2, and 66.7% (95%CI, 29.9-92.5) in cohort 3. All responders had partial responses. The most common adverse events included fatigue (52.4%; 4.8% grade ≥3), nausea (42.9%; 0% grade ≥3), neutropenia (28.6%; 19% grade ≥3), and constipation (28.6%; 0% grade ≥3). Two (9.5%) patients suffered grade 1 interstitial lung disease/pneumonitis. CONCLUSIONS: T-DXd showed intracranial activity with manageable toxicity and maintained the quality of life in pretreated HER2-positive ABC patients with stable, untreated, or progressing BMs. Further studies are needed to validate these results in larger cohorts. CI - © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. FAU - Pérez-García, José Manuel AU - Pérez-García JM AD - International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Ridgewood, New Jersey, USA. FAU - Vaz Batista, Marta AU - Vaz Batista M AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Ridgewood, New Jersey, USA. AD - Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal. FAU - Cortez, Patricia AU - Cortez P AD - IOB Institute of Oncology, Hospital Ruber Internacional, Quiron Group, Madrid, Spain. FAU - Ruiz-Borrego, Manuel AU - Ruiz-Borrego M AD - Hospital Universitario Virgen del Rocío, Sevilla, Spain. FAU - Cejalvo, Juan Miguel AU - Cejalvo JM AD - Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain. FAU - de la Haba-Rodriguez, Juan AU - de la Haba-Rodriguez J AD - Instituto Maimonides de Investigacion Biomedica, Hospital Reina Sofia, Universidad de Córdoba, Córdoba, Spain. FAU - Garrigós, Laia AU - Garrigós L AD - International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. AD - Hospital Universitari Dexeus, Barcelona, Spain. FAU - Racca, Fabricio AU - Racca F AD - IOB Institute of Oncology, Quiron Group, Madrid and Barcelona, Spain. FAU - Servitja, Sonia AU - Servitja S AD - Hospital del Mar, Barcelona, Spain. FAU - Blanch, Salvador AU - Blanch S AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Ridgewood, New Jersey, USA. AD - Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal. AD - Fundación Instituto Valenciano de Oncología, Valencia, Spain. FAU - Gion, María AU - Gion M AD - University Hospital Ramon y Cajal, Madrid, Spain. FAU - Nave, Monica AU - Nave M AD - Hospital da Luz, Lisbon, Portugal. FAU - Fernández-Abad, María AU - Fernández-Abad M AD - University Hospital Ramon y Cajal, Madrid, Spain. FAU - Martinez-Bueno, Alejandro AU - Martinez-Bueno A AD - Hospital Universitari Dexeus, Barcelona, Spain. FAU - Llombart-Cussac, Antonio AU - Llombart-Cussac A AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Ridgewood, New Jersey, USA. AD - Hospital Arnau de Vilanova, FISABIO, Valencia, Spain. AD - Universidad Católica de Valencia, Valencia, Spain. FAU - Sampayo-Cordero, Miguel AU - Sampayo-Cordero M AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Ridgewood, New Jersey, USA. FAU - Malfettone, Andrea AU - Malfettone A AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Ridgewood, New Jersey, USA. FAU - Cortés, Javier AU - Cortés J AUID- ORCID: 0000-0001-7623-1583 AD - International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Ridgewood, New Jersey, USA. AD - Universidad Europea de Madrid, Madrid, Spain. FAU - Braga, Sofía AU - Braga S AD - International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Ridgewood, New Jersey, USA. AD - Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal. AD - Fundación Instituto Valenciano de Oncología, Valencia, Spain. LA - eng GR - Daiichi Sankyo/ GR - AstraZeneca/ PT - Clinical Trial, Phase II PT - Journal Article PL - England TA - Neuro Oncol JT - Neuro-oncology JID - 100887420 RN - 5384HK7574 (trastuzumab deruxtecan) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Antibodies, Monoclonal, Humanized) RN - P188ANX8CK (Trastuzumab) RN - XT3Z54Z28A (Camptothecin) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Quality of Life MH - Receptor, ErbB-2 MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Trastuzumab/therapeutic use MH - Camptothecin/adverse effects MH - Central Nervous System/pathology PMC - PMC9825345 OTO - NOTNLM OT - HER2-positive OT - T-DXd OT - advanced breast cancer OT - brain metastases OT - trastuzumab deruxtecan EDAT- 2022/06/01 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/05/31 16:16 PHST- 2022/06/01 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/05/31 16:16 [entrez] AID - 6593857 [pii] AID - noac144 [pii] AID - 10.1093/neuonc/noac144 [doi] PST - ppublish SO - Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144. PMID- 36611922 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 12 IP - 1 DP - 2022 Dec 28 TI - The Role of PPARs in Breast Cancer. LID - 10.3390/cells12010130 [doi] LID - 130 AB - Breast cancer is a malignant tumor with high morbidity and lethality. Its pathogenesis is related to the abnormal expression of many genes. The peroxisome proliferator-activated receptors (PPARs) are a class of ligand-dependent transcription factors in the nuclear receptor superfamily. They can regulate the transcription of a large number of target genes, which are involved in life activities such as cell proliferation, differentiation, metabolism, and apoptosis, and regulate physiological processes such as glucose metabolism, lipid metabolism, inflammation, and wound healing. Further, the changes in its expression are associated with various diseases, including breast cancer. The experimental reports related to "PPAR" and "breast cancer" were retrieved from PubMed since the discovery of PPARs and summarized in this paper. This review (1) analyzed the roles and potential molecular mechanisms of non-coordinated and ligand-activated subtypes of PPARs in breast cancer progression; (2) discussed the correlations between PPARs and estrogen receptors (ERs) as the nuclear receptor superfamily; and (3) investigated the interaction between PPARs and key regulators in several signaling pathways. As a result, this paper identifies PPARs as targets for breast cancer prevention and treatment in order to provide more evidence for the synthesis of new drugs targeting PPARs or the search for new drug combination treatments. FAU - Zhao, Binggong AU - Zhao B AD - Key Laboratory of Protein Modification and Disease, School of Bioengineering, Dalian University of Technology, Dalian 116024, China. FAU - Xin, Zhiqiang AU - Xin Z AUID- ORCID: 0000-0002-2127-9042 AD - Hospital Office, The Second Hospital of Dalian Medical University, Dalian 116023, China. FAU - Ren, Ping AU - Ren P AD - Hospital Office, The Second Hospital of Dalian Medical University, Dalian 116023, China. FAU - Wu, Huijian AU - Wu H AD - Key Laboratory of Protein Modification and Disease, School of Bioengineering, Dalian University of Technology, Dalian 116024, China. LA - eng GR - 81872263/National Natural Science Foundation of China/ PT - Journal Article PT - Review DEP - 20221228 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 0 (Peroxisome Proliferator-Activated Receptors) RN - 0 (Ligands) RN - 0 (Transcription Factors) RN - 0 (Receptors, Cytoplasmic and Nuclear) SB - IM MH - Humans MH - Female MH - *Peroxisome Proliferator-Activated Receptors/metabolism MH - Ligands MH - Transcription Factors/genetics MH - Receptors, Cytoplasmic and Nuclear MH - *Breast Neoplasms/genetics PMC - PMC9818187 OTO - NOTNLM OT - ERs OT - PPARs OT - breast cancer OT - ligands COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:06 PHST- 2022/11/11 00:00 [received] PHST- 2022/12/07 00:00 [revised] PHST- 2022/12/26 00:00 [accepted] PHST- 2023/01/08 01:06 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - cells12010130 [pii] AID - cells-12-00130 [pii] AID - 10.3390/cells12010130 [doi] PST - epublish SO - Cells. 2022 Dec 28;12(1):130. doi: 10.3390/cells12010130. PMID- 36327626 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Inclusion of premenopausal women in breast cancer clinical trials. PG - 204-207 LID - S0960-9776(22)00178-3 [pii] LID - 10.1016/j.breast.2022.10.013 [doi] AB - BACKGROUND: Patients with premenopausal breast cancer (PMBC) have been historically excluded from some clinical trials because of the limitations of using endocrine therapy (ET) in this population. We analyzed breast cancer randomized clinical trials (RCTs) to determine the rates of and factors associated with inclusion of PMBC patients to provide a benchmark for PMBC inclusion in RCTs moving forward. METHODS: Using ClinicalTrials.Gov, we identified breast cancer phase III RCTs and extracted inclusion criteria and patient enrollment information. Multiple binary logistic regression modeling was used to assess trial-related factors that were associated with PMBC patient inclusion. RESULTS: Of 170 breast cancer RCTs identified, 131 (77.1%) included PMBC patients. Sixty-five (38.2%) trials analyzed patients with hormone-receptor-positive (HR+) and HER2-negative (HER2-) breast cancer, of which 31 (47.7%) allowed for enrollment of PMBC patients. Lower rates of PMBC inclusion were seen in trials that studied HR+/HER2-patients (47.7% PMBC inclusion in HR+/HER2-trials vs. 94.3% in non-HR+/HER2-trials, aOR 0.07 [95% CI: 0.02-0.19], p < 0.001) and in trials that randomized or mandated ET (44.4% in ET trials vs. 83.2% in non-ET trials, aOR 0.21 [95% CI: 0.10-0.83], p = 0.02). Trials studying chemotherapy (CT) were associated with inclusion of PMBC patients (100% in CT trials vs. 70.5% in non-CT trials, a OR 14.02 [95% CI: 1.54-127.91], p = 0.01). All surgical and radiation therapy clinical trials allowed for the inclusion of PMBC patients in their eligibility criteria. CONCLUSIONS: Breast cancer clinical trials should carefully select their enrollment criteria and consider inclusion of premenopausal patients when appropriate. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Corrigan, Kelsey L AU - Corrigan KL AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: klcorrigan@mdanderson.org. FAU - Kouzy, Ramez AU - Kouzy R AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Jaoude, Joseph Abi AU - Jaoude JA AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Patel, Roshal R AU - Patel RR AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Layman, Rachel M AU - Layman RM AD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Giordano, Sharon H AU - Giordano SH AD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Woodward, Wendy A AU - Woodward WA AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Smith, Benjamin D AU - Smith BD AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Shaitelman, Simona F AU - Shaitelman SF AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Ludmir, Ethan B AU - Ludmir EB AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: EBLudmir@mdanderson.org. LA - eng PT - Journal Article DEP - 20221026 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy MH - Receptor, ErbB-2 MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use PMC - PMC9637813 OTO - NOTNLM OT - Breast cancer OT - Eligibility criteria OT - Food and drug administration OT - Premenopausal OT - Randomized controlled trial COIS- Declaration of competing interest SFS has COI unrelated to this work (funding/contracted research agreements from Artios Pharma, Alpha Tau, TAE Life Sciences, Exact Sciences, Emerson Collective Foundation). The authors declare no other conflicts of interests. EDAT- 2022/11/04 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/03 19:19 PHST- 2022/09/26 00:00 [received] PHST- 2022/10/20 00:00 [revised] PHST- 2022/10/22 00:00 [accepted] PHST- 2022/11/04 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/03 19:19 [entrez] AID - S0960-9776(22)00178-3 [pii] AID - 10.1016/j.breast.2022.10.013 [doi] PST - ppublish SO - Breast. 2022 Dec;66:204-207. doi: 10.1016/j.breast.2022.10.013. Epub 2022 Oct 26. PMID- 36547182 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230112 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 29 IP - 12 DP - 2022 Dec 12 TI - Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective? PG - 9767-9787 LID - 10.3390/curroncol29120768 [doi] AB - Radiation therapy represents, together with surgery and systemic treatment, the triad on which the current management of patients with breast cancer is based, achieving high control and survival rates. In recent years we have witnessed a (r)evolution in the conception of breast cancer treatment. The classic scheme of surgery followed by systemic treatment and radiotherapy is being subverted and it is becoming more and more frequent to propose the primary administration of systemic treatment before surgery, seeking to maximize its effect and favoring not only the performance of more conservative surgeries but also, in selected cases, increasing the rates of disease-free survival and overall survival. Radiotherapy is also evolving toward a change in perspective: considering preoperative primary administration of radiotherapy may be useful in selected groups. Advances in radiobiological knowledge, together with technological improvements that are constantly being incorporated into clinical practice, support the administration of increasingly reliable, precise, and effective radiotherapy, as well as its safe combination with antitumor drugs or immunotherapy in the primary preoperative context. In this paper, we present a narrative review of the usefulness of preoperative radiotherapy for breast cancer patients and the possibilities for its combination with other therapies. FAU - Montero, Angel AU - Montero A AD - Department of Radiation Oncolo Gy, HM Sanchinarro University Hospital, HM Hospitales, 28050 Madrid, Spain. FAU - Ciérvide, Raquel AU - Ciérvide R AUID- ORCID: 0000-0003-0130-878X AD - Department of Radiation Oncolo Gy, HM Sanchinarro University Hospital, HM Hospitales, 28050 Madrid, Spain. LA - eng PT - Journal Article PT - Review DEP - 20221212 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/pathology MH - Neoadjuvant Therapy MH - Combined Modality Therapy MH - Disease-Free Survival MH - *Antineoplastic Agents/therapeutic use PMC - PMC9777182 OTO - NOTNLM OT - breast cancer OT - neoadjuvant radiochemotherapy OT - preoperative radiotherapy COIS- The authors declare no conflict of interest. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 09:54 PHST- 2022/11/14 00:00 [received] PHST- 2022/12/02 00:00 [revised] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/22 09:54 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - curroncol29120768 [pii] AID - curroncol-29-00768 [pii] AID - 10.3390/curroncol29120768 [doi] PST - epublish SO - Curr Oncol. 2022 Dec 12;29(12):9767-9787. doi: 10.3390/curroncol29120768. PMID- 36327625 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy. PG - 199-203 LID - S0960-9776(22)00180-1 [pii] LID - 10.1016/j.breast.2022.10.015 [doi] AB - Although breast cancer has a good prognosis compared with various cancers, metastatic breast cancer has an aggressive disease course and remains incurable. Therefore, treatment of early breast cancer to prevent recurrence and metastasis is crucial. Recently, the development of anti-cancer drugs, such as targeted agents and immuno-oncology, has been accelerating. Antibody-drug conjugates (ADCs) are also building a new paradigm. Particularly, ADCs targeting Trop-2 were approved for their efficacy in metastatic triple-negative breast cancer patients who received ≥2 prior systemic therapies and showed significant results in heavily pretreated hormone receptor-positive/HER2-negative breast cancer. In this brief review, we provide an overview of ongoing clinical trials of ADCs targeting Trop-2 in early breast cancer, specifically sacituzumab govitecan. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Jeong, Jae Ho AU - Jeong JH AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Kim, Sung-Bae AU - Kim SB AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: sbkim3@amc.seoul.kr. LA - eng PT - Journal Article PT - Review DEP - 20221026 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Antineoplastic Agents) RN - 0 (Immunoconjugates) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - *Antineoplastic Agents/therapeutic use MH - *Immunoconjugates/therapeutic use MH - *Triple Negative Breast Neoplasms/drug therapy MH - Medical Oncology PMC - PMC9634352 OTO - NOTNLM OT - Adjuvant OT - Antibody-drug conjugates OT - Early breast cancer OT - Neoadjuvant OT - Sacituzumab govitecan OT - Trop-2 COIS- Declaration of competing interest JH Jeong has received honoraria from AstraZeneca, Boryung Pharmaceutical, Eisai, Lilly, Kyowa Kirin, Novartis, Pfizer, and Roche. He has been a consultant on advisory boards for Boryung Pharmaceutical, Eisai, Lilly, Novartis, and Pfizer. SB Kim received research funding from Novartis, Sanofi-Aventis, and DongKook Pharm Co. He has been a consultant on advisory boards for Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, OBI Pharma, Beigene, and Daiichi-Sankyo. He owns stocks of Genopeaks and NeogeneTC. EDAT- 2022/11/04 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/03 19:19 PHST- 2022/09/05 00:00 [received] PHST- 2022/10/23 00:00 [revised] PHST- 2022/10/25 00:00 [accepted] PHST- 2022/11/04 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/03 19:19 [entrez] AID - S0960-9776(22)00180-1 [pii] AID - 10.1016/j.breast.2022.10.015 [doi] PST - ppublish SO - Breast. 2022 Dec;66:199-203. doi: 10.1016/j.breast.2022.10.015. Epub 2022 Oct 26. PMID- 36332545 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Acinic cell carcinoma of the breast: A comprehensive review. PG - 208-216 LID - S0960-9776(22)00177-1 [pii] LID - 10.1016/j.breast.2022.10.012 [doi] AB - Acinic cell carcinoma of the breast is a rare special subtype of breast cancer in the category of salivary gland-type tumors. It is morphologically similar to acinic cell carcinomas of salivary glands and pancreas and has a triple-negative phenotype (estrogen receptor-negative, progesterone receptor-negative, and Her-2/neu negative). Its molecular genomic features are more similar to triple-negative breast cancer of no special type than to its salivary gland counterpart. However, the clinical course of the mammary acinic cell carcinoma appears to be less aggressive than the usual triple-negative breast carcinomas. This review comprehensively summarizes the current literature on the clinicopathologic, immunohistochemical, and molecular features of this rare and distinct subtype of breast cancer. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Ajkunic, Azra AU - Ajkunic A AD - Fred Hutchinson Cancer Research Center, Seattle, WA, USA. FAU - Skenderi, Faruk AU - Skenderi F AD - Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina. FAU - Shaker, Nada AU - Shaker N AD - Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. FAU - Akhtar, Saghir AU - Akhtar S AD - College of Medicine, QU Health, Qatar University, Doha, Qatar. FAU - Lamovec, Janez AU - Lamovec J AD - Institute of Oncology Ljubljana, Ljubljana, Slovenia. FAU - Gatalica, Zoran AU - Gatalica Z AD - Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. FAU - Vranic, Semir AU - Vranic S AD - College of Medicine, QU Health, Qatar University, Doha, Qatar. Electronic address: semir.vranic@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20221028 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/therapy/metabolism MH - *Carcinoma, Acinar Cell/genetics/metabolism/pathology MH - Breast/pathology MH - *Triple Negative Breast Neoplasms/pathology MH - *Salivary Gland Neoplasms/genetics/metabolism/pathology PMC - PMC9636467 OTO - NOTNLM OT - Acinic cell carcinoma OT - Breast cancer OT - Salivary gland-type tumors OT - Special types COIS- Declaration of competing interest The authors declare no conflict of interest. EDAT- 2022/11/05 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/04 19:27 PHST- 2022/06/25 00:00 [received] PHST- 2022/10/03 00:00 [revised] PHST- 2022/10/19 00:00 [accepted] PHST- 2022/11/05 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/04 19:27 [entrez] AID - S0960-9776(22)00177-1 [pii] AID - 10.1016/j.breast.2022.10.012 [doi] PST - ppublish SO - Breast. 2022 Dec;66:208-216. doi: 10.1016/j.breast.2022.10.012. Epub 2022 Oct 28. PMID- 36626445 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230115 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 49 DP - 2022 Dec 9 TI - Prognosis and clinicopathological characteristics of metaplastic breast cancer: A meta-analysis. PG - e32226 LID - 10.1097/MD.0000000000032226 [doi] LID - e32226 AB - BACKGROUND: To compare the clinicopathological characteristics and prognosis of metaplastic breast cancer (MBC) and triple-negative breast cancer (TNBC). METHODS: A meta-analysis was performed on relevant cohort or case-control studies retrieved by a literature search of the PubMed, EMBASE, Ovid, and Web of Science databases. Hazard ratio (HR) was used to evaluate disease-free survival (DFS) and overall survival (OS), and the odds ratio (OR) and corresponding 95% confidence interval (CI) was used to evaluate clinicopathological characteristics, including age, tumor diameter, lymph node metastasis status, distant metastasis status, TNM staging, and histological grade. RESULTS: Nine studies were included in the meta-analysis. Compared with TNBC patients, the HRs for 5-year DFS and 5-year OS of those with MBC were 1.64 (95% confidence interval [CI] 1.36 - 1.98; P < .001) and 1.52 (95% CI 1.27 - 1.81; P < .001), respectively. The OR for age ≥ 50 years, tumor diameter ≤ 5 cm, lymph node-negative, distant metastasis, TNM stage III and IV, and histological grade 3 was 1.63 (95% CI 1.45-1.84), 0.29 (95% CI 0.14-0.58), 1.46 (95% CI 1.13-1.88), 1.59 (95% CI 0.89-2.81), 1.49 (95% CI 0.80-2.77), and 2.25 (95% CI 0.85-5.97), respectively. CONCLUSION: Patients with MBC had worse prognosis than those with TNBC. Furthermore, regarding clinicopathological characteristics, patients with MBC mostly presented at ≥ 50 years of age, with tumor diameter > 5 cm, and negative lymph nodes at first diagnosis. Moreover, there were no statistically significant differences in the occurrence of distant metastasis, TNM stages III and IV, or histological grade 3. MBC treatment was not assessed in this study. Data from randomized controlled trials are needed to guide the treatment of patients with MBC. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Yang, Xiaolu AU - Yang X AD - Department of Breast Cancer Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Tang, Tiantian AU - Tang T FAU - Zhou, Tao AU - Zhou T LA - eng PT - Journal Article PT - Meta-Analysis PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Breast Neoplasms/pathology MH - *Triple Negative Breast Neoplasms/pathology MH - Prognosis MH - Neoplasm Staging MH - Disease-Free Survival MH - Lymphatic Metastasis PMC - PMC9750705 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/01/11 06:00 MHDA- 2023/01/13 06:00 CRDT- 2023/01/10 13:35 PHST- 2023/01/10 13:35 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - 00005792-202212090-00095 [pii] AID - 10.1097/MD.0000000000032226 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 9;101(49):e32226. doi: 10.1097/MD.0000000000032226. PMID- 36613528 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 1 DP - 2022 Dec 21 TI - Roles and Mechanisms of Long Non-Coding RNAs in Breast Cancer. LID - 10.3390/ijms24010089 [doi] LID - 89 AB - Breast cancer is a major health threat and the second leading cause of cancer-related deaths in women worldwide. The detailed mechanisms involved in the initiation and progression of breast cancer remain unclear. In recent years, amounting evidence indicated that long non-coding RNAs (lncRNAs) played crucial roles in regulating various biological processes and malignancy tumors, including breast cancer. In this review, we briefly introduce the functions and underlying mechanisms by which lncRNAs are involved in breast cancer. We summarize the roles of the lncRNAs in regulating malignant behaviors of breast cancer, such as cell proliferation, migration and invasion, epithelial-mesenchymal transition (EMT), apoptosis, and drug resistance. Additionally, we also briefly summarize the roles of circular RNAs (circRNAs) in breast cancer carcinogenesis. FAU - Su, Jia AU - Su J AD - State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Deng, Lihao AU - Deng L AD - State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. FAU - Wang, Yan-Dong AU - Wang YD AD - State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. LA - eng GR - Grant No. 81970551/the National Natural Science Foundation of China/ GR - 2021YFC2103900/National Key R&D Program of China/ PT - Journal Article PT - Review DEP - 20221221 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (RNA, Long Noncoding) RN - 0 (RNA, Circular) SB - IM MH - Humans MH - Female MH - *RNA, Long Noncoding/genetics MH - *Breast Neoplasms/genetics MH - Carcinogenesis MH - RNA, Circular/genetics MH - Epithelial-Mesenchymal Transition/genetics PMC - PMC9820050 OTO - NOTNLM OT - breast cancer OT - circRNAs OT - lncRNAs OT - ncRNAs COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:19 PHST- 2022/10/24 00:00 [received] PHST- 2022/11/21 00:00 [revised] PHST- 2022/11/23 00:00 [accepted] PHST- 2023/01/08 01:19 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - ijms24010089 [pii] AID - ijms-24-00089 [pii] AID - 10.3390/ijms24010089 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 21;24(1):89. doi: 10.3390/ijms24010089. PMID- 36641658 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Platelet count and breast cancer stage. PG - 489-493 LID - 10.3233/BD-229007 [doi] AB - INTRODUCTION: The relationship between increased platelet count and cancer classification stage has long been established. The prevalence of thrombocytosis varies from 10% to 57% in cancer patients. The pathogenesis of thrombocytosis in malignancy is uncertain. However, there is evidence that tumor cells secrete humoral factors that can cause thrombocytosis. Preoperative thrombocytosis is a poor prognostic variable in malignancies. This study investigated the correlation between platelet count and breast cancer stage. METHODS: This cross-sectional study was conducted from February 2020 to January 2021. Patient data were collected from medical records. The study population comprised breast cancer patients at Dr. Wahidin Sudirohusodo Makassar. The staging examinations were based on the tumor, node, metastasis (TNM) classification according to the American Joint Committee on Cancer (AJCC) 8th Edition. RESULTS: The study group comprised 171 breast cancer patients of varying ages. Metastasis was present in five (2.92%) patients and absent in 166 (97.8%) patients. Analyses found no statistically significant differences between the three staging groups based on the platelet count (p = 0.952). CONCLUSION: There was no statistically significant relationship between increased platelet count and staging according to the TNM classification in breast cancer patients. FAU - Fahdrin, Andi AU - Fahdrin A AD - Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Sampepajung, Elridho AU - Sampepajung E AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Pieter, John AU - Pieter J AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Kasim, Firdaus AU - Kasim F AD - Department of Biostatistics, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia. FAU - Smaradhania, Nilam AU - Smaradhania N AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Prihantono, Prihantono AU - Prihantono P AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Mariana, Nita AU - Mariana N AD - Division of Pediatric Surgery, Department of Surgery, Hasanuddin University, >Makassar, Indonesia. FAU - Sampepajung, Daniel AU - Sampepajung D AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Faruk, Muhammad AU - Faruk M AD - Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. LA - eng PT - Journal Article PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 SB - IM MH - Humans MH - Female MH - Platelet Count MH - *Breast Neoplasms/pathology MH - Cross-Sectional Studies MH - Retrospective Studies MH - Prognosis MH - Neoplasm Staging MH - *Thrombocytosis/pathology OTO - NOTNLM OT - American Joint Committee on Cancer OT - breast cancer OT - platelet counts OT - staging EDAT- 2023/01/16 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/15 05:22 PHST- 2023/01/15 05:22 [entrez] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - BD229007 [pii] AID - 10.3233/BD-229007 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):489-493. doi: 10.3233/BD-229007. PMID- 36613047 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230119 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 20 IP - 1 DP - 2022 Dec 30 TI - Virtual Therapy Complementary Prehabilitation of Women Diagnosed with Breast Cancer-A Pilot Study. LID - 10.3390/ijerph20010722 [doi] LID - 722 AB - Breast cancer is becoming an important issue due to its various consequences and epidemiology. Studies are showing that it extremely impacts the mental health as well as the physical activity of the patients. In addition to the most common symptom, which is fatigue, patients also have problems with the quality of sleep. Therefore, this study aimed to evaluate the effectiveness of virtual reality (VR) therapy in improving the mental state and quality of sleep, as well as increasing the physical activity (PA) of patients diagnosed with breast cancer. The study was conducted in a hospital's Breast Unit and included patients at the time of diagnosis of malignant breast cancer. A total of 16 subjects randomly divided into experimental (n = 9), and control (n = 7) groups were measured with the Beck Depression Scale, Mental Adjustment to Cancer Scale, International Physical Activity Questionnaire, and Pittsburgh Sleep Quality Index at two timepoints. The experimental intervention consisted of a 2-week (8 sessions) Virtual Therapeutic Garden (VRTierOne) procedure performed daily for about 15 min. Significant differences were identified between groups in the interactions between the main factors seen in the destructive style of the Mini-Mac scale: F(1.14) = 4.82, p = 0.04, and between multiple experiments: F(1.14)= 5.54, p = 0.03 showing a significant reduction in the destructive style of coping with the disease in the study group after therapy (32.44 vs. 28.33, p = 0.003). The level of main effects [study] for the constructive style is F(1.14) = 3.93, p = 0.06 with a significant increase in constructive style in the study group (43.33 vs. 45.33, p = 0.044). Significant differences in levels of depression between multiple experiments: F(1.14) = 5.04, p = 0.04, show a significant reduction in the severity of depressive symptoms was found in the experimental group after therapy (13.33 vs. 8.11, p = 0.02). However, the analysis did not show significant differences between group analyses (p = 0.25). It seems that VR reduces the severity of depressive symptoms and reduces the destructive style and can be an effective option in improving the mental state of patients diagnosed with breast cancer. FAU - Czech, Oliver AU - Czech O AUID- ORCID: 0000-0002-8515-9920 AD - Department of Physiotherapy, Wroclaw University of Health and Sport Sciences, 51-612 Wroclaw, Poland. FAU - Siewierska, Katarzyna AU - Siewierska K AD - Department of Physiotherapy, Wroclaw University of Health and Sport Sciences, 51-612 Wroclaw, Poland. FAU - Krzywińska, Aleksandra AU - Krzywińska A AD - Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland. FAU - Skórniak, Jakub AU - Skórniak J AD - Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland. FAU - Maciejczyk, Adam AU - Maciejczyk A AD - Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland. AD - Department of Oncology, Wroclaw Medical University, 50-367 Wroclaw, Poland. FAU - Matkowski, Rafał AU - Matkowski R AUID- ORCID: 0000-0002-1705-5097 AD - Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland. AD - Department of Oncology, Wroclaw Medical University, 50-367 Wroclaw, Poland. FAU - Szczepańska-Gieracha, Joanna AU - Szczepańska-Gieracha J AUID- ORCID: 0000-0001-5191-3799 AD - Department of Physiotherapy, Wroclaw University of Health and Sport Sciences, 51-612 Wroclaw, Poland. FAU - Malicka, Iwona AU - Malicka I AUID- ORCID: 0000-0002-7668-001X AD - Department of Physiotherapy, Wroclaw University of Health and Sport Sciences, 51-612 Wroclaw, Poland. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20221230 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/therapy MH - Depression/psychology MH - Exercise MH - Pilot Projects MH - Preoperative Exercise MH - Quality of Life/psychology PMC - PMC9819944 OTO - NOTNLM OT - physical activity OT - physical health OT - psychotherapy OT - quality of sleep OT - virtual reality COIS- Authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:15 PHST- 2022/11/28 00:00 [received] PHST- 2022/12/23 00:00 [revised] PHST- 2022/12/27 00:00 [accepted] PHST- 2023/01/08 01:15 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - ijerph20010722 [pii] AID - ijerph-20-00722 [pii] AID - 10.3390/ijerph20010722 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Dec 30;20(1):722. doi: 10.3390/ijerph20010722. PMID- 36555400 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 24 DP - 2022 Dec 12 TI - Crosstalk between Methylation and ncRNAs in Breast Cancer: Therapeutic and Diagnostic Implications. LID - 10.3390/ijms232415759 [doi] LID - 15759 AB - Breast cancer, as a highly heterogeneous malignant tumor, is one of the primary causes of death among females worldwide. The etiology of breast cancer involves aberrant epigenetic mechanisms and abnormal expression of certain non-coding RNA (ncRNAs). DNA methylation, N6-methyladenosine(m6A), and histone methylation are widely explored epigenetic regulation types in breast cancer. ncRNAs are a group of unique RNA transcripts, mainly including microRNA (miRNAs), long non-coding RNA (lncRNAs), circular RNA (circRNAs), small interfering RNA (siRNAs), piwi-interacting RNA (piRNAs), etc. Different types of methylation and ncRNAs mutually regulate and interact to form intricate networks to mediate precisely breast cancer genesis. In this review, we elaborate on the crosstalk between major methylation modifications and ncRNAs and discuss the role of their interaction in promoting breast cancer oncogenesis. This review can provide novel insights into establishing a new diagnostic marker system on methylation patterns of ncRNAs and therapeutic perspectives of combining ncRNA oligonucleotides and phytochemical drugs for breast cancer therapy. FAU - Liu, Yitong AU - Liu Y AD - College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610000, China. FAU - Leng, Ping AU - Leng P AD - College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610000, China. FAU - Liu, Yan AU - Liu Y AD - College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610000, China. FAU - Guo, Jinlin AU - Guo J AD - College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610000, China. FAU - Zhou, Hao AU - Zhou H AD - College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610000, China. LA - eng GR - MPRC2021043/Chengdu University of Traditional Chinese Medicine/ GR - ZRYY2023/Chengdu University of Traditional Chinese Medicine/ PT - Journal Article PT - Review DEP - 20221212 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (RNA, Untranslated) RN - 0 (MicroRNAs) RN - 0 (RNA, Long Noncoding) RN - 0 (RNA, Small Interfering) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/diagnosis/drug therapy/genetics MH - Epigenesis, Genetic MH - RNA, Untranslated/genetics MH - *MicroRNAs/genetics MH - DNA Methylation MH - *RNA, Long Noncoding/genetics MH - RNA, Small Interfering PMC - PMC9779155 OTO - NOTNLM OT - DNA methylation OT - N6-methyladenosine OT - breast cancer OT - diagnostic strategy OT - epigenetic OT - histone methylation OT - ncRNAs OT - therapeutic COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:33 PHST- 2022/11/06 00:00 [received] PHST- 2022/12/05 00:00 [revised] PHST- 2022/12/08 00:00 [accepted] PHST- 2022/12/23 01:33 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - ijms232415759 [pii] AID - ijms-23-15759 [pii] AID - 10.3390/ijms232415759 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 12;23(24):15759. doi: 10.3390/ijms232415759. PMID- 33053607 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230123 IS - 2573-8348 (Electronic) IS - 2573-8348 (Linking) VI - 5 IP - 12 DP - 2022 Dec TI - Role of eIF4A1 in triple-negative breast cancer stem-like cell-mediated drug resistance. PG - e1299 LID - 10.1002/cnr2.1299 [doi] LID - e1299 AB - In cap-dependent translation, the eukaryotic translation initiation factor 4A (eIF4A1) is an mRNA helicase is involved in unwinding of the secondary structure, such as the stem-loops, at the 5'-leader regions of the key oncogenic mRNAs. This facilitates ribosomal scanning and translation of the oncogenic mRNAs. eIF4A1 has a regulatory role in translating many oncoproteins that have vital roles in several steps of metastases. Sridharan et. al. have discovered and provide a novel insight into how eIF4A1 can play a regulatory role in drug resistance by influencing the levels of pluripotent Yamanaka transcription factors and ATP-binding cassette (ABC) transporters in triple-negative breast cancer (TNBC) stem-like cells. These findings may help us understand the molecular underpinnings of chemoresistance, especially in established metastases in TNBC. Importantly, eIF4A1 may form a novel clinical target in metastatic TNBC and the drug eFT226 from Effector Therapeutics targeting eIF4A1 is already in phase1-2 clinical trial. CI - © 2020 The Authors. Cancer Reports published by Wiley Periodicals LLC. FAU - Raman, Dayanidhi AU - Raman D AD - Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, Ohio. FAU - Tiwari, Amit K AU - Tiwari AK AUID- ORCID: 0000-0002-7427-7155 AD - Department of Pharmacology & Experimental Therapeutics, University of Toledo Health Science Campus, Toledo, Ohio. LA - eng GR - R21 CA202176/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20201014 PL - United States TA - Cancer Rep (Hoboken) JT - Cancer reports (Hoboken, N.J.) JID - 101747728 RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/drug therapy/genetics MH - Drug Resistance MH - RNA, Messenger/genetics PMC - PMC9780423 OTO - NOTNLM OT - ABC transporters OT - breast cancer stemness OT - chemoresistance OT - eIF4A1 OT - triple-negative breast cancer COIS- The authors have stated explicitly that there are no conflicts of interest in connection with this article. EDAT- 2020/10/15 06:00 MHDA- 2022/12/27 06:00 CRDT- 2020/10/14 20:08 PHST- 2020/07/29 00:00 [revised] PHST- 2020/03/11 00:00 [received] PHST- 2020/08/17 00:00 [accepted] PHST- 2020/10/15 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2020/10/14 20:08 [entrez] AID - CNR21299 [pii] AID - 10.1002/cnr2.1299 [doi] PST - ppublish SO - Cancer Rep (Hoboken). 2022 Dec;5(12):e1299. doi: 10.1002/cnr2.1299. Epub 2020 Oct 14. PMID- 36265208 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20221229 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis. PG - 126-135 LID - S0960-9776(22)00139-4 [pii] LID - 10.1016/j.breast.2022.08.006 [doi] AB - BACKGROUND: Evidence for the preferred neoadjuvant therapy regimen in triple-negative breast cancer (TNBC) is not yet established. METHODS: Literature search was conducted from inception to February 12, 2022. Phase 2 and 3 randomized controlled trials (RCTs) investigating neoadjuvant therapy for TNBC were eligible. The primary outcome was pathologic complete response (pCR); the secondary outcomes were all-cause treatment discontinuation, disease-free survival or event-free survival (DFS/EFS), and overall survival. Odd ratios (OR) with 95% credible intervals (CrI) were used to estimate binary outcomes; hazard ratios (HR) with 95% CrI were used to estimate time-to-event outcomes. Bayesian network meta-analysis was implemented for each endpoint. Sensitivity analysis and network meta-regression were done. RESULTS: 41 RCTs (N = 7109 TNBC patients) were eligible. Compared with anthracycline- and taxane-based chemotherapy (ChT), PD-1 inhibitor plus platinum plus anthracycline- and taxane-based ChT was associated with a significant increased pCR rate (OR 3.95; 95% CrI 1.81-9.44) and a higher risk of premature treatment discontinuation (3.25; 1.26-8.29). Compared with dose-dense anthracycline- and taxane-based ChT, the combined treatment was not associated with significantly improved pCR (OR 2.57; 95% CrI 0.69-9.92). In terms of time-to-event outcomes, PD-1 inhibitor plus platinum plus anthracycline- and taxane-based ChT was associated with significantly improved DFS/EFS (HR 0.42; 95% CrI 0.19-0.81). CONCLUSIONS: PD-1 inhibitor plus platinum and anthracycline- and taxane-based ChT was currently the most efficacious regimen for pCR and DFS/EFS improvement in TNBC. The choice of chemotherapy backbone, optimization of patient selection with close follow-up and proactive symptomatic managements are essential to the antitumor activity of PD-1 inhibitor. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Lin, Ying-Yi AU - Lin YY AD - Shantou University Medical College, Shantou, 515041, Guangdong, China; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Gao, Hong-Fei AU - Gao HF AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Yang, Xin AU - Yang X AD - Shantou University Medical College, Shantou, 515041, Guangdong, China; Department of Anesthesiology, the First Affiliated Hospital of Shantou University Medical College, 57 Changping Road, Shantou, 515041, Guangdong, China. FAU - Zhu, Teng AU - Zhu T AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Zheng, Xing-Xing AU - Zheng XX AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China; Southern Medical University, Guangzhou, 510515, Guangdong, China. FAU - Ji, Fei AU - Ji F AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Zhang, Liu-Lu AU - Zhang LL AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Yang, Ci-Qiu AU - Yang CQ AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Yang, Mei AU - Yang M AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Li, Jie-Qing AU - Li JQ AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Cheng, Min-Yi AU - Cheng MY AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. FAU - Wang, Kun AU - Wang K AD - Shantou University Medical College, Shantou, 515041, Guangdong, China; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. Electronic address: gzwangkun@126.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220820 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Anthracyclines) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Immune Checkpoint Inhibitors) RN - 49DFR088MY (Platinum) RN - 1605-68-1 (taxane) RN - 0 (Taxoids) SB - IM MH - Female MH - Humans MH - Anthracyclines/therapeutic use MH - Antibiotics, Antineoplastic MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Breast Neoplasms/drug therapy MH - Immune Checkpoint Inhibitors/therapeutic use MH - Neoadjuvant Therapy MH - Network Meta-Analysis MH - Platinum/therapeutic use MH - Taxoids MH - *Triple Negative Breast Neoplasms/drug therapy PMC - PMC9587342 OTO - NOTNLM OT - Neoadjuvant therapy OT - Network meta-analysis OT - Triple-negative breast cancer COIS- Declaration of competing interest The authors declare that there is no conflict of interest. EDAT- 2022/10/21 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/20 18:14 PHST- 2022/04/07 00:00 [received] PHST- 2022/08/05 00:00 [revised] PHST- 2022/08/15 00:00 [accepted] PHST- 2022/10/21 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/20 18:14 [entrez] AID - S0960-9776(22)00139-4 [pii] AID - 10.1016/j.breast.2022.08.006 [doi] PST - ppublish SO - Breast. 2022 Dec;66:126-135. doi: 10.1016/j.breast.2022.08.006. Epub 2022 Aug 20. PMID- 36567400 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 2589-0409 (Electronic) IS - 1110-0362 (Print) IS - 1110-0362 (Linking) VI - 34 IP - 1 DP - 2022 Dec 26 TI - Primary therapy of early breast cancer: Egyptian view of 2021 St. Gallen consensus. PG - 56 LID - 10.1186/s43046-022-00156-x [doi] LID - 56 AB - PURPOSE: The theme of the St. Gallen International Breast Cancer Conference 2021 held virtually for the first time, due to the COVID-19 pandemic, was on tailoring therapies for patients with early breast cancer. A monkey survey that included an Egyptian Panel voted on most of the questions of the original St. Gallen consensus, and some added new questions most relevant to oncology practice in the country, to be able to compare voting results that reflect differences in breast cancer management and decision making. METHODS: The panel included 74 Egyptian scientists from different oncology specialties. Management issues including controversial diagnostic and therapeutic interventions were prepared by a small committee and then projected using the online monkey survey website: https://www.surveymonkey.com . The survey included 130 questions. Results were then analyzed, tabulated, and compared to the voting results of the original St. Gallen consensus. RESULTS AND CONCLUSIONS: Voting questions and resulting percentages of answers from the Egyptian panel were summarized. There was no consensus between the Egyptian and the original St. Gallen panels on 28/130 statements. They mostly included genetic and pathologic aspects, specifically the routine use of gene signature assays and a few queries involving surgical, radiotherapeutic, and systemic interventions. Probably, available resources and healthcare system differences in Egypt compared to European and the USA were the cause of these differences. This would also be applicable to other low- and low-middle-income healthcare scenarios present in many countries, especially with the present constraints of the COVID-19 pandemic. CI - © 2022. The Author(s). FAU - Khaled, Hussein AU - Khaled H AD - Medical Oncology, National Cancer Institute, Cairo University, El-Khalig Square, Cairo, 11796, Egypt. khaledh@cu.edu.eg. FAU - Nada, Yousry Wasef AU - Nada YW AD - Medical Oncology Department, Maadi Armed Forces Medical Compound, Cairo, Egypt. FAU - Ramadan, Kareem Mohamed AU - Ramadan KM AD - Medical Oncology Department, Maadi Armed Forces Medical Compound, Cairo, Egypt. FAU - Fekry, Shawkat AU - Fekry S AD - Medical Oncology Department, Maadi Armed Forces Medical Compound, Cairo, Egypt. FAU - Seleam, Mohamed Samy AU - Seleam MS AD - Medical Oncology Department, Maadi Armed Forces Medical Compound, Cairo, Egypt. FAU - Gaafar, Rabab AU - Gaafar R AD - Medical Oncology, National Cancer Institute, Cairo University, El-Khalig Square, Cairo, 11796, Egypt. FAU - Lotayef, Mohamed AU - Lotayef M AD - Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt. LA - eng PT - Journal Article DEP - 20221226 PL - England TA - J Egypt Natl Canc Inst JT - Journal of the Egyptian National Cancer Institute JID - 9424566 SB - IM MH - Humans MH - Female MH - Egypt/epidemiology MH - Pandemics MH - *COVID-19/epidemiology MH - *Breast Neoplasms/diagnosis/epidemiology/therapy MH - Combined Modality Therapy PMC - PMC9790763 OTO - NOTNLM OT - Adjuvant therapy OT - Breast cancer OT - Egypt COIS- Prof Hussein Khaled is a co-author of this study and the Editor-in-Chief of the journal. He was not involved in handling this manuscript during the review process. The rest of the authors have no conflict of interest to declare. EDAT- 2022/12/26 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/25 23:19 PHST- 2022/06/09 00:00 [received] PHST- 2022/10/04 00:00 [accepted] PHST- 2022/12/25 23:19 [entrez] PHST- 2022/12/26 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - 10.1186/s43046-022-00156-x [pii] AID - 156 [pii] AID - 10.1186/s43046-022-00156-x [doi] PST - epublish SO - J Egypt Natl Canc Inst. 2022 Dec 26;34(1):56. doi: 10.1186/s43046-022-00156-x. PMID- 36308925 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - The impact of standardized structured reporting of pathology reports for breast cancer care. PG - 178-182 LID - S0960-9776(22)00176-X [pii] LID - 10.1016/j.breast.2022.10.011 [doi] AB - PURPOSE: With the increasing complexity of modern oncological patient management and the growing amount of information needed from the pathologist, traditional narrative pathology reports (NR) do not suffice. Standardized synoptic reporting (SR) increases both completeness and readability. In the Netherlands SR for breast cancer was introduced in 2009. We explore the impact of synoptic reporting on breast cancer care. METHODS: Using data from the Netherlands Cancer Registry and Dutch Nationwide Pathology Databank, a retrospective population-based cohort study was performed. Data of breast cancer resections from 2007 to 2014 were collected to compare NR and SR for all outcome measures. Kaplan-Meier analyses and log-rank testing were used to estimate overall survival. RESULTS: Over time there was an increase from 12% to 78.9% in the use of SR. SR resulted in higher completeness of pathology reports, particularly for hormone and HER2/neu receptor status. Although there was no difference in the administration of antihormonal therapy, anti-HER2 treatment was more frequently administered to eligible patients in the SR group. An effect on overall survival could not yet be confirmed on multivariate analysis. CONCLUSIONS: We demonstrate that SR has led to more complete pathology reports, which meets the needs for precision of information in breast cancer care. This is expected to improve communication and discussions between specialists regarding parameters important for adjuvant breast cancer treatment decisions. SR thereby improves breast cancer care and leads to improved allocation of treatment based on pathologic parameters and more personalized treatment regimens. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Snoek, J A A AU - Snoek JAA AD - Radboud University Medical Center, Department of Pathology, Nijmegen, the Netherlands. FAU - Nagtegaal, I D AU - Nagtegaal ID AD - Radboud University Medical Center, Department of Pathology, Nijmegen, the Netherlands. Electronic address: iris.nagtegaal@radboudumc.nl. FAU - Siesling, S AU - Siesling S AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands. FAU - van den Broek, E AU - van den Broek E AD - PALGA Foundation, Houten, the Netherlands. FAU - van Slooten, H J AU - van Slooten HJ AD - DNA Pathology, Nieuwegein, the Netherlands. FAU - Hugen, N AU - Hugen N AD - Radboud University Medical Center, Department of Surgery, Nijmegen, the Netherlands; Rijnstate Hospital, Department of Surgery, Arnhem, the Netherlands. LA - eng PT - Journal Article DEP - 20221021 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/pathology MH - Cohort Studies MH - Retrospective Studies MH - Research Report MH - Netherlands PMC - PMC9619179 OTO - NOTNLM OT - Breast cancer OT - Pathology OT - Reporting OT - Treatment COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/10/30 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/29 18:27 PHST- 2022/06/22 00:00 [received] PHST- 2022/09/21 00:00 [revised] PHST- 2022/10/19 00:00 [accepted] PHST- 2022/10/30 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/29 18:27 [entrez] AID - S0960-9776(22)00176-X [pii] AID - 10.1016/j.breast.2022.10.011 [doi] PST - ppublish SO - Breast. 2022 Dec;66:178-182. doi: 10.1016/j.breast.2022.10.011. Epub 2022 Oct 21. PMID- 36399953 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230106 IS - 2059-7029 (Electronic) IS - 2059-7029 (Linking) VI - 7 IP - 6 DP - 2022 Dec TI - Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. PG - 100629 LID - S2059-7029(22)00263-0 [pii] LID - 10.1016/j.esmoop.2022.100629 [doi] LID - 100629 AB - BACKGROUND: Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments' value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in breast cancer (BC), using various questionnaires at different timepoints. HR-QoL reports from BC patients treated with CDK4/6i in the real-world setting are also available. METHODS: We systematically reviewed the literature, searching for full-length articles, and selected conference abstracts reporting data on HR-QoL in BC patients at any stage and of any molecular subtype treated with abemaciclib, palbociclib or ribociclib. RESULTS: A total of 533 full-length articles and 143 abstracts were retrieved. After screening for eligibility, 38 records were included (31 clinical trials; 7 real-world reports). Assessment methods were heterogeneous across studies in terms of questionnaires, evaluation timepoints and endpoints. Overall, adding CDK4/6i to endocrine therapy did not worsen patients' HR-QoL, with a positive trend towards pain improvement. Gastrointestinal scores (diarrhea, nausea and appetite loss) statistically favored the control arm among metastatic BC patients receiving abemaciclib, whereas they were superimposable in the early setting. The combination of palbociclib and endocrine therapy showed similar HR-QoL outcomes compared with endocrine therapy alone, but determined better scores compared with chemotherapy. HR-QoL was specifically assessed in premenopausal patients treated with ribociclib, showing similar scores compared with postmenopausal patients. CONCLUSIONS: Despite methodological heterogeneity does not allow a proper comparison, HR-QoL was generally maintained with CDK4/6i. However, differences between abemaciclib, palbociclib and ribociclib exist and mainly rely on the distinct safety profiles of the compounds. These differences should be acknowledged and taken into account in the clinical practice. CI - Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Di Lauro, V AU - Di Lauro V AD - Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples. FAU - Barchiesi, G AU - Barchiesi G AD - Department of Radiology, Oncology and Pathology Science, University of Rome La Sapienza, Rome. FAU - Martorana, F AU - Martorana F AD - Department of Clinical and Experimental Medicine, University of Catania, Catania. Electronic address: federica.martorana@phd.unict.it. FAU - Zucchini, G AU - Zucchini G AD - Oncology Department, Michele e Pietro Ferrero Hospital, Verduno (CN). FAU - Muratore, M AU - Muratore M AD - Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome. FAU - Fontanella, C AU - Fontanella C AD - Oncology Unit, AULSS 1 Dolomiti, Belluno. FAU - Arpino, G AU - Arpino G AD - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples. FAU - Del Mastro, L AU - Del Mastro L AD - Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa. FAU - Giuliano, M AU - Giuliano M AD - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples. FAU - Puglisi, F AU - Puglisi F AD - Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano; Department of Medicine (DAME), University of Udine, Udine, Italy. FAU - De Laurentiis, M AU - De Laurentiis M AD - Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples. LA - eng PT - Journal Article PT - Review PT - Systematic Review DEP - 20221116 PL - England TA - ESMO Open JT - ESMO open JID - 101690685 RN - 60UAB198HK (abemaciclib) RN - 0 (Aminopyridines) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 4) RN - TK8ERE8P56 (ribociclib) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 6) RN - 0 (Protein Kinase Inhibitors) SB - IM MH - Female MH - Humans MH - Aminopyridines/pharmacology/therapeutic use MH - *Breast Neoplasms/drug therapy/pathology MH - Cyclin-Dependent Kinase 4/antagonists & inhibitors MH - *Quality of Life MH - Cyclin-Dependent Kinase 6/antagonists & inhibitors MH - *Protein Kinase Inhibitors/therapeutic use PMC - PMC9808450 OTO - NOTNLM OT - abemaciclib OT - cyclin-dependent 4/6 inhibitors OT - health-related quality of life OT - palbociclib OT - ribociclib EDAT- 2022/11/19 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/18 18:25 PHST- 2022/09/06 00:00 [received] PHST- 2022/09/30 00:00 [revised] PHST- 2022/10/08 00:00 [accepted] PHST- 2022/11/19 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/18 18:25 [entrez] AID - S2059-7029(22)00263-0 [pii] AID - 100629 [pii] AID - 10.1016/j.esmoop.2022.100629 [doi] PST - ppublish SO - ESMO Open. 2022 Dec;7(6):100629. doi: 10.1016/j.esmoop.2022.100629. Epub 2022 Nov 16. PMID- 36573110 OWN - NLM STAT- MEDLINE DCOM- 20221228 LR - 20230103 IS - 1748-6718 (Electronic) IS - 1748-670X (Print) IS - 1748-670X (Linking) VI - 2022 DP - 2022 TI - Pancancer Analysis of the Prognostic and Immunotherapeutic Value of Progestin and AdipoQ Receptor 4. PG - 2528164 LID - 10.1155/2022/2528164 [doi] LID - 2528164 AB - AdipoQ receptor 4 (PAQR4) belongs to the family of progestin and AdipoQ receptors. PAQR4 plays an oncogenic role in lung and breast cancer. However, systematic pancancer analyses of PAQR4 have not been performed. The purpose was to investigate the prognostic and immunological significance of PAQR4 across 31 tumor types. Data were obtained from the following sources: TCGA, GEO, UALCAN, TIMER, GEPIA2, KM plotter, and TISIDB databases. The results proved that PAQR4 expression was significantly elevatory in most cancer types. We then explored the utility of PAQR4 as a prognostic indicator across all cancers. Using Cox proportional risk regression models, it has been demonstrated that PAQR4 is an independent risk factor in. High PAQR4 expression was not associated with other prognostic indicators, including overall survival, disease-free interval, disease-specific survival, and progression-free period. Subsequently, we explored the immunological value of PAQR4 and found that PAQR4 expression significantly correlated with tumor mutational burden, microsatellite instability, neoantigen, and immune checkpoint genes in tumors. It also significantly negatively correlated with most tumors' ESTIMATE scores, indicating that PAQR4 can influence the cellular composition of the tumor microenvironment. Our findings suggest the immunotherapeutic potential of PAQR4 in tumors. Finally, we explored the role of PAQR4 in tumor drug resistance and found that PAQR4 expression affected the sensitivity to multiple chemotherapeutic agents. A significant role for PAQR4 in tumor immunity is evident in these studies, as well as its potential role in cancer diagnosis, prognosis, and treatment precision. CI - Copyright © 2022 Ziyue Yang et al. FAU - Yang, Ziyue AU - Yang Z AD - Department of Blood Transfusion, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. AD - NHC Key Laboratory of Cancer Proteomics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. FAU - Zhu, Yuanyuan AU - Zhu Y AD - Department of Blood Transfusion, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. AD - NHC Key Laboratory of Cancer Proteomics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. FAU - Li, Zhenfen AU - Li Z AD - Department of Blood Transfusion, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. AD - NHC Key Laboratory of Cancer Proteomics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. FAU - Pu, Zhangya AU - Pu Z AD - Department of Infectious Diseases and Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. FAU - Lin, Ying AU - Lin Y AD - Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, China. FAU - Deng, Ying AU - Deng Y AD - People's Hospital of Ningxiang, Changsha, Hunan Province 410600, China. FAU - Li, Ning AU - Li N AD - Department of Blood Transfusion, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. FAU - Peng, Fang AU - Peng F AUID- ORCID: 0000-0002-4660-194X AD - Department of Blood Transfusion, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. AD - NHC Key Laboratory of Cancer Proteomics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China. LA - eng PT - Journal Article DEP - 20221217 PL - United States TA - Comput Math Methods Med JT - Computational and mathematical methods in medicine JID - 101277751 RN - 0 (Progestins) RN - 0 (Steroids) RN - 0 (Biomarkers, Tumor) RN - 0 (ADIPOQ protein, human) RN - 0 (Adiponectin) SB - IM MH - Humans MH - Female MH - *Progestins MH - Prognosis MH - Steroids MH - *Breast Neoplasms/drug therapy/genetics MH - Immunotherapy MH - Biomarkers, Tumor/genetics MH - Tumor Microenvironment/genetics MH - Adiponectin/genetics PMC - PMC9789910 COIS- The authors declare that they have no competing interests. EDAT- 2022/12/28 06:00 MHDA- 2022/12/29 06:00 CRDT- 2022/12/27 01:44 PHST- 2022/10/12 00:00 [received] PHST- 2022/11/09 00:00 [revised] PHST- 2022/11/10 00:00 [accepted] PHST- 2022/12/27 01:44 [entrez] PHST- 2022/12/28 06:00 [pubmed] PHST- 2022/12/29 06:00 [medline] AID - 10.1155/2022/2528164 [doi] PST - epublish SO - Comput Math Methods Med. 2022 Dec 17;2022:2528164. doi: 10.1155/2022/2528164. eCollection 2022. PMID- 36547140 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230112 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 29 IP - 12 DP - 2022 Nov 27 TI - Association of Surgical Margin Status with Oncologic Outcome in Patients Treated with Breast-Conserving Surgery. PG - 9271-9283 LID - 10.3390/curroncol29120726 [doi] AB - We aimed to compare the prognosis of patients with close resection margins after breast-conserving surgery (BCS) with that of patients with negative margins and identified predictors of residual disease. A total of 542 patients with breast cancer who underwent BCS between 2003 and 2019 were selected and divided into the close margin (114 patients) and negative margin (428 patients) groups. The median follow-up period was 72 (interquartile range, 42-113) months. Most patients received radiation therapy (RTx) and systemic therapy according to their stage and molecular subtype. The 10-year locoregional recurrence-free survival rates of the close and negative margin groups were 88.2% and 95.5%, respectively (p = 0.001). Multivariable analysis showed that adjuvant RTx and margin status after definitive surgery were significantly associated with locoregional recurrence. Of the 57 patients who underwent re-excision, 34 (59.6%) had residual disease. Multivariable analysis revealed that a histological type of positive or close margins and multifocality were independent predictive factors for residual disease. Although the current guidelines suggest that no ink on tumor is an adequate margin after BCS, a close resection margin may be associated with locoregional failure. The treatment strategy for close resection margins after BCS should be based on individual clinicopathological features. FAU - Chae, Sumin AU - Chae S AUID- ORCID: 0000-0001-7888-9098 AD - Department of Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. AD - Department of Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul 02447, Republic of Korea. FAU - Min, Sun Young AU - Min SY AD - Department of Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul 02447, Republic of Korea. LA - eng PT - Journal Article DEP - 20221127 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM MH - Humans MH - Female MH - *Mastectomy, Segmental MH - Margins of Excision MH - Neoplasm Staging MH - Neoplasm Recurrence, Local/surgery/pathology MH - *Breast Neoplasms/pathology PMC - PMC9777347 OTO - NOTNLM OT - breast-conserving surgery OT - close resection margin OT - locoregional recurrence OT - residual disease COIS- The authors declare no conflict of interest. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 09:54 PHST- 2022/11/03 00:00 [received] PHST- 2022/11/18 00:00 [revised] PHST- 2022/11/24 00:00 [accepted] PHST- 2022/12/22 09:54 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - curroncol29120726 [pii] AID - curroncol-29-00726 [pii] AID - 10.3390/curroncol29120726 [doi] PST - epublish SO - Curr Oncol. 2022 Nov 27;29(12):9271-9283. doi: 10.3390/curroncol29120726. PMID- 36113374 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Prognosis stratification and postoperative radiation therapy utilization in adenoid cystic carcinoma of the breast. PG - 40-48 LID - S0960-9776(22)00148-5 [pii] LID - 10.1016/j.breast.2022.09.003 [doi] AB - PURPOSE: Adenoid cystic carcinoma of the breast (ACCB) is a rare malignancy with a favorable prognosis. Little information exists regarding the impact of postoperative radiation therapy (RT) on survival outcome in patients with ACCB. This study aimed to evaluate the clinical significance of postoperative RT in ACCB. METHODS: Data of patients with ACCB were extracted from the Surveillance, Epidemiology, and End Results database (2000-2019). Univariate and multivariable Cox regression analyses were performed to identify prognostic factors. In addition, a nomogram model was constructed and internally validated for discrimination and calibration. The value of postoperative RT was respectively accessed in each risk subgroup according to nomogram-deduced individualized score. RESULTS: A total of 689 eligible patients were included in the analysis. Partial mastectomy was associated with an increased risk of death compared with partial mastectomy plus postoperative RT (P = 0.020), but total mastectomy with or without postoperative RT was comparable (P = 0.624). Then, in-depth analysis was performed for patients receiving breast-conserving therapy (n = 485, the training set vs. the testing set = 340 vs. 145). Age at diagnosis, histological grade, and T stage were identified as prognostic factors for overall survival (OS) (All P < 0.05). A nomogram was constructed to provide predictive accuracy toward individual OS rates of ACCB and to divide patients into different risk subgroups. Notably, compared with non-RT, postoperative RT significantly improved OS in the high-risk subgroup (P = 0.006 for the training set, and P = 0.013 for the overall population) but not in the low-risk subgroup (P = 0.807 for the training set, and P = 0.293 for the overall population), suggesting that these patients may be able to exempt from postoperative RT. CONCLUSION: A robust and effective nomogram was developed to predict prognosis and assist in treatment decisions in patients with ACCB undergoing partial mastectomy. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Zhang, Di AU - Zhang D AD - National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: irisaaron@163.com. FAU - Li, Lixi AU - Li L AD - National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: 13552075722@163.com. FAU - Ma, Fei AU - Ma F AD - National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: drmafei@126.com. LA - eng PT - Journal Article DEP - 20220910 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/radiotherapy/surgery MH - Mastectomy/methods MH - *Carcinoma, Adenoid Cystic/radiotherapy/surgery/pathology MH - Prognosis MH - Breast/pathology MH - Nomograms MH - SEER Program PMC - PMC9483639 OTO - NOTNLM OT - Adenoid cystic carcinoma of the breast OT - And end results database OT - Breast OT - Epidemiology OT - Nomogram OT - Partial mastectomy OT - Postoperative radiation therapy OT - Surveillance COIS- Declaration of competing interest The authors declare to have no competing interests. EDAT- 2022/09/17 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/09/16 18:28 PHST- 2022/06/26 00:00 [received] PHST- 2022/08/26 00:00 [revised] PHST- 2022/09/05 00:00 [accepted] PHST- 2022/09/17 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/09/16 18:28 [entrez] AID - S0960-9776(22)00148-5 [pii] AID - 10.1016/j.breast.2022.09.003 [doi] PST - ppublish SO - Breast. 2022 Dec;66:40-48. doi: 10.1016/j.breast.2022.09.003. Epub 2022 Sep 10. PMID- 35385829 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 20 IP - 6 DP - 2022 Apr 6 TI - Adjuvant Hormone Therapy-Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis. PG - 683-689.e2 LID - 10.6004/jnccn.2021.7116 [doi] AB - BACKGROUND: Clinical trials have shown that adjuvant hormone therapy (AHT)-related hot flashes can predict better breast cancer outcomes. This population-based cohort study investigated whether this result can be generalized to a real-world setting. PATIENTS AND METHODS: By linking the National Quality Registry for Breast Cancer, Prescribed Drug Register, and Cause-of-Death Register, we identified 7,152 chemotherapy-free patients with breast cancer who initiated AHT in Stockholm from 2006 through 2019, and followed them until 2020. Hot flashes were defined as new use of drugs for hot flashes within 6 months after initiating AHT. We used Cox models to compare disease-free survival and treatment discontinuation among patients with and without hot flashes. RESULTS: Patients who newly used drugs for hot flashes shortly after AHT initiation had worse disease-free survival (adjusted hazard ratio [HR], 1.67; 95% CI, 1.11-2.52) and a higher treatment discontinuation rate (adjusted HR, 1.47; 95% CI, 1.21-1.78). The association between drugs for hot flashes and discontinuation of AHT differed by patient characteristics, with stronger associations among low-income patients (HR, 1.91; 95% CI, 1.41-2.59) and those without first-degree relatives who had cancer (HR, 1.81; 95% CI, 1.39-2.35) or died from cancer (HR, 1.71; 95% CI, 1.37-2.12). CONCLUSIONS: AHT-related hot flashes predict worse, rather than better, breast cancer outcomes among patients in clinical routine practice. The identification of adverse effects by the initiation of hot flash medications may identify a subset of patients with more severe hot flashes who are more likely to discontinue AHT and need more support for treatment adherence. FAU - Zeng, Erwei AU - Zeng E AD - 1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. FAU - He, Wei AU - He W AD - 1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. AD - 2Chronic Disease Research Institute, the Children's Hospital, and. AD - 3Department of Nutrition and Food Hygiene, and National Clinical Research Center for Child Health, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; and. FAU - Smedby, Karin E AU - Smedby KE AD - 4Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. FAU - Czene, Kamila AU - Czene K AD - 1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. LA - eng PT - Journal Article DEP - 20220406 PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 RN - 0 (Hormones) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/complications/drug therapy MH - Cohort Studies MH - Hot Flashes/epidemiology/etiology MH - Chemotherapy, Adjuvant/adverse effects MH - Prognosis MH - Hormones/therapeutic use EDAT- 2022/04/07 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/04/06 20:06 PHST- 2021/09/01 00:00 [received] PHST- 2021/11/29 00:00 [accepted] PHST- 2022/04/07 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/04/06 20:06 [entrez] AID - jnccn21455 [pii] AID - 10.6004/jnccn.2021.7116 [doi] PST - epublish SO - J Natl Compr Canc Netw. 2022 Apr 6;20(6):683-689.e2. doi: 10.6004/jnccn.2021.7116. PMID- 36584059 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230104 IS - 1221-9118 (Print) IS - 1221-9118 (Linking) VI - 117 IP - 6 DP - 2022 Dec TI - Charcoal Localization for Surgical Resection of Non-Palpable Suspicious Breast Lesions. PG - 671-680 LID - 5 [pii] LID - 10.21614/chirurgia.2802 [doi] AB - Background: Breast cancer is more frequently detected as radiographic non-palpable lesions with the increased utilization of national screening programs. Moreover, the sizes of tumors detected have decreased in recent years, increasing the need for accurate image-directed localization for surgical excision in a significant portion of cases. Although Wire guided localization has been the most commonly used method for many years, inherent problems remain and limit its practice. Radio-guided occult lesion localization (ROLL) is currently the standard method of localization, however, it is unavailable in most low resource communities. This encourages us to use charcoal localization which is a simple and cheap method of surgical localization of non-palpable suspicious breast lesions. Methods: This prospective study included 34 patients who presented with non-palpable suspicious breast lesions (BIRADS 4 or 5). All patients were injected 1-3 ml of sterilized 3% aqueous suspension of charcoal granules under the guidance of ultrasound at the superficial border of the suspicious lesion and the track between the lesion and the needle entry point in the skin which will occur at the future incision. This method was carried out in most patients one day before the operation, however, two patients underwent surgical excision after 6 days of localization without any interruption. Results: Thirty-four patients had 36 Lesions. The median age was 43 years. The mean diameter of lesions was 10.9 mm. Of 36 lesions; the BIRADS as follow10 (4a), 12 (4b), 8 (4c), and 6 (5). Postoperative investigations revealed 16 malignant lesions and 20 benign lesions. All 20 benign lesions were managed by wide local excision; All 14 BIRADS 4a lesions were proved to be benign. Sixteen malignant lesions were managed as the following; nine patients had breast-conserving surgery, five patients had modified radical mastectomy (three patients had past history of modified radical mastectomy, one patient had Multicentric IDC and one patient had infiltrated safety margins on conservation), and one patient had Nipple Sparing Mastectomy with immediate breast reconstruction by Latissimus Dorsi Flap. There was no reaction or infection reported in our study. Conclusion: Charcoal localization has many advantages and helps surgical localization. CI - Celsius. FAU - Farouk, Omar AU - Farouk O FAU - Ezzat, Mohamed AU - Ezzat M FAU - El-Badrawy, Adel AU - El-Badrawy A FAU - Fady, Tamer AU - Fady T FAU - El-Kashef, Wagdi AU - El-Kashef W FAU - Shams, Nazem AU - Shams N FAU - Senbel, Ahmed AU - Senbel A LA - eng GR - I 2978/FWF_/Austrian Science Fund FWF/Austria PT - Journal Article PL - Romania TA - Chirurgia (Bucur) JT - Chirurgia (Bucharest, Romania : 1990) JID - 9213031 RN - 16291-96-6 (Charcoal) SB - IM MH - Humans MH - Adult MH - Female MH - *Breast Neoplasms/diagnostic imaging/surgery MH - Mammography/methods MH - Charcoal MH - Prospective Studies MH - Mastectomy MH - Treatment Outcome MH - Mastectomy, Segmental OTO - NOTNLM OT - Charcoallocalization OT - breastcancer OT - breastsurgery OT - lowresourcescommunities OT - non-palpablebreastlesions EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 13:44 PHST- 2022/12/01 00:00 [accepted] PHST- 2022/12/30 13:44 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 5 [pii] AID - 10.21614/chirurgia.2802 [doi] PST - ppublish SO - Chirurgia (Bucur). 2022 Dec;117(6):671-680. doi: 10.21614/chirurgia.2802. PMID- 36602869 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1944-7930 (Electronic) IS - 1539-6509 (Linking) VI - 34 IP - 173 DP - 2022 Nov-Dec TI - Metastatic Pattern of Breast Cancer by Histologic Grade: A SEER Population-based Study. PG - 189-197 AB - Population-based estimates of the differences -in metastatic pattern, incidence, and prognosis of breast cancer patients by histologic grade at breast cancer diagnosis are lacking. Patients with breast cancer and metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Multivariable logistic and Cox regression were performed to determine the effect of histologic grade on the presence of metastases at diagnosis and all-cause mortality. We identified a population-based sample of adult patients diagnosed with invasive breast cancer between 2010 and 2015 for whom the presence or absence of metastases was known. We depicted the landscape of metastatic pattern of breast cancer histologic grade that the percentage of bone metastasis was decreasing with higher histologic grade, while the percentages of lung and brain metastasis were increasing. Higher histologic grade was associated with a greater incidence of all metastatic lesions. Median durations of survival with distant metastasis were 41 months (Grade I), 34 months (Grade II), 21 months (Grade III), 13 months (Grade IV), and 16 months (unknown histologic grade). Grade III and unknown histologic grade represent the most common part of patients with metastatic disease, but not for breast cancer patients without metastasis. In multivariate analysis, Grade II, III, IV, and unknown histologic grade were associated with significantly greater odds of patients with metastatic disease to any distant site, compared with Grade I, but not to bone. Grade III was associated with increased all-cause mortality among patients having metastases to any sites, bone, brain, liver, and lung compared with Grade I, but not Grade II and Grade IV. Breast cancer histologic grades are associated with distinct patterns of metastatic spread and notable differences in survival. FAU - Gao, Chaowei AU - Gao C AD - Department of Breast Surgery, Chongqing University Three Gorges Hospital, Chongqing, 404100, China. FAU - Wang, Jiangen AU - Wang J AD - Department of Breast Surgery, Chongqing University Three Gorges Hospital, Chongqing, 404100, China. FAU - He, Peisheng AU - He P AD - Department of Breast Surgery, Chongqing University Three Gorges Hospital, Chongqing, 404100, China. FAU - Xiong, Xin AU - Xiong X AD - Department of Breast Surgery, Chongqing University Three Gorges Hospital, Chongqing, 404100, China. AD - Corresponding author. LA - eng PT - Journal Article PL - United States TA - Discov Med JT - Discovery medicine JID - 101250006 SB - IM MH - Adult MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Neoplasm Staging MH - Kaplan-Meier Estimate MH - SEER Program MH - Prognosis EDAT- 2023/01/06 06:00 MHDA- 2023/01/10 06:00 CRDT- 2023/01/05 12:03 PHST- 2023/01/05 12:03 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PST - ppublish SO - Discov Med. 2022 Nov-Dec;34(173):189-197. PMID- 36375389 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Real-world data of HER2-low metastatic breast cancer: A population based cohort study. PG - 278-284 LID - S0960-9776(22)00186-2 [pii] LID - 10.1016/j.breast.2022.11.003 [doi] AB - BACKGROUND: With the introduction of investigational human epidermal growth factor receptor 2 (HER2) targeting treatments, thorough understanding of breast cancer with different HER2 expression levels is critical. The aim of this study was to compare clinicopathologic characteristics and survival of patients with metastatic breast cancer according to the level of HER2 expression. METHODS: Women with distant metastatic breast cancer during 2008-2016 were selected from PALGA, the Dutch Pathology Registry, and linked to the PHARMO Database Network. Breast cancer samples were categorised as HER2 immunohistochemistry score 0 (IHC0), HER2-low or HER2+. RESULTS: Among women with hormone receptor (HR) positive metastatic breast cancer (n = 989), 373 (38%) cancers were HER2 IHC0, 472 (48%) were HER2-low and 144 (15%) were HER2+. Among HR negative patients (n = 272), the proportion of HER2 IHC0, HER2-low and HER2+ was 110 (40%), 104 (38%) and 58 (21%) respectively. Within the HR + cohort, patients with HER2 IHC0 or HER2-low cancer were significantly older compared to HER2+ patients. This age difference was not seen in the HR-cohort. The localisation of distant metastases differed significantly between HER2 IHC0 or HER2-low versus HER2+ cases. Survival rates did not differ markedly by subtypes. CONCLUSION: Substantial proportion of patients had a HER2-low breast cancer. No clear differences in survival were found when comparing HER2 and HR status. Getting more granular insights in the level of HER2 expression and addressing HER2-low as a separate category could help to assess the impact of emerging treatment strategies. Therefore, more detailed information on HER2 expression should be routinely reported. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Holthuis, Emily I AU - Holthuis EI AD - PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands. Electronic address: e.holthuis@nki.nl. FAU - Vondeling, Gerard T AU - Vondeling GT AD - University of Groningen, Groningen, Netherlands. FAU - Kuiper, Josephina G AU - Kuiper JG AD - PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands. FAU - Dezentjé, Vincent AU - Dezentjé V AD - The Netherlands Cancer Institute, Amsterdam, the Netherlands. FAU - Rosenlund, Mats AU - Rosenlund M AD - Daiichi-Sankyo Europe GmbH; and Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, Stockholm, Sweden. FAU - Overbeek, Jetty A AU - Overbeek JA AD - PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands. FAU - van Deurzen, Carolien H M AU - van Deurzen CHM AD - Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands. LA - eng PT - Journal Article DEP - 20221110 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Prognosis MH - Cohort Studies MH - Receptor, ErbB-2/metabolism MH - Breast/pathology PMC - PMC9663525 OTO - NOTNLM OT - HER2 status OT - HER2-low OT - Hormone receptor status OT - Metastatic breast cancer EDAT- 2022/11/15 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/14 18:29 PHST- 2022/09/26 00:00 [received] PHST- 2022/11/04 00:00 [revised] PHST- 2022/11/07 00:00 [accepted] PHST- 2022/11/15 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/14 18:29 [entrez] AID - S0960-9776(22)00186-2 [pii] AID - 10.1016/j.breast.2022.11.003 [doi] PST - ppublish SO - Breast. 2022 Dec;66:278-284. doi: 10.1016/j.breast.2022.11.003. Epub 2022 Nov 10. PMID- 36619302 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2022 DP - 2022 TI - Breast Cancer and Arsenic Anticancer Effects: Systematic Review of the Experimental Data from In Vitro Studies. PG - 8030931 LID - 10.1155/2022/8030931 [doi] LID - 8030931 AB - Arsenic is a known environmental carcinogenic agent. However, under certain circumstances, it may exert anticancer effects. In this systematic review, we aim to provide information on recent developments in studies on arsenic antitumor effects in breast cancer. Research included in the review refers to experimental data from in vitro studies. The data was collected using search terms "breast cancer," "arsenic," and "anticancer" (25.05.2021). Only studies in English and published in the last 10 years were included. The search identified 123 studies from the EBSCOhost, PubMed, and Scopus databases. In the selection process, thirty full-texts were evaluated as eligible for the review. The literature of the last decade provides a lot of information on mechanisms behind anticancer effects of arsenic on breast cancer. Similar to arsenic-induced carcinogenesis, these mechanisms include the activation of the redox system and the increased production of free radicals. Targets of arsenic action are systems of cell membranes, mitochondria, pathways of intracellular transmission, and the genetic apparatus of the cell. Beneficial effects of arsenic use are possible due to significant metabolic differences between cancer and healthy cells. Further efforts are needed in order to establish modes and doses of treatment with arsenic that would provide anticancer activity with minimal toxicity. CI - Copyright © 2022 Anna Skoczynska and Marta Skoczynska. FAU - Skoczynska, Anna AU - Skoczynska A AUID- ORCID: 0000-0002-1699-8448 AD - Wrocław Medical University. Department of Internal and Occupational Diseases, Hypertension and Clinical Oncology, Pasteura 1, 50-556 Wrocław, Poland. FAU - Skoczynska, Marta AU - Skoczynska M AD - Lower Silesia Specialist Hospital, Department of Rheumatology and Internal Diseases, Fieldorfa 2, 54-049 Wrocław, Poland. LA - eng PT - Journal Article PT - Review PT - Systematic Review DEP - 20221229 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - N712M78A8G (Arsenic) RN - 0 (Carcinogens) RN - 0 (Free Radicals) SB - IM MH - Humans MH - Female MH - *Arsenic/toxicity MH - *Breast Neoplasms/drug therapy MH - Carcinogenesis MH - Carcinogens/toxicity MH - Free Radicals PMC - PMC9815927 COIS- The authors declare that they have no conflicts of interest. EDAT- 2023/01/10 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/09 03:49 PHST- 2022/06/27 00:00 [received] PHST- 2022/11/17 00:00 [revised] PHST- 2022/12/02 00:00 [accepted] PHST- 2023/01/09 03:49 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - 10.1155/2022/8030931 [doi] PST - epublish SO - Biomed Res Int. 2022 Dec 29;2022:8030931. doi: 10.1155/2022/8030931. eCollection 2022. PMID- 36591651 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230112 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Evaluation of breast cancer metastasis and mortality rates based on molecular subtype: A description study. PG - 427-432 LID - 10.3233/BD-229000 [doi] AB - BACKGROUND: Breast cancer in Indonesia has continued to increase. One diagnostic modality is immunohistochemical examination to determine breast cancer subtypes. OBJECTIVE: To determine breast cancer metastasis and mortality rates based on molecular subtypes. METHODS: A descriptive study was conducted based on retrospective data from hospital medical records from January 2016 to December 2019. The data comprised age, clinical stage, histopathological grade, molecular subtype, location, metastasis, and breast cancer mortality. The data were processed and analyzed. RESULTS: This study involved 172 patients. The most prevalent breast cancer subtypes were luminal A (60, 34.8%), followed by HER2 (47, 27.4%), triple-negative (38, 22.4%), and luminal B (27, 15.4%). The metastasis rate was 37.21% (64/172), with bone the tissue most affected (32 cases, 50%), followed by lung (24 cases, 37.5%) and liver (8 cases, 12.5%). The highest rates of bone, lung, and liver metastases were subtypes luminal A (31%), HER2 (29%), and triple-negative (38%), respectively. The mortality rate was 21% (36/172), with most in the triple-negative group (28.9%), followed by luminal B (25.9%), HER2 (21.2%), and luminal A (13.3%). CONCLUSIONS: Determination of breast cancer molecular subtypes through immunohistochemistry can determine the level of metastasis and mortality in breast cancer. FAU - Kurniawan, Benny Nanda AU - Kurniawan BN AD - Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Ferianto, Djonny AU - Ferianto D AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Pieter, John Jr AU - Pieter J Jr AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. LA - eng PT - Journal Article PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Receptors, Progesterone) SB - IM MH - Female MH - Humans MH - Biomarkers, Tumor/genetics MH - *Breast Neoplasms/genetics/mortality/secondary MH - Prognosis MH - Receptor, ErbB-2 MH - Receptors, Progesterone MH - Retrospective Studies OTO - NOTNLM OT - Breast cancer OT - metastasis OT - molecular subtype OT - mortality EDAT- 2023/01/03 06:00 MHDA- 2023/01/04 06:00 CRDT- 2023/01/02 05:02 PHST- 2023/01/02 05:02 [entrez] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - BD229000 [pii] AID - 10.3233/BD-229000 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):427-432. doi: 10.3233/BD-229000. PMID- 36574048 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230103 IS - 1433-7339 (Electronic) IS - 0941-4355 (Linking) VI - 31 IP - 1 DP - 2022 Dec 27 TI - A systematic review of m-health apps on managing side effects of breast cancer treatment. PG - 86 LID - 10.1007/s00520-022-07464-x [doi] AB - PURPOSE: After breast cancer treatment, women with breast cancer may experience distress caused by treatment side effects, both in physical and psychological aspects. Technology use is increasing in favor among women. Therefore, it is essential to update the scientific evidence regarding mobile and web apps' effectiveness in managing the side effects of breast cancer treatments for breast cancer survivors. The purpose of this systematic review was to investigate the scientific evidence on the effectiveness of mobile and web apps in managing the side effects of breast cancer treatments among this group. METHODS: A literature search was conducted using ScienceDirect, Scopus, PubMed, CINAHL, and Cochrane. Published papers in English focused on mobile and web apps and the side effects of breast cancer treatment in breast cancer survivors were selected. The search reviewed studies from January 2011 to December 2021. From a total of 925 retrieved manuscripts, 11 studies were included for analysis. RESULTS: The findings showed that mobile apps were more frequently used and more likely to be an effective method for managing the side effects of breast cancer treatment among breast cancer survivors. The content in web or mobile apps for breast cancer survivors should include five categories: (1) information about cancer, (2) overview of cancer care, (3) opportunities for interaction with other people, (4) symptom management strategies, and (5) feedback about cancer treatment side effect management. However, a few studies examined the effects of a combination of mobile and web apps in managing breast cancer treatment side effects. Therefore, future research is needed to examine solo and combination use. In addition, more rigorous studies are warranted to examine these interventions. CONCLUSIONS: Nurses may refer survivors to these resources to obtain more information and effectively manage the signs and symptoms of breast cancer and its treatment side effects. CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Wanchai, Ausanee AU - Wanchai A AD - Boromarajonani College of Nursing Buddhachinaraj, Faculty of Nursing, Praboromarajchanok Institute, Phitsanulok, Thailand. ausanee@bcnb.ac.th. FAU - Anderson, Elizabeth A AU - Anderson EA AD - Sinclair School of Nursing, University of Missouri, Columbia, MO, 65211, USA. FAU - Armer, Jane M AU - Armer JM AD - Sinclair School of Nursing, University of Missouri, Columbia, MO, 65211, USA. AD - American Lymphedema Framework Project, Columbia, MO, 65211, USA. LA - eng PT - Journal Article PT - Systematic Review DEP - 20221227 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/psychology MH - *Mobile Applications MH - *Drug-Related Side Effects and Adverse Reactions MH - *Cancer Survivors/psychology MH - *Telemedicine EDAT- 2022/12/28 06:00 MHDA- 2022/12/30 06:00 CRDT- 2022/12/27 11:14 PHST- 2022/08/04 00:00 [received] PHST- 2022/11/12 00:00 [accepted] PHST- 2022/12/27 11:14 [entrez] PHST- 2022/12/28 06:00 [pubmed] PHST- 2022/12/30 06:00 [medline] AID - 10.1007/s00520-022-07464-x [pii] AID - 10.1007/s00520-022-07464-x [doi] PST - epublish SO - Support Care Cancer. 2022 Dec 27;31(1):86. doi: 10.1007/s00520-022-07464-x. PMID- 36413823 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20221230 IS - 1744-7658 (Electronic) IS - 1354-3784 (Linking) VI - 31 IP - 11 DP - 2022 Nov TI - The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. PG - 1203-1226 LID - 10.1080/13543784.2022.2151433 [doi] AB - INTRODUCTION: Triple-negative breast cancer (TNBC) accounts for 15-20% of breast cancers (BC) and has the worst prognosis. It is characterized by the absence of both hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2). TNBC has more limited therapeutic options compared to other subtypes, meaning that there is still a long way to go to discover target treatments. AREAS COVERED: Our review aims to summarize phase II/III clinical trials enrolling patients with TNBC that have been published between 2017 and 2022 but failed to reach their primary endpoint. We here try to emphasize the limitations and weaknesses noted in negative studies and to point out unexpected results which might be useful to enhance the therapeutic approach to TNBC disease. EXPERT OPINION: A deeper understanding of the mechanisms behind TNBC heterogeneity allowed to enhance the knowledge of new prognostic and predictive biomarkers of response. However, it is also through several failed clinical trials that we were able to define new therapeutic approaches which improved TNBC patients' clinical outcomes. Nowadays, we still need to overcome several difficulties to fully recognize different intracellular and extracellular pathways that crosstalk in TNBC and the mechanisms of resistance to identify novel tailored-patients' therapies. FAU - Taurelli Salimbeni, Beatrice AU - Taurelli Salimbeni B AUID- ORCID: 0000-0002-7345-4148 AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Irccs, Milan, Italy. AD - Department of Clinical and Molecular Medicine, Oncology Unit, "la Sapienza" University of Rome, Azienda Ospedaliera Sant'Andrea, Rome, Italy. FAU - Corvaja, Carla AU - Corvaja C AUID- ORCID: 0000-0002-2535-7538 AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Irccs, Milan, Italy. AD - Department of Medicine, University of Udine, Udine, Italy. FAU - Valenza, Carmine AU - Valenza C AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Irccs, Milan, Italy. AD - Department of Oncology and Haematology, University of Milan, Milan, Italy. FAU - Zagami, Paola AU - Zagami P AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Irccs, Milan, Italy. AD - Department of Oncology and Haematology, University of Milan, Milan, Italy. AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Curigliano, Giuseppe AU - Curigliano G AUID- ORCID: 0000-0003-1781-2518 AD - Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Irccs, Milan, Italy. AD - Department of Oncology and Haematology, University of Milan, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20221222 PL - England TA - Expert Opin Investig Drugs JT - Expert opinion on investigational drugs JID - 9434197 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Biomarkers, Tumor/metabolism MH - Cemeteries MH - Prognosis MH - *Triple Negative Breast Neoplasms/drug therapy MH - Precision Medicine MH - Clinical Trials as Topic OTO - NOTNLM OT - combined treatments OT - failed clinical trials OT - targeted therapy OT - triple-negative breast cancer EDAT- 2022/11/23 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/22 18:14 PHST- 2022/11/23 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/22 18:14 [entrez] AID - 10.1080/13543784.2022.2151433 [doi] PST - ppublish SO - Expert Opin Investig Drugs. 2022 Nov;31(11):1203-1226. doi: 10.1080/13543784.2022.2151433. Epub 2022 Dec 22. PMID- 36547132 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230112 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 29 IP - 12 DP - 2022 Nov 25 TI - Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis. PG - 9172-9180 LID - 10.3390/curroncol29120718 [doi] AB - To identify the advantageous therapy as the first-line treatment for patients with triple-negative breast cancer (TNBC). Randomized controlled trials were searched for on Medline, Embase, ClinicalTrials.gov, and the Cochrane Library between January 2001 and December 2021. The primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival (OS) and treatment-related adverse events (TRAEs). A Bayesian framework was applied to facilitate indirect comparisons, of which the outcomes were presented using cumulative ranking curve (SUCRA) values, synthesized hazard ratio, risk ratio, and 95% credible interval. A total of 3140 patients were identified. Pooled results of PFS revealed that chemotherapy plus AKT inhibitors (AKTi) was likely the most effective therapy among enrolled therapies (SUCRA = 91.6%), of which the result remained consistent in comparative analysis for OS. In addition, no significant difference was detected between PD-1/PD-L1 antibodies in patients, whereas the PD-1 inhibitors (PD-1i) regimen was advantageous over PD-L1 inhibitor (PD-L1i) therapy for PD-L1 positive TNBC. Concerning TRAEs, an apparent heterogeneity associated with safety profiles were denoted among enrolled agents. Chemotherapy plus AKTi was the most effective therapy with comparable safety profiles. Chemotherapy plus the anti-PD-1 regimen was advantageous over the combination therapy based on the PD-L1 blockade. FAU - Han, Yiqun AU - Han Y AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. FAU - Wang, Jiayu AU - Wang J AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. FAU - Wu, Yun AU - Wu Y AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. FAU - Xu, Hangcheng AU - Xu H AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. FAU - Wang, Yan AU - Wang Y AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. FAU - Xu, Binghe AU - Xu B AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20221125 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (B7-H1 Antigen) RN - 0 (Angiogenesis Inhibitors) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/drug therapy MH - B7-H1 Antigen MH - Network Meta-Analysis MH - Bayes Theorem MH - Progression-Free Survival MH - Angiogenesis Inhibitors/therapeutic use PMC - PMC9777258 OTO - NOTNLM OT - first-line OT - metastases OT - network meta-analysis OT - therapy OT - triple-negative breast cancer COIS- The authors declare no conflict of interest. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 09:54 PHST- 2022/10/15 00:00 [received] PHST- 2022/11/15 00:00 [revised] PHST- 2022/11/21 00:00 [accepted] PHST- 2022/12/22 09:54 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - curroncol29120718 [pii] AID - curroncol-29-00718 [pii] AID - 10.3390/curroncol29120718 [doi] PST - epublish SO - Curr Oncol. 2022 Nov 25;29(12):9172-9180. doi: 10.3390/curroncol29120718. PMID- 36577919 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230121 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Dec 28 TI - Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer. PG - 22498 LID - 10.1038/s41598-022-27093-y [doi] LID - 22498 AB - Limited data exist regarding the associations between TROP-2 protein expression, clinical-pathological characteristics, and outcome in triple-negative breast cancer (TNBC). TROP-2 expression was determined for patients diagnosed with TNBC between 2000 and 2017 by immunohistochemistry (IHC) (ab227689, Abcam) on whole slide tumor sections, and assessed as continuous and categorical variables (H-score high, 201-300, medium 100-200 and low < 100). We investigated the prognostic value of TROP-2 expression for relapse and survival, associations between TROP-2 expression and baseline patient and tumor characteristics, stromal tumor-infiltrating lymphocytes (sTILs), androgen receptor (AR), standardized mitotic index (SMI) and pathological complete response (pCR, in patients with neoadjuvant chemotherapy) were assessed. We included 685 patients with a median age at diagnosis of 54 years (range 22-90 years). After median follow-up of 9.6 years, 17.5% of patients experienced distant relapse. TROP-2 expression was high, medium and low in 97 (16.5%), 149 (25.3%) and 343 (58.2%) of patients, respectively. The presence of LVI, associated DCIS, nodal involvement, apocrine histology and AR expression were correlated with higher TROP-2 levels. There were no associations between TROP-2 expression and sTILs, time-to-event outcomes, or pCR rate after neoadjuvant chemotherapy. TROP-2 expression is not associated with sTILs level and has no prognostic value in our cohort of stage 1-3 TNBC. However, an association with histotype and AR expression was found, suggesting a histotype specific TROP-2 expression pattern with highest expression in apocrine subtype, warranting further research. CI - © 2022. The Author(s). FAU - Izci, Hava AU - Izci H AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. hava.izci@kuleuven.be. FAU - Punie, Kevin AU - Punie K AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. AD - Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. FAU - Waumans, Lise AU - Waumans L AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. AD - Department of Imaging & Pathology, University Hospitals Leuven, Leuven, Belgium. FAU - Laenen, Annouschka AU - Laenen A AD - Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium. FAU - Wildiers, Hans AU - Wildiers H AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. AD - Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. FAU - Verdoodt, Freija AU - Verdoodt F AD - Research Department, Belgian Cancer Registry, Brussels, Belgium. FAU - Desmedt, Christine AU - Desmedt C AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. FAU - Ardui, Jan AU - Ardui J AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. FAU - Smeets, Ann AU - Smeets A AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. AD - Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium. FAU - Han, Sileny N AU - Han SN AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. AD - Department of Gynecological Oncology, University Hospitals Leuven, Leuven, Belgium. FAU - Nevelsteen, Ines AU - Nevelsteen I AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. AD - Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium. FAU - Neven, Patrick AU - Neven P AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. AD - Department of Gynecological Oncology, University Hospitals Leuven, Leuven, Belgium. FAU - Floris, Giuseppe AU - Floris G AD - Department of Oncology, KU Leuven, Herestraat 49, Box 7003-06, 3000, Leuven, Belgium. AD - Department of Imaging & Pathology, University Hospitals Leuven, Leuven, Belgium. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221228 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Young Adult MH - Adult MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - *Triple Negative Breast Neoplasms/metabolism MH - Neoplasm Recurrence, Local/pathology MH - Prognosis MH - Lymphocytes, Tumor-Infiltrating/pathology MH - Gene Expression MH - Neoadjuvant Therapy MH - Biomarkers, Tumor/metabolism PMC - PMC9797547 COIS- The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: K.P.’s institution received speaker fees, honoraria for advisory/consultancy roles and/or research funding from AstraZeneca, Eli Lilly, Gilead Sciences, Medscape, MSD, Mundi Pharma, Novartis, Pfizer, Pierre Fabre, Hoffmann/La Roche, Sanofi, Teva, Vifor Pharma. K.P. received travel support from AstraZeneca, Novartis, Pfizer, PharmaMar, Hoffmann/La Roche. K.P. received speaker fees and honoraria for advisory/consultancy roles from AstraZeneca, Gilead Sciences, Novartis, Roche and Seattle Genetics (all outside the submitted work). H.W.’s institution received speaker fees, honoraria for advisory/consultancy roles and/or research funding from AstraZeneca, Daiichi Sankyo/Lily, Lilly, PSI, KCE, Immutep Pty, MSD, AstraZeneca Pharmaceuticals Ireland, CRO, Daiichi Sankyo, Lilly, Roche, and Daiichi Sankyo. Travel support from Pfizer and Roche, and honoraria from Eisai, AstraZeneca and MSD. P.N.’s institution received speaker fees, honoraria for advisory/consultancy roles and/or research funding from Lilly, Novartis, Pfizer, Radius Health and Roche. Travel support from Lilly, Pfizer and Roche. EDAT- 2022/12/29 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/12/28 23:34 PHST- 2022/06/28 00:00 [received] PHST- 2022/12/26 00:00 [accepted] PHST- 2022/12/28 23:34 [entrez] PHST- 2022/12/29 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] AID - 10.1038/s41598-022-27093-y [pii] AID - 27093 [pii] AID - 10.1038/s41598-022-27093-y [doi] PST - epublish SO - Sci Rep. 2022 Dec 28;12(1):22498. doi: 10.1038/s41598-022-27093-y. PMID- 36537474 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230119 IS - 1097-0142 (Electronic) IS - 0008-543X (Linking) VI - 129 IP - 4 DP - 2023 Feb 15 TI - Neurologic complications of breast cancer. PG - 505-520 LID - 10.1002/cncr.34518 [doi] AB - Breast cancer is a heterogeneous disease with unique neurologic complications that can arise from central nervous system (CNS) involvement or secondary to treatments themselves. As progress is made, with more targeted therapies and combinations available, particularly in the realm of human epidermal growth factor receptor 2 (HER2)-positive disease, the role of these new agents in patients with CNS disease is gradually evolving, although intracranial efficacy itself is lagging. At the same time, both systemic and local standard therapies pose clinical challenges regarding neurologic complications, such as peripheral neuropathy and cognitive changes. The development of new agents, such as immunotherapy, and new strategies, such as incorporating systemic therapies into local therapy, unveil new presentations of neurological complications. CI - © 2022 American Cancer Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA. FAU - Atkins, Sarah L P AU - Atkins SLP AUID- ORCID: 0000-0002-8937-7431 AD - Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. FAU - Zimmer, Alexandra S AU - Zimmer AS AUID- ORCID: 0000-0001-6789-0982 AD - Hematology and Medical Oncology Division, Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon, USA. LA - eng PT - Journal Article PT - Review DEP - 20221220 PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/drug therapy MH - *Nervous System Diseases/etiology MH - Receptor, ErbB-2/metabolism MH - *Peripheral Nervous System Diseases/etiology OTO - NOTNLM OT - brain neoplasms OT - breast cancer OT - breast neoplasms OT - central nervous system diseases OT - peripheral nervous system diseases OT - peripheral neuropathy EDAT- 2022/12/21 06:00 MHDA- 2023/01/20 06:00 CRDT- 2022/12/20 06:23 PHST- 2022/08/14 00:00 [revised] PHST- 2022/06/01 00:00 [received] PHST- 2022/08/22 00:00 [accepted] PHST- 2022/12/21 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/12/20 06:23 [entrez] AID - 10.1002/cncr.34518 [doi] PST - ppublish SO - Cancer. 2023 Feb 15;129(4):505-520. doi: 10.1002/cncr.34518. Epub 2022 Dec 20. PMID- 36565097 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20221230 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Fibroadenoma of the breast; incidence of malignancy and indicators for surgical intervention: An analysis of 1392 patients. PG - 421-426 LID - 10.3233/BD-210074 [doi] AB - BACKGROUND: Fibroadenomas are common among young females. The size of the lesion used to be an indication for further assessment or excision. With arising of the watch and see proponents, criteria for selecting patients are important to establish. METHODS: This is a retrospective study of a prospectively maintained database where all patients having the clinical/radiological provisional diagnosis of fibroadenoma and attending our center - from January 2008 to March 2020 - were enrolled. The primary outcome was the incidence of malignancy and the secondary outcomes were the correlation of malignancy-risk with epidemiologic and radiologic criteria. RESULTS: The study enrolled 1392 patients. The mean age of the patients was 35.7 + ∕- 13.1 years. The median of the longest diameter of the detected breast lesions was 25 mm. The incidence of malignancy was 188 (13.5%). The size of the lesion measured by largest diameter was insignificant (p = 0.99), while the patients' age, marital status, and imaging criteria as measured by BIRADS score were significant (<0.001). CONCLUSION: Approaching patients with the age above 35 or with BIRADS 4 provisionally diagnosed with fibroadenomas should be cautious with biopsy and short-term follow-ups The size of the tumor alone should not be used as an indication for surgical intervention. FAU - Elnahas, Waleed AU - Elnahas W AD - Surgical Oncology Unit, Oncology Center Mansoura University (OCMU), Mansoura, Egypt. FAU - Metwally, Islam H AU - Metwally IH AD - Surgical Oncology Unit, Oncology Center Mansoura University (OCMU), Mansoura, Egypt. FAU - Bonna, Khaled AU - Bonna K AD - Surgical Oncology Unit, Oncology Center Mansoura University (OCMU), Mansoura, Egypt. FAU - Youssef, Marco AU - Youssef M AD - Surgical Oncology Unit, Oncology Center Mansoura University (OCMU), Mansoura, Egypt. FAU - AbdAllah, Samar AU - AbdAllah S AD - Surgical Oncology Unit, Oncology Center Mansoura University (OCMU), Mansoura, Egypt. FAU - Bonna, Mohamed AU - Bonna M AD - Medical Students, Mansoura University Faculty of Medicine, Mansoura, Egypt. FAU - Ali Faried, Mohamed AU - Ali Faried M AD - Medical Students, Mansoura University Faculty of Medicine, Mansoura, Egypt. FAU - Atef Tira, Mohamed AU - Atef Tira M AD - Medical Students, Mansoura University Faculty of Medicine, Mansoura, Egypt. FAU - Hamdy, Omar AU - Hamdy O AD - Surgical Oncology Unit, Oncology Center Mansoura University (OCMU), Mansoura, Egypt. LA - eng PT - Journal Article PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 SB - IM MH - Female MH - Humans MH - Young Adult MH - Adult MH - Middle Aged MH - *Breast Neoplasms/epidemiology/surgery/diagnosis MH - *Fibroadenoma/diagnosis/epidemiology/surgery MH - Incidence MH - Retrospective Studies MH - Breast/diagnostic imaging/surgery/pathology MH - *Phyllodes Tumor/pathology OTO - NOTNLM OT - Breast lump OT - breast cancer OT - fibroepithelial tumor OT - phyllodes tumor EDAT- 2022/12/25 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/24 04:23 PHST- 2022/12/24 04:23 [entrez] PHST- 2022/12/25 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - BD210074 [pii] AID - 10.3233/BD-210074 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):421-426. doi: 10.3233/BD-210074. PMID- 36564734 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1471-2342 (Electronic) IS - 1471-2342 (Linking) VI - 22 IP - 1 DP - 2022 Dec 23 TI - A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer. PG - 225 LID - 10.1186/s12880-022-00956-6 [doi] LID - 225 AB - BACKGROUND: Medical image analysis has evolved to facilitate the development of methods for high-throughput extraction of quantitative features that can potentially contribute to the diagnostic and treatment paradigm of cancer. There is a need for further improvement in the accuracy of predictive markers of response to neo-adjuvant chemotherapy (NAC). The aim of this study was to develop a radiomic classifier to enhance current approaches to predicting the response to NAC breast cancer. METHODS: Data on patients treated for breast cancer with NAC prior to surgery who had a pre-NAC dynamic contrast enhanced breast MRI were included. Response to NAC was assessed using the Miller-Payne system on the excised tumor. Tumor segmentation was carried out manually under the supervision of a consultant breast radiologist. Features were selected using least absolute shrinkage selection operator regression. A support vector machine learning model was used to classify response to NAC. RESULTS: 74 patients were included. Patients were classified as having a poor response to NAC (reduction in cellularity < 90%, n = 44) and an excellent response (> 90% reduction in cellularity, n = 30). 4 radiomics features (discretized kurtosis, NGDLM contrast, GLZLM_SZE and GLZLM_ZP) were identified as pertinent predictors of response to NAC. A SVM model using these features stratified patients into poor and excellent response groups producing an AUC of 0.75. Addition of estrogen receptor status improved the accuracy of the model with an AUC of 0.811. CONCLUSION: This study identified a radiomic classifier incorporating 4 radiomics features to augment subtype based classification of response to NAC in breast cancer. CI - © 2022. The Author(s). FAU - McAnena, Peter AU - McAnena P AUID- ORCID: 0000-0003-1179-7150 AD - Department of Surgery, Clinical Sciences Institute, University Hospital Galway, Galway, Ireland. pmcanuig@gmail.com. FAU - Moloney, Brian M AU - Moloney BM AD - Department of Radiology, University Hospital Galway, Galway, Ireland. FAU - Browne, Robert AU - Browne R AD - Department of Surgery, Clinical Sciences Institute, University Hospital Galway, Galway, Ireland. FAU - O'Halloran, Niamh AU - O'Halloran N AD - Department of Radiology, University Hospital Galway, Galway, Ireland. FAU - Walsh, Leon AU - Walsh L AD - Department of Radiology, University Hospital Galway, Galway, Ireland. FAU - Walsh, Sinead AU - Walsh S AD - Department of Radiology, University Hospital Galway, Galway, Ireland. FAU - Sheppard, Declan AU - Sheppard D AD - Department of Radiology, University Hospital Galway, Galway, Ireland. FAU - Sweeney, Karl J AU - Sweeney KJ AD - Department of Surgery, Clinical Sciences Institute, University Hospital Galway, Galway, Ireland. FAU - Kerin, Michael J AU - Kerin MJ AD - Department of Surgery, Clinical Sciences Institute, University Hospital Galway, Galway, Ireland. AD - Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland. FAU - Lowery, Aoife J AU - Lowery AJ AD - Department of Surgery, Clinical Sciences Institute, University Hospital Galway, Galway, Ireland. AD - Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland. LA - eng PT - Journal Article DEP - 20221223 PL - England TA - BMC Med Imaging JT - BMC medical imaging JID - 100968553 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - Neoadjuvant Therapy/methods MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Breast/diagnostic imaging/surgery/pathology MH - Magnetic Resonance Imaging/methods MH - Retrospective Studies PMC - PMC9789647 OTO - NOTNLM OT - Biomarker OT - Breast cancer OT - MRI OT - Neoadjuvant chemotherapy OT - Radiomics COIS- We disclose no conflict of interest and none of the authors are/ have been employed or consulted to companies in the medical industry. EDAT- 2022/12/24 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/23 23:47 PHST- 2021/10/13 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2022/12/23 23:47 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - 10.1186/s12880-022-00956-6 [pii] AID - 956 [pii] AID - 10.1186/s12880-022-00956-6 [doi] PST - epublish SO - BMC Med Imaging. 2022 Dec 23;22(1):225. doi: 10.1186/s12880-022-00956-6. PMID- 36581908 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230106 IS - 1465-542X (Electronic) IS - 1465-5411 (Print) IS - 1465-5411 (Linking) VI - 24 IP - 1 DP - 2022 Dec 29 TI - SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. PG - 99 LID - 10.1186/s13058-022-01596-y [doi] LID - 99 AB - Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor tyrosine kinase (nRTK) family, which has eleven members sharing similar structure and function. Among them, SRC is the first identified proto-oncogene in mammalian cells. Oncogenic overexpression or activation of SRC has been revealed to play essential roles in multiple events of BC progression, including tumor initiation, growth, metastasis, drug resistance and stemness regulations. In this review, we will first give an overview of SRC kinase and SRC-relevant functions in various subtypes of BC and then systematically summarize SRC-mediated signaling transductions, with particular emphasis on SRC-mediated substrate phosphorylation in BC. Furthermore, we will discuss the progress of SRC-based targeted therapies in BC and the potential future direction. CI - © 2022. The Author(s). FAU - Luo, Juan AU - Luo J AD - Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Zou, Hailin AU - Zou H AD - Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Guo, Yibo AU - Guo Y AD - Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Tong, Tongyu AU - Tong T AD - Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. AD - Department of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Ye, Liping AU - Ye L AD - Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Zhu, Chengming AU - Zhu C AD - Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Deng, Liang AU - Deng L AD - Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Wang, Bo AU - Wang B AD - Department of Oncology, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Pan, Yihang AU - Pan Y AD - Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. AD - Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. FAU - Li, Peng AU - Li P AD - Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. lipeng56@mail.sysu.edu.cn. AD - Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China. lipeng56@mail.sysu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20221229 PL - England TA - Breast Cancer Res JT - Breast cancer research : BCR JID - 100927353 RN - EC 2.7.10.2 (src-Family Kinases) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy/genetics MH - Phosphorylation MH - Signal Transduction MH - *src-Family Kinases/genetics/metabolism PMC - PMC9798727 OTO - NOTNLM OT - Breast cancer OT - SRC kinase OT - Signaling transduction OT - Targeted therapy OT - Tyrosine phosphorylation COIS- The authors declare no conflicts of interest. EDAT- 2022/12/30 06:00 MHDA- 2023/01/03 06:00 CRDT- 2022/12/29 23:41 PHST- 2022/09/19 00:00 [received] PHST- 2022/12/17 00:00 [accepted] PHST- 2022/12/29 23:41 [entrez] PHST- 2022/12/30 06:00 [pubmed] PHST- 2023/01/03 06:00 [medline] AID - 10.1186/s13058-022-01596-y [pii] AID - 1596 [pii] AID - 10.1186/s13058-022-01596-y [doi] PST - epublish SO - Breast Cancer Res. 2022 Dec 29;24(1):99. doi: 10.1186/s13058-022-01596-y. PMID- 36617275 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 2239-253X (Electronic) IS - 0003-469X (Linking) VI - 93 DP - 2022 TI - Comparison of PET-CT and MRI for evaluation of axillary lymph nodes in early breast cancer patients. PG - 648-655 LID - S0003469X22037794 [pii] AB - BACKGROUND: Evaluation of axillary lymph node in women with breast cancer is very important as it can change the initial treatment decision. None of the noninvasive methods used for assessment of axilla is accurate as sentinel lymph node biopsy (SLNB) yet. This study compared the diagnostic performance of 18-fluorodeoxyglucose positron emission tomography/ computed tomography (PET-CT) and Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in preoperative axillary evaluation of women diagnosed with early breast cancer (EBC). METHODS: The records of 1246 patients operated for EBC between 2016-2019 were analyzed retrospectively. Pathological evaluations of axillary lymph nodes and the data of these two imaging modalities were analyzed. RESULTS: Forty patients operated for EBC had both DCE-MRI and PET-CT. Axillary metastasis were detected in 12 patients (27.5%). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of DCE-MRI/ PET-CT for determining axillary lymph node metastases were 25/66.6%, 75/67.8%, 30/47%, 70/82.6%, and 60/67.5%, respectively. DISCUSSION: Any method has yet reached the performance of sentinel lymph node biopsy in the axillary mapping of patients with EBC. If a clinically EBC patient is suspected of axillary involvement in DCE-MRI or PET-CT (since have low PPV and sensitivity), a biopsy should be performed. KEY WORDS: Breast Cancer, Magnetic Resonance Imaging, Positron Emission Tomography, Staging. FAU - Dulgeroglu, Onur AU - Dulgeroglu O FAU - Arikan, Akif Enes AU - Arikan AE FAU - Capkinoglu, Emir AU - Capkinoglu E FAU - Kara, Halil AU - Kara H FAU - Uras, Cihan AU - Uras C LA - eng PT - Journal Article PL - Italy TA - Ann Ital Chir JT - Annali italiani di chirurgia JID - 0372343 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/surgery MH - Positron Emission Tomography Computed Tomography MH - Axilla/pathology MH - Retrospective Studies MH - Sensitivity and Specificity MH - Lymph Nodes/diagnostic imaging/pathology MH - Sentinel Lymph Node Biopsy MH - Magnetic Resonance Imaging/methods MH - Fluorodeoxyglucose F18 MH - Lymphatic Metastasis/diagnostic imaging/pathology MH - Neoplasm Staging EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 04:03 PHST- 2023/01/08 04:03 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - S0003469X22037794 [pii] PST - ppublish SO - Ann Ital Chir. 2022;93:648-655. PMID- 36137495 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer? PG - 49-53 LID - S0960-9776(22)00147-3 [pii] LID - 10.1016/j.breast.2022.09.002 [doi] AB - The 21-gene recurrence score assay has been validated as a predictive biomarker in early-stage HR+ and HER2-breast cancer. It is not indicated for use in HER2+ disease based on national guidelines. In this study, we assessed the value of 21-gene recurrence score (RS), or OncotypeDX (ODX), testing in HR+/HER2+ breast cancer. We used the National Cancer Database to identify patients with stages I-II, HR+/HER2+ breast cancer who received multi-gene testing with ODX. We then explored the prognostic and predictive value of this biomarker through various forms of survival modeling. ODX testing was performed in n = 5,280 patients. N = 2,678 patients (50.7%) had a RS < 26, while n = 2,602 (49.3%) had a RS ≥26. In Kaplan-Meier survival modeling for patients with recurrence scores <26, there was no significant difference in overall survival (p = 0.445) between patients receiving different systemic treatment regimens. However, when recurrence scores were ≥26, there was a statistically-significant difference in overall survival between systemic treatment regimens (p < 0.001). 5-year overall survival was highest (97.4%) for patients receiving triple therapy (anti-HER2 with chemotherapy and endocrine therapy), followed by those receiving dual therapy with endocrine and anti-HER2 (96.7%), and endocrine with chemotherapy (94.9%). Patients receiving endocrine therapy alone exhibited the lowest 5-year overall survival (88.5%). RESULTS: Analysis from this large national cancer registry suggests that multigene testing may have predictive value in treatment selection for patients with early-stage, HR+/HER2+ breast cancer. Prospective trials are warranted to identify subgroups of patients with HR+/HER2+ breast cancer who can be spared anti-HER2 treatments and cytotoxic chemotherapy. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Bilani, Nadeem AU - Bilani N AD - Department of Internal Medicine, Icahn School of Medicine at Mount Sinai Morningside-West, New York, NY, 10029, USA. Electronic address: nadeem.bilani@mountsinai.org. FAU - Crowley, Fionnuala AU - Crowley F AD - Department of Internal Medicine, Icahn School of Medicine at Mount Sinai Morningside-West, New York, NY, 10029, USA. FAU - Mohanna, Mohamed AU - Mohanna M AD - Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA. FAU - Itani, Mira AU - Itani M AD - Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA. FAU - Yaghi, Marita AU - Yaghi M AD - Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA. FAU - Saravia, Diana AU - Saravia D AD - Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA. FAU - Jabbal, Iktej AU - Jabbal I AD - Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA. FAU - Dominguez, Barbara AU - Dominguez B AD - Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA. FAU - Liang, Hong AU - Liang H AD - Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA. FAU - Nahleh, Zeina AU - Nahleh Z AD - Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, 33331, USA. LA - eng PT - Journal Article DEP - 20220906 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics MH - Receptor, ErbB-2/genetics/analysis MH - Biomarkers, Tumor/genetics/analysis MH - Prospective Studies MH - Prognosis MH - Neoplasm Recurrence, Local/genetics/drug therapy MH - Chemotherapy, Adjuvant PMC - PMC9493134 COIS- Declaration of competing interest The authors declare no competing financial or non-financial interests. EDAT- 2022/09/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/09/22 18:28 PHST- 2022/07/11 00:00 [received] PHST- 2022/08/27 00:00 [revised] PHST- 2022/09/05 00:00 [accepted] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/09/22 18:28 [entrez] AID - S0960-9776(22)00147-3 [pii] AID - 10.1016/j.breast.2022.09.002 [doi] PST - ppublish SO - Breast. 2022 Dec;66:49-53. doi: 10.1016/j.breast.2022.09.002. Epub 2022 Sep 6. PMID- 36647948 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 18 IP - 7 DP - 2022 Dec TI - Analysis of risk factors related to acute radiation dermatitis in breast cancer patients during radiotherapy. PG - 1903-1909 LID - 10.4103/jcrt.jcrt_1203_22 [doi] AB - AIMS: To investigate the incidence and influencing factors of acute radiation dermatitis (ARD) induced by radiotherapy in postoperative patients with breast cancer. METHODS AND MATERIALS: A retrospective analysis was conducted on 598 patients with breast cancer who received postoperative radiotherapy from November 18, 2014 to September 14, 2019. The radiotherapy technology included two-dimensional radiotherapy, three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and tomotherapy. The occurrence of ARD in patients was then followed up and recorded. The independent risk factors for radiation-induced dermatitis were analyzed by using an orderly logistic regression model. RESULTS: Of the 598 patients, 431 had mild skin reactions, including pigmentation and dry desquamation (grade 1), 151 developed wet desquamation and tender erythema (grade 2), and 16 had severe skin reactions, including flaky wet scaling and erosion (grade 3). There were no grade 4 skin reactions. The severity of ARD was independent of the following factors: Age, diabetes, allergy, quadrant, pathological type, the clinical stage, the tumor stage, triple-negative breast cancer, ki-67 expression, adjuvant chemotherapy, endocrine therapy, targeted therapy, radiotherapy area, and boost irradiation. However, it was found to be dependent on the body mass index, surgery type, radiotherapy technique, node stage, and the prophylactic use of topical agents. CONCLUSIONS: ARD in response to postoperative radiotherapy in patients with breast cancer is common and mild. Clinicians and patients need to cultivate awareness of the potential risk factors involved and then intervene to alleviate skin reactions and improve the quality of life. FAU - Liu, Di AU - Liu D AD - Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan Province; Hubei Key Laboratory of Tumour Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China. FAU - Zheng, Zhewen AU - Zheng Z AD - Hubei Key Laboratory of Tumour Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China. FAU - Zhang, Shuyuan AU - Zhang S AD - Hubei Key Laboratory of Tumour Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China. FAU - Zhu, Chunmei AU - Zhu C AD - Hubei Key Laboratory of Tumour Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China. FAU - Zhang, Hongyan AU - Zhang H AD - Department of Radiation and Medical Oncology; Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China. FAU - Zhou, Yunfeng AU - Zhou Y AD - Department of Radiation and Medical Oncology; Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China. LA - eng PT - Journal Article PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 SB - IM MH - Humans MH - Female MH - *Radiodermatitis/etiology/prevention & control MH - *Breast Neoplasms/radiotherapy/surgery/pathology MH - Retrospective Studies MH - Quality of Life MH - *Radiotherapy, Intensity-Modulated/adverse effects MH - Risk Factors MH - Radiotherapy, Adjuvant/adverse effects OTO - NOTNLM OT - Acute radiation dermatitis OT - breast cancer OT - factor analysis OT - radiotherapy COIS- None EDAT- 2023/01/18 06:00 MHDA- 2023/01/19 06:00 CRDT- 2023/01/17 06:30 PHST- 2023/01/17 06:30 [entrez] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] AID - JCanResTher_2022_18_7_1903_367455 [pii] AID - 10.4103/jcrt.jcrt_1203_22 [doi] PST - ppublish SO - J Cancer Res Ther. 2022 Dec;18(7):1903-1909. doi: 10.4103/jcrt.jcrt_1203_22. PMID- 36121313 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230112 IS - 1745-4514 (Electronic) IS - 0145-8884 (Linking) VI - 46 IP - 12 DP - 2022 Dec TI - Role of Medicinal plant-derived Nutraceuticals as a potential target for the treatment of breast cancer. PG - e14387 LID - 10.1111/jfbc.14387 [doi] AB - Breast cancer (BC) is one of the most challenging cancers to treat, accounting for many cancer-related deaths. Over some years, chemotherapy, hormone treatment, radiation, and surgeries have been used to treat cancer. Unfortunately, these treatment options are unsuccessful due to crucial adverse reactions and multidrug tolerance/resistance. Although it is clear that substances in the nutraceuticals category have a lot of anti-cancer activity, using a supplementary therapy strategy, in this case, could be very beneficial. Nutraceuticals are therapeutic agents, which are nutrients that have drug-like characteristics and can be used to treat diseases. Plant nutraceuticals categorized into polyphenols, terpenoids, vitamins, alkaloids, and flavonoids are part of health food products, that have great potential for combating BC. Nutraceuticals can reduce BC's severity, limit malignant cell growth, and modify cancer-related mechanisms. Nutraceuticals acting by attenuating Hedgehog, Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), Notch, and Wnt/β-catenin signaling are the main pathways in controlling the self-renewal of breast cancer stem cells (BCSCs). This article reviews some important nutraceuticals and their modes of action, which can be very powerful versus BC. PRACTICAL APPLICATIONS: Nutraceuticals' importance to the control and diagnosis of breast cancer is undeniable and cannot be overlooked. Natural dietary compounds have a wide range of uses and have been used in traditional medicine. In addition, these natural chemicals can enhance the effectiveness of other traditional medicines. They may also be used as a treatment process independently because of their capacity to affect several cancer pathways. This study highlights a variety of natural chemicals, and their mechanisms of action, routes, synergistic effects, and future potentials are all examined. CI - © 2022 The Authors. Journal of Food Biochemistry published by Wiley Periodicals LLC. FAU - Alharbi, Khalid Saad AU - Alharbi KS AD - Department of Pharmacology, College of Pharmacy, Jouf University, Al-Jouf, Saudi Arabia. FAU - Almalki, Waleed Hassan AU - Almalki WH AUID- ORCID: 0000-0003-2584-8510 AD - Department of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. FAU - Makeen, Hafiz A AU - Makeen HA AD - Pharmacy Practice Research Unit, Clinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan, Saudi Arabia. FAU - Albratty, Mohammed AU - Albratty M AD - Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia. FAU - Meraya, Abdulkarim M AU - Meraya AM AD - Pharmacy Practice Research Unit, Clinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan, Saudi Arabia. FAU - Nagraik, Rupak AU - Nagraik R AD - School of Bioengineering and Food Technology, Faculty of Applied Sciences and Biotechnology, Shoolini University, Solan, Himachal Pradesh, India. FAU - Sharma, Avinash AU - Sharma A AD - School of Bioengineering and Food Technology, Faculty of Applied Sciences and Biotechnology, Shoolini University, Solan, Himachal Pradesh, India. FAU - Kumar, Deepak AU - Kumar D AD - Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, India. FAU - Chellappan, Dinesh Kumar AU - Chellappan DK AD - Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia. FAU - Singh, Sachin Kumar AU - Singh SK AD - School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India. AD - Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, New South Wales, Australia. FAU - Dua, Kamal AU - Dua K AUID- ORCID: 0000-0002-7685-7145 AD - Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, New South Wales, Australia. AD - Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia. FAU - Gupta, Gaurav AU - Gupta G AD - School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India. AD - Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India. AD - Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220919 PL - United States TA - J Food Biochem JT - Journal of food biochemistry JID - 7706045 RN - 0 (Vitamins) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - *Plants, Medicinal MH - Dietary Supplements MH - Diet MH - Vitamins OTO - NOTNLM OT - Hedgehog OT - Nutraceuticals OT - Wnt/β-catenin OT - breast cancer OT - polyphenols EDAT- 2022/09/20 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/09/19 09:23 PHST- 2022/08/20 00:00 [revised] PHST- 2022/06/28 00:00 [received] PHST- 2022/08/23 00:00 [accepted] PHST- 2022/09/20 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/09/19 09:23 [entrez] AID - 10.1111/jfbc.14387 [doi] PST - ppublish SO - J Food Biochem. 2022 Dec;46(12):e14387. doi: 10.1111/jfbc.14387. Epub 2022 Sep 19. PMID- 36462463 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230106 IS - 2059-7029 (Electronic) IS - 2059-7029 (Linking) VI - 7 IP - 6 DP - 2022 Dec TI - The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer. PG - 100648 LID - S2059-7029(22)00282-4 [pii] LID - 10.1016/j.esmoop.2022.100648 [doi] LID - 100648 AB - BACKGROUND: An effect of non-oncology medications on cancer outcome has been proposed. In this study, we aimed to systematically examine the impact of commonly prescribed non-oncology drugs on clinical risk and on the genomic risk [based on the Oncotype DX recurrence score (RS)] in early breast cancer (BC). EXPERIMENTAL DESIGN: We collected data on clinical risk (stage and grade), genomic risk (Oncotype DX RS), and on non-oncology medications administered to 1423 patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative BC during the month of their surgery. The influence of various medications on clinical and genomic risks was evaluated by statistical analysis. RESULTS: Out of the multiple drugs we examined, levothyroxine was significantly associated with a high Oncotype DX RS (mean 24.78; P < 0.0001) and metformin with a low Oncotype DX RS (mean 14.87; P < 0.01) compared with patients not receiving other non-oncology drugs (mean 18.7). By contrast, there were no differences in the clinical risk between patients receiving metformin, levothyroxine, or no other non-oncology drugs. Notably, there was no association between the consumption of levothyroxine and metformin and proliferation marker (Ki67) levels, but both drugs were significantly associated with progesterone-related features, suggesting that they influence genomic risk through estrogen-dependent signaling. CONCLUSIONS: The results of this study indicate a significant impact of metformin and levothyroxine on clinical decisions in luminal BC, with potential impact on the clinical course of these patients. CI - Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Waissengrin, B AU - Waissengrin B AD - The Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv; Sackler School of Medicine, Tel Aviv University, Tel Aviv. FAU - Zahavi, T AU - Zahavi T AD - Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel. FAU - Salmon-Divon, M AU - Salmon-Divon M AD - Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel. FAU - Goldberg, A AU - Goldberg A AD - Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel. FAU - Wolf, I AU - Wolf I AD - The Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv; Sackler School of Medicine, Tel Aviv University, Tel Aviv. FAU - Rubinek, T AU - Rubinek T AD - The Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv; Sackler School of Medicine, Tel Aviv University, Tel Aviv. FAU - Winkler, T AU - Winkler T AD - Department of Human Molecular Genetics & Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Farkash, O AU - Farkash O AD - The Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv. FAU - Grinshpun, A AU - Grinshpun A AD - Breast Oncology Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA. FAU - Zubkov, A AU - Zubkov A AD - Pathology Department, Pathology Institute, Tel Aviv Medical Center, Tel Aviv. FAU - Khatib, M AU - Khatib M AD - Division of General Surgery, Tel Aviv Medical Center, Tel Aviv. FAU - Shachar, S S AU - Shachar SS AD - The Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv; Sackler School of Medicine, Tel Aviv University, Tel Aviv. FAU - Keren, N AU - Keren N AD - The Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv; Sackler School of Medicine, Tel Aviv University, Tel Aviv. FAU - Carmi-Levy, I AU - Carmi-Levy I AD - Aummune Ltd, Tel Aviv, Israel. FAU - Ben-David, U AU - Ben-David U AD - Sackler School of Medicine, Tel Aviv University, Tel Aviv. FAU - Sonnenblick, A AU - Sonnenblick A AD - The Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv; Sackler School of Medicine, Tel Aviv University, Tel Aviv. Electronic address: amirson@tlvmc.gov.il. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221130 PL - England TA - ESMO Open JT - ESMO open JID - 101690685 RN - Q51BO43MG4 (Thyroxine) RN - 9100L32L2N (Metformin) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Thyroxine MH - Neoplasm Recurrence, Local/genetics MH - *Metformin MH - Genomics PMC - PMC9808449 OTO - NOTNLM OT - Oncotype DX OT - breast cancer OT - clinical risk OT - estrogen receptor OT - genomic risk OT - levothyroxine OT - metformin EDAT- 2022/12/04 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/03 18:26 PHST- 2022/08/17 00:00 [received] PHST- 2022/10/21 00:00 [revised] PHST- 2022/10/24 00:00 [accepted] PHST- 2022/12/04 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/12/03 18:26 [entrez] AID - S2059-7029(22)00282-4 [pii] AID - 100648 [pii] AID - 10.1016/j.esmoop.2022.100648 [doi] PST - ppublish SO - ESMO Open. 2022 Dec;7(6):100648. doi: 10.1016/j.esmoop.2022.100648. Epub 2022 Nov 30. PMID- 36595824 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 51 DP - 2022 Dec 23 TI - Breast cancer combined prognostic model based on lactate metabolism genes. PG - e32485 LID - 10.1097/MD.0000000000032485 [doi] LID - e32485 AB - To investigate the impact of lactate metabolism genes, lactate metabolism-related genes (LMRG), and immune infiltrating cells on the prognosis of breast cancer. LMRG was identified via single-cell sequencing. Immune cell infiltration was obtained by the CIBERSORT method. The prognostic genes were chosen by cox regression and the least absolute selection operator approach. lactate metabolism-associated immune-infiltrating cells was determined by difference analysis. The GSE20685 dataset was used as an external validation cohort. The model's prognostic usefulness was evaluated utilizing survival, immunological microenvironment, and drug sensitivity assessments. NDUFAF6 was most associated with breast cancer prognosis. We obtained a total of 450 LMRG. SUSD3, IL18, MAL2, and CDKN1C comprised the Model2. NK cell activation was most relevant to lactate metabolism. The combined prognostic model outperformed the individual model, with the area under the curve ranging from 0.7 to 0.8 in all three cohorts. The lactate metabolism-related combination model assisted in evaluating breast cancer prognosis, providing new insights for treatment, particularly immunotherapy. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Lu, Na AU - Lu N AD - Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. FAU - Guan, Xiao AU - Guan X AD - Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. FAU - Bao, Wei AU - Bao W AD - Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Fan, Zongyao AU - Fan Z AD - Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zhang, Jianping AU - Zhang J AUID- ORCID: 0000-0003-2008-1592 AD - Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Lactates) RN - 0 (MAL2 protein, human) RN - 0 (Myelin and Lymphocyte-Associated Proteolipid Proteins) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - Prognosis MH - Breast MH - Immunotherapy MH - Lactates MH - Tumor Microenvironment MH - Myelin and Lymphocyte-Associated Proteolipid Proteins PMC - PMC9794285 COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/03 16:08 PHST- 2023/01/03 16:08 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 00005792-202212230-00085 [pii] AID - 10.1097/MD.0000000000032485 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 23;101(51):e32485. doi: 10.1097/MD.0000000000032485. PMID- 36625258 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1752-0371 (Electronic) IS - 1752-0363 (Linking) VI - 16 IP - 16 DP - 2022 Nov TI - Low expression of MEOX2 is associated with poor survival in patients with breast cancer. PG - 1161-1170 LID - 10.2217/bmm-2022-0468 [doi] AB - Aim: To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients. Materials & methods: We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test. Survival analysis was determined using a Kaplan-Meier curve. Multivariate Cox regression was used to determine associations of MEOX2 expression with overall survival. Results: We found that 74.1% of patients (100/135) had expression of MEOX2 at varying levels. MEOX2 was associated with histological grade and negatively correlated with Ki67 expression. Lower MEOX2 expression was significantly associated with decreased overall survival (p = 0.0011). Conclusion: MEOX2 expression could be a novel diagnostic and prognostic biomarker of breast cancer. FAU - Wang, Huxia AU - Wang H AD - Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. AD - Department of Mammary, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, China. FAU - Tang, Yanan AU - Tang Y AD - Department of Vascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Wang, Meixia AU - Wang M AD - Department of Health Examination, Shenmu Hospital, Yulin, 719300, China. FAU - Zhao, Jing AU - Zhao J AD - Department of Mammary, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, China. FAU - Ding, Caixia AU - Ding C AD - Department of Pathology, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, China. FAU - Yang, Xiaomin AU - Yang X AD - Department of Mammary, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, China. FAU - Han, Pihua AU - Han P AD - Department of Mammary, Shaanxi Provincial Cancer Hospital, Xi'an, 710061, China. FAU - Liu, Peijun AU - Liu P AUID- ORCID: 0000-0003-0529-387X AD - Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. LA - eng PT - Journal Article DEP - 20230110 PL - England TA - Biomark Med JT - Biomarkers in medicine JID - 101312535 RN - 0 (Biomarkers, Tumor) RN - 0 (MEOX2 protein, human) RN - 0 (Homeodomain Proteins) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/metabolism MH - Prognosis MH - Biomarkers, Tumor MH - Survival Analysis MH - Immunohistochemistry MH - Kaplan-Meier Estimate MH - Disease-Free Survival MH - Homeodomain Proteins/genetics OAB - In this study we found that lower expression of the protein MEOX2 was associated with poor overall survival in breast cancer. MEOX2 is an independent prognostic factor for breast cancer patients. It would be a new diagnostic and prognostic biomarker for breast cancer. OABL- eng OTO - NOTNLM OT - Ki67 OT - MEOX2 OT - biomarker OT - breast cancer OT - clinicopathological features OT - diagnosis OT - histological grade OT - overall survival OT - prognosis EDAT- 2023/01/11 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/10 05:03 PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2023/01/10 05:03 [entrez] AID - 10.2217/bmm-2022-0468 [doi] PST - ppublish SO - Biomark Med. 2022 Nov;16(16):1161-1170. doi: 10.2217/bmm-2022-0468. Epub 2023 Jan 10. PMID- 36130112 OWN - NLM STAT- MEDLINE DCOM- 20221207 LR - 20221230 IS - 1365-2168 (Electronic) IS - 0007-1323 (Linking) VI - 109 IP - 12 DP - 2022 Nov 22 TI - Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis. PG - 1206-1215 LID - 10.1093/bjs/znac319 [doi] AB - BACKGROUND: Circulating markers of the systemic inflammatory response are prognostic in several cancers, but their role in operable breast cancer is unclear. A systematic review and meta-analysis of the literature was carried out. METHODS: A search of electronic databases up to August 2020 identified studies that examined the prognostic value of preoperative circulating markers of the systemic inflammatory response in primary operable breast cancer. A meta-analysis was carried out for each marker with more than three studies, reporting a HR and 95 per cent confidence interval for disease-free survival (DFS), breast cancer-specific survival (BCSS) or overall survival (OS). RESULTS: In total, 57 studies were reviewed and 42 were suitable for meta-analysis. Higher neutrophil-to-lymphocyte ratio (NLR) was associated with worse overall survival (OS) (pooled HR 1.75, 95 per cent c.i. 1.52 to 2.00; P < 0.001), disease-free survival (DFS) (HR 1.67, 1.50 to 1.87; P < 0.001), and breast cancer-specific survival (BCSS) (HR 1.89, 1.35 to 2.63; P < 0.001). This effect was also seen with an arithmetically-derived NLR (dNLR). Higher platelet-to-lymphocyte ratio (PLR) was associated with worse OS (HR 1.29, 1.10 to 1.50; P = 0.001) and DFS (HR 1.58, 1.33 to 1.88; P < 0.001). Higher lymphocyte-to-monocyte ratio (LMR) was associated with improved DFS (HR 0.65, 0.51 to 0.82; P < 0.001), and higher C-reactive protein (CRP) level was associated with worse BCSS (HR 1.22, 1.07 to 1.39; P = 0.002) and OS (HR 1.24, 1.14 to 1.35; P = 0.002). CONCLUSION: Current evidence suggests a role for preoperative NLR, dNLR, LMR, PLR, and CRP as prognostic markers in primary operable breast cancer. Further work should define their role in clinical practice, particularly reproducible thresholds and molecular subtypes for which these may be of most value. CI - © Crown copyright 2022. FAU - Savioli, Francesca AU - Savioli F AD - Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. FAU - Morrow, Elizabeth S AU - Morrow ES AD - Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. FAU - Dolan, Ross D AU - Dolan RD AD - Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. FAU - Romics, Laszlo AU - Romics L AUID- ORCID: 0000-0001-8824-5501 AD - Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. FAU - Lannigan, Alison AU - Lannigan A AD - Department of Breast Surgery, University Hospital Wishaw, Wishaw, UK. FAU - Edwards, Joanne AU - Edwards J AD - Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. FAU - McMillan, Donald C AU - McMillan DC AD - Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - England TA - Br J Surg JT - The British journal of surgery JID - 0372553 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - Prognosis MH - *Breast Neoplasms/surgery MH - Lymphocytes MH - Biomarkers, Tumor MH - Systemic Inflammatory Response Syndrome EDAT- 2022/09/22 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/09/21 15:23 PHST- 2022/04/28 00:00 [received] PHST- 2022/06/27 00:00 [revised] PHST- 2022/08/17 00:00 [accepted] PHST- 2022/09/22 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/09/21 15:23 [entrez] AID - 6706820 [pii] AID - 10.1093/bjs/znac319 [doi] PST - ppublish SO - Br J Surg. 2022 Nov 22;109(12):1206-1215. doi: 10.1093/bjs/znac319. PMID- 36595868 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 51 DP - 2022 Dec 23 TI - Combination of Chinese medicinal formulas and chemotherapy for triple-negative breast cancer strengthens body resistance to eliminate pathogenic factors. PG - e32350 LID - 10.1097/MD.0000000000032350 [doi] LID - e32350 AB - BACKGROUND: To evaluate the efficacy and safety of strengthening the body's resistance to eliminate pathogenic factors in Chinese medicinal formulas combined with chemotherapy (hereafter referred to as combined therapy [CT]) in triple-negative breast cancer. METHODS: By searching the 7 electronic databases, PubMed, EMBASE, Web of Science, Cochrane Library, Chinese Academic Journal, Wanfang Database, and Chinese Science and Technology Journal, from the beginning of the establishment to April 2022 to identify eligible randomized controlled trial studies. RESULTS: The meta-analysis showed that compared with chemotherapy, CT can effectively improve the objective remission rate (risk ratio [RR]: 1.39; 95% confidence interval [CI]: 1.28, 1.52; P < .00001, I2 = 3%), reduce the recurrence rate (RR: 0.33; 95% CI: 0.14, 0.78; P = .01, I2 = 0%) metastasis rate (RR: 0.48; 95% CI: 0.31, 0.73; P = .0006, I2 = 0%) and the incidence of toxic and side reactions, lower tumor marker levels, regulated T lymphocyte subset changes, and increased average progression-free survival (standardized mean difference: 2.78; 95% CI: 1.41, 4.14; P < .0001, I2 = 97%), and improve the quality of life (RR: 1.55; 95% CI: 1.21, 1.99; P = .0005, I2 = 52%). CONCLUSION: This study suggests that CT appears to be an effective and safe treatment approach. Although this conclusion requires further confirmation owing to insufficient quality of the included trials. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Zhang, Yiyi AU - Zhang Y AUID- ORCID: 0000-0002-1753-9446 AD - College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Mo, Jing-Wen AU - Mo JW AD - College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Lu, Hai-Zhen AU - Lu HZ AD - College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Han, Ling-Ling AU - Han LL AD - College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Liu, Chengjiang AU - Liu C AD - Department of General Medicine, Affiliated Anqing First People's Hospital of Anhui Medical University, Hefei, China. FAU - Zhou, Yi AU - Zhou Y AUID- ORCID: 0000-0003-1857-6879 AD - College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. LA - eng PT - Journal Article PT - Meta-Analysis PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - *Quality of Life MH - *Triple Negative Breast Neoplasms/drug therapy MH - Randomized Controlled Trials as Topic PMC - PMC9794332 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/03 16:08 PHST- 2023/01/03 16:08 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 00005792-202212230-00129 [pii] AID - 10.1097/MD.0000000000032350 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 23;101(51):e32350. doi: 10.1097/MD.0000000000032350. PMID- 36552828 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230115 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 11 IP - 24 DP - 2022 Dec 15 TI - MST4: A Potential Oncogene and Therapeutic Target in Breast Cancer. LID - 10.3390/cells11244057 [doi] LID - 4057 AB - The mammalian STE 20-like protein kinase 4 (MST4) gene is highly expressed in several cancer types, but little is known about the role of MST4 in breast cancer, and the function of MST4 during epithelial-mesenchymal transition (EMT) has not been fully elucidated. Here we report that overexpression of MST4 in breast cancer results in enhanced cell growth, migration, and invasion, whereas inhibition of MST4 expression significantly attenuates these properties. Further study shows that MST4 promotes EMT by activating Akt and its downstream signaling molecules such as E-cadherin/N-cadherin, Snail, and Slug. MST4 also activates AKT and its downstream pro-survival pathway. Furthermore, by analyzing breast cancer patient tissue microarray and silicon datasets, we found that MST4 expression is much higher in breast tumor tissue compared to normal tissue, and significantly correlates with cancer stage, lymph node metastasis and a poor overall survival rate (p < 0.05). Taken together, our findings demonstrate the oncogenic potential of MST4 in breast cancer, highlighting its role in cancer cell proliferation, migration/invasion, survival, and EMT, suggesting a possibility that MST4 may serve as a novel therapeutic target for breast cancer. FAU - Arora, Ritu AU - Arora R AD - Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA. FAU - Kim, Jin-Hwan AU - Kim JH AD - Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA. AD - Markey Cancer Center, Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40508, USA. FAU - Getu, Ayechew A AU - Getu AA AUID- ORCID: 0000-0002-1192-3359 AD - Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan. AD - Department of Physiology, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar P.O. Box 196, Ethiopia. FAU - Angajala, Anusha AU - Angajala A AD - Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA. FAU - Chen, Yih-Lin AU - Chen YL AUID- ORCID: 0000-0003-1151-1706 AD - Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan. FAU - Wang, Bin AU - Wang B AUID- ORCID: 0000-0002-3689-6932 AD - Department of Mathematics and Statistics, University of South Alabama, Mobile, AL 36688, USA. FAU - Kahn, Andrea G AU - Kahn AG AUID- ORCID: 0000-0003-3905-0390 AD - Department of Pathology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. FAU - Chen, Hong AU - Chen H AUID- ORCID: 0000-0002-8146-0943 AD - Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan. FAU - Reshi, Latif AU - Reshi L AD - Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan. FAU - Lu, Jianrong AU - Lu J AUID- ORCID: 0000-0002-4969-6040 AD - Department of Biochemistry & Molecular Biology, College of Medicine, University of Florida, Gainesville, FL 32610, USA. FAU - Zhang, Wenling AU - Zhang W AUID- ORCID: 0000-0002-1586-6363 AD - Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha 410013, China. FAU - Zhou, Ming AU - Zhou M AUID- ORCID: 0000-0003-4938-5397 AD - Cancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha 410013, China. FAU - Tan, Ming AU - Tan M AUID- ORCID: 0000-0003-2007-9898 AD - Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan. AD - Research Center for Cancer Biology, China Medical University, Taichung 406040, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221215 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.1.- (STK26 protein, human) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Epithelial-Mesenchymal Transition/genetics MH - Lymphatic Metastasis MH - Oncogenes MH - *Proto-Oncogene Proteins c-akt/metabolism MH - Signal Transduction MH - *Protein Serine-Threonine Kinases/genetics PMC - PMC9777386 OTO - NOTNLM OT - AKT OT - EMT OT - MST4 OT - apoptosis OT - breast cancer COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:18 PHST- 2022/11/17 00:00 [received] PHST- 2022/12/12 00:00 [revised] PHST- 2022/12/13 00:00 [accepted] PHST- 2022/12/23 01:18 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - cells11244057 [pii] AID - cells-11-04057 [pii] AID - 10.3390/cells11244057 [doi] PST - epublish SO - Cells. 2022 Dec 15;11(24):4057. doi: 10.3390/cells11244057. PMID- 36575513 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230103 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 20 IP - 1 DP - 2022 Dec 27 TI - Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. PG - 498 LID - 10.1186/s12916-022-02708-3 [doi] LID - 498 AB - BACKGROUND: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We further assessed addition of pyrotinib to trastuzumab and docetaxel in the neoadjuvant setting. METHODS: In this multicenter, double-blind, phase 3 study (PHEDRA), treatment-naive women with HER2-positive early or locally advanced breast cancer were randomly assigned (1:1) to receive four neoadjuvant cycles of oral pyrotinib or placebo (400 mg) once daily, plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m(2)) every 3 weeks. The primary endpoint was the total pathological complete response (tpCR; ypT0/is and ypN0) rate per independent central review. RESULTS: Between Jul 23, 2018, and Jan 8, 2021, 355 patients were randomly assigned, 178 to the pyrotinib group and 177 to the placebo group. The majority of patients completed four cycles of neoadjuvant treatment as planned (92.7% and 97.7% in the pyrotinib and placebo groups, respectively). The tpCR rate was 41.0% (95% CI 34.0 to 48.4) in the pyrotinib group compared with 22.0% (95% CI 16.6 to 28.7) in the placebo group (difference, 19.0% [95% CI 9.5 to 28.4]; one-sided P < 0.0001). The objective response rate per investigator was 91.6% (95% CI 86.6 to 94.8) in the pyrotinib group and 81.9% (95% CI 75.6 to 86.9) in the placebo group after the neoadjuvant treatment, resulting in an increase of 9.7% (95% CI 2.7 to 16.6). The most common grade 3 or worse adverse events were diarrhea (79 [44.4%] in the pyrotinib group and nine [5.1%] in the placebo group), neutropenia (33 [18.5%] and 36 [20.3%]), and decreased white blood cell count (29 [16.3%] and 24 [13.6%]). No deaths were reported during neoadjuvant treatment. CONCLUSIONS: The primary endpoint of the study was met. Neoadjuvant pyrotinib, trastuzumab, and docetaxel significantly improved the tpCR rate compared with placebo, trastuzumab, and docetaxel, with manageable toxicity, providing a new option for HER2-positive early or locally advanced breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03588091. CI - © 2022. The Author(s). FAU - Wu, Jiong AU - Wu J AD - Department of Breast Surgery, Fudan University Shanghai Cancer Center, No.270, Dong'an Road, Xuhui District, Shanghai, 200032, China. wujiong1122@vip.sina.com. FAU - Jiang, Zefei AU - Jiang Z AD - Department of Medical Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Liu, Zhenzhen AU - Liu Z AD - Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Yang, Benlong AU - Yang B AD - Department of Breast Surgery, Fudan University Shanghai Cancer Center, No.270, Dong'an Road, Xuhui District, Shanghai, 200032, China. FAU - Yang, Hongjian AU - Yang H AD - Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, China. FAU - Tang, Jinhai AU - Tang J AD - Breast Surgery, Jiangsu Province Hospital, Nanjing, China. FAU - Wang, Kun AU - Wang K AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. FAU - Liu, Yunjiang AU - Liu Y AD - Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. FAU - Wang, Haibo AU - Wang H AD - Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Fu, Peifen AU - Fu P AD - Breast Surgery, The First Affiliated Hospital Zhejiang University, Hangzhou, China. FAU - Zhang, Shuqun AU - Zhang S AD - Oncology Department, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Liu, Qiang AU - Liu Q AD - Department of Breast Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. FAU - Wang, Shusen AU - Wang S AD - Internal Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. FAU - Huang, Jian AU - Huang J AD - Breast Surgery, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China. FAU - Wang, Chuan AU - Wang C AD - Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, China. FAU - Wang, Shu AU - Wang S AD - Department of Breast Surgery, Peking University People's Hospital, Beijing, China. FAU - Wang, Yongsheng AU - Wang Y AD - Department of Breast, Shandong Cancer Hospital, Jinan, China. FAU - Zhen, Linlin AU - Zhen L AD - Department of Thyroid and Breast Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, China. FAU - Zhu, Xiaoyu AU - Zhu X AD - Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China. FAU - Wu, Fei AU - Wu F AD - Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China. FAU - Lin, Xiang AU - Lin X AD - Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China. FAU - Zou, Jianjun AU - Zou J AD - Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China. LA - eng SI - ClinicalTrials.gov/NCT03588091 PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20221227 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 RN - P188ANX8CK (Trastuzumab) RN - 15H5577CQD (Docetaxel) RN - 0 (pyrotinib) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM MH - Humans MH - Female MH - Trastuzumab MH - *Breast Neoplasms/pathology MH - Docetaxel/therapeutic use MH - Neoadjuvant Therapy/adverse effects MH - Receptor, ErbB-2/genetics MH - Antibodies, Monoclonal, Humanized/adverse effects MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Treatment Outcome PMC - PMC9795751 OTO - NOTNLM OT - Breast cancer OT - HER2 OT - Neoadjuvant treatment OT - Phase 3 OT - Pyrotinib COIS- XZ, FW, XL, and JZ reported being employed by Hengrui when conducting this study. No other disclosures were reported. EDAT- 2022/12/28 06:00 MHDA- 2022/12/30 06:00 CRDT- 2022/12/27 23:49 PHST- 2022/09/27 00:00 [received] PHST- 2022/12/12 00:00 [accepted] PHST- 2022/12/27 23:49 [entrez] PHST- 2022/12/28 06:00 [pubmed] PHST- 2022/12/30 06:00 [medline] AID - 10.1186/s12916-022-02708-3 [pii] AID - 2708 [pii] AID - 10.1186/s12916-022-02708-3 [doi] PST - epublish SO - BMC Med. 2022 Dec 27;20(1):498. doi: 10.1186/s12916-022-02708-3. PMID- 36626437 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230113 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 49 DP - 2022 Dec 9 TI - Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies. PG - e31799 LID - 10.1097/MD.0000000000031799 [doi] LID - e31799 AB - BACKGROUND: Experiments have shown that metformin can inhibit cancer cell growth, but clinical observations have been inconsistent, so we pooled the currently available data to evaluate the impact of metformin on cancer survival and progression. METHODS: PubMed, web of science, Embase, and Cochrane databases were searched. Pooled hazard ratios (HRs) were identified using a random-effects model to estimate the strength of the association between metformin and survival and progression in cancer patients. RESULTS: We incorporated 80 articles published from all databases which satisfied the inclusion criterion. It showed that metformin was associated with better overall survival (hazard ratio [HR] = 0. 81; 95% confidence interval [CI]: [0.77-0.85]) and cancer-specific survival (HR = 0.79; 95% CI: [0.73-0.86]), and metformin was associated with progression-free survival (HR = 0.76; 95% CI: [0.66-0.87]). In patients with diabetes mellitus, the HR of overall survival was 0.79(95% CI: [0.75-0.83]), progression-free survival was 0.72(95% CI: [0.60-0.85]), and the cancer-specific survival was 0.76(95% CI: [0.68-0.86]). It was proposed that metformin can improve the prognosis of cancer patients with diabetes mellitus. CONCLUSION: Based on cohort studies, metformin therapy has potential survival benefits for patients with malignancy, especially with the greatest benefits seen in breast cancer on overall survival, progression-free survival, and cancer-specific survival. And metformin also showed potential benefits in cancer-specific survival in colorectal and prostate cancer. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Yang, Jing AU - Yang J AUID- ORCID: 0000-0002-7763-6571 AD - Oncology Center, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Wujiang, Jiangsu Province, P.R. China. FAU - Yang, Hang AU - Yang H AD - Oncology Center, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Wujiang, Jiangsu Province, P.R. China. FAU - Cao, Ling AU - Cao L AD - Oncology Center, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Wujiang, Jiangsu Province, P.R. China. FAU - Yin, Yuzhen AU - Yin Y AD - Oncology Center, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Wujiang, Jiangsu Province, P.R. China. FAU - Shen, Ying AU - Shen Y AD - Department of Endocrinology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Wujiang, Jiangsu Province, P.R. China. FAU - Zhu, Wei AU - Zhu W AUID- ORCID: 0000-0002-5744-5962 AD - Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, P.R. China. LA - eng PT - Journal Article PT - Meta-Analysis PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 9100L32L2N (Metformin) RN - 0 (Hypoglycemic Agents) SB - IM MH - Male MH - Humans MH - *Metformin/therapeutic use MH - Hypoglycemic Agents/therapeutic use MH - Prognosis MH - *Diabetes Mellitus/drug therapy MH - Cohort Studies MH - *Breast Neoplasms/drug therapy PMC - PMC9750609 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/01/11 06:00 MHDA- 2023/01/13 06:00 CRDT- 2023/01/10 13:35 PHST- 2023/01/10 13:35 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - 00005792-202212090-00087 [pii] AID - 10.1097/MD.0000000000031799 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 9;101(49):e31799. doi: 10.1097/MD.0000000000031799. PMID- 36375386 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. PG - 255-261 LID - S0960-9776(22)00183-7 [pii] LID - 10.1016/j.breast.2022.10.018 [doi] AB - BACKGROUND: CDK4/6 inhibitors combined with endocrine therapy are standard first- or second-line treatment for patients with HR-positive and HER2-negative advanced breast cancer, however, there is currently no optimal recommendation for therapeutic strategies after progression on CDK4/6i. The aim of this study is to analyze the efficacy and safety of HDAC inhibitor Tucidinostat combined with endocrine therapy in patients after prior CDK4/6 inhibitor progression. METHODS: The pathological and clinical data of 44 HR-positive and HER2-negative breast cancer patients treated with tucidinostat after progression on CDK4/6i at the Breast Oncology Department of the Fifth Medical Center of the PLA General Hospital from July 2019 to October 2021 were retrospectively analyzed. Observation indexes included progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR), objective response rate (ORR) and adverse events. At the same time, we attempted to identify potential genomic predictors using available next-generation sequencing (NGS). RESULTS: A total of 44 patients were enrolled in this study. Median follow-up was 10 months (1-26 months) by the data cutoff date (February 2022). The CBR was 6.8% (3/44), the median PFS was 2.0 months (95% CI 1.9-2.1), and the median OS was 14 months (95% CI 6.3-21.7). The mPFS was 4.1 months (95%CI: 0-8.2) in patients with 1 metastatic site, and the mPFS was 4.5 months (95%CI: 4.2-4.8) in patients who received sequential tucidinostat after CDK4/6i failure. Multivariate analysis showed that patients with 1 metastatic site or sequential tucidinostat treatment after failure of CDK4/6i were more likely to benefit from tucidinostat combined with endocrine therapy. Preliminary data showed PIK3CA mutation may be associated with resistance of tucidinostat therapy. No grade 4 adverse events and no treatment-related deaths were recorded in the study. Dose reductions because of adverse events occurred in 4 (9.1%) patients. CONCLUSIONS: This study preliminarily shows that tucidinostat combined with endocrine therapy may be an optional sequential strategy for patients with HR+/HER2-advanced breast cancer that has progressed on CDK4/6 inhibitor, especially for these with lower tumor burden and fewer prior palliative treatment. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Zhou, Jinmei AU - Zhou J AD - Breast Cancer Department of Oncology Institute, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Wu, Xuexue AU - Wu X AD - Breast Cancer Department of Oncology Institute, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Zhang, Huiqiang AU - Zhang H AD - Breast Cancer Department of Oncology Institute, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Wang, Xiaobo AU - Wang X AD - Breast Cancer Department of Oncology Institute, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Yuan, Yang AU - Yuan Y AD - Breast Cancer Department of Oncology Institute, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Zhang, Shaohua AU - Zhang S AD - Breast Cancer Department of Oncology Institute, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Jiang, Zefei AU - Jiang Z AD - Breast Cancer Department of Oncology Institute, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. Electronic address: jiangzefei@csco.org.cn. FAU - Wang, Tao AU - Wang T AD - Breast Cancer Department of Oncology Institute, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China; Anhui Medical University, Hefei, China; Southern Medical University, Guangzhou, China. Electronic address: wangtao733073@163.com. LA - eng PT - Journal Article DEP - 20221102 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Receptors, Estrogen) RN - 87CIC980Y0 (N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 4) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 6) RN - EC 2.7.11.22 (CDK4 protein, human) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Retrospective Studies MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Receptor, ErbB-2/genetics MH - Receptors, Estrogen MH - Cyclin-Dependent Kinase 4/genetics MH - Cyclin-Dependent Kinase 6/genetics PMC - PMC9661714 OTO - NOTNLM OT - CDK4/6 inhibitor OT - Endocrine therapy OT - Hormone receptor-positive OT - Metastatic breast cancer OT - Tucidinostat COIS- Declaration of competing interest All authors have no conflicts of interest. EDAT- 2022/11/15 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/14 18:29 PHST- 2022/09/13 00:00 [received] PHST- 2022/10/31 00:00 [revised] PHST- 2022/10/31 00:00 [accepted] PHST- 2022/11/15 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/14 18:29 [entrez] AID - S0960-9776(22)00183-7 [pii] AID - 10.1016/j.breast.2022.10.018 [doi] PST - ppublish SO - Breast. 2022 Dec;66:255-261. doi: 10.1016/j.breast.2022.10.018. Epub 2022 Nov 2. PMID- 36524240 OWN - NLM STAT- MEDLINE DCOM- 20230102 LR - 20230103 IS - 1756-5391 (Electronic) IS - 1756-5391 (Linking) VI - 15 IP - 4 DP - 2022 Dec TI - Effect of adjuvant chemotherapy on the survival outcomes of elderly breast cancer: A retrospective cohort study based on SEER database. PG - 354-364 LID - 10.1111/jebm.12506 [doi] AB - BACKGROUND: Currently, the proportion of standard chemotherapy for elderly patients is much lower than that for young patients, with little evidence from clinical trials supporting the use of chemotherapy for elderly patients. The effectiveness of chemotherapy for the elderly suffering from breast cancer remains to be further verified. METHODS: A total of 75,525 female breast cancer patients aged 70 years or older were hereby identified, all from the Surveillance, Epidemiology, and End Results (SEER) database from January 1, 2010 to December 31, 2016. Kaplan-Meier analysis and multivariable Cox proportional model were performed to evaluate the effectiveness of chemotherapy on overall survival (OS) and breast cancer-specific survival (BCSS). Propensity score matching (PSM) (PSM ratio: 1:1, caliper: 0.2 standard deviation of propensity score) was applied to construct balanced cohorts with or without chemotherapy based on demographic and pathophysiological characteristics. RESULTS: A total of 33,177 eligible patients were included, with 5273 (15.89%) receiving chemotherapy. Through PSM, 8360 patients were successfully matched, and balances between groups were almost reached. In the matched data set, multivariable Cox analysis reveals that chemotherapy was associated with a 36% and 21% risk reduction on OS (HR = 0.64, 95% CI 0.58 to 0.71) and BCSS (HR = 0.79, 95% CI 0.69 to 0.91), respectively. Furthermore, subgroups with more adjacent lymph nodes involved by tumor, or nonluminal A, were inclined to benefit more from chemotherapy. Moreover, chemotherapy did not increase the chances of dying from heart disease. CONCLUSIONS: The present study provided evidence that chemotherapy may improve the prognosis of elderly breast cancer, especially for those subpopulations that benefit more from chemotherapy treatment. CI - © 2022 The Authors. Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd. FAU - Wu, Yunhao AU - Wu Y AUID- ORCID: 0000-0003-2435-0585 AD - Department of Breast Center and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China. FAU - Qi, Yana AU - Qi Y AD - Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Yang, Jiqiao AU - Yang J AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Yang, Ruoning AU - Yang R AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Lui, Weijing AU - Lui W AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Huang, Ya AU - Huang Y AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhao, Xin AU - Zhao X AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Chen, Ruixian AU - Chen R AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - He, Tao AU - He T AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Lu, Shan AU - Lu S AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Wang, Zhu AU - Wang Z AD - Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Hongjiang AU - Li H AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Sun, Xin AU - Sun X AUID- ORCID: 0000-0002-6554-7088 AD - Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Li, Qintong AU - Li Q AD - Departments of Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, China. FAU - Zhou, Li AU - Zhou L AD - Public Experimental Technology Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Chen, Jie AU - Chen J AD - Department of Breast Center, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20221215 PL - England TA - J Evid Based Med JT - Journal of evidence-based medicine JID - 101497477 SB - IM MH - Aged MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/pathology MH - Retrospective Studies MH - Chemotherapy, Adjuvant/methods MH - Proportional Hazards Models MH - Prognosis OTO - NOTNLM OT - aged OT - breast cancer OT - chemotherapy OT - survival analysis EDAT- 2022/12/17 06:00 MHDA- 2023/01/03 06:00 CRDT- 2022/12/16 02:38 PHST- 2022/09/07 00:00 [received] PHST- 2022/11/30 00:00 [accepted] PHST- 2022/12/17 06:00 [pubmed] PHST- 2023/01/03 06:00 [medline] PHST- 2022/12/16 02:38 [entrez] AID - 10.1111/jebm.12506 [doi] PST - ppublish SO - J Evid Based Med. 2022 Dec;15(4):354-364. doi: 10.1111/jebm.12506. Epub 2022 Dec 15. PMID- 35676850 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230111 IS - 1875-5453 (Electronic) IS - 1389-2002 (Linking) VI - 23 IP - 10 DP - 2022 TI - Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review. PG - 781-799 LID - 10.2174/1389200223666220608144551 [doi] AB - Breast cancer is the most prevalent cancer in women around the world, having a sudden spread nowadays because of the poor sedentary lifestyle of people. Comprising several subtypes, one of the most dangerous and aggressive ones is triple-negative breast cancer or TNBC. Even though conventional surgical approaches like single and double mastectomy and preventive chemotherapeutic approaches are available, they are not selective to cancer cells and are only for symptomatic treatment. A new branch called nanotechnology has emerged in the last few decades that offers various novel characteristics, such as size in nanometric scale, enhanced adherence to multiple targeting moieties, active and passive targeting, controlled release, and site-specific targeting. Among various nanotherapeutic approaches like dendrimers, lipid-structured nanocarriers, carbon nanotubes, etc., nanoparticle targeted therapeutics can be termed the best among all for their specific cytotoxicity to cancer cells and increased bioavailability to a target site. This review focuses on the types and molecular pathways involving TNBC, existing treatment strategies, various nanotechnological approaches like exosomes, carbon nanotubes, dendrimers, lipid, and carbon-based nanocarriers, and especially various nanoparticles (NPs) like polymeric, photodynamic, peptide conjugated, antibody-conjugated, metallic, inorganic, natural product capped, and CRISPR based nanoparticles already approved for treatment or are under clinical and pre-clinical trials for TNBC. CI - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Guha, Lahanya AU - Guha L AD - Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Mohali, S.A.S Nagar, Punjab 160062, India. FAU - Bhat, Ishfaq Ahmad AU - Bhat IA AD - Northern Railway Hospital, Sri Mata Vaishno Devi, Katra, Reasi 182320, India. FAU - Bashir, Aasiya AU - Bashir A AD - Department of Pharmaceutical Sciences, Faculty of Applied Sciences and Technology, University of Kashmir, Hazratbal, Srinagar-190006, J&K, India. FAU - Rahman, Jawad Ur AU - Rahman JU AD - Department of Microbiology, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O.BOX 1982, Dammam 31441, Saudi Arabia. FAU - Pottoo, Faheem Hyder AU - Pottoo FH AD - Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P.O.BOX 1982, Dammam 31441, Saudi Arabia. LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Curr Drug Metab JT - Current drug metabolism JID - 100960533 RN - 0 (Nanotubes, Carbon) RN - 0 (Dendrimers) RN - 0 (Lipids) SB - IM MH - Female MH - Humans MH - *Triple Negative Breast Neoplasms/drug therapy/metabolism MH - *Nanotubes, Carbon MH - *Dendrimers/therapeutic use MH - Mastectomy MH - Nanotechnology MH - Lipids OTO - NOTNLM OT - Triple-negative breast cancer OT - estrogen receptor (ER) OT - human epidermal growth factor receptor 2 (HER2) OT - nanoparticles OT - nanotechnology OT - progesterone receptor (PR) OT - targeted therapy EDAT- 2022/06/10 06:00 MHDA- 2023/01/05 06:00 CRDT- 2022/06/09 01:23 PHST- 2021/12/03 00:00 [received] PHST- 2022/02/01 00:00 [revised] PHST- 2022/03/10 00:00 [accepted] PHST- 2022/06/10 06:00 [pubmed] PHST- 2023/01/05 06:00 [medline] PHST- 2022/06/09 01:23 [entrez] AID - CDM-EPUB-124274 [pii] AID - 10.2174/1389200223666220608144551 [doi] PST - ppublish SO - Curr Drug Metab. 2022;23(10):781-799. doi: 10.2174/1389200223666220608144551. PMID- 36270084 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Influence of age as a continuous variable on the prognosis of patients with pT1-2N1 breast cancer. PG - 136-144 LID - S0960-9776(22)00138-2 [pii] LID - 10.1016/j.breast.2022.08.005 [doi] AB - PURPOSE: To assess the influence of age as a continuous variable on the prognosis of pT1-2N1 breast cancer and examine its decision-making value for postmastectomy radiotherapy (PMRT). METHODS: We retrospectively evaluated 5438 patients with pT1-2N1 breast cancer after mastectomy in 11 hospitals. A multivariable Cox proportional hazards regression model with penalized splines was used to examine the relationship between age and oncologic outcomes. RESULTS: The median follow-up was 67.0 months. After adjustments for confounding characteristics, nonsignificant downward trend in locoregional recurrence (LRR) risk was observed with increasing age (P-non-linear association = 0.640; P-linear association = 0.078). A significant non-linear association was found between age and disease-free survival (DFS) and overall survival (OS) (P-non-linear association <0.05; P-linear association >0.05, respectively). The DFS and OS exhibited U-shaped relationships, with the hazard ratios (HRs), reaching a nadir at 50 years old. A decreased risk of LRR with PMRT vs. no PMRT (HR = 0.304, 95% CI: 0.204-0.454) was maintained in all ages. The HR of PMRT vs. no PMRT for DFS and OS gradually increased with age. In patients ≤50 years old, PMRT was independently associated with favorable LRR, DFS, and OS, all P < 0.05). In patients >50 years old, PMRT was independently associated with reduced LRR (P = 0.004), but had no effect on DFS or OS. CONCLUSIONS: Age was an independent prognostic factor for pT1-2N1 breast cancer; PMRT provided survival benefits for patients ≤50 years old, but not for patients >50 years old. CI - Copyright © 2022. Published by Elsevier Ltd. FAU - Zhao, Xu-Ran AU - Zhao XR AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: 923791362@qq.com. FAU - Tang, Yu AU - Tang Y AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Wu, Hong-Fen AU - Wu HF AD - Department of Radiation Oncology, Jilin Cancer Hospital, Changchun, China. FAU - Guo, Qi-Shuai AU - Guo QS AD - Department of Radiation Oncology, Affiliated Cancer Hospital of Chongqing University, Chongqing, China. FAU - Zhang, Yu-Jing AU - Zhang YJ AD - Department of Radiation Oncology, Sun Yat-sen University Affiliated Tumor Hospital, Guangzhou, China. FAU - Shi, Mei AU - Shi M AD - Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. FAU - Cheng, Jing AU - Cheng J AD - Department of Breast Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Hong-Mei AU - Wang HM AD - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Liu, Min AU - Liu M AD - Department of Radiation Oncology, First Hospital of Jilin University, Changchun, China. FAU - Ma, Chang-Ying AU - Ma CY AD - Department of Radiation Oncology, First Hospital of Qiqihaer, Qiqihaer, China. FAU - Wen, Ge AU - Wen G AD - Department of Radiation Oncology, Sun Yat-sen University Affiliated Tumor Hospital, Guangzhou, China; Department of Radiation Oncology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. FAU - Wang, Xiao-Hu AU - Wang XH AD - Department of Radiation Oncology, Gansu Cancer Hospital, Lanzhou, China. FAU - Fang, Hui AU - Fang H AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Jing, Hao AU - Jing H AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Song, Yong-Wen AU - Song YW AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Jin, Jing AU - Jin J AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Liu, Yue-Ping AU - Liu YP AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Chen, Bo AU - Chen B AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Qi, Shu-Nan AU - Qi SN AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Li, Ning AU - Li N AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Tang, Yuan AU - Tang Y AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Lu, Ning-Ning AU - Lu NN AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. FAU - Zhang, Na AU - Zhang N AD - Department of Radiation Oncology, Liaoning Cancer Hospital, Shenyang, China. Electronic address: zhangna@cancerhosp-ln-cmu.com. FAU - Li, Ye-Xiong AU - Li YX AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: yexiong12@163.com. FAU - Wang, Shu-Lian AU - Wang SL AD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address: wangsl@cicams.ac.cn. LA - eng PT - Journal Article DEP - 20220816 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Breast Neoplasms/surgery MH - Mastectomy MH - Retrospective Studies MH - Neoplasm Staging MH - Radiotherapy, Adjuvant MH - Neoplasm Recurrence, Local/pathology MH - Prognosis PMC - PMC9587343 OTO - NOTNLM OT - 1–3 positive lymph nodes OT - Age OT - Breast neoplasm OT - Mastectomy OT - Radiotherapy COIS- Declaration of competing interest All listed authors declare that they have no conflict of interests. EDAT- 2022/10/22 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/21 18:18 PHST- 2022/06/21 00:00 [received] PHST- 2022/07/31 00:00 [revised] PHST- 2022/08/10 00:00 [accepted] PHST- 2022/10/22 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/21 18:18 [entrez] AID - S0960-9776(22)00138-2 [pii] AID - 10.1016/j.breast.2022.08.005 [doi] PST - ppublish SO - Breast. 2022 Dec;66:136-144. doi: 10.1016/j.breast.2022.08.005. Epub 2022 Aug 16. PMID- 36375390 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Patterns of care over 10 years in young breast cancer patients in the Netherlands, a nationwide population-based study. PG - 285-292 LID - S0960-9776(22)00185-0 [pii] LID - 10.1016/j.breast.2022.11.002 [doi] AB - INTRODUCTION: Each year, around 600 young (<40 years) breast cancer (BC) patients are registered in the national NABON Breast Cancer Audit (NBCA). The aim of this study is to compare patient and treatment characteristics of young and older age BC patients over time with a focus on outcome of quality indicators (QIs). Furthermore, we analysed whether de-escalation trends of treatment can be recognized to the same degree in both patient groups. MATERIAL AND METHODS: From October 2011 to October 2020 all patients treated for stage I-III invasive BC were included. Tumour characteristics, treatment variables and outcome of QIs of two age categories young (<40 years) and older patient (≥40 years) were analysed. RESULTS: In total 114,700 patients were included: 4.6% young patients and 95.4% older patients. Young patients more often presented with a palpable mass, higher stage, and triple-negative BC. Overall, young patients more often started with neoadjuvant systemic treatment (NST) (54.3% vs. 18.6%) and a greater proportion of the young patients retained their breast contour after surgery (73.5% vs. 69.3%). De-escalation trends such as decrease in axillary lymph node dissections and in the use of boost were observed. The omission of radiation treatment after breast conserving surgery was only observed in older patients. CONCLUSION: Although this study shows that young women more often present with unfavourable tumours, therapeutic procedures are performed with a higher adherence to the QIs than for older patients and young women do benefit from some de-escalation trends to the same extend as older patients. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Maliko, Nansi AU - Maliko N AD - Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, the Netherlands. FAU - Bijker, Nina AU - Bijker N AD - Department of Radiation Oncology, AmsterdamUMC, Amsterdam, the Netherlands. FAU - Bos, Monique Emm AU - Bos ME AD - Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, the Netherlands. FAU - Wouters, Michel Wjm AU - Wouters MW AD - Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands. FAU - Vrancken Peeters, Marie-Jeanne Tfd AU - Vrancken Peeters MT AD - Department of Surgical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Department of Surgery, AmsterdamUMC, Amsterdam, the Netherlands. Electronic address: m.vrancken@nki.nl. CN - NABON Breast Cancer Audit LA - eng PT - Journal Article DEP - 20221109 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - Female MH - Aged MH - Adult MH - *Breast Neoplasms/pathology MH - Netherlands MH - *Triple Negative Breast Neoplasms/surgery MH - Lymph Node Excision MH - Neoadjuvant Therapy MH - Mastectomy, Segmental PMC - PMC9663518 OTO - NOTNLM OT - Breast cancer OT - Incidence OT - NABON Breast cancer audit (NBCA) OT - National clinical audit OT - Quality indicators OT - Quality of care OT - Treatment OT - Young patients COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/15 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/14 18:29 PHST- 2022/09/22 00:00 [received] PHST- 2022/11/06 00:00 [revised] PHST- 2022/11/07 00:00 [accepted] PHST- 2022/11/15 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/14 18:29 [entrez] AID - S0960-9776(22)00185-0 [pii] AID - 10.1016/j.breast.2022.11.002 [doi] PST - ppublish SO - Breast. 2022 Dec;66:285-292. doi: 10.1016/j.breast.2022.11.002. Epub 2022 Nov 9. PMID- 36641655 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Prognostic factors in inflammatory breast cancer: A single-center study. PG - 461-469 LID - 10.3233/BD-220034 [doi] AB - BACKGROUND: Previous studies have shown that poor prognostic indicators of inflammatory breast cancer (IBC) include younger age at diagnosis, poorer tumor grade, negative estrogen receptor, lesser degree of pathological response in the breast and lymph nodes. METHODS: This is a retrospective study conducted over a period of 12 years between January 2008 and December 2019 at the medical oncology department at Habib Bourguiba University Hospital in Sfax. We included in this study women with confirmed IBC. We excluded patients with no histological evidence, those whose medical records were unusable. Data collection was done from patient files. The aim of this study was to analyze the factors of poor prognosis of this entity. RESULTS: During a period of 12 years (2008-2019), 2879 cases of breast cancer were treated at Habib Bourguiba hospital in Sfax. 81 IBC were included. The incidence of IBC was 3%. The average age was 52.4 years (26-87 years). Invasive ductal carcinoma was the most frequent histological type (85.7%). Hormone receptor were positive in 64%. Human Epidermal Growth Factor Receptor-2 (HER2) was overexpressed in 35.9% of cases. The proliferation index Ki-67 was analyzed in 34 cases. It was >20% in 24 cases. Luminal A, luminal B, HER2+++, triple negative were found in 13%, 50.7%, 16% and 20% respectively. Metastases at diagnosis were found in 38%. Poor prognostic factors significantly influencing overall survival in univariate analysis were metastatic stage, high SBR grade, lymph node involvement, in particular greater than 3 nodes, negative hormone receptors, triple-negative molecular profile and occurrence of relapse. CONCLUSION: Number of positive lymph nodes greater than 3 and the occurrence of relapse were independent prognostic factors in case of localized IBC. Metastatic stage was associated with a very poor prognosis. FAU - Kridis, Wala Ben AU - Kridis WB AD - Department of Medical Oncology, Habib Bourguiba Hospital University of Sfax, Sfax, Tunisia. FAU - Feki, Ameni AU - Feki A AD - Department of Medical Oncology, Habib Bourguiba Hospital University of Sfax, Sfax, Tunisia. FAU - Khmiri, Souhir AU - Khmiri S AD - Department of Medical Oncology, Habib Bourguiba Hospital University of Sfax, Sfax, Tunisia. FAU - Toumi, Nabil AU - Toumi N AD - Department of Medical Oncology, Habib Bourguiba Hospital University of Sfax, Sfax, Tunisia. FAU - Chaabene, Kais AU - Chaabene K AD - Department of Gynecology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia. FAU - Daoud, Jamel AU - Daoud J AD - Department of Radiotherapy, Habib Bourguiba Hospital University of Sfax, Sfax, Tunisia. FAU - Ayedi, Ines AU - Ayedi I AD - Department of Medical Oncology, Habib Bourguiba Hospital University of Sfax, Sfax, Tunisia. FAU - Khanfir, Afef AU - Khanfir A AD - Department of Medical Oncology, Habib Bourguiba Hospital University of Sfax, Sfax, Tunisia. LA - eng PT - Journal Article PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 RN - 0 (Hormones) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Receptors, Progesterone) SB - IM MH - Female MH - Humans MH - Middle Aged MH - *Breast Neoplasms/diagnosis/genetics MH - Hormones MH - *Inflammatory Breast Neoplasms/diagnosis/genetics MH - Neoplasm Recurrence, Local MH - Prognosis MH - Receptor, ErbB-2/genetics/metabolism MH - Receptors, Progesterone/metabolism MH - Retrospective Studies MH - Adult MH - Aged MH - Aged, 80 and over OTO - NOTNLM OT - Inflammatory breast cancer OT - overall survival OT - prognosis EDAT- 2023/01/16 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/15 05:22 PHST- 2023/01/15 05:22 [entrez] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - BD220034 [pii] AID - 10.3233/BD-220034 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):461-469. doi: 10.3233/BD-220034. PMID- 36373309 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20221230 IS - 1875-8592 (Electronic) IS - 1574-0153 (Linking) VI - 35 IP - 4 DP - 2022 TI - Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment. PG - 379-393 LID - 10.3233/CBM-220073 [doi] AB - BACKGROUND: Intercellular adhesion molecules (ICAMs) in the tumor microenvironment are closely related to immunity and affect the prognosis of cancer patients. OBJECTIVE: The aim of our study is to explore the correlation between ICAM expression, mutation, methylation and immunity and their prognostic value in breast cancer (BC) is not clear. METHODS: Online databases and tools such as UALCAN, COSMIC, cBioPortal, MethSurv, PrognoScan, Kaplan-Meier Plotter, GSCA and TIMER were utilized in this study. RESULTS: We found that the mRNA and protein expression levels of ICAM1 were upregulated in triple-negative breast cancer (TNBC) compared with normal tissues, and TNBC patients with high expression of ICAM1 had better overall survival (OS) and recurrence-free survival (RFS). The main types of ICAM1 gene variants were missense mutation and amplification, and ICAM1 showed a lower level of methylation in TNBC cancer tissues than in normal tissues, which was contrary to the high expression levels of ICAM1 mRNA and protein. Next, the function of ICAM1 was mainly related to the activation of apoptosis, epithelial-mesenchymal transition (EMT) and inhibition of the androgen receptor (AR) and estrogen receptor (ER) pathways. Meanwhile, functional pathway enrichment results showed that ICAM1 was also involved in the immune regulation process of BC. Furthermore, the expression of ICAM1 was positively associated with 6 types of tumor-infiltrating immune cells (CD8+ T cells, CD4+ T cells, B cells, neutrophils, macrophages and dendritic cells) and was also positively related to the expression of programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA4). CONCLUSIONS: Our research indicated that ICAM1 was likely to be a potential therapeutic target in TNBC. FAU - Chen, Heyan AU - Chen H AD - Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. FAU - Pu, Shengyu AU - Pu S AD - Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. FAU - Mei, Nan AU - Mei N AD - Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. FAU - Liu, Xiaoxu AU - Liu X AD - Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. FAU - He, Jianjun AU - He J AD - Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. FAU - Zhang, Huimin AU - Zhang H AD - Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. LA - eng PT - Journal Article PL - Netherlands TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (Biomarkers) RN - 0 (Cell Adhesion Molecules) RN - 0 (RNA, Messenger) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Prognosis MH - *Triple Negative Breast Neoplasms/drug therapy MH - Tumor Microenvironment/genetics MH - Biomarkers MH - Cell Adhesion Molecules MH - RNA, Messenger MH - Biomarkers, Tumor/genetics OTO - NOTNLM OT - Breast cancer OT - ICAMs OT - immune checkpoint therapy OT - prognostic biomarkers OT - tumor microenvironment EDAT- 2022/11/15 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/14 03:33 PHST- 2022/11/15 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/14 03:33 [entrez] AID - CBM220073 [pii] AID - 10.3233/CBM-220073 [doi] PST - ppublish SO - Cancer Biomark. 2022;35(4):379-393. doi: 10.3233/CBM-220073. PMID- 34399407 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1540-1413 (Electronic) IS - 1540-1405 (Print) IS - 1540-1405 (Linking) VI - 19 IP - 11 DP - 2021 Aug 16 TI - Receipt of Guideline-Concordant Care Does Not Explain Breast Cancer Mortality Disparities by Race in Metropolitan Atlanta. PG - 1242-1251 LID - 10.6004/jnccn.2020.7694 [doi] AB - BACKGROUND: Racial disparities in breast cancer mortality in the United States are well documented. Non-Hispanic Black (NHB) women are more likely to die of their disease than their non-Hispanic White (NHW) counterparts. The disparity is most pronounced among women diagnosed with prognostically favorable tumors, which may result in part from variations in their receipt of guideline care. In this study, we sought to estimate the effect of guideline-concordant care (GCC) on prognosis, and to evaluate whether receipt of GCC modified racial disparities in breast cancer mortality. PATIENTS AND METHODS: Using the Georgia Cancer Registry, we identified 2,784 NHB and 4,262 NHW women diagnosed with a stage I-III first primary breast cancer in the metropolitan Atlanta area, Georgia, between 2010 and 2014. Women were included if they received surgery and information on their breast tumor characteristics was available; all others were excluded. Receipt of recommended therapies (chemotherapy, radiotherapy, endocrine therapy, and anti-HER2 therapy) as indicated was considered GCC. We used Cox proportional hazards models to estimate the impact of receiving GCC on breast cancer mortality overall and by race, with multivariable adjusted hazard ratios (HRs). RESULTS: We found that NHB and NHW women were almost equally likely to receive GCC (65% vs 63%, respectively). Failure to receive GCC was associated with an increase in the hazard of breast cancer mortality (HR, 1.74; 95% CI, 1.37-2.20). However, racial disparities in breast cancer mortality persisted despite whether GCC was received (HRGCC: 2.17 [95% CI, 1.61-2.92]; HRnon-GCC: 1.81 [95% CI, 1.28-2.91] ). CONCLUSIONS: Although receipt of GCC is important for breast cancer outcomes, racial disparities in breast cancer mortality did not diminish with receipt of GCC; differences in mortality between Black and White patients persisted across the strata of GCC. FAU - Collin, Lindsay J AU - Collin LJ AD - 1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. AD - 2Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. FAU - Yan, Ming AU - Yan M AD - 1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. FAU - Jiang, Renjian AU - Jiang R AD - 1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. AD - 3Winship Cancer Institute, Emory University, and. FAU - Gogineni, Keerthi AU - Gogineni K AD - 3Winship Cancer Institute, Emory University, and. AD - 4Emory University School of Medicine, Atlanta, Georgia; and. FAU - Subhedar, Preeti AU - Subhedar P AD - 3Winship Cancer Institute, Emory University, and. AD - 4Emory University School of Medicine, Atlanta, Georgia; and. FAU - Ward, Kevin C AU - Ward KC AD - 1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. AD - 3Winship Cancer Institute, Emory University, and. FAU - Switchenko, Jeffrey M AU - Switchenko JM AD - 3Winship Cancer Institute, Emory University, and. AD - 5Department of Biostatistics and Bioinformatics, and. FAU - Lipscomb, Joseph AU - Lipscomb J AD - 3Winship Cancer Institute, Emory University, and. AD - 6Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia. FAU - Miller-Kleinhenz, Jasmine AU - Miller-Kleinhenz J AD - 1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. FAU - Torres, Mylin A AU - Torres MA AD - 3Winship Cancer Institute, Emory University, and. AD - 4Emory University School of Medicine, Atlanta, Georgia; and. FAU - Lin, Jolinta AU - Lin J AD - 3Winship Cancer Institute, Emory University, and. AD - 4Emory University School of Medicine, Atlanta, Georgia; and. FAU - McCullough, Lauren E AU - McCullough LE AD - 1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. AD - 3Winship Cancer Institute, Emory University, and. LA - eng GR - TL1 TR002540/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20210816 PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 SB - IM MH - Female MH - Humans MH - Black or African American MH - *Breast Neoplasms/mortality/pathology MH - Ethnicity MH - Healthcare Disparities MH - Prognosis MH - Proportional Hazards Models MH - United States MH - Registries PMC - PMC8847540 MID - NIHMS1754430 EDAT- 2021/08/17 06:00 MHDA- 2023/01/21 06:00 CRDT- 2021/08/16 20:23 PHST- 2020/05/18 00:00 [received] PHST- 2020/12/02 00:00 [accepted] PHST- 2021/08/17 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2021/08/16 20:23 [entrez] AID - jnccn20258 [pii] AID - 10.6004/jnccn.2020.7694 [doi] PST - epublish SO - J Natl Compr Canc Netw. 2021 Aug 16;19(11):1242-1251. doi: 10.6004/jnccn.2020.7694. PMID- 36633901 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1878-5921 (Electronic) IS - 0895-4356 (Linking) VI - 152 DP - 2022 Dec TI - The majority of 922 prediction models supporting breast cancer decision-making are at high risk of bias. PG - 238-247 LID - S0895-4356(22)00266-9 [pii] LID - 10.1016/j.jclinepi.2022.10.016 [doi] AB - OBJECTIVES: To systematically review the currently available prediction models that may support treatment decision-making in breast cancer. STUDY DESIGN AND SETTING: Literature was systematically searched to identify studies reporting on development of prediction models aiming to support breast cancer treatment decision-making, published between January 2010 and December 2020. Quality and risk of bias were assessed using the Prediction model Risk Of Bias (ROB) Assessment Tool (PROBAST). RESULTS: After screening 20,460 studies, 534 studies were included, reporting on 922 models. The 922 models predicted: mortality (n = 417 45%), recurrence (n = 217, 24%), lymph node involvement (n = 141, 15%), adverse events (n = 58, 6%), treatment response (n = 56, 6%), or other outcomes (n = 33, 4%). In total, 285 models (31%) lacked a complete description of the final model and could not be applied to new patients. Most models (n = 878, 95%) were considered to contain high ROB. CONCLUSION: A substantial overlap in predictor variables and outcomes between the models was observed. Most models were not reported according to established reporting guidelines or showed methodological flaws during the development and/or validation of the model. Further development of prediction models with thorough quality and validity assessment is an essential first step for future clinical application. CI - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Hueting, Tom A AU - Hueting TA AD - Department of Health Technology & Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands. FAU - van Maaren, Marissa C AU - van Maaren MC AD - Department of Health Technology & Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. FAU - Hendriks, Mathijs P AU - Hendriks MP AD - Department of Health Technology & Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; Department of Medical Oncology, Northwest Clinics, Alkmaar, The Netherlands. FAU - Koffijberg, Hendrik AU - Koffijberg H AD - Department of Health Technology & Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands. FAU - Siesling, Sabine AU - Siesling S AD - Department of Health Technology & Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. Electronic address: s.siesling@iknl.nl. LA - eng PT - Journal Article PT - Review PT - Systematic Review DEP - 20221027 PL - United States TA - J Clin Epidemiol JT - Journal of clinical epidemiology JID - 8801383 SB - IM MH - Humans MH - Female MH - Prognosis MH - *Breast Neoplasms/therapy MH - Risk Assessment MH - Bias OTO - NOTNLM OT - Breast cancer OT - Clinical prediction models OT - Nomograms OT - Prognostic models OT - Risk of bias OT - Systematic review OT - Treatment decision support EDAT- 2023/01/13 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/12 11:56 PHST- 2022/03/21 00:00 [received] PHST- 2022/09/25 00:00 [revised] PHST- 2022/10/20 00:00 [accepted] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2023/01/12 11:56 [entrez] AID - S0895-4356(22)00266-9 [pii] AID - 10.1016/j.jclinepi.2022.10.016 [doi] PST - ppublish SO - J Clin Epidemiol. 2022 Dec;152:238-247. doi: 10.1016/j.jclinepi.2022.10.016. Epub 2022 Oct 27. PMID- 36642742 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 2047-783X (Electronic) IS - 0949-2321 (Print) IS - 0949-2321 (Linking) VI - 28 IP - 1 DP - 2023 Jan 16 TI - Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases. PG - 27 LID - 10.1186/s40001-022-00894-7 [doi] LID - 27 AB - Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiotherapy for brain metastases has also become an important issue of clinical concern. It remained unclear how to achieve the balance of efficacy and toxicity with the application of new radiotherapy techniques and new targeted therapy drugs. This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases. CI - © 2023. The Author(s). FAU - Yang, Xiaojing AU - Yang X AD - Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233, China. AD - Department of Radiation Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Ren, Hanru AU - Ren H AD - Department of Orthopedics, Pudong Medical Center, Shanghai Pudong Hospital, Fudan University, Shanghai, China. FAU - Xu, Yi AU - Xu Y AD - Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233, China. FAU - Peng, Xue AU - Peng X AD - Department of Breast Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yu, Wenxi AU - Yu W AD - Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233, China. old.007@hotmail.com. FAU - Shen, Zan AU - Shen Z AD - Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai, 200233, China. sshenzzan@vip.sina.com. LA - eng GR - ynqn202118/Shanghai Sixth People's Hospital/ PT - Journal Article PT - Review DEP - 20230116 PL - England TA - Eur J Med Res JT - European journal of medical research JID - 9517857 RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Female MH - Humans MH - *Brain Neoplasms/drug therapy/radiotherapy/secondary MH - *Breast Neoplasms/genetics/radiotherapy PMC - PMC9841677 OTO - NOTNLM OT - Brain metastasis OT - Breast cancer OT - Human epidermal growth factor receptor 2 OT - Radiation therapy OT - Targeted therapy COIS- The authors declare that they have no competing interests. EDAT- 2023/01/16 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/15 23:15 PHST- 2022/09/28 00:00 [received] PHST- 2022/11/09 00:00 [accepted] PHST- 2023/01/15 23:15 [entrez] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - 10.1186/s40001-022-00894-7 [pii] AID - 894 [pii] AID - 10.1186/s40001-022-00894-7 [doi] PST - epublish SO - Eur J Med Res. 2023 Jan 16;28(1):27. doi: 10.1186/s40001-022-00894-7. PMID- 36661672 OWN - NLM STAT- MEDLINE DCOM- 20230125 LR - 20230125 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 1 DP - 2022 Dec 25 TI - A Prospective Population-Based Study of Cardiovascular Disease Mortality following Treatment for Breast Cancer among Men in the United States, 2000-2019. PG - 284-297 LID - 10.3390/curroncol30010023 [doi] AB - Male breast cancer is rare but its incidence and mortality are increasing in the United States, with racial/ethnic disparities in survival reported. There is limited evidence for cardiotoxicity of cancer treatment among men with breast cancer. We evaluated the relation between breast cancer treatment and cardiovascular disease (CVD) mortality among men and investigated the salient roles that race/ethnicity play on this relation. Data were from 5216 men with breast cancer aged ≥ 40 years from the Surveillance, Epidemiology, and End Results program who were diagnosed from 2000 to 2019 and underwent surgery. Competing risk models were used to estimate hazards ratios (HR) and 95% confidence intervals (CI). During a median follow-up of 5.6 years, 1914 deaths occurred with 25% attributable to CVD. In multivariable-adjusted models, men who received chemotherapy had elevated risk for CVD (HR: 1.55, 95%CI: 1.18-2.04). This risk was higher among Hispanic men (HR: 3.96, 95%CI: 1.31-12.02) than non-Hispanic Black and non-Hispanic White men. There was no significant association between radiotherapy and CVD deaths. In this population-based study, treatment with chemotherapy was associated with elevated risk of CVD mortality in men with breast cancer. Racial/ethnic disparities in the association of chemotherapy and CVD mortality were observed. FAU - Appiah, Duke AU - Appiah D AD - Department of Public Health, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. FAU - Mai, Megan AU - Mai M AD - School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. FAU - Parmar, Kanak AU - Parmar K AD - Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. LA - eng PT - Journal Article DEP - 20221225 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM MH - Humans MH - Male MH - *Breast Neoplasms, Male/ethnology/therapy MH - *Cardiovascular Diseases/epidemiology/ethnology MH - Ethnicity MH - Prospective Studies MH - United States/epidemiology PMC - PMC9857851 OTO - NOTNLM OT - breast cancer OT - cardiovascular disease OT - chemotherapy OT - mortality OT - radiotherapy COIS- The authors declare no conflict of interest. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 09:34 PHST- 2022/12/02 00:00 [received] PHST- 2022/12/19 00:00 [revised] PHST- 2022/12/23 00:00 [accepted] PHST- 2023/01/20 09:34 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - curroncol30010023 [pii] AID - curroncol-30-00023 [pii] AID - 10.3390/curroncol30010023 [doi] PST - epublish SO - Curr Oncol. 2022 Dec 25;30(1):284-297. doi: 10.3390/curroncol30010023. PMID- 36582108 OWN - NLM STAT- MEDLINE DCOM- 20230102 LR - 20230103 IS - 2313-4607 (Electronic) IS - 2304-8336 (Linking) VI - 27 DP - 2022 Dec TI - CARDIOTOXICITY IN BREAST CANCER PATIENTS: RELATIONSHIP OF HS-TROPONIN T CHANGES AND HEART FUNCTION IN CANCER TREATMENT. PG - 440-454 LID - 10.33145/2304-8336-2022-27-440-454 [doi] AB - Breast cancer patients (BC) have a high risk of cardiotoxicity (CT) due to a combination of cancer treatments.Cardiovascular (CV) complications lead to delay or withdrawal of BC therapy and worsen the survival. Therefore, it isimportant to detect CT at the early stages before the occurrence of cardiac dysfunction and heart failure (HF) signs. OBJECTIVE: to study the dynamic changes of high-sensitivity (hs) troponin (Tn) T (hs-TnT) level in BC patients during cancer treatment with the use of chemotherapy and radiation therapy (RT) to predict and prevent CV complications during individualized management. MATERIAL AND METHODS: 40 BC patients were included in the pilot study. The analysis of the dynamic changes of hs-TnT and ejection fraction (EF) of the left ventricle (LV) was performed before and within 6 months of cancer treatment. Based on the data analysis, a definition of a significant increase in hs-TnT was developed and proposed. Therise of hs-TnT was calculated by the difference (%) between its baseline level and in the 6 months of cancer treatment. BC patients are grouped into tertiles according to the hs-TnT increase: group 1 - low level (0-50 %), group 2 -moderate level (> 50-100 %), and group 3 - high level (> 100 %). RESULTS: Before the start of cancer treatment, LVEF did not differ significantly between groups (mean EF (62.6 ± 1.0) %)and the hs-TnT level was also within normal values (0.008±0.001 ng/ml). In 6 months of cancer treatment, LVEF waswithin the normal ranges and did not differ significantly in patients of group 1. However, in patients of groups 2and 3 - LVEF drop (δLV EF) was 5.7 % (р < 0.01) and 10.8 % (р < 0.01), consequently. According to the correlationanalysis, the percentage of increase in hs-TnT (δhs-TnT) was associated with δEF LV (r = 0.39, р < 0.05) and the useof anthracyclines (AC) (r = 0.37, р < 0.05). Using logistic regression and ROC analysis, the diagnostic threshold valueof the hs-TnT increase > 165 % was defined, which can be considered as a reliable marker of early biochemical CT,with a sensitivity of 99 % and a specificity of 56 %. CONCLUSIONS: In BC patients, based on the level of hs-TnT increase, proposed a new early biochemical CT detectionmethod. Under the new approach, BC patients with hsTnT increase of > 165 % from baseline can be considered as areliable marker of early biochemical CT, with a sensitivity of 99 % and a specificity of 56 %. CI - N. V. Dovganych, S. M. Kozhukhov, I. I. Smolanka, O. F. Lygyrda, О. Ye. Bazyka, S. A. Lyalkin, O. M. Ivankova, О. A. Yarynkina, N. V. Tkhor. FAU - Dovganych, N V AU - Dovganych NV AD - SI National Scientific Center The M.D. Strazhesko Institute of Cardiology of the NAMS of Ukraine, 5 Narodnoho Opolchennia St., Kyiv, 03680, Ukraine. FAU - Kozhukhov, S M AU - Kozhukhov SM AD - SI National Scientific Center The M.D. Strazhesko Institute of Cardiology of the NAMS of Ukraine, 5 Narodnoho Opolchennia St., Kyiv, 03680, Ukraine. FAU - Smolanka, I I AU - Smolanka II AD - National Cancer Institute of the Ministry of Health of Ukraine, 33/43 Lomonosova St., Kyiv, 03022, Ukraine. FAU - Lygyrda, O F AU - Lygyrda OF AD - National Cancer Institute of the Ministry of Health of Ukraine, 33/43 Lomonosova St., Kyiv, 03022, Ukraine. FAU - Bazyka, O Ye AU - Bazyka OY AD - SI National Scientific Center The M.D. Strazhesko Institute of Cardiology of the NAMS of Ukraine, 5 Narodnoho Opolchennia St., Kyiv, 03680, Ukraine. FAU - Lyalkin, S A AU - Lyalkin SA AD - National Cancer Institute of the Ministry of Health of Ukraine, 33/43 Lomonosova St., Kyiv, 03022, Ukraine. FAU - Ivankova, O M AU - Ivankova OM AD - National Cancer Institute of the Ministry of Health of Ukraine, 33/43 Lomonosova St., Kyiv, 03022, Ukraine. FAU - Yarynkina, O A AU - Yarynkina OA AD - SI National Scientific Center The M.D. Strazhesko Institute of Cardiology of the NAMS of Ukraine, 5 Narodnoho Opolchennia St., Kyiv, 03680, Ukraine. FAU - Tkhor, N V AU - Tkhor NV AD - SI National Scientific Center The M.D. Strazhesko Institute of Cardiology of the NAMS of Ukraine, 5 Narodnoho Opolchennia St., Kyiv, 03680, Ukraine. LA - eng LA - ukr PT - Journal Article TT - KARDIOTOKSYChNIST' U KhVORYKh NA RAK GRUDNOÏ ZALOZY: VZAIeMOZVIaZOK ZMIN TROPONINU T TA FUNKTsIÏ SERTsIa NA FONI KOMPLEKSNOÏ PROTYPUKhLYNNOÏ TERAPIÏ. PL - Ukraine TA - Probl Radiac Med Radiobiol JT - Problemy radiatsiinoi medytsyny ta radiobiolohii JID - 101560511 RN - 0 (Troponin T) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/complications MH - Troponin T/therapeutic use MH - Cardiotoxicity/etiology MH - Pilot Projects MH - *Heart Failure OTO - NOTNLM OT - breast cancer OT - cardiotoxicity OT - heart failure OT - heart function OT - troponin T EDAT- 2022/12/31 06:00 MHDA- 2023/01/03 06:00 CRDT- 2022/12/30 01:03 PHST- 2022/04/18 00:00 [received] PHST- 2022/12/30 01:03 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/03 06:00 [medline] AID - 10.33145/2304-8336-2022-27-440-454 [doi] PST - ppublish SO - Probl Radiac Med Radiobiol. 2022 Dec;27:440-454. doi: 10.33145/2304-8336-2022-27-440-454. PMID- 35648170 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1439-099X (Electronic) IS - 0179-7158 (Linking) VI - 199 IP - 1 DP - 2023 Jan TI - Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer. PG - 30-37 LID - 10.1007/s00066-022-01960-z [doi] AB - INTRODUCTION: Chemorefractory nonmetastatic inflammatory breast cancer (IBC) which progresses under neoadjuvant chemotherapy poses specific therapeutic challenges: either pursuing a curative-intent treatment with a salvage combination of radiotherapy and surgery or switching to second-line systemic treatments despite the absence of metastasis. Due to the rarity of this situation, no specific management guidelines exist and the outcomes of these patients remain uncertain. In this retrospective observational study, we aimed to report the clinical outcomes of patients treated in a curative intent for chemorefractory nonmetastatic IBC, with a multimodal salvage treatment combining radiotherapy and surgery. MATERIALS AND METHODS: This single-center retrospective observational study included all chemorefractory nonmetastatic IBC treated at the Institut Curie (Paris, France). Overall survival (OS), disease-free survival (DFS), and locoregional relapse-free survival (LRRFS) were calculated from the time of diagnosis and from the time of neoadjuvant chemotherapy interruption. RESULTS: Between January 2010 and January 2018, 7 patients presented with chemorefractory nonmetastatic IBC with a progressive disease during neoadjuvant chemotherapy. Overall, chemorefractory IBC patients were young (median age of 50 years), had a good performance status, and usually presented with node-positive tumors characterized by a combination of adverse histological factors such as triple-negative breast cancer (TNBC), grade III, and high proliferation index. From the date of pathological diagnosis, 1‑year OS, DFS, and LRRFS were 64.3%, 53.6%, and 71.4%, respectively. From the date of neoadjuvant chemotherapy interruption, 1‑year OS, DFS, and LRRFS were 47.6%, 19.0%, and 45.7%, respectively, and median OS, DFS, and LRRFS were 8.3, 5.0, and 5.0 months, respectively. CONCLUSION: The prognosis of chemorefractory nonmetastatic IBC treated with a multimodal approach combining surgery and radiotherapy is particularly reserved, despite the curative intent of the salvage treatment and the lack of distant metastasis at the time of treatment. Optimal treatment modalities are still to be defined in this rare but critical presentation of IBC. CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. FAU - Loap, Pierre AU - Loap P AUID- ORCID: 0000-0001-8863-8110 AD - Institut Curie, Department of Radiation Oncology, Paris, France. pierre.loap@gmail.com. FAU - Nicaise, Benjamin AU - Nicaise B AD - Institut Curie, Department of Radiation Oncology, Paris, France. FAU - Laki, Fatima AU - Laki F AD - Institut Curie, Department of Surgery, Paris, France. FAU - Loirat, Delphine AU - Loirat D AD - Institut Curie, Department of Medical Oncology, Paris, France. FAU - Pierga, Jean-Yves AU - Pierga JY AD - Institut Curie, Department of Medical Oncology, Paris, France. FAU - Fourquet, Alain AU - Fourquet A AD - Institut Curie, Department of Radiation Oncology, Paris, France. FAU - Kirova, Youlia AU - Kirova Y AD - Institut Curie, Department of Radiation Oncology, Paris, France. LA - eng PT - Journal Article PT - Observational Study DEP - 20220601 PL - Germany TA - Strahlenther Onkol JT - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] JID - 8603469 SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Inflammatory Breast Neoplasms/radiotherapy/drug therapy MH - *Breast Neoplasms/therapy MH - Neoplasm Recurrence, Local MH - Prognosis MH - Disease-Free Survival MH - Combined Modality Therapy MH - Retrospective Studies MH - Neoadjuvant Therapy OTO - NOTNLM OT - Breast cancer OT - Breast radiotherapy OT - Breast surgery OT - Chemoradiotherapy OT - Chemorefractoriness EDAT- 2022/06/02 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/06/01 12:15 PHST- 2022/01/03 00:00 [received] PHST- 2022/05/08 00:00 [accepted] PHST- 2022/06/02 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/06/01 12:15 [entrez] AID - 10.1007/s00066-022-01960-z [pii] AID - 10.1007/s00066-022-01960-z [doi] PST - ppublish SO - Strahlenther Onkol. 2023 Jan;199(1):30-37. doi: 10.1007/s00066-022-01960-z. Epub 2022 Jun 1. PMID- 36555156 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 24 DP - 2022 Dec 8 TI - Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer. LID - 10.3390/ijms232415515 [doi] LID - 15515 AB - Breast cancer is a heterogeneous disease with distinct clinical and molecular characteristics. Scientific advances in molecular subtype differentiation support the understanding of cellular signaling, crosstalk, proliferation, survival, migration, and invasion mechanisms, allowing the development of new molecular drug targets. The breast cancer subtype with super expression and/or amplification of human growth factor receptor 2 (HER2) is clinically aggressive, but prognosis significantly shifted with the advent of anti-HER2 targeted therapy. Zoledronic-acid (ZOL) combined with a neoadjuvant Trastuzumab-containing chemotherapy regimen (Doxorubicin, Cyclophosphamide followed by Docetaxel, Trastuzumab) increased the pCR rate in a RH-positive/ HER2-positive subgroup, according to the phase II Zo-NAnTax trial. To verify genes that could be related to this response, a microarray assay was performed finding 164 differentially expressed genes. Silico analysis of these genes showed signaling pathways related to growth factors, apoptosis, invasion, and metabolism, as well as differentially expressed genes related to estrogen response. In addition, the RAC3 gene was found to interact with the MVD gene, a member of the mevalonate pathway. Taken together, these results indicate that RH-positive/ HER2-positive patients present gene alterations before treatment, and these could be related to the improvement of pCR. FAU - Crocamo, Susanne AU - Crocamo S AUID- ORCID: 0000-0002-5463-5517 AD - Núcleo de Pesquisa Clínica, Hospital de Câncer III, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro 20560-121, Brazil. FAU - Binato, Renata AU - Binato R AD - Laboratório de Célula-Tronco, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro 20230-130, Brazil. FAU - Dos Santos, Everton Cruz AU - Dos Santos EC AUID- ORCID: 0000-0002-3412-5325 AD - Laboratório de Célula-Tronco, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro 20230-130, Brazil. FAU - de Paula, Bruno AU - de Paula B AUID- ORCID: 0000-0001-6427-229X AD - Núcleo de Pesquisa Clínica, Hospital de Câncer III, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro 20560-121, Brazil. FAU - Abdelhay, Eliana AU - Abdelhay E AD - Laboratório de Célula-Tronco, Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro 20230-130, Brazil. LA - eng GR - E501 26/202.981/2016./Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro/ GR - E-26/210.725/2014/Ministry of Health/ GR - 303479/2015/National Council for Scientific and Technological Development/ PT - Clinical Trial, Phase II PT - Journal Article DEP - 20221208 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 6XC1PAD3KF (Zoledronic Acid) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - P188ANX8CK (Trastuzumab) RN - 8N3DW7272P (Cyclophosphamide) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Zoledronic Acid/therapeutic use MH - Neoadjuvant Therapy MH - Receptor, ErbB-2/genetics/metabolism MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Trastuzumab/therapeutic use MH - Cyclophosphamide/therapeutic use MH - Treatment Outcome PMC - PMC9779412 OTO - NOTNLM OT - HER2-positive OT - breast cancer OT - differential expression genes OT - zoledronic acid COIS- The authors declare no conflict of interests. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:32 PHST- 2022/10/12 00:00 [received] PHST- 2022/11/16 00:00 [revised] PHST- 2022/11/17 00:00 [accepted] PHST- 2022/12/23 01:32 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - ijms232415515 [pii] AID - ijms-23-15515 [pii] AID - 10.3390/ijms232415515 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 8;23(24):15515. doi: 10.3390/ijms232415515. PMID- 36542678 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1651-226X (Electronic) IS - 0284-186X (Linking) VI - 61 IP - 12 DP - 2022 Dec TI - Age-specific survival trends and life-years lost in women with breast cancer 1990-2016: the NORDCAN survival studies. PG - 1481-1489 LID - 10.1080/0284186X.2022.2156811 [doi] AB - BACKGROUND: A recent overview of cancer survival trends 1990-2016 in the Nordic countries reported continued improvements in age-standardized breast cancer survival among women. The aim was to estimate age-specific survival trends over calendar time, including life-years lost, to evaluate if improvements have benefited patients across all ages in the Nordic countries. METHODS: Data on breast cancers diagnosed 1990-2016 in Denmark, Finland, Iceland, Norway, and Sweden were obtained from the NORDCAN database. Age-standardized and age-specific relative survival (RS) was estimated using flexible parametric models, as was reference-adjusted crude probabilities of death and life-years lost. RESULTS: Age-standardized period estimates of 5-year RS in women diagnosed with breast cancer ranged from 87% to 90% and 10-year RS from 74% to 85%. Ten-year RS increased with 15-18 percentage points from 1990 to 2016, except in Sweden (+9 percentage points) which had the highest survival in 1990. The largest improvements were observed in Denmark, where a previous survival disadvantage diminished. Most recent 5-year crude probabilities of cancer death ranged from 9% (Finland, Sweden) to 12% (Denmark, Iceland), and life-years lost from 3.3 years (Finland) to 4.6 years (Denmark). Although survival improvements were consistent across different ages, women aged ≥70 years had the lowest RS in all countries. Period estimates of 5-year RS were 94-95% in age 55 years and 84-89% in age 75 years, while 10-year RS were 88-91% in age 55 years and 69-84% in age 75 years. Women aged 40 years lost on average 11.0-13.8 years, while women lost 3.8-6.0 years if aged 55 and 1.9-3.5 years if aged 75 years. CONCLUSIONS: Survival for Nordic women with breast cancer improved from 1990 to 2016 in all age groups, albeit with larger country variation among older women where survival was also lower. Women over 70 years of age have not had the same survival improvement as women of younger age. FAU - Lundberg, Frida E AU - Lundberg FE AUID- ORCID: 0000-0001-7061-7178 AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. FAU - Kroman, Niels AU - Kroman N AD - Department Breast Surgery, Copenhagen University Hospital (Herlev/Gentofte), Copenhagen, Denmark. FAU - Lambe, Mats AU - Lambe M AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. AD - Regional Cancer Centre Uppsala Örebro, Uppsala, Sweden. FAU - Andersson, Therese M-L AU - Andersson TM AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. FAU - Engholm, Gerda AU - Engholm G AD - Danish Cancer Society, Cancer Surveillance and Pharmacoepidemiology, Copenhagen, Denmark. FAU - Johannesen, Tom Børge AU - Johannesen TB AD - Cancer Registry of Norway, Oslo, Norway. FAU - Virtanen, Anni AU - Virtanen A AD - Finnish Cancer Registry, Helsinki, Finland. AD - Department of Pathology, University of Helsinki, and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland. FAU - Pettersson, David AU - Pettersson D AD - Swedish Cancer Registry, National Board of Health and Welfare, Stockholm, Sweden. FAU - Ólafsdóttir, Elínborg J AU - Ólafsdóttir EJ AD - Icelandic Cancer Registry, Reykjavík, Iceland. FAU - Birgisson, Helgi AU - Birgisson H AD - Icelandic Cancer Registry, Reykjavík, Iceland. FAU - Lambert, Paul C AU - Lambert PC AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. AD - Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK. FAU - Mørch, Lina Steinrud AU - Mørch LS AD - Danish Cancer Society, Cancer Surveillance and Pharmacoepidemiology, Copenhagen, Denmark. FAU - Johansson, Anna L V AU - Johansson ALV AUID- ORCID: 0000-0002-1191-7231 AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. AD - Cancer Registry of Norway, Oslo, Norway. LA - eng PT - Journal Article DEP - 20221221 PL - England TA - Acta Oncol JT - Acta oncologica (Stockholm, Sweden) JID - 8709065 SB - IM MH - Humans MH - Female MH - Aged MH - Aged, 80 and over MH - *Breast Neoplasms/therapy MH - Survival Rate MH - Risk Factors MH - Scandinavian and Nordic Countries/epidemiology MH - Finland/epidemiology MH - Sweden/epidemiology MH - Norway/epidemiology MH - Registries MH - Age Factors MH - Denmark/epidemiology OTO - NOTNLM OT - Breast cancer OT - NORDCAN OT - Nordic cancer registries OT - comparison OT - survival EDAT- 2022/12/22 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/12/21 13:52 PHST- 2022/12/22 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/12/21 13:52 [entrez] AID - 10.1080/0284186X.2022.2156811 [doi] PST - ppublish SO - Acta Oncol. 2022 Dec;61(12):1481-1489. doi: 10.1080/0284186X.2022.2156811. Epub 2022 Dec 21. PMID- 36547124 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230112 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 29 IP - 12 DP - 2022 Nov 23 TI - The Clinicopathological Significance of BiP/GRP-78 in Breast Cancer: A Meta-Analysis of Public Datasets and Immunohistochemical Detection. PG - 9066-9087 LID - 10.3390/curroncol29120710 [doi] AB - The endoplasmic reticulum chaperone BiP (also known as GRP-78 or HSPA5) maintains protein folding to allow cell proliferation and survival and has been implicated in carcinogenesis, tumor progression, and therapy resistance. BiP's association with clinical factors and prognostic potential in breast cancer remains unclear. In this work, three types of analysis were conducted to improve the knowledge of BiP's clinicopathological potential: (1) analysis of publicly available RNA-seq and proteomics datasets stratified as high and low quartiles; (2) a systematic review and meta-analysis of immunohistochemical detection of BIP; (3) confirmation of findings by BiP immunohistochemical detection in two luminal-like breast cancer small cohorts of paired samples (pre- vs. post-endocrine therapy, and primary pre- vs. metastasis post-endocrine therapy). The TCGA PanCancer dataset and CPTAC showed groups with high BiP mRNA and protein associated with HER2, basal-like subtypes, and higher immune scores. The meta-analysis of BiP immunohistochemistry disclosed an association between higher BiP positivity and reduced relapse-free survival. BiP immunohistochemistry confirmed increased BiP expression in metastasis, an association of BiP positivity with HER2 expression, and nuclear BiP localization with higher a tumor stage and poor outcome. Therefore, three independent approaches showed that BiP protein is associated with worse outcomes and holds prognostic potential for breast cancer. FAU - Direito, Inês AU - Direito I AD - iBiMED-Institute of Biomedicine, University of Aveiro, Agra do Crasto 30, 3810-193 Aveiro, Portugal. FAU - Gomes, Daniela AU - Gomes D AD - iBiMED-Institute of Biomedicine, University of Aveiro, Agra do Crasto 30, 3810-193 Aveiro, Portugal. FAU - Monteiro, Fátima Liliana AU - Monteiro FL AUID- ORCID: 0000-0002-8438-0332 AD - iBiMED-Institute of Biomedicine, University of Aveiro, Agra do Crasto 30, 3810-193 Aveiro, Portugal. FAU - Carneiro, Isa AU - Carneiro I AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC) & RISE@CI-IPOP (Health Research Network), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. FAU - Lobo, João AU - Lobo J AUID- ORCID: 0000-0001-6829-1391 AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC) & RISE@CI-IPOP (Health Research Network), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. AD - Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal. FAU - Henrique, Rui AU - Henrique R AUID- ORCID: 0000-0003-3171-4666 AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC) & RISE@CI-IPOP (Health Research Network), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. AD - Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal. FAU - Jerónimo, Carmen AU - Jerónimo C AUID- ORCID: 0000-0003-4186-5345 AD - Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. AD - Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC) & RISE@CI-IPOP (Health Research Network), R. Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. AD - Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal. FAU - Helguero, Luisa Alejandra AU - Helguero LA AUID- ORCID: 0000-0001-8237-2390 AD - iBiMED-Institute of Biomedicine, University of Aveiro, Agra do Crasto 30, 3810-193 Aveiro, Portugal. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20221123 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Endoplasmic Reticulum Chaperone BiP) RN - 0 (Heat-Shock Proteins) SB - IM MH - Humans MH - Female MH - *Endoplasmic Reticulum Chaperone BiP MH - Heat-Shock Proteins/genetics/metabolism MH - *Breast Neoplasms/genetics MH - Neoplasm Recurrence, Local MH - Prognosis PMC - PMC9777260 OTO - NOTNLM OT - BiP/GRP-78 OT - TCGA OT - breast cancer outcomes OT - immunohistochemistry OT - therapy resistance OT - unfolded protein response COIS- The authors declare no conflict of interest. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 09:53 PHST- 2022/10/21 00:00 [received] PHST- 2022/11/15 00:00 [revised] PHST- 2022/11/17 00:00 [accepted] PHST- 2022/12/22 09:53 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - curroncol29120710 [pii] AID - curroncol-29-00710 [pii] AID - 10.3390/curroncol29120710 [doi] PST - epublish SO - Curr Oncol. 2022 Nov 23;29(12):9066-9087. doi: 10.3390/curroncol29120710. PMID- 36632469 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1449-2288 (Electronic) IS - 1449-2288 (Linking) VI - 19 IP - 2 DP - 2023 TI - Targeting Breast Cancer Stem Cells. PG - 552-570 LID - 10.7150/ijbs.76187 [doi] AB - The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence have been recognized for many decades. Due to their strong capacity for self-renewal and differentiation, BCSCs are the major reasons for poor clinical outcomes and low therapeutic response. Several hypotheses on the origin of cancer stem cells have been proposed, including critical gene mutations in stem cells, dedifferentiation of somatic cells, and cell plasticity remodeling by epithelial-mesenchymal transition (EMT) and the tumor microenvironment. Moreover, the tumor microenvironment, including cellular components and cytokines, modulates the self-renewal and therapeutic resistance of BCSCs. Small molecules, antibodies, and chimeric antigen receptor (CAR)-T cells targeting BCSCs have been developed, and their applications in combination with conventional therapies are undergoing clinical trials. In this review, we focus on the features of BCSCs, emphasize the major factors and tumor environment that regulate the stemness of BCSCs, and discuss potential BCSC-targeting therapies. CI - © The author(s). FAU - Zhang, Lu AU - Zhang L AD - Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; State Key Laboratory of Genetic Engineering; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; The Shanghai paracrine Key Laboratory of Medical Epigenetics; Shanghai Key Laboratory of Radiation Oncology; The International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology; Shanghai Medical College; Fudan University, Shanghai 200032, China. FAU - Chen, Wenmin AU - Chen W AD - Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming 650201, China. AD - Kunming College of Life Sciences, the University of the Chinese Academy of Sciences, Kunming 650201, China. FAU - Liu, Suling AU - Liu S AD - Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; State Key Laboratory of Genetic Engineering; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; The Shanghai paracrine Key Laboratory of Medical Epigenetics; Shanghai Key Laboratory of Radiation Oncology; The International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology; Shanghai Medical College; Fudan University, Shanghai 200032, China. AD - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing 211166, China. FAU - Chen, Ceshi AU - Chen C AD - Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming 650201, China. AD - Academy of Biomedical Engineering, Kunming Medical University, Kunming 650500, China. AD - The Third Affiliated Hospital, Kunming Medical University, Kunming 650118, China. LA - eng PT - Journal Article PT - Review DEP - 20230101 PL - Australia TA - Int J Biol Sci JT - International journal of biological sciences JID - 101235568 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/therapy/pathology MH - Breast/pathology MH - Cell Transformation, Neoplastic/pathology MH - Epithelial-Mesenchymal Transition MH - Neoplastic Stem Cells/pathology MH - Tumor Microenvironment PMC - PMC9830502 OTO - NOTNLM OT - Breast cancer stem cell OT - Epithelial-Mesenchymal Transition OT - Therapeutic strategies OT - Tumor microenvironment COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2023/01/13 06:00 MHDA- 2023/01/14 06:00 CRDT- 2023/01/12 02:01 PHST- 2022/06/15 00:00 [received] PHST- 2022/12/09 00:00 [accepted] PHST- 2023/01/12 02:01 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] AID - ijbsv19p0552 [pii] AID - 10.7150/ijbs.76187 [doi] PST - epublish SO - Int J Biol Sci. 2023 Jan 1;19(2):552-570. doi: 10.7150/ijbs.76187. eCollection 2023. PMID- 36551262 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 2218-273X (Electronic) IS - 2218-273X (Linking) VI - 12 IP - 12 DP - 2022 Dec 8 TI - Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer. LID - 10.3390/biom12121834 [doi] LID - 1834 AB - Anthracycline is a mainstay of treatment for breast cancer patients because of its antitumor activity. However, anthracycline resistance is a critical barrier in treating breast cancer. Thus, it is of great importance to uncover the molecular mechanisms underlying anthracycline resistance in breast cancer. Herein, we integrated transcriptome data, genetic alterations data, and clinical data of The Cancer Genome Atlas (TCGA) to identify the molecular mechanisms involved in anthracycline resistance in breast cancer. Two hundred and four upregulated genes and 1376 downregulated genes were characterized between the anthracycline-sensitive and anthracycline-resistant groups. It was found that drug resistance-associated genes such as ABCB5, CYP1A1, and CYP4Z1 were significantly upregulated in the anthracycline-resistant group. The gene set enrichment analysis (GSEA) suggested that the P53 signaling pathway, DNA replication, cysteine, and methionine metabolism pathways were associated with anthracycline sensitivity. Somatic TP53 mutation was a common genetic abnormality observed in the anthracycline-sensitive group, while CDH1 mutation was presented in the anthracycline-resistant group. Immune infiltration patterns were extremely different between the anthracycline-sensitive and anthracycline-resistant groups. Immune-associated chemokines and cytokines, immune regulators, and human leukocyte antigen genes were significantly upregulated in the anthracycline-sensitive group. These results reveal potential molecular mechanisms associated with anthracycline resistance. FAU - Liu, Zihao AU - Liu Z AD - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. AD - Department of Breast and Thyroid Surgery, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen 518020, China. FAU - Gao, Jingbo AU - Gao J AD - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. FAU - Gu, Ran AU - Gu R AD - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. FAU - Shi, Yu AU - Shi Y AD - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. FAU - Hu, Hong AU - Hu H AD - Department of Breast and Thyroid Surgery, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen 518020, China. FAU - Liu, Jianlan AU - Liu J AD - Department of Pathology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen 518020, China. FAU - Huang, Jiefeng AU - Huang J AD - Department of Breast and Thyroid Surgery, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen 518020, China. FAU - Zhong, Caineng AU - Zhong C AD - Department of Breast and Thyroid Surgery, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen 518020, China. FAU - Zhou, Wenbin AU - Zhou W AD - Department of Breast and Thyroid Surgery, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen 518020, China. FAU - Yang, Yaping AU - Yang Y AD - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. FAU - Gong, Chang AU - Gong C AD - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221208 PL - Switzerland TA - Biomolecules JT - Biomolecules JID - 101596414 RN - 0 (Anthracyclines) RN - 0 (Antibiotics, Antineoplastic) RN - EC 1.14.14.1 (CYP4Z1 protein, human) RN - EC 1.14.14.1 (Cytochrome P450 Family 4) SB - IM MH - Female MH - Humans MH - *Anthracyclines/pharmacology/therapeutic use MH - *Antibiotics, Antineoplastic/pharmacology/therapeutic use MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Cytochrome P450 Family 4/genetics MH - *Drug Resistance, Neoplasm/genetics MH - Mutation MH - *Transcriptome MH - *Gene Expression Profiling PMC - PMC9775906 OTO - NOTNLM OT - anthracycline OT - breast cancer OT - resistance COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:09 PHST- 2022/10/31 00:00 [received] PHST- 2022/12/01 00:00 [revised] PHST- 2022/12/06 00:00 [accepted] PHST- 2022/12/23 01:09 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - biom12121834 [pii] AID - biomolecules-12-01834 [pii] AID - 10.3390/biom12121834 [doi] PST - epublish SO - Biomolecules. 2022 Dec 8;12(12):1834. doi: 10.3390/biom12121834. PMID- 36162712 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1878-5921 (Electronic) IS - 0895-4356 (Linking) VI - 152 DP - 2022 Dec TI - Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score. PG - 101-109 LID - S0895-4356(22)00231-1 [pii] LID - 10.1016/j.jclinepi.2022.09.010 [doi] AB - BACKGROUND AND OBJECTIVES: The EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) and the Patient-Reported Outcome Measurement Information System Preference Score (PROPr) are new health state utility (HSU) scores for quality-adjusted life years in cost-effectiveness analyses. Both are expected to measure HSU more comprehensively than existing measures in cancer patients by including cancer-related health domains such as fatigue. The aim of this study is to compare both scores in a sample of breast cancer patients. METHODS: We collected QLU-C10D and PROPr from 291 patients 90 days after treatment in the outpatient clinic of the breast cancer center at Charité - University Medicine Berlin between June 2018 and April 2021. We assessed both scores' convergent and known-groups validity, agreement, and ceiling and floor effects. RESULTS: The mean QLU-C10D score [0.71, 95% confidence interval (CI) 0.69-0.74] and the mean PROPr score (0.43, 95% CI 0.41-0.46) differed systematically (0.28, 95% CI 0.27-0.30) and showed fair agreement (intraclass correlation coefficient 0.46, 95% CI 0.32-0.57). The Pearson correlation coefficient was 0.83 (95% CI 0.79-0.86). Both scores showed similar discrimination across known groups of age, treatment, cancer stage, marital status, and education. The QLU-C10D showed relevant ceiling effects. CONCLUSION: QLU-C10D and PROPr measure HSU differently as a result of different utility models. The choice between QLU-C10D and PROPr should be informed by context, population, disease, and treatment. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Klapproth, Christoph Paul AU - Klapproth CP AD - Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité-Universitätsmedizin, Berlin, Germany. Electronic address: christoph-paul.klapproth@charite.de. FAU - Fischer, Felix AU - Fischer F AD - Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité-Universitätsmedizin, Berlin, Germany. FAU - Rose, Matthias AU - Rose M AD - Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité-Universitätsmedizin, Berlin, Germany; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA. FAU - Karsten, Maria Margarete AU - Karsten MM AD - Department of Gynecology with Breast Cancer, Charité-Universitätsmedizin, Berlin, Germany. LA - eng PT - Journal Article DEP - 20220924 PL - United States TA - J Clin Epidemiol JT - Journal of clinical epidemiology JID - 8801383 SB - IM MH - Humans MH - Female MH - *Quality of Life MH - *Breast Neoplasms/therapy MH - Surveys and Questionnaires MH - Quality-Adjusted Life Years MH - Cost-Effectiveness Analysis OTO - NOTNLM OT - Breast cancer OT - EORTC QLU-C10D OT - Health-related quality of life OT - PROPr OT - Patient-reported outcomes OT - QALY EDAT- 2022/09/27 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/09/26 19:36 PHST- 2022/01/28 00:00 [received] PHST- 2022/09/09 00:00 [revised] PHST- 2022/09/19 00:00 [accepted] PHST- 2022/09/27 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/09/26 19:36 [entrez] AID - S0895-4356(22)00231-1 [pii] AID - 10.1016/j.jclinepi.2022.09.010 [doi] PST - ppublish SO - J Clin Epidemiol. 2022 Dec;152:101-109. doi: 10.1016/j.jclinepi.2022.09.010. Epub 2022 Sep 24. PMID- 36379199 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. PG - 293-304 LID - S0960-9776(22)00179-5 [pii] LID - 10.1016/j.breast.2022.10.014 [doi] AB - BACKGROUND: Approximately 5-10% of unselected breast cancer (BC) patients retain a hereditary predisposition related to a germline mutation in BRCA1/2 genes. The poly-ADP ribose polymerase (PARP)-inhibitors olaparib and talazoparib have been granted marketing authorization by both FDA and EMA for adults with BRCA1/2 germline mutations and HER2-negative (HER2-) advanced BC based on the results from the phase III OlympiAd and EMBRACA trials. METHODS: The panel of the Italian Association of Medical Oncology (AIOM) Clinical Practice Guidelines on Breast Cancer addressed two critical clinical questions, adopting the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach and the Evidence to Decision framework (EtD), to develop recommendations on the use of PARP-inhibitors, with respect to single-agent chemotherapy, in patients with BRCA-related triple-negative (clinical question 1) and hormone receptor-positive (HR+)/HER2- (clinical question 2) advanced BC. RESULTS: Two studies were eligible (OlympiAd and EMBRACA). For both clinical questions, the Panel judged the benefit/harm balance probably in favor of the intervention, given the favorable impact in terms of PFS, ORR, and QoL at an acceptable cost in terms of toxicity; the overall certainty of the evidence was low. The panel's final recommendations were conditional in favor of PARP-inhibitors over single-agent chemotherapy in both HR+/HER2-and triple-negative BC. Finally, the Panel identified and discussed areas of uncertainty calling for further exploration. CONCLUSIONS: The Panel of AIOM BC Clinical Practice Guideline provided clinical recommendations on the use of PARP-inhibitors, with respect to single-agent chemotherapy, in patients with BRCA-related HER2-advanced BC by adopting the GRADE methodology. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Miglietta, Federica AU - Miglietta F AD - Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. Electronic address: federica.miglietta@iov.veneto.it. FAU - Cinquini, Michela AU - Cinquini M AD - Istituto di Ricerche Farmacologiche Mario Negri IRCCS., Laboratory of Methodology of Sistematic Reviews and Guidelines production; Department of Oncology, Milano, Italy. FAU - Dieci, Maria Vittoria AU - Dieci MV AD - Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy. FAU - Cortesi, Laura AU - Cortesi L AD - Department of Oncology and Hematology Azienda Ospedaliero-Universitaria di Modena, Italy. FAU - Criscitiello, Carmen AU - Criscitiello C AD - European Institute of Oncology IRCCS, Milan, Italy; University of Milan, Milan, Italy. FAU - Montemurro, Filippo AU - Montemurro F AD - Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. FAU - Del Mastro, Lucia AU - Del Mastro L AD - Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialities, School of Medicine, University of Genova, Genova, Italy. FAU - Zambelli, Alberto AU - Zambelli A AD - Department of Biomedical Sciences, Humanitas University, Milan, Italy; IRCCS Humanitas Research Hospital, Milan, Italy. FAU - Biganzoli, Laura AU - Biganzoli L AD - Medical Oncology Division, Hospital of Prato, Prato, Italy. FAU - Levaggi, Alessia AU - Levaggi A AD - Department of Oncology, Sant'Andrea Hospital, La Spezia, Italy. FAU - Delle Piane, Chiara AU - Delle Piane C AD - Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Marchiò, Caterina AU - Marchiò C AD - Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy; Department of Medical Sciences, University of Turin, Turin, Italy. FAU - Calabrese, Massimo AU - Calabrese M AD - Senologia Diagnostica, IRCCS-Ospedale Policlinico San Martino - Genova, Italy. FAU - Fortunato, Lucio AU - Fortunato L AD - Centro di Senologia - Azienda Ospedaliera San Giovanni-Addolorata, Roma, Italy. FAU - Franco, Pierfrancesco AU - Franco P AD - Department of Translational Medicine (DIMET), University of Eastern Piedmont, Novara, Italy. FAU - Meduri, Bruno AU - Meduri B AD - Radioterapia - Azienda ospedaliera-Universitaria di Modena, Modena, Italy. FAU - Fittipaldo, Veronica Andrea AU - Fittipaldo VA AD - Istituto di Ricerche Farmacologiche Mario Negri IRCCS., Laboratory of Methodology of Sistematic Reviews and Guidelines production; Department of Oncology, Milano, Italy. FAU - Gori, Stefania AU - Gori S AD - Medical Oncology Unit, Sacro Cuore - Don Calabria Hospital, Cancer Care Center, Negrar, Italy. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20221029 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Poly(ADP-ribose) Polymerase Inhibitors) RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) SB - IM MH - Adult MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/chemically induced MH - Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use MH - Quality of Life MH - BRCA1 Protein/genetics MH - *Triple Negative Breast Neoplasms/drug therapy MH - Genes, BRCA1 MH - Germ-Line Mutation PMC - PMC9663524 OTO - NOTNLM OT - BRCA germline mutations OT - Breast cancer OT - GRADE methodology OT - HER2-negative OT - PARP-Inhibitors COIS- Declaration of competing interest FM personal fee from Roche, Novartis and Gilead outside the submitted work. MVD: personal fees from Eli Lilly, MSD, Exact Sciences, Novartis, Pfizer, Seagen, outside the submitted work; CC: consultan-cy/advisory role/speaker bureau: Pfizer, Novartis, Lilly, Roche, Gilead, MSD, Seagen, outside the submitted work; FM: Fees for advisory board participation; Novartis, Astra Zeneca, Daiichi Sankyo, SeaGen, MSD, Pfizer, Roche, PUMA, outside the submitted work; LDM: grants from Eli Lilly, personal fees from Eli Lilly, personal fees from Novartis, personal fees and non-financial support from Roche, personal fees from MSD, personal fees and non-financial support from Pfiz-er, personal fees from Genomic health, personal fees from Pierre Fabre, personal fees from Daiichi Sankyo, personal fees from Astrazeneca, personal fees from Seagen, personal fees and non-financial support from Eisai, personal fees from Ipsen, personal fees from Gilead, outside the submitted work; AZ: fees for advisory board; Lilly, Novartis, Astra Zeneca, Daiichi Sankyo, SeaGen, MSD, Pfizer, Roche, ExactSciences; LB: honoraria, consulting or advisory role Astra-Zeneca, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Lilly, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Seattle Genetics; research Funding Celgene, Genomic Health, Novartis, all outside the submitted work; CM: personal consultancy fees from Bayer, Roche, Astrazeneca, Daiichi Sankyo, outside the submitted work. EDAT- 2022/11/16 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/15 18:28 PHST- 2022/09/15 00:00 [received] PHST- 2022/10/21 00:00 [revised] PHST- 2022/10/23 00:00 [accepted] PHST- 2022/11/16 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/15 18:28 [entrez] AID - S0960-9776(22)00179-5 [pii] AID - 10.1016/j.breast.2022.10.014 [doi] PST - ppublish SO - Breast. 2022 Dec;66:293-304. doi: 10.1016/j.breast.2022.10.014. Epub 2022 Oct 29. PMID- 36671422 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 2218-273X (Electronic) IS - 2218-273X (Linking) VI - 13 IP - 1 DP - 2022 Dec 25 TI - CISD1 Is a Breast Cancer Prognostic Biomarker Associated with Diabetes Mellitus. LID - 10.3390/biom13010037 [doi] LID - 37 AB - Women with diabetes mellitus are believed to have increased risk of developing breast cancer and lower life expectancies. This study aims to depict the association between the CISD1, the co-expressed genes, and diabetes mellitus to offer potential therapeutic targets for further mechanical research. The TCGA-BRCA RNAseq data is acquired. All the data and analyzed using R packages and web-based bioinformatics tools. CISD1 gene expression was evaluated between tumor bulk and adjacent tissue. Immune cell infiltration evaluation was performed. CISD1 expressed significantly higher in tumor tissue than that of the normal tissue, indicating poor overall survival rates. High expression level of CISD1 in tumor shows less pDC and NK cells penetration. There are 138 genes shared between CISD1 co-expressed gene pool in BRCA and diabetes mellitus related genes using "diabetes" as the term for text mining. These shared genes enrich in "cell cycle" and other pathways. MCODE analysis demonstrates that p53-independent G1/S DNA damage checkpoint, p53-independent DNA damage response, and ubiquitin mediated degradation of phosphorylated cdc25A are top-ranked than other terms. CISD1 and co-expressed genes, especially shared ones with diabetes mellitus, can be the focused genes considered when addressing clinical problems in breast cancer with a diabetes mellitus background. FAU - Liu, Fangfang AU - Liu F AD - Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. FAU - Dong, Yifeng AU - Dong Y AD - State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, Jinghai District, Tianjin 301617, China. FAU - Zhong, Fuyu AU - Zhong F AD - State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, Jinghai District, Tianjin 301617, China. FAU - Guo, Haodan AU - Guo H AD - State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, Jinghai District, Tianjin 301617, China. FAU - Dong, Pengzhi AU - Dong P AD - State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, Jinghai District, Tianjin 301617, China. LA - eng GR - 2018/Outstanding Young Talents Grand of Tianjin Medical University Cancer Institute and Hospital/ GR - 2018YFC1704502/the National Key Research and Development Program of China/ PT - Journal Article DEP - 20221225 PL - Switzerland TA - Biomolecules JT - Biomolecules JID - 101596414 RN - 0 (Tumor Suppressor Protein p53) RN - 0 (Biomarkers) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/genetics MH - Prognosis MH - Tumor Suppressor Protein p53 MH - *Diabetes Mellitus MH - Biomarkers PMC - PMC9855828 OTO - NOTNLM OT - CISD1 OT - bioinformatics OT - breast cancer OT - diabetes mellitus OT - ferroptosis COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:06 PHST- 2022/11/19 00:00 [received] PHST- 2022/12/19 00:00 [revised] PHST- 2022/12/22 00:00 [accepted] PHST- 2023/01/21 01:06 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - biom13010037 [pii] AID - biomolecules-13-00037 [pii] AID - 10.3390/biom13010037 [doi] PST - epublish SO - Biomolecules. 2022 Dec 25;13(1):37. doi: 10.3390/biom13010037. PMID- 36585623 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1471-2482 (Electronic) IS - 1471-2482 (Linking) VI - 22 IP - 1 DP - 2022 Dec 30 TI - Perioperative pectoral nerve block type II and postoperative recurrence in breast cancer: a randomized controlled trial. PG - 447 LID - 10.1186/s12893-022-01895-3 [doi] LID - 447 AB - BACKGROUND: A new technique for analgesia called pectoral nerve block is widely used in surgeries of breast cancer. Pectoral nerve block type II (Pecs II) block has less influence on immunity when compared with general anesthesia method. The purpose of this research is to demonstrate whether Pecs II block has influence on the recurrence of breast cancer after surgical operation. METHODS: 526 breast cancer patients were recruited in this research and randomized into general anesthesia group and general anesthesia with Pecs II block group. Recurrence-free survival (RFS), distant recurrence-free survival (DRFS), and overall survival (OS) were evaluated for the two groups. RESULTS: Based on the statistical data, only the consumption of remifentanil was dramatically reduced by the performance of Pecs II block when compared with general anesthesia method. The performance of Pecs II block had no significant influence on OS, RFS, and DRFS of breast cancer patients after surgery. ASA physical status III, TNM stage 2 + 3, and mastectomy were proved to have association with lower recurrence-free survival. CONCLUSION: In conclusion, the performance of Pecs II block declined the remifentanil consumption during surgery of breast cancer. Meanwhile, the performance of Pecs II block had no significant influence on the OS, RFS, and DRFS of breast cancer patients after surgical resection. CI - © 2022. The Author(s). FAU - Yu, Lili AU - Yu L AD - Department of Anesthesiology, Cangzhou Central Hospital, No.16, Xinhua Road, Cangzhou, 061000, Hebei, China. 18713057030@163.com. FAU - Cui, Xiuling AU - Cui X AD - Department of Anesthesiology, Cangzhou Central Hospital, No.16, Xinhua Road, Cangzhou, 061000, Hebei, China. FAU - Song, Panpan AU - Song P AD - Department of Anesthesiology, Cangzhou Central Hospital, No.16, Xinhua Road, Cangzhou, 061000, Hebei, China. FAU - Li, Chunlei AU - Li C AD - Department of Anesthesiology, Cangzhou Central Hospital, No.16, Xinhua Road, Cangzhou, 061000, Hebei, China. FAU - Zhao, Haochen AU - Zhao H AD - Department of Anesthesiology, Cangzhou Central Hospital, No.16, Xinhua Road, Cangzhou, 061000, Hebei, China. FAU - Chang, Yulin AU - Chang Y AD - Department of Anesthesiology, Cangzhou Central Hospital, No.16, Xinhua Road, Cangzhou, 061000, Hebei, China. LA - eng GR - 204106120/Hebei Cangzhou Guidance Project of Key R&D Program of China/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20221230 PL - England TA - BMC Surg JT - BMC surgery JID - 100968567 RN - P10582JYYK (Remifentanil) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery MH - Mastectomy/methods MH - Remifentanil MH - Pain, Postoperative/surgery MH - *Thoracic Nerves MH - Neoplasm Recurrence, Local/prevention & control/surgery PMC - PMC9805115 OTO - NOTNLM OT - Breast cancer OT - Pectoral nerve block type II OT - Postoperative recurrence COIS- No conflicts of interest have been declared. EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 23:44 PHST- 2021/12/10 00:00 [received] PHST- 2022/12/23 00:00 [accepted] PHST- 2022/12/30 23:44 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 10.1186/s12893-022-01895-3 [pii] AID - 1895 [pii] AID - 10.1186/s12893-022-01895-3 [doi] PST - epublish SO - BMC Surg. 2022 Dec 30;22(1):447. doi: 10.1186/s12893-022-01895-3. PMID- 36645520 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1433-7339 (Electronic) IS - 0941-4355 (Linking) VI - 31 IP - 2 DP - 2023 Jan 16 TI - Retrospective cohort study of scalp cooling in breast cancer patients. PG - 118 LID - 10.1007/s00520-022-07562-w [doi] AB - For patients with cancer, alopecia is a common side effect that negatively impacts personal identity, body image, self-esteem, quality of life, and medical decision-making. Scalp cooling is a technique used to prevent alopecia in patients undergoing chemotherapy in which patients wear a cooled cap during chemotherapy infusions, causing localized vasoconstriction of blood vessels on the scalp. Because of the recent emergence of scalp cooling, there is a need to explore further the reasons why patients pursue this treatment. A retrospective chart review of women with breast cancer treated at The Ohio State University was conducted to investigate how factors such as patient age, race, ethnicity, insurance status, stage of cancer, and chemotherapy regimen influenced patients' decisions to incorporate scalp cooling into their treatment plan as compared to those who did not. Findings revealed that patient age, race, insurance status, and chemotherapy regimen were predictors of a patient's likelihood to undergo scalp cooling. Patients diagnosed at younger age and those with private insurance were more likely to utilize scalp cooling. In comparison to White patients, non-White patients were less likely to choose scalp cooling. Furthermore, patients placed on the chemotherapy regimen of AC or AC-T were less likely to pursue scalp cooling than patients on PTCH or TC regimens. These findings provide background for the development of educational resources for both patients interested in this therapy and healthcare providers discussing this treatment option in dermatology and oncology settings. CI - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Rose, Lucy AU - Rose L AD - The Ohio State University College of Medicine, Columbus, OH, USA. FAU - Schnell, Patrick M AU - Schnell PM AD - The Ohio State University Wexner Medical Center, Columbus, OH, USA. FAU - Radcliff, Lindsey AU - Radcliff L AD - The Ohio State University Wexner Medical Center, Columbus, OH, USA. FAU - Lustberg, Maryam AU - Lustberg M AD - Breast Cancer Center, Smilow Cancer Hospital, Yale University, New Haven, CT, USA. FAU - Dulmage, Brittany AU - Dulmage B AD - The Ohio State University Wexner Medical Center, Columbus, OH, USA. Brittany.Dulmage@osumc.edu. AD - Department of Dermatology, The Ohio State University Wexner Medical Center, 540 Officenter Place, Suite 240, OH, 43230, Gahanna, USA. Brittany.Dulmage@osumc.edu. LA - eng PT - Journal Article DEP - 20230116 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Retrospective Studies MH - Scalp MH - *Hypothermia, Induced/methods MH - Quality of Life MH - Alopecia/chemically induced/prevention & control MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - *Antineoplastic Agents/adverse effects OTO - NOTNLM OT - Alopecia OT - Oncodermatology OT - Scalp cooling OT - Survivorship EDAT- 2023/01/17 06:00 MHDA- 2023/01/19 06:00 CRDT- 2023/01/16 11:17 PHST- 2022/04/05 00:00 [received] PHST- 2022/12/21 00:00 [accepted] PHST- 2023/01/16 11:17 [entrez] PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] AID - 10.1007/s00520-022-07562-w [pii] AID - 10.1007/s00520-022-07562-w [doi] PST - epublish SO - Support Care Cancer. 2023 Jan 16;31(2):118. doi: 10.1007/s00520-022-07562-w. PMID- 36585729 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 17 IP - 1 DP - 2022 Dec 31 TI - Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features. PG - 101 LID - 10.1186/s13000-022-01284-7 [doi] LID - 101 AB - BACKGROUND: Secretory breast carcinoma (SBC) is a rare malignant breast neoplasm with distinct histological features, including solid, microcystic, tubular, and rarely papillary structures, traditionally characterized by a t (12;15) (p13:q25) translocation, which usually leads to ETV6-NTRK3 fusion, suggesting an early event in tumorigenesis. Due to the rarity of this disease, very few genome sequencing studies have been performed on a series of cases, especially progressive cases. METHODS: Seven lesions from 5 patients diagnosed at the Third Affiliated Hospital of Soochow University from 2007 to 2021 were included. Clinicopathological features and prognosis/survival data were collected. Next-generation DNA sequencing was performed on six of the seven lesions. RESULTS: In total, 3/7 (42.9%) lesions demonstrated estrogen receptor (ER) expression, including weak, moderate to strong staining, and no lesion demonstrated progesterone receptor (PR) expression. There were no cases of human epidermal growth factor (HER2) overexpression, and the Ki-67 index was low. S-100 and pan-TRK protein were diffusely positively expressed in all cases. All lesions were characterized by a t(12;15) (p13:q25) translocation, leading to ETV6-NTRK3 fusion confirmed by fluorescence in situ hybridization (FISH). The sequencing results showed that ETV6-NTRK3 fusion was the main driver of early tumorigenesis, while SBC with invasive biological behavior had more complex genomic variation in which TERT promoter mutation was detected. CONCLUSIONS: Immunohistochemical staining of a biomarker panel, including ER, PR, HER2, Ki-67, S-100 and pan-TRK, can be used as an auxiliary diagnostic tool, and FISH detection can be used as a diagnostic tool. ETV6-NTRK3 gene fusion involving multiple sites may drive tumorigenesis, while mutations in the TERT promoter region may be a factor driving tumor progression. CI - © 2022. The Author(s). FAU - Lei, Ting AU - Lei T AUID- ORCID: 0000-0003-2278-9965 AD - Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, P.R. China. FAU - Yang, Yuyan AU - Yang Y AD - Department of Pathology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, P.R. China. FAU - Shi, Yongqiang AU - Shi Y AD - Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, P.R. China. FAU - Deng, Xu AU - Deng X AD - Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, P.R. China. FAU - Peng, Yan AU - Peng Y AD - Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, P.R. China. FAU - Wang, Hui AU - Wang H AD - Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, P.R. China. FAU - Chen, Tongbing AU - Chen T AUID- ORCID: 0000-0002-0311-7074 AD - Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, P.R. China. 11030523@163.com. LA - eng GR - QN202114/Changzhou Science and Technology Project/ PT - Journal Article DEP - 20221231 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 RN - 0 (Ki-67 Antigen) RN - 0 (Receptors, Estrogen) RN - 0 (Oncogene Proteins, Fusion) RN - 0 (Biomarkers, Tumor) RN - Secretory breast carcinoma SB - IM MH - Humans MH - Female MH - In Situ Hybridization, Fluorescence/methods MH - Ki-67 Antigen/genetics MH - *Breast Neoplasms/genetics/pathology MH - Translocation, Genetic MH - Receptors, Estrogen MH - Genomics MH - Carcinogenesis/genetics MH - Oncogene Proteins, Fusion/genetics MH - Biomarkers, Tumor/genetics PMC - PMC9805283 OTO - NOTNLM OT - ETV6-NTRK3 OT - Secretory breast carcinoma OT - TERT OT - Tumor progression COIS- None declared. Patient consent for publication. Not required. EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 23:52 PHST- 2022/08/15 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2022/12/30 23:52 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 10.1186/s13000-022-01284-7 [pii] AID - 1284 [pii] AID - 10.1186/s13000-022-01284-7 [doi] PST - epublish SO - Diagn Pathol. 2022 Dec 31;17(1):101. doi: 10.1186/s13000-022-01284-7. PMID- 35932230 OWN - NLM STAT- MEDLINE DCOM- 20221207 LR - 20221230 IS - 1365-2168 (Electronic) IS - 0007-1323 (Linking) VI - 109 IP - 12 DP - 2022 Nov 22 TI - Antibiotic prophylaxis in breast cancer surgery (PAUS trial): randomised clinical double-blind parallel-group multicentre superiority trial. PG - 1224-1231 LID - 10.1093/bjs/znac280 [doi] AB - BACKGROUND: Participants were patients with invasive breast cancer undergoing primary surgery. The aim was to test whether a single dose of amoxicillin-clavulanic acid would reduce wound infection at 30 days postoperatively, and to identify risk factors for infection. METHODS: Participants were randomised to either a single bolus of 1.2 g intravenous amoxicillin-clavulanic acid after the induction of anaesthesia (intervention) or no antibiotic (control). The primary outcome was the incidence of wound infection at 30 days postoperatively. RESULTS: There were 871 evaluable patients. Of these, 438 received prophylactic antibiotic and 433 served as controls. Seventy-one (16.2 per cent) patients in the intervention group developed a wound infection by 30 days, while there were 83 (19.2 per cent) infections in the control group. This was not statistically significant (odds ratio (OR) 0.82, 95 per cent c.i. 0.58 to 1.15; P = 0.250). The risk of infection increased for every 5 kg/m2 of BMI (OR 1.29, 95 per cent c.i. 1.10 to 1.52; P = 0.003). Patients who were preoperative carriers of Staphylococcus aureus had an increased risk of postoperative wound infection; however, there was no benefit of preoperative antibiotics for patients with either a high BMI or who were carriers of S. aureus. CONCLUSION: There was no statistically significant or clinically meaningful reduction in wound infection at 30 days following breast cancer surgery in patients who received a single dose of amoxicillin-clavulanic acid preoperatively. REGISTRATION NUMBER: N0399145605 (National Research Register). CI - © The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. FAU - Stallard, Sheila AU - Stallard S AD - Gartnavel General Hospital, Gartnavel General Hospital, Glasgow, UK. FAU - Savioli, Francesca AU - Savioli F AD - Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK. FAU - McConnachie, Alex AU - McConnachie A AUID- ORCID: 0000-0002-7262-7000 AD - Robertson Centre for Biostatistics, Glasgow, UK. FAU - Norrie, John AU - Norrie J AD - Usher Institute, College of Medicine and Veterinary Medicine, Edinburgh, UK. FAU - Dudman, Katie AU - Dudman K AD - Robertson Centre for Biostatistics, Glasgow, UK. FAU - Morrow, Elizabeth S AU - Morrow ES AD - Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK. FAU - Romics, Laszlo AU - Romics L AUID- ORCID: 0000-0001-8824-5501 AD - Academic Unit of Surgery, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK. AD - New Victoria Hospital, Glasgow, UK. LA - eng GR - GA391/British Society of Antimicrobial Chemotherapy/ PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - England TA - Br J Surg JT - The British journal of surgery JID - 0372553 RN - 74469-00-4 (Amoxicillin-Potassium Clavulanate Combination) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Female MH - *Antibiotic Prophylaxis MH - Amoxicillin-Potassium Clavulanate Combination/therapeutic use MH - *Breast Neoplasms/drug therapy MH - Staphylococcus aureus MH - Surgical Wound Infection/etiology MH - Anti-Bacterial Agents/therapeutic use OAB - There is little research about antibiotics in breast cancer surgery. Surgeons are not certain whether or not to use antibiotics for their patients. The aim of the Prophylactic Antibiotic Use in Surgery (PAUS) trial was to ask a question, ‘Do preoperative antibiotics have any benefit for patients having surgery for breast cancer?’ In the PAUS trial patients were given information to decide whether they wished to take part in the trial or not. Participants were randomly placed in one of two groups. Half were given one dose of the amoxicillin–clavulanic acid antibiotic at the time of their operation. The other half had no antibiotic. Neither the patient nor the surgeon knew which group the patient was in. Patients were carefully checked until 30 days after their operation for signs of wound infection. Altogether, 871 patients agreed to take part in the PAUS trial. Of these, 438 patients had the antibiotic and 433 had no antibiotic. The PAUS trial showed that there was no difference in the number of wound infections when comparing the two groups. Seventy-one patients (16.2 per cent) who had been given the antibiotic developed a wound infection by 30 days versus 83 (19.2 per cent) in the group who had not been given the antibiotic. This trial shows that antibiotics may not be needed for breast cancer surgery. PAUS may help to cut down on unnecessary antibiotic use. OABL- eng EDAT- 2022/08/07 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/08/06 08:43 PHST- 2022/03/15 00:00 [received] PHST- 2022/06/08 00:00 [revised] PHST- 2022/07/19 00:00 [accepted] PHST- 2022/08/07 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/08/06 08:43 [entrez] AID - 6657706 [pii] AID - 10.1093/bjs/znac280 [doi] PST - ppublish SO - Br J Surg. 2022 Nov 22;109(12):1224-1231. doi: 10.1093/bjs/znac280. PMID- 36552844 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230115 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 11 IP - 24 DP - 2022 Dec 16 TI - Ursolic Acid Impairs Cellular Lipid Homeostasis and Lysosomal Membrane Integrity in Breast Carcinoma Cells. LID - 10.3390/cells11244079 [doi] LID - 4079 AB - Cancer is one of the leading causes of death worldwide, thus the search for new cancer therapies is of utmost importance. Ursolic acid is a naturally occurring pentacyclic triterpene with a wide range of pharmacological activities including anti-inflammatory and anti-neoplastic effects. The latter has been assigned to its ability to promote apoptosis and inhibit cancer cell proliferation by poorly defined mechanisms. In this report, we identify lysosomes as the essential targets of the anti-cancer activity of ursolic acid. The treatment of MCF7 breast cancer cells with ursolic acid elevates lysosomal pH, alters the cellular lipid profile, and causes lysosomal membrane permeabilization and leakage of lysosomal enzymes into the cytosol. Lysosomal membrane permeabilization precedes the essential hallmarks of apoptosis placing it as an initial event in the cascade of effects induced by ursolic acid. The disruption of the lysosomal function impairs the autophagic pathway and likely partakes in the mechanism by which ursolic acid kills cancer cells. Furthermore, we find that combining treatment with ursolic acid and cationic amphiphilic drugs can significantly enhance the degree of lysosomal membrane permeabilization and cell death in breast cancer cells. FAU - Fogde, Ditte L AU - Fogde DL AD - Cell Death and Metabolism Group, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. FAU - Xavier, Cristina P R AU - Xavier CPR AUID- ORCID: 0000-0002-4613-1917 AD - Cell Death and Metabolism Group, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. AD - Department of Biology, University of Minho, 4710-057 Braga, Portugal. FAU - Balnytė, Kristina AU - Balnytė K AD - Cell Death and Metabolism Group, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. FAU - Holland, Lya K K AU - Holland LKK AD - Cell Death and Metabolism Group, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. FAU - Stahl-Meyer, Kamilla AU - Stahl-Meyer K AD - Cell Death and Metabolism Group, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. FAU - Dinant, Christoffel AU - Dinant C AD - Core Facility for Bioimaging, Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. FAU - Corcelle-Termeau, Elisabeth AU - Corcelle-Termeau E AD - Cell Death and Metabolism Group, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. FAU - Pereira-Wilson, Cristina AU - Pereira-Wilson C AD - Department of Biology, University of Minho, 4710-057 Braga, Portugal. AD - Centre of Biological Engineering, LABBELS Associate Laboratory, University of Minho, 4710-057 Braga, Portugal. FAU - Maeda, Kenji AU - Maeda K AUID- ORCID: 0000-0002-9080-5691 AD - Cell Death and Metabolism Group, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. FAU - Jäättelä, Marja AU - Jäättelä M AUID- ORCID: 0000-0001-5950-7111 AD - Cell Death and Metabolism Group, Center for Autophagy, Recycling and Disease (CARD), Danish Cancer Society Research Center, 2100 Copenhagen, Denmark. AD - Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221216 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - P3M2575F3F (ursolic acid) RN - 0 (Lipids) SB - IM MH - Humans MH - Female MH - *Lysosomes/metabolism MH - Homeostasis MH - *Breast Neoplasms/drug therapy/metabolism MH - Lipids/pharmacology PMC - PMC9776894 OTO - NOTNLM OT - autophagy OT - cancer OT - cationic amphiphilic drugs OT - cell death OT - lysosomal membrane permeabilization OT - ursolic acid COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:18 PHST- 2022/10/31 00:00 [received] PHST- 2022/12/02 00:00 [revised] PHST- 2022/12/14 00:00 [accepted] PHST- 2022/12/23 01:18 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - cells11244079 [pii] AID - cells-11-04079 [pii] AID - 10.3390/cells11244079 [doi] PST - epublish SO - Cells. 2022 Dec 16;11(24):4079. doi: 10.3390/cells11244079. PMID- 36596061 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230120 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 52 DP - 2022 Dec 30 TI - Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy. PG - e32545 LID - 10.1097/MD.0000000000032545 [doi] LID - e32545 AB - Axillary staging is 1 of the major issues of current breast cancer management after neoadjuvant systemic therapy (NST). Sentinel lymph node biopsy (SLNB) is an option for clinically node negative patients. Axillary reverse mapping (ARM) was introduced to identify and preserve the lymphatic drainage from the arm. The aim of the presented study is to employ triple mapping (radiocolloid, blue dye and indocyanine green [ICG]) to assess the crossover rate and metastatic involvement of ARM nodes after NST. Clinically node positive patients before NST who were converted to N0 and scheduled for targeted axillary dissection were included. sentinel lymph node (SLN) mapping was performed via dual agent mapping. ICG was used for ARM procedure. Blue, hot and fluorescent nodes and lymphatics were visualized in the axilla using infrared camera system and dual opto-nuclear probe (Euoroprobe3). Fifty-two patients underwent targeted axillary dissection and ARM procedures 12 out of whom had axillary node dissection. 45 of the 52 patients had at least 1 hot or blue SLN identified intraoperatively. Of these, 61.5% cases had hot SLNs, 42.3% had hot and blue, 15.4% had hot/blue/fluorescent, 7.7% had blue/fluorescent, 6 11.5% had hot/fluorescent and 7 13.5% had only clipped nodes. The overall identification rate of ARM-nodes by means of ICG technique was 86.5%. Overall crossover of ARM nodes with SLNs was determined in 36.5%. The ICG intensity was found to be higher in both hot and blue SLNS (8 out of 18 ICG positive cases, 44.4%). In 3 of 52 patients (5.7%) metastatic SLNs were hot or blue but fluorescent which predicts metastatic involvement of the ARM-nodes. More than 1-third of the patients revealed a crossover between arm and breast draining nodes. The higher observed rate of overlap might partially explain why more patients develop clinically significant lymphedema after NST even after sentinel lymph node biopsy alone. The triple mapping provides valuable data regarding the competency of lymphatic drainage and would have the potential to serve selecting patients for lymphovenous by-pass procedures at the index procedure. NST reduces the metastatic involvement of the ARM nodes. However, conservative axillary staging with sparing ARM nodes after NST necessitates further studies with larger sample size and longer follow-up. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Tasdoven, Ilhan AU - Tasdoven I AD - Zonguldak Bulent Ecevit University, School of Medicine, Department of General Surgery, Zonguldak, Turkey. FAU - Balbaloglu, Hakan AU - Balbaloglu H AD - Zonguldak Bulent Ecevit University, School of Medicine, Department of General Surgery, Zonguldak, Turkey. FAU - Erdemir, Rabiye Uslu AU - Erdemir RU AUID- ORCID: 0000-0002-5542-7453 AD - Zonguldak Bulent Ecevit University, School of Medicine, Department of Nuclear Medicine, Zonguldak, Turkey. FAU - Bahadir, Burak AU - Bahadir B AD - Zonguldak Bulent Ecevit University, School of Medicine, Department of Clinical Pathology, Zonguldak, Turkey. FAU - Guldeniz Karadeniz, Cakmak AU - Guldeniz Karadeniz C AD - Zonguldak Bulent Ecevit University, School of Medicine, Department of General Surgery, Zonguldak, Turkey. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - IX6J1063HV (Indocyanine Green) RN - 0 (Coloring Agents) SB - IM MH - Humans MH - Female MH - *Sentinel Lymph Node Biopsy/methods MH - Indocyanine Green MH - Neoadjuvant Therapy MH - Axilla/pathology MH - Lymph Nodes/pathology MH - Lymph Node Excision/methods MH - *Breast Neoplasms/surgery/pathology MH - Coloring Agents PMC - PMC9803496 COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/03 16:18 PHST- 2023/01/03 16:18 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 00005792-202212300-00093 [pii] AID - 10.1097/MD.0000000000032545 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 30;101(52):e32545. doi: 10.1097/MD.0000000000032545. PMID- 36395883 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230126 IS - 1083-351X (Electronic) IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 298 IP - 12 DP - 2022 Dec TI - Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment. PG - 102700 LID - S0021-9258(22)01143-7 [pii] LID - 10.1016/j.jbc.2022.102700 [doi] LID - 102700 AB - HSP90 inhibitors can target many oncoproteins simultaneously, but none have made it through clinical trials due to dose-limiting toxicity and induction of heat shock response, leading to clinical resistance. We identified diptoindonesin G (dip G) as an HSP90 modulator that can promote degradation of HSP90 clients by binding to the middle domain of HSP90 (K(d) = 0.13 ± 0.02 μM) without inducing heat shock response. This is likely because dip G does not interfere with the HSP90-HSF1 interaction like N-terminal inhibitors, maintaining HSF1 in a transcriptionally silent state. We found that binding of dip G to HSP90 promotes degradation of HSP90 client protein estrogen receptor α (ER), a major oncogenic driver protein in most breast cancers. Mutations in the ER ligand-binding domain (LBD) are an established mechanism of endocrine resistance and decrease the binding affinity of mainstay endocrine therapies targeting ER, reducing their ability to promote ER degradation or transcriptionally silence ER. Because dip G binds to HSP90 and does not bind to the LBD of ER, unlike endocrine therapies, it is insensitive to ER LBD mutations that drive endocrine resistance. Additionally, we determined that dip G promoted degradation of WT and mutant ER with similar efficacy, downregulated ER- and mutant ER-regulated gene expression, and inhibited WT and mutant cell proliferation. Our data suggest that dip G is not only a molecular probe to study HSP90 biology and the HSP90 conformation cycle, but also a new therapeutic avenue for various cancers, particularly endocrine-resistant breast cancer harboring ER LBD mutations. CI - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Donahue, Kristine AU - Donahue K AD - McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Xie, Haibo AU - Xie H AD - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Li, Miyang AU - Li M AD - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Gao, Ang AU - Gao A AD - McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Ma, Min AU - Ma M AD - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Wang, Yidan AU - Wang Y AD - McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Tipton, Rose AU - Tipton R AD - Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA. FAU - Semanik, Nicole AU - Semanik N AD - Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA. FAU - Primeau, Tina AU - Primeau T AD - Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA. FAU - Li, Shunqiang AU - Li S AD - Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA. FAU - Li, Lingjun AU - Li L AD - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. FAU - Tang, Weiping AU - Tang W AD - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. Electronic address: weiping.tang@wisc.edu. FAU - Xu, Wei AU - Xu W AD - McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, USA. Electronic address: wxu@oncology.wisc.edu. LA - eng GR - R01 CA268183/CA/NCI NIH HHS/United States GR - T32 CA009135/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20221114 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (diptoindonesin G) RN - 0 (HSP90 Heat-Shock Proteins) RN - 0 (Antineoplastic Agents) RN - 0 (Benzofurans) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy/metabolism MH - Cell Proliferation/drug effects MH - HSP90 Heat-Shock Proteins/metabolism MH - Mutation MH - *Antineoplastic Agents/pharmacology MH - *Benzofurans/pharmacology PMC - PMC9771721 OTO - NOTNLM OT - ESR1 OT - LBD mutations OT - breast cancer OT - estrogen receptor OT - heat shock factor protein 1 OT - heat shock protein 90 OT - inhibitor COIS- Conflict of interest W. X. and W. T. are the inventors, and the Wisconsin Alumni Research Foundation is the assignee, on patent number 10508092, “Synthesis of novel analogs of diptoindonesin G, compounds formed thereby, and pharmaceutical compositions containing them”. All other authors declare no competing interests. EDAT- 2022/11/18 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/11/17 19:23 PHST- 2022/07/11 00:00 [received] PHST- 2022/10/31 00:00 [revised] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/11/17 19:23 [entrez] AID - S0021-9258(22)01143-7 [pii] AID - 102700 [pii] AID - 10.1016/j.jbc.2022.102700 [doi] PST - ppublish SO - J Biol Chem. 2022 Dec;298(12):102700. doi: 10.1016/j.jbc.2022.102700. Epub 2022 Nov 14. PMID- 36612831 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 20 IP - 1 DP - 2022 Dec 28 TI - Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation. LID - 10.3390/ijerph20010512 [doi] LID - 512 AB - Palbociclib and ribociclib are indicated in the first-line treatment of hormonal-receptor-positive HER-2 negative (HR+/HER-2 negative) advanced breast cancer. Despite their clinical benefit, they can increase healthcare expenditure. Yet, there are no comparative pharmacoeconomic evaluations for them in developing countries, the Middle East, or Gulf countries. This study compared the cost-effectiveness of palbociclib and ribociclib in Qatar. A 10-year within-cycle-corrected Markov's model was developed using TreeAge Pro(®) software. The model consisted of three main health states: progression-free (PFS), progressed-disease (PD), and death. Costs were obtained from the actual hospital settings, transition probabilities were calculated from individual-patient data, and utilities were summarized from the published literature. The incremental cost-effectiveness ratio (ICER) and the incremental cost-utility ratio (ICUR) were calculated and compared to three gross-domestic-products per capita. Deterministic and probabilistic sensitivity analyses were performed. Ribociclib dominated palbociclib in terms of costs, life-years gained, and quality-adjusted life-years gained. The conclusions remained robust in the different cases of the deterministic sensitivity analyses. Taking all combined uncertainties into account, the confidence in the base-case conclusion was approximately 60%. Therefore, in HR+/HER-2 negative stage IV breast cancer patients, the use of ribociclib is considered cost-saving compared to palbociclib. FAU - Al-Ziftawi, Nour Hisham AU - Al-Ziftawi NH AUID- ORCID: 0000-0002-4152-9870 AD - Clinical Pharmacy and Practice Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar. FAU - Alam, Mohammed Fasihul AU - Alam MF AD - Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar. FAU - Elazzazy, Shereen AU - Elazzazy S AUID- ORCID: 0000-0002-0017-4401 AD - Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar. FAU - Shafie, Asrul Akmal AU - Shafie AA AUID- ORCID: 0000-0002-5629-9270 AD - School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Malaysia. FAU - Hamad, Anas AU - Hamad A AUID- ORCID: 0000-0001-8606-8521 AD - Clinical Pharmacy and Practice Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar. AD - Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar. FAU - Mohamed Ibrahim, Mohamed Izham AU - Mohamed Ibrahim MI AUID- ORCID: 0000-0001-9757-3574 AD - Clinical Pharmacy and Practice Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar. LA - eng GR - QUST-1- CPH- 2019-12/Qatar University/ PT - Journal Article DEP - 20221228 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - G9ZF61LE7G (palbociclib) RN - TK8ERE8P56 (ribociclib) RN - 0 (Pyridines) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Cost-Benefit Analysis MH - Pyridines/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use PMC - PMC9819837 OTO - NOTNLM OT - advanced breast cancer OT - cost-effectiveness OT - cost-saving OT - cost-utility OT - cyclin-dependent-kinase 4/6 inhibitors COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:13 PHST- 2022/10/11 00:00 [received] PHST- 2022/12/19 00:00 [revised] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/08 01:13 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - ijerph20010512 [pii] AID - ijerph-20-00512 [pii] AID - 10.3390/ijerph20010512 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Dec 28;20(1):512. doi: 10.3390/ijerph20010512. PMID- 36550894 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230103 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 50 DP - 2022 Dec 16 TI - Improving the quality of life in a breast cancer patient and caregiver: Protocol for the application of the integrative medical service model. PG - e32244 LID - 10.1097/MD.0000000000032244 [doi] LID - e32244 AB - BACKGROUND: Patients with chronic diseases require ongoing treatment, and caregivers face financial burdens as well as psychological and physical difficulties. However, the current healthcare system does not provide adequate systems or services to address the difficulties that patients and caregivers face. PURPOSE: The purpose of this study was to conduct an observational case study in order to evaluate and improve the application of an integrative healthcare service model developed for distress management and improved quality of life in breast cancer (BC) patients and caregivers. METHOD: The integrative healthcare service model was intensively applied to a patient-caregiver pair in this observational study. This was followed by gathering feedback from participants and experts, as well as reflecting on the content of the feedback in order to improve the model further. RESULTS: This study will then modify and improve the program with feedback and provide integrative medical services to a BC patient and caregiver. CONCLUSION: This study used the BC patients' pain management and quality of life enhancement model, aiming to provide basic data for the establishment of a healthcare service system for patients suffering from chronic pain due to diseases such as BC by systematically integrating previously applied interventions into the current healthcare system and soliciting feedback from patients and caregivers. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Cheong, Moon Joo AU - Cheong MJ AD - Rare Diseases Integrative Treatment Research Institute, Wonkwang University Jangheung Integrative Medical Hospital, Anyang-myeon, Jangheung-gun, Jeollanam-do, Republic of Korea. FAU - Ha, Won-Bae AU - Ha WB AD - Department of Korean Medicine Rehabilitation, College of Korean Medicine, Wonkwang University, Iksan-si, Jeollabuk-do, Republic of Korea. FAU - Cho, Han-Baek AU - Cho HB AD - Department of Korean Medicine Obstetrics & Gynecology, College of Korean Medicine, Wonkwang University, Iksan-si, Jeollabuk-do, Republic of Korea. FAU - Choi, Un-Jong AU - Choi UJ AD - Department of Surgery, Wonkwang University School of Medicine, Iksan-si, Jeollabuk-do, Republic of Korea. FAU - Woo, Hyeon-Jun AU - Woo HJ AD - Department of Korean Medicine Rehabilitation, College of Korean Medicine, Wonkwang University, Iksan-si, Jeollabuk-do, Republic of Korea. FAU - Han, Yun-Hee AU - Han YH AD - Department of Korean Medicine Rehabilitation, College of Korean Medicine, Wonkwang University, Iksan-si, Jeollabuk-do, Republic of Korea. FAU - Kang, Hyung Won AU - Kang HW AUID- ORCID: 0000-0001-6497-0100 AD - Rare Diseases Integrative Treatment Research Institute, Wonkwang University Jangheung Integrative Medical Hospital, Anyang-myeon, Jangheung-gun, Jeollanam-do, Republic of Korea. AD - Department of Korean Neuropsychiatry Medicine, College of Korean Medicine, Wonkwang University, Iksan-si, Jeollabuk-do, Republic of Korea. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy MH - Quality of Life/psychology MH - Caregivers/psychology MH - Pain Management MH - Anxiety/psychology MH - Observational Studies as Topic PMC - PMC9771164 COIS- The authors have no conflicts of interest to disclose. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:07 PHST- 2022/12/23 01:07 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - 00005792-202212160-00102 [pii] AID - 10.1097/MD.0000000000032244 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 16;101(50):e32244. doi: 10.1097/MD.0000000000032244. PMID- 36613648 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230111 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 1 DP - 2022 Dec 22 TI - Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes. LID - 10.3390/ijms24010207 [doi] LID - 207 AB - The concept of BRCAness was developed because of similarities between sporadic and hereditary breast cancer. BRCAness defines the pathogenesis and treatment sensitivity of many types of cancer, as well as the presence of a defect in the homologous recombination repair of tumor cells simulating the loss of BRCA1 or BRCA2, as in the presence of germline mutations. The question of treatment effectiveness for BRCA-like tumors is controversial and open. Thus, the aim of this work was to study the effectiveness of neoadjuvant chemotherapy (NAC) in BRCA-deficient breast cancer patients without germline mutations. The study involved 130 patients with breast cancer in stages IIA-IIIB. The treatment regimen included neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy. The materials used were tumor samples from before and after chemotherapy. DNA and RNA were isolated from the tumor material. RNA was used to assess the expression level of BRCA1, while DNA was used for methyl-sensitive PCR. A microarray analysis was performed on high-density DNA chips from an Affymetrix CytoScan(TM) HD Array to assess DNA copy number aberration (CNA status) and loss of heterozygosity. A statistical analysis was performed using the Statistica 8.0 application package. It was noted that the existence of copy number aberrations in genes was statistically significantly associated with tumor treatment response and disease prognosis. Patients with partial regression had a statistically significantly higher amount of deletion than patients without an objective response (5/25 patients; 16%), as shown in the general sample of patients (52.9% versus 27.1%, respectively) at p = 0.0001 and in patients treated with anthracycline-containing regimen (p = 0.0001). In addition, it was shown that patients with BRCA1 deletion had higher rates of metastatic-free survival (log rank test, p = 0.009). BRCAness patients had a higher rate of 5-year metastatic survival, but not of treatment efficacy. The prospective study showed the positive effect of assessing the BRCAness phenotype of a tumor before treatment and of prescribing personalized NAC regimens. The objective response rate was statistically significantly more often observed in the group of patients with personalized chemotherapy (85.0% (34/40 patients) versus 62.3% (56/90 patients); p = 0.007). Despite the controversial effectiveness of BRCA-like tumor treatment, our data showed high predictive and prognostic significance of the BRCAness phenotype for the personalization of platinum and taxane regimens. FAU - Tsyganov, Matvey Mihajlovich AU - Tsyganov MM AD - Department of Experimental Oncology, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, St. Kooperativny 5, Tomsk 634009, Russia. AD - Faculty of Medicine and Biology, Siberian State Medical University, 2 Moskovsky Trakt, Tomsk 634050, Russia. FAU - Ibragimova, Marina K AU - Ibragimova MK AD - Department of Experimental Oncology, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, St. Kooperativny 5, Tomsk 634009, Russia. AD - Faculty of Medicine and Biology, Siberian State Medical University, 2 Moskovsky Trakt, Tomsk 634050, Russia. AD - Biological Institute, The National Research Tomsk State University, Prospekt Lenina, 36, Tomsk 634050, Russia. FAU - Garbukov, Evgeniy Y AU - Garbukov EY AD - Department of Experimental Oncology, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, St. Kooperativny 5, Tomsk 634009, Russia. FAU - Bragina, Olga D AU - Bragina OD AD - Department of Experimental Oncology, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, St. Kooperativny 5, Tomsk 634009, Russia. FAU - Karchevskaya, Ariana A AU - Karchevskaya AA AD - Faculty of Medicine and Biology, Siberian State Medical University, 2 Moskovsky Trakt, Tomsk 634050, Russia. FAU - Usynin, Evgeny A AU - Usynin EA AD - Department of Experimental Oncology, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, St. Kooperativny 5, Tomsk 634009, Russia. FAU - Litvyakov, Nikolai V AU - Litvyakov NV AUID- ORCID: 0000-0002-0714-8927 AD - Department of Experimental Oncology, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, St. Kooperativny 5, Tomsk 634009, Russia. LA - eng GR - 22-15-00169/Russian Science Foundation/ PT - Journal Article DEP - 20221222 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BRCA1 Protein) RN - 0 (BRCA2 Protein) RN - 49DFR088MY (Platinum) RN - 0 (Taxoids) SB - IM MH - Female MH - Humans MH - BRCA1 Protein/genetics MH - BRCA2 Protein/genetics MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Neoadjuvant Therapy MH - Phenotype MH - Platinum/therapeutic use MH - Prospective Studies MH - Taxoids/therapeutic use PMC - PMC9820727 OTO - NOTNLM OT - BRCAness OT - DNA copy number aberration OT - breast cancer OT - gene expression OT - homologous recombination OT - homologous recombination deficiency OT - loss of heterozygosity OT - microarray analysis OT - neoadjuvant chemotherapy OT - personalized treatment COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:20 PHST- 2022/11/21 00:00 [received] PHST- 2022/12/19 00:00 [revised] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/08 01:20 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - ijms24010207 [pii] AID - ijms-24-00207 [pii] AID - 10.3390/ijms24010207 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 22;24(1):207. doi: 10.3390/ijms24010207. PMID- 36619604 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230111 IS - 2046-1402 (Electronic) IS - 2046-1402 (Linking) VI - 11 DP - 2022 TI - Effects of evidence-based clinical practice guidelines for breast cancer in health care quality improvements. A second systematic review. PG - 1213 LID - 10.12688/f1000research.126126.2 [doi] AB - Background: Traditionally, EB-CPGs have been believed to mainly improve the quality and consistency of health care, but this claim must be conclusively proven. We used the Donabedian three-dimensional model (structure, process, and patient outcomes) to assess improvements in the quality of medical care derived from implementing EB-CPGs. This study corresponds to the second systematic review carried out as a series of studies on different clinical issues that aim to evaluate the effectiveness of the application of the EB-CPG for improving the quality of care. Methods: We followed the methods described by the Cochrane Handbook and presented a descriptive analysis because of the high heterogeneity found across the included studies. We searched the Cochrane Central Register of Controlled Trials, PubMed, and EBSCO Host databases, as well as the grey literature, between 1990 and April 2021. No language restrictions were applied. Only randomised clinical trials (RCTs) were selected. Results: Of the total of 364 interventions included in the eleven RCTs evaluated, 11 (3%) were related to healthcare structure, 51 (14%) to the healthcare delivery process and 302 (83%) to patient outcomes. Regarding the impact of using the EB-CPGs, in 303 interventions (83%), there were no significant differences between the control and experimental groups. In 4 interventions (1%), the result favoured the control and intervention groups in 57 of the interventions (16%). Conclusions: Our study showed that EB-CPGs slightly enhanced the quality of health care in the three dimensions described by Donabedian. Future RCTs should improve their design and methodological rigour by considering the certainty of the evidence supporting the EB-CPGs recommendations. In that context, broader analyses could be performed, having more concise hypotheses for further research. Registration: PROSPERO CRD42020205594. CI - Copyright: © 2022 Ramírez-Morera A et al. FAU - Ramírez-Morera, Anggie AU - Ramírez-Morera A AUID- ORCID: 0000-0003-0793-4626 AD - Cochrane Central America & Caribbean Spanish, IHCAI Foundation, San José, San José, 10101, Costa Rica. AD - Universitat Autònoma de Barcelona, Barcelona, Catalunya, 08041, Spain. AD - Caja Costarricense de Seguro Social, San José, San José, 10105, Costa Rica. FAU - Tristán, Mario AU - Tristán M AUID- ORCID: 0000-0001-6732-3398 AD - Cochrane Central America & Caribbean Spanish, IHCAI Foundation, San José, San José, 10101, Costa Rica. FAU - Salazar-Vargas, Jordan AU - Salazar-Vargas J AUID- ORCID: 0000-0002-9174-4835 AD - Caja Costarricense de Seguro Social, San José, San José, 10105, Costa Rica. FAU - Rivera-Chavarría, Ana Leonor AU - Rivera-Chavarría AL AUID- ORCID: 0000-0002-7457-4547 AD - Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Tres Ríos, Cartago, 42250, Costa Rica. LA - eng PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20221025 PL - England TA - F1000Res JT - F1000Research JID - 101594320 SB - IM MH - Humans MH - Female MH - *Quality Improvement MH - *Breast Neoplasms/therapy MH - Delivery of Health Care PMC - PMC9780606 OTO - NOTNLM OT - Clinical Practice Guidelines; CPG; effect; health care quality. COIS- No competing interests were disclosed. EDAT- 2023/01/11 06:00 MHDA- 2023/01/12 06:00 CRDT- 2023/01/10 01:39 PHST- 2022/12/01 00:00 [accepted] PHST- 2023/01/10 01:39 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] AID - 10.12688/f1000research.126126.2 [doi] PST - epublish SO - F1000Res. 2022 Oct 25;11:1213. doi: 10.12688/f1000research.126126.2. eCollection 2022. PMID- 36555431 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 24 DP - 2022 Dec 13 TI - Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. LID - 10.3390/ijms232415789 [doi] LID - 15789 AB - BRCA1 and BRCA2 are the most frequently mutated genes in ovarian cancer (OC) crucial both for the identification of cancer predisposition and therapeutic choices. However, germline variants in other genes could be involved in OC susceptibility. We characterized OC patients to detect mutations in genes other than BRCA1/2 that could be associated with a high risk of developing OC and permit patients to enter the most appropriate treatment and surveillance program. Next-generation sequencing analysis with a 94-gene panel was performed on germline DNA of 219 OC patients. We identified 34 pathogenic/likely pathogenic variants in BRCA1/2 and 38 in other 21 genes. The patients with pathogenic/likely pathogenic variants in the non-BRCA1/2 genes mainly developed OC alone compared to the other groups that also developed breast cancer or other tumors (p = 0.001). Clinical correlation analysis showed that the low-risk patients were significantly associated with platinum sensitivity (p < 0.001). Regarding PARP inhibitors (PARPi) response, the patients with pathogenic mutations in the non-BRCA1/2 genes had worse PFS and OS. Moreover, a statistically significantly worse PFS was found for every increase of one thousand platelets before PARPi treatment. To conclude, knowledge about molecular alterations in genes beyond BRCA1/2 in OC could allow for more personalized diagnostic, predictive, prognostic, and therapeutic strategies for OC patients. FAU - Gurioli, Giorgia AU - Gurioli G AUID- ORCID: 0000-0003-4036-5568 AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Tedaldi, Gianluca AU - Tedaldi G AUID- ORCID: 0000-0003-0540-6694 AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Farolfi, Alberto AU - Farolfi A AUID- ORCID: 0000-0002-3289-8041 AD - Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Petracci, Elisabetta AU - Petracci E AD - Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Casanova, Claudia AU - Casanova C AD - Oncology Department, Santa Maria Delle Croci Hospital, 48121 Ravenna, Italy. FAU - Comerci, Giuseppe AU - Comerci G AUID- ORCID: 0000-0003-3723-5391 AD - Department of Obstetrics and Gynaecology, AUSL Romagna, Santa Maria Delle Croci Hospital, 48121 Ravenna, Italy. FAU - Danesi, Rita AU - Danesi R AUID- ORCID: 0000-0002-6535-1608 AD - Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Arcangeli, Valentina AU - Arcangeli V AD - Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Ravegnani, Mila AU - Ravegnani M AD - Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Calistri, Daniele AU - Calistri D AUID- ORCID: 0000-0002-5064-2023 AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Zampiga, Valentina AU - Zampiga V AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Cangini, Ilaria AU - Cangini I AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Fonzi, Eugenio AU - Fonzi E AUID- ORCID: 0000-0001-8389-8220 AD - Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Virga, Alessandra AU - Virga A AUID- ORCID: 0000-0001-9427-3875 AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - Tassinari, Davide AU - Tassinari D AD - Department of Oncology, Ospedale Infermi, 47923 Rimini, Italy. FAU - Rosati, Marta AU - Rosati M AD - Department of Oncology, Ospedale Infermi, 47923 Rimini, Italy. FAU - Ulivi, Paola AU - Ulivi P AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. FAU - De Giorgi, Ugo AU - De Giorgi U AUID- ORCID: 0000-0001-7520-2908 AD - Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. LA - eng PT - Journal Article DEP - 20221213 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - Female MH - Genetic Predisposition to Disease MH - BRCA1 Protein/genetics MH - Mutation MH - *Ovarian Neoplasms/drug therapy MH - Genes, BRCA2 MH - Germ-Line Mutation MH - *Breast Neoplasms/genetics MH - High-Throughput Nucleotide Sequencing PMC - PMC9779064 OTO - NOTNLM OT - BRCA1/2 OT - PARP inhibitors OT - cancer predisposition OT - ovarian cancer OT - platelets OT - platinum sensitivity COIS- U.D.G. received advisory board or consultant fees from Merck Sharp & Dohme, Bristol Myers Squibb, Janssen, Astellas, Sanofi, Bayer, Pfizer, Ipsen, Novartis, and Pharmamar and institutional research grants from AstraZeneca, Sanofi, and Roche. A.F. has received personal honoraria for lectures from AstraZeneca, GSK-Tesaro, and Clovis and institutional research grants from Astellas, MSD, Bayer, advisory board fees from Janssen, AstraZeneca, and GSK-Tesaro. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:34 PHST- 2022/10/18 00:00 [received] PHST- 2022/12/01 00:00 [revised] PHST- 2022/12/08 00:00 [accepted] PHST- 2022/12/23 01:34 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - ijms232415789 [pii] AID - ijms-23-15789 [pii] AID - 10.3390/ijms232415789 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 13;23(24):15789. doi: 10.3390/ijms232415789. PMID- 36554712 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230120 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 24 DP - 2022 Dec 15 TI - Diagnostic Accuracy of Machine-Learning Models on Predicting Chemo-Brain in Breast Cancer Survivors Previously Treated with Chemotherapy: A Meta-Analysis. LID - 10.3390/ijerph192416832 [doi] LID - 16832 AB - We performed a meta-analysis of chemo-brain diagnostic, pooling sensitivities, and specificities in order to assess the accuracy of a machine-learning (ML) algorithm in breast cancer survivors previously treated with chemotherapy. We searched PubMed, Web of Science, and Scopus for eligible articles before 30 September 2022. We identified three eligible studies from which we extracted seven ML algorithms. For our data, the χ(2) tests demonstrated the homogeneity of the sensitivity's models (χ(2) = 7.6987, df = 6, p-value = 0.261) and the specificities of the ML models (χ(2) = 3.0151, df = 6, p-value = 0.807). The pooled area under the curve (AUC) for the overall ML models in this study was 0.914 (95%CI: 0.891-0.939) and partial AUC (restricted to observed false positive rates and normalized) was 0.844 (95%CI: 0.80-0.889). Additionally, the pooled sensitivity and pooled specificity values were 0.81 (95% CI: 0.75-0.86) and 0.82 (95% CI: 0.76-0.86), respectively. From all included ML models, support vector machine demonstrated the best test performance. ML models represent a promising, reliable modality for chemo-brain prediction in breast cancer survivors previously treated with chemotherapy, demonstrating high accuracy. FAU - Turcu-Stiolica, Adina AU - Turcu-Stiolica A AUID- ORCID: 0000-0003-1374-276X AD - Department of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Bogdan, Maria AU - Bogdan M AUID- ORCID: 0000-0001-8089-1787 AD - Department of Pharmacology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Dumitrescu, Elena Adriana AU - Dumitrescu EA AD - Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. FAU - Zob, Daniela Luminita AU - Zob DL AD - Institute of Oncology, Prof Dr. Alexandru Trestioreanu, Soseaua Fundeni, 022328 Bucharest, Romania. FAU - Gheorman, Victor AU - Gheorman V AD - Department of Psychiatry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Aldea, Madalina AU - Aldea M AD - Department of Psychiatry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Dinescu, Venera Cristina AU - Dinescu VC AD - Department of Health Promotion and Occupational Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Subtirelu, Mihaela-Simona AU - Subtirelu MS AD - Department of Pharmacoeconomics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Stanculeanu, Dana-Lucia AU - Stanculeanu DL AD - Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. FAU - Sur, Daniel AU - Sur D AUID- ORCID: 0000-0002-0926-4614 AD - 11th Department of Medical Oncology, University of Medicine and Pharmacy "Iuliu Hatieganu", 400125 Cluj-Napoca, Romania. FAU - Lungulescu, Cristian Virgil AU - Lungulescu CV AD - Department of Oncology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20221215 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/diagnosis MH - *Cancer Survivors MH - Breast MH - Brain MH - *Brain Neoplasms MH - Machine Learning PMC - PMC9779296 OTO - NOTNLM OT - breast cancer OT - chemo-brain OT - chemotherapy OT - diagnostic accuracy OT - machine learning COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:29 PHST- 2022/11/15 00:00 [received] PHST- 2022/12/11 00:00 [revised] PHST- 2022/12/12 00:00 [accepted] PHST- 2022/12/23 01:29 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - ijerph192416832 [pii] AID - ijerph-19-16832 [pii] AID - 10.3390/ijerph192416832 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Dec 15;19(24):16832. doi: 10.3390/ijerph192416832. PMID- 36661743 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 1 DP - 2023 Jan 16 TI - Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy? PG - 1220-1231 LID - 10.3390/curroncol30010094 [doi] AB - BACKGROUND: Aromatase inhibitors (AI) are widely used for treating hormone-sensitive breast cancer (BC). Obesity, however, due to aromatase-mediated androgen conversion into estradiol in the peripheral adipose tissue, might impair AI inhibitory capacity. We aimed at identifying a cut-off of body mass index (BMI) with significant prognostic impact, in a cohort of stage I-II BC patients on systemic adjuvant therapy with AI. METHODS: we retrospectively evaluated routinely collected baseline parameters. The optimal BMI cut-off affecting disease-free survival (DFS) in AI-treated BC patients was identified through maximally selected rank statistics; non-linear association between BMI and DFS in the AI cohort was assessed by hazard-ratio-smoothed curve analysis using BMI as continuous variable. The impact of the BMI cut-off on survival outcomes was estimated through Kaplan-Meier plots, with log-rank test and hazard ratio estimation comparing patient subgroups. RESULTS: A total of 319 BC patients under adjuvant endocrine therapy and/or adjuvant chemotherapy were included. Curve-fitting analysis showed that for a BMI cut-off >29 in AI-treated BC patients (n = 172), DFS was increasingly deteriorating and that the impact of BMI on 2-year DFS identified a cut-off specific only for the cohort of postmenopausal BC patients under adjuvant therapy with AI. CONCLUSION: in radically resected hormone-sensitive BC patients undergoing neoadjuvant or adjuvant chemotherapy and treated with AI, obesity represents a risk factor for recurrence, with a significantly reduced 2-year DFS. FAU - Riondino, Silvia AU - Riondino S AUID- ORCID: 0000-0002-2965-402X AD - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00152 Rome, Italy. FAU - Formica, Vincenzo AU - Formica V AD - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00152 Rome, Italy. FAU - Valenzi, Elena AU - Valenzi E AD - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00152 Rome, Italy. FAU - Morelli, Cristina AU - Morelli C AD - Medical Oncology Unit, University Hospital Tor Vergata, Viale Oxford, 81, 00133 Rome, Italy. FAU - Flaminio, Valeria AU - Flaminio V AD - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00152 Rome, Italy. FAU - Portarena, Ilaria AU - Portarena I AD - Medical Oncology Unit, University Hospital Tor Vergata, Viale Oxford, 81, 00133 Rome, Italy. FAU - Torino, Francesco AU - Torino F AUID- ORCID: 0000-0001-5828-4438 AD - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00152 Rome, Italy. FAU - Roselli, Mario AU - Roselli M AUID- ORCID: 0000-0002-2431-6689 AD - Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00152 Rome, Italy. LA - eng PT - Journal Article DEP - 20230116 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Aromatase Inhibitors) RN - 0 (Hormones) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Retrospective Studies MH - Aromatase Inhibitors/therapeutic use MH - Obesity/complications/drug therapy MH - Hormones/therapeutic use PMC - PMC9857850 OTO - NOTNLM OT - BMI OT - aromatase inhibitors OT - breast cancer OT - obesity COIS- The authors declare no conflict of interest. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 09:35 PHST- 2022/11/17 00:00 [received] PHST- 2023/01/12 00:00 [revised] PHST- 2023/01/13 00:00 [accepted] PHST- 2023/01/20 09:35 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - curroncol30010094 [pii] AID - curroncol-30-00094 [pii] AID - 10.3390/curroncol30010094 [doi] PST - epublish SO - Curr Oncol. 2023 Jan 16;30(1):1220-1231. doi: 10.3390/curroncol30010094. PMID- 36549771 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 0386-300X (Print) IS - 0386-300X (Linking) VI - 76 IP - 6 DP - 2022 Dec TI - An Evaluation of the Efficacy of Compression Therapy Using Sleeves and Stockings to Prevent Docetaxel-induced Peripheral Neuropathy in Breast Cancer Patients. PG - 689-694 LID - 10.18926/AMO/64119 [doi] AB - Taxanes are key drugs for patients with breast cancer. A major adverse effect of taxanes is peripheral neuropathy (PN). To investigate the ability of compression therapy using sleeves and stockings to prevent PN due to the taxane docetaxel, we conducted a single-center historical control trial. Patients receiving docetaxel at 75 mg/m2 every 3 weeks for 4 cycles as first-line chemotherapy for breast cancer were eligible. PN was evaluated using the common terminology criteria for adverse events version 4.0. The primary endpoint was the incidence of allgrade PN until 3 weeks after the fourth docetaxel administration. We evaluated 26 patients in the intervention group and compared their data to those collected retrospectively from 52 patients treated with docetaxel without compression. Neither the incidence of all-grade PN until 3 weeks after the fourth docetaxel administration (63.5% in the control group vs. 76.9% in the intervention group, p=0.31) nor that of PN grade ≥ 2 (13.5% vs. 15.4%, p=0.99) differed between the groups. In this study, the efficacy of compression therapy using sleeves and stockings to prevent PN induced by docetaxel was not demonstrated. Further clinical studies including medications or intervention are needed to reduce the incidence and severity of PN induced by chemotherapy. FAU - Yamanouchi, Kosho AU - Yamanouchi K AD - Department of Surgery, Nagasaki University Graduate School of Biomedical Science. AD - Department of Surgery, Nagasaki Prefecture Shimabara Hospital. FAU - Kuba, Sayaka AU - Kuba S AD - Department of Surgery, Nagasaki University Graduate School of Biomedical Science. FAU - Matsumoto, Megumi AU - Matsumoto M AD - Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science. FAU - Yano, Hiroshi AU - Yano H AD - Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science. AD - Department of Breast Surgery, Sasebo City General Hospital. FAU - Morita, Michi AU - Morita M AD - Department of Surgery, Nagasaki University Graduate School of Biomedical Science. FAU - Sakimura, Chika AU - Sakimura C AD - Department of Surgery, Nagasaki University Graduate School of Biomedical Science. AD - Department of Breast and Endocrine Surgery, Nagasaki Harbor Medical Center. FAU - Otsubo, Ryota AU - Otsubo R AD - Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science. FAU - Hidaka, Masaaki AU - Hidaka M AD - Department of Surgery, Nagasaki University Graduate School of Biomedical Science. FAU - Nagayasu, Takeshi AU - Nagayasu T AD - Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science. FAU - Eguchi, Susumu AU - Eguchi S AD - Department of Surgery, Nagasaki University Graduate School of Biomedical Science. LA - eng PT - Journal Article PL - Japan TA - Acta Med Okayama JT - Acta medica Okayama JID - 0417611 RN - 15H5577CQD (Docetaxel) RN - 0 (Taxoids) SB - IM MH - Humans MH - Female MH - Docetaxel/adverse effects MH - *Breast Neoplasms/drug therapy MH - Retrospective Studies MH - Taxoids/adverse effects MH - *Peripheral Nervous System Diseases/chemically induced/prevention & control MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use OTO - NOTNLM OT - breast cancer OT - compression OT - docetaxel OT - neuropathy COIS- No potential conflict of interest relevant to this article was reported. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 20:53 PHST- 2022/12/22 20:53 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - 10.18926/AMO/64119 [doi] PST - ppublish SO - Acta Med Okayama. 2022 Dec;76(6):689-694. doi: 10.18926/AMO/64119. PMID- 36564800 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1477-7525 (Electronic) IS - 1477-7525 (Linking) VI - 20 IP - 1 DP - 2022 Dec 23 TI - The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression. PG - 169 LID - 10.1186/s12955-022-02067-w [doi] LID - 169 AB - INTRODUCTION: An increasing number of postmenopausal women are diagnosed with breast cancer at an older age (≥ 70 years). There is a lack of synthesised health utility data to support decision-making for managing breast cancer in this older population. This study aimed to identify the availability of, and the subsequent impact of age on, health state utility values (HSUVs) measured by the EQ-5D for older women with early-stage breast cancer. METHOD: This systematic review identified EQ-5D (3L or 5L version) HSUVs for postmenopausal women with early-stage breast cancer. Studies were identified from a previous systematic review (inception to 2009) and an electronic database search (Medline and Embase; 2009 to September 2021). Mean HSUVs were summarised by health state. Quality appraisal was performed on studies reporting HSUVs for older ages (≥ 70 years). Multivariable meta-regression assessed the association between HSUVs and age, health state, treatments received, and time of measuring the utility values (greater or less than one year post-treatment). RESULTS: Fifty EQ-5D HSUVs were identified from 13 studies. Mean HSUVs decreased as health state worsened: from the stable (mean=0.83) to progression (mean=0.79) and advanced (mean=0.68) states. Two studies reported six HSUVs estimated from the sample of women with a mean age ≥ 70. Meta-regression model fit improved by including age as an independent variable and attenuated the estimated utility decrements associated with worse health states. Utility decrements for the progression and advanced states were -0.052 (95%CI: -0.097, -0.007) and -0.143 (95%CI: -0.264, -0.022) respectively. The breast cancer-specific utility decrement associated with a one-year increase in age was -0.001 (95%CI: -0.004, 0.002). CONCLUSION: Relevant and accurate HSUVs are essential to help support decision-making about the most effective and cost-effective ways to manage early-stage breast cancer in older women. Age has a vital role in determining health utility values in this population. This study provides analysts and decision-makers with HSUVs and utility decrements that reflect the disease process in this older population. CI - © 2022. The Author(s). FAU - Wang, Yubo AU - Wang Y AUID- ORCID: 0000-0002-2686-8946 AD - Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Stopford Building, Oxford Road, 1stFloor Stopford Building, Manchester, M13 9PT, UK. yubo.wang@manchester.ac.uk. FAU - Gavan, Sean P AU - Gavan SP AUID- ORCID: 0000-0003-3659-056X AD - Manchester Centre for Health Economics, Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK. FAU - Steinke, Douglas AU - Steinke D AUID- ORCID: 0000-0001-8917-2674 AD - Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Stopford Building, Oxford Road, 1stFloor Stopford Building, Manchester, M13 9PT, UK. FAU - Cheung, Kwok-Leung AU - Cheung KL AUID- ORCID: 0000-0003-2973-0755 AD - School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Uttoxeter Road, Derby, DE22 3DT, UK. FAU - Chen, Li-Chia AU - Chen LC AUID- ORCID: 0000-0002-6158-6645 AD - Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Stopford Building, Oxford Road, 1stFloor Stopford Building, Manchester, M13 9PT, UK. LA - eng PT - Journal Article PT - Review PT - Systematic Review DEP - 20221223 PL - England TA - Health Qual Life Outcomes JT - Health and quality of life outcomes JID - 101153626 SB - IM MH - Humans MH - Female MH - Aged MH - *Quality of Life MH - *Breast Neoplasms/therapy MH - Health Status MH - Cost-Benefit Analysis PMC - PMC9789668 OTO - NOTNLM OT - Early-stage breast cancer OT - Economic evaluation OT - Health state utility values OT - Meta-regression OT - Older women OT - Systematic review COIS- Kwok-Leung Cheung has served in a consultancy capacity for Roche. All other authors (Yubo Wang, Sean P Gavan, Douglas Steinke and Li-Chia Chen) declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/23 23:52 PHST- 2022/08/16 00:00 [received] PHST- 2022/11/07 00:00 [accepted] PHST- 2022/12/23 23:52 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - 10.1186/s12955-022-02067-w [pii] AID - 2067 [pii] AID - 10.1186/s12955-022-02067-w [doi] PST - epublish SO - Health Qual Life Outcomes. 2022 Dec 23;20(1):169. doi: 10.1186/s12955-022-02067-w. PMID- 36357711 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer. PG - 223-233 LID - 10.1007/s10549-022-06704-2 [doi] AB - PURPOSE: Over 50% of breast cancer patients prescribed a 5-year course of daily oral adjuvant endocrine therapy (ET) are nonadherent. We investigated the role of costs and cancer medication delivery mode and other medication delivery factors on adherence. METHODS: We conducted a retrospective cohort study of commercially insured and Medicare advantage patients with newly diagnosed breast cancer in 2007-2015 who initiated ET. We examined the association between 12-month ET adherence (proportion of days covered by fills ≥ 0.80) and ET copayments, 90-day prescription refill use, mail order pharmacy use, number of pharmacies, and synchronization of medications. We used regression models to estimate nonadherence risk ratios adjusted for demographics (age, income, race, urbanicity), comorbidities, total medications, primary cancer treatments, and generic AI availability. Sensitivity analyses were conducted using alternative specifications for independent variables. RESULTS: Mail order users had higher adherence in both commercial and Medicare-insured cohorts. Commercially insured patients who used mail order were more likely to be adherent if they had low copayments (< $5) and 90-day prescription refills. For commercially insured patients who used local pharmacies, use of one pharmacy and better synchronized refills were also associated with adherence. Among Medicare patients who used mail order pharmacies, only low copayments were associated with adherence, while among Medicare patients using local pharmacies both low copayments and 90-day prescriptions were associated with ET adherence. CONCLUSION: Out-of-pocket costs, medication delivery mode, and other pharmacy-related medication delivery factors are associated with adherence to breast cancer ET. Future work should investigate whether interventions aimed at streamlining medication delivery could improve adherence for breast cancer patients. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Neuner, Joan M AU - Neuner JM AUID- ORCID: 0000-0003-0031-5988 AD - Division of General Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. jneuner@mcw.edu. AD - Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, WI, USA. jneuner@mcw.edu. FAU - Fergestrom, Nicole AU - Fergestrom N AD - Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Pezzin, Liliana E AU - Pezzin LE AD - Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Laud, Purushottam W AU - Laud PW AD - Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, WI, USA. AD - Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA. FAU - Ruddy, Kathryn J AU - Ruddy KJ AD - The Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. FAU - Winn, Aaron N AU - Winn AN AD - School of Pharmacy, Medical College of Wisconsin, Milwaukee, WI, USA. LA - eng GR - R01 MD010728/MD/NIMHD NIH HHS/United States GR - MD01-0728/MD/NIMHD NIH HHS/United States GR - MD01-0728/MD/NIMHD NIH HHS/United States PT - Journal Article DEP - 20221110 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Aged MH - United States/epidemiology MH - Female MH - *Breast Neoplasms/drug therapy MH - Retrospective Studies MH - Medicare MH - Medication Adherence MH - *Pharmaceutical Services MH - Adjuvants, Immunologic/therapeutic use OTO - NOTNLM OT - Breast cancer OT - Cost-related nonadherence OT - Medication adherence EDAT- 2022/11/11 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/10 23:59 PHST- 2022/04/29 00:00 [received] PHST- 2022/07/31 00:00 [accepted] PHST- 2022/11/11 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/10 23:59 [entrez] AID - 10.1007/s10549-022-06704-2 [pii] AID - 10.1007/s10549-022-06704-2 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):223-233. doi: 10.1007/s10549-022-06704-2. Epub 2022 Nov 10. PMID- 36580423 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1945-7170 (Electronic) IS - 0013-7227 (Linking) VI - 164 IP - 3 DP - 2023 Jan 9 TI - Adrenal Steroids and Resistance to Hormonal Blockade of Prostate and Breast Cancer. LID - bqac218 [pii] LID - 10.1210/endocr/bqac218 [doi] AB - Prostate cancer and breast cancer are sex-steroid-dependent diseases that are driven in major part by gonadal sex steroids. Testosterone (T) is converted to 5α-dihydrotestosterone, both of which stimulate the androgen receptor (AR) and prostate cancer progression. Estradiol is the major stimulus for estrogen receptor-α (ERα) and proliferation of ERα-expressing breast cancer. However, the human adrenal provides an alternative source for sex steroids. A number of different androgens are produced by the adrenals, the most abundant of which is dehydroepiandrosterone (DHEA) and DHEA sulfate. These precursor steroids are subject to metabolism by peripherally expressed enzymes that are responsible for the synthesis of potent androgens and estrogens. In the case of prostate cancer, the regulation of one of these enzymatic steps occurs at least in part by way of a germline-encoded missense in 3β-hydroxysteroid dehydrogenase-1 (3βHSD1), which regulates potent androgen biosynthesis and clinical outcomes in men with advanced prostate cancer treated with gonadal T deprivation. The sex steroids that drive prostate cancer and breast cancer require a common set of enzymes for their generation. However, the pathways diverge once 3-keto, Δ4-androgens are generated and these steroids are either turned into potent androgens by steroid-5α-reductase, or into estrogens by aromatase. Alternative steroid receptors have also emerged as disease- and treatment-resistance modifiers, including a role for AR in breast cancer and glucocorticoid receptor both in breast and prostate cancer. In this review, we integrate the commonalities of adrenal steroid physiology that regulate both prostate and breast cancer while recognizing the clear distinctions between these diseases. CI - © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Michael, Patrick AU - Michael P AD - Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. FAU - Roversi, Gustavo AU - Roversi G AD - Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. FAU - Brown, Kristy AU - Brown K AD - Sandra and Edward Meyer Cancer Center and Department of Medicine, Weill Cornell Medicine, New York, New York 10065, USA. FAU - Sharifi, Nima AU - Sharifi N AUID- ORCID: 0000-0003-1281-3474 AD - Genitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. AD - Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. AD - Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. LA - eng GR - R01 CA172382/CA/NCI NIH HHS/United States GR - R01 CA236780/CA/NCI NIH HHS/United States GR - R01 CA261995/CA/NCI NIH HHS/United States GR - R01 CA249279/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Review PL - United States TA - Endocrinology JT - Endocrinology JID - 0375040 RN - 0 (Androgens) RN - 08J2K08A3Y (Dihydrotestosterone) RN - 0 (Estrogen Receptor alpha) RN - 0 (Estrogens) RN - 0 (Steroids) SB - IM MH - Humans MH - Male MH - Androgens/metabolism MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Dihydrotestosterone/metabolism MH - Estrogen Receptor alpha/metabolism MH - Estrogens/metabolism MH - Prostate/metabolism MH - *Prostatic Neoplasms/drug therapy/genetics/metabolism MH - Steroids MH - Female OTO - NOTNLM OT - adrenals OT - androgens OT - breast cancer OT - estrogens OT - hormones OT - metabolism OT - prostate cancer OT - steroids EDAT- 2022/12/30 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/12/29 13:12 PHST- 2022/11/30 00:00 [received] PHST- 2022/12/30 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/12/29 13:12 [entrez] AID - 6965271 [pii] AID - 10.1210/endocr/bqac218 [doi] PST - ppublish SO - Endocrinology. 2023 Jan 9;164(3):bqac218. doi: 10.1210/endocr/bqac218. PMID- 36288635 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy. PG - 162-168 LID - S0960-9776(22)00171-0 [pii] LID - 10.1016/j.breast.2022.10.006 [doi] AB - INTRODUCTION: Whether adjuvant therapy with aromatase inhibitors (AIs) causes sleep disturbances or not in postmenopausal women with early breast cancer (EBC) is still a controversial issue. METHODS: Between March 2014 and November 2017, validated questionnaires for assessing insomnia, anxiety, depression, quality of life (QoL) and restless legs syndrome (RLS) were administered to 160 EBC patients at baseline and after 3, 6, 12, and 24 months of AI therapy. RESULTS: AI therapy significantly decreased the patients' QoL, but did not influence insomnia, anxiety or depression. However, it significantly increased the frequency and severity of RLS. Patients with RLS at baseline (19%) or who developed RLS during AI therapy (26.3%) reported statistically lower quality of sleep, higher anxiety and depression, and worse QoL compared to patients who never reported RLS (54.7%). CONCLUSION: Although AI therapy does not affect sleep quality, it may increase RLS frequency. The presence of RLS could identify a group of EBC patients who may benefit from psychological support. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Pedersini, Rebecca AU - Pedersini R AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy; SSVD Breast Unit, ASST-Spedali Civili of Brescia, Brescia, Italy. FAU - di Mauro, Pierluigi AU - di Mauro P AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. Electronic address: p.dimauro001@unibs.it. FAU - Amoroso, Vito AU - Amoroso V AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. FAU - Castronovo, Vincenza AU - Castronovo V AD - Sleep Disorders Center, Department of Clinical Neurosciences, San Raffaele Hospital and University Vita-Salute San Raffaele, Milan, Italy. FAU - Zamparini, Manuel AU - Zamparini M AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. FAU - Monteverdi, Sara AU - Monteverdi S AD - Santa Chiara Hospital, Trento, Italy. FAU - Laini, Lara AU - Laini L AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. FAU - Schivardi, Greta AU - Schivardi G AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. FAU - Cosentini, Deborah AU - Cosentini D AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. FAU - Grisanti, Salvatore AU - Grisanti S AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. FAU - Marelli, Sara AU - Marelli S AD - Sleep Disorders Center, Department of Clinical Neurosciences, San Raffaele Hospital and University Vita-Salute San Raffaele, Milan, Italy. FAU - Ferini Strambi, Luigi AU - Ferini Strambi L AD - Sleep Disorders Center, Department of Clinical Neurosciences, San Raffaele Hospital and University Vita-Salute San Raffaele, Milan, Italy. FAU - Berruti, Alfredo AU - Berruti A AD - Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. LA - eng PT - Journal Article DEP - 20221018 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Aromatase Inhibitors) SB - IM MH - Humans MH - Female MH - Aromatase Inhibitors/adverse effects MH - *Breast Neoplasms/complications/drug therapy MH - Quality of Life/psychology MH - *Sleep Initiation and Maintenance Disorders/chemically induced/complications MH - *Restless Legs Syndrome/etiology/psychology MH - Postmenopause MH - Sleep MH - Surveys and Questionnaires MH - *Sleep Wake Disorders/chemically induced MH - Severity of Illness Index PMC - PMC9593725 OTO - NOTNLM OT - Aromatase inhibitors OT - Early breast cancer OT - Insomnia OT - Quality of life OT - Restless legs syndrome COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/10/27 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/26 18:14 PHST- 2022/08/14 00:00 [received] PHST- 2022/09/29 00:00 [revised] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/26 18:14 [entrez] AID - S0960-9776(22)00171-0 [pii] AID - 10.1016/j.breast.2022.10.006 [doi] PST - ppublish SO - Breast. 2022 Dec;66:162-168. doi: 10.1016/j.breast.2022.10.006. Epub 2022 Oct 18. PMID- 36641654 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Downregulation of MICA/B tumor surface expressions and augmented soluble MICA serum levels correlate with disease stage in breast cancer. PG - 471-480 LID - 10.3233/BD-220023 [doi] AB - OBJECTIVE: In this study, the profiling of the expression of major histocompatibility complex (MHC) class I-related chain A and B (MICA/B) in human breast cancer tumor tissue, saliva, and urine samples of breast cancer patients and control is carried out. MICA/B is ligand of NKG2D receptor expressed on malignant cells. The release of MICA/B from tumor tissue comprises an immune escape mechanism that impairs antitumor immunity. Based on this literature we explored the potential of soluble MICA (sMICA) as a marker in breast cancer (BC). METHODS: The expression was profiled by using immunohistochemistry (MICA/B), western blot (MICA/B) and ELISA (MICA). RESULTS: The optical density of western blot of MICA/B in different stages of BC illustrated significant difference as per one way analysis of variance and significant difference with stage III and IV by Dunnett's multiple comparisons test respectively. Analysis of sMICA in serum, saliva and urine of BC patients revealed significantly higher levels (median 41.0 ± 4.1 pg/ml in pre-treatment sera, 181.9 ± 1.6 pg/ml in saliva and 90.7 ± 1.7 pg/ml in urine) than in control (median <1.2 pg/ml). The elevated levels of sMICA were related to the cancer stage. CONCLUSIONS: The elevated levels of sMICA were observed in patients with well differentiated cancer while the poor expression of sMICA was observed in patients with poorly differentiated tumors. Tumor immunity is impaired by the release of MICA in the biofluids and may be useful for detection and diagnosis of the stage of BC. FAU - Kshersagar, Jeevitaa AU - Kshersagar J AD - Department of Stem Cells & Regenerative Medicine, D. Y. Patil Deemed to be University, D. Y. Patil Vidyanagar, Kasba Bawda, Kolhapur, Maharashtra, India. FAU - Damle, Mrunal N AU - Damle MN AD - Department of Stem Cells & Regenerative Medicine, D. Y. Patil Deemed to be University, D. Y. Patil Vidyanagar, Kasba Bawda, Kolhapur, Maharashtra, India. AD - Stem Plus Biotech, SMK Commercial Complex, Near Shivaji Maharaj Putla, Gaon Bhag, Sangli, Maharashtra, India. FAU - Bedge, Poonam AU - Bedge P AD - Department of Stem Cells & Regenerative Medicine, D. Y. Patil Deemed to be University, D. Y. Patil Vidyanagar, Kasba Bawda, Kolhapur, Maharashtra, India. FAU - Jagdale, Rakhi AU - Jagdale R AD - Department of Pathology, Shri Siddhivinayak Ganpati Cancer Hospital, Miraj, Sangli, Maharashtra, India. FAU - Tardalkar, Kishor AU - Tardalkar K AD - Department of Stem Cells & Regenerative Medicine, D. Y. Patil Deemed to be University, D. Y. Patil Vidyanagar, Kasba Bawda, Kolhapur, Maharashtra, India. FAU - Jadhav, Dhanaji AU - Jadhav D AD - Department of Statistics, Yashavantrao Chavan Institute of Science, Satara, Maharashtra, India. FAU - Jagadale, Swapnali AU - Jagadale S AD - Department of Stem Cells & Regenerative Medicine, D. Y. Patil Deemed to be University, D. Y. Patil Vidyanagar, Kasba Bawda, Kolhapur, Maharashtra, India. FAU - Toro, Yashwant AU - Toro Y AD - Department of Scientific and Industrial Research Organization, Shri Siddhivinayak Ganpati Cancer Hospital, Miraj, Sangli, Maharashtra, India. FAU - Sharma, Rakesh AU - Sharma R AD - Department of Obstetrics and Gynaecology, Dr. D Y Patil Medical College, Hospital and Research Institute, Kadamwadi, Kolhapur, Maharashtra, India. FAU - Joshi, Meghnad G AU - Joshi MG AD - Department of Stem Cells & Regenerative Medicine, D. Y. Patil Deemed to be University, D. Y. Patil Vidyanagar, Kasba Bawda, Kolhapur, Maharashtra, India. AD - Stem Plus Biotech, SMK Commercial Complex, Near Shivaji Maharaj Putla, Gaon Bhag, Sangli, Maharashtra, India. LA - eng PT - Journal Article PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 RN - 0 (Histocompatibility Antigens Class I) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms MH - Down-Regulation MH - Histocompatibility Antigens Class I/genetics/metabolism MH - Neoplasm Staging MH - Immunohistochemistry OTO - NOTNLM OT - Breast cancer OT - MICA/B OT - sMICA/B EDAT- 2023/01/16 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/15 05:22 PHST- 2023/01/15 05:22 [entrez] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - BD220023 [pii] AID - 10.3233/BD-220023 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):471-480. doi: 10.3233/BD-220023. PMID- 36547175 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230112 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 29 IP - 12 DP - 2022 Dec 8 TI - Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances. PG - 9695-9710 LID - 10.3390/curroncol29120761 [doi] AB - PURPOSE: Biomarker discordances and alterations can be encountered between tru-cut biopsy and residual tumor in breast cancer treated with neoadjuvant chemotherapy (NACTx). We aimed to investigate the effect of NACTx on major biomarker expression (ER, PR, HER2, Ki-67) and tumor grade, the frequency and causes of receptor discordances, and the clinical significance of changes in terms of adjuvant therapy need and chemosensitivity. METHODS: In this retrospective study, ER, PR, HER2, and Ki-67 expression and tumor grades were compared between pre- and post-NACTx tumor samples using the Wilcoxon signed-rank test. The frequencies of receptor discordances and the need for new adjuvant therapy due to discordances were calculated. The effect of patient and tumor characteristics and NACTx regimens on discordances was investigated using multivariate analysis. Using histopathological examinations, residual tumors were divided into chemotherapy-responsive and chemotherapy-unresponsive tumors. Biomarker changes in both groups were analyzed for predictability of chemosensitivity. RESULTS: Of the 169 patients who received NACTx, 102 patients having enough residual tumors in the surgical pathology specimen were enrolled in the study. Histopathologically, about 70% of tumors were partially responsive to NACTx and 30% were unresponsive (chemo-resistant). The concordance and discordance rates were 95.1% versus 4.9% for ER (p = 0.180), 97.1% versus 2.9% for PR (p = 0.083), and 89.2% versus 10.8% for HER2 (p = 0.763), respectively. In addition, 15% of hormone receptor (HR)-negative patients became HR(+) and 5.7% of HER2(-) patients became HER2(+) in the residual tumors, requiring adjuvant endocrine or anti-HER2 therapy. In particular, 18% of triple-negative patients became HR(+) and 12% became HER2(+). HER2 loss was detected in 40% of HER2(+) patients. Multivariate logistic regression analysis revealed that lower estrogen expression (p = 0.046), a smaller tumor size (p = 0.029), and anti-HER2 therapy (p < 0.001) have independent efficacy on ER discordance, PR discordance, and HER2 discordance, respectively. Ki-67 and PR expression significantly decreased in chemotherapy-responsive tumors (p = 0.001 and p = 0.004), and the tumor grade increased in chemotherapy-unresponsive tumors (p = 0.034). CONCLUSIONS: Approximately 3-5% of HR discordance and about 10% of HER2 discordance can be observed in breast cancer after currently used NACTx regimens. Discordances are bi-directional (from positive to negative and vice versa), and their causes are multifactorial; they should be assessed accordingly. The NACTx effect alone cannot explain observed discordances but can cause biomarker alterations. The change in receptor status from positive to negative, especially HER2 loss, is mainly associated with the NACTx effect. However, the shift from negative to positive is thought to be primarily related to intratumoral heterogeneity. Receptor statuses becoming positive are of more clinical importance due to adjuvant therapy requirements. Biomarker alterations in PR, Ki-67, and tumor grade can provide predictive information about tumor chemosensitivity. FAU - Yilmaz, Cengiz AU - Yilmaz C AD - Department of Medical Oncology, Bozyaka Training and Research Hospital, The University of Health Sciences, Izmir 35170, Turkey. FAU - Cavdar, Demet Kocatepe AU - Cavdar DK AD - Department of Pathology, Bozyaka Training and Research Hospital, The University of Health Sciences, Izmir 35170, Turkey. LA - eng PT - Journal Article DEP - 20221208 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Biomarkers, Tumor) RN - 0 (Ki-67 Antigen) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Receptors, Estrogen) RN - 0 (Receptors, Progesterone) SB - IM MH - Female MH - Humans MH - *Biomarkers, Tumor/metabolism MH - *Breast Neoplasms/diagnosis/therapy MH - Clinical Relevance MH - Ki-67 Antigen/metabolism MH - *Neoadjuvant Therapy MH - Neoplasm, Residual MH - Receptor, ErbB-2/metabolism MH - Receptors, Estrogen/metabolism MH - Receptors, Progesterone/metabolism MH - Retrospective Studies MH - Neoplasm Grading PMC - PMC9776827 OTO - NOTNLM OT - biomarker alteration OT - biomarker discordance OT - breast cancer OT - chemosensitivity OT - neoadjuvant chemotherapy COIS- The authors declare no conflict of interest. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 09:54 PHST- 2022/11/02 00:00 [received] PHST- 2022/12/01 00:00 [revised] PHST- 2022/12/06 00:00 [accepted] PHST- 2022/12/22 09:54 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - curroncol29120761 [pii] AID - curroncol-29-00761 [pii] AID - 10.3390/curroncol29120761 [doi] PST - epublish SO - Curr Oncol. 2022 Dec 8;29(12):9695-9710. doi: 10.3390/curroncol29120761. PMID- 36335747 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer. PG - 227-235 LID - S0960-9776(22)00184-9 [pii] LID - 10.1016/j.breast.2022.11.001 [doi] AB - INTRODUCTION: Traditionally, Nottingham prognostic index (NPI) informed prognosis in patients with estrogen receptor positive, human epidermal growth factor receptor-2 negative, node negative (ER+/HER2-/LN-) breast cancer. At present, OncotypeDX© Recurrence Score (RS) predicts prognosis and response to adjuvant chemotherapy (AC). AIMS: To compare NPI and RS for estimating prognosis in ER + breast cancer. METHODS: Consecutive patients with ER+/HER2-/LN- disease were included. Disease-free (DFS) and overall survival (OS) were determined using Kaplan-Meier and Cox regression analyses. RESULTS: 1471 patients met inclusion criteria. The mean follow-up was 110.7months. NPI was calculable for 1382 patients: 19.8% had NPI≤2.4 (291/1471), 33.0% had NPI 2.41-3.4 (486/1471), 30.0% had NPI 3.41-4.4 (441/1471), 10.9% had NPI 4.41-5.4 (160/1471), and 0.3% had NPI>5.4 (4/1471). In total, 329 patients underwent RS (mean RS: 18.7) and 82.1% had RS < 25 (270/329) and 17.9% had RS ≥ 25 (59/329). Using multivariable Cox regression analyses (n = 1382), NPI independently predicted DFS (Hazard ratio (HR): 1.357, 95% confidence interval (CI): 1.140-1.616, P < 0.001) and OS (HR: 1.003, 95% CI: 1.001-1.006, P = 0.024). When performing a focused analysis of those who underwent both NPI and RS (n = 329), neither biomarker predicted DFS or OS. Using Kaplan Meier analyses, NPI category predicted DFS (P = 0.008) and (P = 0.026) OS. Conversely, 21-gene RS group failed to predict DFS (P = 0.187) and OS (P = 0.296). CONCLUSION: In our focused analysis, neither NPI nor RS predicted survival outcomes. However, in the entire series, NPI independently predicted both DFS and OS. On the 40th anniversary since its derivation, NPI continues to provide accurate prognostication in breast cancer, outperforming RS in the current study. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Kerin, Eoin P AU - Kerin EP AD - Discipline of Surgery, Lambe Institute for Translational Research, University of Galway, Galway, Ireland. FAU - Davey, Matthew G AU - Davey MG AD - Discipline of Surgery, Lambe Institute for Translational Research, University of Galway, Galway, Ireland. Electronic address: m.davey7@nuigalway.ie. FAU - McLaughlin, Ray P AU - McLaughlin RP AD - Department of Surgery, Galway University Hospitals, Galway, Ireland. FAU - Sweeney, Karl J AU - Sweeney KJ AD - Department of Surgery, Galway University Hospitals, Galway, Ireland. FAU - Barry, Michael K AU - Barry MK AD - Department of Surgery, Galway University Hospitals, Galway, Ireland. FAU - Malone, Carmel M AU - Malone CM AD - Department of Surgery, Galway University Hospitals, Galway, Ireland. FAU - Elwahab, Sami Abd AU - Elwahab SA AD - Discipline of Surgery, Lambe Institute for Translational Research, University of Galway, Galway, Ireland; Department of Surgery, Galway University Hospitals, Galway, Ireland. FAU - Lowery, Aoife J AU - Lowery AJ AD - Discipline of Surgery, Lambe Institute for Translational Research, University of Galway, Galway, Ireland; Department of Surgery, Galway University Hospitals, Galway, Ireland. FAU - Kerin, Michael J AU - Kerin MJ AD - Discipline of Surgery, Lambe Institute for Translational Research, University of Galway, Galway, Ireland; Department of Surgery, Galway University Hospitals, Galway, Ireland. LA - eng PT - Journal Article DEP - 20221103 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Receptors, Estrogen) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Prognosis MH - Receptors, Estrogen/metabolism MH - Proportional Hazards Models MH - Kaplan-Meier Estimate MH - Receptor, ErbB-2 PMC - PMC9647009 OTO - NOTNLM OT - Breast cancer OT - Cancer surgery OT - Oncological outcomes OT - Surgical oncology EDAT- 2022/11/07 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/06 18:13 PHST- 2022/09/18 00:00 [received] PHST- 2022/10/22 00:00 [revised] PHST- 2022/11/02 00:00 [accepted] PHST- 2022/11/07 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/06 18:13 [entrez] AID - S0960-9776(22)00184-9 [pii] AID - 10.1016/j.breast.2022.11.001 [doi] PST - ppublish SO - Breast. 2022 Dec;66:227-235. doi: 10.1016/j.breast.2022.11.001. Epub 2022 Nov 3. PMID- 36219945 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis. PG - 97-109 LID - S0960-9776(22)00166-7 [pii] LID - 10.1016/j.breast.2022.10.001 [doi] AB - BACKGROUND: This meta-analysis assessed the predictive and prognostic value of tumor infiltrating lymphocytes (TILs) in neoadjuvant chemotherapy (NACT) treated breast cancer and an optimal threshold for predicting pathologic complete response (pCR). METHODS: A systematic search of PubMed, EMBASE and Web of Science electronic databases was conducted to identify eligible studies published before April 2022. Either a fixed or random effects model was applied to estimate the pooled hazard ratio (HR) and odds ratio (OR) for prognosis and predictive values of TILs in breast cancer patients treated with NACT. The study is registered with PROSPERO (CRD42020221521). RESULTS: A total of 29 published studies were eligible. Increased levels of TILs predicted response to NACT in HER2 positive breast cancer (OR = 2.54 95%CI, 1.50-4.29) and triple negative breast cancer (TNBC) (OR = 3.67, 95%CI, 1.93-6.97), but not for hormone receptor (HR) positive breast cancer (OR = 1.68, 95 %CI, 0.67-4.25). A threshold of 20% of H & E-stained TILs was associated with prediction of pCR in both HER2 positive breast cancer (P = 0.035) and TNBC (P = 0.001). Moreover, increased levels of TILs (either iTILs or sTILs) were associated with survival benefit in HER2-positive breast cancer and TNBC. However, an increased level of TILs was not a prognostic factor for survival in HR positive breast cancer (pooled HR = 0.64, 95%CI: 0.03-14.1, P = 0.78). CONCLUSIONS: Increased levels of TILs were associated with increased rates of response to NACT and improved prognosis for the molecular subtypes of TNBC and HER2-positive breast cancer, but not for patients with HR positive breast cancer. A threshold of 20% TILs was the most powerful outcome prognosticator of pCR. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Li, Shiqi AU - Li S AD - Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. FAU - Zhang, Ying AU - Zhang Y AD - Department of Clinical Pharmacy, School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China. FAU - Zhang, Peigen AU - Zhang P AD - Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. FAU - Xue, Shuijing AU - Xue S AD - Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. FAU - Chen, Yu AU - Chen Y AD - Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. FAU - Sun, Lihua AU - Sun L AD - Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. Electronic address: slh-3632@163.com. FAU - Yang, Rui AU - Yang R AD - Clinical Pharmacology Laboratory, The Second Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang, 110034, China. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20221005 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Prognosis MH - Neoadjuvant Therapy MH - *Triple Negative Breast Neoplasms/pathology MH - Lymphocytes, Tumor-Infiltrating/pathology MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use PMC - PMC9550538 OTO - NOTNLM OT - Breast cancer OT - Meta-analysis OT - Neoadjuvant chemotherapy OT - Prognosis and predictive OT - Tumor infiltrating lymphocytes COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/10/12 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/11 18:30 PHST- 2022/04/05 00:00 [received] PHST- 2022/08/11 00:00 [revised] PHST- 2022/10/03 00:00 [accepted] PHST- 2022/10/12 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/11 18:30 [entrez] AID - S0960-9776(22)00166-7 [pii] AID - 10.1016/j.breast.2022.10.001 [doi] PST - ppublish SO - Breast. 2022 Dec;66:97-109. doi: 10.1016/j.breast.2022.10.001. Epub 2022 Oct 5. PMID- 36305867 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 29 IP - 1 DP - 2023 Jan 4 TI - Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape. PG - 8-10 LID - 10.1158/1078-0432.CCR-22-2853 [doi] AB - Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs, patient-derived xenograft models from human brain metastases and phase 0 and window-of-opportunity trials are of utmost importance. See related article by Kabraji et al., p. 174. CI - ©2022 American Association for Cancer Research. FAU - Soffietti, Riccardo AU - Soffietti R AUID- ORCID: 0000-0002-9204-7038 FAU - Pellerino, Alessia AU - Pellerino A AUID- ORCID: 0000-0003-3243-0059 LA - eng PT - Comment PT - Editorial PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 5384HK7574 (trastuzumab deruxtecan) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Antibodies, Monoclonal, Humanized) RN - P188ANX8CK (Trastuzumab) RN - XT3Z54Z28A (Camptothecin) RN - 0 (Immunoconjugates) SB - IM CIN - Clin Cancer Res. 2023 Jan 4;29(1):174-182. PMID: 36074155 CON - Clin Cancer Res. 2022 Sep 8;:. PMID: 36074155 MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/pathology MH - Receptor, ErbB-2/genetics MH - Antibodies, Monoclonal, Humanized MH - Trastuzumab/therapeutic use MH - Camptothecin MH - *Immunoconjugates MH - Treatment Outcome MH - *Brain Neoplasms/drug therapy/genetics/secondary EDAT- 2022/10/29 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/10/28 11:03 PHST- 2022/10/03 00:00 [received] PHST- 2022/10/12 00:00 [revised] PHST- 2022/10/27 00:00 [accepted] PHST- 2022/10/29 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/10/28 11:03 [entrez] AID - 710102 [pii] AID - 10.1158/1078-0432.CCR-22-2853 [doi] PST - ppublish SO - Clin Cancer Res. 2023 Jan 4;29(1):8-10. doi: 10.1158/1078-0432.CCR-22-2853. PMID- 36423362 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230106 IS - 2059-7029 (Electronic) IS - 2059-7029 (Linking) VI - 7 IP - 6 DP - 2022 Dec TI - COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy. PG - 100637 LID - S2059-7029(22)00271-X [pii] LID - 10.1016/j.esmoop.2022.100637 [doi] LID - 100637 AB - BACKGROUND: COGNITION (Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials) is a diagnostic registry trial that employs genomic and transcriptomic profiling to identify biomarkers in patients with early breast cancer with a high risk for relapse after standard neoadjuvant chemotherapy (NACT) to guide genomics-driven targeted post-neoadjuvant therapy. PATIENTS AND METHODS: At National Center for Tumor Diseases Heidelberg patients were biopsied before starting NACT, and for patients with residual tumors after NACT additional biopsy material was collected. Whole-genome/exome and transcriptome sequencing were applied on tumor and corresponding blood samples. RESULTS: In the pilot phase 255 patients were enrolled, among which 213 were assessable: thereof 48.8% were identified to be at a high risk for relapse following NACT; 86.4% of 81 patients discussed in the molecular tumor board were eligible for a targeted therapy within the interventional multiarm phase II trial COGNITION-GUIDE (Genomics-guided targeted post neoadjuvant therapy in patients with early breast cancer) starting enrolment in Q4/2022. An in-depth longitudinal analysis at baseline and in residual tumor tissue of 16 patients revealed some cases with clonal evolution but largely stable genetic alterations, suggesting restricted selective pressure of broad-acting cytotoxic neoadjuvant chemotherapies. CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates. CI - Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Pixberg, C AU - Pixberg C AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany. FAU - Zapatka, M AU - Zapatka M AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany. FAU - Hlevnjak, M AU - Hlevnjak M AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Research Group Computational Oncology, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany. FAU - Benedetto, S AU - Benedetto S AD - Division of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Suppelna, J P AU - Suppelna JP AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany. FAU - Heil, J AU - Heil J AD - Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany. FAU - Smetanay, K AU - Smetanay K AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany; Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany. FAU - Michel, L AU - Michel L AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany. FAU - Fremd, C AU - Fremd C AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, University Hospital Heidelberg, Heidelberg, Germany. FAU - Körber, V AU - Körber V AD - Division of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Rübsam, M AU - Rübsam M AD - Research Group Computational Oncology, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany. FAU - Buschhorn, L AU - Buschhorn L AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany. FAU - Heublein, S AU - Heublein S AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany; Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany. FAU - Schäfgen, B AU - Schäfgen B AD - Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany. FAU - Golatta, M AU - Golatta M AD - Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany. FAU - Gomez, C AU - Gomez C AD - Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany. FAU - von Au, A AU - von Au A AD - Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany. FAU - Wallwiener, M AU - Wallwiener M AD - Department of Obstetrics and Gynecology, Medical School, University of Heidelberg, Heidelberg, Germany. FAU - Wolf, S AU - Wolf S AD - Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Dikow, N AU - Dikow N AD - Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany. FAU - Schaaf, C AU - Schaaf C AD - Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany. FAU - Gutjahr, E AU - Gutjahr E AD - Department of General Pathology, University Hospital Heidelberg, Heidelberg, Germany. FAU - Allgäuer, M AU - Allgäuer M AD - Department of General Pathology, University Hospital Heidelberg, Heidelberg, Germany. FAU - Stenzinger, A AU - Stenzinger A AD - Department of General Pathology, University Hospital Heidelberg, Heidelberg, Germany. FAU - Pfütze, K AU - Pfütze K AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany. FAU - Kirsten, R AU - Kirsten R AD - Liquid Biobank, National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany. FAU - Hübschmann, D AU - Hübschmann D AD - German Cancer Consortium (DKTK), Heidelberg, Germany; Research Group Computational Oncology, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany. FAU - Sinn, H-P AU - Sinn HP AD - Department of General Pathology, University Hospital Heidelberg, Heidelberg, Germany. FAU - Jäger, D AU - Jäger D AD - Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, University Hospital Heidelberg, Heidelberg, Germany. FAU - Trumpp, A AU - Trumpp A AD - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Schlenk, R AU - Schlenk R AD - Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, University Hospital Heidelberg, Heidelberg, Germany; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; NCT Trial Center, National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center and DKFZ, Heidelberg, Germany. FAU - Höfer, T AU - Höfer T AD - Division of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Thewes, V AU - Thewes V AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany. FAU - Schneeweiss, A AU - Schneeweiss A AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Lichter, P AU - Lichter P AD - National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and Heidelberg University Medical Center, Heidelberg, Germany; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: peter.lichter@dkfz-heidelberg.de. LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221121 PL - England TA - ESMO Open JT - ESMO open JID - 101690685 SB - IM MH - Female MH - Humans MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Neoadjuvant Therapy MH - Neoplasm Recurrence, Local/drug therapy MH - Precision Medicine MH - Prospective Studies PMC - PMC9808485 OTO - NOTNLM OT - curative precision oncology OT - early breast cancer OT - molecularly targeted therapy OT - prospective precision oncology trial OT - tumor evolution COIS- Disclosure MH has received speaker’s fee from Merck Sharp & Dohme (MSD). KS has received honoraria from Pfizer, MSD, and Gilead. LM has received speaker honoraria or travel support from Roche, Eisai, Pfizer, Gilead, AstraZeneca, Lilly, MSD, Celgene, and Novartis. CF has received honoraria for advisory activity from Roche, Pfizer, MSD, and Eisai; travel grants from Celgene, Roche, and Amgen; and honoraria from Roche, Celgene/BMS, Pfizer, Astra Zeneca, GSK, and Novartis. SH reports research support, honoraria, and/or travel expenses from AstraZeneca, Clovis, Novartis, Pfizer, and GSK outside the submitted work. BS is supported by a Physician Scientist scholarship of the Medical Faculty of Heidelberg University. MW received speaker honoraria from AstraZeneca Celgene Roche, MSD, and Novartis. A.Stenzinger has received honoraria for advisory board/speaker’s bureau activities at Astra Zeneca, AGCT, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, and Thermo Fisher; and grants from Bayer, BMS, Chugai, and Incyte. DJ has received consulting fees for participation on a data safety monitoring board or advisory board from CureVac AG, Definiens, F. Hoffmann-La Roche Ltd, Genmab A-S, Life Science Inkubator GmbH, VAXIMM AG, OncoOne Research & Development Research GmbH, Oncolytics Biotech Inc., Zelluna, HDIT GmbH, AYOXXA, Seattle Genetics, BreakBio Corp., and Roche Pharma AG; honoraria from SKK Kliniken Heilbronn GmbH, Georg Thieme Verlag, Terrapinn, Touch Medical Media, BMS GmbH & Co KGaA, MSD, Gruppe 5 Filmproduktion GmbH, AstraZeneca GmbH, Department of Radiation Medicine University Kentucky, and The Norwegian Cancer Society Oslo; payment for expert testimony from expert opinions for courts, Wilhelm-Sander-Stiftung, Else Kröner-Fresenius-Stiftung, Schering Stiftung, and NordForsk; support for attending meeting and/or travel from Amgen Inc., Oryx GmbH, Roche Glycart AG, Parexel.com, IKTZ HD GmbH, and BMS; honoraria for a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from BMS Stiftung Immunonkologie. RS reports consulting for or advisory board membership with Daiichi Sankyo, Pfizer, Astellas, and Novartis; research funding from PharmaMar, AstraZeneca, Pfizer, Roche, Boehringer Ingelheim, and Daiichi Sankyo; travel, accommodations, and expenses covered by Daiichi Sankyo. A. Schneeweiss has received research grants from Celgene, Roche, and AbbVie; honoraria from Roche, Celgene, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, GSK, Seagen, Gilead, Bayer, Amgen, Pierre Fabre, streamedup!, promedicis, onkowissen.de, Metaplan, and Connectmedica Sp; and travel support from Roche, Celgene, and Pfizer. All remaining authors have declared no conflicts of interest. EDAT- 2022/11/25 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/24 18:13 PHST- 2022/08/03 00:00 [received] PHST- 2022/10/09 00:00 [revised] PHST- 2022/10/18 00:00 [accepted] PHST- 2022/11/25 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/24 18:13 [entrez] AID - S2059-7029(22)00271-X [pii] AID - 100637 [pii] AID - 10.1016/j.esmoop.2022.100637 [doi] PST - ppublish SO - ESMO Open. 2022 Dec;7(6):100637. doi: 10.1016/j.esmoop.2022.100637. Epub 2022 Nov 21. PMID- 36462594 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 181 DP - 2023 Jan TI - Status of breast cancer in Latin American: Results of the breast cancer revealed initiative. PG - 103890 LID - S1040-8428(22)00314-6 [pii] LID - 10.1016/j.critrevonc.2022.103890 [doi] AB - The Breast Cancer Revealed initiative was designed and conducted to know the status of breast cancer at each point of breast cancer care, through i) prevention, ii) detection, iii) diagnosis, iv) treatment, and iv) the capacity of our health systems. The expert panel from 11 Latin American countries identified several strategies and proposed high impact priorities, including implementation of prevention policies, improve primary healthcare capacity for breast cancer screening, have adequate infrastructure to make effective and timely diagnoses, have a multidisciplinary team in the treatment process, access to a variety of treatments for all types of patients, have a coordinated and articulated system from primary care to specialized hospital. In a region with limited resources, prioritization in high-impact strategies for breast cancer control could lead to improved clinical outcomes and quality of life for our patients. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Ayala, Natalia AU - Ayala N AD - Servicio de Oncología Clínica, Hospital Dr. Jose Ramon Vidal, Corrientes, Argentina. FAU - Barchuk, Sabrina AU - Barchuk S AD - Sección Patología Mamaria, División Ginecología, Hospital General de Agudos Juan A. Fernández, Buenos Aires, Argentina. FAU - Inurrigarro, Gloria AU - Inurrigarro G AD - Departamento de Patología, Sanatorio Mater Dei, Buenos Aires, Argentina; Departamento de Patología, Hospital Maria Curie, Buenos Aires, Argentina. FAU - Celano, Constanza AU - Celano C AD - Secretaria Académica de la Especialidad en Enfermería Oncológica, Universidad Austral, Buenos Aires, Argentina. FAU - Soriano-García, Jorge Luis AU - Soriano-García JL AD - Departamento de Oncología, Hospital Ameijeiras, La Habana, Cuba. FAU - Bolaños, Patricia AU - Bolaños P AD - Departamento de Enfermería, Oncomédica, Ciudad de Guatemala, Guatemala. FAU - Mohs-Alfaro, Mónica AU - Mohs-Alfaro M AD - Departamento de Patología, Hospital Rafael Ángel Calderón Guardia, Costa Rica. FAU - Tapia-González, Hector AU - Tapia-González H AD - Departamento de Radiología, Instituto Oncológico Nacional, Panama. FAU - Perez-Martinez, Ramón AU - Perez-Martinez R AD - Servicio de Tumores Mamarios del Instituto de Oncología Dr. Heriberto Pieter, República Dominicana. FAU - Samtani, Suraj AU - Samtani S AD - Medical Oncology Department, Clinica Las Condes, Santiago, Chile. FAU - Alvarado-Cabrero, Isabel AU - Alvarado-Cabrero I AD - Departamento de Patología, Centro Médico Nacional Siglo XXI, Ciudad de Mexico, Mexico. FAU - Villarreal-Garza, Cynthia AU - Villarreal-Garza C AD - Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico. FAU - Tamez-Salazar, Jaime AU - Tamez-Salazar J AD - Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico. FAU - Magallanes-Garza, Gerardo I AU - Magallanes-Garza GI AD - Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Servicio de Ginecologia y Obstetricia Tec Salud, Monterrey, México. FAU - Vazquez, Daniela AU - Vazquez D AD - Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico. FAU - Castro, Janeth AU - Castro J AD - Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico. FAU - Gómez-Macías, Gabriela S AU - Gómez-Macías GS AD - Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Monterrey, Mexico. FAU - Ferrigno, Ana AU - Ferrigno A AD - Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico. FAU - Morante, Zaida AU - Morante Z AD - Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. FAU - Vilchez, Sheila AU - Vilchez S AD - Departamento de Cirugía en Mamas y Tejidos Blandos, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. FAU - Cotrina, José Manuel AU - Cotrina JM AD - Departamento de Cirugía en Mamas y Tejidos Blandos, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. FAU - Doimi, Franco AU - Doimi F AD - Departamento de Patología, Oncosalud-Auna, Lima, Peru. FAU - Santander, Guianeya AU - Santander G AD - Servicio de Oncología, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay. FAU - Acevedo, Carlos AU - Acevedo C AD - Servicio de Mastología, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay. FAU - Ortega, Virginia AU - Ortega V AD - Diagnóstico SRL, Montevideo, Uruguay. FAU - Lavista, Fernando AU - Lavista F AD - Departamento de Radiología, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay. FAU - Richter, Lucía AU - Richter L AD - Servicio de Oncología Médica, Caja Petrolera Santa Cruz, Santa Cruz de la Sierra, Bolivia. FAU - Gianella, Mario AU - Gianella M AD - Servicio de Cirugía Oncológica, Caja Petrolera Santa Cruz, Santa Cruz de la Sierra, Bolivia. FAU - Paredes, Maria AU - Paredes M AD - Servicio de Oncología, Instituto de Previsión Social, Asunción, Paraguay. FAU - Flores-Balcázar, Christian H AU - Flores-Balcázar CH AD - Servicio de Radioterapia y Física Médica del Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico. FAU - Pinto, Joseph A AU - Pinto JA AD - Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Ica, Peru. Electronic address: jpinto@gecoperu.org. FAU - Gomez, Henry L AU - Gomez HL AD - Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto de Investigaciones en Ciencias Biomedicas, Universidad Ricardo Palma. Lima-Peru. LA - eng PT - Journal Article PT - Review DEP - 20221130 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/epidemiology/therapy MH - Latin America/epidemiology MH - Quality of Life MH - Delivery of Health Care MH - Early Detection of Cancer OTO - NOTNLM OT - Breast cancer OT - Breast cancer management OT - Breast cancer screening OT - Cancer care OT - Latin America OT - Public health COIS- Conflict of Interest Statement JMC received grants from Roche and Genomic Health and payment for lectures from BRP Oncology Updates and Roche Bolivia. The other authors declare they have not potential conflict of interests with this research. EDAT- 2022/12/04 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/03 19:24 PHST- 2022/09/08 00:00 [received] PHST- 2022/11/25 00:00 [revised] PHST- 2022/11/27 00:00 [accepted] PHST- 2022/12/04 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/03 19:24 [entrez] AID - S1040-8428(22)00314-6 [pii] AID - 10.1016/j.critrevonc.2022.103890 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2023 Jan;181:103890. doi: 10.1016/j.critrevonc.2022.103890. Epub 2022 Nov 30. PMID- 36084385 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis. PG - 8-14 LID - S0960-9776(22)00145-X [pii] LID - 10.1016/j.breast.2022.08.011 [doi] AB - PURPOSE: Triple-negative apocrine carcinoma (TNAC) is a sort of triple-negative breast cancer (TNBC) that is rare and prognosis of these patients is unclear. The present study constructed an effective nomogram to assist in predicting TNAC patients overall survival (OS). METHODS: A total of 373 TNAC patients from the surveillance, epidemiology, and end results (SEER) got extracted from 2010 to 2016 and were divided into training (n = 261) and external validation (n = 112) groups (split ratio, 7:3) randomly. A Cox regression model was utilized to creating a nomogram according to the risk factors affecting prognosis. The predictive capability of the nomogram was estimated with receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA). RESULTS: Multivariate Cox regression analysis revealed age, surgery, chemotherapy, stage, and first malignant primary as independent predictors of OS. A prediction model was constructed and virtualized using the nomogram. The time-dependent area under the curve (AUC) showed satisfactory discrimination of the nomogram. Good consistency was shown on the calibration curves in OS between actual observations and the nomogram prediction. What's more, DCA showed that the nomogram had incredible clinical utility. Through separating the patients into groups of low and high risk group that connects with the risk system that shows a huge difference between the low-risk and high risk OS (P < 0.001). CONCLUSION: To predict the OS in TNAC patients, the nomogram utilizing the risk stratification system that is corresponding. These tools may help to evaluate patient prognosis and guide treatment decisions. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Xu, Yinggang AU - Xu Y AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - Zhang, Weiwei AU - Zhang W AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - He, Jinzhi AU - He J AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - Wang, Ye AU - Wang Y AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - Chen, Rui AU - Chen R AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - Shi, Wenjie AU - Shi W AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - Wan, Xinyu AU - Wan X AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - Shi, Xiaoqing AU - Shi X AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - Huang, Xiaofeng AU - Huang X AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China. FAU - Wang, Jue AU - Wang J AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210000, China. Electronic address: wangjue200011@njmu.edu.cn. FAU - Zha, Xiaoming AU - Zha X AD - Department of Breast Disease, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210000, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210000, China. Electronic address: njzhaxm@njmu.edu.cn. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20220902 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/therapy MH - Nomograms MH - Epithelial Cells MH - Area Under Curve MH - Cell Movement MH - SEER Program PMC - PMC9465364 OTO - NOTNLM OT - Breast cancer OT - Nomogram OT - SEER OT - Survival COIS- Declaration of competing interest The authors declare no conflict of interest. EDAT- 2022/09/10 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/09/09 18:16 PHST- 2022/08/01 00:00 [received] PHST- 2022/08/29 00:00 [accepted] PHST- 2022/09/10 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/09/09 18:16 [entrez] AID - S0960-9776(22)00145-X [pii] AID - 10.1016/j.breast.2022.08.011 [doi] PST - ppublish SO - Breast. 2022 Dec;66:8-14. doi: 10.1016/j.breast.2022.08.011. Epub 2022 Sep 2. PMID- 36654075 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 1551-0018 (Electronic) IS - 1547-1063 (Linking) VI - 19 IP - 12 DP - 2022 Sep 22 TI - An explorative study for leveraging transcriptomic data of embryonic stem cells in mining cancer stemness genes, regulators, and networks. PG - 13949-13966 LID - 10.3934/mbe.2022650 [doi] AB - Due to the exquisite ability of cancer stemness to facilitate tumor initiation, metastasis, and cancer therapy resistance, targeting cancer stemness is expected to have clinical implications for cancer treatment. Genes are fundamental for forming and maintaining stemness. Considering shared genetic programs and pathways between embryonic stem cells and cancer stem cells, we conducted a study analyzing transcriptomic data of embryonic stem cells for mining potential cancer stemness genes. Firstly, we integrated co-expression and regression models and predicted 820 stemness genes. Results of gene enrichment analysis confirmed the good prediction performance for enriched signatures in cancer stem cells. Secondly, we provided an application case using the predicted stemness genes to construct a breast cancer stemness network. Mining on the network identified CD44, SOX2, TWIST1, and DLG4 as potential regulators of breast cancer stemness. Thirdly, using the signature of 31,028 chemical perturbations and their correlation with stemness marker genes, we predicted 67 stemness inhibitors with reasonable accuracy of 78%. Two drugs, namely Rigosertib and Proscillaridin A, were first identified as potential stemness inhibitors for melanoma and colon cancer, respectively. Overall, mining embryonic stem cell data provides a valuable way to identify cancer stemness regulators. FAU - Yang, Jihong AU - Yang J AD - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. AD - BoYu Intelligent Health Innovation Laboratory, Hangzhou 311121, China. FAU - Xu, Hao AU - Xu H AD - Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, Guangdong 524001, China. FAU - Li, Congshu AU - Li C AD - BoYu Intelligent Health Innovation Laboratory, Hangzhou 311121, China. FAU - Li, Zhenhao AU - Li Z AD - College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. AD - BoYu Intelligent Health Innovation Laboratory, Hangzhou 311121, China. FAU - Hu, Zhe AU - Hu Z AD - Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, Guangdong 524001, China. LA - eng PT - Journal Article PL - United States TA - Math Biosci Eng JT - Mathematical biosciences and engineering : MBE JID - 101197794 SB - IM MH - Humans MH - Female MH - *Transcriptome MH - *Breast Neoplasms/genetics MH - Gene Expression Profiling MH - Embryonic Stem Cells/pathology MH - Genes, Regulator MH - Neoplastic Stem Cells/metabolism OTO - NOTNLM OT - cancer OT - cancer stem cell OT - embryonic stem cell OT - stemness gene OT - stemness inhibitor EDAT- 2023/01/20 06:00 MHDA- 2023/01/21 06:00 CRDT- 2023/01/19 01:00 PHST- 2023/01/19 01:00 [entrez] PHST- 2023/01/20 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] AID - 10.3934/mbe.2022650 [doi] PST - ppublish SO - Math Biosci Eng. 2022 Sep 22;19(12):13949-13966. doi: 10.3934/mbe.2022650. PMID- 36269525 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - A systematic review of multimodal prehabilitation in breast cancer. PG - 1-37 LID - 10.1007/s10549-022-06759-1 [doi] AB - PURPOSE: Breast cancer is the most prevalent malignancy in women. Prehabilitation may offer improvements in physical and psychological wellbeing among participants prior to treatment. This systematic review aimed to determine the efficacy of prehabilitation in participants diagnosed with breast cancer. METHODS: A systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. Studies exploring the impact of prehabilitation in participants with breast cancer were included. Studies were assessed independently according to pre-eligibility criteria, with data extraction and methodological quality assessed in parallel. RESULTS: 3184 records were identified according to our search criteria, and 14 articles were included. Articles comprised of quantitative randomised controlled trials (n = 7), quantitative non-randomised studies (n = 5), a qualitative study (n = 1), and a mixed-method study (n = 1). The majority of selected studies completed exercise programs (n = 4) or had exercise components (n = 2), with two focusing on upper-limb exercise. Five articles reported complementary and alternative therapies (n = 5). Two articles reported smoking cessation (n = 2), with a single study reporting multi-modal prehabilitation (n = 1). Mostly, prehabilitation improved outcomes including physical function, quality of life, and psychosocial variables (P < 0.05). The qualitative data identified preferences for multimodal prehabilitation, compared to unimodal with  an interest in receiving support for longer. CONCLUSIONS: Prehabilitation for patients with breast cancer is an emerging research area that appears to improve outcomes, however, ensuring that adequate intervention timeframes, follow-up, and population groups should be considered for future investigations. IMPLICATIONS FOR CANCER SURVIVORS: The implementation of prehabilitation interventions for individuals diagnosed with breast cancer should be utilised by multidisciplinary teams to provide holistic care to patients as it has the potential to improve outcomes across the cancer care trajectory. CI - © 2022. The Author(s). FAU - Toohey, Kellie AU - Toohey K AUID- ORCID: 0000-0002-1776-6200 AD - Faculty of Health, University of Canberra, Bruce ACT, 2617, Australia. kellie.toohey@canberra.edu.au. AD - Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce ACT, Australia. kellie.toohey@canberra.edu.au. FAU - Hunter, Maddison AU - Hunter M AD - Faculty of Health, University of Canberra, Bruce ACT, 2617, Australia. AD - Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce ACT, Australia. FAU - McKinnon, Karen AU - McKinnon K AD - Australian Capital Territory Breast Care, Calvary Public Hospital, Bruce ACT, Australia. FAU - Casey, Tamara AU - Casey T AD - Australian Capital Territory Breast Care, Calvary Public Hospital, Bruce ACT, Australia. FAU - Turner, Murray AU - Turner M AD - Faculty of Health, University of Canberra, Bruce ACT, 2617, Australia. FAU - Taylor, Suzanne AU - Taylor S AD - Australian Capital Territory Breast Care, Calvary Public Hospital, Bruce ACT, Australia. FAU - Paterson, Catherine AU - Paterson C AD - Faculty of Health, University of Canberra, Bruce ACT, 2617, Australia. AD - Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce ACT, Australia. AD - Robert Gordon University, Aberdeen, AB10 7QB, Scotland. LA - eng PT - Controlled Clinical Trial PT - Journal Article PT - Review PT - Systematic Review DEP - 20221021 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery MH - Preoperative Exercise MH - Quality of Life/psychology MH - Exercise MH - Delivery of Health Care MH - Randomized Controlled Trials as Topic PMC - PMC9823038 OTO - NOTNLM OT - Cancer care OT - Exercise OT - Nursing OT - Nutrition OT - Psychology OT - Wellness COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/10/22 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/10/21 11:41 PHST- 2022/08/21 00:00 [received] PHST- 2022/10/02 00:00 [accepted] PHST- 2022/10/22 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/10/21 11:41 [entrez] AID - 10.1007/s10549-022-06759-1 [pii] AID - 6759 [pii] AID - 10.1007/s10549-022-06759-1 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):1-37. doi: 10.1007/s10549-022-06759-1. Epub 2022 Oct 21. PMID- 36617771 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Association of chemokine (CXC motif) receptor 4 expression with lymphovascular invasion and lymph node metastasis of invasive breast cancer. PG - 447-453 LID - 10.3233/BD-229003 [doi] AB - BACKGROUND: The histological tumor grade influences the prognosis of breast cancer. In metastatic breast cancer, stromal cells produce chemokine (CXC motif) ligand 12 or stromal cell-derived factor-1 as a chemoattractant, which binds to chemokine (CXC motif) receptor 4 (CXCR4) expressed by breast cancer cells. OBJECTIVE: This study aimed to determine the expression of CXCR4 in invasive breast cancer in relation to lymphovascular invasion (LVI) and lymph node metastasis. METHODS: This observational study retrospectively investigated a paraffin block archived sample diagnosed with invasive breast cancer. The results of immunohistochemical staining with CXCR4 antibody and expression analysis were evaluated using light microscopy. The data were statistically analyzed using the chi-square test and presented in a table using SPSS version 18. P-values of <0.05 were considered statistically significant. RESULTS: The expression of CXCR4 was significantly associated with the incidence of LVI and lymph node metastasis in invasive breast cancer (both p = 0.001). CONCLUSIONS: The results show that the expression of CXCR4 varies and support its decisive role in the incidence of LVI and lymph node metastasis in invasive breast cancer. FAU - Mamonto, Lidya AU - Mamonto L AD - Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Nelwan, Berti J AU - Nelwan BJ AD - Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Sungowati, Ni Ketut AU - Sungowati NK AD - Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Miskad, Upik A AU - Miskad UA AD - Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Cangara, Muh Husni AU - Cangara MH AD - Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Zainuddin, Andi Alfian AU - Zainuddin AA AD - Department of Public Health and Community Medicine Science, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. LA - eng PT - Journal Article PT - Observational Study PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Lymphatic Metastasis MH - Retrospective Studies MH - Prognosis MH - Signal Transduction MH - Neoplasm Invasiveness/pathology MH - Lymph Nodes/pathology OTO - NOTNLM OT - CXCR4 OT - invasive breast cancer OT - lymphovascular invasion OT - metastasis EDAT- 2023/01/10 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/09 01:32 PHST- 2023/01/09 01:32 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - BD229003 [pii] AID - 10.3233/BD-229003 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):447-453. doi: 10.3233/BD-229003. PMID- 36581893 OWN - NLM STAT- MEDLINE DCOM- 20230102 LR - 20230126 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 20 IP - 1 DP - 2022 Dec 29 TI - Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. PG - 629 LID - 10.1186/s12967-022-03809-6 [doi] LID - 629 AB - BACKGROUND: Obesity is a major health concern for breast cancer survivors, being associated with high recurrence and reduced efficacy during cancer treatment. Metformin treatment is associated with reduced breast cancer incidence, recurrence and mortality. To better understand the underlying mechanisms through which metformin may reduce recurrence, we aimed to conduct metabolic profiling of overweight/obese breast cancer survivors before and after metformin treatment. METHODS: Fasting plasma samples from 373 overweight or obese breast cancer survivors randomly assigned to metformin (n = 194) or placebo (n = 179) administration were collected at baseline, after 6 months (Reach For Health trial), and after 12 months (MetBreCS trial). Archival samples were concurrently analyzed using three complementary methods: untargeted LC-QTOF-MS metabolomics, targeted LC-MS metabolomics (AbsoluteIDQ p180, Biocrates), and gas chromatography phospholipid fatty acid assay. Multivariable linear regression models and family-wise error correction were used to identify metabolites that significantly changed after metformin treatment. RESULTS: Participants (n = 352) with both baseline and study end point samples available were included in the analysis. After adjusting for confounders such as study center, age, body mass index and false discovery rate, we found that metformin treatment was significantly associated with decreased levels of citrulline, arginine, tyrosine, caffeine, paraxanthine, and theophylline, and increased levels of leucine, isoleucine, proline, 3-methyl-2-oxovalerate, 4-methyl-2-oxovalerate, alanine and indoxyl-sulphate. Long-chain unsaturated phosphatidylcholines (PC ae C36:4, PC ae C38:5, PC ae C36:5 and PC ae C38:6) were significantly decreased with the metformin treatment, as were phospholipid-derived long-chain n-6 fatty acids. The metabolomic profiles of metformin treatment suggest change in specific biochemical pathways known to impair cancer cell growth including activation of CYP1A2, alterations in fatty acid desaturase activity, and altered metabolism of specific amino acids, including impaired branched chain amino acid catabolism. CONCLUSIONS: Our results in overweight breast cancer survivors identify new metabolic effects of metformin treatment that may mechanistically contribute to reduced risk of recurrence in this population and reduced obesity-related cancer risk reported in observational studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01302379 and EudraCT Protocol #: 2015-001001-14. CI - © 2022. The Author(s). FAU - Bellerba, Federica AU - Bellerba F AD - Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. FAU - Chatziioannou, Anastasia Chrysovalantou AU - Chatziioannou AC AD - International Agency for Research on Cancer, Nutrition and Metabolism Branch, Lyon, France. FAU - Jasbi, Paniz AU - Jasbi P AD - College of Health Solutions, Arizona State University, Phoenix, AZ, USA. AD - School of Molecular Sciences, Arizona State University, Tempe, AZ, USA. FAU - Robinot, Nivonirina AU - Robinot N AD - International Agency for Research on Cancer, Nutrition and Metabolism Branch, Lyon, France. FAU - Keski-Rahkonen, Pekka AU - Keski-Rahkonen P AD - International Agency for Research on Cancer, Nutrition and Metabolism Branch, Lyon, France. FAU - Trolat, Amarine AU - Trolat A AD - International Agency for Research on Cancer, Nutrition and Metabolism Branch, Lyon, France. FAU - Vozar, Béatrice AU - Vozar B AD - International Agency for Research on Cancer, Nutrition and Metabolism Branch, Lyon, France. FAU - Hartman, Sheri J AU - Hartman SJ AD - Herbert Wertheim School of Public Health and Human Longevity Science, UC San Diego, La Jolla, CA, USA. AD - Moores Cancer Center, UC San Diego, La Jolla, CA, USA. FAU - Scalbert, Augustin AU - Scalbert A AD - International Agency for Research on Cancer, Nutrition and Metabolism Branch, Lyon, France. FAU - Bonanni, Bernardo AU - Bonanni B AD - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141, Milan, Italy. FAU - Johansson, Harriet AU - Johansson H AUID- ORCID: 0000-0002-4131-2030 AD - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti 435, 20141, Milan, Italy. harriet.johansson@ieo.it. FAU - Sears, Dorothy D AU - Sears DD AD - College of Health Solutions, Arizona State University, Phoenix, AZ, USA. AD - Moores Cancer Center, UC San Diego, La Jolla, CA, USA. AD - Department of Medicine, UC San Diego, La Jolla, CA, USA. FAU - Gandini, Sara AU - Gandini S AD - Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. LA - eng SI - ClinicalTrials.gov/NCT01302379 SI - EudraCT/2015-001001-14 GR - U54 CA155435/CA/NCI NIH HHS/United States GR - CA155435/NH/NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20221229 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 RN - 9100L32L2N (Metformin) RN - 0 (Phospholipids) SB - IM MH - Humans MH - Female MH - *Metformin/pharmacology/therapeutic use MH - *Breast Neoplasms/complications/drug therapy MH - Overweight/complications MH - *Cancer Survivors MH - Obesity/complications MH - Metabolomics/methods MH - Phospholipids MH - Randomized Controlled Trials as Topic PMC - PMC9798585 OTO - NOTNLM OT - Cancer OT - Lipids OT - Metabolic syndrome OT - Prevention OT - Recurrence OT - Weight loss COIS- The authors declare no potential financial and non-financial competing interests. EDAT- 2022/12/30 06:00 MHDA- 2023/01/03 06:00 CRDT- 2022/12/29 23:39 PHST- 2022/09/07 00:00 [received] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/29 23:39 [entrez] PHST- 2022/12/30 06:00 [pubmed] PHST- 2023/01/03 06:00 [medline] AID - 10.1186/s12967-022-03809-6 [pii] AID - 3809 [pii] AID - 10.1186/s12967-022-03809-6 [doi] PST - epublish SO - J Transl Med. 2022 Dec 29;20(1):629. doi: 10.1186/s12967-022-03809-6. PMID- 36096071 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer. PG - 31-39 LID - S0960-9776(22)00142-4 [pii] LID - 10.1016/j.breast.2022.08.012 [doi] AB - INTRODUCTION: Platinum-based chemotherapy (PBC) remains the mainstay of treatments for triple-negative breast cancer (TNBC). TNBC is a heterogeneous group, the issue of whether BRCA1/2 mutation carriers have a particular sensitivity to platinum agents is inconclusive. We conducted a meta-analysis to explore the relationship between BRCA1/2 mutation and PBC susceptibility in individuals with TNBC, aiming to gain more information on the size of the benefit of PBC in BRCA1/2 mutation carriers. MATERIALS AND METHODS: All studies applying PBC with a subgroup of BRCA1/2 status were included. All endpoints, including pCR and RCB in the neoadjuvant phase, DFS in the adjuvant phase, ORR, PFS, and OS in the advanced phase, were assessed using HRs and 95% Cl. RESULTS: From the 22 studies included, there were 2158 patients with TNBC, with 392 (18%) bearing the BRCA1/2 gene mutation. Based on 13 studies applying neoadjuvant PBC, we discovered that BRCA1/2 mutation was substantially associated with a 17.6% increased pCR rate (HR 1.32, 95% CI 1.17-1.49, p < 0.00001; I(2) = 51%). Same result was observed in RCB0/I index (HR 1.38, 95% CI 1.08-1.76, P = 0.009; I(2) = 0%). The meta-analysis of 6 trials addressing advanced therapy revealed that ORR rates were significantly higher in patients with BRCA1/2 mutation (HR 1.91, 95% CI 1.48-2.47, p < 0.00001; I(2) = 32%), as well as PFS(HR 1.13, 95% CI 0.81-1.57, P = 0.47; I(2) = 0%) and OS (HR 1.89, 95% CI 1.22-2.92, P = 0.004; I(2) = 0%). CONCLUSION: According to our meta-analysis of 22 trials in TNBC, BRCA1/2 mutation carriers were significantly more sensitive to PBC regimens, especially in neoadjuvant and advanced therapy. CI - Copyright © 2022. Published by Elsevier Ltd. FAU - Jia, Xiaomeng AU - Jia X AD - Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China. FAU - Wang, Kainan AU - Wang K AD - Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China. FAU - Xu, Lingzhi AU - Xu L AD - Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China. FAU - Li, Ning AU - Li N AD - Department of Foreign Language, Dalian Medical University, Dalian, 116050, China. FAU - Zhao, Zuowei AU - Zhao Z AD - Department of Breast Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China. Electronic address: dmuzhaozuowei@163.com. FAU - Li, Man AU - Li M AD - Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China. Electronic address: man_li@dmu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220902 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 49DFR088MY (Platinum) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - Female MH - Platinum/therapeutic use MH - *Triple Negative Breast Neoplasms/drug therapy/genetics MH - *Breast Neoplasms/drug therapy MH - Mutation MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Neoadjuvant Therapy MH - BRCA1 Protein/genetics PMC - PMC9471971 OTO - NOTNLM OT - BRCA1/2 mutation OT - Platinum OT - Triple-negative breast cancer COIS- Declaration of competing interest The authors confirm that this article content involves no conflicts of interest. EDAT- 2022/09/13 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/09/12 18:30 PHST- 2022/07/05 00:00 [received] PHST- 2022/08/26 00:00 [revised] PHST- 2022/08/26 00:00 [accepted] PHST- 2022/09/13 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/09/12 18:30 [entrez] AID - S0960-9776(22)00142-4 [pii] AID - 10.1016/j.breast.2022.08.012 [doi] PST - ppublish SO - Breast. 2022 Dec;66:31-39. doi: 10.1016/j.breast.2022.08.012. Epub 2022 Sep 2. PMID- 36569222 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20221230 IS - 1875-8630 (Electronic) IS - 0278-0240 (Print) IS - 0278-0240 (Linking) VI - 2022 DP - 2022 TI - A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. PG - 8044550 LID - 10.1155/2022/8044550 [doi] LID - 8044550 AB - BACKGROUND: It has been demonstrated that inflammatory and nutritional variables are associated with poor breast cancer survival. However, some studies do not include these variables due to missing data. To investigate the predictive potential of the INPS, we constructed a novel inflammatory-nutritional prognostic scoring (INPS) system with machine learning. METHODS: This retrospective analysis included 249 patients with malignant breast tumors undergoing neoadjuvant chemotherapy (NAC). After comparing seven potent machine learning models, the best model, Xgboost, was applied to construct an INPS system. K-M survival curves and the log-rank test were employed to determine OS and DFS. Univariate and multivariate analyses were carried out with the Cox regression model. Additionally, we compared the predictive power of INPS, inflammatory, and standard nutritional variables using the Z test. RESULTS: After comparing seven machine learning models, it was determined that the XGBoost model had the best OS and DFS performance (AUC = 0.865 and 0.771, respectively). For overall survival (OS, cutoff value = 0.3917) and disease-free survival (cutoff value = 0.4896), all patients were divided into two groups by the INPS. Those with low INPS had higher 5-year OS and DFS rates (77.2% vs. 50.0%, P < 0.0001; and 59.6% vs. 32.1%, P < 0.0001, respectively) than patients with high INPS. For OS and DFS, the INPS exhibited the highest AUC compared to the other inflammatory and nutritional variables (AUC = 0.615, P = 0.0003; AUC = 0.596, P = 0.0003, respectively). CONCLUSION: The INPS was an independent predictor of OS and DFS and exhibited better predictive ability than BMI, PNI, and MLR. For patients undergoing NAC for nonpCR breast cancer, INPS was a crucial and comprehensive biomarker. It could also forecast individual survival in breast cancer patients with low HER-2 expression. CI - Copyright © 2022 Cong Jiang et al. FAU - Jiang, Cong AU - Jiang C AUID- ORCID: 0000-0002-6436-4386 AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Xiu, Yuting AU - Xiu Y AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Zhang, Shiyuan AU - Zhang S AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Yu, Xiao AU - Yu X AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Qiao, Kun AU - Qiao K AUID- ORCID: 0000-0002-1830-4702 AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. FAU - Huang, Yuanxi AU - Huang Y AUID- ORCID: 0000-0002-6265-0688 AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China. LA - eng PT - Journal Article DEP - 20221216 PL - United States TA - Dis Markers JT - Disease markers JID - 8604127 SB - IM MH - Humans MH - Female MH - Prognosis MH - *Breast Neoplasms/pathology MH - Neoadjuvant Therapy MH - Retrospective Studies MH - Kaplan-Meier Estimate PMC - PMC9788886 COIS- There are no conflicts of interest for all authors. EDAT- 2022/12/27 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/26 04:08 PHST- 2022/07/17 00:00 [received] PHST- 2022/11/08 00:00 [revised] PHST- 2022/11/22 00:00 [accepted] PHST- 2022/12/26 04:08 [entrez] PHST- 2022/12/27 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - 10.1155/2022/8044550 [doi] PST - epublish SO - Dis Markers. 2022 Dec 16;2022:8044550. doi: 10.1155/2022/8044550. eCollection 2022. PMID- 36617772 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Correlation between the expression of Ki67 and histopathological grade, tumor size, disease-free survival, and overall survival among breast cancer patients. PG - 455-460 LID - 10.3233/BD-229005 [doi] AB - INTRODUCTION: Identifying Ki67, a monoclonal antibody that recognizes proliferating cells, is important for defining the level of proliferative activity among patients with breast cancer. The purpose of our study was to evaluate the correlation between Ki67's expression and histopathological grade, tumor size, disease-free survival (DFS), and overall survival (OS) among breast cancer patients. METHODS: Our retrospective cohort study involved examining 114 patients with breast cancer at our institution from January 2018 to December 2019. Participants were retrospectively followed to determine the progression of their disease, and their 2-year progress was examined with survival analysis, especially regarding whether they had postoperative relapse (i.e., DFS) or had died since being diagnosed (i.e., OS). The data were processed with a chi-square test and Kaplan-Meier test, with significance set at p < 0.05. RESULT: The overexpression of Ki67 correlated significantly with histopathological grade (p = 0.001), tumor size (p = 0.001), DFS (p = 0.001), and OS (p = 0.003). CONCLUSION: Ki67's overexpression is significantly correlated with the tumor size, DFS, and OS of patients with breast cancer. FAU - Leksono, Radityo Budi AU - Leksono RB AD - Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Thabry, Rudy AU - Thabry R AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Mulawarman University, Samarinda, Indonesia. FAU - Prihantono, Prihantono AU - Prihantono P AD - Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Nahusuly, Fritz AU - Nahusuly F AD - Department of Surgery, Faculty of Medicine, Mulawarman University, Samarinda, Indonesia. FAU - Kasim, Firdaus AU - Kasim F AD - Department of Biostatistics, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia. FAU - Hamdani, William AU - Hamdani W AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Pieter, John AU - Pieter J AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Indra, Indra AU - Indra I AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Syamsu, Salman Ardi AU - Syamsu SA AD - Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Faruk, Muhammad AU - Faruk M AD - Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. LA - eng PT - Journal Article PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 RN - 0 (Ki-67 Antigen) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Disease-Free Survival MH - Ki-67 Antigen/genetics/metabolism MH - Retrospective Studies MH - Neoplasm Recurrence, Local/pathology MH - Prognosis OTO - NOTNLM OT - Ki67 OT - disease-free survival OT - histopathological grade OT - overall survival OT - tumor size EDAT- 2023/01/10 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/09 01:32 PHST- 2023/01/09 01:32 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - BD229005 [pii] AID - 10.3233/BD-229005 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):455-460. doi: 10.3233/BD-229005. PMID- 36575361 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230121 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Dec 27 TI - Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. PG - 22397 LID - 10.1038/s41598-022-27048-3 [doi] LID - 22397 AB - Radiation therapy (RT) can enhance the abscopal effect of immune checkpoint blockade. This phase I/II study investigated the efficacy and safety of nivolumab plus RT in HER2-negative metastatic breast cancer requiring palliative RT for bone metastases. Cohort A included luminal-like disease, and cohort B included both luminal-like and triple-negative disease refractory to standard systemic therapy. Patients received 8 Gy single fraction RT for bone metastasis on day 0. Nivolumab was administered on day 1 for each 14-day cycle. In cohort A, endocrine therapy was administered. The primary endpoint was the objective response rate (ORR) of the unirradiated lesions. Cohorts A and B consisted of 18 and 10 patients, respectively. The ORR was 11% (90% CI 4-29%) in cohort A and 0% in cohort B. Disease control rates were 39% (90% CI 23-58%) and 0%. Median progression-free survival was 4.1 months (95% CI 2.1-6.1 months) and 2.0 months (95% CI 1.2-3.7 months). One patient in cohort B experienced a grade 3 adverse event. Palliative RT combined with nivolumab was safe and showed modest anti-tumor activity in cohort A. Further investigations to enhance the anti-tumor effect of endocrine therapy combined with RT plus immune checkpoint blockade are warranted.Trial registration number and date of registration UMIN: UMIN000026046, February 8, 2017; ClinicalTrials.gov: NCT03430479, February 13, 2018; Date of the first registration: June 22, 2017. CI - © 2022. The Author(s). FAU - Takada, Masahiro AU - Takada M AUID- ORCID: 0000-0002-5954-1296 AD - Department of Breast Surgery, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan. masahiro@kuhp.kyoto-u.ac.jp. FAU - Yoshimura, Michio AU - Yoshimura M AD - Department of Radiation Oncology and Image-Applied Therapy, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kotake, Takeshi AU - Kotake T AD - Department of Medical Oncology, Kansai Electric Power Hospital, Osaka, Japan. FAU - Kawaguchi, Kosuke AU - Kawaguchi K AD - Department of Breast Surgery, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan. FAU - Uozumi, Ryuji AU - Uozumi R AD - Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kataoka, Masako AU - Kataoka M AD - Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Kato, Hironori AU - Kato H AD - Department of Breast Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. FAU - Yoshibayashi, Hiroshi AU - Yoshibayashi H AD - Wakayama Breast Clinic, Wakayama, Japan. FAU - Suwa, Hirofumi AU - Suwa H AD - Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan. FAU - Tsuji, Wakako AU - Tsuji W AD - Department of Breast Surgery, Shiga General Hospital, Moriyama, Japan. FAU - Yamashiro, Hiroyasu AU - Yamashiro H AD - Department of Breast Surgery, Tenri Hospital, Tenri, Japan. FAU - Suzuki, Eiji AU - Suzuki E AD - Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan. FAU - Torii, Masae AU - Torii M AD - Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan. FAU - Yamada, Yosuke AU - Yamada Y AD - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. FAU - Kataoka, Tatsuki AU - Kataoka T AD - Department of Pathology, Iwate Medical University, Yahaba, Japan. FAU - Ishiguro, Hiroshi AU - Ishiguro H AD - Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Japan. FAU - Morita, Satoshi AU - Morita S AD - Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Toi, Masakazu AU - Toi M AD - Department of Breast Surgery, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan. LA - eng SI - ClinicalTrials.gov/NCT03430479 PT - Clinical Trial, Phase I PT - Clinical Trial, Phase II PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221227 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 31YO63LBSN (Nivolumab) RN - 0 (Immune Checkpoint Inhibitors) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Nivolumab/therapeutic use MH - Immune Checkpoint Inhibitors/adverse effects MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Progression-Free Survival MH - Neoplasm Metastasis PMC - PMC9794767 COIS- MTa received research grants from the Kyoto Breast Cancer Research Network (KBCRN), Daiichi Sankyo, Yakult, AstraZeneca, Japan Breast Cancer Research Group (JBCRG), and Medbis. MTa received honoraria from Chugai, Eisai, AstraZeneca, Eli Lily, Daiichi Sankyo, Nippon Kayaku, Pfizer, and Mitaka Kohki. KK received research support from Eli Lily, TELUMO, and KBCRN. KK received a speaking fee from Chugai Pharmaceutical and Eisai. RU received consulting fees from Eisai, Sawai Pharmaceutical, and EP Croit, outside this work. HY received honoraria from Chugai, Daiichi-Sankyo, Pfizer, Kyowa Kirin, Eisai, Eli Lilly, Takeda, and Taiho. SM received honoraria from AstraZeneca K.K., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co. Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Pfizer Japan Inc., Ono Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd. SM received research funding (institution) from Eisai Co., Ltd. MTo received research grants from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG assoc., Eisai, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science. MTo received lecture honoraria from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, Nippon Kayaku. MTo is a member of the advisory board of Kyowa-Kirin, Daiichi-Sankyo, Eli Lilly, Konica Minolta, BMS, Athenex Oncology, Bertis, Terumo, Kansai Medical Net. MTo is also a member of the board of directors (no salary) of KBCRN, JBCRN, and Organisation for Oncology and Translational Research (OOTR). All remaining authors declare no conflicts of interest. EDAT- 2022/12/28 06:00 MHDA- 2022/12/30 06:00 CRDT- 2022/12/27 23:37 PHST- 2022/03/11 00:00 [received] PHST- 2022/12/23 00:00 [accepted] PHST- 2022/12/27 23:37 [entrez] PHST- 2022/12/28 06:00 [pubmed] PHST- 2022/12/30 06:00 [medline] AID - 10.1038/s41598-022-27048-3 [pii] AID - 27048 [pii] AID - 10.1038/s41598-022-27048-3 [doi] PST - epublish SO - Sci Rep. 2022 Dec 27;12(1):22397. doi: 10.1038/s41598-022-27048-3. PMID- 36574052 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230103 IS - 1433-7339 (Electronic) IS - 0941-4355 (Linking) VI - 31 IP - 1 DP - 2022 Dec 27 TI - Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS. PG - 82 LID - 10.1007/s00520-022-07561-x [doi] AB - PURPOSE: The most appropriate criteria and timing for palliative care referral remain a critical issue, especially in patients with metastatic breast cancer for whom long-term chemosensibility and survival are observed. We aimed to compare the impact of early palliative care including formal concertation with oncologists on decision for an additional line of chemotherapy compared with usual oncology care. METHODS: This randomized prospective study enrolled adult women with metastatic breast cancer and visceral metastases with a 3rd- or 4th-line chemotherapy (CT). Patients received usual oncology care with a palliative care consultation only upon patient or oncologist request (standard group, S) or were referred to systematic palliative care consultation including a regular concertation between palliative care team and oncologists (early palliative care group, EPC). The primary endpoint was the rate of an additional CT (4th or 5th line) decision. Quality of life, symptoms, social support and satisfaction were self-evaluated at 6 and 12 months, at treatment discontinuation or 3 months after discontinuation. RESULTS: From January 2009 to November 2012, two authorized cancer centers included 98 women (EPC: 50; S: 48). Thirty-seven (77.1%, 95%CI 62.7-88%) patients in the EPC group had a subsequent chemotherapy prescribed and 36 (72.0%, 95%CI 57.5-83.8%) in the S group (p = 0.646). No differences in symptom control and global quality of life were observed, but less deterioration in physical functioning was reported in EPC (EPC: 0 [- 53-40]; S: - 6; 7 [- 60 to - 20]; p = 0.027). Information exchange and communication were significant improved in EPC (exchange, EPC: - 8.3 [- 30 to + 7]; S: 0.0 [- 17 to + 23]; p = 0.024; communication, EPC: 12.5 [- 8 to - 37]; S: 0.0 [- 21 to + 17]; p = 0.004). CONCLUSION: EPC in metastatic breast cancer patients did not impact the prescription rate of additional chemotherapy in patients a 3rd- or 4th-line chemotherapy for metastatic breast cancer; however, EPC may contribute to alleviate deterioration in physical functioning, while facilitating communication. TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT00905281, May 20, 2009. CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Chvetzoff, Gisèle AU - Chvetzoff G AD - Supportive Care Department, Centre Léon Bérard, 28 rue Laennec, 69373, Lyon, France. gisele.chvetzoff@lyon.unicancer.fr. AD - University Claude Bernard, Lyon, France. gisele.chvetzoff@lyon.unicancer.fr. FAU - Bouleuc, Carole AU - Bouleuc C AD - Supportive Care Department, Institut Curie, Paris, France. FAU - Lardy-Cléaud, Audrey AU - Lardy-Cléaud A AD - Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France. FAU - Saltel, Pierre AU - Saltel P AD - Supportive Care Department, Centre Léon Bérard, 28 rue Laennec, 69373, Lyon, France. FAU - Dieras, Véronique AU - Dieras V AD - Medical Oncology Department, Institut Curie, Paris, France. FAU - Morelle, Magali AU - Morelle M AD - Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France. FAU - Guastalla, Jean-Paul AU - Guastalla JP AD - Medical Oncology Department, Centre Léon Bérard, Lyon, France. FAU - Tredan, Olivier AU - Tredan O AD - Medical Oncology Department, Centre Léon Bérard, Lyon, France. FAU - Rebattu, Paul AU - Rebattu P AD - Medical Oncology Department, Centre Léon Bérard, Lyon, France. FAU - Pop, Simona AU - Pop S AD - Medical Oncology Department, Institut Curie, Paris, France. FAU - Ray-Coquard, Isabelle AU - Ray-Coquard I AD - University Claude Bernard, Lyon, France. AD - Medical Oncology Department, Centre Léon Bérard, Lyon, France. FAU - Pierga, Jean-Yves AU - Pierga JY AD - Medical Oncology Department, Institut Curie, Paris, France. FAU - Mignot, Laurent AU - Mignot L AD - Medical Oncology Department, Institut Curie, Paris, France. FAU - Laurence, Valérie AU - Laurence V AD - Medical Oncology Department, Institut Curie, Paris, France. FAU - Bourne-Branchu, Valérie AU - Bourne-Branchu V AD - Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France. FAU - Pérol, David AU - Pérol D AD - Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France. FAU - Bachelot, Thomas AU - Bachelot T AD - Medical Oncology Department, Centre Léon Bérard, Lyon, France. LA - eng SI - ClinicalTrials.gov/NCT00905281 PT - Journal Article PT - Randomized Controlled Trial DEP - 20221227 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 SB - IM MH - Adult MH - Humans MH - Female MH - Palliative Care/methods MH - *Breast Neoplasms/drug therapy MH - Quality of Life MH - Prospective Studies MH - *Hospice and Palliative Care Nursing MH - *Neoplasms OTO - NOTNLM OT - Advanced breast cancer OT - Chemotherapy OT - Early palliative care OT - Supportive care EDAT- 2022/12/28 06:00 MHDA- 2022/12/30 06:00 CRDT- 2022/12/27 11:14 PHST- 2022/07/13 00:00 [received] PHST- 2022/12/21 00:00 [accepted] PHST- 2022/12/27 11:14 [entrez] PHST- 2022/12/28 06:00 [pubmed] PHST- 2022/12/30 06:00 [medline] AID - 10.1007/s00520-022-07561-x [pii] AID - 10.1007/s00520-022-07561-x [doi] PST - epublish SO - Support Care Cancer. 2022 Dec 27;31(1):82. doi: 10.1007/s00520-022-07561-x. PMID- 36208540 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study. PG - 85-88 LID - S0960-9776(22)00163-1 [pii] LID - 10.1016/j.breast.2022.09.009 [doi] AB - BACKGROUND: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer. Therefore; we aimed to investigate the treatment responses of metastatic HR+, HER2-male breast cancer patients treated with CDK 4-6 inhibitors in a multicenter real-life cohort. METHODS: Male patients with a diagnosis of HR+ and HER2-metastatic breast cancer, treated with any CDK 4-6 inhibitor, were included in the study. Demographic and clinical characteristics of the patients were recorded. We aimed to determine progression-free survival (PFS) time, response rates and drug related side effects. RESULTS: A total 25 patients from 14 institutions were recruited. The mean age at diagnosis was 57 years. Median follow-up was 19.53 (95% CI: 14.04-25.02) months. The overall response rate was 60%. While the median PFS was 20.6 months in the whole cohort, it wasn't reached in those using CDK 4-6 inhibitors in first line and 10 months in the subsequent lines (p:0.009). No new adverse events were encountered. CONCLUSION: In our study, we found that CDK 4-6 inhibitors are effective and safe options in men with HR+ and HER2-metastatic breast cancer as in women. Our results support the use of CDK 4-6 inhibitor-based combinations in the first-line treatment of HR+ and HER2-metastatic male breast cancer. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Yıldırım, Hasan Çağrı AU - Yıldırım HÇ AD - Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey. Electronic address: cagri.yildirim@hacettepe.edu.tr. FAU - Mutlu, Emel AU - Mutlu E AD - Erciyes University Faculty of Medicine, Department of Medical Oncology, Kayseri, Turkey. FAU - Chalabiyev, Elvin AU - Chalabiyev E AD - Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey. FAU - Özen, Miraç AU - Özen M AD - Sakarya University Faculty of Medicine, Department of Medical Oncology, Sakarya, Turkey. FAU - Keskinkılıç, Merve AU - Keskinkılıç M AD - 9 Eylül University Faculty of Medicine, Department of Medical Oncology, İzmir, Turkey. FAU - Ön, Sercan AU - Ön S AD - Ege University Faculty of Medicine, Department of Medical Oncology, İzmir, Turkey. FAU - Çelebi, Abdussamet AU - Çelebi A AD - Marmara University Faculty of Medicine, Department of Medical Oncology, İstanbul, Turkey. FAU - Dursun, Bengü AU - Dursun B AD - Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey. FAU - Acar, Ömer AU - Acar Ö AD - Manisa Celal Bayar University Faculty of Medicine, Department of Medical Oncology, Manisa, Turkey. FAU - Kahraman, Seda AU - Kahraman S AD - Ankara Yıldırım Beyazıt University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey. FAU - Aykan, Musa Barış AU - Aykan MB AD - Gulhane Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey. FAU - Kaman, Ömür AU - Kaman Ö AD - Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey. FAU - Doğan, Akif AU - Doğan A AD - Kartal Dr. Lütfi Kirdar City Hospital, Department of Medical Oncology, İstanbul, Turkey. FAU - Erdoğan, Atike Pınar AU - Erdoğan AP AD - Manisa Celal Bayar University Faculty of Medicine, Department of Medical Oncology, Manisa, Turkey. FAU - Melisa Celayir, Özde AU - Melisa Celayir Ö AD - MAA Acıbadem University, Department of Medical Oncology, İstanbul, Turkey. FAU - Günenç, Damla AU - Günenç D AD - Ege University Faculty of Medicine, Department of Medical Oncology, İzmir, Turkey. FAU - Güven, Deniz Can AU - Güven DC AD - Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey. FAU - Vedat Bayoğlu, İbrahim AU - Vedat Bayoğlu İ AD - Marmara University Faculty of Medicine, Department of Medical Oncology, İstanbul, Turkey. FAU - Yavuzşen, Tuğba AU - Yavuzşen T AD - 9 Eylül University Faculty of Medicine, Department of Medical Oncology, İzmir, Turkey. FAU - Hacıbekiroğlu, İlhan AU - Hacıbekiroğlu İ AD - Sakarya University Faculty of Medicine, Department of Medical Oncology, Sakarya, Turkey. FAU - İnanç, Mevlüde AU - İnanç M AD - Erciyes University Faculty of Medicine, Department of Medical Oncology, Kayseri, Turkey. FAU - Kılıçkap, Saadettin AU - Kılıçkap S AD - İstinye University Liv Hospital, Department of Medical Oncology, Ankara, Turkey. FAU - Yalçın, Şuayib AU - Yalçın Ş AD - Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey. FAU - Aksoy, Sercan AU - Aksoy S AD - Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20220930 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Aminopyridines) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 4) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 6) SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - *Breast Neoplasms/pathology MH - *Breast Neoplasms, Male/drug therapy MH - Aminopyridines/therapeutic use MH - Cyclin-Dependent Kinase 4 MH - Receptor, ErbB-2/metabolism MH - Protein Kinase Inhibitors/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Cyclin-Dependent Kinase 6 PMC - PMC9547301 OTO - NOTNLM OT - Cyclin-dependent kinase 4–6 inhibitors OT - Male breast cancer OT - Palbociclib OT - Ribociclib COIS- Declaration of competing interest The authors have declared no conflicts of interest. EDAT- 2022/10/09 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/08 18:17 PHST- 2022/08/09 00:00 [received] PHST- 2022/09/26 00:00 [revised] PHST- 2022/09/30 00:00 [accepted] PHST- 2022/10/09 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/08 18:17 [entrez] AID - S0960-9776(22)00163-1 [pii] AID - 10.1016/j.breast.2022.09.009 [doi] PST - ppublish SO - Breast. 2022 Dec;66:85-88. doi: 10.1016/j.breast.2022.09.009. Epub 2022 Sep 30. PMID- 36640225 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1438-7948 (Electronic) IS - 1438-793X (Linking) VI - 23 IP - 1 DP - 2023 Jan 14 TI - Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. PG - 38 LID - 10.1007/s10142-023-00963-y [doi] AB - Breast cancer is the most common tumor and the leading cause of cancer death in women. Cuproptosis is a new type of cell death, which can induce proteotoxic stress and eventually lead to cell death. Therefore, regulating copper metabolism in tumor cells is a new therapeutic approach. Long non-coding RNAs play an important regulatory role in immune response. At present, cuproptosis-related lncRNAs in breast cancer have not been reported. Breast cancer RNA sequencing, genomic mutations, and clinical data were downloaded from The Cancer Genome Atlas (TCGA). Patients with breast cancer were randomly assigned to the train group or the test group. Co-expression network analysis, Cox regression method, and least absolute shrinkage and selection operator (LASSO) method were used to identify cuproptosis-related lncRNAs and to construct a risk prognostic model. The prediction performance of the model is verified and recognized. In addition, the nomogram was used to predict the prognosis of breast cancer patients. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and immunoassay were used to detect the differences in biological function. Tumor mutation burden (TMB) was used to measure immunotherapy response. A total of 19 cuproptosis genes were obtained and a prognostic model based on 10 cuproptosis-related lncRNAs was constructed. Kaplan-Meier survival curves showed statistically significant overall survival (OS) between the high-risk and low-risk groups. Receiver operating characteristic curve (ROC) and principal component analysis (PCA) show that the model has accurate prediction ability. Compared with other clinical features, cuproptosis-related lncRNAs model has higher diagnostic efficiency. Univariate and multivariate Cox regression analysis showed that risk score was an independent prognostic factor for breast cancer patients. In addition, the nomogram model analysis showed that the tumor mutation burden was significantly different between the high-risk and low-risk groups. Of note, the additive effect of patients in the high-risk group and patients with high TMB resulted in reduced survival in breast cancer patients. Our study identified 10 cuproptosis-related lncRNAs, which may be promising biomarkers for predicting the survival prognosis of breast cancer. CI - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Pan, Yue AU - Pan Y AD - Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China. FAU - Zhang, Qianqian AU - Zhang Q AD - Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhang, Hongwei AU - Zhang H AD - Department of Emergency Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China. FAU - Kong, Fanhua AU - Kong F AD - Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China. kongfanhua1001@163.com. AD - Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Hubei Clinical Research Center for Natural Polymer Biological Liver, Hubei Engineering Center of Natural Polymer-based Medical Materials, Wuhan, Hubei, China. kongfanhua1001@163.com. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20230114 PL - Germany TA - Funct Integr Genomics JT - Functional & integrative genomics JID - 100939343 RN - 789U1901C5 (Copper) RN - 0 (RNA, Long Noncoding) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/genetics MH - Copper MH - Gene Ontology MH - Prognosis MH - *RNA, Long Noncoding/genetics MH - Tumor Microenvironment/genetics MH - *Apoptosis OTO - NOTNLM OT - Breast cancer OT - Cuproptosis OT - LncRNA OT - Prognostic marker OT - Prognostic model OT - Tumor mutational burden EDAT- 2023/01/15 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/14 11:17 PHST- 2022/08/30 00:00 [received] PHST- 2023/01/02 00:00 [accepted] PHST- 2022/12/14 00:00 [revised] PHST- 2023/01/14 11:17 [entrez] PHST- 2023/01/15 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - 10.1007/s10142-023-00963-y [pii] AID - 10.1007/s10142-023-00963-y [doi] PST - epublish SO - Funct Integr Genomics. 2023 Jan 14;23(1):38. doi: 10.1007/s10142-023-00963-y. PMID- 36600573 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1472-4146 (Electronic) IS - 0021-9746 (Linking) VI - 76 IP - 2 DP - 2023 Feb TI - Gene of the month: PALB2. PG - 73-75 LID - 10.1136/jcp-2022-208461 [doi] AB - The partner and localiser of BRCA2 (PALB2) gene, located on chromosome 16, functions as a tumour suppressor that plays a critical role in homologous recombination repair after DNA double-strand breaks. It encodes proteins involved in the BRCA2 and BRCA1, and RAD51 pathways. Heterozygous germline mutations in PALB2 have been implicated in the development of breast, pancreatic and ovarian cancers. Whereas biallelic mutations of PALB2 have been associated with Fanconi anaaemia. Currently, 604 distinct PALB2 variants have been discovered. However, only 140 variants are thought to be pathogenic and approximately 400 are variants of unknown significance. Further studies are needed before the presence of PLAB2 mutations can be implemented as a routine clinical biomarker. CI - © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Hamdan, Omar AU - Hamdan O AD - University Health Network Laboratory Medicine Program, Toronto, Ontario, Canada. FAU - Nowak, Klaudia M AU - Nowak KM AUID- ORCID: 0000-0001-9750-2573 AD - University Health Network Laboratory Medicine Program, Toronto, Ontario, Canada klaudia.nowak@uhn.ca. LA - eng PT - Journal Article DEP - 20221207 PL - England TA - J Clin Pathol JT - Journal of clinical pathology JID - 0376601 RN - 0 (Tumor Suppressor Proteins) RN - 0 (Nuclear Proteins) RN - 0 (Fanconi Anemia Complementation Group N Protein) RN - 0 (BRCA2 Protein) RN - 0 (BRCA1 Protein) RN - 0 (PALB2 protein, human) SB - IM MH - Female MH - Humans MH - *Tumor Suppressor Proteins/genetics/metabolism MH - Nuclear Proteins/genetics MH - Fanconi Anemia Complementation Group N Protein/genetics/metabolism MH - BRCA2 Protein/genetics/metabolism MH - BRCA1 Protein/genetics MH - DNA Repair MH - Mutation MH - *Breast Neoplasms/genetics MH - Genetic Predisposition to Disease OTO - NOTNLM OT - BREAST OT - Breast Neoplasms OT - Genes, Neoplasm OT - PANCREAS OT - Pancreatic Neoplasms COIS- Competing interests: None declared. EDAT- 2023/01/06 06:00 MHDA- 2023/01/24 06:00 CRDT- 2023/01/05 01:22 PHST- 2022/10/28 00:00 [accepted] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2023/01/05 01:22 [entrez] AID - jcp-2022-208461 [pii] AID - 10.1136/jcp-2022-208461 [doi] PST - ppublish SO - J Clin Pathol. 2023 Feb;76(2):73-75. doi: 10.1136/jcp-2022-208461. Epub 2022 Dec 7. PMID- 36507879 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230103 IS - 1790-5427 (Print) IS - 1790-5427 (Linking) VI - 25 IP - 3 DP - 2022 Sep-Dec TI - The role of basal metabolic and volumetric (18)F-FDG PET/CT parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. PG - 235-246 LID - 10.1967/s002449912511 [doi] AB - OBJECTIVE: The aim of this study is to investigate the roles of pre- and post- treatment quantitative fluorine-18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) parameters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) and their rate of change in predicting pathological complete response (pCR) in patients with local and locally advanced invasive breast cancer receiving neoadjuvant chemotherapy (NAC). SUBJECTS AND METHODS: Ninety-eight patients who received NAC after being diagnosed with local and locally advanced invasive breast cancer between January 2017 and September 2021 were retrospectively included in our study. Molecular subtypes of all patients were determined. Maximum SUV, MTV, TLG, percent change in SUVmax (ΔSUVmax), ΔMTV, and ΔTLG obtained from PET/CT scans performed before and after NAC were calculated. The cut-off, AUC, sensitivity, and specificity values of these parameters in predicting pCR were calculated using receiver operating characteristic (ROC) curves. RESULTS: ΔTMTV (cut-off 94.01%, AUC: 0.846), ΔTTLG (cut-off 97.36%, AUC: 0.870), B2MTV (cut-off<1.75, AUC: 0.764), B2TLG (cut-off<2.11, AUC: 0.764), B2SUVmax (cut-off<1.58, AUC: 0.767), ΔBMTV (cut-off 93.67%, AUC: 0.851), ΔBTLG (cut-off 97.22%, AUC: 0.870), ΔBSUVmax (cut-off 84.99%, AUC: 0.846) calculated using ROC curves were found to significantly predict pCR with high sensitivity and specificity. CONCLUSION: We concluded that metabolic and volumetric PET/CT parameters, the rates of their change, and metabolic response during NAC may be important variables in predicting pCR in patients with breast cancer. FAU - Kepenek, Ferat AU - Kepenek F AD - Department of Nuclear Medicine, GaziYaşargil Training and Research Hospital, University of Health Sciences, Diyarbakır, Turkey. feratkepenek@hotmail.com. FAU - Karaoğlan, Hüseyin AU - Karaoğlan H FAU - Can, Canan AU - Can C FAU - Kömek, Halil AU - Kömek H FAU - Kaplan, İhsan AU - Kaplan İ FAU - Etem, Hülya AU - Etem H FAU - Ebinç, Senar AU - Ebinç S FAU - Kavak, Şeyhmus AU - Kavak Ş FAU - Gündoğan, Cihan AU - Gündoğan C LA - eng PT - Journal Article DEP - 20221214 PL - Greece TA - Hell J Nucl Med JT - Hellenic journal of nuclear medicine JID - 101257471 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM MH - Humans MH - Female MH - *Fluorodeoxyglucose F18 MH - Positron Emission Tomography Computed Tomography MH - Neoadjuvant Therapy MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - Retrospective Studies MH - Radiopharmaceuticals MH - Prognosis EDAT- 2022/12/13 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/12/12 11:55 PHST- 2022/03/08 00:00 [received] PHST- 2022/08/31 00:00 [accepted] PHST- 2022/12/13 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/12/12 11:55 [entrez] AID - s002449912511 [pii] AID - 10.1967/s002449912511 [doi] PST - ppublish SO - Hell J Nucl Med. 2022 Sep-Dec;25(3):235-246. doi: 10.1967/s002449912511. Epub 2022 Dec 14. PMID- 36194950 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer. PG - 69-76 LID - S0960-9776(22)00159-X [pii] LID - 10.1016/j.breast.2022.09.005 [doi] AB - BACKGROUND: Paclitaxel is commonly used as first-line chemotherapy for HER2-negative metastatic breast cancer (MBC) patients. However, with response rates of 21.5-53.7% and significant risk of peripheral neuropathy, there is need for better chemotherapy. PATIENTS AND METHODS: This open-label phase II/III trial randomised HER2-negative MBC patients 1:1 to either 6 cycles of three-weekly cabazitaxel (25 mg/m(2)), or, weekly paclitaxel (80 mg/m(2)) over 18 weeks. The primary endpoint was progression free survival (PFS). Secondary endpoints included objective response rate (ORR), time to response (TTR), overall survival (OS), safety and tolerability and quality of life (QoL). RESULTS: 158 patients were recruited. Comparing cabazitaxel to paclitaxel, median PFS was 6.7 vs 5.8 months (HR 0.87; 80%CI 0.70-1.08, P = 0.4). There was no difference in median OS (20.6 vs 18.2 months, HR 1.00; 95%CI 0.69-1.45, P = 0.99), ORR (41.8% vs 36.7%) or TTR (HR 1.09; 95%CI 0.68-1.75, P = 0.7). Grade ≥3 adverse events occurred in 41.8% on cabazitaxel and 46.8% on paclitaxel; the most common being neutropenia (16.5%) and febrile neutropenia (12.7%) cabazitaxel and neutropenia (8.9%) and lung infection (7.6%) paclitaxel. Peripheral neuropathy of any grade occurred in 54.5% paclitaxel vs 16.5% cabazitaxel. Mean EQ-5D-5L single index utility score (+0.05; 95%CI 0.004-0.09, P = 0.03) and visual analogue scale score (+7.7; 95%CI 3.1-12.3, P = 0.001) were higher in cabazitaxel vs paclitaxel. CONCLUSIONS: Three-weekly cabazitaxel in HER2-negative MBC does not significantly improve PFS compared to weekly paclitaxel, although it has a lower risk of peripheral neuropathy with better patient reported QoL outcomes. It is well tolerated and requires fewer hospital visits. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Bahl, Amit AU - Bahl A AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Wilson, William AU - Wilson W AD - Cancer Research UK & UCL Cancer Trials Centre, UK. FAU - Ball, Jessica AU - Ball J AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Renninson, Emily AU - Renninson E AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. Electronic address: Amit.Bahl@uhbw.nhs.uk. FAU - Dubey, Sidharth AU - Dubey S AD - Derriford Hospital, Plymouth, UK. FAU - Bravo, Alicia AU - Bravo A AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Foulstone, Emily AU - Foulstone E AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Spensley, Saiqa AU - Spensley S AD - Musgrove Hospital, Taunton, UK. FAU - Bowen, Rebecca AU - Bowen R AD - Royal United Hospital, Bath, UK. FAU - Mansi, Janine AU - Mansi J AD - Guy's Hospital, London, UK. FAU - Waters, Simon AU - Waters S AD - Velindre Cancer Centre, Cardiff, UK. FAU - Riddle, Pippa AU - Riddle P AD - Charing Cross Hospital, London, UK. FAU - Wheatley, Duncan AU - Wheatley D AD - Royal Cornwall Hospital, Truro, UK. FAU - Stephens, Peter AU - Stephens P AD - Royal Devon and Exeter Hospital, Exeter, UK. FAU - Bezecny, Pavel AU - Bezecny P AD - Blackpool Victoria Hospital, Blackpool, UK. FAU - Madhusudan, Srinivasan AU - Madhusudan S AD - City Hospital, Nottingham, UK. FAU - Verrill, Mark AU - Verrill M AD - Freeman Hospital, Newcastle, UK. FAU - Braybrooke, Jeremy AU - Braybrooke J AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Comins, Charles AU - Comins C AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Mohan, Vivek AU - Mohan V AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Gee, Abigail AU - Gee A AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Kirk, Hannah AU - Kirk H AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Markham, Alison AU - Markham A AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Evans, Heidi AU - Evans H AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Watson, Eve AU - Watson E AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Callaway, Mark AU - Callaway M AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Pearson, Sylvia AU - Pearson S AD - Bristol Haematology and Oncology Clinical Trial Unit, University Hospitals Bristol and Weston NHS Foundation Trust, UK. FAU - Hackshaw, Allan AU - Hackshaw A AD - Cancer Research UK & UCL Cancer Trials Centre, UK. FAU - Churn, Mark AU - Churn M AD - Worcester Royal Hospital, Worcester, UK. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20220924 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - P88XT4IS4D (Paclitaxel) RN - 51F690397J (cabazitaxel) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Paclitaxel MH - Quality of Life MH - Receptor, ErbB-2 MH - *Neutropenia/chemically induced MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Treatment Outcome PMC - PMC9530955 COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/10/05 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/04 18:18 PHST- 2022/08/22 00:00 [received] PHST- 2022/09/16 00:00 [revised] PHST- 2022/09/19 00:00 [accepted] PHST- 2022/10/05 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/04 18:18 [entrez] AID - S0960-9776(22)00159-X [pii] AID - 10.1016/j.breast.2022.09.005 [doi] PST - ppublish SO - Breast. 2022 Dec;66:69-76. doi: 10.1016/j.breast.2022.09.005. Epub 2022 Sep 24. PMID- 36641657 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Correlation analysis of HIF-1α and Ca15-3 in response to neoadjuvant chemotherapy in locally advanced breast cancer: A cohort study in Indonesia. PG - 481-487 LID - 10.3233/BD-229004 [doi] AB - BACKGROUND: Breast cancer (BC) is the most common cancer among women worldwide and a leading cause of death in Indonesia. The primary treatment of locally advanced BC is neoadjuvant chemotherapy (NAC). The rapid proliferation of tumor cells in a neoplastic microenvironment is largely due to hypoxia, which also encourages the development of chemoresistant BC. The master regulator of the hypoxia response is hypoxia-inducible factor-1α (HIF-1α). The response evaluation criteria in solid tumors (RECIST) is an objective response metric that demonstrates the efficacy of a NAC based mostly on the size of the tumor. Ca15-3 is the protein product of the MUC1 gene and is the most widely used serum marker in BC. The purpose of this study is to investigate the relationship between HIF-1α and RECIST and between Ca15-3 and RECIST and to assess the relationship among all of them in BC. METHODS: This observational study used the prospective cohort method included 11 patients with histopathologically confirmed BC, specifically invasive ductal carcinoma. We evaluated the changes in HIF-1α and Ca15-3 serum levels using ELISA and measured tumor lesions with RECIST. The procedure was carried out twice. Serum levels were measured at baseline, and after receiving two cycles of NAC (5 weeks). RESULTS: Among the 11 patients included in this study, HIF-1α, Ca15-3, and RECIST decreased significantly after NAC. The changes in RECIST correlated with Ca15-3: each unit decrease in RECIST score was associated with a 0.3-unit decrease in Ca15-3 levels (p = 0.019). CONCLUSIONS: There was a decrease in HIF-1α, followed by a decrease in Ca15-3 and RECIST in response to chemotherapy. There was a statistically significant correlation between Ca15-3 and response to chemotherapy. This study evidences the relationship between factors that shape the local tumor microenvironment. FAU - Manginstar, Christian AU - Manginstar C AD - Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Sam Ratulangi University, Manado, North Sulawesi, Indonesia. AD - Division of Surgical Oncology, Department of Surgery, R. D. Kandou Hospital, Manado, North Sulawesi, Indonesia. FAU - Oley, Mendy Hatibie AU - Oley MH AD - Division of Plastic Reconstructive & Aesthetic Surgery, Department of Surgery, Faculty of Medicine, Sam Ratulangi University, Manado, Indonesia. AD - Division of Plastic Reconstructive & Aesthetic Surgery, Department of Surgery, R. D. Kandou Hospital, Manado, North Sulawesi, Indonesia. FAU - Oley, Maximillian Christian AU - Oley MC AD - Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Sam Ratulangi University, Manado, Indonesia. AD - Division of Neurosurgery, Department of Surgery, R. D. Kandou Hospital, Manado, North Sulawesi, Indonesia. FAU - Merung, Marselus AU - Merung M AD - Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Sam Ratulangi University, Manado, North Sulawesi, Indonesia. AD - Division of Surgical Oncology, Department of Surgery, R. D. Kandou Hospital, Manado, North Sulawesi, Indonesia. FAU - Langi, Fima Lanra Fredrik G AU - Langi FLFG AD - Department Epidemiology and Biostatistics, Public Health Faculty, Sam Ratulangi University, Manado, Indonesia. FAU - Kepel, Billy Johnson AU - Kepel BJ AD - Department of Chemistry, Faculty of Medicine, Sam Ratulangi University, Manado, Indonesia. FAU - Rusli, Lie Venny AU - Rusli LV AD - Department of Surgery, Faculty of Medicine, Sam Ratulangi University, Manado, Indonesia. FAU - Islam, Andi Asadul AU - Islam AA AD - Department of Neurosurgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Faruk, Muhammad AU - Faruk M AD - Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. LA - eng PT - Journal Article PT - Observational Study PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 RN - 0 (Biomarkers, Tumor) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Prognosis MH - Biomarkers, Tumor/metabolism MH - Cohort Studies MH - Neoadjuvant Therapy MH - Prospective Studies MH - Hypoxia-Inducible Factor 1, alpha Subunit/therapeutic use MH - Indonesia MH - Hypoxia MH - Tumor Microenvironment OTO - NOTNLM OT - Breast cancer OT - Ca15-3 OT - HIF1α OT - RECIST OT - ductal carcinoma OT - neoadjuvant chemotherapy EDAT- 2023/01/16 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/15 05:22 PHST- 2023/01/15 05:22 [entrez] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - BD229004 [pii] AID - 10.3233/BD-229004 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):481-487. doi: 10.3233/BD-229004. PMID- 36553480 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230110 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 13 IP - 12 DP - 2022 Nov 25 TI - The Identification of Large Rearrangements Involving Intron 2 of the CDH1 Gene in BRCA1/2 Negative and Breast Cancer Susceptibility. LID - 10.3390/genes13122213 [doi] LID - 2213 AB - E-cadherin, a CDH1 gene product, is a calcium-dependent cell-cell adhesion molecule playing a critical role in the establishment of epithelial architecture, maintenance of cell polarity, and differentiation. Germline pathogenic variants in the CDH1 gene are associated with hereditary diffuse gastric cancer (HDGC), and large rearrangements in the CDH1 gene are now being reported as well. Because CDH1 pathogenic variants could be associated with breast cancer (BC) susceptibility, CDH1 rearrangements could also impact it. The aim of our study is to identify rearrangements in the CDH1 gene in 148 BC cases with no BRCA1 and BRCA2 pathogenic variants. To do so, a zoom-in CGH array, covering the exonic, intronic, and flanking regions of the CDH1 gene, was used to screen our cohort. Intron 2 of the CDH1 gene was specifically targeted because it is largely reported to include several regulatory regions. As results, we detected one large rearrangement causing a premature stop in exon 3 of the CDH1 gene in a proband with a bilateral lobular breast carcinoma and a gastric carcinoma (GC). Two large rearrangements in the intron 2, a deletion and a duplication, were also reported only with BC cases without any familial history of GC. No germline rearrangements in the CDH1 coding region were detected in those families without GC and with a broad range of BC susceptibility. This study confirms the diversity of large rearrangements in the CDH1 gene. The rearrangements identified in intron 2 highlight the putative role of this intron in CDH1 regulation and alternative transcripts. Recurrent duplication copy number variations (CNV) are found in this region, and the deletion encompasses an alternative CDH1 transcript. Screening for large rearrangements in the CDH1 gene could be important for genetic testing of BC. FAU - Ben Aissa-Haj, Jihenne AU - Ben Aissa-Haj J AUID- ORCID: 0000-0002-1368-7169 AD - Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia. AD - Laboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia. FAU - Pinheiro, Hugo AU - Pinheiro H AD - Faculty of Medicine, University of Porto, Rua Dr Roberto Frias s/n, 4200-465 Porto, Portugal. FAU - Cornelis, François AU - Cornelis F AD - University Hospital Center Gabriel-Montpied, Clermont-Ferrand, 58 Rue Montalembert, 63000 Clermont-Ferrand, France. FAU - Sebai, Molka AU - Sebai M AD - Department of Biology and Pathology, Laboratory of Cancer Genetics Institut Gustave Roussy, 94805 Villejuif, France. FAU - Meseure, Didier AU - Meseure D AD - Anatomopathological Service, Curie Institute, 26 Rue d'Ulm, 75005 Paris, France. FAU - Briaux, Adrien AU - Briaux A AD - Oncogenetic Laboratory, Departement of Genetics, Curie Institute, 26 Rue d'Ulm, 75005 Paris, France. FAU - Berteaux, Philippe AU - Berteaux P AD - University Hospital Center Gabriel-Montpied, Clermont-Ferrand, 58 Rue Montalembert, 63000 Clermont-Ferrand, France. FAU - Lefol, Cedric AU - Lefol C AD - Centre Leon Berard, 28 Promenade Léa et Napoléon Bullukian, 96008 Lyon, France. FAU - Des Guetz, Gaëtan AU - Des Guetz G AUID- ORCID: 0000-0001-9643-6877 AD - Medical Oncology Department, Delafontaine Hospital, 93200 St. Denis, France. FAU - Trassard, Martine AU - Trassard M AD - Anatomopathological Service, Curie Institute, 26 Rue d'Ulm, 75005 Paris, France. FAU - Stevens, Denise AU - Stevens D AD - Biostatistic Service, René Huguenin Hospital, Curie Institute, 35 rue Dailly, 92210 Saint Cloud, France. FAU - Vialard, François AU - Vialard F AUID- ORCID: 0000-0002-5774-2756 AD - Genetics Department, Intermunicipal Hospital Center Poissy St. Germain-en-Laye, 78300 Poissy, France. FAU - Bieche, Ivan AU - Bieche I AD - Oncogenetic Laboratory, Departement of Genetics, Curie Institute, 26 Rue d'Ulm, 75005 Paris, France. FAU - Noguès, Catherine AU - Noguès C AD - Department of Cancer Anticipation and Monitoring, Clinical Oncogenetics, Paoli-Calmettes Institute, 13009 Marseille, France. AD - INSERM, IRD Laboratory, Economic and Social Sciences of Health & Processing of Medical Information, Aix Marseille University, 13009 Marseille, France. FAU - Tang, Roseline AU - Tang R AD - Department of Biology and Pathology, Laboratory of Cancer Genetics Institut Gustave Roussy, 94805 Villejuif, France. FAU - Oliveira, Carla AU - Oliveira C AUID- ORCID: 0000-0001-8340-2264 AD - Faculty of Medicine, University of Porto, Rua Dr Roberto Frias s/n, 4200-465 Porto, Portugal. FAU - Stoppat-Lyonnet, Dominique AU - Stoppat-Lyonnet D AUID- ORCID: 0000-0002-5438-8309 AD - Oncogenetic Laboratory, Departement of Genetics, Curie Institute, 26 Rue d'Ulm, 75005 Paris, France. FAU - Lidereau, Rosette AU - Lidereau R AD - Oncogenetic Laboratory, Departement of Genetics, Curie Institute, 26 Rue d'Ulm, 75005 Paris, France. FAU - Rouleau, Etienne AU - Rouleau E AD - Department of Biology and Pathology, Laboratory of Cancer Genetics Institut Gustave Roussy, 94805 Villejuif, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221125 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - 0 (BRCA1 protein, human) RN - 0 (BRCA1 Protein) RN - 0 (CDH1 protein, human) RN - 0 (Antigens, CD) RN - 0 (Cadherins) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/pathology MH - Introns/genetics MH - DNA Copy Number Variations MH - Genetic Predisposition to Disease MH - Pedigree MH - BRCA1 Protein/genetics MH - Antigens, CD/genetics MH - Cadherins/genetics PMC - PMC9778491 OTO - NOTNLM OT - BRCA1/2 negative cases OT - CDH1 rearrangements OT - CGH array OT - CNV OT - breast carcinoma OT - gastric carcinoma COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:21 PHST- 2022/09/30 00:00 [received] PHST- 2022/11/03 00:00 [revised] PHST- 2022/11/14 00:00 [accepted] PHST- 2022/12/23 01:21 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - genes13122213 [pii] AID - genes-13-02213 [pii] AID - 10.3390/genes13122213 [doi] PST - epublish SO - Genes (Basel). 2022 Nov 25;13(12):2213. doi: 10.3390/genes13122213. PMID- 36279153 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1538-7445 (Electronic) IS - 0008-5472 (Linking) VI - 83 IP - 1 DP - 2023 Jan 4 TI - Sex Hormones in Breast Cancer Immunity. PG - 12-19 LID - 10.1158/0008-5472.CAN-22-1829 [doi] AB - Sex hormones, such as estrogens and androgens, regulate genomic and cellular processes that contribute to sex-specific disparities in the pathophysiology of various cancers. Sex hormones can modulate the immune signals and activities of tumor cells and tumor-associated leukocytes to support or suppress cancer progression. Therefore, hormonal differences between males and females play a crucial role in cancer immunity and in the response to therapies that exploit the intrinsic immune system to eliminate malignant cells. In this review, we summarize the impact of sex hormones in the breast cancer microenvironment, with a focus on how the hormonal environment affects tumor immunity. We also discuss the potential benefits of endocrine therapy used in combination with immunotherapy to strengthen the antitumor immune response. CI - ©2022 American Association for Cancer Research. FAU - Hargrove-Wiley, Ebony AU - Hargrove-Wiley E AUID- ORCID: 0000-0003-4452-4917 AD - Program in Cancer Biology, Department of Pharmacology, Vanderbilt University, Nashville, Tennessee. FAU - Fingleton, Barbara AU - Fingleton B AUID- ORCID: 0000-0003-1132-0782 AD - Program in Cancer Biology, Department of Pharmacology, Vanderbilt University, Nashville, Tennessee. LA - eng GR - National Science Foundation (NSF)/ GR - METAvivor/ PT - Journal Article PT - Review PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R RN - 0 (Gonadal Steroid Hormones) RN - 0 (Estrogens) RN - 0 (Androgens) SB - IM MH - Male MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy MH - Gonadal Steroid Hormones/physiology MH - Estrogens MH - Androgens MH - Immunotherapy MH - Tumor Microenvironment EDAT- 2022/10/25 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/10/24 11:43 PHST- 2022/06/03 00:00 [received] PHST- 2022/09/22 00:00 [revised] PHST- 2022/10/18 00:00 [accepted] PHST- 2022/10/25 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/10/24 11:43 [entrez] AID - 711843 [pii] AID - 10.1158/0008-5472.CAN-22-1829 [doi] PST - ppublish SO - Cancer Res. 2023 Jan 4;83(1):12-19. doi: 10.1158/0008-5472.CAN-22-1829. PMID- 34632941 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230104 IS - 1538-0254 (Electronic) IS - 0739-1102 (Linking) VI - 40 IP - 23 DP - 2022 TI - Modulation of interaction of BRCA1-RAD51 and BRCA1-AURKA protein complexes by natural metabolites using as possible therapeutic intervention toward cardiotoxic effects of cancer drugs: an in-silico approach. PG - 12863-12879 LID - 10.1080/07391102.2021.1976278 [doi] AB - Breast cancer type 1 susceptibility protein (BRCA1) plays an important role in maintaining genome stability and is known to interact with several proteins involved in cellular pathways, gene transcription regulation and DNA damage response. More than 40% of inherited breast cancer cases are due to BRCA1 mutation. It is also a prognostic marker in non-small cell lung cancer patients as well as a gatekeeper of cardiac function. Interaction of mutant BRCA1 with other proteins is known to disrupt the tumor suppression mechanism. Two directly interacting proteins with BRCA1 namely, DNA repair protein RAD51 (RAD51) and Aurora kinase A (AURKA), known to regulate homologous recombination (HR) and G/M cell cycle transition, respectively, form protein complex with both wild and mutant BRCA1. To analyze the interactions, protein-protein complexes were generated for each pair of proteins. In order to combat the cardiotoxic effects of cancer drugs, pharmacokinetically screened natural metabolites derived from plant, marine and bacterial sources and along with FDA-approved cancer drugs as control, were subjected to molecular docking. Piperoleine B and dihydrocircumin were the best docked natural metabolites in both RAD51 and AURKA complexes, respectively. Molecular dynamics simulation (MDS) analysis and binding free energy calculations for the best docked natural metabolite and drug for both the mutant BRCA1 complexes suggested better stability for the natural metabolites piperolein B and dihydrocurcumin as compared to drug. Thus, both natural metabolites could be further analyzed for their role against the cardiotoxic effects of cancer drugs through wet lab experiments.Communicated by Ramaswamy H. Sarma. FAU - Tiwari, Sameeksha AU - Tiwari S AD - Department of Biochemistry, University of Lucknow, Lucknow, India. FAU - Pandey, Veda P AU - Pandey VP AD - Department of Biochemistry, University of Lucknow, Lucknow, India. FAU - Yadav, Kusum AU - Yadav K AD - Department of Biochemistry, University of Lucknow, Lucknow, India. FAU - Dwivedi, Upendra N AU - Dwivedi UN AD - Department of Biochemistry, University of Lucknow, Lucknow, India. AD - Institute for Development of Advanced Computing, ONGC Centre for Advanced Studies, University of Lucknow, Lucknow, India. LA - eng PT - Journal Article DEP - 20211011 PL - England TA - J Biomol Struct Dyn JT - Journal of biomolecular structure & dynamics JID - 8404176 RN - 0 (Antineoplastic Agents) RN - EC 2.7.11.1 (AURKA protein, human) RN - EC 2.7.11.1 (Aurora Kinase A) RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) RN - EC 2.7.7.- (RAD51 protein, human) RN - EC 2.7.7.- (Rad51 Recombinase) SB - IM MH - Female MH - Humans MH - *Antineoplastic Agents/pharmacology/therapeutic use MH - Aurora Kinase A/genetics/metabolism MH - BRCA1 Protein/genetics/metabolism MH - *Breast Neoplasms/drug therapy MH - *Carcinoma, Non-Small-Cell Lung/drug therapy MH - DNA Damage MH - DNA Repair MH - *Lung Neoplasms/drug therapy MH - Molecular Docking Simulation MH - Rad51 Recombinase/genetics/metabolism OTO - NOTNLM OT - BRCA1 OT - cardiotoxicity OT - molecular docking OT - natural metabolites OT - pharmacokinetics EDAT- 2021/10/12 06:00 MHDA- 2022/12/28 06:00 CRDT- 2021/10/11 08:48 PHST- 2021/10/12 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2021/10/11 08:48 [entrez] AID - 10.1080/07391102.2021.1976278 [doi] PST - ppublish SO - J Biomol Struct Dyn. 2022;40(23):12863-12879. doi: 10.1080/07391102.2021.1976278. Epub 2021 Oct 11. PMID- 36595800 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 51 DP - 2022 Dec 23 TI - Aerobic exercise combined with resistance exercise training improves cardiopulmonary function and blood lipid of patients with breast cancer: A systematic review and meta-analysis. PG - e32391 LID - 10.1097/MD.0000000000032391 [doi] LID - e32391 AB - BACKGROUND: To compare the therapy effects following the aerobic exercise combined with resistance exercise training (AET + RET) and common care treatment for patients with breast cancer. METHODS: Articles about the effects of AET + RET on the breast cancer patients in 4 online databases were searched. The differences of cardiopulmonary function, blood pressure, blood lipid, and body mass index between the AET + RET treatment and the usual care treatment were compared. RESULTS: Totally, 8 articles were involved into the meta-analysis. The qualities of the 8 articles were medium. The combination results showed that AET + RET increased the VO2peak (weighted mean difference (WMD) = 2.93 mL/kg/min; 95% CI: 0.38, 5.49; P = .02) and VO2max (WMD = 6.98 mL/kg/min; 95% CI: 2.04, 15.92; P = .01), demonstrating its improving effects in cardiopulmonary function. Moreover, the AET + RET decreased the TG (WMD = -57.95 mg/dL; 95% CI: -112.25, -3.64; P = .04), demonstrating its improving effects in blood lipid. While or the HRpeak, RERpeak, systolic blood pressure, diastolic blood pressure, high-density lipoprotein cholesterol, and body mass index, there are no significant differences between the AET + RET and usual care treatment (P < .05). CONCLUSION: Our results demonstrated that AET + RET can significantly improve the cardiopulmonary function and blood lipid for breast cancer patients. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Kong, Lingfeng AU - Kong L AD - Physical Education Department, Hohai University, Nanjing, Jiangsu, China. FAU - Gao, Run AU - Gao R AUID- ORCID: 0000-0002-0063-1975 AD - Department of Rehabilitation, Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Lipids) SB - IM MH - Humans MH - Female MH - *Resistance Training/methods MH - *Breast Neoplasms/therapy MH - Exercise/physiology MH - Exercise Therapy/methods MH - Lipids PMC - PMC9794326 COIS- The authors declare that they have no conflict of interest. EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/03 16:08 PHST- 2023/01/03 16:08 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 00005792-202212230-00061 [pii] AID - 10.1097/MD.0000000000032391 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 23;101(51):e32391. doi: 10.1097/MD.0000000000032391. PMID- 36371994 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study. PG - 245-254 LID - S0960-9776(22)00182-5 [pii] LID - 10.1016/j.breast.2022.10.017 [doi] AB - PURPOSE: To gauge the effects of treatment practices on prognosis for older patients with HER2-positive early breast cancer, particularly to determine whether adjuvant trastuzumab alone can offer benefit over no adjuvant therapy. This is a prospective cohort study which accompanies the RESPECT that is a randomized-controlled trial (RCT). METHODS: Patients who declined the RCT were treated based on the physician's discretion. We studied the 1) trastuzumab-plus-chemotherapy group, 2) trastuzumab-monotherapy group, and 3) non-trastuzumab group (no therapy or anticancer therapy without trastuzumab). The primary endpoint was disease-free survival (DFS), which was compared using the propensity-score method. Relapse-free survival (RFS) and health-related quality of life (HRQoL) were assessed. RESULTS: We enrolled 123 patients aged over 70 years (median: 74.5). Treatment categories were: trastuzumab-plus-chemotherapy group (n = 36, 30%), trastuzumab-monotherapy group (n = 52, 43%), and non-trastuzumab group (n = 32, 27%). The 3-year DFS was 96.7% in trastuzumab-plus-chemotherapy group, 89.2% in trastuzumab-monotherapy group, and 82.5% in non-trastuzumab group. DFS in non-trastuzumab group was lower than in trastuzumab-plus-chemotherapy and trastuzumab-monotherapy groups (propensity-adjusted hazard ratio; HR: 3.29; 95% CI: 1.15-9.39; P = 0.026). The RFS in non-trastuzumab group was lower than in trastuzumab-plus-chemotherapy and trastuzumab-monotherapy groups (propensity-adjusted HR = 7.80; 95% CI: 2.32-26.2, P < 0.0001). There were no significant intergroup differences in the proportions of patients showing HRQoL deterioration at 36 months (P = 0.717). CONCLUSION: Trastuzumab-treated patients had better prognoses than patients not treated with trastuzumab without deterioration of HRQoL. Trastuzumab monotherapy could be considered for older patients who reject chemotherapy. CI - Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Sawaki, Masataka AU - Sawaki M AD - Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. Electronic address: m-sawaki@aichi-cc.jp. FAU - Taira, Naruto AU - Taira N AD - Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama, Japan. FAU - Uemura, Yukari AU - Uemura Y AD - Biostatistics Section, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. FAU - Saito, Tsuyoshi AU - Saito T AD - Department of Surgery, Japanese Red Cross Saitama Hospital, Saitama, Japan. FAU - Baba, Shinichi AU - Baba S AD - Department of Surgery, Sagara Hospital, Kagoshima, Japan. FAU - Kobayashi, Kokoro AU - Kobayashi K AD - Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Kawashima, Hiroaki AU - Kawashima H AD - Department of Surgery, Aomori City Hospital, Aomori, Japan. FAU - Tsuneizumi, Michiko AU - Tsuneizumi M AD - Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan. FAU - Sagawa, Noriko AU - Sagawa N AD - Department of Breast Surgery, Kyoundo Hospital, Tokyo, Japan. FAU - Bando, Hiroko AU - Bando H AD - Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. FAU - Takahashi, Masato AU - Takahashi M AD - Department of Breast Surgery, Hokkaido University Hospital, Sapporo, Japan. FAU - Yamaguchi, Miki AU - Yamaguchi M AD - Department of Breast Surgery, JCHO Kurume General Hospital, Kurume, Japan. FAU - Takashima, Tsutomu AU - Takashima T AD - Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan. FAU - Nakayama, Takahiro AU - Nakayama T AD - Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan. FAU - Kashiwaba, Masahiro AU - Kashiwaba M AD - Department of Breast Surgery, Adachi Breast Clinic, Kyoto, Japan. FAU - Mizuno, Toshiro AU - Mizuno T AD - Department of Medical Oncology, Mie University Hospital, Tsu, Japan. FAU - Yamamoto, Yutaka AU - Yamamoto Y AD - Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. FAU - Iwata, Hiroji AU - Iwata H AD - Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. FAU - Toyama, Tatsuya AU - Toyama T AD - Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. FAU - Tsugawa, Koichiro AU - Tsugawa K AD - Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Japan. FAU - Kawahara, Takuya AU - Kawahara T AD - Clinical Research Promotion Center, The University of Tokyo Hospital, Tokyo, Japan. FAU - Mukai, Hirofumi AU - Mukai H AD - Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. CN - RESPECT study group LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20221107 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - P188ANX8CK (Trastuzumab) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Aged MH - Aged, 80 and over MH - Female MH - Trastuzumab/therapeutic use MH - *Breast Neoplasms MH - Propensity Score MH - Receptor, ErbB-2 MH - Neoplasm Recurrence, Local/etiology MH - Disease-Free Survival MH - Antineoplastic Combined Chemotherapy Protocols MH - Cohort Studies MH - Chemotherapy, Adjuvant MH - Treatment Outcome PMC - PMC9661716 OTO - NOTNLM OT - Breast cancer OT - HER2 OT - Older OT - Trastuzumab OT - Without chemotherapy COIS- Declaration of competing interest YU reports honoraria for consulting from Chugai pharmaceutical Co., Ltd. TT reports honoraria for lectures from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Novartis Pharma K·K., AstraZeneca K·K., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K·K., and Daiichi Sankyo Co., Ltd. TN reports fees for Non-CME services and honoraria for lectures from Chugai pharmaceutical Co., Ltd., AstraZeneca K·K., Novartis Pharma K·K., Eli Lilly Japan K·K., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, and Eisai Co., Ltd. TM reports fees for non-CME services and honoraria for lectures from AstraZeneca K·K, Chugai pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K·K., Daiichi Sankyo Co., Ltd., Nippon Kayaku Co., Ltd., and Pfizer Japan Inc. HI reports honoraria for lectures from Chugai pharmaceutical Co., Ltd. HM reports honoraria from AstraZeneca K·K, Pfizer Japan Inc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Co., Ltd and Taiho Pharmaceutical Co., Ltd; and research grants from the Japanese government, Daiichi Sankyo Co., Ltd, Eisai Co., Ltd, Nippon Kayaku Co., Ltd and Pfizer Japan Inc, outside the submitted work. EDAT- 2022/11/14 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/13 18:30 PHST- 2022/09/24 00:00 [received] PHST- 2022/10/26 00:00 [revised] PHST- 2022/10/30 00:00 [accepted] PHST- 2022/11/14 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/13 18:30 [entrez] AID - S0960-9776(22)00182-5 [pii] AID - 10.1016/j.breast.2022.10.017 [doi] PST - ppublish SO - Breast. 2022 Dec;66:245-254. doi: 10.1016/j.breast.2022.10.017. Epub 2022 Nov 7. PMID- 36575482 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230103 IS - 1472-6874 (Electronic) IS - 1472-6874 (Linking) VI - 22 IP - 1 DP - 2022 Dec 28 TI - Effects of mindfulness-based stress reduction training on rumination in patients with breast cancer. PG - 552 LID - 10.1186/s12905-022-02124-y [doi] LID - 552 AB - BACKGROUND: Breast cancer has been a serious public health dilemma for women worldwide, with not only physical and social impairments but also psychological stress responses such as rumination. Rumination is a constant preoccupation with thoughts. The present study aimed to investigate the effectiveness of mindfulness-based stress reduction training in lowering rumination among women diagnosed with breast cancer. METHOD: This randomized controlled trial with a pretest, posttest, control group, and one-month follow-up design included 46 female breast cancer survivors, recruited from the clinics and hematology wards of Bushehr, Iran. The inclusion criterion was that at least three months should have passed since the last chemotherapy/radiotherapy. The participants were randomly assigned to two experimental and control groups. The experimental group received eight sessions of mindfulness-based stress reduction training. A demographic information form and a rumination questionnaire were used for data collection, and the participants completed the questionnaire in the pretest, posttest, and follow-up stages. Chi-square, Mann-Whitney U, and repeated-measures ANOVA were used to analyze the data. P < 0.05 was considered statistically significant. RESULTS: There was no significant difference in the rumination scores of the experimental group at three measurement stages. For the control group, the mean rumination scores on the posttest and follow-up were both significantly higher than on the pre-test (P < 0.001). The control group's mean follow-up rumination score was significantly higher than that of the post-test (P = 0.02). A comparison of the two groups adjusted for the baseline showed a significant difference between them in terms of the mean rumination score on the post-test (P = 0.01) and follow-up (P < 0.001). CONCLUSION: The experimental group was more successful in avoiding increased rumination than the control group, an ability that can be attributed to the effect of mindfulness training. The use of this method is recommended because it is non-invasive, non-pharmacological, free from complications, and can be easily performed by women. However, future studies should consider larger samples and long-term follow-ups. CI - © 2022. The Author(s). FAU - Bagherzadeh, Razieh AU - Bagherzadeh R AD - Department of Midwifery, Nursing and Midwifery Faculty, Bushehr University of Medical Sciences, Bushehr, Iran. FAU - Sohrabineghad, Rezvan AU - Sohrabineghad R AD - Department of Nursing, Nursing and Midwifery Faculty, Bushehr University of Medical Sciences, Bushehr, Iran. FAU - Gharibi, Taiebeh AU - Gharibi T AD - Department of Midwifery, Nursing and Midwifery Faculty, Bushehr University of Medical Sciences, Bushehr, Iran. FAU - Mehboodi, Farkhondeh AU - Mehboodi F AD - Department of Nursing, Nursing and Midwifery Faculty, Bushehr University of Medical Sciences, Bushehr, Iran. FAU - Vahedparast, Hakimeh AU - Vahedparast H AD - Department of Nursing, Nursing and Midwifery Faculty, Bushehr University of Medical Sciences, Bushehr, Iran. h.vahedparast@bpums.ac.ir. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20221228 PL - England TA - BMC Womens Health JT - BMC women's health JID - 101088690 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/psychology MH - *Mindfulness/methods MH - Stress, Psychological/therapy/etiology MH - Surveys and Questionnaires MH - Research Design PMC - PMC9795671 OTO - NOTNLM OT - Breast cancer OT - Mindfulness-based stress reduction OT - Rumination OT - Women COIS- The authors report no conflicts of interest in this work. EDAT- 2022/12/28 06:00 MHDA- 2022/12/30 06:00 CRDT- 2022/12/27 23:47 PHST- 2022/06/29 00:00 [received] PHST- 2022/12/12 00:00 [accepted] PHST- 2022/12/27 23:47 [entrez] PHST- 2022/12/28 06:00 [pubmed] PHST- 2022/12/30 06:00 [medline] AID - 10.1186/s12905-022-02124-y [pii] AID - 2124 [pii] AID - 10.1186/s12905-022-02124-y [doi] PST - epublish SO - BMC Womens Health. 2022 Dec 28;22(1):552. doi: 10.1186/s12905-022-02124-y. PMID- 36550413 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 22 IP - 1 DP - 2022 Dec 22 TI - Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel. PG - 1343 LID - 10.1186/s12885-022-10325-9 [doi] LID - 1343 AB - BACKGROUND: In clinical trials, poly (ADP-ribose) polymerase inhibitors (PARPi) versus chemotherapy resulted in significantly improved progression-free survival, manageable adverse event profiles, and favorable patient-reported outcomes (PROs) in patients with human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) and germline BRCA1/2 mutations (gBRCA1/2mut). The objective of this study was to evaluate PROs and physician satisfaction with treatment in patients with gBRCA1/2mut HER2- ABC receiving PARPi or physician's choice of chemotherapy in a multi-country, real-world setting. METHODS: This retrospective analysis used data from the Adelphi Real World ABC Disease Specific Programmes in the United States, European Union, and Israel. PROs were assessed at a single timepoint using the EuroQol 5-Dimensions 5-Level (EQ-5D-5L) scale, Cancer Therapy Satisfaction Questionnaire (CTSQ), and European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) and the breast cancer-specific module (QLQ-BR23). Baseline PROs were not assessed. Physician satisfaction with treatment scores was dichotomized to a 0/1 variable (0 = very dissatisfied/dissatisfied/moderately satisfied; 1 = satisfied/very satisfied). Scores were compared using inverse-probability-weighted regression adjustment, controlling for multiple confounding factors. RESULTS: The study included 96 patients (PARPi, n = 38; platinum/non-platinum-based chemotherapy, n = 58). Patients receiving PARPi versus chemotherapy reported significantly better scores on the EQ-5D-5L Health Utility Index. On the EORTC QLQ-C30 functional scales, patients receiving PARPi reported significantly better scores (mean ± SE) for physical functioning (80.0 ± 2.4 vs 71.9 ± 3.4; p < 0.05) and social functioning (82.0 ± 6.2 vs 63.6 ± 3.7; p < 0.05) and, on the symptom scales, reported significantly better scores for constipation (1.9 ± 1.8 vs 18.7 ± 3.2; p < 0.001), breast symptoms (0.4 ± 3.9 vs 13.3 ± 2.6; p < 0.01), arm symptoms (2.6 ± 1.3 vs 11.4 ± 2.4; p = 0.001), and systemic therapy side effects (13.5 ± 1.8 vs 29.4 ± 2.3; p < 0.001). In contrast, patients receiving chemotherapy scored significantly better on the nausea/vomiting scale (18.3 ± 2.8 vs 34.5 ± 5.1; p < 0.01). Patients receiving PARPi reported numerically better satisfaction scores on the CTSQ scales. Physicians were more likely to be satisfied/very satisfied with PARPi versus chemotherapy (95.4% ± 7.3% vs 40.8% ± 6.2%; p < 0.001). CONCLUSIONS: The PRO findings in this real-world population of patients with gBRCA1/2mut HER2- ABC complement those from the pivotal clinical trials, providing further support for treatment with PARPi in these patients. CI - © 2022. Pfizer Inc. FAU - Mahtani, Reshma AU - Mahtani R AUID- ORCID: 0000-0002-7711-8627 AD - Miami Cancer Institute, 1228 S Pine Island Road, Plantation, Miami, FL, 33324, USA. rmahtani@baptisthealth.net. FAU - Niyazov, Alexander AU - Niyazov A AD - Pfizer Inc, 235 42nd St, New York, NY, 10017, USA. FAU - Arondekar, Bhakti AU - Arondekar B AD - Pfizer Inc, 500 Arcola Road, Collegeville, PA, 19426, USA. FAU - Lewis, Katie AU - Lewis K AD - Adelphi Real World, Adelphi Mill, Cheshire, Bollington, SK10 5JB, UK. FAU - Rider, Alex AU - Rider A AD - Adelphi Real World, Adelphi Mill, Cheshire, Bollington, SK10 5JB, UK. FAU - Massey, Lucy AU - Massey L AD - Adelphi Real World, Adelphi Mill, Cheshire, Bollington, SK10 5JB, UK. FAU - Lux, Michael Patrick AU - Lux MP AD - Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Frauen- und Kinderklinik St. Louise, Salzkotten Husener Straße 81, 33098, Paderborn, Germany. LA - eng PT - Journal Article DEP - 20221222 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Poly(ADP-ribose) Polymerase Inhibitors) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - 681HV46001 (Ribose) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - United States MH - Female MH - *Poly(ADP-ribose) Polymerase Inhibitors/adverse effects MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Ribose/therapeutic use MH - Israel MH - Retrospective Studies MH - Patient Satisfaction MH - Quality of Life MH - Patient Reported Outcome Measures MH - BRCA1 Protein/genetics PMC - PMC9773591 OTO - NOTNLM OT - Advanced breast cancer OT - BRCA1/2 mutation OT - Chemotherapy OT - Patient-reported outcomes OT - Poly (ADP-ribose) polymerase inhibitors OT - Quality of life OT - Real-world COIS- RM has acted as consultant for Agendia, Amgen, AstraZeneca, Daiichi-Sankyo, Eisai, Genentech, Gilead, Hologic, Eli Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, and SeaGen; and has contracted research for AstraZeneca, Genentech, and Veru. AN, BA are employees of and own stock in Pfizer Inc. KL, AR, and LM are employees of Adelphi Real World. MPL has received honoraria for lectures, consulting, and/or working in an advisory role for Eli Lilly, AstraZeneca, MSD, Novartis, Pfizer, Eisai, Exact Sciences, Daiichi-Sankyo, Grünenthal, Gilead, Pierre Fabre, PharmaMar, Onkowissen, and Roche; received fees for travel, accommodations, and/or expenses from Roche and Pfizer; acted as editorial board member of Medac; and received fees for non-CME services from Eli Lilly, Roche, MSD, Novartis, Pfizer, Exact Sciences, Daiichi-Sankyo, Gilead, Grünenthal, AstraZeneca, and Eisai. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 23:44 PHST- 2022/05/09 00:00 [received] PHST- 2022/11/16 00:00 [accepted] PHST- 2022/12/22 23:44 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - 10.1186/s12885-022-10325-9 [pii] AID - 10325 [pii] AID - 10.1186/s12885-022-10325-9 [doi] PST - epublish SO - BMC Cancer. 2022 Dec 22;22(1):1343. doi: 10.1186/s12885-022-10325-9. PMID- 36462308 OWN - NLM STAT- MEDLINE DCOM- 20221228 LR - 20221228 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study. PG - 310-316 LID - S0960-9776(22)00190-4 [pii] LID - 10.1016/j.breast.2022.11.007 [doi] AB - First-line treatment in postmenopausal women with estrogen- and/or progesterone-positive breast cancer consists of aromatase inhibitors (AROi). The ability of AROi to promote or worsen cognitive function, depressive symptoms, sleep quality and performance in basic activities of daily life as primary and concomitant outcomes in long longitudinal studies in post-menopausal women has been seldom investigated. This study is a cohort trial which aimed to determine if there were differences in cognitive function assessment, depressive symptoms, and sleep quality after 1 year under AROi treatment and to determine the interrelations between these symptoms. METHODS: A prospective 1-year longitudinal study was performed in a representative sample of tertiary hospital. Women with localized breast cancer newly treated with AROi therapy were evaluated for cognitive functions, depressive symptoms, sleep problems and ability to perform basic activities of the daily life at baseline and after 6 months and 12 months under adjuvant AROi treatment. RESULTS: Analysis of cognitive functions by the Mini-Mental State Examination (MMSE) scores did not show significantly worsening under AROi treatment after 6 months and 12 months of treatment compared to the baseline. Analysis of depressive symptoms with the Geriatric Depression Scale and sleep quality with the Athens Insomnia Scale (AIS) scores showed significant (p < 0.05) changes after 6 and 12 months of treatment with AROi, with women describing more depressive symptoms and more sleep disturbances. CONCLUSIONS: Our study found impairments in sleep quality and an increase in depressive symptoms, which has important implications for clinicians as they impair quality of life and adherence to treatment. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - García-Sánchez, Javier AU - García-Sánchez J AD - Medical Oncology Department, Doctor Peset University Hospital, Valencia, Spain; Medical Oncology Department, Hospital Center of Wallonie Picarde, Tournai, Belgium. FAU - Mafla-España, Mayra Alejandra AU - Mafla-España MA AD - Frailty Research Organized Group, University of Valencia, Valencia, Spain; Department of Nursing, University of Valencia, Valencia, Spain. FAU - Torregrosa, María Dolores AU - Torregrosa MD AD - Medical Oncology Department, Doctor Peset University Hospital, Valencia, Spain. FAU - Cauli, Omar AU - Cauli O AD - Frailty Research Organized Group, University of Valencia, Valencia, Spain; Department of Nursing, University of Valencia, Valencia, Spain. Electronic address: Omar.Cauli@uv.es. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20221124 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - 0 (Aromatase Inhibitors) SB - IM MH - Aged MH - Female MH - Humans MH - *Aromatase Inhibitors/adverse effects MH - *Breast Neoplasms/therapy MH - Depression/chemically induced/psychology MH - Follow-Up Studies MH - Longitudinal Studies MH - Postmenopause MH - Prospective Studies MH - Quality of Life MH - Sleep Quality PMC - PMC9712768 OTO - NOTNLM OT - Aromatase inhibitors OT - Breast cancer OT - Cognitive impairment OT - Depression OT - Insomnia COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/04 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/03 18:17 PHST- 2022/09/13 00:00 [received] PHST- 2022/11/22 00:00 [revised] PHST- 2022/11/23 00:00 [accepted] PHST- 2022/12/04 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/12/03 18:17 [entrez] AID - S0960-9776(22)00190-4 [pii] AID - 10.1016/j.breast.2022.11.007 [doi] PST - ppublish SO - Breast. 2022 Dec;66:310-316. doi: 10.1016/j.breast.2022.11.007. Epub 2022 Nov 24. PMID- 36543686 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1878-4046 (Electronic) IS - 1076-6332 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - Pregnancy-Associated Breast Cancer in BRCA1/2 Carriers: Is Intensified Breast Ultrasound Surveillance Warranted? PG - 255-257 LID - S1076-6332(22)00595-5 [pii] LID - 10.1016/j.acra.2022.11.004 [doi] FAU - Fruchtman-Brot, Hila AU - Fruchtman-Brot H AD - Memorial Sloan Kettering Cancer Center, NYC, NY, USA. Electronic address: fruchtmh@mskcc.org. FAU - Mango, Victoria L AU - Mango VL AD - Memorial Sloan Kettering Cancer Center, NYC, NY, USA. LA - eng PT - Editorial DEP - 20221219 PL - United States TA - Acad Radiol JT - Academic radiology JID - 9440159 RN - 0 (BRCA1 Protein) RN - 0 (BRCA2 Protein) RN - 0 (BRCA1 protein, human) SB - IM MH - Female MH - Pregnancy MH - Humans MH - *Breast Neoplasms/diagnostic imaging/genetics MH - BRCA1 Protein/genetics MH - Ultrasonography, Mammary MH - Mutation MH - Heterozygote MH - BRCA2 Protein/genetics EDAT- 2022/12/22 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/12/21 21:56 PHST- 2022/11/01 00:00 [received] PHST- 2022/11/02 00:00 [accepted] PHST- 2022/12/22 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/12/21 21:56 [entrez] AID - S1076-6332(22)00595-5 [pii] AID - 10.1016/j.acra.2022.11.004 [doi] PST - ppublish SO - Acad Radiol. 2023 Feb;30(2):255-257. doi: 10.1016/j.acra.2022.11.004. Epub 2022 Dec 19. PMID- 36553667 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230109 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 13 IP - 12 DP - 2022 Dec 18 TI - Revealing the Potential Markers of N(4)-Acetylcytidine through acRIP-seq in Triple-Negative Breast Cancer. LID - 10.3390/genes13122400 [doi] LID - 2400 AB - Understanding the causes of tumorigenesis and progression in triple-receptor negative breast cancer (TNBC) can help the design of novel and personalized therapies and prognostic assessments. Abnormal RNA modification is a recently discovered process in TNBC development. TNBC samples from The Cancer Genome Atlas database were categorized according to the expression level of NAT10, which drives acetylation of cytidine in RNA to N(4)-acetylcytidine (ac4C) and affects mRNA stability. A total of 703 differentially expressed long non-coding RNAs (lncRNAs) were found between high- and low-expressed NAT10 groups in TNBC. Twenty of these lncRNAs were significantly associated with prognosis. Two breast cancer tissues and their paired normal tissues were sequenced at the whole genome level using acetylated RNA immunoprecipitation sequencing (acRIP-seq) technology to identify acetylation features in TNBC, and 180 genes were significantly differentially ac4c acetylated in patients. We also analyzed the genome-wide lncRNA expression profile and constructed a co-expression network, containing 116 ac4C genes and 1080 lncRNAs. Three of these lncRNAs were prognostic risk lncRNAs affected by NAT10 and contained in the network. The corresponding reciprocal pairs were "LINC01614-COL3A1", "OIP5-AS1-USP8", and "RP5-908M14.9-TRIR". These results indicate that RNA ac4c acetylation involves lncRNAs and affects the tumor process and prognosis of TNBC. This will aid the prediction of drug targets and drug sensitivity. FAU - Zhang, Xingda AU - Zhang X AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital,150 Haping Road, Harbin 150081, China. FAU - Zeng, Jiaqi AU - Zeng J AD - School of Life Science and Technology, Computational Biology Research Center, Harbin Institute of Technology, Harbin 150001, China. FAU - Wang, Jianyu AU - Wang J AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital,150 Haping Road, Harbin 150081, China. FAU - Yang, Zihan AU - Yang Z AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital,150 Haping Road, Harbin 150081, China. FAU - Gao, Song AU - Gao S AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital,150 Haping Road, Harbin 150081, China. FAU - Liu, Honghao AU - Liu H AD - School of Life Science and Technology, Computational Biology Research Center, Harbin Institute of Technology, Harbin 150001, China. FAU - Li, Guozheng AU - Li G AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital,150 Haping Road, Harbin 150081, China. FAU - Zhang, Xin AU - Zhang X AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital,150 Haping Road, Harbin 150081, China. FAU - Gu, Yue AU - Gu Y AD - School of Life Science and Technology, Computational Biology Research Center, Harbin Institute of Technology, Harbin 150001, China. FAU - Pang, Da AU - Pang D AD - Department of Breast Surgery, Harbin Medical University Cancer Hospital,150 Haping Road, Harbin 150081, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221218 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - 3768-18-1 (N-acetylcytidine) RN - 0 (RNA, Long Noncoding) RN - 5CSZ8459RP (Cytidine) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/genetics/pathology MH - *RNA, Long Noncoding/genetics/metabolism MH - Cytidine/genetics/metabolism MH - Prognosis PMC - PMC9777589 OTO - NOTNLM OT - N(4)-acetylcytidine (ac4C) OT - TNBC OT - acRIP-seq OT - drug target prediction OT - prognostic risk marker COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:22 PHST- 2022/10/28 00:00 [received] PHST- 2022/12/09 00:00 [revised] PHST- 2022/12/13 00:00 [accepted] PHST- 2022/12/23 01:22 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - genes13122400 [pii] AID - genes-13-02400 [pii] AID - 10.3390/genes13122400 [doi] PST - epublish SO - Genes (Basel). 2022 Dec 18;13(12):2400. doi: 10.3390/genes13122400. PMID- 36308926 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer：A multicenter study. PG - 183-190 LID - S0960-9776(22)00169-2 [pii] LID - 10.1016/j.breast.2022.10.004 [doi] AB - INTRODUCTION: Predicting pathological complete response (pCR) for patients receiving neoadjuvant chemotherapy (NAC) is crucial in establishing individualized treatment. Whole-slide images (WSIs) of tumor tissues reflect the histopathologic information of the tumor, which is important for therapeutic response effectiveness. In this study, we aimed to investigate whether predictive information for pCR could be detected from WSIs. MATERIALS AND METHODS: We retrospectively collected data from four cohorts of 874 patients diagnosed with biopsy-proven breast cancer. A deep learning pathological model (DLPM) was constructed to predict pCR using biopsy WSIs in the primary cohort, and it was then validated in three external cohorts. The DLPM could generate a deep learning pathological score (DLPs) for each patient; stromal tumor-infiltrating lymphocytes (TILs) were selected for comparison with DLPs. RESULTS: The WSI feature-based DLPM showed good predictive performance with the highest area under the curve (AUC) of 0.72 among the cohorts. Alternatively, the combination of the DLPM and clinical characteristics offered a better prediction performance (AUC >0.70) in all cohorts. We also evaluated the performance of DLPM in three different breast subtypes with the best prediction for the triple-negative breast cancer (TNBC) subtype (AUC: 0.73). Moreover, DLPM combined with clinical characteristics and stromal TILs achieved the highest AUC in the primary cohort (AUC: 0.82) and validation cohort 1 (AUC: 0.80). CONCLUSION: Our study suggested that WSIs integrated with deep learning could potentially predict pCR to NAC in breast cancer. The predictive performance will be improved by combining clinical characteristics. DLPs from DLPM can provide more information compared to stromal TILs for pCR prediction. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Li, Bao AU - Li B AD - Center for Biomedical Imaging, University of Science and Technology of China, Hefei, 230026, China; CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China. FAU - Li, Fengling AU - Li F AD - Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China; Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China. FAU - Liu, Zhenyu AU - Liu Z AD - CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, 100080, China. FAU - Xu, FangPing AU - Xu F AD - Department of Pathology, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. FAU - Ye, Guolin AU - Ye G AD - The First People's Hospital of Foshan, Foshan, 528000, China. FAU - Li, Wei AU - Li W AD - The First People's Hospital of Foshan, Foshan, 528000, China. FAU - Zhang, Yimin AU - Zhang Y AD - Diagnosis & Treatment Center of Breast Diseases, Clinical Research Center, Shantou Central Hospital, Shantou, 515000, China. FAU - Zhu, Teng AU - Zhu T AD - Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. FAU - Shao, Lizhi AU - Shao L AD - CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China. FAU - Chen, Chi AU - Chen C AD - CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Engineering Medicine, Beihang University, Beijing, 100191, China. FAU - Sun, Caixia AU - Sun C AD - CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Engineering Medicine, Beihang University, Beijing, 100191, China. FAU - Qiu, Bensheng AU - Qiu B AD - Center for Biomedical Imaging, University of Science and Technology of China, Hefei, 230026, China. FAU - Bu, Hong AU - Bu H AD - Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China; Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: hongbu@scu.edu.cn. FAU - Wang, Kun AU - Wang K AD - Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. Electronic address: wangkun@gdph.org.cn. FAU - Tian, Jie AU - Tian J AD - Center for Biomedical Imaging, University of Science and Technology of China, Hefei, 230026, China; CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Engineering Medicine, Beihang University, Beijing, 100191, China; Key Laboratory of Big Data-Based Precision Medicine, Beihang University, Ministry of Industry and Information Technology, People's Republic of China, Beijing, 100191, China. Electronic address: jie.tian@ia.ac.cn. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20221019 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Neoadjuvant Therapy/methods MH - Retrospective Studies MH - *Deep Learning MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Triple Negative Breast Neoplasms/drug therapy/pathology MH - Lymphocytes, Tumor-Infiltrating/pathology MH - Biopsy PMC - PMC9619175 OTO - NOTNLM OT - Breast cancer OT - Deep learning OT - Neoadjuvant chemotherapy OT - Pathological complete response OT - Whole-slide image COIS- Conflicts of interest All authors declare no competing interests. EDAT- 2022/10/30 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/29 18:27 PHST- 2021/11/09 00:00 [received] PHST- 2022/09/18 00:00 [revised] PHST- 2022/10/11 00:00 [accepted] PHST- 2022/10/30 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/29 18:27 [entrez] AID - S0960-9776(22)00169-2 [pii] AID - 10.1016/j.breast.2022.10.004 [doi] PST - ppublish SO - Breast. 2022 Dec;66:183-190. doi: 10.1016/j.breast.2022.10.004. Epub 2022 Oct 19. PMID- 36368161 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel. PG - 236-244 LID - S0960-9776(22)00174-6 [pii] LID - 10.1016/j.breast.2022.10.009 [doi] AB - BACKGROUND: Current guidelines for the treatment of human epidermal growth factor receptor 2‒negative (HER2-) advanced breast cancer (ABC) are informed by tumor characteristics and include platinum- and non-platinum-based chemotherapy, chemotherapy plus immunotherapy, endocrine monotherapy, or endocrine therapy plus a targeted therapy. In addition, poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have recently demonstrated improved clinical and patient-reported outcomes and manageable toxicity profiles compared with chemotherapy in patients with germline breast cancer susceptibility gene 1 or 2 (gBRCA1/2)‒mutated HER2- ABC in clinical trials and are now approved to treat this patient population. This study provides complementary real-world data regarding treatment patterns, adverse events, and physician-reported treatment satisfaction in this population. METHODS: This retrospective analysis using the Adelphi Real World ABC Disease Specific Programme in the United States, European Union, and Israel included patients aged ≥18 years receiving therapy for stage IIIb or IV gBRCA1/2-mutated HER2- ABC. Oncologists completed a patient record form detailing patient demographics, clinical assessments, and treatment history and a survey regarding their use of and satisfaction with treatments. RESULTS: Among the 543 patients, mean age was 55 years, 25% were premenopausal, 70% had hormone receptor‒positive (HR+) ABC, and 30% had triple-negative breast cancer (TNBC). PARPi were used in 5%, 11%, and 12% of first-line, second-line, and third-line therapies, respectively, for patients with HR+ ABC; for TNBC, percentages were 18%, 44%, and 36%. Across treatment lines, neutropenia, anemia, and nausea occurred in 16%, 24%, and 32% of patients receiving PARPi, respectively; 22%, 38%, and 33% of patients receiving platinum chemotherapy; and 20%, 20%, and 33% of patients receiving non-platinum-based chemotherapy. Physician satisfaction was highest with PARPi and with chemotherapy plus immunotherapy. CONCLUSIONS: Findings in this real-world population complement clinical trial observations and provide further support for treatment of patients with PARPi in gBRCA1/2-mutated HER2- ABC. CI - Copyright © 2022 The Pfizer, The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Mahtani, Reshma AU - Mahtani R AD - Miami Cancer Institute, 1228 S Pine Island Road, Plantation, FL, 33324, USA. Electronic address: rmahtani@baptisthealth.net. FAU - Niyazov, Alexander AU - Niyazov A AD - Pfizer Inc, 235 42nd St, New York, NY, 10017, USA. Electronic address: Alexander.Niyazov@pfizer.com. FAU - Arondekar, Bhakti AU - Arondekar B AD - Pfizer Inc, 500 Arcola Rd, Collegeville, PA, 19426, USA. Electronic address: Bhakti.Arondekar@pfizer.com. FAU - Lewis, Katie AU - Lewis K AD - Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire, SK10 5JB, UK. Electronic address: katie.lewis@adelphigroup.com. FAU - Rider, Alex AU - Rider A AD - Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire, SK10 5JB, UK. Electronic address: Alex.Rider@adelphigroup.com. FAU - Massey, Lucy AU - Massey L AD - Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire, SK10 5JB, UK. Electronic address: lucy.massey@adelphigroup.com. FAU - Lux, Michael Patrick AU - Lux MP AD - Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Paderborn, Frauenklinik St. Josefs, Salzkotten Husener Straße 81, 33098, Paderborn, Germany. Electronic address: M.Lux@vincenz.de. LA - eng PT - Journal Article DEP - 20221018 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - United States MH - Adolescent MH - Adult MH - Middle Aged MH - Female MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - *Triple Negative Breast Neoplasms/drug therapy MH - Retrospective Studies MH - Israel MH - Patient Satisfaction MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Receptor, ErbB-2/genetics/metabolism MH - *Physicians MH - Demography MH - BRCA1 Protein/genetics PMC - PMC9650077 OTO - NOTNLM OT - Breast cancer susceptibility gene 1 or 2 OT - Hereditary breast cancer OT - Real-world OT - Safety OT - Treatment patterns OT - poly(adenosine diphosphate-ribose) polymerase inhibitors COIS- Declaration of competing interest RM contracted research funding from Genentech and acted as consultant for Agendia, Amgen, AstraZeneca, Biotheranostics, Daiichi Sankyo, Eisai, Eli Lilly, Genentech, Immunomedics, Merck, Novartis, Pfizer, Puma, Sanofi, and SeaGen. AN and BA are employees of and own stock in Pfizer Inc. KL, AR, and LM are employees of Adelphi Real World. MPL received honoraria for lectures, consulting, or advisory role for AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Grünenthal, Medac, MSD, Novartis, Pfizer, PharmaMar, Pierre Fabre, and Roche and travel and accommodations expenses from Pfizer and Roche. EDAT- 2022/11/12 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/11 18:22 PHST- 2022/07/07 00:00 [received] PHST- 2022/10/14 00:00 [revised] PHST- 2022/10/17 00:00 [accepted] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/11 18:22 [entrez] AID - S0960-9776(22)00174-6 [pii] AID - 10.1016/j.breast.2022.10.009 [doi] PST - ppublish SO - Breast. 2022 Dec;66:236-244. doi: 10.1016/j.breast.2022.10.009. Epub 2022 Oct 18. PMID- 36549768 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 0386-300X (Print) IS - 0386-300X (Linking) VI - 76 IP - 6 DP - 2022 Dec TI - Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients. PG - 661-671 LID - 10.18926/AMO/64116 [doi] AB - Chemotherapy-induced peripheral neuropathy (CIPN) is an important clinical challenge that threatens patients' quality of life. This sub-study of the ABROAD trial investigated the influence of single nucleotide polymorphisms (SNPs) on CIPN, using genotype data from a randomized study to determine the optimal dose of a 3-week-cycle regimen of nab-paclitaxel (q3w nab-PTX) in patients with metastatic breast cancer (MBC). Patients with HER2-negative MBC were randomly assigned to three doses of q3w nab-PTX (SD: 260 mg/m2 vs. MD: 220 mg/m2 vs. LD: 180 mg/m2). Five SNPs (EPHA4-rs17348202, EPHA5-rs7349683, EPHA6-rs301927, LIMK2-rs5749248, and XKR4-rs4737264) were analyzed based on the results of a previous genome-wide association study. Per-allele SNP associations were assessed by a Cox regression to model the cumulative dose of nab-PTX up to the onset of severe or worsening sensory neuropathy. A total of 141 patients were enrolled in the parent study; 91(65%) were included in this sub-study. Worsening of CIPN was significantly greater in the cases with XKR4 AC compared to those with a homozygote AA (HR 1.86, 95%CI: 1.00001-3.46, p=0.049). There was no significant correlation of CIPN with any other SNP. A multivariate analysis showed that the cumulative dose of nab-PTX was most strongly correlated with CIPN (p<0.01). FAU - Abe, Yuko AU - Abe Y AD - Department of Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. FAU - Taira, Naruto AU - Taira N AD - Department of Breast and Endocrine surgery, Kawasaki Medical School Hospital. FAU - Kashiwabara, Kosuke AU - Kashiwabara K AD - Clinical Research Promotion Center, University of Tokyo Hospital. FAU - Tsurutani, Junji AU - Tsurutani J AD - Advanced Cancer Translational Research Institute, Showa University. FAU - Kitada, Masahiro AU - Kitada M AD - Breast Disease Center, Asahikawa Medical University Hospital. FAU - Takahashi, Masato AU - Takahashi M AD - Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center. FAU - Kato, Hiroaki AU - Kato H AD - Department of Breast Surgery, Teine Keijinkai Hospital. FAU - Kikawa, Yuichiro AU - Kikawa Y AD - Department of Breast Surgery, Kansai Medical University Hospital. FAU - Sakata, Eiko AU - Sakata E AD - Department of Breast Surgery, Niigata City General Hospital. FAU - Naito, Yoichi AU - Naito Y AD - Department of Medical Oncology, National Cancer Center Hospital East. FAU - Hasegawa, Yoshie AU - Hasegawa Y AD - Department of Breast Surgery, Hachinohe City Hospital. FAU - Saito, Tsuyoshi AU - Saito T AD - Department of Breast Surgery, Japanese Red Cross Saitama Hospital. FAU - Iwasa, Tsutomu AU - Iwasa T AD - Department of Medical Oncology, Kindai University Faculty of Medicine. FAU - Takashima, Tsutomu AU - Takashima T AD - Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine. FAU - Aihara, Tomohiko AU - Aihara T AD - Breast Center, Aihara Hospital. FAU - Mukai, Hirofumi AU - Mukai H AD - Department of Medical Oncology, National Cancer Center Hospital East. FAU - Hara, Fumikata AU - Hara F AD - Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research. FAU - Shien, Tadahiko AU - Shien T AD - Department of Breast and Endocrine surgery, Okayama University Hospital. FAU - Doihara, Hiroyoshi AU - Doihara H AD - Department of Breast surgery, Kawasaki Medical School General Medical Center. FAU - Toyooka, Shinichi AU - Toyooka S AD - Department of Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PL - Japan TA - Acta Med Okayama JT - Acta medica Okayama JID - 0417611 RN - 0 (130-nm albumin-bound paclitaxel) RN - 1605-68-1 (taxane) RN - 0 (Taxoids) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Quality of Life MH - Genome-Wide Association Study MH - Taxoids/adverse effects MH - *Peripheral Nervous System Diseases/chemically induced/genetics MH - Polymorphism, Single Nucleotide MH - Antineoplastic Combined Chemotherapy Protocols OTO - NOTNLM OT - chemotherapy-induced peripheral neuropathy OT - metastatic breast cancer OT - nab-paclitaxel OT - single nucleotide polymorphism OT - taxane-induced peripheral neuropathy COIS- No potential conflict of interest relevant to this article was reported. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 20:53 PHST- 2022/12/22 20:53 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - 10.18926/AMO/64116 [doi] PST - ppublish SO - Acta Med Okayama. 2022 Dec;76(6):661-671. doi: 10.18926/AMO/64116. PMID- 36403182 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery. PG - 333-341 LID - 10.1007/s10549-022-06811-0 [doi] AB - PURPOSE: The aim of the study was to analyze the impact of neoadjuvant systemic treatment (NST) on postoperative complications and the beginning of adjuvant treatment. METHODS: This study includes data from a prospectively maintained database including patients with breast cancer (BC) stage I-IV with or without NST undergoing breast cancer surgery between January 2010 and September 2021. RESULTS: Out of 517 enrolled patients, 77 received NST, 440 had primary breast surgery. After NST patients underwent surgery after a meantime of 34 days (26.5-40 days). No statistical significance could be found comparing the complication grading according to the Clavien Dindo classification. The complications were most frequently rated as grade 3b. There were no complications with grade 4 or higher. When differentiating into short and long-term, the overall rate of short-term complications was 20.3% with no significant difference between the two groups (20.8% vs. 20.2%). Regarding long-term complications, there was more impairment of shoulder mobility (26.0% vs. 9.5%, p ≤ 0.001) and chronic pain (42.9% vs. 28.6%, p ≤ 0.016) for patients with NST. The beginning of the administration of the adjuvant treatment was comparable in both groups (46.3 days vs. 50.5 days). CONCLUSION: In our cohort, complications between both groups were comparable according to Clavien Dindo. This study shows that NST has no negative impact on postoperative short-term complications and most importantly did not lead to a delay of the beginning of adjuvant treatment. Therefore, NST can be safely admitted, even when followed by extensive breast reconstruction surgery. CI - © 2022. The Author(s). FAU - Nussbaumer, R L AU - Nussbaumer RL AD - Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland. AD - Breast Center, University Hospital of Basel, Basel, Switzerland. FAU - Maggi, N AU - Maggi N AUID- ORCID: 0000-0002-9483-0245 AD - Breast Center, University Hospital of Basel, Basel, Switzerland. FAU - Castrezana, L AU - Castrezana L AD - Breast Center, University Hospital of Basel, Basel, Switzerland. FAU - Zehnpfennig, L AU - Zehnpfennig L AD - University of Basel, Basel, Switzerland. FAU - Schwab, F D AU - Schwab FD AD - Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland. AD - Breast Center, University Hospital of Basel, Basel, Switzerland. AD - University of Basel, Basel, Switzerland. FAU - Krol, J AU - Krol J AD - Breast Center, University Hospital of Basel, Basel, Switzerland. FAU - Oberhauser, I AU - Oberhauser I AD - Breast Center, University Hospital of Basel, Basel, Switzerland. FAU - Weber, W P AU - Weber WP AD - Breast Center, University Hospital of Basel, Basel, Switzerland. AD - University of Basel, Basel, Switzerland. FAU - Kurzeder, C AU - Kurzeder C AD - Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland. AD - Breast Center, University Hospital of Basel, Basel, Switzerland. AD - University of Basel, Basel, Switzerland. FAU - Haug, M D AU - Haug MD AD - Breast Center, University Hospital of Basel, Basel, Switzerland. AD - University of Basel, Basel, Switzerland. AD - Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital of Basel, Basel, Switzerland. FAU - Kappos, Elisabeth A AU - Kappos EA AD - Breast Center, University Hospital of Basel, Basel, Switzerland. Elisabeth.kappos@usb.ch. AD - University of Basel, Basel, Switzerland. Elisabeth.kappos@usb.ch. AD - Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital of Basel, Basel, Switzerland. Elisabeth.kappos@usb.ch. LA - eng PT - Journal Article DEP - 20221120 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/surgery MH - Neoadjuvant Therapy/adverse effects MH - Mastectomy/adverse effects MH - Postoperative Complications/epidemiology/etiology MH - Retrospective Studies PMC - PMC9823081 OTO - NOTNLM OT - Breast cancer surgery OT - Neoadjuvant OT - Surgery complications OT - Systemic therapy COIS- W.P. Weber has received research support from Takeda Pharmaceuticals International paid to the Swiss Group for Clinical Cancer Research (SAKK) and personal honoraria from Genomic Health, Inc., USA. Support for meetings was paid to his institution from Sandoz, Genomic Health, Medtronic, Novartis Oncology, Pfizer and Eli Lilly. Jeremy Levy has received personal fees for his work from the Department of Plastic, Reconstructive and Aesthetic Surgery and the Department of Breast Surgery. All other authors declare no competing interests. EDAT- 2022/11/21 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/20 14:01 PHST- 2022/09/14 00:00 [received] PHST- 2022/11/09 00:00 [accepted] PHST- 2022/11/21 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/20 14:01 [entrez] AID - 10.1007/s10549-022-06811-0 [pii] AID - 6811 [pii] AID - 10.1007/s10549-022-06811-0 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):333-341. doi: 10.1007/s10549-022-06811-0. Epub 2022 Nov 20. PMID- 36482103 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230113 IS - 1546-170X (Electronic) IS - 1078-8956 (Print) IS - 1078-8956 (Linking) VI - 28 IP - 12 DP - 2022 Dec TI - Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. PG - 2573-2583 LID - 10.1038/s41591-022-02126-1 [doi] AB - Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1(positive) disease. The randomized, placebo-controlled ALICE trial ( NCT03164993 , 24 May 2017) evaluated the addition of atezolizumab (anti-PD-L1) to immune-stimulating chemotherapy in mTNBC. Patients received pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide in combination with atezolizumab (atezo-chemo; n = 40) or placebo (placebo-chemo; n = 28). Primary endpoints were descriptive assessment of progression-free survival in the per-protocol population (>3 atezolizumab and >2 PLD doses; n = 59) and safety in the full analysis set (FAS; all patients starting therapy; n = 68). Adverse events leading to drug discontinuation occurred in 18% of patients in the atezo-chemo arm (7/40) and in 7% of patients in the placebo-chemo arm (2/28). Improvement in progression-free survival was indicated in the atezo-chemo arm in the per-protocol population (median 4.3 months versus 3.5 months; hazard ratio (HR) = 0.57; 95% confidence interval (CI) 0.33-0.99; log-rank P = 0.047) and in the FAS (HR = 0.56; 95% CI 0.33-0.95; P = 0.033). A numerical advantage was observed for both the PD-L1(positive) (n = 27; HR = 0.65; 95% CI 0.27-1.54) and PD-L1(negative) subgroups (n = 31; HR = 0.57, 95% CI 0.27-1.21). The progression-free proportion after 15 months was 14.7% (5/34; 95% CI 6.4-30.1%) in the atezo-chemo arm versus 0% in the placebo-chemo arm. The addition of atezolizumab to PLD/cyclophosphamide was tolerable with an indication of clinical benefit, and the findings warrant further investigation of PD1/PD-L1 blockers in combination with immunomodulatory chemotherapy. CI - © 2022. The Author(s). FAU - Røssevold, Andreas Hagen AU - Røssevold AH AUID- ORCID: 0000-0002-7212-0111 AD - Department of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway. AD - Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. FAU - Andresen, Nikolai Kragøe AU - Andresen NK AUID- ORCID: 0000-0001-9386-1368 AD - Department of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway. AD - Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. FAU - Bjerre, Christina Annette AU - Bjerre CA AUID- ORCID: 0000-0003-0530-8090 AD - Department of Oncology, Rigshospitalet, Copenhagen, Denmark. FAU - Gilje, Bjørnar AU - Gilje B AD - Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway. FAU - Jakobsen, Erik Hugger AU - Jakobsen EH AD - Department of Oncology, Sygehuset Lillebælt, Vejle, Denmark. FAU - Raj, Sunil Xavier AU - Raj SX AD - Department of Oncology, St. Olav University Hospital, Trondheim, Norway. FAU - Falk, Ragnhild Sørum AU - Falk RS AD - Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. FAU - Russnes, Hege Giercksky AU - Russnes HG AD - Department of Pathology, Oslo University Hospital, Oslo, Norway. FAU - Jahr, Thea AU - Jahr T AD - Department of Radiology and Nuclear medicine, Oslo University Hospital, Oslo, Norway. FAU - Mathiesen, Randi Ruud AU - Mathiesen RR AD - Department of Oncology, Oslo University Hospital, Oslo, Norway. FAU - Lømo, Jon AU - Lømo J AD - Department of Pathology, Oslo University Hospital, Oslo, Norway. FAU - Garred, Øystein AU - Garred Ø AD - Department of Pathology, Oslo University Hospital, Oslo, Norway. FAU - Chauhan, Sudhir Kumar AU - Chauhan SK AD - Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. FAU - Lereim, Ragnhild Reehorst AU - Lereim RR AD - Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. FAU - Dunn, Claire AU - Dunn C AD - Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. FAU - Naume, Bjørn AU - Naume B AD - Department of Oncology, Oslo University Hospital, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo, Oslo, Norway. FAU - Kyte, Jon Amund AU - Kyte JA AUID- ORCID: 0000-0002-2854-3694 AD - Department of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway. jonky@ous-hf.no. AD - Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. jonky@ous-hf.no. LA - eng SI - ClinicalTrials.gov/NCT03164993 PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20221208 PL - United States TA - Nat Med JT - Nature medicine JID - 9502015 RN - 0 (Anthracyclines) RN - 52CMI0WC3Y (atezolizumab) RN - 0 (B7-H1 Antigen) RN - 8N3DW7272P (Cyclophosphamide) SB - IM MH - Humans MH - *Anthracyclines MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - B7-H1 Antigen/therapeutic use MH - Cyclophosphamide/adverse effects MH - *Triple Negative Breast Neoplasms/drug therapy/pathology MH - Double-Blind Method PMC - PMC9800277 COIS- J.A.K. has, in the last 3 years, received research support from Bristol Myers Squibb, F. Hoffmann-La Roche, NanoString and NEC OncoImmunity and has previously received advisory board/lecture honoraria from pharmaceutical companies, including Roche. B.G. has, in the last 3 years, received honoraria for advisory boards from Eli Lilly, Gilead Sciences, Daiichi Sankyo, Roche and Pierre Fabre. S.X.R. and J.L. have received lecture honoraria from Pfizer, Novartis and AstraZeneca. C.B. has received travel grants or advisory board/consultant honoraria from Eli Lilly, Pfizer, AstraZeneca, Gilead Sciences, MSD and Daiichi Sankyo. All other authors declare no competing interests. EDAT- 2022/12/10 06:00 MHDA- 2023/01/03 06:00 CRDT- 2022/12/09 00:42 PHST- 2022/10/17 00:00 [received] PHST- 2022/11/08 00:00 [accepted] PHST- 2022/12/10 06:00 [pubmed] PHST- 2023/01/03 06:00 [medline] PHST- 2022/12/09 00:42 [entrez] AID - 10.1038/s41591-022-02126-1 [pii] AID - 2126 [pii] AID - 10.1038/s41591-022-02126-1 [doi] PST - ppublish SO - Nat Med. 2022 Dec;28(12):2573-2583. doi: 10.1038/s41591-022-02126-1. Epub 2022 Dec 8. PMID- 35993523 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1364-6893 (Electronic) IS - 0144-3615 (Linking) VI - 42 IP - 7 DP - 2022 Oct TI - Effects of Cimicifuga racemosa (L.) Nutt on sexual function in women receiving tamoxifen for breast cancer. PG - 3236-3240 LID - 10.1080/01443615.2022.2111517 [doi] AB - To assess the effects of Cimicifuga racemosa (L.) Nutt on climacteric symptoms and sexual function in women receiving tamoxifen after breast cancer treatment. A prospective study of women treated at the Mastology Outpatient Clinic of the Department of Obstetrics and Gynecology of the Santa Casa de Sao Paulo School of Medical Science of the hospital was conducted between 2018 and 2021. Patients diagnosed with breast cancer that underwent surgical, radiotherapy and chemotherapy treatment more than one year prior, receiving tamoxifen, exhibited climacteric symptoms and were sexually active were selected. Total of 34 women were recruited and during outpatient visits completed sociodemographic questionnaire, Blatt-Kupperman Index (KI) and Female Sexual Function Index (FSFI). The group showed improvements in climacteric symptoms (p<.001) and sexual function (p=.011) after the 6-month follow-up. Cimicifuga racemosa (L.) Nutt promoted improvements in climacteric symptoms and sexual function in women surgically treated for breast cancer. Clinical Trials.gov ID: NCT02467686.Impact StatementWhat is already known on this subject? The medications used for the treatment of breast cancer can lead to important complaints of vasomotor manifestations with a negative impact on the success of their treatment, and cases have been described until their interruption. Cimicifuga racemosa (L.) Nutt. is described in several works as a therapy to alleviate these symptoms. Numerous works in the literature present climatic symptoms and sexual function with a selective approach to the themes.What do the results of this study add? Our study evaluated a group of women who were treated for breast cancer after menopause taking into account the following aspects: climacteric symptoms and sexual function. When we reviewed the literature, we did not find, so far, work similar to ours.What are the implications of these findings for clinical practice and/or further research? In clinical practice, assessing vasomotor symptoms and sexual response of breast cancer patients can contribute towards improving the lives of this patient group. Prescribing Cimicifuga racemosa (L.) Nutt in cases with climacteric complaints and poor sexual response can relieve distress and promote better health and life status for these women. Although the present investigation has generated important data on female breast cancer survivors, there are limitations regarding the number of participants. We recommend further clinical research with expansion of the sample studied and the results presented. FAU - Furtado Macruz, Carolina AU - Furtado Macruz C AUID- ORCID: 0000-0002-4717-4513 AD - Department of Obstetrics and Gynecology, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil. FAU - Lima, Sônia Maria Rolim Rosa AU - Lima SMRR AUID- ORCID: 0000-0003-3815-2360 AD - Department of Obstetrics and Gynecology, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20220822 PL - England TA - J Obstet Gynaecol JT - Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology JID - 8309140 RN - 094ZI81Y45 (Tamoxifen) RN - 0 (Plant Extracts) SB - IM MH - Female MH - Humans MH - Tamoxifen/adverse effects MH - *Breast Neoplasms/drug therapy MH - Phytotherapy MH - *Cimicifuga MH - Prospective Studies MH - Brazil MH - Plant Extracts/adverse effects MH - Menopause OTO - NOTNLM OT - Black cohosh OT - Cimicifuga racemosa OT - breast cancer OT - climacteric symptoms OT - sexuality OT - tamoxifen EDAT- 2022/08/23 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/08/22 07:42 PHST- 2022/08/23 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/08/22 07:42 [entrez] AID - 10.1080/01443615.2022.2111517 [doi] PST - ppublish SO - J Obstet Gynaecol. 2022 Oct;42(7):3236-3240. doi: 10.1080/01443615.2022.2111517. Epub 2022 Aug 22. PMID- 36585183 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 43 IP - 1 DP - 2023 Jan TI - Histological Risk Factors for Local Recurrence of Phyllodes Tumors of the Breast. PG - 143-147 LID - 10.21873/anticanres.16143 [doi] AB - BACKGROUND/AIM: The rate of local recurrence (LR) of phyllodes tumor (PT) varies from 4 to 18%. Several histological risk factors of LR of PT are known. The aim of this study was to estimate the LR rate of PT according to PT grade and to evaluate histological risk factors of PT LR in our retrospective cohort. PATIENTS AND METHODS: This was a two-center study, conducted from 1995 to 2019. All patients with PT diagnosed on surgical specimen were included. PT was diagnosed histologically according to the grade category defined by the 2012 World Health Organization classification as benign, borderline or malignant PT. Univariate analysis and then multivariate logistic regression analysis were performed to determine histological risk factors of LR of PT. RESULTS: A total of 224 patients with PT were included: 152 with benign, 49 with borderline and 23 with malignant PT. The median and standard deviation for the duration of follow-up was 136.60 ± 167.43 months, and 18 patients (8.04%) developed LR: 7 (4.61%), 7 and (14.29%) and 4 (17.39%) with benign, borderline and malignant PT, respectively. In univariate analysis, LR was statistically increased for histological size ≥45 mm (p=0.003), borderline/malignant TP (p=0.006) and dense stromal cellularity (p<0.001). In multivariate analysis, only histological size ≥45 mm and cellularity were statistically associated with LR (odds ratio=1.83, 95% confidence interval=1.06-9.83, p=0.04; and odds ratio=3.69, 95% confidence interval=1.11-12.28, p=0.03, respectively). CONCLUSION: Histological size ≥45 mm and dense stromal cellularity were demonstrated as histological risk factors of LR of PT. In our cohort, no association was found between LR and PT grade nor LR and surgical margins ≥10 mm. CI - Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Mimoun, Camille AU - Mimoun C AD - Breast Surgery Department, Saint Louis Hospital, Paris, France; mimouncamille@gmail.com. AD - Gynecological Surgery Department, Lariboisiere Hospital, Paris, France. AD - Faculty of Health, Paris Cité University, Paris, France. FAU - Legay, Ludivine AU - Legay L AD - Breast Surgery Department, Saint Louis Hospital, Paris, France. FAU - Lorphelin, Henri AU - Lorphelin H AD - Breast Surgery Department, Saint Louis Hospital, Paris, France. FAU - Leveau-Vallier, Anne Sophie AU - Leveau-Vallier AS AD - Anatomy and Cytopathological Department, Lariboisiere Hospital, Paris, France. FAU - Cornelis, Francoise AU - Cornelis F AD - Anatomy and Cytopathological Department, Lariboisiere Hospital, Paris, France. FAU - Miquel, Catherine AU - Miquel C AD - Anatomy and Cytopathological Department, Saint Louis Hospital, Paris, France. FAU - Marchand, Eva AU - Marchand E AD - Breast Surgery Department, Saint Louis Hospital, Paris, France. AD - Gynecological Surgery Department, Lariboisiere Hospital, Paris, France. FAU - Mezzadri, Matthieu AU - Mezzadri M AD - Breast Surgery Department, Saint Louis Hospital, Paris, France. AD - Gynecological Surgery Department, Lariboisiere Hospital, Paris, France. FAU - Teixeira, Luis AU - Teixeira L AD - Oncology Department, Saint Louis Hospital, Paris, France. FAU - Cahen-Doidy, Laurence AU - Cahen-Doidy L AD - Breast Surgery Department, Saint Louis Hospital, Paris, France. FAU - Huchon, Cyrille AU - Huchon C AD - Breast Surgery Department, Saint Louis Hospital, Paris, France. AD - Gynecological Surgery Department, Lariboisiere Hospital, Paris, France. AD - Faculty of Health, Paris Cité University, Paris, France. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 SB - IM MH - Humans MH - Female MH - *Phyllodes Tumor/diagnosis MH - Retrospective Studies MH - Neoplasm Recurrence, Local/pathology MH - Risk Factors MH - *Breast Neoplasms/surgery/complications OTO - NOTNLM OT - Phyllode tumor OT - breast OT - histological risk factors OT - local recurrence EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 21:03 PHST- 2022/09/23 00:00 [received] PHST- 2022/11/15 00:00 [revised] PHST- 2022/11/30 00:00 [accepted] PHST- 2022/12/30 21:03 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 43/1/143 [pii] AID - 10.21873/anticanres.16143 [doi] PST - ppublish SO - Anticancer Res. 2023 Jan;43(1):143-147. doi: 10.21873/anticanres.16143. PMID- 36644991 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230120 IS - 1745-5065 (Electronic) IS - 1745-5057 (Print) IS - 1745-5057 (Linking) VI - 19 DP - 2023 Jan-Dec TI - Review of bone health in women with estrogen receptor-positive breast cancer receiving endocrine therapy. PG - 17455057221149493 LID - 10.1177/17455057221149493 [doi] LID - 17455057221149493 AB - In estrogen-receptor-positive tumors, adjuvant endocrine therapy has been shown to be highly beneficial for both overall and disease-free survival. Estradiol is key in regulating bone and mineral physiology, and several studies found a strong correlation between these therapies and the risk of fractures. Since these therapies are often given for 5 through 10 years, the timing for bisphosphonates or denosumab initiation seems essential to managing bone metabolism. However, gray zones and discrepancies between guidelines remain as to the best threshold when to start antiresorptive treatment, or whether antiresorptive treatment should be administered to every woman undergoing adjuvant endocrine therapy, independent of their risk factors for fractures. Treatment options and strategies should be discussed at the start of hormone adjuvant therapy to come to a shared decision with the patient, with the final aim of reducing the risk of future fractures as much as possible. This review will cover present guidelines and literature on antiresorptive treatment in this setting, to provide clinicians with useful clues for managing these patients. FAU - Malagrinò, Matteo AU - Malagrinò M AUID- ORCID: 0000-0001-8157-6279 AD - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Zavatta, Guido AU - Zavatta G AUID- ORCID: 0000-0003-3657-2070 AD - Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy. LA - eng PT - Journal Article PT - Review PL - United States TA - Womens Health (Lond) JT - Women's health (London, England) JID - 101271249 RN - 0 (Aromatase Inhibitors) RN - 0 (Bone Density Conservation Agents) RN - 0 (Receptors, Estrogen) SB - IM MH - Female MH - Humans MH - Aromatase Inhibitors/adverse effects/therapeutic use MH - Bone Density MH - *Bone Density Conservation Agents/adverse effects/therapeutic use MH - *Breast Neoplasms/drug therapy MH - *Fractures, Bone/prevention & control/chemically induced MH - Receptors, Estrogen/metabolism PMC - PMC9846301 OTO - NOTNLM OT - aromatase inhibitors OT - bisphosphonates OT - bone OT - breast cancer OT - denosumab OT - fracture COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/01/17 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/16 05:23 PHST- 2023/01/16 05:23 [entrez] PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - 10.1177_17455057221149493 [pii] AID - 10.1177/17455057221149493 [doi] PST - ppublish SO - Womens Health (Lond). 2023 Jan-Dec;19:17455057221149493. doi: 10.1177/17455057221149493. PMID- 36357268 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1938-0666 (Electronic) IS - 1526-8209 (Linking) VI - 23 IP - 1 DP - 2023 Jan TI - Serratus Plane Block in Breast Cancer Surgery: A Systematic Review and Meta-Analysis. PG - e1-e13 LID - S1526-8209(22)00231-2 [pii] LID - 10.1016/j.clbc.2022.10.009 [doi] AB - The serratus plane block is a regional anesthesia technique awaiting efficacy and safety evaluation in breast cancer surgery, but evidence is unclear. This meta-analysis evaluates the analgesic effectiveness of serratus plane block vis-à-vis general anesthesia and paravertebral block for breast cancer surgery. We searched for randomized controlled trials in PubMed, the Cochrane Library, and Web of Science with no language limitation, comparing the serratus plane block with multimodal analgesia or the thoracic paravertebral block in breast cancer surgery. The Hartung-Knapp-Sidik-Jonkman method in combination with a random-effects model was used to pool data. We included 12 randomized controlled trials (799 patients). Compared with multimodal analgesia, pooled outcomes favored the use of serratus plane block for effectively alleviating acute postoperative pain severity at multiple time points. The serratus plane block also resulted in decreased postoperative analgesic consumption of 28.81mg (95% confidence interval [CI]: -51.20, -6.43), decreased intraoperative fentanyl consumption of -56.46 mg (95% CI: -79.61, -33.30), increased duration of postoperative anesthesia of 243.85 min (95% CI: 104.38, 383.31), and reduced postoperative nausea and vomiting with a log relative risk of -1.07 (95% CI: -1.90, -0.24). Compared with the thoracic paravertebral block, the serratus plane block was not statically worse for all of the outcomes assessed. No adverse effects were reported. The serratus plane block effectively alleviates acute postoperative pain, reduces the rate of postoperative nausea and vomiting, and improves perioperative anesthesia outcomes in breast cancer surgery, and it may represent an alternative to thoracic paravertebral block. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Li, Zhen-Hao AU - Li ZH AD - Jinan University, Guangzhou City, Guangdong Province, China; Department of Plastic and Reconstructive Surgery, Guangdong Second Provincial General Hospital, Guangzhou City, Guangdong Province, China. FAU - Hong, Wei-Jin AU - Hong WJ AD - Department of Plastic and Reconstructive Surgery, Guangdong Second Provincial General Hospital, Guangzhou City, Guangdong Province, China. FAU - Guo, Xiao-Liang AU - Guo XL AD - Department of Plastic and Reconstructive Surgery, Guangdong Second Provincial General Hospital, Guangzhou City, Guangdong Province, China. FAU - Li, Xin-Rui AU - Li XR AD - Department of Plastic and Reconstructive Surgery, Guangdong Second Provincial General Hospital, Guangzhou City, Guangdong Province, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou City, Guangdong Province, China. FAU - Jiang, Xuan-Yu AU - Jiang XY AD - Jinan University, Guangzhou City, Guangdong Province, China; Department of Plastic and Reconstructive Surgery, Guangdong Second Provincial General Hospital, Guangzhou City, Guangdong Province, China. FAU - Jiang, Yu AU - Jiang Y AD - Department of Anesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou City, Guangdong Province, China. FAU - Luo, Sheng-Kang AU - Luo SK AD - Department of Plastic and Reconstructive Surgery, Guangdong Second Provincial General Hospital, Guangzhou City, Guangdong Province, China; Jinan University, Guangzhou City, Guangdong Province, China. Electronic address: luoshk@gd2h.org.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20221019 PL - United States TA - Clin Breast Cancer JT - Clinical breast cancer JID - 100898731 RN - 0 (Analgesics) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery/etiology MH - Postoperative Nausea and Vomiting/etiology/surgery MH - Mastectomy/adverse effects MH - Analgesics MH - Pain, Postoperative/etiology/prevention & control OTO - NOTNLM OT - Breast surgery OT - Multimodal analgesia OT - Pectoral nerve block OT - Perioperative pain OT - Regional anesthesia EDAT- 2022/11/11 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/10 22:05 PHST- 2022/03/29 00:00 [received] PHST- 2022/10/10 00:00 [revised] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/10 22:05 [entrez] AID - S1526-8209(22)00231-2 [pii] AID - 10.1016/j.clbc.2022.10.009 [doi] PST - ppublish SO - Clin Breast Cancer. 2023 Jan;23(1):e1-e13. doi: 10.1016/j.clbc.2022.10.009. Epub 2022 Oct 19. PMID- 36565894 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 181 DP - 2023 Jan TI - Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives. PG - 103900 LID - S1040-8428(22)00324-9 [pii] LID - 10.1016/j.critrevonc.2022.103900 [doi] AB - Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, it has been proposed as a logical alternative to NACT in patients with HR+/HER2- BC candidate to a neoadjuvant approach. Nevertheless, potential barriers to the widespread use of NET include the heterogeneous nature of patient response coupled with the long duration needed to achieve a clinical response. However, interest in NET has significantly increased in the last decade, owing to more in-depth investigation of several biomarkers for a more adequate patient selection and on-treatment benefit monitoring, such as PEPI score, Ki67 and genomic assays. This review is intended to describe the state-of-the-art regarding NET, its future perspectives and potential integration with molecular biomarkers for the optimal selection of patients, regimen and duration of (neo)adjuvant treatments. CI - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Sirico, Marianna AU - Sirico M AD - Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Virga, Alessandra AU - Virga A AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Conte, Benedetta AU - Conte B AD - Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. FAU - Urbini, Milena AU - Urbini M AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Ulivi, Paola AU - Ulivi P AD - Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Gianni, Caterina AU - Gianni C AD - Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Merloni, Filippo AU - Merloni F AD - Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Palleschi, Michela AU - Palleschi M AD - Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Gasperoni, Marco AU - Gasperoni M AD - Breast Surgery Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy. FAU - Curcio, Annalisa AU - Curcio A AD - Breast Surgery Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy. FAU - Saha, Debjani AU - Saha D AD - Department of Surgery and Cancer, Imperial College London, London, UK. FAU - Buono, Giuseppe AU - Buono G AD - Department of Breast and Thoracic Oncology, National Cancer Institute, Fondazione G. Pascale, Naples, Italy. FAU - Muñoz, Montserrat AU - Muñoz M AD - Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Faculty of Medicine, University of Barcelona, Barcelona, Spain. FAU - De Giorgi, Ugo AU - De Giorgi U AD - Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Schettini, Francesco AU - Schettini F AD - Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Faculty of Medicine, University of Barcelona, Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20221221 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Neoadjuvant Therapy MH - *Breast Neoplasms/genetics MH - Mastectomy MH - Chemotherapy, Adjuvant MH - Receptor, ErbB-2 MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use OTO - NOTNLM OT - Biomarker OT - Breast cancer OT - Endocrine receptor OT - Endocrine therapy OT - Ki67 OT - Neoadjuvant therapy COIS- Declaration of Competing Interest MP, received advisory board fees from Novartis. GB received honoraria or speaker’s fee from Novartis, GSK, Eli-Lilly, Pfizer, Astra-Zeneca, Roche and Genetic Spa. UDG received honoraria for advisory boards or invited speaker fees from Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Novartis, Roche, Clovis, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche. The other authors declare no conflict of interests. EDAT- 2022/12/25 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/24 19:15 PHST- 2022/05/02 00:00 [received] PHST- 2022/12/16 00:00 [revised] PHST- 2022/12/19 00:00 [accepted] PHST- 2022/12/25 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/24 19:15 [entrez] AID - S1040-8428(22)00324-9 [pii] AID - 10.1016/j.critrevonc.2022.103900 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2023 Jan;181:103900. doi: 10.1016/j.critrevonc.2022.103900. Epub 2022 Dec 21. PMID- 36661710 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 1 DP - 2023 Jan 6 TI - Caregiving and Shared Decision Making in Breast and Prostate Cancer Patients: A Systematic Review. PG - 803-823 LID - 10.3390/curroncol30010061 [doi] AB - BACKGROUND: A cancer diagnosis can impact patients' and caregivers' lives, posing different challenging situations. In particular, breast cancer and prostate cancer are two types of cancer involving families and especially spouses in challenges linked with the diagnosis and treatment process. Caregivers are usually involved in the treatment decision-making (TDM) process concerning patients' clinical pathway, cancer treatment, and ongoing therapies. To date, no contributions provide an exhaustive overview of the role of caregivers in cancer care and their involvement in the TDM process related to the therapies. METHODS: We performed a systematic review of caregiver and patients experiences and perceptions of caregiver involvement in cancer TDM. Articles were searched on Public/Publisher MEDLINE (PubMed), Excerpta Medica Database (Embase), Medical Literature Analysis and Retrieval System Online (Medline), and American Psychological Association APA PsycINFO. RESULTS: 17 studies were included, 10 on prostate cancer and 7 on breast cancer. According to the reviewed studies, patients and caregivers experienced the cancer diagnosis with a sense of unity. Most patients preferred to have an active or collaborative role with caregivers in TDM, feeling it was important to consult or share the decision made with their caregivers. Caregivers preferred to collaborate with patients or let patients decide by themselves after considering their opinions. Caregiver involvement could have a positive influence on the patient's medical decisions, even if cancer diagnosis and treatments overwhelmed patients and caregivers. CONCLUSIONS: These findings highlight the importance of using a perspective that focuses on the relationship between a patient and caregivers when they receive a cancer diagnosis and have to make a treatment decision. Targeting caregiver-patient dyads, rather than individuals, is important since a supported relationship could have a protective effect on psychological distress, quality of life (QOL), and relationship satisfaction. Moreover, dyads may benefit from interventions that focus on the needs of both the patient and caregiver. FAU - Cincidda, Clizia AU - Cincidda C AUID- ORCID: 0000-0002-1967-9565 AD - Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, 20141 Milano, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milano, Italy. FAU - Pizzoli, Silvia Francesca Maria AU - Pizzoli SFM AUID- ORCID: 0000-0001-9378-8447 AD - Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milano, Italy. FAU - Ongaro, Giulia AU - Ongaro G AUID- ORCID: 0000-0003-1287-4015 AD - Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, 20141 Milano, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milano, Italy. FAU - Oliveri, Serena AU - Oliveri S AD - Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, 20141 Milano, Italy. FAU - Pravettoni, Gabriella AU - Pravettoni G AD - Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, 20141 Milano, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milano, Italy. LA - eng GR - none/The present work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5 x 1000 funds for IEO European Institute of Oncology IRCSS./ PT - Journal Article PT - Review PT - Systematic Review DEP - 20230106 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM MH - Male MH - Humans MH - Quality of Life MH - Decision Making, Shared MH - *Prostatic Neoplasms/therapy MH - *Breast Neoplasms/therapy PMC - PMC9857468 OTO - NOTNLM OT - breast cancer OT - caregivers OT - decision-making OT - prostate cancer COIS- The authors declare no conflict of interest. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 09:35 PHST- 2022/11/21 00:00 [received] PHST- 2022/12/20 00:00 [revised] PHST- 2023/01/04 00:00 [accepted] PHST- 2023/01/20 09:35 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - curroncol30010061 [pii] AID - curroncol-30-00061 [pii] AID - 10.3390/curroncol30010061 [doi] PST - epublish SO - Curr Oncol. 2023 Jan 6;30(1):803-823. doi: 10.3390/curroncol30010061. PMID- 36561309 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1177-8881 (Electronic) IS - 1177-8881 (Linking) VI - 16 DP - 2022 TI - Effects of the Different Doses of Esketamine on Postoperative Quality of Recovery in Patients Undergoing Modified Radical Mastectomy: A Randomized, Double-Blind, Controlled Trial. PG - 4291-4299 LID - 10.2147/DDDT.S392784 [doi] AB - PURPOSE: This study aims to investigate the effects of the different doses of esketamine on postoperative quality of recovery in patients undergoing modified radical mastectomy. METHODS: Ninety-nine female patients were randomly allocated to three groups: the low-dose esketamine group (group E(1)) (0.5 mg/kg loading, 2 µg/kg/h infusion), the high-dose esketamine group (group E(2)) (0.5 mg/kg loading, 4 µg/kg/h infusion), the control group (group C) (received normal saline). The primary outcome was the quality of recovery-15 (QoR-15) scores on postoperative day 1 (POD1) and days 3 (POD3). The secondary outcomes were the sleep quality scores on POD1, bispectral index (BIS) value at 10, 30, and 60 min after operation, numeric rating scale (NRS) pain scores within 24 h after surgery, nausea, vomiting, drowsiness, nightmare, and intraoperative awareness. RESULTS: The total QoR-15 scores were higher in group E(1) and group E(2) than in group C on POD1 and POD3 (P<0.05). The sleep quality scores on POD1 and BIS value at 10, 30, and 60 min after operation were higher in group E(1) and group E(2) than in group C (P<0.05). The NRS pain scores at 2, 4 and 6 h after surgery in group E(1) and at 2, 4, 6, 12 and 24 h after surgery in group E(2) were lower than in group C (P<0.05). The NRS pain scores at 6, 12 and 24 h after surgery in group E(2) were lower than in group E(1) (P<0.05). The incidence of drowsiness was higher in group E(1) and group E(2) than in group C (P<0.05). CONCLUSION: Esketamine infusion improved to some extent the quality of recovery on POD1 and POD3 in patients undergoing modified radical mastectomy, especially 4 µg/kg/h esketamine was better, but the BIS value and incidence of drowsiness were significantly increased. CI - © 2022 Zhu et al. FAU - Zhu, Min AU - Zhu M AD - Department of Anesthesiology, The Anqing Medical Center of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Anqing, People's Republic of China. FAU - Xu, Siqi AU - Xu S AD - Department of Anesthesiology, The Anqing Medical Center of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Anqing, People's Republic of China. FAU - Ju, Xia AU - Ju X AD - Department of Anesthesiology, The Anqing Medical Center of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Anqing, People's Republic of China. FAU - Wang, Shengbin AU - Wang S AD - Department of Anesthesiology, The Anqing Medical Center of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Anqing, People's Republic of China. FAU - Yu, Xitong AU - Yu X AD - Department of Anesthesiology, The Anqing Medical Center of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Anqing, People's Republic of China. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20221216 PL - New Zealand TA - Drug Des Devel Ther JT - Drug design, development and therapy JID - 101475745 RN - 50LFG02TXD (Esketamine) SB - IM MH - Humans MH - Female MH - *Mastectomy, Modified Radical MH - *Breast Neoplasms/drug therapy/surgery MH - Mastectomy MH - Pain, Postoperative/epidemiology MH - Double-Blind Method PMC - PMC9766490 OTO - NOTNLM OT - esketamine OT - postoperative quality of recovery OT - radical mastectomy COIS- The authors report no conflicts of interest in this work. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 02:22 PHST- 2022/10/09 00:00 [received] PHST- 2022/12/07 00:00 [accepted] PHST- 2022/12/23 02:22 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - 392784 [pii] AID - 10.2147/DDDT.S392784 [doi] PST - epublish SO - Drug Des Devel Ther. 2022 Dec 16;16:4291-4299. doi: 10.2147/DDDT.S392784. eCollection 2022. PMID- 36446254 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1532-1967 (Electronic) IS - 0305-7372 (Linking) VI - 112 DP - 2023 Jan TI - Targeting NaPi2b in ovarian cancer. PG - 102489 LID - S0305-7372(22)00158-X [pii] LID - 10.1016/j.ctrv.2022.102489 [doi] AB - Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment options are limited, particularly in the platinum-resistant setting. NaPi2b is a cell surface sodium-dependent phosphate transporter that regulates phosphate homeostasis under normal physiological conditions and is a lineage marker that is expressed in select cancers, including ovarian, lung, thyroid, and breast cancers, with limited expression in normal tissues. Based on its increased expression in ovarian tumors, NaPi2b is a promising candidate to be studied as a biomarker for treatment and patient selection in ovarian cancer. In preclinical studies, the use of antibodies against NaPi2b showed that this protein can be exploited for tumor mapping and therapeutic targeting. Emerging data from phase 1 and 2 clinical trials in ovarian cancer have suggested that NaPi2b can be successfully detected in patient biopsy samples using immunohistochemistry, and the NaPi2b-targeting antibody-drug conjugate under evaluation appeared to elicit therapeutic responses. The aim of this review is to examine literature supporting NaPi2b as a novel biomarker for potential treatment and patient selection in ovarian cancer and to discuss the critical next steps and future analyses necessary to drive the study of this biomarker and therapeutic targeting forward. CI - Copyright © 2022. Published by Elsevier Ltd. FAU - Banerjee, Susana AU - Banerjee S AD - Royal Marsden NHS Foundation Trust, London, United Kingdom. Electronic address: susana.banerjee@rmh.nhs.uk. FAU - Drapkin, Ronny AU - Drapkin R AD - Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: rdrapkin@pennmedicine.upenn.edu. FAU - Richardson, Debra L AU - Richardson DL AD - Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: debra-richardson@ouhsc.edu. FAU - Birrer, Michael AU - Birrer M AD - Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, United States. Electronic address: mjbirrer@uams.edu. LA - eng PT - Journal Article PT - Review DEP - 20221114 PL - Netherlands TA - Cancer Treat Rev JT - Cancer treatment reviews JID - 7502030 RN - 0 (Biomarkers) RN - 0 (Immunoconjugates) RN - 49DFR088MY (Platinum) SB - IM MH - Humans MH - Female MH - *Ovarian Neoplasms/drug therapy/pathology MH - Immunohistochemistry MH - *Breast Neoplasms/drug therapy MH - Biomarkers MH - *Immunoconjugates/therapeutic use MH - Platinum OTO - NOTNLM OT - Antibody-drug conjugate OT - Biomarker OT - Ovarian cancer COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [S. Banerjee: research funding: AstraZeneca, GlaxoSmithKline, Verastem; advisory boards: Amgen, AstraZeneca, GlaxoSmithKline, Immunogen, Merck & Co., Mersana, Novartis, OncXerna, Regeneron, Seagen, Shattuck; honoraria: Amgen, AstraZeneca, Clovis, GlaxoSmithKline, Immunogen, Merck & Co., Mersana, Pfizer, Roche, Takeda; stock or other ownership: Perci Health. R. Drapkin: advisory boards: Repare Therapeutics and VOC Health, Inc. D. Richardson: Consultancy/advisory role with Mersana, AstraZeneca, Genentech, GlaxoSmithKline, Immunogen, and Deciphera; research funding from GlaxoSmithKline, Celsion, Roche, Aravive, Shattuck, Mersana, Syros, Arch Oncology, Harpoon, Hookipa, Clovis, and Karyopharm. M. Birrer: advisory boards: AstraZeneca, Merck.]. EDAT- 2022/11/30 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/11/29 18:19 PHST- 2022/10/13 00:00 [received] PHST- 2022/11/08 00:00 [revised] PHST- 2022/11/09 00:00 [accepted] PHST- 2022/11/30 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/29 18:19 [entrez] AID - S0305-7372(22)00158-X [pii] AID - 10.1016/j.ctrv.2022.102489 [doi] PST - ppublish SO - Cancer Treat Rev. 2023 Jan;112:102489. doi: 10.1016/j.ctrv.2022.102489. Epub 2022 Nov 14. PMID- 36672769 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 14 IP - 1 DP - 2022 Dec 22 TI - Identifying Associations between DCE-MRI Radiomic Features and Expression Heterogeneity of Hallmark Pathways in Breast Cancer: A Multi-Center Radiogenomic Study. LID - 10.3390/genes14010028 [doi] LID - 28 AB - BACKGROUND: To investigate the relationship between dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) radiomic features and the expression activity of hallmark pathways and to develop prediction models of pathway-level heterogeneity for breast cancer (BC) patients. METHODS: Two radiogenomic cohorts were analyzed (n = 246). Tumor regions were segmented semiautomatically, and 174 imaging features were extracted. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were performed to identify significant imaging-pathway associations. Random forest regression was used to predict pathway enrichment scores. Five-fold cross-validation and grid search were used to determine the optimal preprocessing operation and hyperparameters. RESULTS: We identified 43 pathways, and 101 radiomic features were significantly related in the discovery cohort (p-value < 0.05). The imaging features of the tumor shape and mid-to-late post-contrast stages showed more transcriptional connections. Ten pathways relevant to functions such as cell cycle showed a high correlation with imaging in both cohorts. The prediction model for the mTORC1 signaling pathway achieved the best performance with the mean absolute errors (MAEs) of 27.29 and 28.61% in internal and external test sets, respectively. CONCLUSIONS: The DCE-MRI features were associated with hallmark activities and may improve individualized medicine for BC by noninvasively predicting pathway-level heterogeneity. FAU - Ming, Wenlong AU - Ming W AD - State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. AD - Division of Medical Image Computing, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. FAU - Zhu, Yanhui AU - Zhu Y AD - Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China. FAU - Li, Fuyu AU - Li F AD - State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. FAU - Bai, Yunfei AU - Bai Y AUID- ORCID: 0000-0002-4088-4117 AD - State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. FAU - Gu, Wanjun AU - Gu W AD - State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. AD - Collaborative Innovation Center of Jiangsu Province of Cancer Prevention and Treatment of Chinese Medicine, School of Artificial Intelligence and Information Technology, Nanjing University of Chinese Medicine, Nanjing 210023, China. FAU - Liu, Yun AU - Liu Y AD - Department of Information, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China. FAU - Sun, Xiao AU - Sun X AUID- ORCID: 0000-0003-1048-7775 AD - State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. FAU - Liu, Xiaoan AU - Liu X AD - Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China. FAU - Liu, Hongde AU - Liu H AUID- ORCID: 0000-0001-8768-764X AD - State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. LA - eng GR - 81830053/National Natural Science Foundation of China/ GR - 61972084/National Natural Science Foundation of China/ GR - 61871121/National Natural Science Foundation of China/ PT - Journal Article PT - Multicenter Study DEP - 20221222 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - 0 (Contrast Media) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/genetics/pathology MH - Contrast Media MH - Magnetic Resonance Imaging/methods PMC - PMC9858814 OTO - NOTNLM OT - DCE-MRI OT - association analysis OT - breast cancer OT - machine learning OT - pathway OT - radiogenomics OT - radiomics COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:14 PHST- 2022/11/03 00:00 [received] PHST- 2022/12/12 00:00 [revised] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/21 01:14 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - genes14010028 [pii] AID - genes-14-00028 [pii] AID - 10.3390/genes14010028 [doi] PST - epublish SO - Genes (Basel). 2022 Dec 22;14(1):28. doi: 10.3390/genes14010028. PMID- 36136295 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230103 IS - 1543-2165 (Electronic) IS - 0003-9985 (Linking) VI - 147 IP - 1 DP - 2023 Jan 1 TI - Molecular Classification of Breast Cancer: Relevance and Challenges. PG - 46-51 LID - 10.5858/arpa.2022-0070-RA [doi] AB - CONTEXT.—: Appropriate patient management requires precise and meaningful tumor classification. Breast cancer classification continues to evolve from traditional morphologic evaluation to more sophisticated systems with the integration of new knowledge from research being translated into practice. Breast cancer is heterogeneous at the molecular level, with diversified patterns of gene expression, which is presumably responsible for the difference in tumor behavior and prognosis. Since the beginning of this century, new molecular technology has been gradually applied to breast cancer research on issues pertinent to prognosis (prognostic signature) and therapeutic prediction (predictive signature), and much progress has been made. OBJECTIVE.—: To summarize the current state and the prospective future of molecular classification of breast cancer. DATA SOURCES.—: Sources include recent medical literature on molecular classification of breast cancer. CONCLUSIONS.—: Identification of intrinsic tumor subtypes has set a foundation for refining the breast cancer molecular classification. Studies have explored the genetic features within the intrinsic cancer subtypes and have identified novel molecular targets that led to the innovation of clinical assays to predict a patient's prognosis and to provide specific guidelines for therapeutic decisions. With the development and implication of these molecular tools, we have remarkably advanced our knowledge and enhanced our power to provide optimal management to patients. However, challenges still exist. Besides accurate prediction of prognosis, we are still in urgent need of more molecular predictors for tumor response to therapeutic regimes. Further exploration along this path will be critical for improving a patient's prognosis. CI - © 2023 College of American Pathologists. FAU - Zhang, Xinmin AU - Zhang X AD - From the Department of Pathology, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, New Jersey. LA - eng PT - Journal Article PL - United States TA - Arch Pathol Lab Med JT - Archives of pathology & laboratory medicine JID - 7607091 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/genetics/drug therapy MH - Prognosis MH - Gene Expression Profiling EDAT- 2022/09/23 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/09/22 11:22 PHST- 2022/05/04 00:00 [accepted] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/09/22 11:22 [entrez] AID - 486473 [pii] AID - 10.5858/arpa.2022-0070-RA [doi] PST - ppublish SO - Arch Pathol Lab Med. 2023 Jan 1;147(1):46-51. doi: 10.5858/arpa.2022-0070-RA. PMID- 36468340 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1099-1611 (Electronic) IS - 1057-9249 (Linking) VI - 32 IP - 1 DP - 2023 Jan TI - Global Breast Cancer Initiative: A platform to address the psycho-oncology of cancer in low- and middle-income countries for improving global breast cancer outcomes. PG - 6-9 LID - 10.1002/pon.5969 [doi] AB - BACKGROUND: Psycho-oncology is a clinical specialty in which the humanistic aspects of cancer diagnoses and treatment are addressed to reduce the psychological burden for patients and their caregivers to optimize patient participation, cancer outcomes and quality-of-life, which is especially critical in cultures where cancer is perceived as invariably fatal. Psycho-oncology programs face multiple barriers in low- and middle-income countries, including limited resource allocation and lack of training, both of which have been impediments to psycho-oncology programs becoming recognized as core competencies in cancer management and part of a standard medical curriculum. PURPOSE: This paper discusses the role of the Global Breast Cancer Initiative (GBCI) in helping to overcome inequities in breast cancer care and improve clinical outcomes from a psycho-oncology perspective as a model for improved cancer care in limited resource settings. FINDINGS: GBCI applies a comprehensive framework encompassing all phases of cancer care (defined through three pillars spanning the continuum of cancer management) and includes addressing the physical, psychological, and social needs of women throughout the life-course. Efforts to promote policies that increase access to early detection and treatment programs and improve health literacy among the public are important strategies to mitigate the most common emotional and physical challenges reported by people with cancer accessing care. CONCLUSIONS: Future efforts will focus on the integration of culturally appropriate guidance to promote early cancer detection and treatment completion through training programs for clinicians to establish core competencies in psycho-oncology. Emerging advocacy efforts in the oncology arena may help guide the integration of psycho-oncology services into routine care in countries where these services are not already integrated into the standard curriculum. CI - © 2022 John Wiley & Sons Ltd. FAU - Bergerot, Cristiane Decat AU - Bergerot CD AD - Centro de Câncer de Brasília, Instituto Unity de Ensino e Pesquisa, Brasília, Distrito Federal, Brazil. FAU - Dizon, Don S AU - Dizon DS AD - Brown University, Lifespan Cancer Institute, Providence, Rhode Island, USA. FAU - Ilbawi, Andre M AU - Ilbawi AM AD - Department of Noncommunicable Diseases, World Health Organization (WHO), Geneva, Switzerland. FAU - Anderson, Benjamin O AU - Anderson BO AD - Department of Noncommunicable Diseases, World Health Organization (WHO), Geneva, Switzerland. AD - Departments of Surgery and Global Health-Medicine, University of Washington, Seattle, Washington, USA. LA - eng PT - Editorial DEP - 20221205 PL - England TA - Psychooncology JT - Psycho-oncology JID - 9214524 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy MH - Psycho-Oncology MH - Developing Countries MH - Medical Oncology MH - Quality of Life OTO - NOTNLM OT - advocacy OT - breast cancer OT - cancer fatalism OT - culturally appropriate guidance OT - health literacy OT - inequities in cancer care OT - low- and middle-income countries OT - oncology OT - psycho-oncology EDAT- 2022/12/06 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/12/05 04:49 PHST- 2022/12/06 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/12/05 04:49 [entrez] AID - 10.1002/pon.5969 [doi] PST - ppublish SO - Psychooncology. 2023 Jan;32(1):6-9. doi: 10.1002/pon.5969. Epub 2022 Dec 5. PMID- 36566189 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 22 IP - 1 DP - 2022 Dec 24 TI - Finding My Way-Advanced: can a web-based psychosocial intervention improve the mental quality of life for women with metastatic breast cancer vs attention-control? Study protocol of a randomised controlled trial. PG - 1353 LID - 10.1186/s12885-022-10410-z [doi] LID - 1353 AB - BACKGROUND: Women living with metastatic breast cancer (MBC) are at risk of significantly impaired quality of life (QOL), symptom burden, distress and fear of progression, and unmet needs, yet they face barriers to accessing evidence-based psychosocial treatments. Our group therefore developed Finding My Way-Advanced (FMW-A), a web-based self-guided psychosocial program for women with MBC. This study aims to assess its efficacy in improving mental and other QOL domains, distress, fear of progression, unmet needs, and health service utilisation. METHODS: The multi-site randomised controlled trial (RCT) will enrol 370 Australian participants. Eligible participants are adult (18 years +) women diagnosed with MBC, with a life expectancy of 6 months or more, with sufficient English-language literacy to provide informed consent. Participants will be identified, screened and referred from one of 10 Australian sites, or via self-referral in response to advertisements. Participants complete four online questionnaires: prior to accessing their program ('baseline'), 6 weeks later ('post-intervention'), then 3 months and 6 months post-intervention. Consenting participants will be randomised to either FMW-A (intervention), or Breast Cancer Network Australia's (BCNA) online/app resource My Journey (minimal intervention attention-control). This is a single-blind study, with randomisation computer-generated and stratified by site. FMW-A is a 6-module program addressing some of the most common issues experienced by women with MBC, with BCNA control resources integrated within the 'resources' section. All modules are immediately accessible, with an additional booster module released 10 weeks later. The primary outcome is mental QOL; statistical criteria for superiority is defined as a 4-point difference between groups at post-treatment. Secondary outcomes include other QOL domains, distress, fear of progression, health service use, intervention adherence, and user satisfaction. DISCUSSION: This will be the first adequately powered RCT of a self-directed online intervention for women with MBC. If efficacious, FMW-A will help address two national key priorities for management of MBC - enhancing QOL and reducing symptom burden. FMW-A has the potential to address unmet needs and overcome access barriers for this overlooked population, while reducing health system burden. TRIAL REGISTRATION: The study was registered prospectively with the ANZCTR on 29/10/2021. Trial ID ACTRN12621001482853p.  https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382714&isReview=true. CI - © 2022. The Author(s). FAU - Beatty, Lisa AU - Beatty L AUID- ORCID: 0000-0001-8847-8452 AD - Flinders University, Adelaide, Australia. lisa.beatty@flinders.edu.au. FAU - Kemp, Emma AU - Kemp E AD - Flinders University, Adelaide, Australia. FAU - Butow, Phyllis AU - Butow P AD - University of Sydney, Sydney, Australia. FAU - Girgis, Afaf AU - Girgis A AD - University of NSW, Sydney, Australia. FAU - Hulbert-Williams, Nicholas AU - Hulbert-Williams N AD - Edge Hill University, Ormskirk, UK. FAU - Kaambwa, Billingsley AU - Kaambwa B AD - Flinders University, Adelaide, Australia. FAU - Schofield, Penelope AU - Schofield P AD - Swinburne University, Melbourne, Australia. AD - Peter MacCallum Cancer Centre, Melbourne, Australia. FAU - Turner, Jane AU - Turner J AD - University of Queensland, St Lucia, Australia. FAU - Woodman, Richard AU - Woodman R AD - Flinders University, Adelaide, Australia. FAU - Boyle, Frances AU - Boyle F AD - Mater, Sydney, Australia. FAU - Daly, Anthony AU - Daly A AD - Cancer Council South Australia, Adelaide, Australia. FAU - Jones, Amanda AU - Jones A AD - Southern Adelaide Local Health Network, Bedford Park, Australia. FAU - Kiely, Belinda AU - Kiely B AD - Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, Australia. FAU - Zdenkowski, Nicholas AU - Zdenkowski N AD - University of Newcastle, Newcastle, Australia. CN - FMW-A Authorship Group FAU - Koczwara, Bogda AU - Koczwara B AD - Flinders University, Adelaide, Australia. AD - Southern Adelaide Local Health Network, Bedford Park, Australia. LA - eng GR - 2000514/Cancer Australia/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20221224 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adult MH - Female MH - Humans MH - *Internet-Based Intervention MH - Psychosocial Intervention MH - Australia MH - *Breast Neoplasms/therapy MH - Quality of Life/psychology MH - Randomized Controlled Trials as Topic PMC - PMC9789659 OTO - NOTNLM OT - CBT OT - Digital health OT - Distress OT - Intervention OT - Metastatic breast cancer OT - Psycho-oncology OT - QOL OT - RCT COIS- The authors declare that they have no competing interests. EDAT- 2022/12/25 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/24 23:14 PHST- 2022/10/06 00:00 [received] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/24 23:14 [entrez] PHST- 2022/12/25 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - 10.1186/s12885-022-10410-z [pii] AID - 10410 [pii] AID - 10.1186/s12885-022-10410-z [doi] PST - epublish SO - BMC Cancer. 2022 Dec 24;22(1):1353. doi: 10.1186/s12885-022-10410-z. PMID- 36587198 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 22 IP - 1 DP - 2022 Dec 31 TI - Health system barriers influencing timely breast cancer diagnosis and treatment among women in low and middle-income Asian countries: evidence from a mixed-methods systematic review. PG - 1601 LID - 10.1186/s12913-022-08927-x [doi] LID - 1601 AB - BACKGROUND: Globally, breast cancer is the most common cancer type and the leading cause of cancer mortality among women in developing countries. A high prevalence of late breast cancer diagnosis and treatment has been reported predominantly in Low- and Middle-Income Countries (LMICs), including those in Asia. Thus, this study utilized a mixed-methods systematic review to synthesize the health system barriers influencing timely breast cancer diagnosis and treatment among women in Asian countries. METHODS: We systematically searched five electronic databases for studies published in English from 2012 to 2022 on health system barriers that influence timely breast cancer diagnosis and treatment among women in Asian countries. The review was conducted per the methodology for systematic reviews and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, while health system barriers were extracted and classified based on the World Health Organization (WHO)'s Health Systems Framework. The mixed-methods appraisal tool was used to assess the methodological quality of the included studies. RESULTS: Twenty-six studies were included in this review. Fifteen studies were quantitative, nine studies were qualitative, and two studies used a mixed-methods approach. These studies were conducted across ten countries in Asia. This review identified health systems barriers that influence timely breast cancer diagnosis and treatment. The factors were categorized under the following: (1) delivery of health services (2) health workforce (3) financing for health (4) health information system and (5) essential medicines and technology. Delivery of health care (low quality of health care) was the most occurring barrier followed by the health workforce (unavailability of physicians), whilst health information systems were identified as the least barrier. CONCLUSION: This study concluded that health system factors such as geographical accessibility to treatment, misdiagnosis, and long waiting times at health facilities were major barriers to early breast cancer diagnosis and treatment among Asian women in LMICs. Eliminating these barriers will require deliberate health system strengthening, such as improving training for the health workforce and establishing more healthcare facilities. CI - © 2022. The Author(s). FAU - Afaya, Agani AU - Afaya A AUID- ORCID: 0000-0002-7918-2999 AD - Mo-Im Nursing Research Institute, College of Nursing, Yonsei University, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. AD - Department of Nursing, School of Nursing and Midwifery, University of Health and Allied Sciences, Ho, Ghana. FAU - Ramazanu, Sheena AU - Ramazanu S AUID- ORCID: 0000-0002-8526-5352 AD - Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Bolarinwa, Obasanjo Afolabi AU - Bolarinwa OA AUID- ORCID: 0000-0002-9208-6408 AD - Department of Global Public Health, Canterbury Christ Church University, Canterbury, UK. FAU - Yakong, Vida Nyagre AU - Yakong VN AUID- ORCID: 0000-0001-8014-2989 AD - Department of Preventive Health Nursing, School of Nursing and Midwifery, University for Development Studies, Tamale, Ghana. FAU - Afaya, Richard Adongo AU - Afaya RA AUID- ORCID: 0000-0003-4616-7642 AD - Department of Midwifery and Women's Health, School of Nursing and Midwifery, University for Development Studies, Tamale, Ghana. FAU - Aboagye, Richard Gyan AU - Aboagye RG AUID- ORCID: 0000-0002-3498-2909 AD - Department of Family and Community Health, Fred N. Binka School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana. FAU - Daniels-Donkor, Silas Selorm AU - Daniels-Donkor SS AD - Department of Nursing, School of Health Sciences, University of Dundee, Scotland, Dundee, UK. FAU - Yahaya, Ahmed-Rufai AU - Yahaya AR AD - Hariri School of Nursing, American University of Beruit, Beirut, Lebanon. AD - Department of Internal Medicine, Tamale Teaching Hospital, Tamale, Ghana. FAU - Shin, Jinhee AU - Shin J AUID- ORCID: 0000-0001-5715-3815 AD - Woosuk University, College of Nursing, Wanju, Republic of Korea. jini2112@yonsei.ac.kr. FAU - Dzomeku, Veronica Millicent AU - Dzomeku VM AUID- ORCID: 0000-0003-0568-5910 AD - Department of Nursing, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. FAU - Ayanore, Martin Amogre AU - Ayanore MA AUID- ORCID: 0000-0002-4095-3047 AD - Department of Health Policy Planning and Management, Fred N. Binka School of Public Health, University of Health and Allied Sciences, Ho, Ghana. FAU - Alhassan, Robert Kaba AU - Alhassan RK AUID- ORCID: 0000-0003-4227-4854 AD - Centre for Health Policy and Implementation Research. Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana. LA - eng PT - Journal Article PT - Systematic Review DEP - 20221231 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Female MH - Humans MH - *Developing Countries MH - *Breast Neoplasms/diagnosis/therapy MH - Delivery of Health Care MH - Health Facilities MH - Asia PMC - PMC9805268 OTO - NOTNLM OT - Asia OT - Barriers OT - Breast cancer OT - Health systems COIS- The authors declare that they have no competing interests. EDAT- 2023/01/01 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/31 23:54 PHST- 2022/06/11 00:00 [received] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/31 23:54 [entrez] PHST- 2023/01/01 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 10.1186/s12913-022-08927-x [pii] AID - 8927 [pii] AID - 10.1186/s12913-022-08927-x [doi] PST - epublish SO - BMC Health Serv Res. 2022 Dec 31;22(1):1601. doi: 10.1186/s12913-022-08927-x. PMID- 36635998 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 2224-5839 (Electronic) IS - 2224-5820 (Linking) VI - 11 IP - 12 DP - 2022 Dec TI - Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis. PG - 3727-3742 LID - 10.21037/apm-22-1306 [doi] AB - BACKGROUND: In previous studies on the application of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in advanced breast cancer, the outcomes of overall survival (OS) were inconsistent. This systematic review and meta-analysis aimed to further evaluate the clinical efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy on patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. METHODS: Randomized controlled trials (RCTs) comparing CDK4/6 inhibitors plus endocrine therapy and endocrine therapy alone in patients with HR-positive and HER2-negative advanced breast cancer were searched in the databases of PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), WANFANG and China Science and Technology Journal Database (VIP) up to November 2022. Hazard ratios (HRs) and confidence intervals (CI) of OS, progression-free survival (PFS), the time from randomization to the first recorded disease progression while the patient was receiving next-line therapy or death from any cause (PFS2), time to first subsequent chemotherapy after discontinuation (TTC), and objective response rate (ORR), clinical benefit rate (CBR), safety indicators were extracted. Stata 14.0 software was used for meta analysis and the Cochrane risk-of-bias tool 2.0 was used to evaluate the bias risk. RESULTS: A total of 9 RCTs with 4,920 participants were included. The addition of CDK4/6 inhibitors to endocrine therapy significantly prolonged OS (HR 0.76; 95% CI: 0.69-0.84; P<0.001), regardless of the application in first-line and second-line treatment, compared with endocrine therapy alone. Similar benefit was observed in PFS (HR 0.56; 95% CI: 0.52-0.60; P<0.001). Moreover, the CDK4/6 inhibitors group improved results of ORR [relative risk (RR) 1.43; 95% CI: 1.27-1.62; P<0.001], CBR (RR 1.24; 95% CI: 1.08-1.41; P<0.01 and RR 1.11; 95% CI: 1.06-1.18; P<0.001), PFS2 (HR 0.68; 95% CI: 0.60-0.76; P<0.001) and TTC (HR 0.65; 95% CI: 0.58-0.72; P<0.001). One of the included RCTs had performance bias. Publication bias was not significant. CONCLUSIONS: CDK4/6 inhibitors combined with endocrine therapy effectively prolong OS, PFS, PFS2, and TTC, and also improve ORR and CBR in patients with HR-positive, HER2-negative advanced breast cancer, and the safety was within the controllable range. FAU - Dai, Qiuying AU - Dai Q AD - Department of Breast Surgery, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Wang, Yongling AU - Wang Y AD - Department of Traditional Chinese Medicine, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Liao, Mingjuan AU - Liao M AD - Department of Traditional Chinese Medicine, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. FAU - Chen, Hongfeng AU - Chen H AD - Department of Breast Surgery, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - China TA - Ann Palliat Med JT - Annals of palliative medicine JID - 101585484 RN - EC 2.7.11.22 (CDK4 protein, human) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 4) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 6) RN - 0 (Protein Kinase Inhibitors) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy MH - *Cyclin-Dependent Kinase 4/antagonists & inhibitors MH - *Cyclin-Dependent Kinase 6/antagonists & inhibitors MH - Progression-Free Survival MH - Treatment Outcome MH - *Protein Kinase Inhibitors/therapeutic use OTO - NOTNLM OT - Advanced breast cancer OT - CDK4/6 inhibitors OT - endocrine therapy OT - meta-analysis EDAT- 2023/01/14 06:00 MHDA- 2023/01/17 06:00 CRDT- 2023/01/13 01:52 PHST- 2022/10/20 00:00 [received] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/13 01:52 [entrez] PHST- 2023/01/14 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] AID - 10.21037/apm-22-1306 [doi] PST - ppublish SO - Ann Palliat Med. 2022 Dec;11(12):3727-3742. doi: 10.21037/apm-22-1306. PMID- 36577958 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230104 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 22 IP - 1 DP - 2022 Dec 28 TI - Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial. PG - 1357 LID - 10.1186/s12885-022-10439-0 [doi] LID - 1357 AB - PURPOSE: The combination of taxanes and anthracyclines is still the mainstay of chemotherapy for early breast cancer. Capecitabine is an active drug with a favorable toxicity profile, showing strong anti-tumor activity against metastatic breast cancer. This trial assessed the efficacy and safety of the TX regimen (docetaxel and capecitabine) and compared it with the TE (docetaxel and epirubicin) regimen in locally advanced or high risk early HER2-negative breast cancer. PATIENTS AND METHODS: This randomized clinical trial was conducted at five academic centers in China. Eligible female patients were randomly assigned (1:1) to the TX (docetaxel 75 mg/m(2) d1 plus capecitabine 1000 mg/m(2) twice d1-14, q3w) or TE (docetaxel 75 mg/m(2) d1 plus epirubicin 75 mg/m(2) d1, q3w) groups for four cycles. The primary endpoint was a pathological complete response in the breast (pCR). Secondary endpoints included pCR in the breast and axilla, invasive disease-free survival (iDFS), overall survival (OS), and safety. RESULTS: Between September 1, 2012, and December 31, 2018, 113 HER2-negative patients were randomly assigned to the study groups (TX: n = 54; TE: n = 59). In the primary endpoint analysis, 14 patients in the TX group achieved a pCR, and nine patients in the TE group achieved a pCR (25.9% vs. 15.3%), with a not significant difference of 10.6% (95% CI -6.0-27.3%; P = 0.241). In a subgroup with high Ki-67 score, TX increased the pCR rate by 24.2% (95% CI 2.2-46.1%; P = 0.029). At the end of the 69-month median follow-up period, both groups had equivalent iDFS and OS rates. TX was associated with a higher incidence of hand-foot syndrome and less alopecia, with a manageable toxicity profile. CONCLUSION: The anthracycline-free TX regimen yielded comparable pCR and long-term survival rates to the TE regimen. Thus, this anthracycline-free regimen could be considered in selected patients. TRIAL REGISTRATION: ACTRN12613000206729 on 21/02/2013, retrospectively registered. CI - © 2022. The Author(s). FAU - Yang, Houpu AU - Yang H AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Xu, Ling AU - Xu L AD - Breast Disease Center, Peking University First Hospital, Beijing, China. FAU - Guan, Shan AU - Guan S AD - Department of Breast Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. FAU - Hao, Xiaopeng AU - Hao X AD - Department of General Surgery, First Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Ge, Zhicheng AU - Ge Z AD - Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China. FAU - Tong, Fuzhong AU - Tong F AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Cao, Yingming AU - Cao Y AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Liu, Peng AU - Liu P AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Zhou, Bo AU - Zhou B AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Cheng, Lin AU - Cheng L AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Liu, Miao AU - Liu M AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Liu, Hongjun AU - Liu H AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Xie, Fei AU - Xie F AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Wang, Siyuan AU - Wang S AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Peng, Yuan AU - Peng Y AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Wang, Chaobin AU - Wang C AD - Peking University People's Hospital Breast Center, Beijing, China. FAU - Wang, Shu AU - Wang S AD - Peking University People's Hospital Breast Center, Beijing, China. shuwang@pkuph.edu.cn. LA - eng PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial DEP - 20221228 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Anthracyclines) RN - 6804DJ8Z9U (Capecitabine) RN - 8N3DW7272P (Cyclophosphamide) RN - 15H5577CQD (Docetaxel) RN - 3Z8479ZZ5X (Epirubicin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Female MH - Humans MH - Anthracyclines/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - *Breast Neoplasms/drug therapy/pathology MH - Capecitabine/adverse effects MH - Cyclophosphamide/therapeutic use MH - Docetaxel/therapeutic use MH - Epirubicin/adverse effects MH - Fluorouracil/adverse effects MH - *Neoadjuvant Therapy MH - Treatment Outcome PMC - PMC9795638 OTO - NOTNLM OT - Anthracycline OT - Breast neoplasms OT - Capecitabine OT - Neoadjuvant therapy OT - Taxane COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/12/29 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/12/28 23:38 PHST- 2022/09/12 00:00 [received] PHST- 2022/12/12 00:00 [accepted] PHST- 2022/12/28 23:38 [entrez] PHST- 2022/12/29 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] AID - 10.1186/s12885-022-10439-0 [pii] AID - 10439 [pii] AID - 10.1186/s12885-022-10439-0 [doi] PST - epublish SO - BMC Cancer. 2022 Dec 28;22(1):1357. doi: 10.1186/s12885-022-10439-0. PMID- 36356839 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1873-4332 (Electronic) IS - 1083-3188 (Linking) VI - 36 IP - 1 DP - 2023 Feb TI - Pediatric and Adolescent Breast Conditions: A Review. PG - 5-13 LID - S1083-3188(22)00335-7 [pii] LID - 10.1016/j.jpag.2022.11.001 [doi] AB - Breast conditions in pediatric and adolescent patients vary from benign congenital changes to pathological findings. Although most breast conditions are benign, there are rare cases of malignancy that are important to identify during development. As such, it is critical to understand the classification and management of the different pediatric and adolescent breast conditions that might present to clinicians who care for pediatric and adolescent patients. In this review, congenital, benign, and malignant pediatric/adolescent breast conditions are discussed. CI - Copyright © 2022. Published by Elsevier Inc. FAU - Adekeye, Adeseye AU - Adekeye A AD - Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: Adeseye.Adekeye@jefferson.edu. FAU - Lung, Kirsten C AU - Lung KC AD - Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania. FAU - Brill, Kristin L AU - Brill KL AD - Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania. LA - eng PT - Journal Article PT - Review DEP - 20221108 PL - United States TA - J Pediatr Adolesc Gynecol JT - Journal of pediatric and adolescent gynecology JID - 9610774 SB - IM MH - Child MH - Humans MH - Adolescent MH - Female MH - Breast/pathology MH - *Breast Diseases/diagnosis/therapy MH - Syndrome MH - *Breast Neoplasms/diagnosis/therapy/pathology MH - Retrospective Studies OTO - NOTNLM OT - Adolescent breast disorders OT - Pediatric breast disorders OT - Young female breast conditions COIS- Conflict of Interest Statement None. EDAT- 2022/11/11 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/11/10 19:27 PHST- 2022/05/16 00:00 [received] PHST- 2022/10/14 00:00 [revised] PHST- 2022/11/04 00:00 [accepted] PHST- 2022/11/11 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/11/10 19:27 [entrez] AID - S1083-3188(22)00335-7 [pii] AID - 10.1016/j.jpag.2022.11.001 [doi] PST - ppublish SO - J Pediatr Adolesc Gynecol. 2023 Feb;36(1):5-13. doi: 10.1016/j.jpag.2022.11.001. Epub 2022 Nov 8. PMID- 36581983 OWN - NLM STAT- MEDLINE DCOM- 20230102 LR - 20230103 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 9 DP - 2022 Sep 1 TI - Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial. PG - e062034 LID - 10.1136/bmjopen-2022-062034 [doi] LID - e062034 AB - INTRODUCTION: Short course regimen has become the major trend in the field of adjuvant radiotherapy for patients with breast cancer. Hypofractionated radiotherapy (HF-RT) regimen of 40-42.5 Gy in 15-16 fractions has been established as a preferred option for whole breast irradiation. However, few evidences of hypofractionated regional nodal irradiation (RNI), especially involving internal mammary nodes (IMNs), could be available during the era of intensity-modulated radiation therapy (IMRT). Against this background, we design this trial to explore the hypothesis that HF-RT regimen involving RNI (including infraclavicular, supraclavicular nodes and IMNs) will be non-inferior to a standard schedule by using IMRT technique. METHODS AND ANALYSIS: This is an open-label randomised, non-inferior, multicentre phase III trial. Patients with breast cancer with an indication for RNI after breast conserving surgery or mastectomy are randomised at a ratio of 1:1 into the following two groups: hypofractionated regimen of 2.67 Gy for 16 fractions or conventional regimen of 2 Gy for 25 fractions. The dose was prescribed to ipsilateral chest wall or whole breast and RNI (including infraclavicular, supraclavicular nodes and IMNs, lower axilla if indicated). The trial plans to enrol a total of 801 patients and all patients will be treated using IMRT technique. The primary endpoint is 5-year locoregional recurrence. The secondary endpoints include 5-year distant metastasis free survival, invasive recurrence-free survival, overall survival, accumulative acute radiation-induced toxicity and accumulative late radiation-induced toxicity, cosmetic outcomes and quality of life. ETHICS AND DISSEMINATION: The study has been approved by the Ethical Committee of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine (version 2018-95-3) and approvals from ethical committee of each participating centre have also been obtained. Research findings will be submitted for publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT03829553. CI - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Xie, Jinrong AU - Xie J AUID- ORCID: 0000-0002-4025-7367 AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Xu, Feifei AU - Xu F AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Zhao, Yutian AU - Zhao Y AD - Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China. FAU - Cai, Gang AU - Cai G AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Lin, Xiao AU - Lin X AD - Yat-Sen Breast Tumor Hospital, Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China. FAU - Zhu, Qiwei AU - Zhu Q AD - Department of Radiation Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China. FAU - Lin, Qing AU - Lin Q AD - Department of Radiation Oncology, Shanghai Tenth People's Hospital, Shanghai, Shanghai, China. FAU - Yao, Yuan AU - Yao Y AD - Department of Radiation Oncology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, Shanghai, Shanghai, China. FAU - Xu, Cheng AU - Xu C AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Cai, Rong AU - Cai R AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Wang, Shubei AU - Wang S AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Tang, Xiaolu AU - Tang X AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Chen, Chuying AU - Chen C AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Zheng, Siyue AU - Zheng S AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Chen, Mei AU - Chen M AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Chen, Min AU - Chen M AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Qian, Xiaofang AU - Qian X AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Shen, Chunhong AU - Shen C AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Li, Jian AU - Li J AD - Clinical Research Centre, Ruijin Hospital, Shanghai Jiaotong university School of Medicine, Shanghai, Shanghai, China. FAU - Xu, Haoping AU - Xu H AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Xu, Fei AU - Xu F AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Han, Yimin AU - Han Y AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Li, Min AU - Li M AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Ou, Dan AU - Ou D AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Shen, Kun Wei AU - Shen KW AD - Department of General Surgery, Comprehensive Breast Health Centre, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China. FAU - Qi, Wei-Xiang AU - Qi WX AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Cao, Lu AU - Cao L AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China. FAU - Huang, Xiaobo AU - Huang X AD - Yat-Sen Breast Tumor Hospital, Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China. AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China. AD - Department of Radiation Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China. FAU - Chen, Jiayi AU - Chen J AD - Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, Shanghai, China cjy11756@rjh.com.cn. LA - eng SI - ClinicalTrials.gov/NCT03829553 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220901 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Adjuvants, Immunologic) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/radiotherapy/surgery MH - Mastectomy MH - *Radiotherapy, Intensity-Modulated/adverse effects/methods MH - Quality of Life MH - Neoplasm Recurrence, Local/pathology MH - China MH - *Radiation Injuries/etiology MH - Adjuvants, Immunologic MH - Radiotherapy, Adjuvant MH - Randomized Controlled Trials as Topic MH - Multicenter Studies as Topic MH - Clinical Trials, Phase III as Topic PMC - PMC9438188 OTO - NOTNLM OT - Adult radiotherapy OT - Breast tumours OT - Radiation oncology COIS- Competing interests: None declared. EDAT- 2022/12/30 06:00 MHDA- 2023/01/03 06:00 CRDT- 2022/12/29 23:44 PHST- 2022/12/29 23:44 [entrez] PHST- 2022/12/30 06:00 [pubmed] PHST- 2023/01/03 06:00 [medline] AID - bmjopen-2022-062034 [pii] AID - 10.1136/bmjopen-2022-062034 [doi] PST - epublish SO - BMJ Open. 2022 Sep 1;12(9):e062034. doi: 10.1136/bmjopen-2022-062034. PMID- 36223695 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study. PG - 110-117 LID - S0960-9776(22)00167-9 [pii] LID - 10.1016/j.breast.2022.10.002 [doi] AB - BACKGROUND: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into the thigh compared to the intravenous formulation. Other body regions for injection have not been investigated but might be more convenient for patients. METHODS: After surgery, patients were randomised to receive either subcutaneous trastuzumab into the thigh or into the abdominal wall (AW). Patient preferences were evaluated using validated questionnaires (PINT). Primary objectives of this multicentre, non-blinded, randomised substudy of the GAIN-2 study were to investigate pharmacokinetics of the injection into the thigh versus AW and to determine patients' preferences of either administration site versus the previously received intravenous application. RESULTS: 226 patients were randomised and 219 patients (thigh: N = 110; AW: N = 109) formed the modified intent-to-treat (mITT). Overall, 83.5% (out of N = 182 with information about patients' preference) preferred subcutaneous over previous intravenous application or had no preference. Preference was similar between both administration sites (thigh: 80.6%; AW: 86.5; p = 0.322). Pharmacokinetic analysis included 30 patients. Geometric means of C(max) and AUC(0-21d) were higher in thigh than in AW group (geometric mean ratio with body weight adjustment: C(max): 1.291, 90%-CI 1.052-1.584; AUC(0-21d): 1.291, 90%-CI 1.026-1.626). Safety profile was in line with previous reports of subcutaneous trastuzumab. CONCLUSION: Subcutaneous trastuzumab into the thigh showed an approximately 30% higher bioavailability. Injections were well tolerated and preferred over intravenous administration. The subcutaneous injection into the thigh should remain the standard of care. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Reinisch, Mattea AU - Reinisch M AD - Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany. FAU - Untch, Michael AU - Untch M AD - Department of Gynaecology and Obstetrics, Breast Cancer and Gynecologic Oncology Center, HELIOS Klinikum Berlin Buch, Germany. FAU - Mahlberg, Rolf AU - Mahlberg R AD - Klinikum Mutterhaus der Borromäerinnen, Trier, Germany. FAU - Reimer, Toralf AU - Reimer T AD - Universitätsfrauenklinik und Poliklinik Am Klinikum Südstadt Rostock, Germany. FAU - Hitschold, Thomas AU - Hitschold T AD - Klinikum Worms, Frauenklinik, Germany. FAU - Marmé, Frederik AU - Marmé F AD - Department of Gynaecology and Obstetrics, University Hospital Mannheim, Germany. FAU - Aydogdu, Mustafa AU - Aydogdu M AD - Klinikum Bremen-Mitte, Frauenklinik, Germany. FAU - Schmatloch, Sabine AU - Schmatloch S AD - Elisabeth Krankenhaus Kassel, Brustzentrum, Germany. FAU - Lück, Hans-Joachim AU - Lück HJ AD - Gynaecologic Oncology Practice, Hannover, Germany. FAU - Schmidt, Marcus AU - Schmidt M AD - Department of Obstetrics and Gynaecology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. FAU - Ladda, Ekkehart AU - Ladda E AD - Onkologische Praxis Neumarkt, Germany. FAU - Sinn, Bruno Valentin AU - Sinn BV AD - Department of Pathology, Charité-Universitätsmedizin Berlin, Germany. FAU - Klare, Peter AU - Klare P AD - Praxisklinik Krebsheilkunde für Frauen Berlin, Germany. FAU - Janni, Wolfgang AU - Janni W AD - Uniklinikum Ulm, Germany. FAU - Jackisch, Christian AU - Jackisch C AD - Sana Klinikum Offenbach, Germany. FAU - Denkert, Carsten AU - Denkert C AD - Institute of Pathology Philipps-University Marburg, Germany. FAU - Seiler, Sabine AU - Seiler S AD - German Breast Group, Neu-Isenburg, Germany. FAU - Göhler, Thomas AU - Göhler T AD - Fachärzte für Innere Medizin, Hämatologie und Internistische Onkologie, Onkozentrum Dresden, Germany. FAU - Michel, Laura AU - Michel L AD - National Center for Tumour Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany. FAU - Burchardi, Nicole AU - Burchardi N AD - German Breast Group, Neu-Isenburg, Germany. FAU - Stickeler, Elmar AU - Stickeler E AD - Universitätsklinikum RWTH Aachen, Germany. FAU - Rey, Julia AU - Rey J AD - German Breast Group, Neu-Isenburg, Germany. FAU - Klutinus, Nicole AU - Klutinus N AD - HELIOS Klinikum Pforzheim GmbH Brustzentrum, Pforzheim, Germany. FAU - Möbus, Volker AU - Möbus V AD - Department of Medicine II, Haematology & Oncology, University of Frankfurt, Germany. FAU - Loibl, Sibylle AU - Loibl S AD - German Breast Group, Neu-Isenburg, Germany. Electronic address: sibylle.loibl@gbg.de. LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20221005 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - P188ANX8CK (Trastuzumab) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - Trastuzumab/therapeutic use MH - *Breast Neoplasms/drug therapy/chemically induced MH - Patient Preference MH - Thigh MH - *Abdominal Wall MH - Injections, Subcutaneous MH - Receptor, ErbB-2 MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use PMC - PMC9563210 OTO - NOTNLM OT - Breast cancer OT - Pharmacokinetic OT - Safety OT - Thigh or abdominal wall OT - Trastuzumab subcutaneous OT - patients' preference COIS- Declaration of competing interest MR reports travel support from AstraZeneca, Celgene, Daiichi Sankyo, Lilly, MSD, Novartis, Pfizer, Seagen, Somatex and Roche. MU reports personal fees for lectures and/or consultancy from Abbvie, Amgen, Astra Zeneca, BMS, Celgene, Daiji Sankyo, Gilead, GSK, Lilly, MSD Merck, Mundipharma, Myriad Genetics, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi Aventis, Saegen. MS reports personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work. Institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and SeaGen; has a patent for EP2390370 B1 issued and a patent for EP2951317 B1issued. SL reports other from Amgen, other from BMS, grants and other from Celgene, grants, non-financial support and other from Roche, during the conduct of the study; grants and other from Abbvie, grants and other from AstraZeneca, other from Eirgenix, other from GSK, grants, non-financial support and other from Gilead, other from Lilly, other from Merck, grants, non-financial support and other from Novartis, grants, non-financial support and other from Pfizer, other from Pierre Fabre, non-financial support and other from Seagen, grants, non-financial support and other from Daiichi-Sankyo, other from Sanofi, outside the submitted work; In addition; has a patent EP14153692.0 pending, a patent EP21152186.9 pending, a patent EP15702464.7 issued, a patent EP19808852.8 pending, and a patent Digital Ki67 Evaluator with royalties paid. ES reports honoraria from Pfizer, Roche, AstraZeneca, MSD, Gilead, Daiichi-Sankyo, Novartis, Seagen, Lilly, Pierre Fabre. SaS reports grants and non-financial support from F. Hoffman-La Roche, grants from BMS (Celgene), Amgen, during the conduct of the study; personal fees from Abbvie, outside the submitted work. CJ reports Honoraria from Amgen, AstraZeneca, Roche, Lilly, Novartis, Pfizer, Exact Sciences, Pierre-Fabré, Molecular Health. FM reports personal fees from Roche, AstraZeneca, Pfizer, Tesaro, Novartis, Amgen, PharmaMar, GenomicHealth, CureVac, EISAI outside the submitted work. CD reports stock and other ownership interest from Sividon Diagnostics (until 2016); consulting or advisor role from MSD Oncology, Daiichi Sankyo, Molecular Health, AstraZeneca, Merck, Roche, Lilly; research funding from Myriad Genetics, Roche; patents, royalties or other intellectual property from VMScope digital pathology software, patent applications WO2015114146A1 and WO2010076322A1-therapy response, patent application WO2020109570A1-immunotherapy. No other potential conflict of interest relevant to this article was reported. EDAT- 2022/10/13 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/12 18:16 PHST- 2022/08/04 00:00 [received] PHST- 2022/09/29 00:00 [revised] PHST- 2022/10/04 00:00 [accepted] PHST- 2022/10/13 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/12 18:16 [entrez] AID - S0960-9776(22)00167-9 [pii] AID - 10.1016/j.breast.2022.10.002 [doi] PST - ppublish SO - Breast. 2022 Dec;66:110-117. doi: 10.1016/j.breast.2022.10.002. Epub 2022 Oct 5. PMID- 36547151 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230112 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 29 IP - 12 DP - 2022 Nov 30 TI - Controlateral Symmetrisation in SRM for Breast Cancer: Now or Then? Immediate versus Delayed Symmetrisation in a Two-Stage Breast Reconstruction. PG - 9391-9400 LID - 10.3390/curroncol29120737 [doi] AB - Introduction: The timing of contralateral symmetrisation in patients with large and ptotic breasts undergoing a unilateral skin-reducing mastectomy (SRM) is one of the most debated topics in the reconstructive field. There is no evidence to support the advantage of immediate or delayed symmetrisation to help surgeons with this decision. The aim of this study was to investigate the clinical and aesthetic outcomes of immediate symmetrisation. Methods: A randomised observational study was conducted on patients who underwent an SRM for unilateral breast cancer. Based on a simple randomisation list, patients were divided into two groups: a delayed symmetrisation group versus an immediate symmetrisation group. The postoperative complications, BREAST-Q outcomes and reoperations were compared. Results: Out of a total of 84 patients undergoing an SRM between January 2018 and January 2021, 42 patients underwent immediate symmetrisation and 42 patients had delayed symmetrisation. Three implant losses (7.2%) were observed and we reported three wound dehiscences; one of these was in a contralateral breast reconstruction in the immediate symmetrisation group. The BREAST-Q patient-reported outcome measures recorded better aesthetic outcomes and a high patient satisfaction for the immediate symmetrisation group. Conclusions: Simultaneous controlateral symmetrisation is a good alternative to achieve better satisfaction and quality of life for patients; from a surgical point of view, it does not excessively impact on the second time of reconstruction. FAU - Casella, Donato AU - Casella D AD - Department of Medicine, Surgery and Neurosciences, Unit of Breast Cancer Surgery, University of Siena, 53100 Siena, Italy. FAU - Fusario, Daniele AU - Fusario D AUID- ORCID: 0000-0002-2804-2814 AD - Department of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, 53100 Siena, Italy. FAU - Cassetti, Dario AU - Cassetti D AD - Unit of General Surgery, USL Toscana Sud-Est, Valdarno Hospital Santa Maria alla Gruccia, 52025 Arezzo, Italy. FAU - Pesce, Anna Lisa AU - Pesce AL AD - Department of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, 53100 Siena, Italy. FAU - De Luca, Alessandro AU - De Luca A AUID- ORCID: 0000-0003-0897-3547 AD - Department of Surgery, Sapienza Università di Roma, 00185 Rome, Italy. FAU - Guerra, Maristella AU - Guerra M AD - Unit of Plastica Surgery, Polo Ospedaliero Santo Spirito ASL/RME, 00193 Rome, Italy. FAU - Cuomo, Roberto AU - Cuomo R AUID- ORCID: 0000-0002-8396-095X AD - Department of Medicine, Surgery and Neurosciences, Unit of Plastic and Reconstructive Surgery, University of Siena, 53100 Siena, Italy. FAU - Ribuffo, Diego AU - Ribuffo D AD - Department of Plastic Reconstructive and Aesthetic Surgery, Sapienza Università di Roma, 00185 Rome, Italy. FAU - Neri, Alessandro AU - Neri A AD - Unit of Breast Surgery, USL Toscana Sud-Est, San Donato Hospital, 52100 Arezzo, Italy. FAU - Marcasciano, Marco AU - Marcasciano M AD - Unit of Plastic and Reconstructive Surgery, University of Catanzaro "Magna Graecia", 88100 Catanzaro, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20221130 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery/complications MH - Mastectomy/adverse effects MH - Quality of Life MH - *Mammaplasty/adverse effects MH - Patient Satisfaction MH - Postoperative Complications/etiology PMC - PMC9777212 OTO - NOTNLM OT - breast reconstruction OT - controlateral breast symmetrisation OT - implant-based breast reconstruction OT - skin-reducing mastectomy OT - subcutaneous implant positioning COIS- Author Donato Casella has received a speaker honorarium from Pfm Medical and TiLOOP Bra manufacturing company. The other authors declare that they have no conflict of interest. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 09:54 PHST- 2022/11/14 00:00 [received] PHST- 2022/11/24 00:00 [revised] PHST- 2022/11/27 00:00 [accepted] PHST- 2022/12/22 09:54 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - curroncol29120737 [pii] AID - curroncol-29-00737 [pii] AID - 10.3390/curroncol29120737 [doi] PST - epublish SO - Curr Oncol. 2022 Nov 30;29(12):9391-9400. doi: 10.3390/curroncol29120737. PMID- 36240525 OWN - NLM STAT- MEDLINE DCOM- 20221228 LR - 20221228 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscope for intraoperative margin assessment - POLARHIS study. PG - 118-125 LID - S0960-9776(22)00168-0 [pii] LID - 10.1016/j.breast.2022.10.003 [doi] AB - INTRODUCTION: Breast-conserving surgery (BCS) in case of breast cancer and/or in-situ-carcinoma lesions (DCIS) intends to completely remove breast cancer while saving healthy tissue as much as possible to achieve better aesthetic and psychological outcomes for the patient. Such modality should result in postoperative tumor-free margins of the surgical resection in order to carry on with the next therapeutical steps of the patient care. However, 10-40% of patients undergo more than one procedure to achieve acceptable cancer-negative margins. A 2nd operation or further operation (re-operation) has physical, psychological, and economic consequences. It also delays the administration of adjuvant therapy, and has been associated with an elevated risk of local and distant disease relapse. In addition, a high re-operation rate can have significant economic effects - both for the service provider and for the payer. A more efficient intraoperative assessment of the margin may address these issues. Recently, a large field-of-view confocal laser scanning microscope designed to allow real-time intraoperative margin assessment has arrived on the market - the Histolog Scanner. In this paper, we present the first evaluation of lumpectomy margins assessment with this new device. MATERIALS AND METHODS: 40 consecutive patients undergoing BCS with invasive and/or DCIS were included. The whole surface of the surgical specimens was imaged right after the operation using the Histolog Scanner (HLS). The assessment of all the specimen margins was performed intraoperatively according to the standard-of-care of the center which consists of combined ultrasound (IOUS) and/or conventional specimen radiography (CSR), and gross surgical inspection. Margin assessment on HLS images was blindly performed after the surgery by 5 surgeons and one pathologist. The capabilities to correctly determine margin status in HLS images was compared to the final histopathological assessment. Furthermore, the potential reduction of positive-margin and re-operation rates by utilization of the HLS were extrapolated. RESULTS: The study population included 7/40 patients with DCIS (17.5%), 17/40 patients with DCIS and invasive ductal cancer (IDC NST) (42.5%), 10/40 patients with IDC NST (25%), 4/40 with invasive lobular cancer (ILC) (10%), and 1/40 patients with a mix of IDC NST, DCIS, and ILC. Clinical routine resulted in 13 patients with positive margins identified by final histopathological assessment, resulting in 12 re-operations (30% re-operation rate). Amongst these 12 patients, 10 had DCIS components involved in their margin, confirming the importance of improving the detection accuracy of this specific lesion. Surgeons, who were given a short familiarization on HLS images, and a pathologist were able to detect positive margins in 4/12 and 7/12 patients (33% and 58%), respectively, that were missed by the intraoperative standard of care. In addition, a retrospective analysis of the HLS images revealed that cancer lesions can be identified in 9/12 (75%) patients with positive margins. CONCLUSION: The present study presents that breast cancer can be detected by surgeons and pathologists in HLS images of lumpectomy margins leading to a potential reduction of 30% and 75% of the re-operations. The Histolog Scanner is easily inserted into the clinical workflow and has the potential to improve the intraoperative standard-of-care for the assessment of breast conserving treatments. In addition, it has the potential to increase oncological safety and cosmetics by avoiding subsequent resections and can also have a significant positive economic effect for service providers and cost bearers. The data presented in this study will have to be further confirmed in a prospective phase-III-trial. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Sandor, Mariana-Felicia AU - Sandor MF AD - Department of Gynecology and Obstetrics, Women's Hospital St. Louise, Paderborn, Women's Hospital, St. Josefs, Salzkotten, St. Vincenz-Krankenhaus GmbH, Husener Str. 81, 33098, Paderborn, Germany. FAU - Schwalbach, Beatrice AU - Schwalbach B AD - Department of Gynecology and Obstetrics, Women's Hospital St. Louise, Paderborn, Women's Hospital, St. Josefs, Salzkotten, St. Vincenz-Krankenhaus GmbH, Husener Str. 81, 33098, Paderborn, Germany. FAU - Hofmann, Viktoria AU - Hofmann V AD - Department of Gynecology and Obstetrics, Women's Hospital St. Louise, Paderborn, Women's Hospital, St. Josefs, Salzkotten, St. Vincenz-Krankenhaus GmbH, Husener Str. 81, 33098, Paderborn, Germany. FAU - Istrate, Simona-Elena AU - Istrate SE AD - Department of Gynecology and Obstetrics, Women's Hospital St. Louise, Paderborn, Women's Hospital, St. Josefs, Salzkotten, St. Vincenz-Krankenhaus GmbH, Husener Str. 81, 33098, Paderborn, Germany. FAU - Schuller, Zlatna AU - Schuller Z AD - Department of Gynecology and Obstetrics, Women's Hospital St. Louise, Paderborn, Women's Hospital, St. Josefs, Salzkotten, St. Vincenz-Krankenhaus GmbH, Husener Str. 81, 33098, Paderborn, Germany. FAU - Ionescu, Elena AU - Ionescu E AD - Department of Gynecology and Obstetrics, Women's Hospital St. Louise, Paderborn, Women's Hospital, St. Josefs, Salzkotten, St. Vincenz-Krankenhaus GmbH, Husener Str. 81, 33098, Paderborn, Germany. FAU - Heimann, Sara AU - Heimann S AD - Department of Gynecology and Obstetrics, Women's Hospital St. Louise, Paderborn, Women's Hospital, St. Josefs, Salzkotten, St. Vincenz-Krankenhaus GmbH, Husener Str. 81, 33098, Paderborn, Germany. FAU - Ragazzi, Moira AU - Ragazzi M AD - Pathology Unit, Azienda USL - IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy. FAU - Lux, Michael P AU - Lux MP AD - Department of Gynecology and Obstetrics, Women's Hospital St. Louise, Paderborn, Women's Hospital, St. Josefs, Salzkotten, St. Vincenz-Krankenhaus GmbH, Husener Str. 81, 33098, Paderborn, Germany. Electronic address: m.lux@vincenz.de. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20221005 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/diagnostic imaging/surgery/pathology MH - *Carcinoma, Ductal, Breast/diagnostic imaging/surgery/pathology MH - *Carcinoma, Intraductal, Noninfiltrating/diagnostic imaging/surgery/pathology MH - Lasers MH - Margins of Excision MH - Mastectomy, Segmental/methods MH - Neoplasm Recurrence, Local/pathology MH - Prospective Studies MH - Reoperation MH - Retrospective Studies PMC - PMC9574757 OTO - NOTNLM OT - Breast conserving surgery OT - Confocal microscopy OT - Ductal carcinoma in-situ OT - Fresh tissue imaging OT - Histolog scanner OT - Re-excision COIS- Declaration of competing interest M.P. Lux has received honoraria from AstraZeneca, Daiichi-Sankyo Eisai, Exact Sciences, Gilead, Grünenthal, Lilly, medac, MSD, Novartis, Pfizer, pfm, PharmaMar, Pierre-Fabre, Roche, Samantree and Sysmex for advisory boards, lectures, and travel support. M.F. Sandor received travel expenses by Samantree. Other authors have no conflicts of interest. EDAT- 2022/10/15 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/10/14 18:13 PHST- 2022/06/24 00:00 [received] PHST- 2022/09/23 00:00 [revised] PHST- 2022/10/04 00:00 [accepted] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/10/14 18:13 [entrez] AID - S0960-9776(22)00168-0 [pii] AID - 10.1016/j.breast.2022.10.003 [doi] PST - ppublish SO - Breast. 2022 Dec;66:118-125. doi: 10.1016/j.breast.2022.10.003. Epub 2022 Oct 5. PMID- 36661681 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 1 DP - 2022 Dec 27 TI - Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy? PG - 392-400 LID - 10.3390/curroncol30010032 [doi] AB - Omission of radiotherapy among older women taking 5 years of adjuvant endocrine therapy following breast conserving surgery for early-stage, hormone sensitive breast cancers is well-studied. However, endocrine therapy toxicities are significant, and many women have difficulty tolerating endocrine therapy, particularly elderly patients with comorbidities. Omission of endocrine therapy among women receiving adjuvant radiation is less well-studied, but available randomized and non-randomized data suggest that this approach may confer equivalent local control and survival for select patients. Herein we review available randomized and non-randomized outcome data for women treated with radiation monotherapy and emphasize the need for future prospective, randomized studies of endocrine therapy omission. FAU - McDuff, Susan G R AU - McDuff SGR AD - Department of Radiation Oncology, Duke Cancer Center, Durham, NC 27710, USA. FAU - Blitzblau, Rachel C AU - Blitzblau RC AD - Department of Radiation Oncology, Duke Cancer Center, Durham, NC 27710, USA. LA - eng PT - Journal Article PT - Review DEP - 20221227 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM MH - Humans MH - Female MH - Aged MH - *Breast Neoplasms/drug therapy MH - Combined Modality Therapy MH - Radiotherapy, Adjuvant PMC - PMC9857309 OTO - NOTNLM OT - breast cancer OT - endocrine therapy OT - radiotherapy COIS- The authors declare no conflict of interest. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 09:34 PHST- 2022/11/14 00:00 [received] PHST- 2022/12/16 00:00 [revised] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/20 09:34 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - curroncol30010032 [pii] AID - curroncol-30-00032 [pii] AID - 10.3390/curroncol30010032 [doi] PST - epublish SO - Curr Oncol. 2022 Dec 27;30(1):392-400. doi: 10.3390/curroncol30010032. PMID- 36305556 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1099-1611 (Electronic) IS - 1057-9249 (Linking) VI - 32 IP - 1 DP - 2023 Jan TI - Fear of Cancer Recurrence and associated factors among breast cancer survivors in South India. PG - 107-112 LID - 10.1002/pon.6056 [doi] AB - OBJECTIVE: Fear of Cancer Recurrence (FCR) is a universal phenomenon widely reported as an unmet need among cancer survivors. The present study aims to determine the patterns of FCR and its associated factors among breast cancer survivors in South India. METHODS: A longitudinal study was carried out with pre and post-assessment. RESULTS: Two hundred and forty eight breast cancer survivors (BCSv) were included in the study. The main finding for the pre versus post-study was the pattern of mean scores. It is observed that in all factors, the pre-mean scores were steadily higher than the post-mean scores the predictors for FCR scores were decrease of age (p = 0.016), BCSv living in joint family (p = 0.008) and who were self-funded (p = 0.031). CONCLUSIONS: FCR was a relatively common symptom reported by BCSv. The predictors for FCR were younger age, BCSv living in a joint family and who were self-funding for their treatment. In the pre and post-assessment, it could be concluded that BCSv has reported that the overall FCR and on other variables higher FCR mean scores were reported during the preassessment period. CI - © 2022 John Wiley & Sons Ltd. FAU - Devi, Nandakumar AU - Devi N AUID- ORCID: 0000-0003-2133-7588 AD - Department of Psycho Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India. FAU - Surendran, Veeraiah AU - Surendran V AD - Department of Psycho Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India. FAU - Arvind, Krishnamurthy AU - Arvind K AD - Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India. FAU - Sridevi, Veluswami AU - Sridevi V AD - Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India. FAU - Anandi, Balasubramanian AU - Anandi B AD - Department of Radiation Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India. LA - eng PT - Journal Article DEP - 20221103 PL - England TA - Psychooncology JT - Psycho-oncology JID - 9214524 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy MH - *Cancer Survivors MH - Fear MH - Longitudinal Studies MH - Neoplasm Recurrence, Local/epidemiology OTO - NOTNLM OT - Fear of Cancer Recurrence OT - South India OT - breast cancer survivors EDAT- 2022/10/29 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/10/28 07:23 PHST- 2022/10/01 00:00 [revised] PHST- 2022/04/26 00:00 [received] PHST- 2022/10/18 00:00 [accepted] PHST- 2022/10/29 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/10/28 07:23 [entrez] AID - 10.1002/pon.6056 [doi] PST - ppublish SO - Psychooncology. 2023 Jan;32(1):107-112. doi: 10.1002/pon.6056. Epub 2022 Nov 3. PMID- 36615883 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 15 IP - 1 DP - 2023 Jan 1 TI - Dysgeusia in Patients with Breast Cancer Treated with Chemotherapy-A Narrative Review. LID - 10.3390/nu15010226 [doi] LID - 226 AB - Breast cancer (BC) is the most common cancer worldwide. Chemotherapy (CT) is essential for the treatment of BC, but is often accompanied by several side effects, including taste alterations, due to different mechanisms. Although dysgeusia is usually underestimated by clinicians, it is considered very worrying and disturbing by cancer patients undergoing CT, because it induces changes in dietary choices and social habits, affecting their physical and psychological health, with a profound impact on their quality of life. Several strategies and therapies have been proposed to prevent or alleviate CT-induced dysgeusia. This review aimed to evaluate the available evidence on prevalence, pathophysiological mechanisms, clinical consequences, and strategies for managing dysgeusia in BC patients receiving CT. We queried the National Library of Medicine, the Cochrane Library, Excerpta Medica dataBASE, and the Cumulative Index to Nursing and Allied Health Literature database, performing a search strategy using database-specific keywords. We found that the literature on this topic is scarce, methodologically limited, and highly heterogeneous in terms of study design and criteria for patient inclusion, making it difficult to obtain definitive results and make recommendations for clinical practice. FAU - Pellegrini, Marianna AU - Pellegrini M AUID- ORCID: 0000-0003-3150-8483 AD - Department of Medical Sciences, University of Torino, 10126 Torino, Italy. FAU - Merlo, Fabio Dario AU - Merlo FD AD - Dietetic and Clinical Nutrition Unit, Città della Salute e della Scienza Hospital, 10126 Torino, Italy. FAU - Agnello, Elena AU - Agnello E AD - Dietetic and Clinical Nutrition Unit, Città della Salute e della Scienza Hospital, 10126 Torino, Italy. FAU - Monge, Taira AU - Monge T AD - Dietetic and Clinical Nutrition Unit, Città della Salute e della Scienza Hospital, 10126 Torino, Italy. FAU - Devecchi, Andrea AU - Devecchi A AD - University of Gastronomic Sciences, 12042 Pollenzo, Italy. FAU - Casalone, Valentina AU - Casalone V AUID- ORCID: 0000-0003-1806-3192 AD - Clinical Nutrition and Dietetics Unit, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy. FAU - Montemurro, Filippo AU - Montemurro F AUID- ORCID: 0000-0003-4231-2291 AD - Breast Unit, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy. FAU - Ghigo, Ezio AU - Ghigo E AUID- ORCID: 0000-0002-2809-8105 AD - Department of Medical Sciences, University of Torino, 10126 Torino, Italy. FAU - Sapino, Anna AU - Sapino A AUID- ORCID: 0000-0003-3542-9571 AD - Department of Medical Sciences, University of Torino, 10126 Torino, Italy. AD - Pathology Division, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy. FAU - Bo, Simona AU - Bo S AUID- ORCID: 0000-0001-6862-8628 AD - Department of Medical Sciences, University of Torino, 10126 Torino, Italy. AD - Dietetic and Clinical Nutrition Unit, Città della Salute e della Scienza Hospital, 10126 Torino, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230101 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 SB - IM MH - Humans MH - Female MH - *Dysgeusia/chemically induced/epidemiology MH - *Breast Neoplasms/complications/drug therapy/psychology MH - Quality of Life MH - Diet PMC - PMC9823517 OTO - NOTNLM OT - breast cancer OT - chemotherapy OT - dysgeusia OT - dysosmia OT - taste alterations COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:37 PHST- 2022/11/03 00:00 [received] PHST- 2022/12/27 00:00 [revised] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/01/08 01:37 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - nu15010226 [pii] AID - nutrients-15-00226 [pii] AID - 10.3390/nu15010226 [doi] PST - epublish SO - Nutrients. 2023 Jan 1;15(1):226. doi: 10.3390/nu15010226. PMID- 36555293 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 24 DP - 2022 Dec 9 TI - NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in Breast Cancer. LID - 10.3390/ijms232415641 [doi] LID - 15641 AB - Pigment epithelium-derived factor (PEDF) protein regulates normal bone, with anti-tumour roles in bone and breast cancer (BC). Pre- and post-menopausal oestrogen levels may regulate PEDF expression and function in BC, though the mechanisms behind this remain unknown. In this study, in vitro models simulating pre- and post-menopausal bone microenvironments were used to evaluate if PEDF regulates pro-metastatic biomarker expression and downstream functional effects on BC cells. PEDF treatment reduced phosphorylated-nuclear factor-κB p65 subunit (p-NFκB-p65), tumour necrosis factor-α (TNFα), C-X-C chemokine receptor type-4 (CXCR4), and urokinase plasminogen activator receptor (uPAR) in oestrogen receptor (ER)+/human epidermal growth factor receptor-2 (HER2)- BC cells under post-menopausal oestrogen conditions. In triple negative BC (TNBC) cells, PEDF treatment reduced pNFκB-p65 and uPAR expression under pre-menopausal oestrogen conditions. A potential reciprocal regulatory axis between p-NFκB-65 and PEDF in BC was identified, which was BC subtype-specific and differentially regulated by menopausal oestrogen conditions. The effects of PEDF treatment and NFκB inhibition on BC cell function under menopausal conditions were also compared. PEDF treatment exhibited superior anti-viability effects, while combined PEDF and NFκB-p65 inhibitor treatment was superior in reducing BC cell colony formation in a subtype-specific manner. Lastly, immunohistochemical evaluation of p-NFκB-p65 and PEDF expression in human BC and bone metastases specimens revealed an inverse correlation between nuclear PEDF and NFκB expression in bone metastases. We propose that menopausal status is associated with a PEDF/NFκB reciprocal regulatory axis, which drives PEDF expression and anti-metastatic function in a subtype-specific manner. Altogether, our findings identify pre-menopausal TNBC and post-menopausal ER+/HER2- BC patients as target populations for future PEDF research. FAU - Brook, Naomi AU - Brook N AD - Curtin Medical School, Curtin University, Bentley, WA 6102, Australia. AD - Curtin Health Innovation Research Institute, Bentley, WA 6102, Australia. FAU - Gill, Jespal AU - Gill J AD - Pathwest, Fiona Stanley Hospital, Murdoch, WA 6150, Australia. FAU - Dharmarajan, Arun AU - Dharmarajan A AD - Curtin Medical School, Curtin University, Bentley, WA 6102, Australia. AD - Curtin Health Innovation Research Institute, Bentley, WA 6102, Australia. AD - Department of Biomedical Sciences, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai 600116, India. FAU - Chan, Arlene AU - Chan A AD - Curtin Medical School, Curtin University, Bentley, WA 6102, Australia. AD - Breast Cancer Research Centre-Western Australia, Hollywood Private Hospital, Nedlands, WA 6009, Australia. FAU - Dass, Crispin R AU - Dass CR AUID- ORCID: 0000-0001-7087-7957 AD - Curtin Medical School, Curtin University, Bentley, WA 6102, Australia. AD - Curtin Health Innovation Research Institute, Bentley, WA 6102, Australia. LA - eng PT - Journal Article DEP - 20221209 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (pigment epithelium-derived factor) RN - 0 (NF-kappa B) RN - 0 (Estrogens) RN - 0 (Eye Proteins) RN - 0 (Serpins) RN - 0 (Receptors, Estrogen) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - NF-kappa B/metabolism MH - *Triple Negative Breast Neoplasms/pathology MH - Postmenopause MH - Estrogens MH - Eye Proteins/genetics/metabolism MH - *Serpins/genetics/metabolism MH - Receptors, Estrogen/genetics MH - Tumor Microenvironment PMC - PMC9779285 OTO - NOTNLM OT - breast cancer OT - estrone OT - estrone sulphate OT - menopausal status OT - metastasis OT - oestradiol OT - pigment epithelium-derived factor COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:33 PHST- 2022/11/03 00:00 [received] PHST- 2022/12/02 00:00 [revised] PHST- 2022/12/04 00:00 [accepted] PHST- 2022/12/23 01:33 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - ijms232415641 [pii] AID - ijms-23-15641 [pii] AID - 10.3390/ijms232415641 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 9;23(24):15641. doi: 10.3390/ijms232415641. PMID- 36584053 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230113 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 12 DP - 2022 TI - Erector spinae plane block versus thoracic paravertebral block for the prevention of acute postsurgical pain in breast cancer surgery: A prospective observational study compared with a propensity score-matched historical cohort. PG - e0279648 LID - 10.1371/journal.pone.0279648 [doi] LID - e0279648 AB - BACKGROUND: Preventing acute postsurgical pain (PSP) following breast cancer surgery is a major issue. Thoracic paravertebral block (TPVB) has been widely studied for this indication. Erector spinae plane block (ESPB) has been assumed to be effective. We aimed to compare the efficacy and safety of ESPB over TPVB in preventing acute PSP. METHODS: In this prospective observational study, 120 patients admitted for unilateral major oncologic breast surgery received T2/T3 ESPB (ropivacaine 0.75%, 0.35 ml.kg-1), and 102 were analysed. Then, the ESPB cohort was compared to a TPVB cohort from the experimental arm of a randomized controlled study with the same protocol (NCT02408393) using propensity score matching analysis. The primary outcome was the need for morphine consumption in the PACU. Secondary outcomes were the morphine total dose, the incidence of ESPB and TPVB complications, and discontinuous visual analogue scale measurement trends at rest and at mobilization in the 24 hours after surgery. RESULTS: A total of 102 patients completed the study between December 2018 and August 2019. Propensity score matching formed 94 matched pairs. The proportion of morphine titration in the PACU was higher in the ESPB group than in the TPVB group (74.5% vs. 41.5%, p<0.001), with a between-group difference of 33.0% (95% CI [19.3%, 46.7%]). No ESPB-related complications were observed. CONCLUSION: ESPB is less effective in preventing morphine consumption in the PACU than TPVB. Our findings do not support the use of ESPB as the first-line regional anaesthesia for major breast cancer surgery. Randomized trials comparing ESPB and TPVB are needed. CI - Copyright: © 2022 Premachandra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Premachandra, Antoine AU - Premachandra A AUID- ORCID: 0000-0002-8663-2484 AD - Department of Anaesthesiology, Institut Curie, PSL Research University, Saint-Cloud, France. FAU - Wang, Xiaomeng AU - Wang X AUID- ORCID: 0000-0001-5436-5003 AD - INSERM, U900, Institut Curie, PSL Research University, Saint-Cloud, France. AD - Department of Research and Development, Sanofi, Chilly Mazarin, France. FAU - Saad, Mary AU - Saad M AUID- ORCID: 0000-0002-2918-1330 AD - Department of Anaesthesiology, Institut Curie, PSL Research University, Saint-Cloud, France. AD - INSERM, U900, Institut Curie, PSL Research University, Saint-Cloud, France. AD - Conservatoire National des Arts et Métiers, Paris, France. FAU - Moussawy, Sahar AU - Moussawy S AD - Department of Anaesthesiology, Institut Curie, PSL Research University, Saint-Cloud, France. FAU - Rouzier, Roman AU - Rouzier R AD - INSERM, U900, Institut Curie, PSL Research University, Saint-Cloud, France. AD - Department of Surgical Oncology, Centre François Baclesse, Caen, France. FAU - Latouche, Aurélien AU - Latouche A AUID- ORCID: 0000-0001-9218-0333 AD - INSERM, U900, Institut Curie, PSL Research University, Saint-Cloud, France. AD - Conservatoire National des Arts et Métiers, Paris, France. FAU - Albi-Feldzer, Aline AU - Albi-Feldzer A AD - Department of Anaesthesiology, Institut Curie, PSL Research University, Saint-Cloud, France. LA - eng PT - Journal Article PT - Observational Study PT - Randomized Controlled Trial DEP - 20221230 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 76I7G6D29C (Morphine) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery MH - Propensity Score MH - *Nerve Block MH - *Acute Pain MH - Chest Pain MH - Morphine MH - Pain, Postoperative/prevention & control PMC - PMC9803227 COIS- The authors have declared that no competing interests exist. EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 13:44 PHST- 2022/08/27 00:00 [received] PHST- 2022/12/12 00:00 [accepted] PHST- 2022/12/30 13:44 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - PONE-D-22-23785 [pii] AID - 10.1371/journal.pone.0279648 [doi] PST - epublish SO - PLoS One. 2022 Dec 30;17(12):e0279648. doi: 10.1371/journal.pone.0279648. eCollection 2022. PMID- 36628788 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230124 IS - 1873-2860 (Electronic) IS - 0933-3657 (Linking) VI - 135 DP - 2023 Jan TI - Open-set recognition of breast cancer treatments. PG - 102451 LID - S0933-3657(22)00203-2 [pii] LID - 10.1016/j.artmed.2022.102451 [doi] AB - Open-set recognition generalizes a classification task by classifying test samples as one of the known classes from training or "unknown." As novel cancer drug cocktails with improved treatment are continually discovered, classifying patients by treatments can naturally be formulated in terms of an open-set recognition problem. Drawbacks, due to modeling unknown samples during training, arise from straightforward implementations of prior work in healthcare open-set learning. Accordingly, we reframe the problem methodology and apply a recent Gaussian mixture variational autoencoder model, which achieves state-of-the-art results for image datasets, to breast cancer patient data. Not only do we obtain more accurate and robust classification results (14% average F1 increase compared to recent methods), but we also reexamine open-set recognition in terms of deployability to a clinical setting. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Cao, Alexander AU - Cao A AD - Department of Industrial Engineering and Management Sciences, Northwestern University, Evanston, IL, USA. Electronic address: a-cao@u.northwestern.edu. FAU - Klabjan, Diego AU - Klabjan D AD - Department of Industrial Engineering and Management Sciences, Northwestern University, Evanston, IL, USA. Electronic address: d-klabjan@northwestern.edu. FAU - Luo, Yuan AU - Luo Y AD - Department of Preventive Medicine, Northwestern University, Chicago, IL, USA. Electronic address: yuan.luo@northwestern.edu. LA - eng GR - T32 LM012203/LM/NLM NIH HHS/United States PT - Journal Article DEP - 20221115 PL - Netherlands TA - Artif Intell Med JT - Artificial intelligence in medicine JID - 8915031 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy MH - Image Processing, Computer-Assisted/methods MH - Learning MH - Normal Distribution MH - Neural Networks, Computer OTO - NOTNLM OT - Autoencoder OT - Breast cancer treatments OT - Deep neural networks OT - Open-set recognition COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/01/12 06:00 MHDA- 2023/01/13 06:00 CRDT- 2023/01/11 04:27 PHST- 2022/01/14 00:00 [received] PHST- 2022/11/07 00:00 [revised] PHST- 2022/11/11 00:00 [accepted] PHST- 2023/01/11 04:27 [entrez] PHST- 2023/01/12 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - S0933-3657(22)00203-2 [pii] AID - 10.1016/j.artmed.2022.102451 [doi] PST - ppublish SO - Artif Intell Med. 2023 Jan;135:102451. doi: 10.1016/j.artmed.2022.102451. Epub 2022 Nov 15. PMID- 36563600 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1532-1967 (Electronic) IS - 0305-7372 (Linking) VI - 112 DP - 2023 Jan TI - Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. PG - 102496 LID - S0305-7372(22)00172-4 [pii] LID - 10.1016/j.ctrv.2022.102496 [doi] AB - Traditionally, the classification of breast cancer relies on the expression of immunohistochemical (IHC) biomarkers readily available in clinical practice. Using highly standardized and reproducible assays across patient cohorts, intrinsic molecular subtypes of breast cancer - also called "intrinsic subtypes" (IS) - have been identified based on the expression of 50 genes. Although IHC-based subgroups and IS moderately correlate to each other, they are not superimposable. In fact, non-luminal biology has been detected in a substantial proportion (5-20%) of hormone receptor-positive (HoR+) tumors, has prognostic value, and identifies reduced and increased sensitivity to endocrine therapy and chemotherapy, respectively. During tumor progression, a shift toward a non-luminal estrogen-independent and more aggressive phenotype has been demonstrated. Intrinsic genomic instability and cell plasticity, alone or combined with external constraints deriving from treatment selective pressure or interplay with the tumor microenvironment, may represent the determinants of such biological diversity between primary and metastatic disease, and during metastatic tumor evolution. In this review, we describe the distribution and the clinical behavior of IS as the disease progresses, focusing on HoR+/HER2-negative advanced breast cancer. In addition, we provide an overview of the ongoing clinical trials aiming to validate the predictive and prognostic value of IS towards their incorporation into routine care. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Falato, Claudette AU - Falato C AD - Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; SOLTI Cancer Research Group, Barcelona, Spain; Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden. Electronic address: claudette.falato@gruposolti.org. FAU - Schettini, Francesco AU - Schettini F AD - Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain; Faculty of Medicine, University of Barcelona, Barcelona, Spain. Electronic address: SCHETTINI@clinic.cat. FAU - Pascual, Tomás AU - Pascual T AD - Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; SOLTI Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain. Electronic address: tomas.pascual@gruposolti.org. FAU - Brasó-Maristany, Fara AU - Brasó-Maristany F AD - Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address: FBRASO@recerca.clinic.cat. FAU - Prat, Aleix AU - Prat A AD - Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Faculty of Medicine, University of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. Electronic address: ALPRAT@clinic.cat. LA - eng PT - Journal Article PT - Review DEP - 20221209 PL - Netherlands TA - Cancer Treat Rev JT - Cancer treatment reviews JID - 7502030 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Progesterone) SB - IM MH - Humans MH - Female MH - *Receptor, ErbB-2/metabolism MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Prognosis MH - Biomarkers, Tumor/genetics MH - Receptors, Progesterone/metabolism MH - Tumor Microenvironment OTO - NOTNLM OT - CDK4/6 inhibitors OT - HARMONIA clinical trial OT - Intrinsic subtypes OT - PAM50 OT - Precision oncology OT - Predictive biomarkers COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CF declares no competing financial and non-financial interests; FS declares no competing financial and non-financial interests but reports personal fees from Novartis for educational activities; TP declares no competing financial and non-financial interests; FBM declares no competing financial and non-financial interests but reports patent application EP21383165 and patent application on DNA-based predictors of breast tumor phenotypes filed; AP declares no competing non-financial interests but reports advisory and consulting fees from Roche, Pfizer, Novartis, Amgen, BMS, Puma, Oncolytics Biotech, MSD, Guardant Health, Peptomyc, and Lilly, lecture fees from Roche, Pfizer, Novartis, Amgen, BMS, Nanostring Technologies and Daiichi Sankyo, institutional financial interests from Boehringer, Novartis, Roche, Nanostring, Sysmex Europa GmbH, Medica Scientia inno. Research, SL, Celgene, Astellas, and Pfizer; a leadership role in Reveal Genomics, SL; and a patent PCT/EP2016/080056. EDAT- 2022/12/24 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/23 18:20 PHST- 2022/10/03 00:00 [received] PHST- 2022/11/30 00:00 [revised] PHST- 2022/12/03 00:00 [accepted] PHST- 2022/12/24 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/23 18:20 [entrez] AID - S0305-7372(22)00172-4 [pii] AID - 10.1016/j.ctrv.2022.102496 [doi] PST - ppublish SO - Cancer Treat Rev. 2023 Jan;112:102496. doi: 10.1016/j.ctrv.2022.102496. Epub 2022 Dec 9. PMID- 36550153 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230118 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Dec 22 TI - MicroRNAs within the Basal-like signature of Quadruple Negative Breast Cancer impact overall survival in African Americans. PG - 22178 LID - 10.1038/s41598-022-26000-9 [doi] LID - 22178 AB - We previously found that QNBC tumors are more frequent in African Americans compared to TNBC tumors. To characterize this subtype further, we sought to determine the miRNA-mRNA profile in QNBC patients based on race. Both miRNA and mRNA expression data were analyzed from TCGA and validated using datasets from the METABRIC, TCGA proteomic, and survival analysis by KMPLOT. miRNA-mRNAs which include FOXA1 and MYC (mir-17/20a targets); GATA3 and CCNG2 (mir-135b targets); CDKN2A, CDK6, and B7-H3 (mir-29c targets); and RUNX3, KLF5, IL1-β, and CTNNB1 (mir-375 targets) were correlated with basal-like and immune subtypes in QNBC patients and associated with a worse survival. Thus, QNBC tumors have an altered gene signature implicated in racial disparity and poor survival. CI - © 2022. The Author(s). FAU - Angajala, Anusha AU - Angajala A AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. AD - Department of Pathology, University of South Alabama, Mobile, AL, 36604, USA. FAU - Raymond, Hughley AU - Raymond H AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. FAU - Muhammad, Aliyu AU - Muhammad A AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. AD - Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, 810107, Kaduna State, Nigeria. FAU - Uddin Ahmed, Md Shakir AU - Uddin Ahmed MS AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. AD - Bangladesh Council of Scientific and Industrial Research (BCSIR), Dhaka, Bangladesh. FAU - Haleema, Saadia AU - Haleema S AD - Department of Pathology, University of South Alabama, Mobile, AL, 36604, USA. FAU - Haque, Monira AU - Haque M AD - Department of Pathology, University of South Alabama, Mobile, AL, 36604, USA. FAU - Wang, Honghe AU - Wang H AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. FAU - Campbell, Moray AU - Campbell M AD - Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA. FAU - Martini, Rachel AU - Martini R AD - Department of Surgery, Weill Cornell Medicine, New York, NY, 10021, USA. FAU - Karanam, Balasubramanian AU - Karanam B AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. FAU - Kahn, Andrea G AU - Kahn AG AD - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, 35249-7331, USA. FAU - Bedi, Deepa AU - Bedi D AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. FAU - Davis, Melissa AU - Davis M AD - Department of Surgery, Weill Cornell Medicine, New York, NY, 10021, USA. FAU - Tan, Ming AU - Tan M AD - Graduate Institute of Biomedical Sciences and Research Center for Cancer Biology, China Medical University, Taichung, 406040, Taiwan. FAU - Dean-Colomb, Windy AU - Dean-Colomb W AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. AD - Department of Hematology/Oncology, Piedmont Hospital, Newnan, GA, 30265, USA. FAU - Yates, Clayton AU - Yates C AD - Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL, 36088, USA. cyates10@jhmi.edu. AD - Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, 21218, USA. cyates10@jhmi.edu. AD - Cancer Genetics and Epigenetics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, The Bunting-Blaustein Cancer Research Building 1, 1650 Orleans Street - Room 1M44, Baltimore, MD, 21287-0013, USA. cyates10@jhmi.edu. AD - Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21218, USA. cyates10@jhmi.edu. LA - eng GR - R21 CA188799/CA/NCI NIH HHS/United States GR - U54 CA118623/CA/NCI NIH HHS/United States GR - U54 MD007585/MD/NIMHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20221222 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (MicroRNAs) RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - Female MH - *MicroRNAs/genetics/metabolism MH - *Breast Neoplasms/genetics MH - *Triple Negative Breast Neoplasms/pathology MH - Black or African American/genetics MH - Proteomics MH - RNA, Messenger MH - Gene Expression Regulation, Neoplastic PMC - PMC9780260 COIS- CY is a shareholder in Riptide Biosciences and is a consultant for QED Therapeutics, Riptide Biosciences, and Amgen. There has been no financial support for this work that could have influenced its outcome. All other authors do not have competing interests. EDAT- 2022/12/23 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/22 23:27 PHST- 2022/07/30 00:00 [received] PHST- 2022/12/07 00:00 [accepted] PHST- 2022/12/22 23:27 [entrez] PHST- 2022/12/23 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - 10.1038/s41598-022-26000-9 [pii] AID - 26000 [pii] AID - 10.1038/s41598-022-26000-9 [doi] PST - epublish SO - Sci Rep. 2022 Dec 22;12(1):22178. doi: 10.1038/s41598-022-26000-9. PMID- 36585168 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 43 IP - 1 DP - 2023 Jan TI - Factor Analysis of Intraoperative Bleeding Loss and its Impact on Prognosis in Breast Cancer. PG - 191-200 LID - 10.21873/anticanres.16149 [doi] AB - BACKGROUND/AIM: Intraoperative blood loss (IBL) during the surgical treatment of various cancers affects complication rates and prognosis. However, few studies have examined the importance of minimal IBL in breast cancer surgery. We used factor analysis to examine the prognostic importance of IBL in breast cancer. PATIENTS AND METHODS: One hundred ninety-seven patients who underwent mastectomy plus axillary lymph node dissection (level II) after preoperative chemotherapy between June 2007 and June 2021 were included. Pearson's Chi-square test was used to confirm the relationships between different factors. Kaplan-Meier survival curves and the log-rank test were used to examine prognosis. Logistic regression was performed using a Cox proportional hazards model. RESULTS: The median IBL was 55.0 g (range=5.0-420.0 g). IBL was <100 g in 143 patients (72.5%), 100-200 g in 39 patients (19.8%), and >200 g in 15 patients (7.6%). Logistic regression analysis showed that patients with IBL ≥200 g had a significantly worse prognosis (disease-free survival: p=0.003, log-rank test; overall survival: p<0.001, log-rank test). Factor analysis revealed that HER2-negative status (p=0.015), non-pathological complete response (p=0.031), obesity (p=0.001), heavy smoking (p=0.047), and diabetes mellitus (p=0.004) were significantly associated with increased IBL. CONCLUSION: IBL in breast cancer was correlated with various clinicopathological factors associated with a poor prognosis, suggesting that increased IBL may be associated with poor prognosis in breast cancer as well. CI - Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Takada, Koji AU - Takada K AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Kashiwagi, Shinichiro AU - Kashiwagi S AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; spqv9ke9@view.con.ne.jp. FAU - Iimori, Nozomi AU - Iimori N AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Kouhashi, Rika AU - Kouhashi R AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Yabumoto, Akimichi AU - Yabumoto A AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Goto, Wataru AU - Goto W AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Asano, Yuka AU - Asano Y AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Tauchi, Yukie AU - Tauchi Y AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Ogisawa, Kana AU - Ogisawa K AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Morisaki, Tamami AU - Morisaki T AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Shibutani, Masatsune AU - Shibutani M AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Tanaka, Hiroaki AU - Tanaka H AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Maeda, Kiyoshi AU - Maeda K AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Mastectomy/adverse effects MH - Prognosis MH - Blood Loss, Surgical MH - Factor Analysis, Statistical MH - Retrospective Studies OTO - NOTNLM OT - Breast cancer OT - bleeding OT - chemotherapy OT - prognosis OT - surgery EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 21:03 PHST- 2022/11/03 00:00 [received] PHST- 2022/11/14 00:00 [revised] PHST- 2022/11/15 00:00 [accepted] PHST- 2022/12/30 21:03 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 43/1/191 [pii] AID - 10.21873/anticanres.16149 [doi] PST - ppublish SO - Anticancer Res. 2023 Jan;43(1):191-200. doi: 10.21873/anticanres.16149. PMID- 36641174 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1879-1344 (Electronic) IS - 0144-8617 (Linking) VI - 304 DP - 2023 Mar 15 TI - Carbohydrate polymer-based nanocomposites for breast cancer treatment. PG - 120510 LID - S0144-8617(22)01415-1 [pii] LID - 10.1016/j.carbpol.2022.120510 [doi] AB - Breast cancer is known as the most common invasive malignancy in women with the highest mortality rate worldwide. This concerning disease may be presented in situ (relatively easier treatment) or be invasive, especially invasive ductal carcinoma which is highly worrisome nowadays. Among several strategies used in breast cancer treatment, nanotechnology-based targeted therapy is currently being investigated, as it depicts advanced technological features able of preventing drugs' side effects on normal cells while effectively acting on tumor cells. In this context, carbohydrate polymer-based nanocomposites have gained particular interest among the biomedical community for breast cancer therapy applications due to their advantage features, including abundance in nature, biocompatibility, straightforward fabrication methods, and good physicochemical properties. In this review, the physicochemical properties and biological activities of carbohydrate polymers and their derivate nanocomposites were discussed. Then, various methods for the fabrication of carbohydrate polymer-based nanocomposites as well as their application in breast cancer therapy and future perspectives were discussed. CI - Copyright © 2022 Elsevier Ltd. All rights reserved. FAU - Moghaddam, Farnaz Dabbagh AU - Moghaddam FD AD - Institute for Photonics and Nanotechnologies, National Research Council, Via Fosso del Cavaliere, 100, 00133, Rome, Italy. FAU - Heidari, Golnaz AU - Heidari G AD - School of Chemistry, Damghan University, Damghan 36716-45667, Iran. FAU - Zare, Ehsan Nazarzadeh AU - Zare EN AD - School of Chemistry, Damghan University, Damghan 36716-45667, Iran. Electronic address: e.nazarzadeh@du.ac.ir. FAU - Djatoubai, Essossimna AU - Djatoubai E AD - International Research Center for Renewable Energy (IRCRE), State Key Laboratory of Multiphase Flow in Power Engineering (MPFE), Xi'an Jiaotong University, 28 West Xianning Road, Xi'an 710049, PR China. FAU - Paiva-Santos, Ana Cláudia AU - Paiva-Santos AC AD - Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal. FAU - Bertani, Francesca Romana AU - Bertani FR AD - Institute for Photonics and Nanotechnologies, National Research Council, Via Fosso del Cavaliere, 100, 00133, Rome, Italy. FAU - Wu, Aimin AU - Wu A AD - Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang Provincial Key Laboratory of Orthopaedics, Wenzhou, Zhejiang, 325027, China. LA - eng PT - Journal Article PT - Review DEP - 20221229 PL - England TA - Carbohydr Polym JT - Carbohydrate polymers JID - 8307156 RN - 0 (Polymers) RN - 0 (Carbohydrates) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Polymers/therapeutic use/chemistry MH - *Nanocomposites/therapeutic use/chemistry MH - Carbohydrates OTO - NOTNLM OT - Breast cancer OT - Carbohydrate OT - Nanocarrier OT - Nanocomposite OT - Treatment COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that might have been known in the current work reported in this paper. EDAT- 2023/01/15 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/14 20:56 PHST- 2022/10/31 00:00 [received] PHST- 2022/12/23 00:00 [revised] PHST- 2022/12/24 00:00 [accepted] PHST- 2023/01/14 20:56 [entrez] PHST- 2023/01/15 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - S0144-8617(22)01415-1 [pii] AID - 10.1016/j.carbpol.2022.120510 [doi] PST - ppublish SO - Carbohydr Polym. 2023 Mar 15;304:120510. doi: 10.1016/j.carbpol.2022.120510. Epub 2022 Dec 29. PMID- 36427119 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis. PG - 245-254 LID - 10.1007/s10549-022-06800-3 [doi] AB - PURPOSE: Ductal carcinoma in situ (DCIS) associated with invasive carcinoma ≤ 1 mm in size is defined as DCIS with microinvasion (DCIS/microinvasion) rather than as invasive breast carcinoma. The number of patients with microinvasion accounts for < 1% of all breast cancer in published studies. As the numbers are limited, the prognostic significance of DCIS/microinvasion has not been clearly elucidated. This meta-analysis aimed to investigate the survival differences between patients with DCIS/microinvasion and those with pure DCIS. METHODS: A meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology was performed. We searched three electronic databases (MEDLINE, Cochrane Library, and EMBASE) and included observational studies published in English that contained survival details of patients with either DCIS or DCIS/microinvasion. RESULTS: This study identified 26 studies that described the clinicopathological characteristics of patients in both the DCIS and DCIS/microinvasion groups. Survival differences were evaluated in 10 of 26 studies. Disease-free survival and loco-regional recurrence-free survival were significantly shorter in patients with DCIS/microinvasion than in those with DCIS (Hazard ratio, 1.52; 95% confidence interval, 1.11-2.08; p = 0.01 and hazard ratio, 2.53; 95% confidence interval, 1.45-4.41; p = 0.001, respectively). Both overall survival and distant metastasis-free survival tended to be shorter in patients with DCIS/microinvasion than in patients with DCIS (Hazard ratio, 1.63; 95% CI, 0.63-4.23; p = 0.31 and hazard ratio, 1.85; 95% confidence interval, 0.74-4.66; p = 0.19, respectively) but the difference was not statistically significant. CONCLUSION: Our meta-analysis suggests that DCIS/microinvasion may display more aggressive biological and clinical behavior than pure DCIS, highlighting the potential need for closer follow-up and consideration of adjuvant treatment strategies in DCIS patients with microinvasive disease. CI - © 2022. The Author(s). FAU - Shiino, Sho AU - Shiino S AD - Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK. AD - Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan. FAU - Quinn, Cecily AU - Quinn C AD - Histopathology, Irish National Breast Screening Programme, St. Vincent's University Hospital, Dublin, Ireland. FAU - Ball, Graham AU - Ball G AD - John Van Geest Cancer Research Centre, School of Science & Technology, Nottingham Trent University, Clifton Campus, Clifton Lane, Nottingham, UK. FAU - Syed, Binafsha M AU - Syed BM AD - Medical Research Centre, Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan. FAU - Kurozumi, Sasagu AU - Kurozumi S AD - Department of Breast Surgery, International University of Health and Welfare, Narita, Japan. AD - Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan. FAU - Tsuda, Hitoshi AU - Tsuda H AD - Department of Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Japan. FAU - Rakha, Emad A AU - Rakha EA AUID- ORCID: 0000-0002-5009-5525 AD - Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK. emad.rakha@nottingham.ac.uk. AD - Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK. emad.rakha@nottingham.ac.uk. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20221124 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Carcinoma, Intraductal, Noninfiltrating/pathology MH - *Breast Neoplasms/pathology MH - Prognosis MH - Breast/pathology MH - Disease-Free Survival MH - *Carcinoma, Ductal, Breast/pathology MH - Neoplasm Invasiveness/pathology MH - Retrospective Studies PMC - PMC9823049 OTO - NOTNLM OT - Breast cancer OT - Ductal carcinoma in situ OT - Ductal carcinoma in situ with microinvasion OT - Meta-analysis OT - Prognosis COIS- CQ has received speaker fees from Exact Sciences. SK has received honoraria from Daiichi Sankyo co. ltd, Taiho Pharmaceutical co. ltd, Eli Lilly and Company, MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical, Ltd., Dinow Inc., and Novartis Japan. The other authors declare no conflict of interest. EDAT- 2022/11/26 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/25 11:05 PHST- 2022/05/12 00:00 [received] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/26 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/25 11:05 [entrez] AID - 10.1007/s10549-022-06800-3 [pii] AID - 6800 [pii] AID - 10.1007/s10549-022-06800-3 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):245-254. doi: 10.1007/s10549-022-06800-3. Epub 2022 Nov 24. PMID- 36384074 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 1877-783X (Electronic) IS - 1877-7821 (Linking) VI - 82 DP - 2023 Feb TI - The delay of breast cancer diagnosis and management during the Syrian war. PG - 102290 LID - S1877-7821(22)00195-3 [pii] LID - 10.1016/j.canep.2022.102290 [doi] AB - BACKGROUND: Early detection of breast cancer (BC) is crucial for better prognosis especially in low-income countries, where advanced cancer stages are common. The Syrian war severely affected the healthcare system restraining the proper timely management of BC cases. We aimed to investigate the prevalence of patient- and system-related delays in BC diagnosis and management in Syria in addition to their predisposing characteristics and impact on the staging. METHODS: This is a cross-sectional retrospective cohort study on patients followed by the BC unit at Al-Bairouni main cancer center in Syria. The data were collected through personal interviews and retrospective revision of patients' records. RESULTS: A total number of 519 patients were recruited; A quarter of them (n = 126) reported more than three months intervals between symptoms recognition and presentation to a physician. Additionally, 72 (13.9 %) patients received a confirmed diagnosis more than three months after presentation, and 12 (2.3 %) started treatment at least three months after the diagnosis. Patients who suffered from war-related inaccessibility to healthcare were 2.55 [1.58-4.11] times more likely to report significant delays. Additionally, the most common self-reported reasons for patient delay were the lack of awareness, which was more evident for less common symptoms like the change in breasts size, and shyness. Patients who reported significant delays were more likely to receive an advanced-stage diagnosis. CONCLUSION: War-related inaccessibility to healthcare rendered a significant group of BC patient susceptible to evident delay. This combined with significant system delays because of the overwhelmed hospitals, high costs, and insufficient personnel, equipment, medications, and training. However, personal factors, which might not be directly related to the war, like the inadequate awareness of rare symptoms and shyness still necessitate urgent interventions on the public knowledge and performed screening practices. These delays associated with receiving advanced-stage diagnoses and minimizing them can return better prognoses. CI - Copyright © 2022 Elsevier Ltd. All rights reserved. FAU - Hanafi, Ibrahem AU - Hanafi I AD - Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Damascus University, Damascus, Syria. Electronic address: Ibrahem.W.Hanafi@gmail.com. FAU - Alsalkini, Marah AU - Alsalkini M AD - Faculty of Medicine, Albaath University, Homs, Syria. FAU - Husein, Sara AU - Husein S AD - Faculty of Medicine, Damascus University, Damascus, Syria. FAU - Salamoon, Maher AU - Salamoon M AD - Department of Oncology, Faculty of Medicine, Damascus University, Damascus, Syria. LA - eng PT - Journal Article DEP - 20221113 PL - Netherlands TA - Cancer Epidemiol JT - Cancer epidemiology JID - 101508793 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/epidemiology/therapy MH - Retrospective Studies MH - Syria/epidemiology MH - Cross-Sectional Studies MH - Prognosis OTO - NOTNLM OT - Advanced breast cancer OT - Breast cancer OT - Diagnosis delay OT - Healthcare inaccessibility OT - Syria COIS- Conflict of interest statement None of the authors has any conflicts of interests to be reported. EDAT- 2022/11/18 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/11/17 09:24 PHST- 2022/05/12 00:00 [received] PHST- 2022/10/23 00:00 [revised] PHST- 2022/10/29 00:00 [accepted] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/11/17 09:24 [entrez] AID - S1877-7821(22)00195-3 [pii] AID - 10.1016/j.canep.2022.102290 [doi] PST - ppublish SO - Cancer Epidemiol. 2023 Feb;82:102290. doi: 10.1016/j.canep.2022.102290. Epub 2022 Nov 13. PMID- 36626523 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230113 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 49 DP - 2022 Dec 9 TI - Uncovering the molecular mechanism of Gynostemma pentaphyllum (Thunb.) Makino against breast cancer using network pharmacology and molecular docking. PG - e32165 LID - 10.1097/MD.0000000000032165 [doi] LID - e32165 AB - Because of their strong anti-cancer efficacy with fewer side effects, traditional Chinese medicines (TCM) have attracted considerable attention for their potential application in treating breast cancer (BC). However, knowledge about the underlying systematic mechanisms is scarce. Gynostemma pentaphyllum (Thunb.) Makino (GP), a creeping herb, has been regularly used as a TCM to prevent and treat tumors including BC. Again, mechanisms underlying its anti-BC properties have remained elusive. We used network pharmacology and molecular docking to explore the mechanistic details of GP against BC. The TCM systems pharmacology database and analysis platform and PharmMapper Server database were used to retrieve the chemical constituents and potential targets in GP. In addition, targets related to BC were identified using DrugBank and Therapeutic Target Database. Protein-protein interaction network, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses of crucial targets were performed using the Search Tool for the Retrieval of Interacting Genes/Proteins and database for annotation, visualization, and integrated discovery databases, whereas the network visualization analysis was performed using Cytoscape 3.8.2. In addition, the molecular docking technique was used to validate network pharmacology-based predictions. A comparison of the predicted targets of GP with those of BC-related drugs revealed 26 potential key targets related to the treatment of BC, among which ALB, EGFR, ESR1, AR, PGR, and HSP90AA1 were considered the major potential targets. Finally, network pharmacology-based prediction results were preliminarily verified by molecular docking experiments. In addition, chemical constituents and potential target proteins were scored, followed by a comparison with the ligands of the protein. We provide a network of pharmacology-based molecular mechanistic insights on the therapeutic action of GP against BC. We believe that our data will serve as a basis to conduct future studies and promote the clinical applications of GP. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Wang, Wen-Xiang AU - Wang WX AUID- ORCID: 0000-0001-8797-1413 AD - School of Pharmacy of Chongqing Three Gorges Medical College, Chongqing, China. FAU - He, Xiao-Yan AU - He XY AD - Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Yi, Dong-Yang AU - Yi DY AD - School of Pharmacy of Chongqing Three Gorges Medical College, Chongqing, China. FAU - Tan, Xiao-Yan AU - Tan XY AD - School of Pharmacy of Chongqing Three Gorges Medical College, Chongqing, China. FAU - Wu, Li-Juan AU - Wu LJ AD - Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Li, Ning AU - Li N AD - School of Pharmacy of Chongqing Three Gorges Medical College, Chongqing, China. FAU - Feng, Bin-Bin AU - Feng BB AD - School of Pharmacy of Chongqing Three Gorges Medical College, Chongqing, China. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Molecular Docking Simulation MH - Gynostemma MH - Network Pharmacology MH - Protein Interaction Maps MH - Medicine, Chinese Traditional MH - *Drugs, Chinese Herbal/pharmacology/therapeutic use PMC - PMC9750687 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/01/11 06:00 MHDA- 2023/01/13 06:00 CRDT- 2023/01/10 13:35 PHST- 2023/01/10 13:35 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - 00005792-202212090-00037 [pii] AID - 10.1097/MD.0000000000032165 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 9;101(49):e32165. doi: 10.1097/MD.0000000000032165. PMID- 36633970 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 1527-1323 (Electronic) IS - 0271-5333 (Linking) VI - 43 IP - 2 DP - 2023 Feb TI - Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. PG - e220103 LID - 10.1148/rg.220103 [doi] AB - Human epidermal growth factor receptor 2 (HER2/neu or ErbB2)-positive breast cancers comprise 15%-20% of all breast cancers. The most common manifestation of HER2-positive breast cancer at mammography or US is an irregular mass with spiculated margins that often contains calcifications; at MRI, HER2-positive breast cancer may appear as a mass or as nonmass enhancement. HER2-positive breast cancers are often of intermediate to high nuclear grade at histopathologic analysis, with increased risk of local recurrence and metastases and poorer overall prognosis. However, treatment with targeted monoclonal antibody therapies such as trastuzumab and pertuzumab provides better local-regional control and leads to improved survival outcome. With neoadjuvant treatments, including monoclonal antibodies, taxanes, and anthracyclines, women are now potentially able to undergo breast conservation therapy and sentinel lymph node biopsy versus mastectomy and axillary lymph node dissection. Thus, the radiologist's role in assessing the extent of local-regional disease and response to neoadjuvant treatment at imaging is important to inform surgical planning and adjuvant treatment. However, assessment of treatment response remains difficult, with the potential for different imaging modalities to result in underestimation or overestimation of disease to varying degrees when compared with surgical pathologic analysis. In particular, the presence of calcifications at mammography is especially difficult to correlate with the results of pathologic analysis after chemotherapy. Breast MRI findings remain the best predictor of pathologic response. The authors review the initial manifestations of HER2-positive tumors, the varied responses to neoadjuvant chemotherapy, and the challenges in assessing residual cancer burden through a multimodality imaging review with pathologic correlation. (©) RSNA, 2023 Quiz questions for this article are available through the Online Learning Center. FAU - Portnow, Leah H AU - Portnow LH AUID- ORCID: 0000-0001-5146-7135 AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. FAU - Kochkodan-Self, Jeanne M AU - Kochkodan-Self JM AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. FAU - Maduram, Amy AU - Maduram A AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. FAU - Barrios, Mirelys AU - Barrios M AUID- ORCID: 0000-0001-7195-271X AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. FAU - Onken, Allison M AU - Onken AM AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. FAU - Hong, Xuefei AU - Hong X AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. FAU - Mittendorf, Elizabeth A AU - Mittendorf EA AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. FAU - Giess, Catherine S AU - Giess CS AUID- ORCID: 0000-0002-5923-523X AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. FAU - Chikarmane, Sona A AU - Chikarmane SA AUID- ORCID: 0000-0001-7326-4312 AD - From the Departments of Radiology (L.H.P., J.M.K.S., A.M., M.B., C.S.G., S.A.C.), Pathology (A.M.O., X.H.), and Surgery (E.A.M.), Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. LA - eng PT - Journal Article PL - United States TA - Radiographics JT - Radiographics : a review publication of the Radiological Society of North America, Inc JID - 8302501 RN - P188ANX8CK (Trastuzumab) RN - 0 (Antibodies, Monoclonal) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - Neoadjuvant Therapy MH - Mastectomy MH - Trastuzumab/therapeutic use MH - Antibodies, Monoclonal/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Chemotherapy, Adjuvant EDAT- 2023/01/13 06:00 MHDA- 2023/01/17 06:00 CRDT- 2023/01/12 13:03 PHST- 2023/01/12 13:03 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] AID - 10.1148/rg.220103 [doi] PST - ppublish SO - Radiographics. 2023 Feb;43(2):e220103. doi: 10.1148/rg.220103. PMID- 34514973 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1538-0254 (Electronic) IS - 0739-1102 (Linking) VI - 40 IP - 23 DP - 2022 TI - Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach. PG - 12772-12784 LID - 10.1080/07391102.2021.1975570 [doi] AB - Human epidermal growth factor receptor 2 (HER2) is a member of epidermal growth factor receptors with tyrosine kinase functionality. The dimerization of HER2 leads to the autophosphorylation of tyrosine residues within its cytoplasmic domain, resulting in hyperactivation of several downstream signal transduction pathways that play an important role in tumorigenesis, cancer aggressiveness and cell proliferation. Amplification or overexpression of HER2 has been found in approximately 15-30% of breast cancers. Hence, HER2 serve as a therapeutic biomarker in breast cancer. Herein, we applied structural bioinformatics techniques via molecular docking, molecular dynamics simulations, Molecular mechanics/generalized Born surface area (MM/GBSA) calculations and pharmacokinetic models to identify putative HER2 inhibitors. Application of stringent molecular docking results in the identification of bioactive compounds from Mangifera indica as selective, potent inhibitors of HER2. However, only the top three compounds with the highest negative docking score (< -9kcal/mol) was considered in reference to neratinib (-8.601 kcal/mol) for computational analysis. The molecular dynamics simulations and post-simulation analysis of docked HER2-ligand complexes unveil the substantial stability for M. indica ligands over the 100 ns simulation period. Additionally, MM/GBSA binding free energy calculation supports the inhibitory potential for the docked ligands, which exclusively revealed the highest binding energy for selected M. indica ligands than the reference compound (neratinib). The pharmacokinetic model showed that M. indica ligands are promising therapeutic agents. Conclusively, bioactive compounds from M. indica may serve as lead molecules that could be developed into potent and effective HER2 inhibitors for breast cancer treatment.Communicated by Ramaswamy H. Sarma. FAU - Balogun, Toheeb Adewale AU - Balogun TA AUID- ORCID: 0000-0002-6267-425X AD - Department of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria. FAU - Iqbal, Muhammad Nasir AU - Iqbal MN AUID- ORCID: 0000-0002-8875-8400 AD - Department of Biosciences, COMSATS University Islamabad, Islamabad, ICT, Pakistan. FAU - Saibu, Oluwatosin Abideen AU - Saibu OA AUID- ORCID: 0000-0002-2337-5046 AD - Department of Environmental Toxicology, Universitat Duisburg-Essen, NorthRhine-Westphalia, Germany. FAU - Akintubosun, Michael Olawale AU - Akintubosun MO AD - Department of Applied Biotechnology, Warsaw University of Technology, Warszawa, Poland. FAU - Lateef, Olubodun Michael AU - Lateef OM AD - Department of Applied Biotechnology, Warsaw University of Technology, Warszawa, Poland. FAU - Nneka, Uche Catherine AU - Nneka UC AD - Department of Quality Assurance, Loving Gaze-SHOPS Plus Tuberculosis USAID Project, Nsukka, Nigeria. FAU - Abdullateef, Olayemi Taye AU - Abdullateef OT AD - Department of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria. FAU - Omoboyowa, Damilola Alex AU - Omoboyowa DA AUID- ORCID: 0000-0002-1740-9764 AD - Department of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria. LA - eng PT - Journal Article DEP - 20210913 PL - England TA - J Biomol Struct Dyn JT - Journal of biomolecular structure & dynamics JID - 8404176 RN - 0 (Protein Kinase Inhibitors) RN - 0 (Ligands) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Molecular Docking Simulation MH - *Mangifera/metabolism MH - Protein Kinase Inhibitors/chemistry MH - Molecular Dynamics Simulation MH - Ligands OTO - NOTNLM OT - Breast cancer OT - HER2 OT - Mangifera indica OT - molecular docking OT - molecular dynamics simulations EDAT- 2021/09/14 06:00 MHDA- 2022/12/28 06:00 CRDT- 2021/09/13 09:01 PHST- 2021/09/14 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2021/09/13 09:01 [entrez] AID - 10.1080/07391102.2021.1975570 [doi] PST - ppublish SO - J Biomol Struct Dyn. 2022;40(23):12772-12784. doi: 10.1080/07391102.2021.1975570. Epub 2021 Sep 13. PMID- 36334190 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230118 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Implications of missing data on reported breast cancer mortality. PG - 177-187 LID - 10.1007/s10549-022-06764-4 [doi] AB - BACKGROUND: National cancer registries are valuable tools to analyze patterns of care and clinical outcomes; yet, missing data may impact the accuracy and generalizability of these data. We sought to evaluate the association between missing data and overall survival (OS). METHODS: Using the NCDB (National Cancer Database) and SEER (Surveillance, Epidemiology, End Results Program), we assessed data missingness among patients diagnosed with invasive breast cancer from 2010 to 2014. Key variables included demographic (age, race, ethnicity, insurance, education, income), tumor (grade, ER, PR, HER2, TNM stages), and treatment (surgery in both databases; chemotherapy and radiation in NCDB). OS was compared between those with and without missing data using Cox proportional hazards models. RESULTS: Overall, 775,996 patients in the NCDB and 263,016 in SEER were identified; missing at least 1 key variable occurred for 29% and 13%, respectively. Of those, the overwhelming majority (NCDB 80%; SEER 88%) were missing tumor variables. When compared to patients with complete data, missingness was associated with a greater risk of death: NCDB HR 1.23 (99% CI 1.21-1.25) and SEER HR 2.11 (99% CI 2.05-2.18). Patients with complete tumor data had higher unadjusted OS estimates than that of the entire sample: NCDB 82.7% vs 81.8% and SEER 83.5% vs 81.7% for 5-year OS. CONCLUSIONS: Missingness of select variables is not uncommon within large national cancer registries and is associated with a worse OS. Exclusion of patients with missing variables may introduce unintended bias into analyses and result in findings that underestimate breast cancer mortality. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Plichta, Jennifer K AU - Plichta JK AUID- ORCID: 0000-0002-7411-0558 AD - Department of Surgery, Duke University Medical Center, Durham, NC, DUMC 351327710, USA. jennifer.plichta@duke.edu. AD - Department of Population Health Sciences, Duke University Medical Center, Durham, NC, DUMC 351327710, USA. jennifer.plichta@duke.edu. AD - Duke Cancer Institute, Durham, NC, USA. jennifer.plichta@duke.edu. FAU - Rushing, Christel N AU - Rushing CN AD - Duke Cancer Institute, Durham, NC, USA. AD - Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC, USA. FAU - Lewis, Holly C AU - Lewis HC AD - Department of Surgery, Duke University Medical Center, Durham, NC, DUMC 351327710, USA. FAU - Rooney, Marguerite M AU - Rooney MM AD - Department of Surgery, Duke University Medical Center, Durham, NC, DUMC 351327710, USA. FAU - Blazer, Dan G AU - Blazer DG AD - Department of Surgery, Duke University Medical Center, Durham, NC, DUMC 351327710, USA. AD - Duke Cancer Institute, Durham, NC, USA. FAU - Thomas, Samantha M AU - Thomas SM AD - Duke Cancer Institute, Durham, NC, USA. AD - Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC, USA. AD - Department of Biostatistics & Bioinformatics, Duke University, Durham, NC, USA. FAU - Hwang, E Shelley AU - Hwang ES AD - Department of Surgery, Duke University Medical Center, Durham, NC, DUMC 351327710, USA. AD - Duke Cancer Institute, Durham, NC, USA. FAU - Greenup, Rachel A AU - Greenup RA AD - Department of Surgery, Duke University Medical Center, Durham, NC, DUMC 351327710, USA. AD - Department of Population Health Sciences, Duke University Medical Center, Durham, NC, DUMC 351327710, USA. AD - Duke Cancer Institute, Durham, NC, USA. LA - eng GR - P30 CA014236/CA/NCI NIH HHS/United States GR - P30CA014236/GF/NIH HHS/United States PT - Journal Article DEP - 20221105 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/epidemiology/therapy MH - SEER Program MH - Registries MH - Ethnicity MH - Proportional Hazards Models OTO - NOTNLM OT - Breast cancer OT - Cancer registry OT - Data missingness OT - Databases OT - Outcomes OT - Survival EDAT- 2022/11/06 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/05 12:26 PHST- 2022/04/25 00:00 [received] PHST- 2022/10/06 00:00 [accepted] PHST- 2022/11/06 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/05 12:26 [entrez] AID - 10.1007/s10549-022-06764-4 [pii] AID - 10.1007/s10549-022-06764-4 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):177-187. doi: 10.1007/s10549-022-06764-4. Epub 2022 Nov 5. PMID- 36672847 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 14 IP - 1 DP - 2022 Dec 29 TI - Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study. LID - 10.3390/genes14010106 [doi] LID - 106 AB - BACKGROUND: Precision oncology has been increasingly used in clinical practice and rapidly evolving in the oncology field. Thus, this study was performed to assess the frequency of germline mutations in early and late onset familial breast cancer (BC) Egyptian patients using multi-gene panel sequencing to better understand the contribution of the inherited germline mutations in BC predisposition. Moreover, to determine the actionable deleterious mutations associated with familial BC that might be used as biomarker for early cancer detection. METHODS: Whole blood samples were collected from 101 Egyptian patients selected for BC family history, in addition to 50 age-matched healthy controls. A QIAseq targeted DNA panel (human BC panel) was used to assess the frequency of germline mutations. RESULTS: A total of 58 patients (57.4%) out of 101 were found to have 27 deleterious germline mutations in 11 cancer susceptibility genes. Of them, 32 (31.6%) patients carried more than one pathogenic mutation and each one carried at least one pathogenic mutation. The major genes harboring the pathogenic mutations were: ATM, BRCA2, BRCA1, VHL, MSH6, APC, CHEK2, MSH2, MEN1, PALB2, and MUTYH. Thirty-one patients (30.6%) had BRCA2 mutations and twenty (19.8%) had BRCA1 mutations. Our results showed that exon 10 and exon 11 harbored 3 and 5 mutations, respectively, in BRCA1 and BRCA2 genes. Our analysis also revealed that the VHL gene significantly co-occurred with each of the BRCA2 gene (p = 0.003, event ratio 11/21), the MSH2 gene (p = 0.01, 4/10), the CHEK2 gene (p = 0.02, 4/11), and the MSH6 gene (p = 0.04, 4/12). In addition, the APC gene significantly co-occurred with the MSH2 gene (p = 0.01, 3/7). Furthermore, there was a significant mutually exclusive event between the APC gene and the ATM gene (p = 0.04, 1/36). Interestingly, we identified population specific germline mutations in genes showing potentials for targeted therapy to meet the need for incorporating precision oncology into clinical practice. For example, the mutations identified in the ATM, APC, and MSH2 genes. CONCLUSIONS: Multi-gene panel sequencing was used to detect the deleterious mutations associated with familial BC, which in turns mitigate the essential need for implementing next generation sequencing technologies in precision oncology to identify cancer predisposing genes. Moreover, identifying DNA repair gene mutations, with focus on non-BRCA genes, might serve as candidates for targeted therapy and will be increasingly used in precision oncology. FAU - Nassar, Auhood AU - Nassar A AUID- ORCID: 0000-0002-5704-9281 AD - Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. FAU - Zekri, Abdel-Rahman N AU - Zekri AN AUID- ORCID: 0000-0003-3939-0416 AD - Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. FAU - Kamel, Mahmoud M AU - Kamel MM AUID- ORCID: 0000-0003-0264-3096 AD - Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. AD - Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza 3546211, Egypt. FAU - Elberry, Mostafa H AU - Elberry MH AD - Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. FAU - Lotfy, Mai M AU - Lotfy MM AUID- ORCID: 0000-0001-8282-8773 AD - Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. FAU - Seadawy, Mohamed G AU - Seadawy MG AD - Biological Prevention Department, Chemical Warfare, 4.5 km Suez-Cairo Rd, Almaza, Cairo 11351, Egypt. FAU - Hassan, Zeinab K AU - Hassan ZK AD - Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. FAU - Soliman, Hany K AU - Soliman HK AD - Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. FAU - Lymona, Ahmed M AU - Lymona AM AD - Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. FAU - Youssef, Amira Salah El-Din AU - Youssef ASE AUID- ORCID: 0000-0003-3091-691X AD - Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt. LA - eng GR - 41907/Science and Technology Development Fund/ PT - Journal Article DEP - 20221229 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - EC 3.6.1.3 (MutS Homolog 2 Protein) RN - Breast Cancer, Familial SB - IM MH - Humans MH - Female MH - *Germ-Line Mutation MH - *Breast Neoplasms/genetics MH - Egypt MH - MutS Homolog 2 Protein/genetics MH - Genetic Predisposition to Disease MH - Precision Medicine PMC - PMC9858960 OTO - NOTNLM OT - BRCA1 OT - BRCA2 OT - familial breast cancer OT - germline mutations OT - multi-gene panel sequencing OT - precision oncology COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:15 PHST- 2022/10/11 00:00 [received] PHST- 2022/11/23 00:00 [revised] PHST- 2022/12/08 00:00 [accepted] PHST- 2023/01/21 01:15 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - genes14010106 [pii] AID - genes-14-00106 [pii] AID - 10.3390/genes14010106 [doi] PST - epublish SO - Genes (Basel). 2022 Dec 29;14(1):106. doi: 10.3390/genes14010106. PMID- 36619544 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 13 DP - 2022 TI - Editorial: Underlying molecular interconnections of the estrogen receptor alpha and associated factors involved in breast cancer development: The way to new therapeutic approaches. PG - 1094711 LID - 10.3389/fendo.2022.1094711 [doi] LID - 1094711 FAU - Leclercq, Guy AU - Leclercq G AD - Institute Jules Bordet, Cancer Center of the Université Libre de Bruxelles, Brussels, Belgium. FAU - Acconcia, Filippo AU - Acconcia F AD - Department of Science, University Roma TRE, Rome, Italy. LA - eng PT - Editorial DEP - 20221220 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 0 (Estrogen Receptor alpha) RN - 0 (Receptors, G-Protein-Coupled) SB - IM CON - Editorial on the Research TopicUnderlying molecular interconnections of the estrogen receptor alpha and associated factors involved in breast cancer development: The way to new therapeutic approaches MH - Humans MH - Female MH - *Estrogen Receptor alpha/genetics MH - *Breast Neoplasms/genetics/therapy MH - Receptors, G-Protein-Coupled MH - Signal Transduction PMC - PMC9810493 OTO - NOTNLM OT - ER alpha OT - GPR30 OT - estrogen OT - receptor,breast cancer OT - therapy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/10 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/09 03:53 PHST- 2022/11/10 00:00 [received] PHST- 2022/11/30 00:00 [accepted] PHST- 2023/01/09 03:53 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - 10.3389/fendo.2022.1094711 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2022 Dec 20;13:1094711. doi: 10.3389/fendo.2022.1094711. eCollection 2022. PMID- 34388731 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1540-1413 (Electronic) IS - 1540-1405 (Print) IS - 1540-1405 (Linking) VI - 19 IP - 10 DP - 2021 Aug 13 TI - Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial. PG - 1133-1140 LID - 10.6004/jnccn.2021.7032 [doi] AB - BACKGROUND: Most breast cancer clinicians lack training to counsel patients about sexual concerns. The purpose of this study was to assess the feasibility, acceptability, and preliminary effects of a mobile learning (mLearning) intervention (improving Sexual Health and Augmenting Relationships through Education [iSHARE]) aimed at enhancing breast cancer clinicians' knowledge of, beliefs about, and comfort with discussing patients' sexual health concerns. METHODS: Clinicians listened to a 2-part educational podcast series offering information on breast cancer-related sexual health concerns and effective communication on the topic, which consisted of interviews with expert guests. Intervention feasibility was assessed through rates of enrollment, retention, and intervention completion, with benchmarks of 40%, 70%, and 60%, respectively. Acceptability was assessed through program evaluations, with 75% of clinicians rating the intervention favorably (eg, relevance, satisfaction) signifying acceptability. Clinicians self-reported their knowledge about breast cancer-related sexual health concerns, beliefs (ie, self-efficacy for discussing sexual health concerns), and comfort with discussing sexual concerns measured at preintervention and postintervention. Qualitative analysis examined clinicians' perceptions of lessons learned from the intervention. RESULTS: A total of 32 breast cancer clinicians enrolled (46% of those invited; 97% of those who responded and screened eligible), 30 (94%) completed both the intervention and study surveys, and 80% rated the intervention favorably, demonstrating feasibility and acceptability. Results showed positive trends for improvement in clinician knowledge, beliefs, and comfort with discussing sexual health concerns. Clinicians reported key lessons learned, including taking a proactive approach to discussing sexual health concerns, normalizing the topic, addressing vaginal health, sending the message that help is available, and assessing sexual health concerns with patients from different backgrounds. CONCLUSIONS: Breast cancer clinicians were amenable to participating in the iSHARE intervention and found it useful. iSHARE showed promise for improving clinician's knowledge and comfort discussing patients' sexual health concerns. A larger trial is required to demonstrate efficacy. Future studies should also examine whether iSHARE can improve patient-clinician communication and address patients' sexual concerns. FAU - Reese, Jennifer Barsky AU - Reese JB AD - 1Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Zimmaro, Lauren A AU - Zimmaro LA AD - 1Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Bober, Sharon L AU - Bober SL AD - 2Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts. AD - 3Division of Palliative Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. FAU - Sorice, Kristen AU - Sorice K AD - 1Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Handorf, Elizabeth AU - Handorf E AD - 1Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. AD - 4Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania. FAU - Wittenberg, Elaine AU - Wittenberg E AD - 5Department of Communication Studies, California State University, Los Angeles, Los Angeles, California. FAU - El-Jawahri, Areej AU - El-Jawahri A AD - 6Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts. FAU - Beach, Mary Catherine AU - Beach MC AD - 7Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. FAU - Wolff, Antonio C AU - Wolff AC AD - 8Women's Malignancies Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. FAU - Daly, Mary B AU - Daly MB AD - 9Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and. FAU - Izquierdo, Brynna AU - Izquierdo B AD - 10Department of Epidemiology and Biostatistics, and. FAU - Lepore, Stephen J AU - Lepore SJ AD - 1Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. AD - 11Department of Social and Behavioral Sciences, College of Public Health, Temple University, Philadelphia, Pennsylvania. LA - eng GR - P30 CA006927/CA/NCI NIH HHS/United States GR - R03 CA235238/CA/NCI NIH HHS/United States GR - T32 CA009035/CA/NCI NIH HHS/United States PT - Clinical Trial PT - Journal Article DEP - 20210813 PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/therapy MH - Communication MH - Pilot Projects MH - Sexual Behavior MH - *Sexual Health PMC - PMC8840991 MID - NIHMS1748382 EDAT- 2021/08/14 06:00 MHDA- 2023/01/21 06:00 CRDT- 2021/08/13 20:24 PHST- 2021/01/21 00:00 [received] PHST- 2021/03/02 00:00 [accepted] PHST- 2021/08/14 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2021/08/13 20:24 [entrez] AID - jnccn21045 [pii] AID - 10.6004/jnccn.2021.7032 [doi] PST - epublish SO - J Natl Compr Canc Netw. 2021 Aug 13;19(10):1133-1140. doi: 10.6004/jnccn.2021.7032. PMID- 36271187 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy. PG - 151-155 LID - 10.1007/s12282-022-01410-9 [doi] AB - PURPOSE: Oral hygiene is crucial in the management of oral and febrile complications during chemotherapy for cancer. This study aimed to investigate the impact of oral hygiene on the incidence of febrile neutropenia (FN) throughout the course of chemotherapy for breast cancer. METHODS: A total of 137 patients with breast cancer who underwent four cycles of adjuvant chemotherapy with docetaxel and cyclophosphamide (TC) combination therapy or docetaxel alone were assessed for oral hygiene by quantifying the number of oral bacteria they harbored. These patients received professional oral health care (POHC). Eighteen patients underwent primary prophylaxis with granulocyte colony-stimulating factors. The relationship between oral bacteria count and FN incidence was retrospectively assessed. RESULTS: The FN incidence rate was 47.4% throughout all treatment cycles (32.8%, 13.5%, 14.3%, and 14.4% in cycles 1, 2, 3, and 4, respectively). The oral bacteria count decreased with each treatment cycle (cycle 1: 9.10 × 10(6) colony-forming units (CFU)/mL, cycle 2: 5.89 × 10(6) CFU/mL, cycle 3: 4.61 × 10(6) CFU/mL, cycle 4: 5.85 × 10(6) CFU/mL, P = 0.004). Among 281 treatment cycles, FN occurred in 63 (22.4%). In the treatment cycle-based analysis, high oral bacteria count was an independent risk factor for FN. CONCLUSION: FN incidence decreased with each treatment cycle and was associated with changes in oral bacteria counts. The oral bacterial count was one of risk factors for FN development in breast cancer. CI - © 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society. FAU - Suzuki, Kanako AU - Suzuki K AUID- ORCID: 0000-0002-9199-0104 AD - Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. FAU - Sasada, Shinsuke AU - Sasada S AUID- ORCID: 0000-0003-1623-869X AD - Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. shsasada@hiroshima-u.ac.jp. AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. shsasada@hiroshima-u.ac.jp. FAU - Nishi, Hiromi AU - Nishi H AUID- ORCID: 0000-0003-0741-9886 AD - Department of General Dentistry, Hiroshima University Hospital, Hiroshima, Japan. FAU - Kimura, Yuri AU - Kimura Y AUID- ORCID: 0000-0002-3457-9378 AD - Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. FAU - Shintani, Tomoaki AU - Shintani T AUID- ORCID: 0000-0002-0789-3273 AD - Center of Oral Examination, Hiroshima University Hospital, Hiroshima, Japan. FAU - Emi, Akiko AU - Emi A AUID- ORCID: 0000-0003-3034-6080 AD - Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. FAU - Masumoto, Norio AU - Masumoto N AUID- ORCID: 0000-0002-8924-8971 AD - Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. FAU - Kadoya, Takayuki AU - Kadoya T AUID- ORCID: 0000-0003-1835-1266 AD - Department of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan. AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. FAU - Kawaguchi, Hiroyuki AU - Kawaguchi H AUID- ORCID: 0000-0001-8775-1082 AD - Department of General Dentistry, Hiroshima University Hospital, Hiroshima, Japan. FAU - Okada, Morihito AU - Okada M AUID- ORCID: 0000-0001-7068-6608 AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. LA - eng PT - Journal Article DEP - 20221021 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 RN - 15H5577CQD (Docetaxel) RN - 143011-72-7 (Granulocyte Colony-Stimulating Factor) SB - IM MH - Female MH - Humans MH - Antineoplastic Combined Chemotherapy Protocols MH - *Breast Neoplasms/drug therapy/etiology MH - Docetaxel/therapeutic use MH - *Febrile Neutropenia/chemically induced/epidemiology/prevention & control MH - Granulocyte Colony-Stimulating Factor/therapeutic use MH - Oral Hygiene MH - Retrospective Studies OTO - NOTNLM OT - Breast cancer OT - Chemotherapy OT - Febrile neutropenia OT - Oral bacteria count OT - Oral hygiene EDAT- 2022/10/23 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/10/21 23:59 PHST- 2022/07/21 00:00 [received] PHST- 2022/10/16 00:00 [accepted] PHST- 2022/10/23 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/10/21 23:59 [entrez] AID - 10.1007/s12282-022-01410-9 [pii] AID - 10.1007/s12282-022-01410-9 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):151-155. doi: 10.1007/s12282-022-01410-9. Epub 2022 Oct 21. PMID- 36635514 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Jan 12 TI - Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients. PG - 614 LID - 10.1038/s41598-023-27787-x [doi] LID - 614 AB - To compare region of interest (ROI)-apparent diffusion coefficient (ADC) on diffusion-weighted imaging (DWI) measurements and Ki-67 proliferation index before and after neoadjuvant chemotherapy (NACT) for breast cancer. 55 women were enrolled in this prospective single-center study, with a final population of 47 women (49 cases of invasive breast cancer). ROI-ADC measurements were obtained on MRI before and after NACT and were compared to histological findings, including the Ki-67 index in the whole study population and in subgroups of "pathologic complete response" (pCR) and non-pCR. Nineteen percent of women experienced pCR. There was a significant inverse correlation between Ki-67 index and ROI-ADC before NACT (r = - 0.443, p = 0.001) and after NACT (r = - 0.614, p < 0.001). The mean Ki-67 index decreased from 45.8% before NACT to 18.0% after NACT (p < 0.001), whereas the mean ROI-ADC increased from 0.883 × 10(-3) mm(2)/s before NACT to 1.533 × 10(-3) mm(2)/s after NACT (p < 0.001). The model for the prediction of Ki67 index variations included patient age, hormonal receptor status, human epidermal growth factor receptor 2 status, Scarff-Bloom-Richardson grade 2, and ROI-ADC variations (p = 0.006). After NACT, a significant increase in breast cancer ROI-ADC on diffusion-weighted imaging was observed and a significant decrease in the Ki-67 index was predicted. Clinical trial registration number: clinicaltrial.gov NCT02798484, date: 14/06/2016. CI - © 2023. The Author(s). FAU - Hottat, Nathalie A AU - Hottat NA AD - Department of Radiology, University Hospital Brugmann, Université Libre de Bruxelles, Place A. Van Gehuchten 4, 1020, Brussels, Belgium. nathalie.hottat@chu-brugmann.be. AD - Department of Radiology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium. nathalie.hottat@chu-brugmann.be. FAU - Badr, Dominique A AU - Badr DA AD - Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium. FAU - Lecomte, Sophie AU - Lecomte S AD - Department of Pathology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium. FAU - Besse-Hammer, Tatiana AU - Besse-Hammer T AD - Clinical Research Unit, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium. FAU - Jani, Jacques C AU - Jani JC AD - Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium. FAU - Cannie, Mieke M AU - Cannie MM AD - Department of Radiology, University Hospital Brugmann, Université Libre de Bruxelles, Place A. Van Gehuchten 4, 1020, Brussels, Belgium. AD - Department of Radiology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium. LA - eng SI - ClinicalTrials.gov/NCT02798484 PT - Journal Article DEP - 20230112 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Ki-67 Antigen) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - Neoadjuvant Therapy/methods MH - Prospective Studies MH - Ki-67 Antigen MH - Diffusion Magnetic Resonance Imaging/methods MH - Magnetic Resonance Imaging/methods PMC - PMC9837175 COIS- The authors declare no competing interests. EDAT- 2023/01/13 06:00 MHDA- 2023/01/17 06:00 CRDT- 2023/01/12 23:26 PHST- 2022/07/11 00:00 [received] PHST- 2023/01/09 00:00 [accepted] PHST- 2023/01/12 23:26 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] AID - 10.1038/s41598-023-27787-x [pii] AID - 27787 [pii] AID - 10.1038/s41598-023-27787-x [doi] PST - epublish SO - Sci Rep. 2023 Jan 12;13(1):614. doi: 10.1038/s41598-023-27787-x. PMID- 36647876 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 27 IP - 1 DP - 2023 Jan TI - Integrative analyses of radiation-related genes and biomarkers associated with breast cancer. PG - 256-274 LID - 30907 [pii] LID - 10.26355/eurrev_202301_30907 [doi] AB - OBJECTIVE: In addition to significantly reducing breast cancer recurrence risk, radiotherapy also prolongs patients' lives. However, radiotherapy-related genes and biomarkers still remain poorly understood. The present study aimed to identify radiation-associated genes in breast cancer. MATERIALS AND METHODS: Breast cancer data were downloaded from Gene Expression Omnibus (GEO) and UCSC Xena database. The gene ontology (GO) enrichment and gene set enrichment analysis (GSEA) were performed for annotation and integrated discovery. Protein-protein interaction (PPI) network was constructed by STRING database and hub genes were identified. Then, immunohistochemistry and tissue expression of key genes was analyzed by using the Human Protein Atlas (HPA) and GEPIA database. Genes associated with prognosis were identified by performing univariate cox analysis. RESULTS: We identified 341 differentially expressed genes related to radiotherapy in breast cancer patients. PPI analysis revealed a total of 129 nodes and 516 interactions and identified five hub genes (EGFR, FOS, ESR1, JUN, and IL6). In addition, 11 SDEGs THBS1, SERPINA11, NFIL3, METTL7A, KCTD12, HSPA6, EGR1, DDIT4, CCDC3, C11orf96, and BCL2A1 candidate genes can be used as potential diagnostic markers. The calibration curve and ROC indicate good probability consistencies of 3-years and 5-year survival rates of patients between estimation and observation. CONCLUSIONS: Our findings provide novel insight into the functional characteristics of breast cancer through integrative analysis of GEO data and suggest potential biomarkers and therapeutic targets for breast cancer. FAU - Dan, W-C AU - Dan WC AD - Department of Dermatology, Beijing Traditional Chinese Medicine Hospital affiliated to Capital Medical University, Beijing, China. 458967607@qq.com. FAU - Guo, X-Y AU - Guo XY FAU - Zhang, G-Z AU - Zhang GZ FAU - Wang, S-L AU - Wang SL FAU - Deng, M AU - Deng M FAU - Liu, J-L AU - Liu JL LA - eng PT - Journal Article PL - Italy TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/radiotherapy MH - Gene Expression Profiling MH - Biomarkers, Tumor/genetics MH - Protein Interaction Maps/genetics MH - Prognosis MH - Computational Biology MH - Gene Expression Regulation, Neoplastic EDAT- 2023/01/18 06:00 MHDA- 2023/01/19 06:00 CRDT- 2023/01/17 06:03 PHST- 2023/01/17 06:03 [entrez] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] AID - 30907 [pii] AID - 10.26355/eurrev_202301_30907 [doi] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2023 Jan;27(1):256-274. doi: 10.26355/eurrev_202301_30907. PMID- 36614207 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 1 DP - 2023 Jan 1 TI - The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows. LID - 10.3390/ijms24010764 [doi] LID - 764 AB - All cancers develop as a result of mutations in genes. DNA damage induces genomic instability and subsequently increases susceptibility to tumorigenesis. Women who carry mutations of BRCA 1 and BRCA2 genes have an augmented risk of breast and ovarian cancer and a markedly augmented probability of dying because of cancer compared to the general population. As a result, international guidelines recommend that all BRCA1\2 mutation carriers be offered risk-reducing bilateral salpingo-oophorectomy at an early age to reduce the risk of cancer and decrease the mortality rate of this high-risk population. NCCN guidelines recommend risk-reducing bilateral salpingo-oophorectomy in pre-menopausal women, between 35-40 years in BRCA1 mutation carriers and between 40-45 years in BRCA2 mutation carriers. Unfortunately, the well-documented reduction of cancer risk is counterbalanced by early sterility and premature ovarian failure with an early onset of secondary menopausal syndromes such as neuromotor, cardiovascular, cognitive and urogenital deficiency. Hormonal replacement therapy significantly compensates for hormonal deprivation and counteracts menopausal syndrome morbidity and mortality; however, some data suggest a possible correlation between hormonal medications and cancer risk, especially in BRCA1\2 carriers who undergo long-term regimens. Conversely, short-term treatment before the age of natural menopause does not appear to increase the cancer risk in BRCA1 mutation carriers without a personal history of breast cancer after prophylactic surgery. Few data are available on BRCA2 mutation carriers and more well-designed studies are needed. In conclusion, clinicians should propose short-term hormone replacement therapy to BRCA 1 carriers to counteract hormonal deprivation; personalized counselling should be offered to BRCA2 mutation carriers for a balance between the risks and benefits of the treatment. FAU - Loizzi, Vera AU - Loizzi V AUID- ORCID: 0000-0002-4006-6421 AD - Oncology Unit IRCSS Istituto Tumori "Giovanni Paolo II", Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", 70124 Bari, Italy. FAU - Dellino, Miriam AU - Dellino M AUID- ORCID: 0000-0003-3522-4648 AD - Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of "Aldo Moro", 70124 Bari, Italy. FAU - Cerbone, Marco AU - Cerbone M AUID- ORCID: 0000-0003-2918-3608 AD - Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of "Aldo Moro", 70124 Bari, Italy. FAU - Arezzo, Francesca AU - Arezzo F AD - Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of "Aldo Moro", 70124 Bari, Italy. FAU - Cazzato, Gerardo AU - Cazzato G AUID- ORCID: 0000-0003-0325-4316 AD - Section of Pathology, Department of Emergency and organ transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy. FAU - Damiani, Gianluca Raffaello AU - Damiani GR AUID- ORCID: 0000-0003-0614-8068 AD - Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of "Aldo Moro", 70124 Bari, Italy. FAU - Pinto, Vincenzo AU - Pinto V AD - Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of "Aldo Moro", 70124 Bari, Italy. FAU - Silvestris, Erica AU - Silvestris E AUID- ORCID: 0000-0001-7415-5986 AD - Gynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy. FAU - Kardhashi, Anila AU - Kardhashi A AD - Gynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy. FAU - Cicinelli, Ettore AU - Cicinelli E AUID- ORCID: 0000-0003-2390-4582 AD - Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of "Aldo Moro", 70124 Bari, Italy. FAU - Cascardi, Eliano AU - Cascardi E AUID- ORCID: 0000-0003-1287-4285 AD - Pathology Unit, FPO-IRCCS Candiolo Cancer Institute, 10060 Candiolo, Italy. AD - Department of Medical Sciences, University of Turin, 10124 Turin, Italy. FAU - Cormio, Gennaro AU - Cormio G AUID- ORCID: 0000-0001-5745-372X AD - Oncology Unit IRCSS Istituto Tumori "Giovanni Paolo II", Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", 70124 Bari, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230101 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BRCA1 Protein) RN - 0 (BRCA2 Protein) SB - IM MH - Humans MH - Female MH - Hormone Replacement Therapy/adverse effects MH - Salpingo-oophorectomy MH - BRCA1 Protein/genetics MH - Genes, BRCA2 MH - Menopause MH - *Breast Neoplasms/genetics/prevention & control MH - Mutation MH - *Ovarian Neoplasms/genetics/prevention & control MH - Ovariectomy MH - BRCA2 Protein/genetics MH - Genetic Predisposition to Disease PMC - PMC9821191 OTO - NOTNLM OT - BRCA OT - BRCA1 OT - BRCA2 OT - HRT OT - RRSO OT - breast cancer OT - endometrial cancer OT - hormonal deprivation OT - menopausal syndrome COIS- The authors declare no conflict of interest. EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:26 PHST- 2022/11/08 00:00 [received] PHST- 2022/12/18 00:00 [revised] PHST- 2022/12/23 00:00 [accepted] PHST- 2023/01/08 01:26 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - ijms24010764 [pii] AID - ijms-24-00764 [pii] AID - 10.3390/ijms24010764 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 1;24(1):764. doi: 10.3390/ijms24010764. PMID- 36675313 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 16 TI - An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer. LID - 10.3390/ijms24021799 [doi] LID - 1799 AB - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer due to its molecular heterogeneity and poor clinical outcomes. Analysis of circulating cell-free tumor nucleic acids (ctNAs) can improve our understanding of TNBC and provide efficient and non-invasive clinical biomarkers that may be representative of tumor heterogeneity. In this review, we summarize the potential of ctNAs to aid TNBC diagnosis and prognosis. For example, tumor fraction of circulating cell-free DNA (TFx) may be useful for molecular prognosis of TNBC: high TFx levels after neoadjuvant chemotherapy have been associated with shorter progression-free survival and relapse-free survival. Mutations and copy number variations of TP53 and PIK3CA/AKT genes in plasma may be important markers of TNBC onset, progression, metastasis, and for clinical follow-up. In contrast, the expression profile of circulating cell-free tumor non-coding RNAs (ctncRNAs) can be predictive of molecular subtypes of breast cancer and thus aid in the identification of TBNC. Finally, dysregulation of some circulating cell-free tumor miRNAs (miR17, miR19a, miR19b, miR25, miR93, miR105, miR199a) may have a predictive value for chemotherapy resistance. In conclusion, a growing number of efforts are highlighting the potential of ctNAs for future clinical applications in the diagnosis, prognosis, and follow-up of TNBC. FAU - Tierno, Domenico AU - Tierno D AUID- ORCID: 0000-0003-0858-6192 AD - Department of Life Sciences, University of Trieste, 34127 Trieste, Italy. FAU - Grassi, Gabriele AU - Grassi G AUID- ORCID: 0000-0001-9704-6651 AD - Department of Life Sciences, University of Trieste, 34127 Trieste, Italy. FAU - Zanconati, Fabrizio AU - Zanconati F AD - Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, 34149 Trieste, Italy. FAU - Bortul, Marina AU - Bortul M AD - Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, 34149 Trieste, Italy. FAU - Scaggiante, Bruna AU - Scaggiante B AUID- ORCID: 0000-0002-8662-138X AD - Department of Life Sciences, University of Trieste, 34127 Trieste, Italy. LA - eng GR - dicembre 2022/Lega Italiana per la Lotta contro i Tumori, Associazione Provinciale di Trieste-Italy/ PT - Journal Article PT - Review DEP - 20230116 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Cell-Free Nucleic Acids) RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (Circulating MicroRNA) RN - 0 (MIRN105 microRNA, human) RN - 0 (MIRN25 microRNA, human) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/diagnosis/genetics/drug therapy MH - *Cell-Free Nucleic Acids/genetics MH - DNA Copy Number Variations MH - Biomarkers, Tumor/genetics MH - Neoplasm Recurrence, Local MH - *MicroRNAs/genetics MH - *Circulating MicroRNA/therapeutic use PMC - PMC9864244 OTO - NOTNLM OT - TNBC OT - circulating cell-free nucleic acids OT - circulating cell-free tumor DNA OT - circulating cell-free tumor lncRNA OT - circulating cell-free tumor miRNA OT - liquid biopsy COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:29 PHST- 2023/01/04 00:00 [received] PHST- 2023/01/13 00:00 [revised] PHST- 2023/01/14 00:00 [accepted] PHST- 2023/01/21 01:29 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijms24021799 [pii] AID - ijms-24-01799 [pii] AID - 10.3390/ijms24021799 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 16;24(2):1799. doi: 10.3390/ijms24021799. PMID- 36354368 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230121 IS - 1538-7445 (Electronic) IS - 0008-5472 (Print) IS - 0008-5472 (Linking) VI - 83 IP - 2 DP - 2023 Jan 18 TI - Genome-Wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk. PG - 332-345 LID - 10.1158/0008-5472.CAN-22-1888 [doi] AB - Numerous common genetic variants have been linked to breast cancer risk, but they only partially explain the total breast cancer heritability. Inference from Nordic population-based twin data indicates rare high-risk loci as the chief determinant of breast cancer risk. Here, we use haplotypes, rather than single variants, to identify rare high-risk loci for breast cancer. With computationally phased genotypes from 181,034 white British women in the UK Biobank, a genome-wide haplotype-breast cancer association analysis was conducted using sliding windows of 5 to 500 consecutive array-genotyped variants. In the discovery stage, haplotype-breast cancer associations were evaluated retrospectively in the prestudy-enrollment data including 5,487 breast cancer cases. Breast cancer hazard ratios (HR) for additive haplotypic effects were estimated using Cox regression. The replication analysis included a prospective cohort of women free of breast cancer at enrollment, of whom 3,524 later developed breast cancer. This two-stage analysis detected 13 rare loci (frequency <1%), each associated with an appreciable breast cancer-risk increase (discovery: HRs = 2.84-6.10, P < 5 × 10-8; replication: HRs = 2.08-5.61, P < 0.01). In contrast, the variants that formed these rare haplotypes individually exhibited much smaller effects. Functional annotation revealed extensive cis-regulatory DNA elements in breast cancer-related cells underlying the replicated rare haplotypes. Using phased, imputed genotypes from 30,064 cases and 25,282 controls in the DRIVE OncoArray case-control study, 6 of the 13 rare-loci associations were found generalizable (odds ratio estimates: 1.48-7.67, P < 0.05). This study demonstrates the complementary advantage of utilizing rare haplotypes to capture novel risk loci and suggests the potential for the discovery of more genetic elements contributing to cancer heritability as large data sets of germline whole-genome sequencing become available. SIGNIFICANCE: A genome-wide two-stage haplotype analysis identifies rare haplotypes associated with breast cancer risk and suggests that the rare risk haplotypes represent long-range interactions with regulatory consequences influencing cancer risk. CI - ©2022 American Association for Cancer Research. FAU - Wang, Fan AU - Wang F AUID- ORCID: 0000-0001-9806-5037 AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. FAU - Moon, Wonjong AU - Moon W AUID- ORCID: 0000-0002-2544-1801 AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. FAU - Letsou, William AU - Letsou W AUID- ORCID: 0000-0002-4969-2330 AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. FAU - Sapkota, Yadav AU - Sapkota Y AUID- ORCID: 0000-0001-5943-9454 AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. FAU - Wang, Zhaoming AU - Wang Z AUID- ORCID: 0000-0001-7556-3869 AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. FAU - Im, Cindy AU - Im C AUID- ORCID: 0000-0003-0931-9432 AD - School of Public Health, University of Alberta, Edmonton, Canada. FAU - Baedke, Jessica L AU - Baedke JL AUID- ORCID: 0000-0001-5085-4985 AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. FAU - Robison, Leslie AU - Robison L AUID- ORCID: 0000-0001-7460-8578 AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. FAU - Yasui, Yutaka AU - Yasui Y AUID- ORCID: 0000-0002-7717-8638 AD - Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. AD - School of Public Health, University of Alberta, Edmonton, Canada. LA - eng GR - R01 CA216354/CA/NCI NIH HHS/United States GR - Alberta Machine Intelligence Institute (AMII)/ GR - R01 CA216354/CA/NCI NIH HHS/United States GR - American Lebanese Syrian Associated Charities (ALSAC)/ PT - Journal Article PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R SB - IM MH - Humans MH - Female MH - Haplotypes MH - *Breast Neoplasms/genetics MH - Case-Control Studies MH - Prospective Studies MH - Retrospective Studies MH - Polymorphism, Single Nucleotide MH - Genome-Wide Association Study MH - Genetic Predisposition to Disease PMC - PMC9852031 MID - NIHMS1851169 COIS- Declaration of conflict interests The authors declare no potential conflicts of interest. EDAT- 2022/11/11 06:00 MHDA- 2023/01/20 06:00 PMCR- 2023/07/18 CRDT- 2022/11/10 09:23 PHST- 2022/06/13 00:00 [received] PHST- 2022/09/09 00:00 [revised] PHST- 2022/11/08 00:00 [accepted] PHST- 2023/07/18 00:00 [pmc-release] PHST- 2022/11/11 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/11/10 09:23 [entrez] AID - 715067 [pii] AID - 10.1158/0008-5472.CAN-22-1888 [doi] PST - ppublish SO - Cancer Res. 2023 Jan 18;83(2):332-345. doi: 10.1158/0008-5472.CAN-22-1888. PMID- 36574653 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230103 IS - 1091-6490 (Electronic) IS - 0027-8424 (Linking) VI - 120 IP - 1 DP - 2023 Jan 3 TI - Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction. PG - e2209856120 LID - 10.1073/pnas.2209856120 [doi] AB - Breast cancer (BC) is a complex disease comprising multiple distinct subtypes with different genetic features and pathological characteristics. Although a large number of antineoplastic compounds have been approved for clinical use, patient-to-patient variability in drug response is frequently observed, highlighting the need for efficient treatment prediction for individualized therapy. Several patient-derived models have been established lately for the prediction of drug response. However, each of these models has its limitations that impede their clinical application. Here, we report that the whole-tumor cell culture (WTC) ex vivo model could be stably established from all breast tumors with a high success rate (98 out of 116), and it could reassemble the parental tumors with the endogenous microenvironment. We observed strong clinical associations and predictive values from the investigation of a broad range of BC therapies with WTCs derived from a patient cohort. The accuracy was further supported by the correlation between WTC-based test results and patients' clinical responses in a separate validation study, where the neoadjuvant treatment regimens of 15 BC patients were mimicked. Collectively, the WTC model allows us to accomplish personalized drug testing within 10 d, even for small-sized tumors, highlighting its potential for individualized BC therapy. Furthermore, coupled with genomic and transcriptomic analyses, WTC-based testing can also help to stratify specific patient groups for assignment into appropriate clinical trials, as well as validate potential biomarkers during drug development. FAU - Chen, Xinsong AU - Chen X AUID- ORCID: 0000-0002-3214-9075 AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. FAU - Sifakis, Emmanouil G AU - Sifakis EG AUID- ORCID: 0000-0001-9919-4471 AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. FAU - Robertson, Stephanie AU - Robertson S AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. AD - Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm 17176, Sweden. FAU - Neo, Shi Yong AU - Neo SY AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. FAU - Jun, Seong-Hwan AU - Jun SH AD - Department of Computational Biology, Royal Institute of Technology, Science for Life Laboratory, Stockholm 17165, Sweden. FAU - Tong, Le AU - Tong L AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. FAU - Hui Min, Apple Tay AU - Hui Min AT AUID- ORCID: 0000-0002-0600-6599 AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. AD - School of Biological Sciences, Nanyang Technological University, Singapore 637551. FAU - Lövrot, John AU - Lövrot J AUID- ORCID: 0000-0002-9339-8059 AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. FAU - Hellgren, Roxanna AU - Hellgren R AUID- ORCID: 0000-0003-4234-8323 AD - Department of Breast Imaging, Södersjukhuset, Stockholm 11828, Sweden. FAU - Margolin, Sara AU - Margolin S AD - Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm 11883, Sweden. FAU - Bergh, Jonas AU - Bergh J AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. AD - Breast Center, Theme Cancer, Karolinska University Hospital, Stockholm 17176, Sweden. FAU - Foukakis, Theodoros AU - Foukakis T AUID- ORCID: 0000-0001-8952-9987 AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. AD - Breast Center, Theme Cancer, Karolinska University Hospital, Stockholm 17176, Sweden. FAU - Lagergren, Jens AU - Lagergren J AUID- ORCID: 0000-0002-4552-0240 AD - Department of Computational Biology, Royal Institute of Technology, Science for Life Laboratory, Stockholm 17165, Sweden. FAU - Lundqvist, Andreas AU - Lundqvist A AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. FAU - Ma, Ran AU - Ma R AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. FAU - Hartman, Johan AU - Hartman J AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17164, Sweden. AD - Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm 17176, Sweden. LA - eng GR - 2018-06217/Swedish research council/ PT - Journal Article DEP - 20221227 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - *Antineoplastic Agents/pharmacology/therapeutic use MH - Gene Expression Profiling MH - Biomarkers MH - Cell Culture Techniques MH - Tumor Microenvironment OTO - NOTNLM OT - breast cancer OT - drug profiling OT - ex vivo culture OT - precision oncology OT - whole-tumor cell culture EDAT- 2022/12/28 06:00 MHDA- 2022/12/30 06:00 CRDT- 2022/12/27 16:22 PHST- 2022/12/27 16:22 [entrez] PHST- 2022/12/28 06:00 [pubmed] PHST- 2022/12/30 06:00 [medline] AID - 10.1073/pnas.2209856120 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2209856120. doi: 10.1073/pnas.2209856120. Epub 2022 Dec 27. PMID- 36591767 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 0043-5147 (Print) IS - 0043-5147 (Linking) VI - 75 IP - 11 pt 2 DP - 2022 TI - CORRELATION BETWEEN PRIMARY TUMOR SIZES WITH PROGNOSTIC MARKERS IN BREAST CARCINOMA IN IRAQI WOMEN: IMMUNOHISTOCHEMICAL STUDY. PG - 2771-2778 LID - 10.36740/WLek202211210 [doi] AB - OBJECTIVE: The aim: The study aimed assessment of immunohistochemical expression of ER, PR, Ki-67 and HER2 in breast carcinoma, studied the relation between size of primary tumor and these markers and distribution of molecular subtypes between both study groups. PATIENTS AND METHODS: Materials and methods: The study was implemented immunohistochemistry laboratories of Al-Sadder Teaching Medical City in Al Najaf during the period from September 2020-september2021, forty four women with breast carcinoma who undergone modified radical mastectomy were involved in this study, aged between 29 -81 years, mean age being 47.3 yr. we divided study group into two categories; depending on tumor size, with cutoff point of 2 cm. Envision technique applied for evaluation of expression of ER, PR, Ki-67 and HER2. RESULTS: Results: Among all patients, ER expressed in 70.45%, PR in 68.18%, HER2/neu in 18.18%, High ki-67 index in 52.27%. CONCLUSION: Conclusions: Molecular subtype luminal A tend to occur in smaller tumor size compared to basal subtype which tend to occur in larger size of tumors. Breast carcinoma tumor size showed no significant correlation regarding histological grade, immunohistochemical expression of ER, PR, HER2, and Ki-67 labeling index. FAU - Dosh, Zainab Nassir AU - Dosh ZN AD - DEPARTMENT OF PATHOLOGY AND FORENSIC MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF KUFA, NAJAF, IRAQ. FAU - Muslim, Liqaa Mohammed AU - Muslim LM AD - DEPARTMENT OF HISTOPATHOLOGY, AL SADDER MEDICAL CITY, NAJAF, IRAQ. FAU - Hasan, Mais Mohammed Salim M AU - Hasan MMSM AD - DEPARTMENT OF PATHOLOGY AND FORENSIC MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF KUFA, NAJAF, IRAQ. FAU - Al Janabi, Asaad AU - Al Janabi A AD - DEPARTMENT OF PATHOLOGY AND FORENSIC MEDICINE, FACULTY OF MEDICINE, UNIVERSITY OF KUFA, NAJAF, IRAQ. LA - eng PT - Journal Article PL - Poland TA - Wiad Lek JT - Wiadomosci lekarskie (Warsaw, Poland : 1960) JID - 9705467 RN - 0 (Ki-67 Antigen) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Progesterone) SB - IM MH - Humans MH - Female MH - Adult MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - *Breast Neoplasms/surgery MH - Prognosis MH - Ki-67 Antigen/metabolism MH - Receptor, ErbB-2/metabolism MH - Iraq MH - Mastectomy MH - Biomarkers, Tumor MH - Receptors, Progesterone OTO - NOTNLM OT - breast cancer OT - immunohistochemistry OT - molecular subtypes EDAT- 2023/01/03 06:00 MHDA- 2023/01/04 06:00 CRDT- 2023/01/02 05:03 PHST- 2023/01/02 05:03 [entrez] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 10.36740/WLek202211210 [doi] PST - ppublish SO - Wiad Lek. 2022;75(11 pt 2):2771-2778. doi: 10.36740/WLek202211210. PMID- 36595649 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1473-656X (Electronic) IS - 1040-872X (Linking) VI - 35 IP - 1 DP - 2023 Feb 1 TI - Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023. PG - 67-72 LID - 10.1097/GCO.0000000000000835 [doi] AB - PURPOSE OF REVIEW: In recent years, the therapy of breast carcinoma has evolved at a rapid pace. Therapies from metastasis are pushing into the (neo)adjuvant treatment of breast carcinoma at ever shorter intervals. RECENT FINDINGS: Biomarker-based therapeutic approaches became more and more en vogue to guide (neo)adjuvant endocrine therapy and chemotherapy. SUMMARY: This article reviews recent data developments in early breast cancer (EBC) and current recommendations in diagnosis and therapy. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Köpke, Melitta M AU - Köpke MM AD - University Hospital Augsburg, Augsburg. FAU - Aktas, Bahriye AU - Aktas B AD - University hospital Leipzig, Germany. FAU - Ditsch, Nina AU - Ditsch N AD - University Hospital Augsburg, Augsburg. LA - eng PT - Journal Article PT - Review PL - England TA - Curr Opin Obstet Gynecol JT - Current opinion in obstetrics & gynecology JID - 9007264 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/drug therapy MH - Chemotherapy, Adjuvant MH - Combined Modality Therapy MH - Endocrine System/pathology EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/03 14:53 PHST- 2023/01/03 14:53 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 00001703-202302000-00011 [pii] AID - 10.1097/GCO.0000000000000835 [doi] PST - ppublish SO - Curr Opin Obstet Gynecol. 2023 Feb 1;35(1):67-72. doi: 10.1097/GCO.0000000000000835. PMID- 36305029 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 1555-9823 (Electronic) IS - 0003-1348 (Linking) VI - 89 IP - 2 DP - 2023 Feb TI - Response Rates of Invasive Lobular Cancer in Patients Undergoing Neoadjuvant Endocrine or Chemotherapy. PG - 230-237 LID - 10.1177/00031348221135778 [doi] AB - BACKGROUND: A gap remains in the role of neoadjuvant therapy for patients with ILC. METHOD: Single-institution retrospective review of patients with ILC who received neoadjuvant therapy between 2008 and 2019. RESULTS: 141 patients met inclusion criteria: 71 neoadjuvant chemotherapy (NACT) and 70 neoadjuvant endocrine therapy (NET). 7/71 (9.9%) patients had a pCR following NACT compared to 1/70 (1.4%) with NET (P = .063). pCR was observed in 5/18 (27.8%) patients with Her2Neu-positive disease following NACT, compared to 2/53 (3.8%) with Her2Neu-negative disease (P = .01).For luminal B tumors, median Ki-67 decrease was similar following NACT and NET (18.3 vs 16.3, P = .26).T category decreased in 59 (42.1%) patients following neoadjuvant therapy, increased in 9 (6.4%), and was unchanged in 72 (51.4%). More patients had an increase (28.6%) than decrease (12.1%) in their N category, including 13/60 (21.7%) who were clinically node-negative at diagnosis and identified to have node-positive disease following neoadjuvant therapy, at definitive surgery. CONCLUSION: In Her2Neu-negative ILC, the potential of a pCR with NACT or NET is low. Most patients' nodal status and tumor size remain unchanged. There is a potential for pathologic stage to be higher at surgery compared to the clinical stage prior to neoadjuvant therapy. FAU - Jakub, James W AU - Jakub JW AUID- ORCID: 0000-0002-8005-1072 AD - Division of Surgical Oncology, 156400Mayo Clinic, Jacksonville, FL, USA. FAU - Zhang, Wenexia AU - Zhang W AUID- ORCID: 0000-0001-8123-6186 AD - Department of Breast Surgery, Shenzhen Maternity & Child Healthcare Hospital, 248258Nanfang Medical University, Shen Zhen Shi, Guangdong, China. FAU - Solanki, Malvika AU - Solanki M AD - Department of Laboratory Medicine and Pathology, 4352Mayo Clinic, Rochester, MN, USA. FAU - Yonkus, Jennifer AU - Yonkus J AD - Department of Surgery, 4352Mayo Clinic, Rochester, MN, USA. FAU - Boughey, Judy C AU - Boughey JC AD - Division of Breast & Melanoma Surgical Oncology, 4352Mayo Clinic, Rochester, MN, USA. FAU - Harmsen, Scott AU - Harmsen S AD - Department of Biostatistics, 4352Mayo Clinic, Rochester, MN, USA. FAU - Giridhar, Karthik V AU - Giridhar KV AD - Department of Medical Oncology, 4352Mayo Clinic, Rochester, MN, USA. LA - eng PT - Journal Article DEP - 20221027 PL - United States TA - Am Surg JT - The American surgeon JID - 0370522 SB - IM MH - Humans MH - Female MH - *Neoadjuvant Therapy MH - *Breast Neoplasms/drug therapy/surgery MH - Chemotherapy, Adjuvant MH - Retrospective Studies MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use OTO - NOTNLM OT - Her2Neu OT - Ki-67 OT - PEPI OT - complete response OT - downstage EDAT- 2022/10/29 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/10/28 03:04 PHST- 2022/10/29 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/10/28 03:04 [entrez] AID - 10.1177/00031348221135778 [doi] PST - ppublish SO - Am Surg. 2023 Feb;89(2):230-237. doi: 10.1177/00031348221135778. Epub 2022 Oct 27. PMID- 35943552 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1439-099X (Electronic) IS - 0179-7158 (Linking) VI - 199 IP - 1 DP - 2023 Jan TI - Hypofractionated radiotherapy after breast-conserving surgery: Clinical and dosimetric factors predictive of acute skin toxicity. PG - 48-54 LID - 10.1007/s00066-022-01985-4 [doi] AB - PURPOSE: The purpose of this study was to evaluate acute skin toxicity in early breast cancer patients treated with hypofractionated radiotherapy (HFRT) after breast-conserving surgery and to identify factors predictive for grade ≥ 2 acute skin toxicity. MATERIALS AND METHODS: A monocentric retrospective study was carried out using cases treated between December 2017 and November 2020. We analyzed data from 202 patients with early breast cancer treated with 3D hypofractionated RT (40.05 Gy in 15 fractions) to the whole breast with or without regional lymph nodes, followed by 13.35 Gy in 5 fractions to the tumor bed. Acute skin toxicity was monitored during RT according to CTCAE (common toxicity criteria for adverse events) scale. Univariate and multivariate analyses were performed to assess predictive factors of acute skin toxicity. RESULTS: Overall, there was no erythema in 9%, grade 1 erythema in 64.5%, grade 2 in 24%, and grade 3 in 2.5%. No grade 4 erythema was seen. Median delay between RT initiating and maximum skin reaction was 22 days (range 4-44 days). No patient interrupted treatment. In univariate analysis, the rate of acute skin toxicity grade 2---3 (G2-3) was significantly higher for patients with larger tumor size (p = 0.02), body mass index > 27 (p = 0.04), and time between chemotherapy (CT) and RT less than 20 days (p = 0.01). Dosimetric risk factors for acute skin toxicity G2‑3 were breast volume > 800 cc (p = 0.000), boost volume > 18 cc (p = 0.002), V105% > 40 cc (p = 0.03), and Dmax > 56 Gy (p = 0.007). CT, trastuzumab, regional lymph node radiation, and age were not correlated with increased skin toxicity. In multivariate analysis, acute skin toxicity correlated with T stage (p = 0.032), breast volume > 800 cc (p = 0.012), boost volume > 18 cc (p = 0.04), and Dmax > 56 Gy (p = 0.035). CONCLUSION: Our results confirm that whole breast with or without lymph nodes hypofractionated RT is safe and well tolerated. The factors strongly associated with a decreased risk of G2‑3 skin toxicity are T1, breast volume < 800 c, boost volume < 18 cc, and Dmax < 56 Gy. Long-term follow-up is needed to evaluate late toxicity. CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. FAU - Ben Amor, Raouia AU - Ben Amor R AD - Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia. raouia_ben_amor@hotmail.fr. AD - Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia. raouia_ben_amor@hotmail.fr. FAU - Bohli, Meriem AU - Bohli M AD - Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia. AD - Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia. FAU - Naimi, Zeineb AU - Naimi Z AD - Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia. AD - Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia. FAU - Aissaoui, Dorra AU - Aissaoui D AD - Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia. AD - Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia. FAU - Mejri, Nesrine AU - Mejri N AD - Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia. AD - Department of Medical Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia. FAU - Yahyaoui, Jamel AU - Yahyaoui J AD - Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia. FAU - Hamdoun, Awatef AU - Hamdoun A AD - Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia. FAU - Kochbati, Lotfi AU - Kochbati L AD - Faculty of Medicine, University of Tunis El Manar, 1007, Tunis, Tunisia. AD - Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana, Tunisia. LA - eng PT - Journal Article DEP - 20220809 PL - Germany TA - Strahlenther Onkol JT - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] JID - 8603469 SB - IM MH - Humans MH - Female MH - *Mastectomy, Segmental MH - Retrospective Studies MH - Neoplasm Staging MH - *Breast Neoplasms/radiotherapy/surgery/pathology MH - Breast/pathology MH - Radiotherapy, Adjuvant/adverse effects/methods OTO - NOTNLM OT - Breast cancer OT - Dose Hypofractionation OT - Predectifs factors OT - Regional lymph node hypofractionated radiation OT - Side effects EDAT- 2022/08/10 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/08/09 11:14 PHST- 2021/07/06 00:00 [received] PHST- 2022/07/07 00:00 [accepted] PHST- 2022/08/10 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/08/09 11:14 [entrez] AID - 10.1007/s00066-022-01985-4 [pii] AID - 10.1007/s00066-022-01985-4 [doi] PST - ppublish SO - Strahlenther Onkol. 2023 Jan;199(1):48-54. doi: 10.1007/s00066-022-01985-4. Epub 2022 Aug 9. PMID- 36661670 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 1 DP - 2022 Dec 24 TI - Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer. PG - 261-273 LID - 10.3390/curroncol30010021 [doi] AB - BACKGROUND: Adjuvant radiotherapy (RT) is an integral component of a multidisciplinary treatment strategy for early-stage breast cancer. It significantly reduces the incidence of loco-regional recurrence but also of distant events. Distant events are due to tumor cells disseminated from the primary tumor into lymphatic fluid or blood, circulating epithelial tumor cells (CETC/CTC), which can reach distant tissues and regrow into metastases. The purpose of this study is to determine changes in the number of CETC/CTC in the course of adjuvant RT, and to evaluate whether they are correlated to local recurrence and distant metastases in breast cancer patients. METHODS: Blood from 165 patients irradiated between 2002 and 2012 was analyzed 0-6 weeks prior to and 0-6 weeks after RT using the maintrac(®) method, and patients were followed over a median period of 8.97 (1.16-19.09) years. RESULTS: Patients with an increase in CETC/CTC numbers over the course of adjuvant RT had a significantly worse disease-free survival (p = 0.004) than patients with stable or decreasing CETC/CTC numbers. CETC/CTC behavior was the most important factor in predicting subsequent relapse-free survival. In particular, patients who had received neoadjuvant chemotherapy were disproportionately more likely to develop metastases when cell counts increased over the course of RT (p = 0.003; hazard ratio 4.886). CONCLUSIONS: Using the maintrac(®) method, CETC/CTC were detected in almost all breast cancer patients after surgery. The increase in CETC/CTC numbers over the course of RT represents a potential predictive biomarker to judge relative risk/benefit in patients with early breast cancer. The results of this study highlight the need for prospective clinical trials on CETC/CTC status as a predictive criterion and for individualization of treatment. CLINICAL TRIAL REGISTRATION: The trial is registered (2 May 2019) at trials.gov under NCT03935802. FAU - Mäurer, Matthias AU - Mäurer M AUID- ORCID: 0000-0001-9662-3082 AD - Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Bachstraße 18, 07743 Jena, Germany. AD - Clinician Scientist Program OrganAge, Interdisciplinary Center for Clinical Research (IZKF), Jena University Hospital, 07747 Jena, Germany. FAU - Schott, Dorothea AU - Schott D AD - Transfusionsmedizinisches Zentrum Bayreuth, Kurpromenade 2, 95448 Bayreuth, Germany. FAU - Pizon, Monika AU - Pizon M AUID- ORCID: 0000-0002-6599-3731 AD - Transfusionsmedizinisches Zentrum Bayreuth, Kurpromenade 2, 95448 Bayreuth, Germany. FAU - Drozdz, Sonia AU - Drozdz S AD - Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Bachstraße 18, 07743 Jena, Germany. FAU - Wendt, Thomas AU - Wendt T AD - Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Bachstraße 18, 07743 Jena, Germany. FAU - Wittig, Andrea AU - Wittig A AD - Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Bachstraße 18, 07743 Jena, Germany. FAU - Pachmann, Katharina AU - Pachmann K AD - Transfusionsmedizinisches Zentrum Bayreuth, Kurpromenade 2, 95448 Bayreuth, Germany. LA - eng SI - ClinicalTrials.gov/NCT03935802 GR - 413668513/Deutsche Forschungsgemeinschaft/ PT - Journal Article DEP - 20221224 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 10175-24-3 (bis(beta-carboxyethyl)tin dichloride) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Prospective Studies MH - Radiotherapy, Adjuvant MH - *Carcinoma PMC - PMC9857667 OTO - NOTNLM OT - biomarkers OT - circulating epithelial tumor cells OT - early-stage breast cancer OT - prediction OT - radiotherapy COIS- K.P. is the holder of the patents for the herein described method maintrac(®) to detect CETCs. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 09:34 PHST- 2022/11/03 00:00 [received] PHST- 2022/12/16 00:00 [revised] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/20 09:34 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - curroncol30010021 [pii] AID - curroncol-30-00021 [pii] AID - 10.3390/curroncol30010021 [doi] PST - epublish SO - Curr Oncol. 2022 Dec 24;30(1):261-273. doi: 10.3390/curroncol30010021. PMID- 36661668 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 1 DP - 2022 Dec 23 TI - Effects and Working Mechanisms of a Multilevel Implementation Program for Applying Shared Decision-Making while Discussing Systemic Treatment in Breast Cancer. PG - 236-249 LID - 10.3390/curroncol30010019 [doi] AB - BACKGROUND: Enhancing the application of shared decision-making (SDM) is critical for integrating patient preferences in breast cancer treatment choices. We investigated the effect of an adapted multilevel SDM implementation program in breast cancer care. METHODS: Breast cancer patients qualifying for (neo)adjuvant systemic treatment were included in a multicenter before-after study. Consultations were audio recorded between June 2018 and July 2019 and analyzed using the five-item Observing Patient Involvement in Decision-Making (OPTION-5) instrument to score SDM application by clinicians. The Shared Decision-Making Questionnaire (SDM-Q-9) was used to rate patients' perceived SDM level. Consultation duration, decision types, number of options discussed and consultations per patient were monitored. Regression analysis was used to investigate the correlated variables and program components. RESULTS: Mean OPTION-5 scores increased from 33.9 (n = 63) before implementation to 54.3 (n = 49) after implementation (p < 0.001). The SDM-Q-9 scores did not change: 91.1 (n = 51) at baseline versus 88.9 (n = 23) after implementation (p = 0.81). Without increasing consultation time, clinicians discussed more options after implementation. The regression analysis showed that exposure to the implementation program, redistribution of tasks and discussing feedback from consultations was associated with a higher level of SDM. CONCLUSION: The multilevel program helped clinicians achieve clinically relevant improvement in SDM, especially when it is tailored to (individuals in) teams and includes (e-)training, discussing feedback on consultations and redistribution of tasks. FAU - van Veenendaal, Haske AU - van Veenendaal H AUID- ORCID: 0000-0001-7423-5564 AD - Erasmus School of Health Policy & Management, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands. AD - Dutch Association of Oncology Patient Organizations, Godebaldkwartier 363, 3511 DT Utrecht, The Netherlands. FAU - Peters, Loes J AU - Peters LJ AUID- ORCID: 0000-0003-0332-6842 AD - Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. FAU - van Weele, Esther AU - van Weele E AD - Dutch Association of Oncology Patient Organizations, Godebaldkwartier 363, 3511 DT Utrecht, The Netherlands. AD - Vestalia, Acaciapark 136, 1213 LD Hilversum, The Netherlands. FAU - Hendriks, Mathijs P AU - Hendriks MP AUID- ORCID: 0000-0001-6687-5393 AD - Department of Medical Oncology, Northwest Clinics, Wilhelminalaan 12, 1815 JD Alkmaar, The Netherlands. FAU - Schuurman, Maaike AU - Schuurman M AD - Dutch Association of Breast Cancer Patients, Godebaldkwartier 363, 3511 DT Utrecht, The Netherlands. FAU - Visserman, Ella AU - Visserman E AD - Dutch Association of Oncology Patient Organizations, Godebaldkwartier 363, 3511 DT Utrecht, The Netherlands. FAU - Hilders, Carina G J M AU - Hilders CGJM AD - Erasmus School of Health Policy & Management, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands. AD - Board of Directors, Reinier de Graaf Hospital, Reinier de Graafweg 5, 2625 AD Delft, The Netherlands. FAU - Ubbink, Dirk T AU - Ubbink DT AUID- ORCID: 0000-0001-9398-8879 AD - Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. LA - eng GR - Not applicable/Dutch Ministry of Health, Welfare and Sport/ GR - Not applicable/Zilveren Kruis Healthcare Insurance Company/ PT - Journal Article PT - Multicenter Study DEP - 20221223 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy MH - Decision Making, Shared MH - Referral and Consultation MH - Patient Preference MH - Patient Participation PMC - PMC9857756 OTO - NOTNLM OT - breast cancer OT - multilevel implementation OT - shared decision-making OT - working mechanisms COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 09:34 PHST- 2022/11/25 00:00 [received] PHST- 2022/12/19 00:00 [revised] PHST- 2022/12/21 00:00 [accepted] PHST- 2023/01/20 09:34 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - curroncol30010019 [pii] AID - curroncol-30-00019 [pii] AID - 10.3390/curroncol30010019 [doi] PST - epublish SO - Curr Oncol. 2022 Dec 23;30(1):236-249. doi: 10.3390/curroncol30010019. PMID- 36409395 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer. PG - 343-354 LID - 10.1007/s10549-022-06791-1 [doi] AB - PURPOSE: Whether peripheral immune cell subsets can predict pathological complete response (pCR) in breast cancer patients remains to be elucidated. We aimed to dissect the relationship between peripheral immune cell subsets and pCR. METHODS: Two hundred and twenty-six eligible patients from two prospective clinical trials (SHPD001 and SHPD002) in China were randomly divided into a training cohort and a validation cohort. The breast cancer subtypes in this study included hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative (n = 95), HER2-positive (n = 100), and triple negative (n = 31) breast cancer. We defined the "Neo-Peripheral Adaptive Immune Score" for neoadjuvant chemotherapy (neoPAI Score) based on the percentages of CD4 + T cells, CD8 + T cells, B cells, and the CD4 + /CD8 + ratio in peripheral blood. We also evaluated the ability of the neoPAI Score derived from tumor-infiltrating immune cells (TIICs) to predict survival by employing The Cancer Genome Atlas-Breast Cancer (TCGA-BRCA) database. RESULTS: In the training cohort, multivariate analysis showed that HR status [odds ratio (OR) 0.325; 95% confidence interval (CI) 0.135-0.761; P = 0.010], HER2 status (OR 2.657; 95% CI 1.266-5.730; P = 0.011), Ki67 index (OR 3.191; 95% CI 1.509-6.956; P = 0.003), histological grade (OR 2.297; 95% CI 1.031-5.290; P = 0.045) and neoPAI Score (OR 4.451; 95% CI 1.608-13.068; P = 0.005) were independent predictors of pCR. In the validation cohort, histological grade (OR 3.779; 95% CI 3.793-1.136 × 10(3); P = 0.008) and neoPAI Score (OR 90.828; 95% CI 3.827-9.843 × 10(3); P = 0.019) were independent predictors of pCR. The Immune Model that integrated the neoPAI Score was more accurate in predicting pCR than the Clinical Model that exclusively contained clinicopathological parameters in both cohorts. In TCGA-BRCA database, the neoPAI Score constructed from TIICs can predict the progression-free interval (P = 0.048) of breast cancer. CONCLUSION: The neoPAI Score defined by the percentages of peripheral immune cell subsets could be used as a potential biomarker for neoadjuvant chemotherapy efficacy. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Wang, Huiling AU - Wang H AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. FAU - Sheng, Xiaonan AU - Sheng X AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. FAU - Yan, Tingting AU - Yan T AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. FAU - Xu, Yaqian AU - Xu Y AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. AD - Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China. FAU - Wang, Yaohui AU - Wang Y AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. wangyaohui@renji.com. FAU - Lin, Yanping AU - Lin Y AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. FAU - Zhang, Jie AU - Zhang J AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. FAU - Ye, Yumei AU - Ye Y AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. FAU - Xu, Shuguang AU - Xu S AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. FAU - Zhou, Liheng AU - Zhou L AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. FAU - Yin, Wenjin AU - Yin W AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. yinwenjin@renji.com. FAU - Lu, Jinsong AU - Lu J AUID- ORCID: 0000-0003-3147-0702 AD - Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, People's Republic of China. lujjss@163.com. LA - eng GR - 22YF1424500/Shanghai Sailing Program/ GR - 82103695/National Natural Science Foundation of China/ GR - SHDC2020CR3003A/Clinical Research Plan of Shanghai Hospital Development Center/ GR - YG2019QNA28/Multidisciplinary Cross Research Foundation of Shanghai Jiao Tong University/ GR - RJPY-LX-002/Nurturing Fund of Renji Hospital/ GR - PYIII20-09/Nurturing Fund of Renji Hospital/ GR - 21RJLY-002/Clinical Research Innovation Nurturing Fund of Renji Hospital and United Imaging/ GR - 20DZ2201600/Science and Technology Commission of Shanghai Municipality, Shanghai Municipal Key Clinical Specialty/ GR - 22QC1400200/Shanghai Rising-Star Program/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20221121 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Prospective Studies MH - Neoadjuvant Therapy MH - Disease-Free Survival MH - Receptor, ErbB-2/metabolism MH - Remission Induction MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use OTO - NOTNLM OT - Breast cancer OT - Immune score OT - Neoadjuvant chemotherapy OT - Peripheral immune cell subsets EDAT- 2022/11/22 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/21 11:17 PHST- 2022/05/10 00:00 [received] PHST- 2022/10/28 00:00 [accepted] PHST- 2022/11/22 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/21 11:17 [entrez] AID - 10.1007/s10549-022-06791-1 [pii] AID - 10.1007/s10549-022-06791-1 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):343-354. doi: 10.1007/s10549-022-06791-1. Epub 2022 Nov 21. PMID- 36552834 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230115 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 11 IP - 24 DP - 2022 Dec 15 TI - eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model. LID - 10.3390/cells11244069 [doi] LID - 4069 AB - Cells employ several adaptive mechanisms under conditions of accelerated cell division, such as the unfolded protein response (UPR). The UPR is composed of a tripartite signaling system that involves ATF6, PERK, and IRE1, which maintain protein homeostasis (proteostasis). However, deregulation of protein translation initiation could be associated with breast cancer (BC) chemoresistance. Specifically, eukaryotic initiation factor-4A (eIF4A) is involved in the unfolding of the secondary structures of several mRNAs at the 5' untranslated region (5'-UTR), as well as in the regulation of targets involved in chemoresistance. Importantly, the tumor suppressor gene PDCD4 could modulate this process. This regulation might be disrupted in chemoresistant triple negative-BC (TNBC) cells. Therefore, we characterized the effect of doxorubicin (Dox), a commonly used anthracycline medication, on human breast carcinoma MDA-MB-231 cells. Here, we generated and characterized models of Dox chemoresistance, and chemoresistant cells exhibited lower Dox internalization levels followed by alteration of the IRE1 and PERK arms of the UPR and triggering of the antioxidant Nrf2 axis. Critically, chemoresistant cells exhibited PDCD4 downregulation, which coincided with a reduction in eIF4A interaction, suggesting a sophisticated regulation of protein translation. Likewise, Dox-induced chemoresistance was associated with alterations in cellular migration and invasion, which are key cancer hallmarks, coupled with changes in focal adhesion kinase (FAK) activation and secretion of matrix metalloproteinase-9 (MMP-9). Moreover, eIF4A knockdown via siRNA and its overexpression in chemoresistant cells suggested that eIF4A regulates FAK. Pro-atherogenic low-density lipoproteins (LDL) promoted cellular invasion in parental and chemoresistant cells in an MMP-9-dependent manner. Moreover, Dox only inhibited parental cell invasion. Significantly, chemoresistance was modulated by cryptotanshinone (Cry), a natural terpene purified from the roots of Salvia brandegeei. Cry and Dox co-exposure induced chemosensitization, connected with the Cry effect on eIF4A interaction. We further demonstrated the Cry binding capability on eIF4A and in silico assays suggest Cry inhibition on the RNA-processing domain. Therefore, strategic disruption of protein translation initiation is a druggable pathway by natural compounds during chemoresistance in TNBC. However, plasmatic LDL levels should be closely monitored throughout treatment. FAU - González-Ortiz, Alina AU - González-Ortiz A AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Pulido-Capiz, Angel AU - Pulido-Capiz A AUID- ORCID: 0000-0001-9650-2555 AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio de Biología Molecular, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Castañeda-Sánchez, César Y AU - Castañeda-Sánchez CY AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Ibarra-López, Esmeralda AU - Ibarra-López E AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Galindo-Hernández, Octavio AU - Galindo-Hernández O AUID- ORCID: 0000-0003-4960-7551 AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Calderón-Fernández, Maritza Anahí AU - Calderón-Fernández MA AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - López-Cossio, Leslie Y AU - López-Cossio LY AUID- ORCID: 0000-0003-4443-0267 AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Díaz-Molina, Raul AU - Díaz-Molina R AUID- ORCID: 0000-0002-9400-5683 AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Chimal-Vega, Brenda AU - Chimal-Vega B AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Serafín-Higuera, Nicolás AU - Serafín-Higuera N AUID- ORCID: 0000-0002-0402-3985 AD - Facultad de Odontología Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. FAU - Córdova-Guerrero, Iván AU - Córdova-Guerrero I AUID- ORCID: 0000-0002-5528-400X AD - Facultad de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Tijuana 22424, Mexico. FAU - García-González, Victor AU - García-González V AUID- ORCID: 0000-0002-9421-3730 AD - Departamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. AD - Laboratorio Multidisciplinario de Estudios Metabólicos y Cáncer, Universidad Autónoma de Baja California, Mexicali 21000, Mexico. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221215 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - EC 2.7.7.- (Eukaryotic Initiation Factor-4A) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - 0 (RNA-Binding Proteins) RN - 0 (Apoptosis Regulatory Proteins) RN - 80168379AG (Doxorubicin) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - 0 (PDCD4 protein, human) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/drug therapy/genetics MH - Eukaryotic Initiation Factor-4A/chemistry/genetics/metabolism MH - Matrix Metalloproteinase 9/metabolism MH - Drug Resistance, Neoplasm MH - RNA-Binding Proteins/metabolism MH - Apoptosis Regulatory Proteins/metabolism MH - Doxorubicin/pharmacology MH - Protein Serine-Threonine Kinases/metabolism PMC - PMC9776898 OTO - NOTNLM OT - PDCD4 OT - breast cancer OT - chemoresistance OT - cryptotanshinone OT - eIF4A OT - proteostasis COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:18 PHST- 2022/07/28 00:00 [received] PHST- 2022/11/28 00:00 [revised] PHST- 2022/12/02 00:00 [accepted] PHST- 2022/12/23 01:18 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - cells11244069 [pii] AID - cells-11-04069 [pii] AID - 10.3390/cells11244069 [doi] PST - epublish SO - Cells. 2022 Dec 15;11(24):4069. doi: 10.3390/cells11244069. PMID- 36179501 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy. PG - 54-61 LID - S0960-9776(22)00158-8 [pii] LID - 10.1016/j.breast.2022.09.004 [doi] AB - AIM: Both skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) have been widely adopted. Although postmastectomy radiation therapy (PMRT) can improve clinical outcomes, it can worsen cosmesis following reconstruction. Therefore, identifying risk factors of ipsilateral breast tumor recurrence (IBTR) could help de-escalate PMRT after NSM/SSM in patients with pT1-2 disease. METHODS: We retrospectively reviewed patients treated with SSM (N = 400) and NSM (N = 156) in patients with pT1-2N0-1 disease between 2009 and 2016. Seventy-four patients received PMRT with 50-50.4 Gy in 25-28 fractions. The Cox proportional hazards model was used to analyze the prognostic factors of IBTR. RESULTS: With a median follow-up of 66.2 months, 17 IBTR events were observed, with 5-year IBTR-free rate of 97.2%. Although only one IBTR was observed after PMRT, there was no statistical difference in the 5-year IBTR-free rate (PMRT vs. no PMRT, 98.6% vs. 97.0%, p = 0.360). Multivariable analyses demonstrated that age ≤45 years and lymphovascular invasion (LVI) were adverse features of IBTR. The low-risk group (0 risk factor) showed a better 5-year IBTR-free rate than the high-risk group (≥1 risk factor) (100.0% vs. 95.8%, p = 0.003). In the high-risk group, PMRT slightly improved 5-year IBTR-free rate compared with no PMRT (98.6% vs. 95.2%, p = 0.166). In addition, PMRT increased 5-year cumulative incidence of reconstruction failure (10.0% vs. 2.8%, p = 0.001). CONCLUSION: We identified risk factors (age and LVI) related to IBTR following upfront SSM/NSM with pT1-2 disease. As a hypothesis-generating study, de-escalation of PMRT by omitting chest wall irradiation in selective patients could improve reconstruction-related complications without compromising oncologic outcomes. CI - Copyright © 2022. Published by Elsevier Ltd. FAU - Kim, Nalee AU - Kim N AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Park, Won AU - Park W AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: wonro.park@samsung.com. FAU - Cho, Won Kyung AU - Cho WK AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Kim, Hae Young AU - Kim HY AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Choi, Doo Ho AU - Choi DH AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Nam, Seok Jin AU - Nam SJ AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Kim, Seok Won AU - Kim SW AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Lee, Jeong Eon AU - Lee JE AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Yu, Jonghan AU - Yu J AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Chae, Byung Joo AU - Chae BJ AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Lee, Se Kyung AU - Lee SK AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Ryu, Jai Min AU - Ryu JM AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Mun, Goo-Hyun AU - Mun GH AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Pyon, Jai-Kyong AU - Pyon JK AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Jeon, Byung-Joon AU - Jeon BJ AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20220923 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 SB - IM MH - Humans MH - Middle Aged MH - Female MH - Mastectomy MH - *Breast Neoplasms/radiotherapy/surgery/pathology MH - Retrospective Studies MH - Nipples/surgery/pathology MH - *Thoracic Wall/pathology/surgery MH - Neoplasm Recurrence, Local/pathology MH - *Mammaplasty PMC - PMC9526229 OTO - NOTNLM OT - Breast cancer OT - Local recurrence OT - Mastectomy OT - Nipple-sparing mastectomy OT - Radiation therapy OT - Skin-sparing mastectomy COIS- Declaration of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/10/01 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/09/30 18:24 PHST- 2022/07/20 00:00 [received] PHST- 2022/08/24 00:00 [revised] PHST- 2022/09/19 00:00 [accepted] PHST- 2022/10/01 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/09/30 18:24 [entrez] AID - S0960-9776(22)00158-8 [pii] AID - 10.1016/j.breast.2022.09.004 [doi] PST - ppublish SO - Breast. 2022 Dec;66:54-61. doi: 10.1016/j.breast.2022.09.004. Epub 2022 Sep 23. PMID- 36641650 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Vitamin D during treatment for breast cancer - the perspective of active self-help group leaders. PG - 503-511 LID - 10.3233/BD-210070 [doi] AB - BACKGROUND: In breast cancer patients, there is an elevated risk of developing osteoporosis during treatment which should be addressed by optimizing 25(OH) levels. OBJECTIVE: The aim was to assess the prescription, information and physician-patient communication on vitamin D and bone density in Germany. METHODS: We developed a standardized questionnaire concerning bone density measurement, vitamin D (blood level testing, prescription), information and communication regarding vitamin D. The questionnaire was distributed at the annual meeting of all group leaders of the Women's Cancer Support Association to all participants. RESULTS: Overall, 224 participants completed the questionnaire; 77.7% reported having had at least one bone density measurement test. The number was 84.4% in patients treated with aromatase inhibitor and 43.7% reported that their bone density was too low. In total, 51.3% patients reported at least one vitamin D blood test and 45.1% reported that vitamin D had been primarily addressed by a physician. As many as 74.1% of those reporting a test result had a deficiency; 91.6% of those with a low level got a prescription and 28.4% took vitamin D autonomously. CONCLUSIONS: The awareness on risk of osteoporosis, prevention, early diagnosis and treatment are insufficiently addressed in a patient group with high risk of osteoporosis. More attention should be paid to the phenomenon of vitamin D deficiency or insufficiency in routine care. FAU - Muecke, Ralph AU - Muecke R AD - Department of Radiotherapy and Radiation Oncology, Marien Hospital Herne, Ruhr University Bochum, Bochum, Germany. AD - Radiotherapy RheinMainNahe, Bad Kreuznach, Germany. FAU - Dubois, Clara AU - Dubois C AD - Department of Internal Medicine II, Jena University Hospital, Jena, Germany. FAU - Micke, Oliver AU - Micke O AD - Department of Radiotherapy and Radiation Oncology, Franziskus Hospital, Bielefeld, Germany. FAU - Keinki, Christian AU - Keinki C AD - Department of Internal Medicine II, Jena University Hospital, Jena, Germany. FAU - Huebner, Jutta AU - Huebner J AD - Department of Internal Medicine II, Jena University Hospital, Jena, Germany. LA - eng PT - Journal Article PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 RN - 1406-16-2 (Vitamin D) SB - IM MH - Humans MH - Female MH - Vitamin D/therapeutic use MH - *Breast Neoplasms/drug therapy MH - *Osteoporosis/diagnosis/prevention & control MH - *Vitamin D Deficiency/complications/prevention & control MH - Self-Help Groups OTO - NOTNLM OT - Vitamin D OT - breast cancer OT - endocrine therapy OT - osteoporosis OT - patient information needs OT - patient-physician communication EDAT- 2023/01/16 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/15 05:22 PHST- 2023/01/15 05:22 [entrez] PHST- 2023/01/16 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - BD210070 [pii] AID - 10.3233/BD-210070 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):503-511. doi: 10.3233/BD-210070. PMID- 36350472 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Development of a key performance indicator for breast cancer in Queensland, Australia. PG - 211-221 LID - 10.1007/s10549-022-06796-w [doi] AB - PURPOSE: Using population-based data for women diagnosed with stage I-III breast cancer, our aim was to examine the impact of time to treatment completion on survival and to identify factors associated with treatment delay. METHODS: This retrospective study used clinical and treatment data from the Queensland Oncology Repository. Time from diagnosis to completing surgery, chemotherapy and radiation therapy identified a cut-off of 37 weeks as the optimal threshold for completing treatment. Logistic regression was used to identify factors associated with the likelihood of completing treatment > 37 weeks. Overall (OS) and breast cancer-specific survival (BCSS) were examined using Cox proportional hazards models. RESULTS: Of 8279 women with stage I-III breast cancer, 31.9% completed treatment > 37 weeks. Apart from several clinical factors, being Indigenous (p = 0.002), living in a disadvantaged area (p = 0.003) and receiving ≥ two treatment modalities within the public sector (p < 0.001) were associated with an increased likelihood of completing treatment > 37 weeks. The risk of death from any cause was about 40% higher for women whose treatment went beyond 37 weeks (HR 1.37, 95%CI 1.16-1.61), a similar result was observed for BCSS. Using the surgery + chemotherapy + radiation pathway, a delay of > 6.9 weeks from surgery to starting chemotherapy was significantly associated with poorer survival (p = 0.001). CONCLUSIONS: Several sociodemographic and system-related factors were associated with a greater likelihood of treatment completion > 37 weeks. We are proposing a key performance indicator for the management of early breast cancer where a facility should have > 90% of patients with a time from surgery to adjuvant chemotherapy < 6.9 weeks. CI - © 2022. Crown. FAU - Walpole, Euan T AU - Walpole ET AUID- ORCID: 0000-0001-6105-9039 AD - Division of Cancer Services, Princess Alexandra Hospital, Ipswich Road, Brisbane, Woolloongabba, QLD, 4102, Australia. Euan.Walpole@health.qld.gov.au. AD - The University of Queensland, Brisbane, QLD, Australia. Euan.Walpole@health.qld.gov.au. AD - Queensland Cancer Control Safety and Quality Partnership, Metro South Hospital and Health Service, Woolloongabba, QLD, Australia. Euan.Walpole@health.qld.gov.au. FAU - Youl, Philippa H AU - Youl PH AD - Cancer Alliance Queensland, Metro South Hospital and Health Service, Princess Alexandra Hospital, Burke Street, Woolloongabba, Qld, 4102, Australia. FAU - Moore, Julie AU - Moore J AD - Cancer Alliance Queensland, Metro South Hospital and Health Service, Princess Alexandra Hospital, Burke Street, Woolloongabba, Qld, 4102, Australia. FAU - Morris, Michelle AU - Morris M AD - Sunshine Coast Hospital and Health Service, Sunshine Coast University Hospital, 6 Doherty Street, Birtinya, Qld, 4575, Australia. FAU - Cossio, Danica AU - Cossio D AD - Cancer Alliance Queensland, Metro South Hospital and Health Service, Princess Alexandra Hospital, Burke Street, Woolloongabba, Qld, 4102, Australia. FAU - Dhanda, Pardeep AU - Dhanda P AD - Cancer Alliance Queensland, Metro South Hospital and Health Service, Princess Alexandra Hospital, Burke Street, Woolloongabba, Qld, 4102, Australia. FAU - Theile, David E AU - Theile DE AD - Queensland Cancer Control Safety and Quality Partnership, Metro South Hospital and Health Service, Woolloongabba, QLD, Australia. AD - Cancer Alliance Queensland, Metro South Hospital and Health Service, Princess Alexandra Hospital, Burke Street, Woolloongabba, Qld, 4102, Australia. AD - Translational Research Institute, University of Queensland, Brisbane, Qld, Australia. FAU - Philpot, Shoni AU - Philpot S AD - Cancer Alliance Queensland, Metro South Hospital and Health Service, Princess Alexandra Hospital, Burke Street, Woolloongabba, Qld, 4102, Australia. LA - eng PT - Journal Article DEP - 20221109 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/epidemiology/therapy MH - Queensland/epidemiology MH - Retrospective Studies MH - Combined Modality Therapy MH - Chemotherapy, Adjuvant MH - Australia MH - Proportional Hazards Models MH - Neoplasm Staging PMC - PMC9823022 OTO - NOTNLM OT - Breast cancer OT - Management OT - Survival OT - Treatment COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/11/10 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/09 11:19 PHST- 2022/08/23 00:00 [received] PHST- 2022/10/30 00:00 [accepted] PHST- 2022/11/10 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/09 11:19 [entrez] AID - 10.1007/s10549-022-06796-w [pii] AID - 6796 [pii] AID - 10.1007/s10549-022-06796-w [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):211-221. doi: 10.1007/s10549-022-06796-w. Epub 2022 Nov 9. PMID- 36417042 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry. PG - 377-385 LID - 10.1007/s10549-022-06807-w [doi] AB - PURPOSE: The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LIR after primary IBC. METHODS: We designed a retrospective study using data from the specialized Côte d'Or Breast and Gynecological cancer registry, between 1998 and 2015, to compare outcomes between 3 matched groups of patients with localized IBC: patients with LIR following CIS (CIS-LIR), patients with de novo IBC (de novo IBC), and patients with LIR following a first IBC (IBC-LIR). Distant relapse-free (D-RFS), overall survival (OS), clinical, and treatment features between the 3 groups were studied. RESULTS: Among 8186 women initially diagnosed with IBC during our study period, we retrieved and matched 49 CIS-LIR to 49 IBC, and 46 IBC-LIR patients. At diagnosis, IBC/LIR in the 3 groups were mainly stage I, grade II, estrogen receptor-positive, and HER2 negative. Metastatic diseases at diagnosis were higher in CIS-LIR group. A majority of patients received adjuvant systemic treatment, with no statistically significant differences between the 3 groups. There was no significant difference between the 3 groups in terms of OS or D-RFS. CONCLUSION: LIR after CIS does not appear to impact per se on survival of IBC. CI - © 2022. The Author(s). FAU - Kada Mohammed, Samia AU - Kada Mohammed S AUID- ORCID: 0000-0001-8782-6849 AD - Department of Gynaecology and Obstetrics, Assistance Publique des Hôpitaux de Paris (APHP), Jean Verdier Hospital, Avenue du 14 Juillet, 93140, Bondy, France. FAU - Dabakuyo Yonli, Tienhan Sandrine AU - Dabakuyo Yonli TS AD - Breast and Gynaecologic Cancer Registry of Côte d'Or, Epidemiology and Quality of Life Research Unit, Georges-François Leclerc Comprehensive Cancer Centre-UNICANCER, 1 rue du Professeur Marion, 21000, Dijon, France. AD - INSERM U1231, 21000, Dijon, France. FAU - Desmoulins, Isabelle AU - Desmoulins I AD - Department of Medical Oncology, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Manguem Kamga, Ariane AU - Manguem Kamga A AD - Breast and Gynaecologic Cancer Registry of Côte d'Or, Epidemiology and Quality of Life Research Unit, Georges-François Leclerc Comprehensive Cancer Centre-UNICANCER, 1 rue du Professeur Marion, 21000, Dijon, France. AD - INSERM U1231, 21000, Dijon, France. FAU - Jankowski, Clémentine AU - Jankowski C AD - Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Padeano, Marie-Martine AU - Padeano MM AD - Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Loustalot, Catherine AU - Loustalot C AD - Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Costaz, Hélène AU - Costaz H AD - Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Causeret, Sylvain AU - Causeret S AD - Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Peignaux, Karine AU - Peignaux K AD - Department of Radiotherapy, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Rouffiac, Magali AU - Rouffiac M AD - Department of Radiotherapy, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Coutant, Charles AU - Coutant C AD - Department of Surgery, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. AD - University of Burgundy-Franche Comté, 21000, Dijon, France. FAU - Arnould, Laurent AU - Arnould L AD - Unit of Pathology, Department of Tumour Biology and Pathology, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. FAU - Ladoire, Sylvain AU - Ladoire S AD - INSERM U1231, 21000, Dijon, France. sladoire@cgfl.fr. AD - Department of Medical Oncology, Georges-François Leclerc Centre, 1 rue du Professeur Marion, 21000, Dijon, France. sladoire@cgfl.fr. AD - University of Burgundy-Franche Comté, 21000, Dijon, France. sladoire@cgfl.fr. LA - eng PT - Journal Article DEP - 20221123 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/epidemiology/therapy/pathology MH - Retrospective Studies MH - *Carcinoma, Intraductal, Noninfiltrating/pathology MH - Neoplasm Recurrence, Local/epidemiology MH - Prognosis MH - *Carcinoma in Situ/epidemiology/therapy PMC - PMC9823085 OTO - NOTNLM OT - Breast cancer OT - DCIS OT - Ductal carcinoma in situ OT - Local invasive recurrence OT - Survival OT - Systemic adjuvant therapies COIS- The authors declare no competing interests. EDAT- 2022/11/24 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/23 12:09 PHST- 2022/07/01 00:00 [received] PHST- 2022/10/30 00:00 [accepted] PHST- 2022/11/24 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/23 12:09 [entrez] AID - 10.1007/s10549-022-06807-w [pii] AID - 6807 [pii] AID - 10.1007/s10549-022-06807-w [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):377-385. doi: 10.1007/s10549-022-06807-w. Epub 2022 Nov 23. PMID- 36287309 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Combining reconstructive and ablative surgical treatment of chronic breast cancer-related lymphedema (BCRL): safe and effective. PG - 83-92 LID - 10.1007/s10549-022-06778-y [doi] AB - PURPOSE: We investigated whether a one-stage combination of vascularized lymph node transfer (VLNT) with water jet-assisted liposuction (WAL) can be safely performed and results in improved patient outcomes such as a greater reduction in arm volume when treating chronic breast cancer-related lymphedema (BCRL). METHODS: In this retrospective cohort study, we included all patients from our encrypted lymphedema database treated for chronic BCRL with VLNT or VLNT + WAL who had a minimum follow-up of two years. We analyzed patient-specific variables including arm circumferences as well as patient-reported outcomes before and after surgery as well as surgery time, surgery-related complications and patient satisfaction. RESULTS: Only the mean preoperative differences of the circumferences between the lymphedematous and the unaffected arm in individual patients showed a statistically significant difference between treatment groups (p < 0.05). Indeed, patients treated with VLNT + WAL had consistently larger differences in individual sets of arms and therefore more pronounced chronic BCRL. The mean surgery time was significantly longer in the VLNT + WAL group (p < 0.05). Complications were seldom and similar in both groups. Using a numeric rating scale, the level of patient satisfaction following treatment did not differ significantly between groups (p = 0.323). CONCLUSIONS: Our findings suggest that a one-stage combination of VLNT with WAL does not result in more complications even though it also entails a longer surgery time. This is acceptable as secondary interventions resulting in overall longer surgery times and higher costs can be avoided. A one-stage combination might be especially favourable for patients suffering from more severe chronic BCRL. CI - © 2022. The Author(s). FAU - Ghazaleh, Alina A AU - Ghazaleh AA AD - Department of Plastic, Reconstructive and Aesthetic Surgery, Sana Hospital Benrath, Duesseldorf, Germany. FAU - Handschin, Tristan M AU - Handschin TM AUID- ORCID: 0000-0002-4384-6319 AD - Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital of Basel, Basel, Switzerland. AD - University of Basel, Basel, Switzerland. FAU - Buckowiecki, Julia AU - Buckowiecki J AD - Department of Plastic, Reconstructive and Aesthetic Surgery, Sana Hospital Benrath, Duesseldorf, Germany. FAU - Chammartin, Frédérique S AU - Chammartin FS AD - Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital and University of Basel, Basel, Switzerland. FAU - Andree, Christoph AU - Andree C AD - Department of Plastic, Reconstructive and Aesthetic Surgery, Sana Hospital Gerresheim, Duesselorf, Germany. FAU - Schaefer, Dirk J AU - Schaefer DJ AD - Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital of Basel, Basel, Switzerland. AD - University of Basel, Basel, Switzerland. FAU - Haug, Martin AU - Haug M AD - Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital of Basel, Basel, Switzerland. AD - University of Basel, Basel, Switzerland. AD - Breast Center, University Hospital of Basel, Basel, Switzerland. FAU - Kappos, Elisabeth A AU - Kappos EA AD - Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital of Basel, Basel, Switzerland. elisabeth.kappos@usb.ch. AD - University of Basel, Basel, Switzerland. elisabeth.kappos@usb.ch. AD - Breast Center, University Hospital of Basel, Basel, Switzerland. elisabeth.kappos@usb.ch. FAU - Seidenstuecker, Katrin AU - Seidenstuecker K AD - Department of Plastic, Reconstructive and Aesthetic Surgery, Sana Hospital Benrath, Duesseldorf, Germany. LA - eng PT - Journal Article DEP - 20221026 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - *Breast Neoplasms/complications/surgery MH - *Breast Cancer Lymphedema/etiology/surgery MH - *Lymphedema/etiology/surgery MH - Arm MH - Lymph Nodes PMC - PMC9823021 OTO - NOTNLM OT - Breast cancer OT - Breast cancer-related lymphedema OT - Chronic lymphedema OT - Lymphatic surgery OT - VLNT OT - WAL EDAT- 2022/10/27 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/10/26 11:17 PHST- 2022/09/15 00:00 [received] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/10/27 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/10/26 11:17 [entrez] AID - 10.1007/s10549-022-06778-y [pii] AID - 6778 [pii] AID - 10.1007/s10549-022-06778-y [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):83-92. doi: 10.1007/s10549-022-06778-y. Epub 2022 Oct 26. PMID- 35636394 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 1877-8879 (Electronic) IS - 1877-8860 (Linking) VI - 23 IP - 1 DP - 2023 Jan 27 TI - Neuropathy and pain after breast cancer treatment: a prospective observational study. PG - 49-58 LID - 10.1515/sjpain-2022-0017 [doi] AB - OBJECTIVES: Neurological complications including pain are common after treatment for breast cancer. This prospective study investigated the symptoms, intensity and interference of chemotherapy-induced peripheral neuro-pathy. (CIPN) in the feet and hands compared to surgery- and radiation-induced neuropathy in the breast and upper arm. METHODS: Consecutive patients referred to surgery for breast cancer were included in a prospective study and completed a questionnaire at baseline and a follow-up questionnaire and interview after one year. CIPN was assessed with the CIPN20 questionnaire and the Michigan Neuropathy Screening Instrument questionnaire (MNSIq). Pain intensity was rated on a numeric rating scale (NRS, 0-10). RESULTS: In total 144 patients were included, of which 73 received chemotherapy. At one-year follow-up, symptoms of polyneuropathy were more common in patients treated with chemotherapy. Tingling or numbness in the feet in those treated/not treated with chemotherapy was reported by 44 (62%) and 15 (21%), respectively. Pain was present in 22 (30%) and 10 (14%), respectively. Pain in the area of surgery was reported by 66 (46%). Although less common, pain in the feet in those treated with chemotherapy was rated as more intense and with more daily life interference than pain in the surgical area (NRS 5.5 (SD 1.9) vs. 3.1 (SD 1.9). CONCLUSIONS: Neurological complications including pain following surgery and chemotherapy represent a burden to breast cancer survivors. In those who had received chemotherapy, pain in the feet was less common than pain in the surgical area, but pain in the feet was more intense and had a higher interference with daily life. Our study emphasizes the need for either baseline data or a control population for improved estimation of the presence and severity of CIPN and pain from questionnaires. CI - © 2022 Kristine Bennedsgaard et al., published by De Gruyter, Berlin/Boston. FAU - Bennedsgaard, Kristine AU - Bennedsgaard K AD - Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. FAU - Grosen, Kasper AU - Grosen K AD - Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Research Centre for Health and Welfare Technology, VIA University College, Aarhus, Denmark. FAU - Attal, Nadine AU - Attal N AD - Inserm U987, AP-HP, CHU Ambroise Paré hospital, UVSQ, Paris-Saclay University, Boulogne-Billancourt, France. FAU - Bouhassira, Didier AU - Bouhassira D AD - Inserm U987, AP-HP, CHU Ambroise Paré hospital, UVSQ, Paris-Saclay University, Boulogne-Billancourt, France. FAU - Crombez, Geert AU - Crombez G AD - Department of Experimental Clinical and Health Psychology, Ghent University, Ghent, Belgium. FAU - Jensen, Troels S AU - Jensen TS AD - Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Bennett, David L AU - Bennett DL AD - Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK. FAU - Ventzel, Lise AU - Ventzel L AD - Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. AD - Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark. FAU - Andersen, Inge S AU - Andersen IS AD - Department of Breast Surgery, Hospitalsenheden Midt, Viborg, Denmark. FAU - Finnerup, Nanna B AU - Finnerup NB AUID- ORCID: 0000-0001-5541-0240 AD - Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. LA - eng PT - Journal Article PT - Observational Study DEP - 20220601 PL - Germany TA - Scand J Pain JT - Scandinavian journal of pain JID - 101520867 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/complications/drug therapy MH - Prospective Studies MH - *Peripheral Nervous System Diseases/chemically induced/diagnosis/therapy MH - Pain/diagnosis MH - Surveys and Questionnaires OTO - NOTNLM OT - CIPN OT - breast cancer OT - chemotherapy OT - lumpectomy OT - mastectomy OT - polyneuropathy EDAT- 2022/06/01 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/05/31 13:20 PHST- 2022/01/19 00:00 [received] PHST- 2022/05/17 00:00 [accepted] PHST- 2022/06/01 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/05/31 13:20 [entrez] AID - sjpain-2022-0017 [pii] AID - 10.1515/sjpain-2022-0017 [doi] PST - epublish SO - Scand J Pain. 2022 Jun 1;23(1):49-58. doi: 10.1515/sjpain-2022-0017. Print 2023 Jan 27. PMID- 36535227 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 241 DP - 2023 Jan TI - Expression of Treg-associated lncRNAs in breast cancer. PG - 154270 LID - S0344-0338(22)00514-3 [pii] LID - 10.1016/j.prp.2022.154270 [doi] AB - Regulatory T cells (Tregs) have important functions in tumor microenvironment, particularly for induction of immune evasion. In order to find the underlying mechanism of dysregulation of Tregs in breast cancer tissues, we designed the current study to appraise expression of five Treg-related long non-coding RNAs (lncRNAs), namely FLICR (FOXP3 Regulating Long Intergenic Non-Coding RNA), NEST (IFNG-AS1), RMRP (RNA Component of Mitochondrial RNA Processing Endoribonuclease), MAFTRR (MAF Transcriptional Regulator RNA) and TH2-LCR (Th2 Cytokine Locus Control Region) in paired breast cancer and nearby noncancerous tissues. Expression levels of RMRP, TH2-LCR, MAFTRR and GATA3-AS1 were significantly higher in breast cancer samples compared with non-tumoral tissues. The calculated AUC values for GATA3-AS1, TH2-LCR, RMRP and MAFTRR were 0.66, 0.63, 0.63 and 0.60, respectively. There were significant positive associations between expression level of RMRP gene in tumor tissues and nuclear grade, tubule formation and tumor sizes. In addition, there was a significant positive association between expression levels of MAFTRR genes in tumor tissues and nuclear grade. Besides, expression levels of FLICR were different among tumors with different levels of HER2/neu receptor. Taken together, Treg-associated lncRNAs might contribute to the pathogenesis of breast cancer. CI - Copyright © 2022 Elsevier GmbH. All rights reserved. FAU - Moallemi-Rad, Lina AU - Moallemi-Rad L AD - Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Islamic Republic of Iran. FAU - Ghorbani, Amin AU - Ghorbani A AD - Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Islamic Republic of Iran. FAU - Dadyar, Maryam AU - Dadyar M AD - Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran. FAU - Hussen, Bashdar Mahmud AU - Hussen BM AD - Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, Iraq. FAU - Rasul, Mohammed Fatih AU - Rasul MF AD - Department of Pharmaceutical Basic Science, Faculty of Pharmacy, Tishk International University, Erbil, Kurdistan Region, Iraq. FAU - Eslami, Solat AU - Eslami S AD - Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Islamic Republic of Iran; Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Islamic Republic of Iran. FAU - Taheri, Mohammad AU - Taheri M AD - Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran; Institute of Human Genetics, Jena University Hospital, Jena, Germany. Electronic address: mohammad.taheri@uni-jena.de. FAU - Jamali, Elena AU - Jamali E AD - Department of Pathology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran. Electronic address: elena.jamali@yahoo.com. FAU - Ghafouri-Fard, Soudeh AU - Ghafouri-Fard S AD - Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran. Electronic address: s.ghaforuifard@sbmu.ac.ir. LA - eng PT - Journal Article DEP - 20221207 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (RNA, Long Noncoding) RN - 0 (Cytokines) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/pathology MH - *RNA, Long Noncoding/genetics/metabolism MH - T-Lymphocytes, Regulatory/metabolism MH - Cytokines/metabolism MH - Gene Expression Regulation, Neoplastic/genetics MH - Tumor Microenvironment OTO - NOTNLM OT - Breast cancer OT - LncRNA OT - Regulatory T cell COIS- Competing interest The authors declare they have no conflict of interest. EDAT- 2022/12/20 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/12/19 18:27 PHST- 2022/11/06 00:00 [received] PHST- 2022/12/04 00:00 [revised] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/20 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/12/19 18:27 [entrez] AID - S0344-0338(22)00514-3 [pii] AID - 10.1016/j.prp.2022.154270 [doi] PST - ppublish SO - Pathol Res Pract. 2023 Jan;241:154270. doi: 10.1016/j.prp.2022.154270. Epub 2022 Dec 7. PMID- 36472353 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1537-453X (Electronic) IS - 0277-3732 (Linking) VI - 46 IP - 1 DP - 2023 Jan 1 TI - Accelerated Partial Breast Irradiation: Florence Phase 3 Trial Experience and Future Perspectives. PG - 10-15 LID - 10.1097/COC.0000000000000968 [doi] AB - Accelerated partial breast irradiation Florence phase 3 trial is a single-center study comparing intensity-modulated based accelerated partial breast irradiation (PBI, 30 Gy in 5 fractions) and whole breast irradiation (50 Gy in 25 fractions) followed by a tumor bed boost (10 Gy in 5 fractions). This easy-to-deliver PBI approach showed excellent long-term disease control with favorable safety and cosmetic outcome profiles. A plateau has been probably reached concerning the reduction of the number of fractions in the postoperative PBI setting. A 5-fraction schedule is the standard regimen and probably the appropriate compromise in terms of efficacy, safety, and quality of life, also considering the negative results of most intraoperative single-fraction PBI trials. A new frontier is now open on the potential benefit of preoperative PBI delivery, although concerns remain on the optimal dose, fractionation, and technique. Hereby we report the accelerated PBI Florence phase 3 trial experience and future perspectives. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Meattini, Icro AU - Meattini I AUID- ORCID: 0000-0002-1861-2895 AD - Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence. AD - Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. FAU - Kim, Kyubo AU - Kim K AD - Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. AD - Department of Radiation Oncology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea. FAU - Livi, Lorenzo AU - Livi L AD - Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence. AD - Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. LA - eng PT - Clinical Trial, Phase III PT - Journal Article DEP - 20221206 PL - United States TA - Am J Clin Oncol JT - American journal of clinical oncology JID - 8207754 SB - IM MH - Humans MH - Female MH - *Quality of Life MH - Mastectomy, Segmental MH - Dose Fractionation, Radiation MH - *Breast Neoplasms/radiotherapy/surgery/pathology MH - Breast/pathology/radiation effects COIS- I.M.: reports as occasional speaker honoraria supported by Eli Lilly, Novartis, Pfizer, Accuray, and Seagen, outside the submitted work. The remaining authors declare no conflicts of interest. EDAT- 2022/12/07 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/06 07:33 PHST- 2022/12/07 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/12/06 07:33 [entrez] AID - 00000421-990000000-00056 [pii] AID - 10.1097/COC.0000000000000968 [doi] PST - ppublish SO - Am J Clin Oncol. 2023 Jan 1;46(1):10-15. doi: 10.1097/COC.0000000000000968. Epub 2022 Dec 6. PMID- 36462440 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1768-3254 (Electronic) IS - 0223-5234 (Linking) VI - 246 DP - 2023 Jan 15 TI - Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents. PG - 114971 LID - S0223-5234(22)00873-X [pii] LID - 10.1016/j.ejmech.2022.114971 [doi] AB - The biochemical role of the PI3K/PKB/mTOR signalling pathway in cell-cycle regulation is now well known. During the onset and development of different forms of cancer it becomes overactive reducing apoptosis and allowing cell proliferation. Therefore, this pathway has become an important target for the treatment of various forms of malignant tumors, including breast cancer and follicular lymphoma. Recently, several more or less selective inhibitors targeting these proteins have been identified. In general, drugs that act on multiple targets within the entire pathway are more efficient than single targeting inhibitors. Multiple inhibitors exhibit high potency and limited drug resistance, resulting in promising anticancer agents. In this context, the present survey focuses on small molecule drugs capable of modulating the PI3K/PKB/mTOR signalling pathway, thus representing drugs or drug candidates to be used in the pharmacological treatment of different forms of cancer. CI - Copyright © 2022 Elsevier Masson SAS. All rights reserved. FAU - Occhiuzzi, Maria Antonietta AU - Occhiuzzi MA AD - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. FAU - Lico, Gernando AU - Lico G AD - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. FAU - Ioele, Giuseppina AU - Ioele G AD - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. FAU - De Luca, Michele AU - De Luca M AD - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. FAU - Garofalo, Antonio AU - Garofalo A AD - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. FAU - Grande, Fedora AU - Grande F AD - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. Electronic address: fedora.grande@unical.it. LA - eng PT - Journal Article PT - Review DEP - 20221128 PL - France TA - Eur J Med Chem JT - European journal of medicinal chemistry JID - 0420510 RN - 0 (MTOR Inhibitors) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 0 (Antineoplastic Agents) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.1.1 (MTOR protein, human) SB - IM MH - Humans MH - Female MH - MTOR Inhibitors MH - Phosphatidylinositol 3-Kinases/metabolism MH - TOR Serine-Threonine Kinases/metabolism MH - *Antineoplastic Agents/chemistry MH - *Breast Neoplasms/drug therapy MH - Proto-Oncogene Proteins c-akt/metabolism OTO - NOTNLM OT - Cancer therapy OT - Dual inhibitors OT - Protein kinases OT - Rapamycin COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/04 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/03 18:24 PHST- 2022/08/17 00:00 [received] PHST- 2022/11/22 00:00 [revised] PHST- 2022/11/23 00:00 [accepted] PHST- 2022/12/04 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/03 18:24 [entrez] AID - S0223-5234(22)00873-X [pii] AID - 10.1016/j.ejmech.2022.114971 [doi] PST - ppublish SO - Eur J Med Chem. 2023 Jan 15;246:114971. doi: 10.1016/j.ejmech.2022.114971. Epub 2022 Nov 28. PMID- 36632463 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1449-2288 (Electronic) IS - 1449-2288 (Linking) VI - 19 IP - 2 DP - 2023 TI - Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression. PG - 377-392 LID - 10.7150/ijbs.75852 [doi] AB - HER2 is a transmembrane receptor with intrinsic tyrosine kinase activity that is overexpressed in almost 25% of human breast cancers. Here, we report that the neddylation of HER2 is a new post-translational modification that controls its expression and oncogenic activity in human breast cancer. Two critical members in the neddylation pathway, NEDD8 and NEDD8-activating enzyme E1 subunit 1 (NAE1), are detected in human breast specimens. Overexpressed NEDD8 and NAE1 are positively correlated with HER2 expression in human breast cancer. Subsequent structure and function experiments show that HER2 directly interacts with NEDD8 and NAE1, whereas HER2 protein expression is decreased by neddylation depletion. Mechanistically, neddylation inhibition promotes the degradation of HER2 protein by improving its ubiquitination. HER2 overexpression abrogates neddylation depletion-triggered cell growth suppression. The inhibition of neddylation synergized with trastuzumab significantly suppresses growth of HER2 positive breast cancer. Collectively, this study demonstrates a previously undiscovered role of NEDD8-dependent HER2 neddylation promotes tumor growth in breast cancer. CI - © The author(s). FAU - Xia, Xiaohong AU - Xia X AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. FAU - Hu, Tumei AU - Hu T AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. FAU - He, Xiaoyue AU - He X AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. FAU - Liu, Yuan AU - Liu Y AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. FAU - Yu, Cuifu AU - Yu C AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. FAU - Kong, Weiyao AU - Kong W AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. FAU - Liao, Yuning AU - Liao Y AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. FAU - Tang, Daolin AU - Tang D AD - Department of Surgery, UT Southwestern Medical Center, Dallas, Texas 75390, USA. FAU - Liu, Jinbao AU - Liu J AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. FAU - Huang, Hongbiao AU - Huang H AD - Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China. AD - Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China. LA - eng PT - Journal Article DEP - 20230101 PL - Australia TA - Int J Biol Sci JT - International journal of biological sciences JID - 101235568 RN - 0 (Ubiquitins) SB - IM MH - Humans MH - Female MH - Proteolysis MH - *Breast Neoplasms/drug therapy/genetics MH - Ubiquitins/genetics/metabolism MH - Protein Processing, Post-Translational MH - Ubiquitination PMC - PMC9830515 OTO - NOTNLM OT - HER2 OT - breast cancer OT - degradation OT - neddylation OT - ubiquitin COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2023/01/13 06:00 MHDA- 2023/01/14 06:00 CRDT- 2023/01/12 02:01 PHST- 2022/06/06 00:00 [received] PHST- 2022/11/19 00:00 [accepted] PHST- 2023/01/12 02:01 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] AID - ijbsv19p0377 [pii] AID - 10.7150/ijbs.75852 [doi] PST - epublish SO - Int J Biol Sci. 2023 Jan 1;19(2):377-392. doi: 10.7150/ijbs.75852. eCollection 2023. PMID- 36566598 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 241 DP - 2023 Jan TI - Identification of KCNK1 as a potential prognostic biomarker and therapeutic target of breast cancer. PG - 154286 LID - S0344-0338(22)00530-1 [pii] LID - 10.1016/j.prp.2022.154286 [doi] AB - BACKGROUND: Breast cancer is the most common malignant cancer and is the second most common cause of cancer-related deaths among females worldwide. Thus, it warrants the urgent development of new therapeutic targets and strategies. Potassium channels are aberrantly expressed in various tumors and are related to tumor progression. However, studies on potassium channels in breast cancer remain limited. METHOD: First, The Cancer Genome Atlas (TCGA) and Gene Set Enrichment Analysis (GSEA) were used to screen the differentially expressed potassium channels in breast cancer. Several other databases were utilized for further data analysis and visualization, including Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Human Protein Atlas (HPA), GeneMANIA, Tumor Immune Estimation Resource 2 (TIMER2), Catalog of Somatic Mutations in Cancer (COSMIC), cBioPortal, and UCSC Xena tool. Besides, cell proliferation was detected by cell counting kit-8 (CCK8) and 5-Ethynyl-20-deoxyuridine (EdU), and cell migration was detected by wound healing and Transwell assays after knocking down KCNK1. Furthermore, the effect of KCNK1 knockdown on the sensitivity of breast cancer cells to paclitaxel was also evaluated. RESULT: KCNK1 was overexpressed in breast cancer. Higher KCNK1 expression predicted an unfavorable prognosis. Moreover, the abnormal expression of KCNK1 was attributed to promoter hypomethylation of KCNK1 in breast cancer. Besides, cell proliferation and migration were significantly inhibited post-KCNK1 silencing, while KCNK1 knockdown significantly increased breast cancer cell sensitivity to paclitaxel. CONCLUSION: Taken together, our findings demonstrated that KCNK1 is a potential prognostic biomarker and therapeutic target of breast cancer. Thus, targeting KCNK1 might help synergize with paclitaxel function in breast cancer treatment. CI - Copyright © 2022 Elsevier GmbH. All rights reserved. FAU - Sun, Xinyuan AU - Sun X AD - Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China. FAU - Li, Yizhi AU - Li Y AD - Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Lan, Hua AU - Lan H AD - Department of Gynecology and Obstetrics, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. FAU - Jiang, Ting AU - Jiang T AD - Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China. FAU - Wan, Xiaoya AU - Wan X AD - Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Cheng, Yan AU - Cheng Y AD - Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address: yancheng@csu.edu.cn. LA - eng PT - Journal Article DEP - 20221220 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - P88XT4IS4D (Paclitaxel) RN - 0 (Potassium Channels) RN - 0 (Biomarkers) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/genetics MH - Prognosis MH - Paclitaxel MH - Potassium Channels MH - Biomarkers OTO - NOTNLM OT - Breast cancer OT - KCNK1 OT - Potassium channel OT - Prognostic biomarker OT - Therapeutic target COIS- Declaration of Competing Interest The authors declare no conflicts of interest. EDAT- 2022/12/26 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/12/25 18:12 PHST- 2022/07/22 00:00 [received] PHST- 2022/12/12 00:00 [revised] PHST- 2022/12/18 00:00 [accepted] PHST- 2022/12/26 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/12/25 18:12 [entrez] AID - S0344-0338(22)00530-1 [pii] AID - 10.1016/j.prp.2022.154286 [doi] PST - ppublish SO - Pathol Res Pract. 2023 Jan;241:154286. doi: 10.1016/j.prp.2022.154286. Epub 2022 Dec 20. PMID- 34427538 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230111 IS - 1096-4665 (Electronic) IS - 0739-9332 (Linking) VI - 44 IP - 1 DP - 2023 Jan TI - Patient experience of implant loss after immediate breast reconstruction: An interpretative phenomenological analysis. PG - 61-79 LID - 10.1080/07399332.2021.1944152 [doi] AB - Immediate breast reconstruction (IBR) is an integral part of modern breast cancer treatment. Our aim was to investigate patient experience with implant loss after IBR by using interpretative phenomenological analysis (IPA). We conducted semi-structured interviews with eight informants. We analyzed data according to the IPA flexible seven-stage process and four main themes were developed: immediate breast reconstruction as the indisputable choice, a difficult experience, an altered body: redefining normality, and trying to cope. The experience of implant loss appears to affect women for many years and might overshadow some of the benefits of IBR. FAU - Weick, Linn AU - Weick L AD - Department of Plastic and Reconstructive Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. FAU - Ericson, Alice AU - Ericson A AD - Department of Psychology, Gothenburg University, Gothenburg, Sweden. FAU - Sandman, Lars AU - Sandman L AUID- ORCID: 0000-0003-0987-7653 AD - National Centre for Priorities in Health, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden. AD - Västra Götaland Region, Gothenburg, Sweden. AD - Faculty of Police Work, department of Campus Police Education, Borås University, Borås, Sweden. FAU - Boström, Petra AU - Boström P AUID- ORCID: 0000-0002-7952-8283 AD - Department of Psychology, Gothenburg University, Gothenburg, Sweden. FAU - Hansson, Emma AU - Hansson E AUID- ORCID: 0000-0002-3218-0881 AD - Department of Plastic and Reconstructive Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. AD - Department of Clinical Sciences, Gothenburg University, Gothenburg, Sweden. LA - eng PT - Journal Article DEP - 20210824 PL - England TA - Health Care Women Int JT - Health care for women international JID - 8411543 MH - Female MH - Humans MH - Mastectomy MH - *Mammaplasty/adverse effects MH - *Breast Neoplasms/surgery MH - Patient Outcome Assessment EDAT- 2021/08/25 06:00 MHDA- 2023/01/12 06:00 CRDT- 2021/08/24 12:15 PHST- 2021/08/25 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] PHST- 2021/08/24 12:15 [entrez] AID - 10.1080/07399332.2021.1944152 [doi] PST - ppublish SO - Health Care Women Int. 2023 Jan;44(1):61-79. doi: 10.1080/07399332.2021.1944152. Epub 2021 Aug 24. PMID- 35468270 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 2005-9256 (Electronic) IS - 1598-2998 (Linking) VI - 55 IP - 1 DP - 2023 Jan TI - Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer. PG - 145-154 LID - 10.4143/crt.2022.001 [doi] AB - PURPOSE: The purpose of this study was to investigate the concordance rate of PIK3CA mutations between primary and matched distant metastatic sites in patients with breast cancer and to verify whether there are differences in the frequency of PIK3CA hotspot mutations depending on the metastatic sites involved. MATERIALS AND METHODS: Archived formalin-fixed paraffin-embedded (FFPE) specimens of primary breast and matched distant metastatic tumors were retrospectively obtained for 49 patients. Additionally, 40 archived FFPE specimens were independently collected from different breast cancer metastatic sites, which were limited to three common sites: the liver, brain, and lung. PIK3CA mutations were analyzed using droplet digital PCR, including hotspots involving exons 9 and 20. RESULTS: After analysis of 49 breast tumors with matched metastasis sites, 87.8% showed concordance in PIK3CA mutation status. According to PIK3CA hotspot mutation testing in 89 cases of breast cancer metastatic sites, the proportion of PIK3CA mutations at sites of metastasis involving the liver, brain, and lung was 37.5%, 28.6%, and 42.9%, respectively, which did not result in statistical significance. CONCLUSION: The high concordance of PIK3CA mutation status between primary and matched metastasis sites suggests that metastatic sites, regardless of the metastatic organ, could be considered sample sources for PIK3CA mutation testing for improved therapeutic strategies in patients with metastatic breast cancer. FAU - Park, Jieun AU - Park J AD - Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea. FAU - Cho, Soo Youn AU - Cho SY AD - Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Chang, Eun Sol AU - Chang ES AD - Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. AD - Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Sung, Minjung AU - Sung M AD - Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Song, Ji-Young AU - Song JY AD - Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Jung, Kyungsoo AU - Jung K AD - Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Sung-Su AU - Kim SS AD - Central Laboratory, LOGONE Bio-Convergence Research Foundation, Seoul, Korea. FAU - Shin, Young Kee AU - Shin YK AD - Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea. AD - Laboratory of Molecular Pathology and Cancer Genomics, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea. FAU - Choi, Yoon-La AU - Choi YL AD - Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. AD - Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. AD - Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. LA - eng GR - HI19C0141/Ministry of Health & Welfare/ GR - 5120200513755/National Research Foundation of Korea/ GR - 2016R1A5A2945889/Ministry of Science, ICT and Future Planning/ GR - 2019R1A2B5B02069979/Ministry of Science, ICT and Future Planning/ PT - Journal Article DEP - 20220420 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.137 (PIK3CA protein, human) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/pathology MH - Mutation MH - Retrospective Studies MH - Class I Phosphatidylinositol 3-Kinases/genetics OTO - NOTNLM OT - Breast neoplasms OT - Droplet Digital PCR OT - Molecular Diagnostics OT - Neoplasm metastasis OT - PIK3CA EDAT- 2022/04/26 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/04/25 19:41 PHST- 2022/01/02 00:00 [received] PHST- 2022/04/19 00:00 [accepted] PHST- 2022/04/26 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/04/25 19:41 [entrez] AID - crt.2022.001 [pii] AID - 10.4143/crt.2022.001 [doi] PST - ppublish SO - Cancer Res Treat. 2023 Jan;55(1):145-154. doi: 10.4143/crt.2022.001. Epub 2022 Apr 20. PMID- 36535490 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 181 DP - 2023 Jan TI - Role of DEK in carcinogenesis, diagnosis, prognosis, and therapeutic outcome of breast cancer: An evidence-based clinical review. PG - 103897 LID - S1040-8428(22)00321-3 [pii] LID - 10.1016/j.critrevonc.2022.103897 [doi] AB - Breast cancer is a significantly burdening women's cancer with limited diagnostic modalities. DEK is a novel biomarker overexpressed in breast cancers, currently exhaustively researched for its diagnosis and prognosis. Search for relevant meta-analyses, cohorts, and experimental studies in the last fifteen years was done in five large scientific databases. Non-English, non-full text articles or unrelated studies were excluded. Thirteen articles discussed the potential of DEK to estimate breast cancer characteristics, treatment outcomes, and prognosis. This proto-oncogene plays a role in breast carcinogenesis, increasing tumour proliferation and invasion, preventing apoptosis, and creating an immunodeficient tumour milieu with M2 tumour-associated macrophages. DEK is also associated with worse clinicopathological features and survival in breast cancer patients. Using a Kaplan-Meier plotter data analysis, DEK expression predicts worse overall survival (HR 1.24, 95%CI: 1.01-1.52, p = 0.039), comparable to other biomarkers. DEK is a promising novel biomarker requiring further research to determine its bedside applications. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Habiburrahman, Muhammad AU - Habiburrahman M AD - Faculty of Medicine Universitas Indonesia, Central Jakarta, DKI Jakarta, Indonesia; Dr. Cipto Mangunkusumo Hospital, Central Jakarta, DKI Jakarta, Indonesia. Electronic address: muhammad.habiburrahman51@ui.ac.id. FAU - Sutopo, Stefanus AU - Sutopo S AD - Faculty of Medicine Universitas Indonesia, Central Jakarta, DKI Jakarta, Indonesia. FAU - Wardoyo, Muhammad Prasetio AU - Wardoyo MP AD - Faculty of Medicine Universitas Indonesia, Central Jakarta, DKI Jakarta, Indonesia; Dr. Cipto Mangunkusumo Hospital, Central Jakarta, DKI Jakarta, Indonesia. LA - eng PT - Journal Article PT - Review DEP - 20221216 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 RN - 0 (Oncogene Proteins) RN - 0 (Poly-ADP-Ribose Binding Proteins) RN - 0 (Dek protein, human) RN - 0 (Chromosomal Proteins, Non-Histone) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/therapy/metabolism MH - Oncogene Proteins/genetics/metabolism MH - Prognosis MH - Kaplan-Meier Estimate MH - Carcinogenesis MH - Poly-ADP-Ribose Binding Proteins/genetics MH - Chromosomal Proteins, Non-Histone OTO - NOTNLM OT - Biomarker OT - Breast cancer OT - Cancer stem cells OT - Clinical outcomes OT - DEK OT - Diagnosis OT - Prognosis OT - Tumour-associated macrophages COIS- Conflict of interest The authors of this paper declare no conflicts of interest. EDAT- 2022/12/20 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/19 19:24 PHST- 2022/09/02 00:00 [received] PHST- 2022/12/13 00:00 [revised] PHST- 2022/12/14 00:00 [accepted] PHST- 2022/12/20 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/19 19:24 [entrez] AID - S1040-8428(22)00321-3 [pii] AID - 10.1016/j.critrevonc.2022.103897 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2023 Jan;181:103897. doi: 10.1016/j.critrevonc.2022.103897. Epub 2022 Dec 16. PMID- 36161271 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 152 IP - 5 DP - 2023 Mar 1 TI - Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. PG - 921-931 LID - 10.1002/ijc.34304 [doi] AB - The outcomes and best treatment strategies for germline BRCA1/2 mutation (gBRCAm) carriers with metastatic breast cancer (MBC) remain uncertain. We compared the overall survival and the first line progression free survival (PFS1) of patients with a gBRCAm identified at initiation of first-line treatment with those of BRCA wild-type (WT) and not-tested (NT) individuals in the ESME real-world database of MBC patients between 2008 and 2016 (NCT03275311). Among the 20 624 eligible patients, 325 had a gBRCAm, 1138 were WT and 19 161 NT. Compared with WT, gBRCAm carriers were younger, and had more aggressive diseases. At a median follow-up of 50.5 months, median OS was 30.6 (95%CI: 21.9-34.3), 35.8 (95%CI: 32.2-37.8) and 39.3 months (95% CI: 38.3-40.3) in the gBRCAm, WT and NT subgroups, respectively. Median PFS1 was 7.9 (95%CI: 6.6-9.3), 7.8 (95%CI: 7.3-8.5) and 9.7 months (95%CI, 9.5-10.0). In the multivariable analysis conducted in the whole cohort, gBRCAm status had however no independent prognostic impact on OS and PFS1. Though, in the triple-negative subgroup, gBRCAm patients had better OS and PFS1 (HR vs WT = 0.76; 95%CI: 0.60-0.97; P = .027 and 0.69; 95% CI: 0.55-0.86; P = .001, respectively). In contrast, in patients with HR+/HER2 negative cancers, PFS1 appeared significantly and OS non significantly lower for gBRCAm carriers (PFS1: HR vs WT = 1.23; 95%CI: 1.03-1.46; P = .024; OS:HR = 1.22, 95% CI: 0.97-1.52, P = .089). In conclusion, gBRCA1/2 status appears to have divergent survival effects in MBC according to IHC subtype. CI - © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Mailliez, Audrey AU - Mailliez A AUID- ORCID: 0000-0002-0475-8631 AD - Center Oscar Lambret, Lille, France. FAU - D'Hondt, Veronique AU - D'Hondt V AD - Institut régional du Cancer Montpellier/Val d'Aurelle, Montpellier, France. FAU - Lusque, Amelie AU - Lusque A AD - Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France. FAU - Caron, Olivier AU - Caron O AD - Institut Gustave Roussy, Villejuif, France. FAU - Cabel, Luc AU - Cabel L AUID- ORCID: 0000-0001-5515-9180 AD - Institut Curie, Paris et Saint Cloud, France. FAU - Goncalves, Anthony AU - Goncalves A AD - Institut Paoli-Calmette, Marseille, France. FAU - Debled, Marc AU - Debled M AD - Institut Bergonié, Bordeaux, France. FAU - Gladieff, Laurence AU - Gladieff L AD - Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France. FAU - Ferrero, Jean-Marc AU - Ferrero JM AD - Center Antoine Lacassagne, Nice, France. FAU - Petit, Thierry AU - Petit T AD - Center Paul Strauss, Strasbourg, France. FAU - Mouret-Reynier, Marie Ange AU - Mouret-Reynier MA AD - Center Jean Perrin, Clermont Ferrand, France. FAU - Eymard, Jean-Christophe AU - Eymard JC AD - Institut Jean Godinot, Reims, France. FAU - Levy, Christelle AU - Levy C AD - Center François Baclesse, Caen, France. FAU - Uwer, Lionel AU - Uwer L AD - Institut de Cancerologie de Lorraine, Vandoeuvre-lès-Nancy, France. FAU - Leheurteur, Marianne AU - Leheurteur M AD - Center Henri Becquerel, Rouen, France. FAU - Desmoulins, Isabelle AU - Desmoulins I AD - Center Georges François Leclerc, Dijon, France. FAU - Bachelot, Thomas AU - Bachelot T AD - Center Léon Bérard, Lyon, France. FAU - Frenel, Jean-Sebastien AU - Frenel JS AD - Institut de cancérologie de l'Ouest, Nantes et Angers, France. FAU - de la Motte Rouge, Thibault AU - de la Motte Rouge T AD - Center Eugène Marquis, Rennes, France. FAU - Simon, Gaëtane AU - Simon G AD - Unicancer, Paris, France. FAU - Jacot, William AU - Jacot W AUID- ORCID: 0000-0001-7834-061X AD - Institut régional du Cancer Montpellier/Val d'Aurelle, Montpellier, France. FAU - Delaloge, Suzette AU - Delaloge S AD - Institut Gustave Roussy, Villejuif, France. LA - eng GR - AstraZeneca/ GR - Daiichi Sankyo Company/ GR - Eisai/ GR - Merck Sharp and Dohme/ GR - Pfizer/ GR - Roche/ PT - Journal Article PT - Multicenter Study DEP - 20221008 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA2 protein, human) SB - IM MH - Female MH - Humans MH - BRCA1 Protein/genetics MH - *Breast Neoplasms/pathology MH - Prognosis MH - Progression-Free Survival OTO - NOTNLM OT - germline BRCA mutation OT - metastatic breast cancer OT - real world OT - survival EDAT- 2022/09/27 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/09/26 18:03 PHST- 2022/07/17 00:00 [revised] PHST- 2022/04/05 00:00 [received] PHST- 2022/08/09 00:00 [accepted] PHST- 2022/09/27 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/09/26 18:03 [entrez] AID - 10.1002/ijc.34304 [doi] PST - ppublish SO - Int J Cancer. 2023 Mar 1;152(5):921-931. doi: 10.1002/ijc.34304. Epub 2022 Oct 8. PMID- 36672750 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 14 IP - 1 DP - 2022 Dec 21 TI - Polymorphisms in COMT and OPRM1 Collectively Contribute to Chronic Shoulder Pain and Disability in South African Breast Cancer Survivors'. LID - 10.3390/genes14010009 [doi] LID - 9 AB - Chronic shoulder pain and disability is a common adverse effect experienced by >40% of breast cancer survivors (BCS). Pain management protocols for acute and chronic pain include the use of opioids and opioid derivatives. Furthermore, pain-modulating genes, such as COMT and OPRM1, have been linked to the aetiology of chronic pain. This study aimed to investigate the association between genetic variants of major pain modulator genes and chronic pain/disability in BCS. Assessment of pain, disability and combined (pain and disability) symptoms were determined using the Shoulder Pain and Disability Index (SPADI). Participants were grouped according to their scores such as no-low (<30%) and moderate-high (≥30%) groups of pain, disability and combined (pain and disability). Genotyping of the COMT rs6269 (A > G), rs4633 (C > T), rs4818 (C > G) and the functional rs4680(G > A) SNPs within the BCS (N = 252) cohort were conducted using TaqMan(®) SNP assays. Genotype, allele, haplotype, and allele-allele combination frequencies were evaluated. Statistical analysis was applied, with significance accepted at p < 0.05. The COMT rs4680:A/A genotype was significantly associated with moderate-high pain (p = 0.024, OR: 3.23, 95% CI: 1.33-7.81) and combined (pain and disability) (p = 0.015, OR: 3.81, 95% CI: 1.47-9.85). The rs4680:A allele was also significantly associated with moderate-high pain (p = 0.035, OR: 1.58, 95% CI: 1.03-2.43) and combined (pain and disability) (p = 0.017, OR: 1.71, 95% CI: 1.07-2.71). For the inferred COMT (rs6269 A > G-rs4680 G > A) haplotype analyses, the G-G (p = 0.026, OR: 0.67, 95% CI: 0.38-1.18) and A-A (p = 0.007, OR: 2.09, 95% CI: 0.89-4.88) haplotypes were significantly associated with reduced and increased likelihoods of reporting moderate-high pain, respectively. The inferred A-A (p = 0.003, OR: 2.18, 95% CI: 0.92-5.17) haplotype was also significantly associated with combined (pain and disability). Gene-gene interaction analyses further showed allele-allele combinations for COMT (rs4680 G > A)-OPRM1 (rs1799971 A > G) and COMT (rs4680 G > A)-OPRM1(rs540825 T > A) were associated with reporting pain and combined (pain and disability) symptoms, p < 0.05. The findings of this study suggest that COMT and OPRM1 SNPs play a role in the development of chronic shoulder pain/disability in BCS in a unique South African cohort from the Western Cape. FAU - Firfirey, Firzana AU - Firfirey F AUID- ORCID: 0000-0002-8750-1654 AD - Division of Physiological Sciences, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town 7700, South Africa. AD - Health through Physical Activity, Lifestyle and Sport Research Centre (HPALS), Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town 7700, South Africa. FAU - Shamley, Delva AU - Shamley D AUID- ORCID: 0000-0003-2355-6629 AD - Division of Clinical Anatomy & Biological Anthropology, Department of Human Biology, Anatomy Building, Medical School, University of Cape Town, Cape Town 7700, South Africa. FAU - September, Alison V AU - September AV AD - Division of Physiological Sciences, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town 7700, South Africa. AD - Health through Physical Activity, Lifestyle and Sport Research Centre (HPALS), Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town 7700, South Africa. AD - International Federation of Sports Medicine (FIMS), Collaborative Centre of Sports Medicine, Department of Human Biology, University of Cape Town, Cape Town 7700, South Africa. LA - eng GR - 102470/National Research Foundation/ PT - Journal Article DEP - 20221221 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - 0 (Analgesics, Opioid) RN - 0 (OPRM1 protein, human) RN - 0 (Receptors, Opioid, mu) RN - EC 2.1.1.6 (COMT protein, human) RN - EC 2.1.1.6 (Catechol O-Methyltransferase) SB - IM MH - Humans MH - Female MH - *Chronic Pain/genetics MH - *Breast Neoplasms/genetics MH - *Cancer Survivors MH - Shoulder Pain/genetics MH - South Africa MH - Analgesics, Opioid MH - Receptors, Opioid, mu/genetics MH - Catechol O-Methyltransferase/genetics PMC - PMC9858584 OTO - NOTNLM OT - Breast Cancer Survivors (BCS) OT - Gene-Gene interactions OT - chronic shoulder pain and disability OT - genetic association COIS- The authors declare no conflict of interest surrounding the research conducted in this study. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:14 PHST- 2022/11/23 00:00 [received] PHST- 2022/12/12 00:00 [revised] PHST- 2022/12/16 00:00 [accepted] PHST- 2023/01/21 01:14 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - genes14010009 [pii] AID - genes-14-00009 [pii] AID - 10.3390/genes14010009 [doi] PST - epublish SO - Genes (Basel). 2022 Dec 21;14(1):9. doi: 10.3390/genes14010009. PMID- 36541124 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230119 IS - 2050-7518 (Electronic) IS - 2050-750X (Linking) VI - 11 IP - 3 DP - 2023 Jan 18 TI - Novel manganese and polyester dendrimer-based theranostic nanoparticles for MRI and breast cancer therapy. PG - 648-656 LID - 10.1039/d2tb01855a [doi] AB - Therapeutic nanoplatforms are widely used in the diagnosis and treatment of breast cancer due to the merits of enabling high soft-tissue resolution and the availability of numerous therapeutic nanoparticles. It is thus vital to develop multifunctional theranostic nanoparticles for the visualization and dynamic monitoring of tumor therapy. In this study, we designed a manganese-based and hypericin-loaded polyester dendrimer nanoparticle (MHD) for magnetic resonance imaging (MRI) and hypericin-based photodynamic therapy (PDT) enhancement. We found that MHD could greatly enhance MRI contrast with a longitudinal relaxivity of 5.8 mM(-1) s(-1) due to the Mn-based paramagnetic dendrimer carrier. Meanwhile, the MRI-guided PDT inhibition of breast tumors could be achieved by the hypericin-carrying MHD and further improved by Mn(2+)-mediated alleviation of the hypoxic microenvironment and the enhancement of cellular ROS. Besides, MHD showed excellent biocompatibility and biosafety with liver and kidney clearance mechanisms. Thus, the high efficiency in MRI contrast enhancement and excellent tumor-inhibiting effects indicate MHD's potential as a novel, stable, and multifunctional nanotheranostic agent for breast cancer. FAU - Zhou, Xiaoxuan AU - Zhou X AD - Department of Radiology, Sir Run Run Shaw Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China. orangutan@zju.edu.cn. FAU - Xu, Xiaodan AU - Xu X AD - Key Laboratory of Smart Biomaterials of Zhejiang Province, ZJU-Hangzhou Global Scientific and Technological Innovation Center, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China. jianbin@zju.edu.cn. FAU - Hu, Qiuhui AU - Hu Q AD - Department of Radiology, Sir Run Run Shaw Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China. orangutan@zju.edu.cn. FAU - Wu, Yan AU - Wu Y AD - Department of Radiology, Sir Run Run Shaw Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China. orangutan@zju.edu.cn. FAU - Yu, Feidan AU - Yu F AD - Department of Radiology, Sir Run Run Shaw Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China. orangutan@zju.edu.cn. FAU - He, Chengbin AU - He C AD - Department of Radiology, Sir Run Run Shaw Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China. orangutan@zju.edu.cn. FAU - Qian, Yue AU - Qian Y AD - Department of Radiology, Sir Run Run Shaw Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China. orangutan@zju.edu.cn. FAU - Han, Yuxin AU - Han Y AD - Department of Radiology, Sir Run Run Shaw Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China. orangutan@zju.edu.cn. FAU - Tang, Jianbin AU - Tang J AUID- ORCID: 0000-0003-4498-5705 AD - Key Laboratory of Smart Biomaterials of Zhejiang Province, ZJU-Hangzhou Global Scientific and Technological Innovation Center, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China. jianbin@zju.edu.cn. FAU - Hu, Hongjie AU - Hu H AD - Department of Radiology, Sir Run Run Shaw Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China. orangutan@zju.edu.cn. LA - eng PT - Journal Article DEP - 20230118 PL - England TA - J Mater Chem B JT - Journal of materials chemistry. B JID - 101598493 RN - 42Z2K6ZL8P (Manganese) RN - 0 (Dendrimers) RN - 0 (Polyesters) RN - 7V2F1075HD (hypericin) SB - IM MH - Humans MH - Female MH - Manganese MH - *Dendrimers MH - *Breast Neoplasms/diagnostic imaging/drug therapy MH - Precision Medicine MH - Polyesters MH - *Nanoparticles/therapeutic use MH - Magnetic Resonance Imaging/methods MH - Tumor Microenvironment EDAT- 2022/12/22 06:00 MHDA- 2023/01/20 06:00 CRDT- 2022/12/21 04:12 PHST- 2022/12/22 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/12/21 04:12 [entrez] AID - 10.1039/d2tb01855a [doi] PST - epublish SO - J Mater Chem B. 2023 Jan 18;11(3):648-656. doi: 10.1039/d2tb01855a. PMID- 36375387 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1532-3080 (Electronic) IS - 0960-9776 (Print) IS - 0960-9776 (Linking) VI - 66 DP - 2022 Dec TI - Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer. PG - 262-271 LID - S0960-9776(22)00173-4 [pii] LID - 10.1016/j.breast.2022.10.008 [doi] AB - Upon its establishment for the treatment of metastatic breast cancer (mBC), continuing trastuzumab beyond disease progression was an important paradigm shift that became the recommendation by major guidelines. However, data supporting continuation of human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab beyond the second-line setting are limited, resulting in a lack of approval of, or access to, this therapeutic strategy in many countries. This study aimed to provide additional data on the continued use of trastuzumab and trastuzumab-based therapies in combination with chemotherapy (CT) as third-line treatment for patients with mBC. This open-cohort, retrospective, observational study used deidentified patient-level data from an electronic health record-derived database that included patients with mBC who initiated third-line treatment with trastuzumab-based therapy combined with CT (Tras + CT; n = 288) or CT alone (CT; n = 49). Patients who received Tras + CT had a longer weighted median overall survival vs those who received CT only: 20.6 months (95% CI, 18.3-26.4 months) vs 10.1 months (95% CI, 7.8-12.3 months), respectively (hazard ratio [HR], 0.29; 95% CI, 0.16-0.53). This study provides additional support for maintaining trastuzumab-based therapies for patients with HER2+ mBC beyond second-line treatment. This treatment option should be available for all patients with mBC worldwide. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Sanglier, Thibaut AU - Sanglier T AD - F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Bldg 1, Floor 8, NBH 02, 4070, Basel, Switzerland. Electronic address: thibaut.sanglier@roche.com. FAU - Ross, Ryan AU - Ross R AD - Genesis Research, 111 River St Ste 1120, Hoboken, NJ, 07030, USA. Electronic address: rross@genesisrg.com. FAU - Shi, Tianlai AU - Shi T AD - F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Bldg 1, Floor 8, NBH 02, 4070, Basel, Switzerland. Electronic address: tianlai.shi@roche.com. FAU - Mouta, João AU - Mouta J AD - F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Bldg 1, Floor 8, NBH 02, 4070, Basel, Switzerland. Electronic address: joao.mouta@roche.com. FAU - Swain, Sandra AU - Swain S AD - Georgetown Lombardi Comprehensive Cancer Center and MedStar Health, 3800 Reservoir Rd NW, Washington, DC, 20007, USA. Electronic address: sandra.swain@georgetown.edu. FAU - Cardoso, Fatima AU - Cardoso F AD - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation and ABC Global Alliance, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt. LA - eng PT - Journal Article PT - Observational Study DEP - 20221018 PL - Netherlands TA - Breast JT - Breast (Edinburgh, Scotland) JID - 9213011 RN - P188ANX8CK (Trastuzumab) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Retrospective Studies MH - Disease-Free Survival MH - Trastuzumab/therapeutic use MH - Receptor, ErbB-2/metabolism MH - Proportional Hazards Models MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use PMC - PMC9663523 OTO - NOTNLM OT - Advanced breast cancer OT - Beyond progression OT - Metastatic breast cancer OT - Overall survival OT - Real-world data OT - Trastuzumab COIS- Declaration of competing interest TSa, RR, TS and JM are employed by and own stock in Roche. FC has received advisory/consultancy fees from Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, IQVIA, Macrogenics, Medscape, MSD, Merus B.V., Mylan, Mundipharma, Novartis, Pfizer, Pierre Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva Pharmaceuticals and touchIME. SMS has received advisory/consultancy fees from AstraZeneca, Genentech/Roche, Molecular Therapeutics, Merck, Daiichi Sankyo, Lilly, Athenex, Exact Sciences and Natura; in-kind third-party writing assistance from AstraZeneca and Genentech/Roche; and research funding to institution from Genentech and Kailos Genetics. EDAT- 2022/11/15 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/11/14 18:29 PHST- 2022/07/27 00:00 [received] PHST- 2022/10/13 00:00 [revised] PHST- 2022/10/17 00:00 [accepted] PHST- 2022/11/15 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/14 18:29 [entrez] AID - S0960-9776(22)00173-4 [pii] AID - 10.1016/j.breast.2022.10.008 [doi] PST - ppublish SO - Breast. 2022 Dec;66:262-271. doi: 10.1016/j.breast.2022.10.008. Epub 2022 Oct 18. PMID- 36002764 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1699-3055 (Electronic) IS - 1699-048X (Linking) VI - 25 IP - 1 DP - 2023 Jan TI - The role of LncRNA MCM3AP-AS1 in human cancer. PG - 33-47 LID - 10.1007/s12094-022-02904-w [doi] AB - Long noncoding RNAs (lncRNA) play pivotal roles in every level of gene and genome regulation. MCM3AP-AS1 is a lncRNA that has an oncogenic role in several kinds of cancers. Aberrant expression of MCM3AP-AS1 has been reported to be involved in the progression of diverse malignancies, including colorectal, cervical, prostate, lymphoma, lung, ovary, liver, bone, and breast cancers. It is generally believed that MCM3AP-AS1 expression is associated with cancer cell growth, proliferation, angiogenesis, and metastasis. MCM3AP-AS1 by targeting various signaling pathways and microRNAs (miRNAs) presents an important role in cancer pathogenesis. MCM3AP-AS1 as a competitive endogenous RNA has the ability to sponge miRNA, inhibit their expressions, and bind to different target mRNAs related to cancer development. Therefore, MCM3AP-AS1 by targeting several signaling pathways, including the FOX family, Wnt, EGF, and VEGF can be a potent target for cancer prediction and diagnosis. In this review, we will summarize the role of MCM3AP-AS1 in various human cancers. CI - © 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO). FAU - Azizidoost, Shirin AU - Azizidoost S AD - Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Ghaedrahmati, Farhoodeh AU - Ghaedrahmati F AD - Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Sheykhi-Sabzehpoush, Mohadeseh AU - Sheykhi-Sabzehpoush M AD - Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Uddin, Shahab AU - Uddin S AD - Translational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar. FAU - Ghafourian, Mehri AU - Ghafourian M AD - Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. AD - Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Mousavi Salehi, Abdolah AU - Mousavi Salehi A AD - Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Keivan, Mona AU - Keivan M AD - Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. FAU - Cheraghzadeh, Maryam AU - Cheraghzadeh M AD - Department of Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Nazeri, Zahra AU - Nazeri Z AD - Department of Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Farzaneh, Maryam AU - Farzaneh M AUID- ORCID: 0000-0001-6239-8745 AD - Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. farzaneh-m@ajums.ac.ir. FAU - Khoshnam, Seyed Esmaeil AU - Khoshnam SE AD - Persian Gulf Physiology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Khoshnam-SE@ajums.ac.ir. LA - eng PT - Journal Article PT - Review DEP - 20220824 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 RN - 0 (RNA, Long Noncoding) RN - 0 (MicroRNAs) RN - EC 2.3.1.- (MCM3AP protein, human) RN - EC 2.3.1.- (Acetyltransferases) RN - 0 (Intracellular Signaling Peptides and Proteins) SB - IM MH - Male MH - Female MH - Humans MH - *RNA, Long Noncoding/genetics/metabolism MH - *MicroRNAs/genetics MH - *Breast Neoplasms/genetics MH - Signal Transduction MH - Liver MH - Gene Expression Regulation, Neoplastic MH - Cell Proliferation MH - Acetyltransferases/genetics/metabolism MH - Intracellular Signaling Peptides and Proteins/genetics OTO - NOTNLM OT - Cancer OT - Long non-coding RNAs OT - MCM3AP-AS1 OT - Signaling pathways OT - miRNAs EDAT- 2022/08/25 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/08/24 23:31 PHST- 2022/05/22 00:00 [received] PHST- 2022/07/18 00:00 [accepted] PHST- 2022/08/25 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/08/24 23:31 [entrez] AID - 10.1007/s12094-022-02904-w [pii] AID - 10.1007/s12094-022-02904-w [doi] PST - ppublish SO - Clin Transl Oncol. 2023 Jan;25(1):33-47. doi: 10.1007/s12094-022-02904-w. Epub 2022 Aug 24. PMID- 36652446 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230122 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 1 DP - 2023 TI - The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups. PG - e0280474 LID - 10.1371/journal.pone.0280474 [doi] LID - e0280474 AB - OBJECTIVE: The aim of the current study was to explore the association between age and outcomes in breast cancer. METHODS: Patients during 2010-2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Overall survival (OS) and breast cancer-specific death (BCSD) were taken as endpoints. The restrict cubic spline graph (RCS) was used to explore the relationship between age and outcomes in patients, and the cumulative incidence of BCSD and non-BCSD was calculated using the Gray method. Age-specific gene expression profiles were studied using RNA sequence data from the Cancer Genome Atlas (TCGA) database to explore whether there were young age-related gene or gene sets. RESULTS: A total of 142,755 patients with breast cancer were included. The hazard ratio (HR) of OS for Patients with stage I-III breast cancer was roughly stable before 53 years old and increased significantly after that, and the HR of BCSD for these patients showed a U-shaped distribution when plotted against age, with patients younger than 50 years and patients older than 70 years experiencing the worst survival. Further stratified analysis according to molecular subtype revealed that the U-shaped distribution of the HR of BCSD with was only found in the Hormone receptor-positive/HER2-negative (HoR+/HER2-) subgroup. The cumulative incidence plots showed that young age was associated with worse BCSD in the breast cancer patients with stage I-III and HoR+/HER2- subgroup. In stage IV breast cancer, there was a linearity of the relationship between poor OS and increasing age. We failed to find any differentially expressed age-specific genes between 20-40 years and 41-60 years groups in 258 patients with stage I-III and HoR+/HER2- subtype. CONCLUSION: Young age could predict worse BCSD of patient with stage I-III and HoR+/HER2- breast cancer. The escalating therapy was recommended to young age breast cancer with stage I-III and HoR+/HER2- subtype. CI - Copyright: © 2023 Zheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Zheng, Hongjuan AU - Zheng H AD - Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Ge, Chenyang AU - Ge C AD - Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Lin, Haiping AU - Lin H AD - Department of Hepatobiliary Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Zhou, Shishi AU - Zhou S AD - Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Tang, Wanfen AU - Tang W AD - Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Wang, Qinghua AU - Wang Q AD - Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Zhang, Xia AU - Zhang X AD - Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Jin, Xiayun AU - Jin X AD - Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Xu, Xifeng AU - Xu X AD - Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Du, Jinlin AU - Du J AD - Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. FAU - Fu, Jianfei AU - Fu J AUID- ORCID: 0000-0002-3036-1056 AD - Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. LA - eng PT - Journal Article DEP - 20230118 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Receptors, Estrogen) RN - 0 (Receptors, Progesterone) RN - 0 (Hormones) SB - IM MH - Humans MH - Middle Aged MH - Young Adult MH - Adult MH - Female MH - *Breast Neoplasms/metabolism MH - Neoplasm Staging MH - Receptor, ErbB-2/genetics/metabolism MH - Receptors, Estrogen/metabolism MH - SEER Program MH - Receptors, Progesterone/genetics/metabolism MH - Hormones MH - Prognosis PMC - PMC9847906 COIS- The authors have declared that no competing interests exist. EDAT- 2023/01/19 06:00 MHDA- 2023/01/21 06:00 CRDT- 2023/01/18 13:43 PHST- 2022/09/13 00:00 [received] PHST- 2023/01/02 00:00 [accepted] PHST- 2023/01/18 13:43 [entrez] PHST- 2023/01/19 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] AID - PONE-D-22-24956 [pii] AID - 10.1371/journal.pone.0280474 [doi] PST - epublish SO - PLoS One. 2023 Jan 18;18(1):e0280474. doi: 10.1371/journal.pone.0280474. eCollection 2023. PMID- 36584427 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230119 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 158 DP - 2023 Feb TI - Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands. PG - 114158 LID - S0753-3322(22)01547-5 [pii] LID - 10.1016/j.biopha.2022.114158 [doi] AB - The aim of this study was to describe health-related quality of life (HRQoL) and productivity in Dutch breast cancer patients treated with tamoxifen in an adjuvant setting. Patients who started treatment with a standard dose of tamoxifen and who gave written informed consent, were eligible for participation in this trial. A total of 145 patients were asked to complete a survey at 3 months (T1) and 6 months (T2) after initiation of tamoxifen. HRQoL was measured by the EQ-5D-5L and the FACT-B questionnaire, and productivity by using the iMTA Productivity Costs Questionnaire. At 3 months 137 (95%) and at 6 months 133 (92%) patients responded to the surveys. EQ-5D-5 L utility values for T1 and T2 were 0.81 ± 0.17 and 0.81 ± 0.18, respectively. FACT-B scores for T1 and T2 were 109 ± 17.9 and 108 ± 20.0, respectively. No differences in both EQ-5D-5 L utility and FACT-B scores were found between T1 and T2 (p > 0.05). Age and employment status were statistically significantly associated with FACT-B scores (p = 0.04 and p = 0.03, respectively), indicating that younger and unemployed respondents had lower FACT-B scores. Importantly, both short-term and long-term productivity improved during the first six months of tamoxifen treatment (p < 0.05). Here, short-term productivity losses (consisting of absenteeism, presenteeism and unpaid work) for T1 and T2 were estimated at € 855,- and € 396,-, respectively. Long-term productivity losses (consisting of absenteeism) for T1 and T2 were estimated at € 2876,- and € 1104,-, respectively. In conclusion, this study presents HRQoL scores using different instruments and detailed loss of productivity estimates for breast cancer patients treated with adjuvant endocrine therapy. The results presented here can be used to inform input parameters in health economic evaluations of interventions for patients with breast cancer in the Netherlands and other Western countries and ultimately support decision making. CI - Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Kleijburg, Anne AU - Kleijburg A AD - Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, the Netherlands; CAPHRI School of Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands; Centre of Economic Evaluation & Machine Learning, Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands. FAU - Braal, C Louwrens AU - Braal CL AD - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: c.braal@erasmusmc.nl. FAU - Westenberg, Justin D AU - Westenberg JD AD - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. FAU - Jager, Agnes AU - Jager A AD - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. FAU - Koolen, Stijn L W AU - Koolen SLW AD - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Mathijssen, Ron H J AU - Mathijssen RHJ AD - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. FAU - Uyl-de Groot, Carin A AU - Uyl-de Groot CA AD - Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, the Netherlands; Institute for Medical Technology Assessment, Erasmus University, Rotterdam, the Netherlands. FAU - Wetzelaer, Pim AU - Wetzelaer P AD - Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, the Netherlands. FAU - Penton, Hannah AU - Penton H AD - Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, the Netherlands. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20221228 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy MH - Netherlands MH - *Quality of Life MH - Surveys and Questionnaires MH - Tamoxifen/therapeutic use OTO - NOTNLM OT - EQ-5D-5 L OT - Early breast cancer OT - FACT-B OT - Productivity OT - Quality of Life OT - Tamoxifen treatment COIS- Conflict of interest statement This work was supported by an unrestricted MRACE grant (Erasmus MC, the Netherlands (grant number 2017–17108)). C. Louwrens Braal, Anne Kleijburg, Justin D. Westenberg, Agnes Jager, Stijn L.W. Koolen, Ron H.J. Mathijssen, Carin A Uyl-de Groot, Pim Wetzelaer, Hannah Penton declare they have no conflicts of interest that might be relevant to the contents of this manuscript. EDAT- 2022/12/31 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/12/30 18:04 PHST- 2022/10/01 00:00 [received] PHST- 2022/12/15 00:00 [revised] PHST- 2022/12/21 00:00 [accepted] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/12/30 18:04 [entrez] AID - S0753-3322(22)01547-5 [pii] AID - 10.1016/j.biopha.2022.114158 [doi] PST - ppublish SO - Biomed Pharmacother. 2023 Feb;158:114158. doi: 10.1016/j.biopha.2022.114158. Epub 2022 Dec 28. PMID- 36409394 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Return of individual genomic research results within the PRAEGNANT multicenter registry study. PG - 355-368 LID - 10.1007/s10549-022-06795-x [doi] AB - PURPOSE: The PRAEGNANT study is a registry study for metastatic breast cancer patients, focusing on biomarker detection. Recently, within this study, genetic alterations in 37 breast cancer predisposition genes were analyzed and genetic findings were detected for 396 participants. The aim of this project was to return genetic results to the physicians and to analyze actions taken (e.g., disclosure of results to patients, validation of results, clinical impact, and impact on the patient's quality of life) using a questionnaire. METHODS: 235 questionnaires were sent out to the study centers, with each questionnaire representing one patient with a genetic finding. The questionnaire consisted of twelve questions in the German language, referring to the disclosure of results, validation of test results, and their impact on treatment decisions and on the patient's quality of life. RESULTS: 135 (57.5%) questionnaires were completed. Of these, 46 (34.1%) stated that results were returned to the patients. In 80.0% (N = 36) of cases where results were returned, the patient had not been aware of the finding previously. For 27 patients (64.3%), genetic findings had not been validated beforehand. All validation procedures (N = 15) were covered by the patients' health insurance. For 11 (25.0%) patients, physicians reported that the research results influenced current or future decision-making on treatment, and for 37.8% (N = 17) the results influenced whether family members will be genetically tested. CONCLUSION: This study provides novel insights into the return of research results and into clinical and personal benefits of disclosure of genetic findings within a German registry. CI - © 2022. The Author(s). FAU - Huebner, Hanna AU - Huebner H AD - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. FAU - Ruebner, Matthias AU - Ruebner M AD - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. FAU - Kurbacher, Christian AU - Kurbacher C AD - Department of Gynecology and Obstetrics, Medizinisches Zentrum Bonn Friedensplatz, Bonn, Germany. FAU - Hadji, Peyman AU - Hadji P AD - Frankfurt Center for Bone Health, 60313, Frankfurt, Germany. FAU - Hartkopf, Andreas D AU - Hartkopf AD AD - Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany. FAU - Lux, Michael P AU - Lux MP AD - Klinik Für Gynäkologie und Geburtshilfe Frauenklinik St. Louise, St. Josefs-Krankenhaus, Salzkotten, Kooperatives Brustzentrum Paderborn, Paderborn, Germany. FAU - Huober, Jens AU - Huober J AD - Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany. FAU - Uhrig, Sabrina AU - Uhrig S AD - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. FAU - Taran, Florin-Andrei AU - Taran FA AD - Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany. FAU - Overkamp, Friedrich AU - Overkamp F AD - OncoConsult Overkamp GmbH, Berlin, Germany. FAU - Tesch, Hans AU - Tesch H AD - Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany. FAU - Häberle, Lothar AU - Häberle L AD - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. AD - Biostatistics Unit, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany. FAU - Lüftner, Diana AU - Lüftner D AD - Immanuel Hospital Märkische Schweiz, Buckow, Germany. AD - Immanuel Campus Rüdersdorf/Medical University of Brandenburg, Brandenburg, Germany. FAU - Wallwiener, Markus AU - Wallwiener M AD - Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany. FAU - Müller, Volkmar AU - Müller V AD - Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany. FAU - Beckmann, Matthias W AU - Beckmann MW AD - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. FAU - Hein, Alexander AU - Hein A AD - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. FAU - Belleville, Erik AU - Belleville E AD - ClinSol, GmbH & Co KG, Würzburg, Germany. FAU - Untch, Michael AU - Untch M AD - Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany. FAU - Janni, Wolfgang AU - Janni W AD - Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany. FAU - Fehm, Tanja N AU - Fehm TN AD - Department of Gynecology and Obstetrics, University Hospital of Düsseldorf, Düsseldorf, Germany. FAU - Kolberg, Hans-Christian AU - Kolberg HC AD - Marienhospital Bottrop, Bottrop, Germany. FAU - Wallwiener, Diethelm AU - Wallwiener D AD - Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany. FAU - Brucker, Sara Y AU - Brucker SY AD - Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany. FAU - Schneeweiss, Andreas AU - Schneeweiss A AD - National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany. FAU - Ettl, Johannes AU - Ettl J AD - Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. FAU - Fasching, Peter A AU - Fasching PA AUID- ORCID: 0000-0003-4885-8471 AD - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. peter.fasching@uk-erlangen.de. FAU - Michel, Laura L AU - Michel LL AD - National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20221121 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/epidemiology/genetics/therapy MH - Quality of Life MH - Genomics MH - Disclosure MH - Registries MH - Surveys and Questionnaires PMC - PMC9822879 OTO - NOTNLM OT - Breast cancer OT - Genetic testing OT - Incidental findings OT - Research results OT - Return of results COIS- E.B. has received honoraria from Novartis, Celgene, EISAI, Daiichi Sankyo, Merrimack, AstraZeneca, Riemser, Pfizer, Hexal, Amgen, and onkowissen.de for consulting, clinical research management, or medical education activities. J.E. has received honoraria from Roche, Celgene, Novartis, Pfizer, Lilly, Pierre Fabre, Teva, and Tesaro, as well as travel support from Celgene, Novartis, Lilly, Pfizer, Teva, and Tesaro. P.A.F. has received honoraria from Roche, Pfizer, Novartis, and Celgene; his institution conducts research for Novartis. A.D.H. has received honoraria from Teva, Genomic Health, Celgene, AstraZeneca, Novartis, Pfizer, and Roche. C.K. has received honoraria from Amgen, Roche, Teva, Novartis, MSD, Axios, and Riemser. H.C.K. has received honoraria from Carl Zeiss meditec, Teva, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche, MSD, SurgVision, Onkowissen, and Genomic Health. H.H. received speaker honorary from LEO Pharma. M.P.L. has received honoraria from Lilly, Pfizer, Roche, MSD, Hexal, Novartis, AstraZeneca, Eisai, Exact Sciences, Daiichi-Sankyo, Grünenthal, Gilead, Pierre Fabre, PharmaMar, Samantree, Sysmex, pfm and medac for advisory boards, lectures, and travel support. V.M. has received speaker honoraria from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Pfizer, Pierre Fabre, Novartis, Roche, Teva, and Janssen–Cilag, and consultancy honoraria from Genomic Health, Roche, Pierre Fabre, Amgen, Daiichi-Sankyo, and Eisai. F.O. has received speaker and consultancy honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer, Celgene, Chugai, Eisai, Gilead, Hexal, Ipsen, Janssen, Merck, MSD, Novartis, Novonordisc, Riemser, Roche, Servier, Shire, Tesaro, and Teva. P.H. has received honoraria, unrestricted educational grants, and research funding from Amgen, AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, and Roche. A.S. has received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH, and promedicis GmbH. H.T. has received honoraria from Novartis, Roche, Celgene, Teva, and Pfizer, as well as travel support from Roche, Celgene, and Pfizer. M.W. has received speaker honoraria from AstraZeneca, Celgene, Roche, MSD and Novartis. F.A.T. has received honoraria from AstraZeneca, Genomic Health, Novartis, Roche, Tesaro, and Teva, as well as travel support from Novartis and Tesaro. D.L. has received honoraria from Amgen, Loreal, Pfizer, Novartis, Eli Lilly, Samsung, Celgene, Astra Zeneca, Teva and GSK. All remaining authors have declared that they have no conflicts of interest. EDAT- 2022/11/22 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/21 11:17 PHST- 2022/07/26 00:00 [received] PHST- 2022/10/30 00:00 [accepted] PHST- 2022/11/22 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/21 11:17 [entrez] AID - 10.1007/s10549-022-06795-x [pii] AID - 6795 [pii] AID - 10.1007/s10549-022-06795-x [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):355-368. doi: 10.1007/s10549-022-06795-x. Epub 2022 Nov 21. PMID- 36435297 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 181 DP - 2023 Jan TI - Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis. PG - 103880 LID - S1040-8428(22)00304-3 [pii] LID - 10.1016/j.critrevonc.2022.103880 [doi] AB - BACKGROUND: Outcomes for breast cancer patients with residual disease (RD) after neoadjuvant chemotherapy (NACT) and HER2-targeted therapy may be better than anticipated leading to a smaller absolute benefit of adjuvant trastuzumab emtansine (T-DM1). Therefore, accurate estimates of 3-year disease-free survival (DFS) can aid in treatment planning. METHODS: We reviewed randomized trials of NACT and HER2-targeted therapy in breast cancer (excluding T-DM1) and calculated mean 3-year DFS weighted by study sample size. Meta-regression comprising linear regression weighted by sample size (mixed-effects) was performed to explore associations between 3-year DFS and year of accrual and trial-level patient, disease, and treatment factors. Data were reported quantitatively irrespective of statistical significance. RESULTS: Eleven studies (N = 3581) were included in the primary analysis. The mean 3-year DFS for patients with RD was 79.7% (95% CI 77.4-80.9). This was higher for trials completing accrual after 2010 [83% (95% CI 79.3-86.3)] and for those receiving dual HER2 targeted therapy [83.4% (95% CI 79.2-87.7]. Better outcomes for ER positivity, later accrual and dual Her-2 targeted therapy were confirmed in meta-regression. Negative quantitative significance was observed for larger clinical tumor size and nodal involvement. CONCLUSIONS: The 3-year DFS for patients with RD has improved over time possibly due to dual HER2 targeted therapy. This will reduce the absolute benefit of adjuvant T-DM1 in this group of patients. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Mittal, Abhenil AU - Mittal A AD - Division of Medical Oncology and Haematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, ON, Canada. FAU - Tamimi, Faris AU - Tamimi F AD - Division of Medical Oncology and Haematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, ON, Canada. FAU - Molto, Consolacion AU - Molto C AD - Division of Medical Oncology and Haematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, ON, Canada. FAU - Meti, Nicholas AU - Meti N AD - Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. FAU - Al-Showbaki, Laith AU - Al-Showbaki L AD - Division of Hematology and Medical Oncology, Department of Medicine, University Hospital and School of Medicine, University of Jordan, Amman, Jordan. FAU - Wilson, Brooke E AU - Wilson BE AD - Collaboration for Cancer Outcomes, Research and Evaluation, South West Clinical School, University of New South Wales, Liverpool, NSW, Australia; Department of Oncology, Queen's University, Kingston, Ontario, Canada. FAU - Amir, Eitan AU - Amir E AD - Division of Medical Oncology and Haematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, ON, Canada. Electronic address: eitan.amir@uhn.ca. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20221123 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 RN - P188ANX8CK (Trastuzumab) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - SE2KH7T06F (Ado-Trastuzumab Emtansine) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Disease-Free Survival MH - Trastuzumab/therapeutic use MH - Neoadjuvant Therapy MH - Treatment Outcome MH - Randomized Controlled Trials as Topic MH - Receptor, ErbB-2 MH - Ado-Trastuzumab Emtansine/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Chemotherapy, Adjuvant OTO - NOTNLM OT - Disease-free survival OT - Dual HER2-targeted therapy OT - Meta-analysis OT - Neoadjuvant therapy OT - Randomized controlled trial COIS- Conflict of Interest Statement E. Amir: Honoraria from Sandoz, Novartis, and Exact Sciences outside the submitted work. All remaining authors have declared no conflicts of interest. EDAT- 2022/11/27 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/11/26 19:24 PHST- 2022/03/30 00:00 [received] PHST- 2022/10/26 00:00 [revised] PHST- 2022/11/21 00:00 [accepted] PHST- 2022/11/27 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/26 19:24 [entrez] AID - S1040-8428(22)00304-3 [pii] AID - 10.1016/j.critrevonc.2022.103880 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2023 Jan;181:103880. doi: 10.1016/j.critrevonc.2022.103880. Epub 2022 Nov 23. PMID- 36627606 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230113 IS - 1472-6874 (Electronic) IS - 1472-6874 (Linking) VI - 23 IP - 1 DP - 2023 Jan 10 TI - Trajectories of quality of life in breast cancer survivors during the first year after treatment: a longitudinal study. PG - 12 LID - 10.1186/s12905-022-02153-7 [doi] LID - 12 AB - BACKGROUND: Although quality of life (QOL) improves over time for most breast cancer patients after their treatment, some patients may show different patterns of QOL. Beyond determining distinct QOL trajectories, identifying characteristics of patients who have different trajectories can help identify breast cancer patients who may benefit from intervention. We aimed to identify trajectories of QOL in breast cancer patients for one year after the end of primary treatment, to determine the factors influencing these changes. METHODS: This longitudinal study recruited 140 breast cancer patients. Patients' QOL, symptom experience, self-efficacy, and social support were assessed using the Functional Assessment of Cancer Therapy Scale-G, Memorial Symptom Assessment Scale-Short Form, Self-Efficacy Scale for Self-Management of Breast Cancer, and Interpersonal Support Evaluation List-12. Data were collected immediately after the end of primary treatment (T1) and at three (T2), six (T3), and 12 months (T4) after primary treatment. Group-based trajectory modeling was used to identify distinct subgroups of patients with similar patterns of QOL change after treatment. A one-way analysis of variance was used to determine which variables were associated with trajectory membership. A multinomial logistic regression was performed to identify factors associated with trajectory group membership. RESULTS: We analyzed 124 patients (mean age: 48.75 years). Latent class analysis of the QOL identified three trajectory groups: the low QOL group (n = 27; 21.1%), moderate QOL group (n = 57; 45.3%), and high QOL group (n = 40; 33.6%). The low QOL group showed consistently low QOL after the end of primary treatment, and the moderate QOL group showed a slight decrease in QOL from T1 to T3, which returned to the T1 level at T4. The high QOL group maintained a consistently high QOL. By multinomial logistic regression, psychological symptoms (odds ratio [OR] 0.46, 95% confidence interval [CI] 0.22-0.99) predicted a moderate QOL, and both psychological symptoms (OR 0.19, 95% CI 0.07-0.51) and belonging support (OR 1.60, 95% CI 1.06-2.39) predicted a high QOL. CONCLUSION: Identifying high-risk groups for reduced QOL after the end of primary treatment is necessary. Moreover, psychosocial interventions should be provided to alleviate psychological symptoms and increase belonging support to enhance patients' QOL. Trial registration Not registered. CI - © 2023. The Author(s). FAU - Park, Jin-Hee AU - Park JH AUID- ORCID: 0000-0002-0069-7819 AD - College of Nursing, Research Institute of Nursing Science, Ajou University, 164, World cup-ro, Yeongtong-gu, Suwon, 16499, Korea. FAU - Jung, Yong Sik AU - Jung YS AUID- ORCID: 0000-0002-2011-1459 AD - Department of Breast Surgery, School of Medicine, Ajou University, Suwon, Korea. FAU - Kim, Ji Young AU - Kim JY AUID- ORCID: 0000-0001-5539-7269 AD - Department of Breast Surgery, School of Medicine, Ajou University, Suwon, Korea. FAU - Bae, Sun Hyoung AU - Bae SH AUID- ORCID: 0000-0002-4890-619X AD - College of Nursing, Research Institute of Nursing Science, Ajou University, 164, World cup-ro, Yeongtong-gu, Suwon, 16499, Korea. shyoung@ajou.ac.kr. LA - eng GR - No. 2018R1A2B6004553/National Research Foundation of Korea/ PT - Journal Article DEP - 20230110 PL - England TA - BMC Womens Health JT - BMC women's health JID - 101088690 SB - IM MH - Humans MH - Middle Aged MH - Female MH - Quality of Life/psychology MH - *Breast Neoplasms/therapy/psychology MH - *Cancer Survivors/psychology MH - Longitudinal Studies MH - Breast PMC - PMC9832601 OTO - NOTNLM OT - Breast neoplasms OT - Cancer survivors OT - Longitudinal studies OT - Quality of life COIS- The authors declare that they have no competing interests. EDAT- 2023/01/11 06:00 MHDA- 2023/01/13 06:00 CRDT- 2023/01/10 23:33 PHST- 2022/03/22 00:00 [received] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/01/10 23:33 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - 10.1186/s12905-022-02153-7 [pii] AID - 2153 [pii] AID - 10.1186/s12905-022-02153-7 [doi] PST - epublish SO - BMC Womens Health. 2023 Jan 10;23(1):12. doi: 10.1186/s12905-022-02153-7. PMID- 36476677 OWN - NLM STAT- MEDLINE DCOM- 20221228 LR - 20230103 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 158 DP - 2023 Jan TI - Shear-wave elastography-based nomograms predicting 21-gene recurrence score for adjuvant chemotherapy decisions in patients with breast cancer. PG - 110638 LID - S0720-048X(22)00488-0 [pii] LID - 10.1016/j.ejrad.2022.110638 [doi] AB - PURPOSE: To develop and validate nomograms based on shear-wave elastography (SWE) combined with clinicopathologic features for predicting Oncotype DX recurrence score (RS) for use with adjuvant systemic therapy guidelines. METHODS: In a retrospective study, patients with breast cancer who underwent definitive surgery of the breast between August 2011 and December 2019 were eligible for this study. Those with surgery between August 2011 and March 2019 were assigned to a development set and the rest were assigned to an independent validation set. Clinicopathologic features and SWE elasticity indices were assessed with logistic regression to develop nomograms for predicting RS ≥ 16 and ≥ 26. Analysis of the area under the receiver operating characteristic curve (AUROC) was used to assess the performance of the nomograms. RESULTS: Of a total 381 women (mean age, 51 ± 9 years), 286 (mean age, 51 ± 9 years) were in the development set and 95 (mean age, 51 ± 9 years) in the validation set. All SWE elasticity indices were independently associated with each RS cutoff (odds ratio, 1.006-1.039 for RS ≥ 16; odds ratio, 1.008-1.076 for RS ≥ 26). Nomograms based on SWE combined with clinicopathologic features were developed and validated for RS ≥ 16 (mean elasticity [AUROC, 0.74; 95% CI: 0.68, 0.80] and maximum elasticity [AUROC, 0.74; 95% CI: 0.69, 0.80]) and for RS ≥ 26 (mean elasticity [AUROC, 0.81; 95% CI: 0.73, 0.89], maximum elasticity [AUROC, 0.82; 95% CI: 0.74, 0.89], and elasticity ratio [AUROC, 0.86; 95% CI: 0.80, 0.93]). CONCLUSION: Nomograms based on SWE can predict Oncotype DX RS for use in adjuvant systemic therapy decisions. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Youk, Ji Hyun AU - Youk JH AD - Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: jhyouk@yuhs.ac. FAU - Son, Eun Ju AU - Son EJ AD - Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. FAU - Jeong, Joon AU - Jeong J AD - Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. FAU - Gweon, Hye Mi AU - Gweon HM AD - Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. FAU - Eun, Na Lae AU - Eun NL AD - Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. FAU - Kim, Jeong-Ah AU - Kim JA AD - Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. LA - eng PT - Journal Article DEP - 20221128 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 SB - IM MH - Humans MH - Female MH - Adult MH - Middle Aged MH - *Breast Neoplasms/diagnostic imaging/drug therapy/genetics MH - Nomograms MH - *Elasticity Imaging Techniques MH - Retrospective Studies MH - Chemotherapy, Adjuvant OTO - NOTNLM OT - Adjuvant chemotherapy OT - Breast neoplasm OT - Elastography OT - Gene expression profiling OT - Ultrasound COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/09 06:00 MHDA- 2022/12/29 06:00 CRDT- 2022/12/08 10:49 PHST- 2022/07/21 00:00 [received] PHST- 2022/11/07 00:00 [revised] PHST- 2022/11/25 00:00 [accepted] PHST- 2022/12/09 06:00 [pubmed] PHST- 2022/12/29 06:00 [medline] PHST- 2022/12/08 10:49 [entrez] AID - S0720-048X(22)00488-0 [pii] AID - 10.1016/j.ejrad.2022.110638 [doi] PST - ppublish SO - Eur J Radiol. 2023 Jan;158:110638. doi: 10.1016/j.ejrad.2022.110638. Epub 2022 Nov 28. PMID- 36414796 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study. PG - 449-459 LID - 10.1007/s10549-022-06814-x [doi] AB - BACKGROUND: Latin American (LA) studies on triple-negative breast cancer (TNBC) and their characteristics are scarce. This forces physicians to make clinical decisions based on data obtained from studies that include non-Hispanic patients. Our study sought to obtain local epidemiological data, including risk factors and clinical outcomes from a Chilean BC registry. METHODS: This was a retrospective population-cohort study that included patients treated at a community hospital (mid-low income) or an academic private center (high income), in the 2010-2021 period. Univariate and multivariate analyses were performed to identify prognostic factors associated with survival. RESULTS: 647 out of 5,806 BC patients (11.1%) were TNBC. These patients were younger (p = 0.0001) and displayed lower rates of screening-detected cases (p = 0.0001) compared to non-TNBC counterparts. Among TNBC patients, lower income (i. e., receiving treatment at a community hospital) was associated with poorer overall survival (HR: 1.53; p = 0.0001) and poorer BC specific survival (HR: 1.29; p = 0.004). Other risk factors showed no significant differences between TNBC and non-TNBC. As expected, 5-year OS was significantly shorter on TNBC versus non-TNBC patients (p = 0.00001). In our multivariate analyses TNBC subtype (HR: 2.30), locally advanced stage (HR: 7.04 for stage III), lower income (HR: 1.64), or non-screening detected BC (HR: 1.32) were associated with poorer OS. CONCLUSION: To the best of our knowledge, this is the largest LA cohort of TNBC patients. Interestingly, the proportion of TNBC among Chileans was smaller compared to similar studies within LA. As expected, TNBC patients had poorer survival and higher risk for early recurrence versus non-TNBC. Other relevant findings include a higher proportion of premenopausal patients among TNBC. Also, mid/low-income patients that received medical attention at a community hospital displayed lower survival versus private health center counterparts. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Acevedo, Francisco AU - Acevedo F AD - Departamento de Hematología-Oncología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile. FAU - Walbaum, Benjamín AU - Walbaum B AD - Departamento de Hematología-Oncología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile. FAU - Medina, Lidia AU - Medina L AD - Centro de Cáncer, Red de Salud UC Christus, Pontificia Universidad Católica de Chile, Santiago, Chile. FAU - Merino, Tomas AU - Merino T AD - Departamento de Hematología-Oncología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile. FAU - Camus, Mauricio AU - Camus M AD - Departamento de Cirugía Oncológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. FAU - Puschel, Klaus AU - Puschel K AD - Departmento de Medicina Familiar, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. FAU - Ramírez, Karol AU - Ramírez K AD - Departamento Ciencias de la Salud, Facultad de Medicina, Carrera de Kinesiología, Pontificia Universidad Católica de Chile, Santiago, Chile. FAU - Manzor, Manuel AU - Manzor M AD - Hospital Dr. Sotero del Rio, Puente Alto, Santiago, Chile. FAU - Veglia, Paulina AU - Veglia P AD - Hospital Dr. Sotero del Rio, Puente Alto, Santiago, Chile. FAU - Martinez, Raúl AU - Martinez R AD - Hospital Dr. Sotero del Rio, Puente Alto, Santiago, Chile. FAU - Guerra, Constanza AU - Guerra C AD - Hospital Dr. Sotero del Rio, Puente Alto, Santiago, Chile. FAU - Navarro, Marisel AU - Navarro M AD - Hospital Dr. Sotero del Rio, Puente Alto, Santiago, Chile. FAU - Bauerle, Catherine AU - Bauerle C AD - Departamento de Hematología-Oncología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile. FAU - Dominguez, Francisco AU - Dominguez F AD - Departamento de Cirugía Oncológica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. FAU - Sánchez, César AU - Sánchez C AUID- ORCID: 0000-0001-7512-6474 AD - Departamento de Hematología-Oncología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile. cgsanche@uc.cl. LA - eng GR - 11161103/Fondecyt/ GR - 60322449/Pfizer/ PT - Journal Article DEP - 20221121 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - Cohort Studies MH - Retrospective Studies MH - *Triple Negative Breast Neoplasms/epidemiology/therapy/diagnosis MH - *Breast Neoplasms MH - Chile/epidemiology MH - Risk Factors MH - Prognosis OTO - NOTNLM OT - Breast neoplasm OT - Latin-American OT - Risk factors OT - Triple negative EDAT- 2022/11/23 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/22 23:33 PHST- 2022/08/16 00:00 [received] PHST- 2022/11/09 00:00 [accepted] PHST- 2022/11/23 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/22 23:33 [entrez] AID - 10.1007/s10549-022-06814-x [pii] AID - 10.1007/s10549-022-06814-x [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):449-459. doi: 10.1007/s10549-022-06814-x. Epub 2022 Nov 21. PMID- 36374011 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 2159-8290 (Electronic) IS - 2159-8274 (Linking) VI - 13 IP - 1 DP - 2023 Jan 9 TI - OS Trending Positive for Abemaciclib. PG - OF3 LID - 10.1158/2159-8290.CD-NB2022-0070 [doi] AB - The latest interim analysis from the MONARCH 3 trial of abemaciclib for patients with hormone receptor-positive, HER2-negative breast cancer did not show a statistically significant survival benefit. Patients who received abemaciclib lived a median of 12.6 months longer than patients in the control group. CI - ©2022 American Association for Cancer Research. LA - eng PT - Journal Article PL - United States TA - Cancer Discov JT - Cancer discovery JID - 101561693 RN - 60UAB198HK (abemaciclib) RN - 0 (Aminopyridines) RN - 0 (Benzimidazoles) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Aminopyridines/therapeutic use MH - *Breast Neoplasms/drug therapy MH - Benzimidazoles/therapeutic use MH - Receptor, ErbB-2 MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use EDAT- 2022/11/15 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/14 08:53 PHST- 2022/11/15 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/14 08:53 [entrez] AID - 710678 [pii] AID - 10.1158/2159-8290.CD-NB2022-0070 [doi] PST - ppublish SO - Cancer Discov. 2023 Jan 9;13(1):OF3. doi: 10.1158/2159-8290.CD-NB2022-0070. PMID- 36557969 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221227 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 27 IP - 24 DP - 2022 Dec 13 TI - Docetaxel Loaded in Copaiba Oil-Nanostructured Lipid Carriers as a Promising DDS for Breast Cancer Treatment. LID - 10.3390/molecules27248838 [doi] LID - 8838 AB - Breast cancer is the neoplasia of highest incidence in women worldwide. Docetaxel (DTX), a taxoid used to treat breast cancer, is a BCS-class-IV compound (low oral bioavailability, solubility and intestinal permeability). Nanotechnological strategies can improve chemotherapy effectiveness by promoting sustained release and reducing systemic toxicity. Nanostructured lipid carriers (NLC) encapsulate hydrophobic drugs in their blend-of-lipids matrix, and imperfections prevent drug expulsion during storage. This work describes the preparation, by design of experiments (2(3) factorial design) of a novel NLC formulation containing copaiba oil (CO) as a functional excipient. The optimized formulation (NLC(DTX)) showed approximately 100% DTX encapsulation efficiency and was characterized by different techniques (DLS, NTA, TEM/FE-SEM, DSC and XRD) and was stable for 12 months of storage, at 25 °C. Incorporation into the NLC prolonged drug release for 54 h, compared to commercial DTX (10 h). In vitro cytotoxicity tests revealed the antiproliferative effect of CO and NLC(DTX), by reducing the cell viability of breast cancer (4T1/MCF-7) and healthy (NIH-3T3) cells more than commercial DTX. NLC(DTX) thus emerges as a promising drug delivery system of remarkable anticancer effect, (strengthened by CO) and sustained release that, in clinics, may decrease systemic toxicity at lower DTX doses. FAU - Carvalho, Fabiola Vieira de AU - Carvalho FV AUID- ORCID: 0000-0002-4450-0563 AD - Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-862, Brazil. FAU - Ribeiro, Ligia Nunes de Morais AU - Ribeiro LNM AUID- ORCID: 0000-0001-6097-5449 AD - Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-862, Brazil. AD - Institute of Biotechnology, Federal University of Uberlandia-UFU, Uberlandia 38405-319, Brazil. FAU - Moura, Ludmilla David de AU - Moura LD AUID- ORCID: 0000-0002-8449-5762 AD - Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-862, Brazil. FAU - Rodrigues da Silva, Gustavo Henrique AU - Rodrigues da Silva GH AUID- ORCID: 0000-0001-7377-8532 AD - Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-862, Brazil. FAU - Mitsutake, Hery AU - Mitsutake H AUID- ORCID: 0000-0002-8769-0301 AD - Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-862, Brazil. AD - Department of Analytical Chemistry, Institute of Chemistry, UNICAMP, Campinas 13083-970, Brazil. FAU - Mendonça, Talita Cesarim AU - Mendonça TC AD - Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-862, Brazil. FAU - Geronimo, Gabriela AU - Geronimo G AD - Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-862, Brazil. FAU - Breitkreitz, Marcia Cristina AU - Breitkreitz MC AD - Department of Analytical Chemistry, Institute of Chemistry, UNICAMP, Campinas 13083-970, Brazil. FAU - de Paula, Eneida AU - de Paula E AUID- ORCID: 0000-0003-4504-5723 AD - Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas-UNICAMP, Campinas 13083-862, Brazil. LA - eng GR - # 19/17784-0/São Paulo Research Foundation/ GR - F.V.C. scholarship/Coordenação de Aperfeicoamento de Pessoal de Nível Superior/ GR - E.P. fellowship/National Council for Scientific and Technological Development/ PT - Journal Article DEP - 20221213 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - 15H5577CQD (Docetaxel) RN - 0 (Antineoplastic Agents) RN - 0 (Delayed-Action Preparations) RN - 0 (Drug Carriers) RN - 0 (Oils, Volatile) SB - IM MH - Female MH - Humans MH - Docetaxel/pharmacology/therapeutic use MH - *Breast Neoplasms/drug therapy MH - *Antineoplastic Agents/chemistry MH - Delayed-Action Preparations/therapeutic use MH - Drug Carriers/chemistry MH - *Nanostructures/chemistry MH - *Oils, Volatile/therapeutic use MH - Particle Size MH - *Nanoparticles/chemistry PMC - PMC9788038 OTO - NOTNLM OT - breast cancer OT - docetaxel OT - nanostructured lipid carriers COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:49 PHST- 2022/11/15 00:00 [received] PHST- 2022/12/06 00:00 [revised] PHST- 2022/12/10 00:00 [accepted] PHST- 2022/12/23 01:49 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - molecules27248838 [pii] AID - molecules-27-08838 [pii] AID - 10.3390/molecules27248838 [doi] PST - epublish SO - Molecules. 2022 Dec 13;27(24):8838. doi: 10.3390/molecules27248838. PMID- 36427769 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 181 DP - 2023 Jan TI - HER2-low breast cancer: Novel detections and treatment advances. PG - 103883 LID - S1040-8428(22)00307-9 [pii] LID - 10.1016/j.critrevonc.2022.103883 [doi] AB - Breast cancer (BC), which has the highest cancer incidence in women, seriously threatens women's health. Since human epidermal growth factor receptor-2 (HER2) characterization, breast cancer treatment has entered an era of individualized targeted therapy. With the emergence of anti-HER2 targeting agents, monoclonal antibodies (mAbs) and tyrosine kinase inhibitors have considerably improved the prognosis of HER2-positive BC. However, HER2-low BC, accounting for 45-55% of BC patients, is less likely to benefit from conventional HER2-targeting mAbs. The growing success of the new generation of drugs, especially promising HER2-directed antibody-drug conjugates, has changed the treatment landscape for patients with HER2-low BC, leading to a research boom. HER-2-low BC is a heterogeneous entity, and there many areas remain to be explored. In this article, we review the literature on HER2-low BC, mainly focusing on its detection assays, clinicopathological profiles and treatment landscape, and hopefully provide insight into future perspectives. CI - Copyright © 2022. Published by Elsevier B.V. FAU - Wu, Yun AU - Wu Y AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Zhong, Ruiqi AU - Zhong R AD - Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. FAU - Ma, Fei AU - Ma F AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: drmafei@126.com. LA - eng PT - Journal Article PT - Review DEP - 20221123 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/drug therapy MH - Receptor, ErbB-2/metabolism MH - *Antineoplastic Agents/adverse effects MH - Prognosis MH - Oncogenes OTO - NOTNLM OT - Antibody drug conjugates OT - Breast cancer OT - Clinicopathological features OT - Detection OT - HER2-low COIS- Conflict of interest The authors declare that they have no conflicts of interest. EDAT- 2022/11/26 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/11/25 19:27 PHST- 2022/06/23 00:00 [received] PHST- 2022/10/20 00:00 [revised] PHST- 2022/11/21 00:00 [accepted] PHST- 2022/11/26 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/25 19:27 [entrez] AID - S1040-8428(22)00307-9 [pii] AID - 10.1016/j.critrevonc.2022.103883 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2023 Jan;181:103883. doi: 10.1016/j.critrevonc.2022.103883. Epub 2022 Nov 23. PMID- 36662756 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 1 DP - 2023 TI - Low pretreatment prognostic nutritional index predicts poor survival in breast cancer patients: A meta-analysis. PG - e0280669 LID - 10.1371/journal.pone.0280669 [doi] LID - e0280669 AB - BACKGROUND: Prognostic nutritional index (PNI), as an indicator of nutritional immune status, has been shown to be associated with therapeutic effects and survival of solid tumors. However, the prognostic role of PNI before treatment in human breast cancer (BC) is still not conclusive. Hence, we performed this meta-analysis to assess the value of it in prognosis prediction for BC patients. MATERIALS AND METHODS: We searched PubMed, Embase, Web of Science and EBSCO to identify the studies evaluating the association between PNI and survival such as overall survival (OS), disease-free survival (DFS) of BC, and computed extracted data into hazard ratios (HRs) for OS, DFS and clinicopathological features with STATA 12.0. RESULTS: A total of 2322 patients with BC from 8 published studies were incorporated into this meta-analysis. We discovered that low pretreatment PNI was significantly associated with worse OS, but not with DFS in BC patients. In stratified analyses, the result showed that decreased PNI before treatment was remarkably related with lower 3-year, 5-year, 8-year and 10-year OS, but not with 1-year survival rate in BC. In addition, although reduced PNI could not impact 1-year, 3-year or 5-year DFS, it considerably deteriorated 8-year and 10-year DFS in patients. CONCLUSION: Low pretreatment PNI deteriorated OS, 8-year and 10-year DFS in BC patients, implicating that it is a valuable prognostic index and improving the nutritional immune status may offer a therapeutic strategy for these patients. CI - Copyright: © 2023 Hu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Hu, Guoming AU - Hu G AUID- ORCID: 0000-0001-7923-6232 AD - Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China. AD - Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, Zhejiang, China. AD - Shaoxing Key Laboratory of Functional Molecular Imaging of Tumor and Interventional Diagnosis and Treatment, Shaoxing, Zhejiang, China. FAU - Ding, Qiannan AU - Ding Q AD - Medical Research Center, Shaoxing People's Hospital; Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China. FAU - Zhong, Kefang AU - Zhong K AD - Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China. FAU - Wang, Shimin AU - Wang S AD - Department of Nephrology, Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China. FAU - Wang, Songxiang AU - Wang S AD - Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China. FAU - Huang, Liming AU - Huang L AD - Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20230120 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Female MH - *Nutrition Assessment MH - Prognosis MH - *Breast Neoplasms MH - Nutritional Status MH - Disease-Free Survival PMC - PMC9858712 COIS- The authors have declared that no competing interests exist. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 13:44 PHST- 2021/10/07 00:00 [received] PHST- 2023/01/05 00:00 [accepted] PHST- 2023/01/20 13:44 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - PONE-D-21-32231 [pii] AID - 10.1371/journal.pone.0280669 [doi] PST - epublish SO - PLoS One. 2023 Jan 20;18(1):e0280669. doi: 10.1371/journal.pone.0280669. eCollection 2023. PMID- 35764299 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1098-8947 (Electronic) IS - 0743-684X (Linking) VI - 39 IP - 2 DP - 2023 Feb TI - A Paradigm Shift: Outcomes of Early Autologous Breast Reconstruction after Radiation Therapy. PG - 111-119 LID - 10.1055/s-0042-1750139 [doi] AB - BACKGROUND:  Radiation creates significant challenges for breast reconstruction. There is no consensus regarding optimal timing for autologous reconstruction following radiation. This study explores clearly defined, shorter time intervals between completion of radiation and reconstruction than previously reported. METHODS:  A retrospective review was performed on patients who underwent autologous reconstruction by five microsurgeons at an academic institution from 2009 to 2020. Cohorts were selected by time elapsed between radiation and autologous reconstruction including <3 months, 3 to 6 months, 6 to 9 months, 9 to 12 months, 12 to 24 months, and >24 months. Analysis compared baseline characteristics, operative details, complications, revision rates, and BREAST-Q scores. Analysis of variance was used for continuous variables and chi-square for discrete variables. RESULTS:  In total, 462 radiated patients underwent 717 flaps. There were 69 patients at <3 months (14.9%), 97 at 3 to 6 months (21%), 64 at 6 to 9 months (13.9%), 36 at 9 to 12 months (7.8%), 73 at 12 to 24 months (15.8%), and 123 at >24 months (26.6%). Age, time from mastectomy, and failure of primary reconstruction were higher at >24 months (p < 0.001). There was no difference between cohorts in intraoperative complications in radiated or nonradiated breasts. There was no difference in acute and late postoperative complications between cohorts. Wound-healing complications in radiated sides were lowest at <3 months and 3 to 6 months (5/69 [7.3%] and 11/97 [11.3%], respectively) compared with other groups (18.8-22.2%) but did not reach significance (p = 0.11). More fat graft revisions occurred at <3 months (p = 0.003). CONCLUSION:  Reconstruction can be safely performed within 3 months after radiation without increases in intraoperative, acute, or late reconstructive complications. CI - Thieme. All rights reserved. FAU - Elver, Ashlie A AU - Elver AA AUID- ORCID: 0000-0001-6706-359X AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas. FAU - Egan, Katie G AU - Egan KG AUID- ORCID: 0000-0001-8336-2127 AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas. FAU - Cullom, Melissa E AU - Cullom ME AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas. FAU - Nazir, Niaman AU - Nazir N AD - Department of Population Health, University of Kansas Medical Center, Kansas City, Kansas. FAU - Johnson, Braden M AU - Johnson BM AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas. FAU - Limpiado, MarcArthur AU - Limpiado M AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas. FAU - Holding, Julie AU - Holding J AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas. FAU - Lai, Eric C AU - Lai EC AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas. FAU - Butterworth, James A AU - Butterworth JA AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas. LA - eng PT - Journal Article DEP - 20220628 PL - United States TA - J Reconstr Microsurg JT - Journal of reconstructive microsurgery JID - 8502670 SB - IM MH - Humans MH - Child, Preschool MH - Female MH - Mastectomy MH - *Breast Neoplasms/radiotherapy/surgery/complications MH - Radiotherapy, Adjuvant/adverse effects MH - *Mammaplasty/adverse effects MH - Breast/surgery MH - Postoperative Complications/surgery MH - Retrospective Studies COIS- None declared. EDAT- 2022/06/29 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/06/28 20:02 PHST- 2022/06/29 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/06/28 20:02 [entrez] AID - 10.1055/s-0042-1750139 [doi] PST - ppublish SO - J Reconstr Microsurg. 2023 Feb;39(2):111-119. doi: 10.1055/s-0042-1750139. Epub 2022 Jun 28. PMID- 36652567 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1728-7731 (Electronic) IS - 1726-4901 (Linking) VI - 86 IP - 2 DP - 2023 Feb 1 TI - Cytotoxic T-lymphocyte antigen 4 polymorphisms and breast cancer susceptibility: Evidence from a meta-analysis. PG - 207-219 LID - 10.1097/JCMA.0000000000000851 [doi] AB - BACKGROUND: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an immune checkpoint and regulates the immune function of T cells. However, previous findings regarding the association of CTLA-4 polymorphisms and breast cancer remain inconclusive. Therefore, we performed a meta-analysis to investigate the potential effects of five polymorphisms (-1722 T/C, -1661 A/G -318 C/T, +49 A/G, and CT60 A/G) in the CTLA-4 gene on breast cancer susceptibility. METHODS: Relevant literatures were systematically searched through electronic databases including PubMed, EMBASE, and Web of Science up to October 10, 2021. Available data were extracted and odds ratios (ORs) with 95% confidence intervals were used to estimate the pooling effect size. The Newcastle-Ottawa Scale was applied for assessing the quality of included studies. We conducted subgroup analyses based on ethnicity and control sources to explore levels of heterogeneity. Moreover, sensitivity analysis and publication bias were assessed. RESULTS: Finally, a total of 12 eligible studies regarding CTLA-4 polymorphisms and breast cancer were included. For overall analyses, only the +49 A/G polymorphism was significantly associated with breast cancer under allelic (OR = 1.19), dominant (OR = 1.27), and recessive (OR = 1.27) models. Ethnicity-based subgroup analysis found that the +49 A/G polymorphism has a significant risk (OR = 2.03) of breast cancer under the recessive model in the non-Asian population. Studies with hospital-based controls showed that the +49 A/G polymorphism has significant breast cancer risks under allelic (OR = 1.44), dominant (OR = 1.86), and recessive (OR = 1.60) models. In addition, those with population-based controls found that -1722 T/C polymorphism has a significant breast cancer risk under allelic (OR = 1.19) and dominant (OR = 1.26) models. CONCLUSION: This meta-analysis suggested that CTLA-4 + 49 A/G polymorphism may significantly associate with breast cancer susceptibility. Future studies containing various populations are helpful for evaluating the impacts of CTLA-4 polymorphisms on breast cancer susceptibility. CI - Copyright © 2023, the Chinese Medical Association. FAU - Chang, Hao-Yun AU - Chang HY AD - School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC. AD - Division of General Medicine, Department of Medical Education, Far Eastern Memorial Hospital, New Taipei City, Taiwan, ROC. FAU - Liu, Chao-Yu AU - Liu CY AD - Division of Traumatology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan, ROC. FAU - Lo, Yen-Li AU - Lo YL AD - Institute of Biomedical Sciences, Academia Sinica, Nankang, Taipei, Taiwan, ROC. FAU - Chiou, Shih-Hwa AU - Chiou SH AD - Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Stem Cell & Genomic Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Genomic Research Center, Academia Sinica, Taipei, Taiwan, ROC. FAU - Lu, Kai-Hsi AU - Lu KH AD - Department of Medical Research and Education, Cheng-Hsin General Hospital, Taipei, Taiwan, ROC. FAU - Lee, Ming-Cheng AU - Lee MC AD - Division of Infectious Diseases, Department of Internal Medicine, Cheng-Hsin General Hospital, Taipei, Taiwan, ROC. FAU - Wang, Yuan-Hung AU - Wang YH AD - Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC. AD - Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, ROC. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230118 PL - Netherlands TA - J Chin Med Assoc JT - Journal of the Chinese Medical Association : JCMA JID - 101174817 RN - 0 (CTLA-4 Antigen) RN - 0 (CTLA4 protein, human) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/genetics MH - *CTLA-4 Antigen/genetics MH - Genetic Predisposition to Disease MH - Polymorphism, Single Nucleotide COIS- Conflicts of interest: Dr. Shih-Hwa Chiou, an editorial board member at the Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article EDAT- 2023/01/19 06:00 MHDA- 2023/01/21 06:00 CRDT- 2023/01/18 14:43 PHST- 2023/01/18 14:43 [entrez] PHST- 2023/01/19 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] AID - 02118582-202302000-00011 [pii] AID - 10.1097/JCMA.0000000000000851 [doi] PST - ppublish SO - J Chin Med Assoc. 2023 Feb 1;86(2):207-219. doi: 10.1097/JCMA.0000000000000851. Epub 2023 Jan 18. PMID- 36607982 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 1 DP - 2023 TI - Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients. PG - e0280148 LID - 10.1371/journal.pone.0280148 [doi] LID - e0280148 AB - The goal of this study was to employ novel deep-learning convolutional-neural-network (CNN) to predict pathological complete response (PCR), residual cancer burden (RCB), and progression-free survival (PFS) in breast cancer patients treated with neoadjuvant chemotherapy using longitudinal multiparametric MRI, demographics, and molecular subtypes as inputs. In the I-SPY-1 TRIAL, 155 patients with stage 2 or 3 breast cancer with breast tumors underwent neoadjuvant chemotherapy met the inclusion/exclusion criteria. The inputs were dynamic-contrast-enhanced (DCE) MRI, and T2- weighted MRI as three-dimensional whole-images without the tumor segmentation, as well as molecular subtypes and demographics. The outcomes were PCR, RCB, and PFS. Three ("Integrated", "Stack" and "Concatenation") CNN were evaluated using receiver-operating characteristics and mean absolute errors. The Integrated approach outperformed the "Stack" or "Concatenation" CNN. Inclusion of both MRI and non-MRI data outperformed either alone. The combined pre- and post-neoadjuvant chemotherapy data outperformed either alone. Using the best model and data combination, PCR prediction yielded an accuracy of 0.81±0.03 and AUC of 0.83±0.03; RCB prediction yielded an accuracy of 0.80±0.02 and Cohen's κ of 0.73±0.03; PFS prediction yielded a mean absolute error of 24.6±0.7 months (survival ranged from 6.6 to 127.5 months). Deep learning using longitudinal multiparametric MRI, demographics, and molecular subtypes accurately predicts PCR, RCB, and PFS in breast cancer patients. This approach may prove useful for treatment selection, planning, execution, and mid-treatment adjustment. CI - Copyright: © 2023 Dammu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Dammu, Hongyi AU - Dammu H AD - Department of Radiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America. FAU - Ren, Thomas AU - Ren T AD - Department of Radiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America. FAU - Duong, Tim Q AU - Duong TQ AUID- ORCID: 0000-0001-6403-2827 AD - Department of Radiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America. LA - eng PT - Journal Article DEP - 20230106 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - *Deep Learning MH - Progression-Free Survival MH - Neoplasm, Residual/etiology MH - Magnetic Resonance Imaging/methods MH - Neoadjuvant Therapy/methods MH - Retrospective Studies MH - Treatment Outcome PMC - PMC9821469 COIS- The authors have declared that no competing interests exist. EDAT- 2023/01/07 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/06 13:43 PHST- 2022/03/30 00:00 [received] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/06 13:43 [entrez] PHST- 2023/01/07 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - PONE-D-22-09310 [pii] AID - 10.1371/journal.pone.0280148 [doi] PST - epublish SO - PLoS One. 2023 Jan 6;18(1):e0280148. doi: 10.1371/journal.pone.0280148. eCollection 2023. PMID- 36575447 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230104 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 20 IP - 1 DP - 2022 Dec 27 TI - Accurate genome-wide genotyping from archival tissue to explore the contribution of common genetic variants to pre-cancer outcomes. PG - 623 LID - 10.1186/s12967-022-03810-z [doi] LID - 623 AB - PURPOSE: The contribution of common genetic variants to pre-cancer progression is understudied due to long follow-up time, rarity of poor outcomes and lack of available germline DNA collection. Alternatively, DNA from diagnostic archival tissue is available, but its somatic nature, limited quantity and suboptimal quality would require an accurate cost-effective genome-wide germline genotyping methodology. EXPERIMENTAL DESIGN: Blood and tissue DNA from 10 individuals were used to benchmark the accuracy of Single Nucleotide Polymorphisms (SNP) genotypes, Polygenic Risk Scores (PRS) or HLA haplotypes using low-coverage whole-genome sequencing (lc-WGS) and genotype imputation. Tissue-derived PRS were further evaluated for 36 breast cancer patients (11.7 years median follow-up time) diagnosed with DCIS and used to model the risk of Breast Cancer Subsequent Events (BCSE). RESULTS: Tissue-derived germline DNA profiling resulted in accurate genotypes at common SNPs (blood correlation r(2) > 0.94) and across 22 disease-related polygenic risk scores (PRS, mean correlation r = 0.93). Imputed Class I and II HLA haplotypes were 96.7% and 82.5% concordant with clinical-grade blood HLA haplotypes, respectively. In DCIS patients, tissue-derived PRS was significantly associated with BCSE (HR = 2, 95% CI 1.2-3.8). The top and bottom decile patients had an estimated 28% and 5% chance of BCSE at 10 years, respectively. CONCLUSIONS: Archival tissue DNA germline profiling using lc-WGS and imputation, represents a cost and resource-effective alternative in the retrospective design of long-term disease genetic studies. Initial results in breast cancer suggest that common risk variants contribute to pre-cancer progression. CI - © 2022. The Author(s). FAU - Nachmanson, Daniela AU - Nachmanson D AD - Bioinformatics and Systems Biology Graduate Program, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA. FAU - Pagadala, Meghana AU - Pagadala M AD - Biomedical Science Graduate Program, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA. FAU - Steward, Joseph AU - Steward J AD - Moores Cancer Center, University of California San Diego, 3855 Health Science Drive, San Diego, CA, 92093, USA. FAU - Cheung, Callie AU - Cheung C AD - Moores Cancer Center, University of California San Diego, 3855 Health Science Drive, San Diego, CA, 92093, USA. FAU - Bruce, Lauryn Keeler AU - Bruce LK AD - Bioinformatics and Systems Biology Graduate Program, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA. FAU - Lee, Nicole Q AU - Lee NQ AD - Moores Cancer Center, University of California San Diego, 3855 Health Science Drive, San Diego, CA, 92093, USA. FAU - O'Keefe, Thomas J AU - O'Keefe TJ AD - Department of Surgery, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA. FAU - Lin, Grace Y AU - Lin GY AD - Department of Pathology, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA. FAU - Hasteh, Farnaz AU - Hasteh F AD - Department of Pathology, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA. FAU - Morris, Gerald P AU - Morris GP AD - Department of Pathology, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA. FAU - Carter, Hannah AU - Carter H AD - Moores Cancer Center, University of California San Diego, 3855 Health Science Drive, San Diego, CA, 92093, USA. AD - Division of Medical Genetics, Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA. FAU - Harismendy, Olivier AU - Harismendy O AUID- ORCID: 0000-0002-8098-9888 AD - Moores Cancer Center, University of California San Diego, 3855 Health Science Drive, San Diego, CA, 92093, USA. oharismendy@ucsd.edu. AD - Division of Biomedical Informatics, Department of Medicine, University of California San Diego, 9500 Gilman Drive, San Diego, CA, 92093, USA. oharismendy@ucsd.edu. LA - eng GR - U01CA196406/NH/NIH HHS/United States GR - U01CA196383/NH/NIH HHS/United States GR - T32GM008806/NH/NIH HHS/United States GR - T15LM011271/NH/NIH HHS/United States GR - U54CA209891/NH/NIH HHS/United States GR - P30CA023100/NH/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20221227 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 SB - IM MH - Humans MH - Female MH - Genotype MH - Retrospective Studies MH - *Carcinoma, Intraductal, Noninfiltrating MH - Genome-Wide Association Study/methods MH - Polymorphism, Single Nucleotide/genetics MH - *Breast Neoplasms/genetics PMC - PMC9793518 OTO - NOTNLM OT - Breast cancer OT - Ductal carcinoma in situ OT - Genotyping OT - Low-coverage whole-genome sequencing OT - Polygenic risk score OT - Pre-cancer COIS- O.H. is an employee of Zentalis Pharmaceuticals. D.N. is an employee of TwinStrand Inc. The other authors declare no potential conflicts of interest. EDAT- 2022/12/28 06:00 MHDA- 2022/12/30 06:00 CRDT- 2022/12/27 23:44 PHST- 2022/09/03 00:00 [received] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/27 23:44 [entrez] PHST- 2022/12/28 06:00 [pubmed] PHST- 2022/12/30 06:00 [medline] AID - 10.1186/s12967-022-03810-z [pii] AID - 3810 [pii] AID - 10.1186/s12967-022-03810-z [doi] PST - epublish SO - J Transl Med. 2022 Dec 27;20(1):623. doi: 10.1186/s12967-022-03810-z. PMID- 36601658 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230112 IS - 1533-0338 (Electronic) IS - 1533-0346 (Print) IS - 1533-0338 (Linking) VI - 22 DP - 2023 Jan-Dec TI - Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review. PG - 15330338221145246 LID - 10.1177/15330338221145246 [doi] LID - 15330338221145246 AB - Breast cancer is the most common malignancy and the second most common cause of cancer-related mortality in women. Triple-negative breast cancers do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 and have a higher recurrence rate, greater metastatic potential, and lower overall survival rate than those of other breast cancers. Treatment of triple-negative breast cancer is challenging; molecular-targeted therapies are largely ineffective and there is no standard treatment. In this review, we evaluate current attempts to classify triple-negative breast cancers based on their molecular features. We also describe promising treatment methods with different advantages and discuss genetic biomarkers and other prediction tools. Accurate molecular classification of triple-negative breast cancers is critical for patient risk categorization, treatment decisions, and surveillance. This review offers new ideas for more effective treatment of triple-negative breast cancer and identifies novel targets for drug development. FAU - Lu, Boya AU - Lu B AUID- ORCID: 0000-0001-8870-2944 AD - Department of Mechanical Engineering, Faculty of Engineering, Technology and Built Environment, 125743UCSI University, Kuala Lumpur, Malaysia. FAU - Natarajan, Elango AU - Natarajan E AD - Department of Mechanical Engineering, Faculty of Engineering, Technology and Built Environment, 125743UCSI University, Kuala Lumpur, Malaysia. FAU - Balaji Raghavendran, Hanumantha Rao AU - Balaji Raghavendran HR AD - Faculty of Clinical Research, Central Research Facility, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India. FAU - Markandan, Uma Devi AU - Markandan UD AD - Faculty of Medicine, 37447University of Malaya, Kuala Lumpur, Malaysia. LA - eng PT - Journal Article PT - Review PL - United States TA - Technol Cancer Res Treat JT - Technology in cancer research & treatment JID - 101140941 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Triple Negative Breast Neoplasms/diagnosis/genetics/therapy MH - Receptor, ErbB-2/genetics/metabolism MH - *Breast Neoplasms/pathology MH - Treatment Outcome MH - Biomarkers, Tumor/genetics/metabolism PMC - PMC9829998 OTO - NOTNLM OT - biomarkers OT - molecular classification OT - prediction OT - treatment OT - triple-negative breast cancer COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/01/06 06:00 MHDA- 2023/01/07 06:00 CRDT- 2023/01/05 02:38 PHST- 2023/01/05 02:38 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] AID - 10.1177_15330338221145246 [pii] AID - 10.1177/15330338221145246 [doi] PST - ppublish SO - Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221145246. doi: 10.1177/15330338221145246. PMID- 36371776 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Association between nociplastic pain and premature endocrine therapy discontinuation in breast cancer patients. PG - 397-404 LID - 10.1007/s10549-022-06806-x [doi] AB - PURPOSE: At least 5 years of adjuvant endocrine therapy (ET) is recommended for patients with hormone receptor-positive invasive breast cancer to reduce cancer recurrence risk. Up to half of patients prematurely discontinue ET, often due to musculoskeletal pain. Nociplastic pain is abnormal central nervous system pain processing without evidence of tissue or neuronal damage. This study aimed to evaluate the relationship between baseline nociplastic pain and ET discontinuation. METHODS: This was a retrospective, single center, cohort study. Included patients were female, had stage 0-III invasive breast cancer, did not receive neoadjuvant therapy, and completed quality of life questionnaires prior to breast surgery, including Fibromyalgia Survey for nociplastic pain. Clinical data including duration of ET were abstracted from the medical record. Patient characteristics were analyzed with t-tests and Chi-squared tests, as appropriate. Univariate and multivariable regressions were performed with Cox proportional hazard models. RESULTS: Six hundred eighty-one patients diagnosed between 2012 and 2019 met inclusion criteria; 480 initiated ET and were included in the analysis. Of these 480 patients, 203 (42.3%) prematurely discontinued initial ET therapy. On univariate analysis, tamoxifen use (hazard ratio [HR] 0.70, p = 0.021) and premenopausal status (HR 0.73, p = 0.04) were inversely associated with ET discontinuation, while Fibromyalgia Score was positively associated (HR 1.04, p = 0.043). On multivariable analysis, baseline Fibromyalgia Score remained associated with ET discontinuation. CONCLUSION: Nociplastic pain present prior to surgery was associated with premature ET discontinuation. Fibromyalgia Score screening may be useful for evaluating ET discontinuation risk. Treatments targeting nociplastic pain may be more effective for treating ET-emergent pain. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Joyce, Elizabeth AU - Joyce E AUID- ORCID: 0000-0002-8133-2298 AD - University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Carr, Grant AU - Carr G AD - Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. FAU - Wang, Sidi AU - Wang S AD - Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. FAU - Brummett, Chad M AU - Brummett CM AD - Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Kidwell, Kelley M AU - Kidwell KM AD - Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. FAU - Henry, N Lynn AU - Henry NL AUID- ORCID: 0000-0002-4771-5930 AD - Department of Internal Medicine, University of Michigan Medical School, 1500 East Medical Center Dr. Room 7322, Ann Arbor, MI, 48109, USA. norahh@umich.edu. LA - eng GR - 1R01CA266012-01/CA/NCI NIH HHS/United States GR - T32 CA083654/CA/NCI NIH HHS/United States GR - R01 CA266012/CA/NCI NIH HHS/United States GR - TL1 TR002242/TR/NCATS NIH HHS/United States GR - 5T32CA083654/Center for Biomedical Informatics and Information Technology, National Cancer Institute/ GR - 5TL1TR002242/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20221113 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (Aromatase Inhibitors) RN - 0 (Antineoplastic Agents, Hormonal) SB - IM MH - Humans MH - Female MH - Male MH - *Breast Neoplasms/complications/drug therapy/chemically induced MH - Retrospective Studies MH - Cohort Studies MH - *Fibromyalgia/chemically induced/complications/drug therapy MH - Quality of Life MH - Neoplasm Recurrence, Local/drug therapy MH - *Musculoskeletal Pain/chemically induced MH - Chemotherapy, Adjuvant/adverse effects MH - Aromatase Inhibitors/adverse effects MH - Antineoplastic Agents, Hormonal/adverse effects PMC - PMC9825644 MID - NIHMS1853244 OTO - NOTNLM OT - Aromatase inhibitor-associated musculoskeletal symptoms OT - Aromatase inhibitors OT - Breast cancer OT - Endocrine therapy OT - Endocrine therapy toxicity OT - Musculoskeletal pain COIS- Competing Interests: Financial Interests: NLH reports research contracting to her institution from Blue Note Therapeutics, consulting from Myovant Pharmaceuticals, and royalties from Up-to-Date, none of which are related to this work. CMB is a consultant for Heron Therapeutics, Vertex Pharmaceuticals, Alosa Health and Benter Foundation; and he provides expert medical testimony, none of which are related to this work. The remaining authors have no disclosures to report. EDAT- 2022/11/14 06:00 MHDA- 2023/01/11 06:00 PMCR- 2024/01/01 CRDT- 2022/11/13 14:36 PHST- 2022/09/28 00:00 [received] PHST- 2022/11/03 00:00 [accepted] PHST- 2024/01/01 00:00 [pmc-release] PHST- 2022/11/14 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/13 14:36 [entrez] AID - 10.1007/s10549-022-06806-x [pii] AID - 10.1007/s10549-022-06806-x [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):397-404. doi: 10.1007/s10549-022-06806-x. Epub 2022 Nov 13. PMID- 36601118 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230119 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8(+) tumor-infiltrating lymphocytes in breast cancer. PG - 1080048 LID - 10.3389/fimmu.2022.1080048 [doi] LID - 1080048 AB - Infiltration of CD8(+) T cells and their spatial contexture, represented by immunophenotype, predict the prognosis and therapeutic response in breast cancer. However, a non-surgical method using radiomics to evaluate breast cancer immunophenotype has not been explored. Here, we assessed the CD8(+) T cell-based immunophenotype in patients with breast cancer undergoing upfront surgery (n = 182). We extracted radiomic features from the four phases of dynamic contrast-enhanced magnetic resonance imaging, and randomly divided the patients into training (n = 137) and validation (n = 45) cohorts. For predicting the immunophenotypes, radiomic models (RMs) that combined the four phases demonstrated superior performance to those derived from a single phase. For discriminating the inflamed tumor from the non-inflamed tumor, the feature-based combination model from the whole tumor (RM-whole(FC)) showed high performance in both training (area under the receiver operating characteristic curve [AUC] = 0.973) and validation cohorts (AUC = 0.985). Similarly, the feature-based combination model from the peripheral tumor (RM-peri(FC)) discriminated between immune-desert and excluded tumors with high performance in both training (AUC = 0.993) and validation cohorts (AUC = 0.984). Both RM-whole(FC) and RM-peri(FC) demonstrated good to excellent performance for every molecular subtype. Furthermore, in patients who underwent neoadjuvant chemotherapy (n = 64), pre-treatment images showed that tumors exhibiting complete response to neoadjuvant chemotherapy had significantly higher scores from RM-whole(FC) and lower scores from RM-peri(FC). Our RMs predicted the immunophenotype of breast cancer based on the spatial distribution of CD8(+) T cells with high accuracy. This approach can be used to stratify patients non-invasively based on the status of the tumor-immune microenvironment. CI - Copyright © 2022 Jeon, Kim, Na, Seo, Sohn and Lim. FAU - Jeon, Seung Hyuck AU - Jeon SH AD - Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea. FAU - Kim, So-Woon AU - Kim SW AD - Department of Pathology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea. FAU - Na, Kiyong AU - Na K AD - Department of Pathology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea. FAU - Seo, Mirinae AU - Seo M AD - Department of Radiology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea. FAU - Sohn, Yu-Mee AU - Sohn YM AD - Department of Radiology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea. FAU - Lim, Yu Jin AU - Lim YJ AD - Department of Radiation Oncology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221219 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/therapy/pathology MH - Lymphocytes, Tumor-Infiltrating MH - CD8-Positive T-Lymphocytes MH - Retrospective Studies MH - Magnetic Resonance Imaging/methods MH - Tumor Microenvironment PMC - PMC9806253 OTO - NOTNLM OT - CD8+ T cells OT - breast cancer OT - immunophenotype OT - magnetic resonanace imaging OT - radiomics COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/06 06:00 MHDA- 2023/01/07 06:00 CRDT- 2023/01/05 02:25 PHST- 2022/10/25 00:00 [received] PHST- 2022/12/07 00:00 [accepted] PHST- 2023/01/05 02:25 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] AID - 10.3389/fimmu.2022.1080048 [doi] PST - epublish SO - Front Immunol. 2022 Dec 19;13:1080048. doi: 10.3389/fimmu.2022.1080048. eCollection 2022. PMID- 36170550 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230120 IS - 1530-0315 (Electronic) IS - 0195-9131 (Print) IS - 0195-9131 (Linking) VI - 55 IP - 2 DP - 2023 Feb 1 TI - WISER Survivor Trial: Combined Effect of Exercise and Weight Loss Interventions on Inflammation in Breast Cancer Survivors. PG - 209-215 LID - 10.1249/MSS.0000000000003050 [doi] AB - PURPOSE: Physical inactivity and obesity increase risk for breast cancer recurrence and cardiovascular death; inflammation is hypothesized to mediate these associations. METHODS: In a four-arm randomized controlled trial, 318 breast cancer survivors with overweight or obesity were randomized to exercise alone, weight loss alone, exercise plus weight loss, or control for 12 months. Inflammation outcomes included C-reactive protein (CRP), serum amyloid A (SAA), intracellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1). RESULTS: Compared with control, exercise alone increased ICAM-1 (9.3%; 95% confidence interval [CI] = 1.6-16.9) and VCAM-1 (8.6%; 95% CI = 2.6-14.5) but did not change CRP or SAA. Compared with control, weight loss alone reduced CRP (-35.2%; 95% CI = -49.9 to -20.7), and SAA (-25.6%; 95% CI = -39.8 to -11.9) but did not change ICAM-1 or VCAM-1. Compared with control, exercise plus weight loss reduced CRP (-44.1%; 95% CI = -57.1 to -31.1) and SAA (-26.6%; 95% CI = -40.5 to -12.6) but did not change ICAM-1 or VCAM-1. Among 194 participants with elevated CRP at baseline (e.g., >3 mg·L -1 ), compared with control, weight loss alone (0.17; 95% CI = 0.04-0.30) and exercise plus weight loss (0.31; 95% CI = 0.16-0.46) increased the probability of achieving normal CRP at month 12. In analyses that consolidated randomized groups, body weight and adiposity reductions, but not change in fitness level, correlated with decreased CRP, SAA, and ICAM-1 levels. CONCLUSIONS: In breast cancer survivors with overweight or obesity, weight loss or exercise plus weight loss reduced measures of inflammation that are associated with breast cancer recurrence and cardiovascular death. CI - Copyright © 2022 by the American College of Sports Medicine. FAU - Sturgeon, Kathleen M AU - Sturgeon KM AD - Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA. FAU - Brown, Justin C AU - Brown JC AD - Cancer Metabolism Program, Pennington Biomedical Research Center, Baton Rouge, LA. FAU - Sears, Dorothy D AU - Sears DD FAU - Sarwer, David B AU - Sarwer DB AD - Center for Obesity Research and Education, College of Public Health, Temple University, Philadelphia, PA. FAU - Schmitz, Kathryn H AU - Schmitz KH AD - Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA. LA - eng SI - ClinicalTrials.gov/NCT01515124 GR - R25 CA203650/CA/NCI NIH HHS/United States GR - UL1 TR001878/TR/NCATS NIH HHS/United States GR - KL2 TR002015/TR/NCATS NIH HHS/United States GR - P30 DK072476/DK/NIDDK NIH HHS/United States GR - R00 CA218603/CA/NCI NIH HHS/United States GR - U54 GM104940/GM/NIGMS NIH HHS/United States GR - U54 CA155435/CA/NCI NIH HHS/United States GR - U54 CA155850/CA/NCI NIH HHS/United States GR - P30 CA016520/CA/NCI NIH HHS/United States GR - UL1 TR002014/TR/NCATS NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial DEP - 20220929 PL - United States TA - Med Sci Sports Exerc JT - Medicine and science in sports and exercise JID - 8005433 RN - 0 (Vascular Cell Adhesion Molecule-1) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - 9007-41-4 (C-Reactive Protein) RN - 0 (Serum Amyloid A Protein) SB - IM MH - Humans MH - Female MH - Overweight MH - *Breast Neoplasms/therapy/complications MH - *Cancer Survivors MH - Vascular Cell Adhesion Molecule-1 MH - Intercellular Adhesion Molecule-1 MH - Neoplasm Recurrence, Local/complications MH - Obesity/complications MH - C-Reactive Protein/analysis MH - Inflammation MH - Survivors MH - Serum Amyloid A Protein/analysis/metabolism MH - Weight Loss PMC - PMC9840668 MID - NIHMS1837504 EDAT- 2022/09/29 06:00 MHDA- 2023/01/17 06:00 PMCR- 2024/02/01 CRDT- 2022/09/28 14:42 PHST- 2024/02/01 00:00 [pmc-release] PHST- 2022/09/29 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/09/28 14:42 [entrez] AID - 00005768-202302000-00007 [pii] AID - 10.1249/MSS.0000000000003050 [doi] PST - ppublish SO - Med Sci Sports Exerc. 2023 Feb 1;55(2):209-215. doi: 10.1249/MSS.0000000000003050. Epub 2022 Sep 29. PMID- 36116086 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1099-1611 (Electronic) IS - 1057-9249 (Linking) VI - 32 IP - 1 DP - 2023 Jan TI - Feasibility and acceptability of written exposure therapy in addressing posttraumatic stress disorder in Iranian patients with breast cancer. PG - 68-76 LID - 10.1002/pon.6037 [doi] AB - OBJECTIVE: This study examined the feasibility and acceptability of written exposure therapy (WET) in reducing symptoms of posttraumatic stress disorder (PTSD) in Iranian women with breast cancer. Secondary aims included examining the influence of WET on quality of life (QoL), overgeneral memory and illness perceptions. METHOD: Forty-six females with breast cancer and clinical symptoms of PTSD referred to the Razi Hospital in Rasht, Iran were randomly assigned to either WET (n = 23) or control (n = 23) groups. WET is a 5-session low-intensity exposure-based intervention for treating PTSD. The control group had no additional contact. Measures assessing PTSD, illness perceptions, overgeneral memory, and QoL were administered at baseline, post-intervention and 3-month follow-up. RESULTS: Acceptability of WET was high; all participants completed all WET sessions. At post-intervention, 95.65% of the WET group met criteria for reliable change and 100% met criteria for minimal clinically important difference (MCID) and clinically significant change in PTSD symptom improvement. At follow-up, all WET participants met criteria for reliable change, MCID and clinically significant change in PTSD symptom improvement. No participants in the control group met reliable change, MCID or clinically significant change. The WET group had improved QoL and memory specificity and decreased threatening illness perceptions at post-intervention and follow-up when compared to controls. CONCLUSION: WET may be a useful intervention for use with breast cancer patients with PTSD symptoms and may be an important adjunct to medical and pharmacological treatments, particularly in low- and middle-income countries. This study indicates further research in this area is warranted. CI - © 2022 John Wiley & Sons Ltd. FAU - Zolfa, Reihane AU - Zolfa R AD - Department of Clinical Psychology, Kharazmi University, Tehran, Iran. FAU - Moradi, Alireza AU - Moradi A AD - Kharazmi University and Institute for Cognitive Science Studies, Tehran, Iran. FAU - Mahdavi, Mohammad AU - Mahdavi M AD - Kharazmi University and Institute for Cognitive Science Studies, Tehran, Iran. FAU - Parhoon, Hadi AU - Parhoon H AD - Department of Psychology, Razi University, Kermanshah, Iran. FAU - Parhoon, Kamal AU - Parhoon K AD - Postdoc Researcher in Cognitive Psychology, Kharazmi University, Tehran, Iran. FAU - Jobson, Laura AU - Jobson L AUID- ORCID: 0000-0002-1534-897X AD - Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20220928 PL - England TA - Psychooncology JT - Psycho-oncology JID - 9214524 SB - IM MH - Humans MH - Female MH - *Stress Disorders, Post-Traumatic/therapy/diagnosis MH - *Implosive Therapy MH - Iran MH - Quality of Life MH - *Breast Neoplasms/therapy MH - Feasibility Studies OTO - NOTNLM OT - LMIC OT - PTSD OT - autobiographical memory OT - breast cancer OT - illness perception OT - oncology OT - quality of life OT - written exposure therapy EDAT- 2022/09/19 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/09/18 13:54 PHST- 2022/07/18 00:00 [revised] PHST- 2022/02/12 00:00 [received] PHST- 2022/07/26 00:00 [accepted] PHST- 2022/09/19 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/09/18 13:54 [entrez] AID - 10.1002/pon.6037 [doi] PST - ppublish SO - Psychooncology. 2023 Jan;32(1):68-76. doi: 10.1002/pon.6037. Epub 2022 Sep 28. PMID- 36258148 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis. PG - 2-12 LID - 10.1007/s12282-022-01403-8 [doi] AB - PURPOSE: We conducted a systematic review and meta-analysis to investigate the effectiveness of moisturizers on acute radiation dermatitis (ARD) in breast cancer patients receiving radiotherapy (RT). METHODS: PubMed, the Cochrane Library, CINAHL, and Ichushi-Web were searched for randomized controlled trials (RCTs) from April 2015 to March 2020. Assessments included type of intervention, cohort, outcomes, and quality of evidence. To evaluate the effect of moisturizer on ARD, we restricted analyses to studies comparing with standard skin care or no treatment. Outcomes were ARD severity and skin-related QOL (quality of life). Eligible studies were identified, and risk ratios and mean differences were extracted to compare outcome data. RESULTS: We screened 210 RCTs along with 14 studies included in a previous iteration of this analysis (2016), supplemented by a hand search (n = 9). Finally, we included 6 RCTs that investigated the effectiveness of standard type moisturizers in breast cancer patients receiving RT. Evidence (weak certainty) suggests that moisturizer use might reduce ≥ grade 3 ARD. QOL assessed by Skindex-16 improved with moisturizer use. Pain and pruritus measured by the visual analog scale (VAS) resulted in a smaller and nonsignificant difference in favor of moisturizer use. However, the certainty of the evidence was very weak in QOL. CONCLUSIONS: The proactive use of moisturizer may play a role in reducing ARD and improving skin-related QOL, although the certainty of the evidence was weak to very weak. Future high-quality RCTs should be initiated to strengthen these results. CI - © 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society. FAU - Sekiguchi, Kenji AU - Sekiguchi K AUID- ORCID: 0000-0002-2310-1221 AD - Sonoda-kai Radiation Oncology Clinic, 3-4-19 Hokima, Adachi-ku, Tokyo, 121-0064, Japan. kenjisek@luke.ac.jp. AD - Department of Radiation Oncology, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. kenjisek@luke.ac.jp. FAU - Sumi, Minako AU - Sumi M AD - Radiation Oncology Department, Metropolitan Geriatric Hospital, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan. FAU - Saito, Anneyuko AU - Saito A AD - Department of Radiation Oncology, Faculty of Medicine, Juntendo University, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan. FAU - Zenda, Sadamoto AU - Zenda S AD - Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. FAU - Arahira, Satoko AU - Arahira S AD - Division of Radiation Oncology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki, Kanagawa, 211-8510, Japan. FAU - Iino, Keiko AU - Iino K AD - National College of Nursing, 1-2-1 Umezono, Kiyose, Tokyo, 204-8575, Japan. FAU - Okumura, Masayuki AU - Okumura M AD - Department of Radiology, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Japan. FAU - Kawai, Fujimi AU - Kawai F AD - Library, Center for Academic Resources, St. Luke's International University, 10-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan. FAU - Nozawa, Keiko AU - Nozawa K AD - Faculty of Nursing, Mejiro University, 320 Ukiya, Iwatsuki-ku, Saitama, Saitama, 339-8501, Japan. LA - eng GR - 20EA1016/the Ministry of Health, Labor and Welfare/ PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20221018 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 SB - IM EIN - Breast Cancer. 2022 Nov 17;:. PMID: 36396905 MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/radiotherapy MH - *Radiodermatitis/drug therapy/etiology MH - Skin OTO - NOTNLM OT - Acute radiation dermatitis OT - Breast cancer OT - Moisturizer OT - QOL EDAT- 2022/10/19 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/10/18 23:34 PHST- 2022/07/30 00:00 [received] PHST- 2022/09/11 00:00 [accepted] PHST- 2022/10/19 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/10/18 23:34 [entrez] AID - 10.1007/s12282-022-01403-8 [pii] AID - 10.1007/s12282-022-01403-8 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):2-12. doi: 10.1007/s12282-022-01403-8. Epub 2022 Oct 18. PMID- 36674436 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 4 TI - Impact of Physical Rehabilitation on Bone Biomarkers in Non-Metastatic Breast Cancer Women: A Systematic Review and Meta-Analysis. LID - 10.3390/ijms24020921 [doi] LID - 921 AB - Rehabilitation might improve bone health in breast cancer (BC) patients, but the effects on bone biomarkers are still debated. Thus, this meta-analysis of randomized controlled trials (RCTs) aims at characterizing the impact of rehabilitation on bone health biomarkers in BC survivors. On 2 May 2022, PubMed, Scopus, Web of Science, Cochrane, and PEDro were systematically searched for RCTs assessing bone biomarker modifications induced by physical exercise in BC survivors. The quality assessment was performed with the Jadad scale and the Cochrane risk-of-bias tool for randomized trials (RoBv.2). Trial registration number: CRD42022329766. Ten studies were included for a total of 873 patients. The meta-analysis showed overall significant mean difference percentage decrease in collagen type 1 cross-linked N-telopeptide (NTX) serum level [ES: -11.65 (-21.13, -2.17), p = 0.02)] and an increase in bone-specific alkaline phosphatase (BSAP) levels [ES: +6.09 (1.56, 10.62). According to the Jadad scale, eight RCTs were considered high-quality studies. Four studies showed a low overall risk of bias, according to RoBv.2. The significant effects of rehabilitation on bone biomarkers suggested a possible implication for a precision medicine approach targeting bone remodeling. Future research might clarify the role of bone biomarkers monitoring in rehabilitation management of cancer treatment induced bone-loss. FAU - de Sire, Alessandro AU - de Sire A AUID- ORCID: 0000-0002-5541-8346 AD - Physical and Rehabilitative Medicine, Department of Medical and Surgical Sciences, University of Catanzaro "Magna Graecia", Viale Europa, 88100 Catanzaro, Italy. FAU - Lippi, Lorenzo AU - Lippi L AUID- ORCID: 0000-0001-9035-1485 AD - Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont "A. Avogadro", 28100 Novara, Italy. AD - Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Translational Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy. FAU - Marotta, Nicola AU - Marotta N AUID- ORCID: 0000-0002-5568-7909 AD - Physical and Rehabilitative Medicine, Department of Medical and Surgical Sciences, University of Catanzaro "Magna Graecia", Viale Europa, 88100 Catanzaro, Italy. FAU - Folli, Arianna AU - Folli A AUID- ORCID: 0000-0003-2948-8540 AD - Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont "A. Avogadro", 28100 Novara, Italy. FAU - Calafiore, Dario AU - Calafiore D AUID- ORCID: 0000-0001-9221-2497 AD - Physical Medicine and Rehabilitation Unit, Department of Neurosciences, ASST Carlo Poma, 46100 Mantova, Italy. FAU - Moalli, Stefano AU - Moalli S AUID- ORCID: 0000-0001-8936-8757 AD - Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont "A. Avogadro", 28100 Novara, Italy. FAU - Turco, Alessio AU - Turco A AUID- ORCID: 0000-0003-0510-0329 AD - Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont "A. Avogadro", 28100 Novara, Italy. FAU - Ammendolia, Antonio AU - Ammendolia A AUID- ORCID: 0000-0002-2828-2455 AD - Physical and Rehabilitative Medicine, Department of Medical and Surgical Sciences, University of Catanzaro "Magna Graecia", Viale Europa, 88100 Catanzaro, Italy. FAU - Fusco, Nicola AU - Fusco N AUID- ORCID: 0000-0002-9101-9131 AD - Division of Pathology, IEO, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, 20141 Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy. FAU - Invernizzi, Marco AU - Invernizzi M AUID- ORCID: 0000-0001-5141-0681 AD - Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont "A. Avogadro", 28100 Novara, Italy. AD - Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Translational Medicine, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20230104 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Biomarkers) SB - IM MH - Female MH - Humans MH - *Quality of Life MH - Exercise MH - *Breast Neoplasms/therapy MH - Exercise Therapy MH - Biomarkers PMC - PMC9863706 OTO - NOTNLM OT - biomarkers OT - breast cancer OT - osteoporosis OT - physical exercise OT - precision medicine OT - rehabilitation COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:24 PHST- 2022/11/18 00:00 [received] PHST- 2022/12/08 00:00 [revised] PHST- 2022/12/14 00:00 [accepted] PHST- 2023/01/21 01:24 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijms24020921 [pii] AID - ijms-24-00921 [pii] AID - 10.3390/ijms24020921 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 4;24(2):921. doi: 10.3390/ijms24020921. PMID- 36481308 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 181 DP - 2023 Jan TI - The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis. PG - 103893 LID - S1040-8428(22)00317-1 [pii] LID - 10.1016/j.critrevonc.2022.103893 [doi] AB - This study reviewed the prognostic effect of tumor-infiltrating B lymphocytes (TIBLs) on solid malignancies, to determine the potential role of TIBLs in predicting cancer patient's prognosis and their response to immunotherapy. A total of 45 original papers involving 11,099 individual patients were included in this meta-analysis covering 7 kinds of cancer. The pooled results suggested that high levels of TIBLs were correlated with favorable OS in lung, esophageal, gastric, colorectal, liver, and breast cancer; improved RFS in lung cancer; and improved DFS in gastrointestinal neoplasms. Additionally, TIBLs were significantly correlated with negative lymphatic invasion in gastric cancer, small tumor size in hepatocellular carcinoma, and negative distant metastasis in colorectal cancer. Additionally, TIBLs were reported as a discriminative feature of patients treated with immunotherapy with improved survival. We concluded that TIBLs play a favorable prognostic role among the common solid malignancie, providing theoretical evidence for further prognosis prediction for solid tumors. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Liu, Hao AU - Liu H AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Department of Orthopaedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. FAU - Li, Zhuoqun AU - Li Z AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Han, Xuan AU - Han X AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Li, Zhujun AU - Li Z AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Zhao, Yan AU - Zhao Y AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Liu, Fenghua AU - Liu F AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Zhu, Ziyu AU - Zhu Z AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Lv, Yi AU - Lv Y AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. FAU - Liu, Zhijun AU - Liu Z AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. Electronic address: zhijun_liu@xjtufh.edu.cn. FAU - Zhang, Nana AU - Zhang N AD - Institute of Regenerative and Reconstructive Medicine, Med-X Institute, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China; National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. Electronic address: znn164503047@mail.xjtu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20221205 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 SB - IM MH - Humans MH - Female MH - Prognosis MH - *B-Lymphocyte Subsets MH - *Carcinoma, Hepatocellular/pathology MH - *Breast Neoplasms/pathology MH - *Liver Neoplasms/pathology MH - Lymphocytes, Tumor-Infiltrating OTO - NOTNLM OT - Meta-analysis OT - Prognostic impact OT - Solid malignancy OT - Tumor-infiltrating B lymphocytes COIS- Declaration of Competing Interest The authors declare no conflicts of interest. EDAT- 2022/12/09 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/08 23:28 PHST- 2022/08/11 00:00 [received] PHST- 2022/11/22 00:00 [revised] PHST- 2022/12/01 00:00 [accepted] PHST- 2022/12/09 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/08 23:28 [entrez] AID - S1040-8428(22)00317-1 [pii] AID - 10.1016/j.critrevonc.2022.103893 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2023 Jan;181:103893. doi: 10.1016/j.critrevonc.2022.103893. Epub 2022 Dec 5. PMID- 36536225 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1615-7605 (Electronic) IS - 1615-7591 (Print) IS - 1615-7591 (Linking) VI - 46 IP - 1 DP - 2023 Jan TI - In vitro anticancer and antibacterial performance of biosynthesized Ag and Ce co-doped ZnO NPs. PG - 89-103 LID - 10.1007/s00449-022-02815-8 [doi] AB - The great potential of zinc oxide nanoparticles (ZnO NPs) for biomedical applications is attributed to their physicochemical properties. In this work, pure and Ag and Ce dual-doped ZnO NPs were synthesized through a facile and green route to examine their cytotoxicity in breast cancer and normal cells. The initial preparation of dual-doped nanoparticles was completed by the usage of taranjabin. The synthesis of Ag and Ce dual-doped ZnO NPs was started with preparing the Ce:Ag ratios of 1:1, 1:2, and 1:4. The cytotoxicity effects of synthesized nanoparticles against breast normal cells (MCF-10A) and breast cancer cells (MDA-MB-231) were examined. The hexagonal structure of synthesized nanoparticles was observed through the results of X-ray diffraction (XRD). Scanning electron microscopy (SEM) images exhibited the spherical shape and smooth surfaces of prepared particles along with the homogeneous distribution of Ag and Ce in ZnO with high-quality lattice fringes without any distortions. According to the cytotoxic results, the effects of Ag/Ce dual-doped ZnO NPs on breast cancer (MDA-MB-231) cells were significantly more than of pure ZnO NPs, while dual-doped and pure nanoparticles remained indifferent towards breast normal (MCF-10A) cells. In addition, we investigated the antimicrobial activity against harmful bacteria. CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Al-Enazi, Nouf M AU - Al-Enazi NM AD - Department of Biology, College of Science and Humanities in Al-Kharj, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia. n.alenazi@psau.edu.sa. FAU - Alsamhary, Khawla AU - Alsamhary K AD - Department of Biology, College of Science and Humanities in Al-Kharj, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia. FAU - Kha, Mansour AU - Kha M AUID- ORCID: 0000-0002-9373-1966 AD - Antibacterial Materials R&D Centre, China Metal New Materials (Huzhou) Institute, Huzhou, Zhejiang, China. FAU - Ameen, Fuad AU - Ameen F AD - Department of Botany & Microbiology, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia. LA - eng PT - Journal Article DEP - 20221220 PL - Germany TA - Bioprocess Biosyst Eng JT - Bioprocess and biosystems engineering JID - 101088505 RN - SOI2LOH54Z (Zinc Oxide) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Female MH - *Zinc Oxide/pharmacology/chemistry MH - *Nanoparticles MH - Anti-Bacterial Agents/pharmacology/chemistry MH - Microscopy, Electron, Scanning MH - *Breast Neoplasms/drug therapy MH - X-Ray Diffraction MH - *Metal Nanoparticles/chemistry MH - Microbial Sensitivity Tests PMC - PMC9763817 OTO - NOTNLM OT - Ag and Ce dual-doped ZnO NPs OT - Green synthesis OT - MDA-MB-231 cells OT - MTT assay COIS- The authors confirm that the content of this article involves no competing interests. EDAT- 2022/12/20 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/12/19 23:41 PHST- 2022/08/17 00:00 [received] PHST- 2022/11/14 00:00 [accepted] PHST- 2022/12/20 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/12/19 23:41 [entrez] AID - 10.1007/s00449-022-02815-8 [pii] AID - 2815 [pii] AID - 10.1007/s00449-022-02815-8 [doi] PST - ppublish SO - Bioprocess Biosyst Eng. 2023 Jan;46(1):89-103. doi: 10.1007/s00449-022-02815-8. Epub 2022 Dec 20. PMID- 36597150 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 0717-6287 (Electronic) IS - 0716-9760 (Print) IS - 0716-9760 (Linking) VI - 56 IP - 1 DP - 2023 Jan 3 TI - Cell cycle related long non-coding RNAs as the critical regulators of breast cancer progression and metastasis. PG - 1 LID - 10.1186/s40659-022-00411-4 [doi] LID - 1 AB - Cell cycle is one of the main cellular mechanisms involved in tumor progression. Almost all of the active molecular pathways in tumor cells directly or indirectly target the cell cycle progression. Therefore, it is necessary to assess the molecular mechanisms involved in cell cycle regulation in tumor cells. Since, early diagnosis has pivotal role in better cancer management and treatment, it is required to introduce the non-invasive diagnostic markers. Long non-coding RNAs (LncRNAs) have higher stability in body fluids in comparison with mRNAs. Therefore, they can be used as efficient non-invasive markers for the early detection of breast cancer (BCa). In the present review we have summarized all of the reported lncRNAs involved in cell cycle regulation in BCa. It has been reported that lncRNAs mainly affect the cell cycle in G1/S transition through the CCND1/CDK4-6 complex. Present review paves the way of introducing the cell cycle related lncRNAs as efficient markers for the early detection of BCa. CI - © 2023. The Author(s). FAU - Zangouei, Amir Sadra AU - Zangouei AS AD - Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Zangoue, Malihe AU - Zangoue M AD - Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. AD - Department of Anesthesiology, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran. FAU - Taghehchian, Negin AU - Taghehchian N AD - Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Zangooie, Alireza AU - Zangooie A AD - Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. AD - Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran. FAU - Rahimi, Hamid Reza AU - Rahimi HR AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Saburi, Ehsan AU - Saburi E AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Alavi, Mahya Sadat AU - Alavi MS AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Moghbeli, Meysam AU - Moghbeli M AUID- ORCID: 0000-0001-9680-0309 AD - Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Meysam_moghbeli@yahoo.com. AD - Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Meysam_moghbeli@yahoo.com. LA - eng PT - Journal Article PT - Review DEP - 20230103 PL - England TA - Biol Res JT - Biological research JID - 9308271 RN - 0 (RNA, Long Noncoding) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/genetics/pathology MH - *RNA, Long Noncoding/genetics/metabolism MH - Cell Cycle/genetics MH - Cell Division MH - Cell Cycle Checkpoints PMC - PMC9808980 OTO - NOTNLM OT - Breast cancer OT - Cell cycle OT - Diagnosis OT - Liquid biopsy OT - LncRNAs COIS- The authors declare that they have no competing interests. EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/03 23:39 PHST- 2021/11/17 00:00 [received] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/01/03 23:39 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 10.1186/s40659-022-00411-4 [pii] AID - 411 [pii] AID - 10.1186/s40659-022-00411-4 [doi] PST - epublish SO - Biol Res. 2023 Jan 3;56(1):1. doi: 10.1186/s40659-022-00411-4. PMID- 36328930 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1938-0666 (Electronic) IS - 1526-8209 (Linking) VI - 23 IP - 1 DP - 2023 Jan TI - The Accuracy of Mammography, Ultrasound, and Magnetic Resonance Imaging For the Measurement of Invasive Breast Cancer With Extensive Intraductal Components. PG - 45-53 LID - S1526-8209(22)00227-0 [pii] LID - 10.1016/j.clbc.2022.10.004 [doi] AB - BACKGROUND: The precise preoperative evaluation of radiologic tumor size with extensive intraductal component (EIC) is important. This study compared the accuracy of mammography, ultrasound (US), and magnetic resonance imaging (MRI) to measure invasive breast cancer with EIC. METHODS: Between 2007 and 2012, we collected data from 6816 patients who underwent surgery for invasive breast cancer at our institution. We reviewed the postoperative surgical reports of the tumors, in which the invasive tumor size and EIC were measured separately. Finally, we included 370 women who underwent preoperative mammography, US, and MRI. Each modality was retrospectively reviewed to measure the size of invasive breast cancer with EIC. The reference standard was surgical pathologic size and the accuracies of the image were evaluated. RESULTS: Spearman's correlation coefficient for the size of invasive cancer with EIC was good between MRI (r = 0.741) and pathology, and moderate between mammography (r = 0.661) or US (r = 0.514) and pathology. Both mass and nonmass lesions showed good correlations (intraclass correlation coefficient [ICC] = 0.672 and 0.612, respectively) in MRI. Furthermore, the subgroup of tumors without microcalcifications showed a higher correlation with MRI (ICC = 0.796) than with mammography (ICC = 0.620). However, the subgroup with microcalcifications showed a good correlation with mammography (ICC = 0.702) compared to MRI (ICC = 0.680) and US (ICC = 0.532). CONCLUSION: The lesion on mammography, US, and MRI reflected preoperative size of invasive cancer with EIC. MRI shows a higher correlation than mammography and US. However, cancer with calcifications of mammography shows a more accurate size than MRI or US. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Kim, Young Eun AU - Kim YE AD - Department of Radiology, Seoul Medical Center, Seoul, Korea. FAU - Cha, Joo Hee AU - Cha JH AD - Department of Radiology, Research Institute of Radiology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea. Electronic address: jhcha@amc.seoul.kr. FAU - Kim, Hak Hee AU - Kim HH AD - Department of Radiology, Research Institute of Radiology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea. FAU - Shin, Hee Jung AU - Shin HJ AD - Department of Radiology, Research Institute of Radiology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea. FAU - Chae, Eun Young AU - Chae EY AD - Department of Radiology, Research Institute of Radiology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea. FAU - Choi, Woo Jung AU - Choi WJ AD - Department of Radiology, Research Institute of Radiology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea. LA - eng PT - Journal Article PT - Review DEP - 20221013 PL - United States TA - Clin Breast Cancer JT - Clinical breast cancer JID - 100898731 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/diagnostic imaging/surgery MH - Ultrasonography, Mammary MH - Retrospective Studies MH - Mammography/methods MH - *Calcinosis MH - Magnetic Resonance Imaging/methods OTO - NOTNLM OT - Breast cancer OT - Extensive intraductal component OT - MRI OT - Mammography OT - Radiologic-pathologic correlation EDAT- 2022/11/04 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/03 23:07 PHST- 2022/02/21 00:00 [received] PHST- 2022/10/06 00:00 [revised] PHST- 2022/10/08 00:00 [accepted] PHST- 2022/11/04 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/03 23:07 [entrez] AID - S1526-8209(22)00227-0 [pii] AID - 10.1016/j.clbc.2022.10.004 [doi] PST - ppublish SO - Clin Breast Cancer. 2023 Jan;23(1):45-53. doi: 10.1016/j.clbc.2022.10.004. Epub 2022 Oct 13. PMID- 36269530 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1437-7772 (Electronic) IS - 1341-9625 (Linking) VI - 28 IP - 1 DP - 2023 Jan TI - Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer. PG - 89-98 LID - 10.1007/s10147-022-02255-0 [doi] AB - BACKGROUND: Chemotherapy efficacy is largely dependent on treatment adherence, defined by the relative dose intensity (RDI). Identification of new modifiable risk factors associated with low RDI might improve chemotherapy delivery. Here, we evaluated the association between low RDI and pre-chemotherapy factors, including patient- and treatment-related characteristics and markers of inflammation. METHODS: This exploratory analysis assessed data from 267 patients with early-stage breast cancer scheduled to undergo (neo-)adjuvant chemotherapy included in the Physical training and Cancer (Phys-Can) trial. The association between low RDI, defined as < 85%, patient-related (age, body mass index, co-morbid condition, body surface area) and treatment-related factors (cancer stage, receptor status, chemotherapy duration, chemotherapy dose, granulocyte colony-stimulating factor) was investigated. Analyses further included the association between RDI and pre-chemotherapy levels of interleukin (IL)-6, IL-8, IL-10, C-reactive protein (CRP) and Tumor Necrosis Factor-alpha (TNF-α) in 172 patients with available blood samples. RESULTS: An RDI of < 85% occurred in 31 patients (12%). Univariable analysis revealed a significant association with a chemotherapy duration above 20 weeks (p < 0.001), chemotherapy dose (p = 0.006), pre-chemotherapy IL-8 (OR 1.61; 95% CI (1.01; 2.58); p = 0.040) and TNF-α (OR 2.2 (1.17; 4.53); p = 0.019). In multivariable analyses, inflammatory cytokines were significant association with low RDI for IL-8 (OR: 1.65 [0.99; 2.69]; p = 0.044) and TNF-α (OR 2.95 [1.41; 7.19]; p = 0.007). CONCLUSIONS: This exploratory analysis highlights the association of pre-chemotherapy IL-8 and TNF-α with low RDI of chemotherapy for breast cancer. IL-8 and TNF-α may therefore potentially help to identify patients at risk for experiencing dose reductions. Clinical trial number NCT02473003 (registration: June 16, 2015). CI - © 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. FAU - Schauer, Tim AU - Schauer T AUID- ORCID: 0000-0002-0717-3954 AD - Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark. tim.schauer.01@regionh.dk. FAU - Henriksson, Anna AU - Henriksson A AUID- ORCID: 0000-0002-2631-7757 AD - Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden. FAU - Strandberg, Emelie AU - Strandberg E AUID- ORCID: 0000-0001-5549-8326 AD - Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden. FAU - Lindman, Henrik AU - Lindman H AUID- ORCID: 0000-0002-2068-4708 AD - Department of Oncology, Uppsala University, 751 85, Sjukhusvägen, Uppsala, Sweden. FAU - Berntsen, Sveinung AU - Berntsen S AD - Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden. AD - Department of Sport Science and Physical Education, University of Agder, Universitetsveien 25, 4630, Kristiansand, Norway. FAU - Demmelmaier, Ingrid AU - Demmelmaier I AD - Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden. AD - Department of Sport Science and Physical Education, University of Agder, Universitetsveien 25, 4630, Kristiansand, Norway. FAU - Raastad, Truls AU - Raastad T AUID- ORCID: 0000-0002-2567-3004 AD - Department of Sport Science and Physical Education, University of Agder, Universitetsveien 25, 4630, Kristiansand, Norway. AD - Department of Physical Performance, Norwegian School of Sport Sciences, Sognsveien 220, 0806, Oslo, Norway. FAU - Nordin, Karin AU - Nordin K AUID- ORCID: 0000-0001-8685-3722 AD - Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden. FAU - Christensen, Jesper F AU - Christensen JF AUID- ORCID: 0000-0003-4858-1505 AD - Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark. AD - Institute of Exercise and Biomechanics, University of Southern Denmark, Odense, Denmark. AD - Digestive Disease Center, Bispebjerg Hospital, Copenhagen, Denmark. LA - eng SI - ClinicalTrials.gov/NCT02473003 GR - 150841/The Swedish Cancer Society/ GR - 160483/The Swedish Cancer Society/ GR - KDB/9514/The Swedish Research Council/ GR - 2015/The Nordic Cancer Union/ GR - 2016/The Oncology Department Foundations Reseach Fund in Uppsala/ GR - 2017/The Oncology Department Foundations Reseach Fund in Uppsala/ GR - 101390/Trygfonden/ GR - 20045/Trygfonden/ GR - IIG_2016_1635/Wereld Kanker Onderzoek Fonds/ PT - Journal Article DEP - 20221021 PL - Japan TA - Int J Clin Oncol JT - International journal of clinical oncology JID - 9616295 RN - 0 (Interleukin-8) RN - 0 (Tumor Necrosis Factor-alpha) RN - 143011-72-7 (Granulocyte Colony-Stimulating Factor) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/pathology MH - Interleukin-8/therapeutic use MH - Tumor Necrosis Factor-alpha MH - Chemotherapy, Adjuvant MH - Granulocyte Colony-Stimulating Factor/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects OTO - NOTNLM OT - Breast cancer OT - Chemotherapy OT - Interleukin-8 OT - Relative dose intensity OT - Tumor necrosis factor-alpha EDAT- 2022/10/22 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/10/21 11:42 PHST- 2022/05/18 00:00 [received] PHST- 2022/10/09 00:00 [accepted] PHST- 2022/10/22 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/10/21 11:42 [entrez] AID - 10.1007/s10147-022-02255-0 [pii] AID - 10.1007/s10147-022-02255-0 [doi] PST - ppublish SO - Int J Clin Oncol. 2023 Jan;28(1):89-98. doi: 10.1007/s10147-022-02255-0. Epub 2022 Oct 21. PMID- 36649477 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230125 IS - 2058-7384 (Electronic) IS - 0394-6320 (Print) IS - 0394-6320 (Linking) VI - 37 DP - 2023 Jan-Dec TI - Changes in breast cancer staging trends among Egyptian women after COVID-19: A retrospective single-center study. PG - 3946320231152835 LID - 10.1177/03946320231152835 [doi] LID - 03946320231152835 AB - OBJECTIVES: Since being declared a global pandemic, the SARS-CoV-2 virus had a significant impact on the entire globe. The pandemic has placed a heavy burden on healthcare systems worldwide, and cancer patients are particularly prone. Despite the fact that initial international reports suggest delays in breast cancer (BC) diagnosis and screening programs, the Egyptian context requires additional research on this topic. To examine whether COVID-19 has changed the pattern of disease presentation before and after the pandemic, focusing on the tumor, node, and metastasis (TNM) staging of the disease at the initial presentation. METHODS: This single-center, retrospective study of female BC patients initially diagnosed at Baheya Foundation was conducted during the following time frames: from Jan 2019 to Jan 2020 (Pre COVID-19 cohort) and from Mar 2020 to Mar 2021 (post-COVID-19 cohort). We compared the two cohorts in terms of clinical characteristics, tumor characteristics, and the number of days from presentation to treatment. Our primary endpoint was the difference in the TNM stage of BC at the initial presentation. RESULTS: This analysis included 710 BC patients, 350 from the pre-COVID cohort and 360 from the post-COVID group. We detected a 27.9% increase in late-stage BC (stages III-IV) in the post-pandemic cohort compared to the pre-pandemic (60.1% vs. 47%, p < 0.001). The time from diagnosis to commencement of treatment was significantly longer (28.34 ± 18.845 vs 36.04 ± 23.641 days, p < 0.001) in the post-COVID cohort (mean difference = 7.702, 95% CI 4.54-10.85, p < 0.001). A higher percentage of patients in the post-pandemic cohort received systemic neoadjuvant therapy (p-value for Exact's test for all treatment options = 0.001). CONCLUSIONS: The number of patients requiring systemic neoadjuvant chemotherapy increased dramatically in the post-pandemic group with advanced stages of BC at presentation. This study highlights the need for proper management of cancer patients during any future pandemic. FAU - Abd El Wahab, Mostafa H AU - Abd El Wahab MH AUID- ORCID: 0000-0001-5079-7466 AD - 68792Ain Shams University, Cairo, Egypt. FAU - Ibrahim, Ahmed H AU - Ibrahim AH AUID- ORCID: 0000-0002-9134-3492 AD - Baheya Charity's Women Cancer Hospital, Cairo, Egypt 1. Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt. FAU - Gado, Omar AU - Gado O AUID- ORCID: 0000-0003-4272-507X AD - 68792Ain Shams University, Cairo, Egypt. FAU - Bahbah, Ali M AU - Bahbah AM AUID- ORCID: 0000-0001-8117-8190 AD - 68792Ain Shams University, Cairo, Egypt. FAU - Fadlalla, Waleed AU - Fadlalla W AUID- ORCID: 0000-0002-2567-8059 AD - Baheya Charity's Women Cancer Hospital, Cairo, Egypt 1. Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt. AD - 68804National Cancer Institute, Cairo University, Cairo, Egypt. FAU - Fakhry, Sherihan AU - Fakhry S AUID- ORCID: 0000-0002-2957-517X AD - Baheya Charity's Women Cancer Hospital, Cairo, Egypt 1. Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt. AD - Radiology Department, Cairo University, Cairo, Egypt. FAU - Mamdouh, Mona M AU - Mamdouh MM AUID- ORCID: 0000-0002-9565-6111 AD - Baheya Charity's Women Cancer Hospital, Cairo, Egypt 1. Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt. AD - 68804National Cancer Institute, Cairo University, Cairo, Egypt. FAU - Kamel, Mahmoud M AU - Kamel MM AUID- ORCID: 0000-0003-0264-3096 AD - 68804National Cancer Institute, Cairo University, Cairo, Egypt. FAU - Moaz, Inas AU - Moaz I AUID- ORCID: 0000-0002-1874-0539 AD - Epidemiology and Preventive Medicine Department, 68873National Liver Institute, Menofia, Egypt Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Egypt. FAU - Rabea, Ahmed AU - Rabea A AUID- ORCID: 0000-0001-9060-6492 AD - Baheya Charity's Women Cancer Hospital, Cairo, Egypt 1. Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt. AD - 68804National Cancer Institute, Cairo University, Cairo, Egypt. FAU - Helal, Amany M AU - Helal AM AD - Baheya Charity's Women Cancer Hospital, Cairo, Egypt 1. Baheya Centre for Early Detection and Treatment of Breast Cancer, Giza, Egypt. AD - 68804National Cancer Institute, Cairo University, Cairo, Egypt. LA - eng PT - Journal Article PL - England TA - Int J Immunopathol Pharmacol JT - International journal of immunopathology and pharmacology JID - 8911335 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/diagnosis MH - *COVID-19 MH - Retrospective Studies MH - SARS-CoV-2 MH - Neoplasm Staging MH - Egypt/epidemiology PMC - PMC9852965 OTO - NOTNLM OT - COVID-19 OT - Egypt OT - TNM OT - breast cancer OT - staging COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/01/18 06:00 MHDA- 2023/01/20 06:00 CRDT- 2023/01/17 14:32 PHST- 2023/01/17 14:32 [entrez] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] AID - 10.1177_03946320231152835 [pii] AID - 10.1177/03946320231152835 [doi] PST - ppublish SO - Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231152835. doi: 10.1177/03946320231152835. PMID- 35344650 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 2005-9256 (Electronic) IS - 1598-2998 (Linking) VI - 55 IP - 1 DP - 2023 Jan TI - Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09). PG - 123-135 LID - 10.4143/crt.2021.1561 [doi] AB - PURPOSE: The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea. MATERIALS AND METHODS: We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016. RESULTS: The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003). CONCLUSION: Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients. FAU - Lee, Jieun AU - Lee J AD - Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. FAU - Lee, Keun Seok AU - Lee KS AD - Center for Breast Cancer, National Cancer Center, Goyang, Korea. FAU - Sim, Sung Hoon AU - Sim SH AD - Center for Breast Cancer, National Cancer Center, Goyang, Korea. FAU - Chae, Heejung AU - Chae H AD - Center for Breast Cancer, National Cancer Center, Goyang, Korea. FAU - Sohn, Joohyuk AU - Sohn J AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, College of Medicine, Yonsei University, Seoul, Korea. FAU - Kim, Gun Min AU - Kim GM AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, College of Medicine, Yonsei University, Seoul, Korea. FAU - Lee, Kyung-Hee AU - Lee KH AD - Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea. FAU - Kang, Su Hwan AU - Kang SH AD - Department of Surgery, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea. FAU - Jung, Kyung Hae AU - Jung KH AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Jeong, Jae-Ho AU - Jeong JH AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Byun, Jae Ho AU - Byun JH AD - Division of Medical Oncology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. FAU - Koh, Su-Jin AU - Koh SJ AD - Department of Internal Medicine, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Korea. FAU - Lee, Kyoung Eun AU - Lee KE AD - Department of Hematology and Oncology, Ewha Womans University Hospital, Seoul, Korea. FAU - Lim, Seungtaek AU - Lim S AD - Department of Hemato-Oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea. FAU - Kim, Hee Jun AU - Kim HJ AD - Division of Hematology-Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. FAU - Won, Hye Sung AU - Won HS AD - Division of Medical Oncology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. FAU - Park, Hyung Soon AU - Park HS AD - Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. FAU - Lee, Guk Jin AU - Lee GJ AD - Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. FAU - Hong, Soojung AU - Hong S AD - Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea. FAU - Baek, Sun Kyung AU - Baek SK AD - Division of Hematology and Oncology, Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea. FAU - Lee, Soon Il AU - Lee SI AD - Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea. FAU - Choi, Moon Young AU - Choi MY AD - Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. FAU - Woo, In Sook AU - Woo IS AD - Division of Medical Oncology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20220324 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Humans MH - Male MH - Middle Aged MH - *Breast Neoplasms/pathology MH - *Breast Neoplasms, Male/drug therapy MH - Prognosis MH - Republic of Korea/epidemiology MH - Retrospective Studies MH - *Triple Negative Breast Neoplasms/drug therapy OTO - NOTNLM OT - Asia OT - Breast neoplasms OT - Male OT - Prognosis OT - Type EDAT- 2022/03/29 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/03/28 19:59 PHST- 2021/12/05 00:00 [received] PHST- 2022/03/23 00:00 [accepted] PHST- 2022/03/29 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/03/28 19:59 [entrez] AID - crt.2021.1561 [pii] AID - 10.4143/crt.2021.1561 [doi] PST - ppublish SO - Cancer Res Treat. 2023 Jan;55(1):123-135. doi: 10.4143/crt.2021.1561. Epub 2022 Mar 24. PMID- 36626455 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230113 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 49 DP - 2022 Dec 9 TI - Sarcopenia using pectoralis muscle area and lymphocyte-to-monocyte ratio (LMR) are independent prognostic factors in patients for nonmetastatic breast cancer. PG - e32229 LID - 10.1097/MD.0000000000032229 [doi] LID - e32229 AB - Sarcopenia is defined as loss of skeletal muscle mass and strength. This can lead to adverse clinical outcomes in patients with advanced cancer. The lymphocyte-to-monocyte ratio (LMR), a converted inflammatory response, is associated with poor prognosis in patients with malignancies. Herein, we examined the prognostic influence of sarcopenia status assessed by pectoralis muscle area (PMA), inflammatory status calculated by LMR, and its association with disease-free survival (DFS) in a cohort of women diagnosed with nonmetastatic breast cancer. A total of 293 patients with nonmetastatic breast cancer who underwent primary mass resection and radiotherapy between January 2011 and December 2017 were enrolled. The cross-sectional area of the muscle (cm2) at PMA was measured using computed tomography before radiation therapy. Baseline monocyte and lymphocyte counts were obtained from the complete blood count to calculate the LMR. Most of the patients (248/293, 84.6%) underwent breast conservation surgery. Lymph node involvement at diagnosis (hazard ratio [HR], 5.08; P < .001), low LMR (HR, 2.79; P = .007), and low PMA (HR, 3.80; P < .001) were independent poor prognostic factors in multivariate analysis. The mean DFS of sarcopenic and nonsarcopenic patients was 89.8 months and 118.8 months, respectively (P < .001). Sarcopenic patients with low LMR showed the worst outcomes, whereas nonsarcopenic patients with high LMR showed the best outcomes. Low PMA and low LMR were independent poor prognostic factors for DFS in patients with nonmetastatic breast cancer. CI - Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Song, Haa-Na AU - Song HN AUID- ORCID: 0000-0002-7229-0153 AD - Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University of Medicine and Gyeongsang National University Hospital, Jinju, Korea. AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. FAU - Kim, Ju Yeon AU - Kim JY AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Surgery, Gyeongsang National University of Medicine and Gyeongsang National University Hospital, Jinju, Korea. FAU - Kim, Jae Myung AU - Kim JM AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Surgery, Gyeongsang National University of Medicine and Gyeongsang National University Hospital, Jinju, Korea. FAU - Kang, Ki Mun AU - Kang KM AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Radiation Oncology, Gyeongsang National University Changwon Hospital, Gyeongsang National University of Medicine, Changwon, Korea. FAU - Choi, Hoon Sik AU - Choi HS AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Radiation Oncology, Gyeongsang National University Changwon Hospital, Gyeongsang National University of Medicine, Changwon, Korea. FAU - Jeong, Jin Hee AU - Jeong JH AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Emergency Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Korea. FAU - Ha, In Bong AU - Ha IB AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Radiation Oncology, Gyeongsang National University of Medicine and Gyeongsang National University Hospital, Jinju, Korea. FAU - Jeong, Bae-Kwon AU - Jeong BK AUID- ORCID: 0000-0001-8015-6061 AD - Institute of Health Science, Gyeongsang National University, Jinju, Korea. AD - Department of Radiation Oncology, Gyeongsang National University of Medicine and Gyeongsang National University Hospital, Jinju, Korea. LA - eng PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - Female MH - Monocytes/pathology MH - *Sarcopenia/pathology MH - *Breast Neoplasms/pathology MH - Prognosis MH - Pectoralis Muscles/pathology MH - Retrospective Studies MH - Lymphocytes/pathology MH - Lymphocyte Count PMC - PMC9750599 COIS- The authors have no conflicts of interest to disclose. EDAT- 2023/01/11 06:00 MHDA- 2023/01/13 06:00 CRDT- 2023/01/10 13:35 PHST- 2023/01/10 13:35 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - 00005792-202212090-00105 [pii] AID - 10.1097/MD.0000000000032229 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Dec 9;101(49):e32229. doi: 10.1097/MD.0000000000032229. PMID- 36521658 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1872-7980 (Electronic) IS - 0304-3835 (Linking) VI - 555 DP - 2023 Feb 28 TI - Extracellular vesicles as a novel approach for breast cancer therapeutics. PG - 216036 LID - S0304-3835(22)00523-7 [pii] LID - 10.1016/j.canlet.2022.216036 [doi] AB - Breast cancer (BC) still lacks effective management approaches to control metastatic and therapy-resistant disease. Extracellular vesicles (EVs), with a diameter of 50-1000 nm, are secreted by all types of living cells, are protected by a lipid bilayer and encapsulate biological cargos including RNAs, proteins and lipids. They play an important role in intercellular communications and are significantly associated with pathological conditions. Accumulating evidence indicates that cancer cells secrete EVs and communicate with neighboring cells within the tumor microenvironment (TME), which plays an important role in BC metastasis, immune escape and chemoresistance, thus providing a new therapeutic window. EVs can stimulate angiogenesis and extracellular matrix remodeling, establish premetastatic niches, inhibit immune response and promote cancer metastasis. Recent advances have demonstrated that EVs are a potential therapeutic target or carrier and have emerged as promising strategies for BC treatment. In this review, we summarize the role of EVs in BC metastasis, chemoresistance and immune escape, which provides the foundation for developing novel therapeutic approaches. We also focus on current EV-based drug delivery strategies in BC and EV cargo-targeted BC therapy and discuss the limitations and future perspectives of EV-based drug delivery in BC. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Lee, Yujin AU - Lee Y AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, UNSW Sydney, Kensington, NSW, 2052, Australia; Cancer Care Centre, St. George Hospital, Kogarah, NSW, 2217, Australia. FAU - Graham, Peter AU - Graham P AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, UNSW Sydney, Kensington, NSW, 2052, Australia; Cancer Care Centre, St. George Hospital, Kogarah, NSW, 2217, Australia. FAU - Li, Yong AU - Li Y AD - St George and Sutherland Clinical Campuses, School of Clinical Medicine, UNSW Sydney, Kensington, NSW, 2052, Australia; Cancer Care Centre, St. George Hospital, Kogarah, NSW, 2217, Australia. Electronic address: y.li@unsw.edu.au. LA - eng PT - Journal Article PT - Review DEP - 20221212 PL - Ireland TA - Cancer Lett JT - Cancer letters JID - 7600053 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/metabolism MH - Drug Delivery Systems MH - *Extracellular Vesicles/metabolism MH - Tumor Microenvironment OTO - NOTNLM OT - Breast cancer therapy OT - Drug delivery OT - Extracellular vesicle engineering OT - Nanocarrier OT - Tumor microenvironment COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/16 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/12/15 19:25 PHST- 2022/10/06 00:00 [received] PHST- 2022/11/28 00:00 [revised] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/16 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/12/15 19:25 [entrez] AID - S0304-3835(22)00523-7 [pii] AID - 10.1016/j.canlet.2022.216036 [doi] PST - ppublish SO - Cancer Lett. 2023 Feb 28;555:216036. doi: 10.1016/j.canlet.2022.216036. Epub 2022 Dec 12. PMID- 36129636 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node. PG - 77-87 LID - 10.1007/s12282-022-01400-x [doi] AB - PURPOSE: Little is known about the host-tumor interaction in the lymph-node basin at a single cell level. This study examines single cell sequences in breast cancer nodal metastases of a patient with triple-negative breast cancer. METHODS: The primary breast tumor, sentinel lymph node, an adjacent lymph node with metastatic involvement and a clinically normal-appearing lymph node were collected during surgery. Single-cell sequencing was performed on all four specimens. RESULTS: 14,016 cells were clustered into 6 cell subpopulations. Cancer cells demonstrated the molecular characteristics of TNBC basal B subtype and highly expressed genes in the MAPK signaling cascade. Tumor-associated macrophages regulated antigen processing and presentation and other immune-related pathways to promote tumor invasion. CD8 + and CD4 + T lymphocytes concentrated more in sentinel lymph node and mainly stratified into two transcriptional states. The immune-cell amount variation among primary tumor, sentinel and normal lymph nodes showed a similar tendency between the sc-RNA-seq profile of TNBC samples and a previous reported bulk RNA-seq profile of a breast cancer cohort, including all four breast cancer subtype samples. DISCUSSION: Single-cell sequencing analysis suggested that the sentinel lymph node was the initial meeting site of tumor infiltration and immune response, where partial T lymphocytes perform anti-tumor activity, while other T cells exhibit an exhausted state. We proposed a molecular explanation to the well-established clinical principle that the 5-year and 10-year survival outcomes were noninferior between SLND and ALND. CI - © 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society. FAU - Liao, Ning AU - Liao N AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. drningliao@163.com. FAU - Li, Cheukfai AU - Li C AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Cao, Li AU - Cao L AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Chen, Yanhua AU - Chen Y AD - Berry Oncology Corporation, No.2 Road Donghu, Fuzhou, 350200, China. FAU - Ren, Chongyang AU - Ren C AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Chen, Xiaoqing AU - Chen X AD - Foshan Maternity and Children's Healthcare Hospital, Affiliated to Southern Medical University, Foshan, China. FAU - Mok, Hsiaopei AU - Mok H AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Wen, Lingzhu AU - Wen L AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Li, Kai AU - Li K AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Wang, Yulei AU - Wang Y AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Zhang, Yuchen AU - Zhang Y AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Li, Yingzi AU - Li Y AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Lv, Jiaoyi AU - Lv J AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Cao, Fangrong AU - Cao F AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Luo, Yuting AU - Luo Y AD - Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China. FAU - Li, Hongrui AU - Li H AD - Berry Oncology Corporation, No.2 Road Donghu, Fuzhou, 350200, China. FAU - Wu, Wendy AU - Wu W AUID- ORCID: 0000-0001-6048-405X AD - Berry Oncology Corporation, No.2 Road Donghu, Fuzhou, 350200, China. wujiayan@me.com. FAU - Balch, Charles M AU - Balch CM AD - University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Giuliano, Armando E AU - Giuliano AE AD - Cedars-Sinai Medical Center, Los Angeles, CA, USA. LA - eng GR - 81071851/National Natural Science Foundation of China/ GR - 81001189/National Natural Science Foundation of China/ GR - 81602645/National Natural Science Foundation of China/ GR - 81902828/National Natural Science Foundation of China/ GR - 82003066/National Natural Science Foundation of China/ GR - 82002928/National Natural Science Foundation of China/ GR - 2016A030313768/Natural Science Foundation of Guangdong Province/ GR - 2018A030313292/Natural Science Foundation of Guangdong Province/ GR - A2020025/Medical scientific research foundation of Guangdong province/ GR - B2019039/Medical scientific research foundation of Guangdong province/ GR - 201707010418/Guangzhou municipal science and technology project/ GR - 201804010430/Guangzhou municipal science and technology project/ GR - CORP-239-S24/China Anti-Cancer Association-HER2 Target China Scientific Research Fund/ PT - Journal Article DEP - 20220921 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 SB - IM MH - Humans MH - Female MH - *Sentinel Lymph Node/pathology MH - *Breast Neoplasms/genetics/surgery/pathology MH - Sentinel Lymph Node Biopsy MH - Lymphatic Metastasis/pathology MH - *Triple Negative Breast Neoplasms/genetics/surgery/pathology MH - Lymph Nodes/pathology MH - Lymph Node Excision MH - Axilla/pathology OTO - NOTNLM OT - Breast cancer OT - Immune response OT - Sentinel lymph node OT - sc-RNA-seq EDAT- 2022/09/22 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/09/21 11:20 PHST- 2022/03/08 00:00 [received] PHST- 2022/08/24 00:00 [accepted] PHST- 2022/09/22 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/09/21 11:20 [entrez] AID - 10.1007/s12282-022-01400-x [pii] AID - 10.1007/s12282-022-01400-x [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):77-87. doi: 10.1007/s12282-022-01400-x. Epub 2022 Sep 21. PMID- 36239907 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Print) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - The effects of home-based exercise therapy for breast cancer-related fatigue induced by radical radiotherapy. PG - 139-150 LID - 10.1007/s12282-022-01408-3 [doi] AB - BACKGROUND: Radiotherapy (RT) can lead to cancer-related fatigue (CRF) and decreased health-related quality of life (HRQoL) in breast cancer patients. The purpose of this trial was to examine the feasibility and efficacy of a home-based resistance and aerobic exercise intervention for reducing CRF and improving HRQoL in breast cancer patients during RT. METHODS: Women with breast cancer (N = 106) commencing RT were randomized to 12 weeks of home-based resistance and aerobic exercise (EX) or usual care/control (CON). The primary endpoint was CRF, with secondary endpoints of HRQoL, sleep duration and quality, and physical activity. Measurements were undertaken prior to RT, at completion of RT (~ 6 weeks), at completion of the intervention (12 weeks), and 6 and 12 months after RT completion, while CRF was also measured weekly during RT. RESULTS: Eighty-nine women completed the study (EX = 43, CON = 46). Over the 12-week intervention, EX completed 1-2 resistance training sessions and accumulated 30-40 min of aerobic exercise weekly. For CRF, EX had a quicker recovery both during and post-RT compared to CON (p < 0.05). Moreover, there was a significant difference in HRQoL between groups at RT completion, with HRQoL unchanged in CON and higher in EX (p < 0.05). There was no change in sleep duration or quality for either group and there were no exercise-related adverse effects. CONCLUSIONS: Home-based resistance and aerobic exercise during RT is safe, feasible, and effective in accelerating CRF recovery and improving HRQoL. Improvements in CRF and HRQoL for these patients can be achieved with smaller exercise dosages than stated in the generic recommendations for breast cancer. CI - © 2022. The Author(s). FAU - Mavropalias, Georgios AU - Mavropalias G AUID- ORCID: 0000-0001-7753-5693 AD - Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia. AD - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia. AD - Centre for Molecular Medicine and Innovative Therapeutics, and Centre for Healthy Aging, Health Futures Institute, Murdoch University, Perth, Australia. AD - Discipline of Exercise Science, Murdoch University, Perth, Australia. FAU - Cormie, Prue AU - Cormie P AD - Peter MacCallum Cancer Centre, Melbourne, Australia. FAU - Peddle-McIntyre, Carolyn J AU - Peddle-McIntyre CJ AD - Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia. AD - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia. FAU - Galvão, Daniel A AU - Galvão DA AD - Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia. AD - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia. FAU - Taaffe, Dennis R AU - Taaffe DR AD - Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia. AD - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia. FAU - Schofield, Christelle AU - Schofield C AD - Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia. AD - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia. FAU - Ray, Sharon AU - Ray S AD - Department of Radiation Oncology, Genesis Cancer Care, Perth, Australia. FAU - Zissiadis, Yvonne AU - Zissiadis Y AD - Department of Radiation Oncology, Genesis Cancer Care, Perth, Australia. FAU - Newton, Robert U AU - Newton RU AUID- ORCID: 0000-0003-0302-6129 AD - Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia. r.newton@ecu.edu.au. AD - School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia. r.newton@ecu.edu.au. AD - School of Human Movement and Nutrition Sciences, University of Queensland, Brisbane, Australia. r.newton@ecu.edu.au. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20221014 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/radiotherapy MH - Exercise Therapy MH - Quality of Life MH - Muscle Fatigue MH - Exercise PMC - PMC9813229 OTO - NOTNLM OT - Behavior change OT - Breast cancer OT - Cancer-related fatigue OT - Home-based exercise OT - Quality of life OT - Radiotherapy COIS- The authors declare that they have no conflicts of interest. No funding was received for this work. EDAT- 2022/10/15 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/10/14 11:22 PHST- 2022/06/03 00:00 [received] PHST- 2022/10/05 00:00 [accepted] PHST- 2022/10/15 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/10/14 11:22 [entrez] AID - 10.1007/s12282-022-01408-3 [pii] AID - 1408 [pii] AID - 10.1007/s12282-022-01408-3 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):139-150. doi: 10.1007/s12282-022-01408-3. Epub 2022 Oct 14. PMID- 36566321 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230121 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Dec 24 TI - An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer. PG - 22322 LID - 10.1038/s41598-022-26894-5 [doi] LID - 22322 AB - Breast cancer (BC) is one of the most frequent malignancies among women worldwide. Accumulating evidence indicates that long non-coding RNA (lncRNA) may affect BC progression. Exosomes, a class of small membrane vesicles, have been reported to promote tumor progression through transporting proteins, mRNAs, lncRNAs and some other small molecules. However, the interaction between exosome-related lncRNAs and the microenvironment of malignancies is unclear. Hence, we proceeded to investigate the relationship between exosome-related lncRNAs and BC microenvironment. 121 exosome-associated genes were extracted from ExoBCD database. Then, the Pearson analysis was used to screened out the exosome-related lncRNAs. After that, 15 exosome-related differentially expressed lncRNAs were identified by the correlation with BC prognosis. According to the sum of the expression of these 15 lncRNAs, extracted from The Cancer Genome Atlas, and the regression coefficients, an exosome-related lncRNAs signature was developed by using Cox regression analysis. With the median risk score of the training set, the patients in training and validation sets were separated to low-risk group and high-risk group. Subsequently, the lncRNA-mRNA co-expression network was constructed. The distinct enrichment pathways were compared among the different risk groups by using the R package clusterProfiler. The ESTIMATE method and ssGESA database were adopted to study the ESTIMATE Score and immune cell infiltration. Eventually, the expression of immune checkpoint associated genes, microsatellite instable and the immunophenoscore were further analyzed between different risk groups. Different risk groups exhibited different prognosis, with lower survival rate in the high-risk group. The differentially expressed genes between the different risk groups were enriched in biological processes pathways as well as immune responses. BC patients in high-risk group were identified with lower scores of ESTIMATE scores. Subsequently, we noticed that the infiltrating levels of aDCs, B cells, CD8+ T cells, iDCs, DCs, Neutrophils, macrophages, NK cells, pDCs, Tfh, T helper cells, TIL and Tregs were obvious elevated with the decreased risk score in training and validation cohorts. And some immune signatures were significantly activated with the decreased risk score in both cohorts. Eventually, the exosome-associated lncRNAs risk model was demonstrated to accurately predict immunotherapy response in patients with BC. The results of our study suggest that exosome-related lncRNAs risk model has close relationship with prognosis and immune cells infiltration in BC patients. These findings could make a great contribution to improving BC immunotherapy. CI - © 2022. The Author(s). FAU - Qiu, Pengjun AU - Qiu P AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Quanzhou, China. FAU - Guo, Qiaonan AU - Guo Q AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Quanzhou, China. FAU - Lin, Jianqing AU - Lin J AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Quanzhou, China. FAU - Pan, Kelun AU - Pan K AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Quanzhou, China. FAU - Chen, Jianpeng AU - Chen J AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Quanzhou, China. FAU - Ding, Mingji AU - Ding M AD - Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Quanzhou, China. dmj13313831340@163.com. LA - eng PT - Journal Article DEP - 20221224 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (RNA, Long Noncoding) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/diagnosis/genetics/immunology MH - *Exosomes/genetics MH - Prognosis MH - Risk Factors MH - *RNA, Long Noncoding/genetics MH - Tumor Microenvironment/immunology PMC - PMC9789946 COIS- The authors declare no competing interests. EDAT- 2022/12/25 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/24 23:33 PHST- 2022/06/09 00:00 [received] PHST- 2022/12/21 00:00 [accepted] PHST- 2022/12/24 23:33 [entrez] PHST- 2022/12/25 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - 10.1038/s41598-022-26894-5 [pii] AID - 26894 [pii] AID - 10.1038/s41598-022-26894-5 [doi] PST - epublish SO - Sci Rep. 2022 Dec 24;12(1):22322. doi: 10.1038/s41598-022-26894-5. PMID- 36130057 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230112 IS - 1460-2105 (Electronic) IS - 0027-8874 (Print) IS - 0027-8874 (Linking) VI - 115 IP - 1 DP - 2023 Jan 10 TI - Improving biobehavioral health in younger breast cancer survivors: Pathways to Wellness trial secondary outcomes. PG - 83-92 LID - 10.1093/jnci/djac180 [doi] AB - BACKGROUND: The Pathways to Wellness trial tested the efficacy of 2 interventions for younger breast cancer survivors: mindful awareness practices (MAPs) and survivorship education (SE). This planned secondary analysis examines intervention effects on stress, positive psychological outcomes, and inflammation (Clincaltrials.gov NCT03025139). METHODS: Women diagnosed with breast cancer at or before age 50 years who had completed treatment and had elevated depressive symptoms were randomly assigned to 6 weeks of MAPs, SE, or wait-list control (WLC). Assessments conducted at pre- and postintervention and at 3- and 6-month follow-up measured general stress perceptions, cancer-related intrusive thoughts and worry, positive affect, meaning and peace in life, altruism and empathy, and markers of inflammation. Analyses compared change in outcomes over time in each intervention group relative to WLC using linear mixed models. RESULTS: A total 247 women were randomly assigned to MAPs (n = 85), SE (n = 81), or WLC (n = 81). MAPs statistically significantly decreased intrusive thoughts and worry at postintervention and 3-month follow-up relative to WLC (P < .027) and statistically significantly increased positive affect and meaning and peace at postintervention, with positive affect persisting at 3-month follow-up (P < .027). SE statistically significantly decreased intrusive thoughts at 3-month follow-up and statistically significantly increased positive affect at 6-month follow-up relative to WLC (P < .01). Proinflammatory gene expression increased in WLC relative to MAPs (P = .016) but did not differ from SE. There were no intervention effects on other outcomes. CONCLUSION: MAPs had beneficial effects on psychological and immune outcomes in younger breast cancer survivors and is a promising approach for enhancing biobehavioral health. CI - © The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Bower, Julienne E AU - Bower JE AUID- ORCID: 0000-0003-0813-4444 AD - Department of Psychology, University of California, Los Angeles, Los Angeles, CA, USA. AD - Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. AD - Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA. AD - Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. FAU - Partridge, Ann H AU - Partridge AH AD - Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. AD - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. FAU - Wolff, Antonio C AU - Wolff AC AD - The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. FAU - Cole, Steve W AU - Cole SW AD - Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. AD - Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA. AD - Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. AD - Department of Medicine (Hematology-Oncology), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. FAU - Irwin, Michael R AU - Irwin MR AD - Department of Psychology, University of California, Los Angeles, Los Angeles, CA, USA. AD - Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. AD - Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA. AD - Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. FAU - Thorner, Elissa D AU - Thorner ED AD - The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. FAU - Joffe, Hadine AU - Joffe H AUID- ORCID: 0000-0002-7035-8249 AD - Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Petersen, Laura AU - Petersen L AUID- ORCID: 0000-0002-4843-2692 AD - Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. FAU - Crespi, Catherine M AU - Crespi CM AD - Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. AD - Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA. FAU - Ganz, Patricia A AU - Ganz PA AD - Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. AD - Department of Medicine (Hematology-Oncology), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. AD - Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA. LA - eng SI - ClinicalTrials.gov/NCT03025139 GR - R01 CA200977/CA/NCI NIH HHS/United States GR - National Center for Advancing Translational Science/ GR - P30 CA006973/CA/NCI NIH HHS/United States GR - UL1TR001881/NH/NIH HHS/United States GR - SAC 170001/Komen Foundation/ GR - Breast Cancer Research Foundation/ GR - BCRF Scientific Advisory Board/ GR - UL1 TR001881/TR/NCATS NIH HHS/United States GR - R01 CA200977/NH/NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - J Natl Cancer Inst JT - Journal of the National Cancer Institute JID - 7503089 SB - IM MH - Female MH - Humans MH - Middle Aged MH - *Cancer Survivors/psychology MH - *Breast Neoplasms/therapy/psychology MH - Cognition MH - Inflammation PMC - PMC9830488 EDAT- 2022/09/22 06:00 MHDA- 2023/01/12 06:00 PMCR- 2023/09/20 CRDT- 2022/09/21 14:42 PHST- 2022/04/27 00:00 [received] PHST- 2022/07/27 00:00 [revised] PHST- 2022/09/12 00:00 [accepted] PHST- 2023/09/20 00:00 [pmc-release] PHST- 2022/09/22 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] PHST- 2022/09/21 14:42 [entrez] AID - 6706813 [pii] AID - djac180 [pii] AID - 10.1093/jnci/djac180 [doi] PST - ppublish SO - J Natl Cancer Inst. 2023 Jan 10;115(1):83-92. doi: 10.1093/jnci/djac180. PMID- 35788694 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1439-099X (Electronic) IS - 0179-7158 (Print) IS - 0179-7158 (Linking) VI - 199 IP - 1 DP - 2023 Jan TI - Prerequisites for the clinical implementation of a markerless SGRT-only workflow for the treatment of breast cancer patients. PG - 22-29 LID - 10.1007/s00066-022-01966-7 [doi] AB - PURPOSE: A markerless workflow for the treatment of breast cancer patients has been introduced and evaluated retrospectively. It includes surface-guided radiation therapy (SGRT)-only positioning for patients with small cone beam CT (CBCT) position corrections during the first five fractions. Prerequisites and the frequency of its clinical application were evaluated, as well as potential benefits in terms of treatment time and dose savings, the frequency of CBCT scans, and the accuracy of the positioning. METHODS: A group of 100 patients treated with the new workflow on two Versa HD linacs has been compared to a matched control group of patients treated with the former workflow, which included prepositioning with skin markings and lasers, SGRT and daily CBCT. The comparison was based on the evaluation of logfiles. RESULTS: Of the patients treated with the new workflow, 40% did not receive daily CBCT scans. This resulted in mean time savings of 97 s, 166 s and 239 s per fraction for the new workflow, for patients treated without daily CBCT and for SGRT-only fractions, respectively, when compared to the old workflow. Dose savings amounted to a weighted computed tomography dose index reduction of CTDI(W) = 2.56 cGy on average for normofractionated treatment and weekly CBCTs, while for patients not treated with daily CBCT, SGRT-based positioning accuracy was 5.2 mm for the mean translational magnitude, as evaluated by CBCT. CONCLUSION: For 40% of the patients, after five fractions with small CBCT corrections, the workflow could be changed to SGRT-only positioning with weekly CBCT. This leads to imaging dose and time savings and thus also reduced intrafraction motion, potentially increased patient throughput and patient comfort, while assuring appropriate positioning accuracy. CI - © 2022. The Author(s). FAU - Sauer, Tim-Oliver AU - Sauer TO AUID- ORCID: 0000-0002-0059-2355 AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 27, 91054, Erlangen, Germany. tim-oliver.sauer@uk-erlangen.de. AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. tim-oliver.sauer@uk-erlangen.de. FAU - Ott, Oliver J AU - Ott OJ AUID- ORCID: 0000-0001-5806-6158 AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 27, 91054, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. FAU - Lahmer, Godehard AU - Lahmer G AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 27, 91054, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. FAU - Fietkau, Rainer AU - Fietkau R AUID- ORCID: 0000-0001-8295-7145 AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 27, 91054, Erlangen, Germany. AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. FAU - Bert, Christoph AU - Bert C AUID- ORCID: 0000-0002-8539-6600 AD - Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 27, 91054, Erlangen, Germany. christoph.bert@uk-erlangen.de. AD - Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. christoph.bert@uk-erlangen.de. LA - eng PT - Journal Article DEP - 20220704 PL - Germany TA - Strahlenther Onkol JT - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] JID - 8603469 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/radiotherapy MH - Patient Positioning/methods MH - Workflow MH - Retrospective Studies MH - *Radiotherapy, Image-Guided/methods MH - Cone-Beam Computed Tomography/methods MH - Radiotherapy Planning, Computer-Assisted/methods PMC - PMC9839804 OTO - NOTNLM OT - Breast neoplasms OT - Interfraction motion management OT - Intrafraction motion management OT - Markerless radiation therapy OT - Surface-guided radiation therapy COIS- T.-O. Sauer was a speaker at an SGRT expert panel organized by VisionRT, London (no speakers fee was received). Rainer Fietkau is editor of Strahlentherapie und Onkologie. O.J. Ott, G. Lahmer, R. Fietkau and C. Bert declare that they have no competing interests. EDAT- 2022/07/06 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/07/05 18:44 PHST- 2022/02/22 00:00 [received] PHST- 2022/05/23 00:00 [accepted] PHST- 2022/07/06 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/07/05 18:44 [entrez] AID - 10.1007/s00066-022-01966-7 [pii] AID - 1966 [pii] AID - 10.1007/s00066-022-01966-7 [doi] PST - ppublish SO - Strahlenther Onkol. 2023 Jan;199(1):22-29. doi: 10.1007/s00066-022-01966-7. Epub 2022 Jul 4. PMID- 36171531 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - The Role of Cryoablation in Breast Cancer Beyond the Oncologic Control: COST and Breast-Q Patient-Reported Outcomes. PG - 1029-1037 LID - 10.1245/s10434-022-12570-5 [doi] AB - BACKGROUND: Cryoablation has been established as a minimally invasive alternative to resection of early-stage breast cancer; however, there are no data on the cost and impact on patients' financial, psychosocial, sexual, physical, and cosmetic outcomes utilizing this approach. This study compares cost-effectiveness and patient-reported quality-of-life factors in cryoablation versus resection. METHODS: Women with early-stage, low-risk infiltrating ductal carcinomas ≤ 1.5 cm underwent cryoablation or resection. Adjuvant therapy was provided according to tumor board recommendations. Direct and indirect costs were tracked for both groups. Financial toxicity and well-being outcome were measured by administering the Comprehensive Score of Financial Toxicity (COST) and BREAST-Q surveys, respectively, at 6-month follow-up. RESULTS: Of the 34 eligible patients, 14 (41.1%) consented for cryoablation and 20 (58.8%) underwent resection. The median (centile) (range) follow-up was 35.0 (21.3) (15-50) months for cryoablation vs. 25 (20.8) (17-50) months for resection [p = 0.6479]. Mean (standard deviation) cost of care for cryoablation versus resection was $2221.70 (615.70) versus $16,896.50 (1332.40) [p < 0.0001], and median financial well-being scores for the cryoablation versus resection groups were 38.0 (34.5, 40.0) versus 10 (5.3, 14.0) [p < 0.0001]. Poor financial well-being was directly correlated with the cost of care [p < 0.0001]. Median psychosocial well-being scores were similar across both groups, however the cryoablation group had higher scores for physical [100 (100, 100) vs. 89 (79, 100); p = 0.0141], sexual [100 (91, 100) vs. 91 (87.5, 91); p = 0.0079], and cosmetic [100 (100, 100) vs. 88 (88, 100); p = 0.0171] outcomes. CONCLUSION: Cryoablation offers a cost-effective and quality-of-life advantage compared with resection for early-stage, low-risk breast cancer. CI - © 2022. Society of Surgical Oncology. FAU - Khan, Sonia Y AU - Khan SY AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. AD - Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, USA. FAU - Snitman, Annie AU - Snitman A AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. FAU - Habrawi, Zaina AU - Habrawi Z AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. AD - Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, USA. FAU - Crawford, Sybil AU - Crawford S AD - Division of Preventive and Behavioral Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA. FAU - Melkus, Michael W AU - Melkus MW AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. AD - Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, USA. FAU - Layeequr Rahman, Rakhshanda AU - Layeequr Rahman R AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. rakhshanda.rahman@ttuhsc.edu. AD - Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, USA. rakhshanda.rahman@ttuhsc.edu. LA - eng PT - Journal Article DEP - 20220928 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - Ann Surg Oncol. 2023 Feb;30(2):1038-1039. PMID: 36245055 MH - Humans MH - Female MH - *Breast Neoplasms/surgery/pathology MH - *Cryosurgery MH - *Carcinoma, Ductal/surgery MH - Quality of Life MH - Treatment Outcome EDAT- 2022/09/29 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/09/28 23:40 PHST- 2022/06/15 00:00 [received] PHST- 2022/08/28 00:00 [accepted] PHST- 2022/09/29 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/09/28 23:40 [entrez] AID - 10.1245/s10434-022-12570-5 [pii] AID - 10.1245/s10434-022-12570-5 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1029-1037. doi: 10.1245/s10434-022-12570-5. Epub 2022 Sep 28. PMID- 36603407 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1618-0631 (Electronic) IS - 0344-0338 (Linking) VI - 241 DP - 2023 Jan TI - The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas. PG - 154299 LID - S0344-0338(22)00543-X [pii] LID - 10.1016/j.prp.2022.154299 [doi] AB - PRAME and NY-ESO-1 are cancer-testis antigens (CTAs) reported to be highly enriched in triple-negative breast cancers (TNBCs), against which vaccines and immunotherapies are currently being developed. This study aims to analyze PRAME and NY-ESO-1 expression in TNBCs and their correlation with clinical outcomes. This is a retrospective cohort study of TNBC patients who have undergone neoadjuvant chemotherapy. PRAME and NY-ESO-1 expression were assessed on pre-therapy biopsies as H-scores (percentage x intensity) with final H scores of 2-3 considered as positive. Association between expression and pathologic complete response (pCR), metastasis, and residual cancer burden (RCB) were assessed via logistic regression. Cox proportional hazards models were used to assess the association with progression-free survival. P-values < 0.05 were considered statistically significant. Sixty-three percent of 76 patients were positive for PRAME. In contrast, only 5 % were positive for NY-ESO-1. PRAME positivity was significantly associated with a lower likelihood of early metastatic disease (OR = 0.24, 95 % CI 0.08-0.62; P = 0.005). However, it was not significantly associated with pCR, RCB category, or progression-free survival. NY-ESO1 score was not significantly associated with early metastatic disease, pCR, RCB category, or progression-free survival. Our results suggest that PRAME positivity may be associated with a lower risk of early metastasis in TNBCs, but not with response to neoadjuvant chemotherapy or progression-free survival. The high expression of PRAME in TNBCs makes it a potential therapeutic target, while NY-ESO1 appears to be a less useful marker. However, further larger studies are needed to ascertain the utility of these markers. CI - Copyright © 2023 Elsevier GmbH. All rights reserved. FAU - See, Sharlene Helene C AU - See SHC AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: sharlene.see@northwestern.edu. FAU - Smith, Steven H AU - Smith SH AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Finkelman, Brian S AU - Finkelman BS AD - Department of Pathology, University of Rochester School of Medicine, Rochester, NY, USA. FAU - LaBoy, Carissa AU - LaBoy C AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Novo, Jorge E AU - Novo JE AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Siziopikou, Kalliopi P AU - Siziopikou KP AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. FAU - Blanco, Luis Z Jr AU - Blanco LZ Jr AD - Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. LA - eng PT - Journal Article DEP - 20221231 PL - Germany TA - Pathol Res Pract JT - Pathology, research and practice JID - 7806109 RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) RN - 0 (Antibodies) RN - 0 (PRAME protein, human) SB - IM MH - Male MH - Humans MH - *Antigens, Neoplasm/metabolism MH - Biomarkers, Tumor/analysis MH - Prognosis MH - *Triple Negative Breast Neoplasms/pathology MH - Retrospective Studies MH - Antibodies OTO - NOTNLM OT - Breast carcinoma OT - Gene expression OT - NY-ESO-1 OT - PRAME OT - Triple-negative COIS- Declaration of Competing Interest The authors declare no competing interests. EDAT- 2023/01/06 06:00 MHDA- 2023/01/24 06:00 CRDT- 2023/01/05 18:14 PHST- 2022/12/03 00:00 [received] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2023/01/05 18:14 [entrez] AID - S0344-0338(22)00543-X [pii] AID - 10.1016/j.prp.2022.154299 [doi] PST - ppublish SO - Pathol Res Pract. 2023 Jan;241:154299. doi: 10.1016/j.prp.2022.154299. Epub 2022 Dec 31. PMID- 35220928 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1973-9478 (Electronic) IS - 1120-009X (Linking) VI - 35 IP - 1 DP - 2023 Feb TI - Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. PG - 29-38 LID - 10.1080/1120009X.2022.2043514 [doi] AB - Majority of patients with breast cancer were diagnosed with locally advanced stages of the disease (54%). This study aimed to explain the pathological response received to neoadjuvant chemotherapy (NACT) according to the molecular classification of breast cancer in patients with locally advanced tumors. One hundred and one patients with locally advanced breast cancer treated with neoadjuvant chemotherapy were analyzed. Patients were classified into five molecular subtypes based on the profile of the estrogen receptor, progesterone receptor, HER2, and Ki-67. We determined associations between complete pathological response (no invasive tumor after neoadjuvant chemotherapy) and molecular subgroups. Most patients had luminal A tumors (n: 28, 27.7%). The overall rate of complete pathological response (pCR) was 34.7% (n:35). Tumors that presented with the highest rate of pCR were pure HER2-positive, at 60% (n:6; OR, 3.2; 95% CI, 0.8-12.2). According to logistic regression analysis, the factors affecting pCR were HER2 positivity and clinically positive axilla before NACT. Luminal A tumors had a significantly lower pCR rate. (7.1%,p: 0.001). Despite the low pCR rate, Luminal A tumor had the best survival rate in the subgroups (p < 0.001). However, there was no difference between EFS and OS according to pCR in any molecular subgroups. Pathological complete response is directly related to the subtypes of breast cancer. A high complete pathological response rate is observed in the pure HER2-positive group. However, EFS and OS were not statistically significant in patients with and without pCR. FAU - Değerli, Ezgi AU - Değerli E AUID- ORCID: 0000-0002-8664-5701 AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Şentürk Öztaş, Nihan AU - Şentürk Öztaş N AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Alkan, Gülin AU - Alkan G AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Bedir, Şahin AU - Bedir Ş AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Derin, Sümeyra AU - Derin S AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Valıkhanova, Nahıda AU - Valıkhanova N AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Saraç, Betül AU - Saraç B AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Kacar, Ezgi AU - Kacar E AD - Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa. FAU - Demirci, Nebi Serkan AU - Demirci NS AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Demirelli, Hulusi Fuat AU - Demirelli HF AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Turna, Hande AU - Turna H AD - Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20220226 PL - England TA - J Chemother JT - Journal of chemotherapy (Florence, Italy) JID - 8907348 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/pathology MH - Neoadjuvant Therapy MH - Receptor, ErbB-2 MH - Remission Induction MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Chemotherapy, Adjuvant MH - Treatment Outcome OTO - NOTNLM OT - Breast cancer OT - complete pathological response OT - endocrine therapy OT - molecular subtypes OT - neoadjuvant chemotherapy OT - preoperative chemotherapy EDAT- 2022/03/01 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/02/28 05:27 PHST- 2022/03/01 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/02/28 05:27 [entrez] AID - 10.1080/1120009X.2022.2043514 [doi] PST - ppublish SO - J Chemother. 2023 Feb;35(1):29-38. doi: 10.1080/1120009X.2022.2043514. Epub 2022 Feb 26. PMID- 36089454 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1532-2157 (Electronic) IS - 0748-7983 (Linking) VI - 49 IP - 1 DP - 2023 Jan TI - Ultrasonic scissors decrease postoperative bleeding complications in mastectomy: A retrospective multicenter cohort study on 728 patients. PG - 68-75 LID - S0748-7983(22)00641-2 [pii] LID - 10.1016/j.ejso.2022.08.030 [doi] AB - INTRODUCTION: The aim of this study was to evaluate the rate of postoperative bleeding complications (primary outcome) and any other surgical complications (secondary outcome) in mastectomy between two surgical instruments, ultrasonic SonoSurg® scissors (US) and traditional electrocautery (EC). MATERIALS AND METHODS: In total 728 patients undergoing mastectomy in two adjacent university hospitals were retrospectively evaluated in terms of postoperative bleeding episodes, surgical site infections, skin flap necrosis, and any reoperations for 30 postoperative days. A propensity score matching was performed to acquire balanced groups. Patients consuming medications affecting hemostasis were excluded from the study. A multivariable logistic regression analysis was conducted to define the odds ratio (OR) for each complication separately. A cost analysis was performed. RESULTS: The rate of postoperative bleeding complications was significantly lower in patients operated with US (0.3% vs 11.5%, OR 0.020, 95% CI 0.034-0.14) when compared to EC. The rate of surgical site infections (OR 0.65, 95% CI 0.35-1.23) was similar with both instruments, but there were less skin flap necroses (OR 0.35, 95% CI 0.13-0.98) in US group. For any reoperation, the OR for US was 0.13 (95% CI 0.046-0.39), mainly due to the lower number of acute bleeding complications. Even though the US instrument is more expensive than EC, the total cost of the treatment is lower in patients operated with US (3419 vs. 3475 euro). CONCLUSIONS: US seems to be associated with a lower risk of bleeding complications in mastectomy. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Tamminen, Anselm AU - Tamminen A AD - Department of Plastic and General Surgery, Turku University Hospital and University of Turku, Turku, Finland. Electronic address: anselm.tamminen@utu.fi. FAU - Huttunen, Tuomas AU - Huttunen T AD - Department of Breast Surgery, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Meretoja, Tuomo AU - Meretoja T AD - Department of Breast Surgery, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Niinikoski, Laura AU - Niinikoski L AD - Department of Breast Surgery, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. FAU - Koskivuo, Ilkka AU - Koskivuo I AD - Department of Plastic and General Surgery, Turku University Hospital and University of Turku, Turku, Finland. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20220831 PL - England TA - Eur J Surg Oncol JT - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology JID - 8504356 SB - IM MH - Humans MH - Female MH - Mastectomy/adverse effects MH - Surgical Wound Infection/epidemiology/prevention & control MH - Cohort Studies MH - Retrospective Studies MH - Ultrasonics MH - *Breast Neoplasms/surgery/complications MH - Treatment Outcome MH - Postoperative Hemorrhage/epidemiology/etiology MH - Postoperative Complications/epidemiology/prevention & control/etiology MH - *Mammaplasty/adverse effects OTO - NOTNLM OT - Bleeding OT - Complications OT - Haematoma OT - Mastectomy OT - Ultrasonic scissors COIS- Declaration of competing interest None of the authors have any conflict of interest with respect to this manuscript. EDAT- 2022/09/12 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/09/11 22:05 PHST- 2022/03/04 00:00 [received] PHST- 2022/08/05 00:00 [revised] PHST- 2022/08/25 00:00 [accepted] PHST- 2022/09/12 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/09/11 22:05 [entrez] AID - S0748-7983(22)00641-2 [pii] AID - 10.1016/j.ejso.2022.08.030 [doi] PST - ppublish SO - Eur J Surg Oncol. 2023 Jan;49(1):68-75. doi: 10.1016/j.ejso.2022.08.030. Epub 2022 Aug 31. PMID- 36585206 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 43 IP - 1 DP - 2023 Jan TI - Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. PG - 247-254 LID - 10.21873/anticanres.16156 [doi] AB - BACKGROUND/AIM: Febrile neutropenia (FN) is a potentially life-threatening complication of chemotherapy. In this study, we evaluated the predictors for FN according to neoadjuvant chemotherapy (NAC) in all breast cancer subtypes. PATIENTS AND METHODS: We examined 327 patients with breast cancer treated with NAC. The correlation between the development of FN and clinicopathological features, including systemic inflammatory markers, and prognosis was evaluated retrospectively. RESULTS: There were no significant differences between patients with and without FN in terms of disease-free survival or overall survival (p=0.562, p=0.149, log-rank, respectively). Low body mass index (BMI) (p<0.001), white blood cells (WBC) at baseline (p=0.008), and NAC regimen (p=0.026) significantly related with FN in all patients with breast cancer. Moreover, among patients with hormone receptor-positive/human epidermal growth factor receptor 2-positive breast cancer, low WBC (p=0.007) and low absolute lymphocyte counts (ALC) at baseline (p=0.039) were significantly associated with FN, and overall survival was significantly worse in patients with FN development (p=0.039, log-rank). CONCLUSION: Poor immune activity-related factors, low ALC or BMI, may be useful to predict the development of FN in patients with breast cancer. CI - Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Goto, Wataru AU - Goto W AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Kashiwagi, Shinichiro AU - Kashiwagi S AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; spqv9ke9@view.con.ne.jp. FAU - Matsuoka, Kohei AU - Matsuoka K AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Iimori, Nozomi AU - Iimori N AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Kouhashi, Rika AU - Kouhashi R AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Yabumoto, Akimichi AU - Yabumoto A AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Takada, Koji AU - Takada K AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Asano, Yuka AU - Asano Y AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Tauchi, Yukie AU - Tauchi Y AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Ogisawa, Kana AU - Ogisawa K AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Morisaki, Tamami AU - Morisaki T AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Shibutani, Masatsune AU - Shibutani M AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Tanaka, Hiroaki AU - Tanaka H AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. FAU - Maeda, Kiyoshi AU - Maeda K AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 143011-72-7 (Granulocyte Colony-Stimulating Factor) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Retrospective Studies MH - Neoadjuvant Therapy/adverse effects MH - Prognosis MH - *Febrile Neutropenia/chemically induced MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Granulocyte Colony-Stimulating Factor OTO - NOTNLM OT - Febrile neutropenia OT - breast cancer OT - neoadjuvant chemotherapy OT - risk factors EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 21:03 PHST- 2022/11/06 00:00 [received] PHST- 2022/11/16 00:00 [revised] PHST- 2022/11/17 00:00 [accepted] PHST- 2022/12/30 21:03 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 43/1/247 [pii] AID - 10.21873/anticanres.16156 [doi] PST - ppublish SO - Anticancer Res. 2023 Jan;43(1):247-254. doi: 10.21873/anticanres.16156. PMID- 36653787 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230122 IS - 1465-542X (Electronic) IS - 1465-5411 (Print) IS - 1465-5411 (Linking) VI - 25 IP - 1 DP - 2023 Jan 18 TI - Sustained postconfluent culture of human mammary epithelial cells enriches for luminal and c-Kit+ subtypes. PG - 6 LID - 10.1186/s13058-022-01595-z [doi] LID - 6 AB - BACKGROUND: A challenge in human mammary epithelial cell (HMEC) culture is sustaining the representation of competing luminal, myoepithelial, and progenitor lineages over time. As cells replicate in culture, myoepithelial cells come to dominate the composition of the culture with serial passaging. This drift in composition presents a challenge for studying luminal and progenitor cells, which are prospective cells of origin for most breast cancer subtypes. METHODS: We demonstrate the use of postconfluent culture on HMECs. Postconfluent culture entails culturing HMECs for 2-5 weeks without passaging but maintaining frequent feedings in low-stress M87A culture medium. In contrast, standard HMEC culture entails enzymatic subculturing every 3-5 days to maintain subconfluent density. RESULTS: When compared to standard HMEC culture, postconfluent culture yields increased proportions of luminal cells and c-Kit+ progenitor cells. Postconfluent cultures develop a distinct multilayered morphology with individual cells showing decreased physical deformability as compared to cells in standard culture. Gene expression analysis of postconfluent cells shows increased expression of lineage-specific markers and extracellular matrix components. CONCLUSIONS: Postconfluent culture is a novel, useful strategy for altering the lineage composition of HMECs, by increasing the proportional representation of luminal and progenitor cells. We speculate that postconfluent culture creates a microenvironment with cellular composition closer to the physiological state and eases the isolation of scarce cell subtypes. As such, postconfluent culture is a valuable tool for researchers using HMECs for breast cancer research. CI - © 2023. The Author(s). FAU - Todhunter, Michael E AU - Todhunter ME AD - Department of Population Sciences, Beckman Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. FAU - Miyano, Masaru AU - Miyano M AD - Department of Population Sciences, Beckman Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. FAU - Carlson, Eric G AU - Carlson EG AD - Department of Population Sciences, Beckman Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. AD - Irell and Manella Graduate School of Biological Sciences, City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. FAU - Hinz, Stefan AU - Hinz S AD - Department of Population Sciences, Beckman Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. FAU - LaBarge, Mark A AU - LaBarge MA AD - Department of Population Sciences, Beckman Research Institute at City of Hope, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. mlabarge@coh.org. LA - eng GR - Postdoctoral Fellowship (131311-PF-18-188-01-TBG)/American Cancer Society/ GR - Breast Cancer Era of Hope Scholar Award (BC141351)/U.S. Department of Defense/ PT - Journal Article DEP - 20230118 PL - England TA - Breast Cancer Res JT - Breast cancer research : BCR JID - 100927353 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/metabolism MH - Breast MH - Epithelial Cells/metabolism MH - Tumor Microenvironment PMC - PMC9847146 OTO - NOTNLM OT - Human mammary epithelial culture OT - Luminal OT - Multilayered OT - Myoepithelial OT - Postconfluent OT - c-Kit COIS- We have no competing interests to report. EDAT- 2023/01/19 06:00 MHDA- 2023/01/21 06:00 CRDT- 2023/01/18 23:35 PHST- 2022/03/02 00:00 [received] PHST- 2022/12/16 00:00 [accepted] PHST- 2023/01/18 23:35 [entrez] PHST- 2023/01/19 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] AID - 10.1186/s13058-022-01595-z [pii] AID - 1595 [pii] AID - 10.1186/s13058-022-01595-z [doi] PST - epublish SO - Breast Cancer Res. 2023 Jan 18;25(1):6. doi: 10.1186/s13058-022-01595-z. PMID- 35802266 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230111 IS - 1573-7292 (Electronic) IS - 1389-9600 (Linking) VI - 22 IP - 1 DP - 2023 Jan TI - Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan. PG - 31-41 LID - 10.1007/s10689-022-00304-1 [doi] AB - The Fanconi anemia complementation group M (FANCM) gene is a potential candidate for breast/ovarian cancer susceptibility in European populations. Here, we examined the contribution of FANCM germline variants to hereditary breast and/or ovarian cancer in Pakistan. Comprehensive FANCM variant screening was performed in 201 BRCA1 and BRCA2 (BRCA1/2) negative Pakistani patients with and without triple-negative breast cancer (TNBC) and/or ovarian cancer, using denaturing high-performance liquid chromatography analysis (DHPLC) followed by DNA sequencing. Novel variants were tested for their potential effect on protein function using in silico tools. Reverse transcription (RT)-PCR analysis of RNA extracted from one deletion/insertion (delins) variant (p.K1780delinsNGIT) carrier and three non-carriers was performed to evaluate the impact of this variant on splicing. Furthermore, potentially functional variants were evaluated in 200 healthy female controls. A missense variant (p.V1857M) was identified in a 50-year-old TNBC patient with a family history of breast cancer. It was also identified in the index patient´s daughter, who was diagnosed with osteosarcoma at 15 years of age. Further, one delins variant (p.K1780delinsNGIT) was identified in a 45-year-old non-TNBC patient, but not detected in her brother, who was diagnosed with Hodgkin's lymphoma at 38 years of age. Based on in silico and RNA analyses, p.V1857M and p.K1780delinsNGIT were predicted as variants of uncertain significance (VUS), respectively. Both variants were absent in 200 healthy controls. Our findings suggest a marginal contribution of FANCM variants to hereditary breast/ovarian cancer in Pakistan, which need to be confirmed in larger studies. CI - © 2022. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Rashid, Muhammad Usman AU - Rashid MU AUID- ORCID: 0000-0002-7684-3122 AD - Basic Sciences Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), 7A, Block R3, Johar Town, Lahore, 54000, Punjab, Pakistan. usmanr@skm.org.pk. FAU - Muhammad, Noor AU - Muhammad N AD - Basic Sciences Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), 7A, Block R3, Johar Town, Lahore, 54000, Punjab, Pakistan. FAU - Shehzad, Umara AU - Shehzad U AD - Basic Sciences Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), 7A, Block R3, Johar Town, Lahore, 54000, Punjab, Pakistan. FAU - Khan, Faiz Ali AU - Khan FA AD - Basic Sciences Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), 7A, Block R3, Johar Town, Lahore, 54000, Punjab, Pakistan. FAU - Loya, Asif AU - Loya A AD - Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), Lahore, Pakistan. FAU - Hamann, Ute AU - Hamann U AD - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. LA - eng GR - ONC-BRCA-001/002/Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan/ PT - Journal Article DEP - 20220708 PL - Netherlands TA - Fam Cancer JT - Familial cancer JID - 100898211 RN - 0 (BRCA1 Protein) RN - 0 (BRCA2 Protein) RN - 63231-63-0 (RNA) RN - 0 (BRCA1 protein, human) RN - EC 3.6.1.- (FANCM protein, human) RN - EC 3.6.4.- (DNA Helicases) RN - Breast Cancer, Familial SB - IM MH - Male MH - Humans MH - Female MH - Middle Aged MH - Pakistan/epidemiology MH - *Triple Negative Breast Neoplasms/epidemiology/genetics MH - Prevalence MH - Genetic Predisposition to Disease MH - *Breast Neoplasms/epidemiology/genetics/pathology MH - BRCA1 Protein/genetics MH - *Ovarian Neoplasms/epidemiology/genetics MH - Germ-Line Mutation MH - BRCA2 Protein/genetics MH - RNA MH - Germ Cells/pathology MH - DNA Helicases/genetics OTO - NOTNLM OT - FANCM OT - Germline alterations OT - Pakistan OT - TNBC EDAT- 2022/07/09 06:00 MHDA- 2023/01/12 06:00 CRDT- 2022/07/08 11:18 PHST- 2022/01/28 00:00 [received] PHST- 2022/06/18 00:00 [accepted] PHST- 2022/07/09 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] PHST- 2022/07/08 11:18 [entrez] AID - 10.1007/s10689-022-00304-1 [pii] AID - 10.1007/s10689-022-00304-1 [doi] PST - ppublish SO - Fam Cancer. 2023 Jan;22(1):31-41. doi: 10.1007/s10689-022-00304-1. Epub 2022 Jul 8. PMID- 36632454 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1449-2288 (Electronic) IS - 1449-2288 (Linking) VI - 19 IP - 2 DP - 2023 TI - Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner. PG - 449-464 LID - 10.7150/ijbs.76798 [doi] AB - Metastasis leads to the vast majority of breast cancer mortality. Increasing evidence has shown that N6-methyladenosine (m6A) modification and its associated regulators play a pivotal role in breast cancer metastasis. Here, we showed that overexpression of the m6A reader IGF2BP1 was clinically correlated with metastasis in breast cancer patients. Moreover, IGF2BP1 promoted distant metastasis in vitro and in vivo. Mechanistically, we first identified USP10 as the IGF2BP1 deubiquitinase. USP10 can bind to, deubiquitinate, and stabilize IGF2BP1, resulting in its higher expression level in breast cancer. Furthermore, by MeRIP-seq and experimental verification, we found that IGF2BP1 directly recognized and bound to the m6A sites on CPT1A mRNA and enhanced its stability, which ultimately mediated IGF2BP1-induced breast cancer metastasis. In clinical samples, USP10 levels correlated with IGF2BP1 and CPT1A levels, and breast cancer patients with high levels of USP10, IGF2BP1, and CPT1A had the worst outcome. Therefore, these findings suggest that the USP10/IGF2BP1/CPT1A axis facilitates breast cancer metastasis, and this axis may be a promising prognostic biomarker and therapeutic target for breast cancer. CI - © The author(s). FAU - Shi, Jiajun AU - Shi J AD - Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Zhang, Qianyi AU - Zhang Q AD - Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Yin, Xi AU - Yin X AD - Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Ye, Jiahui AU - Ye J AD - Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Gao, Shengqing AU - Gao S AD - Department of Neurosurgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Chen, Chen AU - Chen C AD - Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Yang, Yaxuan AU - Yang Y AD - Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Wu, Baojuan AU - Wu B AD - Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Fu, Yuping AU - Fu Y AD - Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Zhang, Hongmei AU - Zhang H AD - Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Wang, Zhangding AU - Wang Z AD - Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Wang, Bo AU - Wang B AD - Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Zhu, Yun AU - Zhu Y AD - Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Wu, Hongyan AU - Wu H AD - Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Yao, Yongzhong AU - Yao Y AD - Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Xu, Guifang AU - Xu G AD - Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Wang, Qiang AU - Wang Q AD - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, People's Republic of China. FAU - Wang, Shouyu AU - Wang S AD - Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210000, Jiangsu Province, People's Republic of China. AD - Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. AD - Center for Public Health Research, Medical School of Nanjing University, Nanjing 210000, Jiangsu Province, People's Republic of China. FAU - Zhang, Weijie AU - Zhang W AD - Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, Jiangsu Province, People's Republic of China. LA - eng PT - Journal Article DEP - 20230101 PL - Australia TA - Int J Biol Sci JT - International journal of biological sciences JID - 101235568 RN - 0 (RNA, Messenger) RN - 0 (USP10 protein, human) RN - EC 3.4.19.12 (Ubiquitin Thiolesterase) RN - Melanoma, Cutaneous Malignant SB - IM MH - Humans MH - Female MH - *Liver Neoplasms/metabolism MH - *Breast Neoplasms/genetics MH - RNA, Messenger/metabolism MH - *Melanoma MH - Ubiquitin Thiolesterase/genetics PMC - PMC9830507 OTO - NOTNLM OT - Breast cancer OT - CPT1A OT - IGF2BP1 OT - USP10 OT - m6A OT - metastasis COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2023/01/13 06:00 MHDA- 2023/01/14 06:00 CRDT- 2023/01/12 02:01 PHST- 2022/07/04 00:00 [received] PHST- 2022/11/21 00:00 [accepted] PHST- 2023/01/12 02:01 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] AID - ijbsv19p0449 [pii] AID - 10.7150/ijbs.76798 [doi] PST - epublish SO - Int J Biol Sci. 2023 Jan 1;19(2):449-464. doi: 10.7150/ijbs.76798. eCollection 2023. PMID- 36054346 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1097-0096 (Electronic) IS - 0091-2751 (Linking) VI - 51 IP - 1 DP - 2023 Jan TI - Establishment and validation of an ultrasound-based nomogram with risk stratification for short disease-free survival in breast cancer. PG - 134-147 LID - 10.1002/jcu.23296 [doi] AB - PURPOSE: This retrospective study aimed to develop and validate an Ultrasound (US)-based nomogram to predict short disease-free survival (short-DFS, less than 120 months DFS) in breast cancer (BC). METHODS: Nomogram was established based on a training data of 311 BC patients by multivariable logistic regression, and were assessed by discrimination, calibration, and clinical usefulness. Risk stratification was performed by X-tile. An independent testing data of 200 patients with BC was used for external validation. RESULTS: Nine predictors including three US features and six clinical parameters were screened into the nomogram by Lasso (log λ = -3.594) in training data. Better performance was obtained in the training data (C-index: 0.942) and testing data (C-index: 0.914). Calibration analysis indicated optimal agreement between nomogram predictions and actual observations (p = 0.67). Decision curve analysis showed a great clinical benefit (Youden index: 0.634). Three risk levels are low-risk (<184.0), moderate-risk (184.0-345.3) and high-risk (>345.3). Our nomograms had larger area under the receiver operating characteristic (ROC) curves compared with Magee Equation and Nottingham Prognostic models (0.942 vs. 0.824, 0.790). CONCLUSION: The US-based nomogram and the practical score system facilitate individualized prediction of short-DFS to optimize clinical decisions and improve prognosis in patients with BC. CI - © 2022 Wiley Periodicals LLC. FAU - Guo, Qiang AU - Guo Q AUID- ORCID: 0000-0003-4167-6368 AD - Department of Ultrasound Medicine, Jinshan Branch of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China. FAU - Dong, Zhiwu AU - Dong Z AD - Department of Laboratory Medicine, Jinshan Branch of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China. FAU - Jiang, Lixin AU - Jiang L AD - Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Institute of Ultrasound in Medicine, Shanghai, China. FAU - Zhang, Lei AU - Zhang L AD - Department of Ultrasound Medicine, Second Affiliated Hospital of Harbin Medical University, Harbin, China. FAU - Li, Ziyao AU - Li Z AD - Department of Ultrasound Medicine, Second Affiliated Hospital of Harbin Medical University, Harbin, China. FAU - Wang, Dongmo AU - Wang D AD - Department of Ultrasound Medicine, Second Affiliated Hospital of Harbin Medical University, Harbin, China. LA - eng GR - 201940189/Project of Shanghai Municipal Health Commission/ GR - 81701705/National Natural Science Foundation of China/ GR - 81071216/National Natural Science Foundation of China/ PT - Journal Article DEP - 20220827 PL - United States TA - J Clin Ultrasound JT - Journal of clinical ultrasound : JCU JID - 0401663 SB - IM MH - Humans MH - Female MH - *Nomograms MH - Retrospective Studies MH - Disease-Free Survival MH - *Breast Neoplasms/diagnostic imaging MH - Prognosis MH - Risk Assessment OTO - NOTNLM OT - breast cancer OT - disease-free survival OT - nomogram OT - prognosis OT - ultrasonography EDAT- 2022/09/03 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/09/02 14:04 PHST- 2022/06/07 00:00 [revised] PHST- 2022/02/18 00:00 [received] PHST- 2022/07/07 00:00 [accepted] PHST- 2022/09/03 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/09/02 14:04 [entrez] AID - 10.1002/jcu.23296 [doi] PST - ppublish SO - J Clin Ultrasound. 2023 Jan;51(1):134-147. doi: 10.1002/jcu.23296. Epub 2022 Aug 27. PMID- 36126235 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230118 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 41 IP - 2 DP - 2023 Jan 10 TI - Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study. PG - 307-315 LID - 10.1200/JCO.22.01217 [doi] AB - PURPOSE: Older breast cancer survivors are at increased risk of clinical decline after adjuvant chemotherapy. This study aimed to evaluate whether inflammatory markers assessed before adjuvant chemotherapy are associated with chemotherapy-induced clinical decline in a population of fit older adults with breast cancer. METHODS: In a prospective study of women age ≥ 65 years with stage I-III breast cancer treated with chemotherapy, we measured interleukin-6 (IL-6) and C-reactive protein (CRP) prechemotherapy (T1). We assessed frailty status, using a Deficit Accumulation Index (DAI; categorized as robust, prefrail, and frail), at T1 and postchemotherapy (T2). The population of interest was robust women at T1. The primary outcome was chemotherapy-induced decline in frailty status, defined as decline in DAI from robust (T1) to prefrail or frail (T2). Multivariable logistic regression was used to examine the association between inflammatory markers and the primary outcome, adjusted for sociodemographic and clinical characteristics. RESULTS: Of the 295 robust women at T1, 76 (26%) experienced chemotherapy-induced decline in frailty status, among whom 66% had high IL-6, 63% had high CRP, and 46% had high IL-6 and CRP at T1. After adjusting for sociodemographic and clinical characteristics, women with high IL-6 and CRP had a > three-fold (odds ratio, 3.52; 95% CI, 1.55 to 8.01; P = .003) odds of chemotherapy-induced decline in frailty status compared with women with low IL-6 and CRP. CONCLUSION: In this cohort of older women with early breast cancer who were clinically fit before chemotherapy initiation, high IL-6 and CRP prechemotherapy were associated with chemotherapy-induced decline in frailty status independent of sociodemographic and clinical risk factors. Further research is needed to examine whether inflammatory markers can inform more personalized approaches to treating older breast cancer survivors. FAU - Ji, Jingran AU - Ji J AUID- ORCID: 0000-0002-7284-0709 AD - City of Hope National Medical Center, Duarte, CA. FAU - Sun, Can-Lan AU - Sun CL AD - City of Hope National Medical Center, Duarte, CA. FAU - Cohen, Harvey J AU - Cohen HJ AD - Duke University Medical Center, Durham, NC. FAU - Synold, Timothy AU - Synold T AD - City of Hope National Medical Center, Duarte, CA. FAU - Muss, Hyman AU - Muss H AUID- ORCID: 0000-0003-2862-9970 AD - UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC. FAU - Sedrak, Mina S AU - Sedrak MS AUID- ORCID: 0000-0002-8379-391X AD - City of Hope National Medical Center, Duarte, CA. LA - eng PT - Journal Article DEP - 20220920 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - 0 (Interleukin-6) RN - 9007-41-4 (C-Reactive Protein) RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - Female MH - Aged MH - Prospective Studies MH - *Breast Neoplasms/drug therapy/etiology MH - *Frailty/chemically induced/epidemiology MH - Interleukin-6 MH - Inflammation MH - Chemotherapy, Adjuvant/adverse effects MH - C-Reactive Protein MH - *Antineoplastic Agents/therapeutic use MH - Frail Elderly PMC - PMC9839275 COIS- Mina S. Sedrak Research Funding: Novartis (Inst), Seattle Genetics (Inst), Lilly (Inst), Pfizer (Inst) No other potential conflicts of interest were reported. EDAT- 2022/09/21 06:00 MHDA- 2023/01/10 06:00 PMCR- 2024/01/10 CRDT- 2022/09/20 16:02 PHST- 2024/01/10 00:00 [pmc-release] PHST- 2022/09/21 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/09/20 16:02 [entrez] AID - JCO.22.01217 [pii] AID - 10.1200/JCO.22.01217 [doi] PST - ppublish SO - J Clin Oncol. 2023 Jan 10;41(2):307-315. doi: 10.1200/JCO.22.01217. Epub 2022 Sep 20. PMID- 36683492 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1558-1551 (Electronic) IS - 0888-6008 (Linking) VI - 41 IP - 1 DP - 2022 TI - Sonographic visibility of the UltraCorTM TwirlTM tissue marker. PG - 535-543 LID - 10.3233/BD-210078 [doi] AB - BACKGROUND: Tissue markers are inserted into the breast after percutaneous biopsy to mark the site of the lesion to facilitate potential re-localisation. Tissue markers are increasingly developed with improved sonographic visibility due to benefits conferred by ultrasound-guided localisation. OBJECTIVES: We aim to study the sonographic visibility of the recently-introduced UltracorTM TwirlTM tissue marker and feasibility of its pre-operative localisation under ultrasound guidance. METHODS: All patients who underwent insertion of the UltracorTM TwirlTM tissue marker in our institution from July 2017 to December 2018 were reviewed. Retrospective data including sonographic visibility, evidence of migration and rate of successful surgical excision were collected. RESULTS: All tissue markers were visible on subsequent ultrasound with 198 (85.0%) well-visualised with high degree of confidence while 35 (15.0%) were moderately well-visualised with moderate level of confidence. None of the tissue markers were poorly visualised and none demonstrated migration. No statistical difference in sonographic visibility is seen based on interval duration between deployment and subsequent ultrasound assessment or depth of tissue marker. CONCLUSION: UltracorTM TwirlTM demonstrates consistent sonographic visibility, identifiable with a high or moderate level of confidence with no associated migration. Its use in pre-operative localisation with ultrasound guidance is therefore both reliable and feasible. FAU - Lee, Shu Yi Sonia AU - Lee SYS AD - Department of Radiology, Changi General Hospital, Singapore. FAU - Win, Thida AU - Win T AD - Department of Diagnostic and Interventional Imaging, KK Women's and Children's Hospital, Singapore. FAU - Lee, Yien Sien AU - Lee YS AD - Department of Diagnostic and Interventional Imaging, KK Women's and Children's Hospital, Singapore. FAU - Teo, Sze Yiun AU - Teo SY AD - Department of Diagnostic and Interventional Imaging, KK Women's and Children's Hospital, Singapore. LA - eng PT - Journal Article PL - Netherlands TA - Breast Dis JT - Breast disease JID - 8801277 SB - IM MH - Female MH - Humans MH - *Ultrasonography, Mammary MH - Retrospective Studies MH - *Breast Neoplasms/diagnostic imaging/surgery/pathology MH - Ultrasonography MH - Breast/diagnostic imaging/surgery/pathology OTO - NOTNLM OT - Breast ultrasound OT - breast cancer OT - preoperative localization OT - tissue marker EDAT- 2023/01/24 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/23 03:33 PHST- 2023/01/23 03:33 [entrez] PHST- 2023/01/24 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - BD210078 [pii] AID - 10.3233/BD-210078 [doi] PST - ppublish SO - Breast Dis. 2022;41(1):535-543. doi: 10.3233/BD-210078. PMID- 36535489 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 181 DP - 2023 Jan TI - Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: A systematic review with network meta-analysis. PG - 103898 LID - S1040-8428(22)00322-5 [pii] LID - 10.1016/j.critrevonc.2022.103898 [doi] AB - Aromatase inhibitor-induced arthralgia (AIA) contributes to poor adherence of aromatase inhibitor therapies in patients with breast cancer. A systematic review using network meta-analysis (NMA) was conducted to examine the clinical effectiveness of multiple therapies and rank probabilities for the management of AIA. Randomized controlled trials (RCTs) assessing treatments for AIA in postmenopausal women with stage 0-III hormone receptor-positive breast cancer were searched from inception to October 2021. The main NMA involved 1516 participants from 17 RCTs. Acupuncture was the highest ranked intervention to improve pain intensity followed by sham acupuncture, multicomponent herbal medicine, exercise, duloxetine, vitamin D, omega-3 fatty acids, physical therapy, testosterone, and inactive controls. Single natural products were inferior to controls. The current review provides new insights into the management of AIA in breast cancer survivors for increased survival and can be utilized to make evidence-based decisions regarding treatment. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Bae, Kyeore AU - Bae K AD - Integrative Cancer Center, Doban Hospital, Seoul, 03170, Republic of Korea; Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia. Electronic address: kyeorebae@gmail.com. FAU - Lamoury, Gillian AU - Lamoury G AD - Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, 2006, Australia. Electronic address: Gillian.Lamoury@health.nsw.gov.au. FAU - Carroll, Susan AU - Carroll S AD - Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, 2006, Australia. Electronic address: Susan.Carroll@health.nsw.gov.au. FAU - Morgia, Marita AU - Morgia M AD - Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia. Electronic address: Marita.Morgia@health.nsw.gov.au. FAU - Lim, Stephanie AU - Lim S AD - Medical Oncology Department, Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, 2560, Australia; Western Sydney University, Campbelltown, New South Wales, 2560, Australia. Electronic address: Stephanie.Lim@health.nsw.gov.au. FAU - Baron-Hay, Sally AU - Baron-Hay S AD - Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, 2006, Australia. Electronic address: sbaronha@med.usyd.edu.au. FAU - Shin, In-Soo AU - Shin IS AD - Department of Graduate School of Education, Dongguk University, Seoul, 04620, Republic of Korea. Electronic address: 9065031@daum.net. FAU - Park, So-Jung AU - Park SJ AD - Department of Internal Medicine, Korean Medicine Hospital of Pusan National University, Yangsan, Gyeongnam, 50612, Republic of Korea. Electronic address: vivies@hanmail.net. FAU - Oh, Byeongsang AU - Oh B AD - Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, 2006, Australia. Electronic address: byeong.oh@sydney.edu.au. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20221216 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 RN - 0 (Aromatase Inhibitors) SB - IM MH - Female MH - Humans MH - *Aromatase Inhibitors/adverse effects MH - Network Meta-Analysis MH - Arthralgia/chemically induced/therapy MH - Treatment Outcome MH - *Breast Neoplasms/complications/drug therapy/chemically induced OTO - NOTNLM OT - Aromatase inhibitor OT - Breast cancer OT - Network meta-analysis OT - Pain OT - Quality of life COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kyeore Bae reports article publishing charges of protocol publication was provided by the Research Supporting Program, MIMICUS Inc. (MIMIC2019-RS07). EDAT- 2022/12/20 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/19 19:24 PHST- 2022/07/18 00:00 [received] PHST- 2022/12/08 00:00 [revised] PHST- 2022/12/14 00:00 [accepted] PHST- 2022/12/20 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/19 19:24 [entrez] AID - S1040-8428(22)00322-5 [pii] AID - 10.1016/j.critrevonc.2022.103898 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2023 Jan;181:103898. doi: 10.1016/j.critrevonc.2022.103898. Epub 2022 Dec 16. PMID- 36375540 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1873-2941 (Electronic) IS - 0009-3084 (Linking) VI - 250 DP - 2023 Jan TI - Challenges and emerging strategies for next generation liposomal based drug delivery: An account of the breast cancer conundrum. PG - 105258 LID - S0009-3084(22)00086-X [pii] LID - 10.1016/j.chemphyslip.2022.105258 [doi] AB - The global cancer burden is witnessing an upsurge with breast cancer surpassing other cancers worldwide. Furthermore, an escalation in the breast cancer caseload is also expected in the coming years. The conventional therapeutic regimens practiced routinely are associated with many drawbacks to which nanotechnological interventions offer a great advantage. But how eminent could liposomes and their advantages be in superseding these existing therapeutic modalities? A solution is reflected in this review that draws attention to a decade-long journey embarked upon by researchers in this wake. This text is a comprehensive discussion of liposomes, the front runners of the drug delivery systems, and their active and passive targeting approaches for breast cancer management. Active targeting has been studied over the decade by many receptors overexpressed on the breast cancer cells and passive targeting with many drug combinations. The results converge on the fact that the actively targeted formulations exhibit a superior efficacy over their non-targeted counterparts and the all liposomal formulations are efficacious over the free drugs. This undoubtedly underlines the dominion of liposomal formulations over conventional chemotherapy. These investigations have led to the development of different liposomal formulations with active and passive targeting capacities that could be explored in depth. Acknowledging and getting a deeper insight into the liposomal evolution through time also unveiled many imperfections and unchartered territories that can be explored to deliver dexterous liposomal formulations against breast cancer and more in the clinical trial pipeline. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Moudgil, Aliesha AU - Moudgil A AD - Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pashan, Pune 411008, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address: a.moudgil@ncl.res.in. FAU - Salve, Rajesh AU - Salve R AD - Nanobioscience Group, Agharkar Research Institute, Pune 411004, India. Electronic address: rsalve@aripune.org. FAU - Gajbhiye, Virendra AU - Gajbhiye V AD - Nanobioscience Group, Agharkar Research Institute, Pune 411004, India. Electronic address: virendragajbhiye@aripune.org. FAU - Chaudhari, Bhushan P AU - Chaudhari BP AD - Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pashan, Pune 411008, India. Electronic address: bp.chaudhari@ncl.res.in. LA - eng PT - Journal Article PT - Review DEP - 20221112 PL - Ireland TA - Chem Phys Lipids JT - Chemistry and physics of lipids JID - 0067206 RN - 0 (Liposomes) SB - IM MH - Humans MH - Female MH - *Liposomes/therapeutic use MH - *Breast Neoplasms/drug therapy MH - Drug Delivery Systems MH - Nanotechnology OTO - NOTNLM OT - Breast cancer OT - Liposomal metamorphosis OT - Receptor-ligand dynamics OT - Targeted drug delivery COIS- Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/15 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/11/14 19:24 PHST- 2022/09/20 00:00 [received] PHST- 2022/11/07 00:00 [revised] PHST- 2022/11/09 00:00 [accepted] PHST- 2022/11/15 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/14 19:24 [entrez] AID - S0009-3084(22)00086-X [pii] AID - 10.1016/j.chemphyslip.2022.105258 [doi] PST - ppublish SO - Chem Phys Lipids. 2023 Jan;250:105258. doi: 10.1016/j.chemphyslip.2022.105258. Epub 2022 Nov 12. PMID- 36477768 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230117 IS - 1365-2168 (Electronic) IS - 0007-1323 (Linking) VI - 110 IP - 2 DP - 2023 Jan 10 TI - Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study. PG - 217-224 LID - 10.1093/bjs/znac391 [doi] AB - BACKGROUND: Image-guided vacuum-assisted breast biopsy (VABB) of the tumour bed, performed after neoadjuvant therapy, is increasingly being used to assess residual cancer and to potentially identify to identify pathological complete response (pCR). In this study, the accuracy of preoperative VABB specimens was assessed and compared with surgical specimens in patients with triple-negative or human epidermal growth factor receptor 2 (HER2)-positive invasive ductal breast cancer after neoadjuvant therapy. As a secondary endpoint, the performance of contrast-enhanced MRI of the breast and PET-CT for response prediction was assessed. METHODS: This single-institution prospective pilot study enrolled patients from April 2018 to April 2021 with a complete response on imaging (iCR) who subsequently underwent VABB before surgery. Those with a pCR at VABB were included in the primary analysis of the accuracy of VABB. The performance of imaging (MRI and PET-CT) was analysed for prediction of a pCR considering both patients with an iCR and those with residual disease at postneoadjuvant therapy imaging. RESULTS: Twenty patients were included in the primary analysis. The median age was 44 (range 35-51) years. At surgery, 18 of 20 patients showed a complete response (accuracy 90 (95 per cent exact c.i. 68 to 99) per cent). Only two patients showed residual ductal intraepithelial neoplasia of grade 2 and 3 respectively. In the secondary analysis, accuracy was similar for MRI and PET-CT (77 versus 78 per cent; P = 0.76). CONCLUSION: VABB in patients with an iCR might be a promising method to select patients for de-escalation of surgical treatment in triple-negative or HER2-positive breast cancer. The present results support such an approach and should inform the design of future trials on de-escalation of surgery. CI - © The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. FAU - Rossi, Elisabetta M C AU - Rossi EMC AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Invento, Alessandra AU - Invento A AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Pesapane, Filippo AU - Pesapane F AUID- ORCID: 0000-0002-0374-5054 AD - Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Pagan, Eleonora AU - Pagan E AD - Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. FAU - Bagnardi, Vincenzo AU - Bagnardi V AD - Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. FAU - Fusco, Nicola AU - Fusco N AD - Division of Pathology, IEO European Institute of Oncology IRCSS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Venetis, Konstantinos AU - Venetis K AD - Division of Pathology, IEO European Institute of Oncology IRCSS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Dominelli, Valeria AU - Dominelli V AD - Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Trentin, Chiara AU - Trentin C AD - Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Cassano, Enrico AU - Cassano E AD - Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Gilardi, Laura AU - Gilardi L AD - Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Mazza, Manuelita AU - Mazza M AD - Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Lazzeroni, Matteo AU - Lazzeroni M AUID- ORCID: 0000-0002-2162-4002 AD - Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - De Lorenzi, Francesca AU - De Lorenzi F AD - Department of Plastic and Reconstructive Surgery, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Caldarella, Pietro AU - Caldarella P AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - De Scalzi, Alessandra AU - De Scalzi A AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Girardi, Antonia AU - Girardi A AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Sangalli, Claudia AU - Sangalli C AD - Data Management, European Institute of Oncology IRCCS, Milan, Italy. FAU - Alberti, Luca AU - Alberti L AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Sacchini, Virgilio AU - Sacchini V AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. AD - Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. FAU - Galimberti, Viviana AU - Galimberti V AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Veronesi, Paolo AU - Veronesi P AD - Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. LA - eng GR - NH/NIH HHS/United States GR - CA/NCI NIH HHS/United States GR - NH/NIH HHS/United States GR - CA/NCI NIH HHS/United States PT - Journal Article PL - England TA - Br J Surg JT - The British journal of surgery JID - 0372553 SB - IM MH - Humans MH - Adult MH - Middle Aged MH - Female MH - *Breast Neoplasms/diagnostic imaging/surgery MH - Pilot Projects MH - Prospective Studies MH - Neoadjuvant Therapy MH - Positron Emission Tomography Computed Tomography MH - Breast/diagnostic imaging/pathology MH - Image-Guided Biopsy/methods EDAT- 2022/12/09 06:00 MHDA- 2023/01/13 06:00 CRDT- 2022/12/08 12:16 PHST- 2022/05/18 00:00 [received] PHST- 2022/07/14 00:00 [revised] PHST- 2022/10/23 00:00 [accepted] PHST- 2022/12/09 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] PHST- 2022/12/08 12:16 [entrez] AID - 6880671 [pii] AID - 10.1093/bjs/znac391 [doi] PST - ppublish SO - Br J Surg. 2023 Jan 10;110(2):217-224. doi: 10.1093/bjs/znac391. PMID- 36357267 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1938-0666 (Electronic) IS - 1526-8209 (Linking) VI - 23 IP - 1 DP - 2023 Jan TI - Frequency and Influencing Factors of Shared Decision Making Among Breast Cancer Patients Receiving Surgery: A Systematic Review and Meta-Analysis. PG - e20-e31 LID - S1526-8209(22)00230-0 [pii] LID - 10.1016/j.clbc.2022.10.007 [doi] AB - Due to the diversified and high sensitivity of breast cancer surgical treatment, various decision making styles show different functions in making trade-offs and sharing information. Shared decision making is the best practice paradigm to promote health outcomes. This study aimed to determine the overall frequency of shared decision making and explore influencing factors during the surgical decision-making process from breast cancer patients' perspectives. We searched 8 databases for studies about breast cancer patients' surgical decisional control preferences and shared decision making preference. Two researchers screened the literature, extracted the data, and evaluated the literature quality. Meta-analysis of the frequency of preferred and actual shared decision making and decision congruence was performed. Due to the limited studies of influencing factors, descriptive analysis was used. Fourteen original studies were included in this study. We found the overall pooled frequency of the preferred shared decision making of 48.1% (95%CI 33.5%, 62.6%) and the actual shared decision making of 38.1% (95%CI 33.9%, 42.2%). Moreover, the pooled frequency of the decision congruence between preferred and actual decision styles was 61.7% (95%CI 54.6%, 68.8%). The descriptive analysis findings indicated that the influencing factors of shared decision making included individual factors, surgeon-patient communication factors, and health setting factors. There was a gap between the preferred and actual decision styles in the surgical context. Therefore, health care providers should identify potential shared decision making barriers and facilitators, and advocate the clinical shared decision making model to embed shared decision making into routine practice. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Zheng, Hongying AU - Zheng H AD - School of Nursing, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yang, Linning AU - Yang L AD - Reproductive Medicine Center, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Hu, Jiale AU - Hu J AD - Department of Nurse Anesthesia, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: jhu4@vcu.edu. FAU - Yang, Yan AU - Yang Y AD - School of Nursing, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: renji_yy@126.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20221018 PL - United States TA - Clin Breast Cancer JT - Clinical breast cancer JID - 100898731 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery MH - Decision Making, Shared MH - Decision Making MH - Health Promotion MH - Patient Participation OTO - NOTNLM OT - Breast neoplasms OT - Decision preference OT - Health Promotion OT - Shared decision making OT - Surgical decision making EDAT- 2022/11/11 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/10 22:05 PHST- 2022/05/27 00:00 [received] PHST- 2022/10/05 00:00 [accepted] PHST- 2022/11/11 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/10 22:05 [entrez] AID - S1526-8209(22)00230-0 [pii] AID - 10.1016/j.clbc.2022.10.007 [doi] PST - ppublish SO - Clin Breast Cancer. 2023 Jan;23(1):e20-e31. doi: 10.1016/j.clbc.2022.10.007. Epub 2022 Oct 18. PMID- 36627701 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230113 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 18 IP - 1 DP - 2023 Jan 10 TI - Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar. PG - 3 LID - 10.1186/s13000-022-01278-5 [doi] LID - 3 AB - BACKGROUND: Much is known about tumor infiltrating lymphocytes (Tils) in primary breast cancer, as this has been the focus of much research in recent years, but regarding recurrent breast cancer, only few studies have been done. Our aim was to compare the quantities of Tils in primary breast carcinomas and their corresponding recurrences and to analyze the differences in the tumor Tils compositions in correlations with recurrence-free times and the clinicopathology of the tumor. METHODS: One hundred thirty-seven breast cancer patients self-paired for primary- tumor-recurrence were divided into three groups based on the length of the recurrence-free interval. H&E-staining and immunohistochemical staining with antiCD3, antiCD4, antiCD8 and antiCD56 were performed. Differences in Tils between primaries and recurrences, between the recurrence-free interval groups, and between different clinicopathologic parameters were statistically analyzed. RESULTS: Fewer stromal CD3+, CD8+ and CD56+ lymphocytes were found at recurrences compared to the primaries. No significant change in the percentage of CD4+ stromal lymphocytes. ER-negative primaries, PR-negative or HER2-positive tumors had more Tils in some subgroups. Ductal primaries had more Tils than lobular primaries and G3 tumors had more Tils than lower-grade tumors. The corresponding differences at recurrences could either not be detected or they were reversed. The fastest recurring group had generally more Tils than the slower groups. CONCLUSIONS: CD4+ cell numbers did not decline from primary to recurrence in contrast to all other subclasses of lymphocytes. The proportion of CD4+ cells was higher in recurrences than in primaries. Tumors with a higher grade and proliferation rate had higher percentages of Tils. HER2+ and hormone receptor negative tumors tended to have higher Tils scores. In recurrences these differences were not seen or they were reversed. CI - © 2022. The Author(s). FAU - Mutka, Minna AU - Mutka M AD - Department of Pathology, HUSLAB, Helsinki University Hospital and University of Helsinki, FIN-00290, Helsinki, Finland. minna.mutka@hus.fi. FAU - Joensuu, Kristiina AU - Joensuu K AD - University of Helsinki, FIN-00290, Helsinki, Finland. FAU - Eray, Mine AU - Eray M AD - Department of Pathology, HUSLAB, Helsinki University Hospital and University of Helsinki, FIN-00290, Helsinki, Finland. FAU - Heikkilä, Päivi AU - Heikkilä P AD - Department of Pathology, HUSLAB, Helsinki University Hospital and University of Helsinki, FIN-00290, Helsinki, Finland. LA - eng PT - Journal Article DEP - 20230110 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Neoplasm Recurrence, Local/pathology MH - CD4-Positive T-Lymphocytes/pathology MH - Lymphocytes, Tumor-Infiltrating/pathology MH - CD8-Positive T-Lymphocytes/pathology MH - Prognosis PMC - PMC9830729 OTO - NOTNLM OT - Cancer immunoediting OT - Cancer immunoescape OT - Recurrence OT - Tumor infiltrating lymphocytes OT - Tumor stroma COIS- The authors declare that they have no competing interests. EDAT- 2023/01/11 06:00 MHDA- 2023/01/13 06:00 CRDT- 2023/01/10 23:38 PHST- 2022/08/12 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/10 23:38 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - 10.1186/s13000-022-01278-5 [pii] AID - 1278 [pii] AID - 10.1186/s13000-022-01278-5 [doi] PST - epublish SO - Diagn Pathol. 2023 Jan 10;18(1):3. doi: 10.1186/s13000-022-01278-5. PMID- 36674951 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 11 TI - Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer. LID - 1433 [pii] LID - 10.3390/ijms24021433 [doi] AB - The problem of finding more precise stratification criteria for identifying the cohort of patients who would obtain the maximum benefit from immunotherapy is acute in modern times. In our study were enrolled 18 triple-negative breast cancer patients. The Ventana SP142 test was used for PD-L1 detection. Spatial transcriptomic analysis by 10x Genomics was used to compare PD-L1-positive and PD-L1-negative tumors. The seven-color multiplex immunofluorescence (by Akoya) was used for the detection of the type of cells that carried the PD1 receptor and the PD-L1 ligand. Using pathway analysis, we showed that PD-L1-positive tumors demonstrate signatures of a cell response to cytokines, among others, and PD-L1-negative tumors demonstrate signatures of antigen presentation. PD-L1-positive and PD-L1-negative tumors have different tumor microenvironment (TME) compositions according to CIBERSORT analysis. Multiplex immunohistochemistry (IHC) confirmed the prevalence of PD1-negative M2 macrophages and PD1-negative T lymphocytes in PD-L1-positive tumors. PD-L1-positive tumors are not characterized by direct contact between cells carrying the PD1 receptor and the PD-L1 ligand. So, the absence of specific immune reactions against the tumor, predominance of pro-tumor microenvironment, and rare contact between PDL1 and PD1-positive cells may be the potential reasons for the lack of an immune checkpoint inhibitor (ICI) effect in triple-negative breast cancer patients. FAU - Tashireva, Liubov A AU - Tashireva LA AUID- ORCID: 0000-0003-2061-8417 AD - Laboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634009, Russia. AD - Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634009, Russia. FAU - Kalinchuk, Anna Yu AU - Kalinchuk AY AUID- ORCID: 0000-0003-2106-3513 AD - Laboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634009, Russia. FAU - Gerashchenko, Tatiana S AU - Gerashchenko TS AUID- ORCID: 0000-0002-7283-0092 AD - Laboratory of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634009, Russia. FAU - Menyailo, Maksim AU - Menyailo M AUID- ORCID: 0000-0003-4630-4934 AD - Laboratory of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634009, Russia. FAU - Khozyainova, Anna AU - Khozyainova A AD - Laboratory of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634009, Russia. FAU - Denisov, Evgeniy V AU - Denisov EV AUID- ORCID: 0000-0003-2923-9755 AD - Laboratory of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634009, Russia. FAU - Perelmuter, Vladimir M AU - Perelmuter VM AD - Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634009, Russia. LA - eng PT - Journal Article DEP - 20230111 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (B7-H1 Antigen) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Ligands) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/genetics/pathology MH - B7-H1 Antigen MH - Tumor Microenvironment/genetics MH - Programmed Cell Death 1 Receptor/metabolism MH - Ligands MH - Biomarkers, Tumor/metabolism PMC - PMC9862087 OTO - NOTNLM OT - PD-L1 OT - immune checkpoint inhibitors OT - spatial transcriptomic analysis OT - triple-negative breast cancer OT - tumor microenvironment EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:27 PHST- 2022/11/29 00:00 [received] PHST- 2022/12/20 00:00 [revised] PHST- 2023/01/10 00:00 [accepted] PHST- 2023/01/21 01:27 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijms24021433 [pii] AID - 10.3390/ijms24021433 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 11;24(2):1433. doi: 10.3390/ijms24021433. PMID- 36562693 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1537-453X (Electronic) IS - 0277-3732 (Linking) VI - 46 IP - 1 DP - 2023 Jan 1 TI - The Role of the Quality of Relationship in Couples Facing Treatment for Breast Cancer: A Qualitative Italian Study. PG - 36-42 LID - 10.1097/COC.0000000000000962 [doi] AB - INTRODUCTION: Breast cancer is the leading cause of cancer death in women worldwide. Recently, the focus of research has shifted from psychiatric, psychological, and social consequences on the woman who gets sick from breast cancer to the impact on the couple. Indeed, the psychosocial perspective has developed the construct of the Quality of Relationship (QoR) that affects the quality of life of both members of the dyad. OBJECTIVE: The aim of this study was to extend knowledge in this field by identifying and analyzing what dimensions of QoR may impact couples' psychosocial adjustment to breast cancer and related treatments. PATIENTS AND METHODS: Semistructured interviews explored couples' experiences of breast cancer diagnosis and treatment. Transcripts were analyzed using inductive thematic analysis. RESULTS: Twelve couples were interviewed. Results showed how the dimensions of psychosocial support, dyadic coping, communication, and intimacy are associated and define the construct of QoR, thus affecting the couples' adjustment to breast cancer diagnosis and to the disease pathway. CONCLUSION: Assessment procedures of couple functioning since and after diagnosis could increase the appropriateness and benefits of integrating existing clinical practice in oncological settings. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Valente, Marco AU - Valente M AD - Department of Psychology, Alma Mater Studiorum-University of Bologna, Bologna, Italy. FAU - Chirico, Ilaria AU - Chirico I FAU - Girotti, Chiara AU - Girotti C FAU - Ottoboni, Giovanni AU - Ottoboni G FAU - Chattat, Rabih AU - Chattat R LA - eng PT - Journal Article DEP - 20221201 PL - United States TA - Am J Clin Oncol JT - American journal of clinical oncology JID - 8207754 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/psychology MH - Quality of Life MH - Adaptation, Psychological MH - Communication MH - Interpersonal Relations MH - Spouses/psychology COIS- The authors declare no conflicts of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/23 09:53 PHST- 2022/12/23 09:53 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - 00000421-202301000-00009 [pii] AID - 10.1097/COC.0000000000000962 [doi] PST - ppublish SO - Am J Clin Oncol. 2023 Jan 1;46(1):36-42. doi: 10.1097/COC.0000000000000962. Epub 2022 Dec 1. PMID- 36542934 OWN - NLM STAT- MEDLINE DCOM- 20221228 LR - 20230103 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 158 DP - 2023 Jan TI - Relationship between FDG-PET and the immune microenvironment in breast cancer. PG - 110661 LID - S0720-048X(22)00511-3 [pii] LID - 10.1016/j.ejrad.2022.110661 [doi] AB - OBJECTIVE: To investigate the relationship between fluorodeoxyglucose (FDG) uptake (maximum standardised uptake value [SUVmax]) and immune markers (tumour-infiltrating lymphocytes [TILs] and neutrophil-to-lymphocyte ratio [NLR]) and evaluate the potential prognostic value of any correlations. METHODS: Data from 502 patients with breast cancer, including 346 oestrogen receptor (ER)-positive / human epidermal growth factor receptor 2 (HER2)-negative, 88 HER2-positive, and 68 triple-negative cases, who had undergone surgery were reviewed. Relationships between the clinicopathological factors, SUVmax, TILs, NLR, recurrence-free survival (RFS), and overall survival of all patients and each subtype were evaluated using a Cox proportional hazards model and log-rank test. A sub-analysis of patients divided into low and high TIL groups was also undertaken. RESULTS: High SUVmax was significantly related to high TILs (p < 0.0001). In low TIL (TILs1) group, patients with high SUVmax (≥3.585) had a significantly shorter RFS than those with low SUVmax (<3.585; p < 0.0001). In high TIL (TILs2,3) group, patients with high SUVmax had a shorter RFS than those with low SUVmax without a significant difference (p = 0.35). Multivariate analysis of 502 patients showed high SUVmax, high T status, and nodal metastasis were independent negative predictors of RFS. In 317 TILs-low patients, high SUVmax, high T status, nodal metastasis, and ER-positivity were independent predictors of RFS. In 185 TILs-high patients, nodal metastasis was an independent predictor of RFS. In ER-positive/HER2-negative and HER2-positive subtypes, SUVmax was a significant predictive parameter in the TILs-low but not TILs-high groups. CONCLUSION: FDG uptake may be predictive of immunological features and aggressive features in breast cancer patients. CI - Copyright © 2022. Published by Elsevier B.V. FAU - Kitajima, Kazuhiro AU - Kitajima K AD - Department of Radiology, Hyogo College of Medicine, Hyogo, Japan. Electronic address: kazu10041976@yahoo.co.jp. FAU - Higuchi, Tomoko AU - Higuchi T AD - Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Hyogo, Japan. Electronic address: qfpjq032@yahoo.co.jp. FAU - Fujimoto, Yukie AU - Fujimoto Y AD - Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Hyogo, Japan. Electronic address: yu-fuzimoto@hyo-med.ac.jp. FAU - Ishikawa, Eri AU - Ishikawa E AD - Department of Surgical Pathology, Hyogo College of Medicine, Hyogo, Japan. Electronic address: er-ishikawa@hyo-med.ac.jp. FAU - Yokoyama, Hiroyuki AU - Yokoyama H AD - Department of Radiology, Hyogo College of Medicine, Hyogo, Japan. Electronic address: h-yokoyama@hyo-med.ac.jp. FAU - Komoto, Hisashi AU - Komoto H AD - Department of Radiology, Hyogo College of Medicine, Hyogo, Japan. Electronic address: hi-koumoto@hyo-med.ac.jp. FAU - Inao, Yoshie AU - Inao Y AD - Department of Radiology, Hyogo College of Medicine, Hyogo, Japan. Electronic address: y-aka@hyo-med.ac.jp. FAU - Yamakado, Koichiro AU - Yamakado K AD - Department of Radiology, Hyogo College of Medicine, Hyogo, Japan. Electronic address: ko-yamakado@hyo-med.ac.jp. FAU - Miyoshi, Yasuo AU - Miyoshi Y AD - Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Hyogo, Japan. Electronic address: ymiyoshi@hyo-med.ac.jp. LA - eng PT - Journal Article DEP - 20221219 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/metabolism MH - Fluorodeoxyglucose F18/metabolism MH - Radiopharmaceuticals/metabolism MH - Positron-Emission Tomography MH - Prognosis MH - Retrospective Studies MH - Positron Emission Tomography Computed Tomography MH - Tumor Microenvironment OTO - NOTNLM OT - Breast cancer OT - Fluorodeoxyglucose F18 OT - Immune marker OT - Positron emission tomography COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/22 06:00 MHDA- 2022/12/29 06:00 CRDT- 2022/12/21 18:09 PHST- 2022/09/03 00:00 [received] PHST- 2022/12/13 00:00 [revised] PHST- 2022/12/15 00:00 [accepted] PHST- 2022/12/22 06:00 [pubmed] PHST- 2022/12/29 06:00 [medline] PHST- 2022/12/21 18:09 [entrez] AID - S0720-048X(22)00511-3 [pii] AID - 10.1016/j.ejrad.2022.110661 [doi] PST - ppublish SO - Eur J Radiol. 2023 Jan;158:110661. doi: 10.1016/j.ejrad.2022.110661. Epub 2022 Dec 19. PMID- 36674372 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230125 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 20 IP - 2 DP - 2023 Jan 16 TI - Development and Assessment of a Novel Core Biopsy-Based Prediction Model for Pathological Complete Response to Neoadjuvant Chemotherapy in Women with Breast Cancer. LID - 10.3390/ijerph20021617 [doi] LID - 1617 AB - PURPOSE: Pathological complete response (pCR), the goal of NAC, is considered a surrogate for favorable outcomes in breast cancer (BC) patients administrated neoadjuvant chemotherapy (NAC). This study aimed to develop and assess a novel nomogram model for predicting the probability of pCR based on the core biopsy. METHODS: This was a retrospective study involving 920 BC patients administered NAC between January 2012 and December 2018. The patients were divided into a primary cohort (769 patients from January 2012 to December 2017) and a validation cohort (151 patients from January 2017 to December 2018). After converting continuous variables to categorical variables, variables entering the model were sequentially identified via univariate analysis, a multicollinearity test, and binary logistic regression analysis, and then, a nomogram model was developed. The performance of the model was assessed concerning its discrimination, accuracy, and clinical utility. RESULTS: The optimal predictive threshold for estrogen receptor (ER), Ki67, and p53 were 22.5%, 32.5%, and 37.5%, respectively (all p < 0.001). Five variables were selected to develop the model: clinical T staging (cT), clinical nodal (cN) status, ER status, Ki67 status, and p53 status (all p ≤ 0.001). The nomogram showed good discrimination with the area under the curve (AUC) of 0.804 and 0.774 for the primary and validation cohorts, respectively, and good calibration. Decision curve analysis (DCA) showed that the model had practical clinical value. CONCLUSIONS: This study constructed a novel nomogram model based on cT, cN, ER status, Ki67 status, and p53 status, which could be applied to personalize the prediction of pCR in BC patients treated with NAC. FAU - Lan, Ailin AU - Lan A AUID- ORCID: 0000-0002-3649-1011 AD - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. FAU - Chen, Junru AU - Chen J AD - Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. FAU - Li, Chao AU - Li C AD - Department of Vascular Surgery, Southwest Hospital, Army Medical University, 38 Main Street, Gaotanyan, Shapingba, Chongqing 400038, China. FAU - Jin, Yudi AU - Jin Y AD - Department of Pathology, Chongqing University Cancer Hospital, No. 181, Hanyu Road, Shapingba District, Chongqing 400030, China. FAU - Wu, Yinan AU - Wu Y AD - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. FAU - Dai, Yuran AU - Dai Y AD - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. FAU - Jiang, Linshan AU - Jiang L AD - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. FAU - Li, Han AU - Li H AD - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. FAU - Peng, Yang AU - Peng Y AD - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. FAU - Liu, Shengchun AU - Liu S AD - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. LA - eng GR - CSTC2021jscx-gksb-N0027/Key Research and Development Project of Chongqing's Technology Innovation and Application Development Special Big Health Field/ PT - Journal Article DEP - 20230116 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (Ki-67 Antigen) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy MH - Neoadjuvant Therapy MH - Ki-67 Antigen MH - Retrospective Studies MH - Tumor Suppressor Protein p53 MH - Biopsy PMC - PMC9867383 OTO - NOTNLM OT - breast cancer OT - neoadjuvant chemotherapy OT - nomogram OT - pathological complete response OT - prediction model COIS- The authors declare that the research was conducted with no commercial or financial relationships that could be construed as potential conflicts of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:23 PHST- 2022/11/22 00:00 [received] PHST- 2023/01/11 00:00 [revised] PHST- 2023/01/12 00:00 [accepted] PHST- 2023/01/21 01:23 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijerph20021617 [pii] AID - ijerph-20-01617 [pii] AID - 10.3390/ijerph20021617 [doi] PST - epublish SO - Int J Environ Res Public Health. 2023 Jan 16;20(2):1617. doi: 10.3390/ijerph20021617. PMID- 36219736 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230111 IS - 2768-3613 (Electronic) IS - 2768-3605 (Linking) VI - 29 IP - 1 DP - 2023 Jan TI - Effects of Chicory and Fumitory on Hot Flashes Among Breast Cancer Survivors: A Randomized, Double-Blind Placebo-Controlled Trial. PG - 31-41 LID - 10.1089/jicm.2022.0624 [doi] AB - Objectives: Hot flashes are unpleasant long-term complications of breast cancer. This study aimed to evaluate the effects of a traditional Persian medicine containing extracts of Cichorium intybus L. (chicory) and Fumaria parviflora L. (Fumitory) extract syrup (CFS) compared with placebo when used as intended. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting/Location: The Oncology Ward of Shahid Modarres Hospital (Tehran, Iran). Subjects: Breast cancer survivors undergoing hormone deprivation therapy. Interventions: Patients were randomly allocated to receive 5 mL CFS or placebo syrup three times a day, for 4 weeks. Outcome measures: The co-primary outcomes were self-reported daily hot flashes frequency and severity scores assessed using self-reported daily dairies, including 1 week of baseline data. Results: Of the 148 patients screened, 137 were eligible, and 96 were randomly allocated to receive either CFS (n = 48) or placebo (n = 48). All participants who returned their dairies were compliant and analyzed as randomized in the a priori per-protocol analysis. After 4 weeks of treatment, both the mean daily hot flashes frequency and severity score had reduced by 57% in the CFS group and 10% in the placebo group. The overall weekly mean daily hot flashes frequency (effect size η(p)(2) 0.221, p < 0.001, n = 66) and severity scores (effect size η(p)(2) 0.160, p = 0.001, n = 66) were significantly lower in the CFS group compared with the placebo group (one-within one-between repeated-measures analysis of variance adjusted for baseline). CFS was well tolerated, with similar proportions of serious and nonserious adverse events occurring in both groups. Conclusions: This is the first study to report the effects of chicory or fumitory for the treatment of hot flashes. The findings provide preliminary evidence that CFS can improve hot flashes in breast cancer survivors undergoing hormone deprivation therapy. More research is warranted to confirm its effectiveness, safety, and mechanisms of action. Clinical Trial Registration: IRCT20210226050506N1. FAU - Khosropanah, Alireza AU - Khosropanah A AD - Department of Internal Medicine, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran. FAU - Mehri Ardestani, Mojgan AU - Mehri Ardestani M AD - Department of Persian Medicine, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran. FAU - Rostami, Nematollah AU - Rostami N AD - Department of Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Hashemi, Fatemeh AU - Hashemi F AD - Department of Neonatal Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Pasalar, Mehdi AU - Pasalar M AUID- ORCID: 0000-0003-2458-2626 AD - Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Hunter, Jennifer AU - Hunter J AUID- ORCID: 0000-0002-6109-9134 AD - Health Research Group, Sydney, New South Wales, Australia. FAU - Heydarirad, Ghazaleh AU - Heydarirad G AUID- ORCID: 0000-0003-4301-5918 AD - Department of Traditional Medicine, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20221010 PL - United States TA - J Integr Complement Med JT - Journal of integrative and complementary medicine JID - 9918283075806676 RN - 0 (Hormones) SB - IM MH - Humans MH - Female MH - Hot Flashes/drug therapy/complications MH - *Breast Neoplasms/complications/drug therapy MH - *Chicory MH - *Fumaria MH - *Cancer Survivors MH - *Fatigue Syndrome, Chronic/complications MH - Treatment Outcome MH - Iran/epidemiology MH - Hormones/therapeutic use OTO - NOTNLM OT - Cichorium intybus OT - Fumaria parviflora OT - Persian medicine OT - breast cancer OT - complementary therapies OT - hot flashes EDAT- 2022/10/12 06:00 MHDA- 2023/01/12 06:00 CRDT- 2022/10/11 14:52 PHST- 2022/10/12 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] PHST- 2022/10/11 14:52 [entrez] AID - 10.1089/jicm.2022.0624 [doi] PST - ppublish SO - J Integr Complement Med. 2023 Jan;29(1):31-41. doi: 10.1089/jicm.2022.0624. Epub 2022 Oct 10. PMID- 36342241 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 1095-8355 (Electronic) IS - 1065-6995 (Linking) VI - 47 IP - 2 DP - 2023 Feb TI - Recent advances in cold atmospheric plasma (CAP) for breast cancer therapy. PG - 327-340 LID - 10.1002/cbin.11939 [doi] AB - The serious problems of conventional breast cancer therapy strategies such as drug resistance, severe side effects, and lack of selectivity prompted the development of various cold atmospheric plasma (CAP) devices. Due to its advanced technology, CAP can produce a unique environment rich in reactive oxygen and nitrogen species (RONS), photons, charged ions, and an electric field, making it a promising revolutionary platform for cancer therapy. Despite substantial technological successes, CAP-based therapeutic systems are encounter with distinct limitations, including low control of the generated RONS, poor knowledge about its anticancer mechanisms, and challenges concerning designing, manufacturing, clinical translation, and commercialization, which must be resolved. The latest developments in CAP-based therapeutic systems for breast cancer treatment are discussed in this review. More significantly, the integration of CAP-based medicine approaches with other breast cancer therapies, including chemo- and nanotherapy is thoroughly addressed. CI - © 2022 International Federation for Cell Biology. FAU - Chupradit, Supat AU - Chupradit S AD - Department of Occupational Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Suthep, Chiang Mai, Thailand. FAU - Widjaja, Gunawan AU - Widjaja G AD - Universitas Krisnadwipayana, Universitas Indonesia, Jakarta, Indonesia. FAU - Radhi Majeed, Basman AU - Radhi Majeed B AD - College of Dentistry, Al-Ayen University, Dhi-Qar, Iraq. FAU - Kuznetsova, Maria AU - Kuznetsova M AD - Department of Propaedeutics of Dental Diseases, I.M. Sechenov First Moscow State Medical University, Moskva, Russia. FAU - Ansari, Mohammad Javed AU - Ansari MJ AD - Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj, Saudi Arabia. FAU - Suksatan, Wanich AU - Suksatan W AD - HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Faculty of Nursing, Bangkok, Thailand. FAU - Turki Jalil, Abduladheem AU - Turki Jalil A AD - Faculty of Biology and Ecology, Yanka Kupala State University of Grodno, Grodno, Belarus. AD - College of Technical Engineering, The Islamic University, Najaf, Iraq. AD - Department of Dentistry, Kut University College, Kut, Wasit, Iraq. FAU - Ghazi Esfahani, Bahar AU - Ghazi Esfahani B AUID- ORCID: 0000-0002-2898-7279 AD - Department of Biological Sciences and Technologies, University of Isfahan, Iran, Isfahan. LA - eng PT - Journal Article PT - Review DEP - 20221107 PL - England TA - Cell Biol Int JT - Cell biology international JID - 9307129 RN - 0 (Plasma Gases) RN - 0 (Reactive Oxygen Species) RN - 0 (Reactive Nitrogen Species) RN - S88TT14065 (Oxygen) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - *Plasma Gases/therapeutic use MH - Reactive Oxygen Species MH - Reactive Nitrogen Species MH - Oxygen OTO - NOTNLM OT - breast cancer OT - cold atmospheric plasma (CAP) OT - plasma medicine OT - reactive nitrogen species (RNS) OT - reactive oxygen species (ROS) EDAT- 2022/11/08 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/11/07 08:42 PHST- 2022/08/29 00:00 [revised] PHST- 2022/05/10 00:00 [received] PHST- 2022/10/11 00:00 [accepted] PHST- 2022/11/08 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/11/07 08:42 [entrez] AID - 10.1002/cbin.11939 [doi] PST - ppublish SO - Cell Biol Int. 2023 Feb;47(2):327-340. doi: 10.1002/cbin.11939. Epub 2022 Nov 7. PMID- 36444726 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1744-7666 (Electronic) IS - 1465-6566 (Linking) VI - 24 IP - 1 DP - 2023 Jan TI - Current challenges in the pharmacological management of genitourinary syndrome of menopause. PG - 23-28 LID - 10.1080/14656566.2022.2152326 [doi] AB - INTRODUCTION: Genitourinary syndrome of menopause is caused by climacteric estrogens drop and leads to bothersome and progressive genital and urinary symptoms. Considering the high frequency in the population and the impact on quality of life, it is crucial to find a safe and effective treatment. Pharmacological therapies aim to modulate the hormonal system and reverse tissue changes due to hypoestrogenism and consequently the symptoms. AREAS COVERED: We analyzed the scientific evidence concerning the main pharmacological treatments, which include systemic and topical estrogens, prasterone and ospemifene. This literature review focused on recent safety and efficacy findings in an attempt to identify the best treatment choice for each individual patient. EXPERT OPINION: There are encouraging data regarding the efficacy of all currently available pharmacological options and concerning their short and long-term safety. There are still doubts regarding best treatment choice for oncological high-risk population, in particular for breast cancer survivors, and some issues relative to patients' poor compliance and treatment adherence. For these reasons further studies need to be conducted with a patient-tailored focus. FAU - Salvatore, Stefano AU - Salvatore S AD - Department of Urogynecology, Gynecology and Obstetrics Unit, San Raffaele Hospital, Milan, Italy. FAU - Benini, Vittoria AU - Benini V AD - Department of Urogynecology, Gynecology and Obstetrics Unit, San Raffaele Hospital, Milan, Italy. FAU - Ruffolo, Alessandro Ferdinando AU - Ruffolo AF AUID- ORCID: 0000-0002-9983-523X AD - Department of Urogynecology, Gynecology and Obstetrics Unit, San Raffaele Hospital, Milan, Italy. FAU - Degliuomini, Rebecca S AU - Degliuomini RS AD - Department of Urogynecology, Gynecology and Obstetrics Unit, San Raffaele Hospital, Milan, Italy. FAU - Redaelli, Anna AU - Redaelli A AD - Department of Urogynecology, Gynecology and Obstetrics Unit, San Raffaele Hospital, Milan, Italy. FAU - Casiraghi, Arianna AU - Casiraghi A AD - Department of Urogynecology, Gynecology and Obstetrics Unit, San Raffaele Hospital, Milan, Italy. FAU - Candiani, Massimo AU - Candiani M AD - Department of Urogynecology, Gynecology and Obstetrics Unit, San Raffaele Hospital, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230109 PL - England TA - Expert Opin Pharmacother JT - Expert opinion on pharmacotherapy JID - 100897346 RN - 0 (Estrogens) RN - 459AG36T1B (Dehydroepiandrosterone) SB - IM MH - Female MH - Humans MH - *Quality of Life MH - Menopause MH - *Breast Neoplasms/drug therapy MH - Estrogens/therapeutic use MH - Dehydroepiandrosterone/therapeutic use MH - Syndrome MH - Vagina/pathology MH - Atrophy/drug therapy OTO - NOTNLM OT - DHEA OT - GSM OT - Menopause OT - breast cancer OT - genitourinary syndrome menopause OT - hormone replacement therapy OT - ospemifene OT - vaginal atrophy EDAT- 2022/11/30 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/11/29 05:03 PHST- 2022/11/30 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/11/29 05:03 [entrez] AID - 10.1080/14656566.2022.2152326 [doi] PST - ppublish SO - Expert Opin Pharmacother. 2023 Jan;24(1):23-28. doi: 10.1080/14656566.2022.2152326. Epub 2023 Jan 9. PMID- 36442749 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 181 DP - 2023 Jan TI - Gene expression signatures in older patients with breast cancer: A systematic review. PG - 103884 LID - S1040-8428(22)00308-0 [pii] LID - 10.1016/j.critrevonc.2022.103884 [doi] AB - BACKGROUND: Gene expression signatures have emerged to predict prognosis and guide the use of adjuvant therapy in patients with hormone receptor-positive breast cancer. The objective of this systematic review was to evaluate the prognostic and predictive value of commercially available gene expression signatures as a tool in adjuvant treatment decision-making in older patients with breast cancer. METHODS: PubMed, MEDLINE, Embase, Web of Science, Cochrane Library, and Emcare were reviewed for relevant articles published before December 2021. Eligible studies were randomised trials and cohort studies that externally validated commercially available gene expression signatures in patients aged 65 years and older, including studies that presented subanalyses of this age group. Data extraction and risk of bias assessment was performed independently by two investigators. RESULTS: Fifteen studies were included. Most studies investigated Oncotype DX, while results from other gene expression signatures were limited. Several studies underlined the prognostic performance of Oncotype DX and Prosigna Risk of Recurrence in older patients. Moreover, Oncotype DX was predictive for older patients with an intermediate-risk recurrence score; chemotherapy could be spared in both lymph node-positive and lymph node-negative disease. CONCLUSIONS: Prognostic performance has been demonstrated in older patients for several gene expression signatures. However, additional validation in patients with high-risk tumours is needed before gene expression signatures can be implemented in clinical practice as a prediction tool for adjuvant chemotherapy decision-making in the older age group. CI - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Lemij, A A AU - Lemij AA AD - Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. FAU - Baltussen, J C AU - Baltussen JC AD - Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. FAU - de Glas, N A AU - de Glas NA AD - Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. FAU - Kroep, J R AU - Kroep JR AD - Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. FAU - Derks, M G M AU - Derks MGM AD - Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. FAU - Liefers, G J AU - Liefers GJ AD - Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. FAU - Portielje, J E A AU - Portielje JEA AD - Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: J.E.A.Portielje@lumc.nl. LA - eng PT - Journal Article PT - Review PT - Systematic Review DEP - 20221126 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 SB - IM MH - Humans MH - Aged MH - Female MH - *Breast Neoplasms/diagnosis/genetics/therapy MH - Transcriptome MH - Gene Expression Profiling/methods MH - Prognosis MH - Chemotherapy, Adjuvant MH - Neoplasm Recurrence, Local/drug therapy MH - Randomized Controlled Trials as Topic OTO - NOTNLM OT - Adjuvant therapy OT - Breast cancer OT - Gene expression signature OT - Older patients COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Competing interests The remaining authors declare no competing interests. EDAT- 2022/11/29 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/11/28 19:35 PHST- 2022/07/19 00:00 [received] PHST- 2022/09/15 00:00 [revised] PHST- 2022/11/21 00:00 [accepted] PHST- 2022/11/29 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/11/28 19:35 [entrez] AID - S1040-8428(22)00308-0 [pii] AID - 10.1016/j.critrevonc.2022.103884 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2023 Jan;181:103884. doi: 10.1016/j.critrevonc.2022.103884. Epub 2022 Nov 26. PMID- 36677797 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 28 IP - 2 DP - 2023 Jan 11 TI - Novel Anti-Cancer Products Targeting AMPK: Natural Herbal Medicine against Breast Cancer. LID - 10.3390/molecules28020740 [doi] LID - 740 AB - Breast cancer is a common cancer in women worldwide. The existing clinical treatment strategies have been able to limit the progression of breast cancer and cancer metastasis, but abnormal metabolism, immunosuppression, and multidrug resistance involving multiple regulators remain the major challenges for the treatment of breast cancer. Adenosine 5'-monophosphate (AMP)-Activated Protein Kinase (AMPK) can regulate metabolic reprogramming and reverse the "Warburg effect" via multiple metabolic signaling pathways in breast cancer. Previous studies suggest that the activation of AMPK suppresses the growth and metastasis of breast cancer cells, as well as stimulating the responses of immune cells. However, some other reports claim that the development and poor prognosis of breast cancer are related to the overexpression and aberrant activation of AMPK. Thus, the role of AMPK in the progression of breast cancer is still controversial. In this review, we summarize the current understanding of AMPK, particularly the comprehensive bidirectional functions of AMPK in cancer progression; discuss the pharmacological activators of AMPK and some specific molecules, including the natural products (including berberine, curcumin, (-)-epigallocatechin-3-gallate, ginsenosides, and paclitaxel) that influence the efficacy of these activators in cancer therapy; and elaborate the role of AMPK as a potential therapeutic target for the treatment of breast cancer. FAU - Peng, Bo AU - Peng B AD - Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China. FAU - Zhang, Si-Yuan AU - Zhang SY AD - Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China. FAU - Chan, Ka Iong AU - Chan KI AD - Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China. FAU - Zhong, Zhang-Feng AU - Zhong ZF AD - Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China. FAU - Wang, Yi-Tao AU - Wang YT AUID- ORCID: 0000-0003-4355-6490 AD - Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China. LA - eng PT - Journal Article PT - Review DEP - 20230111 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) RN - 0 (Plant Extracts) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy/pathology MH - AMP-Activated Protein Kinases/metabolism MH - Breast MH - Signal Transduction MH - Plant Extracts/therapeutic use PMC - PMC9863744 OTO - NOTNLM OT - AMPK OT - breast cancer OT - immunity OT - metabolism OT - metastasis OT - multidrug resistance OT - natural products COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:44 PHST- 2022/10/31 00:00 [received] PHST- 2023/01/01 00:00 [revised] PHST- 2023/01/04 00:00 [accepted] PHST- 2023/01/21 01:44 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - molecules28020740 [pii] AID - molecules-28-00740 [pii] AID - 10.3390/molecules28020740 [doi] PST - epublish SO - Molecules. 2023 Jan 11;28(2):740. doi: 10.3390/molecules28020740. PMID- 36641175 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1879-1344 (Electronic) IS - 0144-8617 (Linking) VI - 304 DP - 2023 Mar 15 TI - An injectable and pH-responsive hyaluronic acid hydrogel as metformin carrier for prevention of breast cancer recurrence. PG - 120493 LID - S0144-8617(22)01398-4 [pii] LID - 10.1016/j.carbpol.2022.120493 [doi] AB - To achieve the pH-responsive release of metformin in tumor acidic microenvironment, we prepared OHA-Met by covalently grafting metformin (Met) onto oxidized hyaluronic acid (OHA) through imine bonds, and then prepared carboxymethyl chitosan (CMCS)/OHA-Met drug loaded hydrogels. The CMCS/OHA-Met hydrogels showed the in-situ injection performance. At pH = 7.4, the cumulative release rate of metformin from CMCS/OHA-Met20 hydrogel was 42.7 ± 2.6 % in 6 h, and the release tended to balance after 72 h. At pH = 5.5, the release kept constant and the cumulative release rate was 79.3 ± 4.7 % at 6 h, showing good pH-responsive behavior. Metformin induced apoptosis of MCF-7 cells through the caspase 3/PARP pathway. CMCS/OHA-Met20 hydrogel could effectively kill MCF-7 cells, while reducing the cytotoxicity of free metformin to L929 cells. In vivo breast cancer recurrence experiments showed CMCS/OHA-Met20 hydrogel could achieve local injection and pH-responsive smart drug delivery at the tumor resection site, inhibiting breast cancer recurrence. Compared with direct administration, CMCS/OHA-Met20 hydrogel reduced the metformin dosage, frequency of administration and systemic side effects. CI - Copyright © 2022. Published by Elsevier Ltd. FAU - Zheng, Zexiang AU - Zheng Z AD - Department of Materials Science and Engineering, Engineering Research Center of Artificial Organs and Materials, Jinan University, Guangzhou 510632, PR China. FAU - Yang, Xing AU - Yang X AD - Department of Materials Science and Engineering, Engineering Research Center of Artificial Organs and Materials, Jinan University, Guangzhou 510632, PR China. FAU - Zhang, Yifan AU - Zhang Y AD - Department of Materials Science and Engineering, Engineering Research Center of Artificial Organs and Materials, Jinan University, Guangzhou 510632, PR China. FAU - Zu, Weiqiang AU - Zu W AD - Department of Materials Science and Engineering, Engineering Research Center of Artificial Organs and Materials, Jinan University, Guangzhou 510632, PR China. FAU - Wen, Minna AU - Wen M AD - Department of Materials Science and Engineering, Engineering Research Center of Artificial Organs and Materials, Jinan University, Guangzhou 510632, PR China. FAU - Liu, Taisheng AU - Liu T AD - Laboratory Animal Center, Guangdong Pharmaceutical University, PR China. FAU - Zhou, Changren AU - Zhou C AD - Department of Materials Science and Engineering, Engineering Research Center of Artificial Organs and Materials, Jinan University, Guangzhou 510632, PR China. FAU - Li, Lihua AU - Li L AD - Department of Materials Science and Engineering, Engineering Research Center of Artificial Organs and Materials, Jinan University, Guangzhou 510632, PR China. Electronic address: tlihuali@jnu.edu.cn. LA - eng PT - Journal Article DEP - 20221224 PL - England TA - Carbohydr Polym JT - Carbohydrate polymers JID - 8307156 RN - 9004-61-9 (Hyaluronic Acid) RN - 0 (Hydrogels) RN - 9012-76-4 (Chitosan) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Hyaluronic Acid/chemistry MH - Hydrogels/pharmacology/chemistry MH - Drug Delivery Systems MH - Hydrogen-Ion Concentration MH - *Chitosan/chemistry MH - Tumor Microenvironment OTO - NOTNLM OT - Breast cancer OT - Drug loaded hydrogel OT - Metformin OT - Oxidized hyaluronic acid OT - pH-responsive COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/01/15 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/14 20:56 PHST- 2022/09/11 00:00 [received] PHST- 2022/12/13 00:00 [revised] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/14 20:56 [entrez] PHST- 2023/01/15 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - S0144-8617(22)01398-4 [pii] AID - 10.1016/j.carbpol.2022.120493 [doi] PST - ppublish SO - Carbohydr Polym. 2023 Mar 15;304:120493. doi: 10.1016/j.carbpol.2022.120493. Epub 2022 Dec 24. PMID- 36221929 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 1552-4981 (Electronic) IS - 1552-4973 (Linking) VI - 111 IP - 3 DP - 2023 Mar TI - Cerium oxide nanoparticles exert antitumor effects and enhance paclitaxel toxicity and activity against breast cancer cells. PG - 579-589 LID - 10.1002/jbm.b.35175 [doi] AB - Cerium oxide nanoparticles (CeONPs) displayed cytotoxic properties against some cancer cells. However, there is very limited data about the possible antitumoral potential of them in breast cancer cells when used alone and/or together with a chemotherapeutic drug. We investigated the effects of CeONPs alone or in combination with paclitaxel (PAC) on healthy or carcinoma breast cells. After human breast cancer cells (MCF-7) treated with CeONPs alone or together with PAC for 24, 48, and 72 h, the effects of CeONPs on cell viability, apoptosis, migration, and adhesion were investigated. All cell viability and IC50 values of CeONPs and PAC treatments in healthy breast cells (HTERT-HME1) were higher than MCF-7 cells. They showed higher cytotoxicity against MCF-7 cells. CeONPs (10, 20, and 30 mM) and/or abraxane (AB) (2 μM) significantly decreased cell viability values in MCF-7 cells. All CeONPs concentrations increased the number of apoptotic MCF-7 cells. CeONPs (20 and 30 mM) alone or in combination with AB for 72 h treatment also significantly increased the apoptosis in compared to AB alone. CeONPs and/or AB can significantly inhibit the migratory ability of breast cancer cells. The migration rates in co-treated groups with CeONPs and AB were lower than CeONPs treatments. Higher concentrations of CeONPs alone or together with AB inhibited cell adhesion. Our results showed CeONPs can increase cytotoxicity and apoptosis and decrease cell migration and cell adhesion when used alone or together with AB. Therefore, combination of chemotherapeutics with CeONPs may provide a good strategy against cancer. CI - © 2022 Wiley Periodicals LLC. FAU - Atlı Şekeroğlu, Zülal AU - Atlı Şekeroğlu Z AUID- ORCID: 0000-0002-3552-3819 AD - Department of Molecular Biology and Genetics, Faculty of Science and Letters, Ordu University, Ordu, Turkey. FAU - Şekeroğlu, Vedat AU - Şekeroğlu V AD - Department of Molecular Biology and Genetics, Faculty of Science and Letters, Ordu University, Ordu, Turkey. FAU - Aydın, Birsen AU - Aydın B AD - Department of Biology, Faculty of Medicine, Faculty of Science and Letters, Amasya University, Amasya, Turkey. FAU - Kontaş Yedier, Seval AU - Kontaş Yedier S AD - Department of Molecular Biology and Genetics, Faculty of Science and Letters, Ordu University, Ordu, Turkey. LA - eng GR - FMB-BAP-17-0249/Scientific Research Funding of Funding of Amasya University (Turkey)/ GR - A-2014/Scientific Research Funding of Ordu University (Turkey)/ PT - Journal Article DEP - 20221011 PL - United States TA - J Biomed Mater Res B Appl Biomater JT - Journal of biomedical materials research. Part B, Applied biomaterials JID - 101234238 RN - P88XT4IS4D (Paclitaxel) RN - 619G5K328Y (ceric oxide) RN - 0 (Antineoplastic Agents) RN - 0 (Albumin-Bound Paclitaxel) SB - IM MH - Humans MH - Female MH - Paclitaxel/pharmacology MH - *Breast Neoplasms/drug therapy/pathology MH - *Antineoplastic Agents/pharmacology/therapeutic use MH - *Nanoparticles/therapeutic use MH - Apoptosis MH - Albumin-Bound Paclitaxel/pharmacology/therapeutic use OTO - NOTNLM OT - adhesion OT - apoptosis OT - breast cancer OT - cerium oxide nanoparticles OT - migration OT - paclitaxel EDAT- 2022/10/13 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/10/12 02:52 PHST- 2022/09/01 00:00 [revised] PHST- 2022/06/22 00:00 [received] PHST- 2022/09/22 00:00 [accepted] PHST- 2022/10/13 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/10/12 02:52 [entrez] AID - 10.1002/jbm.b.35175 [doi] PST - ppublish SO - J Biomed Mater Res B Appl Biomater. 2023 Mar;111(3):579-589. doi: 10.1002/jbm.b.35175. Epub 2022 Oct 11. PMID- 36670144 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Jan 20 TI - Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. PG - 1171 LID - 10.1038/s41598-023-27518-2 [doi] LID - 1171 AB - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Neoadjuvant systemic therapy (NAST) followed by surgery are currently standard of care for TNBC with 50-60% of patients achieving pathologic complete response (pCR). We investigated ability of deep learning (DL) on dynamic contrast enhanced (DCE) MRI and diffusion weighted imaging acquired early during NAST to predict TNBC patients' pCR status in the breast. During the development phase using the images of 130 TNBC patients, the DL model achieved areas under the receiver operating characteristic curves (AUCs) of 0.97 ± 0.04 and 0.82 ± 0.10 for the training and the validation, respectively. The model achieved an AUC of 0.86 ± 0.03 when evaluated in the independent testing group of 32 patients. In an additional prospective blinded testing group of 48 patients, the model achieved an AUC of 0.83 ± 0.02. These results demonstrated that DL based on multiparametric MRI can potentially differentiate TNBC patients with pCR or non-pCR in the breast early during NAST. CI - © 2023. The Author(s). FAU - Zhou, Zijian AU - Zhou Z AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1472, Houston, TX, 77030, USA. FAU - Adrada, Beatriz E AU - Adrada BE AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Candelaria, Rosalind P AU - Candelaria RP AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Elshafeey, Nabil A AU - Elshafeey NA AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Boge, Medine AU - Boge M AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Mohamed, Rania M AU - Mohamed RM AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Pashapoor, Sanaz AU - Pashapoor S AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Sun, Jia AU - Sun J AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Xu, Zhan AU - Xu Z AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1472, Houston, TX, 77030, USA. FAU - Panthi, Bikash AU - Panthi B AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1472, Houston, TX, 77030, USA. FAU - Son, Jong Bum AU - Son JB AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1472, Houston, TX, 77030, USA. FAU - Guirguis, Mary S AU - Guirguis MS AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Patel, Miral M AU - Patel MM AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Whitman, Gary J AU - Whitman GJ AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Moseley, Tanya W AU - Moseley TW AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. AD - Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Scoggins, Marion E AU - Scoggins ME AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - White, Jason B AU - White JB AD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Litton, Jennifer K AU - Litton JK AD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Valero, Vicente AU - Valero V AD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Hunt, Kelly K AU - Hunt KK AD - Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Tripathy, Debu AU - Tripathy D AD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Yang, Wei AU - Yang W AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Wei, Peng AU - Wei P AD - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Yam, Clinton AU - Yam C AD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Pagel, Mark D AU - Pagel MD AD - Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Rauch, Gaiane M AU - Rauch GM AD - Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. gmrauch@mdanderson.org. AD - Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1473, Houston, TX, 77030, USA. gmrauch@mdanderson.org. FAU - Ma, Jingfei AU - Ma J AD - Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1472, Houston, TX, 77030, USA. jma@mdanderson.org. LA - eng PT - Journal Article DEP - 20230120 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Female MH - *Triple Negative Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - *Breast Neoplasms/pathology MH - *Multiparametric Magnetic Resonance Imaging MH - *Deep Learning MH - Neoadjuvant Therapy/methods MH - Prospective Studies MH - Magnetic Resonance Imaging/methods MH - Retrospective Studies PMC - PMC9859781 COIS- The authors declare no competing interests. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 23:17 PHST- 2022/07/05 00:00 [received] PHST- 2023/01/03 00:00 [accepted] PHST- 2023/01/20 23:17 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.1038/s41598-023-27518-2 [pii] AID - 27518 [pii] AID - 10.1038/s41598-023-27518-2 [doi] PST - epublish SO - Sci Rep. 2023 Jan 20;13(1):1171. doi: 10.1038/s41598-023-27518-2. PMID- 36345154 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1099-1611 (Electronic) IS - 1057-9249 (Linking) VI - 32 IP - 1 DP - 2023 Jan TI - Duration of the patient interval in breast cancer and factors associated with longer delays in low-and middle-income countries: A systematic review with meta-analysis. PG - 13-24 LID - 10.1002/pon.6064 [doi] AB - OBJECTIVE: Breast cancer survival is lower in low- and middle-income countries (LMICs) partially due to many women being diagnosed with late-stage disease. The patient interval refers to the time elapsed between the detection of symptoms and the first consultation with a healthcare provider and is considered one of the core indicators for early diagnosis and treatment. The goal of the current research was to conduct a meta-analysis of the duration of the patient interval in LMICs and investigate the socio-demographic and socio-cultural factors related to longer delays in presentation. METHODS: We conducted a systematic review with meta-analysis (pre-registered protocol CRD42020200752). We searched seven information sources (2009-2022) and included 50 articles reporting the duration of patient intervals for 18,014 breast cancer patients residing in LMICs. RESULTS: The longest patient intervals were reported in studies from the Middle East (3-4 months), followed by South-East Asia (2 months), Africa (1-2 months), Latin America (1 month), and Eastern Europe (1 month). Older age, not being married, lower socio-economic status, illiteracy, low knowledge about cancer, disregarding symptoms or not attributing them to cancer, fear, negative beliefs about cancer, and low social support were related to longer delays across most regions. Longer delays were also related to use of alternative medicine in the Middle East, South-East Asia, and Africa and distrust in the healthcare system in Eastern Europe. CONCLUSIONS: There is large variation in the duration of patient intervals across LMICs in different geographical regions. Patient intervals should be reduced and, for this purpose, it is important to explore their determinants taking into account the social, cultural, and economic context. CI - © 2022 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd. FAU - Petrova, Dafina AU - Petrova D AUID- ORCID: 0000-0002-0346-6776 AD - Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. AD - Escuela Andaluza de Salud Pública (EASP), Granada, Spain. AD - CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. FAU - Garrido, Dunia AU - Garrido D AUID- ORCID: 0000-0001-9603-961X AD - Department of Developmental and Educational Psychology, University of Granada, Granada, Spain. FAU - Špacírová, Zuzana AU - Špacírová Z AD - Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. AD - Escuela Andaluza de Salud Pública (EASP), Granada, Spain. AD - CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. FAU - Fernández-Martínez, Nicolás Francisco AU - Fernández-Martínez NF AUID- ORCID: 0000-0001-8257-4304 AD - Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. AD - Escuela Andaluza de Salud Pública (EASP), Granada, Spain. AD - CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. AD - Interlevel Clinical Management Unit for Prevention, Promotion and Health Surveillance, Reina Sofía University Hospital, Córdoba, Spain. FAU - Ivanova, Ganka AU - Ivanova G AUID- ORCID: 0000-0001-5847-3087 AD - Department of Applied Psychology, College of Education, Social Sciences and Humanities, Al-Ain University, Abu Dhabi, United Arab Emirates. FAU - Rodríguez-Barranco, Miguel AU - Rodríguez-Barranco M AUID- ORCID: 0000-0002-9972-9779 AD - Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. AD - Escuela Andaluza de Salud Pública (EASP), Granada, Spain. AD - CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. FAU - Pollán, Marina AU - Pollán M AD - CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. AD - National Center for Epidemiology, Health Institute Carlos III, Madrid, Spain. FAU - Barrios-Rodríguez, Rocío AU - Barrios-Rodríguez R AD - Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. AD - CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. AD - Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. FAU - Sánchez, Maria José AU - Sánchez MJ AUID- ORCID: 0000-0003-4817-0757 AD - Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. AD - Escuela Andaluza de Salud Pública (EASP), Granada, Spain. AD - CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. LA - eng GR - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública/ GR - Agencia Estatal de Investigación/ GR - Fundación Científica Asociación Española Contra el Cáncer/ PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20221115 PL - England TA - Psychooncology JT - Psycho-oncology JID - 9214524 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/diagnosis/therapy MH - Developing Countries MH - Delivery of Health Care MH - Social Class OTO - NOTNLM OT - cancer OT - early diagnosis OT - help-seeking OT - low- and middle-income countries OT - oncology OT - patient interval OT - psycho-oncology OT - psychosocial determinants EDAT- 2022/11/09 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/11/08 00:33 PHST- 2022/10/02 00:00 [revised] PHST- 2022/04/27 00:00 [received] PHST- 2022/10/31 00:00 [accepted] PHST- 2022/11/09 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/11/08 00:33 [entrez] AID - 10.1002/pon.6064 [doi] PST - ppublish SO - Psychooncology. 2023 Jan;32(1):13-24. doi: 10.1002/pon.6064. Epub 2022 Nov 15. PMID- 36399309 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 2092-9293 (Electronic) IS - 1976-9571 (Linking) VI - 45 IP - 1 DP - 2023 Jan TI - PLAGL2 increases adriamycin resistance and EMT in breast cancer cells by activating the Wnt pathway. PG - 49-57 LID - 10.1007/s13258-022-01330-0 [doi] AB - BACKGROUND: Adriamycin (ADR) is an effective treatment for breast cancer; nevertheless, it is often linked with acquired resistance in breast cancer cells, reducing ADR's therapeutic efficacy and increasing the risk of recurrence and poor prognosis. It has been revealed that the zinc-finger transcription factor pleomorphic adenoma gene like-2 (PLAGL2) is required for epithelial to mesenchymal transition (EMT) in cancer cells. Recent data indicates that PLAGL2 is also involved in regulating chemotherapeutic drug resistance, albeit the exact mechanism by which this happens remains unknown. OBJECTIVE: This study examines the effect of PLAGL2 on adriamycin resistance and EMT in breast cancer cells. METHODS: The small interfering RNA (siRNA) targeting PLAGL2 was transfected to breast cancer cells to alter PLAGL2 expression. Cell counting kit-8 (CCK-8) and colony formation assay detected cell growth and proliferation rate. Moreover, wound-healing and transwell assays were conducted to evaluate migration and invasion. Western blot (WB) checked the apoptosis and EMT-associated proteins. RESULTS: PLAGL2 expression is associated with breast cancer cells' acquired resistance to ADR in this investigation. Additionally, deletion of PLAGL2 was associated with enhanced sensitivity to ADR, reduced proliferation, migration, and invasion capabilities, increased E-cadherin levels, and reduced Wnt6, β-catenin, and DVL1 levels in ADR-resistant breast cancer cells (MCF-7/ADR and MDA-MB-231/ADR cells). PLAGL2 could bind to the promoter region of Wnt6 and promote its expression. Additionally, the results of this research established that Wnt signaling is implicated in breast cancer cells' resistance to ADR since BML-284, a Wnt signaling activator partly restored the sensitivity of MCF-7/ADR and MDA-MB-231/ADR cells to ADR. CONCLUSION: PLAGL2 promotes adriamycin resistance and cell aggressiveness in breast cancer cells via activating the Wnt signaling pathway. CI - © 2022. The Author(s) under exclusive licence to The Genetics Society of Korea. FAU - Li, Yuxiao AU - Li Y AD - Department of Basic Teaching, Zhuhai Campus of Zunyi Medical University, 368 Jinwan Road, Zhuhai, 519041, Guangdong, China. FAU - Liu, Ruolin AU - Liu R AD - College of Basic Medicine, Hebei Medical University, Shijiazhuang, 050000, China. FAU - Han, Xingzhao AU - Han X AD - Department of Basic Teaching, Zhuhai Campus of Zunyi Medical University, 368 Jinwan Road, Zhuhai, 519041, Guangdong, China. FAU - Xu, Wei AU - Xu W AD - Business School of International Medicine, China Pharmaceutical University, Nanjing, 210009, China. FAU - Liu, Yahui AU - Liu Y AUID- ORCID: 0000-0003-4030-0369 AD - Department of Basic Teaching, Zhuhai Campus of Zunyi Medical University, 368 Jinwan Road, Zhuhai, 519041, Guangdong, China. liuyh_zmu@163.com. LA - eng PT - Journal Article DEP - 20221118 PL - Korea (South) TA - Genes Genomics JT - Genes & genomics JID - 101481027 RN - 80168379AG (Doxorubicin) RN - 0 (Transcription Factors) RN - 0 (RNA, Small Interfering) RN - 0 (PLAGL2 protein, human) RN - 0 (DNA-Binding Proteins) RN - 0 (RNA-Binding Proteins) SB - IM MH - Humans MH - Female MH - *Doxorubicin/pharmacology MH - Wnt Signaling Pathway MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Epithelial-Mesenchymal Transition/genetics MH - Transcription Factors/genetics/metabolism MH - RNA, Small Interfering MH - DNA-Binding Proteins/genetics/metabolism MH - RNA-Binding Proteins/genetics OTO - NOTNLM OT - Adriamycin resistance OT - Breast cancer OT - EMT OT - PLAGL2 EDAT- 2022/11/19 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/11/18 11:18 PHST- 2022/05/26 00:00 [received] PHST- 2022/10/14 00:00 [accepted] PHST- 2022/11/19 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/11/18 11:18 [entrez] AID - 10.1007/s13258-022-01330-0 [pii] AID - 10.1007/s13258-022-01330-0 [doi] PST - ppublish SO - Genes Genomics. 2023 Jan;45(1):49-57. doi: 10.1007/s13258-022-01330-0. Epub 2022 Nov 18. PMID- 36692626 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1433-7339 (Electronic) IS - 0941-4355 (Print) IS - 0941-4355 (Linking) VI - 31 IP - 2 DP - 2023 Jan 24 TI - Long-term effects of exercise interventions on physical activity in breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. PG - 130 LID - 10.1007/s00520-022-07485-6 [doi] LID - 130 AB - BACKGROUND: Benefits of exercise interventions for cancer patients are well established. This systematic review aimed to investigate the sustainability of exercise interventions with respect to physical activity behaviour of breast cancer patients in the longer term. METHODS: The databases Pubmed, Cochrane, Embase, and Web of Science were systematically searched for randomized controlled trials (RCTs) investigating aerobic exercise, resistance exercise, or combined exercise interventions in breast cancer patients and assessing physical activity at least 2 months after the intervention. Random-effect models were used to calculate standardized mean differences (SMD). RESULTS: A total of 27 RCTs with 4120 participants were included in the review, of which 11 RCTs with 1545 participants had appropriate data for the meta-analyses. Physical activity was mainly self-reported, and most exercise interventions were supervised. Exercise interventions tended to show a moderate significant effect up to 6 months for moderate to vigorous physical activity (SMD [95% CI] = 0.39 [0.07, 0.70]) and small, non-significant effects on total physical activity at 6 months (SMD [95% CI] = 0.14 [- 0.00, 0.28]) and up to 60 months after the intervention (SMD = 0.29 [-0.31, 0.90]). Differences between intervention characteristics, such as supervised versus unsupervised, were inconclusive due to the small number of RCTs. CONCLUSIONS: The physical activity behaviour in breast cancer patients remained improved for several months beyond the end of exercise interventions, but effects were small to moderate and diminished over time. Future studies should clarify how to maintain a healthy level of physical activity after completion of an exercise intervention. CI - © 2023. The Author(s). FAU - Goldschmidt, Siri AU - Goldschmidt S AUID- ORCID: 0000-0001-9198-5623 AD - Division of Physical Activity, Prevention and Cancer (C110), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany. AD - Medical Faculty of the University of Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg, Germany. FAU - Schmidt, Martina E AU - Schmidt ME AUID- ORCID: 0000-0002-2095-2426 AD - Division of Physical Activity, Prevention and Cancer (C110), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany. FAU - Steindorf, Karen AU - Steindorf K AUID- ORCID: 0000-0001-5215-5651 AD - Division of Physical Activity, Prevention and Cancer (C110), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany. k.steindorf@dkfz.de. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review DEP - 20230124 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 SB - IM MH - Humans MH - Female MH - Randomized Controlled Trials as Topic MH - *Exercise MH - *Breast Neoplasms/therapy MH - Health Status MH - Exercise Therapy PMC - PMC9873715 OTO - NOTNLM OT - Breast neoplasms OT - Cancer survivorship OT - Maintenance OT - Training COIS- The authors declare no competing interests. EDAT- 2023/01/25 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/24 11:08 PHST- 2022/07/01 00:00 [received] PHST- 2022/11/04 00:00 [accepted] PHST- 2023/01/24 11:08 [entrez] PHST- 2023/01/25 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.1007/s00520-022-07485-6 [pii] AID - 7485 [pii] AID - 10.1007/s00520-022-07485-6 [doi] PST - epublish SO - Support Care Cancer. 2023 Jan 24;31(2):130. doi: 10.1007/s00520-022-07485-6. PMID- 36319507 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1938-0666 (Electronic) IS - 1526-8209 (Linking) VI - 23 IP - 1 DP - 2023 Jan TI - The Use of Intraoperative Ultrasound During Breast Conserving Surgery. PG - 54-59 LID - S1526-8209(22)00226-9 [pii] LID - 10.1016/j.clbc.2022.10.003 [doi] AB - OBJECTIVES: The purpose of this study is to evaluate the utilization of intraoperative ultrasound (IOUS) for tumor localization in breast-conserving surgery and to examine its impact on margin positivity and re-excision rates. Additionally, the study seeks to identify factors contributing to surgeon utilization of IOUS. METHODS: A retrospective chart review was conducted of patients with preoperative diagnosis of breast cancer undergoing breast-conserving surgery by breast surgeons at multiple centers within a single healthcare system. Characteristics such as lesion size, palpability, histology, receptor status, and use of neoadjuvant chemotherapy were recorded. Re-excision rates were determined based on localization technique and surgeons' status of breast ultrasound certification. RESULTS: A total of 671 cases were performed, with 322 meeting study inclusion. 57 cases utilized IOUS, 250 utilized preoperative wire-guided localization (WGL), 10 used both methods and 5 cases used neither method. There was no significant difference in re-excision rates between IOUS and WGL or among the four surgeons. Ultrasound-certified surgeons were more likely to utilize IOUS, and re-excision rates trended higher for WGL, which may be clinically significant. CONCLUSION: Increasing familiarity with and utilization of IOUS during breast-conserving surgery may be clinically advantageous over traditional localization techniques. Ultrasound certification may lead to increased use of IOUS among surgeons. CI - Published by Elsevier Inc. FAU - Fosko, Nicole K AU - Fosko NK AD - Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey. FAU - Gribkova, Yelizaveta AU - Gribkova Y AD - Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey. FAU - Krupa, Kelly AU - Krupa K AD - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. FAU - Bs, Kavita Jain AU - Bs KJ AD - Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey. FAU - Moore, Dirk AU - Moore D AD - Rutgers School of Public Health, New Brunswick, New Jersey. FAU - Chen, Chunxia AU - Chen C AD - Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey. FAU - Potdevin, Lindsay AU - Potdevin L AD - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. FAU - Kumar, Shicha AU - Kumar S AD - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. FAU - Eladoumikdachi, Firas AU - Eladoumikdachi F AD - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. FAU - Kowzun, Maria J AU - Kowzun MJ AD - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. Electronic address: maria.kowzun@rutgers.edu. LA - eng PT - Journal Article DEP - 20221011 PL - United States TA - Clin Breast Cancer JT - Clinical breast cancer JID - 100898731 SB - IM MH - Female MH - Humans MH - *Mastectomy, Segmental/methods MH - *Breast Neoplasms/diagnostic imaging/surgery/drug therapy MH - Retrospective Studies MH - Breast/pathology MH - Ultrasonography, Mammary/methods OTO - NOTNLM OT - Breast cancer OT - Breast conserving surgery OT - Localization methods OT - Oncoplastic surgery EDAT- 2022/11/02 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/01 23:03 PHST- 2022/07/18 00:00 [received] PHST- 2022/10/07 00:00 [accepted] PHST- 2022/11/02 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/01 23:03 [entrez] AID - S1526-8209(22)00226-9 [pii] AID - 10.1016/j.clbc.2022.10.003 [doi] PST - ppublish SO - Clin Breast Cancer. 2023 Jan;23(1):54-59. doi: 10.1016/j.clbc.2022.10.003. Epub 2022 Oct 11. PMID- 36194069 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230124 IS - 1529-4242 (Electronic) IS - 0032-1052 (Linking) VI - 151 IP - 1 DP - 2023 Jan 1 TI - Fold Flaps to the Rescue in Postmastectomy Breast Reconstruction. PG - 35-38 LID - 10.1097/PRS.0000000000009778 [doi] AB - SUMMARY: Ischemic complications following postmastectomy breast reconstruction are not uncommon and can lead to reconstructive failure, especially with implant reconstruction. The authors propose a simple local flap for management of such complications. This flap is easily raised from the upper abdomen or lateral chest as a medially or laterally based fasciocutaneous flap, and the donor site is hidden in the inframammary or lateral mammary fold. The authors present a case series of these "fold flaps" that were used to manage complications following implant-based breast reconstruction. All patients between 2007 and 2021 who underwent a fold flap for breast reconstruction salvage were queried from a prospectively maintained database. Demographic variables, clinical factors, and surgical details were analyzed. Outcomes assessed included complications, appropriate wound healing, and reconstructive salvage. Fourteen patients underwent thoracoepigastric or thoracoabdominal fold flaps following breast reconstruction for soft-tissue coverage with an underlying prosthesis. The mean age was 54 years, mean body mass index was 30 kg/m 2 , and mean follow-up duration was 18.5 months. Fold flap indications included mastectomy skin flap necrosis ( n = 9), infection ( n = 4), and chronic seroma ( n = 1). Eleven reconstructions (79%) were salvaged and three (21%) required eventual prosthesis explantation secondary to infection or delayed wound healing. Fold flaps are a reliable option for managing ischemic complications following postmastectomy breast reconstruction. The benefits include improved soft-tissue coverage with a high salvage rate. These flaps are simple to raise, and their donor site is concealed within the folds. Furthermore, they provide a reliable early option to manage complications and potentially prevent reconstructive failure. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV. CI - Copyright © 2022 by the American Society of Plastic Surgeons. FAU - Brown, Ciara A AU - Brown CA AD - From the Division of Plastic and Reconstructive Surgery, Emory University. FAU - Losken, Albert AU - Losken A AD - From the Division of Plastic and Reconstructive Surgery, Emory University. LA - eng PT - Journal Article DEP - 20221004 PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 SB - IM MH - Humans MH - Middle Aged MH - Female MH - Mastectomy/adverse effects MH - *Breast Neoplasms/surgery/complications MH - *Mammaplasty/adverse effects MH - Surgical Flaps MH - Breast MH - Postoperative Complications/etiology/surgery MH - Retrospective Studies EDAT- 2022/10/05 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/10/04 09:23 PHST- 2022/10/05 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/10/04 09:23 [entrez] AID - 00006534-202301000-00007 [pii] AID - 10.1097/PRS.0000000000009778 [doi] PST - ppublish SO - Plast Reconstr Surg. 2023 Jan 1;151(1):35-38. doi: 10.1097/PRS.0000000000009778. Epub 2022 Oct 4. PMID- 36515701 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1439-099X (Electronic) IS - 0179-7158 (Print) IS - 0179-7158 (Linking) VI - 199 IP - 1 DP - 2023 Jan TI - Systematic risk analysis of radiation pneumonitis in breast cancer: role of cotreatment with chemo-, endocrine, and targeted therapy. PG - 67-77 LID - 10.1007/s00066-022-02032-y [doi] AB - PURPOSE: A major complication of sequential and concomitant chemoradiation in breast cancer treatment is interstitial pneumonitis induced by radiation therapy (RT), systemic therapy, or a combination of both. Dose and volume of co-irradiated lung tissue directly correlate with the risk of radiation pneumonitis. Especially in case of combined treatment, it is often unclear which of the used therapeutic agents promote pneumonitis. METHODS: This was a prospective monocentric study including 396 breast cancer patients. A systematic analysis of single and combined therapeutic measures was performed in order to identify treatment-related factors enhancing the risk of pneumonitis post RT. RESULTS: Overall incidence of pneumonitis of any grade was 38%; 28% were asymptomatic (grade 1) and 10% were symptomatic (> grade 1). Pneumonitis > grade 2 did not occur. Beside age, smoking status, and mean lung dose, the combined treatment with goserelin and tamoxifen significantly enhanced the risk of pneumonitis in a supra-additive pattern (odds ratio [OR] 4.38), whereas each agent alone or combined with other drugs only nonsignificantly contributed to a higher pneumonitis incidence post RT (OR 1.52 and OR 1.16, respectively). None of the other systemic treatments, including taxanes, increased radiation pneumonitis risk in sequential chemoradiation. CONCLUSION: Common treatment schedules in sequential chemoradiation following breast-conserving surgery only moderately increase lung toxicity, mainly as an asymptomatic complication, or to a minor extent, as transient pneumonitis ≤ grade 2. However, combined treatment with tamoxifen and the LHRH analog goserelin significantly increased the risk of pneumonitis in breast cancer patients after chemoradiation. Thus, closer surveillance of involved patients is advisable. CI - © 2022. The Author(s). FAU - Mangesius, Julian AU - Mangesius J AUID- ORCID: 0000-0003-0855-1870 AD - Department of Radiation Oncology, Medical University of Innsbruck, 6020, Innsbruck, Anichstr. 35, Austria. julian.mangesius@i-med.ac.at. FAU - Minasch, Danijela AU - Minasch D AD - Department of Radiation Oncology, Medical University of Innsbruck, 6020, Innsbruck, Anichstr. 35, Austria. FAU - Fink, Katharina AU - Fink K AD - Department of Radiation Oncology, Medical University of Innsbruck, 6020, Innsbruck, Anichstr. 35, Austria. FAU - Nevinny-Stickel, Meinhard AU - Nevinny-Stickel M AD - Department of Radiation Oncology, Medical University of Innsbruck, 6020, Innsbruck, Anichstr. 35, Austria. FAU - Lukas, Peter AU - Lukas P AD - Department of Radiation Oncology, Medical University of Innsbruck, 6020, Innsbruck, Anichstr. 35, Austria. FAU - Ganswindt, Ute AU - Ganswindt U AD - Department of Radiation Oncology, Medical University of Innsbruck, 6020, Innsbruck, Anichstr. 35, Austria. FAU - Seppi, Thomas AU - Seppi T AD - Department of Radiation Oncology, Medical University of Innsbruck, 6020, Innsbruck, Anichstr. 35, Austria. LA - eng PT - Journal Article DEP - 20221214 PL - Germany TA - Strahlenther Onkol JT - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] JID - 8603469 RN - 0F65R8P09N (Goserelin) RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/radiotherapy/drug therapy MH - Goserelin/therapeutic use MH - Prospective Studies MH - *Radiation Pneumonitis/epidemiology/etiology MH - Risk Assessment MH - Tamoxifen/therapeutic use PMC - PMC9839789 OTO - NOTNLM OT - Breast cancer OT - Goserelin OT - Lung toxicity OT - Normal tissue complications OT - Organs at risk OT - Radiation pneumonitis OT - Radiation therapy OT - Tamoxifen COIS- J. Mangesius, D. Minasch, K. Fink, M. Nevinny-Stickel, P. Lukas, U. Ganswindt, and T. Seppi declare that they have no competing interests. EDAT- 2022/12/15 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/12/14 11:12 PHST- 2022/06/16 00:00 [received] PHST- 2022/11/20 00:00 [accepted] PHST- 2022/12/15 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/12/14 11:12 [entrez] AID - 10.1007/s00066-022-02032-y [pii] AID - 2032 [pii] AID - 10.1007/s00066-022-02032-y [doi] PST - ppublish SO - Strahlenther Onkol. 2023 Jan;199(1):67-77. doi: 10.1007/s00066-022-02032-y. Epub 2022 Dec 14. PMID- 36694207 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1465-542X (Electronic) IS - 1465-5411 (Print) IS - 1465-5411 (Linking) VI - 25 IP - 1 DP - 2023 Jan 24 TI - Association between human blood metabolome and the risk of breast cancer. PG - 9 LID - 10.1186/s13058-023-01609-4 [doi] LID - 9 AB - BACKGROUND: Breast cancer is the most common cancer among women with limited treatment options. To identify promising drug targets for breast cancer, we conducted a systematical Mendelian randomization (MR) study to screen blood metabolome for potential causal mediators of breast cancer and further predict target-mediated side effects. METHODS: We selected 112 unique blood metabolites from 3 large-scale European ancestry-based genome-wide association studies (GWASs) with a total of 147,827 participants. Breast cancer data were obtained from a GWAS in the Breast Cancer Association Consortium (BCAC), involving 122,977 cases and 105,974 controls of European ancestry. We conducted MR analyses to systematically assess the associations of blood metabolites with breast cancer, and a phenome-wide MR analysis was further applied to ascertain the potential on-target side effects of metabolite interventions. RESULTS: Two blood metabolites were identified as the potential causal mediators for breast cancer, including high-density lipoprotein cholesterol (HDL-C) (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06-1.12; P = 9.67 × 10(-10)) and acetate (OR, 1.24; 95% CI, 1.13-1.37; P = 1.35 × 10(-5)). In the phenome-wide MR analysis, lowering HDL-C might have deleterious effects on the risk of the circulatory system and foreign body injury, while lowering acetate had deleterious effects on mental disorders disease. CONCLUSIONS: The present systematic MR analysis revealed that HDL-C and acetate may be the causal mediators in the risk of developing breast cancer. Side-effect profiles were characterized to help inform drug target prioritization for breast cancer prevention. HDL-C and acetate might be promising drug targets for preventing breast cancer, but they should be applied under weighting advantages and disadvantages. CI - © 2023. The Author(s). FAU - Wang, Yu AU - Wang Y AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. FAU - Liu, Fanghua AU - Liu F AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. FAU - Sun, Lulu AU - Sun L AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. FAU - Jia, Yiming AU - Jia Y AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. FAU - Yang, Pinni AU - Yang P AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. FAU - Guo, Daoxia AU - Guo D AD - School of Nursing, Suzhou Medical College of Soochow University, Suzhou, China. FAU - Shi, Mengyao AU - Shi M AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. FAU - Wang, Aili AU - Wang A AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. FAU - Chen, Guo-Chong AU - Chen GC AD - Department of Nutrition and Food Hygiene, School of Public Health, Medical College of Soochow University, Suzhou, China. FAU - Zhang, Yonghong AU - Zhang Y AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. yhzhang@suda.edu.cn. FAU - Zhu, Zhengbao AU - Zhu Z AD - Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou, 215123, Jiangsu Province, China. zbzhu@suda.edu.cn. LA - eng GR - 82020108028/National Natural Science Foundation of China/ GR - 82103917/National Natural Science Foundation of China/ GR - 21KJB330006/Natural Science Research Project of Jiangsu Provincial Higher Education/ PT - Journal Article DEP - 20230124 PL - England TA - Breast Cancer Res JT - Breast cancer research : BCR JID - 100927353 RN - 0 (Triglycerides) RN - 0 (Cholesterol, HDL) SB - IM MH - Humans MH - Female MH - Triglycerides MH - Risk Factors MH - *Breast Neoplasms/etiology/genetics MH - Genome-Wide Association Study MH - Cholesterol, HDL/genetics MH - Metabolome MH - Polymorphism, Single Nucleotide PMC - PMC9872401 OTO - NOTNLM OT - Breast cancer OT - Mendelian randomization OT - Metabolites COIS- The authors report no disclosures. EDAT- 2023/01/25 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/24 23:38 PHST- 2022/12/13 00:00 [received] PHST- 2023/01/20 00:00 [accepted] PHST- 2023/01/24 23:38 [entrez] PHST- 2023/01/25 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.1186/s13058-023-01609-4 [pii] AID - 1609 [pii] AID - 10.1186/s13058-023-01609-4 [doi] PST - epublish SO - Breast Cancer Res. 2023 Jan 24;25(1):9. doi: 10.1186/s13058-023-01609-4. PMID- 36658418 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1546-170X (Electronic) IS - 1078-8956 (Linking) VI - 29 IP - 1 DP - 2023 Jan TI - Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer. PG - 135-146 LID - 10.1038/s41591-022-02155-w [doi] AB - Triple-negative breast cancer (TNBC) is a rare cancer, characterized by high metastatic potential and poor prognosis, and has limited treatment options. The current standard of care in nonmetastatic settings is neoadjuvant chemotherapy (NACT), but treatment efficacy varies substantially across patients. This heterogeneity is still poorly understood, partly due to the paucity of curated TNBC data. Here we investigate the use of machine learning (ML) leveraging whole-slide images and clinical information to predict, at diagnosis, the histological response to NACT for early TNBC women patients. To overcome the biases of small-scale studies while respecting data privacy, we conducted a multicentric TNBC study using federated learning, in which patient data remain secured behind hospitals' firewalls. We show that local ML models relying on whole-slide images can predict response to NACT but that collaborative training of ML models further improves performance, on par with the best current approaches in which ML models are trained using time-consuming expert annotations. Our ML model is interpretable and is sensitive to specific histological patterns. This proof of concept study, in which federated learning is applied to real-world datasets, paves the way for future biomarker discovery using unprecedentedly large datasets. CI - © 2023. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Ogier du Terrail, Jean AU - Ogier du Terrail J AUID- ORCID: 0000-0001-6320-819X AD - Owkin, Inc., New York, NY, USA. jean.du-terrail@owkin.com. FAU - Leopold, Armand AU - Leopold A AUID- ORCID: 0000-0002-5909-2689 AD - Institut Curie, Paris, France. FAU - Joly, Clément AU - Joly C AD - Centre Léon Bérard, Lyon, France. FAU - Béguier, Constance AU - Béguier C AD - Owkin, Inc., New York, NY, USA. FAU - Andreux, Mathieu AU - Andreux M AUID- ORCID: 0000-0001-5778-9979 AD - Owkin, Inc., New York, NY, USA. FAU - Maussion, Charles AU - Maussion C AD - Owkin, Inc., New York, NY, USA. FAU - Schmauch, Benoît AU - Schmauch B AUID- ORCID: 0000-0002-9478-6395 AD - Owkin, Inc., New York, NY, USA. FAU - Tramel, Eric W AU - Tramel EW AD - Owkin, Inc., New York, NY, USA. FAU - Bendjebbar, Etienne AU - Bendjebbar E AD - Owkin, Inc., New York, NY, USA. FAU - Zaslavskiy, Mikhail AU - Zaslavskiy M AD - Owkin, Inc., New York, NY, USA. FAU - Wainrib, Gilles AU - Wainrib G AD - Owkin, Inc., New York, NY, USA. FAU - Milder, Maud AU - Milder M AD - Institut Curie, Paris, France. FAU - Gervasoni, Julie AU - Gervasoni J AD - Centre Léon Bérard, Lyon, France. FAU - Guerin, Julien AU - Guerin J AUID- ORCID: 0000-0002-3024-8483 AD - Institut Curie, Paris, France. FAU - Durand, Thierry AU - Durand T AUID- ORCID: 0000-0003-3861-8394 AD - Centre Léon Bérard, Lyon, France. FAU - Livartowski, Alain AU - Livartowski A AD - Institut Curie, Paris, France. FAU - Moutet, Kelvin AU - Moutet K AD - Owkin, Inc., New York, NY, USA. FAU - Gautier, Clément AU - Gautier C AD - Owkin, Inc., New York, NY, USA. FAU - Djafar, Inal AU - Djafar I AD - Owkin, Inc., New York, NY, USA. FAU - Moisson, Anne-Laure AU - Moisson AL AD - Owkin, Inc., New York, NY, USA. FAU - Marini, Camille AU - Marini C AD - Owkin, Inc., New York, NY, USA. FAU - Galtier, Mathieu AU - Galtier M AD - Owkin, Inc., New York, NY, USA. FAU - Balazard, Félix AU - Balazard F AD - Owkin, Inc., New York, NY, USA. FAU - Dubois, Rémy AU - Dubois R AD - Owkin, Inc., New York, NY, USA. FAU - Moreira, Jeverson AU - Moreira J AUID- ORCID: 0000-0003-3478-7158 AD - Owkin, Inc., New York, NY, USA. FAU - Simon, Antoine AU - Simon A AD - Owkin, Inc., New York, NY, USA. FAU - Drubay, Damien AU - Drubay D AUID- ORCID: 0000-0002-9997-9727 AD - Institut Gustave Roussy, Villejuif, France. FAU - Lacroix-Triki, Magali AU - Lacroix-Triki M AUID- ORCID: 0000-0002-6641-8536 AD - Institut Gustave Roussy, Villejuif, France. FAU - Franchet, Camille AU - Franchet C AD - Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France. FAU - Bataillon, Guillaume AU - Bataillon G AD - Institut Curie, Paris, France. FAU - Heudel, Pierre-Etienne AU - Heudel PE AUID- ORCID: 0000-0002-2155-549X AD - Centre Léon Bérard, Lyon, France. LA - eng PT - Journal Article DEP - 20230119 PL - United States TA - Nat Med JT - Nature medicine JID - 9502015 SB - IM MH - Humans MH - Female MH - *Neoadjuvant Therapy/methods MH - *Triple Negative Breast Neoplasms/drug therapy/pathology MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Treatment Outcome EDAT- 2023/01/20 06:00 MHDA- 2023/01/20 06:00 CRDT- 2023/01/19 23:29 PHST- 2021/05/20 00:00 [received] PHST- 2022/11/23 00:00 [accepted] PHST- 2023/01/20 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2023/01/19 23:29 [entrez] AID - 10.1038/s41591-022-02155-w [pii] AID - 10.1038/s41591-022-02155-w [doi] PST - ppublish SO - Nat Med. 2023 Jan;29(1):135-146. doi: 10.1038/s41591-022-02155-w. Epub 2023 Jan 19. PMID- 36156086 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 53 IP - 1 DP - 2023 Jan 6 TI - Survival and clinicopathological significance of blood vessel invasion in operable breast cancer: a systematic review and meta-analysis. PG - 35-45 LID - 10.1093/jjco/hyac149 [doi] AB - BACKGROUND: Lymphovascular invasion, including lymphatic-vessel invasion and blood-vessel invasion, plays an important role in distant metastases. The metastatic pattern of blood-vessel invasion may differ from that of lymphatic-vessel invasion. However, its prognostic significance in breast cancer remains controversial. We evaluated the role of blood-vessel invasion in the prognosis of operable breast-cancer patients and its association with clinicopathological characteristics. METHODS: We systematically searched EMBASE, PubMed, the Cochrane Library and Web of Science for studies in English through December 2020. Disease-free survival, overall survival and cancer-specific survival were the primary outcomes. Pooled hazard ratios and 95% confidence intervals were assessed using a random-effects model. RESULTS: Twenty-seven studies involving 7954 patients were included. Blood-vessel invasion occurred in 20.4% of tumor samples. Pooled results showed significant associations of blood-vessel invasion with worse disease-free survival (hazard ratio = 1.82; 95% confidence interval = 1.43-2.31) and overall survival (hazard ratio = 1.86; 95% confidence interval = 1.16-2.99) in multivariate analyses. The results of the univariate analyses were similar. Among the clinicopathological factors, blood-vessel invasion was associated with larger tumor size, lymph-node metastasis, nonspecific invasive type, higher histological grade, estrogen receptor-negative breast cancer, human epidermal growth factor receptor 2-positive breast cancer and lymphatic-vessel invasion. In the lymph-node-negative subgroup analyses, the presence of blood-vessel invasion led to poorer disease-free survival (hazard ratio = 2.46; 95%confidence interval = 1.64-3.70) and overall survival (hazard ratio = 2.94; 95%confidence interval = 1.80-4.80). CONCLUSIONS: We concluded that blood-vessel invasion is an independent predictor of poor prognosis in operable breast cancer and is associated with aggressive clinicopathological features. Breast-cancer patients with blood-vessel invasion require more aggressive treatments after surgery. CI - © The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Lin, Yingxin AU - Lin Y AUID- ORCID: 0000-0002-9406-5205 AD - Department of Breast Cancer Oncology, The Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, P. R. China. FAU - Zhang, Yuehua AU - Zhang Y AD - Department of Pathology, The Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, P. R. China. FAU - Fang, Huiqiong AU - Fang H AD - Department of Pathology, The Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, P. R. China. FAU - Hu, Qian AU - Hu Q AD - Department of Breast Cancer Oncology, The Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, P. R. China. FAU - Duan, Haibo AU - Duan H AD - Department of Breast Cancer Oncology, The Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, P. R. China. FAU - Zhang, Liangyun AU - Zhang L AD - Department of Pathology, The Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, P. R. China. FAU - Pang, Danmei AU - Pang D AD - Department of Breast Cancer Oncology, The Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, P. R. China. LA - eng GR - 2019D054/Special Fund of Foshan Summit Plan/ GR - 20200187/Medical Research Funding of Foshan City/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Neoplasm Invasiveness/pathology MH - Breast/pathology MH - Prognosis MH - Disease-Free Survival OTO - NOTNLM OT - blood vessel invasion OT - breast cancer OT - clinicopathological significance OT - meta-analysis OT - prognosis EDAT- 2022/09/27 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/09/26 16:15 PHST- 2021/12/22 00:00 [received] PHST- 2022/09/27 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/09/26 16:15 [entrez] AID - 6713910 [pii] AID - 10.1093/jjco/hyac149 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2023 Jan 6;53(1):35-45. doi: 10.1093/jjco/hyac149. PMID- 36591654 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1875-8592 (Electronic) IS - 1574-0153 (Linking) VI - 36 IP - 1 DP - 2023 TI - Construction of a lncRNA-mediated ceRNA network and a genomic-clinicopathologic nomogram to predict survival for breast cancer patients. PG - 83-96 LID - 10.3233/CBM-210545 [doi] AB - Breast cancer (BC) is the most common cancer among women and a leading cause of cancer-related deaths worldwide. The diagnosis of early patients and the prognosis of advanced patients have not improved over the past several decades. The purpose of the present study was to identify the lncRNA-related genes based on ceRNA network and construct a credible model for prognosis in BC. Based on The Cancer Genome Atlas (TCGA) database, prognosis-related differently expressed genes (DEGs) and a lncRNA-associated ceRNA regulatory network were obtained in BC. The patients were randomly divided into a training group and a testing group. A ceRNA-related prognostic model as well as a nomogram was constructed for further study. A total of 844 DElncRNAs, 206 DEmiRNAs and 3295 DEmRNAs were extracted in BC, and 12 RNAs (HOTAIR, AC055854.1, ST8SIA6-AS1, AC105999.2, hsa-miR-1258, hsa-miR-7705, hsa-miR-3662, hsa-miR-4501, CCNB1, UHRF1, SPC24 and SHCBP1) among them were recognized for the construction of a prognostic risk model. Patients were then assigned to high-risk and low-risk groups according to the risk score. The Kaplan-Meier (K-M) analysis demonstrated that the high-risk group was closely associated with poor prognosis. The predictive nomogram combined with clinical features showed performance in clinical practice. In a nutshell, our ceRNA-related gene model and the nomogram graph are accurate and reliable tools for predicting prognostic outcomes of BC patients, and may make great contributions to modern precise medicine. FAU - Wu, Mengni AU - Wu M FAU - Lu, Linlin AU - Lu L FAU - Dai, Tiantian AU - Dai T FAU - Li, Aoshuang AU - Li A FAU - Yu, Yue AU - Yu Y FAU - Li, Yadi AU - Li Y FAU - Xu, Zhihua AU - Xu Z FAU - Chen, Yan AU - Chen Y LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - Netherlands TA - Cancer Biomark JT - Cancer biomarkers : section A of Disease markers JID - 101256509 RN - 0 (RNA, Long Noncoding) RN - 0 (MicroRNAs) RN - EC 2.3.2.27 (UHRF1 protein, human) RN - 0 (CCAAT-Enhancer-Binding Proteins) RN - EC 2.3.2.27 (Ubiquitin-Protein Ligases) RN - 0 (SHCBP1 protein, human) RN - 0 (Shc Signaling Adaptor Proteins) RN - 0 (MIRN1258 microRNA, human) RN - 0 (MIRN-3662 microRNA, human) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - *RNA, Long Noncoding/genetics MH - Nomograms MH - Gene Regulatory Networks MH - *MicroRNAs/genetics MH - Prognosis MH - Genomics MH - CCAAT-Enhancer-Binding Proteins/genetics MH - Ubiquitin-Protein Ligases/genetics MH - Shc Signaling Adaptor Proteins/genetics OTO - NOTNLM OT - Breast cancer OT - ceRNA OT - nomogram OT - prognosis OT - risk model EDAT- 2023/01/03 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/02 05:02 PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2023/01/02 05:02 [entrez] AID - CBM210545 [pii] AID - 10.3233/CBM-210545 [doi] PST - ppublish SO - Cancer Biomark. 2023;36(1):83-96. doi: 10.3233/CBM-210545. PMID- 36426808 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230125 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 28 IP - 1 DP - 2023 Jan 18 TI - Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study. PG - 86-e76 LID - 10.1093/oncolo/oyac223 [doi] AB - BACKGROUND: The anti-tumor activity of nab-paclitaxel followed by epirubicin/cyclophosphamide (EC) as neoadjuvant chemotherapy (NAC) in Asian patients remain unclear, particularly in the aggressive subtype triple-negative breast cancer (TNBC). This study aimed to evaluate the efficacy and safety of this NAC regimen in TNBC. METHODS: In this Simon's two-stage, phase II study, treatment-naïve patients with unilateral primary invasive TNBC were enrolled. Eligible patients received nab-paclitaxel 125 mg/m2 weekly on day 1 for 12 weeks, followed by dose-dense EC (epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2) on day 1 for four 2-week cycles. The primary endpoint was the total pathological complete response (tpCR, ypT0/is ypN0) rate. RESULTS: A total of 55 eligible patients were enrolled and treated. After NAC, tpCR and breast pathological complete response were respectively observed in 43.1% (95% CI, 29.3-57.8) and 49.0% (95% CI, 34.8-63.4) of 51 evaluable patients for pathological response evaluation. 44 had an objective response as their best response (80.0%; 95% CI, 67.0-89.6). No correlations between clinicopathological variables and pathological/clinical response were observed. Grade 3 or more adverse events (AEs) occurred in 63.6% of 55 patients. The most frequent AEs were alopecia. No treatment-related surgical delay or death occurred. CONCLUSION: Nab-paclitaxel followed by dose-dense EC as NAC demonstrates promising anti-tumor activity and acceptable tolerability for patients with TNBC. (ClinicalTrials.gov Identifier: NCT03799679). CI - © The Author(s) 2022. Published by Oxford University Press. FAU - Liu, Yin AU - Liu Y AD - Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. FAU - Fan, Lei AU - Fan L AD - Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. FAU - Wang, Zhong-Hua AU - Wang ZH AD - Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. FAU - Shao, Zhi-Ming AU - Shao ZM AUID- ORCID: 0000-0002-4503-148X AD - Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China. LA - eng SI - ClinicalTrials.gov/NCT03799679 GR - CSPC Ouyi Pharmaceutical Co., Ltd/ GR - 21ZR1414700/Natural Science Foundation of Shanghai/ PT - Clinical Trial, Phase II PT - Journal Article PL - England TA - Oncologist JT - The oncologist JID - 9607837 RN - 0 (130-nm albumin-bound paclitaxel) RN - 8N3DW7272P (Cyclophosphamide) RN - 3Z8479ZZ5X (Epirubicin) RN - P88XT4IS4D (Paclitaxel) SB - IM MH - Female MH - Humans MH - *Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Cyclophosphamide/therapeutic use MH - Epirubicin/therapeutic use MH - *Neoadjuvant Therapy/adverse effects MH - Paclitaxel/therapeutic use MH - Treatment Outcome MH - *Triple Negative Breast Neoplasms/drug therapy/pathology PMC - PMC9847528 OTO - NOTNLM OT - nab-paclitaxel OT - breast cancer OT - neoadjuvant chemotherapy OT - triple-negative breast cancer EDAT- 2022/11/26 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/11/25 07:12 PHST- 2022/06/28 00:00 [received] PHST- 2022/09/26 00:00 [accepted] PHST- 2022/11/26 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/11/25 07:12 [entrez] AID - 6847064 [pii] AID - oyac223 [pii] AID - 10.1093/oncolo/oyac223 [doi] PST - ppublish SO - Oncologist. 2023 Jan 18;28(1):86-e76. doi: 10.1093/oncolo/oyac223. PMID- 36585173 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 43 IP - 1 DP - 2023 Jan TI - Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years. PG - 217-221 LID - 10.21873/anticanres.16152 [doi] AB - BACKGROUND/AIM: Despite advances in the treatment of breast cancer, metastatic breast cancer (MBC) remains difficult to cure, and few MBC patients survive 10 years after receiving a breast cancer metastasis diagnosis. We collected the cases of patients with MBC who survived >10 years post-metastasis diagnosis and assessed the patients' characteristics. PATIENTS AND METHODS: We retrospectively analyzed the cases of 245 consecutive patients diagnosed with MBC between January 2005 and December 2012 at our institution. Among them, 167 patients with confirmed survival of >10 years (i.e., long-term survival) or confirmed death at ≤10 years post-metastasis diagnosis were enrolled. RESULTS: There were 22 patients with MBC who survived >10 years. Regarding the cancer subtypes, 11 patients (50%) with long-term survival were HER2-positive. Seven of the 11 patients with HER2-positive MBC have been without recurrence although anti-HER2 therapy was discontinued. Triple-negative breast cancer (TNBC) was most common in the patients who survived ≤5 years but was not present in the >10-year survival group. In the HER2-negative cases, more cases in the long-term survival group were treated with local therapy (34.4% in the <5-year survival group, 43.8% in the 5-10-year group, and 72.7% in the >10-year group). CONCLUSION: MBC patients who survive >10 years after being diagnosed with metastasis are more likely to be HER2-positive and treated with local therapy. This suggests the efficacy of anti-HER2 therapy, and, conversely, clarifies unmet needs in TNBC and luminal-type MBC. The usefulness of local therapy was also supported by our findings. CI - Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Kikuchi, Mami AU - Kikuchi M AD - Division of Breast and Endocrine Surgery, Graduate School of Medicine, Gunma University, Gunma, Japan. AD - Center for Medical Education, Graduate School of Medicine, Gunma University, Gunma, Japan. FAU - Fujii, Takaaki AU - Fujii T AD - Division of Breast and Endocrine Surgery, Graduate School of Medicine, Gunma University, Gunma, Japan; ftakaaki@gunma-u.ac.jp. FAU - Honda, Chikako AU - Honda C AD - Division of Breast and Endocrine Surgery, Graduate School of Medicine, Gunma University, Gunma, Japan. FAU - Tanabe, Keiko AU - Tanabe K AD - Division of Breast and Endocrine Surgery, Graduate School of Medicine, Gunma University, Gunma, Japan. FAU - Nakazawa, Yuko AU - Nakazawa Y AD - Division of Breast and Endocrine Surgery, Graduate School of Medicine, Gunma University, Gunma, Japan. FAU - Ogino, Misato AU - Ogino M AD - Division of Breast and Endocrine Surgery, Graduate School of Medicine, Gunma University, Gunma, Japan. FAU - Obayashi, Sayaka AU - Obayashi S AD - Division of Breast and Endocrine Surgery, Graduate School of Medicine, Gunma University, Gunma, Japan. FAU - Shirabe, Ken AU - Shirabe K AD - Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - *Triple Negative Breast Neoplasms/pathology MH - Retrospective Studies MH - Prognosis MH - Receptor, ErbB-2 MH - Disease-Free Survival OTO - NOTNLM OT - HER2-positive OT - Metastatic breast cancer OT - local therapy OT - long-term prognosis EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 21:03 PHST- 2022/11/03 00:00 [received] PHST- 2022/11/14 00:00 [revised] PHST- 2022/11/15 00:00 [accepted] PHST- 2022/12/30 21:03 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 43/1/217 [pii] AID - 10.21873/anticanres.16152 [doi] PST - ppublish SO - Anticancer Res. 2023 Jan;43(1):217-221. doi: 10.21873/anticanres.16152. PMID- 36588130 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 2589-0409 (Electronic) IS - 1110-0362 (Linking) VI - 34 IP - 1 DP - 2023 Jan 2 TI - Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer. PG - 58 LID - 10.1186/s43046-022-00159-8 [doi] AB - HYPOTHESIS: Biological response modifiers (immunotherapy) in combination to chemotherapy are superior to that of chemotherapy in treatment of breast cancer (triple-negative/HER-2 ( +)), multiple myeloma, and non-small-cell lung cancer. METHODS: This review article consists of a total of eighteen independent randomized controlled clinical trials ranging from phases one to three. Patients were randomly selected for immunomodulatory treatment or chemotherapy and assessed for a specific mutation expression that the immunomodulatory agent targets. Kaplan-Meier plots, swimmer plots, and bar graphs depict overall/progression-free survival, objective response, and clinical response rates. The data collected was assessed by using 95% confidence interval and a p value of 0.05. Patients were treated until disease progression. RESULTS: Biological response modifiers (immunotherapy) resulted in significantly longer median progression-free survival in PD-L1-positive breast cancer (7.5 months compared to 5.0 months in control group), multiple myeloma (60.7% compared to 26.9% in the daratumumab and placebo groups, respectively), and in non-small-cell lung cancer (median progression-free survival was 10.3 months in the pembrolizumab group compared to 6.0 months in the chemotherapy group): higher complete responses in multiple myeloma (79% and 66% in the elotuzumab and control groups, respectively) and lower disease progression in PD-L1-positive non-small-cell lung cancer (62.1% of pembrolizumab versus 50.3% of chemotherapy patients had no disease progression at 6 months). CONCLUSION: Combination biological response modifiers (immunotherapy) and chemotherapy displayed benefit in overall/progression-free survival, response rate, duration of response, clinical benefit, and invasive disease-free survival in triple-negative/HER2-2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer. CI - © 2023. The Author(s). FAU - Morse, William AU - Morse W AD - Ross University School of Medicine, Miramar, USA. Wmorse001@gmail.com. FAU - Nawaz, Haroon AU - Nawaz H AD - Westside Regional Medical Center, Miramar, USA. FAU - Choudhry, Ayesha A AU - Choudhry AA AD - Fatima Jinnah Medical University, Lahore, Pakistan. LA - eng PT - Journal Article PT - Review DEP - 20230102 PL - England TA - J Egypt Natl Canc Inst JT - Journal of the Egyptian National Cancer Institute JID - 9424566 RN - 0 (B7-H1 Antigen) RN - 0 (Immunologic Factors) SB - IM MH - Humans MH - Female MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics MH - *Lung Neoplasms/genetics MH - *Breast Neoplasms/drug therapy MH - *Multiple Myeloma/drug therapy MH - B7-H1 Antigen MH - Immunologic Factors/therapeutic use MH - Immunotherapy MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects OTO - NOTNLM OT - Cancer OT - Chemotherapy OT - Immunotherapy OT - Myeloma OT - Non-small-cell lung cancer OT - Triple-negative breast EDAT- 2023/01/02 06:00 MHDA- 2023/01/04 06:00 CRDT- 2023/01/01 23:15 PHST- 2022/01/25 00:00 [received] PHST- 2022/11/26 00:00 [accepted] PHST- 2023/01/01 23:15 [entrez] PHST- 2023/01/02 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 10.1186/s43046-022-00159-8 [pii] AID - 10.1186/s43046-022-00159-8 [doi] PST - epublish SO - J Egypt Natl Canc Inst. 2023 Jan 2;34(1):58. doi: 10.1186/s43046-022-00159-8. PMID- 36074320 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Print) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study. PG - 23-35 LID - 10.1007/s12282-022-01394-6 [doi] AB - BACKGROUND: We aimed to quantify patients' benefit-risk preferences for attributes associated with human epidermal growth factor receptor 2 (HER2)-targeted breast cancer treatments and estimate minimum acceptable benefits (MABs), denominated in additional months of progression-free survival (PFS), for given treatment-related adverse events (AEs). METHODS: We conducted an online discrete-choice experiment (DCE) among patients with self-reported advanced/metastatic breast cancer in the United States, United Kingdom, and Japan (N = 302). In a series of nine DCE questions, respondents chose between two hypothetical treatment profiles created by an experimental design. Profiles were defined by six attributes with varying levels: PFS, nausea/vomiting, diarrhea, liver function problems, risk of heart failure, and risk of serious lung damage and infections. Data were analyzed using an error component random-parameters logit model. RESULTS: Among the attributes, patients placed the most importance on a change in PFS from 5 to 26 months; change from no diarrhea to severe diarrhea was the least important. Avoiding a 15% risk of heart failure had the largest MAB (5.8 additional months of PFS), followed by avoiding a 15% risk of serious lung damage and infections (4.6 months), possible severe liver function problems (4.2 months), severe nausea/vomiting (3.7 months), and severe diarrhea (2.3 months) compared with having none of the AEs. The relative importance of 21 additional months of PFS (increasing from 5 to 26 months) increased for women with HER2-negative disease and those with children. CONCLUSIONS: Patients valued PFS gain higher than the potential risk of AEs when deciding between hypothetical breast cancer treatments. CI - © 2022. The Author(s). FAU - Mansfield, Carol AU - Mansfield C AUID- ORCID: 0000-0002-3144-8938 AD - RTI Health Solutions, Research Triangle Park, NC, USA. carolm@rti.org. FAU - Botha, Willings AU - Botha W AD - RTI Health Solutions, Manchester, UK. FAU - Vondeling, Gerard T AU - Vondeling GT AD - Daiichi Sankyo Europe, Munich, Germany. FAU - Klein, Kathleen AU - Klein K AD - RTI Health Solutions, Research Triangle Park, NC, USA. FAU - Wang, Kongming AU - Wang K AD - Daiichi Sankyo Inc, Basking Ridge, NJ, USA. FAU - Singh, Jasmeet AU - Singh J AD - Daiichi Sankyo Inc, Basking Ridge, NJ, USA. FAU - Hackshaw, Michelle D AU - Hackshaw MD AD - Daiichi Sankyo Inc, Basking Ridge, NJ, USA. LA - eng PT - Journal Article DEP - 20220908 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 SB - IM MH - Child MH - Humans MH - Female MH - United States MH - *Breast Neoplasms/drug therapy MH - Patient Preference MH - Progression-Free Survival MH - Nausea MH - Vomiting PMC - PMC9454390 OTO - NOTNLM OT - Conjoint analysis OT - Discrete choice OT - Risk–benefit OT - Trade-off COIS- KW and JS are employees of Daiichi Sankyo, Inc. GTV and MDH were employees of Daiichi Sankyo, Inc., when this research was conducted. CM, WB, and KK are employees of RTI Health Solutions, which received funding from Daiichi Sankyo, Inc. to conduct the study. EDAT- 2022/09/09 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/09/08 11:21 PHST- 2022/02/01 00:00 [received] PHST- 2022/08/08 00:00 [accepted] PHST- 2022/09/09 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/09/08 11:21 [entrez] AID - 10.1007/s12282-022-01394-6 [pii] AID - 1394 [pii] AID - 10.1007/s12282-022-01394-6 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):23-35. doi: 10.1007/s12282-022-01394-6. Epub 2022 Sep 8. PMID- 36611165 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Jan 7 TI - High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation. PG - 26 LID - 10.1186/s12885-022-10412-x [doi] LID - 26 AB - BACKGROUND: High-dose chemotherapy with autologous stem cell rescue (HDCT) is a promising treatment for patients with stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer. Clinical effectiveness and cost-effectiveness are currently under investigation in an international multicenter randomized controlled trial. To increase the chance of successful introduction of HDCT into daily clinical practice, we aimed to identify relevant factors for smooth implementation using an early comprehensive assessment framework. METHODS: This is a qualitative, multi-stakeholder, exploratory research using semi-structured interviews guided by the Constructive Technology Assessment model, which evaluates the quality of a novel health technology by clinical, economic, patient-related, and organizational factors. Stakeholders were recruited by purposeful stratified sampling and interviewed until sufficient content saturation was reached. Two researchers independently created themes, categories, and subcategories by following inductive coding steps, these were verified by a third researcher. RESULTS: We interviewed 28 stakeholders between June 2019 and April 2021. In total, five overarching themes and seventeen categories were identified. Important findings for optimal implementation included the structural identification and referral of all eligible patients, early integration of supportive care, multidisciplinary collaboration between- and within hospitals, (de)centralization of treatment aspects, the provision of information for patients and healthcare professionals, and compliance to new regulation for the BRCA1-like test. CONCLUSIONS: In anticipation of a positive reimbursement decision, we recommend to take the highlighted implementation factors into consideration. This might expedite and guide high-quality equitable access to HDCT for patients with stage III, HER2-negative, HRD breast cancer in the Netherlands. CI - © 2023. The Author(s). FAU - Verbeek, Joost G E AU - Verbeek JGE AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands. AD - Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands. FAU - de Jong, Vincent M T AU - de Jong VMT AD - Department of Molecular Pathology, Antoni Van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands. FAU - Wijnja, Hanna M AU - Wijnja HM AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands. FAU - Jager, Agnes AU - Jager A AD - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Linn, Sabine C AU - Linn SC AD - Department of Molecular Pathology, Antoni Van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Department of Medical Oncology, Antoni Van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands. AD - Department of Pathology, Utrecht University Medical Centre, Utrecht, The Netherlands. FAU - Retèl, Valesca P AU - Retèl VP AUID- ORCID: 0000-0002-5624-3234 AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands. v.retel@nki.nl. AD - Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands. v.retel@nki.nl. FAU - van Harten, Wim H AU - van Harten WH AD - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands. AD - Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands. LA - eng GR - NKI2014-7052/KWF Kankerbestrijding/ GR - 843004015/ZONMW_/ZonMw/Netherlands PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20230107 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy/genetics MH - Health Personnel MH - Homologous Recombination MH - Stem Cells MH - Treatment Outcome PMC - PMC9824989 OTO - NOTNLM OT - Breast Neoplasms OT - Drug Therapy OT - Homologous Recombination OT - Implementation Science OT - Qualitative Research OT - Translational Research COIS- SL receives research funding to her institution from Agendia, AstraZeneca, Eurocept-pharmaceuticals, Genentech, GSK (formerly Tesaro), Immunomedics, Merck, Novartis, Roche; has acted as a consultant (not compensated) for Cergentis and Philips Health; has acted as a consultant (paid to her institution) for AstraZeneca and IBM; has received educational funding to her institution from Bayer and Daiichi-Sankyo. In addition, SL has a patent UN23A01/P-EP pending. VR and WvH received unrestricted research grants from Agendia BV and Intuitive BV, outside the scope of the current research. The other authors declare that they have no conflict of interest. EDAT- 2023/01/08 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/07 23:24 PHST- 2022/03/01 00:00 [received] PHST- 2022/12/05 00:00 [accepted] PHST- 2023/01/07 23:24 [entrez] PHST- 2023/01/08 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - 10.1186/s12885-022-10412-x [pii] AID - 10412 [pii] AID - 10.1186/s12885-022-10412-x [doi] PST - epublish SO - BMC Cancer. 2023 Jan 7;23(1):26. doi: 10.1186/s12885-022-10412-x. PMID- 36174113 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 1527-7755 (Electronic) IS - 0732-183X (Linking) VI - 41 IP - 3 DP - 2023 Jan 20 TI - A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. PG - 599-608 LID - 10.1200/JCO.22.00628 [doi] AB - PURPOSE: Estrogen receptor (ER)-positive endometrial cancers (ECs) are characterized by phosphatidylinositol 3-kinase (PI3K) and receptor tyrosine kinase (RTK)/RAS/β-catenin (CTNNB1) pathway alterations in approximately 90% and 80% of cases, respectively. Extensive cross-talk between ER, PI3K, and RTK/RAS/CTNNB1 pathways leads to both ligand-dependent and ligand-independent ER transcriptional activity as well as upregulation of cyclin D1 which, in complex with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), is a critical regulator of cell cycle progression and a key mediator of resistance to hormonal therapy. We hypothesized that the combination of the aromatase inhibitor letrozole and CDK4/6 inhibitor abemaciclib would demonstrate promising activity in this setting. METHODS: We conducted a phase II, two-stage study of letrozole/abemaciclib in recurrent ER-positive EC. Eligibility criteria included measurable disease, no limit on prior therapies, and all EC histologies; prior hormonal therapy was allowed. Primary end points were objective response rate by RECIST 1.1 and progression-free survival (PFS) rate at 6 months. RESULTS: At the data cutoff date (December 03, 2021), 30 patients (28 with endometrioid EC) initiated protocol therapy; 15 (50%) patients had prior hormonal therapy. There were nine total responses (eight confirmed), for an objective response rate of 30% (95% CI, 14.7 to 49.4), all in endometrioid adenocarcinomas. Median PFS was 9.1 months, PFS at 6 months was 55.6% (95% CI, 35.1 to 72), and median duration of response was 7.4 months. Most common ≥ grade 3 treatment-related adverse events were neutropenia (20%) and anemia (17%). Responses were observed regardless of grade, prior hormonal therapy, mismatch repair, and progesterone receptor status. Exploratory tumor profiling revealed several mechanistically relevant candidate predictors of response (CTNNB1, KRAS, and CDKN2A mutations) or absence of response (TP53 mutations), which require independent validation. CONCLUSION: Letrozole/abemaciclib demonstrated encouraging and durable evidence of activity in recurrent ER positive endometrioid EC. FAU - Konstantinopoulos, Panagiotis A AU - Konstantinopoulos PA AUID- ORCID: 0000-0002-1032-1479 AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Lee, Elizabeth K AU - Lee EK AUID- ORCID: 0000-0001-7533-7853 AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Xiong, Niya AU - Xiong N AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Krasner, Carolyn AU - Krasner C AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Campos, Susana AU - Campos S AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Kolin, David L AU - Kolin DL AUID- ORCID: 0000-0002-7631-6525 AD - Brigham and Women's Hospital, Boston, MA. FAU - Liu, Joyce F AU - Liu JF AUID- ORCID: 0000-0003-3888-3972 AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Horowitz, Neil AU - Horowitz N AD - Brigham and Women's Hospital, Boston, MA. FAU - Wright, Alexi A AU - Wright AA AUID- ORCID: 0000-0002-9776-7114 AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Bouberhan, Sara AU - Bouberhan S AUID- ORCID: 0000-0002-0315-2152 AD - Massachusetts General Hospital, Boston, MA. FAU - Penson, Richard T AU - Penson RT AUID- ORCID: 0000-0002-8091-8588 AD - Massachusetts General Hospital, Boston, MA. FAU - Yeku, Oladapo AU - Yeku O AUID- ORCID: 0000-0002-6319-1647 AD - Massachusetts General Hospital, Boston, MA. FAU - Bowes, Brittany AU - Bowes B AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Needham, Hope AU - Needham H AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Hayes, Martin AU - Hayes M AUID- ORCID: 0000-0001-8998-9713 AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Sawyer, Hannah AU - Sawyer H AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Polak, Madeline AU - Polak M AUID- ORCID: 0000-0002-1331-3845 AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Shea, Meghan AU - Shea M AUID- ORCID: 0000-0001-5262-1245 AD - Beth Israel Deaconess Medical Center, Boston, MA. FAU - Cheng, Su-Chun AU - Cheng SC AD - Dana-Farber Cancer Institute, Boston, MA. FAU - Castro, Cesar AU - Castro C AUID- ORCID: 0000-0002-1159-5658 AD - Massachusetts General Hospital, Boston, MA. FAU - Matulonis, Ursula A AU - Matulonis UA AUID- ORCID: 0000-0002-3103-6992 AD - Dana-Farber Cancer Institute, Boston, MA. LA - eng SI - ClinicalTrials.gov/NCT03675893 PT - Clinical Trial, Phase II PT - Journal Article DEP - 20220929 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - 60UAB198HK (abemaciclib) RN - 0 (Biomarkers, Tumor) RN - 7LKK855W8I (Letrozole) RN - 0 (Ligands) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Receptors, Estrogen) SB - IM MH - Female MH - Humans MH - Antineoplastic Combined Chemotherapy Protocols MH - Biomarkers, Tumor/genetics/metabolism MH - *Breast Neoplasms/etiology MH - *Endometrial Neoplasms/drug therapy MH - Letrozole MH - Ligands MH - Neoplasm Recurrence, Local/drug therapy/etiology MH - Phosphatidylinositol 3-Kinases MH - Receptor, ErbB-2/metabolism MH - Receptors, Estrogen/metabolism MH - Treatment Outcome EDAT- 2022/09/30 06:00 MHDA- 2023/01/20 06:00 CRDT- 2022/09/29 16:02 PHST- 2022/09/30 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/09/29 16:02 [entrez] AID - 10.1200/JCO.22.00628 [doi] PST - ppublish SO - J Clin Oncol. 2023 Jan 20;41(3):599-608. doi: 10.1200/JCO.22.00628. Epub 2022 Sep 29. PMID- 36455743 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 1879-1026 (Electronic) IS - 0048-9697 (Linking) VI - 861 DP - 2023 Feb 25 TI - Whole transcriptome sequencing and competitive endogenous RNA regulation network construction analysis in benzo[a]pyrene-treated breast cancer cells. PG - 160564 LID - S0048-9697(22)07667-7 [pii] LID - 10.1016/j.scitotenv.2022.160564 [doi] AB - Breast cancer is the most common malignant tumor in women worldwide, and environmental pollutants are considered to be risk factors. Currently, most studies into benzo[a]pyrene (B[a]P)-induced breast cancer focus on biological effects such as proliferation, invasion, and metastasis, DNA damage, estrogen receptor (ER)-related molecular mechanisms, oxidative damage, and other metabolic pathways. This study aims to provide insights into the role of B[a]P in breast cancer development through RNA-seq and bioinformatics analysis and construction of a competing endogenous RNA (ceRNA) regulatory network. By analyzing RNA-seq results, we identified 144 differentially-expressed circRNAs, 69 differentially-expressed lncRNAs, 20 differentially-expressed miRNAs, and 212 differentially-expressed mRNAs. Following on, we analyzed the gene ontology (GO) and KEGG enrichment functions of the differentially-expressed RNAs. In addition, the protein-protein interaction (PPI) network was mapped for differentially-expressed mRNAs. Subsequently, we constructed ceRNA networks, one of which consisted of 45 dysregulated circRNAs, 11 miRNAs, and 9 mRNAs, and a second consisted of 40 lncRNAs, 11 miRNAs, and 9 mRNAs. Finally, 6 circRNAs, 4 lncRNAs, 1 miRNA, and 4 mRNAs were randomly selected for quantitative real-time PCR verification. PCR results were further verified by Western blotting assays. These results show that the expression level of differentially-expressed RNA was consistent with the sequencing data, and the Western blotting results were highly consistent with the PCR results, confirming that the sequencing result was very reliable. This study systematically explores the ceRNA atlas of differentially-expressed genes related to B[a]P exposure in breast cancer cells, providing new insights into mechanisms of environmental pollutants in breast cancer. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Lao, Qiu-Feng AU - Lao QF AD - Guangxi Key Laboratory of Environmental Exposomics and Entire Lifecycle Heath, Guilin Medical University, Guilin 541199, Guangxi, China; School of Public Health, Guilin Medical University, Guilin 541199, Guangxi, China. FAU - Zhang, Qing-Quan AU - Zhang QQ AD - Guangxi Key Laboratory of Environmental Exposomics and Entire Lifecycle Heath, Guilin Medical University, Guilin 541199, Guangxi, China; School of Public Health, Guilin Medical University, Guilin 541199, Guangxi, China. FAU - Qiao, Zi-Peng AU - Qiao ZP AD - Guangxi Key Laboratory of Environmental Exposomics and Entire Lifecycle Heath, Guilin Medical University, Guilin 541199, Guangxi, China; School of Public Health, Guilin Medical University, Guilin 541199, Guangxi, China. FAU - Li, Sheng-le AU - Li SL AD - Guangxi Key Laboratory of Environmental Exposomics and Entire Lifecycle Heath, Guilin Medical University, Guilin 541199, Guangxi, China; School of Public Health, Guilin Medical University, Guilin 541199, Guangxi, China. FAU - Liu, Liu AU - Liu L AD - School of Pharmacy, Guilin Medical University, Guilin 541199, Guangxi, China. FAU - Martin, Francis L AU - Martin FL AD - Biocel UK Ltd, Hull HU10 6TS, UK; Department of Cellular Pathology, Blackpool Teaching Hospitals NHS Foundation Trust, Whinney Heys Road, Blackpool FY3 8NR, UK. FAU - Pang, Wei-Yi AU - Pang WY AD - Guangxi Key Laboratory of Environmental Exposomics and Entire Lifecycle Heath, Guilin Medical University, Guilin 541199, Guangxi, China; School of Public Health, Guilin Medical University, Guilin 541199, Guangxi, China; School of Humanities and Management, Guilin Medical University, Guilin 541199, Guangxi, China. Electronic address: p.weiyi@live.cn. LA - eng PT - Journal Article DEP - 20221128 PL - Netherlands TA - Sci Total Environ JT - The Science of the total environment JID - 0330500 RN - 3417WMA06D (Benzo(a)pyrene) RN - 0 (RNA, Circular) RN - 0 (RNA, Long Noncoding) RN - 0 (MicroRNAs) RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - Female MH - Benzo(a)pyrene/toxicity MH - RNA, Circular MH - *Breast Neoplasms/genetics MH - *RNA, Long Noncoding/genetics MH - Exome Sequencing MH - Gene Regulatory Networks MH - *MicroRNAs/genetics MH - RNA, Messenger/genetics MH - Transcriptome OTO - NOTNLM OT - Benzo[a]pyrene (B[a]P) OT - Breast cancer OT - RNA-seq OT - ceRNA network COIS- Declaration of competing interest The authors declare that there are no conflicts of interest. EDAT- 2022/12/02 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/12/01 19:25 PHST- 2022/03/26 00:00 [received] PHST- 2022/11/23 00:00 [revised] PHST- 2022/11/25 00:00 [accepted] PHST- 2022/12/02 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/12/01 19:25 [entrez] AID - S0048-9697(22)07667-7 [pii] AID - 10.1016/j.scitotenv.2022.160564 [doi] PST - ppublish SO - Sci Total Environ. 2023 Feb 25;861:160564. doi: 10.1016/j.scitotenv.2022.160564. Epub 2022 Nov 28. PMID- 35633055 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230124 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 1 DP - 2023 Jan TI - Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control. PG - 297-305 LID - 10.1002/cam4.4862 [doi] AB - BACKGROUND: Contemporary therapies improve breast cancer (BC) outcomes. Yet, many of these therapies have been increasingly linked with serious cardiotoxicity, including reports of profound hypertension. Yet, the incidence, predictors, and impacts of these events are largely unknown. METHODS: Leveraging two large U.S.-based registries, the National Inpatient Sample (NIS) and the Food and Drug Administration Adverse Event Reporting System (FAERS) databases, we assessed the incidence, factors, and outcomes of hypertensive events among BC patients from 2007 to 2015. Differences in baseline characteristics, hypertension-related discharges, and complications were examined over time. Further, we performed a disproportionality analysis using reporting-odds-ratios (ROR) to determine the association between individual BC drugs and hypertensive events. Utilizing an ROR cutoff of >1.0, we quantified associations by drug-class, and individual drugs with the likelihood of excess hypertension. RESULTS: Overall, there were 5,464,401 BC-admissions, of which 46,989 (0.8%) presented with hypertension. Hypertensive BC patients were older, and saw initially increased in-hospital mortality, which equilibrated over time. The mean incidence of hypertension-related admissions was 732 per 100,000 among BC patients, versus 96 per 100,000 among non-cancer patients (RR 7.71, p < 0.001). Moreover, in FAERS, those with hypertension versus other BC-treatment side-effects were more frequently hospitalized (40.1% vs. 36.7%, p < 0.001), and were most commonly associated with chemotherapy (45.9%). Outside of Eribulin (ROR 3.36; 95% CI 1.37-8.22), no specific drug was associated with a higher reporting of hypertension; however, collectively BC drugs were associated with a higher odds of hypertension (ROR 1.66; 95% CI 1.09-2.53). CONCLUSIONS: BC therapies are associated with a substantial increase in limiting hypertension. CI - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Carter, Rebecca R AU - Carter RR AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. AD - The Center for the Advancement of Team Science, Analytics, and Systems Thinking (CATALYST), Ohio State University, Columbus, Ohio, USA. FAU - Chum, Aaron P AU - Chum AP AUID- ORCID: 0000-0002-9467-6890 AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. FAU - Sanchez, Reynaldo AU - Sanchez R AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. FAU - Guha, Avirup AU - Guha A AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. AD - Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio, USA. FAU - Dey, Amit K AU - Dey AK AD - National Heart Lung and Blood Institute, Bethesda, Maryland, USA. FAU - Reinbolt, Raquel AU - Reinbolt R AUID- ORCID: 0000-0002-1250-2222 AD - Solove Research Institute, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital, Columbus, Ohio, USA. FAU - Kim, Lisa AU - Kim L AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. FAU - Otchere, Prince AU - Otchere P AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. FAU - Oppong-Nkrumah, Oduro AU - Oppong-Nkrumah O AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. FAU - Abraham, William T AU - Abraham WT AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. FAU - Lustberg, Maryam AU - Lustberg M AD - Solove Research Institute, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital, Columbus, Ohio, USA. FAU - Addison, Daniel AU - Addison D AD - Cardio-Oncology Program, Division of Cardiology, Ohio State University, Columbus, Ohio, USA. AD - Cancer Control Program, Department of Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA. LA - eng GR - K12-CA133250/Daniel Addison/ GR - Mary H. and J. Churchill Hodges Clinical Preventio/Rebecca R. Carter/ GR - Robert Wood Johnson Foundation (Harold Amos)- Amer/Daniel Addison/ GR - NH/NIH HHS/United States GR - K23 HL155890/HL/NHLBI NIH HHS/United States GR - K23-HL155890/Daniel Addison/ GR - NH/NIH HHS/United States PT - Journal Article DEP - 20220527 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - United States/epidemiology MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/epidemiology MH - Adverse Drug Reaction Reporting Systems MH - *Drug-Related Side Effects and Adverse Reactions MH - Cardiotoxicity MH - *Hypertension/chemically induced/epidemiology MH - Databases, Factual PMC - PMC9844596 OTO - NOTNLM OT - FDA adverse event reporting system OT - cardio-oncology OT - hypertension OT - national inpatient sample EDAT- 2022/05/29 06:00 MHDA- 2023/01/20 06:00 CRDT- 2022/05/28 02:13 PHST- 2022/05/03 00:00 [revised] PHST- 2021/10/05 00:00 [received] PHST- 2022/05/11 00:00 [accepted] PHST- 2022/05/29 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/05/28 02:13 [entrez] AID - CAM44862 [pii] AID - 10.1002/cam4.4862 [doi] PST - ppublish SO - Cancer Med. 2023 Jan;12(1):297-305. doi: 10.1002/cam4.4862. Epub 2022 May 27. PMID- 36403174 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1749-0774 (Electronic) IS - 0914-7470 (Linking) VI - 36 IP - 1 DP - 2023 Jan TI - Identification and validation of an m6A-related gene signature to predict prognosis and evaluate immune features of breast cancer. PG - 393-408 LID - 10.1007/s13577-022-00826-x [doi] AB - Breast cancer is the most prevalent cancer, and it is accompanied by high heterogeneity. N6-methyladenosine (m6A) modification significantly contributes to breast cancer tumorigenesis and progression. However, how m6A-related genes affect the clinical outcomes and tumor immune microenvironment (TIME) of breast cancer is largely unknown. Our study developed an m6A-related gene signature on the basis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The m6A-related gene signature was constructed using univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses. Breast cancer patients were classified into low- and high-risk groups depending on the median risk score. The reliability and efficiency of the signature were validated using Kaplan-Meier analysis, receiver operating characteristic (ROC) curves, and principal component analysis (PCA). The risk score was validated as an independent indicator associated with overall survival, and a nomogram model was created to estimate the overall survival of patients with breast cancer. Functional annotation suggested that the risk score had a strong relationship with immune-related pathways. Different proportions of immune cell infiltration between the two groups were evaluated using various algorithms. The high-risk group had higher immune checkpoint expression levels. We discovered that one of the 6 prognostic genes, TMEM71, was downregulated in breast cancer tissues. In vitro experiments indicated that overexpression of TMEM71 suppressed breast cancer cell proliferation and migration. In conclusion, the m6A-related gene signature may be a sensitive biomarker for overall survival prediction and guide the individualized treatment for breast cancer patients. CI - © 2022. The Author(s) under exclusive licence to Japan Human Cell Society. FAU - Li, Wenhao AU - Li W AD - Department of Breast Surgery, General Surgery, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, 250012, Shandong, China. FAU - Wang, Xiaolong AU - Wang X AD - Department of Breast Surgery, General Surgery, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, 250012, Shandong, China. FAU - Li, Chen AU - Li C AD - Department of Breast Surgery, General Surgery, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, 250012, Shandong, China. FAU - Chen, Tong AU - Chen T AD - Department of Breast Surgery, General Surgery, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, 250012, Shandong, China. FAU - Zhou, Xianyong AU - Zhou X AD - Department of Breast Surgery, General Surgery, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, 250012, Shandong, China. AD - Department of Breast Surgery, Binzhou People's Hospital, Binzhou, Shandong, China. FAU - Li, Zheng AU - Li Z AD - Department of Breast Surgery, General Surgery, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, 250012, Shandong, China. FAU - Yang, Qifeng AU - Yang Q AD - Department of Breast Surgery, General Surgery, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, 250012, Shandong, China. qifengy_sdu@163.com. AD - Department of Pathology Tissue Bank, Cheeloo College of Medicine, Qilu Hospital of Shandong University, Wenhua Xi Road No. 107, Jinan, 250012, Shandong, China. qifengy_sdu@163.com. AD - Research Institute of Breast Cancer, Shandong University, Wenhua Xi Road No. 107, JinanShandong, 250012, China. qifengy_sdu@163.com. LA - eng GR - No. 2020YFA0712400/National Key Research and Development Program/ GR - No. 81874119/National Natural Science Foundation of China/ GR - No. 82072912/National Natural Science Foundation of China/ GR - No. 82004122/National Natural Science Foundation of China/ GR - No. ZR2020QH335/Shandong Provincial Natural Science Foundation, China/ GR - No. ZR2019LZL003/Shandong Provincial Natural Science Foundation, China/ GR - CXPJJH121001-2021003/Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province/ GR - YXH2022ZX02160/2021 Shandong Medical Association Clinical Research Fund -- Qilu Special Project/ GR - No.2020SDUCRCA015/Foundation from Clinical Research Center of Shandong University/ GR - No. 2019-3/Qilu Hospital Clinical New Technology Developing Foundation/ GR - No. ts20190971/Special Foundation for Taishan Scholars/ GR - No. 2020M682199/China Postdoctoral Science Foundation/ PT - Journal Article DEP - 20221120 PL - Japan TA - Hum Cell JT - Human cell JID - 8912329 RN - K72T3FS567 (Adenosine) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - Reproducibility of Results MH - Adenosine MH - Algorithms MH - Carcinogenesis MH - Tumor Microenvironment/genetics OTO - NOTNLM OT - Breast cancer OT - N6-methyladenosine OT - Prognosis OT - Signature OT - Tumor immune microenvironment EDAT- 2022/11/21 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/11/20 14:00 PHST- 2022/07/25 00:00 [received] PHST- 2022/11/11 00:00 [accepted] PHST- 2022/11/21 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/11/20 14:00 [entrez] AID - 10.1007/s13577-022-00826-x [pii] AID - 10.1007/s13577-022-00826-x [doi] PST - ppublish SO - Hum Cell. 2023 Jan;36(1):393-408. doi: 10.1007/s13577-022-00826-x. Epub 2022 Nov 20. PMID- 36649275 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 1 DP - 2023 TI - Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer. PG - e0280259 LID - 10.1371/journal.pone.0280259 [doi] LID - e0280259 AB - BACKGROUND: Designing clinical trials with the emphasis on the patient-centered approach and focusing on clinical outcomes that are meaningful to patients is viewed as a priority by drug developers, regulatory agencies, payers, clinicians, and patients. This study aimed to capture information on clinical trial endpoints that would be most important and relevant for patients with advanced breast cancer, based on patient-reported outcomes. METHODS: Patients with either advanced triple-negative breast cancer [TNBC] and a maximum of two lines of systemic therapy or hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR+/HER2-] breast cancer and a maximum of three lines of systemic therapy, participated in semi-structured concept elicitation interviews. Concept saturation was assessed. A sign, symptom, or impact was defined as "salient" if mentioned by ≥ 60% of participants, with an average bother rating of ≥ 5 (0-10 Scale). Participants were also asked about treatment priorities and to evaluate hypothetical scenarios showing different health-related functioning and quality-of-life treatment outcomes, using graphical representations. RESULTS: Thirty-two participants (97% women; aged 29+ years) with TNBC (n = 17) or HR+/HER2- breast cancer (n = 15) provided generally similar reports on symptom experience, with fatigue and pain being most salient, though importance of certain treatment-related symptoms varied between the two groups. Patients reported consistent perspectives on the importance of treatment outcomes: when considering a new treatment, they prioritized efficacy of the therapy, acceptable tolerability, stability, predictability of symptoms over time, and the duration of preserved health-related quality of life and physical functioning. The meaningful difference in preserved physical functioning was 2-3 months for 46% of participants with TNBC, whereas for most participants with HR+/HER2- breast cancer it started from 6-7 months. Both groups of participants found it easier to accept some toxicity at the beginning of therapy if it was followed by improvement, as opposed to improvement followed by deterioration. CONCLUSION: The results may help to inform the design of patient-centered clinical trials, to interpret health-related quality of life and/or patient-reported outcomes, and to optimize care for patients with advanced breast cancer. CI - Copyright: © 2023 Flood et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Flood, Emuella AU - Flood E AUID- ORCID: 0000-0002-3526-9670 AD - AstraZeneca plc, Patient-Centered Science, Gaithersburg, Maryland, United States of America. FAU - Krasnow, Anna AU - Krasnow A AD - IQVIA Real World Solutions, Patient-Centered Solutions, London, United Kingdom. FAU - Orbegoso, Cecilia AU - Orbegoso C AD - AstraZeneca plc, R&D Oncology, Cambridge, United Kingdom. FAU - Karantzoulis, Stella AU - Karantzoulis S AD - IQVIA Real World Solutions, Patient-Centered Solutions, New York, New York, United States of America. FAU - Bailey, Julie AU - Bailey J AD - IQVIA Real World Solutions, Patient-Centered Solutions, New York, New York, United States of America. FAU - Bayet, Solène AU - Bayet S AD - IQVIA Real World Solutions, Patient-Centered Solutions, Courbevoie, France. FAU - Elghouayel, Arthur AU - Elghouayel A AD - IQVIA Real World Solutions, Patient-Centered Solutions, New York, New York, United States of America. FAU - Foxley, Andrew AU - Foxley A AD - AstraZeneca plc, R&D Oncology, Cambridge, United Kingdom. FAU - Sommavilla, Roberto AU - Sommavilla R AD - AstraZeneca plc, R&D Oncology, Cambridge, United Kingdom. FAU - Schiavon, Gaia AU - Schiavon G AD - AstraZeneca plc, R&D Oncology, Cambridge, United Kingdom. LA - eng PT - Journal Article DEP - 20230117 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Female MH - Humans MH - Male MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Breast Neoplasms/drug therapy/metabolism MH - Patient Reported Outcome Measures MH - Quality of Life MH - Receptor, ErbB-2/metabolism MH - Treatment Outcome MH - *Triple Negative Breast Neoplasms/drug therapy MH - Adult PMC - PMC9844842 COIS- EF, AF, and GS are employees of AstraZeneca and AstraZeneca shareholders; RS is an employee of AstraZeneca and has AstraZeneca stock options; AK, SK, JB, SB, and AE received consultancy fees from AstraZeneca (paid to IQVIA). This does not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2023/01/18 06:00 MHDA- 2023/01/20 06:00 CRDT- 2023/01/17 13:43 PHST- 2022/02/01 00:00 [received] PHST- 2022/12/23 00:00 [accepted] PHST- 2023/01/17 13:43 [entrez] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] AID - PONE-D-22-03215 [pii] AID - 10.1371/journal.pone.0280259 [doi] PST - epublish SO - PLoS One. 2023 Jan 17;18(1):e0280259. doi: 10.1371/journal.pone.0280259. eCollection 2023. PMID- 36613590 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 1 DP - 2022 Dec 21 TI - Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis. LID - 10.3390/ijms24010146 [doi] LID - 146 AB - Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, invasive procedures are still required for diagnosis. Herein, we developed a novel ultrasensitive pipeline to detect circulating tumor DNA (ctDNA) in a series of 75 plasma samples from localized BC patients prior to any medical intervention. We first performed a tumor-informed analysis to correlate the mutations found in tumor tissue and plasma. Disregarding the tumor data next, we developed an approach to detect tumor mutations in plasma. We observed a mutation concordance between the tumor and plasma of 29.50% with a sensitivity down to 0.03% in mutant variant allele frequency (VAF). We detected mutations in 33.78% of the samples, identifying eight patients with plasma-only mutations. Altogether, we determined a specificity of 86.36% and a positive predictive value of 88.46% for BC detection. We demonstrated an association between higher ctDNA median VAF and higher tumor grade, multiple plasma mutations with a likelihood of relapse and more frequent TP53 plasma mutations in hormone receptor-negative tumors. Overall, we have developed a unique ultra-sensitive sequencing workflow with a technology not previously employed in early BC, paving the way for its application in BC screening. FAU - Jiménez-Rodríguez, Begoña AU - Jiménez-Rodríguez B AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC-CB16/12/00481), 28029 Madrid, Spain. FAU - Alba-Bernal, Alfonso AU - Alba-Bernal A AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Andalusia-Roche Network in Precision Medical Oncology, 41092 Sevilla, Spain. FAU - López-López, Esperanza AU - López-López E AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. FAU - Quirós-Ortega, María Elena AU - Quirós-Ortega ME AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Andalusia-Roche Network in Precision Medical Oncology, 41092 Sevilla, Spain. FAU - Carbajosa, Guillermo AU - Carbajosa G AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Department of Surgical Specialties, Biochemical and Immunology, Faculty of Medicine, University of Málaga, 29071 Malaga, Spain. FAU - Garrido-Aranda, Alicia AU - Garrido-Aranda A AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Andalusia-Roche Network in Precision Medical Oncology, 41092 Sevilla, Spain. FAU - Álvarez, Martina AU - Álvarez M AUID- ORCID: 0000-0002-0303-2871 AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC-CB16/12/00481), 28029 Madrid, Spain. AD - Andalusia-Roche Network in Precision Medical Oncology, 41092 Sevilla, Spain. AD - Department of Surgical Specialties, Biochemical and Immunology, Faculty of Medicine, University of Málaga, 29071 Malaga, Spain. FAU - Godoy-Ortiz, Ana AU - Godoy-Ortiz A AUID- ORCID: 0000-0002-5503-6946 AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC-CB16/12/00481), 28029 Madrid, Spain. FAU - Queipo-Ortuño, María Isabel AU - Queipo-Ortuño MI AUID- ORCID: 0000-0002-2867-0845 AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Andalusia-Roche Network in Precision Medical Oncology, 41092 Sevilla, Spain. AD - Department of Surgical Specialties, Biochemical and Immunology, Faculty of Medicine, University of Málaga, 29071 Malaga, Spain. FAU - Vicioso, Luis AU - Vicioso L AD - Faculty of Medicine, University of Málaga, 29010 Malaga, Spain. AD - Histopathology Department, Hospital Clínico Universitario Virgen de la Victoria de Malaga, 29010 Malaga, Spain. FAU - Díaz-Córdoba, Gema AU - Díaz-Córdoba G AD - Radiology Department, Hospital Clínico Universitario Virgen de la Victoria de Málaga, 29010 Malaga, Spain. FAU - Roldán-Díaz, María Dunia AU - Roldán-Díaz MD AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. FAU - Velasco-Suelto, Jesús AU - Velasco-Suelto J AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. FAU - Hernando, Cristina AU - Hernando C AUID- ORCID: 0000-0002-6865-4196 AD - Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, 46010 Valencia, Spain. FAU - Bermejo, Begoña AU - Bermejo B AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC-CB16/12/00481), 28029 Madrid, Spain. AD - Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, 46010 Valencia, Spain. FAU - Julve-Parreño, Ana AU - Julve-Parreño A AUID- ORCID: 0000-0001-5185-9411 AD - Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, 46010 Valencia, Spain. FAU - Lluch, Ana AU - Lluch A AD - Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, 46010 Valencia, Spain. FAU - Pascual, Javier AU - Pascual J AUID- ORCID: 0000-0003-3874-2782 AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC-CB16/12/00481), 28029 Madrid, Spain. AD - Andalusia-Roche Network in Precision Medical Oncology, 41092 Sevilla, Spain. FAU - Comino-Méndez, Iñaki AU - Comino-Méndez I AUID- ORCID: 0000-0003-1926-9432 AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC-CB16/12/00481), 28029 Madrid, Spain. AD - Andalusia-Roche Network in Precision Medical Oncology, 41092 Sevilla, Spain. FAU - Alba, Emilio AU - Alba E AD - Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Malaga, Spain. AD - The Biomedical Research Institute of Málaga (IBIMA-CIMES-UMA), 29010 Malaga, Spain. AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC-CB16/12/00481), 28029 Madrid, Spain. AD - Andalusia-Roche Network in Precision Medical Oncology, 41092 Sevilla, Spain. AD - Faculty of Medicine, University of Málaga, 29010 Malaga, Spain. LA - eng GR - Postdoctoral Fellowship/Asociación Española Contra el Cáncer/ GR - PI-0291-2019/Consejería de Salud y Familias/ GR - Alba-Bernal´s contract/Fundación Unicaja/ GR - Quirós-Ortega´s contract/Andalusia-Roche Network in Precision Medical Oncology/ GR - Ayudas María Zambrano para la atracción de talento internacional - Universidad de Málaga/University of Malaga/ PT - Journal Article DEP - 20221221 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Circulating Tumor DNA) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Circulating Tumor DNA/genetics MH - *Breast Neoplasms/diagnosis/genetics MH - Neoplasm Recurrence, Local/genetics MH - Mutation MH - Biomarkers, Tumor/genetics MH - High-Throughput Nucleotide Sequencing/methods PMC - PMC9820510 OTO - NOTNLM OT - circulating tumor DNA OT - early breast cancer OT - liquid biopsy OT - ultra-deep sequencing COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:20 PHST- 2022/11/15 00:00 [received] PHST- 2022/12/15 00:00 [revised] PHST- 2022/12/17 00:00 [accepted] PHST- 2023/01/08 01:20 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - ijms24010146 [pii] AID - ijms-24-00146 [pii] AID - 10.3390/ijms24010146 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 21;24(1):146. doi: 10.3390/ijms24010146. PMID- 36316969 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1099-1611 (Electronic) IS - 1057-9249 (Linking) VI - 32 IP - 1 DP - 2023 Jan TI - Effect of a novel pilot support group on distress and quality of life in breast cancer patients in Nigeria. PG - 133-138 LID - 10.1002/pon.6062 [doi] AB - OBJECTIVE: To assess the effect of a new breast cancer support group (BCSG) on breast cancer patients' self-reported distress and quality of life. METHODS: A single arm pre-post trial providing an eight session healthcare provider led BCSG. Primary outcome variables were distress and quality of life assessed using the National Comprehensive Cancer Network Distress Thermometer (DT) and The Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4), respectively. Topics in each session addressed a wide range of issues some of which were pre-selected by the patients themselves. DATA ANALYSIS: Paired sample t-test was used for data analysis on International Business Machine Statistical Package for the Social Sciences 21. RESULTS: The participants (N = 18) had a mean age of 51. Most had secondary school level education (54%), were traders (59%) and had stage 3 or 4 disease (67%). A larger proportion (78% or n = 14) of the patients lived in rural areas, while 4 (22%) of the patients lived in Ibadan. Out of the 8 sessions, 12 (67%) of the participants attended 1-3 sessions while 6 (33%) attended 4-8 sessions. There were, significant improvements in emotional wellbeing (t = -4.253; p < 0.05) and functional wellbeing (t = -2.191; p < 0.05) on the FACT-B+4. There was a significant reduction in the DT score (t = 2.345; p < 0.05) but the number of items on the problem list were not significantly reduced (t = 1.191; p > 0.05). Majority (75%) of the patients rated the support group activities as satisfactory. CONCLUSION: These data show that the support group can benefit breast cancer patients in terms of reduced distress levels along with satisfaction and improvement in the functional and emotional wellbeing indices of quality of life. CI - © 2022 John Wiley & Sons Ltd. FAU - Asuzu, Chioma C AU - Asuzu CC AUID- ORCID: 0000-0002-9975-2928 AD - Department of Radiation Oncology, University of Ibadan, Ibadan, Nigeria. AD - Department of Counselling and Human Development Studies, University of Ibadan, Ibadan, Nigeria. FAU - Akin-Odanye, Elizabeth O AU - Akin-Odanye EO AD - Department of Clinical Psychology, University College Hospital, Ibadan, Nigeria. FAU - Asuzu, Michael C AU - Asuzu MC AD - Department of Community Medicine, University of Ibadan, Ibadan, Nigeria. FAU - Adedokun, Tunde AU - Adedokun T AD - Centre for Observational Research, Amgen, Califonia, USA. FAU - Ntekem, Atara AU - Ntekem A AD - Department of Radiation Oncology, University of Ibadan, Ibadan, Nigeria. FAU - Ogundiran, Temidayo AU - Ogundiran T AD - Department of Surgery, University of Ibadan, Ibadan, Nigeria. FAU - Henry, Mellissa AU - Henry M AD - Department of Oncology, McGill University, Montreal, Quebec, Canada. FAU - Watson, Maggie AU - Watson M AD - University College, London, UK. LA - eng GR - Union for International Cancer Control/ PT - Journal Article DEP - 20221111 PL - England TA - Psychooncology JT - Psycho-oncology JID - 9214524 SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Breast Neoplasms/therapy/psychology MH - Quality of Life/psychology MH - Nigeria MH - Self-Help Groups MH - Health Services MH - Stress, Psychological/therapy/psychology OTO - NOTNLM OT - Nigeria OT - breast cancer OT - distress OT - psycho-oncology OT - psychosocial OT - quality of life OT - support group EDAT- 2022/11/02 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/11/01 01:32 PHST- 2022/10/23 00:00 [revised] PHST- 2022/05/17 00:00 [received] PHST- 2022/10/26 00:00 [accepted] PHST- 2022/11/02 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/11/01 01:32 [entrez] AID - 10.1002/pon.6062 [doi] PST - ppublish SO - Psychooncology. 2023 Jan;32(1):133-138. doi: 10.1002/pon.6062. Epub 2022 Nov 11. PMID- 36571841 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1539-3704 (Electronic) IS - 0003-4819 (Linking) VI - 176 IP - 1 DP - 2023 Jan TI - Assessing Performance and Clinical Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox Proportional Hazards Models. PG - 105-114 LID - 10.7326/M22-0844 [doi] AB - Risk prediction models need thorough validation to assess their performance. Validation of models for survival outcomes poses challenges due to the censoring of observations and the varying time horizon at which predictions can be made. This article describes measures to evaluate predictions and the potential improvement in decision making from survival models based on Cox proportional hazards regression. As a motivating case study, the authors consider the prediction of the composite outcome of recurrence or death (the "event") in patients with breast cancer after surgery. They developed a simple Cox regression model with 3 predictors, as in the Nottingham Prognostic Index, in 2982 women (1275 events over 5 years of follow-up) and externally validated this model in 686 women (285 events over 5 years). Improvement in performance was assessed after the addition of progesterone receptor as a prognostic biomarker. The model predictions can be evaluated across the full range of observed follow-up times or for the event occurring by the end of a fixed time horizon of interest. The authors first discuss recommended statistical measures that evaluate model performance in terms of discrimination, calibration, or overall performance. Further, they evaluate the potential clinical utility of the model to support clinical decision making according to a net benefit measure. They provide SAS and R code to illustrate internal and external validation. The authors recommend the proposed set of performance measures for transparent reporting of the validity of predictions from survival models. FAU - McLernon, David J AU - McLernon DJ AUID- ORCID: 0000-0001-8905-2429 AD - Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom (D.J.M.). FAU - Giardiello, Daniele AU - Giardiello D AUID- ORCID: 0000-0002-9005-9430 AD - Netherlands Cancer Institute, Amsterdam, the Netherlands, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands, and Institute of Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Bolzano, Italy (D.G.). FAU - Van Calster, Ben AU - Van Calster B AUID- ORCID: 0000-0003-1613-7450 AD - Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands, and Department of Development and Regeneration, Katholieke Universiteit Leuven, Leuven, Belgium (B.V.). FAU - Wynants, Laure AU - Wynants L AUID- ORCID: 0000-0002-3037-122X AD - School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands (L.W.). FAU - van Geloven, Nan AU - van Geloven N AUID- ORCID: 0000-0002-5600-9093 AD - Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (N.V., E.W.S.). FAU - van Smeden, Maarten AU - van Smeden M AUID- ORCID: 0000-0002-5529-1541 AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands (M.V.). FAU - Therneau, Terry AU - Therneau T AUID- ORCID: 0000-0003-1490-6711 AD - Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota (T.T.). FAU - Steyerberg, Ewout W AU - Steyerberg EW AUID- ORCID: 0000-0002-7787-0122 AD - Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands (N.V., E.W.S.). CN - topic groups 6 and 8 of the STRATOS Initiative LA - eng PT - Journal Article DEP - 20221227 PL - United States TA - Ann Intern Med JT - Annals of internal medicine JID - 0372351 SB - IM MH - Humans MH - Female MH - Proportional Hazards Models MH - *Breast Neoplasms MH - Prognosis FIR - McLernon, David J IR - McLernon DJ FIR - Giardiello, Daniele IR - Giardiello D FIR - Van Calster, Ben IR - Van Calster B FIR - Wynants, Laure IR - Wynants L FIR - van Geloven, Nan IR - van Geloven N FIR - van Smeden, Maarten IR - van Smeden M FIR - Therneau, Terry IR - Therneau T FIR - Steyerberg, Ewout W IR - Steyerberg EW FIR - Bossuyt, Patrick IR - Bossuyt P FIR - Boyles, Tom IR - Boyles T FIR - Collins, Gary IR - Collins G FIR - Karr, Kathleen IR - Karr K FIR - Macaskill, Petra IR - Macaskill P FIR - Moons, Carl IR - Moons C FIR - Vickers, Andrew IR - Vickers A FIR - Westphal, Max IR - Westphal M FIR - Abrahamowicz, Michal IR - Abrahamowicz M FIR - Gorfine, Malka IR - Gorfine M FIR - Ambrogi, Federico IR - Ambrogi F FIR - Cook, Richard IR - Cook R FIR - Joly, Pierre IR - Joly P FIR - Andersen, Per Kragh IR - Andersen PK FIR - Martinussen, Torben IR - Martinussen T FIR - Pohar-Perme, Maja IR - Pohar-Perme M FIR - Putter, Hein IR - Putter H FIR - Taylor, Jeremy IR - Taylor J EDAT- 2022/12/27 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/12/26 17:02 PHST- 2022/12/27 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/12/26 17:02 [entrez] AID - 10.7326/M22-0844 [doi] PST - ppublish SO - Ann Intern Med. 2023 Jan;176(1):105-114. doi: 10.7326/M22-0844. Epub 2022 Dec 27. PMID- 35244958 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230111 IS - 1098-2752 (Electronic) IS - 0738-1085 (Linking) VI - 43 IP - 1 DP - 2023 Jan TI - Treatment of multiple limb lymphedema with combined supermicrosurgical techniques. PG - 13-19 LID - 10.1002/micr.30878 [doi] AB - INTRODUCTION: Lymphedema surgery including lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT) are effective treatments for lymphedema; however, treating multiple limbs in a single operation using both approaches has not been described. We hypothesize multiple limb lymphedema can be treated effectively in one operation. PATIENT AND METHODS: Retrospective review of seven patients undergoing extreme lymphedema surgery (mean age: 53.2 years; range: 33-66 years) with an average BMI of 34.8 kg/m(2) (range: 17.6-53.6 kg/m(2) ). Two patients developed bilateral upper extremity (UE) lymphedema secondary to breast cancer treatment, three had bilateral lower extremity (LE) lymphedema, and two suffered from lymphedema of all four extremities due to breast cancer treatment. RESULTS: One patient with bilateral UE lymphedema was treated with bilateral inguinal node transfers with LVA and the other with combined bilateral DIEP flaps and inguinal node transfers with LVA. Three patients had bilateral LE lymphedema: two were treated with split omental/gastroepiploic nodes, and one underwent simultaneous supraclavicular and submental node transfers. LVAs were performed in one leg in each patient. Two patients with four-limb lymphedema underwent bilateral inguinal node transfers with DIEP flaps and bilateral LE LVA. In total, there were eight UE and 10 LE treated. Average follow-up was 15.8 months (range: 12.6-28.4 months), all patients reported subjective improvement in symptoms, were able to decrease use of compression garments and pumps, and no patients developed cellulitis. CONCLUSION: Patients suffering from lymphedema of multiple extremities can be treated safely and effectively combining both LVA and VLNT in a single operation. CI - © 2022 Wiley Periodicals LLC. FAU - Chu, Carrie K AU - Chu CK AUID- ORCID: 0000-0002-7317-4779 AD - Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Hanasono, Matthew M AU - Hanasono MM AD - Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. FAU - Chang, Edward I AU - Chang EI AUID- ORCID: 0000-0003-1067-9750 AD - Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. LA - eng PT - Journal Article DEP - 20220304 PL - United States TA - Microsurgery JT - Microsurgery JID - 8309230 SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Lymphedema/etiology/surgery/pathology MH - Treatment Outcome MH - *Mammaplasty MH - *Breast Neoplasms/complications/surgery MH - Upper Extremity/surgery MH - Lymph Nodes/surgery MH - *Lymphatic Vessels/surgery/pathology MH - Anastomosis, Surgical/methods EDAT- 2022/03/05 06:00 MHDA- 2023/01/12 06:00 CRDT- 2022/03/04 12:19 PHST- 2022/01/01 00:00 [revised] PHST- 2021/07/04 00:00 [received] PHST- 2022/02/24 00:00 [accepted] PHST- 2022/03/05 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] PHST- 2022/03/04 12:19 [entrez] AID - 10.1002/micr.30878 [doi] PST - ppublish SO - Microsurgery. 2023 Jan;43(1):13-19. doi: 10.1002/micr.30878. Epub 2022 Mar 4. PMID- 36331686 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer. PG - 103-112 LID - 10.1007/s10549-022-06776-0 [doi] AB - PURPOSE: This study investigates the impact of different subtypes of pathogenic BRCA variants on the prognosis and on the survival of breast cancer (BC) patients. METHODS: Associations between BRCA1/2 pathogenic variants (PVs) mutations, clinicopathological features, locoregional tumor reappearance, and survival data were analyzed. The Gray's test was used to test difference of the cumulative incidence of local relapse between missense/splicing and other mutations, taking into of competing events. The multivariate proportional hazard model was used to assess the independent association between type of mutation and local relapse, after adjustment for other prognostic factors and clinicopathological characteristics. RESULTS: Out of 482 patients, 285 presented 98 different BRCA1 PVs and 201 harbored 103 different BRCA2 PVs. Missense mutations were found in 46 BC patients (9.5%), splicing mutations in 42 (8.6%), deletions in 206 (42.4%), insertions in 73 (15%), indel mutations in 6 (1.2%), nonsense mutations in 86 (17.7%), and large rearrangements in 27 (5.6%). Kalbfleisch and Prentice cumulative incidence curves analysis showed a significantly lower locoregional recurrence incidence in the missense/splicing group (Gray-test P-value = 0.011). We found that the risk of local relapse was 58% less likely in women carrying missense/splicing variants than in those with other PV subtypes (HR 95% CI 0.42 [0.21-0.82]; P-value = 0.0108). No significant differences were observed in overall survival (OS) in all groups. CONCLUSIONS: Having been found to be associated with a lower risk of BC reappearance, germline BRCA1/2 PVs of the missense/splicing subtypes can be used as prognostic predictors and are likely to improve BC patients' management. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Corso, Giovanni AU - Corso G AUID- ORCID: 0000-0002-9269-0146 AD - Division of Breast Surgery, IEO, European Institute of Oncology, IRCCS, Via Ripamonti, 435, 20141, Milan, Italy. giovanni.corso@ieo.it. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. giovanni.corso@ieo.it. AD - European Cancer Prevention Organization (ECP), Milan, Italy. giovanni.corso@ieo.it. FAU - Girardi, Antonia AU - Girardi A AD - Division of Breast Surgery, IEO, European Institute of Oncology, IRCCS, Via Ripamonti, 435, 20141, Milan, Italy. FAU - Calvello, Mariarosaria AU - Calvello M AD - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy. mariarosaria.calvello@ieo.it. FAU - Gandini, Sara AU - Gandini S AD - Division of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Gaeta, Aurora AU - Gaeta A AD - Division of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Marabelli, Monica AU - Marabelli M AD - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Magnoni, Francesca AU - Magnoni F AD - Division of Breast Surgery, IEO, European Institute of Oncology, IRCCS, Via Ripamonti, 435, 20141, Milan, Italy. FAU - Veronesi, Paolo AU - Veronesi P AD - Division of Breast Surgery, IEO, European Institute of Oncology, IRCCS, Via Ripamonti, 435, 20141, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Guerrieri-Gonzaga, Aliana AU - Guerrieri-Gonzaga A AD - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy. FAU - Bonanni, Bernardo AU - Bonanni B AD - Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy. LA - eng PT - Journal Article DEP - 20221104 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (BRCA1 Protein) RN - 0 (BRCA2 Protein) RN - 0 (BRCA1 protein, human) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Prognosis MH - Neoplasm Recurrence, Local/genetics/pathology MH - BRCA1 Protein/genetics MH - BRCA2 Protein/genetics MH - Germ-Line Mutation MH - Germ Cells MH - Genetic Predisposition to Disease OTO - NOTNLM OT - BRCA1 OT - BRCA2 OT - Breast cancer prognosis OT - Germline mutations OT - Hereditary breast cancer EDAT- 2022/11/05 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/04 12:18 PHST- 2022/07/29 00:00 [received] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/11/05 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/04 12:18 [entrez] AID - 10.1007/s10549-022-06776-0 [pii] AID - 10.1007/s10549-022-06776-0 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):103-112. doi: 10.1007/s10549-022-06776-0. Epub 2022 Nov 4. PMID- 36376237 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1938-0666 (Electronic) IS - 1526-8209 (Linking) VI - 23 IP - 1 DP - 2023 Jan TI - Benefits of Homeopathic Complementary Treatment in Patients With Breast Cancer: A Retrospective Cohort Study Based on the French Nationwide Healthcare Database. PG - 60-70 LID - S1526-8209(22)00224-5 [pii] LID - 10.1016/j.clbc.2022.10.001 [doi] AB - BACKGROUND: Complementary therapy in oncology aims to help patients better cope with the illness and side effects (SEs) of cancer treatments that affect their quality of life (QOL). This study aimed to assess the benefits of homeopathic treatment on the health-related QOL (HRQOL) of patients with non-metastatic breast cancer (BC) prescribed in postsurgical complementary therapy. PATIENTS AND METHODS: An extraction from the French nationwide healthcare database targeted all patients who underwent mastectomy for newly diagnosed BC between 2012 and 2013. HRQOL was proxied by the quantity of medication used to palliate the SEs of cancer treatments. RESULTS: A total of 98,009 patients were included (mean age: 61 ± 13 years). Homeopathy was used in 11%, 26%, and 22% of patients respectively during the 7 to 12 months before surgery, the 6 months before, and 6 months after. Thereafter, the use remained stable at 15% for 4 years. Six months after surgery, there was a significant overall decrease (RR = 0.88, confidence interval (CI)(95) = 0.87-0.89) in the dispensing of medication associated with SEs in patients treated with ≥ 3 dispensing of homeopathy compared to none. The decrease appeared to be greater for immunostimulants (RR = 0.79, (CI)(95) = 0.74-0.84), corticosteroids (RR = 0.82, (CI)(95) = 0.79-0.85), and antidiarrheals (RR = 0.83, (CI)(95) = 0.77-0.88). CONCLUSION: The study showed an increasing use of homeopathy in patients with BC following diagnosis. This use was maintained after surgery and seemed to play a role in helping patients to better tolerate the SEs of cancer treatments. CI - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Medioni, Jacques AU - Medioni J AD - APHP Hôpital Européen Georges Pompidou, Paris, France; Université Paris Cité, Paris, France. FAU - Scimeca, Daniel AU - Scimeca D AD - Maisons-Alfort, France. FAU - Marquez, Yecenia Lopez AU - Marquez YL AD - Service d'Hépatogastroentérologie, Hôpital de la Croix Rousse, Lyon, France. FAU - Leray, Emmanuelle AU - Leray E AD - Univ Rennes, EHESP, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, F-35000 Rennes, France. FAU - Dalichampt, Marie AU - Dalichampt M AD - Nantes, France. FAU - Hoertel, Nicolas AU - Hoertel N AD - Université Paris Cité, Paris, France; APHP Corentin Celton, Paris, France. FAU - Bennani, Mohammed AU - Bennani M AD - Qualees, Paris, France. Electronic address: mohammed.bennani@qualees.com. FAU - Trempat, Pascal AU - Trempat P AD - Boiron, Messimy, France. FAU - Boujedaini, Naoual AU - Boujedaini N AD - Boiron, Messimy, France. LA - eng PT - Journal Article DEP - 20221008 PL - United States TA - Clin Breast Cancer JT - Clinical breast cancer JID - 100898731 SB - IM MH - Humans MH - Middle Aged MH - Aged MH - Female MH - *Homeopathy/adverse effects MH - *Breast Neoplasms/therapy/etiology MH - Quality of Life MH - Retrospective Studies MH - Mastectomy/adverse effects MH - Delivery of Health Care OTO - NOTNLM OT - Breast cancer OT - Complementary therapy OT - HRQOL OT - Homeopathy OT - Quality of life EDAT- 2022/11/15 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/14 22:08 PHST- 2022/02/24 00:00 [received] PHST- 2022/09/21 00:00 [revised] PHST- 2022/10/01 00:00 [accepted] PHST- 2022/11/15 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/14 22:08 [entrez] AID - S1526-8209(22)00224-5 [pii] AID - 10.1016/j.clbc.2022.10.001 [doi] PST - ppublish SO - Clin Breast Cancer. 2023 Jan;23(1):60-70. doi: 10.1016/j.clbc.2022.10.001. Epub 2022 Oct 8. PMID- 36647026 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230120 IS - 1755-8794 (Electronic) IS - 1755-8794 (Linking) VI - 16 IP - 1 DP - 2023 Jan 16 TI - Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study. PG - 7 LID - 10.1186/s12920-023-01437-7 [doi] LID - 7 AB - BACKGROUND AND PURPOSE: Over the last decade, the implementation of multigene panels for hereditary tumor syndrome has increased at our institution (Inselspital, University Hospital Berne, Switzerland). The aim of this study was to determine the prevalence of variants of unknown significance (VUS) in patients with suspected Lynch syndrome and suspected hereditary breast and ovarian cancer syndrome, the latter in connection with the trend toward ordering larger gene panels. RESULTS: Retrospectively collected data from 1057 patients at our institution showed at least one VUS in 126 different cases (11.9%). In patients undergoing genetic testing for BRCA1/2, the prevalence of VUS was 6%. When < 10 additional genes were tested in addition to BRCA1/2, the prevalence increased to 13.8%, and 31.8% for > 10 additional genes, respectively. The gene most frequently affected with a VUS was ATM. 6% of our patients who were tested for Lynch syndrome had a VUS result in either MLH1, MSH2 or MSH6. CONCLUSIONS: Our data demonstrate that panel testing statistically significantly increases VUS rates due to variants in non-BRCA genes. Good genetic counseling before and after obtaining results is therefore particularly important when conducting multigene panels to minimize patient uncertainty due to VUS results. CI - © 2023. The Author(s). FAU - Adam, Felicia AU - Adam F AD - Medical Faculty of the University of Bern, Bern, Switzerland. FAU - Fluri, Muriel AU - Fluri M AD - Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Scherz, Amina AU - Scherz A AD - Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Rabaglio, Manuela AU - Rabaglio M AD - Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. manuela.rabaglio@insel.ch. LA - eng PT - Journal Article PT - Review DEP - 20230116 PL - England TA - BMC Med Genomics JT - BMC medical genomics JID - 101319628 SB - IM MH - Humans MH - Female MH - Retrospective Studies MH - *Colorectal Neoplasms, Hereditary Nonpolyposis/genetics MH - *Hereditary Breast and Ovarian Cancer Syndrome/genetics MH - Clinical Relevance MH - Genetic Predisposition to Disease MH - Genetic Testing/methods MH - *Breast Neoplasms/genetics MH - *Ovarian Neoplasms/genetics MH - Observational Studies as Topic PMC - PMC9843935 OTO - NOTNLM OT - BRCA1 OT - BRCA2 OT - Hereditary breast and ovarian cancer OT - Lynch syndrome OT - MMR genes OT - Multigene panel OT - VUS COIS- The authors declare that they have no competing interests. EDAT- 2023/01/17 06:00 MHDA- 2023/01/19 06:00 CRDT- 2023/01/16 23:34 PHST- 2022/07/25 00:00 [received] PHST- 2023/01/09 00:00 [accepted] PHST- 2023/01/16 23:34 [entrez] PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] AID - 10.1186/s12920-023-01437-7 [pii] AID - 1437 [pii] AID - 10.1186/s12920-023-01437-7 [doi] PST - epublish SO - BMC Med Genomics. 2023 Jan 16;16(1):7. doi: 10.1186/s12920-023-01437-7. PMID- 36401659 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1432-0843 (Electronic) IS - 0344-5704 (Linking) VI - 91 IP - 1 DP - 2023 Jan TI - Incidence and risk factors of infusion reactions in patients with breast cancer administered trastuzumab plus pertuzumab-based regimen. PG - 25-31 LID - 10.1007/s00280-022-04492-6 [doi] AB - PURPOSE: Pertuzumab (Per) is a humanized monoclonal antibody used in combination with trastuzumab (Tra) in the treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. The administration of biologics, such as Tra and Per, frequently causes infusion reactions (IRs) with fever and chills. This study aimed to clarify the characteristics of and risk factors for IRs in Tra + Per combination therapy. METHODS: Between March 2013 and December 2019, 64 patients with breast cancer who started Tra + Per combination therapy were included in the study. The severity of IRs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. RESULTS: The incidence of IRs in the Tra + Per combination therapy was 48.4% (31/64). The severity of IRs in the Tra + Per combination therapy was Grade 1 (9 patients) and Grade 2 (22 patients). Lymphocyte counts were significantly different between the IR and non-IR groups in patients receiving Tra + Per combination therapy (univariate analysis, p = 0.006; multivariate analysis, p = 0.050). ROC curve analysis found the cutoff value of lymphocyte counts were 1.60 (× 10(3)/µL). The incidence of IRs in the lymphocyte counts ≥ 1.60 group was significantly higher than that in the lymphocyte counts < 1.60 group (p < 0.001). CONCLUSION: Our study indicates that the severity of IRs in most patients is moderate or less and the risk of IRs is higher in patients with higher lymphocyte counts (≥ 1.60 × 10(3)/µL). CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Tabuchi, Yusuke AU - Tabuchi Y AD - Department of Pharmacy, University Hospital, Kyoto Prefectural University of Medicine, Kajii-Cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, 602-8566, Japan. y-tabu@koto.kpu-m.ac.jp. AD - Department of Clinical Pharmacy, Kyoto Pharmaceutical University, Kyoto, Japan. y-tabu@koto.kpu-m.ac.jp. FAU - Tsujimoto, Masayuki AU - Tsujimoto M AD - Department of Clinical Pharmacy, Kyoto Pharmaceutical University, Kyoto, Japan. FAU - Yamamoto, Kosuke AU - Yamamoto K AD - Department of Pharmacy, University Hospital, North Medical Center Kyoto Prefectural University of Medicine, Kyoto, Japan. FAU - Kosaka, Tadashi AU - Kosaka T AD - Department of Pharmacy, University Hospital, Kyoto Prefectural University of Medicine, Kajii-Cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, 602-8566, Japan. FAU - Sakaguchi, Koichi AU - Sakaguchi K AD - Department of Endocrine and Breast Surgery, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan. FAU - Dobuchi, Naoya AU - Dobuchi N AD - Department of Pharmacy, University Hospital, North Medical Center Kyoto Prefectural University of Medicine, Kyoto, Japan. FAU - Nishiguchi, Kohshi AU - Nishiguchi K AD - Department of Clinical Pharmacy, Kyoto Pharmaceutical University, Kyoto, Japan. FAU - Shikata, Keisuke AU - Shikata K AUID- ORCID: 0000-0002-7601-2185 AD - Department of Pharmacy, University Hospital, Kyoto Prefectural University of Medicine, Kajii-Cho, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, 602-8566, Japan. LA - eng PT - Journal Article DEP - 20221119 PL - Germany TA - Cancer Chemother Pharmacol JT - Cancer chemotherapy and pharmacology JID - 7806519 RN - P188ANX8CK (Trastuzumab) RN - K16AIQ8CTM (pertuzumab) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - Trastuzumab MH - *Breast Neoplasms/drug therapy/metabolism MH - Incidence MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Receptor, ErbB-2/metabolism MH - Risk Factors OTO - NOTNLM OT - Breast cancer OT - Infusion reaction OT - Pertuzumab OT - Risk factor EDAT- 2022/11/20 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/11/19 11:14 PHST- 2022/06/17 00:00 [received] PHST- 2022/11/07 00:00 [accepted] PHST- 2022/11/20 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/11/19 11:14 [entrez] AID - 10.1007/s00280-022-04492-6 [pii] AID - 10.1007/s00280-022-04492-6 [doi] PST - ppublish SO - Cancer Chemother Pharmacol. 2023 Jan;91(1):25-31. doi: 10.1007/s00280-022-04492-6. Epub 2022 Nov 19. PMID- 36398879 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230125 IS - 1549-490X (Electronic) IS - 1083-7159 (Print) IS - 1083-7159 (Linking) VI - 28 IP - 1 DP - 2023 Jan 18 TI - Physical Activity Intervention in Patients with Metastatic Breast Cancer During Active Treatment: Quality of Life and Function. PG - 84-e70 LID - 10.1093/oncolo/oyac232 [doi] AB - BACKGROUND: In this study, we explore recruitment, retention, and potential quality of life (QoL) and function benefits from a self-directed, home-based walking intervention in women during active treatment for metastatic breast cancer (MBC). METHODS: In this single-arm pilot study, women with stage IV BC wore an activity tracker (FitbitTM) to measure steps per week throughout the intervention study. Participants were asked to walk 150 min per week at a comfortable and safe pace. Patient-reported outcome measures (PRO) were collected at baseline and follow-up. RESULTS: Target recruitment of 60 patients was achieved. In 52 patients who completed all baseline measures, mean age was 55 (SD 11.1), 23% were pre-menopausal, and 19% non-White. Forty patients (77%) were retained at 3 months and 29 (56%) at 6 months. Baseline walking was the strongest predictor of retention at 3 months (P = .02). For 24 patients (46%) with analyzable Fitbit data at 3 months, mean steps/week rose from 19,175 to 31,306. Higher number of steps correlated with larger improvements FACT-G General well-being (FACT-G, rho = 0.55, P = .01), FACT-G Physical well-being (rho = 0.48, P = .03), and PROMIS Mental Health (rho = 0.55, P = .01). CONCLUSION: Recruitment into a walking intervention is feasible (a priory target of N = 60) in women during treatment for MBC, but retention at 3 months follow-up fell short (77% versus a priori 80%), yet there were potential benefits in general and physical well-being and mental health. CLINICALTRIALS.GOV IDENTIFIER: NCT02682836. CI - © The Author(s) 2022. Published by Oxford University Press. FAU - Shachar, Shlomit Strulov AU - Shachar SS AUID- ORCID: 0000-0002-3396-8419 AD - Division of Oncology, Sourasky - Tel Aviv Medical Center, Tel Aviv, Israel. AD - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. AD - University of North Carolina at Chapel Hill, NC, USA. FAU - Heiling, Hillary AU - Heiling H AD - University of North Carolina at Chapel Hill, NC, USA. FAU - Muss, Hyman B AU - Muss HB AD - University of North Carolina at Chapel Hill, NC, USA. FAU - Meghan, Damone AU - Meghan D AD - University of North Carolina at Chapel Hill, NC, USA. FAU - Wagoner, Chad W AU - Wagoner CW AD - University of North Carolina at Chapel Hill, NC, USA. FAU - Deal, Allison M AU - Deal AM AD - University of North Carolina at Chapel Hill, NC, USA. FAU - Nyrop, Kirsten A AU - Nyrop KA AD - University of North Carolina at Chapel Hill, NC, USA. LA - eng SI - ClinicalTrials.gov/NCT02682836 GR - BCRF-21-114/Breast Cancer Research Foundation of New York/ GR - BCRF-21-114/Breast Cancer Research Foundation/ PT - Clinical Study PT - Journal Article PL - England TA - Oncologist JT - The oncologist JID - 9607837 SB - IM MH - Female MH - Humans MH - Middle Aged MH - *Breast Neoplasms/therapy/pathology MH - Exercise MH - Pilot Projects MH - Quality of Life MH - Walking PMC - PMC9847548 OTO - NOTNLM OT - breast cancer OT - quality of life EDAT- 2022/11/19 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/11/18 07:53 PHST- 2022/02/03 00:00 [received] PHST- 2022/09/26 00:00 [accepted] PHST- 2022/11/19 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/11/18 07:53 [entrez] AID - 6833027 [pii] AID - oyac232 [pii] AID - 10.1093/oncolo/oyac232 [doi] PST - ppublish SO - Oncologist. 2023 Jan 18;28(1):84-e70. doi: 10.1093/oncolo/oyac232. PMID- 36305646 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 152 IP - 5 DP - 2023 Mar 1 TI - DNA methylation biomarkers for noninvasive detection of triple-negative breast cancer using liquid biopsy. PG - 1025-1035 LID - 10.1002/ijc.34337 [doi] AB - Noninvasive detection of aberrant DNA methylation could provide invaluable biomarkers for earlier detection of triple-negative breast cancer (TNBC) which could help clinicians with easier and more efficient treatment options. We evaluated genome-wide DNA methylation data derived from TNBC and normal breast tissues, peripheral blood of TNBC cases and controls and reference samples of sorted blood and mammary cells. Differentially methylated regions (DMRs) between TNBC and normal breast tissues were stringently selected, verified and externally validated. A machine-learning algorithm was applied to select the top DMRs, which then were evaluated on plasma-derived circulating cell-free DNA (cfDNA) samples of TNBC patients and healthy controls. We identified 23 DMRs accounting for the methylation profile of blood cells and reference mammary cells and then selected six top DMRs for cfDNA analysis. We quantified un-/methylated copies of these DMRs by droplet digital PCR analysis in a plasma test set from TNBC patients and healthy controls and confirmed our findings obtained on tissues. Differential cfDNA methylation was confirmed in an independent validation set of plasma samples. A methylation score combining signatures of the top three DMRs overlapping with the SPAG6, LINC10606 and TBCD/ZNF750 genes had the best capability to discriminate TNBC patients from controls (AUC = 0.78 in the test set and AUC = 0.74 in validation set). Our findings demonstrate the usefulness of cfDNA-based methylation signatures as noninvasive liquid biopsy markers for the diagnosis of TNBC. CI - © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Manoochehri, Mehdi AU - Manoochehri M AUID- ORCID: 0000-0002-2097-2558 AD - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. AD - Department of In Vitro Diagnostics, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart, Germany. FAU - Borhani, Nasim AU - Borhani N AD - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Gerhäuser, Clarissa AU - Gerhäuser C AUID- ORCID: 0000-0002-5792-3901 AD - Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Assenov, Yassen AU - Assenov Y AUID- ORCID: 0000-0002-6992-2092 AD - Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Schönung, Maximilian AU - Schönung M AUID- ORCID: 0000-0002-9778-9698 AD - Section Translational Cancer Epigenomics, Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. AD - National Center for Tumor Diseases (NCT), Heidelberg, Germany. AD - Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. FAU - Hielscher, Thomas AU - Hielscher T AD - Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Christensen, Brock C AU - Christensen BC AUID- ORCID: 0000-0003-3022-426X AD - Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. FAU - Lee, Min Kyung AU - Lee MK AD - Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. FAU - Gröne, Hermann-Josef AU - Gröne HJ AD - Department of Pharmacology, University of Marburg, Marburg, Germany. FAU - Lipka, Daniel B AU - Lipka DB AUID- ORCID: 0000-0001-5081-7869 AD - Section Translational Cancer Epigenomics, Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. AD - National Center for Tumor Diseases (NCT), Heidelberg, Germany. FAU - Brüning, Thomas AU - Brüning T AD - Institute for Prevention & Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany. FAU - Brauch, Hiltrud AU - Brauch H AUID- ORCID: 0000-0001-7531-2736 AD - Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. AD - iFIT Cluster of Excellence, University of Tübingen, Tübingen, Germany. AD - German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Tübingen, Germany. FAU - Ko, Yon-Dschun AU - Ko YD AD - Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. FAU - Hamann, Ute AU - Hamann U AUID- ORCID: 0000-0002-5294-6266 AD - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. LA - eng GR - Deutsches Krebsforschungszentrum/ GR - German Cancer Research Center (DKFZ), Heidelberg/ PT - Journal Article PT - Review DEP - 20221108 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (Biomarkers, Tumor) RN - 9007-49-2 (DNA) RN - 0 (Cell-Free Nucleic Acids) RN - 0 (Genetic Markers) RN - 0 (TBCD protein, human) RN - 0 (Microtubule-Associated Proteins) RN - 0 (ZNF750 protein, human) RN - 0 (Transcription Factors) RN - 0 (Tumor Suppressor Proteins) SB - IM MH - Humans MH - DNA Methylation MH - *Triple Negative Breast Neoplasms/diagnosis/genetics/pathology MH - Biomarkers, Tumor/genetics MH - DNA MH - *Cell-Free Nucleic Acids/genetics MH - Genetic Markers MH - Liquid Biopsy MH - Microtubule-Associated Proteins/genetics MH - Transcription Factors/genetics MH - Tumor Suppressor Proteins/genetics OTO - NOTNLM OT - DNA methylation OT - biomarker OT - liquid biopsy OT - noninvasive detection OT - triple-negative breast cancer EDAT- 2022/10/29 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/10/28 08:52 PHST- 2022/09/06 00:00 [revised] PHST- 2022/04/20 00:00 [received] PHST- 2022/09/20 00:00 [accepted] PHST- 2022/10/29 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/10/28 08:52 [entrez] AID - 10.1002/ijc.34337 [doi] PST - ppublish SO - Int J Cancer. 2023 Mar 1;152(5):1025-1035. doi: 10.1002/ijc.34337. Epub 2022 Nov 8. PMID- 36593486 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230111 IS - 2047-783X (Electronic) IS - 0949-2321 (Print) IS - 0949-2321 (Linking) VI - 28 IP - 1 DP - 2023 Jan 2 TI - Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy. PG - 2 LID - 10.1186/s40001-022-00964-w [doi] LID - 2 AB - BACKGROUND: Lipid metabolism has been recently reported to affect the prognosis and tumor immune activity in cancer patients. However, the effect of lipid metabolism on chemosensitivity in patients with breast cancer treated with neoadjuvant chemotherapy (NAC) remains unclear. METHODS: We examined 327 patients with breast cancer who were treated with NAC followed by curative surgery. The correlations between the serum levels of total cholesterol (TC) and triglyceride (TG) and the clinicopathological features, including the efficacy of NAC, neutrophil-to-lymphocyte ratio (NLR), and absolute lymphocyte count (ALC), were evaluated retrospectively. RESULTS: Serum TG levels were increased after NAC in all the subtypes, and the rate of change was the highest, especially in triple-negative breast cancer (TNBC) (21.0% → 48.1%). In addition, only TNBC patients with an objective response (OR) had significantly higher TG levels after NAC than those without (P = 0.049). Patients with a high ALC before NAC had significantly higher TG levels after NAC than patients with all breast cancer (P = 0.001), HER2-enriched breast cancer (P = 0.021), and TNBC (P = 0.008). Patients with a low NLR before NAC had significantly higher TG levels after NAC only among patients with TNBC (P = 0.025). In patients with human epidermal growth factor receptor 2-enriched breast cancer, the group with normal TC levels before NAC had significantly better OS than those with high TC levels (P = 0.013, log-rank test), and in patients with TNBC, the group with high TC levels after NAC had significantly better OS than those with normal TC levels (P = 0.014, log-rank test). CONCLUSIONS: Good systemic immune activity and chemosensitivity may be associated with lipid metabolism regulated by NAC in TNBC patients. CI - © 2022. The Author(s). FAU - Goto, Wataru AU - Goto W AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. FAU - Kashiwagi, Shinichiro AU - Kashiwagi S AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. spqv9ke9@view.ocn.ne.jp. FAU - Takada, Koji AU - Takada K AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. FAU - Asano, Yuka AU - Asano Y AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. FAU - Ogisawa, Kana AU - Ogisawa K AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. FAU - Morisaki, Tamami AU - Morisaki T AD - Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. FAU - Shibutani, Masatsune AU - Shibutani M AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. FAU - Tanaka, Hiroaki AU - Tanaka H AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. FAU - Maeda, Kiyoshi AU - Maeda K AD - Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. LA - eng GR - 19K18067/Japan Society for the Promotion of Science/ GR - 17K10559/Japan Society for the Promotion of Science,Japan/ PT - Journal Article DEP - 20230102 PL - England TA - Eur J Med Res JT - European journal of medical research JID - 9517857 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - *Triple Negative Breast Neoplasms/drug therapy/metabolism/pathology MH - Neoadjuvant Therapy MH - Retrospective Studies MH - Lipid Metabolism MH - Prognosis MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use PMC - PMC9806883 OTO - NOTNLM OT - Breast cancer OT - Lipid metabolism OT - Neoadjuvant chemotherapy OT - Tumor immune activity COIS- The authors declare that they have no competing interests. EDAT- 2023/01/03 06:00 MHDA- 2023/01/05 06:00 CRDT- 2023/01/02 23:25 PHST- 2022/08/24 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/02 23:25 [entrez] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/05 06:00 [medline] AID - 10.1186/s40001-022-00964-w [pii] AID - 964 [pii] AID - 10.1186/s40001-022-00964-w [doi] PST - epublish SO - Eur J Med Res. 2023 Jan 2;28(1):2. doi: 10.1186/s40001-022-00964-w. PMID- 36481356 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 639 DP - 2023 Jan 8 TI - Aquaporin water channels affect the response of conventional anticancer therapies of 3D grown breast cancer cells. PG - 126-133 LID - S0006-291X(22)01653-9 [pii] LID - 10.1016/j.bbrc.2022.11.096 [doi] AB - Aquaporin (AQP) water channels facilitate water transport across cellular membranes and are essential in regulation of body water balance. Moreover, several AQPs are overexpressed or ectopically expressed in breast cancer. Interestingly, several in vitro studies have suggested that AQPs can affect the response to conventional anticancer chemotherapies. Therefore, we took a systematic approach to test how AQP1, AQP3 and AQP5, which are often over-/ectopically expressed in breast cancer, affect total viability of 3-dimensional (3D) breast cancer cell spheroids when treated with the conventional anticancer chemotherapies Cisplatin, 5-Fluorouracil (5-FU) and Doxorubicin, a Combination of the three drugs as well as the Combination plus the Ras inhibitor Salirasib. Total viability of spheroids overexpressing AQP1 were decreased by all treatments except for 5-FU, which increased total viability by 20% compared to DMSO treated controls. All treatments reduced viability of spheroids overexpressing AQP3. In contrast, only Doxorubicin, Combination and Combination + Salirasib reduced total viability of spheroids overexpressing AQP5. Thus, this study supports a significant role of AQPs in the response to conventional chemotherapies. Evaluating the role of individual proteins that contribute to resistance to chemotherapies is essential in advancing personalized medicine in breast carcinomas. CI - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Edamana, Sarannya AU - Edamana S AD - Department of Clinical Medicine, Aarhus University, 8200, Aarhus N, Denmark. FAU - Pedersen, Stine F AU - Pedersen SF AD - Department of Biology, Section for Cell Biology and Physiology, University of Copenhagen, Universitetsparken 13, 2100, København Ø, Denmark. FAU - Nejsum, Lene N AU - Nejsum LN AD - Department of Clinical Medicine, Aarhus University, 8200, Aarhus N, Denmark. Electronic address: nejsum@clin.au.dk. LA - eng PT - Journal Article DEP - 20221130 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (farnesylthiosalicylic acid) RN - 0 (Aquaporins) RN - U3P01618RT (Fluorouracil) RN - 80168379AG (Doxorubicin) RN - 146410-94-8 (Aquaporin 1) RN - 0 (Aquaporin 5) RN - 158801-98-0 (Aquaporin 3) RN - 0 (Aquaporin 4) RN - 0 (Aquaporin 2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - *Aquaporins/metabolism MH - Fluorouracil/pharmacology MH - Doxorubicin/pharmacology MH - Aquaporin 1/genetics/metabolism MH - Aquaporin 5/metabolism MH - Aquaporin 3/genetics/metabolism MH - Aquaporin 4 MH - Aquaporin 2 OTO - NOTNLM OT - 3D spheroids OT - 5-Fluro uracil OT - AQP OT - Breast cancer OT - Cisplatin OT - Doxorubicin COIS- Declaration of competing interest The authors declare no conflict of interest. EDAT- 2022/12/09 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/08 23:29 PHST- 2022/11/15 00:00 [received] PHST- 2022/11/21 00:00 [revised] PHST- 2022/11/29 00:00 [accepted] PHST- 2022/12/09 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/08 23:29 [entrez] AID - S0006-291X(22)01653-9 [pii] AID - 10.1016/j.bbrc.2022.11.096 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2023 Jan 8;639:126-133. doi: 10.1016/j.bbrc.2022.11.096. Epub 2022 Nov 30. PMID- 36319907 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. PG - 137-148 LID - 10.1007/s10549-022-06771-5 [doi] AB - PURPOSE: Pseudocirrhosis is a term used to describe changes in hepatic contour that mimic cirrhosis radiographically, but lack the classic pathologic features of cirrhosis. This radiographic finding is frequently found in patients with metastatic breast cancer (MBC), but the risk factors and clinical consequences are poorly understood. METHODS: In this retrospective study, we identified patients with MBC and pseudocirrhosis who were treated at a single center from 2002 to 2021. We used chart extraction and radiology review to determine demographic characteristics, treatment history, imaging features, and complications of pseudocirrhosis. RESULTS: 120 patients with MBC and pseudocirrhosis were identified with the following BC subtypes: hormone receptor (HR) positive, HER2 negative (n = 99, 82.5%), HR+/HER2+ (n = 14, 11.7%), HR- /HER2+ (n = 3, 2.5%), and triple negative (TNBC; n = 4, 3.3%). All patients had liver metastases and 82.5% (n = 99) had > 15 liver lesions. Thirty-six patients (30%) presented with de novo metastatic disease. Median time from MBC diagnosis to pseudocirrhosis was 29.2 months. 50% of patients had stable or responding disease at the time of pseudocirrhosis diagnosis. Sequelae of pseudocirrhosis included radiographic ascites (n = 97, 80.8%), gastric/esophageal varices (n = 68, 56.7%), splenomegaly (n = 26, 21.7%), GI bleeding (n = 12, 10.0%), and hepatic encephalopathy (n = 11, 9.2%). Median survival was 7.9 months after pseudocirrhosis diagnosis. Radiographic ascites was associated with shorter survival compared to no radiographic ascites (42.8 vs. 76.2 months, p =  < 0.001). CONCLUSIONS: This is the largest case series of patients with MBC and pseudocirrhosis. Nearly all patients had HR+ MBC and extensive liver metastases. Survival was short after pseudocirrhosis and prognosis worse with radiographic ascites. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Huppert, Laura A AU - Huppert LA AUID- ORCID: 0000-0002-8512-5608 AD - Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. Laura.huppert@ucsf.edu. FAU - Walker, Zak AU - Walker Z AD - Division of Radiology, University of California, San Francisco, San Francisco, CA, USA. FAU - Li, Moming AU - Li M AD - Division of Epidemiology and Biostatistics, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. FAU - Kim, Mi-Ok AU - Kim MO AD - Division of Epidemiology and Biostatistics, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. FAU - Callan, Jennifer AU - Callan J AD - Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. FAU - Brandman, Danielle AU - Brandman D AD - Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. FAU - Majure, Melanie AU - Majure M AD - Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. FAU - Melisko, Michelle E AU - Melisko ME AD - Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. FAU - Rugo, Hope S AU - Rugo HS AD - Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. FAU - Behr, Spencer AU - Behr S AD - Division of Radiology, University of California, San Francisco, San Francisco, CA, USA. FAU - Chien, A Jo AU - Chien AJ AD - Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. LA - eng PT - Journal Article DEP - 20221102 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Retrospective Studies MH - Ascites MH - Prognosis MH - *Liver Neoplasms/secondary MH - Receptor, ErbB-2 OTO - NOTNLM OT - Ascites OT - Cirrhosis OT - Metastatic breast cancer OT - Pseudocirrhosis EDAT- 2022/11/03 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/02 00:40 PHST- 2022/07/28 00:00 [received] PHST- 2022/10/09 00:00 [accepted] PHST- 2022/11/03 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/02 00:40 [entrez] AID - 10.1007/s10549-022-06771-5 [pii] AID - 10.1007/s10549-022-06771-5 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):137-148. doi: 10.1007/s10549-022-06771-5. Epub 2022 Nov 2. PMID- 36396774 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230112 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. PG - 405-416 LID - 10.1007/s10549-022-06802-1 [doi] AB - PURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in either 15 (WB15F, PB15F) or 5 fractions (WB5F, PB5F). In a subgroup ineligible for PB radiotherapy, we compared WB15F to WB5F. METHODS: We developed a Markov cohort model to simulate lifetime healthcare costs and quality-adjusted life years (QALYs) for each modality. This was informed by the clinical analysis of two non-inferiority trials (FAST Forward and IMPORT LOW) and supplemented with external literature. The primary analysis assumed that radiotherapy modality influences health only through its impact on locoregional recurrence and radiotherapy-related adverse events. RESULTS: In the primary analysis, PB5F had the least cost and greatest expected QALYs. WB5F had the least cost and the greatest expected QALYs in those only eligible for WB radiotherapy. Applying a cost-effectiveness threshold of £15,000/QALY, there was a 62% chance that PB5F was the cost-effective alternative in the PB eligible group, and there was a 100% chance that WB5F was cost-effective in the subgroup ineligible for PB radiotherapy. CONCLUSIONS: Hypofractionation to 5 fractions and partial breast radiotherapy modalities offer potentially important benefits to the UK health system. CI - © 2022. The Author(s). FAU - Glynn, David AU - Glynn D AUID- ORCID: 0000-0002-0989-1984 AD - Centre for Health Economics, University of York, Heslington, UK. david.glynn@york.ac.uk. FAU - Bliss, Judith AU - Bliss J AD - Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, UK. FAU - Brunt, Adrian Murray AU - Brunt AM AD - School of Medicine, University of Keele, Staffordshire & Institute of Cancer Research, London, UK. FAU - Coles, Charlotte E AU - Coles CE AD - University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. FAU - Wheatley, Duncan AU - Wheatley D AD - Royal Cornwall Hospital, Treliske, Truro, UK. FAU - Haviland, Joanne S AU - Haviland JS AD - Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, UK. FAU - Kirby, Anna M AU - Kirby AM AD - Royal Marsden NHS Foundation Trust & Institute of Cancer Research, Sutton, UK. FAU - Longo, Francesco AU - Longo F AD - Centre for Health Economics, University of York, Heslington, UK. FAU - Faria, Rita AU - Faria R AUID- ORCID: 0000-0003-3410-1435 AD - Centre for Health Economics, University of York, Heslington, UK. FAU - Yarnold, John R AU - Yarnold JR AD - The Institute of Cancer Research: Royal Cancer Hospital, Sutton, UK. FAU - Griffin, Susan AU - Griffin S AD - Centre for Health Economics, University of York, Heslington, UK. LA - eng GR - 09/01/47/National Institute for Health Research/ GR - C1491/A6035/The institute of Cancer Research/ PT - Journal Article DEP - 20221117 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Female MH - Humans MH - Breast MH - *Breast Neoplasms/epidemiology/radiotherapy MH - Cost-Benefit Analysis MH - Neoplasm Recurrence, Local MH - Quality-Adjusted Life Years MH - United Kingdom/epidemiology MH - Equivalence Trials as Topic PMC - PMC9672618 OTO - NOTNLM OT - Breast cancer OT - Economic evaluation OT - Hypofractionation OT - Partial breast OT - Radiotherapy COIS- AMB, SG, DG, FL, DW, AK, CEC, JSH, JRY declare no conflicts of interest. Since this study was completed, RF became an employee of Astellas Pharma Europe Ltd. JB declares AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Pfizer, Roche, Novartis (previously GSK), Eli Lilly, Janssen-Cilag and Clovis Oncology. The authors acknowledge indirect conflicts through their funding and affiliations described above and through their involvement with the FAST Forward and IMPORT LOW trials. EDAT- 2022/11/18 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/17 23:41 PHST- 2022/01/20 00:00 [received] PHST- 2022/10/18 00:00 [accepted] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/17 23:41 [entrez] AID - 10.1007/s10549-022-06802-1 [pii] AID - 6802 [pii] AID - 10.1007/s10549-022-06802-1 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):405-416. doi: 10.1007/s10549-022-06802-1. Epub 2022 Nov 17. PMID- 36509001 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1879-0852 (Electronic) IS - 0959-8049 (Linking) VI - 179 DP - 2023 Jan TI - Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease. PG - 76-86 LID - S0959-8049(22)01342-9 [pii] LID - 10.1016/j.ejca.2022.11.007 [doi] AB - BACKGROUND: Three partially overlapping breast cancer polygenic risk scores (PRS) comprising 77, 179 and 313 SNPs have been proposed for European-ancestry women by the Breast Cancer Association Consortium (BCAC) for improving risk prediction in the general population. However, the effect of these SNPs may vary from one country to another and within a country because of other factors. OBJECTIVE: To assess their associated risk and predictive performance in French women from (1) the CECILE population-based case-control study, (2) BRCA1 or BRCA2 (BRCA1/2) pathogenic variant (PV) carriers from the GEMO study, and (3) familial breast cancer cases with no BRCA1/2 PV and unrelated controls from the GENESIS study. RESULTS: All three PRS were associated with breast cancer in all studies, with odds ratios per standard deviation varying from 1.7 to 2.0 in CECILE and GENESIS, and hazard ratios varying from 1.1 to 1.4 in GEMO. The predictive performance of PRS(313) in CECILE was similar to that reported in BCAC but lower than that in GENESIS (area under the receiver operating characteristic curve (AUC) = 0.67 and 0.75, respectively). PRS were less performant in BRCA2 and BRCA1 PV carriers (AUC = 0.58 and 0.54 respectively). CONCLUSION: Our results are in line with previous validation studies in the general population and in BRCA1/2 PV carriers. Additionally, we showed that PRS may be of clinical utility for women with a strong family history of breast cancer and no BRCA1/2 PV, and for those carrying a predicted PV in a moderate-risk gene like ATM, CHEK2 or PALB2. CI - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Jiao, Yue AU - Jiao Y AD - INSERM, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France; PSL Research University, Paris, France. FAU - Truong, Thérèse AU - Truong T AD - Université Paris-Saclay, UVSQ, INSERM, U1018, Gustave Roussy, CESP, Team Exposome and Heredity, Villejuif, France. FAU - Eon-Marchais, Séverine AU - Eon-Marchais S AD - INSERM, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France; PSL Research University, Paris, France. FAU - Mebirouk, Noura AU - Mebirouk N AD - INSERM, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France; PSL Research University, Paris, France. FAU - Caputo, Sandrine M AU - Caputo SM AD - PSL Research University, Paris, France; Department of Genetics, Institut Curie, Paris, France. FAU - Dondon, Marie-Gabrielle AU - Dondon MG AD - INSERM, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France; PSL Research University, Paris, France. FAU - Karimi, Mojgan AU - Karimi M AD - Université Paris-Saclay, UVSQ, INSERM, U1018, Gustave Roussy, CESP, Team Exposome and Heredity, Villejuif, France. FAU - Le Gal, Dorothée AU - Le Gal D AD - INSERM, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France; PSL Research University, Paris, France. FAU - Beauvallet, Juana AU - Beauvallet J AD - INSERM, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France; PSL Research University, Paris, France. FAU - Le Floch, Édith AU - Le Floch É AD - Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Université Paris-Saclay, Evry, France. FAU - Dandine-Roulland, Claire AU - Dandine-Roulland C AD - Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Université Paris-Saclay, Evry, France. FAU - Bacq-Daian, Delphine AU - Bacq-Daian D AD - Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Université Paris-Saclay, Evry, France. FAU - Olaso, Robert AU - Olaso R AD - Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Université Paris-Saclay, Evry, France. FAU - Albuisson, Juliette AU - Albuisson J AD - Centre de Lutte contre le Cancer Georges François Leclerc, Dijon, France. FAU - Audebert-Bellanger, Séverine AU - Audebert-Bellanger S AD - CHU Brest, Hôpital Morvan, Département de Génétique Médicale et Biologie de la Reproduction, Brest, France. FAU - Berthet, Pascaline AU - Berthet P AD - Département de Biopathologie, Centre François Baclesse, Caen, France; INSERM, U1245, Rouen, France. FAU - Bonadona, Valérie AU - Bonadona V AD - Université Claude Bernard Lyon 1, Villeurbanne, France; CNRS UMR 5558, Centre Léon Bérard, Unité de Prévention et épidémiologie Génétique, Lyon, France. FAU - Buecher, Bruno AU - Buecher B AD - PSL Research University, Paris, France; Department of Genetics, Institut Curie, Paris, France. FAU - Caron, Olivier AU - Caron O AD - Gustave Roussy, Département de Médecine Oncologique, Villejuif, France. FAU - Cavaillé, Mathias AU - Cavaillé M AD - Université Clermont Auvergne, UMR INSERM, U1240, Clermont Ferrand, France; Département d'Oncogénétique, Centre Jean Perrin, Clermont Ferrand, France. FAU - Chiesa, Jean AU - Chiesa J AD - UF de Génétique Médicale et Cytogénétique, CHRU Caremeau, Nîmes, France. FAU - Colas, Chrystelle AU - Colas C AD - PSL Research University, Paris, France; Department of Genetics, Institut Curie, Paris, France; INSERM, U830, Paris, France. FAU - Collonge-Rame, Marie-Agnès AU - Collonge-Rame MA AD - Service Génétique et Biologie du Développement - Histologie, CHU Hôpital Saint-Jacques, Besançon, France. FAU - Coupier, Isabelle AU - Coupier I AD - Hôpital Arnaud de Villeneuve, CHU Montpellier, Service de Génétique Médicale et Oncogénétique, Montpellier, France; INSERM, U896, CRCM Val d'Aurelle, Montpellier, France. FAU - Delnatte, Capucine AU - Delnatte C AD - Institut de Cancérologie de l'Ouest, Unité d'Oncogénétique, Saint Herblain, France. FAU - De Pauw, Antoine AU - De Pauw A AD - PSL Research University, Paris, France; Department of Genetics, Institut Curie, Paris, France. FAU - Dreyfus, Hélène AU - Dreyfus H AD - Clinique Sainte Catherine, Avignon, CHU de Grenoble, Grenoble, France; Hôpital Couple-Enfant, Département de Génétique, Grenoble, France. FAU - Fert-Ferrer, Sandra AU - Fert-Ferrer S AD - Service de Génétique, Centre Hospitalier de Chambéry, Chambéry, France. FAU - Gauthier-Villars, Marion AU - Gauthier-Villars M AD - PSL Research University, Paris, France; Department of Genetics, Institut Curie, Paris, France. FAU - Gesta, Paul AU - Gesta P AD - CH Georges Renon, Service d'Oncogénétique Régional Poitou-Charentes, Niort, France. FAU - Giraud, Sophie AU - Giraud S AD - Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier Est, Bron, France. FAU - Gladieff, Laurence AU - Gladieff L AD - Institut Claudius Regaud - IUCT-Oncopole, Service d'Oncologie Médicale, Toulouse, France. FAU - Golmard, Lisa AU - Golmard L AD - PSL Research University, Paris, France; Department of Genetics, Institut Curie, Paris, France. FAU - Lasset, Christine AU - Lasset C AD - Université Claude Bernard Lyon 1, Villeurbanne, France; CNRS UMR 5558, Centre Léon Bérard, Unité de Prévention et épidémiologie Génétique, Lyon, France. FAU - Lejeune-Dumoulin, Sophie AU - Lejeune-Dumoulin S AD - CHU Lille, Service de Génétique Clinique Guy Fontaine, Lille, France. FAU - Léoné, Mélanie AU - Léoné M AD - Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier Est, Bron, France. FAU - Limacher, Jean-Marc AU - Limacher JM AD - Hôpital Pasteur, Service d'Onco-hématologie, Colmar, France. FAU - Lortholary, Alain AU - Lortholary A AD - Service d'Oncologie Médicale, Centre Catherine de Sienne, Nantes, France; Hôpital Privé du Confluent, Nantes, France. FAU - Luporsi, Élisabeth AU - Luporsi É AD - Service de Génétique UF4128 CHR Metz-Thionville, Hôpital de Mercy, Metz, France. FAU - Mari, Véronique AU - Mari V AD - Unité d'Oncogénétique, Centre Antoine Lacassagne, Nice, France. FAU - Maugard, Christine M AU - Maugard CM AD - Génétique Oncologique Moléculaire, UF1422, Département d'Oncobiologie, LBBM, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; UF6948 Génétique Oncologique Clinique, évaluation Familiale et Suivi, Strasbourg, France. FAU - Mortemousque, Isabelle AU - Mortemousque I AD - Hôpital Bretonneau, Service de Génétique, Tours, France. FAU - Mouret-Fourme, Emmanuelle AU - Mouret-Fourme E AD - PSL Research University, Paris, France; Department of Genetics, Institut Curie, Paris, France. FAU - Nambot, Sophie AU - Nambot S AD - Centre de Lutte contre le Cancer Georges François Leclerc, Dijon, France; Institut GIMI, CHU de Dijon, Hôpital d'Enfants, France; Oncogénétique, Dijon, France. FAU - Noguès, Catherine AU - Noguès C AD - Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, Marseille, France; Aix Marseille Université, INSERM, IRD, SESSTIM, Marseille, France. FAU - Popovici, Cornel AU - Popovici C AD - Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, Marseille, France. FAU - Prieur, Fabienne AU - Prieur F AD - CHU de Saint-Etienne; Hôpital Nord, Service de Génétique, Saint-Etienne, France. FAU - Pujol, Pascal AU - Pujol P AD - Hôpital Arnaud de Villeneuve, CHU Montpellier, Service de Génétique Médicale et Oncogénétique, Montpellier, France; INSERM, U896, CRCM Val d'Aurelle, Montpellier, France. FAU - Sevenet, Nicolas AU - Sevenet N AD - Institut Bergonié, Bordeaux, France. FAU - Sobol, Hagay AU - Sobol H AD - Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, Marseille, France. FAU - Toulas, Christine AU - Toulas C AD - Institut Claudius Regaud - IUCT-Oncopole, Service d'Oncologie Médicale, Toulouse, France. FAU - Uhrhammer, Nancy AU - Uhrhammer N AD - Centre Jean Perrin, LBM OncoGenAuvergne, Clermont Ferrand, France. FAU - Vaur, Dominique AU - Vaur D AD - Département de Biopathologie, Centre François Baclesse, Caen, France; INSERM, U1245, Rouen, France. FAU - Venat, Laurence AU - Venat L AD - Hôpital Universitaire Dupuytren, Service d'Oncologie Médicale, Limoges, France. FAU - Boland-Augé, Anne AU - Boland-Augé A AD - Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Université Paris-Saclay, Evry, France. FAU - Guénel, Pascal AU - Guénel P AD - Université Paris-Saclay, UVSQ, INSERM, U1018, Gustave Roussy, CESP, Team Exposome and Heredity, Villejuif, France. FAU - Deleuze, Jean-François AU - Deleuze JF AD - Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Université Paris-Saclay, Evry, France. FAU - Stoppa-Lyonnet, Dominique AU - Stoppa-Lyonnet D AD - Department of Genetics, Institut Curie, Paris, France; Département d'Oncogénétique, Centre Jean Perrin, Clermont Ferrand, France; Université Paris-Cité, Paris, France. FAU - Andrieu, Nadine AU - Andrieu N AD - INSERM, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France; PSL Research University, Paris, France. FAU - Lesueur, Fabienne AU - Lesueur F AD - INSERM, U900, Paris, France; Institut Curie, Paris, France; Mines ParisTech, Fontainebleau, France; PSL Research University, Paris, France. Electronic address: fabienne.lesueur@curie.fr. LA - eng PT - Journal Article DEP - 20221113 PL - England TA - Eur J Cancer JT - European journal of cancer (Oxford, England : 1990) JID - 9005373 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/epidemiology/genetics/pathology MH - Case-Control Studies MH - Genetic Predisposition to Disease MH - Risk Factors MH - Genes, BRCA2 OTO - NOTNLM OT - BRCA1 OT - BRCA2 OT - Breast cancer OT - Genetic susceptibility OT - Polygenic risk score OT - Risk prediction OT - SNP COIS- Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DS-L and LG coordinated the genotyping of SNPs included in the PRS of the MammoRisk® test commercialized by Predilife until December 2021. This genotyping was performed in the Department of Genetics of the Institut Curie. All other authors declare no conflicts of interest. EDAT- 2022/12/13 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/12 18:27 PHST- 2022/08/24 00:00 [received] PHST- 2022/10/26 00:00 [revised] PHST- 2022/11/06 00:00 [accepted] PHST- 2022/12/13 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/12 18:27 [entrez] AID - S0959-8049(22)01342-9 [pii] AID - 10.1016/j.ejca.2022.11.007 [doi] PST - ppublish SO - Eur J Cancer. 2023 Jan;179:76-86. doi: 10.1016/j.ejca.2022.11.007. Epub 2022 Nov 13. PMID- 36604691 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1479-7364 (Electronic) IS - 1473-9542 (Print) IS - 1473-9542 (Linking) VI - 17 IP - 1 DP - 2023 Jan 6 TI - Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations. PG - 2 LID - 10.1186/s40246-022-00447-3 [doi] LID - 2 AB - BACKGROUND: Germline mutations of breast cancer susceptibility gene BRCA1 and BRCA2 (gBRCA1/2) are associated with elevated risk of breast cancer in young women in Asia. BRCA1 and BRCA2 proteins contribute to genomic stability through homologous recombination (HR)-mediated double-strand DNA break repair in cooperation with other HR-related proteins. In this study, we analyzed the targeted sequencing data of Korean breast cancer patients with gBRCA1/2 mutations to investigate the alterations in HR-related genes and their clinical implications. MATERIALS AND METHODS: Data of the breast cancer patients with pathogenic gBRCA1/2 mutations and qualified targeted next-generation sequencing, SNUH FiRST cancer panel, were analyzed. Single nucleotide polymorphisms, small insertions, and deletions were analyzed with functional annotations using ANNOVAR. HR-related genes were defined as ABL1, ATM, ATR, BARD1, BRCA1, BRCA2, CDKN1A, CDKN2A, CHEK1, CHEK2, FANCA, FANCD2, FANCG, FANCI, FANCL, KDR, MUTYH, PALB2, POLE, POLQ, RAD50, RAD51, RAD51D, RAD54L, and TP53. Mismatch-repair genes were MLH1, MSH2, and MSH6. Clinical data were analyzed with cox proportional hazard models and survival analyses. RESULTS: Fifty-five Korean breast cancer patients with known gBRCA1/2 mutations and qualified targeted NGS data were analyzed. Ethnically distinct mutations in gBRCA1/2 genes were noted, with higher frequencies of Val1833Ser (14.8%), Glu1210Arg (11.1%), and Tyr130Ter (11.1%) in gBRCA1 and Arg2494Ter (25.0%) and Lys467Ter (14.3%) in gBRCA2. Considering subtypes, gBRCA1 mutations were associated with triple-negative breast cancers (TNBC), while gBRCA2 mutations were more likely hormone receptor-positive breast cancers. At least one missense mutation of HR-related genes was observed in 44 cases (80.0%). The most frequently co-mutated gene was TP53 (38.1%). In patients with gBRCA1/2 mutations, however, genetic variations of TP53 occurred in locations different from the known hotspots of those with sporadic breast cancers. The patients with both gBRCA1/2 and TP53 mutations were more likely to have TNBC, high Ki-67 values, and increased genetic mutations, especially of HR-related genes. Survival benefit was observed in the TP53 mutants of patients with gBRCA2 mutations, compared to those with TP53 wild types. CONCLUSION: Our study showed genetic heterogeneity of breast cancer patients with gBRCA1 and gBRCA2 mutations in the Korean populations. Further studies on precision medicine are needed for tailored treatments of patients with genetic diversity among different ethnic groups. CI - © 2023. The Author(s). FAU - Kim, Jinyong AU - Kim J AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. FAU - Jeong, Kyeonghun AU - Jeong K AD - Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Republic of Korea. AD - Transdisciplinary Department of Medicine and Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Jun, Hyeji AU - Jun H AD - Transdisciplinary Department of Medicine and Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Kim, Kwangsoo AU - Kim K AD - Transdisciplinary Department of Medicine and Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Bae, Jeong Mo AU - Bae JM AD - Department of Pathology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Song, Myung Geun AU - Song MG AD - Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Yi, Hanbaek AU - Yi H AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. FAU - Park, Songyi AU - Park S AD - Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Woo, Go-Un AU - Woo GU AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. FAU - Lee, Dae-Won AU - Lee DW AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. FAU - Kim, Tae-Yong AU - Kim TY AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. FAU - Lee, Kyung-Hun AU - Lee KH AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. kyunghunlee@snu.ac.kr. AD - Cancer Research Institute, Seoul National University, Seoul, Republic of Korea. kyunghunlee@snu.ac.kr. FAU - Im, Seock-Ah AU - Im SA AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. moisa@snu.ac.kr. AD - Cancer Research Institute, Seoul National University, Seoul, Republic of Korea. moisa@snu.ac.kr. LA - eng GR - HI14C1277/Korea Health Industry Development Institute/Republic of Korea PT - Journal Article DEP - 20230106 PL - England TA - Hum Genomics JT - Human genomics JID - 101202210 RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/pathology MH - *Triple Negative Breast Neoplasms/genetics MH - Recombinational DNA Repair/genetics MH - Mutation MH - DNA Repair MH - Germ-Line Mutation/genetics MH - Germ Cells/pathology MH - Genetic Predisposition to Disease MH - Tumor Suppressor Protein p53/genetics MH - BRCA1 Protein/genetics PMC - PMC9817339 OTO - NOTNLM OT - BRCA OT - Breast cancer OT - NGS OT - P53 OT - Signature 3 COIS- The authors declare that they have no competing interests. EDAT- 2023/01/06 06:00 MHDA- 2023/01/10 06:00 CRDT- 2023/01/05 23:40 PHST- 2022/09/25 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/05 23:40 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] AID - 10.1186/s40246-022-00447-3 [pii] AID - 447 [pii] AID - 10.1186/s40246-022-00447-3 [doi] PST - epublish SO - Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3. PMID- 36672233 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 12 IP - 2 DP - 2023 Jan 12 TI - Inhibition of Bone Marrow-Mesenchymal Stem Cell-Induced Carbonic Anhydrase IX Potentiates Chemotherapy Efficacy in Triple-Negative Breast Cancer Cells. LID - 10.3390/cells12020298 [doi] LID - 298 AB - Conventional chemotherapy represents the main systemic treatment used for triple-negative breast cancer (TNBC) patients, although many of them develop drug resistance. The hypoxic TME is the crucial driver in the onset of insensitivity to chemotherapy. In this research, we elucidated the role played by bone marrow-derived mesenchymal stem cells (BM-MSCs) in reducing cisplatin effects in TNBC. BT-549 and MDA-MB-231 cells, grown under hypoxic conditions in the presence of conditioned medium obtained from BM-MSCs (CM-MSCs), showed a strong cisplatin insensitivity and increased expression levels of carbonic anhydrase IX (CA IX). Therefore, we inhibited CM-MSC-induced CA IX by SLC-0111 to potentiate chemotherapy efficacy in TNBC cells. Our results showed that CM-MSCs under hypoxic conditions caused an increase in the ability of TNBC cells to form vascular structures, migrate and invade Matrigel. Cell treatment with cisplatin plus SLC-0111 was able to block these mechanisms, as well as the signaling pathways underlying them, such as p-AKT, p-ERK, CD44, MMP-2, vimentin, β-catenin, and N-cadherin, more effectively than treatment with single agents. In addition, a significant enhancement of apoptosis assessed by annexin V, caspase-3 expression and activity was also shown. Taken together, our results demonstrated the possibility, through CA IX inhibition, of returning TNBC cells to a more chemosensitive state. FAU - Sarnella, Annachiara AU - Sarnella A AD - Institute of Biostructures and Bioimaging, CNR, 80145 Naples, Italy. FAU - Ferrara, Ylenia AU - Ferrara Y AUID- ORCID: 0000-0002-1939-6653 AD - Institute of Biostructures and Bioimaging, CNR, 80145 Naples, Italy. FAU - Albanese, Sandra AU - Albanese S AD - Institute of Biostructures and Bioimaging, CNR, 80145 Naples, Italy. FAU - Omodei, Daniela AU - Omodei D AUID- ORCID: 0000-0001-8710-2971 AD - Institute of Biostructures and Bioimaging, CNR, 80145 Naples, Italy. FAU - Cerchia, Laura AU - Cerchia L AUID- ORCID: 0000-0002-7633-7932 AD - Institute of Experimental Endocrinology and Oncology "G. Salvatore", CNR, 80131 Naples, Italy. FAU - De Simone, Giuseppina AU - De Simone G AUID- ORCID: 0000-0001-9783-5431 AD - Institute of Biostructures and Bioimaging, CNR, 80145 Naples, Italy. FAU - Supuran, Claudiu T AU - Supuran CT AUID- ORCID: 0000-0003-4262-0323 AD - Department of Neurofarba, University of Florence, 50019 Florence, Italy. FAU - Zannetti, Antonella AU - Zannetti A AUID- ORCID: 0000-0002-6753-3659 AD - Institute of Biostructures and Bioimaging, CNR, 80145 Naples, Italy. LA - eng PT - Journal Article DEP - 20230112 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - EC 4.2.1.1 (Carbonic Anhydrase IX) RN - 0 (SLC-0111) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Humans MH - Carbonic Anhydrase IX/metabolism MH - Cisplatin/pharmacology/metabolism MH - *Triple Negative Breast Neoplasms/drug therapy/metabolism MH - Bone Marrow/metabolism MH - *Mesenchymal Stem Cells/metabolism PMC - PMC9857137 OTO - NOTNLM OT - bone-marrow-mesenchymal stem cells OT - carbonic anhydrase IX OT - triple-negative breast cancer OT - tumor microenvironment COIS- The authors, except C.T. Supuran, declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript and in the decision to publish the results. C.T. Supuran declares conflict of interest as he is one of the inventors of SLC-0111. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:11 PHST- 2022/11/16 00:00 [received] PHST- 2023/01/09 00:00 [revised] PHST- 2023/01/10 00:00 [accepted] PHST- 2023/01/21 01:11 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - cells12020298 [pii] AID - cells-12-00298 [pii] AID - 10.3390/cells12020298 [doi] PST - epublish SO - Cells. 2023 Jan 12;12(2):298. doi: 10.3390/cells12020298. PMID- 36624425 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230112 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Jan 10 TI - Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis. PG - 37 LID - 10.1186/s12885-022-10493-8 [doi] LID - 37 AB - BACKGROUND: As a first-line imaging modality, whole-body fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) and 18F-FDG PET/magnetic resonance imaging (MRI) had been widely applied in clinical practice. However, 18F-FDG PET/MRI may be superior to PET/CT for the diagnosis of distant metastases in patients with advanced-stage. Therefore, it is timely and important to systematically determine the diagnostic accuracy of 18F-FDG PET/MRI compared with that of 18F-FDG PET/CT for the diagnosis of distant metastases. METHODS: This study aimed to compare the diagnostic accuracy of 18F-FDG PET/CT and PET/MRI for the diagnosis of distant metastases in patients with malignant tumors. Relevant studies using both 18F-FDG PET/CT and PET/MRI for assessment of distant metastases in patients with malignant tumors were searched in PubMed, Embase, The Cochrane Library, and Scopus from January 2010 to November 2023. Two reviewers independently selected studies according to the inclusion and exclusion criteria. A reviewer extracted relevant data and assessed the quality of the eligible studies. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and area under the summary receiver operating characteristic curve (AUC) for 18F-FDG PET/CT and PET/MRI were analyzed. Subgroup analysis was performed. RESULTS: Across 14 studies (1042 patients), 18F-FDG PET/MRI had a higher sensitivity (0.87 versus 0.81), AUC value (0.98 versus 0.95), and similar specificity (0.97 versus 0.97), than PET/CT for detecting distant metastases. In 3 studies of breast cancer (182 patients), 18F-FDG PET/MRI had a higher sensitivity (0.95 versus 0.87) and specificity (0.96 versus 0.94) than PET/CT. In 5 studies of lung cancer (429 patients), 18F-FDG PET/CT had a higher sensitivity (0.87 versus 0.84) and a lower specificity (0.95 versus 0.96) to PET/MRI. CONCLUSIONS: 18F-FDG PET/MRI and PET/CT both performed well as detectors of distant metastases in patients with malignant tumors, and the former has higher sensitivity. The subgroup analysis highlights that 18F-FDG PET/MRI and PET/CT hold different advantages for distant metastases staging in different tumors, PET/MRI has a higher accuracy in patients with breast cancer patients, while PET/CT has a higher accuracy in patients with lung cancer. CI - © 2023. The Author(s). FAU - Zhang, Cici AU - Zhang C AD - Department of Radiology, Guangzhou Red Cross Hospital, Guangzhou, China. FAU - Liang, Zhishan AU - Liang Z AD - Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. FAU - Liu, Wei AU - Liu W AD - Department of Breast, Guangzhou Red Cross Hospital, Guangzhou, China. FAU - Zeng, Xuwen AU - Zeng X AD - Department of Radiology, Guangzhou Red Cross Hospital, Guangzhou, China. FAU - Mo, Yuzhen AU - Mo Y AD - Department of Radiotherapy, Guangzhou Red Cross Hospital, No.396, TongFu Road, HaiZhu District, Guangzhou, 510220, Guangdong, China. gz202101@yeah.net. LA - eng GR - 20221A011023/the Science and Education Business of Guangzhou Health Commission/ PT - Journal Article PT - Meta-Analysis DEP - 20230110 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM MH - Humans MH - Female MH - Positron Emission Tomography Computed Tomography/methods MH - Fluorodeoxyglucose F18 MH - Radiopharmaceuticals MH - Positron-Emission Tomography MH - Magnetic Resonance Imaging/methods MH - *Lung Neoplasms/pathology MH - *Breast Neoplasms/pathology MH - Sensitivity and Specificity MH - Neoplasm Staging PMC - PMC9830828 OTO - NOTNLM OT - Distant metastases OT - Positron emission tomography/computed tomography OT - Positron emission tomography/magnetic resonance imaging OT - Tumor COIS- The authors declare that they have no competing interests. EDAT- 2023/01/10 06:00 MHDA- 2023/01/12 06:00 CRDT- 2023/01/09 23:31 PHST- 2022/09/08 00:00 [received] PHST- 2022/12/28 00:00 [accepted] PHST- 2023/01/09 23:31 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] AID - 10.1186/s12885-022-10493-8 [pii] AID - 10493 [pii] AID - 10.1186/s12885-022-10493-8 [doi] PST - epublish SO - BMC Cancer. 2023 Jan 10;23(1):37. doi: 10.1186/s12885-022-10493-8. PMID- 36056290 OWN - NLM STAT- MEDLINE DCOM- 20221229 LR - 20230103 IS - 2190-3948 (Electronic) IS - 2190-393X (Linking) VI - 13 IP - 2 DP - 2023 Feb TI - Modeling and simulation of smart magnetic self-assembled nanomicelle trajectories in an internal thoracic artery flow for breast cancer therapy. PG - 675-688 LID - 10.1007/s13346-022-01234-2 [doi] AB - Magnetic drug targeting (MDT) is one of the most modern techniques in cancer therapy for its ability to reduce the side effects of chemotherapy experienced by systemic drug administration. In this study, a comprehensive mathematical model has been developed to predict the drug particle trajectories of anticancer dasatinib magnetic nanomicelles (DAS-MNM) released in an internal thoracic artery (ITA) blood flow for breast cancer therapy using an external magnetic field. Several factors are investigated in regard to the efficiency of MDT through the ITA, including magnetic field strength (MFS), relative magnetic permeability, magnet size, drug particle size, and initial position of drug particle. The drug particle trajectory results confirmed the successful MDT using an external magnetic field with a capture efficiency of more than 90%. This was achieved by employing a wide range of particle sizes of DAS-MNM close to the external magnetic field source at the arterial wall than in other positions. Moreover, the results showed that the number of trapped particles increased with increasing both MFS and drug particle diameter within the target tissue, while the drug particle permeability did not have a considerable effect on the particle retention. In addition, for achieving a successful drug/cargo delivery through the arteries, the magnetic field, the particle size, and the initial release locations should be adjusted simultaneously. The present work offers insights into the critical factors in MDT with a significant impact on breast cancer therapy, tissue engineering, and regenerative medicine. Magnetic drug targeting model of anticancer dasatinib magnetic nanomicelles (DAS-MNM) released in an internal thoracic artery blood flow for breast cancer therapy. CI - © 2022. Crown. FAU - Sulttan, Saad AU - Sulttan S AUID- ORCID: 0000-0001-8526-0626 AD - Department of Chemical and Biochemical Engineering, The University of Western Ontario, London, ON, N6A 5B9, Canada. salsuway@uwo.ca. AD - Department of Chemical Engineering, University of Technology-Iraq, 52 Alsinaa St., PO Box 35010, Baghdad, Iraq. salsuway@uwo.ca. FAU - Rohani, Sohrab AU - Rohani S AD - Department of Chemical and Biochemical Engineering, The University of Western Ontario, London, ON, N6A 5B9, Canada. LA - eng PT - Journal Article DEP - 20220902 PL - United States TA - Drug Deliv Transl Res JT - Drug delivery and translational research JID - 101540061 RN - RBZ1571X5H (Dasatinib) RN - 0 (Drug Carriers) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - *Mammary Arteries MH - Dasatinib MH - Drug Delivery Systems/methods MH - Magnetic Fields MH - Drug Carriers OTO - NOTNLM OT - Breast cancer OT - Dasatinib OT - Drug targeting OT - Internal thoracic artery OT - Micelles OT - Nanomagnetic EDAT- 2022/09/03 06:00 MHDA- 2022/12/30 06:00 CRDT- 2022/09/02 23:39 PHST- 2022/08/25 00:00 [accepted] PHST- 2022/09/03 06:00 [pubmed] PHST- 2022/12/30 06:00 [medline] PHST- 2022/09/02 23:39 [entrez] AID - 10.1007/s13346-022-01234-2 [pii] AID - 10.1007/s13346-022-01234-2 [doi] PST - ppublish SO - Drug Deliv Transl Res. 2023 Feb;13(2):675-688. doi: 10.1007/s13346-022-01234-2. Epub 2022 Sep 2. PMID- 36611131 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Jan 7 TI - Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. PG - 29 LID - 10.1186/s12885-023-10515-z [doi] LID - 29 AB - PURPOSE: Despite the poor prognosis of triple-negative breast cancer (TNBC), it has been demonstrated that neoadjuvant immunotherapy in combination with chemotherapy can improve the pathologic complete response (pCR) rate and/or long-term outcome of TNBC. However, there have been no real-world studies reporting on the effectiveness of neoadjuvant checkpoint inhibitors in early TNBC. METHODS: Between November 2019 and December 2021, 63 early TNBC patients treated with anti-PD-1 antibodies (pembrolizumab or camrelizumab) or anti-PD-L1 antibody (atezolizumab) in combination with chemotherapy at seven institutions were included. PCR1 defined as ypT0/Tis and ypN0 was the primary endpoint. Secondary endpoints included pCR2 defined as ypT0/Tis, overall response rate (ORR), disease-free survival (DFS), drug-related adverse events (AEs) and biomarkers. RESULTS: Among the patients in the current study, 34.9% of patients were able to achieve pCR1, and 47.6% of patients had achieved pCR2. The ORR was 82.5%. 33 patients with non-pCR2 tumors were found to have a median DFS of 20.7 months (95% CI 16.3 months-not reached). The DFS of patients with pCR2 and non-pCR2 after neoadjuvant therapy was significantly different (HR = 0.28, 95% CI 0.10-0.79; P = 0.038). The most common AEs were nausea (63.4%), fatigue (42.7%), leucopenia (30.0%) and elevated transaminase (11.7%). CONCLUSION: It is possible to achieve a meaningful pCR rate and DFS by combining neoadjuvant checkpoint blockade with chemotherapy in patients with high-risk TNBC. Compared to clinical trials, however, there was a slightly lower pCR rate in this multicentered real-world study. CI - © 2023. The Author(s). FAU - Deng, Heran AU - Deng H AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Yanjiang West Road 107#, Guangzhou, 510120, Guangdong, China. FAU - Wang, Liying AU - Wang L AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Yanjiang West Road 107#, Guangzhou, 510120, Guangdong, China. FAU - Wang, Na AU - Wang N AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Sun Yat-Sen University, Dongfeng Road 651#, Guangzhou, 510060, Guangdong, China. FAU - Zhang, Kejin AU - Zhang K AD - Xiangya Hospital of Central South University, Center South University, Changsha, Hunan, China. FAU - Zhao, Yanxia AU - Zhao Y AD - Union Hospital Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Qiu, Pengfei AU - Qiu P AD - Shandong Tumor Hospital, Shandong university, Jinan, Shandong, China. FAU - Qi, Xiaowei AU - Qi X AD - The Southwest Hospital of AMU, Army Medical University, Chongqing, Sichuan, China. FAU - Zhang, Danhua AU - Zhang D AD - The Second Xiangya Hospital of Central South University, Center South University, Changsha, Hunan, China. FAU - Xu, Fei AU - Xu F AD - State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Sun Yat-Sen University, Dongfeng Road 651#, Guangzhou, 510060, Guangdong, China. xufei@sysucc.org.cn. FAU - Liu, Jieqiong AU - Liu J AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Yanjiang West Road 107#, Guangzhou, 510120, Guangdong, China. liujieqiong01@163.com. LA - eng GR - 2021A1515011811/Natural Science Foundation of Guangdong Province/ GR - 2022A1515012238/Natural Science Foundation of Guangdong Province/ PT - Journal Article PT - Multicenter Study DEP - 20230107 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/pathology MH - Neoadjuvant Therapy MH - Disease-Free Survival MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9826585 OTO - NOTNLM OT - Anti-PD-1/L1 antibody OT - Neoadjuvant immunotherapy OT - Real-world study OT - Tripe-negative breast cancer COIS- All authors have no competing interest. EDAT- 2023/01/08 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/07 23:22 PHST- 2022/08/08 00:00 [received] PHST- 2023/01/05 00:00 [accepted] PHST- 2023/01/07 23:22 [entrez] PHST- 2023/01/08 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - 10.1186/s12885-023-10515-z [pii] AID - 10515 [pii] AID - 10.1186/s12885-023-10515-z [doi] PST - epublish SO - BMC Cancer. 2023 Jan 7;23(1):29. doi: 10.1186/s12885-023-10515-z. PMID- 35994199 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery. PG - 56-67 LID - 10.1007/s12282-022-01397-3 [doi] AB - BACKGROUND: Previous studies of immune genomic signatures (IGSs) in breast cancer have attempted to predict the response to chemotherapy or prognosis and were performed using different patient cohorts. The purpose of this study was to evaluate the predictive functions of various IGSs using the same patient cohort that included data for response to chemotherapy as well as the prognosis after surgery. METHODS: We applied five previously described IGS models in a public dataset of 508 breast cancer patients treated with neoadjuvant chemotherapy. The prognostic and predictive values of each model were evaluated, and their correlations were compared. RESULTS: We observed a high proportion of expression concordance among the IGS models (r: 0.56-1). Higher scores of IGSs were detected in aggressive breast cancer subtypes (basal and HER2-enriched) (P < 0.001). Four of the five IGSs could predict chemotherapy responses and two could predict 5-year relapse-free survival in cases with hormone receptor-positive (HR +) tumors. However, the models showed no significant differences in their predictive abilities for hormone receptor-negative (HR-) tumors. CONCLUSIONS: IGSs are, to some extent, useful for predicting prognosis and chemotherapy response; moreover, they show substantial agreement for specific breast cancer subtypes. However, it is necessary to identify more compelling biomarkers for both prognosis and response to chemotherapy in HR- and HER2 + cases. CI - © 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society. FAU - Zhu, Yidan AU - Zhu Y AD - Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. FAU - Iwamoto, Takayuki AU - Iwamoto T AD - Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. tiwamoto@cc.okayama-u.ac.jp. FAU - Kajiwara, Yukiko AU - Kajiwara Y AD - Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. AD - Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. FAU - Takahashi, Yuko AU - Takahashi Y AD - Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. FAU - Kochi, Mariko AU - Kochi M AD - Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. FAU - Shien, Tadahiko AU - Shien T AD - Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. FAU - Taira, Naruto AU - Taira N AD - Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. FAU - Toyooka, Shinichi AU - Toyooka S AD - Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. FAU - Doihara, Hiroyoshi AU - Doihara H AD - Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. LA - eng PT - Journal Article DEP - 20220822 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/surgery MH - Neoadjuvant Therapy MH - Biomarkers, Tumor/genetics/metabolism MH - Receptor, ErbB-2/genetics/metabolism MH - Neoplasm Recurrence, Local/genetics/drug therapy MH - Prognosis MH - Genomics MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use OTO - NOTNLM OT - Breast cancer OT - Immune genomic signatures OT - Prognosis OT - Response to chemotherapy EDAT- 2022/08/23 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/08/22 11:26 PHST- 2022/06/03 00:00 [received] PHST- 2022/08/17 00:00 [accepted] PHST- 2022/08/23 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/08/22 11:26 [entrez] AID - 10.1007/s12282-022-01397-3 [pii] AID - 10.1007/s12282-022-01397-3 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):56-67. doi: 10.1007/s12282-022-01397-3. Epub 2022 Aug 22. PMID- 36323880 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230125 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 128 IP - 1 DP - 2023 Jan TI - PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. PG - 121-129 LID - 10.1038/s41416-022-02021-z [doi] AB - BACKGROUND: Neoadjuvant treatment with a dual anti-human epidermal growth factor receptor 2 (HER2) blockade with pyrotinib and trastuzumab has been shown to be effective for HER2-positive breast cancer. METHODS: The genomic characteristics of 425 cancer-related genes from the archived tumour blocks of 50 patients enrolled in a prospective neoadjuvant pyrotinib and trastuzumab plus chemotherapy clinical trial (ChiCTR1900022293) were assessed by next-generation sequencing (NGS). The relationship between tumour biomarkers and the postoperative pathological complete response (pCR) were explored. RESULTS: Forty-five patients completed neoadjuvant chemotherapy and final surgery, of which 26 (58%) achieved a pCR. Among all driver gene mutations, PIK3CA mutation was screened out for having a significant relationship with the treatment response. The pCR rate of patients with wild-type PIK3CA was significantly higher than patients with mutated PIK3CA (80.8% vs. 26.3%; P = 0.00057), and remained significant after a multiple comparison adjustment (P(adjusted) = 0.024). We further evaluated the predictive value with logistic regression model of clinical features, genetic biomarkers or both, an AUC of 0.912 (95% CI: 0.827-0.997) was achieved in the integrated model. CONCLUSIONS: Our data suggest that HER2-positive breast cancers with activating mutations in PIK3CA are less likely to benefit from pyrotinib combined with trastuzumab neoadjuvant therapy. CI - © 2022. The Author(s). FAU - Shi, Qiyun AU - Shi Q AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Xuhong, Juncheng AU - Xuhong J AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. AD - Shigatse Branch, Xinqiao Hospital, Army Medical University, 857000, Shigatse, China. FAU - Luo, Tao AU - Luo T AD - Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Ge, Jia AU - Ge J AD - Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Liu, Feng AU - Liu F AD - Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Lan, Yang AU - Lan Y AD - Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Chen, Qingqiu AU - Chen Q AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Tang, Peng AU - Tang P AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Fan, Linjun AU - Fan L AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Chen, Li AU - Chen L AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Liang, Yan AU - Liang Y AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Wang, Minghao AU - Wang M AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Hu, Ying AU - Hu Y AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Zhang, Yi AU - Zhang Y AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. FAU - Bian, Xiuwu AU - Bian X AUID- ORCID: 0000-0003-4383-0197 AD - Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China. bianxiuwu@263.net. FAU - Qi, Xiaowei AU - Qi X AUID- ORCID: 0000-0002-5876-4957 AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. qxw9908@foxmail.com. FAU - Jiang, Jun AU - Jiang J AUID- ORCID: 0000-0002-8931-9872 AD - Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. jcbd@medmail.com.cn. LA - eng PT - Journal Article DEP - 20221102 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - P188ANX8CK (Trastuzumab) RN - 0 (pyrotinib) RN - 0 (Antibodies, Monoclonal, Humanized) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.137 (PIK3CA protein, human) SB - IM MH - Humans MH - Female MH - Trastuzumab MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Neoadjuvant Therapy MH - Prospective Studies MH - Antibodies, Monoclonal, Humanized MH - Receptor, ErbB-2/genetics/metabolism MH - Class I Phosphatidylinositol 3-Kinases/genetics MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Treatment Outcome PMC - PMC9814131 COIS- The authors declare no competing interests. EDAT- 2022/11/04 06:00 MHDA- 2023/01/10 06:00 CRDT- 2022/11/03 00:36 PHST- 2022/05/06 00:00 [received] PHST- 2022/10/12 00:00 [accepted] PHST- 2022/10/06 00:00 [revised] PHST- 2022/11/04 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/11/03 00:36 [entrez] AID - 10.1038/s41416-022-02021-z [pii] AID - 2021 [pii] AID - 10.1038/s41416-022-02021-z [doi] PST - ppublish SO - Br J Cancer. 2023 Jan;128(1):121-129. doi: 10.1038/s41416-022-02021-z. Epub 2022 Nov 2. PMID- 36074234 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230112 IS - 1559-0291 (Electronic) IS - 0273-2289 (Linking) VI - 195 IP - 1 DP - 2023 Jan TI - Bioinformatic Analysis Divulged Novel Prognostic Circulating MicroRNAs and Their Potential Target Genes in Breast Cancer. PG - 283-297 LID - 10.1007/s12010-022-04151-9 [doi] AB - Breast cancer (BC) is both an inherited and environmental-based disease which is the leading cause of death among women. Early detection of BC can prevent invasion and metastasis in patients. Currently, researchers endeavor to find non-invasive biological markers from body fluids. Circulating non-coding RNAs such as microRNAs (miRNAs) can potentially be valuable prognostic and detective biomarkers. To identify novel miRNA-based biomarkers, we utilized bioinformatic tools. To reach this goal, the miRNA expression profiles of GSE31309, GSE 44,281, GSE98181, and GSE118782 were analyzed through a limma package of R. Target gene prediction of differentially expressed miRNAs, called differentially expressed miRNAs (DEMs), between samples of healthy individuals and BC patients was implemented through Multimir package of R. Functional enrichment analysis of predicted target genes through Enrich R (online database) revealed that most of the genes are enriched in the mitochondrial outer membrane for cellular component, intrinsic apoptotic signaling regulations for biological processes, transcription co-receptor activity for molecular functions, and dopaminergic synapse pathway. Furthermore, our survival analysis results revealed that miR-29c and mir-361 have the potential to serve as prognostic biomarkers. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Pourgholamali, Babak AU - Pourgholamali B AUID- ORCID: 0000-0002-1259-2440 AD - Cellular and Molecular Research Center, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran. FAU - Sohrabi, Behnoush AU - Sohrabi B AUID- ORCID: 0000-0001-6357-5184 AD - Department of Biology, Faculty of Sciences, Arak University, Arak, Iran. FAU - Salbi, Mandana AU - Salbi M AUID- ORCID: 0000-0001-6957-9450 AD - Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran. FAU - Akbari, Sanaz AU - Akbari S AUID- ORCID: 0000-0001-9155-8728 AD - Nourdanesh Institute, Meymeh, Isfahan, Iran. FAU - Rastan, Iman AU - Rastan I AUID- ORCID: 0000-0002-1459-7341 AD - Department of Electronic and Electrical Engineering, Shiraz Azad University, Shiraz, Iran. FAU - Sayaf, Masoud AU - Sayaf M AUID- ORCID: 0000-0003-4573-9311 AD - Azad University Central Tehran Branch Faculty of Basic Sciences, Department of Cellular and Molecular Biology, Tehran, Iran. FAU - Jalil, Abduladheem Turki AU - Jalil AT AD - Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, 51001, Iraq. FAU - Kadhim, Mustafa M AU - Kadhim MM AD - Medical Laboratory Techniques Department, Al-Farahidi University, Baghdad, Iraq. AD - Department of Dentistry, Kut University College, Kut, Wasit, Iraq. FAU - Sheervalilou, Roghayeh AU - Sheervalilou R AUID- ORCID: 0000-0001-7996-845X AD - Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. sheervalilour@tbzmed.ac.ir. FAU - Mehrzad, Nazanin AU - Mehrzad N AUID- ORCID: 0000-0003-4881-0160 AD - Department of Biology, Science and Research Branch Islamic Azad university, Tehran, Iran. Nazy_mehrzad@yahoo.com. LA - eng PT - Journal Article DEP - 20220908 PL - United States TA - Appl Biochem Biotechnol JT - Applied biochemistry and biotechnology JID - 8208561 RN - 0 (Circulating MicroRNA) RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) SB - IM MH - Humans MH - Female MH - *Circulating MicroRNA/genetics MH - Prognosis MH - *Breast Neoplasms/diagnosis/genetics/pathology MH - Biomarkers, Tumor/genetics/metabolism MH - *MicroRNAs/genetics/metabolism MH - Computational Biology MH - Gene Expression Regulation, Neoplastic MH - Gene Expression Profiling OTO - NOTNLM OT - Bioinformatics OT - Breast cancer (BC) OT - Circulating microRNAs (miRNAs) OT - Differentially expressed miRNAs (DEMs) OT - Prognostic OT - Target genes EDAT- 2022/09/09 06:00 MHDA- 2023/01/13 06:00 CRDT- 2022/09/08 11:17 PHST- 2022/08/28 00:00 [accepted] PHST- 2022/09/09 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] PHST- 2022/09/08 11:17 [entrez] AID - 10.1007/s12010-022-04151-9 [pii] AID - 10.1007/s12010-022-04151-9 [doi] PST - ppublish SO - Appl Biochem Biotechnol. 2023 Jan;195(1):283-297. doi: 10.1007/s12010-022-04151-9. Epub 2022 Sep 8. PMID- 36592995 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230111 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 1 DP - 2023 Jan 2 TI - Effect of cognitive training on patients with breast cancer reporting cognitive changes: a systematic review and meta-analysis. PG - e058088 LID - 10.1136/bmjopen-2021-058088 [doi] LID - e058088 AB - OBJECTIVES: Cognitive training is a non-drug intervention to improve the cognitive function of participants by training them in different cognitive domains. We investigated the effectiveness of cognitive training for patients with breast cancer reporting cognitive changes. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Embase, Cochrane Library, WOS, CINAHL, CNKI, VIP, SinoMed, Wanfang, Grey literature and trial registries were searched (from inception to 1 October 1, 2022). ELIGIBILITY CRITERIA: Inclusion of randomized controlled trials (RCTs) assessing the effects of cognitive training on breast cancer patients reporting cognitive changes The primary outcome was subjective cognitive function. Secondary outcomes were objective cognitive functioning (eg, executive functioning and attention) and psychological outcomes(eg, anxiety, depression, and fatigue). DATA EXTRACTION AND SYNTHESIS: Two reviewers worked independently to screen the literature, extract data, and assess the methodological quality and risk bias of the included studies. Results are reported as standardizedstandardised mean differences (SMDs) with 95% confidence intervals(CI). Grades of Recommendation, Assessment, Development, and Evaluation(GRADE) were used to assess the quality of evidence. MAIN OUTCOMES AND MEASURES: The primary outcome was subjective cognitive function. Secondary outcomes were objective cognitive functioning (eg, executive functioning and attention) and psychological outcomes(eg, anxiety, depression and fatigue). RESULTS: A total of 9 RCTs involving 666 patients with breast cancer were included. The frequency of cognitive training varied and the duration was mostly focused on 5-12 weeks. It can be delivered to patients in an individual or group mode, both online and face to face. Meta-analysis revealed that cognitive training aimed at adaptive training in cognitive field has statistically significant effects on improving subjective cognitive function (SMD=0.30, 95% CI (0.08 to 0.51), moderate certainty). Some objective cognitive functions such as processing speed (SMD=0.28, 95% CI (0.02 to 0.54), low certainty), verbal memory (SMD=0.32, 95% CI (0.05 to 0.58), moderate certainty), working memory (SMD=0.39, 95% CI (0.17 to 0.61), moderate certainty) and episodic memory (SMD=0.40, 95% CI (0.11 to 0.69), moderate certainty) were significantly improved after the intervention. In addition, we did not find statistically significant changes in attention, short-term memory, execution function, depression, anxiety and fatigue in patients with breast cancer after the intervention. Subgroup analyses revealed that based on the delivery of individual sessions, the use of web-based cognitive training software may be more beneficial in improving the outcome of the intervention. CONCLUSION: Evidence of low to moderate certainty suggests that cognitive training may improve subjective cognition, processing speed, verbal memory, working memory and episodic memory in patients with breast cancer reporting cognitive changes. But it did not improve patients' attention, short-term memory, executive function, depression, anxiety and fatigue. PROSPERO REGISTRATION NUMBER: CRD42021264316. CI - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Yan, Xue AU - Yan X AUID- ORCID: 0000-0003-4425-2544 AD - Lanzhou University School of Nursing, Lanzhou, Gansu, China. FAU - Wei, Siqi AU - Wei S AD - Lanzhou University School of Nursing, Lanzhou, Gansu, China wsqlzu@163.com. FAU - Liu, Qianqian AU - Liu Q AD - Lanzhou University School of Nursing, Lanzhou, Gansu, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230102 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - Female MH - Cognitive Training MH - Quality of Life MH - *Breast Neoplasms/complications/therapy/psychology MH - Cognition MH - *Memory, Episodic MH - Fatigue/etiology/therapy PMC - PMC9809226 OTO - NOTNLM OT - Breast tumours OT - COMPLEMENTARY MEDICINE OT - MENTAL HEALTH OT - Rehabilitation medicine OT - SPORTS MEDICINE COIS- Competing interests: None declared. EDAT- 2023/01/03 06:00 MHDA- 2023/01/05 06:00 CRDT- 2023/01/02 20:42 PHST- 2023/01/02 20:42 [entrez] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/05 06:00 [medline] AID - bmjopen-2021-058088 [pii] AID - 10.1136/bmjopen-2021-058088 [doi] PST - epublish SO - BMJ Open. 2023 Jan 2;13(1):e058088. doi: 10.1136/bmjopen-2021-058088. PMID- 36593782 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230111 IS - 1564-0604 (Electronic) IS - 0042-9686 (Print) IS - 0042-9686 (Linking) VI - 101 IP - 1 DP - 2023 Jan 1 TI - Breast cancer molecular diagnostics in Rwanda: a cost-minimization study of immunohistochemistry versus a novel GeneXpert(®) mRNA expression assay. PG - 10-19 LID - 10.2471/BLT.22.288800 [doi] AB - OBJECTIVE: To compare the financial and time cost of breast cancer biomarker analysis by immunohistochemistry with that by the Xpert(®) STRAT4 assay. METHODS: We estimated costs (personnel, location, consumables and indirect) and time involved in breast cancer diagnosis at the Butaro Cancer Centre of Excellence, Rwanda, using time-driven activity-based costing. We performed a cost-minimization analysis to compare the cost of biomarker analysis for estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 status with immunohistochemistry versus STRAT4. We performed sensitivity analyses by altering laboratory-specific parameters for the two methods. FINDINGS: We estimated that breast cancer diagnosis in Rwanda costs 138.29 United States dollars (US$) per patient when conducting biomarker analysis by immunohistochemistry. At a realistic immunohistochemistry antibody utilization efficiency of 70%, biomarker analysis comprises 48.7% (US$ 67.33) of diagnostic costs and takes 33 min. We determined that biomarker analysis with STRAT4 yields a reduction in diagnosis cost of US$ 7.33 (10.9%; 7.33/67.33), and in pathologist and technician time of 20 min (60.6%; 20/33), per patient. Our sensitivity analysis revealed that no cost savings would be made in laboratories with antibody utilization efficiencies over 90%, or where only estrogen and/or progesterone receptor status are assessed; however, such operational efficiencies are unlikely, and more laboratories are pursuing human epidermal growth factor receptor-2 analysis as targeted therapies become increasingly available. CONCLUSION: Breast cancer biomarker analysis with STRAT4 has the potential to reduce the required human and capital resources in sub-Saharan African laboratories, leading to improved treatment selection and better clinical outcomes. CI - (c) 2023 The authors; licensee World Health Organization. FAU - Erfani, Parsa AU - Erfani P AD - Harvard Medical School, Boston, United States of America (USA). FAU - Gaga, Esther AU - Gaga E AD - University of Global Health Equity, Butaro, Rwanda. FAU - Hakizimana, Emmanuel AU - Hakizimana E AD - Ministry of Health, Butaro Hospital, Butaro, Rwanda. FAU - Kayitare, Emmanuel AU - Kayitare E AD - Ministry of Health, Butaro Hospital, Butaro, Rwanda. FAU - Mugunga, Jean Claude AU - Mugunga JC AD - Partners In Health, Boston, USA. FAU - Shyirambere, Cyprien AU - Shyirambere C AD - Partners In Health/Inshuti Mu Buzima, Butaro, Rwanda. FAU - Milner, Dan A AU - Milner DA AD - American Society for Clinical Pathology, Chicago, USA. FAU - Shulman, Lawrence N AU - Shulman LN AD - Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA. FAU - Ruhangaza, Deogratias AU - Ruhangaza D AD - Ministry of Health, Butaro Hospital, Butaro, Rwanda. FAU - Fadelu, Temidayo AU - Fadelu T AD - Dana-Farber Cancer Institute, 450 Brookline Avenue, MA-1B-17, Boston, Massachusetts02215, USA. LA - eng PT - Journal Article DEP - 20221102 PL - Switzerland TA - Bull World Health Organ JT - Bulletin of the World Health Organization JID - 7507052 RN - 0 (Biomarkers, Tumor) RN - 0 (Estrogens) RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/genetics MH - Biomarkers, Tumor/genetics MH - Rwanda MH - Immunohistochemistry MH - Pathology, Molecular MH - Estrogens MH - RNA, Messenger PMC - PMC9795380 EDAT- 2023/01/04 06:00 MHDA- 2023/01/05 06:00 CRDT- 2023/01/03 01:53 PHST- 2022/06/22 00:00 [received] PHST- 2022/09/23 00:00 [revised] PHST- 2022/10/04 00:00 [accepted] PHST- 2023/01/03 01:53 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/05 06:00 [medline] AID - BLT.22.288800 [pii] AID - 10.2471/BLT.22.288800 [doi] PST - ppublish SO - Bull World Health Organ. 2023 Jan 1;101(1):10-19. doi: 10.2471/BLT.22.288800. Epub 2022 Nov 2. PMID- 35689454 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230124 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 1 DP - 2023 Jan TI - Proposal of an automated tumor-stromal ratio assessment algorithm and a nomogram for prognosis in early-stage invasive breast cancer. PG - 131-145 LID - 10.1002/cam4.4928 [doi] AB - BACKGROUND: The tumor-stromal ratio (TSR) has been verified to be a prognostic factor in many solid tumors. In most studies, it was manually assessed on routinely stained H&E slides. This study aimed to assess the TSR using image analysis algorithms developed by the Qupath software, and integrate the TSR into a nomogram for prediction of the survival in invasive breast cancer (BC) patients. METHODS: A modified TSR assessment algorithm based on the recognition of tumor and stroma tissues was developed using the Qupath software. The TSR of 234 invasive BC specimens in H&E-stained tissue microarrays (TMAs) were assessed with the algorithm and categorized as stroma-low or stroma-high. The consistency of TSR estimation between Qupath prediction and pathologist annotation was analyzed. Univariable and multivariable analyses were applied to select potential risk factors and a nomogram for predicting survival in invasive BC patients was constructed and validated. An extra TMA containing 110 specimens was obtained to validate the conclusion as an independent cohort. RESULTS: In the discovery cohort, stroma-low and stroma-high were identified in 43.6% and 56.4% cases, respectively. Good concordance was observed between the pathologist annotated and Qupath predicted TSR. The Kaplan-Meier curve showed that stroma-high patients were associated with worse 5-DFS compared to stroma-low patients (p = 0.007). Multivariable analysis identified age, T stage, N status, histological grade, ER status, HER-2 gene, and TSR as potential risk predictors, which were included in the nomogram. The nomogram was well calibrated and showed a favorable predictive value for the recurrence of BC. Kaplan-Meier curves showed that the nomogram had a better risk stratification capability than the TNM staging system. In the external validation of the nomogram, the results were further validated. CONCLUSIONS: Based on H&E-stained TMAs, this study successfully developed image analysis algorithms for TSR assessment and constructed a nomogram for predicting survival in invasive BC. CI - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Xu, Qian AU - Xu Q AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, China. FAU - Chen, Yuan-Yuan AU - Chen YY AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, China. FAU - Luo, Ying-Hao AU - Luo YH AD - Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, China. FAU - Zheng, Jin-Sen AU - Zheng JS AD - Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, China. FAU - Lin, Zai-Huan AU - Lin ZH AD - Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, China. FAU - Xiong, Bin AU - Xiong B AD - Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, China. FAU - Wang, Lin-Wei AU - Wang LW AUID- ORCID: 0000-0002-9040-816X AD - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China. AD - Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, China. LA - eng GR - YL1400000032/the Project for Young and Middle-aged Medical Backbone Personnel of Wuhan City/ GR - 81701768/the Young Scientists Fund of National Natural Science Foundation/ GR - 81702901/the Young Scientists Fund of National Natural Science Foundation/ PT - Journal Article DEP - 20220611 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis MH - Nomograms MH - Prognosis MH - Neoplasm Staging MH - Algorithms PMC - PMC9844605 OTO - NOTNLM OT - breast cancer OT - image analysis algorithm OT - qupath OT - tumor stromal ratio COIS- The authors declare no conflict of interest. EDAT- 2022/06/12 06:00 MHDA- 2023/01/20 06:00 CRDT- 2022/06/11 04:12 PHST- 2022/05/11 00:00 [revised] PHST- 2022/01/09 00:00 [received] PHST- 2022/05/25 00:00 [accepted] PHST- 2022/06/12 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/06/11 04:12 [entrez] AID - CAM44928 [pii] AID - 10.1002/cam4.4928 [doi] PST - ppublish SO - Cancer Med. 2023 Jan;12(1):131-145. doi: 10.1002/cam4.4928. Epub 2022 Jun 11. PMID- 36648574 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230124 IS - 1433-7339 (Electronic) IS - 0941-4355 (Print) IS - 0941-4355 (Linking) VI - 31 IP - 2 DP - 2023 Jan 17 TI - Impact of the CALM intervention on breast cancer patients during the COVID-19 pandemic. PG - 121 LID - 10.1007/s00520-023-07582-0 [doi] LID - 121 AB - OBJECTIVE: The COVID-19 outbreak has adversely affected breast cancer patients both physically and mentally. Managing Cancer and Living Meaningfully (CALM) is a psychological intervention that is easy to implement. It also decreases the possibility of virus transmission because it can be administered online. Therefore, this study investigated the effects of CALM on the sleep quality, memory, psychological distress, and quality of life (QoL) of breast cancer patients during the ongoing COVID-19 pandemic. METHODS: Sixty breast cancer patients were recruited and randomly assigned to a CALM group and a Care as Usual (CAU) group. They filled in questionnaires before and after the CALM intervention and CAU. These included the Sleep Quality Scale (SQS), Prospective Memory Scale (PM), Retrospective Memory Scale (RM), Psychological Distress Thermometer (DT), and Quality of life (QoL) Scale. RESULTS: The scores of all the aforementioned scales after the CALM intervention (ACM) were significantly lower compared to the said scores before the CALM intervention (BCM) and after Care as Usual (ACU) (t = 12.369/8.013, t = 8.632/4.583, t = 7.500/6.900, t = 12.479/9.780, t = 12.224/6.729 respectively, P < 0.05) There was a linear correlation between the QoL, DT, and SQS scores. CONCLUSION: CALM is an effective psychotherapy for breast cancer patients, especially during the COVID-19 pandemic, for improving the QoL because it relieves psychological distress and enhances sleep quality. CI - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Pang, Lulian AU - Pang L AD - Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. FAU - Yao, Senbang AU - Yao S AD - Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. FAU - Li, Wen AU - Li W AD - Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. FAU - Jing, Yanyan AU - Jing Y AD - Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. FAU - Yin, Xiangxiang AU - Yin X AD - Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. FAU - Cheng, Huaidong AU - Cheng H AD - Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. chd1975ay@126.com. AD - The Third School of Clinical Medicine, Southern Medical University, Guangzhou, 510500, China. chd1975ay@126.com. AD - Department of Oncology, Shenzhen Hospital of Southern Medical University, Shenzhen, 518000, Guangdong, China. chd1975ay@126.com. LA - eng GR - 81872504/National Natural Science Foundation of China/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20230117 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/psychology MH - Quality of Life MH - Pandemics MH - Retrospective Studies MH - *COVID-19 PMC - PMC9843115 OTO - NOTNLM OT - Breast cancer; Sleep quality; Psychological distress; Quality of life; the CALM intervention; COVID-19 COIS- The authors declare no competing interests. EDAT- 2023/01/18 06:00 MHDA- 2023/01/20 06:00 CRDT- 2023/01/17 11:18 PHST- 2022/07/25 00:00 [received] PHST- 2023/01/06 00:00 [accepted] PHST- 2023/01/17 11:18 [entrez] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] AID - 10.1007/s00520-023-07582-0 [pii] AID - 7582 [pii] AID - 10.1007/s00520-023-07582-0 [doi] PST - epublish SO - Support Care Cancer. 2023 Jan 17;31(2):121. doi: 10.1007/s00520-023-07582-0. PMID- 36054865 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221229 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 41 IP - 1 DP - 2023 Jan 1 TI - Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer. PG - 32-42 LID - 10.1200/JCO.21.02473 [doi] AB - PURPOSE: Treatments for endocrine-refractory or triple-negative metastatic breast cancer (mBC) are modestly effective at prolonging life and improving quality of life but can be extremely expensive. Given these tradeoffs in quality of life and cost, the optimal choice of treatment sequencing is unclear. Cost-effectiveness analysis can explicitly quantify such tradeoffs, enabling more informed decision making. Our objective was to estimate the societal cost-effectiveness of different therapeutic alternatives in the first- to third-line sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative mBC. METHODS: Using three dynamic microsimulation models of 10,000 patients each, three cohorts were simulated, based upon prior chemotherapy exposure: (1) unexposed to either taxane or anthracycline, (2) taxane- and anthracycline-exposed, and (3) taxane-exposed/anthracycline-naive. We focused on the following single-agent chemotherapy regimens as reasonable and commonly used options in the first three lines of therapy for each cohort, based upon feedback from oncologists treating endocrine-refractory or triple-negative mBC: (1) for taxane- and anthracycline-unexposed patients, paclitaxel, capecitabine (CAPE), or pegylated liposomal doxorubicin; (2) for taxane- and anthracycline-exposed patients, Eribulin, CAPE, or carboplatin; and (3) for taxane-exposed/anthracycline-naive patients, pegylated liposomal doxorubicin, CAPE, or Eribulin. RESULTS: In each cohort, accumulated quality-adjusted life-years were similar between regimens, but total societal costs varied considerably. Sequences beginning first-line treatment with paclitaxel, carboplatin, and CAPE, respectively, for cohorts 1, 2, and 3, had lower costs and similar or slightly better outcomes compared with alternative options. CONCLUSION: In this setting where multiple single-agent chemotherapy options are recommended by clinical guidelines and share similar survival and adverse event trajectories, treatment sequencing approaches that minimize costs early may improve the value of care. FAU - Wheeler, Stephanie B AU - Wheeler SB AUID- ORCID: 0000-0002-3399-9047 AD - Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC. AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. AD - Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, NC. FAU - Rotter, Jason AU - Rotter J AD - Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC. FAU - Gogate, Anagha AU - Gogate A AUID- ORCID: 0000-0003-2891-8457 AD - Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC. FAU - Reeder-Hayes, Katherine E AU - Reeder-Hayes KE AUID- ORCID: 0000-0001-6903-0177 AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. AD - Division of Medical Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. FAU - Drier, Sarah W AU - Drier SW AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. FAU - Ekwueme, Donatus U AU - Ekwueme DU AD - Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC), Atlanta, GA. FAU - Fairley, Temeika L AU - Fairley TL AD - Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC), Atlanta, GA. FAU - Rocque, Gabrielle B AU - Rocque GB AUID- ORCID: 0000-0003-4188-9785 AD - Division of Hematology/Oncology, Departments of Medicine and Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, AL. FAU - Trogdon, Justin G AU - Trogdon JG AUID- ORCID: 0000-0001-5484-7870 AD - Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC. AD - Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. AD - Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, NC. LA - eng GR - U48DP005017/ACL/ACL HHS/United States PT - Journal Article DEP - 20220902 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - LR24G6354G (eribulin) RN - 0 (liposomal doxorubicin) RN - BG3F62OND5 (Carboplatin) RN - P88XT4IS4D (Paclitaxel) RN - 1605-68-1 (taxane) RN - 0 (Taxoids) RN - 80168379AG (Doxorubicin) RN - 6804DJ8Z9U (Capecitabine) RN - 0 (Antibiotics, Antineoplastic) SB - IM CIN - 3 MH - Humans MH - Female MH - Cost-Benefit Analysis MH - Carboplatin MH - *Quality of Life MH - *Breast Neoplasms/drug therapy/chemically induced MH - Paclitaxel/adverse effects MH - Taxoids MH - Doxorubicin/therapeutic use MH - Capecitabine MH - Antibiotics, Antineoplastic/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9788984 COIS- Gabrielle Rocque Consulting or Advisory Role: Pfizer, Flatiron Health, Gilead Sciences Research Funding: Carevive Systems, Genentech, Pfizer No other potential conflicts of interest were reported. EDAT- 2022/09/03 06:00 MHDA- 2022/12/27 06:00 PMCR- 2024/01/01 CRDT- 2022/09/02 16:02 PHST- 2024/01/01 00:00 [pmc-release] PHST- 2022/09/03 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/09/02 16:02 [entrez] AID - JCO.21.02473 [pii] AID - 10.1200/JCO.21.02473 [doi] PST - ppublish SO - J Clin Oncol. 2023 Jan 1;41(1):32-42. doi: 10.1200/JCO.21.02473. Epub 2022 Sep 2. PMID- 35701689 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1436-2813 (Electronic) IS - 0941-1291 (Linking) VI - 53 IP - 1 DP - 2023 Jan TI - Long-term course of the changes in the nipple position after breast-conserving surgery. PG - 52-61 LID - 10.1007/s00595-022-02531-6 [doi] AB - PURPOSE: Even if favorable cosmetic outcomes are obtained shortly after breast-conserving surgery (BCS), cosmetic changes may occur up to several years after BCS. In the present study, we evaluated cosmetic changes while focusing on changes in the nipple position after BCS. METHODS: We examined the long-term course of changes in the nipple position over time after BCS using the proportion of the distance between the sternal notch and nipple (PDSN) in 196 patients. We also evaluated risk factors for long-term nipple position changes. RESULTS: The median follow-up period was 9.9 years. Nipple position changes occurred within eight years after BCS and seemed to plateau beyond that point. The body mass index (BMI), breast size, proportion of excision volume and axillary treatment were significantly associated with the nipple position changes within one to five years after BCS. The BMI, breast size, axillary treatment, chemotherapy and hormonal therapy were significantly associated with the nipple position changes within five to eight years after BCS. CONCLUSIONS: After BCS, the nipple position changes occur within about eight years. Obesity, large breast size, large excision volume, axillary treatment, chemotherapy and hormone therapy were factors that affected the treated breast shrinkage and increase in the left-right difference after BCS. CI - © 2022. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. FAU - Kimoto, Mao AU - Kimoto M AD - Department of Breast Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. k-mao@med.mie-u.ac.jp. FAU - Ishitobi, Makoto AU - Ishitobi M AD - Department of Breast Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. FAU - Imai, Nao AU - Imai N AD - Department of Breast Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. FAU - Nakamura, Kaho AU - Nakamura K AD - Department of Breast Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. FAU - Kojima, Rena AU - Kojima R AD - Department of Breast Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. FAU - Hatakawa, Erina AU - Hatakawa E AD - Department of Breast Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. FAU - Ogawa, Tomoko AU - Ogawa T AD - Department of Breast Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. LA - eng PT - Journal Article DEP - 20220614 PL - Japan TA - Surg Today JT - Surgery today JID - 9204360 SB - IM MH - Humans MH - Female MH - Mastectomy, Segmental MH - Nipples/surgery MH - Retrospective Studies MH - *Mammaplasty MH - *Breast Neoplasms/surgery/etiology OTO - NOTNLM OT - Breast-conserving surgery OT - Nipple position OT - Oncoplastic breast surgery EDAT- 2022/06/15 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/06/14 23:33 PHST- 2022/01/31 00:00 [received] PHST- 2022/04/24 00:00 [accepted] PHST- 2022/06/15 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/06/14 23:33 [entrez] AID - 10.1007/s00595-022-02531-6 [pii] AID - 10.1007/s00595-022-02531-6 [doi] PST - ppublish SO - Surg Today. 2023 Jan;53(1):52-61. doi: 10.1007/s00595-022-02531-6. Epub 2022 Jun 14. PMID- 36688414 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1552-695X (Electronic) IS - 1534-7354 (Linking) VI - 22 DP - 2023 Jan-Dec TI - Comparison of Quality of Life Between Breast Cancer Patients Treated With and Without Adjunctive Traditional Chinese Medicine in Taiwan. PG - 15347354221150907 LID - 10.1177/15347354221150907 [doi] AB - In Taiwan, breast cancer has the highest incidence among all cancers. Although adjunctive traditional Chinese medicine treatment (TCM) have been used to ameliorate the side effects or discomfort caused by cancer treatments, no study has focused on the assessment of the quality of life of patients undergoing adjunctive TCM treatments. This study compared the quality of life between breast cancer patients treated with and without adjunctive TCM. Questionnaires were collected from 7 hospitals with a Chinese medicine clinic in 2018 to 2019. Breast cancer patients who had cancer stages I, II, or III and also underwent resection surgery were included in the study. They were divided into 2 groups: patients receiving cancer treatments with adjunctive traditional Chinese medicine (TCM group) and those receiving cancer treatments without adjunctive traditional Chinese medicine (non-TCM group). A 1:1 matching was used to obtain the study participants. The EQ-5D questionnaire was used to assess the quality of life. Statistical analysis was performed using the t-test and ANOVA to compare the differences between variables. The conditional multiple regression model was applied to explore the factors associated with quality of life in breast cancer patients. A total of 543 participants were surveyed, and 450 participants were included in the study. The EQ-5D score of the TCM group (81.60 ± 11.67) was significantly higher than that of the non-TCM group (78.80 ± 13.10; P < .05). The results of a conditional multiple regression model showed that the TCM group had a higher (3.45 points) quality of life than non-TCM group (P = .002) after adjusting for other related factors. After stratifying by cancer stage, patients with cancer stages II and III scored 5.58 and 4.35 points higher in the TCM group than did those in the non-TCM group (P < .05). Breast cancer patients undergoing cancer treatment with adjunctive traditional Chinese medicine have a higher quality of life than those treated without adjunctive traditional Chinese medicine. FAU - Chu, Yeong-Ruey AU - Chu YR AUID- ORCID: 0000-0002-5318-9527 AD - China Medical University, Taichung, Taiwan. FAU - Kung, Pei-Tseng AU - Kung PT AD - China Medical University, Taichung, Taiwan. AD - Asia University, Taichung, Taiwan. AD - China Medical University Hospital, Taichung, Taiwan. FAU - Liu, Liang-Chih AU - Liu LC AD - China Medical University Hospital, Taichung, Taiwan. FAU - Lin, Chin-Yao AU - Lin CY AD - Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan. FAU - Ou-Yang, Fu AU - Ou-Yang F AD - Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Yue, Chia-Herng AU - Yue CH AD - Tung's Taichung MetroHarbor Hospital, Taichung, Taiwan. FAU - Su, Shan-Yu AU - Su SY AD - China Medical University Hospital, Taichung, Taiwan. FAU - Chen, Ying-Yu AU - Chen YY AD - China Medical University Hospital, Taichung, Taiwan. FAU - Wang, Wen-Ching AU - Wang WC AD - Chi-Mei Medical Center, Tainan, Taiwan. FAU - Kao, Hui-Fen AU - Kao HF AD - Asia University Hospital, Taichung, Taiwan. FAU - Chou, Wen-Yu AU - Chou WY AD - China Medical University, Taichung, Taiwan. FAU - Tsai, Wen-Chen AU - Tsai WC AUID- ORCID: 0000-0002-9684-0789 AD - China Medical University, Taichung, Taiwan. LA - eng PT - Journal Article PL - United States TA - Integr Cancer Ther JT - Integrative cancer therapies JID - 101128834 RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Humans MH - Female MH - Medicine, Chinese Traditional MH - *Breast Neoplasms/drug therapy MH - Taiwan/epidemiology MH - Quality of Life MH - *Drugs, Chinese Herbal/therapeutic use OTO - NOTNLM OT - Chinese medicine treatment OT - EQ-5D OT - adjunctive traditional Chinese medicine OT - breast cancer OT - quality of life EDAT- 2023/01/24 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/23 06:22 PHST- 2023/01/23 06:22 [entrez] PHST- 2023/01/24 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.1177/15347354221150907 [doi] PST - ppublish SO - Integr Cancer Ther. 2023 Jan-Dec;22:15347354221150907. doi: 10.1177/15347354221150907. PMID- 36598048 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1526-2359 (Electronic) IS - 1073-2748 (Print) IS - 1073-2748 (Linking) VI - 30 DP - 2023 Jan-Dec TI - Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study. PG - 10732748221140289 LID - 10.1177/10732748221140289 [doi] LID - 10732748221140289 AB - PURPOSE: This retrospective analysis aimed to evaluate the clinical outcomes and cost-effectiveness of long-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia caused by chemotherapy for breast cancer. METHODS: Patients with breast cancer who received long- or short-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia were enrolled in this study, and incidences of neutropenia were compared between two groups. A decision-analytic and a Markov model were used to compare the health benefits and costs of utilizing long- vs short-acting granulocyte-colony stimulating factor as the primary prophylaxis from the perspective of the Chinese health service system. Subsequently, one-way deterministic and probabilistic sensitivity analyses were conducted. The incremental cost-effectiveness ratios were calculated in baseline and sensitivity analyses. RESULTS: Patients receiving long-acting granulocyte-colony stimulating factor as the primary prophylaxis of chemotherapy-induced neutropenia experienced a significant lower incidence of this adverse event, compared with the short-acting one for 2 to 7 days. The outcomes of baseline analysis indicated that long-acting granulocyte-colony stimulating factor had a gain of 0.08 quality-adjusted life years and costed $149 more than the short-acting one, yielding an incremental cost-effectiveness ratio of $1792 per quality-adjusted life year. The sensitivity analysis proved the stability of our models and economic efficiency of long-acting granulocyte-colony stimulating factor. CONCLUSIONS: Patients receiving long-acting granulocyte-colony stimulating factor as primary prophylaxis of neutropenia experienced lower risk of this event compared with those underusing short-acting one. The long-acting granulocyte-colony stimulating factor may be a more cost-effective strategy for primary prophylaxis of neutropenia than short-acting one, considering the Chinese willingness-to-pay threshold of $12158.6 per quality-adjusted life year. FAU - Wang, Yaqin AU - Wang Y AD - Department of pharmacy, 89632Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, China. FAU - Zhao, Chenglong AU - Zhao C AD - Department of pharmacy, 89632Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, China. FAU - Ma, Peizhi AU - Ma P AUID- ORCID: 0000-0002-6367-7137 AD - Department of pharmacy, 89632Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, China. FAU - Jiang, Dandan AU - Jiang D AD - Department of pharmacy, 89632Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, China. LA - eng PT - Journal Article PL - United States TA - Cancer Control JT - Cancer control : journal of the Moffitt Cancer Center JID - 9438457 RN - 143011-72-7 (Granulocyte Colony-Stimulating Factor) SB - IM MH - Humans MH - Female MH - Granulocyte Colony-Stimulating Factor/therapeutic use MH - *Breast Neoplasms/drug therapy MH - Retrospective Studies MH - Cost-Effectiveness Analysis MH - Cost-Benefit Analysis MH - *Neutropenia/chemically induced/prevention & control/drug therapy MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9827532 OTO - NOTNLM OT - ICER OT - chemotherapy-induced neutropenia OT - cost-effectiveness OT - granulocyte-colony stimulating factor OT - quality-adjusted life year COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/01/05 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/04 06:53 PHST- 2023/01/04 06:53 [entrez] PHST- 2023/01/05 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 10.1177_10732748221140289 [pii] AID - 10.1177/10732748221140289 [doi] PST - ppublish SO - Cancer Control. 2023 Jan-Dec;30:10732748221140289. doi: 10.1177/10732748221140289. PMID- 36683066 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230125 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Jan 22 TI - Racial disparities in breast cancer treatment patterns and treatment related adverse events. PG - 1233 LID - 10.1038/s41598-023-27578-4 [doi] LID - 1233 AB - The main objective of this work was to perform a comprehensive analysis and provide a race-stratified epidemiological report accounting for differences in treatment patterns and treatment related adverse events in Non-Hispanic women with breast cancer (BC). The cohort included women ≥ 18 years diagnosed with in-situ, early-stage, and late-stage BC (2005-2022). Treatment patterns included: surgery, breast radiation, chemotherapy, endocrine therapy, or biologic therapy. Treatment related adverse events were: chemotherapy complications, cardiovascular toxicities, immune-related adverse events, psychological affectations, or cognitive decline/dementia. The influence of race on the outcomes was measured via Cox proportional-hazards models. We included 17,454 patients (82% non-Hispanic Whites [NHW]). Most of the patients had a Charlson Comorbidity Score between 1 and 2 (68%), and TNM stage I (44.5%). Surgery was performed in 51.5% of the cases, while 30.6% received radiotherapy, 26.4% received chemotherapy, 3.1% received immunotherapy, and 41.2% received endocrine therapy. Non-Hispanic Blacks (NHB) had a lower probability of undergoing breast cancer surgery (aHR = 0.92, 95% CI 0.87-0.97) and of being prescribed endocrine therapy (aHR = 0.83, 95% CI 0.79-0.89), but a higher probability of receiving adjuvant radiotherapy (aHR = 1.40, 95% CI 1.29-1.52). Moreover, NHBs had lower risk of being diagnosed with psychological issues (aHR = 0.71, 95% CI 0.63-0.80) but a higher risk for cognitive decline/dementia (aHR = 1.30, 95% CI 1.08-1.56). In conclusion, NHB women diagnosed with BC were less likely than NHW to undergo curative intent surgery or receive endocrine therapy, and had a higher risk of cognitive decline/dementia after cancer treatment. Public policy measures are urgently needed which equalize access to quality healthcare for all patients and that promote a learning healthcare system which can improve cancer outcomes. CI - © 2023. The Author(s). FAU - Stabellini, Nickolas AU - Stabellini N AD - Graduate Education Office, Case Western Reserve University School of Medicine, Cleveland, OH, USA. nickolas@case.edu. AD - Department of Hematology-Oncology, University Hospitals/Seidman Cancer Center, Breen Pavilion - 11100 Euclid Ave, Cleveland, OH, 44106, USA. nickolas@case.edu. AD - Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. nickolas@case.edu. AD - Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA. nickolas@case.edu. FAU - Cullen, Jennifer AU - Cullen J AD - Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA. AD - Case Western Reserve University/Case Comprehensive Cancer Center, Cleveland, OH, USA. FAU - Cao, Lifen AU - Cao L AD - Department of Hematology-Oncology, University Hospitals/Seidman Cancer Center, Breen Pavilion - 11100 Euclid Ave, Cleveland, OH, 44106, USA. FAU - Shanahan, John AU - Shanahan J AD - Cancer Informatics, University Hospitals/Seidman Cancer Center, Cleveland, OH, USA. FAU - Hamerschlak, Nelson AU - Hamerschlak N AD - Oncohematology Department, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. FAU - Waite, Kristin AU - Waite K AD - Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. FAU - Barnholtz-Sloan, Jill S AU - Barnholtz-Sloan JS AD - Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. AD - Center for Biomedical Informatics and Information Technology (CBIIT), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. FAU - Montero, Alberto J AU - Montero AJ AD - Department of Hematology-Oncology, University Hospitals/Seidman Cancer Center, Breen Pavilion - 11100 Euclid Ave, Cleveland, OH, 44106, USA. AD - Case Western Reserve University/Case Comprehensive Cancer Center, Cleveland, OH, USA. AD - Center for Biomedical Informatics and Information Technology (CBIIT), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. LA - eng PT - Journal Article DEP - 20230122 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Ethnicity MH - White People MH - Black People MH - *Dementia MH - Healthcare Disparities PMC - PMC9868122 COIS- The authors declare no competing interests. JBS is a full-time, paid employee of the NCI/NIH. KW is a full-time, paid contractor of the NCI/NIH. EDAT- 2023/01/23 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/22 23:14 PHST- 2022/09/14 00:00 [received] PHST- 2023/01/04 00:00 [accepted] PHST- 2023/01/22 23:14 [entrez] PHST- 2023/01/23 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.1038/s41598-023-27578-4 [pii] AID - 27578 [pii] AID - 10.1038/s41598-023-27578-4 [doi] PST - epublish SO - Sci Rep. 2023 Jan 22;13(1):1233. doi: 10.1038/s41598-023-27578-4. PMID- 36660776 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1533-0338 (Electronic) IS - 1533-0338 (Linking) VI - 22 DP - 2023 Jan-Dec TI - Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis. PG - 15330338221150325 LID - 10.1177/15330338221150325 [doi] AB - Background: Lymph node downstaging and the achievement of total-pCR (ypT0/is ypN0) after neoadjuvant therapy are of great importance in HER-2 positive breast cancer. We aim to provide an overall review of neoadjuvant regimens for lymph node downstaging and to indirectly compare the total-pCR by various neoadjuvant regimens with network meta-analysis in HER2-positive patients according to their clinical lymph node status. Methods: Five English databases were searched comprehensively and systematically for relevant RCTs and case-control studies. The data extracted from the included studies were analyzed with the use of Review Manager 5.3 or STATA 15.0 software. Results: A total of 1508 published manuscripts were identified, and 17 studies including 4747 patients were finally included in our analysis. The network meta-analysis of total-pCR showed that dual-target therapy is significantly better than single-target therapy in clinically node-positive patients, and carboplatin performed significantly better than anthracycline in single-target condition. Lapatinib performed poorly in clinically node-positive patients. However, lapatinib in combination with trastuzumab was ranked at the top in the clinically node-negative group, and pertuzumab showed dissatisfied performance in contrast to the primacy of pertuzumab in clinically node-positive groups. Conclusion: In summary, different lymph node statuses led to the diverse first choice of neoadjuvant regimen. We highly recommended TCbHP as the first choice for the neoadjuvant treatment in clinically node-positive HER-2 positive breast cancer. Since lapatinib with trastuzumab ranked top in the clinically node-negative group, we looked forward to discovering the potential value of TKI in clinically node-negative patients, which needs further analysis in the future. FAU - Luo, Yunzhao AU - Luo Y AD - 74639Beijing Chaoyang Hospital of Capital Medical University, Beijing, China. FAU - Jiang, Hongchuan AU - Jiang H AD - 74639Beijing Chaoyang Hospital of Capital Medical University, Beijing, China. FAU - Liu, Chengjiang AU - Liu C AD - 12485Anhui Medical University, He Fei, China. FAU - Zhang, Chao AU - Zhang C AUID- ORCID: 0000-0001-8319-2252 AD - 74639Beijing Chaoyang Hospital of Capital Medical University, Beijing, China. LA - eng PT - Journal Article PT - Meta-Analysis PL - United States TA - Technol Cancer Res Treat JT - Technology in cancer research & treatment JID - 101140941 RN - 0VUA21238F (Lapatinib) RN - P188ANX8CK (Trastuzumab) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/etiology MH - Neoadjuvant Therapy/adverse effects MH - Lapatinib/therapeutic use MH - Network Meta-Analysis MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Trastuzumab/therapeutic use MH - Receptor, ErbB-2 OTO - NOTNLM OT - axillary lymph nodes OT - neoadjuvant target therapy OT - pathological complete response OT - personalized healthcare OT - precision medicine EDAT- 2023/01/21 06:00 MHDA- 2023/01/24 06:00 CRDT- 2023/01/20 02:22 PHST- 2023/01/20 02:22 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] AID - 10.1177/15330338221150325 [doi] PST - ppublish SO - Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221150325. doi: 10.1177/15330338221150325. PMID- 36335529 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Investigating the role of core needle biopsy in evaluating tumor-stroma ratio (TSR) of invasive breast cancer: a retrospective study. PG - 113-121 LID - 10.1007/s10549-022-06768-0 [doi] AB - PURPOSE: Tumor-stroma ratio (TSR) of invasive breast carcinoma has gained attention in recent years due to its prognostic significance. Previous studies showed TSR is a potential biomarker for indicating the tumor response to neoadjuvant chemotherapy. However, it is not clear how well TSR evaluation in biopsy specimens might reflect the TSR in resection specimens. We conducted a study to investigate whether biopsy evaluation of TSR can be an alternative method. METHOD: We collected cases with invasive breast carcinoma of no special type (IBC-NST) from University of Yamanashi hospital between 2011 and 2017 whose biopsy and resection specimens both had a pathologically diagnosis of IBC-NST (n = 146). We conceptualized a method for evaluating TSR in biopsy specimens within a preliminary cohort (n = 50). Within the studied cohort (n = 96), biopsy-based TSR (b-TSR) and resection-based TSR (r-TSR) were scored by two pathologists. We then evaluated our method's validity and performance by measuring interobserver variability between the two pathologists, Spearman's correlation between b-TSR and r-TSR, and the receiver operating characteristics (ROC) analysis for defining stroma-rich and stroma-poor tumors. RESULTS: Intra-class coefficient between the two pathologists was 0.59. The correlation coefficients between b-TSR and r-TSR in the two pathologists were 0.45 and 0.37. The ROC areas under the curve were 0.7 and 0.67. By considering an r-TSR of < 50% as stroma-rich, the sensitivity and specificity of detecting stroma-rich tumors were 64.1% and 66.7%, respectively, when b-TSR was < 40%. CONCLUSION: Our current b-TSR evaluation method can provide information about r-TSR and facilitate pre-treatment therapy follow-up. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Le, Minh-Khang AU - Le MK AD - Department of Pathology, University of Yamanashi, Yamanashi, 409-3898, Japan. FAU - Odate, Toru AU - Odate T AD - Department of Pathology, University of Yamanashi, Yamanashi, 409-3898, Japan. FAU - Kawai, Masataka AU - Kawai M AD - Department of Pathology, University of Yamanashi, Yamanashi, 409-3898, Japan. FAU - Oishi, Naoki AU - Oishi N AD - Department of Pathology, University of Yamanashi, Yamanashi, 409-3898, Japan. FAU - Kondo, Tetsuo AU - Kondo T AUID- ORCID: 0000-0003-2268-0302 AD - Department of Pathology, University of Yamanashi, Yamanashi, 409-3898, Japan. ktetsuo@yamanashi.ac.jp. LA - eng PT - Journal Article DEP - 20221106 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/surgery/drug therapy MH - Retrospective Studies MH - Biopsy, Large-Core Needle MH - Prognosis MH - Biopsy OTO - NOTNLM OT - Breast cancer OT - Core needle biopsy OT - Invasive breast carcinoma OT - Tumor-stroma ratio EDAT- 2022/11/07 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/06 14:01 PHST- 2022/04/05 00:00 [received] PHST- 2022/10/06 00:00 [accepted] PHST- 2022/11/07 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/06 14:01 [entrez] AID - 10.1007/s10549-022-06768-0 [pii] AID - 10.1007/s10549-022-06768-0 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):113-121. doi: 10.1007/s10549-022-06768-0. Epub 2022 Nov 6. PMID- 36652665 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 2473-4284 (Electronic) IS - 2473-4284 (Linking) VI - 7 DP - 2023 Jan TI - Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial. PG - e2200337 LID - 10.1200/PO.22.00337 [doi] AB - PURPOSE: Pathologic complete response (pCR) rates of patients with triple-negative breast cancer who were administered docetaxel plus carboplatin were significantly higher than those of patients administered epirubicin/cyclophosphamide followed by docetaxel in the neoadjuvant NeoCART trial. Here, we performed a preplanned secondary analysis of the homologous recombination deficiency (HRD) score as a predictor of the pCR in patients with triple-negative breast cancer from the NeoCART cohort. METHODS: Pretherapeutic tumor tissues were assessed retrospectively by DNA extraction and sequencing. BRCA1/2 mutations were evaluated in both somatic and germline forms. HRD scores were calculated from genome-wide allele-specific copy number results and comprised telomeric allelic imbalance, loss of heterozygosity, and large-scale state transitions. High HRD scores were defined as ≥ 38, and HRD was defined as either a high HRD score or a deleterious BRCA1/2 mutation. RESULTS: HRD testing was completed for 43 (79.6%) of 54 NeoCART cohort patients. Thirty of 43 (69.8%) tumors had high HRD scores, and eight patients had BRCA-mutated tumors. No significant association between BRCA1/2 mutation status and pCR was observed either in the general population or in the two treatment arms. Docetaxel plus carboplatin group patients who achieved pCR had higher HRD scores than non-pCR patients, and this difference approached significance (61.69 ± 24.26 v 39.44 ± 22.83, P = .061). No significant correlations between HRD scores and pCR (61.29 ± 24.02 v 53.21 ± 24.31, P = .480) or residual cancer burden 0/1 (62.50 ± 22.50 v 51.85 ± 24.74, P = .324) were observed in the epirubicin/cyclophosphamide followed by docetaxel group. CONCLUSION: HRD is a potential predictive biomarker for clinical benefit from neoadjuvant carboplatin-based chemotherapy and provides a possibility for screening the optimum chemotherapy backbone to combine with immunotherapy. FAU - Zhang, Liulu AU - Zhang L AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. FAU - Wu, Zhiyong AU - Wu Z AD - Diagnosis & Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, Guangdong, China. FAU - Li, Jie AU - Li J AD - Breast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangdong, China. FAU - Zhu, Dongqin AU - Zhu D AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China. FAU - Yang, Lingling AU - Yang L AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China. FAU - Shao, Yang AU - Shao Y AD - Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China. FAU - Lin, Ying AU - Lin Y AD - Breast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangdong, China. FAU - Liu, Zhenzhen AU - Liu Z AD - Department of Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. FAU - Cao, Yin AU - Cao Y AD - Breast Central, Dongguan People's Hospital, Dongguan, Guangdong, China. FAU - Zhang, Gangling AU - Zhang G AD - Breast Surgery, Baotou Cancer Hospital, Baotou, Inner Mongolia, China. FAU - Shang, Shiyao AU - Shang S AD - Department of Ultrasound, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. FAU - Zhang, Yi AU - Zhang Y AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. FAU - Wang, Kun AU - Wang K AUID- ORCID: 0000-0001-9851-7080 AD - Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. LA - eng SI - ClinicalTrials.gov/NCT03154749 PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - JCO Precis Oncol JT - JCO precision oncology JID - 101705370 RN - BG3F62OND5 (Carboplatin) RN - 3Z8479ZZ5X (Epirubicin) RN - 15H5577CQD (Docetaxel) RN - 0 (BRCA1 Protein) RN - 8N3DW7272P (Cyclophosphamide) SB - IM MH - Humans MH - Carboplatin/therapeutic use MH - Mutation MH - Epirubicin/therapeutic use MH - *Triple Negative Breast Neoplasms/drug therapy/genetics MH - Docetaxel/therapeutic use MH - Neoadjuvant Therapy/methods MH - Retrospective Studies MH - BRCA1 Protein/genetics MH - Homologous Recombination/genetics MH - Cyclophosphamide/therapeutic use EDAT- 2023/01/19 06:00 MHDA- 2023/01/21 06:00 CRDT- 2023/01/18 16:03 PHST- 2023/01/18 16:03 [entrez] PHST- 2023/01/19 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] AID - 10.1200/PO.22.00337 [doi] PST - ppublish SO - JCO Precis Oncol. 2023 Jan;7:e2200337. doi: 10.1200/PO.22.00337. PMID- 36648259 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230120 IS - 1879-1190 (Electronic) IS - 1072-7515 (Print) IS - 1072-7515 (Linking) VI - 236 IP - 2 DP - 2023 Feb 1 TI - Evaluating the Role of Circulating MicroRNAs in Predicting Long-Term Survival Outcomes in Breast Cancer: A Prospective, Multicenter Clinical Trial. PG - 317-327 LID - 10.1097/XCS.0000000000000465 [doi] AB - BACKGROUND: While long-term outcomes have improved for patients with breast cancer, 20% to 30% will still develop recurrence, and identifying these patients remains a challenge. MicroRNAs (miRNAs) are small, noncoding molecules that modulate genetic expression and affect oncogenesis. STUDY DESIGN: This prospective, multicenter trial (ICORG10/11-NCT01722851) recruited patients undergoing neoadjuvant chemotherapy across 8 Irish centers. Predetermined miRNAs were quantified from patient whole blood using quantitative reverse transcriptase polymerase chain reaction. Venous sampling was performed at diagnosis (timepoint 1) and midway during neoadjuvant chemotherapy (timepoint 2 [T2]). miRNA expression profiles were correlated with recurrence-free survival (RFS), disease-free survival (DFS), and overall survival. Data analysis was performed using R v3.2.3. RESULTS: A total of 124 patients were recruited with a median age of 55.0 years. The median follow-up was 103.1 months. Increased miR-145 expression at T2 was associated with improved RFS (hazard ratio 0.00; 95% confidence interval [CI] 0.00 to 0.99; p = 0.050). Using survival regression tree analysis, a relative cutoff of increased miR-145 expression greater than 0.222 was associated with improved RFS (p = 0.041). Increased miR-145 expression at T2 trended towards significance in predicting improved DFS (hazard ratio 0.00; 95% CI 0.00 to 1.42; p = 0.067). Using survival regression tree analysis, a relative cutoff of increased miR-145 expression greater than 0.222 was associated with improved DFS (p = 0.012). No miRNAs correlated with overall survival. CONCLUSIONS: ICORG10/11 is the first Irish multicenter, translational research trial evaluating circulatory miRNAs as biomarkers predictive of long-term survival and correlated increased miR-145 expression with enhanced outcomes in early-stage breast cancer. Validation of these findings is required in the next generation of translational research trials. CI - Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American College of Surgeons. FAU - Davey, Matthew G AU - Davey MG AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). FAU - McGuire, Andrew AU - McGuire A AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). FAU - Casey, Maire Caitlin AU - Casey MC AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). FAU - Waldron, Ronan M AU - Waldron RM AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). FAU - Paganga, Maxwell AU - Paganga M AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). AD - the School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway, Galway, Ireland (Paganga, Holian, Newell). FAU - Holian, Emma AU - Holian E AD - the School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway, Galway, Ireland (Paganga, Holian, Newell). FAU - Newell, John AU - Newell J AD - the School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway, Galway, Ireland (Paganga, Holian, Newell). FAU - Heneghan, Helen M AU - Heneghan HM AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). FAU - McDermott, Ailbhe M AU - McDermott AM AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). FAU - Keane, Maccon M AU - Keane MM AD - the Department of Medical Oncology, Galway University Hospital, Galway, Ireland (Keane). FAU - Lowery, Aoife J AU - Lowery AJ AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). FAU - Miller, Nicola AU - Miller N AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). FAU - Kerin, Michael J AU - Kerin MJ AD - From the Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Ireland (Davey, McGuire, Casey, Waldron, Heneghan, McDermott, Lowery, Miller, Kerin). AD - the Cancer Trials Ireland, Innovation House, Dublin, Ireland (Kerin). LA - eng PT - Journal Article PT - Multicenter Study DEP - 20221102 PL - United States TA - J Am Coll Surg JT - Journal of the American College of Surgeons JID - 9431305 RN - 0 (Circulating MicroRNA) RN - 0 (MicroRNAs) RN - 0 (Biomarkers, Tumor) RN - 0 (MIRN145 microRNA, human) SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Circulating MicroRNA/genetics/therapeutic use MH - *Breast Neoplasms/therapy/drug therapy MH - Prospective Studies MH - Neoplasm Staging MH - *MicroRNAs MH - Biomarkers, Tumor/genetics MH - Prognosis MH - Gene Expression Regulation, Neoplastic PMC - PMC9835657 COIS- Disclosure Information: Nothing to disclose. Disclosures outside the scope of this work: Dr Kerin is a paid consultant to Wavelia. The other authors have nothing to disclose. EDAT- 2023/01/18 06:00 MHDA- 2023/01/20 06:00 CRDT- 2023/01/17 09:23 PHST- 2023/01/17 09:23 [entrez] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] AID - 00019464-202302000-00006 [pii] AID - 10.1097/XCS.0000000000000465 [doi] PST - ppublish SO - J Am Coll Surg. 2023 Feb 1;236(2):317-327. doi: 10.1097/XCS.0000000000000465. Epub 2022 Nov 2. PMID- 35527100 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1878-4046 (Electronic) IS - 1076-6332 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - Pregnancy Associated Breast Cancer Among Israeli BRCA1/BRCA2 Carriers in a High-Risk Clinic. PG - 248-254 LID - S1076-6332(22)00207-0 [pii] LID - 10.1016/j.acra.2022.03.030 [doi] AB - RATIONALE AND OBJECTIVES: Female carriers of pathogenic sequence variants (PSVs) in the BRCA1 /BRCA2 (Breast Cancer gene - BRCA) genes are at a substantially high-risk for developing breast cancer (BC), hence are offered active surveillance scheme based on semiannual breast exam and imaging from age 25 years to facilitate BC early detection (mammography/breast ultrasound depending on the age, and MRI). However, there are not specific guidelines for screening in case of pregnancy or lactation. In the current study, we summarize the experience at the largest high-risk clinic in Israel. MATERIALS AND METHODS: Data of consecutive BRCA-PSV carriers undergoing surveillance as well as diagnostic ultrasound at the Meirav high-risk clinic from January 2014 to 2021 who were pregnant and/or breastfeeding at time of follow-up were identified. Relevant clinical data including results of breast exam, breast ultrasonography, biopsies and histological results were retrieved. Percentage of biopsies with malignancy, cancer detection rate and positive predictive values were calculated. Data is presented in descriptive statistics. RESULTS: A total of 263 BRCA-carriers were included. Of these, 593 breast-ultrasonograms were performed in 263 BRCA-carriers for 292 pregnancies and 409 breast-ultrasonograms for 175 breastfeeding carriers. Of 36 breast biopsies in 292 pregnancies, 4 (PPV = 11%) had BC diagnosed (high grade invasive). Of 175 breastfeeding women, 25 biopsies were performed and 2 (PPV = 8%) were high grade invasive BC. Five of 6 BC were diagnosed in BRCA1 carriers, and 4/6 were screen detected. The rate of pregnancy-associated breast cancer was 6/292 (2.05%). CONCLUSION: The overall detection rate of pregnancy-associated BC in BRCA-carriers is relatively low (2.05%), but still much higher than that in the general population. Two thirds of the BC were detected by screening. Therefore, despite the changes of the glandular breast tissue at time of pregnancy and breastfeeding, screening plays an important role in early detection. Ultrasound should be considered as a screening tool during this period of life of high-risk patients. CI - Copyright © 2022 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved. FAU - Faermann, Renata AU - Faermann R AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. Electronic address: rfaermann@gmail.com. FAU - Friedman, Eitan AU - Friedman E AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Kaidar-Person, Orit AU - Kaidar-Person O AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Brodsky, Malka AU - Brodsky M AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Neiman, Osnat Halshtok AU - Neiman OH AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Shalmon, Anat AU - Shalmon A AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Gotlieb, Michael AU - Gotlieb M AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Yagil, Yael AU - Yagil Y AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Samocha, David AU - Samocha D AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Feldman, Dana Madorsky AU - Feldman DM AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Weidenfeld, Jonathan AU - Weidenfeld J AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. FAU - Sklair-Levy, Miri AU - Sklair-Levy M AD - Meirav Center for Women's Health and High-Risk clinic (R.F., E.F., M.B., O.H.N, A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Division of Diagnostic Imaging (R.F., O.H.N., A.S., M.G., Y.Y., D.S., M.S.L.), Sheba Medical Center, Ramat Gan, Israel; Department of Radiation Oncology (O.K.P.), Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine (R.F., E.F., O.K.P., O.H.N., A.S., M.G., Y.Y., D.S., D.M.F., M.S.L.), Tel-Aviv University, Tel- Aviv, Ramat Gan, Israel; Department of Pathology (J.W.), Sheba Medical Center, Ramat Gan, Israel. LA - eng PT - Journal Article DEP - 20220506 PL - United States TA - Acad Radiol JT - Academic radiology JID - 9440159 RN - 0 (BRCA2 Protein) RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA2 protein, human) SB - IM MH - Pregnancy MH - Humans MH - Female MH - Adult MH - *Breast Neoplasms/diagnostic imaging/epidemiology/genetics MH - Israel/epidemiology MH - Mutation MH - BRCA2 Protein/genetics MH - Genes, BRCA2 MH - BRCA1 Protein/genetics MH - Mammography OTO - NOTNLM OT - BRCA1 BRCA2 mutation carriers OT - Breast cancer OT - Breastfeeding OT - Early detection OT - Imaging OT - Lactation OT - Pregnancy OT - Pregnancy-associated breast cancer EDAT- 2022/05/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/05/08 22:04 PHST- 2022/01/03 00:00 [received] PHST- 2022/03/26 00:00 [revised] PHST- 2022/03/30 00:00 [accepted] PHST- 2022/05/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/05/08 22:04 [entrez] AID - S1076-6332(22)00207-0 [pii] AID - 10.1016/j.acra.2022.03.030 [doi] PST - ppublish SO - Acad Radiol. 2023 Feb;30(2):248-254. doi: 10.1016/j.acra.2022.03.030. Epub 2022 May 6. PMID- 36611214 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1757-2215 (Electronic) IS - 1757-2215 (Linking) VI - 16 IP - 1 DP - 2023 Jan 7 TI - Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. PG - 6 LID - 10.1186/s13048-023-01094-5 [doi] LID - 6 AB - As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment of ovarian cancer, the five-year survival rate of patients is still less than 50%. Based on the concept of synthetic lethality, poly (ADP- ribose) polymerase (PARP) inhibitors target tumor cells with defects in homologous recombination repair(HRR), the most significant being the target gene Breast cancer susceptibility genes(BRCA). PARP inhibitors capture PARP-1 protein at the site of DNA damage to destroy the original reaction, causing the accumulation of PARP-DNA nucleoprotein complexes, resulting in DNA double-strand breaks(DSBs) and cell death. PARP inhibitors have been approved for the treatment of ovarian cancer for several years and achieved good results. However, with the widespread use of PARP inhibitors, more and more attention has been paid to drug resistance and side effects. Therefore, further research is needed to understand the mechanism of PARP inhibitors, to be familiar with the adverse reactions of the drug, to explore the markers of its efficacy and prognosis, and to deal with its drug resistance. This review elaborates the use of PARP inhibitors in ovarian cancer. CI - © 2023. The Author(s). FAU - Wu, Yongsong AU - Wu Y AD - Department of Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai200092, China. AD - Obstetrics and Gynecology, School of Medicine, Renji Hospital, Shanghai Jiaotong University, Shanghai, China. FAU - Xu, Shilin AU - Xu S AD - Obstetrics and Gynecology, School of Medicine, Renji Hospital, Shanghai Jiaotong University, Shanghai, China. FAU - Cheng, Shanshan AU - Cheng S AD - Obstetrics and Gynecology, School of Medicine, Renji Hospital, Shanghai Jiaotong University, Shanghai, China. FAU - Yang, Jiani AU - Yang J AD - Department of Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai200092, China. sjtuyangjiani@163.com. FAU - Wang, Yu AU - Wang Y AD - Department of Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai200092, China. renjiwangyu@126.com. LA - eng GR - 21S31903600/Science and Technology Commission of Shanghai Municipality/ GR - 21S31903600/Science and Technology Commission of Shanghai Municipality/ GR - 21S31903600/Science and Technology Commission of Shanghai Municipality/ GR - 21S31903600/Science and Technology Commission of Shanghai Municipality/ GR - 21S31903600/Science and Technology Commission of Shanghai Municipality/ GR - 82072866, 82272888/National Natural Science Foundation of China/ GR - 82072866, 82272888/National Natural Science Foundation of China/ GR - 82072866, 82272888/National Natural Science Foundation of China/ GR - 82072866, 82272888/National Natural Science Foundation of China/ GR - 82072866, 82272888/National Natural Science Foundation of China/ GR - SHDC2022CRW013, SHDC12022106, SHDC2022CRT015, SHDC12021601, 2022SKLY-12/Shanghai Hospital Development Center Foundation/ GR - SHDC2022CRW013, SHDC12022106, SHDC2022CRT015, SHDC12021601, 2022SKLY-12/Shanghai Hospital Development Center Foundation/ GR - SHDC2022CRW013, SHDC12022106, SHDC2022CRT015, SHDC12021601, 2022SKLY-12/Shanghai Hospital Development Center Foundation/ GR - SHDC2022CRW013, SHDC12022106, SHDC2022CRT015, SHDC12021601, 2022SKLY-12/Shanghai Hospital Development Center Foundation/ GR - SHDC2022CRW013, SHDC12022106, SHDC2022CRT015, SHDC12021601, 2022SKLY-12/Shanghai Hospital Development Center Foundation/ GR - PYII20-02/Cultivation Fund of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine/ GR - PYII20-02/Cultivation Fund of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine/ GR - PYII20-02/Cultivation Fund of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine/ GR - PYII20-02/Cultivation Fund of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine/ GR - PYII20-02/Cultivation Fund of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine/ PT - Journal Article PT - Review DEP - 20230107 PL - England TA - J Ovarian Res JT - Journal of ovarian research JID - 101474849 RN - 0 (Poly(ADP-ribose) Polymerase Inhibitors) RN - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases) SB - IM MH - Humans MH - Female MH - Poly(ADP-ribose) Polymerase Inhibitors/pharmacology/therapeutic use MH - *Ovarian Neoplasms/drug therapy/genetics/pathology MH - DNA Repair MH - Poly(ADP-ribose) Polymerases/genetics/metabolism/therapeutic use MH - *Breast Neoplasms/drug therapy PMC - PMC9826575 OTO - NOTNLM OT - BRCA OT - Biomarkers OT - Chemotherapy resistance OT - Homologous recombination repair OT - Ovarian cancer OT - PARP inhibitor OT - Side effect OT - Synthetic lethality COIS- The authors declare no potential conflicts of interest. EDAT- 2023/01/08 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/07 23:26 PHST- 2022/08/24 00:00 [received] PHST- 2023/01/02 00:00 [accepted] PHST- 2023/01/07 23:26 [entrez] PHST- 2023/01/08 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - 10.1186/s13048-023-01094-5 [pii] AID - 1094 [pii] AID - 10.1186/s13048-023-01094-5 [doi] PST - epublish SO - J Ovarian Res. 2023 Jan 7;16(1):6. doi: 10.1186/s13048-023-01094-5. PMID- 36543006 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1879-0534 (Electronic) IS - 0010-4825 (Linking) VI - 152 DP - 2023 Jan TI - Study of potential inhibition of the estrogen receptor α by cannabinoids using an in silico approach: Agonist vs antagonist mechanism. PG - 106403 LID - S0010-4825(22)01111-8 [pii] LID - 10.1016/j.compbiomed.2022.106403 [doi] AB - Breast cancer is the main cancer type with more than 2.2 million cases in 2020, and is the principal cause of death in women; with 685000 deaths in 2020 worldwide. The estrogen receptor is involved at least in 70% of breast cancer diagnoses, and the agonist and antagonist properties of the drug in this receptor play a pivotal role in the control of this illness. This work evaluated the agonist and antagonist mechanisms of 30 cannabinoids by employing molecular docking and dynamic simulations. Compounds with docking scores < -8 kcal/mol were analyzed by molecular dynamic simulation at 300 ns, and relevant insights are given about the protein's structural changes, centered on the helicity in alpha-helices H3, H8, H11, and H12. Cannabicitran was the cannabinoid that presented the best relative binding-free energy (-34.96 kcal/mol), and based on rational modification, we found a new natural-based compound with relative binding-free energy (-44.83 kcal/mol) better than the controls hydroxytamoxifen and acolbifen. Structure modifications that could increase biological activity are suggested. CI - Copyright © 2022 Elsevier Ltd. All rights reserved. FAU - Rocha-Roa, Cristian AU - Rocha-Roa C AD - Biophysics of Tropical Diseases, Max Planck Tandem Group, University of Antioquia, Medellín, Colombia; Grupo GEPAMOL, Centro de Investigaciones Biomédicas, Universidad del Quindío, Armenia, 630004, Colombia. Electronic address: cristian.rocha@udea.edu.co. FAU - Cortes, Eliceo AU - Cortes E AD - Life Science Research Center, Universidad Simón Bolivar, Barranquilla, 080002, Colombia. Electronic address: eliceo.cortes@unisimon.edu.co. FAU - Cuesta, Sebastián A AU - Cuesta SA AD - Instituto de Simulación Computacional (ISC), Departamento de Ingeniería Química, Universidad San Francisco de Quito, Diego de Robles y Vía Interoceánica, Quito, 170901, Ecuador. Electronic address: morajru@gmail.com. FAU - Mora, José R AU - Mora JR AD - Instituto de Simulación Computacional (ISC), Departamento de Ingeniería Química, Universidad San Francisco de Quito, Diego de Robles y Vía Interoceánica, Quito, 170901, Ecuador. FAU - Paz, José L AU - Paz JL AD - Departamento Académico de Química Inorgánica, Facultad de Química e Ingeniería Química, Universidad Nacional Mayor de San Marcos, Lima, 15081, Peru. FAU - Flores-Sumoza, Máryury AU - Flores-Sumoza M AD - Grupo de Investigación en Química y Biología, Departamento de Química y Biología, Universidad del Norte, Km 5 Vía Puerto Colombia 1569, Barranquilla, Atlántico, 081007, Colombia. FAU - Márquez, Edgar A AU - Márquez EA AD - Grupo de Investigación en Química y Biología, Departamento de Química y Biología, Universidad del Norte, Km 5 Vía Puerto Colombia 1569, Barranquilla, Atlántico, 081007, Colombia. Electronic address: ebrazon@uninorte.edu.co. LA - eng PT - Journal Article DEP - 20221208 PL - United States TA - Comput Biol Med JT - Computers in biology and medicine JID - 1250250 RN - 0 (Estrogen Receptor alpha) RN - 0 (Cannabinoids) RN - 0 (Ligands) SB - IM MH - Female MH - Humans MH - Estrogen Receptor alpha/chemistry MH - Molecular Docking Simulation MH - *Cannabinoids/pharmacology MH - Molecular Dynamics Simulation MH - *Breast Neoplasms/drug therapy MH - Ligands OTO - NOTNLM OT - Cannabinoids OT - Drug discovery OT - Estrogen receptor alpha OT - Molecular modelling OT - Structure-activity relationship COIS- Declaration of competing interest The authors declare no conflict of interest. EDAT- 2022/12/22 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/12/21 18:14 PHST- 2022/09/22 00:00 [received] PHST- 2022/11/13 00:00 [revised] PHST- 2022/12/03 00:00 [accepted] PHST- 2022/12/22 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/12/21 18:14 [entrez] AID - S0010-4825(22)01111-8 [pii] AID - 10.1016/j.compbiomed.2022.106403 [doi] PST - ppublish SO - Comput Biol Med. 2023 Jan;152:106403. doi: 10.1016/j.compbiomed.2022.106403. Epub 2022 Dec 8. PMID- 36050608 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1432-2218 (Electronic) IS - 0930-2794 (Print) IS - 0930-2794 (Linking) VI - 37 IP - 1 DP - 2023 Jan TI - Pediatric endoscopic subcutaneous mastectomy (pesma) with liposuction in adolescents with gynecomastia. PG - 766-773 LID - 10.1007/s00464-022-09550-x [doi] AB - BACKGROUND: Surgical techniques for treatment of gynecomastia are increasingly less invasive. We described technical standardization of pediatric endoscopic subcutaneous mastectomy (PESMA) with liposuction. METHODS: All adolescents with primary gynecomastia, operated using PESMA with liposuction over the period June 2014-July 2021, were included. The video recording of procedures was analyzed to standardize the operative technique. After patient installation, 3 trocars were placed on the mid-axillary line. The technique included 5 steps: (1) subcutaneous injection of lipolysis solution and liposuction; (2) creation of working space using an inflated balloon; (3) gland dissection using 5-mm sealing device; (4) specimen extraction through the largest trocar orifice; and (5) placement of suction drainage tube. RESULTS: Twenty-four male adolescents, operated for Simon's grade 2B and 3 gynecomastia using PESMA with liposuction over the study period, were included. Mean patient age was 16 years (range 15-18). Gynecomastia was bilateral in 19/24 (79.2%) and unilateral in 5/24 (20.8%). One (4.1%) conversion to open was reported. The mean operative time was 87 min (range 98-160) for unilateral and 160 min (range 140-250) for bilateral procedure. The mean length of stay was 2.2 days (range 1-4). Patients wore a thoracic belt for 15 up to 30 days postoperatively. Post-operative complications occurred in 5/24 (20.8%): 2- or 3 mm second-degree burns in 4 (16.7%) and subcutaneous seroma in 1 (4.1%). All complications were Clavien 2 grade and did not require further treatment. Aesthetic outcomes were very good in 21/24 (87.5%). Three (12.5%) boys had persistent minimal breast asymmetry but did never perceive it negatively. CONCLUSION: PESMA combined with liposuction was feasible and safe for surgical treatment of gynecomastia in this selected cohort of patients. Although challenging, this procedure provided good aesthetic results, with no scars on the anterior thoracic wall. Standardization of the operative technique was a key point for successful outcome. CI - © 2022. The Author(s). FAU - Varlet, François AU - Varlet F AD - Division of Pediatric Surgery, Centre Hospitalier Universitaire (CHU) de Saint-Etienne, Saint-Etienne, France. FAU - Esposito, Ciro AU - Esposito C AD - Division of Pediatric Surgery, Federico II University Hospital, Via Pansini 5, 80131, Naples, Italy. ciroespo@unina.it. FAU - Scalabre, Aurelien AU - Scalabre A AD - Division of Pediatric Surgery, Centre Hospitalier Universitaire (CHU) de Saint-Etienne, Saint-Etienne, France. FAU - Lepore, Benedetta AU - Lepore B AD - Division of Pediatric Surgery, Federico II University Hospital, Via Pansini 5, 80131, Naples, Italy. FAU - Vermersch, Sophie AU - Vermersch S AD - Division of Pediatric Surgery, Centre Hospitalier Universitaire (CHU) de Saint-Etienne, Saint-Etienne, France. FAU - Escolino, Maria AU - Escolino M AD - Division of Pediatric Surgery, Federico II University Hospital, Via Pansini 5, 80131, Naples, Italy. LA - eng PT - Journal Article DEP - 20220901 PL - Germany TA - Surg Endosc JT - Surgical endoscopy JID - 8806653 SB - IM MH - Humans MH - Male MH - Adolescent MH - Child MH - Female MH - *Gynecomastia/surgery MH - *Mastectomy, Subcutaneous/methods MH - *Lipectomy/methods MH - *Breast Neoplasms/surgery MH - Mastectomy MH - Retrospective Studies MH - Treatment Outcome PMC - PMC9839820 OTO - NOTNLM OT - Adolescents OT - Endoscopic OT - Gynecomastia OT - Liposuction OT - MIS OT - Technique COIS- Drs François Varlet, Ciro Esposito, Aurelien Scalabre, Benedetta Lepore, Sophie Vermersch, and Maria Escolino have no conflicts of interest or financial ties to disclose. EDAT- 2022/09/02 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/09/01 23:39 PHST- 2022/05/21 00:00 [received] PHST- 2022/08/07 00:00 [accepted] PHST- 2022/09/02 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/09/01 23:39 [entrez] AID - 10.1007/s00464-022-09550-x [pii] AID - 9550 [pii] AID - 10.1007/s00464-022-09550-x [doi] PST - ppublish SO - Surg Endosc. 2023 Jan;37(1):766-773. doi: 10.1007/s00464-022-09550-x. Epub 2022 Sep 1. PMID- 36057014 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Print) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies. PG - 88-100 LID - 10.1007/s12282-022-01399-1 [doi] AB - BACKGROUND: Bevacizumab (BV) plus paclitaxel (PTX) is a treatment option in patients with HER2-negative metastatic breast cancer (mBC). We conducted an international pooled analysis with individual patient data to evaluate the effectiveness of BV + PTX as a first-line treatment for HER2-negative mBC patients under routine practice. METHODS: A total of 2,474 mBC patients treated with BV + PTX from four prospective observational studies were analyzed. The primary endpoint was overall survival (OS). The other endpoints including identifying independent prognostic factors and validation of the modified Prognostic Factor Index (PFI) developed in the ATHENA trial. RESULTS: Median follow-up time was 10.9 months (M). Median OS were 21.4 M (95% confidential interval 19.8-22.7 M). The seven independent prognostic factors (tumor subtype, age, ECOG performance status (PS), disease-free interval (DFI), liver metastases, number of metastatic organs, and prior anthracycline and/or taxane treatment) for OS found in this analysis included the five risk factors (RFs [DFI < 24 months, ECOG PS 2, liver metastases and/or > 3 metastasis organ sites, TNBC, prior anthracycline and/or taxane therapy]). High- (> 3 RFs [median OS 12.6 M]) and intermediate-risk groups (2 RFs [median OS 18.0 M]) had a significantly worse prognosis than the low-risk group (< 1 RF [median OS 27.4 M]), (p < 0.0001). CONCLUSIONS: This international pooled analysis showed the effectiveness of first-line BV + PTX for HER2-negative mBC patients identifying seven independent prognostic factors as real-world evidence. The usefulness of the modified PFI developed in the ATHENA trial in predicting OS among patients receiving BV + PTX was also verified. CI - © 2022. The Author(s). FAU - Yamamoto, Yutaka AU - Yamamoto Y AUID- ORCID: 0000-0001-6147-6828 AD - Department of Breast and Endocrine Surgery, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. yyamamoto@kumamoto-u.ac.jp. FAU - Yamashiro, Hiroyasu AU - Yamashiro H AD - Department of Breast and Endocrine Surgery, Tenri Hospital, Tenri, Japan. FAU - Schneeweiss, Andreas AU - Schneeweiss A AD - Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany. FAU - Müller, Volkmar AU - Müller V AD - Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany. FAU - Gluz, Oleg AU - Gluz O AD - Breast Center Niederrhein, Evangelical Hospital Johanniter Bethesda, Moenchengladbach, Germany. FAU - Klare, Peter AU - Klare P AD - Clinic for Cancer Medicine for Women/Breast Center, Berlin, Germany. FAU - Aktas, Bahriye AU - Aktas B AD - Department of Gynecology and Obstetrics, University of Essen, Essen, Germany. AD - Department of Gynecology, University of Leipzig, Leipzig, Germany. FAU - Magdolna, Dank AU - Magdolna D AD - 1st Department of Internal Medicine Division of Oncology, Semmelweis University, Budapest, Hungary. FAU - Büdi, László AU - Büdi L AD - Clinical Oncology and Radiotherapy Center, B-A-Z County Hospital, Miskolc, Hungary. FAU - Pikó, Béla AU - Pikó B AD - Bekes County Pandy Kalman Hospital, Gyula, Hungary. FAU - Mangel, László AU - Mangel L AD - Medical School, University of Pecs, Pecs, Hungary. FAU - Toi, Masakazu AU - Toi M AD - Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Morita, Satoshi AU - Morita S AD - Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Ohno, Shinji AU - Ohno S AD - Center of Breast Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan. LA - eng PT - Journal Article PT - Observational Study DEP - 20220903 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 RN - 2S9ZZM9Q9V (Bevacizumab) RN - P88XT4IS4D (Paclitaxel) RN - 0 (Taxoids) RN - 0 (Anthracyclines) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - Bevacizumab MH - *Breast Neoplasms/pathology MH - Paclitaxel MH - Prognosis MH - Taxoids/therapeutic use MH - *Liver Neoplasms MH - Anthracyclines/therapeutic use MH - Receptor, ErbB-2 MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Neoplasm Metastasis MH - Treatment Outcome MH - Disease-Free Survival PMC - PMC9813142 OTO - NOTNLM OT - Bevacizumab OT - Metastatic breast cancer OT - Paclitaxel OT - Pooled analysis OT - Real-world evidence COIS- Y. Yamamoto has relevant conflicts of interest, as follows; Personal fees from Chugai, AstraZeneca, Kyowa-Kirin, Pfizer, Novartis, Essai, Takeda, Tiho, GE Health Care Japan, Nippon Kayaku, Daiichi-Sankyo, Sysmex, and Lilly. Grants from Chugai, Pfizer, AstraZeneca, Kyowa-Kirin, Daiichi-Sankyo, Nippon Kayaku and Lilly. Y. Yamashiro has relevant conflicts of interest, as follows; Personal Fees(Hornaria) from Chugai, Daiichi-Sankyo, Kyowa Kirin, Eisai, Pfizer, Takeda, Eli Lilly, Takeda, Taiho outside the submitted work. A. Schneeweiss has relevant conflicts of interest, as follows; grants from Celgene, grants from Roche, grants from AbbVie, personal fees (Travel expenses and Honoraria) from Celgene, personal fees (Travel expenses and Honoraria) from Roche,personal fees (Travel expenses and Honoraria) from Pfizer, Honoraria from AstraZeneca, Honoraria from Novartis, Honoraria from MSD, Honoraria from Tesaro, Honoraria from Lilly, Honoraria from Seagen, Honoraria from Gilead, Honoraria from GSK, Honoraria from Bayer, Honoraria from Amgen, Honoraria from Pierre Fabre, outside the submitted work. V. Müller has relevant conflicts of interest, as follows; personal fees from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva, Seagen, GSK, Gilead, personal fees from Genomic Health, Gilead, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, GSK, Gilead, other from I Novartis, Roche, Seagen, Genentech, outside the submitted work. O. Gluz has relevant conflicts of interest, as follows; personal fees from Roche, personal fees from Celgene, outside the submitted work. B. Aktas has relevant conflicts of interest, as follows; grants from AstraZeneca, Roche, Novartis, Pfizer, Eisai, Daiichi Sankyo, Lilly, MSD, Tesaro, Pharmamar, Promedicis GmbH, Oncowissen.de GmbH, Amgen and Seagen. Honoraria from AstraZeneca, Roche, Novartis, Pfizer, Eisai, Daiichi Sankyo, Lilly, MSD Sharp & Dohme, Tesaro, Pharmamar, Promedicis, Oncowissen.de, Amgen, Seagen. Travel expenses from AstraZeneca, Roche, Novartis, Pfizer, Eisai, Daiichi Sankyo, Lilly, MSD, Tesaro, Pharmamar, Promedicis GmbH, Oncowissen.de GmbH, Amgen and Seagen. Board of Advisory board of AstraZeneca, Roche, Novartis, Pfizer, Eisai, Daiichi Sankyo, Lilly, MSD, Seagen, Tesaro, outside the submitted work. M. Toi has relevant conflicts of interest as follows; grants from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG assoc., Eisai, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi. Lecture honoraria or lecture chair, personal from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, Nippon Kayaku. Advisory board of Kyowa-Kirin, Daiichi-Sankyo, Eli Lilly, Konica Minolta, BMS, Athenex Oncology. Member of the board of directors (no salary) of JBCRG assoc., KBCRN, OOTR, outside the submitted work. S. Morita has relevant conflicts of interest as follows; grants from Eisai, Honoraria from AstraZeneca, Taiho, Chugai, Nippon Boehringer Ingelheim Inc, Bristol Myers Squibb, Novartis, MSD, Kyowa Kirin, Astellas, Pfizer, Ono, Eli Lilly, outside the submitted work. S. Ohno grants from Taiho, grants from Eisai, personal fees from AstraZeneca, personal fees from Chugai, personal fees from Lilly, personal fees from Taiho, personal fees from Pfizer, personal fees from Daiichi-Sankyo, board member of Japan Breast Cancer Research Group, board member of Japan Breast Cancer Society, outside the submitted work. P. Klare, D. Magdolna, L. Büdi, B. Piko, and L. Mangel have nothing to disclose. EDAT- 2022/09/04 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/09/03 11:16 PHST- 2022/05/02 00:00 [received] PHST- 2022/08/24 00:00 [accepted] PHST- 2022/09/04 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/09/03 11:16 [entrez] AID - 10.1007/s12282-022-01399-1 [pii] AID - 1399 [pii] AID - 10.1007/s12282-022-01399-1 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):88-100. doi: 10.1007/s12282-022-01399-1. Epub 2022 Sep 3. PMID- 36512998 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1878-0539 (Electronic) IS - 1748-6815 (Linking) VI - 76 DP - 2023 Jan TI - Capsular inflammation after immediate breast reconstruction - Gene expression patterns and inflammatory cell infiltration in irradiated and non-irradiated breasts. PG - 18-26 LID - S1748-6815(22)00554-X [pii] LID - 10.1016/j.bjps.2022.10.011 [doi] AB - BACKGROUND: Capsular contracture following post-mastectomy radiotherapy (PMRT) is commonly seen in patients undergoing implant-based immediate breast reconstruction (IBR). Further understanding of the underlying biology is needed for the development of preventive or therapeutic strategies. Therefore, we conducted a comparative study of gene expression patterns in capsular tissue from breast cancer patients who had received versus those who had not received PMRT after implant-based IBR. METHODS: Biopsies from irradiated and healthy non-irradiated capsular tissue were harvested during implant exchange following IBR. Biopsies from irradiated (n = 13) and non-irradiated (n = 12) capsules were compared using Affymetrix microarrays to identify the most differentially regulated genes. Further analysis using immunohistochemistry was performed in a subset of materials to compare the presence of T cells, B cells, and macrophages. RESULTS: Enrichment testing using Gene Ontology (GO) analysis revealed that the 227 most differentially expressed genes were mainly involved in an inflammatory response. Twenty-one GO biological processes were identified [p < 0.05, false discovery rate (FDR) < 5%], several with B-cell-associated inflammation. Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) analysis identified macrophages as the most common inflammatory cell type in both groups, further supported by immunostaining of CD68. Radiation remarkably increased B-cell infiltration in the capsular region of biopsies, as quantified by immunostaining of CD20 (p = 0.016). CONCLUSIONS: Transcript analysis and immunohistochemistry revealed inflammatory responses in capsular biopsies regardless of radiotherapy. However, the radiation response specifically involved B-cell-associated inflammatory responses. CI - Copyright © 2022 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved. FAU - Frisell, A AU - Frisell A AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Dermatology, Theme Inflammation and Infection, Karolinska University Hospital, Stockholm, Sweden. FAU - Bergman, O AU - Bergman O AD - Division of Cardiovascular Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden. FAU - Khan, A AU - Khan A AD - Department of Plastic Surgery, The Royal Marsden Hospital NHS Foundation Trust, London, UK. FAU - Gisterå, A AU - Gisterå A AD - Division of Cardiovascular Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden. FAU - Fisher, R M AU - Fisher RM AD - Division of Cardiovascular Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden. FAU - Lagergren, J AU - Lagergren J AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Surgery, Capio St. Göran's Hospital, Stockholm, Sweden. FAU - de Boniface, J AU - de Boniface J AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Surgery, Capio St. Göran's Hospital, Stockholm, Sweden. FAU - Halle, M AU - Halle M AD - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden. Electronic address: martin.halle@karolinska.se. LA - eng PT - Journal Article DEP - 20221017 PL - Netherlands TA - J Plast Reconstr Aesthet Surg JT - Journal of plastic, reconstructive & aesthetic surgery : JPRAS JID - 101264239 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/radiotherapy/surgery MH - Mastectomy MH - *Breast Implants/adverse effects MH - Radiotherapy, Adjuvant/adverse effects MH - *Mammaplasty/adverse effects MH - Inflammation MH - Gene Expression MH - *Breast Implantation OTO - NOTNLM OT - Capsular contracture OT - Implant-based breast reconstruction OT - Inflammation OT - Radiotherapy COIS- Conflict of interest The authors declare no conflict of interest. EDAT- 2022/12/14 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/12/13 18:25 PHST- 2022/07/25 00:00 [received] PHST- 2022/10/04 00:00 [accepted] PHST- 2022/12/14 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/12/13 18:25 [entrez] AID - S1748-6815(22)00554-X [pii] AID - 10.1016/j.bjps.2022.10.011 [doi] PST - ppublish SO - J Plast Reconstr Aesthet Surg. 2023 Jan;76:18-26. doi: 10.1016/j.bjps.2022.10.011. Epub 2022 Oct 17. PMID- 36175750 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Print) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy. PG - 131-138 LID - 10.1007/s12282-022-01406-5 [doi] AB - BACKGROUND: Breast-conserving surgery with radiotherapy is one of standard treatments for early breast cancer. However, it is regarded as an option to treat elderly patients with small hormone receptor-positive breast cancer with breast-conserving surgery and hormone therapy without radiotherapy. We conducted two sequential prospective studies to examine the feasibility of breast-conserving surgery without radiotherapy since 2002 and present the results. PATIENTS AND METHODS: Primary female breast cancer patients who fulfilled the strict eligibility criteria were prospectively enrolled in two sequential studies named WORTH 1 and 2. The surgical materials were sliced in 5-mm intervals and all slices were examined microscopically. Postoperative radiotherapy was not allowed, but tamoxifen or anastrozole was administered for 5 years. Ipsilateral breast tumor recurrence (IBTR)-free survival was the primary outcome. RESULTS: The data of the two studies were combined (N = 321). The median follow-up period for IBTR was 94 months (4-192 months). Only three patients were treated with adjuvant chemotherapy. The 5- and 10-year IBTR-free rates were 97.0% and 90.5%, respectively. The age at operation and PR status affected IBTR rates independently. When we calculated IBTR-free rates of patients who were 65 years of age or older at the time of surgery and had PR-positive tumors, the 5- and 10-year IBTR rates were both 98.4%. CONCLUSIONS:  Our "5-mm-thick slice and 5-mm free-margin" method may be effective to select patients who can be treated by breast-conserving surgery and hormone therapy without radiotherapy. CI - © 2022. The Author(s). FAU - Ohsumi, Shozo AU - Ohsumi S AUID- ORCID: 0000-0002-5989-1763 AD - Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umemoto-machi, Matsuyama, Ehime, 791-0280, Japan. osumi.shozo.ur@mail.hosp.go.jp. FAU - Nishimura, Reiki AU - Nishimura R AD - Department of Breast Oncology, Kumamoto Shinto General Hospital, Kumamoto, Kumamoto, Japan. FAU - Masuda, Norikazu AU - Masuda N AD - Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. FAU - Akashi-Tanaka, Sadako AU - Akashi-Tanaka S AD - Department of Breast Surgical Oncology, Show University School of Medicine, Tokyo, Japan. FAU - Suemasu, Kimito AU - Suemasu K AD - ARCHE Clinic, Saitama, Saitama, Japan. FAU - Yamauchi, Hideko AU - Yamauchi H AD - Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan. FAU - Tokunaga, Eriko AU - Tokunaga E AD - Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan. FAU - Ikeda, Tadashi AU - Ikeda T AD - Department of Surgery, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. FAU - Nishi, Tsunehiro AU - Nishi T AD - Toda Chuo Health Exam Center, Toda, Saitama, Japan. FAU - Hayashi, Hiroto AU - Hayashi H AD - Department of Surgery, National Hospital Organization Kanmon Medical Center, Shimonoseki, Yamaguchi, Japan. FAU - Iino, Yuichi AU - Iino Y AD - Department of Breast and Thyroid Surgery, Kusunoki Hospital, Fujioka, Gunma, Japan. FAU - Takatsuka, Yuichi AU - Takatsuka Y AD - Department of Breast Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan. FAU - Ohashi, Yasuo AU - Ohashi Y AD - Faculty of Science and Engineering, Chuo University, Tokyo, Japan. FAU - Inaji, Hideo AU - Inaji H AD - Department of Breast Surgery, Kaizuka City Hospital, Kaizuka, Osaka, Japan. LA - eng GR - a Grant-in-Aid for research of cancer treatment from the Ministry of Health/Ministry of Health, Labour and Welfare/ GR - Labour/Ministry of Health, Labour and Welfare/ GR - Welfare of Japan/Ministry of Health, Labour and Welfare/ GR - No. 13-9/Ministry of Health, Labour and Welfare/ GR - No. 21-7-4/Ministry of Health, Labour and Welfare/ PT - Journal Article DEP - 20220930 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 RN - 0 (Hormones) SB - IM MH - Female MH - Humans MH - Aged MH - *Breast Neoplasms/radiotherapy/surgery MH - Mastectomy, Segmental MH - Neoplasm Recurrence, Local/epidemiology/prevention & control MH - Prospective Studies MH - Radiotherapy, Adjuvant MH - Hormones PMC - PMC9813112 OTO - NOTNLM OT - Breast cancer OT - Breast-conserving treatment OT - Prospective study OT - Radiotherapy OT - Surgical margins COIS- Ohsumi S.: fees for non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus); AstraZeneca. Nishimura R.: none. Masuda N.: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus); Chugai, AstraZeneca, Pfizer, Eli-Lilly, Eisai, Takeda. Contracted Research; Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, EliLilly, Eisai, DaiichiSankyo. Akashi-Tanaka S.: fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus); AstraZeneca. Suemasu K.: none. Yamauchi H.: contracted Research; AstraZeneca. Tokunaga E.: fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus); AstraZeneca. Ikeda T.: none. Nishi T.: none. Hayashi H.: none. Iino Y.: none. Takatsuka Y.: none. Ohashi Y.: none, Inaji H.: none. EDAT- 2022/09/30 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/09/29 23:38 PHST- 2022/05/09 00:00 [received] PHST- 2022/09/18 00:00 [accepted] PHST- 2022/09/30 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/09/29 23:38 [entrez] AID - 10.1007/s12282-022-01406-5 [pii] AID - 1406 [pii] AID - 10.1007/s12282-022-01406-5 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):131-138. doi: 10.1007/s12282-022-01406-5. Epub 2022 Sep 30. PMID- 36279903 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 152 IP - 4 DP - 2023 Feb 15 TI - Postdiagnosis recreational physical activity and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis. PG - 600-615 LID - 10.1002/ijc.34324 [doi] AB - It is important to clarify the associations between modifiable lifestyle factors such as physical activity and breast cancer prognosis to enable the development of evidence-based survivorship recommendations. We performed a systematic review and meta-analyses to summarise the evidence on the relationship between postbreast cancer diagnosis physical activity and mortality, recurrence and second primary cancers. We searched PubMed and Embase through 31st October 2021 and included 20 observational studies and three follow-up observational analyses of patients enrolled in clinical trials. In linear dose-response meta-analysis of the observational studies, each 10-unit increase in metabolic equivalent of task (MET)-h/week higher recreational physical activity was associated with 15% and 14% lower risk of all-cause (95% confidence interval [CI]: 8%-22%, studies = 12, deaths = 3670) and breast cancer-specific mortality (95% CI: 4%-23%, studies = 11, deaths = 1632), respectively. Recreational physical activity was not associated with breast cancer recurrence (HR = 0.97, 95% CI: 0.91-1.05, studies = 6, deaths = 1705). Nonlinear dose-response meta-analyses indicated 48% lower all-cause and 38% lower breast cancer-specific mortality with increasing recreational physical activity up to 20 MET-h/week, but little further reduction in risk at higher levels. Predefined subgroup analyses across strata of body mass index, hormone receptors, adjustment for confounders, number of deaths, menopause and physical activity intensities were consistent in direction and magnitude to the main analyses. Considering the methodological limitations of the included studies, the independent Expert Panel concluded 'limited-suggestive' likelihood of causality for an association between recreational physical activity and lower risk of all-cause and breast cancer-specific mortality. CI - © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Cariolou, Margarita AU - Cariolou M AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. FAU - Abar, Leila AU - Abar L AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. FAU - Aune, Dagfinn AU - Aune D AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. AD - Department of Nutrition, Bjørknes University College, Oslo, Norway. AD - Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway. AD - Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. FAU - Balducci, Katia AU - Balducci K AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. FAU - Becerra-Tomás, Nerea AU - Becerra-Tomás N AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. FAU - Greenwood, Darren C AU - Greenwood DC AD - Leeds Institute for Data Analytics, Faculty of Medicine and Health, University of Leeds, Leeds, UK. FAU - Markozannes, Georgios AU - Markozannes G AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. AD - Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece. FAU - Nanu, Neesha AU - Nanu N AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. FAU - Vieira, Rita AU - Vieira R AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. FAU - Giovannucci, Edward L AU - Giovannucci EL AD - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. AD - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. FAU - Gunter, Marc J AU - Gunter MJ AD - Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France. FAU - Jackson, Alan A AU - Jackson AA AD - Faculty of Medicine, School of Human Development and Health, University of Southampton, Southampton, UK. AD - National Institute of Health Research Cancer and Nutrition Collaboration, Southampton, UK. FAU - Kampman, Ellen AU - Kampman E AD - Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands. FAU - Lund, Vivien AU - Lund V AD - World Cancer Research Fund International, London, UK. FAU - Allen, Kate AU - Allen K AD - World Cancer Research Fund International, London, UK. FAU - Brockton, Nigel T AU - Brockton NT AD - American Institute for Cancer Research, Arlington, Virginia, USA. FAU - Croker, Helen AU - Croker H AD - World Cancer Research Fund International, London, UK. FAU - Katsikioti, Daphne AU - Katsikioti D AD - World Cancer Research Fund International, London, UK. FAU - McGinley-Gieser, Deirdre AU - McGinley-Gieser D AD - American Institute for Cancer Research, Arlington, Virginia, USA. FAU - Mitrou, Panagiota AU - Mitrou P AD - World Cancer Research Fund International, London, UK. FAU - Wiseman, Martin AU - Wiseman M AD - World Cancer Research Fund International, London, UK. FAU - Cross, Amanda J AU - Cross AJ AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. FAU - Riboli, Elio AU - Riboli E AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. FAU - Clinton, Steven K AU - Clinton SK AD - Division of Medical Oncology, The Department of Internal Medicine, College of Medicine and Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA. FAU - McTiernan, Anne AU - McTiernan A AD - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. FAU - Norat, Teresa AU - Norat T AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. AD - World Cancer Research Fund International, London, UK. FAU - Tsilidis, Konstantinos K AU - Tsilidis KK AUID- ORCID: 0000-0002-8452-8472 AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. AD - Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece. FAU - Chan, Doris S M AU - Chan DSM AUID- ORCID: 0000-0002-0198-1897 AD - Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. LA - eng GR - CUPGLOBAL-SpecialGrant-2018/American Institute for Cancer Research (AICR)/ GR - BCRF-19-107/BCRF-20-107/BCRF-21-107/Breast Cancer Research Foundation/ GR - CUPGLOBAL-SpecialGrant-2018/Wereld Kanker Onderzoek Fonds/ GR - CUPGLOBAL-SpecialGrant-2018/World Cancer Research Fund/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20221024 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/diagnosis MH - Neoplasm Recurrence, Local/epidemiology MH - Risk MH - Prognosis MH - Life Style OTO - NOTNLM OT - breast cancer survival OT - evidence grading OT - expert panel judgement OT - physical activity OT - systematic review EDAT- 2022/10/25 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/10/24 19:13 PHST- 2022/09/20 00:00 [revised] PHST- 2021/10/04 00:00 [received] PHST- 2022/09/23 00:00 [accepted] PHST- 2022/10/25 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/10/24 19:13 [entrez] AID - 10.1002/ijc.34324 [doi] PST - ppublish SO - Int J Cancer. 2023 Feb 15;152(4):600-615. doi: 10.1002/ijc.34324. Epub 2022 Oct 24. PMID- 36162421 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1098-8947 (Electronic) IS - 0743-684X (Linking) VI - 39 IP - 2 DP - 2023 Feb TI - The Use of Ultrasound Imaging for Upper Extremity Lymphedema after Breast Cancer: A Systematic Review. PG - 102-110 LID - 10.1055/s-0042-1750824 [doi] AB - BACKGROUND:  The aim of this study was to analyze the different applications of ultrasound (US) in upper extremity lymphedema (UEL) after breast cancer. METHODS:  A systematic review of the literature was performed in line with the PRISMA statement using MEDLINE/PubMed databases from January 1970 to December 2021. Articles describing the application of US in patients with UEL after breast cancer were included. The quality of the study, the level of reproducibility, and the different applications and type of US technique were analyzed. RESULTS:  In total, 30 articles with 1,193 patients were included in the final review. Five different applications were found: (1) diagnosis of UEL (14 studies found a direct correlation between lymphedema and morphological and/or functional parameters); (2) staging/severity of UEL (9 studies found a direct correlation between the clinical stage and the soft-tissue stiffness/texture/thickness); (3) therapeutic assessment (3 studies found an improvement in the circulatory status or in the muscle/subcutaneous thickness after conservative treatments); (4) prognosis assessment of UEL (1 study found a correlation between the venous flow and the risk of UEL); and (5) surgical planning (3 studies determined the location of the lymphatic vessel for lymphovenous anastomosis [LVA] surgery). CONCLUSION:  Morphological and functional parameters have been correlated with the diagnosis, stage, therapeutic effect, prognosis of UEL, and surgical planning of LVA. CI - Thieme. All rights reserved. FAU - Canales-Lachén, Elena AU - Canales-Lachén E AD - Department of Radiology, University Hospital Ramón y Cajal, Madrid, Spain. FAU - Asunsolo, Ángel AU - Asunsolo Á AD - Department of Surgery, Medical and Social Science, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Madrid, Spain. AD - Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain. FAU - Manrique, Oscar J AU - Manrique OJ AD - Deparment of Plastic Surgery, University of Rochester Medical Center, Rochester, New York. FAU - Blázquez, Javier AU - Blázquez J AD - Department of Radiology, University Hospital Ramón y Cajal, Madrid, Spain. AD - Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain. FAU - Holguín, Purificación AU - Holguín P AD - Department of Plastic Surgery, University Hospital Getafe, Madrid, Spain. FAU - Maldonado, Andrés A AU - Maldonado AA AUID- ORCID: 0000-0002-3703-5667 AD - Department of Surgery, Medical and Social Science, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Madrid, Spain. AD - Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain. AD - Department of Plastic Surgery, University Hospital Getafe, Madrid, Spain. AD - Department of Plastic, Hand and Reconstructive Surgery, BG Trauma Center Frankfurt am Main, Academic Hospital of the Goethe University Frankfurt am Main, Frankfurt am Main, Germany. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220926 PL - United States TA - J Reconstr Microsurg JT - Journal of reconstructive microsurgery JID - 8502670 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/surgery MH - Reproducibility of Results MH - Upper Extremity/diagnostic imaging/surgery MH - *Lymphedema/diagnostic imaging/etiology/surgery MH - Ultrasonography MH - Anastomosis, Surgical MH - *Lymphatic Vessels/surgery COIS- None declared. EDAT- 2022/09/27 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/09/26 19:08 PHST- 2022/09/27 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/09/26 19:08 [entrez] AID - 10.1055/s-0042-1750824 [doi] PST - ppublish SO - J Reconstr Microsurg. 2023 Feb;39(2):102-110. doi: 10.1055/s-0042-1750824. Epub 2022 Sep 26. PMID- 36673982 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 20 IP - 2 DP - 2023 Jan 10 TI - Identification of a Novel Gene Signature with DDR and EMT Difunctionalities for Predicting Prognosis, Immune Activity, and Drug Response in Breast Cancer. LID - 10.3390/ijerph20021221 [doi] LID - 1221 AB - Breast cancer, with an overall poor clinical prognosis, is one of the most heterogeneous cancers. DNA damage repair (DDR) and epithelial-mesenchymal transition (EMT) have been identified to be associated with cancer's progression. Our study aimed to explore whether genes with both functions play a more crucial role in the prognosis, immune, and therapy response of breast cancer patients. Based on the Cancer Genome Atlas (TCGA) cancer database, we used LASSO regression analysis to identify the six prognostic-related genes with both DDR and EMT functions, including TP63, YWHAZ, BRCA1, CCND2, YWHAG, and HIPK2. Based on the six genes, we defined the risk scores of the patients and reasonably analyzed the overall survival rate between the patients with the different risk scores. We found that overall survival in higher-risk-score patients was lower than in lower-risk-score patients. Subsequently, further GO and KEGG analyses for patients revealed that the levels of immune infiltration varied for patients with high and low risk scores, and the high-risk-score patients had lower immune infiltration's levels and were insensitive to treatment with chemotherapeutic agents. Furthermore, the Gene Expression Omnibus (GEO) database validated our findings. Our data suggest that TP63, YWHAZ, BRCA1, CCND2, YWHAG, and HIPK2 can be potential genetic markers of prognostic assessment, immune infiltration and chemotherapeutic drug sensitivity in breast cancer patients. FAU - Zhang, Pan AU - Zhang P AD - Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. AD - Key Laboratory of Watershed Science and Health of Zhejiang Province, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. FAU - Li, Quan AU - Li Q AD - Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. AD - Key Laboratory of Watershed Science and Health of Zhejiang Province, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. FAU - Zhang, Yuni AU - Zhang Y AD - Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. AD - Key Laboratory of Watershed Science and Health of Zhejiang Province, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. FAU - Wang, Qianqian AU - Wang Q AD - Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. AD - Key Laboratory of Watershed Science and Health of Zhejiang Province, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. FAU - Yan, Junfang AU - Yan J AD - Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. AD - Key Laboratory of Watershed Science and Health of Zhejiang Province, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. FAU - Shen, Aihua AU - Shen A AD - Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. AD - Key Laboratory of Watershed Science and Health of Zhejiang Province, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. FAU - Hu, Burong AU - Hu B AD - Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. AD - Key Laboratory of Watershed Science and Health of Zhejiang Province, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, China. LA - eng GR - QTJ20010/Scientific Research Project of Wenzhou Medical University for Talent/ GR - 11635013, 82203981/National Natural Science Foundation of China/ GR - 2020C03028/Key R & D project of the Department of Science and Technology of Zhejiang Province/ GR - ZY2020011/Major Project of Wenzhou Science and Technology Bureau/ PT - Journal Article DEP - 20230110 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - EC 2.7.1.- (HIPK2 protein, human) RN - 0 (Carrier Proteins) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - 0 (YWHAG protein, human) RN - 0 (14-3-3 Proteins) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics MH - Epithelial-Mesenchymal Transition MH - Breast MH - DNA Repair MH - Databases, Factual MH - Carrier Proteins MH - Protein Serine-Threonine Kinases MH - 14-3-3 Proteins PMC - PMC9859620 OTO - NOTNLM OT - DNA damage repair (DDR) OT - breast cancer OT - cancer prognostic model OT - epithelial–mesenchymal transition (EMT) OT - gene signature COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:21 PHST- 2022/11/14 00:00 [received] PHST- 2023/01/02 00:00 [revised] PHST- 2023/01/07 00:00 [accepted] PHST- 2023/01/21 01:21 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijerph20021221 [pii] AID - ijerph-20-01221 [pii] AID - 10.3390/ijerph20021221 [doi] PST - epublish SO - Int J Environ Res Public Health. 2023 Jan 10;20(2):1221. doi: 10.3390/ijerph20021221. PMID- 36084228 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230120 IS - 1530-0315 (Electronic) IS - 0195-9131 (Linking) VI - 55 IP - 2 DP - 2023 Feb 1 TI - The Analgesic Effect of Resistance Training after Breast Cancer (ANTRAC): A Randomized Controlled Trial. PG - 167-176 LID - 10.1249/MSS.0000000000003034 [doi] AB - OBJECTIVE: The objective of this blinded parallel-arm randomized controlled trial was to investigate the effect of resistance training (RT) on pain, maximal strength, and shoulder function in breast cancer survivors (BCS) with persistent pain after treatment. METHODS: Twenty BCS with self-reported pain ≥1.5 yr after treatment were randomized to an experimental group (EXP, n = 10), who performed a supervised progressive total body heavy RT program 2 times per week for 12 wk, or a control group (CON, n = 10), who was instructed to continue their everyday life. Perceived pain intensity, pressure pain threshold (PPT) levels, one-repetition maximum (1RM), and active range of motion were collected pre- and postintervention and at 3 months follow-up. RESULTS: There was a significant 11% decrease in peak pain intensity ( P < 0.05) for both groups, a significant 48% increase in 1RM ( P < 0.05), and a significant 35% increase in PPT levels ( P < 0.001) for EXP, but not for CON. For EXP, maximal strength at follow-up was still significantly greater than at preintervention ( P < 0.05), whereas PPT levels had reverted to baseline levels. There was no change in active range of motion ( P < 0.05) and no change in arm circumference ( P < 0.05). CONCLUSIONS: RT had a significant effect on 1RM and PPT of BCS with persistent pain after treatment, demonstrating both a functional and analgesic effect of progressive RT in this population. Strength was largely maintained after detraining, whereas PPT levels were not, indicating that the process of RT rather than the gain in strength may be associated with analgesia. CI - Copyright © 2022 by the American College of Sports Medicine. FAU - Rasmussen, Gorm Henrik Fogh AU - Rasmussen GHF AD - Sport Sciences-Performance and Technology, Department of Health Science and Technology, Aalborg University, Aalborg, DENMARK. FAU - Kristiansen, Mathias AU - Kristiansen M AD - Sport Sciences-Performance and Technology, Department of Health Science and Technology, Aalborg University, Aalborg, DENMARK. FAU - Arroyo-Morales, Manuel AU - Arroyo-Morales M FAU - Voigt, Michael AU - Voigt M AD - Sport Sciences-Performance and Technology, Department of Health Science and Technology, Aalborg University, Aalborg, DENMARK. FAU - Madeleine, Pascal AU - Madeleine P AD - Sport Sciences-Performance and Technology, Department of Health Science and Technology, Aalborg University, Aalborg, DENMARK. LA - eng SI - ClinicalTrials.gov/NCT04509284 PT - Journal Article PT - Randomized Controlled Trial DEP - 20220907 PL - United States TA - Med Sci Sports Exerc JT - Medicine and science in sports and exercise JID - 8005433 RN - 0 (Analgesics) SB - IM MH - Humans MH - Female MH - *Resistance Training MH - *Breast Neoplasms/therapy MH - Pain MH - Exercise Therapy MH - Analgesics/therapeutic use MH - Muscle Strength EDAT- 2022/09/10 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/09/09 15:23 PHST- 2022/09/10 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/09/09 15:23 [entrez] AID - 00005768-202302000-00003 [pii] AID - 10.1249/MSS.0000000000003034 [doi] PST - ppublish SO - Med Sci Sports Exerc. 2023 Feb 1;55(2):167-176. doi: 10.1249/MSS.0000000000003034. Epub 2022 Sep 7. PMID- 36597031 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Jan 3 TI - Postoperative cosmetic outcome of intraoperative radiotherapy in comparison to whole breast radiotherapy in early stage breast cancer; a retrospective cohort study. PG - 9 LID - 10.1186/s12885-022-10468-9 [doi] LID - 9 AB - BACKGROUND: In this study, we aim to evaluate the cosmetic outcome differences between Intraoperative electron beam radiation therapy (IOERT) and whole breast radiotherapy (WBR) with further investigation of boosted IOERT. METHODS: This retrospective cohort study was conducted in two referral centers in Tehran, Iran. 116 women aged 30 to 79 with early-stage breast cancer (T0-2N0-1M0) eligible for breast conservation were divided into two groups of 58 based on the intervention they received, and further subgroups were defined based on receiving boosted IOERT. Patients in both groups underwent breast conservation surgery and those in the IOERT group received either a 21 Gy radical dose (radical IOERT) or 12 Gy boosted electron beam radiotherapy and a routine fractionated dose of 50 Gy in 25 sessions of WBR (boosted IOERT). Those in the WBR group were administered 50Gy in 32 sessions. Physician-assessed cosmetic outcome was defined as the primary result and incidence of fat necrosis and fibrosis and post-operative chronic pain were secondary outcomes. RESULTS: Post-operative cosmetic outcome scores and chronic pain, showed no significant difference between the two groups. The median cosmetic score in both groups was 9. Fat necrosis and fibrosis had significantly higher rates in the IOERT group (P. VALUE: 0.001). However, the majority (21/34 or 61.8%) of this complication was observed in the boosted IOERT subgroup and no statistical significance was recorded between the radical IOERT subgroup and the WBR group. CONCLUSIONS: In early-stage breast cancer treatment, radical IOERT has noninferiority compared to WBR in terms of cosmesis. Regarding fat necrosis and fibrosis, boosted IOERT was associated with higher rates in comparison to other groups. Therefore, radical IOERT seems to be a better treatment option for selected patients. CI - © 2023. The Author(s). FAU - Nafissi, Nahid AU - Nafissi N AD - Department of Breast, Rasoul Akram Hospital Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran. FAU - Meshkati Yazd, Seyed Mostafa AU - Meshkati Yazd SM AD - Department of Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, 01136746911, Iran. FAU - Shahriarirad, Reza AU - Shahriarirad R AD - Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Science, Shiraz, Iran. AD - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Zangeneh, Saba AU - Zangeneh S AD - Fasa University of Medical Sciences, Fasa, Iran. FAU - Ghorbani, Sahar AU - Ghorbani S AD - Department of Breast, Rasoul Akram Hospital Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran. FAU - Farazmand, Borna AU - Farazmand B AD - Radiation Oncology Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Karoobi, Mohammadreza AU - Karoobi M AD - Department of Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, 01136746911, Iran. Mr.karoobi@gmail.com. AD - Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Science, Shiraz, Iran. Mr.karoobi@gmail.com. AD - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Mr.karoobi@gmail.com. FAU - Mirzaei, Hamid Reza AU - Mirzaei HR AD - Cancer Research Center, Shohadae Tajrish Hospital, Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article DEP - 20230103 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/radiotherapy/surgery MH - Retrospective Studies MH - *Chronic Pain MH - *Fat Necrosis MH - Iran MH - Fibrosis MH - Neoplasm Recurrence, Local/radiotherapy PMC - PMC9811768 OTO - NOTNLM OT - Breast cancer OT - Cosmetics OT - IOERT OT - WBR COIS- There is no conflict of interest to declare in this study. EDAT- 2023/01/04 06:00 MHDA- 2023/01/06 06:00 CRDT- 2023/01/03 23:33 PHST- 2022/06/16 00:00 [received] PHST- 2022/12/21 00:00 [accepted] PHST- 2023/01/03 23:33 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] AID - 10.1186/s12885-022-10468-9 [pii] AID - 10468 [pii] AID - 10.1186/s12885-022-10468-9 [doi] PST - epublish SO - BMC Cancer. 2023 Jan 3;23(1):9. doi: 10.1186/s12885-022-10468-9. PMID- 36394782 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 2190-3883 (Electronic) IS - 1234-1983 (Print) IS - 1234-1983 (Linking) VI - 64 IP - 1 DP - 2023 Feb TI - In silico and in vitro analysis of the impact of single substitutions within EXO-motifs on Hsa-MiR-1246 intercellular transfer in breast cancer cell. PG - 105-124 LID - 10.1007/s13353-022-00730-y [doi] AB - MiR-1246 has recently gained much attention and many studies have shown its oncogenic role in colorectal, breast, lung, and ovarian cancers. However, miR-1246 processing, stability, and mechanisms directing miR-1246 into neighbor cells remain still unclear. In this study, we aimed to determine the role of single-nucleotide substitutions within short exosome sorting motifs - so-called EXO-motifs: GGAG and GCAG present in miR-1246 sequence on its intracellular stability and extracellular transfer. We applied in silico methods such as 2D and 3D structure analysis and modeling of protein interactions. We also performed in vitro validation through the transfection of fluorescently labeled miRNA to MDA-MB-231 cells, which we analyzed by flow cytometry and fluorescent microscopy. Our results suggest that nucleotides alterations that disturbed miR-1246 EXO-motifs were able to modulate miRNA-1246 stability and its transfer level to the neighboring cells, suggesting that the molecular mechanism of RNA stability and intercellular transfer can be closely related. CI - © 2022. The Author(s). FAU - Rybarczyk, Agnieszka AU - Rybarczyk A AUID- ORCID: 0000-0003-4115-0737 AD - Institute of Computing Science, Poznan University of Technology, Piotrowo 2, 60-965, Poznan, Poland. arybarczyk@cs.put.poznan.pl. FAU - Lehmann, Tomasz AU - Lehmann T AD - Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland. tlehmann@ump.edu.pl. FAU - Iwańczyk-Skalska, Ewa AU - Iwańczyk-Skalska E AD - Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland. FAU - Juzwa, Wojciech AU - Juzwa W AD - Biotechnology and Food Microbiology, Poznan University of Life Sciences, Wojska Polskiego 48, 60-627, Poznan, Poland. FAU - Pławski, Andrzej AU - Pławski A AD - Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479, Poznan, Poland. FAU - Kopciuch, Kamil AU - Kopciuch K AD - Institute of Computing Science, Poznan University of Technology, Piotrowo 2, 60-965, Poznan, Poland. FAU - Blazewicz, Jacek AU - Blazewicz J AD - Institute of Computing Science, Poznan University of Technology, Piotrowo 2, 60-965, Poznan, Poland. AD - Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland. FAU - Jagodziński, Paweł P AU - Jagodziński PP AD - Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Fredry 10, 61-701, Poznan, Poland. LA - eng GR - 2020/04/X/ST6/00759/Narodowe Centrum Nauki/ PT - Journal Article DEP - 20221117 PL - England TA - J Appl Genet JT - Journal of applied genetics JID - 9514582 RN - 0 (MIRN1246 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - *MicroRNAs/genetics PMC - PMC9837009 OTO - NOTNLM OT - Breast cancer OT - EXO-motifs OT - Extracellular vesicles OT - MicroRNA OT - RNA structure prediction COIS- The authors declare no competing interests. EDAT- 2022/11/18 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/11/17 13:59 PHST- 2022/07/27 00:00 [received] PHST- 2022/09/27 00:00 [accepted] PHST- 2022/09/26 00:00 [revised] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/11/17 13:59 [entrez] AID - 10.1007/s13353-022-00730-y [pii] AID - 730 [pii] AID - 10.1007/s13353-022-00730-y [doi] PST - ppublish SO - J Appl Genet. 2023 Feb;64(1):105-124. doi: 10.1007/s13353-022-00730-y. Epub 2022 Nov 17. PMID- 36600314 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1470-7330 (Electronic) IS - 1740-5025 (Print) IS - 1470-7330 (Linking) VI - 23 IP - 1 DP - 2023 Jan 4 TI - Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer. PG - 2 LID - 10.1186/s40644-022-00519-6 [doi] LID - 2 AB - BACKGROUND: The aim of this study is to investigate the impact of (18)F-FDG PET/CT on prognosis of stage II invasive ductal carcinoma (IDC) of the breast primarily treated with surgery. METHODS: The clinical records of 297 consecutive IDC with preoperative PET/CT and pathologically staged II in surgery from 2013 to 2017 were retrospectively reviewed. The maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), tumor-to-liver ratio (TLR), and metabolic tumor volume (MTV) were measured. Association of clinicopathologic factors (age, T stage, N stage, AJCC pathologic stage of IIA or IIB, pathologic prognostic stage, grade, hormonal receptor status, HER2 status, Ki-67, and adjuvant therapy) and PET parameters with DFS was assessed using the Cox proportional hazards model. RESULTS: There were 35 recurrences and 10 deaths at a median follow-up of 49 months (range 0.8 ~ 87.3). All PET parameters were significantly associated with DFS in univariate analysis but in multivariate analysis, SUVpeak was the only factor significantly associated with DFS (hazard ratio 2.58, 95% confidence interval 1.29-5.15, P = 0.007). In cohorts with higher values of SUVpeak or TLR, patients who received adjuvant chemotherapy had significantly superior DFS. CONCLUSION: Metabolic parameters derived from preoperative PET/CT was significantly associated with recurrence in stage II IDC primarily treated with surgery. PET/CT can be a powerful prognostic tool in conjunction with novel staging systems and current biomarkers for patients undergoing contemporary therapy. Our results urge to reconsider the currently underestimated value of PET/CT confined to diagnostic aspect and to newly recognize its prognostic impact in these intermediate-risk breast cancer. CI - © 2023. The Author(s). FAU - Park, Hye Lim AU - Park HL AD - Division of Nuclear Medicine, Department of Radiology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. FAU - Lee, Sea-Won AU - Lee SW AD - Department of Radiation Oncology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. FAU - Hong, Ji Hyung AU - Hong JH AD - Division of Medical Oncology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. FAU - Lee, Jieun AU - Lee J AD - Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. FAU - Lee, Ahwon AU - Lee A AD - Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. FAU - Kwon, Soo Jin AU - Kwon SJ AD - Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. FAU - Park, Sonya Youngju AU - Park SY AD - Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. FAU - Yoo, Ie Ryung AU - Yoo IR AUID- ORCID: 0000-0001-9738-3703 AD - Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. iryoo@catholic.ac.kr. LA - eng PT - Journal Article DEP - 20230104 PL - England TA - Cancer Imaging JT - Cancer imaging : the official publication of the International Cancer Imaging Society JID - 101172931 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM MH - Humans MH - Female MH - Positron Emission Tomography Computed Tomography MH - *Breast Neoplasms/pathology MH - Fluorodeoxyglucose F18/metabolism MH - Prognosis MH - Retrospective Studies MH - *Carcinoma, Ductal, Breast/diagnostic imaging/therapy/metabolism MH - Radiopharmaceuticals PMC - PMC9811771 OTO - NOTNLM OT - Breast cancer OT - Invasive ductal carcinoma OT - PET/CT OT - Prognosis OT - Stage II COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2023/01/05 06:00 MHDA- 2023/01/07 06:00 CRDT- 2023/01/04 23:39 PHST- 2022/10/23 00:00 [received] PHST- 2022/12/28 00:00 [accepted] PHST- 2023/01/04 23:39 [entrez] PHST- 2023/01/05 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] AID - 10.1186/s40644-022-00519-6 [pii] AID - 519 [pii] AID - 10.1186/s40644-022-00519-6 [doi] PST - epublish SO - Cancer Imaging. 2023 Jan 4;23(1):2. doi: 10.1186/s40644-022-00519-6. PMID- 36403183 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer. PG - 425-434 LID - 10.1007/s10549-022-06799-7 [doi] AB - PURPOSE: Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never been performed. Our study explores the implications of ECD status on intracranial progression-free survival (iPFS) and overall survival (OS) after first incidence of HER2 + BCBrM and radiation. METHODS: A retrospective analysis was performed of 151 patients diagnosed with initial HER2 + BCBrM who received radiation therapy to the central nervous system (CNS) at Duke between 2008 and 2021. The primary endpoint was iPFS defined as the time from first CNS radiation treatment to intracranial progression or death. OS was defined as the time from first CNS radiation or first metastatic disease to death. Systemic staging scans within 30 days of initial BCBrM defined ECD status as progressive, stable/responding or none (isolated brain relapse). RESULTS: In this cohort, > 70% of patients had controlled ECD with either isolated brain relapse (27%) or stable/responding ECD (44%). OS from initial metastatic disease to death was markedly worse for patients with isolated intracranial relapse (median = 28.4 m) compared to those with progressive or stable/responding ECD (48.8 m and 71.5 m, respectively, p = 0.0028). OS from first CNS radiation to death was significantly worse for patients with progressive ECD (16.9 m) versus stable/responding (36.6 m) or isolated intracranial relapse (28.4 m, p = 0.007). iPFS did not differ statistically based on ECD status. Receipt of systemic therapy after first BCBrM significantly improved iPFS (HR 0.45, 95% CI: 0.25-0.81, p = 0.008) and OS (HR: 0.43 (95% CI: 0.23-0.81); p = 0.001). CONCLUSION: OS in patients with HER2 + isolated BCBrM was inferior to those with concurrent progressive or stable/responding ECD. Studies investigating initiation of brain-penetrable HER2-targeted therapies earlier in the disease course of isolated HER2 + intracranial relapse patients are warranted. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Noteware, Laura AU - Noteware L AUID- ORCID: 0000-0001-9554-8930 AD - Duke University School of Medicine, Durham, North Carolina, USA. FAU - Broadwater, Gloria AU - Broadwater G AD - Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina, USA. FAU - Dalal, Nicole AU - Dalal N AD - Department of Medicine, University of California, San Francisco, California, USA. FAU - Alder, Laura AU - Alder L AD - Duke Cancer Institute, Durham, North Carolina, USA. FAU - Herndon Ii, James E AU - Herndon Ii JE AD - Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina, USA. AD - Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA. FAU - Floyd, Scott AU - Floyd S AD - Duke Cancer Institute, Durham, North Carolina, USA. AD - Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA. FAU - Giles, William AU - Giles W AD - Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA. FAU - Van Swearingen, Amanda E D AU - Van Swearingen AED AUID- ORCID: 0000-0002-4287-9741 AD - Duke Cancer Institute, Durham, North Carolina, USA. AD - Duke Center for Brain and Spine Metastasis, Duke University Medical Center, 10 Bryan Searle Drive, Seeley G. Mudd Bldg., Room 449-A, Durham, North Carolina, USA. FAU - Anders, Carey K AU - Anders CK AD - Duke Cancer Institute, Durham, North Carolina, USA. AD - Duke Center for Brain and Spine Metastasis, Duke University Medical Center, 10 Bryan Searle Drive, Seeley G. Mudd Bldg., Room 449-A, Durham, North Carolina, USA. FAU - Sammons, Sarah AU - Sammons S AUID- ORCID: 0000-0003-2589-9422 AD - Duke Cancer Institute, Durham, North Carolina, USA. sarah.sammons@duke.edu. AD - Duke Center for Brain and Spine Metastasis, Duke University Medical Center, 10 Bryan Searle Drive, Seeley G. Mudd Bldg., Room 449-A, Durham, North Carolina, USA. sarah.sammons@duke.edu. LA - eng PT - Journal Article DEP - 20221120 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms MH - Prognosis MH - Receptor, ErbB-2 MH - Retrospective Studies MH - *Brain Neoplasms/radiotherapy MH - Chronic Disease MH - Recurrence OTO - NOTNLM OT - Brain metastasis OT - Breast cancer OT - Extracranial OT - HER2 OT - Isolated OT - Radiation EDAT- 2022/11/21 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/20 14:01 PHST- 2022/08/05 00:00 [received] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/21 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/20 14:01 [entrez] AID - 10.1007/s10549-022-06799-7 [pii] AID - 10.1007/s10549-022-06799-7 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):425-434. doi: 10.1007/s10549-022-06799-7. Epub 2022 Nov 20. PMID- 36255513 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - Low Rates of Medical Oncology Consultation for Older Women (≥ 70 Years) with Newly Diagnosed, Non-Metastatic Breast Cancer: A Population-Based Study. PG - 1054-1062 LID - 10.1245/s10434-022-12640-8 [doi] AB - BACKGROUND: Curative intent cancer treatment needs to be balanced with patient comorbidities and quality of life when treating older women with breast cancer. We examined consultation patterns and association of age at diagnosis with lack of specialist cancer consultations for older women with breast cancer. METHODS: We conducted a population-based retrospective cohort study of older women (≥ 70 years of age) with incident, non-metastatic breast cancer (2010-2018) by linking administrative databases in Ontario, Canada. The outcomes of interest were lack of specialist cancer consultation (surgeon, medical oncology, or radiation oncology) within 12 months of diagnosis. Association of age with lack of specialist cancer consultation was examined using Poisson regression modeling. RESULTS: Of 21,849 older women, 2.4% (n = 517) did not have any specialist cancer consultation within 12 months of diagnosis; lack of any specialist cancer consultation increased with age (0.8% for age 70-74 years, 1.3% for age 75-79 years, 2.5% for age 80-84 years, and 7.0% for age ≥ 85 years; p < 0.001). The proportion of patients who did not have consultations with surgeons, medical oncologists, and radiation oncologists was 8.6% (n = 1888), 34.4% (n = 7510), and 24.7% (n = 5404), respectively. Older age group was independently associated with an increased likelihood of lacking any specialist consultation, as well as not receiving surgical and medical oncology consultations. CONCLUSION: More than one-third of women ≥ 70 years of age with non-metastatic breast cancer did not have a consultation with a medical oncologist, with women aged ≥ 85 years least likely to have a medical oncology consultation. CI - © 2022. Society of Surgical Oncology. FAU - Ko, Gary AU - Ko G AD - Division of Surgical Oncology, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, ON, Canada. FAU - Hallet, Julie AU - Hallet J AD - Division of Surgical Oncology, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, ON, Canada. AD - Department of Surgery, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. AD - Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, ON, Canada. FAU - Jerzak, Katarzyna J AU - Jerzak KJ AD - ICES, Toronto, ON, Canada. AD - Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, ON, Canada. AD - Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. FAU - Chan, Wing AU - Chan W AD - Department of Surgery, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. FAU - Coburn, Natalie AU - Coburn N AD - Division of Surgical Oncology, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, ON, Canada. AD - Department of Surgery, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. AD - Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, ON, Canada. FAU - Barabash, Victoria AU - Barabash V AD - Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, ON, Canada. FAU - Wright, Frances C AU - Wright FC AD - Division of Surgical Oncology, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, ON, Canada. AD - Department of Surgery, University of Toronto, Toronto, ON, Canada. FAU - Look Hong, Nicole J AU - Look Hong NJ AD - Division of Surgical Oncology, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, ON, Canada. nicole.lookhong@sunnybrook.ca. AD - Department of Surgery, University of Toronto, Toronto, ON, Canada. nicole.lookhong@sunnybrook.ca. LA - eng GR - Understanding and predicting long-term outcomes of/Institute of Health Services and Policy Research/ PT - Journal Article DEP - 20221018 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - Ann Surg Oncol. 2023 Feb;30(2):1063-1064. PMID: 36310314 MH - Humans MH - Female MH - Aged MH - *Breast Neoplasms/surgery MH - Retrospective Studies MH - Quality of Life MH - Medical Oncology MH - Ontario/epidemiology MH - Referral and Consultation EDAT- 2022/10/19 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/10/18 11:16 PHST- 2022/07/01 00:00 [received] PHST- 2022/09/22 00:00 [accepted] PHST- 2022/10/19 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/10/18 11:16 [entrez] AID - 10.1245/s10434-022-12640-8 [pii] AID - 10.1245/s10434-022-12640-8 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1054-1062. doi: 10.1245/s10434-022-12640-8. Epub 2022 Oct 18. PMID- 36074969 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221226 IS - 1078-6791 (Print) IS - 1078-6791 (Linking) VI - 29 IP - 1 DP - 2023 Jan TI - Risk, Prognostic Factors and Nomograms for Bone Metastasis in Young Females with Breast Cancer: A Large Cohort Retrospective Study. PG - 182-190 LID - AT7644 [pii] AB - PURPOSE: To determine the incidence of bone metastasis (BM) in young female patients with breast cancer (BC) and develop 2 robust nomograms for BM in young female patients with BC. METHODS: We searched and downloaded the data from young (age ≤40 years) female patients with bone cancer from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. Univariate and multivariate analyses were performed to screen the potential diagnostic variables and prognostic factors for BM. The diagnostic and prognostic nomograms were generated and evaluated by the area under the receiver operating characteristic (ROC) curve (AUC), calibration curves, and decision curve analysis (DCA). RESULTS: A total of 13 347 young female patients with BC were identified; of these, 462 were initially diagnosed as having BM. The independent risk factors for BM in young female patients with BC were tumor size, BC subtype, American Joint Committee on Cancer (AJCC) T stage, AJCC N stage, age and marital status. The independent prognostic factors in these patients were tumor size, subtype, surgery performed, lung metastasis, liver metastasis and brain metastasis. The AUC values of the diagnostic nomogram were 0.803 (95% CI; 0.795-0.811) and 0.813 (95% CI; 0.800-0.825) in the training and validation cohorts, respectively. The time-dependent AUC values of prognostic nomogram were 0.850, 0.853, and 0.824 at 2, 3 and 4 years in the training cohort, and also >0.700 in the validation cohort. For both nomograms, the discrimination was higher than all independent variables. Calibration curve and decision curve analysis (DCA) indicated that both nomograms had favorable calibration and clinical utilization. Finally, a risk stratification system was generated and the 3 risk subgroups showed significantly distinct prognoses. CONCLUSIONS: A total of 2 nomograms were developed to assess the risk for and in prognosis of young female patients with BC with BM (BCBM). FAU - Liu, Zongtai AU - Liu Z FAU - Xue, Junling AU - Xue J FAU - Liu, Kewen AU - Liu K FAU - Fan, Zhiyi AU - Fan Z FAU - Liu, Dongxu AU - Liu D FAU - Wang, Dalin AU - Wang D LA - eng PT - Journal Article PL - United States TA - Altern Ther Health Med JT - Alternative therapies in health and medicine JID - 9502013 SB - IM MH - Humans MH - Female MH - Adult MH - Retrospective Studies MH - Nomograms MH - Prognosis MH - *Breast Neoplasms/diagnosis MH - *Bone Neoplasms MH - Risk Factors EDAT- 2022/09/09 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/09/08 15:13 PHST- 2022/09/09 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/09/08 15:13 [entrez] AID - AT7644 [pii] PST - ppublish SO - Altern Ther Health Med. 2023 Jan;29(1):182-190. PMID- 36493696 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 158 DP - 2023 Feb TI - BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy. PG - 114090 LID - S0753-3322(22)01479-2 [pii] LID - 10.1016/j.biopha.2022.114090 [doi] AB - Mutations in breast cancer-associated 1 (BRCA1) increase the lifetime risk of developing breast cancer by up to 51% over the risk of the general population. Many aspects of this multifunctional protein have been revealed, including its essential role in homologous recombination repair, E3 ubiquitin ligase activity, transcriptional regulation, and apoptosis. Although most studies have focused on BRCA1 deficiency due to mutations, only a minority of patients carry BRCA1 mutations. A recent study has suggested an expanded definition of BRCA1 deficiency with reduced BRCA1 levels, which accounts for almost half of all triple-negative breast cancer (TNBC) patients. Reduced BRCA1 levels can result from epigenetic modifications or increased proteasomal degradation. In this review, we discuss how this knowledge of BRCA1 function and regulation of BRCA1 protein stability can help overcome the challenges encountered in the clinic and advance current treatment strategies for BRCA1-related breast cancer patients, especially focusing on TNBC. CI - Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Choi, Eun AU - Choi E AD - Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. FAU - Mun, Gil-Im AU - Mun GI AD - Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. FAU - Lee, Joohyun AU - Lee J AD - Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. FAU - Lee, Hanhee AU - Lee H AD - Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. FAU - Cho, Jaeho AU - Cho J AD - Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. FAU - Lee, Yun-Sil AU - Lee YS AD - Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Electronic address: yslee0425@ewha.ac.kr. LA - eng PT - Journal Article PT - Review DEP - 20221206 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/genetics/therapy MH - BRCA1 Protein/genetics/metabolism MH - Mutation MH - DNA Repair MH - Protein Stability OTO - NOTNLM OT - BRCA1 deficiency OT - Chemotherapy resistance OT - Multifunction OT - Proteasomal degradation OT - Triple-negative breast cancer COIS- Declaration of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/10 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/12/09 18:29 PHST- 2022/10/24 00:00 [received] PHST- 2022/11/24 00:00 [revised] PHST- 2022/12/02 00:00 [accepted] PHST- 2022/12/10 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/12/09 18:29 [entrez] AID - S0753-3322(22)01479-2 [pii] AID - 10.1016/j.biopha.2022.114090 [doi] PST - ppublish SO - Biomed Pharmacother. 2023 Feb;158:114090. doi: 10.1016/j.biopha.2022.114090. Epub 2022 Dec 6. PMID- 36400890 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - Homologous Recombination Deficiency in Triple-Negative Breast Cancer: Potential Benefit of a New Target. PG - 678-679 LID - 10.1245/s10434-022-12329-y [doi] FAU - Nakamura, Seigo AU - Nakamura S AUID- ORCID: 0000-0001-6597-9107 AD - Breast Surgical Oncology, Showa University, Tokyo, Japan. seigonak@med.showa-u.ac.jp. AD - Institute for Clinical Genetics and Genomics, Showa University, Tokyo, Japan. seigonak@med.showa-u.ac.jp. LA - eng PT - Editorial DEP - 20221118 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - Female MH - *Triple Negative Breast Neoplasms/genetics MH - *Breast Neoplasms/drug therapy/genetics MH - Homologous Recombination MH - Genes, BRCA1 MH - BRCA1 Protein/genetics EDAT- 2022/11/19 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/11/18 23:43 PHST- 2022/05/20 00:00 [received] PHST- 2022/07/19 00:00 [accepted] PHST- 2022/11/19 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/11/18 23:43 [entrez] AID - 10.1245/s10434-022-12329-y [pii] AID - 10.1245/s10434-022-12329-y [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):678-679. doi: 10.1245/s10434-022-12329-y. Epub 2022 Nov 18. PMID- 36593432 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1572-9249 (Electronic) IS - 1380-7870 (Linking) VI - 29 IP - 1 DP - 2023 Jan TI - A series of two-sample non-parametric tests for quantile residual life time. PG - 234-252 LID - 10.1007/s10985-022-09580-6 [doi] AB - Quantile residual lifetime (QRL) is of significant interest in many clinical studies as an easily interpretable quantity compared to other summary measures of survival distributions. In cancer or other chronic diseases, treatments are often compared based on the distributions or quantiles of the residual lifetime. Thus a common problem of interest is to test the equality of the QRL between two populations. In this paper, we propose two classes of tests to compare two QRLs; one class is based on the difference between two estimated QRLs, and the other is based on the estimating function of the QRL, where the estimated QRL from one sample is plugged into the QRL-estimating-function of the other sample. We outline the asymptotic properties of these test statistics. Simulation studies demonstrate that the proposed tests produced Type I errors closer to the nominal level and are superior to some existing tests based on both Type I error and power. Our proposed test statistics are also computationally less intensive and more straightforward compared to tests based on the confidence intervals. We applied the proposed methods to a randomized multicenter phase III trial for breast cancer patients. CI - © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Liu, Yimeng AU - Liu Y AUID- ORCID: 0000-0002-3688-7876 AD - Department of Biostatistics, University of Pittsburgh, 130 Desoto street, Pittsburgh, PA, 15261, USA. cn.yimeng@gmail.com. FAU - Wu, Liwen AU - Wu L AD - Department of Biostatistics, University of Pittsburgh, 130 Desoto street, Pittsburgh, PA, 15261, USA. FAU - Tang, Gong AU - Tang G AD - Department of Biostatistics, University of Pittsburgh, 130 Desoto street, Pittsburgh, PA, 15261, USA. FAU - Wahed, Abdus S AU - Wahed AS AD - Department of Biostatistics, University of Pittsburgh, 130 Desoto street, Pittsburgh, PA, 15261, USA. LA - eng GR - U10-CA180822/CA/NCI NIH HHS/United States GR - U10-CA180822/CA/NCI NIH HHS/United States PT - Journal Article PT - Multicenter Study DEP - 20230102 PL - United States TA - Lifetime Data Anal JT - Lifetime data analysis JID - 9516348 SB - IM MH - Humans MH - Female MH - Survival Analysis MH - Computer Simulation MH - *Breast Neoplasms OTO - NOTNLM OT - Inverse probability weighting OT - Kaplan–Meier OT - Kernel density estimators OT - Quantile residual lifetime OT - Residual lifetime OT - Wald test EDAT- 2023/01/03 06:00 MHDA- 2023/01/24 06:00 CRDT- 2023/01/02 23:22 PHST- 2021/11/24 00:00 [received] PHST- 2022/09/23 00:00 [accepted] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2023/01/02 23:22 [entrez] AID - 10.1007/s10985-022-09580-6 [pii] AID - 10.1007/s10985-022-09580-6 [doi] PST - ppublish SO - Lifetime Data Anal. 2023 Jan;29(1):234-252. doi: 10.1007/s10985-022-09580-6. Epub 2023 Jan 2. PMID- 36473307 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1879-1913 (Electronic) IS - 0002-9149 (Linking) VI - 188 DP - 2023 Feb 1 TI - Association of Neurohormonal Antagonists on Incident Cardiotoxicity in Patients With Breast Cancer. PG - 68-79 LID - S0002-9149(22)01197-3 [pii] LID - 10.1016/j.amjcard.2022.11.006 [doi] AB - Cardiovascular disease is the leading cause of mortality among breast cancer survivors. Anthracyclines and trastuzumab have been associated with an increased risk of cardiotoxicity, requiring close follow-up for signs of clinical heart failure or asymptomatic left ventricular systolic dysfunction. Whether neurohormonal antagonism with angiotensin-converting enzyme inhibitor (ACE-I), angiotensin receptor blockers (ARBs), or β-blockers can prevent the development of chemotherapy-induced cardiomyopathy in this population remains unknown. We studied 459 women who were diagnosed with breast cancer at our medical center from January 2014 to December 2021 and evaluated baseline characteristics, oncologic treatment, and outcomes. The primary end point was the development of cardiotoxicity, defined as symptomatic decline in ejection fraction of ≥5% below 55% or an asymptomatic decline of ≥10% after treatment with chemotherapy. Patients who were exposed to neurohormonal antagonists were more likely to have hypertension, hyperlipidemia, and diabetes. There was an increased risk of cardiotoxicity noted for patients who were older (hazard ratio [HR] 1.04, 95% confidence interval [CI] 1.01 to 1.1), smokers within the past 10 years (HR 2.54, 95% CI 1.41 to 4.6), or who received a combination of both trastuzumab and anthracycline therapy (HR 2.52, 95% CI 1.01 to 6.3). Over a median follow-up of 12 months, there were no significant protective benefits noted for patients who were taking ACE-I/ARBs (HR 0.49, 95% CI 0.17 to 1.4), β-blockers (HR 0.50, 95% CI 0.16 to 1.6), or both (HR 1.30, 95% CI 0.44 to 3.9). In conclusion, previous use of ACE-I/ARBs and β-blockers, separately or in combination, was not associated with a reduction in the development of cardiotoxicity in patients receiving anthracycline or trastuzumab therapies. Older age, smoking, and combination chemotherapy were found to be associated with an increased risk. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Umadat, Goyal AU - Umadat G AD - Department of Cardiovascular Diseases, Mayo Clinic Jacksonville, Florida. Electronic address: umadat.goyal@mayo.edu. FAU - Ray, Jordan AU - Ray J AD - Department of Cardiovascular Diseases, Mayo Clinic Jacksonville, Florida. FAU - Cornell, Lauren AU - Cornell L AD - Department of Internal Medicine, Mayo Clinic Jacksonville, Florida. FAU - Pillai, Dilip AU - Pillai D AD - Department of Cardiovascular Diseases, Mayo Clinic Jacksonville, Florida. FAU - Gharacholou, S Michael AU - Gharacholou SM AD - Department of Cardiovascular Diseases, Mayo Clinic Jacksonville, Florida. LA - eng PT - Journal Article DEP - 20221205 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Angiotensin Receptor Antagonists) RN - P188ANX8CK (Trastuzumab) RN - 0 (Adrenergic beta-Antagonists) RN - 0 (Anthracyclines) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Cardiotoxicity/epidemiology/etiology MH - Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - Angiotensin Receptor Antagonists/therapeutic use MH - Trastuzumab/adverse effects MH - Adrenergic beta-Antagonists/therapeutic use MH - Anthracyclines/adverse effects COIS- Disclosures The authors have no conflicts of interest to declare. EDAT- 2022/12/07 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/06 18:16 PHST- 2022/07/06 00:00 [received] PHST- 2022/10/04 00:00 [revised] PHST- 2022/11/04 00:00 [accepted] PHST- 2022/12/07 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/12/06 18:16 [entrez] AID - S0002-9149(22)01197-3 [pii] AID - 10.1016/j.amjcard.2022.11.006 [doi] PST - ppublish SO - Am J Cardiol. 2023 Feb 1;188:68-79. doi: 10.1016/j.amjcard.2022.11.006. Epub 2022 Dec 5. PMID- 36649274 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230120 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 1 DP - 2023 TI - Machine learning with textural analysis of longitudinal multiparametric MRI and molecular subtypes accurately predicts pathologic complete response in patients with invasive breast cancer. PG - e0280320 LID - 10.1371/journal.pone.0280320 [doi] LID - e0280320 AB - PURPOSE: To predict pathological complete response (pCR) after neoadjuvant chemotherapy using extreme gradient boosting (XGBoost) with MRI and non-imaging data at multiple treatment timepoints. MATERIAL AND METHODS: This retrospective study included breast cancer patients (n = 117) who underwent neoadjuvant chemotherapy. Data types used included tumor ADC values, diffusion-weighted and dynamic-contrast-enhanced MRI at three treatment timepoints, and patient demographics and tumor data. GLCM textural analysis was performed on MRI data. An extreme gradient boosting machine learning algorithm was used to predict pCR. Prediction performance was evaluated using the area under the curve (AUC) of the receiver operating curve along with precision and recall. RESULTS: Prediction using texture features of DWI and DCE images at multiple treatment time points (AUC = 0.871; 95% CI: (0.768, 0.974; p<0.001) and (AUC = 0.903 95% CI: 0.854, 0.952; p<0.001) respectively), outperformed that using mean tumor ADC (AUC = 0.850 (95% CI: 0.764, 0.936; p<0.001)). The AUC using all MRI data was 0.933 (95% CI: 0.836, 1.03; p<0.001). The AUC using non-MRI data was 0.919 (95% CI: 0.848, 0.99; p<0.001). The highest AUC of 0.951 (95% CI: 0.909, 0.993; p<0.001) was achieved with all MRI and all non-MRI data at all time points as inputs. CONCLUSION: Using XGBoost on extracted GLCM features and non-imaging data accurately predicts pCR. This early prediction of response can minimize exposure to toxic chemotherapy, allowing regimen modification mid-treatment and ultimately achieving better outcomes. CI - Copyright: © 2023 Syed et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Syed, Aaquib AU - Syed A AD - Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America. FAU - Adam, Richard AU - Adam R AD - Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America. FAU - Ren, Thomas AU - Ren T AD - Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America. FAU - Lu, Jinyu AU - Lu J AD - Oncology Division, Department of Medicine, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America. FAU - Maldjian, Takouhie AU - Maldjian T AD - Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America. FAU - Duong, Tim Q AU - Duong TQ AUID- ORCID: 0000-0001-6403-2827 AD - Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America. LA - eng PT - Journal Article DEP - 20230117 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - *Multiparametric Magnetic Resonance Imaging MH - Diffusion Magnetic Resonance Imaging/methods MH - Retrospective Studies MH - Treatment Outcome MH - Magnetic Resonance Imaging/methods MH - Neoadjuvant Therapy/methods MH - Machine Learning PMC - PMC9844845 COIS- The authors have declared that no competing interests exist. EDAT- 2023/01/18 06:00 MHDA- 2023/01/20 06:00 CRDT- 2023/01/17 13:43 PHST- 2022/04/12 00:00 [received] PHST- 2022/12/27 00:00 [accepted] PHST- 2023/01/17 13:43 [entrez] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] AID - PONE-D-22-10717 [pii] AID - 10.1371/journal.pone.0280320 [doi] PST - epublish SO - PLoS One. 2023 Jan 17;18(1):e0280320. doi: 10.1371/journal.pone.0280320. eCollection 2023. PMID- 36018290 OWN - NLM STAT- MEDLINE DCOM- 20221207 LR - 20221230 IS - 1365-2168 (Electronic) IS - 0007-1323 (Linking) VI - 109 IP - 12 DP - 2022 Nov 22 TI - Accuracy of ultrasound-guided targeted fine-needle aspiration in assessing nodal response in node-positive breast cancer after neoadjuvant chemotherapy: prospective feasibility study. PG - 1194-1197 LID - 10.1093/bjs/znac277 [doi] FAU - Wu, Si-Yu AU - Wu SY AD - Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Li, Jian-Wei AU - Li JW AUID- ORCID: 0000-0001-7005-8257 AD - Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Wu, Huai-Liang AU - Wu HL AD - Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Shao, Zhi-Ming AU - Shao ZM AD - Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Liu, Guang-Yu AU - Liu GY AUID- ORCID: 0000-0001-5464-4395 AD - Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Hu, Na AU - Hu N AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. AD - Department of Ultrasound, Fudan University Shanghai Cancer Centre, Shanghai, China. LA - eng GR - 22YF1408600/Shanghai Sailing Programme/ PT - Journal Article PL - England TA - Br J Surg JT - The British journal of surgery JID - 0372553 SB - IM MH - Humans MH - Female MH - Biopsy, Fine-Needle MH - *Neoadjuvant Therapy MH - *Breast Neoplasms/diagnostic imaging/drug therapy/surgery MH - Prospective Studies MH - Feasibility Studies MH - Sentinel Lymph Node Biopsy MH - Axilla MH - Ultrasonography, Interventional MH - Lymph Nodes/diagnostic imaging EDAT- 2022/08/27 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/08/26 10:32 PHST- 2022/05/17 00:00 [received] PHST- 2022/06/19 00:00 [revised] PHST- 2022/07/16 00:00 [accepted] PHST- 2022/08/27 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/08/26 10:32 [entrez] AID - 6677263 [pii] AID - 10.1093/bjs/znac277 [doi] PST - ppublish SO - Br J Surg. 2022 Nov 22;109(12):1194-1197. doi: 10.1093/bjs/znac277. PMID- 36609281 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Jan 6 TI - Predictors of surgery choices in women with early-stage breast cancer in China: a retrospective study. PG - 23 LID - 10.1186/s12885-023-10510-4 [doi] LID - 23 AB - BACKGROUND: The breast-conserving surgery and reconstruction rate in China is relatively low when compared with those in Western countries. Moreover, predictors of surgical choices for women with breast cancer in China have not yet been explored. This study aims to explore differences in the surgical choices of women with different demographic and clinical characteristics and the predictors that influence surgical choices of women with early-stage breast cancer. METHODS: This retrospective study included women with early-stage (0-II) breast cancer who underwent surgeries at one of two Xiamen University-affiliated hospitals between 2009 and 2017. Using medical records, eleven variables were collected: the woman's age, year of diagnosis, hospital, marital status, payment method, cancer stage, presence of positive axillary lymph node, histology, neoadjuvant chemotherapy, radiotherapy, and the type(s) of surgery they chose. Binary logistic regression was used to analyse predictors of surgical choice. RESULTS: A total of 1,787 cases were included in this study. Of the total number of women with breast cancer, 61.3% underwent mastectomy without breast reconstruction, 26.4% underwent mastectomy with breast reconstruction, and the remaining 12.2% chose breast-conserving surgery. Women with different demographic and clinical characteristics underwent different types of surgery. Cancer stage, neoadjuvant chemotherapy, radiotherapy, and the choice of hospital were found to be predictors of breast-conserving surgery. Meanwhile, age, year of diagnosis, payment method, neoadjuvant chemotherapy, and the choice of hospital were found to be predictors of reconstruction after mastectomy in women with early-stage breast cancer. CONCLUSIONS: In China, surgical choices for women with breast cancer have diversified. Healthcare workers should understand the surgical preferences of women of different ages. For early detection of breast cancer, knowledge of breast self-examination and breast cancer screening should be provided. Adequate information about the safety of reconstruction and advocacy for medical insurance coverage of reconstruction should be offer. Breast surgeons need specialised training and standardising protocols towards different types of breast surgery. These actions will help women make better, well-informed decisions about their breast surgeries. CI - © 2023. The Author(s). FAU - Huang, Sijia AU - Huang S AD - Department of Nursing, School of Medicine, Xiamen University, Xiamen, P.R. China. FAU - Yang, Qingmo AU - Yang Q AD - Department of Breast Surgery, First Affiliated Hospital, Xiamen University, Xiamen, P.R. China. FAU - Zheng, Xujuan AU - Zheng X AD - School of Nursing, Health Science Centre, Shenzhen University, Shenzhen, Guangdong Province, P.R. China. FAU - Chow, Ka Ming AU - Chow KM AD - The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, P.R. China. FAU - Wu, Junhua AU - Wu J AD - Department of Nursing, School of Medicine, Xiamen University, Xiamen, P.R. China. FAU - Zhu, Jiemin AU - Zhu J AD - Department of Nursing, School of Medicine, Xiamen University, Xiamen, P.R. China. jieminzhu@xmu.edu.cn. LA - eng GR - 71974162/National Natural Science Foundation of China/ GR - 71974162/National Natural Science Foundation of China/ GR - 71974162/National Natural Science Foundation of China/ PT - Journal Article DEP - 20230106 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/epidemiology/surgery/pathology MH - Mastectomy/methods MH - Retrospective Studies MH - Mastectomy, Segmental MH - China/epidemiology PMC - PMC9825016 OTO - NOTNLM OT - Breast cancer OT - Breast reconstruction OT - Breast-conserving surgery OT - Mastectomy OT - Surgical choices COIS- The authors declare that they have no conflicts of interest. EDAT- 2023/01/08 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/07 16:24 PHST- 2022/03/29 00:00 [received] PHST- 2023/01/03 00:00 [accepted] PHST- 2023/01/07 16:24 [entrez] PHST- 2023/01/08 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - 10.1186/s12885-023-10510-4 [pii] AID - 10510 [pii] AID - 10.1186/s12885-023-10510-4 [doi] PST - epublish SO - BMC Cancer. 2023 Jan 6;23(1):23. doi: 10.1186/s12885-023-10510-4. PMID- 35691022 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230125 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 1 DP - 2023 Jan TI - The interplay between XPG-Asp1104His polymorphism and reproductive risk factors elevates risk of breast cancer in Tanzanian women: A multiple interaction analysis. PG - 472-487 LID - 10.1002/cam4.4914 [doi] AB - BACKGROUND: Reproductive history and genetics are well-known risk factors of breast cancer (BC). Little is known about how these factors interact to effect BC. This study investigated the association of ten polymorphisms in DNA repair genes with BC susceptibility in the Tanzanian samples and further analyzed the association between reproductive risk factors and disease risk METHODS: A hospital-based case-control study in 263 histopathological confirmed BC patients and 250 age-matched cancer-free controls was carried out. Allelic, genotypic, and haplotype association analyses were executed. Also, multifactor dimensionality reduction (MDR), and interaction dendrogram approaches were performed. RESULTS: The frequency of genotypic and allelic variants of XRCC1-Arg399Gln (rs25487), XRCC2-Arg188His (rs3218536), XRCC3-Thr241Met (rs861539), XPG-Asp1104His (rs17655), and MSH2-Gly322Asp (rs4987188) were significantly different between the groups (p < 0.05). Moreover, XRCC1-Arg399Gln (rs25487), XRCC3-Thr241Met (rs861539), and XPG-Asp1104His (rs17655) were associated with the increased risk of BC in co-dominant, dominant, recessive, and additive genetic-inheritance models (p < 0.05). XRCC1-Arg/Gln genotype indicated a 3.1-fold increased risk of BC in pre-menopausal patients (p = 0.001) while XPG-His/His genotype showed a 1.2-fold increased risk in younger BC patients (<40 years) (p = 0.028). Asp/His+His/His genotypes indicated a 1.3-fold increased risk of BC in PR+ patients and a 1.1-fold decreased risk of BC in luminal-A patients (p = 0.014, p = 0.020, respectively). MDR analysis revealed a positive interaction between BC and the XPG-Asp1104His (rs17655) together with family history of cancer in the first-degree relatives. Dendrogram analysis indicated that the XPG-Asp1104His (rs17655) and family history of cancer in first-degree relatives were significantly synergistic and might be associated with an elevated risk of BC in Tanzania. CONCLUSIONS: The XPG-Asp1104His (rs17655) might exert both independent and interactive effects on BC development in the Tanzanian women. CI - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Adolf, Ismael C AU - Adolf IC AD - University of Dar es Salaam, Mbeya College of Health and Allied Sciences, Mbeya, Tanzania. FAU - Rweyemamu, Linus P AU - Rweyemamu LP AUID- ORCID: 0000-0002-8856-8789 AD - University of Dar es Salaam, Mbeya College of Health and Allied Sciences, Mbeya, Tanzania. AD - University of Dar es Salaam, Department of Molecular Biology and Biotechnology, Dar es Salaam, Tanzania. FAU - Akan, Gokce AU - Akan G AUID- ORCID: 0000-0002-3878-1135 AD - Muhimbili University of Health and Allied Sciences, MUHAS Genetic Laboratory, Department of Biochemistry, Dar es Salaam, Tanzania. AD - Near East University, DESAM Research Institute, Nicosia, Cyprus. FAU - Mselle, Ted F AU - Mselle TF AD - Muhimbili University of Health and Allied Sciences, MUHAS Genetic Laboratory, Department of Biochemistry, Dar es Salaam, Tanzania. FAU - Dharsee, Nazima AU - Dharsee N AD - Ocean Road Cancer Institute, Academic, Research and Consultancy Unit, Dar es Salaam, Tanzania. FAU - Namkinga, Lucy A AU - Namkinga LA AD - University of Dar es Salaam, Department of Molecular Biology and Biotechnology, Dar es Salaam, Tanzania. FAU - Lyantagaye, Sylvester L AU - Lyantagaye SL AD - University of Dar es Salaam, Mbeya College of Health and Allied Sciences, Mbeya, Tanzania. FAU - Atalar, Fatmahan AU - Atalar F AUID- ORCID: 0000-0002-1793-9220 AD - Muhimbili University of Health and Allied Sciences, MUHAS Genetic Laboratory, Department of Biochemistry, Dar es Salaam, Tanzania. AD - Istanbul University, Child Health Institute, Department of Rare Diseases, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20220612 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - 0 (XRCC1 protein, human) RN - 0 (X-ray Repair Cross Complementing Protein 1) RN - 0 (XRCC2 protein, human) RN - 0 (DNA-Binding Proteins) SB - IM MH - Humans MH - Female MH - Tanzania/epidemiology MH - *Breast Neoplasms/epidemiology/genetics MH - Reproductive History MH - Case-Control Studies MH - Risk Factors MH - Genotype MH - Genetic Predisposition to Disease MH - Polymorphism, Single Nucleotide MH - DNA Repair MH - X-ray Repair Cross Complementing Protein 1/genetics MH - DNA-Binding Proteins/genetics PMC - PMC9844639 OTO - NOTNLM OT - XPG OT - DNA repair genes OT - breast cancer OT - multifactor dimensionality reduction OT - polymorphism COIS- Authors declare no conflict of interests. EDAT- 2022/06/13 06:00 MHDA- 2023/01/20 06:00 CRDT- 2022/06/12 13:57 PHST- 2022/05/18 00:00 [revised] PHST- 2022/01/28 00:00 [received] PHST- 2022/05/24 00:00 [accepted] PHST- 2022/06/13 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/06/12 13:57 [entrez] AID - CAM44914 [pii] AID - 10.1002/cam4.4914 [doi] PST - ppublish SO - Cancer Med. 2023 Jan;12(1):472-487. doi: 10.1002/cam4.4914. Epub 2022 Jun 12. PMID- 36316558 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1865-8652 (Electronic) IS - 0741-238X (Linking) VI - 40 IP - 1 DP - 2023 Jan TI - Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer. PG - 310-330 LID - 10.1007/s12325-022-02330-y [doi] AB - INTRODUCTION: A high malignancy rate and poor prognosis are common problems with triple-negative breast cancer (TNBC). There is increasing evidence that glycolysis plays vital roles in tumorigenesis, tumor invasion, immune evasion, chemoresistance, and metastasis. However, a comprehensive analysis of the diagnostic and prognostic significance of glycolysis in TNBC is lacking. METHODS: Transcriptomic and clinical data of TNBC patients were obtained from The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) databases, respectively. Glycolysis-related genes (GRGs) were collected from the Molecular Signatures Database (MSigDB). Differential comparative analysis was performed to obtain the differentially expressed (DE)-GRGs associated with TNBC. Based on the DE-GRGs, a glycolysis-related risk signature was established using Least Absolute Shrinkage and Selector Operation (LASSO) and multivariable Cox regression analyses. The prognostic value, tumor microenvironment, mutation status, and chemotherapy response of different risk groups were analyzed. An independent cohort from the METABRIC database was used for external validation. Furthermore, the expression patterns of five genes derived from the prognostic model were validated by quantitative real-time polymerase chain reaction (RT-qPCR). RESULTS: The glycolysis-related prognostic signature included five genes (IFNG, ACSS2, IRS2, GFUS, and GAL3ST1) and predicted the prognosis of TNBC patients independent of clinical factors (p < 0.05). Patients were divided into high- and low-risk groups based on the median risk score. Compared to low-risk TNBC patients, high-risk patients had significantly decreased overall survival (HR = 2.718, p < 0.001). Receiver operating characteristic and calibration curves demonstrated that the model had high performance in terms of predicting survival and risk stratification. The results remained consistent after external verification. Additionally, the tumor immune microenvironment significantly differed between the risk groups. Low-risk TNBC patients had a better immunotherapy response than high-risk patients. High-risk TNBC patients with a poor prognosis may benefit from targeted therapy. CONCLUSIONS: This study developed a novel glycolysis and prognosis-related (GRP) signature based on GRGs to predict the prognosis of TNBC patients, and may aid clinical decision-making for these patients. CI - © 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature. FAU - Zheng, Jian AU - Zheng J AD - Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, 030000, China. AD - Department of Physiology, Shanxi Medical University, Taiyuan, China. AD - Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, China. FAU - Zhang, Yi-Fan AU - Zhang YF AD - Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, 030000, China. AD - Department of Physiology, Shanxi Medical University, Taiyuan, China. AD - The First Clinical Medical College, Shanxi Medical University, Taiyuan, China. FAU - Han, Guo-Hui AU - Han GH AD - Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, China. FAU - Fan, Meng-Ying AU - Fan MY AD - The Anesthesiology College, Shanxi Medical University, Taiyuan, China. FAU - Du, Ming-Hui AU - Du MH AD - The Second Clinical Medical College, Shanxi Medical University, Taiyuan, China. FAU - Zhang, Guo-Chen AU - Zhang GC AD - Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, China. FAU - Zhang, Bo AU - Zhang B AD - Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, China. FAU - Qiao, Jun AU - Qiao J AD - Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, 030000, China. AD - Department of Physiology, Shanxi Medical University, Taiyuan, China. AD - Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China. FAU - Zhang, Sheng-Xiao AU - Zhang SX AD - Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, 030000, China. AD - Department of Physiology, Shanxi Medical University, Taiyuan, China. AD - Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China. FAU - Cao, Ji-Min AU - Cao JM AUID- ORCID: 0000-0002-6546-555X AD - Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, 030000, China. caojimin@sxmu.edu.cn. AD - Department of Physiology, Shanxi Medical University, Taiyuan, China. caojimin@sxmu.edu.cn. LA - eng GR - 81871295/Innovative Research Group Project of the National Natural Science Foundation of China/ GR - 82001740/Innovative Research Group Project of the National Natural Science Foundation of China/ PT - Journal Article DEP - 20221101 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 MH - Humans MH - Cell Transformation, Neoplastic MH - *Glycolysis/genetics MH - Prognosis MH - Risk Factors MH - *Triple Negative Breast Neoplasms/genetics/therapy MH - Tumor Microenvironment OTO - NOTNLM OT - Computational biology OT - Glycolysis OT - Nomogram OT - Prognosis OT - Triple-negative breast cancer OT - Tumor microenvironment EDAT- 2022/11/02 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/11/01 00:38 PHST- 2022/07/19 00:00 [received] PHST- 2022/09/21 00:00 [accepted] PHST- 2022/11/02 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/11/01 00:38 [entrez] AID - 10.1007/s12325-022-02330-y [pii] AID - 10.1007/s12325-022-02330-y [doi] PST - ppublish SO - Adv Ther. 2023 Jan;40(1):310-330. doi: 10.1007/s12325-022-02330-y. Epub 2022 Nov 1. PMID- 36305299 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1465-3621 (Electronic) IS - 0368-2811 (Linking) VI - 53 IP - 1 DP - 2023 Jan 6 TI - Patterns of regional recurrence according to molecular subtype in patients with pN2 breast cancer treated with limited field regional irradiation. PG - 57-62 LID - 10.1093/jjco/hyac161 [doi] AB - OBJECTIVE: There is little evidence regarding the radiotherapy modification based on molecular subtypes in breast cancer. This study aimed to identify the risk and patterns of regional recurrence according to molecular subtype in patients with pN2 breast cancer. METHODS: We identified 454 patients who underwent radical surgery for breast cancer with 4-9 axillary lymph node metastases. All patients underwent axillary lymph node dissection, adjuvant chemotherapy and limited-field regional nodal irradiation. The rates and patterns of regional recurrence were compared between the following three subgroups: luminal type (estrogen receptor- and/or progesterone receptor-positive), HER2-type (estrogen receptor- and progesterone receptor-negative and HER2-positive) and triple-negative type (estrogen receptor-, progesterone receptor- and HER2-negative). RESULTS: Regional recurrence occurred in 18/454 patients (4%). The risk of regional recurrence was higher in the triple-negative (hazard ratio 7.641) and HER2-type (hazard ratio 4.032) subtypes than in the luminal subtype. The predominant pattern of regional recurrence was inside the radiotherapy field in triple-negative breast cancer and outside the radiotherapy field in HER2-type and luminal-type cancers. CONCLUSIONS: In patients with pN2 breast cancer, the risk of regional recurrence was higher in the triple-negative and HER2-type than in the luminal type. In-field recurrence was predominant in triple-negative cancer, while out-field recurrence was frequent in luminal and HER2-type breast cancers. CI - © The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Cho, Won Kyung AU - Cho WK AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Park, Won AU - Park W AUID- ORCID: 0000-0003-4742-2772 AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Jeong, Yuri AU - Jeong Y AD - Department of Radiation Oncology, Wonkwang University Hospital, Iksan, Republic of Korea. FAU - Kim, Haeyoung AU - Kim H AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. FAU - Kim, Nalee AU - Kim N AD - Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. LA - eng PT - Journal Article PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (Biomarkers, Tumor) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Receptors, Progesterone) RN - 0 (Receptors, Estrogen) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/radiotherapy/surgery MH - Biomarkers, Tumor/genetics MH - Receptor, ErbB-2 MH - Receptors, Progesterone MH - Receptors, Estrogen MH - Neoplasm Recurrence, Local/pathology MH - *Triple Negative Breast Neoplasms/genetics/radiotherapy/surgery OTO - NOTNLM OT - breast cancer OT - molecular subtype OT - radiation therapy OT - recurrence EDAT- 2022/10/29 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/10/28 05:03 PHST- 2022/08/16 00:00 [received] PHST- 2022/09/28 00:00 [accepted] PHST- 2022/10/29 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/10/28 05:03 [entrez] AID - 6775596 [pii] AID - 10.1093/jjco/hyac161 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2023 Jan 6;53(1):57-62. doi: 10.1093/jjco/hyac161. PMID- 36661703 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 1 DP - 2023 Jan 5 TI - Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up. PG - 688-703 LID - 10.3390/curroncol30010054 [doi] AB - This study aimed to investigate nutritional status, body composition, dietary protein intake, handgrip strength, 6 min or 4 m walk tests, self-reported physical activity, physical function, and quality of life (QoL-EORTC-QLQc30) at commencement of chemotherapy; to detect changes over time (from commencement of chemotherapy, and after 3, 6, 12, 26 and 52 weeks) in women with metastatic breast cancer (MBC); and to investigate the relationship between nutritional variables. 'Sarcopenia' was defined as low muscle mass and strength, 'myosteatosis' as muscle fat-infiltration (CT scan). Continuous variables were analysed using paired t-tests between baseline and follow-ups. Fifteen women (54y, 95% CI [46.3;61.2]) were recruited. At baseline, malnutrition was present in 3 (20%) participants, sarcopenia in 3 (20%) and myosteatosis in 7 (54%). Thirteen (87%) participants had low protein intake; low handgrip strength was observed in 0, and low walk test distance and physical activity in four (27%) participants. Physical function and QoL were low in 10 (67%) and 9 (60%), respectively. QoL between baseline and 52 weeks decreased by 11.7 (95% CI [2.4;20.9], p = 0.025). Other variables did not significantly change over time. In this small study sample, myosteatosis, low dietary protein intake, low exercise levels and impaired quality of life and physical function are common. FAU - Parkinson, Jessica AU - Parkinson J AUID- ORCID: 0000-0003-1748-8199 AD - Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD 4226, Australia. FAU - Bandera, Amelia AU - Bandera A AD - Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD 4226, Australia. FAU - Crichton, Megan AU - Crichton M AUID- ORCID: 0000-0002-1273-5368 AD - Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD 4226, Australia. FAU - Shannon, Catherine AU - Shannon C AD - Mater Health, Brisbane, QLD 4101, Australia. AD - Mater Research Institute, University of Queensland, Brisbane, QLD 4072, Australia. FAU - Woodward, Natasha AU - Woodward N AD - Mater Health, Brisbane, QLD 4101, Australia. AD - Mater Research Institute, University of Queensland, Brisbane, QLD 4072, Australia. FAU - Hodgkinson, Adam AU - Hodgkinson A AD - Mater Research Institute, University of Queensland, Brisbane, QLD 4072, Australia. FAU - Millar, Luke AU - Millar L AD - Mater Research Institute, University of Queensland, Brisbane, QLD 4072, Australia. FAU - Teleni, Laisa AU - Teleni L AD - Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD 4226, Australia. FAU - van der Meij, Barbara S AU - van der Meij BS AUID- ORCID: 0000-0002-0412-2801 AD - Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD 4226, Australia. AD - Mater Health, Brisbane, QLD 4101, Australia. AD - Mater Research Institute, University of Queensland, Brisbane, QLD 4072, Australia. AD - Department of Nutrition, Dietetics and Lifestyle, HAN University of Applied Sciences, 6525 EN Nijmegen, The Netherlands. AD - Division of Human Nutrition and Health, Wageningen University and Research, 6708 PD Wageningen, The Netherlands. LA - eng PT - Journal Article DEP - 20230105 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 0 (Dietary Proteins) SB - IM MH - Humans MH - Female MH - Quality of Life MH - Muscle Strength/physiology MH - Hand Strength MH - *Breast Neoplasms/drug therapy/pathology MH - Dietary Proteins/therapeutic use MH - Follow-Up Studies MH - *Sarcopenia/etiology MH - Exercise MH - Muscles/pathology PMC - PMC9857792 OTO - NOTNLM OT - malnutrition OT - metastatic breast cancer OT - physical function OT - quality of life OT - sarcopenia COIS- The authors declare no conflict of interest. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 09:35 PHST- 2022/11/09 00:00 [received] PHST- 2022/12/06 00:00 [revised] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/01/20 09:35 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - curroncol30010054 [pii] AID - curroncol-30-00054 [pii] AID - 10.3390/curroncol30010054 [doi] PST - epublish SO - Curr Oncol. 2023 Jan 5;30(1):688-703. doi: 10.3390/curroncol30010054. PMID- 36384817 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230105 IS - 1938-0666 (Electronic) IS - 1526-8209 (Linking) VI - 23 IP - 1 DP - 2023 Jan TI - ABSDELL Model: Development and Internal Validation of a Risk Prediction Model of LVEF Decline in Breast Cancer Patients Treated With Trastuzumab. PG - 23-31 LID - S1526-8209(22)00234-8 [pii] LID - 10.1016/j.clbc.2022.10.010 [doi] AB - INTRODUCTION/BACKGROUND: This study aims to establish an integrated model for predicting trastuzumab-associated decline of Left ventricular ejection fraction (LVEF) during drug administration. METHODS: A retrospective study of 212 women who diagnosed with HER2-positive breast cancer and treated with chemotherapy and trastuzumab was conducted. Medical records were collected from 6 months before staring trastuzumab to 3 years afterwards. The least absolute shrinkage and selection operator (LASSO) regression analysis was used to select variables, time-dependent receiver operating characteristic (ROC) curve and calibration plots were used to evaluate the model. The adjusted C-index and Brier scores were calculated using a bootstrap internal validation procedure. RESULTS: The median age of participants is 53.2 years old. The median length of follow-up was 336 days. There were 72 patients (33.96%) whose LVEF declined ≥ 10% (10 absolute percent points). Seven factors, namely age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), mitral peak E-wave velocity (E-wave), left ventricular end-systolic diameter (LVESD) and LVEF, were selected. The name of the ABSDELL model was formed by the initials of each predictor. The area under the curve (AUC) of the model was 0.802 in 1 year and 0.881 in 3 years. Calibration plots indicate the predicted and actual probabilities were highly consistent. In the internal validation, 1-year and 3-year adjusted C-index was 0.801 and 0.881, and adjusted Brier score was 0.118 and 0.091, separately. CONCLUSION: The ABSDELL model can effectively predicts the probability of LVEF decline in breast cancer patients treated with trastuzumab. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Liu, Xin AU - Liu X AD - Department of Cardiology, Peking University Third Hospital, Beijing, China. FAU - Tao, Liyuan AU - Tao L AD - Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China. FAU - Wang, Mopei AU - Wang M AD - Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China. FAU - Li, Haiyan AU - Li H AD - Department of Cardiology, Peking University Third Hospital, Beijing, China. Electronic address: haiyanli1027@hotmail.com. FAU - Xu, Weixian AU - Xu W AD - Department of Cardiology, Peking University Third Hospital, Beijing, China. Electronic address: xwxbird05@163.com. LA - eng PT - Journal Article DEP - 20221023 PL - United States TA - Clin Breast Cancer JT - Clinical breast cancer JID - 100898731 RN - P188ANX8CK (Trastuzumab) SB - IM MH - Female MH - Humans MH - Middle Aged MH - *Breast Neoplasms/complications/drug therapy MH - Cardiotoxicity/etiology MH - Retrospective Studies MH - Stroke Volume MH - Trastuzumab/adverse effects MH - *Ventricular Dysfunction, Left/chemically induced/diagnosis MH - Ventricular Function, Left OTO - NOTNLM OT - Cardiotoxicity OT - Echocardiography OT - Left ventricular ejection fraction OT - Prediction model OT - Trastuzumab COIS- Disclosure The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/11/18 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/17 10:00 PHST- 2022/04/29 00:00 [received] PHST- 2022/10/11 00:00 [revised] PHST- 2022/10/16 00:00 [accepted] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/17 10:00 [entrez] AID - S1526-8209(22)00234-8 [pii] AID - 10.1016/j.clbc.2022.10.010 [doi] PST - ppublish SO - Clin Breast Cancer. 2023 Jan;23(1):23-31. doi: 10.1016/j.clbc.2022.10.010. Epub 2022 Oct 23. PMID- 36634607 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 1540-1413 (Electronic) IS - 1540-1405 (Linking) VI - 21 IP - 1 DP - 2023 Jan TI - Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. PG - 33-41.e16 LID - 10.6004/jnccn.2022.7065 [doi] AB - BACKGROUND: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment-induced gonadotoxicity. PATIENTS AND METHODS: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the "biological window" of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy). RESULTS: The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33-42 years). AMH values at the 3 time points differed significantly (P<.001). At baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56-2.62 ng/mL). At week 2, a small but significant reduction in AMH levels was observed (median, 1.10 ng/mL; IQR, 0.45-2.09 ng/mL; P<.001). At surgery, a larger significant decline in AMH levels was observed (median, 0.01 ng/mL; IQR, 0.01-0.03 ng/mL; P<.001). Although the type of anti-HER2 treatment (trastuzumab and/or lapatinib) did not seem to impact the results, age and pretreatment ovarian reserve had a major influence on treatment-induced gonadotoxicity risk. CONCLUSIONS: This NeoALTTO biomarker analysis showed that anti-HER2 therapies alone had limited gonadotoxicity but that the addition of weekly paclitaxel resulted in marked AMH decline with possible negative implications for subsequent ovarian function and fertility. FAU - Lambertini, Matteo AU - Lambertini M AD - School of Medicine, University of Genova, Genova, Italy. AD - UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Ceppi, Marcello AU - Ceppi M AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Anderson, Richard A AU - Anderson RA AD - MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, United Kingdom. FAU - Cameron, David A AU - Cameron DA AD - Institute of Genomics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom. FAU - Bruzzone, Marco AU - Bruzzone M AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Franzoi, Maria Alice AU - Franzoi MA AD - Gustave Roussy, Villjuif, France. FAU - Massarotti, Claudia AU - Massarotti C AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. AD - University of Genova, Genova, Italy. FAU - El-Abed, Sarra AU - El-Abed S AD - Breast International Group, Brussels, Belgium. FAU - Wang, Yingbo AU - Wang Y AD - Novartis, Basel, Switzerland. FAU - Lecocq, Christophe AU - Lecocq C AD - BrEAST Data Centre, Institut Jules Bordet, Brussels, Belgium. FAU - Nuciforo, Paolo AU - Nuciforo P AD - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, SOLTI BC Cooperative Group, Barcelona, Spain. FAU - Rolyance, Rebecca AU - Rolyance R AD - North Central London Cancer Alliance, London, United Kingdom. FAU - Pusztai, Lajos AU - Pusztai L AD - Yale School of Medicine, New Haven, Connecticut. FAU - Sohn, Joohyuk AU - Sohn J AD - Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea. FAU - Latocca, Maria Maddalena AU - Latocca MM AD - School of Medicine, University of Genova, Genova, Italy. AD - UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Arecco, Luca AU - Arecco L AD - School of Medicine, University of Genova, Genova, Italy. AD - UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Pistilli, Barbara AU - Pistilli B AD - Gustave Roussy, Villjuif, France. FAU - Ruddy, Kathryn J AU - Ruddy KJ AD - Mayo Clinic, Rochester, Minnesota. FAU - Ballestrero, Alberto AU - Ballestrero A AD - School of Medicine, University of Genova, Genova, Italy. AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Del Mastro, Lucia AU - Del Mastro L AD - School of Medicine, University of Genova, Genova, Italy. AD - UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Peccatori, Fedro A AU - Peccatori FA AD - European Institute of Oncology IRCCS, Milan, Italy. FAU - Partridge, Ann H AU - Partridge AH AD - Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. FAU - Saura, Cristina AU - Saura C AD - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, SOLTI BC Cooperative Group, Barcelona, Spain. FAU - Untch, Michael AU - Untch M AD - Helios Hospital Berlin-Buch, Berlin, Germany. FAU - Piccart, Martine AU - Piccart M AD - Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium. FAU - Di Cosimo, Serena AU - Di Cosimo S AD - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - de Azambuja, Evandro AU - de Azambuja E AD - Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium. FAU - Demeestere, Isabelle AU - Demeestere I AD - Fertility Clinic, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. LA - eng PT - Journal Article PL - United States TA - J Natl Compr Canc Netw JT - Journal of the National Comprehensive Cancer Network : JNCCN JID - 101162515 RN - P88XT4IS4D (Paclitaxel) RN - 0VUA21238F (Lapatinib) RN - 0 (Biomarkers) SB - IM MH - Humans MH - Female MH - Adult MH - *Breast Neoplasms/drug therapy/surgery MH - Paclitaxel/adverse effects MH - *Ovarian Reserve MH - Lapatinib/therapeutic use MH - Biomarkers OTO - NOTNLM OT - Anti-Mullerian hormone OT - anti-HER2 therapy OT - breast cancer OT - gonadotoxicity OT - paclitaxel EDAT- 2023/01/13 06:00 MHDA- 2023/01/17 06:00 CRDT- 2023/01/12 18:21 PHST- 2022/05/29 00:00 [received] PHST- 2022/08/09 00:00 [accepted] PHST- 2023/01/12 18:21 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] AID - 10.6004/jnccn.2022.7065 [doi] PST - ppublish SO - J Natl Compr Canc Netw. 2023 Jan;21(1):33-41.e16. doi: 10.6004/jnccn.2022.7065. PMID- 36562691 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1537-453X (Electronic) IS - 0277-3732 (Linking) VI - 46 IP - 1 DP - 2023 Jan 1 TI - Five Fraction External Beam Partial Breast Irradiation: A User's Guide. PG - 16-19 LID - 10.1097/COC.0000000000000964 [doi] AB - OBJECTIVE: Mature follow up from multiple randomized trials have demonstrated the safety and efficacy of external beam partial breast irradiation (PBI) for appropriately selected patients with early stage breast cancer. Despite this evidence, external beam PBI remains underutilized. In this user guide we outline patient selection, workflow, and address possible challenges to aid in implementation of evidence-based external beam PBI. MATERIALS AND METHODS: Review of the current guidelines for PBI suitability, surgical considerations, treatment technique, simulation, contouring, and treatment planning, citing the latest published literature to support PBI utilization. RESULTS: Prospective data supports the use of 30 Gy in 5 fractions delivered with intensity modulated radiation therapy on a daily or every other day basis for a significant proportion of early stage breast cancer patients. The surgical cavity must be clearly visualized on treatment planning scan, recommend 3-5 weeks post-operatively, and the recommended clinical target volume expansion on the surgical cavity is 0.5-1.0 cm. A planning target volume expansion, based on motion management and image guidance, of 0.5-1.0 cm should be used. Organ at risk dose constraints of heart V3Gy ≤10% and contralateral breast Dmax ≤1 Gy are often achievable. CONCLUSIONS: Five fraction external beam PBI is a highly effective treatment with very limited toxicity for patients with early stage breast cancer following breast conserving surgery. Commonly utilized intensity modulated treatment planning techniques with plan delivery on standard linear accelerators results significant normal tissue sparing and makes implementation feasible at most radiation oncology centers. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Campbell, Shauna R AU - Campbell SR AUID- ORCID: 0000-0002-4486-0294 AD - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic. FAU - Shah, Chirag S AU - Shah CS AD - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic. FAU - Sittenfeld, Sarah M C AU - Sittenfeld SMC AD - Department of Radiation Oncology, Barrett Cancer Center, University of Cincinnati, Cincinnati, OH. FAU - Hoekstra, Nienke AU - Hoekstra N AD - Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands. LA - eng PT - Journal Article DEP - 20221208 PL - United States TA - Am J Clin Oncol JT - American journal of clinical oncology JID - 8207754 SB - IM MH - Humans MH - Female MH - Prospective Studies MH - *Breast/radiation effects MH - *Breast Neoplasms/radiotherapy/surgery MH - Mastectomy, Segmental MH - Radiotherapy Planning, Computer-Assisted/methods COIS- C.S.S. serves as a consultant for Impedimed, PreludeDX, Evicore, and Videra Surgical. He has received grants from PreludeDx, Varian, and Vision RT. The remaining authors declare no conflicts of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/23 09:53 PHST- 2022/12/23 09:53 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - 00000421-202301000-00005 [pii] AID - 10.1097/COC.0000000000000964 [doi] PST - ppublish SO - Am J Clin Oncol. 2023 Jan 1;46(1):16-19. doi: 10.1097/COC.0000000000000964. Epub 2022 Dec 8. PMID- 36459490 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 1473-0804 (Electronic) IS - 1369-7137 (Linking) VI - 26 IP - 1 DP - 2023 Feb TI - Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer. PG - 64-71 LID - 10.1080/13697137.2022.2147821 [doi] AB - OBJECTIVE: Triple-negative breast cancer (TNBC) is highly aggressive and leads to a poor prognosis. microRNA-181a (miR-181a) exhibits strong antineoplastic effects in many types of cancer. In this study, we examine the responses of human miR-181a-transfected TNBC cells and explore the mechanisms underlying the observed effects. METHODS: A series of cellular assays were conducted using cells from the MDA-MB-231 TNBC line to assess the impact of miR-181a overexpression. The extracellular acidification rate, lactate production and glucose uptake were evaluated as a measure of aerobic glycolysis (i.e. the Warburg effect). The expressions of glycolysis-related gene were analyzed. RESULTS: Viability, migration and survival of miR-181a-transfected MDA-MB-231 cells were all significantly reduced. miR-181a inhibited glycolysis in TNBC cells by reducing the rates of glucose uptake and lactate production and a substantial downregulation of factors known to contribute to the Warburg effect, including the serine/threonine kinase, AKT3, hypoxia-inducible factor-1α (HIF-1α) and progesterone receptor membrane component 1 (PGRMC1). CONCLUSION: Our results demonstrate that miR-181a may regulate glycolysis in MDA-MB-231 TNBC cells, potentially via interference with components of the AKT3-HIF-1α and PGRMC1 pathways. These results suggest that miR-181a might be developed as a therapeutic agent for use in antineoplastic regimens directed at TNBC and PGRMC1-overexpressing breast cancers. FAU - Wang, Y AU - Wang Y AD - Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing, China. FAU - Tahiri, H AU - Tahiri H AD - Department of Pediatrics, University of Montréal, Montréal, QC, Canada. AD - Department of Pharmacology and Physiology, University of Montréal, Montréal, QC, Canada. FAU - Yang, C AU - Yang C AUID- ORCID: 0000-0002-2648-9444 AD - Department of Pediatrics, University of Montréal, Montréal, QC, Canada. AD - Department of Pharmacology and Physiology, University of Montréal, Montréal, QC, Canada. FAU - Gu, M AU - Gu M AD - Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing, China. FAU - Ruan, X AU - Ruan X AUID- ORCID: 0000-0001-7777-247X AD - Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing, China. FAU - Hardy, P AU - Hardy P AD - Department of Pediatrics, University of Montréal, Montréal, QC, Canada. AD - Department of Pharmacology and Physiology, University of Montréal, Montréal, QC, Canada. LA - eng PT - Journal Article DEP - 20221202 PL - England TA - Climacteric JT - Climacteric : the journal of the International Menopause Society JID - 9810959 RN - 0 (MicroRNAs) RN - IY9XDZ35W2 (Glucose) RN - 0 (PGRMC1 protein, human) RN - 0 (Membrane Proteins) RN - 0 (Receptors, Progesterone) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/genetics/metabolism MH - *MicroRNAs/genetics MH - Glucose MH - Cell Proliferation MH - Membrane Proteins MH - Receptors, Progesterone OTO - NOTNLM OT - AKT3 OT - PGRMC1 OT - Triple-negative breast cancer OT - Warburg effect OT - glycolysis OT - miR-181a EDAT- 2022/12/03 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/12/02 13:02 PHST- 2022/12/03 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/12/02 13:02 [entrez] AID - 10.1080/13697137.2022.2147821 [doi] PST - ppublish SO - Climacteric. 2023 Feb;26(1):64-71. doi: 10.1080/13697137.2022.2147821. Epub 2022 Dec 2. PMID- 36401611 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1097-0142 (Electronic) IS - 0008-543X (Linking) VI - 129 IP - 3 DP - 2023 Feb 1 TI - Deep learning radiomics of ultrasonography for comprehensively predicting tumor and axillary lymph node status after neoadjuvant chemotherapy in breast cancer patients: A multicenter study. PG - 356-366 LID - 10.1002/cncr.34540 [doi] AB - BACKGROUND: Neoadjuvant chemotherapy (NAC) can downstage tumors and axillary lymph nodes in breast cancer (BC) patients. However, tumors and axillary response to NAC are not parallel and vary among patients. This study aims to explore the feasibility of deep learning radiomics nomogram (DLRN) for independently predicting the status of tumors and lymph node metastasis (LNM) after NAC. METHODS: In total, 484 BC patients who completed NAC from two hospitals (H1: 297 patients in the training cohort and 99 patients in the validation cohort; H2: 88 patients in the test cohort) were retrospectively enrolled. The authors developed two deep learning radiomics (DLR) models for personalized prediction of the tumor pathologic complete response (PCR) to NAC (DLR-PCR) and the LNM status (DLR-LNM) after NAC based on pre-NAC and after-NAC ultrasonography images. Furthermore, they proposed two DLRNs (DLRN-PCR and DLRN-LNM) for two different tasks based on the clinical characteristics and DLR scores, which were generated from both DLR-PCR and DLR-LNM. RESULTS: In the validation and test cohorts, DLRN-PCR exhibited areas under the receiver operating characteristic curves (AUCs) of 0.903 and 0.896 with sensitivities of 91.2% and 75.0%, respectively. DLRN-LNM achieved AUCs of 0.853 and 0.863, specificities of 82.0% and 81.8%, and negative predictive values of 81.3% and 87.2% in the validation and test cohorts, respectively. The two DLRN models achieved satisfactory predictive performance based on different BC subtypes. CONCLUSIONS: The proposed DLRN models have the potential to accurately predict the tumor PCR and LNM status after NAC. PLAIN LANGUAGE SUMMARY: In this study, we proposed two deep learning radiomics nomogram models based on pre-neoadjuvant chemotherapy (NAC) and preoperative ultrasonography images for independently predicting the status of tumor and axillary lymph node (ALN) after NAC. A more comprehensive assessment of the patient's condition after NAC can be achieved by predicting the status of the tumor and ALN separately. Our model can potentially provide a noninvasive and personalized method to offer decision support for organ preservation and avoidance of excessive surgery. CI - © 2022 American Cancer Society. FAU - Gu, Jionghui AU - Gu J AD - Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China. FAU - Tong, Tong AU - Tong T AD - CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China. AD - School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China. FAU - Xu, Dong AU - Xu D AD - Department of Ultrasound, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. FAU - Cheng, Fang AU - Cheng F AD - Department of Ultrasound, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. FAU - Fang, Chengyu AU - Fang C AD - Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. FAU - He, Chang AU - He C AD - Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. FAU - Wang, Jing AU - Wang J AD - Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. FAU - Wang, Baohua AU - Wang B AD - Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. FAU - Yang, Xin AU - Yang X AD - CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China. AD - School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China. FAU - Wang, Kun AU - Wang K AD - CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China. AD - School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China. FAU - Tian, Jie AU - Tian J AUID- ORCID: 0000-0003-0498-0432 AD - CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China. AD - School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China. AD - Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China. FAU - Jiang, Tian'an AU - Jiang T AUID- ORCID: 0000-0002-7672-8394 AD - Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. AD - Zhejiang Provincial Key Laboratory of Pulsed Electric Field Technology Medical Transformation, Hangzhou, China. LA - eng GR - Y202250839/Scientific Research Fund of Zhejiang Provincial Education Department/ GR - 82027803/Development Project of National Major Scientific Research Instrument/ GR - LZ20H180001/Key Project of Natural Science Foundation of Zhejiang Province/ GR - 2017YFA0205200/Ministry of Science and Technology of China/ GR - 2018YFC0114900/Ministry of Science and Technology of China/ GR - 82027803/National Natural Science Foundation of China/ GR - 62027901/National Natural Science Foundation of China/ GR - 81930053/National Natural Science Foundation of China/ GR - 81227901/National Natural Science Foundation of China/ GR - 81971623/National Natural Science Foundation of China/ GR - YJKYYQ20180048/Chinese Academy of Sciences/ GR - QYZDJ-SSW-JSC005/Chinese Academy of Sciences/ GR - Excellent Member Project of Youth Innovation Promotion Association CAS/ GR - Project of High-Level Talents Team Introduction in Zhuhai City/ PT - Journal Article PT - Multicenter Study DEP - 20221119 PL - United States TA - Cancer JT - Cancer JID - 0374236 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - Retrospective Studies MH - Neoadjuvant Therapy/methods MH - *Deep Learning MH - Lymph Nodes/diagnostic imaging/pathology MH - Ultrasonography MH - Lymphatic Metastasis/pathology OTO - NOTNLM OT - breast cancer OT - deep learning OT - lymph node metastasis OT - neoadjuvant chemotherapy OT - pathologic complete response OT - treatment decision OT - ultrasonography EDAT- 2022/11/20 06:00 MHDA- 2023/01/10 06:00 CRDT- 2022/11/19 10:12 PHST- 2022/08/22 00:00 [revised] PHST- 2022/05/29 00:00 [received] PHST- 2022/09/03 00:00 [accepted] PHST- 2022/11/20 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/11/19 10:12 [entrez] AID - 10.1002/cncr.34540 [doi] PST - ppublish SO - Cancer. 2023 Feb 1;129(3):356-366. doi: 10.1002/cncr.34540. Epub 2022 Nov 19. PMID- 36335217 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230125 IS - 1532-1827 (Electronic) IS - 0007-0920 (Print) IS - 0007-0920 (Linking) VI - 128 IP - 1 DP - 2023 Jan TI - A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. PG - 30-41 LID - 10.1038/s41416-022-02025-9 [doi] AB - BACKGROUND: This Phase 1b study (B2151002) evaluated the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with other anti-tumour agents in advanced solid tumours. METHODS: Patients with various malignancies were administered gedatolisib (90‒310 mg intravenously every week [QW]) plus docetaxel (arm A) or cisplatin (arm B) (each 75 mg/m(2) intravenously Q3W) or dacomitinib (30 or 45 mg/day orally). The safety and tolerability of combination therapies were assessed during dose escalation; objective response (OR) and safety were assessed during dose expansion. RESULTS: Of 110 patients enrolled, 107 received gedatolisib combination treatment. Seven of 70 (10.0%) evaluable patients had dose-limiting toxicities; the most common was grade 3 oral mucositis (n = 3). Based upon reprioritisation of the sponsor's portfolio, dose expansion focused on arm B, gedatolisib (180 mg QW) plus cisplatin in patients (N = 22) with triple-negative breast cancer (TNBC). OR (95% CI) was achieved in four of ten patients in first-line (overall response rate 40.0% [12.2-73.8%]) and four of 12 in second/third-line (33.3% [9.9-65.1%]) settings. One patient in each TNBC arm (10%, first-line; 8.3%, second/third-line) achieved a complete response. CONCLUSIONS: Gedatolisib combination therapy showed an acceptable tolerability profile, with clinical activity at the recommended Phase 2 dose in patients with TNBC. CLINICAL TRIAL: ClinicalTrial.gov: NCT01920061. CI - © 2022. The Author(s), under exclusive licence to Springer Nature Limited. FAU - Curigliano, Giuseppe AU - Curigliano G AUID- ORCID: 0000-0003-1781-2518 AD - Istituto Europeo di Oncologia, IRCCS, Milano, Italy. giuseppe.curigliano@ieo.it. AD - University of Milan, Milano, Italy. giuseppe.curigliano@ieo.it. FAU - Shapiro, Geoffrey I AU - Shapiro GI AUID- ORCID: 0000-0002-3331-4095 AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Kristeleit, Rebecca S AU - Kristeleit RS AUID- ORCID: 0000-0003-3825-1326 AD - University College London, Cancer Institute, London, UK. FAU - Abdul Razak, Albiruni R AU - Abdul Razak AR AD - Phase 1 Program, Princess Margaret Cancer Centre, Toronto, ON, Canada. FAU - Leong, Stephen AU - Leong S AD - University of Colorado Cancer Center, Aurora, CO, USA. FAU - Alsina, Maria AU - Alsina M AUID- ORCID: 0000-0003-4835-7159 AD - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. FAU - Giordano, Antonio AU - Giordano A AD - Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. FAU - Gelmon, Karen A AU - Gelmon KA AD - BC Cancer, Vancouver, BC, Canada. FAU - Stringer-Reasor, Erica AU - Stringer-Reasor E AD - University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL, USA. FAU - Vaishampayan, Ulka N AU - Vaishampayan UN AD - University of Michigan/Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. FAU - Middleton, Mark AU - Middleton M AUID- ORCID: 0000-0003-0167-1685 AD - University of Oxford, Oxford, UK. FAU - Olszanski, Anthony J AU - Olszanski AJ AUID- ORCID: 0000-0001-5276-5898 AD - Fox Chase Cancer Center, Philadelphia, PA, USA. FAU - Rugo, Hope S AU - Rugo HS AUID- ORCID: 0000-0001-6710-4814 AD - University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. FAU - Kern, Kenneth A AU - Kern KA AD - Pfizer, San Diego, CA, USA. FAU - Pathan, Nuzhat AU - Pathan N AD - Pfizer, San Diego, CA, USA. FAU - Perea, Rachelle AU - Perea R AD - Pfizer, San Diego, CA, USA. FAU - Pierce, Kristen J AU - Pierce KJ AD - Pfizer, Groton, CT, USA. FAU - Mutka, Sarah C AU - Mutka SC AD - Celcuity, Minneapolis, MD, USA. FAU - Wainberg, Zev A AU - Wainberg ZA AD - David Geffen School of Medicine at University of California, Los Angeles, CA, USA. LA - eng SI - ClinicalTrials.gov/NCT01920061 PT - Clinical Trial, Phase I PT - Journal Article DEP - 20221105 PL - England TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - 96265TNH2R (gedatolisib) RN - Q20Q21Q62J (Cisplatin) RN - 0 (Triazines) RN - 0 (Morpholines) RN - 0 (Antineoplastic Agents) RN - 0 (Phosphoinositide-3 Kinase Inhibitors) SB - IM EIN - Br J Cancer. 2023 Jan 25;:. PMID: 36697966 MH - Humans MH - *Triple Negative Breast Neoplasms/drug therapy MH - Cisplatin/adverse effects MH - Triazines MH - Morpholines/therapeutic use MH - *Antineoplastic Agents/adverse effects MH - Phosphoinositide-3 Kinase Inhibitors MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9814742 COIS- GC: research funding: Merck; personal consultation fees: Pfizer, Roche, AstraZeneca, BMS, Daichii Sankyo, Seagen, Gilead, Novartis, Eli Lilly; Ellipsis, and Merck. GIS: research funding: Eli Lilly, Merck KGaA/EMD-Serono, Merck, and Sierra Oncology; Advisory boards: Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA/EMD-Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros, Zentalis, CytomX Therapeutics and Blueprint Medicines; holds a patent titled “Dosage regimen for sapacitabine and seliciclib” also issued to Cyclacel Pharmaceuticals, and a pending patent titled “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition” together with Liam Cornell. RSK has received grants from MSD and Clovis; Consultancy: Basilea, Pharmamar; Advisor: AstraZeneca, GSK, iTEOS, Eisai, and InCyte. ARAR: research funding: Pfizer. SL: research funding: institution funding as principal investigator on trials for Pfizer, BMS, Deciphera, and Karyopharma; employment: on faculty at University of Colorado at the time of this research, since June 2020 an employee of Merck. MA: consultancy: BMS, MSD, Lilly, and Servier. AG: author declared no conflict of interest. KAG: research funding: Pfizer, AstraZeneca, and BMS; advisory board member: Pfizer, Novartis, Eli Lilly, Roche, Merck, Mylan, AstraZeneca, Gilead, and Ayala. ES-R: research funding: Susan G. Komen, V Foundation and NIH; employment: principal or sub-investigator of Pfizer sponsor clinical trials, fees paid to the institution; consultancy fees: Eli Lilly, Merck, Macrogenics, and AstraZeneca. UNV: research support: Merck, BMS and Astellas Inc. Consulting and Honoraria: Merck, Exelixis, BMS, Pfizer, AAA, Alkermes, Bayer, and EMD-Serono. MM: Grants: Roche, AstraZeneca, GRAIL; grants and personal fees: GSK; personal fees and other: BiolineRx, BMS, Novartis; grants, personal fees and other: Immunocore; other: Pfizer, Regeneron; personal fees, non-financial support and other: Merck/MSD; personal fees and non-financial support: Replimune, personal fees: Kineta and Silicon Therapeutics. AJO: research funding: Pfizer, Merck, and BMS – compensation for ad board. HSR: research support: Pfizer, Merck, Novartis, Lilly, Roche, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, AstraZeneca, Ayala and Gilead; honoraria: Puma, Samsung and NAPO. KAK: an employee of and holds stock options in Pfizer. NP: research funding: Pfizer; an employee of and holds stock options in Pfizer. RP: Was an employee and held stock options in Pfizer at the time the work was done. KJP: an employee of and holds stock options in Pfizer. SCM: an employee of and holds stock options in Celcuity; holds stock in Alpine Immune Sciences. ZAW: research funding: Plexxikon, Novartis and BMS; advisory boards: AstraZeneca, Eli Lilly, Genentech, Merck KGaA/EMD-Serono, Ipsen, Bayer, Daiichi Sankyo, Seagen, Merck, BMS, Amgen, Five Prime and Macrogenics Molecular Templates. EDAT- 2022/11/06 06:00 MHDA- 2023/01/10 06:00 PMCR- 2023/11/05 CRDT- 2022/11/06 00:40 PHST- 2022/08/03 00:00 [received] PHST- 2022/10/12 00:00 [accepted] PHST- 2022/10/07 00:00 [revised] PHST- 2023/11/05 00:00 [pmc-release] PHST- 2022/11/06 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/11/06 00:40 [entrez] AID - 10.1038/s41416-022-02025-9 [pii] AID - 2025 [pii] AID - 10.1038/s41416-022-02025-9 [doi] PST - ppublish SO - Br J Cancer. 2023 Jan;128(1):30-41. doi: 10.1038/s41416-022-02025-9. Epub 2022 Nov 5. PMID- 36442426 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230103 IS - 1095-6859 (Electronic) IS - 0090-8258 (Linking) VI - 168 DP - 2023 Jan TI - Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project. PG - 151-156 LID - S0090-8258(22)01931-X [pii] LID - 10.1016/j.ygyno.2022.11.017 [doi] AB - BACKGROUND: In cervical cancer, presence of lymph-node macrometastases (MAC) is a major prognostic factor and an indication for adjuvant treatment. However, since clinical impact of micrometastases (MIC) and isolated tumor-cells (ITC) remains controversial, we sought to identify a cut-off value for the metastasis size not associated with negative prognosis. METHODS: We analyzed data from 967 cervical cancer patients (T1a1L1-T2b) registered in the SCCAN (Surveillance in Cervical CANcer) database, who underwent primary surgical treatment, including sentinel lymph-node (SLN) biopsy with pathological ultrastaging. The size of SLN metastasis was considered a continuous variable and multiple testing was performed for cut-off values of 0.01-1.0 mm. Disease-free survival (DFS) was compared between N0 and subgroups of N1 patients defined by cut-off ranges. RESULTS: LN metastases were found in 172 (18%) patients, classified as MAC, MIC, and ITC in 79, 54, and 39 patients, respectively. DFS was shorter in patients with MAC (HR 2.20, P = 0.003) and MIC (HR 2.87, P < 0.001), while not differing between MAC/MIC (P = 0.484). DFS in the ITC subgroup was neither different from N0 (P = 0.127) nor from MIC/MAC subgroups (P = 0.449). Cut-off analysis revealed significantly shorter DFS compared to N0 in all subgroups with metastases ≥0.4 mm (HR 2.311, P = 0.04). The significance of metastases <0.4 mm could not be assessed due to limited statistical power (<80%). We did not identify any cut-off for the size of metastasis with significantly better prognosis than the rest of N1 group. CONCLUSIONS: In cervical cancer patients, the presence of LN metastases ≥0.4 mm was associated with a significant negative impact on DFS and no cut-off value for the size of metastasis with better prognosis than N1 was found. Traditional metastasis stratification based on size has no clinical implication. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Dostálek, Lukáš AU - Dostálek L AD - Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic. FAU - Benešová, Klára AU - Benešová K AD - Institute of Biostatistics and Analyses, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. FAU - Klát, Jaroslav AU - Klát J AD - Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic. FAU - Kim, Sarah H AU - Kim SH AD - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. FAU - Falconer, Henrik AU - Falconer H AD - Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. FAU - Kostun, Jan AU - Kostun J AD - Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic. FAU - Dos Reis, Ricardo AU - Dos Reis R AD - Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. FAU - Zapardiel, Ignacio AU - Zapardiel I AD - Gynecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain. FAU - Landoni, Fabio AU - Landoni F AD - Department of Obstetrics and Gynecology, University of Milano-Bicocca, Department of Obstetrics and Gynecology, Gynaecologic Oncology Surgical Unit, ASST-Monza, San Gerardo Hospital, Monza, Italy. FAU - Ortiz, David Isla AU - Ortiz DI AD - Gynecology Oncology Center, National Institute of Cancerology Mexico, Ciudad De Mexico, Mexico. FAU - van Lonkhuijzen, Luc R C W AU - van Lonkhuijzen LRCW AD - Department of Gynecological Oncology, Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Amsterdam, Netherlands. FAU - Lopez, Aldo AU - Lopez A AD - Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru. FAU - Odetto, Diego AU - Odetto D AD - Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina. FAU - Borčinová, Martina AU - Borčinová M AD - Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic. FAU - Jarkovsky, Jiri AU - Jarkovsky J AD - Institute of Biostatistics and Analyses, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. FAU - Salehi, Sahar AU - Salehi S AD - Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. FAU - Němejcová, Kristýna AU - Němejcová K AD - Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic. FAU - Bajsová, Sylva AU - Bajsová S AD - Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic. FAU - Park, Kay J AU - Park KJ AD - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. FAU - Javůrková, Veronika AU - Javůrková V AD - Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic. FAU - Abu-Rustum, Nadeem R AU - Abu-Rustum NR AD - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. FAU - Dundr, Pavel AU - Dundr P AD - Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic. FAU - Cibula, David AU - Cibula D AD - Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic. Electronic address: dc@davidcibula.cz. LA - eng PT - Journal Article DEP - 20221125 PL - United States TA - Gynecol Oncol JT - Gynecologic oncology JID - 0365304 SB - IM MH - Female MH - Humans MH - Lymphatic Metastasis/pathology MH - Neoplasm Micrometastasis/pathology MH - *Uterine Cervical Neoplasms/surgery/pathology MH - Sentinel Lymph Node Biopsy MH - Lymph Nodes/pathology MH - Neoplasm Staging MH - *Breast Neoplasms/pathology MH - *Sentinel Lymph Node/pathology OTO - NOTNLM OT - Cervical cancer OT - Classification OT - Disease-free survival OT - Histopathological ultrastaging OT - Isolated tumor cells OT - Low volume metastasis OT - Macrometastasis OT - Micrometastasis OT - Prognosis OT - Sentinel lymph node COIS- Declaration of Competing Interest The authors have no conflicts of interest to declare. EDAT- 2022/11/29 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/11/28 18:26 PHST- 2022/08/26 00:00 [received] PHST- 2022/11/14 00:00 [revised] PHST- 2022/11/17 00:00 [accepted] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/11/28 18:26 [entrez] AID - S0090-8258(22)01931-X [pii] AID - 10.1016/j.ygyno.2022.11.017 [doi] PST - ppublish SO - Gynecol Oncol. 2023 Jan;168:151-156. doi: 10.1016/j.ygyno.2022.11.017. Epub 2022 Nov 25. PMID- 35311481 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230121 IS - 1540-7586 (Electronic) IS - 0734-7332 (Print) IS - 0734-7332 (Linking) VI - 41 IP - 1 DP - 2023 TI - Role of self-efficacy for pain management and pain catastrophizing in the relationship between pain severity and depressive symptoms in women with breast cancer and pain. PG - 87-103 LID - 10.1080/07347332.2022.2046676 [doi] AB - PURPOSE: This study evaluated the relationship between pain and depressive symptoms through pain self-efficacy and pain catastrophizing in breast cancer patients with pain. DESIGN: Secondary analysis of a randomized trial investigating a cognitive-behavioral pain management protocol. SAMPLE: Females (N = 327) with stage I-III breast cancer and report of at least moderate pain. METHODS: Pain severity, pain self-efficacy, pain catastrophizing, and depressive symptoms were measured. The proposed model was assessed using structural equation modeling. RESULTS: Higher pain severity was significantly related to lower pain self-efficacy and higher pain catastrophizing. Lower pain self-efficacy and higher pain catastrophizing were significantly related to more depressive symptoms. Higher pain severity was significantly associated with more depressive symptoms through lower pain self-efficacy and higher pain catastrophizing. The association between pain severity and depressive symptoms was not significant when specified as a direct effect. CONCLUSION: Pain severity related to depressive symptoms in breast cancer patients via pain self-efficacy and pain catastrophizing. IMPLICATIONS FOR PSYCHOSOCIAL PROVIDERS: Measurement of pain self-efficacy and pain catastrophizing should be incorporated into comprehensive pain assessments for women with breast cancer, as these variables may be relevant therapeutic targets. Psychosocial symptom management interventions should include strategies that increase pain self-efficacy and decrease pain catastrophizing because these pain-related cognitive variables appear to drive the relationship between pain severity and depressive symptoms. FAU - Fisher, Hannah M AU - Fisher HM AD - Pain Prevention and Treatment Research Program, Duke University Medical Center, Durham, North Carolina, USA. FAU - Stalls, Juliann AU - Stalls J AD - Pain Prevention and Treatment Research Program, Duke University Medical Center, Durham, North Carolina, USA. FAU - Winger, Joseph G AU - Winger JG AUID- ORCID: 0000-0001-6278-2560 AD - Pain Prevention and Treatment Research Program, Duke University Medical Center, Durham, North Carolina, USA. FAU - Miller, Shannon N AU - Miller SN AD - Pain Prevention and Treatment Research Program, Duke University Medical Center, Durham, North Carolina, USA. FAU - Plumb Vilardaga, Jennifer C AU - Plumb Vilardaga JC AD - Pain Prevention and Treatment Research Program, Duke University Medical Center, Durham, North Carolina, USA. FAU - Majestic, Catherine AU - Majestic C AD - Pain Prevention and Treatment Research Program, Duke University Medical Center, Durham, North Carolina, USA. FAU - Kelleher, Sarah A AU - Kelleher SA AD - Pain Prevention and Treatment Research Program, Duke University Medical Center, Durham, North Carolina, USA. FAU - Somers, Tamara J AU - Somers TJ AD - Pain Prevention and Treatment Research Program, Duke University Medical Center, Durham, North Carolina, USA. LA - eng GR - R01 CA202779/CA/NCI NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial DEP - 20220321 PL - United States TA - J Psychosoc Oncol JT - Journal of psychosocial oncology JID - 8309337 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/therapy/complications MH - Catastrophization/psychology MH - *Depression/epidemiology MH - *Pain/etiology/psychology MH - Pain Management/psychology MH - Pain Measurement MH - Self Efficacy PMC - PMC9489816 MID - NIHMS1798796 OTO - NOTNLM OT - Breast cancer OT - depression OT - pain catastrophizing OT - pain self-efficacy OT - pain severity EDAT- 2022/03/22 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/03/21 12:14 PHST- 2022/03/22 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/03/21 12:14 [entrez] AID - 10.1080/07347332.2022.2046676 [doi] PST - ppublish SO - J Psychosoc Oncol. 2023;41(1):87-103. doi: 10.1080/07347332.2022.2046676. Epub 2022 Mar 21. PMID- 36528984 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1873-6947 (Electronic) IS - 1744-3881 (Linking) VI - 50 DP - 2023 Feb TI - Efficacy of proprioceptive neuromuscular facilitation in improving shoulder biomechanical parameters, functionality, and pain after axillary lymph node dissection for breast cancer: A randomized controlled study. PG - 101692 LID - S1744-3881(22)00160-8 [pii] LID - 10.1016/j.ctcp.2022.101692 [doi] AB - PURPOSE: Axillary lymph node dissection and radiotherapy have been associated with pain, physical symptoms, and decreased functional abilities in the upper extremity. This study aimed to evaluate the potential effects of the proprioceptive neuromuscular facilitation (PNF) technique on muscle strength, pain and functionality in this patient group in comparison with progressive resistance training (PRT). METHODS: The study was conducted with a randomized clinical trial design. Sixty-six women were included in the study and randomly divided into three groups: the PNF group (n = 22), the PRT group (n = 22), and the control group (n = 22). The participants were evaluated at the baseline and after eight weeks of treatment. Outcome measures were determined as pain (the Visual Analog Scale), upper extremity strength (isokinetic dynamometer), functionality (the Disabilities of the Arm, Shoulder and Hand questionnaire), and perception of change (the Global Rating of Change Scale). TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05288036. RESULTS: The results showed statistically significant changes in both treatment groups in terms of shoulder flexors/extensors, abductor/adductors, internal/external rotators strength/power/endurance measurement, pain, and functionality (p < 0.05). Concerning functionality and perception of change, the PNF group had a statistically significantly higher improvement compared to the remaining two groups (p < 0.05). CONCLUSION: PNF is an effective technique in increasing upper extremity muscle strength, reducing pain during rest and activity, and improving functionality in patients receiving breast cancer treatment. CI - Copyright © 2022 Elsevier Ltd. All rights reserved. FAU - Guloglu, Selen AU - Guloglu S AD - Istanbul Medipol University, Institute of Health Sciences, Department of Physical Therapy and Rehabilitation, Istanbul, Turkey. Electronic address: selensubasi@medipol.edu.tr. FAU - Basim, Pelin AU - Basim P AD - Istanbul Medipol University, Faculty of Medicine, Department of General Surgery, Istanbul, Turkey. Electronic address: pelinakbaba@gmail.com. FAU - Algun, Z Candan AU - Algun ZC AD - Istanbul Medipol University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Istanbul, Turkey. Electronic address: calgun@medipol.edu.tr. LA - eng SI - ClinicalTrials.gov/NCT05288036 PT - Journal Article PT - Randomized Controlled Trial DEP - 20221111 PL - England TA - Complement Ther Clin Pract JT - Complementary therapies in clinical practice JID - 101225531 MH - Humans MH - Female MH - Shoulder MH - Axilla/pathology/surgery MH - *Muscle Stretching Exercises MH - Upper Extremity/pathology MH - Lymph Node Excision/adverse effects MH - *Breast Neoplasms/surgery MH - Pain/etiology OTO - NOTNLM OT - Axillary lymph node dissection (ALND) OT - Breast cancer OT - Muscle strength OT - Proprioceptive neuromuscular facilitation (PNF) OT - Upper extremity function COIS- Declaration of competing interest The authors declare that they have no conflict of interest related to the publication of this manuscript. EDAT- 2022/12/19 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/12/18 18:18 PHST- 2022/08/17 00:00 [received] PHST- 2022/11/02 00:00 [revised] PHST- 2022/11/06 00:00 [accepted] PHST- 2022/12/19 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/12/18 18:18 [entrez] AID - S1744-3881(22)00160-8 [pii] AID - 10.1016/j.ctcp.2022.101692 [doi] PST - ppublish SO - Complement Ther Clin Pract. 2023 Feb;50:101692. doi: 10.1016/j.ctcp.2022.101692. Epub 2022 Nov 11. PMID- 36179271 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230124 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 41 IP - 2 DP - 2023 Jan 10 TI - Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. PG - 295-306 LID - 10.1200/JCO.22.00406 [doi] AB - PURPOSE: To examine longitudinal relationships between levels of C-reactive protein (CRP) and cognition in older breast cancer survivors and noncancer controls. METHODS: English-speaking women age ≥ 60 years, newly diagnosed with primary breast cancer (stage 0-III), and frequency-matched controls were enrolled from September 2010 to March 2020; women with dementia, neurologic disorders, and other cancers were excluded. Assessments occurred presystemic therapy/enrollment and at annual visits up to 60 months. Cognition was measured using the Functional Assessment of Cancer Therapy-Cognitive Function and neuropsychological testing. Mixed linear effect models tested for survivor-control differences in natural log (ln)-transformed CRP at each visit. Random effect-lagged fluctuation models tested directional effects of ln-CRP on subsequent cognition. All models controlled for age, race, study site, cognitive reserve, obesity, and comorbidities; secondary analyses evaluated if depression or anxiety affected results. RESULTS: There were 400 survivors and 329 controls with CRP specimens and follow-up data (average age of 67.7 years; range, 60-90 years). The majority of survivors had stage I (60.9%), estrogen receptor-positive (87.6%) tumors. Survivors had significantly higher adjusted mean ln-CRP than controls at baseline and 12-, 24-, and 60-month visits (all P < .05). Higher adjusted ln-CRP predicted lower participant-reported cognition on subsequent visits among survivors, but not controls (P interaction = .008); effects were unchanged by depression or anxiety. Overall, survivors had adjusted Functional Assessment of Cancer Therapy-Cognitive Function scores that were 9.5 and 14.2 points lower than controls at CRP levels of 3.0 and 10.0 mg/L. Survivors had poorer neuropsychological test performance (v controls), with significant interactions with CRP only for the Trails B test. CONCLUSION: Longitudinal relationships between CRP and cognition in older breast cancer survivors suggest that chronic inflammation may play a role in development of cognitive problems. CRP testing could be clinically useful in survivorship care. FAU - Carroll, Judith E AU - Carroll JE AUID- ORCID: 0000-0001-5516-0819 AD - Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA. AD - Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA. FAU - Nakamura, Zev M AU - Nakamura ZM AUID- ORCID: 0000-0001-9695-1457 AD - Department of Psychiatry, University of North Carolina-Chapel Hill, Chapel Hill, NC. FAU - Small, Brent J AU - Small BJ AUID- ORCID: 0000-0002-7444-4689 AD - School of Aging Studies, University of South Florida, Tampa, FL. FAU - Zhou, Xingtao AU - Zhou X AUID- ORCID: 0000-0002-5164-125X AD - Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC. AD - Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC. FAU - Cohen, Harvey J AU - Cohen HJ AD - Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC. FAU - Ahles, Tim A AU - Ahles TA AUID- ORCID: 0000-0002-7936-2818 AD - Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Ahn, Jaeil AU - Ahn J AUID- ORCID: 0000-0001-7998-4759 AD - Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC. AD - Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC. FAU - Bethea, Traci N AU - Bethea TN AUID- ORCID: 0000-0003-3205-2078 AD - Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC. FAU - Extermann, Martine AU - Extermann M AUID- ORCID: 0000-0003-4381-1199 AD - Department of Oncology, Moffitt Cancer Center, University of South Florida, Tampa, FL. FAU - Graham, Deena AU - Graham D AUID- ORCID: 0000-0003-1111-6984 AD - John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ. FAU - Isaacs, Claudine AU - Isaacs C AUID- ORCID: 0000-0002-9646-1260 AD - Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC. FAU - Jim, Heather S L AU - Jim HSL AUID- ORCID: 0000-0001-7353-3711 AD - Moffitt Cancer Center, Tampa, FL. FAU - Jacobsen, Paul B AU - Jacobsen PB AD - Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD. FAU - McDonald, Brenna C AU - McDonald BC AUID- ORCID: 0000-0001-6895-4490 AD - Department of Radiology and Imaging Sciences, Melvin and Bren Simon Comprehensive Cancer Center, and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN. FAU - Patel, Sunita K AU - Patel SK AUID- ORCID: 0000-0002-9023-8391 AD - City of Hope National Medical Center, Los Angeles, CA. FAU - Rentscher, Kelly AU - Rentscher K AUID- ORCID: 0000-0003-1887-3953 AD - Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA. AD - Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA. FAU - Root, James AU - Root J AD - Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Saykin, Andrew J AU - Saykin AJ AUID- ORCID: 0000-0002-1376-8532 AD - Department of Radiology and Imaging Sciences, Melvin and Bren Simon Comprehensive Cancer Center, and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN. FAU - Tometich, Danielle B AU - Tometich DB AD - Moffitt Cancer Center, Tampa, FL. FAU - Van Dyk, Kathleen AU - Van Dyk K AUID- ORCID: 0000-0003-1500-930X AD - Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA. FAU - Zhai, Wanting AU - Zhai W AD - Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC. AD - Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC. FAU - Breen, Elizabeth C AU - Breen EC AUID- ORCID: 0000-0001-6046-4999 AD - Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA. AD - Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA. FAU - Mandelblatt, Jeanne S AU - Mandelblatt JS AUID- ORCID: 0000-0002-2490-005X AD - Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC. LA - eng GR - K01 AG065485/AG/NIA NIH HHS/United States GR - K01 CA212056/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20220930 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - 9007-41-4 (C-Reactive Protein) SB - IM MH - Female MH - Humans MH - Aged MH - Middle Aged MH - *Cancer Survivors/psychology MH - C-Reactive Protein MH - *Breast Neoplasms/complications MH - Cognition MH - Patient Reported Outcome Measures PMC - PMC9839283 COIS- Andrew J. Saykin Consulting or Advisory Role: Bayer Research Funding: Lilly (Inst) No other potential conflicts of interest were reported. EDAT- 2022/10/01 06:00 MHDA- 2023/01/10 06:00 PMCR- 2024/01/10 CRDT- 2022/09/30 16:02 PHST- 2024/01/10 00:00 [pmc-release] PHST- 2022/10/01 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/09/30 16:02 [entrez] AID - JCO.22.00406 [pii] AID - 10.1200/JCO.22.00406 [doi] PST - ppublish SO - J Clin Oncol. 2023 Jan 10;41(2):295-306. doi: 10.1200/JCO.22.00406. Epub 2022 Sep 30. PMID- 36464173 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230111 IS - 1879-0038 (Electronic) IS - 0378-1119 (Linking) VI - 853 DP - 2023 Feb 15 TI - Novel RNA N6-methyladenosine regulator related signature for predicting clinical and immunological characteristics in breast cancer. PG - 147095 LID - S0378-1119(22)00915-5 [pii] LID - 10.1016/j.gene.2022.147095 [doi] AB - BACKGROUND: Epigenetic mechanismshave been reported to involve in shaping tumor immune microenvironment (TME). However, the role of RNA N6-methyladenosine (m6A) modification in breast cancerhas not been fully explored. METHODS: Based on m6A modification and TME infiltration characteristics of 2249 breast cancer patients, we comprehensively correlated m6A modification with immune landscapeby screeningcandidate genes, function analysis and constructing m6Asignatures. Principal component analysis was used to establish the m6Ascore. Both LASSO and Cox regression analyses were used to evaluate its prognostic value.Functional assays and immunohistochemistry were used to evaluate the expression of m6A regulators and immune cell infiltration. RESULTS: Based on the dysregulated expression of m6A, three distinct clusters were identified that displayed diverse types of tumour-associated TME cell infiltration in breast cancer.Gene signatures, stromal activity, and clinical prognosis were assessed by the m6Ascore. m6Ascore could function as a biomarker for predicting the therapeutic response to targeted therapy and immunotherapy.The dysregulated expression of m6Aregulators mediated the immune cell infiltration in the TME. CONCLUSION: Basedonthestudy,weidentified the signature and potential mechanism of m6AmodificationsthatmodifyTME cell infiltration. Thus, targeting m6A regulators may provide a promisingmethodoftreatingBRCA. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Zhang, Jian AU - Zhang J AD - Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. FAU - Liu, Guihong AU - Liu G AD - Department of Radiation Oncology, Dongguan Tungwah Hospital, Dongguan, China. FAU - Dai, Zili AU - Dai Z AD - Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. FAU - Xie, Fuchuan AU - Xie F AD - Department of Radiation Oncology, Huizhou Municipal Central Hospital, Huizhou, China. FAU - Zheng, Ronghui AU - Zheng R AD - Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. FAU - Yuan, Benchao AU - Yuan B AD - Department of Oncology and Hematology, The Sixth People's Hospital of Huizhou City, Huiyang Hospital Affiliated to Southern Medical University, Huizhou, China. FAU - Guo, Liyi AU - Guo L AD - Department of Oncology and Hematology, The Sixth People's Hospital of Huizhou City, Huiyang Hospital Affiliated to Southern Medical University, Huizhou, China.. Electronic address: 13802869551@139.com. LA - eng PT - Journal Article DEP - 20221201 PL - Netherlands TA - Gene JT - Gene JID - 7706761 RN - K72T3FS567 (Adenosine) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - Breast MH - Adenosine/genetics MH - Epigenomics MH - Tumor Microenvironment/genetics OTO - NOTNLM OT - Bioinformatics OT - Breast cancer OT - N6-methyladenosine OT - Prognosis OT - Tumor microenvironment COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/05 06:00 MHDA- 2023/01/05 06:00 CRDT- 2022/12/04 19:27 PHST- 2022/08/03 00:00 [received] PHST- 2022/11/14 00:00 [revised] PHST- 2022/11/28 00:00 [accepted] PHST- 2022/12/05 06:00 [pubmed] PHST- 2023/01/05 06:00 [medline] PHST- 2022/12/04 19:27 [entrez] AID - S0378-1119(22)00915-5 [pii] AID - 10.1016/j.gene.2022.147095 [doi] PST - ppublish SO - Gene. 2023 Feb 15;853:147095. doi: 10.1016/j.gene.2022.147095. Epub 2022 Dec 1. PMID- 36403344 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1873-6947 (Electronic) IS - 1744-3881 (Linking) VI - 50 DP - 2023 Feb TI - Mat Pilates and belly dance: Effects on patient-reported outcomes among breast cancer survivors receiving hormone therapy and adherence to exercise. PG - 101683 LID - S1744-3881(22)00151-7 [pii] LID - 10.1016/j.ctcp.2022.101683 [doi] AB - BACKGROUND: Breast cancer treatment leads to several side effects. Exercise can help to reduce these side effects. However, it is unknown whether a mat Pilates or a belly dance intervention can improve the patient-reported outcomes of these women. OBJECTIVE: Examine the effects of a 16-week exercise intervention (mat Pilates or belly dance) on patient reported outcomes (PROs) among breast cancer survivors, at 16 weeks, six months, and 12 months; and investigate sociodemographic and clinical predictors of intervention adherence. METHODS: Seventy-four breast cancer survivors who were receiving hormone therapy were randomly allocated into mat Pilates (n = 25), belly dance (n = 25) or control group (educational sessions) (n = 24). Mat Pilates and belly dance groups received a 16-week intervention, delivered three days a week and 60 min a session. The control group received three education sessions and continue usual care. The patient reported outcomes assessed were depressive symptoms (Beck Depression Inventory), stress (Perceived Stress Scale), optimism (Life Orientation Test), fatigue (FACT-F), sleep quality (Pittsburgh Sleep Quality Index) and pain (VAS), clinical and sociodemographic characteristics, and habitual physical activity (IPAQ short). RESULTS: All three groups showed a significant improvement in fatigue, and this effect was maintained during follow-up. No significant effects were found for depressive symptoms, optimism, stress, or pain. A history of exercise prior to breast cancer and be inactive after diagnosis were significant predictors of adherence to interventions. CONCLUSION: Mat Pilates, belly dance and a few educational sessions can be effective in improving fatigue after 16 weeks of intervention. REGISTRATION: ClinicalTrials.gov (NCT03194997). CI - Copyright © 2022 Elsevier Ltd. All rights reserved. FAU - Boing, Leonessa AU - Boing L AD - College of Health and Sport Science, Santa Catarina State University, Florianopolis, Brazil; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia. Electronic address: leonessaboing@gmail.com. FAU - Fretta, Tatiana de Bem AU - Fretta TB AD - Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. Electronic address: tatibem@hotmail.com. FAU - Lynch, Brigid M AU - Lynch BM AD - Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia. Electronic address: Brigid.Lynch@cancervic.org.au. FAU - Dias, Mirella AU - Dias M AD - College of Health and Sport Science, Santa Catarina State University, Florianopolis, Brazil. Electronic address: mirelladias.fisio@gmail.com. FAU - Rosa, Luciana Martins da AU - Rosa LMD AD - Nursing Department, School of Health Sciences, Federal University of Santa Catarina, Florianopolis, Brazil. Electronic address: luciana.m.rosa@ufsc.br. FAU - Baptista, Fátima AU - Baptista F AD - Universidade de Lisboa Faculdade de Motricidade Humana, Exercise and Health Laboratory, Interdisciplinary Center for the Study of Human Performance, Cruz Quebrada, Lisboa, Portugal. Electronic address: fbaptista@fmh.ulisboa.pt. FAU - Bergmann, Anke AU - Bergmann A AD - Clinical Epidemiology, National Institute of Cancer, Rio de Janeiro, Brazil. Electronic address: abergmann@inca.gov.br. FAU - Fausto, Danielly Yani AU - Fausto DY AD - College of Health and Sport Science, Santa Catarina State University, Florianopolis, Brazil. Electronic address: dani.090594@hotmail.com. FAU - Bocchi Martins, Julia Beatriz AU - Bocchi Martins JB AD - College of Health and Sport Science, Santa Catarina State University, Florianopolis, Brazil. Electronic address: juliabocchi@gmail.com. FAU - Guimarães, Adriana Coutinho de Azevedo AU - Guimarães ACA AD - College of Health and Sport Science, Santa Catarina State University, Florianopolis, Brazil. Electronic address: adriana.guimaraes@udesc.br. LA - eng SI - ClinicalTrials.gov/NCT03194997 PT - Journal Article PT - Randomized Controlled Trial DEP - 20221105 PL - England TA - Complement Ther Clin Pract JT - Complementary therapies in clinical practice JID - 101225531 RN - 0 (Hormones) MH - Female MH - Humans MH - *Breast Neoplasms/therapy MH - *Exercise Movement Techniques MH - *Cancer Survivors MH - Exercise MH - Fatigue/etiology/therapy MH - Pain MH - Patient Reported Outcome Measures MH - Hormones OTO - NOTNLM OT - Breast neoplasm OT - Exercise OT - Fatigue OT - Physical activity OT - Randomized clinical trial COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/11/20 18:09 PHST- 2022/08/15 00:00 [received] PHST- 2022/10/16 00:00 [revised] PHST- 2022/10/29 00:00 [accepted] PHST- 2022/11/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/11/20 18:09 [entrez] AID - S1744-3881(22)00151-7 [pii] AID - 10.1016/j.ctcp.2022.101683 [doi] PST - ppublish SO - Complement Ther Clin Pract. 2023 Feb;50:101683. doi: 10.1016/j.ctcp.2022.101683. Epub 2022 Nov 5. PMID- 36602979 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 1 DP - 2023 TI - Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. PG - e0279775 LID - 10.1371/journal.pone.0279775 [doi] LID - e0279775 AB - INTRODUCTION: It is critical to select subsequent treatments for patients after the failure of trastuzumab therapy. Following the failure of standard trastuzumab therapy guidelines in the Chinese Society of Clinical Oncology, pyrotinib and capecitabine is a grade I recommended regimen for treating patients with HER2-positive metastatic breast cancer. Concurrently, in treating patients with HER2-positive metastatic breast cancer, lapatinib and capecitabine are also recommended regimens for those who have previously received taxanes, anthracyclines, and trastuzumab therapy. However, there is currently no systematic review and meta-analysis comparing pyrotinib with lapatinib among HER2+ MBC patients. Therefore, this study aims to perform a systematic review and meta-analysis and assess whether pyrotinib is superior to lapatinib in efficacy and safety. METHODS: Relevant trials were searched in CNKI, Wanfang, VIP, PubMed, Embase, and Cochrane CENTRAL databases from inception until March 27th, 2022. The primary outcomes were PFS and OS, and the secondary outcomes were ORR and grade ≥3 AEs. RESULTS: Five relevant studies were included in this study, including 2 RCTs and 3 retrospective cohort studies. Pyrotinib combined with chemotherapy is superior to lapatinib combined with chemotherapy among HER2+ metastatic breast cancer patients, with a significant improvement in PFS (prior trastuzumab therapy) (HR: 0.47, 95% CI: 0.39-0.57, p<0.001, I2 = 0%, FEM), PFS (trastuzumab resistance) (HR: 0.52, 95% CI: 0.39-0.68, p<0.001, I2 = 40%, FEM) and ORR (RR: 1.45, 95% CI: 1.26-1.67, p<0.001, I2 = 8%, FEM), but has higher grade ≥3 diarrhea incidence (RR: 2.68, 95% CI: 1.85-3.90, p<0.001, I2 = 44%, FEM). CONCLUSIONS: The efficacy of pyrotinib combined with chemotherapy is superior to lapatinib combined with chemotherapy but has more safety risks. CI - Copyright: © 2023 Yuan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Yuan, Ye AU - Yuan Y AUID- ORCID: 0000-0001-8594-7970 AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Liu, Xumei AU - Liu X AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Cai, Yi AU - Cai Y AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Li, Wenyuan AU - Li W AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230105 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0VUA21238F (Lapatinib) RN - 0 (pyrotinib) RN - 6804DJ8Z9U (Capecitabine) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - P188ANX8CK (Trastuzumab) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Lapatinib/therapeutic use MH - Capecitabine MH - Retrospective Studies MH - Receptor, ErbB-2 MH - Trastuzumab/therapeutic use MH - Treatment Failure MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9815638 COIS- The authors have declared that no competing interests exist. EDAT- 2023/01/06 06:00 MHDA- 2023/01/10 06:00 CRDT- 2023/01/05 13:43 PHST- 2022/09/02 00:00 [received] PHST- 2022/12/10 00:00 [accepted] PHST- 2023/01/05 13:43 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] AID - PONE-D-22-24109 [pii] AID - 10.1371/journal.pone.0279775 [doi] PST - epublish SO - PLoS One. 2023 Jan 5;18(1):e0279775. doi: 10.1371/journal.pone.0279775. eCollection 2023. PMID- 36604679 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 23 IP - 1 DP - 2023 Jan 5 TI - A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients. PG - 15 LID - 10.1186/s12885-022-10496-5 [doi] LID - 15 AB - BACKGROUND: The objective of this paper is to explore the value of a delta-radiomic model of the axillary lymph node (ALN) using dynamic contrast-enhanced (DCE) MRI for early prediction of the axillary pathological complete response (pCR) of breast cancer patients after neoadjuvant chemotherapy (NAC). METHODS: A total of 120 patients with ALN-positive breast cancer who underwent breast MRI before and after the first cycle of NAC between October 2018 and May 2021 were prospectively included in this study. Patients were divided into a training (n = 84) and validation (n = 36) cohort based on the temporal order of their treatments. Radiomic features were extracted from the largest slice of targeted ALN on DCE-MRI at pretreatment and after one cycle of NAC, and their changes (delta-) were calculated and recorded. Logistic regression was then applied to build radiomic models using the pretreatment (pre-), first-cycle(1st-), and changes (delta-) radiomic features separately. A clinical model was also built and combined with the radiomic models. The models were evaluated by discrimination, calibration, and clinical application and compared using DeLong test. RESULTS: Among the three radiomic models, the ALN delta-radiomic model performed the best with AUCs of 0.851 (95% CI: 0.770-0.932) and 0.822 (95% CI: 0.685-0.958) in the training and validation cohorts, respectively. The clinical model yielded moderate AUCs of 0.742 (95% CI: 0.637-0.846) and 0.723 (95% CI: 0.550-0.896), respectively. After combining clinical features to the delta-radiomics model, the efficacy of the combined model (AUC = 0.932) in the training cohort was significantly higher than that of both the delta-radiomic model (Delong p = 0.017) and the clinical model (Delong p < 0.001) individually. Additionally, in the validation cohort, the combined model had the highest AUC (0.859) of any of the models we tested although this was not statistically different from any other individual model's validation AUC. Calibration and decision curves showed a good agreement and a high clinical benefit for the combined model. CONCLUSION: This preliminary study indicates that ALN-based delta-radiomic model combined with clinical features is a promising strategy for the early prediction of downstaging ALN status after NAC. Future axillary MRI applications need to be further explored. CI - © 2023. The Author(s). FAU - Liu, Shasha AU - Liu S AD - Department of Radiology, The First Hospital of China Medical University, Shenyang, 110001, China. FAU - Du, Siyao AU - Du S AD - Department of Radiology, The First Hospital of China Medical University, Shenyang, 110001, China. FAU - Gao, Si AU - Gao S AD - Department of Radiology, The First Hospital of China Medical University, Shenyang, 110001, China. FAU - Teng, Yuee AU - Teng Y AD - Departments of Medical Oncology and Thoracic Surgery, The First Hospital of China Medical University, Shenyang, 110001, China. FAU - Jin, Feng AU - Jin F AD - Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, 110001, China. jinfeng@cmu.edu.cn. FAU - Zhang, Lina AU - Zhang L AD - Department of Radiology, The First Hospital of China Medical University, Shenyang, 110001, China. zhanglnda@163.com. LA - eng GR - 36028/the "Set Sail" Project of the First Hospital of China Medical University/ GR - 81971695/National Scientific Foundation of China/ PT - Journal Article DEP - 20230105 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - Neoadjuvant Therapy MH - Retrospective Studies MH - Magnetic Resonance Imaging MH - Lymph Nodes/diagnostic imaging/pathology PMC - PMC9817310 OTO - NOTNLM OT - Axillary lymph node OT - Breast neoplasms OT - DCE-MRI OT - Neoadjuvant chemotherapy OT - Pathological complete response OT - Radiomics COIS- All authors declare that they have no competing interests. EDAT- 2023/01/06 06:00 MHDA- 2023/01/10 06:00 CRDT- 2023/01/05 23:39 PHST- 2022/08/19 00:00 [received] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/01/05 23:39 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] AID - 10.1186/s12885-022-10496-5 [pii] AID - 10496 [pii] AID - 10.1186/s12885-022-10496-5 [doi] PST - epublish SO - BMC Cancer. 2023 Jan 5;23(1):15. doi: 10.1186/s12885-022-10496-5. PMID- 36370117 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1878-0261 (Electronic) IS - 1574-7891 (Print) IS - 1574-7891 (Linking) VI - 17 IP - 1 DP - 2023 Jan TI - Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group. PG - 27-36 LID - 10.1002/1878-0261.13340 [doi] AB - Resistance of advanced hormone-dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves the progression-free rate compared to Anastrozole alone. However, a better patient selection based on biomarkers would improve patient outcome. We evaluate for the first time the usage of ribosome biogenesis (RiBi) factors as a source of innovative markers. Using 47 FFPE tumours (A n = 18; V + A n = 29), 32 blood samples (A n = 13; V + A n = 19) and 30 samples of total RNAs (A n = 12; V + A n = 18) from the VICTORIA clinical trial, we observed an association between RiBi-associated markers and drug activity or prediction of treatment response. NOP10 and NHP2 mRNA levels were significantly higher in non-responders compared to responders in the Vistusertib + Anastrozole arm (P = 0.0194 and P = 0.0002 respectively; i.e. 8 weeks progression-free survival as endpoint). This study provides RiBi-based markers relevant for a better selection of patients with advanced endometrial carcinoma by predicting the response of endocrine therapy combined with mTOR inhibitor. CI - © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. FAU - Mourksi, Nour-El-Houda AU - Mourksi NE AUID- ORCID: 0000-0002-0952-0438 AD - Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Université de Lyon, Lyon, France. AD - Institut Convergence PLAsCAN, Lyon, France. AD - DevWeCan Labex Laboratory, Lyon, France. FAU - Dalban, Cécile AU - Dalban C AD - Clinical Research Department, Centre Léon Bérard, Lyon, France. FAU - Colombe-Vermorel, Amélie AU - Colombe-Vermorel A AD - Biopathology Department, Centre Léon Bérard, GINECO, Lyon, France. FAU - Odeyer, Laetitia AU - Odeyer L AD - Biopathology Department, Centre Léon Bérard, GINECO, Lyon, France. FAU - Simioni, Valentin AU - Simioni V AD - Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Université de Lyon, Lyon, France. AD - Institut Convergence PLAsCAN, Lyon, France. AD - DevWeCan Labex Laboratory, Lyon, France. FAU - Frenel, Jean-Sébastien AU - Frenel JS AD - Medical Oncology Department, Institut Cancérologie de l'Ouest, and GINEGEPS, St Herblain, France. FAU - Fabbro, Michel AU - Fabbro M AD - Department of Surgical Oncology, Institut du Cancer de Montpellier, University of Montpellier, Montpellier, France. FAU - Bazan, Fernando AU - Bazan F AD - Department of Medical Oncology, University Hospital of Besançon, Besançon, France. FAU - Abadie-Lacourtoisie, Sophie AU - Abadie-Lacourtoisie S AD - Institut de Cancérologie de l'Ouest, Angers, France. FAU - Coquan, Elodie AU - Coquan E AD - Department of Clinical Research, Department of Medical Oncology, Comprehensive Cancer Centre François Baclesse, Caen, France. FAU - Martinez, Séverine AU - Martinez S AD - Biological Resource Center, Centre Léon Bérard, Lyon, France. FAU - Garin, Gwenaelle AU - Garin G AD - Clinical Research Department, Centre Léon Bérard, Lyon, France. FAU - Tabone-Eglinger, Séverine AU - Tabone-Eglinger S AD - Biological Resource Center, Centre Léon Bérard, Lyon, France. FAU - Treilleux, Isabelle AU - Treilleux I AD - Biopathology Department, Centre Léon Bérard, GINECO, Lyon, France. FAU - Chabaud, Sylvie AU - Chabaud S AD - Clinical Research Department, Centre Léon Bérard, Lyon, France. FAU - Pérol, David AU - Pérol D AD - Clinical Research Department, Centre Léon Bérard, Lyon, France. FAU - Ray-Coquard, Isabelle AU - Ray-Coquard I AD - Medical Oncology Department, Centre Léon Bérard and University Claude Bernard Lyon 1, GINECO, Lyon, France. FAU - Heudel, Pierre-Etienne AU - Heudel PE AD - Medical Oncology Department, Centre Léon Bérard and University Claude Bernard Lyon 1, GINECO, Lyon, France. FAU - Diaz, Jean-Jacques AU - Diaz JJ AD - Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Université de Lyon, Lyon, France. AD - Institut Convergence PLAsCAN, Lyon, France. AD - DevWeCan Labex Laboratory, Lyon, France. FAU - Marcel, Virginie AU - Marcel V AUID- ORCID: 0000-0002-9557-8221 AD - Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, Université de Lyon, Lyon, France. AD - Institut Convergence PLAsCAN, Lyon, France. AD - DevWeCan Labex Laboratory, Lyon, France. LA - eng GR - CLIPP2 2015-153/Institut National Du Cancer/ GR - Ligue Contre le Cancer/ PT - Journal Article DEP - 20221207 PL - United States TA - Mol Oncol JT - Molecular oncology JID - 101308230 RN - 2Z07MYW1AZ (Anastrozole) RN - 0BSC3P4H5X (vistusertib) RN - 0 (Nitriles) RN - 0 (Triazoles) RN - 0 (Aromatase Inhibitors) RN - 0 (Biomarkers) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 0 (Antineoplastic Agents, Hormonal) RN - EC 2.7.1.1 (MTOR protein, human) SB - IM MH - Humans MH - Female MH - Anastrozole/therapeutic use MH - Nitriles/therapeutic use MH - Triazoles/therapeutic use MH - Aromatase Inhibitors/therapeutic use MH - Biomarkers MH - TOR Serine-Threonine Kinases MH - *Endometrial Neoplasms/drug therapy/genetics MH - Ribosomes MH - *Breast Neoplasms/drug therapy MH - Antineoplastic Agents, Hormonal/therapeutic use PMC - PMC9812831 OTO - NOTNLM OT - advanced endometrial cancer OT - biomarker OT - clinical trial OT - endocrine therapy OT - mTOR inhibitor OT - ribosome biogenesis COIS- The authors declare no conflict of interest. EDAT- 2022/11/13 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/11/12 09:42 PHST- 2022/09/17 00:00 [revised] PHST- 2022/06/16 00:00 [received] PHST- 2022/11/11 00:00 [accepted] PHST- 2022/11/13 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/11/12 09:42 [entrez] AID - MOL213340 [pii] AID - 10.1002/1878-0261.13340 [doi] PST - ppublish SO - Mol Oncol. 2023 Jan;17(1):27-36. doi: 10.1002/1878-0261.13340. Epub 2022 Dec 7. PMID- 36271726 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1365-2265 (Electronic) IS - 0300-0664 (Linking) VI - 98 IP - 2 DP - 2023 Feb TI - Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer. PG - 190-201 LID - 10.1111/cen.14839 [doi] AB - OBJECTIVE: Aromatase inhibitor (AI) therapy provides oncological benefits in postmenopausal women with oestrogen receptor-positive breast cancer. However, AI treatment has been associated with increased cardiovascular risk. In nonbreast cancer populations, experimentally induced low oestrogen states and natural transition to menopause have been associated with increases in visceral adipose tissue (VAT), a known surrogate marker for cardiometabolic risk. Given that AI treatment blocks oestradiol production, we hypothesized that AI treatment would increase VAT. METHODS: We conducted a prospective 12-month cohort study of 52 postmenopausal women newly initiating AI treatment (median age: 64.5 years) and 52 women with breast pathology not requiring endocrine therapy (median age: 63.5 years). VAT area and other body composition parameters were measured at baseline, 6 months and 12 months using dual X-ray absorptiometry. Other risk markers of cardiometabolic health were also assessed. RESULTS: In women initiating AI treatment, there was no statistically significant difference in VAT area after 12 months when compared to controls, with a mean adjusted difference of -5.00 cm(2) (-16.9, 6.91), p = .55. Moreover, changes in total fat mass, lean mass, subcutaneous adipose tissue area, hepatic steatosis and measures in endothelial function were also not statistically different between groups after 12 months. Findings were similar after adjustments for activity levels and coronavirus disease 2019 lockdown duration. CONCLUSIONS: These data provide reassurance that over the initial 12 months of AI therapy, AI treatment is not associated with metabolically adverse changes in body composition, hepatic steatosis or vascular reactivity. The impact of extended AI therapy on cardiometabolic health requires further study. CI - © 2022 John Wiley & Sons Ltd. FAU - Cheung, Yee-Ming M AU - Cheung YM AUID- ORCID: 0000-0003-3875-5698 AD - Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia. AD - Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia. FAU - Hoermann, Rudolf AU - Hoermann R AD - Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia. FAU - Van, Karen AU - Van K AD - Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia. FAU - Wu, Damian AU - Wu D AD - Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia. FAU - Healy, Jenny AU - Healy J AD - Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia. FAU - Chao, Michael AU - Chao M AD - Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia. FAU - White, Shane AU - White S AD - Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia. AD - Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. FAU - Yeo, Belinda AU - Yeo B AD - Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia. AD - Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. FAU - Zajac, Jeffrey AU - Zajac J AD - Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia. AD - Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia. FAU - Grossmann, Mathis AU - Grossmann M AUID- ORCID: 0000-0001-8261-3457 AD - Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia. AD - Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia. LA - eng GR - Australian Heart Foundation Health Professional Scholarship/ GR - Bayer Pharma and Besins Healthcare/ PT - Journal Article DEP - 20221101 PL - England TA - Clin Endocrinol (Oxf) JT - Clinical endocrinology JID - 0346653 RN - 0 (Aromatase Inhibitors) SB - IM MH - Female MH - Humans MH - Middle Aged MH - *Breast Neoplasms/drug therapy MH - Aromatase Inhibitors/therapeutic use MH - Postmenopause MH - Cohort Studies MH - Prospective Studies MH - Intra-Abdominal Fat MH - *COVID-19 MH - Communicable Disease Control MH - *Cardiovascular Diseases/chemically induced MH - Adipose Tissue OTO - NOTNLM OT - aromatase inhibitor OT - breast cancer OT - cardiometabolic risk OT - visceral adipose tissue OT - visceral fat EDAT- 2022/10/23 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/10/22 03:53 PHST- 2022/10/20 00:00 [revised] PHST- 2022/07/19 00:00 [received] PHST- 2022/10/21 00:00 [accepted] PHST- 2022/10/23 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/10/22 03:53 [entrez] AID - 10.1111/cen.14839 [doi] PST - ppublish SO - Clin Endocrinol (Oxf). 2023 Feb;98(2):190-201. doi: 10.1111/cen.14839. Epub 2022 Nov 1. PMID- 36538844 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1879-0739 (Electronic) IS - 0271-5317 (Linking) VI - 109 DP - 2023 Jan TI - Low to moderate adherence to 2018 diet and physical exercise recommendations of the World Cancer Research Fund/American Institute for Cancer Research is associated with prooxidant biochemical profile in women undergoing adjuvant breast cancer treatment. PG - 1-11 LID - S0271-5317(22)00102-6 [pii] LID - 10.1016/j.nutres.2022.09.011 [doi] AB - Adequate adherence to the 2018 diet and exercise recommendations of the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) can possibly result in less oxidative stress, lower risk to chemo- and radiotoxicity, lower risk of relapse, and increased quality of life in breast cancer survivors. This observational study aims to investigate the influence of adherence to updated recommendations of the WCRF/AICR on oxidative stress biomarkers in women with breast cancer undergoing adjuvant treatment (AT). We hypothesized that adherence to WCRF/AICR recommendations is inversely related to oxidative damage biomarkers and directly associated with antioxidant status. Women (n = 78) were evaluated before (T0) and after AT. After collecting anthropometric, physical activity, and food consumption data, a standardized score of adherence to WCRF/AICR recommendations was applied. The sample was divided into low-medium adherence and high adherence groups. Blood samples were collected at both timepoints for oxidative stress biomarkers analysis. Multiple linear regression analyzes were applied to verify associations between WCRF/AICR score and biomarkers. We found that low-medium adherence to WCRF/AICR recommendations at T0 affected lower levels of reduced glutathione (P= .003) and higher levels of lipid hydroperoxides (P= .002) and plasma carbonylated proteins (P= .001) after AT. The WCRF/AICR score at T0 was inversely associated with changes in plasma carbonylated protein concentrations after AT (adjusted β = -0.359; P= .01). Our findings suggest that high WCRF/AICR score before and during AT may provide greater stability of antioxidant capacity and protection against exacerbated oxidative stress. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Schroeder, Jaqueline AU - Schroeder J AD - Post Graduate Program in Nutrition, Health Sciences Center, Federal University of Santa Catarina, Florianopolis, 88040-370, SC, Brazil. FAU - Reitz, Luiza Kuhnen AU - Reitz LK AD - Post Graduate Program in Nutrition, Health Sciences Center, Federal University of Santa Catarina, Florianopolis, 88040-370, SC, Brazil. FAU - Vieira, Francilene Gracieli Kunradi AU - Vieira FGK AD - Post Graduate Program in Nutrition, Health Sciences Center, Federal University of Santa Catarina, Florianopolis, 88040-370, SC, Brazil. FAU - da Silva, Edson Luiz AU - da Silva EL AD - Post Graduate Program in Nutrition, Health Sciences Center, Federal University of Santa Catarina, Florianopolis, 88040-370, SC, Brazil; Department of Clinical Analyses, Health Sciences Center, Federal University of Santa Catarina, Florianopolis, 88010-790, SC, Brazil. FAU - Di Pietro, Patricia Faria AU - Di Pietro PF AD - Post Graduate Program in Nutrition, Health Sciences Center, Federal University of Santa Catarina, Florianopolis, 88040-370, SC, Brazil. Electronic address: patricia.di.pietro@ufsc.br. LA - eng PT - Journal Article PT - Observational Study DEP - 20221102 PL - United States TA - Nutr Res JT - Nutrition research (New York, N.Y.) JID - 8303331 RN - 0 (Reactive Oxygen Species) RN - 0 (Antioxidants) SB - IM MH - Humans MH - Female MH - United States MH - *Breast Neoplasms/prevention & control MH - Quality of Life MH - Reactive Oxygen Species MH - Antioxidants MH - Risk Factors MH - Diet MH - Exercise OTO - NOTNLM OT - Adjuvant treatment OT - Antioxidants OT - Breast neoplasm OT - Oxidative damage OT - WCRF/AICR COIS- Declaration of Competing Interest None. EDAT- 2022/12/21 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/12/20 18:04 PHST- 2022/05/27 00:00 [received] PHST- 2022/08/05 00:00 [revised] PHST- 2022/09/17 00:00 [accepted] PHST- 2022/12/21 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/12/20 18:04 [entrez] AID - S0271-5317(22)00102-6 [pii] AID - 10.1016/j.nutres.2022.09.011 [doi] PST - ppublish SO - Nutr Res. 2023 Jan;109:1-11. doi: 10.1016/j.nutres.2022.09.011. Epub 2022 Nov 2. PMID- 36333567 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 40 IP - 1 DP - 2023 Jan TI - Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel. PG - 331-348 LID - 10.1007/s12325-022-02302-2 [doi] AB - INTRODUCTION: Genetic mutations in breast cancer susceptibility gene 1 or 2 (BRCA1/2) confer a high risk for developing breast cancer; however, at least 50% of women with BRCA1/2 mutations go undiagnosed. This study evaluated differences in patient demographics, clinical characteristics, and BRCA1/2 mutation testing in the USA, European Union (EU4), and Israel in a real-world population of patients with human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). METHODS: This study was a retrospective analysis of data from the Adelphi Real World ABC Disease Specific Programme in the USA, EU4, and Israel. Medical oncologists completed a patient record form, which included detailed questions on demographics, clinical assessments and outcomes, and treatment history. Eligible patients were at least 18 years of age and receiving therapy for stage IIIb-IV ABC. RESULTS: Among the 2527 study patients, 407 were from the USA, 1926 were from the EU4, and 194 were from Israel; 86% had hormone receptor-positive (HR+)/HER2- ABC and 14% had triple-negative breast cancer (TNBC). Israeli patients had a higher rate of family history of BRCA-related cancer (69%) compared with patients in the EU4 (18%; p < 0.0001) and USA (18%; p < 0.0001). Among patients with HR+/HER2- ABC, the BRCA1/2 testing rate was 99% in Israel, 37% in the EU4, and 68% in the USA (p < 0.0001 vs Israel and the EU4). The age of tested patients was significantly younger in Israel (56 years) compared with the EU4 (59 years; p = 0.016 vs Israel) and USA (64 years; p < 0.0001 vs Israel and the EU4). Among patients with TNBC, the BRCA1/2 testing rate was 100% in Israel, 78% in the EU4 (p < 0.0001 vs Israel), and 93% in the USA (p < 0.002 vs the EU4). Among tested patients, genetic counseling rates were also higher in Israel (98%) compared with the EU4 (40%; p < 0.0001) and USA (38%; p < 0.0001). CONCLUSIONS: Testing and genetic counseling rates for BRCA1/2 mutations were very high in Israel, potentially due to the high rate of family history of BRCA-related cancer in this population and higher general awareness of genetic testing. In the EU4 and USA, overall rates of testing for BRCA1/2 mutations and genetic counseling were significantly lower compared with Israel. Given the high risk of breast cancer in BRCA1/2 mutation carriers and the efficacy of new therapies in treating ABC with a BRCA1/2 mutation, efforts should be made to improve BRCA1/2 testing rates in Europe and the USA. CI - © 2022. Pfizer Inc. FAU - Mahtani, Reshma AU - Mahtani R AUID- ORCID: 0000-0002-7711-8627 AD - Miami Cancer Institute, Plantation, FL, USA. rmahtani@baptisthealth.net. FAU - Niyazov, Alexander AU - Niyazov A AD - Patient Health and Impact, Pfizer Inc, New York, NY, USA. FAU - Lewis, Katie AU - Lewis K AD - Oncology Franchise, Adelphi Real World, Adelphi Mill, Bollington, SK10 5JB, UK. FAU - Rider, Alex AU - Rider A AD - Oncology Franchise, Adelphi Real World, Adelphi Mill, Bollington, SK10 5JB, UK. FAU - Massey, Lucy AU - Massey L AD - Department of Statistics and Data Analytics, Adelphi Real World, Bollington, UK. FAU - Arondekar, Bhakti AU - Arondekar B AD - Patient Health and Impact, Pfizer Inc, Collegeville, PA, USA. FAU - Lux, Michael P AU - Lux MP AD - Klinik für Gynäkologie und Geburtshilfe Frauenklinik St. Louise, Paderborn, Frauenklinik St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Kliniken, Paderborn, Germany. LA - eng PT - Journal Article DEP - 20221028 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 RN - EC 2.7.10.1 (ERBB2 protein, human) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA1 Protein) MH - Humans MH - Female MH - United States/epidemiology MH - Middle Aged MH - *Breast Neoplasms/genetics/drug therapy MH - *Triple Negative Breast Neoplasms MH - Israel/epidemiology MH - Retrospective Studies MH - Mutation MH - Europe MH - Demography MH - BRCA1 Protein/genetics PMC - PMC9859923 OTO - NOTNLM OT - Breast cancer susceptibility gene 1 or 2 OT - Genetic testing OT - Human epidermal growth factor receptor 2–negative advanced breast cancer OT - Real-world EDAT- 2022/11/06 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/11/05 00:42 PHST- 2022/07/13 00:00 [received] PHST- 2022/08/10 00:00 [accepted] PHST- 2022/11/06 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/11/05 00:42 [entrez] AID - 10.1007/s12325-022-02302-2 [pii] AID - 2302 [pii] AID - 10.1007/s12325-022-02302-2 [doi] PST - ppublish SO - Adv Ther. 2023 Jan;40(1):331-348. doi: 10.1007/s12325-022-02302-2. Epub 2022 Oct 28. PMID- 36628983 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 1 IP - 1 DP - 2023 Jan 11 TI - Psychological interventions for women with non-metastatic breast cancer. PG - CD008729 LID - 10.1002/14651858.CD008729.pub3 [doi] LID - CD008729 AB - BACKGROUND: Breast cancer is the most common cancer affecting women worldwide. It is a distressing diagnosis and, as a result, considerable research has examined the psychological sequelae of being diagnosed and treated for breast cancer. Breast cancer is associated with increased rates of depression and anxiety and reduced quality of life. As a consequence, multiple studies have explored the impact of psychological interventions on the psychological distress experienced after a diagnosis of breast cancer. This review is an update of a Cochrane Review first published in 2015. OBJECTIVES: To assess the effect of psychological interventions on psychological morbidities and quality of life among women with non-metastatic breast cancer.  SEARCH METHODS: We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov up to 16 March 2021. We also scanned the reference lists of relevant articles. SELECTION CRITERIA: Randomised controlled trials that assessed the effectiveness of psychological interventions for women with non-metastatic breast cancer. DATA COLLECTION AND ANALYSIS: Two review authors independently appraised, extracted data from eligible trials, and assessed risk of bias and certainty of the evidence using the GRADE approach. Any disagreement was resolved by discussion. Extracted data included information about participants, methods, the intervention and outcomes. MAIN RESULTS: We included 60 randomised controlled trials comprising 7998 participants. The most frequent reasons for exclusion were non-randomised trials and the inclusion of women with metastatic disease. The updated review included 7998 randomised women; the original review included 3940 women. A wide range of interventions was evaluated. Most interventions were cognitive- or mindfulness-based, supportive-expressive, and educational. The interventions were mainly delivered face-to-face (56 studies) and in groups (50 studies) rather than individually (10 studies). Most intervention sessions were delivered on a weekly basis with an average duration of 14 hours. Follow-up time ranged from two weeks to 24 months.  Pooled standardised mean differences (SMD) from baseline indicated that the intervention may reduce depression (SMD -0.27, 95% confidence interval (CI) -0.52 to -0.02; P = 0.04; 27 studies, 3321 participants, I(2) = 91%, low-certainty evidence); anxiety (SMD -0.43, 95% CI -0.68 to -0.17; P = 0.0009; 22 studies, 2702 participants, I(2) = 89%, low-certainty evidence); mood disturbance in the intervention group (SMD -0.18, 95% CI -0.31 to -0.04; P = 0.009; 13 studies, 2276 participants, I(2) = 56%, low-certainty evidence); and stress (SMD -0.34, 95% (CI) -0.55 to -0.12; P = 0.002; 8 studies, 564 participants, I(2) = 31%, low-certainty evidence). The intervention is likely to improve quality of life in the intervention group (SMD 0.78, 95% (CI) 0.32 to 1.24; P = 0.0008; 20 studies, 1747 participants, I(2) = 95%, low-certainty evidence). Adverse events were not reported in any of the included studies. AUTHORS' CONCLUSIONS: Based on the available evidence, psychological intervention may have produced favourable effects on psychological outcomes, in particular depression, anxiety, mood disturbance and stress. There was also an improvement in quality of life in the psychological intervention group compared to control group. Overall, there was substantial variation across the studies in the range of psychological interventions used, control conditions, measures of the same outcome and timing of follow-up. CI - Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Jassim, Ghufran A AU - Jassim GA AD - Department of Family & Community Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain (RCSI Bahrain), Busaiteen, Bahrain. FAU - Doherty, Sally AU - Doherty S AD - Psychiatry, Royal College of Surgeons in Ireland- Medical University of Bahrain (RCSI Bahrain), Busaiteen, Bahrain. FAU - Whitford, David L AU - Whitford DL AD - RCSI and UCD Malaysia Campus, Georgetown, Malaysia. FAU - Khashan, Ali S AU - Khashan AS AD - School of Public Health, University College Cork, Cork, Ireland. LA - eng PT - Journal Article PT - Review DEP - 20230111 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - Cochrane Database Syst Rev. 2015 May 28;(5):CD008729. PMID: 26017383 MH - Female MH - Humans MH - Anxiety Disorders/therapy MH - *Breast Neoplasms/therapy/psychology MH - Depression/therapy MH - *Psychosocial Intervention MH - Quality of Life MH - Randomized Controlled Trials as Topic PMC - PMC9832339 COIS- There are no financial conflicts of interest and the authors declare no association with any parties who may have vested interests in the results of this review. EDAT- 2023/01/12 06:00 MHDA- 2023/01/13 06:00 PMCR- 2024/01/11 CRDT- 2023/01/11 05:13 PHST- 2024/01/11 00:00 [pmc-release] PHST- 2023/01/11 05:13 [entrez] PHST- 2023/01/12 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - CD008729.pub3 [pii] AID - 10.1002/14651858.CD008729.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2023 Jan 11;1(1):CD008729. doi: 10.1002/14651858.CD008729.pub3. PMID- 36638314 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1532-0979 (Electronic) IS - 0147-5185 (Linking) VI - 47 IP - 2 DP - 2023 Feb 1 TI - Changes in the Diagnoses of Breast Core Needle Biopsies on Second Review at a Tertiary Care Center: Implications for Surgical Management. PG - 172-182 LID - 10.1097/PAS.0000000000002002 [doi] AB - Core needle biopsy (CNB) of breast lesions is routine for diagnosis and treatment planning. Despite refinement of diagnostic criteria, the diagnosis of breast lesions on CNB can be challenging. At many centers, including ours, confirmation of diagnoses rendered in other laboratories is required before treatment planning. We identified CNBs first diagnosed elsewhere that were reviewed in our department over the course of 1 year because the patients sought care at our center and in which a change in diagnosis had been recorded. The outside and in-house CNB diagnoses were then classified based on Breast WHO Fifth Edition diagnostic categories. The impact of the change in diagnosis was estimated based on the subsequent surgical management. Findings in follow-up surgical excisions (EXCs) were used for validation. In 2018, 4950 outside cases with CNB were reviewed at our center. A total of 403 CNBs diagnoses were discrepant. Of these, 147 had a change in the WHO diagnostic category: 80 (54%) CNBs had a more severe diagnosis and 44 (30%) a less severe diagnosis. In 23 (16%) CNBs, the change of diagnostic category had no impact on management. Intraductal proliferations (n=54), microinvasive carcinoma (n=18), and papillary lesions (n=35) were the most disputed diagnoses. The in-house CNB diagnosis was confirmed in most cases with available excisions. Following CNB reclassification, 22/147 (15%) lesions were not excised. A change affecting the surgical management at our center occurred in 2.5% of all CNBs. Our results support routine review of outside breast CNB as a clinically significant practice before definitive treatment. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Calle, Catarina AU - Calle C AD - Departments of Pathology. AD - Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal. FAU - Zhong, Elaine AU - Zhong E AUID- ORCID: 0000-0003-4676-6434 AD - Departments of Pathology. FAU - Hanna, Matthew G AU - Hanna MG AD - Departments of Pathology. FAU - Ventura, Katia AU - Ventura K AD - Departments of Pathology. FAU - Friedlander, Maria A AU - Friedlander MA AD - Departments of Pathology. FAU - Morrow, Monica AU - Morrow M AD - Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Cody, Hiram 3rd AU - Cody H 3rd AD - Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Brogi, Edi AU - Brogi E AD - Departments of Pathology. LA - eng PT - Journal Article DEP - 20221128 PL - United States TA - Am J Surg Pathol JT - The American journal of surgical pathology JID - 7707904 SB - IM MH - Humans MH - Female MH - Biopsy, Large-Core Needle MH - Tertiary Care Centers MH - Retrospective Studies MH - *Breast/surgery/pathology MH - *Breast Neoplasms/diagnosis/surgery/etiology COIS- Conflicts of Interest and Source of Funding: Supported in part by a Cancer Center Support Grant of the National Institute of Health/National Cancer Institute (grant number P30CA008748). M.G.H. is a consultant of PaigeAI and advisor of PathPresenter. M.M. has received honoraria from Roche and Exact Sciences. For the remaining authors none were declared. EDAT- 2023/01/14 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/13 15:43 PHST- 2023/01/13 15:43 [entrez] PHST- 2023/01/14 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] AID - 00000478-202302000-00003 [pii] AID - 10.1097/PAS.0000000000002002 [doi] PST - ppublish SO - Am J Surg Pathol. 2023 Feb 1;47(2):172-182. doi: 10.1097/PAS.0000000000002002. Epub 2022 Nov 28. PMID- 36661737 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 30 IP - 1 DP - 2023 Jan 13 TI - Different Re-Irradiation Techniques after Breast-Conserving Surgery for Recurrent or New Primary Breast Cancer. PG - 1151-1163 LID - 10.3390/curroncol30010088 [doi] AB - Breast re-irradiation (reRT) after breast-conserving surgery (BCS) using external beam radiation is an increasingly used salvage approach for women presenting with recurrent or new primary breast cancer. However, radiation technique, dose and fractionation as well as eligibility criteria differ between studies. There is also limited data on efficacy and safety of external beam hypofractionation and accelerated partial-breast irradiation (APBI) regimens. This paper reviews existing retrospective and prospective data for breast reRT after BCS, APBI reRT outcomes and delivery at our institution and the need for a randomized controlled trial using shorter courses of radiation to better define patient selection for different reRT fractionation regimens. FAU - Abeloos, Camille Hardy AU - Abeloos CH AD - Department of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USA. FAU - Purswani, Juhi M AU - Purswani JM AUID- ORCID: 0000-0003-1068-9449 AD - Department of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USA. FAU - Galavis, Paulina AU - Galavis P AD - Department of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USA. FAU - McCarthy, Allison AU - McCarthy A AD - Department of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USA. FAU - Hitchen, Christine AU - Hitchen C AD - Department of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USA. FAU - Choi, J Isabelle AU - Choi JI AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. FAU - Gerber, Naamit K AU - Gerber NK AD - Department of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USA. LA - eng PT - Journal Article PT - Review DEP - 20230113 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 SB - IM MH - Female MH - Humans MH - Mastectomy, Segmental/methods MH - *Re-Irradiation MH - *Breast Neoplasms/radiotherapy/surgery MH - Prospective Studies MH - Retrospective Studies PMC - PMC9857440 OTO - NOTNLM OT - breast re-irradiation OT - eligibility OT - outcome OT - toxicity COIS- The authors declare no conflict of interest. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/20 09:35 PHST- 2022/11/14 00:00 [received] PHST- 2023/01/05 00:00 [revised] PHST- 2023/01/12 00:00 [accepted] PHST- 2023/01/20 09:35 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - curroncol30010088 [pii] AID - curroncol-30-00088 [pii] AID - 10.3390/curroncol30010088 [doi] PST - epublish SO - Curr Oncol. 2023 Jan 13;30(1):1151-1163. doi: 10.3390/curroncol30010088. PMID- 36385236 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. PG - 287-297 LID - 10.1007/s10549-022-06787-x [doi] AB - PURPOSE: Stromal tumor-infiltrating lymphocytes (TILs) are independent prognostic factors in systemically untreated early-stage triple-negative breast cancer (TNBC). Other immune biomarkers including CD8, CD20, programmed cell death-ligand 1 (PD-L1), and tertiary lymphoid structures (TLS) are also reported to be associated with prognosis. However, whether combining other immune biomarkers with TILs would allow for further prognostic stratification is unknown. METHODS: We retrospectively analyzed 125 patients with early-stage TNBC not receiving perioperative chemotherapy. Stromal TILs and TLS were evaluated on hematoxylin-eosin slides. PD-L1 expression was evaluated using the SP142 assay. CD8 and CD20 were assessed by immunohistochemistry and counted by digital pathology. RESULTS: Immune biomarker levels were positively correlated (p < 0.001). Adding CD8 and PD-L1 to multivariable analysis including clinicopathological factors (stage and histological grade) and TILs significantly improved the prognostic model (likelihood ratio χ(2) = 9.24, p = 0.01). In Cox regression analysis, high CD8 was significantly associated with better prognosis [hazard ratio (HR) 0.69, 95% confidence interval (CI) 0.48-0.98, p = 0.04], and PD-L1 positivity was significantly associated with worse prognosis (HR 4.33, 95%CI 1.57-11.99, p = 0.005). Patients with high CD8/PD-L1 (-) tumors had the most favorable prognosis [5 year invasive disease-free survival (iDFS), 100%], while patients with low CD8/PD-L1( +) tumors had the worst prognosis (5 year iDFS, 33.3%). CONCLUSION: CD8 and PD-L1 levels add prognostic information beyond TILs for early-stage TNBC not receiving perioperative chemotherapy. CD8-positive T cells and PD-L1 may be useful for prognostic stratification and in designing future clinical trials of TNBC. CI - © 2022. The Author(s). FAU - Yazaki, Shu AU - Yazaki S AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. AD - Cancer Medicine, Jikei University Graduate School of Medicine, Tokyo, Japan. FAU - Shimoi, Tatsunori AU - Shimoi T AUID- ORCID: 0000-0002-3603-8575 AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. tshimoi@ncc.go.jp. FAU - Yoshida, Masayuki AU - Yoshida M AD - Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan. FAU - Sumiyoshi-Okuma, Hitomi AU - Sumiyoshi-Okuma H AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Arakaki, Motoko AU - Arakaki M AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Saito, Ayumi AU - Saito A AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Kita, Shosuke AU - Kita S AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Yamamoto, Kasumi AU - Yamamoto K AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Kojima, Yuki AU - Kojima Y AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Nishikawa, Tadaaki AU - Nishikawa T AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Tanioka, Maki AU - Tanioka M AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Sudo, Kazuki AU - Sudo K AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Noguchi, Emi AU - Noguchi E AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Murata, Takeshi AU - Murata T AD - Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan. FAU - Shiino, Sho AU - Shiino S AD - Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan. FAU - Takayama, Shin AU - Takayama S AD - Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan. FAU - Suto, Akihiko AU - Suto A AD - Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan. FAU - Ohe, Yuichiro AU - Ohe Y AD - Cancer Medicine, Jikei University Graduate School of Medicine, Tokyo, Japan. AD - Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. FAU - Fujiwara, Yasuhiro AU - Fujiwara Y AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. FAU - Yonemori, Kan AU - Yonemori K AD - Department of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. LA - eng PT - Journal Article DEP - 20221116 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (B7-H1 Antigen) RN - 0 (Ligands) RN - 0 (Biomarkers) SB - IM MH - Humans MH - Prognosis MH - *Triple Negative Breast Neoplasms/pathology MH - Retrospective Studies MH - Lymphocytes, Tumor-Infiltrating MH - B7-H1 Antigen/genetics/metabolism MH - *Tertiary Lymphoid Structures/pathology MH - Ligands MH - Biomarkers/metabolism MH - Chemotherapy, Adjuvant MH - CD8-Positive T-Lymphocytes MH - Apoptosis PMC - PMC9823028 OTO - NOTNLM OT - Chemotherapy OT - Prognosis OT - Programmed cell death-ligand 1 OT - Triple-negative breast cancer OT - Tumor-infiltrating lymphocytes COIS- Tadaaki Nishikawa reports personal fees from Takeda Pharmaceutical Company, EISAI, and AstraZeneca, outside the submitted work. Emi Noguchi reports personal fees from Pfizer, Taiho, Eli Lilly, AstraZeneca, Chugai, and EISAI, outside the submitted work. Yuichiro Ohe reports grants and personal fees from AstraZeneca, Amgen, Bristol-Myers Squibb, Chugai, Eli Lilly, Janssen, Kyorin, Nippon Kayaku, Novartis, Ono Pharmaceutical Company, MSD, Pfizer, Taiho, and Takeda Pharmaceutical Company, personal fees from Boehringer Ingelheim and Celtrion, and grants from Kissei, outside the submitted work. Yasuhiro Fujiwara reports personal fees from AstraZeneca, Chugai, Daiichi Sankyo, Bristol-Myers, SRL, and Santen, outside the submitted work. Kan Yonemori reports personal fees from Pfizer, AstraZeneca, EISAI, Takeda Pharmaceutical Company, Chugai, Ono Pharmaceutical Company, Novartis, and Daiichi Sankyo, outside the submitted work. All remaining authors declare no potential conflicts of interest. EDAT- 2022/11/18 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/17 10:42 PHST- 2022/08/11 00:00 [received] PHST- 2022/10/25 00:00 [accepted] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/17 10:42 [entrez] AID - 10.1007/s10549-022-06787-x [pii] AID - 6787 [pii] AID - 10.1007/s10549-022-06787-x [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):287-297. doi: 10.1007/s10549-022-06787-x. Epub 2022 Nov 16. PMID- 36414795 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database. PG - 435-447 LID - 10.1007/s10549-022-06816-9 [doi] AB - PURPOSE: The aim was to understand real-world cyclin-dependent kinase (CDK) 4 and 6 inhibitor use in Japan. METHODS: This retrospective observational study used a Japanese administrative claims database and included patients with presumptive hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) prescribed CDK4 and 6 inhibitor therapy between December 2017 and March 2021. Patient characteristics, treatment patterns, and selected clinical and safety outcomes were descriptively summarized. Time to discontinuation (TTD) and chemotherapy-free survival (CFS) were examined using Kaplan-Meier estimates. RESULTS: The study cohort (N = 6442) was predominantly female (99.4%; median [range] age 64 [26-99] years) with records of metastases (79.6%) within 1 year prior to initiating CDK4 and 6 inhibitor therapy. In total, 4463 (69.3%) and 1979 (30.7%) were prescribed palbociclib and abemaciclib, respectively, as their first CDK4 and 6 inhibitor, most commonly in combination with fulvestrant (n = 3801; 59.0%). Overall, 3756 patients initiated a subsequent anticancer treatment, of whom 748 (19.9%) initiated a different CDK4 and 6 inhibitor in combination with the same or different endocrine therapy. Median TTD (95% confidence interval) was 9.7 (9.3, 10.1) months for the first CDK4 and 6 inhibitor therapy. Median CFS was 26.1 (24.6, 27.8) months. Incidence of clinically relevant diarrhea was higher after abemaciclib initiation (9.8%) than after palbociclib initiation (1.5%). More patients experienced dose reduction with palbociclib (69.3%) than with abemaciclib (53.0%). CONCLUSION: The data provide insights into current clinical practices for CDK4 and 6 inhibitor use in Japan that could help establish future treatment strategies for ABC. CI - © 2022. The Author(s). FAU - Kawai, Masaaki AU - Kawai M AD - Department of Surgery I, Yamagata University Graduate School of Medical Science, Yamagata, Japan. FAU - Takada, Masahiro AU - Takada M AD - Department of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. FAU - Nakayama, Takahiro AU - Nakayama T AD - Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan. FAU - Masuda, Norikazu AU - Masuda N AD - Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Shiheido, Hirokazu AU - Shiheido H AD - Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan. FAU - Cai, Zhihong AU - Cai Z AD - Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan. FAU - Huang, Yu-Jing AU - Huang YJ AD - Global Patient Safety, Eli Lilly and Company, Indianapolis, IN, USA. FAU - Kawaguchi, Tsutomu AU - Kawaguchi T AD - Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan. FAU - Tanizawa, Yoshinori AU - Tanizawa Y AUID- ORCID: 0000-0002-5014-2483 AD - Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan. tanizawa_yoshinori@lilly.com. LA - eng PT - Journal Article PT - Observational Study DEP - 20221121 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 60UAB198HK (abemaciclib) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 4) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Protein Kinase Inhibitors) SB - IM MH - Humans MH - Female MH - Middle Aged MH - Male MH - *Breast Neoplasms/drug therapy/epidemiology/metabolism MH - Cyclin-Dependent Kinase 4 MH - East Asian People MH - *Fatigue Syndrome, Chronic/drug therapy MH - Receptor, ErbB-2/genetics/metabolism MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Protein Kinase Inhibitors/adverse effects PMC - PMC9823084 OTO - NOTNLM OT - Administrative claims database OT - CDK4 and 6 inhibitor OT - Effectiveness OT - Metastatic breast cancer OT - Real-world evidence OT - Safety COIS- Masaaki Kawai declares honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly and Company, Kyowa-Kirin, MSD, Novartis, and Pfizer. Masahiro Takada declares honoraria for lectures from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, Mitaka Khoki, Nippon Kayaku, and Pfizer; and research grants to institute from ABCSG, AstraZeneca, Daiichi Sankyo, Japan Breast Cancer Research Group, Kyoto Breast Cancer Research Network, Medbis, and Yakult. Takahiro Nakayama reports receiving honoraria for lectures from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, Novartis, Pfizer, and Taiho. Norikazu Masuda declares honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly and Company, and Pfizer; research grants to institute from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, Kyowa-Kirin, MSD, Novartis, Pfizer, and Sanofi; and membership on the board of directors for the Japanese Breast Cancer Society and Japan Breast Cancer Research Group Association. Hirokazu Shiheido, Zhihong Cai, Tsutomu Kawaguchi, and Yoshinori Tanizawa are employees of Eli Lilly Japan K.K. and minor shareholders of Eli Lilly and Company. Yu-Jing Huang is an employee and minor shareholder of Eli Lilly and Company. EDAT- 2022/11/23 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/22 23:33 PHST- 2022/08/24 00:00 [received] PHST- 2022/11/09 00:00 [accepted] PHST- 2022/11/23 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/22 23:33 [entrez] AID - 10.1007/s10549-022-06816-9 [pii] AID - 6816 [pii] AID - 10.1007/s10549-022-06816-9 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):435-447. doi: 10.1007/s10549-022-06816-9. Epub 2022 Nov 21. PMID- 36161375 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Print) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients. PG - 1017-1025 LID - 10.1245/s10434-022-12595-w [doi] AB - BACKGROUND: The American Society of Breast Surgeons recommends genetic testing (GT) for all women with breast cancer (BC), but implementation and uptake of GT has not been well-described. METHODS: A retrospective chart review was performed for newly diagnosed BC patients or patients with a newly identified recurrence of BC seen in a multidisciplinary clinic (MDBC) who were offered genetic counseling (GC) and GT. RESULTS: The 138 women attending the MDBC had a median age of 54 years and comprised non-Hispanic whites (46%), Asians (28%), Hispanics (17%), blacks (4%), and other (5%). Of the 105 (76%) patients without prior GT, 100 (95%) accepted GC, with 93 (93%) of these 100 patients undergoing GT. The patients meeting the National Comprehensive Cancer Network (NCCN) guidelines for GT were more likely to undergo GT. Testing was performed with a 67- to 84-gene panel, together with an 8- to 9-gene STAT panel if needed. Among 120 patients with reports available, including 33 patients previously tested, 15 (12%) were positive (1 BLM, 1 BRCA1, 3 BRCA2, 1 BRIP1, 1 CFTR, 1 CHEK2, 1 MUTYH, 1 PALB2, 1 PRSS1, 1 RAD50, 1 RET, and 2 TP53), 44 (37%) were negative, and 61 (51%) had an uncertain variant. The median time to STAT results (n = 50) was 8 days. The STAT results were available before surgery for 47 (98%) of the 48 STAT patients undergoing surgery. CONCLUSIONS: New BC patients attending the MDBC demonstrated high rates of acceptance of GC and GT. The combination of GC and GT can offer timely information critical to patient risk assessment and treatment planning. CI - © 2022. Society of Surgical Oncology. FAU - Culver, Julie O AU - Culver JO AUID- ORCID: 0000-0001-8658-3507 AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. jculver@med.usc.edu. FAU - Freiberg, Yael AU - Freiberg Y AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Ricker, Charité AU - Ricker C AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Comeaux, Jacob G AU - Comeaux JG AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Chang, Emmeline Y AU - Chang EY AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Banerjee, Victoria AU - Banerjee V AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Sturgeon, Duveen AU - Sturgeon D AD - Center for Precision Medicine, City of Hope, Duarte, CA, USA. FAU - Solomon, Ilana AU - Solomon I AD - Center for Precision Medicine, City of Hope, Duarte, CA, USA. FAU - Kagey, Josie AU - Kagey J AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Dobre, Mariana G AU - Dobre MG AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Carey, Joseph AU - Carey J AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Carr, Azadeh AU - Carr A AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Cho, Stephanie AU - Cho S AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Lu, Janice AU - Lu J AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Kang, Irene M AU - Kang IM AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Patel, Ketan AU - Patel K AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Terando, Alicia AU - Terando A AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Ye, Jason C AU - Ye JC AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Li, Ming AU - Li M AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Lerman, Caryn AU - Lerman C AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Spicer, Darcy AU - Spicer D AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Nelson, Maria AU - Nelson M AD - USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. LA - eng GR - P30 CA014089/CA/NCI NIH HHS/United States GR - R35 CA197461/CA/NCI NIH HHS/United States GR - P30-CA14089/NH/NIH HHS/United States GR - R35-CA197461/NH/NIH HHS/United States PT - Journal Article DEP - 20220926 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CIN - Ann Surg Oncol. 2023 Feb;30(2):1026-1027. PMID: 36241948 MH - Humans MH - Female MH - Middle Aged MH - *Breast Neoplasms/genetics/diagnosis MH - Retrospective Studies MH - Genetic Testing/methods MH - Genes, BRCA2 MH - Genetic Counseling MH - Genetic Predisposition to Disease MH - Germ-Line Mutation PMC - PMC9512964 COIS- Irene Kang has accepted consulting fees and speaker bureau fees for Puma Biotechnology and consulting fees for Bristol Myers Squibb. Ketan Patel received textbook royalties from Elsevier. The remaining authors have no conflicts of interest. EDAT- 2022/09/27 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/09/26 18:09 PHST- 2021/08/03 00:00 [received] PHST- 2022/09/09 00:00 [accepted] PHST- 2022/09/27 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/09/26 18:09 [entrez] AID - 10.1245/s10434-022-12595-w [pii] AID - 12595 [pii] AID - 10.1245/s10434-022-12595-w [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1017-1025. doi: 10.1245/s10434-022-12595-w. Epub 2022 Sep 26. PMID- 36603443 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1873-3573 (Electronic) IS - 0039-9140 (Linking) VI - 255 DP - 2023 Apr 1 TI - A novel electrochemical biosensor based on signal amplification of Au HFGNs/PnBA-MXene nanocomposite for the detection of miRNA-122 as a biomarker of breast cancer. PG - 124247 LID - S0039-9140(22)01043-8 [pii] LID - 10.1016/j.talanta.2022.124247 [doi] AB - Cancer is one of the leading causes of death worldwide and a crisis for global health. Breast cancer is the second most common cancer globally. In the perusal, a novel electrochemical biosensor amplified with hierarchical flower-like gold, poly (n-butyl acrylate), and MXene (AuHFGNs/PnBA-MXene) nanocomposite and activated by highly special antisense ssDNA (single-stranded DNA) provide a promising alternative for miRNA-122 detection as a biomarker of breast cancer. The biosensor presented a detection limit of 0.0035 aM (S/N = 3) with a linear range from 0.01 aM to 10 nM. The platform was tried on 20 breast cancer miRNAs extracted from actual serum specimens (10 positives and 10 negatives). Founded on the quantitatively obtained outcomes and statistic analysis (t-test, box-graph, receiver performance characteristic curve, and cut-off amount), the biosensor showed a meaningful discrepancy between the native and positive groups with 100% specificity and 100% sensitivity. While, RT-qPCR showed less specificity and sensitivity (70% specificity, 100% sensitivity) than the proposed biosensor. To assess the quantitative capacity and biosensor detection limit for clinical tests, the biosensor diagnosis performance for continually diluted miRNA extracted from patients was compared to that gained by RT-qPCR results, indicating that the biosensor detection limit was lower than RT-qPCR. ssDNA/AuHFGN/PnBA-MXene/GCE displayed little cross-reaction with other sequences and also showed desirable stability, reproducibility, and specificity and stayed stable until 32 days. As a result, the designed biosensor can perform as a hopeful method for diagnosis applications. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Ranjbari, Sara AU - Ranjbari S AD - Chemical Engineering Department, Faculty of Engineering, Ferdowsi University of Mashhad, Mashhad, Iran. FAU - Rezayi, Majid AU - Rezayi M AD - Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: rezaeimj@mums.ac.ir. FAU - Arefinia, Reza AU - Arefinia R AD - Chemical Engineering Department, Faculty of Engineering, Ferdowsi University of Mashhad, Mashhad, Iran. Electronic address: arefinia@um.ac.ir. FAU - Aghaee-Bakhtiari, Seyed Hamid AU - Aghaee-Bakhtiari SH AD - Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Hatamluyi, Behnaz AU - Hatamluyi B AD - Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Pasdar, Alireza AU - Pasdar A AD - Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. LA - eng PT - Journal Article DEP - 20221231 PL - Netherlands TA - Talanta JT - Talanta JID - 2984816R RN - 0 (MicroRNAs) RN - 0 (MXene) RN - 0 (Biomarkers) RN - 0 (DNA, Single-Stranded) RN - 7440-57-5 (Gold) RN - 0 (MIRN122 microRNA, human) SB - IM MH - Humans MH - Female MH - *MicroRNAs MH - *Breast Neoplasms/diagnosis/genetics MH - Reproducibility of Results MH - Electrochemical Techniques/methods MH - *Nanocomposites MH - Biomarkers MH - DNA, Single-Stranded/genetics MH - *Biosensing Techniques/methods MH - Gold MH - Limit of Detection OTO - NOTNLM OT - AuHFGN/PnBA-MXene OT - Breast cancer OT - Electrochemical biosensor OT - miRNA-122 COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/01/06 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/05 18:16 PHST- 2022/10/03 00:00 [received] PHST- 2022/12/25 00:00 [revised] PHST- 2022/12/30 00:00 [accepted] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2023/01/05 18:16 [entrez] AID - S0039-9140(22)01043-8 [pii] AID - 10.1016/j.talanta.2022.124247 [doi] PST - ppublish SO - Talanta. 2023 Apr 1;255:124247. doi: 10.1016/j.talanta.2022.124247. Epub 2022 Dec 31. PMID- 35596902 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230112 IS - 1573-7292 (Electronic) IS - 1389-9600 (Linking) VI - 22 IP - 1 DP - 2023 Jan TI - Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations. PG - 19-30 LID - 10.1007/s10689-022-00296-y [doi] AB - The spectrum of BRCA1/2 mutations demonstrates significant interethnic variations. We analyzed for the first time the entire BRCA1/2 coding region in 340 Belarusian cancer patients with clinical signs of BRCA1/2-related disease, including 168 women with bilateral and/or early-onset breast cancer (BC), 104 patients with ovarian cancer and 68 subjects with multiple primary malignancies involving BC and/or OC. BRCA1/2 pathogenic alleles were detected in 98 (29%) women, with 67 (68%) of these being represented by founder alleles. Systematic comparison with other relevant studies revealed that the founder effect observed in Belarus is among the highest estimates observed worldwide. These findings are surprising, given that the population of Belarus did not experience geographic or cultural isolation throughout history. CI - © 2022. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Yanus, G A AU - Yanus GA AD - Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia. FAU - Savonevich, E L AU - Savonevich EL AD - Department of Obstetrics and Gynecology, Grodno State Medical University, Grodno, Belarus. FAU - Sokolenko, A P AU - Sokolenko AP AUID- ORCID: 0000-0001-6304-1609 AD - Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia. annasokolenko@mail.ru. AD - Department of Medical Genetics, St.-Petersburg Pediatric Medical University, Saint-Petersburg, Russia. annasokolenko@mail.ru. FAU - Romanko, A A AU - Romanko AA AD - Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia. AD - Department of Medical Genetics, St.-Petersburg Pediatric Medical University, Saint-Petersburg, Russia. FAU - Ni, V I AU - Ni VI AD - Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia. FAU - Bakaeva, E Kh AU - Bakaeva EK AD - Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia. FAU - Gorustovich, O A AU - Gorustovich OA AD - Department of Obstetrics and Gynecology, Grodno State Medical University, Grodno, Belarus. FAU - Bizin, I V AU - Bizin IV AD - Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia. FAU - Imyanitov, E N AU - Imyanitov EN AD - Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia. AD - Department of Medical Genetics, St.-Petersburg Pediatric Medical University, Saint-Petersburg, Russia. AD - Department of Oncology, I.I. Mechnikov North-Western Medical University, St.-Petersburg, Russia. LA - eng GR - 20-515-00002/Russian Foundation for Basic Research/ PT - Journal Article DEP - 20220521 PL - Netherlands TA - Fam Cancer JT - Familial cancer JID - 100898211 RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA2 Protein) SB - IM MH - Female MH - Humans MH - Alleles MH - *BRCA1 Protein/genetics MH - *BRCA2 Protein/genetics MH - *Breast Neoplasms/genetics MH - Founder Effect MH - Genetic Predisposition to Disease MH - Mutation MH - *Ovarian Neoplasms/genetics MH - Republic of Belarus OTO - NOTNLM OT - BRCA1/2 OT - Belarus OT - Breast cancer OT - Founder mutations OT - Ovarian cancer EDAT- 2022/05/22 06:00 MHDA- 2023/01/12 06:00 CRDT- 2022/05/21 11:18 PHST- 2022/04/20 00:00 [received] PHST- 2022/05/08 00:00 [accepted] PHST- 2022/05/22 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] PHST- 2022/05/21 11:18 [entrez] AID - 10.1007/s10689-022-00296-y [pii] AID - 10.1007/s10689-022-00296-y [doi] PST - ppublish SO - Fam Cancer. 2023 Jan;22(1):19-30. doi: 10.1007/s10689-022-00296-y. Epub 2022 May 21. PMID- 36398439 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1465-3621 (Electronic) IS - 0368-2811 (Print) IS - 0368-2811 (Linking) VI - 53 IP - 1 DP - 2023 Jan 6 TI - Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial. PG - 4-15 LID - 10.1093/jjco/hyac166 [doi] AB - BACKGROUND: We aimed to confirm the efficacy and safety of the oral histone deacetylase inhibitor entinostat in Japanese patients with hormone receptor-positive advanced/recurrent breast cancer and to explore potential biomarkers. METHODS: This phase II, double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov; NCT03291886) was conducted at 28 Japanese sites (September 2017-July 2020; interim analysis cutoff: April 2019). Patients with progression/relapse following non-steroidal aromatase inhibitors were randomized 1:1 to entinostat (5 mg/week) or placebo, plus exemestane (25 mg/day). Primary endpoint was progression-free survival; secondary endpoints included overall survival and safety. Exploratory biomarker outcomes included lysine acetylation, immune cell profiles, estrogen receptor 1 mutations and plasma chemokines. RESULTS: Of 133 randomized patients, 131 (65 entinostat, 66 placebo) who received study drug were analyzed. Median (95% confidence interval) progression-free survival was 5.8 (3.2-7.8) months for entinostat and 3.3 (3.1-5.8) months for placebo (hazard ratio [95% confidence interval]: 0.75 [0.50 - 1.14]; P = 0.189). Median overall survival was not reached in either group. Entinostat tended to prolong progression-free survival in patients aged ≥65 years, not endocrine resistant, or with estrogen receptor 1 Y537S mutation. Candidate biomarkers of efficacy (progression-free survival) included lysine acetylation in CD3+ cells, plasma interferon gamma-induced protein 10, dendritic cell CD86 expression, and CD4+ cell expression of human leukocyte antigen-DR and inducible T-cell co-stimulator. Safety was similar to non-Japanese populations; however, seven entinostat-treated patients (10.8%) had reversible lung injury. CONCLUSIONS: In Japanese patients, the safety of entinostat plus exemestane was acceptable and progression-free survival was prolonged, although not significantly. Exploratory analyses identified potential biomarkers, including lysine acetylation, of efficacy. CI - © The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Iwata, Hiroji AU - Iwata H AD - Department of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan. FAU - Nakamura, Rikiya AU - Nakamura R AD - Division of Breast Surgery, Chiba Cancer Center, Chiba, Japan. FAU - Masuda, Norikazu AU - Masuda N AD - Department of Surgery, Breast Oncology, National Hospital Organization, Osaka National Hospital, Osaka, Japan. FAU - Yamashita, Toshinari AU - Yamashita T AUID- ORCID: 0000-0002-6479-1660 AD - Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan. FAU - Yamamoto, Yutaka AU - Yamamoto Y AD - Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. FAU - Kobayashi, Kokoro AU - Kobayashi K AD - Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Tsurutani, Junji AU - Tsurutani J AD - Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan. FAU - Iwasa, Tsutomu AU - Iwasa T AD - Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan. FAU - Yonemori, Kan AU - Yonemori K AD - Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. FAU - Tamura, Kenji AU - Tamura K AD - Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. FAU - Aruga, Tomoyuki AU - Aruga T AD - Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. FAU - Tokunaga, Eriko AU - Tokunaga E AD - Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. FAU - Kaneko, Koji AU - Kaneko K AD - Department of Surgery, Niigata Cancer Center Hospital, Niigata, Japan. FAU - Lee, Min-Jung AU - Lee MJ AD - Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. FAU - Yuno, Akira AU - Yuno A AD - Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. FAU - Kawabata, Azusa AU - Kawabata A AD - R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan. FAU - Seike, Toshihiro AU - Seike T AD - R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan. FAU - Kaneda, Ayumi AU - Kaneda A AD - R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan. FAU - Nishimura, Yozo AU - Nishimura Y AD - R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan. FAU - Trepel, Jane B AU - Trepel JB AD - Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. FAU - Saji, Shigehira AU - Saji S AD - Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan. LA - eng SI - ClinicalTrials.gov/NCT03291886 GR - Kyowa Kirin/ GR - NH/NIH HHS/United States GR - CA/NCI NIH HHS/United States GR - NH/NIH HHS/United States GR - CA/NCI NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PL - England TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 1ZNY4FKK9H (entinostat) RN - 0 (Estrogen Receptor alpha) RN - NY22HMQ4BX (exemestane) RN - K3Z4F929H6 (Lysine) RN - 0 (Receptors, Estrogen) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - Estrogen Receptor alpha MH - Lysine/therapeutic use MH - Receptors, Estrogen/metabolism MH - Neoplasm Recurrence, Local/drug therapy MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Double-Blind Method PMC - PMC9825728 OTO - NOTNLM OT - biomarkers OT - entinostat OT - epigenomics OT - exemestane OT - histone deacetylase inhibitors EDAT- 2022/11/19 06:00 MHDA- 2023/01/11 06:00 PMCR- 2023/11/17 CRDT- 2022/11/18 03:12 PHST- 2022/03/31 00:00 [received] PHST- 2022/10/07 00:00 [accepted] PHST- 2023/11/17 00:00 [pmc-release] PHST- 2022/11/19 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/18 03:12 [entrez] AID - 6832090 [pii] AID - hyac166 [pii] AID - 10.1093/jjco/hyac166 [doi] PST - ppublish SO - Jpn J Clin Oncol. 2023 Jan 6;53(1):4-15. doi: 10.1093/jjco/hyac166. PMID- 36307127 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230124 IS - 2041-2657 (Electronic) IS - 2041-2649 (Print) IS - 2041-2649 (Linking) VI - 22 IP - 1 DP - 2023 Jan 20 TI - Core promoter in TNBC is highly mutated with rich ethnic signature. PG - 9-19 LID - 10.1093/bfgp/elac035 [doi] AB - The core promoter plays an essential role in regulating transcription initiation by controlling the interaction between transcriptional factors and sequence motifs in the core promoter. Although mutation in core promoter sequences is expected to cause abnormal gene expression leading to pathogenic consequences, limited supporting evidence showed the involvement of core promoter mutation in diseases. Our previous study showed that the core promoter is highly polymorphic in worldwide human ethnic populations in reflecting human history and adaptation. Our recent characterization of the core promoter in triple-negative breast cancer (TNBC), a subtype of breast cancer, in a Chinese TNBC cohort revealed the wide presence of core promoter mutation in TNBC. In the current study, we analyzed the core promoter in a Thai TNBC cohort. We also observed rich core promoter mutation in the Thai TNBC patients. We compared the core promoter mutations between Chinese and Thai TNBC cohorts. We observed substantial differences of core promoter mutation in TNBC between the two cohorts, as reflected by the mutation spectrum, mutation-effected gene and functional category, and altered gene expression. Our study confirmed that the core promoter in TNBC is highly mutable, and is highly ethnic-specific. CI - © The Author(s) 2022. Published by Oxford University Press. FAU - Huang, Teng AU - Huang T FAU - Li, Jiaheng AU - Li J FAU - Zhao, Heng AU - Zhao H FAU - Ngamphiw, Chumpol AU - Ngamphiw C FAU - Tongsima, Sissades AU - Tongsima S FAU - Kantaputra, Piranit AU - Kantaputra P FAU - Kittitharaphan, Wiranpat AU - Kittitharaphan W FAU - Wang, San Ming AU - Wang SM AUID- ORCID: 0000-0002-2172-1320 LA - eng GR - FHSIG/ SW/0007/2020P/Faculty of Health Sciences, University of Macau/ GR - 2020-00094-FHS/University of Macau/ GR - 0077/2019/AMJ/Macau Science and Technology Development Fund/ PT - Journal Article PL - England TA - Brief Funct Genomics JT - Briefings in functional genomics JID - 101528229 RN - 0 (Transcription Factors) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/genetics/metabolism/pathology MH - Transcription Factors/genetics MH - Mutation/genetics PMC - PMC9853936 OTO - NOTNLM OT - RNA-seq OT - core promoter OT - exome sequences OT - triple-negative breast cancer OT - variation EDAT- 2022/10/29 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/10/28 20:33 PHST- 2022/06/20 00:00 [received] PHST- 2022/09/23 00:00 [revised] PHST- 2022/09/28 00:00 [accepted] PHST- 2022/10/29 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/10/28 20:33 [entrez] AID - 6777259 [pii] AID - elac035 [pii] AID - 10.1093/bfgp/elac035 [doi] PST - ppublish SO - Brief Funct Genomics. 2023 Jan 20;22(1):9-19. doi: 10.1093/bfgp/elac035. PMID- 36674685 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 6 TI - UPLC-Q-TOF/MS-Based Metabolomics Approach Reveals Osthole Intervention in Breast Cancer 4T1 Cells. LID - 10.3390/ijms24021168 [doi] LID - 1168 AB - Osthole (OST) is a simple coumarin derivative with pharmacological effects in many types of cancer cells. However, its role and its mechanism of action in breast cancer 4T1 cells remain unclear. In this study, we explored the effects and potential mechanisms of action of OST in 4T1 cells. The MTT, PI, and Annexin V-FITC/PI methods were used to evaluate the effects of OST-treated and untreated 4T1 cells on viability, cell cycle, and apoptosis, respectively. UPLC-Q-TOF/MS combined with multivariate data analysis was used to screen potential biomarkers relevant to the therapeutic mechanisms of OST. Additionally, mTOR, SREBP1, and FASN protein levels were detected using western blotting in OST-treated and untreated 4T1 cells. OST inhibited 4T1 cell proliferation, blocked the cells from remaining in S-phase, and induced apoptosis. In 4T1 cells, OST mainly affected the phospholipid biosynthesis, methyl histidine metabolism, pyrimidine metabolism, and β-oxidation of very long chain fatty acid pathways, suggesting that metabolic changes related to lipid metabolism-mediated signaling systems were the most influential pathways, possibly via inhibition of mTOR/SREBP1/FASN signaling. Our findings reveal biomarkers with potential therapeutic effects in breast cancer and provide insight into the therapeutic and metabolic mechanisms of OST in 4T1 cells. FAU - Li, Xiuyun AU - Li X AUID- ORCID: 0000-0003-1499-9102 AD - School of Pharmacy, The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China. FAU - Zhang, Chenglun AU - Zhang C AUID- ORCID: 0000-0002-7804-9301 AD - School of Pharmacy, The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China. FAU - Wu, Enhui AU - Wu E AD - School of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China. FAU - Han, Liang AU - Han L AD - School of Health, Guangdong Light and Health Engineering R&D Center, Guangdong Pharmaceutical University, Guangzhou 510006, China. FAU - Deng, Xiangliang AU - Deng X AD - School of Chinese Medicine, Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou 510006, China. FAU - Shi, Zhongfeng AU - Shi Z AD - School of Pharmacy, The Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China. LA - eng GR - NO. ZY2021T03/Key Discipline Construction Project of Traditional Chinese Medicine of Guangdong Pharmaceutical University (Research Team Project of School of Chinese Medicine)/ PT - Journal Article DEP - 20230106 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - XH1TI1759C (osthol) RN - 0 (Coumarins) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 0 (Biomarkers) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Coumarins/pharmacology MH - TOR Serine-Threonine Kinases MH - Metabolomics MH - Biomarkers PMC - PMC9861432 OTO - NOTNLM OT - UPLC-Q-TOF/MS OT - breast cancer OT - breast cancer 4T1 cell OT - osthole COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:25 PHST- 2022/11/02 00:00 [received] PHST- 2022/12/01 00:00 [revised] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/01/21 01:25 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijms24021168 [pii] AID - ijms-24-01168 [pii] AID - 10.3390/ijms24021168 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 6;24(2):1168. doi: 10.3390/ijms24021168. PMID- 36321415 OWN - NLM STAT- MEDLINE DCOM- 20230125 LR - 20230125 IS - 1098-2744 (Electronic) IS - 0899-1987 (Linking) VI - 62 IP - 2 DP - 2023 Feb TI - POR overexpression induces tamoxifen-resistance in breast cancer through the STAT1/c-Myc pathway. PG - 249-260 LID - 10.1002/mc.23481 [doi] AB - Breast cancer is the most common cancer in women worldwide. Although tamoxifen (TAM), a selective estrogen receptor (ER) modulator, is widely used to treat ER-positive breast cancers, resistance to TAM remains a major clinical problem. NADPH-dependent cytochrome P450 reductase (POR) is known to participate in drug metabolism and steroid metabolism. Recent studies showed that high POR expression was correlated with poor outcomes in triple-negative breast cancer (TNBC), and POR might be a prognostic biomarker in TNBC. However, the role of POR in TAM resistance is still elusive. In this study, we found that high POR expression was associated with poor prognosis of ER-positive and TAM-treated breast cancer patients. In addition, COX analysis showed that POR expression was an independent prognostic biomarker for ER-positive as well as TAM-treated breast cancer patients. Furthermore, our results suggested that POR overexpression promoted TAM resistance by activating the STAT1/c-Myc pathway in ER-positive breast cancer cells. Immunohistochemical analysis showed that high POR/STAT1 expression was correlated with poor prognosis in TAM-treated breast cancer patients. Notably, combined treatment with TAM and a specific STAT1 inhibitor Fludarabine was more effective for inhibiting TAM-resistant breast cancer cells. Altogether, our findings suggested that POR overexpression induced TAM resistance through STAT1/c-Myc pathway and might serve as an independent prognostic biomarker in TAM-treated breast cancer patients. Combining TAM and STAT1 inhibitors might be an effective strategy for treating POR-induced TAM-resistant breast cancer. CI - © 2022 Wiley Periodicals LLC. FAU - Chen, Si AU - Chen S AD - Department of Microbial and Biochemical Pharmacy, School of Pharmacy, China Medical University, Shenyang, Liaoning Province, China. FAU - Wu, Dingjie AU - Wu D AD - Department of Microbial and Biochemical Pharmacy, School of Pharmacy, China Medical University, Shenyang, Liaoning Province, China. FAU - Liu, Qiannan AU - Liu Q AD - Department of Microbial and Biochemical Pharmacy, School of Pharmacy, China Medical University, Shenyang, Liaoning Province, China. FAU - Jin, Feng AU - Jin F AUID- ORCID: 0000-0002-0325-5362 AD - Department of Breast Surgery and Surgical Oncology, Research Unit of General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China. FAU - Yao, Fan AU - Yao F AD - Department of Breast Surgery and Surgical Oncology, Research Unit of General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China. FAU - Fang, Yue AU - Fang Y AUID- ORCID: 0000-0002-0557-2118 AD - Department of Microbial and Biochemical Pharmacy, School of Pharmacy, China Medical University, Shenyang, Liaoning Province, China. LA - eng GR - JC2019002/Basic Research Project of Liaoning Province/ GR - 2019-BS-284/Doctoral Start-up Foundation of Liaoning Province/ GR - 81974418/National Natural Science Foundation of China/ PT - Journal Article DEP - 20221102 PL - United States TA - Mol Carcinog JT - Molecular carcinogenesis JID - 8811105 RN - 0 (Antineoplastic Agents, Hormonal) RN - 0 (Biomarkers) RN - 0 (STAT1 protein, human) RN - 0 (STAT1 Transcription Factor) RN - 094ZI81Y45 (Tamoxifen) RN - 0 (POR protein, human) SB - IM MH - Female MH - Humans MH - Antineoplastic Agents, Hormonal/pharmacology/therapeutic use MH - Biomarkers MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Drug Resistance, Neoplasm/genetics MH - STAT1 Transcription Factor/genetics/metabolism MH - Tamoxifen/pharmacology/therapeutic use MH - *Triple Negative Breast Neoplasms/drug therapy/genetics OTO - NOTNLM OT - NADPH-dependent cytochrome P450 reductase (POR) OT - STAT1/c-Myc pathway OT - breast cancer OT - concomitant drugs OT - tamoxifen resistance EDAT- 2022/11/03 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/11/02 04:43 PHST- 2022/10/09 00:00 [revised] PHST- 2022/08/16 00:00 [received] PHST- 2022/10/12 00:00 [accepted] PHST- 2022/11/03 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/11/02 04:43 [entrez] AID - 10.1002/mc.23481 [doi] PST - ppublish SO - Mol Carcinog. 2023 Feb;62(2):249-260. doi: 10.1002/mc.23481. Epub 2022 Nov 2. PMID- 35778796 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230106 IS - 1742-481X (Electronic) IS - 1742-4801 (Print) IS - 1742-4801 (Linking) VI - 20 IP - 1 DP - 2023 Jan TI - Effect of manual lymphatic drainage combined with vacuum sealing drainage on axillary web syndrome caused by breast cancer surgery. PG - 183-190 LID - 10.1111/iwj.13862 [doi] AB - The aim of the study was to explore the application value of manual lymphatic drainage combined with vacuum sealing drainage in axillary web syndrome (AWS) after breast cancer surgery. From 1 April 2020 to 1 June 2020, a total of 102 patients with AWS after axillary lymph node biopsy or axillary lymph node dissection in our hospital were included in this prospective study. According to the random number table method, all patients were divided into the study group (n = 51) and the control group (n = 51). The study group received the treatment of manual lymphatic drainage combined with vacuum sealing drainage, and the control group received health education and the treatment of functional training. The efficacy observation indicators included duration time to the disappearance of relevant clinical symptoms, degree of pain, angle of abduction of the affected limb, degree of upper limb disability function and quality of life. The duration time to the disappearance of cord-like nodules and tightness in the study group was both significantly shorter than that in the control group (both P < .05). In the time point of 1 and 3 months after the intervention, compared with that in the control group, the study group had a significantly lighter degree of pain, a better degree of upper limb disability function and higher quality of life (all P < .05). Manual lymphatic drainage combined with vacuum sealing drainage can shorten the disappearance time of relevant clinical symptoms, relieve the degree of pain, improve the upper limb disability function and improve the quality of life in patients with AWS. CI - © 2022 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd. FAU - Liu, Jingyi AU - Liu J AD - Department of Breast Surgery, Huizhou Municipal Central People's Hospital, Huizhou, China. FAU - Chen, Di AU - Chen D AD - Department of Breast Surgery, Huizhou Municipal Central People's Hospital, Huizhou, China. FAU - Yin, Xiaoting AU - Yin X AD - Department of Breast Surgery, Huizhou Municipal Central People's Hospital, Huizhou, China. LA - eng PT - Journal Article DEP - 20220701 PL - England TA - Int Wound J JT - International wound journal JID - 101230907 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery/pathology MH - Manual Lymphatic Drainage MH - Prospective Studies MH - Quality of Life MH - *Negative-Pressure Wound Therapy MH - Axilla/surgery/pathology MH - Lymph Node Excision/adverse effects MH - Pain PMC - PMC9797928 OTO - NOTNLM OT - axillary web syndrome OT - breast cancer OT - manual lymphatic drainage OT - vacuum sealing drainage EDAT- 2022/07/03 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/07/02 00:33 PHST- 2022/05/16 00:00 [revised] PHST- 2022/04/19 00:00 [received] PHST- 2022/05/27 00:00 [accepted] PHST- 2022/07/03 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/07/02 00:33 [entrez] AID - IWJ13862 [pii] AID - 10.1111/iwj.13862 [doi] PST - ppublish SO - Int Wound J. 2023 Jan;20(1):183-190. doi: 10.1111/iwj.13862. Epub 2022 Jul 1. PMID- 35107399 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1464-5165 (Electronic) IS - 0963-8288 (Linking) VI - 45 IP - 3 DP - 2023 Feb TI - Mat Pilates improves lower and upper body strength and flexibility in breast cancer survivors undergoing hormone therapy: a randomized controlled trial (HAPiMat study). PG - 494-503 LID - 10.1080/09638288.2022.2032410 [doi] AB - PURPOSE: To evaluate the effects of 24 weeks of Mat Pilates in breast cancer survivors (BCS) undergoing hormone therapy on lower and upper body muscle strength parameters and flexibility. MATERIALS AND METHODS: Forty-three BCS (≥40 years) with confirmed breast cancer stage 0-III undergoing hormone therapy were included. Participants were randomized into Mat Pilates (three times/week, 60 min session) or control group (relaxation activities every two weeks). The difficulty and number of exercise repetitions were increased over the weeks. Assessments were performed at three times points (baseline, 12 weeks, and 24 weeks). The generalized estimating equations (GEE) model was used to compare each outcome measure during the analysis of intention to treat (ITT) and "Per protocol analysis" (PPA). RESULTS: The Pilates group presented significantly increased (p < 0.05) isometric flexor-extensor PT, and concentric and eccentric flexor PT and mechanical work (MW) after the intervention. Most of the upper body strength parameters, time to achieve maximal force (TF(max)), maximal force (F(max)), and rapid force index (RFI) and right-left upper and lower body flexibility (p < 0.05) also improved. CONCLUSIONS: From our findings, we conclude that 24 and 12-weeks of Mat Pilates induced strength and flexibility gains for lower and upper body, respectively.Implications for rehabilitationMat Pilates can be adapted to the fitness level of breast cancer survivors, with a great variety of exercises that can be performed using a mat only or a few pieces of equipment.Patients can practice at home to gain different health benefits (i.e., increasing strength, flexibility, and functional capacity level), which could positively impact on quality of life.Mat Pilates performed three times per week with systematized increments in exercise level, load, and volume throughout the intervention was effective to improve hip extensor-flexor muscles peak torque and mechanical work at different muscle contractions, as well as upper and lower body flexibility.Mat Pilates was also able to improve right-left shoulder abductor and trunk extensor muscles strength parameters after 12 weeks of intervention, as well as both surgery and non-surgery sides of the upper body. FAU - Bertoli, Josefina AU - Bertoli J AUID- ORCID: 0000-0003-1894-4299 AD - Faculdade de Ciência e Tecnologia, Universidade Estadual Paulista, Presidente Prudente, Brazil. FAU - Bezerra, Ewertton de Souza AU - Bezerra ES AUID- ORCID: 0000-0003-4397-1715 AD - Faculdade de Educação Física e Fisioterapia, Universidade Federal do Amazonas, Manaus, Brazil. FAU - Winters-Stone, Kerri M AU - Winters-Stone KM AUID- ORCID: 0000-0003-1706-8020 AD - School of Nursing, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. FAU - Alberto Gobbo, Luis AU - Alberto Gobbo L AUID- ORCID: 0000-0003-4700-0000 AD - Faculdade de Ciência e Tecnologia, Universidade Estadual Paulista, Presidente Prudente, Brazil. FAU - Freitas, Ismael Forte Júnior AU - Freitas IF Júnior AUID- ORCID: 0000-0002-5071-0428 AD - Faculdade de Ciência e Tecnologia, Universidade Estadual Paulista, Presidente Prudente, Brazil. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20220202 PL - England TA - Disabil Rehabil JT - Disability and rehabilitation JID - 9207179 RN - 0 (Hormones) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - *Exercise Movement Techniques/methods MH - *Cancer Survivors MH - Quality of Life MH - Muscle Strength/physiology MH - Hormones OTO - NOTNLM OT - Breast neoplasms OT - endocrine therapy OT - exercise OT - muscle strength OT - range of motion EDAT- 2022/02/03 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/02/02 12:13 PHST- 2022/02/03 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/02/02 12:13 [entrez] AID - 10.1080/09638288.2022.2032410 [doi] PST - ppublish SO - Disabil Rehabil. 2023 Feb;45(3):494-503. doi: 10.1080/09638288.2022.2032410. Epub 2022 Feb 2. PMID- 36615868 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 15 IP - 1 DP - 2023 Jan 1 TI - The Relationship among Bowel [18]F-FDG PET Uptake, Pathological Complete Response, and Eating Habits in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. LID - 10.3390/nu15010211 [doi] LID - 211 AB - Recently, the impact of patients' eating habits on both breast cancer (BC) management and inflammation have been proven. Here, we investigated whether inflammatory habits could correlate with baseline bowel [18]F-fluorodeoxyglucose (FDG) uptake and the latter, in turn, with pathological Complete Response (pCR) to neoadjuvant chemotherapy (NAC). We included stage I-III BC undergoing standard NAC at IRCCS Humanitas Research Hospital, Italy. Patients fulfilled a survey concerning eating/lifestyle behaviors and performed a staging [18]F-FDG positrone emission tomography/computed tomography (PET/CT). In the absence of data on the effects of individual foods, we aggregated drink and food intake for their known inflammatory properties. Data were recorded for 82 women (median age, 48). We found positive correlations between colon mean standardized uptake value (SUV(mean)) and pro-inflammatory drinks (alcohol and spirits; r = +0.33, p < 0.01) and foods (red and cured meats; r = +0.25, p = 0.04), and a significant negative correlation between rectum SUV(mean) and anti-inflammatory foods (fruits and vegetables; r = -0.23, p = 0.04). Furthermore, colon SUV(mean) was significantly lower in patients with pCR compared to non pCR (p = 0.02). Our study showed, for the first time, that patients' eating habits affected bowel [18]F-FDG uptake and that colon SUV(mean) correlated with pCR, suggesting that PET scan could be an instrument for identifying patients presenting unhealthy behaviors. FAU - Tiberio, Paola AU - Tiberio P AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. FAU - Antunovic, Lidija AU - Antunovic L AD - Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. FAU - Gaudio, Mariangela AU - Gaudio M AUID- ORCID: 0000-0003-1004-2063 AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy. FAU - Viganò, Alessandro AU - Viganò A AD - IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy. FAU - Pastore, Manuela AU - Pastore M AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. FAU - Miggiano, Chiara AU - Miggiano C AUID- ORCID: 0000-0002-6580-673X AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy. FAU - Jacobs, Flavia AU - Jacobs F AUID- ORCID: 0000-0001-9126-8325 AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy. FAU - Benvenuti, Chiara AU - Benvenuti C AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy. FAU - Farina, Elisabetta AU - Farina E AD - IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy. FAU - Chiti, Arturo AU - Chiti A AUID- ORCID: 0000-0002-5806-1856 AD - Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy. FAU - Santoro, Armando AU - Santoro A AUID- ORCID: 0000-0003-1709-9492 AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy. FAU - De Sanctis, Rita AU - De Sanctis R AUID- ORCID: 0000-0003-3202-1933 AD - Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy. AD - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy. LA - eng PT - Journal Article DEP - 20230101 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (Radiopharmaceuticals) SB - IM MH - Humans MH - Female MH - Middle Aged MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - Fluorodeoxyglucose F18 MH - Positron Emission Tomography Computed Tomography MH - Radiopharmaceuticals MH - Neoadjuvant Therapy/methods MH - Positron-Emission Tomography MH - Feeding Behavior PMC - PMC9824388 OTO - NOTNLM OT - bowel [18]F-FDG PET uptake OT - bowel inflammation OT - breast cancer OT - neoadjuvant chemotherapy OT - nutrition OT - pathologic complete response COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Armando Santoro: Advisory Board: Bristol-Myers-Squibb (BMS), Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp & Dohme (MSD). Consultancy: Arqule, Sanofi, Incyte. Speaker’s Bureau: Takeda, BMS, Roche, Abb-Vie, Amgen, Celgene, Servier, Gilead, Astrazeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD (all outside the submitted work); Rita De Sanctis: honoraria for advisory board consultancy from Novartis, Istituto Clinico Gentili, Amgen, EISAI, Lilly and Gilead (all outside the present work). EDAT- 2023/01/09 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/08 01:37 PHST- 2022/12/16 00:00 [received] PHST- 2022/12/28 00:00 [revised] PHST- 2022/12/28 00:00 [accepted] PHST- 2023/01/08 01:37 [entrez] PHST- 2023/01/09 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - nu15010211 [pii] AID - nutrients-15-00211 [pii] AID - 10.3390/nu15010211 [doi] PST - epublish SO - Nutrients. 2023 Jan 1;15(1):211. doi: 10.3390/nu15010211. PMID- 35988844 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 2253-8089 (Electronic) IS - 2253-8089 (Linking) VI - 42 IP - 1 DP - 2023 Jan-Feb TI - Is adipose tissue metabolic activity a predictor of pathological responses to neoadjuvant treatment in breast cancer. PG - 10-15 LID - S2253-8089(22)00083-0 [pii] LID - 10.1016/j.remnie.2022.08.003 [doi] AB - INTRODUCTION AND OBJECTIVE: Prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer is essential for optimal treatment strategy. The current approach of adjuvant or neoadjuvant treatment is based on the molecular subtype. Obesity may have affected chemotherapy response. This study aims to evaluate the relationship between metabolic activity of adipose tissue (AT) and pathological responses to NAC. And to define the association with body mass index (BMI) and metabolic parameters of standardized uptake value (SUV) of adipose tissue measured by positron emission computed tomography (PET/CT). MATERIAL AND METHODS: One-hundred and sixteen consecutive patients with stage II and III breast cancer who underwent PET/CT before receiving NAC, were evaluated in the study. Metabolic parameters of visceral adipose tissue (VAT-SUV), subcutaneous adipose tissue (SAT-SUV), and calculated SUV of visceral-to-subcutaneous ratio (V/S-ratio) were regarded. The relationship between SUV of AT and pathologic response was evaluated from medical records retrospectively. RESULTS: Univariate-analysis revealed that good pathological response was significantly associated with clinical stage (P<.001), HER-2 positivity (P<.001), VAT-SUV (P=.037), VAT-density (P=.043) and V/S-ratio (P=.003). In multivariate-analysis clinical stage, HER-2 positivity and V/S-ratio were found to have statistically effect on pathological response. VAT-volume (P<.001), VAT-SUV (P=.016), SAT-volume (P<.001) and SAT-SUV (P<.001) has positive correlation with BMI value. On the other hand, V/S-ratio (P=.039) and SAT-density (P=.003) has negative correlation with BMI. CONCLUSION: Metabolic activity of AT is associated with BMI and effected chemotherapy responses. LowV/S ratio was associated with high BMI and poor pathological response to NAC. V/S ratio may be a useful marker for the prediction of NAC responses. CI - Copyright © 2022 Sociedad Española de Medicina Nuclear e Imagen Molecular. Published by Elsevier España, S.L.U. All rights reserved. FAU - Dulgar, Ozgecan AU - Dulgar O AD - Istanbul Medeniyet University, Göztepe Training and Research Hospital, Department of Medical Oncology, Istanbul 34722, Turkey. Electronic address: ozgecandr@gmail.com. FAU - Ibisoglu, Ebru Orsal AU - Ibisoglu EO AD - Istanbul Medeniyet University, Göztepe Training and Research Hospital, Department of Nuclear Medicine, Istanbul, Turkey. FAU - Ay, Seval AU - Ay S AD - Istanbul Medeniyet University, Göztepe Training and Research Hospital, Department of Medical Oncology, Istanbul 34722, Turkey. FAU - Uslu, Hatice AU - Uslu H AD - Istanbul Medeniyet University, Göztepe Training and Research Hospital, Department of Nuclear Medicine, Istanbul, Turkey. FAU - Gümüş, Mahmut AU - Gümüş M AD - Istanbul Medeniyet University, Göztepe Training and Research Hospital, Department of Medical Oncology, Istanbul 34722, Turkey. LA - eng PT - Journal Article DEP - 20220818 PL - Spain TA - Rev Esp Med Nucl Imagen Mol (Engl Ed) JT - Revista espanola de medicina nuclear e imagen molecular JID - 101770941 SB - IM MH - Humans MH - Female MH - *Neoadjuvant Therapy MH - Positron Emission Tomography Computed Tomography/methods MH - *Breast Neoplasms/diagnostic imaging/drug therapy/pathology MH - Retrospective Studies MH - Adipose Tissue/diagnostic imaging/pathology OTO - NOTNLM OT - Actividad metabólica del tejido adiposo visceral y subcutáneo OT - Breast cancer OT - Cáncer de mama OT - Metabolic activity of visceral and subcutaneous adipose tissue OT - Predicción de la respuesta patológica OT - Prediction of pathological response OT - Response to neoadjuvant chemotherapy OT - Respuesta a la quimioterapia neoadyuvante EDAT- 2022/08/22 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/08/21 19:35 PHST- 2022/01/16 00:00 [received] PHST- 2022/05/18 00:00 [revised] PHST- 2022/05/18 00:00 [accepted] PHST- 2022/08/22 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/08/21 19:35 [entrez] AID - S2253-8089(22)00083-0 [pii] AID - 10.1016/j.remnie.2022.08.003 [doi] PST - ppublish SO - Rev Esp Med Nucl Imagen Mol (Engl Ed). 2023 Jan-Feb;42(1):10-15. doi: 10.1016/j.remnie.2022.08.003. Epub 2022 Aug 18. PMID- 36458938 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1543-8392 (Electronic) IS - 1543-8384 (Linking) VI - 20 IP - 1 DP - 2023 Jan 2 TI - Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3. PG - 491-499 LID - 10.1021/acs.molpharmaceut.2c00741 [doi] AB - The therapeutic modalities that involve the endocytosis pathway, including antibody-drug conjugates (ADCs), have recently been developed. Since the drug escape from endosomes/lysosomes is a determinant of their efficacy, it is important to optimize the escape, and the cellular evaluation system is needed. SLC46A3, a lysosomal membrane protein, has been implicated in the pharmacological efficacy of trastuzumab emtansine (T-DM1), a noncleavable ADC used for the treatment of breast cancer, and the cellular uptake efficacy of lipid-based nanoparticles. Recently, we identified the SLC46A3 function as a proton-coupled steroid conjugate and bile acid transporter, which can directly transport active catabolites of T-DM1. Thus, the rapid and convenient assay systems for evaluating the SLC46A3 function may help to facilitate ADC development and to clarify the physiological roles in endocytosis. Here, we show that SLC46A3 dC, which localizes to the plasma membrane owing to lacking a lysosomal-sorting motif, has a great ability to transport 5-carboxyfluorescein (5-CF), a fluorescent probe, in a pH-dependent manner. 5-CF uptake mediated by SLC46A3 was significantly inhibited by compounds reported to be SLC46A3 substrates/inhibitors and competitively inhibited by estrone 3-sulfate, a typical SLC46A3 substrate. The inhibition assays followed by uptake studies revealed that SG3199, a pyrrolobenzodiazepine dimer, which has been used as an ADC payload, is a substrate of SLC46A3. Accordingly, the fluorescence-based assay system for the SLC46A3 function using 5-CF can provide a valuable tool to evaluate the interaction of drugs/drug candidates with SLC46A3. FAU - Tomabechi, Ryuto AU - Tomabechi R AD - Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo192-0392, Japan. FAU - Miyasato, Miki AU - Miyasato M AD - Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo192-0392, Japan. FAU - Sato, Taeka AU - Sato T AD - Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo192-0392, Japan. FAU - Takada, Tappei AU - Takada T AD - Department of Pharmacy, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo113-8655, Japan. FAU - Higuchi, Kei AU - Higuchi K AD - Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo192-0392, Japan. FAU - Kishimoto, Hisanao AU - Kishimoto H AD - Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo192-0392, Japan. FAU - Shirasaka, Yoshiyuki AU - Shirasaka Y AUID- ORCID: 0000-0003-1472-7449 AD - Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa920-1192, Japan. FAU - Inoue, Katsuhisa AU - Inoue K AUID- ORCID: 0000-0002-5234-6498 AD - Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1, Horinouchi, Hachioji, Tokyo192-0392, Japan. LA - eng PT - Journal Article DEP - 20221202 PL - United States TA - Mol Pharm JT - Molecular pharmaceutics JID - 101197791 RN - P188ANX8CK (Trastuzumab) RN - 76823-03-5 (4-carboxyfluorescein) RN - 14083FR882 (Maytansine) RN - SE2KH7T06F (Ado-Trastuzumab Emtansine) RN - 0 (Immunoconjugates) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Female MH - Trastuzumab/pharmacology MH - *Maytansine/pharmacology/chemistry MH - Fluorescence MH - Ado-Trastuzumab Emtansine MH - *Breast Neoplasms/drug therapy/metabolism MH - *Immunoconjugates/therapeutic use MH - Receptor, ErbB-2/metabolism OTO - NOTNLM OT - SLC46A3 OT - antibody-drug conjugate OT - endocytosis OT - fluorescent probe OT - nanoparticle OT - trastuzumab emtansine EDAT- 2022/12/03 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/02 09:32 PHST- 2022/12/03 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/02 09:32 [entrez] AID - 10.1021/acs.molpharmaceut.2c00741 [doi] PST - ppublish SO - Mol Pharm. 2023 Jan 2;20(1):491-499. doi: 10.1021/acs.molpharmaceut.2c00741. Epub 2022 Dec 2. PMID- 36631725 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1465-542X (Electronic) IS - 1465-5411 (Print) IS - 1465-5411 (Linking) VI - 25 IP - 1 DP - 2023 Jan 11 TI - Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). PG - 2 LID - 10.1186/s13058-022-01587-z [doi] LID - 2 AB - BACKGROUND: KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II-III breast cancer. We investigated the association of biomarkers with clinical outcomes in KRISTINE. METHODS: Patients were randomized to receive neoadjuvant T-DM1 + P or TCH + P and assessed for pathologic complete response (pCR; ypT0/is, ypN0). HER2 status (per central assessment), hormone receptor status, PIK3CA mutation status, HER2/HER3 mRNA levels, tumor-infiltrating lymphocyte levels, PD-L1 status, and NanoString data were analyzed. pCR rates by treatment arm were compared across biomarker subgroups. Analyses were descriptive. RESULTS: Biomarker analyses included data from all 444 patients (T-DM1 + P, n = 223; TCH + P, n = 221) enrolled in KRISTINE. Biomarker distribution was balanced across treatment arms. All subgroups with higher HER2 amplification/expression and immune marker levels showed numerically higher pCR rates in both arms. Mutated versus non-mutated PIK3CA tumors were associated with numerically lower pCR rates in the T-DM1 + P arm but not in the TCH + P arm. In a multivariate analysis, Prediction Analysis of Microarray with the 50-gene classifier (PAM50) HER2-enriched subtype, HER2 gene ratio ≥ 4, and PD-L1-positive status positively influenced the pCR rate. Biomarkers associated with lower pCR rates (e.g., low HER2 levels, positive hormone receptor status, mutated PIK3CA) were more likely to co-occur. Dynamic on-treatment biomarker changes were observed. Differences in the treatment effects for T-DM1 + P versus TCH + P were similar to those observed in the intent-to-treat population for the majority of the biomarker subgroups. CONCLUSIONS: Although our biomarker analysis did not identify a subgroup of patients that benefited from neoadjuvant T-DM1 + P versus TCH + P, the data revealed that patients with higher HER2 amplification/expression and immune marker levels had improved response irrespective of treatment arm. These analyses confirm the role of HER2 tumor biology and the immune microenvironment in influencing pCR in the neoadjuvant setting and reaffirm the molecular diversity of HER2-positive breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov NCT02131064. Registered 06 May 2014. CI - © 2023. The Author(s). FAU - de Haas, Sanne L AU - de Haas SL AD - Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. sanne_lysbet.de_haas@roche.com. FAU - Slamon, Dennis J AU - Slamon DJ AD - Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. FAU - Martin, Miguel AU - Martin M AD - Medical Oncology Service, Hospital Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain. FAU - Press, Michael F AU - Press MF AD - Department of Pathology, Keck School of Medicine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA. FAU - Lewis, Gail D AU - Lewis GD AD - Discovery Oncology, Genentech, Inc., South San Francisco, CA, USA. FAU - Lambertini, Chiara AU - Lambertini C AD - Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. FAU - Prat, Aleix AU - Prat A AD - Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain. AD - Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. AD - Department of Medicine, University of Barcelona, Barcelona, Spain. FAU - Lopez-Valverde, Vanesa AU - Lopez-Valverde V AD - Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland. FAU - Boulet, Thomas AU - Boulet T AD - Product Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd., Basel, Switzerland. FAU - Hurvitz, Sara A AU - Hurvitz SA AD - Division of Hematology-Oncology, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. LA - eng SI - ClinicalTrials.gov/NCT02131064 PT - Clinical Trial, Phase III PT - Journal Article PT - Randomized Controlled Trial DEP - 20230111 PL - England TA - Breast Cancer Res JT - Breast cancer research : BCR JID - 100927353 RN - SE2KH7T06F (Ado-Trastuzumab Emtansine) RN - 0 (Biomarkers, Tumor) RN - K16AIQ8CTM (pertuzumab) RN - 0 (B7-H1 Antigen) RN - P188ANX8CK (Trastuzumab) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) SB - IM MH - Humans MH - Female MH - Ado-Trastuzumab Emtansine/therapeutic use MH - *Breast Neoplasms/drug therapy/genetics MH - Biomarkers, Tumor/genetics/analysis MH - B7-H1 Antigen MH - Trastuzumab/therapeutic use MH - Standard of Care MH - Receptor, ErbB-2/genetics MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - Neoadjuvant Therapy MH - Class I Phosphatidylinositol 3-Kinases/genetics MH - Tumor Microenvironment PMC - PMC9832665 OTO - NOTNLM OT - HER2-positive breast cancer OT - KRISTINE OT - Pertuzumab OT - Trastuzumab emtansine OT - Tumor biomarkers COIS- SLdH is an employee of, and owns stock in, Roche. DJS owns stock in Pfizer, Amgen, Merck, Vertex, and Seattle Genetics; has received consulting fees from Novartis and Pfizer and research funding from Bayer and Novartis; and is a co-founder of 1200Pharma and TORL BioTherapeutics. MM has served as a consultant for F. Hoffmann-La Roche, Genentech, Novartis, and AstraZeneca. His institution has received research funding from Novartis and from Centro de Investigación Biomédica en Red in the thematic area of Breast Oncology (CIBERONC Breast), of the Instituto de Salud Carlos III (ISCIII). MFP has received research grants to his institution from Cepheid, Eli Lilly & Company, Novartis Pharmaceuticals, F. Hoffmann-La Roche Ltd, and Puma; has served as a consultant or advisor with honoraria for AstraZeneca, Biocartis SA, Cepheid, Eli Lilly & Company, Merck & Co, Puma Biotechnology, and Zymeworks Inc; has provided expert testimony for Amgen, Inc; and has private equity in TORL Biotherapeutics, LLA. GLP is an employee of Genentech and owns stock in Roche. CL is an employee of Roche. AP owns stock in Reveal Genomics; has received honoraria from Pfizer, Novartis, Roche, MSD Oncology, Lilly, Daiichi Sankyo, Amgen, and Guardant Health; has served as a consultant or advisor for Amgen, Roche, Novartis, Pfizer, Bristol-Myers Squibb, Boehringer, PUMA, Oncolytics Biotech, Daiichi Sankyo, AbbVie, AstraZeneca, and NanoString Technologies; has received research funding from Roche, Novartis, Incyte, and Puma Biotechnology; and has received royalties for patents/other intellectual property for PCT/EP2016/080056 (HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy), WO/2018/096191 (chemoendocrine score [CES] based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence), HER2DX filing, and US 63/023785 (methods for breast cancer treatment and prediction of therapeutic response. VL-V is an employee of, and owns stock in, Roche. TB is an employee from Parexel International GmbH contracted by F. Hoffmann-La Roche for statistical services in the conduct of the study. SAH has received travel support from F. Hoffmann-La Roche, Boehringer Ingelheim, Novartis, Lilly, Pfizer, and Bayer. Her institution has received research funding from Ambrx, AstraZeneca, Arvinas, Daiichi Sankyo, Dantari, G1-Therapeutics, Gilead, Immunomedics, MacroGenics, Pieris, Radius, Seattle Genetics, Zymeworks, Cytomx, Phoenix Molecular Designs, Ltd, F. Hoffmann-La Roche, Genentech, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, Pfizer, Amgen, OBI Pharma, Puma Biotechnology, Dignitana, Bayer, BioMarin, Lilly, and Merrimack. EDAT- 2023/01/12 06:00 MHDA- 2023/01/14 06:00 CRDT- 2023/01/11 23:28 PHST- 2022/04/22 00:00 [received] PHST- 2022/12/02 00:00 [accepted] PHST- 2023/01/11 23:28 [entrez] PHST- 2023/01/12 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] AID - 10.1186/s13058-022-01587-z [pii] AID - 1587 [pii] AID - 10.1186/s13058-022-01587-z [doi] PST - epublish SO - Breast Cancer Res. 2023 Jan 11;25(1):2. doi: 10.1186/s13058-022-01587-z. PMID- 36326756 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 2374-2445 (Electronic) IS - 2374-2437 (Print) IS - 2374-2437 (Linking) VI - 9 IP - 1 DP - 2023 Jan 1 TI - Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial. PG - 71-78 LID - 10.1001/jamaoncol.2022.5143 [doi] AB - IMPORTANCE: High levels of ERBB2 (formerly HER2)-specific type 1 T cells in the peripheral blood are associated with favorable clinical outcomes after trastuzumab therapy; however, only a minority of patients develop measurable ERBB2 immunity after treatment. Vaccines designed to increase ERBB2-specific T-helper cells could induce ERBB2 immunity in a majority of patients. OBJECTIVE: To determine the safety and immunogenicity of 3 doses (10, 100, and 500 μg) of a plasmid-based vaccine encoding the ERBB2 intracellular domain (ICD). DESIGN, SETTING, AND PARTICIPANTS: Single-arm phase 1 trial including 66 patients with advanced-stage ERBB2-positive breast cancer treated in an academic medical center between 2001 and 2010 with 10-year postvaccine toxicity assessments. Data analysis was performed over 2 periods: January 2012 to March 2013 and July 2021 to August 2022. INTERVENTIONS: Patients were sequentially enrolled to the 3 dose arms. The vaccine was administered intradermally once a month with soluble granulocyte-macrophage colony-stimulating factor as an adjuvant for 3 immunizations. Toxicity evaluations occurred at set intervals and yearly. Peripheral blood mononuclear cells were collected for evaluation of immunity. Biopsy of vaccine sites at weeks 16 and 36 measured DNA persistence. MAIN OUTCOMES AND MEASURES: Safety was graded by Common Terminology Criteria for Adverse Events, version 3.0, and ERBB2 ICD immune responses were measured by interferon-γ enzyme-linked immunosorbent spot. Secondary objectives determined if vaccine dose was associated with immunity and evaluated persistence of plasmid DNA at the vaccine site. RESULTS: A total of 66 patients (median [range] age, 51 [34-77] years) were enrolled. The majority of vaccine-related toxic effects were grade 1 and 2 and not significantly different between dose arms. Patients in arm 2 (100 μg) and arm 3 (500 μg) had higher magnitude ERBB2 ICD type 1 immune responses at most time points than arm 1 (10 μg) (arm 2 compared with arm 1, coefficient, 181 [95% CI, 60-303]; P = .003; arm 3 compared with arm 1, coefficient, 233 [95% CI, 102-363]; P < .001) after adjusting for baseline factors. ERBB2 ICD immunity at time points after the end of immunizations was significantly lower on average in patients with DNA persistence at week 16 compared with those without persistence. The highest vaccine dose was associated with the greatest incidence of persistent DNA at the injection site. CONCLUSIONS AND RELEVANCE: In this phase 1 nonrandomized clinical trial, immunization with the 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with generation of ERBB2-specific type 1 T cells in most patients with ERBB2-expressing breast cancer, and it is currently being evaluated in randomized phase 2 trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00436254. FAU - Disis, Mary L Nora AU - Disis MLN AD - University of Washington Medicine Cancer Vaccine Institute, University of Washington, Seattle. FAU - Guthrie, Katherine A AU - Guthrie KA AD - Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington. FAU - Liu, Ying AU - Liu Y AD - University of Washington Medicine Cancer Vaccine Institute, University of Washington, Seattle. FAU - Coveler, Andrew L AU - Coveler AL AD - University of Washington Medicine Cancer Vaccine Institute, University of Washington, Seattle. FAU - Higgins, Doreen M AU - Higgins DM AD - University of Washington Medicine Cancer Vaccine Institute, University of Washington, Seattle. FAU - Childs, Jennifer S AU - Childs JS AD - University of Washington Medicine Cancer Vaccine Institute, University of Washington, Seattle. FAU - Dang, Yushe AU - Dang Y AD - University of Washington Medicine Cancer Vaccine Institute, University of Washington, Seattle. FAU - Salazar, Lupe G AU - Salazar LG AD - University of Washington Medicine Cancer Vaccine Institute, University of Washington, Seattle. LA - eng SI - ClinicalTrials.gov/NCT00436254 PT - Clinical Trial PT - Clinical Trial, Phase I PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - JAMA Oncol JT - JAMA oncology JID - 101652861 RN - 0 (Vaccines, DNA) RN - 9007-49-2 (DNA) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Breast Neoplasms/drug therapy/genetics MH - *Vaccines, DNA/adverse effects/genetics MH - Leukocytes, Mononuclear/pathology MH - DNA/therapeutic use MH - Plasmids MH - Receptor, ErbB-2/genetics PMC - PMC9634596 COIS- Conflict of Interest Disclosures: Dr Disis reported being a stockholder/founder of EpiThany, and receiving grants from Aston Sci, Veanna, Precigen, and Bavarian Nordisk during the conduct of the study; and serving as Editor of JAMA Oncology outside the submitted work; in addition, Dr Disis had a patent for University of Washington with royalties paid. Dr Coveler reported receiving grants from SeaGen, Abgenomics, Novocure, Medimmune, Nucana, Amgen, Actuate, Pancan, Nextrast, Surface, Mirati, and AstraZeneca outside the submitted work. No other disclosures were reported. EDAT- 2022/11/04 06:00 MHDA- 2023/01/24 06:00 PMCR- 2023/11/03 CRDT- 2022/11/03 11:34 PHST- 2023/11/03 00:00 [pmc-release] PHST- 2022/11/04 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/11/03 11:34 [entrez] AID - 2797975 [pii] AID - coi220061 [pii] AID - 10.1001/jamaoncol.2022.5143 [doi] PST - ppublish SO - JAMA Oncol. 2023 Jan 1;9(1):71-78. doi: 10.1001/jamaoncol.2022.5143. PMID- 35689469 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230125 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 12 IP - 1 DP - 2023 Jan TI - Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines. PG - 122-130 LID - 10.1002/cam4.4929 [doi] AB - BACKGROUND: Although trastuzumab and anthracyclines are frequently used to treat breast cancer (BC) and gastric cancer (GC), cardiotoxicity is a serious concern. The cardiac function assessment is recommended at baseline before initiating treatment. However, the prevalence rates of baseline cardiac checkups are unknown. METHODS: The national database of hospital-based cancer registries linked to the health services-utilization data was used to study patients with newly diagnosed stage IV BC and GC (n = 6271) who received trastuzumab (n = 4324, 69.0%) or anthracyclines between January 2012 and December 2015. The baseline ultrasound echocardiogram (UCG) performance rate and factors related to adequate UCG performance for all patients and those receiving trastuzumab were analyzed. RESULTS: The adequate baseline UCG checkup rate was higher in patients treated with trastuzumab than in those treated with anthracyclines (71.8% vs 44.1%, respectively). Additionally, patients with GC were less likely to receive an adequate baseline UCG performance than those with BC (70.4% vs 75.0%, respectively). After adjusting for potential confounders, patients with anthracycline-treated BC and GC were less likely to receive adequate baseline UCG performance than those with trastuzumab-treated BC (odds ratio [OR]: 0.24, 95% confidence interval [CI]: 0.20-0.28, and OR: 0.07, 95% CI: 0.03-0.16, respectively). Furthermore, patients with trastuzumab-treated GC were less likely to receive adequate baseline UCG performance than those with BC (OR: 0.65, 95% CI: 0.50-0.84). CONCLUSIONS: The baseline UCG was less likely to be performed in patients receiving anthracyclines than in those receiving trastuzumab, as well as in patients with GC than in those with BC. CI - © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Ishii, Taisuke AU - Ishii T AUID- ORCID: 0000-0002-7601-4295 AD - Division of Health Services Research, National Cancer Center, Tokyo, Japan. FAU - Watanabe, Tomone AU - Watanabe T AD - Division of Health Services Research, National Cancer Center, Tokyo, Japan. FAU - Higashi, Takahiro AU - Higashi T AUID- ORCID: 0000-0002-9933-2106 AD - Division of Health Services Research, National Cancer Center, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20220611 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 RN - P188ANX8CK (Trastuzumab) RN - 0 (Anthracyclines) RN - 0 (Antibiotics, Antineoplastic) SB - IM MH - Humans MH - Female MH - Trastuzumab/adverse effects MH - *Breast Neoplasms/drug therapy MH - Anthracyclines/adverse effects MH - Antibiotics, Antineoplastic/therapeutic use MH - Cardiotoxicity/etiology PMC - PMC9844617 OTO - NOTNLM OT - breast cancer OT - gastric cancer OT - ultrasound echocardiogram COIS- The authors have no conflict of interest to declare. EDAT- 2022/06/12 06:00 MHDA- 2023/01/20 06:00 CRDT- 2022/06/11 05:12 PHST- 2022/05/18 00:00 [revised] PHST- 2022/04/26 00:00 [received] PHST- 2022/05/28 00:00 [accepted] PHST- 2022/06/12 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2022/06/11 05:12 [entrez] AID - CAM44929 [pii] AID - 10.1002/cam4.4929 [doi] PST - ppublish SO - Cancer Med. 2023 Jan;12(1):122-130. doi: 10.1002/cam4.4929. Epub 2022 Jun 11. PMID- 36685583 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer. PG - 1042835 LID - 10.3389/fimmu.2022.1042835 [doi] LID - 1042835 AB - INTRODUCTION: Hypoxia is an important characteristic of solid tumors. However, spatial transcriptomics (ST) of hypoxia-associated heterogeneity is not clear. METHODS: This study integrated Spatial Transcriptomics (ST) with immunofluorescence to demonstrate their spatial distribution in human claudin-low breast cancer MDA-MB-231 engraft. ST spots were clustered with differentially expression genes. The data were combined with hypoxia-specific marker and angiogenesis marker-labeled serial sections to indicate the spatial distribution of hypoxia and hypoxia-inducted transcriptional profile. Moreover, marker genes, cluster-specific hypoxia genes, and their co-essential relationship were identified and mapped in every clusters. The clinicopathological association of marker genes of hypoxia-dependent spatial clusters was explored in 1904 breast cancers from METABRIC database. RESULTS: The tumor from center to periphery were enriched into five hypoxia-dependent subgroups with differentially expressed genes, which were matched to necrosis, necrosis periphery, hypoxic tumor, adaptive survival tumor, and invasive tumor, respectively. Different subgroups demonstrated distinct hypoxia condition and spatial heterogeneity in biological behavior and signaling pathways. Cox regression analysis showed that the invasive tumor (cluster 0) and hypoxic tumor (cluster 6) score could be served as independent prognostic factors in claudin-low patients. KM analysis indicated that high invasive tumor (cluster 0) and hypoxic tumor (cluster 6) score was associated with poor prognoses of claudin-low patients. Further analysis showed that hypoxia-induced immune checkpoints, such as CD276 and NRP1, upregulation in invasive tumor to block infiltration and activation of B cells and CD8+ T cells to change tumor immune microenvironment. DISCUSSION: This study reveals hypoxia-dependent spatial heterogeneity in claudin-low breast cancer and highlights its potential value as a predictive biomarker of clinical outcomes and immunotherapy response. The molecules found in this study also provided potential molecular mechanisms and therapeutic targets for subsequent studies. CI - Copyright © 2023 Sun, Li, Zhang, Zhao, Dong, Guo, Mo, Che, Ban, Li, Bai, Li, Hao and Zhang. FAU - Sun, Huizhi AU - Sun H AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Li, Yanlei AU - Li Y AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Zhang, Yanhui AU - Zhang Y AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Zhao, Xiulan AU - Zhao X AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Dong, Xueyi AU - Dong X AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Guo, Yuhong AU - Guo Y AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Mo, Jing AU - Mo J AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Che, Na AU - Che N AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Ban, Xinchao AU - Ban X AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Li, Fan AU - Li F AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Bai, Xiaoyu AU - Bai X AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Li, Yue AU - Li Y AD - Department of Pathology, Tianjin Medical University, Tianjin, China. FAU - Hao, Jihui AU - Hao J AD - Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China. FAU - Zhang, Danfang AU - Zhang D AD - Department of Pathology, Tianjin Medical University, Tianjin, China. LA - eng SI - figshare/10.6084/m9.figshare.21695735.v1 PT - Journal Article DEP - 20230104 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Claudins) RN - 0 (CD276 protein, human) RN - 0 (B7 Antigens) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics/therapy/metabolism MH - Transcriptome MH - Prognosis MH - Hypoxia/genetics MH - Claudins/genetics/metabolism MH - Immunotherapy MH - Tumor Microenvironment/genetics MH - B7 Antigens/genetics PMC - PMC9846556 OTO - NOTNLM OT - Claudin-low tumor OT - breast cancer OT - hypoxia OT - immune cell infiltration OT - spatial transcriptomics COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/24 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/23 04:38 PHST- 2022/09/13 00:00 [received] PHST- 2022/12/09 00:00 [accepted] PHST- 2023/01/23 04:38 [entrez] PHST- 2023/01/24 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.3389/fimmu.2022.1042835 [doi] PST - epublish SO - Front Immunol. 2023 Jan 4;13:1042835. doi: 10.3389/fimmu.2022.1042835. eCollection 2022. PMID- 36410105 OWN - NLM STAT- MEDLINE DCOM- 20230102 LR - 20230111 IS - 2210-7762 (Print) VI - 270-271 DP - 2023 Jan TI - Multi-omics inference of differential breast cancer-related transcriptional regulatory network gene hubs between young Black and White patients. PG - 1-11 LID - S2210-7762(22)00273-3 [pii] LID - 10.1016/j.cancergen.2022.11.001 [doi] AB - OBJECTIVE: Breast cancers (BrCA) are a leading cause of illness and mortality worldwide. Black women have a higher incidence rate relative to white women prior to age 40 years, and a lower incidence rate after 50 years. The objective of this study is to identify -omics differences between the two breast cancer cohorts to better understand the disparities observed in patient outcomes. MATERIALS AND METHODS: Using Standard SQL, we queried ISB-CGC hosted Google BigQuery tables storing TCGA BrCA gene expression, methylation, and somatic mutation data and analyzed the combined multi-omics results using a variety of methods. RESULTS: Among Stage II patients 50 years or younger, genes PIK3CA and CDH1 are more frequently mutated in White (W50) than in Black or African American patients (BAA50), while HUWE1, HYDIN, and FBXW7 mutations are more frequent in BAA50. Over-representation analysis (ORA) and Gene Set Enrichment Analysis (GSEA) results indicate that, among others, the Reactome Signaling by ROBO Receptors gene set is enriched in BAA50. Using the Virtual Inference of Protein-activity by Enriched Regulon analysis (VIPER) algorithm, putative top 20 master regulators identified include NUPR1, NFKBIL1, ZBTB17, TEAD1, EP300, TRAF6, CACTIN, and MID2. CACTIN and MID2 are of prognostic value. We identified driver genes, such as OTUB1, with suppressed expression whose DNA methylation status were inversely correlated with gene expression. Networks capturing microRNA and gene expression correlations identified notable microRNA hubs, such as miR-93 and miR-92a-2, expressed at higher levels in BAA50 than in W50. DISCUSSION/CONCLUSION: The results point to several driver genes as being involved in the observed differences between the cohorts. The findings here form the basis for further mechanistic exploration. CI - Copyright © 2022. Published by Elsevier Inc. FAU - Aguilar, Boris AU - Aguilar B AD - Institute for Systems Biology, Seattle, WA, USA. FAU - Abdilleh, Kawther AU - Abdilleh K AD - Pancreatic Cancer Action Network, Manhattan Beach, CA USA. FAU - Acquaah-Mensah, George K AU - Acquaah-Mensah GK AD - Massachusetts College of Pharmacy and Health Sciences, Worcester, MA, USA. Electronic address: george.acquaah-mensah@mcphs.edu. LA - eng PT - Journal Article DEP - 20221107 PL - United States TA - Cancer Genet JT - Cancer genetics JID - 101539150 RN - 0 (MicroRNAs) RN - EC 2.3.2.26 (HUWE1 protein, human) RN - 0 (Tumor Suppressor Proteins) RN - EC 2.3.2.27 (Ubiquitin-Protein Ligases) SB - IM MH - Humans MH - Female MH - Adult MH - *Breast Neoplasms/genetics/metabolism MH - Multiomics MH - White MH - Oncogenes MH - *MicroRNAs/genetics MH - Tumor Suppressor Proteins/genetics MH - Ubiquitin-Protein Ligases/genetics OTO - NOTNLM OT - Breast cancer OT - Cloud-based Multi-omics OT - Cohort analysis OT - Health disparities OT - Regulatory networks COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/22 06:00 MHDA- 2023/01/03 06:00 CRDT- 2022/11/21 18:18 PHST- 2022/07/08 00:00 [received] PHST- 2022/10/25 00:00 [revised] PHST- 2022/11/04 00:00 [accepted] PHST- 2022/11/22 06:00 [pubmed] PHST- 2023/01/03 06:00 [medline] PHST- 2022/11/21 18:18 [entrez] AID - S2210-7762(22)00273-3 [pii] AID - 10.1016/j.cancergen.2022.11.001 [doi] PST - ppublish SO - Cancer Genet. 2023 Jan;270-271:1-11. doi: 10.1016/j.cancergen.2022.11.001. Epub 2022 Nov 7. PMID- 36675137 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 13 TI - Mining TCGA Database for Genes with Prognostic Value in Breast Cancer. LID - 1622 [pii] LID - 10.3390/ijms24021622 [doi] AB - The aim of the study was to use transcriptomics data to identify genes associated with advanced/aggressive breast cancer and their effect on survival outcomes. We used the publicly available The Cancer Genome Atlas (TCGA) database to obtain RNA sequence data from patients with less than five years survival (Poor Prognosis, n = 101), patients with greater than five years survival (Good Prognosis, n = 200), as well as unpaired normal tissue data (normal, n = 105). The data analyses performed included differential expression between groups and selection of subsets of genes, gene ontology, cell enrichment analysis, and survival analyses. Gene ontology results showed significantly reduced enrichment in gene sets related to tumor immune microenvironment in Poor Prognosis and cell enrichment analysis confirmed significantly reduced numbers of macrophages M1, CD8 T cells, plasma cells and dendritic cells in samples in the Poor Prognosis samples compared with Good Prognosis. A subset of 742 genes derived from differential expression analysis as well as genes coding for immune checkpoint molecules was evaluated for their effect on overall survival. In conclusion, this study may contribute to the better understanding of breast cancer transcriptomics and provide possible targets for further research and eventual therapeutic interventions. FAU - Filippi, Alexandru AU - Filippi A AD - Department of Biochemistry and Biophysics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. FAU - Mocanu, Maria-Magdalena AU - Mocanu MM AD - Department of Biochemistry and Biophysics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. LA - eng PT - Journal Article DEP - 20230113 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - Prognosis MH - Aggression MH - CD8-Positive T-Lymphocytes MH - Data Analysis MH - Tumor Microenvironment/genetics PMC - PMC9862022 OTO - NOTNLM OT - breast cancer OT - differentially expressed genes OT - immune cells OT - immune checkpoints OT - survival markers EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:28 PHST- 2022/11/29 00:00 [received] PHST- 2023/01/06 00:00 [revised] PHST- 2023/01/10 00:00 [accepted] PHST- 2023/01/21 01:28 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijms24021622 [pii] AID - 10.3390/ijms24021622 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 13;24(2):1622. doi: 10.3390/ijms24021622. PMID- 36652909 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 2666-3791 (Electronic) IS - 2666-3791 (Linking) VI - 4 IP - 1 DP - 2023 Jan 17 TI - Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. PG - 100900 LID - S2666-3791(22)00479-7 [pii] LID - 10.1016/j.xcrm.2022.100900 [doi] LID - 100900 AB - Brain metastases (BrMs) are the most common form of brain tumors in adults and frequently originate from lung and breast primary cancers. BrMs are associated with high mortality, emphasizing the need for more effective therapies. Genetic profiling of primary tumors is increasingly used as part of the effort to guide targeted therapies against BrMs, and immune-based strategies for the treatment of metastatic cancer are gaining momentum. However, the tumor immune microenvironment (TIME) of BrM is extremely heterogeneous, and whether specific genetic profiles are associated with distinct immune states remains unknown. Here, we perform an extensive characterization of the immunogenomic landscape of human BrMs by combining whole-exome/whole-genome sequencing, RNA sequencing of immune cell populations, flow cytometry, immunofluorescence staining, and tissue imaging analyses. This revealed unique TIME phenotypes in genetically distinct lung- and breast-BrMs, thereby enabling the development of personalized immunotherapies tailored by the genetic makeup of the tumors. CI - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Álvarez-Prado, Ángel F AU - Álvarez-Prado ÁF AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland; Agora Cancer Research Center, 1011 Lausanne, Switzerland; L. Lundin and Family Brain Tumor Research Center, Departments of Oncology and Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland. FAU - Maas, Roeltje R AU - Maas RR AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland; Agora Cancer Research Center, 1011 Lausanne, Switzerland; L. Lundin and Family Brain Tumor Research Center, Departments of Oncology and Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland; Neuroscience Research Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Soukup, Klara AU - Soukup K AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland; Agora Cancer Research Center, 1011 Lausanne, Switzerland. FAU - Klemm, Florian AU - Klemm F AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland; Agora Cancer Research Center, 1011 Lausanne, Switzerland. FAU - Kornete, Mara AU - Kornete M AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland; Agora Cancer Research Center, 1011 Lausanne, Switzerland. FAU - Krebs, Fanny S AU - Krebs FS AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland. FAU - Zoete, Vincent AU - Zoete V AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland. FAU - Berezowska, Sabina AU - Berezowska S AD - Department of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Brouland, Jean-Philippe AU - Brouland JP AD - Department of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Hottinger, Andreas F AU - Hottinger AF AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; L. Lundin and Family Brain Tumor Research Center, Departments of Oncology and Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland; Brain and Spine Tumor Center, Departments of Clinical Neurosciences and Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Daniel, Roy T AU - Daniel RT AD - L. Lundin and Family Brain Tumor Research Center, Departments of Oncology and Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland; Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Hegi, Monika E AU - Hegi ME AD - L. Lundin and Family Brain Tumor Research Center, Departments of Oncology and Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland; Neuroscience Research Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. FAU - Joyce, Johanna A AU - Joyce JA AD - Department of Oncology, University of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland; Agora Cancer Research Center, 1011 Lausanne, Switzerland; L. Lundin and Family Brain Tumor Research Center, Departments of Oncology and Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland. Electronic address: johanna.joyce@unil.ch. LA - eng PT - Journal Article PL - United States TA - Cell Rep Med JT - Cell reports. Medicine JID - 101766894 SB - IM MH - Adult MH - Humans MH - Female MH - *Brain Neoplasms/genetics MH - *Breast Neoplasms/genetics/pathology MH - *Melanoma MH - Immunotherapy MH - *Skin Neoplasms MH - Tumor Microenvironment/genetics PMC - PMC9873981 OTO - NOTNLM OT - T cells OT - brain metastasis OT - cancer immunology OT - genomics OT - immunogenomics OT - microglia OT - monocyte-derived macrophages OT - neutrophils OT - transcriptomics OT - tumor microenvironment COIS- Declaration of interests F.K. is currently an employee at Sophia Genetics; V.Z. is a consultant for Cellestia Biotech; S.B. has received honoraria from Eli Lilly (Advisory Board) and research funding to the institution from Roche and Basilea (last 3 years); M.E.H. has an advisory role at TME Pharma; J.A.J. has received honoraria for speaking at research symposia organized by Bristol Meyers Squibb and Glenmark Pharmaceuticals (last 3 years) and currently serves on the scientific advisory board of Pionyr Immunotherapeutics. EDAT- 2023/01/19 06:00 MHDA- 2023/01/21 06:00 CRDT- 2023/01/18 18:17 PHST- 2022/05/04 00:00 [received] PHST- 2022/09/20 00:00 [revised] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/18 18:17 [entrez] PHST- 2023/01/19 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] AID - S2666-3791(22)00479-7 [pii] AID - 100900 [pii] AID - 10.1016/j.xcrm.2022.100900 [doi] PST - ppublish SO - Cell Rep Med. 2023 Jan 17;4(1):100900. doi: 10.1016/j.xcrm.2022.100900. PMID- 35946469 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1473-5733 (Electronic) IS - 0957-5235 (Linking) VI - 34 IP - 1 DP - 2023 Jan 1 TI - Interleukin-10 levels and the risk of thromboembolism according to COMPASS-Cancer associated thrombosis score in breast cancer patients prior to undergoing doxorubicin-based chemotherapy. PG - 70-74 LID - 10.1097/MBC.0000000000001159 [doi] AB - Venous thromboembolism (VTE) is an important cause of morbidity/mortality in cancer patients, and COMPASS-CAT score must be used to VTE-risk prediction. There is a relationship between cytokines and thrombus formation and/or resolution. This study aimed to investigate the VTE risk and cytokines level in breast cancer patients prior to chemotherapy with doxorubicin (DOXO). Eighty women with breast cancer and indication for DOXO treatment were selected. TNF, IL-1β, IL-6, and IL-10 were measured after the diagnosis and immediately before DOXO treatment. All 80 patients presented a high risk for VTE when evaluated by COMPASS-CAT model (score ≥7). A positive correlation was observed between IL-10 plasma levels and VTE risk score. Our data showed that higher IL-10 levels before chemotherapy are associated to increased risk of VTE in breast cancer patients. This finding suggests that IL-10 levels and the combination with COMPASS-CAT score could be good markers to predict increased risk of VTE in these patients. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Pestana, Rodrigo M C AU - Pestana RMC AD - Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. FAU - Alves, Michelle T AU - Alves MT AD - Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. FAU - de Oliveira, Angélica N AU - de Oliveira AN AD - Instituto de Hipertensão, Belo Horizonte, Minas Gerais, Brazil. FAU - Oliveira, Heloísa H M AU - Oliveira HHM AD - Fundação Ezequiel Dias, Belo Horizonte, Minas Gerais, Brazil. FAU - Soares, Cintia E AU - Soares CE AD - Fundação Hospitalar do Estado de Minas Gerais (FHEMIG), Belo Horizonte, Minas Gerais, Brazil. FAU - Sabino, Adriano de P AU - Sabino AP AD - Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. FAU - Silva, Luciana M AU - Silva LM AD - Fundação Ezequiel Dias, Belo Horizonte, Minas Gerais, Brazil. FAU - Simões, Ricardo AU - Simões R AD - Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. AD - Instituto de Hipertensão, Belo Horizonte, Minas Gerais, Brazil. AD - Fundação Hospitalar do Estado de Minas Gerais (FHEMIG), Belo Horizonte, Minas Gerais, Brazil. FAU - Gomes, Karina B AU - Gomes KB AD - Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. AD - Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. LA - eng PT - Journal Article DEP - 20220809 PL - England TA - Blood Coagul Fibrinolysis JT - Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis JID - 9102551 RN - 80168379AG (Doxorubicin) RN - 130068-27-8 (Interleukin-10) SB - IM MH - Female MH - Humans MH - Doxorubicin/adverse effects MH - *Interleukin-10/blood/chemistry MH - Risk Factors MH - Thrombosis/etiology MH - *Venous Thromboembolism/etiology MH - *Breast Neoplasms/complications/drug therapy EDAT- 2022/08/11 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/08/10 05:43 PHST- 2022/08/11 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/08/10 05:43 [entrez] AID - 00001721-990000000-00025 [pii] AID - 10.1097/MBC.0000000000001159 [doi] PST - ppublish SO - Blood Coagul Fibrinolysis. 2023 Jan 1;34(1):70-74. doi: 10.1097/MBC.0000000000001159. Epub 2022 Aug 9. PMID- 36396775 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer. PG - 307-317 LID - 10.1007/s10549-022-06794-y [doi] AB - PURPOSE: Increased body mass index (BMI) and metabolic syndrome (MS) are associated with increased breast cancer recurrence risk. Whether this is due to intrinsic tumor biology or modifiable factors of the obese state remains incompletely understood. METHODS: Oncotype DX Recurrence Scores of 751 patients were stratified by BMI to assess association with tumor-intrinsic recurrence risk. Cellular proliferation by Ki67 after 10-21 days of presurgical letrozole treatment was used to stratify endocrine therapy response (sensitive-ln(Ki67) < 1; intermediate-ln(Ki67)1-2; resistant-ln(Ki67) >  = 2). BMI at the time of surgery and MS variables were collected retrospectively for 143 patients to analyze association between therapy response and BMI/MS. Additionally, PI3K pathway signaling was evaluated by immunohistochemistry of phosphorylated Akt and S6. RESULTS: There was no significant association between BMI and recurrence score (p = 0.99), and risk score distribution was similar across BMI groups. However, BMI was associated with short-term endocrine therapy resistance, with a significant enrichment of intermediate and resistant tumors in patients with obesity (55%, p = 0.0392). Similarly, the relative risk of an endocrine therapy-resistant tumor was 1.4-fold greater for patients with MS (p = 0.0197). In evaluating PI3K pathway mediators, we found patients with 3 or more MS criteria had more tumors with pAkt scores above the median (p = 0.0436). There were no significant differences in S6 activation. CONCLUSION: Our findings suggest the association between obesity/metabolic syndrome and breast cancer recurrence is better reflected by response to treatment than tumor-intrinsic properties, suggesting interventions to reverse obesity and/or MS may improve outcomes for breast cancer recurrence. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Bergman, Riley AU - Bergman R AD - Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. FAU - Berko, Yvonne A AU - Berko YA AD - Meharry Medical College, Nashville, TN, USA. AD - Currently Piedmont Newnan Hospital, Newnan, Georgia. FAU - Sanchez, Violeta AU - Sanchez V AD - Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. FAU - Sanders, Melinda E AU - Sanders ME AD - Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. FAU - Gonzalez-Ericsson, Paula I AU - Gonzalez-Ericsson PI AD - Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. FAU - Arteaga, Carlos L AU - Arteaga CL AD - Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. AD - UTSW Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA. FAU - Rexer, Brent N AU - Rexer BN AUID- ORCID: 0000-0002-0341-7392 AD - Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. Brent.rexer@vumc.org. AD - Division of Hematology/Oncology, Vanderbilt University Medical Center, 2220 Pierce Ave, Nashville, TN 777 PRB 37232-6307, USA. Brent.rexer@vumc.org. LA - eng GR - T32GM007347/GM/NIGMS NIH HHS/United States GR - P50CA098131/National Cancer Institute (US)/ GR - T32GM007347/GM/NIGMS NIH HHS/United States PT - Journal Article DEP - 20221117 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (Ki-67 Antigen) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - 0 (Biomarkers, Tumor) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/complications/drug therapy/metabolism MH - Ki-67 Antigen MH - *Metabolic Syndrome/complications MH - Retrospective Studies MH - Phosphatidylinositol 3-Kinases/metabolism MH - Neoplasm Recurrence, Local/pathology MH - Obesity/complications MH - Biomarkers, Tumor/metabolism OTO - NOTNLM OT - Breast cancer OT - Endocrine therapy resistance OT - Metabolic syndrome OT - Obesity OT - Recurrence risk EDAT- 2022/11/18 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/17 23:41 PHST- 2022/08/03 00:00 [received] PHST- 2022/10/30 00:00 [accepted] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/17 23:41 [entrez] AID - 10.1007/s10549-022-06794-y [pii] AID - 10.1007/s10549-022-06794-y [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):307-317. doi: 10.1007/s10549-022-06794-y. Epub 2022 Nov 17. PMID- 36028065 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230113 IS - 1879-355X (Electronic) IS - 0360-3016 (Linking) VI - 115 IP - 2 DP - 2023 Feb 1 TI - Serial Measurement of Global Longitudinal Strain Among Women With Breast Cancer Treated With Proton Radiation Therapy: A Prospective Trial for 70 Patients. PG - 398-406 LID - S0360-3016(22)03141-8 [pii] LID - 10.1016/j.ijrobp.2022.08.036 [doi] AB - PURPOSE: Conventional photon radiation therapy (RT) for breast cancer is associated with a reduction in global longitudinal strain (GLS) and an increase in troponin, N-terminal pro hormone B-type natriuretic peptide (NT-proBNP), and incident heart failure. The cardiac radiation exposure with proton-RT is much reduced and thus may be associated with less cardiotoxicity. The objective was to test the effect of proton-RT on GLS, troponin, and NT-proBNP. METHODS AND MATERIALS: We conducted a prospective, observational, single-center study of 70 women being treated with proton-RT for breast cancer. Serial measurements of GLS, high-sensitivity troponin I, and NT-proBNP were performed at prespecified intervals (before proton-RT, 4 weeks after completion of proton-RT, and again at 2 months after proton-RT). RESULTS: The mean age of the patients was 46 ± 11 years, and the mean body mass index was 25.6 ± 5.2 kg/m(2); 32% of patients had hypertension, and the mean radiation doses to the heart and the left ventricle (LV) were 0.44 Gy and 0.12 Gy, respectively. There was no change in left ventricular ejection fraction (65 ± 5 vs 66 ± 5 vs 64 ± 4%; P = .15), global GLS (-21.7 ± 2.7 vs -22.7 ± 2.3 vs -22.8 ± 2.1%; P = .24), or segmental GLS from before to after proton-RT. Similarly, there was no change in either high-sensitivity troponin or NT-proBNP with proton-RT. However, in a post hoc subset analysis, women with hypertension had a greater decrease in GLS after proton-RT compared with women without hypertension (-21.3 ± 3.5 vs -24.0 ± 2.4%; P = .006). CONCLUSIONS: Proton-RT did not affect LV function and was not associated with an increase in biomarkers. These data support the potential cardiac benefits of proton-RT compared with conventional RT. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Hassan, Malek Z O AU - Hassan MZO AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardiology Department, Royal Papworth Hospital, Trumpington, Cambridge, United Kingdom. Electronic address: malek.hassan@nhs.net. FAU - Awadalla, Magid AU - Awadalla M AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardiology Department, Morriston Hospital, Swansea, Wales, United Kingdom. FAU - Tan, Timothy C AU - Tan TC AD - Division of Cardiology, Westmead and Blacktown Hospitals, University of Western Sydney and School of Medical Sciences, University of New South Wales, Australia. FAU - Scherrer-Crosbie, Marielle AU - Scherrer-Crosbie M AD - Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Philadelphia. FAU - Bakar, Rula Bany AU - Bakar RB AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Drobni, Zsofia D AU - Drobni ZD AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Zarif, Azmaeen AU - Zarif A AD - Cardiology Department, Royal Papworth Hospital, Trumpington, Cambridge, United Kingdom. FAU - Gilman, Hannah K AU - Gilman HK AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Supraja, Sama AU - Supraja S AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Nikolaidou, Sofia AU - Nikolaidou S AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Zhang, Lili AU - Zhang L AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Zlotoff, Daniel A AU - Zlotoff DA AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Hickey, Shea B AU - Hickey SB AD - Radiation Oncology Department, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Patel, Sagar A AU - Patel SA AD - Radiation Oncology Department, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Januzzi, James L AU - Januzzi JL AD - Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston. FAU - Keane, Florence AU - Keane F AD - Radiation Oncology Department, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Passeri, Jonathon J AU - Passeri JJ AD - Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston. FAU - Neilan, Tomas G AU - Neilan TG AD - Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Cardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - MacDonald, Shannon M AU - MacDonald SM AD - Radiation Oncology Department, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Jimenez, Rachel B AU - Jimenez RB AD - Radiation Oncology Department, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. LA - eng PT - Journal Article PT - Observational Study DEP - 20220824 PL - United States TA - Int J Radiat Oncol Biol Phys JT - International journal of radiation oncology, biology, physics JID - 7603616 RN - 0 (Biomarkers) RN - 0 (Peptide Fragments) RN - 0 (Protons) RN - 0 (Troponin) SB - IM MH - Adult MH - Female MH - Humans MH - Middle Aged MH - Biomarkers MH - *Breast Neoplasms/radiotherapy/drug therapy MH - Echocardiography/methods MH - Global Longitudinal Strain MH - *Hypertension MH - Peptide Fragments MH - Prospective Studies MH - Protons MH - Stroke Volume MH - Troponin/therapeutic use MH - *Ventricular Dysfunction, Left MH - Ventricular Function, Left EDAT- 2022/08/27 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/08/26 19:25 PHST- 2022/06/07 00:00 [received] PHST- 2022/08/08 00:00 [revised] PHST- 2022/08/11 00:00 [accepted] PHST- 2022/08/27 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/08/26 19:25 [entrez] AID - S0360-3016(22)03141-8 [pii] AID - 10.1016/j.ijrobp.2022.08.036 [doi] PST - ppublish SO - Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):398-406. doi: 10.1016/j.ijrobp.2022.08.036. Epub 2022 Aug 24. PMID- 36255336 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1537-453X (Electronic) IS - 0277-3732 (Linking) VI - 46 IP - 1 DP - 2023 Jan 1 TI - Accelerated Partial Breast Irradiation: An Opportunity for Therapeutic De-escalation. PG - 2-6 LID - 10.1097/COC.0000000000000945 [doi] AB - Partial breast irradiation (PBI) has been demonstrated to have comparable outcomes to whole breast irradiation based on multiple randomized trials with long-term follow-up. However, despite the strength of the data available, PBI remains underutilized despite being an appropriate option for many women diagnosed with early-stage breast cancer. This is significant, as PBI offers the potential to reduce toxicities and shorten treatment duration without impacting outcomes; in addition, for low-risk patients, PBI alone is being investigated as an alternative to endocrine therapy alone. Modern PBI can be delivered with multiple techniques, and advances in treatment planning have allowed for improved therapeutic ratios compared with earlier techniques; one such approach is utilizing stereotactic body radiation therapy approaches allowing for smaller target margins and therefore lower breast doses. Moving forward, studies are ongoing evaluating the use of radiation alone including PBI as compared with endocrine therapy alone, with prospective studies evaluating stereotactic body radiation therapy. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Shah, Chirag AU - Shah C AD - Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. FAU - Leonardi, Maria C AU - Leonardi MC AD - Department of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milano, Italy. LA - eng PT - Journal Article DEP - 20221017 PL - United States TA - Am J Clin Oncol JT - American journal of clinical oncology JID - 8207754 SB - IM MH - Female MH - Humans MH - Prospective Studies MH - *Breast Neoplasms/radiotherapy/surgery MH - *Radiosurgery MH - Mastectomy, Segmental MH - Thorax EDAT- 2022/10/19 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/10/18 10:22 PHST- 2022/10/19 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/10/18 10:22 [entrez] AID - 00000421-990000000-00039 [pii] AID - 10.1097/COC.0000000000000945 [doi] PST - ppublish SO - Am J Clin Oncol. 2023 Jan 1;46(1):2-6. doi: 10.1097/COC.0000000000000945. Epub 2022 Oct 17. PMID- 36318381 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. PG - 51-56 LID - 10.1007/s10549-022-06780-4 [doi] AB - Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor monotherapy in germline BRCA1 and BRCA2 mutation-associated metastatic breast cancer is a well-tolerated and an effective therapeutic strategy, however, the durability of response can be limited. Checkpoint inhibitors targeting the PD-1/PD-L1 axis as monotherapy in metastatic triple-negative breast cancer (mTNBC) have a limited role due to low response rates, but are capable of long, durable responses. Combination PARP inhibition with checkpoint blockade is an emerging area of investigation with potential synergy to produce robust responses with durability. Mechanistically, PARP inhibition activates the stimulator of interferon gene (STING) pathway to promote dendritic cell and T lymphocyte recruitment, increases tumor neoantigens, and upregulates PD-L1 expression to increase the immunogenicity of the tumor and thereby potentially enhance responses to immunotherapy. Several clinical trials have reported early results on PARP inhibitor and PD-1/PD-L1 checkpoint inhibitor combinations. All studies have shown safety and tolerability of this combination regimen. In advanced breast cancer associated with a germline BRCA1 or BRCA2 mutation, response rates have been high and similar to what is observed with PARP inhibitor monotherapy. Additional follow-up is needed to see if combination with a checkpoint inhibitor can lead to a clinically meaningful extension of durability of response in patients with germline mutations in BRCA1 and BRCA2. In unselected mTNBC in the 1st-3rd line setting, response rates of combined PARP inhibitor and PD-1/PD-L1 inhibitors have ranged from 18-21%, with higher rates of response among those with alterations in homologous recombination DNA repair pathway genes. Multiple ongoing studies will report additional data on combinations of PARP inhibitors and checkpoint blockade in the future and this combination strategy remains an active area of investigation. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Gupta, Tanya AU - Gupta T AUID- ORCID: 0000-0003-0698-9350 AD - Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. tanyag@stanford.edu. FAU - Vinayak, Shaveta AU - Vinayak S AD - Division of Oncology, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington, Seattle, WA, USA. FAU - Telli, Melinda AU - Telli M AD - Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. LA - eng PT - Journal Article PT - Review DEP - 20221101 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (Poly(ADP-ribose) Polymerase Inhibitors) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (B7-H1 Antigen) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Antineoplastic Agents) RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA2 protein, human) RN - 0 (BRCA2 Protein) SB - IM MH - Humans MH - Female MH - Poly(ADP-ribose) Polymerase Inhibitors/pharmacology/therapeutic use MH - *Triple Negative Breast Neoplasms/drug therapy/genetics MH - *Breast Neoplasms/pathology MH - Immune Checkpoint Inhibitors/pharmacology/therapeutic use MH - B7-H1 Antigen/genetics/metabolism MH - Programmed Cell Death 1 Receptor/metabolism MH - *Antineoplastic Agents/therapeutic use MH - BRCA1 Protein/genetics MH - Germ-Line Mutation MH - BRCA2 Protein/genetics OTO - NOTNLM OT - BRCA1 OT - BRCA2 OT - Checkpoint inhibitor OT - Homologous recombination deficiency OT - PARP inhibitor OT - PD-1 OT - PD-L1 OT - STING pathway EDAT- 2022/11/02 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/01 12:20 PHST- 2021/06/06 00:00 [received] PHST- 2022/10/14 00:00 [accepted] PHST- 2022/11/02 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/01 12:20 [entrez] AID - 10.1007/s10549-022-06780-4 [pii] AID - 10.1007/s10549-022-06780-4 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):51-56. doi: 10.1007/s10549-022-06780-4. Epub 2022 Nov 1. PMID- 34957911 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1538-0254 (Electronic) IS - 0739-1102 (Linking) VI - 41 IP - 3 DP - 2023 Feb TI - Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach. PG - 897-911 LID - 10.1080/07391102.2021.2014972 [doi] AB - Breast cancer is the most common cancer among women around the world. Human Epidermal growth factor Receptor-2 (HER2) is a membrane tyrosine kinase overexpressed in 30% of human breast cancers; thus, it serves as an important drug target. Currently available HER2 inhibitor lapatinib targets the ATP binding site of the cytoplasmic kinase domain, blocking autophosphorylation and activation of HER-2. However, it causes side effects like diarrhea, nausea, rash and possible liver toxicity. As phytochemicals have fewer side effects and are relatively affordable, they offer an effective alternative. Hence, we aimed to identify potential phytochemicals that could act as HER2 inhibitors employing computational methods such as molecular docking, molecular dynamic simulation, and ADMET prediction. Out of 1500 phytochemicals docked to the ATP binding site of the HER2 kinase domain, luxenchalcone, rhinacanthin Q, subtrifloralacton D, and 7,7″-dimethyllanaraflavone exhibited higher binding affinity than the reference inhibitor and satisfied the Lipinski's rule of five. Analysis of molecular dynamics simulation trajectory showed that Rhinacanthin Q, subtrifloralacton D, and 7,7″-dimethyllanaraflavone formed a stable and compact complex without vast conformational fluctuations. MM/PBSA binding free energy analysis revealed that Rhinacanthin Q, subtrifloralacton D, and 7,7″-dimethyllanaraflavone have high binding affinity to HER2. Therefore, Rhinacanthin Q, subtrifloralacton D, and 7,7″-dimethyllanaraflavone could be potential bioactive molecules to act as inhibitor of HER2 protein. Eventually, experimental studies are needed to evaluate the potentials of these phytochemicals further. The development of drug for HER2 positive breast cancer could be accelerated with the findings of our research. Communicated by Ramaswamy H. Sarma. FAU - Lamichhane, Sudarshan AU - Lamichhane S AUID- ORCID: 0000-0002-5773-8984 AD - Department of Biotechnology, Kathmandu University, Dhulikhel, Nepal. FAU - Rai, Raj Prateek AU - Rai RP AD - Department of Biotechnology, Kathmandu University, Dhulikhel, Nepal. FAU - Khatri, Amar AU - Khatri A AD - Department of Biotechnology, Kathmandu University, Dhulikhel, Nepal. FAU - Adhikari, Rajendra AU - Adhikari R AUID- ORCID: 0000-0001-6649-7097 AD - Department of Physics, Kathmandu University, Dhulikhel, Nepal. FAU - Shrestha, Bhupal Govinda AU - Shrestha BG AUID- ORCID: 0000-0003-3909-6647 AD - Department of Biotechnology, Kathmandu University, Dhulikhel, Nepal. FAU - Shrestha, Simon Kumar AU - Shrestha SK AUID- ORCID: 0000-0003-3339-7684 AD - Department of Biotechnology, Kathmandu University, Dhulikhel, Nepal. LA - eng PT - Journal Article DEP - 20211226 PL - England TA - J Biomol Struct Dyn JT - Journal of biomolecular structure & dynamics JID - 8404176 RN - 0 (rhinacanthin Q) RN - 0 (Antineoplastic Agents) RN - 8L70Q75FXE (Adenosine Triphosphate) RN - 0 (Phytochemicals) SB - IM MH - Humans MH - Female MH - Molecular Docking Simulation MH - Early Detection of Cancer MH - *Antineoplastic Agents/chemistry MH - *Breast Neoplasms/drug therapy/metabolism MH - Molecular Dynamics Simulation MH - Adenosine Triphosphate MH - Phytochemicals/pharmacology/therapeutic use OTO - NOTNLM OT - Breast cancer OT - HER2 OT - molecular docking OT - molecular dynamics simulation OT - phytochemicals EDAT- 2021/12/28 06:00 MHDA- 2023/01/11 06:00 CRDT- 2021/12/27 08:42 PHST- 2021/12/28 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2021/12/27 08:42 [entrez] AID - 10.1080/07391102.2021.2014972 [doi] PST - ppublish SO - J Biomol Struct Dyn. 2023 Feb;41(3):897-911. doi: 10.1080/07391102.2021.2014972. Epub 2021 Dec 26. PMID- 36307055 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230111 IS - 1569-8041 (Electronic) IS - 0923-7534 (Linking) VI - 34 IP - 1 DP - 2023 Jan TI - Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. PG - 33-47 LID - S0923-7534(22)04193-X [pii] LID - 10.1016/j.annonc.2022.10.004 [doi] FAU - Sessa, C AU - Sessa C AD - Medical Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland. FAU - Balmaña, J AU - Balmaña J AD - Medical Oncology Hospital Vall d'Hebron and Hereditary Cancer Genetics Group, Vall d'Hebron Institut of Oncology, Barcelona, Spain. FAU - Bober, S L AU - Bober SL AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute/Harvard Medical School, Boston, USA. FAU - Cardoso, M J AU - Cardoso MJ AD - Champalimaud Foundation, Breast Unit and Faculdade de Medicina, Lisbon, Portugal. FAU - Colombo, N AU - Colombo N AD - Department of Gynecologic Oncology, Istituto Europeo di Oncologia e IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. FAU - Curigliano, G AU - Curigliano G AD - Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy. FAU - Domchek, S M AU - Domchek SM AD - Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA. FAU - Evans, D G AU - Evans DG AD - Manchester Centre for Genomic Medicine, Division of Evolution Infection and Genomic Sciences, University of Manchester, MAHSC, Manchester, UK; Manchester Centre for Genomic Medicine, MAHSC, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK. FAU - Fischerova, D AU - Fischerova D AD - Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. FAU - Harbeck, N AU - Harbeck N AD - Breast Center, Department of Obstetrics & Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany. FAU - Kuhl, C AU - Kuhl C AD - Department of Diagnostic and Interventional Radiology, University Hospital Aachen, University Hospital Aachen (UKA), RWTH Aachen, Germany. FAU - Lemley, B AU - Lemley B AD - KIU - Patient Organisation for Women with Gynaecological Cancer, Copenhagen, Denmark; Clinical Trials Project, ESGO ENGAGe, Prague, Czech Republic. FAU - Levy-Lahad, E AU - Levy-Lahad E AD - Medical Genetics Institute, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. FAU - Lambertini, M AU - Lambertini M AD - Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. FAU - Ledermann, J A AU - Ledermann JA AD - Department of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, UK. FAU - Loibl, S AU - Loibl S AD - GBG Forschungs GmbH, Neu-Isenburg, Germany. FAU - Phillips, K-A AU - Phillips KA AD - Department of Medical Oncology, Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. FAU - Paluch-Shimon, S AU - Paluch-Shimon S AD - Sharett Institute of Oncology Department, Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel. CN - ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org LA - eng PT - Practice Guideline DEP - 20221025 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology JID - 9007735 RN - Breast Cancer, Familial SB - IM MH - Humans MH - Female MH - Early Detection of Cancer MH - *Breast Neoplasms/diagnosis/genetics/prevention & control MH - *Neoplastic Syndromes, Hereditary MH - *Ovarian Neoplasms/diagnosis/epidemiology/genetics MH - Risk Reduction Behavior MH - Genetic Predisposition to Disease OTO - NOTNLM OT - BRCA OT - ESMO Clinical Practice Guideline OT - hereditary breast and ovarian cancer syndromes OT - risk reduction COIS- Disclosure CS has reported non-remunerated activities as Coordinator Gynecological Programme for the European School of Oncology. JB has reported fees for advisory board membership for AstraZeneca and Pfizer; fees paid to her institute for roles as local principal investigator for AstraZeneca, MedSire and Pfizer. SLB has reported fees as an author for UpToDate. She has also reported non-remunerated activities as the chair of the Scientific Network on Female Sexual Health and Cancer (academic organisation). MJC has reported fees as an invited speaker for Roche (industry-sponsored symposium in National Conference). She has also reported non-remunerated activities as a member of the Board of Directors of EUSOMA, faculty member of ESO, project lead/lead investigator for the Breast Research Group of INESC TEC and President of MAMA Help (non-profit association for breast cancer patients in Portugal). She serves as a Specialty Editor for The Breast. NC has reported fees for advisory board membership for AstraZeneca, BIOCAD, Clovis Oncology, Eisai, GlaxoSmithKline (GSK), ImmunoGen, Mersana, Merck Sharp & Dohme (MSD)/Merck, Nuvation Bio, OncXerna, Pfizer, PharmaMar, Pieris and Roche; fees as an invited speaker for AstraZeneca, Clovis Oncology, GSK and MSD/Merck; institutional research grants from AstraZeneca, PharmaMar and Roche. She has also reported non-remunerated activities as member of the ESMO Guidelines Steering Committee and chair of the Scientific Committee of Alleanza contro il Tumore Ovarico (ACTO). GC has reported fees for advisory board membership for AstraZeneca, Bristol Myers Squibb (BMS), Celcuity, Daiichi Sankyo, Ellipsis, Exact Sciences, Lilly, Merck, Pfizer, Roche and Veracyte; fees as an invited speaker for AstraZeneca, Daiichi Sankyo, Novartis, Pfizer and Roche; fees for a writing engagement from Pfizer; institutional research grant from Merck for an investigator-initiated trial; institutional funding for phase I studies from Astellas, AstraZeneca, Blueprint Medicine, BMS, Daiichi Sankyo, Kymab, Novartis, Philogen, Relay Therapeutics, (coordinating principal investigator), Roche and Sanofi. He has also reported non-remunerated activities as an Italian National Health Council as Advisor for Ministry of Health (Consiglio Superiore di Sanità), member of the Scientific Council for the patient advocacy association Europa Donna, advisory role at the Fondazione Beretta cancer research foundation, member of the Board of Directors for Lega Italian Lotta ai Tumori (public national company for cancer prevention) and member of the Advisory Council of EUSOMA. SMD has reported personal honoraria from AstraZeneca, BMS and Clovis; fees paid to her institute as coordinating principal investigator for AstraZeneca. DGE has reported fees for advisory board membership for Recursion, SpringWorks and Syantra; consultancy fees for a writing engagement for AstraZeneca. DF has declared no conflicts of interest. NH has reported fees for advisory board membership for Aptitude Health, AstraZeneca, Daiichi Sankyo, Gilead, Novartis, Pfizer, Roche, Sandoz-Hexal, Sanofi and SeaGen; fees as an invited speaker for Art Tempi, AstraZeneca, Daiichi Sankyo, Exact Sciences, Gilead, Lilly, Medscape, MSD, Novartis, Onkowissen, Pierre Fabre, Roche, Sanofi and SeaGen; institutional funding from AstraZeneca, BMS, Daiichi Sankyo, Lilly, MSD, Novartis, Palleos, Pierre Fabre, Roche, SeaGen, TRIO and WSG; ownership interest in the West German Study Group. She has also reported non-remunerated activities as a member of the AGO Breast Guideline Committee and member of the ESO/ESCO Breast Cancer Educational Programs. She is the Founding Editor of the Breast Care journal. CK has reported fees for advisory board membership for Guerbet; fees as an invited speaker for Bayer and Bracco. BL has reported fees received from the Rising Tide Foundation as a patient reviewer. She has also reported non-remunerated activities as a member of the European Society of Gynaecological Oncology (ESGO) ENGAGe (Past Executive Board Member) and chair of KIU—Danish Patient Organisation for Women with Gynaecological Cancer. ELL has reported employment as the Director of the Medical Genetics Institute of the Shaare Zedek Medical Center. She has also reported non-remunerated activity as the vice president of the Israel National Academy of Science in Medicine (non-profit). ML has reported fees for advisory board membership and speaker fees for AstraZeneca, Exact Sciences, Gilead, Lilly, MSD, Novartis, Roche and SeaGen; fees as an invited speaker for Ipsen, Knight, Libbs, Pfizer, Sandoz, SeaGen and Takeda. JAL has reported fees for advisory board membership for Artios Pharma, AstraZeneca, BMS, Clovis Oncology, Eisai, Ellipses, GSK, ImmunoGen, Merck/MSD, Nuvation, Pfizer and VBL Therapeutics; speaker fees from AstraZeneca, Clovis Oncology, GSK and Neopharm; fees related to an independent data monitoring committee for Regeneron; institutional research grants from AstraZeneca, Clovis Oncology, Eisai, GSK, MSD/Merck and Pfizer. He has also reported non-remunerated activities as vice president of the European Society of Gynaecological Oncology (2019-2021). He serves as an associate editor of Therapeutic Advances in Medical Oncology (Sage Publishing). SL has reported fees paid to her institute for advisory board membership for AbbVie, Amgen, AstraZeneca, BMS, Celgene, DSI, EirGenix, Gilead, GSK, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Relay Therapeutics, Roche, Sanofi and SeaGen; fees paid to her institute as an invited speaker for AstraZeneca, DSI, Gilead, Novartis, Pfizer and Roche; employment as the Chief Executive officer (CEO) of GBG Forschungs GmbH; licensing fees paid to her institute by VM Scope GmbH; research grants to her institute from AstraZeneca, Celgene, Daiichi Sankyo, Immunomedics/Gilead, Novartis, Pfizer and Roche; institutional funding from AbbVie and Molecular Health; fees paid to her institute as principal investigator (Penelope/Padma) from Pfizer; fees paid to her institute from AstraZeneca (SC Capitello), Daiichi Sankyo (SC Destiny B05), Immunomedics/Gilead (SC ASCENT), Novartis (SC SOLAR1), Pfizer (SC PALOMA3), Roche (SC Inavo and SC Katherine), SeaGen (SC HERCLIMB). She has also reported non-remunerated activities as principal investigator for Aphinity, advisory role to Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Kommission Mamma (group in Germany responsible for breast cancer guidelines), membership of AGO, Deutsche Krebsgesellschaft (DKG), American Society of Clinical Oncology (ASCO) and ESMO including membership of the ESMO Guidelines Committee and past chair of the ESMO Breast Congress. She has reported institutional patents for which she has no financial interests: EP14153692.0, EP21152186.9, EP15702464.7, EP19808852.8. K-AP has reported non-remunerated activities as advisory board member for AstraZeneca, Scientific Advisory Committee member for Breast Cancer Trials, project lead in Australia for the DECRESENDO and OlympiA studies, member of the Expert Advisory Group on Cancer Clusters for the Victorian Department of Health and Human Services, Strategic Advisory Committee member for Breast Cancer Network Australia, Cancer Genetics Reference Committee Member for New South Wales Cancer Institute; advisory role on the register of experts for breast and hereditary cancer for the Medical Oncology Group of Australia and breast cancer optimal care pathway committee member for Cancer Council Victoria. She is also a leadership fellow of the National Health and Medical Research Council (Australia) and a practitioner fellow of the National Breast Cancer Foundation (Australia). SP-S has reported fees paid to her institute for advisory board membership for AstraZeneca, Eli Lilly, Exact Sciences, Medison, Pfizer and Roche; fees paid to her institute as an invited speaker for AstraZeneca, Eli Lilly, Exact Sciences, Medison, Novartis, Pfizer and Roche; fees paid to her institute for consultancy for Medison; personal and institutional research grant for an request for proposal for independent research put out by Shared Progress in Cancer Care and Pfizer. EDAT- 2022/10/29 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/10/28 19:27 PHST- 2022/07/11 00:00 [received] PHST- 2022/10/05 00:00 [revised] PHST- 2022/10/06 00:00 [accepted] PHST- 2022/10/29 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/10/28 19:27 [entrez] AID - S0923-7534(22)04193-X [pii] AID - 10.1016/j.annonc.2022.10.004 [doi] PST - ppublish SO - Ann Oncol. 2023 Jan;34(1):33-47. doi: 10.1016/j.annonc.2022.10.004. Epub 2022 Oct 25. PMID- 36400971 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 1476-5594 (Electronic) IS - 0950-9232 (Linking) VI - 42 IP - 3 DP - 2023 Jan TI - GPER-mediated stabilization of HIF-1α contributes to upregulated aerobic glycolysis in tamoxifen-resistant cells. PG - 184-197 LID - 10.1038/s41388-022-02506-4 [doi] AB - Tamoxifen is a first-line therapeutic drug for oestrogen-receptor positive breast cancer; however, like other therapeutics, its clinical use is limited by acquired resistance. Tamoxifen-resistant cells have demonstrated enhanced aerobic glycolysis; however, the mechanisms underlying this upregulation remain unclear. Here, we demonstrated that G-protein coupled oestrogen receptor (GPER) was involved in the upregulation of aerobic glycolysis via induction of hypoxia-inducible factor-1α (HIF-1α) expression and transcriptional activity in tamoxifen-resistant cells. Additionally, GPER stabilized HIF-1α through inhibiting its hydroxylation and ubiquitin-mediated degradation, which were associated with upregulation of C-terminal hydrolase-L1 (UCH-L1), downregulation of prolyl hydroxylase 2 (PHD2) and von Hippel-Lindau tumour suppressor protein (pVHL), induction of HIF-1α/UCH-L1 interaction, and suppression of HIF-1α/PHD2-pVHL association. The GPER/HIF-1α axis was functionally responsible for regulating tamoxifen sensitivity both in vitro and in vivo. Moreover, there was a positive correlation between GPER and HIF-1α expression in clinical breast cancer tissues, and high levels of GPER combined with nuclear HIF-1α indicated poor overall survival. High levels of the GPER/HIF-1α axis were also correlated with shorter relapse-free survival in patients receiving tamoxifen. Hence, our findings support a critical role of GPER/HIF-1α axis in the regulation of aerobic glycolysis in tamoxifen-resistant cells, offering a potential therapeutic target for tamoxifen-resistant breast cancer. CI - © 2022. The Author(s), under exclusive licence to Springer Nature Limited. FAU - Zhang, Yue AU - Zhang Y AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. FAU - Song, Yuxuan AU - Song Y AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - Translational Medicine Research Center of Guizhou Medical University, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, 550025, Guizhou, China. FAU - Ren, Shuang AU - Ren S AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - Translational Medicine Research Center of Guizhou Medical University, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, 550025, Guizhou, China. FAU - Zhang, Minqin AU - Zhang M AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - Translational Medicine Research Center of Guizhou Medical University, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, 550025, Guizhou, China. FAU - Zhang, Zhao AU - Zhang Z AD - Medical Examination Center, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, China. FAU - Fan, Shuangqin AU - Fan S AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - Translational Medicine Research Center of Guizhou Medical University, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, 550025, Guizhou, China. FAU - Liu, Xing AU - Liu X AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - Translational Medicine Research Center of Guizhou Medical University, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, 550025, Guizhou, China. FAU - Peng, Xiaoyu AU - Peng X AUID- ORCID: 0000-0001-7572-508X AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - Translational Medicine Research Center of Guizhou Medical University, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. AD - The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, 550025, Guizhou, China. FAU - Qi, Qi AU - Qi Q AUID- ORCID: 0000-0003-4460-0713 AD - MOE Key Laboratory of Tumor Molecular Biology, Clinical Translational Center for Targeted Drug, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, China. qiqikc@jnu.edu.cn. FAU - Shen, Xiangchun AU - Shen X AUID- ORCID: 0000-0002-4333-9106 AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. sxc@gmc.edu.cn. AD - Translational Medicine Research Center of Guizhou Medical University, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. sxc@gmc.edu.cn. AD - The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, 550025, Guizhou, China. sxc@gmc.edu.cn. FAU - Chen, Yan AU - Chen Y AUID- ORCID: 0000-0002-6202-4521 AD - The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. chenyan@gmc.edu.cn. AD - Translational Medicine Research Center of Guizhou Medical University, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, Guizhou, China. chenyan@gmc.edu.cn. AD - The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guizhou Medical University, Guiyang, 550025, Guizhou, China. chenyan@gmc.edu.cn. LA - eng PT - Journal Article DEP - 20221118 PL - England TA - Oncogene JT - Oncogene JID - 8711562 RN - 094ZI81Y45 (Tamoxifen) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - EC 2.3.2.27 (Von Hippel-Lindau Tumor Suppressor Protein) SB - IM MH - Humans MH - Female MH - *Tamoxifen/pharmacology MH - Hypoxia-Inducible Factor 1, alpha Subunit/genetics/metabolism MH - Neoplasm Recurrence, Local MH - Von Hippel-Lindau Tumor Suppressor Protein/genetics/metabolism MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Glycolysis EDAT- 2022/11/19 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/11/18 23:51 PHST- 2022/04/22 00:00 [received] PHST- 2022/10/11 00:00 [accepted] PHST- 2022/10/09 00:00 [revised] PHST- 2022/11/19 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/11/18 23:51 [entrez] AID - 10.1038/s41388-022-02506-4 [pii] AID - 10.1038/s41388-022-02506-4 [doi] PST - ppublish SO - Oncogene. 2023 Jan;42(3):184-197. doi: 10.1038/s41388-022-02506-4. Epub 2022 Nov 18. PMID- 36346687 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230126 IS - 1557-3265 (Electronic) IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 29 IP - 2 DP - 2023 Jan 17 TI - Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine. PG - 389-400 LID - 10.1158/1078-0432.CCR-22-2191 [doi] AB - PURPOSE: Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical trials, including non-basal phenotype and biomarkers related to angiogenesis, stroma, and capecitabine activation genes. We aimed to validate these findings on the larger phase III GEICAM/CIBOMA clinical trial. EXPERIMENTAL DESIGN: Tumor tissues from patients with TNBC randomized to standard (neo)adjuvant chemotherapy followed by capecitabine versus observation were analyzed using a 164-gene NanoString custom nCounter codeset measuring mRNA expression. A prespecified statistical plan sought to verify the predictive capacity of PAM50 non-basal molecular subtype and tested the hypotheses that breast tumors with increased expression of (meta)genes for cytotoxic cells, mast cells, endothelial cells, PDL2, and 38 individual genes benefit from adjuvant capecitabine for distant recurrence-free survival (DRFS; primary endpoint) and overall survival. RESULTS: Of the 876 women enrolled in the GEICAM/CIBOMA trial, 658 (75%) were evaluable for analysis (337 with capecitabine and 321 without). Of these cases, 553 (84%) were profiled as PAM50 basal-like whereas 105 (16%) were PAM50 non-basal. Non-basal subtype was the most significant predictor for capecitabine benefit [HRcapecitabine, 0.19; 95% confidence interval (CI), 0.07-0.54; P < 0.001] when compared with PAM50 basal-like (HRcapecitabine, 0.9; 95% CI, 0.63-1.28; P = 0.55; Pinteraction<0.001, adjusted P value = 0.01). Analysis of biological processes related to PAM50 non-basal subtype revealed its enrichment for mast cells, extracellular matrix, angiogenesis, and features of mesenchymal stem-like TNBC subtype. CONCLUSIONS: In this prespecified correlative analysis of the GEICAM/CIBOMA trial, PAM50 non-basal status identified patients with early-stage TNBC most likely to benefit from capecitabine. CI - ©2022 The Authors; Published by the American Association for Cancer Research. FAU - Asleh, Karama AU - Asleh K AUID- ORCID: 0000-0002-2873-7253 AD - Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada. AD - Interdisciplinary Oncology Program, Faculty of Medicine, University of British Columbia, Vancouver, Canada. FAU - Lluch, Ana AU - Lluch A AUID- ORCID: 0000-0003-2766-407X AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Hospital Clínico Universitario de Valencia, Valencia, Spain. AD - Instituto de Investigación Sanitaria INCLIVA, Universidad de Valencia, Valencia, Spain. FAU - Goytain, Angela AU - Goytain A AUID- ORCID: 0000-0003-3991-8321 AD - Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada. FAU - Barrios, Carlos AU - Barrios C AUID- ORCID: 0000-0001-6021-667X AD - Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre, Brazil. AD - LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil. FAU - Wang, Xue Q AU - Wang XQ AUID- ORCID: 0000-0002-7249-1908 AD - Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada. FAU - Torrecillas, Laura AU - Torrecillas L AUID- ORCID: 0000-0003-1302-4389 AD - LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil. AD - Centro Médico Nacional 20 de Noviembre ISSSTE, CDMX, Mexico. FAU - Gao, Dongxia AU - Gao D AUID- ORCID: 0000-0002-7779-4967 AD - Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada. FAU - Ruiz-Borrego, Manuel AU - Ruiz-Borrego M AUID- ORCID: 0000-0002-1181-5622 AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Hospital Universitario Virgen del Rocío, Sevilla, Spain. FAU - Leung, Samuel AU - Leung S AUID- ORCID: 0000-0003-0138-7254 AD - Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada. FAU - Bines, José AU - Bines J AUID- ORCID: 0000-0003-2465-8854 AD - LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil. AD - National Cancer Institute (INCA), Brazil. FAU - Guerrero-Zotano, Ángel AU - Guerrero-Zotano Á AUID- ORCID: 0000-0003-0318-9120 AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Instituto Valenciano de Oncología (IVO), Valencia, Spain. FAU - García-Sáenz, Jose Ángel AU - García-Sáenz JÁ AUID- ORCID: 0000-0001-6880-0301 AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Department of Oncology and Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain. FAU - Cejalvo, Juan Miguel AU - Cejalvo JM AUID- ORCID: 0000-0002-8755-8626 AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Hospital Clínico Universitario de Valencia, Valencia, Spain. AD - Instituto de Investigación Sanitaria INCLIVA, Universidad de Valencia, Valencia, Spain. FAU - Herranz, Jesus AU - Herranz J AUID- ORCID: 0000-0002-7385-1311 AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. FAU - Torres, Roberto AU - Torres R AUID- ORCID: 0000-0002-1397-4993 AD - LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil. AD - Instituto Nacional del Cáncer, Santiago, Chile. FAU - Haba-Rodriguez, Juan de la AU - Haba-Rodriguez J AUID- ORCID: 0000-0001-5111-1702 AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain. AD - Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain. FAU - Ayala, Francisco AU - Ayala F AUID- ORCID: 0000-0001-6311-920X AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Hospital General Universitario Morales Meseguer, Murcia, Spain. FAU - Gómez, Henry AU - Gómez H AUID- ORCID: 0000-0002-3415-9701 AD - LACOG, Latin American Cooperative Oncology Group, Porto Alegre, Brazil. AD - Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru. AD - Universidad Ricardo Palma, Lima, Peru. FAU - Rojo, Federico AU - Rojo F AUID- ORCID: 0000-0001-9989-0290 AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. AD - Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain. FAU - Nielsen, Torsten O AU - Nielsen TO AUID- ORCID: 0000-0003-3769-2517 AD - Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada. FAU - Martin, Miguel AU - Martin M AUID- ORCID: 0000-0001-9237-3231 AD - GEICAM, Spanish Breast Cancer Group, Madrid, Spain. AD - Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain. AD - Instituto de Investigación Sanitaria Gregorio Marañón, Medicine Department, Universidad Complutense, Madrid, Spain. LA - eng GR - 705463/Canadian Cancer Society Research Institute (CCSRI)/ GR - Canadian Institutes of Health Research (IRSC)/ PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 6804DJ8Z9U (Capecitabine) RN - 0 (Adjuvants, Immunologic) SB - IM CIN - 1078-0432. doi: 10.1158/1078-0432.CCR-29-2-HI MH - Humans MH - Female MH - Capecitabine/therapeutic use MH - *Triple Negative Breast Neoplasms/drug therapy/genetics/pathology MH - Endothelial Cells/pathology MH - Adjuvants, Immunologic/therapeutic use MH - *Breast Neoplasms/drug therapy MH - Chemotherapy, Adjuvant MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9873250 EDAT- 2022/11/09 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/11/08 12:12 PHST- 2022/08/01 00:00 [received] PHST- 2022/10/12 00:00 [revised] PHST- 2022/11/01 00:00 [accepted] PHST- 2022/11/09 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/11/08 12:12 [entrez] AID - 710523 [pii] AID - CCR-22-2191 [pii] AID - 10.1158/1078-0432.CCR-22-2191 [doi] PST - ppublish SO - Clin Cancer Res. 2023 Jan 17;29(2):389-400. doi: 10.1158/1078-0432.CCR-22-2191. PMID- 36685664 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1524-4741 (Electronic) IS - 1075-122X (Print) IS - 1075-122X (Linking) VI - 2022 DP - 2022 TI - Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences. PG - 1447545 LID - 10.1155/2022/1447545 [doi] LID - 1447545 AB - BACKGROUND: Patients with unilateral breast cancer carrying pathogenic variants in BRCA1/2 have the option to undergo contralateral prophylactic mastectomy (CPM). However, differences in CPM use and survival outcomes following CPM are poorly understood in this high-risk population, in part due to a lack of data from contemporary clinical cohorts. The objective of this study was to evaluate post-CPM overall survival (OS) and related racial/ethnic differences in a contemporary clinical cohort. METHODS: We retrospectively reviewed the medical records of women with a personal history of unilateral breast cancer carrying pathogenic variants in BRCA1/2 who were diagnosed between 1996 and 2012. Genetic test results, self-reported demographic characteristics, and clinical factors were abstracted from electronic medical records. RESULTS: Of 144 BRCA-positive patients, the majority were White (79.2%, n = 114). Overall, 56.1% (n = 81) of all BRCA1/2 carriers chose to undergo CPM, with no racial/ethnic difference in CPM election (p = 0.78). Of 81 patients who underwent CPM, there is strong evidence of a difference in survival between the racial/ethnic groups, with White patients having the highest OS compared to non-White patients (p = 0.001). Of the 63 patients who did not undergo CPM, there is no racial/ethnic difference in overall survival (p = 0.61). In multivariable cox regression, adjusted for demographic and clinical characteristics, OS was significantly lower among non-Whites than in Whites (HR = 0.39, p = 0.04). CONCLUSIONS: Evaluation of a contemporary clinical cohort of BRCA-positive women with unilateral breast cancer showed no racial/ethnic difference in CPM use, but there was a significant difference in post-CPM overall survival. CI - Copyright © 2022 Sukh Makhnoon et al. FAU - Makhnoon, Sukh AU - Makhnoon S AUID- ORCID: 0000-0002-3380-3833 AD - Department of Behavioral Science, UT MD Anderson Cancer Center, Houston, TX, USA. FAU - Gutierrez Barrera, Angelica M AU - Gutierrez Barrera AM AUID- ORCID: 0000-0002-8582-8186 AD - Department of Breast Medical Oncology Research, UT MD Anderson Cancer Center, Houston, TX, USA. FAU - Bassett, Roland AU - Bassett R AUID- ORCID: 0000-0002-4534-2042 AD - Department of Biostatistics, UT MD Anderson Cancer Center, Houston, TX, USA. FAU - Afrough, Aimaz AU - Afrough A AD - Department of Internal Medicine, Hematology/Oncology, UT Southwestern Medical Center, Dallas, TX, USA. FAU - Bedrosian, Isabelle AU - Bedrosian I AUID- ORCID: 0000-0002-8775-8361 AD - Department of Breast Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. FAU - Arun, Banu K AU - Arun BK AUID- ORCID: 0000-0002-5475-8509 AD - Department of Breast Medical Oncology Research, UT MD Anderson Cancer Center, Houston, TX, USA. LA - eng PT - Journal Article DEP - 20221231 PL - United States TA - Breast J JT - The breast journal JID - 9505539 RN - 0 (BRCA1 protein, human) RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - Female MH - Mastectomy/methods MH - *Prophylactic Mastectomy MH - Retrospective Studies MH - *Unilateral Breast Neoplasms MH - *Breast Neoplasms/genetics/prevention & control/surgery MH - BRCA1 Protein/genetics PMC - PMC9825211 COIS- The authors declare that they have no conflicts of interest. EDAT- 2023/01/24 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/23 04:39 PHST- 2022/03/31 00:00 [received] PHST- 2022/12/13 00:00 [revised] PHST- 2022/12/24 00:00 [accepted] PHST- 2023/01/23 04:39 [entrez] PHST- 2023/01/24 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.1155/2022/1447545 [doi] PST - epublish SO - Breast J. 2022 Dec 31;2022:1447545. doi: 10.1155/2022/1447545. eCollection 2022. PMID- 36394689 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy? PG - 417-423 LID - 10.1007/s10549-022-06813-y [doi] AB - PURPOSE: Invasive lobular breast cancers (ILCs) respond poorly to neoadjuvant chemotherapy (NAC). The degree of benefit of NAC among non-classic ILC (NC-ILC) variants compared with classic ILCs (C-ILCs) is unknown. METHODS: Consecutive patients with Stage I-III ILC treated from 2003 to 2019 with NAC and surgery were identified, and grouped as C-ILC or NC-ILC as per the original surgical pathology report, with pathologist (A.G.) review performed if original categorization was unclear. A subset of similarly treated invasive ductal cancers (IDCs) was identified for comparison. Clinicopathologic characteristics and pathologic complete response (pCR) rates were evaluated. RESULTS: Of 145 patients with ILC, 101 (70%) were C-ILC and 44 (30%) were NC-ILC (IDC cohort: 1157 patients). ILC patients were older, more often cT3/T4 and cN2/N3, and less often high-grade compared to IDC patients. Those with NC-ILC were less often ER+/HER2- (55% versus 93%), and more often HER2 + (25% versus 7%) and TN (21% versus 0%, all p < 0.001). Breast pCR was more common among NC-ILC, but most frequent in IDC. Nodal pCR rates were also lowest among C-ILC patients, but similar among NC-ILC and IDC patients. On multivariable analysis, C-ILC (OR 0.09) and LVI (OR 0.51) were predictive of lack of breast pCR; non-ER+/HER2- subtypes and breast pCR were predictive of nodal pCR. When our analysis was repeated with patients stratified by receptor subtype, histology was not independently predictive of either breast or nodal pCR. CONCLUSION: NC-ILC patients were significantly more likely to achieve breast and nodal pCR compared with C-ILC patients, but when stratified by subtype, histology was not independently predictive of breast or nodal pCR. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Mamtani, Anita AU - Mamtani A AUID- ORCID: 0000-0002-5637-5667 AD - Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66 Street, New York, NY, 10065, USA. mamtana1@mskcc.org. FAU - Grabenstetter, Anne AU - Grabenstetter A AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Sevilimedu, Varadan AU - Sevilimedu V AD - Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. FAU - Morrow, Monica AU - Morrow M AD - Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66 Street, New York, NY, 10065, USA. FAU - Gemignani, Mary L AU - Gemignani ML AUID- ORCID: 0000-0003-1752-5973 AD - Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66 Street, New York, NY, 10065, USA. LA - eng GR - P30CA008748/NIH/NCI Cancer Center Support Grant/ PT - Journal Article DEP - 20221117 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - *Carcinoma, Lobular/pathology MH - *Carcinoma, Ductal, Breast/pathology MH - Neoadjuvant Therapy MH - Breast/pathology OTO - NOTNLM OT - Breast cancer OT - Classic invasive lobular cancers OT - Lobular histology OT - Neoadjuvant chemotherapy OT - Non-classic invasive lobular cancers OT - Pathologic complete response EDAT- 2022/11/18 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/17 13:56 PHST- 2022/10/03 00:00 [received] PHST- 2022/11/09 00:00 [accepted] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/17 13:56 [entrez] AID - 10.1007/s10549-022-06813-y [pii] AID - 10.1007/s10549-022-06813-y [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):417-423. doi: 10.1007/s10549-022-06813-y. Epub 2022 Nov 17. PMID- 36657923 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 2405-4577 (Electronic) IS - 2405-4577 (Linking) VI - 53 DP - 2023 Feb TI - Early nutritional intervention does not prevent long-term adverse events in women with breast cancer: A pilot study. PG - 268-273 LID - S2405-4577(22)01423-1 [pii] LID - 10.1016/j.clnesp.2022.12.013 [doi] AB - AIM: This study aims to evaluate the effect of early nutritional intervention on adverse clinical events in women with breast cancer undergoing neoadjuvant chemotherapy. DESIGN AND SETTINGS: This is a randomized clinical trial performed at the beginning of neoadjuvant chemotherapy for women with breast cancer treated at an oncology referral center (Brazil) and followed until the end of radiotherapy period, at least. Registered under ClinicalTrials.gov Identifier no. RBR-3SHHXS. METHODS: Participants were allocated to a control group - CG (nutritional guidance on healthy eating practices) or an intervention group - IC (nutritional guidance and individualized food plan). Chemotherapy toxicity (primary endpoint) was considered a precocious adverse clinical event and it was evaluated by self-reported gastrointestinal symptoms observed at any time during the first three cycles of treatment. Post-surgical complications, radiotherapy toxicity, and weight change were considered long-term adverse events. RESULTS: 34 women (19 in the IG and 15 in the CG) were evaluated. The early nutritional intervention was associated with low gastrointestinal chemotoxicity (nausea, vomiting, and constipation, p < 0.001, p < 0.048, and p < 0.024, respectively). However, there were no statically significant differences between both groups in the presence of long-term adverse events (radiotherapy toxicity-88.2% vs 76.9%, weight loss-21.1% vs 26.7% for IC and CG respectively, p > 0.05 for both). CONCLUSION: The early nutritional intervention was associated with a low frequency of precocious events, but not with long-term adverse events in women with breast cancer during treatment. CI - Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved. FAU - Denise de Lima Bezerra, Agnes AU - Denise de Lima Bezerra A AD - Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil. FAU - Matias de Sousa, Iasmin AU - Matias de Sousa I AD - Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil. FAU - Silva de Souza, Ana Priscilla AU - Silva de Souza AP AD - Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil. FAU - Miranda de Carvalho, Ana Lúcia AU - Miranda de Carvalho AL AD - Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil; Liga Norteriograndense Contra o Câncer, Natal, RN, Brazil. FAU - Trussardi Fayh, Ana Paula AU - Trussardi Fayh AP AD - Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil; Postgraduate Program in Nutrition, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil. Electronic address: ana.fayh@ufrn.br. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20221216 PL - England TA - Clin Nutr ESPEN JT - Clinical nutrition ESPEN JID - 101654592 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy/radiotherapy MH - Pilot Projects MH - Brazil OTO - NOTNLM OT - Body weight OT - Diet OT - Disease-free survival OT - Neoplasm OT - Nutrition OT - Toxicity COIS- Declaration of competing interest The authors declare no conflict of interest. EDAT- 2023/01/20 06:00 MHDA- 2023/01/24 06:00 CRDT- 2023/01/19 20:59 PHST- 2022/07/03 00:00 [received] PHST- 2022/11/24 00:00 [revised] PHST- 2022/12/12 00:00 [accepted] PHST- 2023/01/19 20:59 [entrez] PHST- 2023/01/20 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] AID - S2405-4577(22)01423-1 [pii] AID - 10.1016/j.clnesp.2022.12.013 [doi] PST - ppublish SO - Clin Nutr ESPEN. 2023 Feb;53:268-273. doi: 10.1016/j.clnesp.2022.12.013. Epub 2022 Dec 16. PMID- 36513135 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1879-016X (Electronic) IS - 0163-7258 (Linking) VI - 241 DP - 2023 Jan TI - Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer. PG - 108331 LID - S0163-7258(22)00225-X [pii] LID - 10.1016/j.pharmthera.2022.108331 [doi] AB - Triple negative breast cancer (TNBC) has the poorest prognosis compared to other breast cancer subtypes, due to a historical lack of targeted therapies and high rates of relapse. Greater insight into the components of signalling pathways in TNBC tumour cells has led to the clinical evaluation, and in some cases approval, of targeted therapies. In the last decade, G protein-coupled receptors, such as the β(2)-adrenoceptor, have emerged as potential new therapeutic targets. Here, we describe how the β(2)-adrenoceptor accelerates TNBC progression in response to stress, and the unique signalling pathway activated by the β(2)-adrenoceptor to drive the invasion of an aggressive TNBC tumour cell. We highlight evidence that supports an altered organisation of GPCRs in tumour cells, and suggests that activation of the same GPCR in a different cellular location can control unique cell responses. Finally, we speculate how the relocation of GPCRs to the "wrong" place in tumour cells presents opportunities to develop targeted anti-cancer GPCR drugs with greater efficacy and minimal adverse effects. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Lam, Terrance AU - Lam T AD - Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. FAU - Mastos, Chantel AU - Mastos C AD - Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. FAU - Sloan, Erica K AU - Sloan EK AD - Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. FAU - Halls, Michelle L AU - Halls ML AD - Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. Electronic address: michelle.halls@monash.edu. LA - eng PT - Journal Article PT - Review DEP - 20221210 PL - England TA - Pharmacol Ther JT - Pharmacology & therapeutics JID - 7905840 RN - 0 (Receptors, G-Protein-Coupled) RN - 0 (Antineoplastic Agents) RN - 0 (Receptors, Adrenergic) SB - IM MH - Humans MH - *Triple Negative Breast Neoplasms/drug therapy/metabolism MH - Neoplasm Recurrence, Local/drug therapy MH - Signal Transduction MH - Receptors, G-Protein-Coupled/metabolism MH - *Antineoplastic Agents/pharmacology/therapeutic use MH - Receptors, Adrenergic/therapeutic use OTO - NOTNLM OT - Compartmentalised signalling OT - G protein-coupled receptors OT - Intracellular receptors OT - Triple negative breast cancer COIS- Declaration of Competing Interest The authors declare that there are no conflicts of interest. EDAT- 2022/12/14 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/12/13 19:22 PHST- 2022/09/08 00:00 [received] PHST- 2022/12/05 00:00 [revised] PHST- 2022/12/07 00:00 [accepted] PHST- 2022/12/14 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/12/13 19:22 [entrez] AID - S0163-7258(22)00225-X [pii] AID - 10.1016/j.pharmthera.2022.108331 [doi] PST - ppublish SO - Pharmacol Ther. 2023 Jan;241:108331. doi: 10.1016/j.pharmthera.2022.108331. Epub 2022 Dec 10. PMID- 36694223 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1601-5223 (Electronic) IS - 0018-0661 (Print) IS - 0018-0661 (Linking) VI - 160 IP - 1 DP - 2023 Jan 25 TI - Identification of the prognostic value of Th1/Th2 ratio and a novel prognostic signature in basal-like breast cancer. PG - 2 LID - 10.1186/s41065-023-00265-0 [doi] LID - 2 AB - BACKGROUND: Breast cancer is a heterogeneous group of diseases. The polarization of CD4+ T helper (Th) lymphocytes (mainly Th1 and Th2) may differ in breast cancers with different outcomes, but this has not been fully validated. METHODS: This study is a bioinformatic analysis, in which differentially expressed genes (DEGs) were identified in patients with low and high Th1/Th2 ratios. And then, DEG functions, hub genes and independent predictors were determined. RESULTS: Low Th1/Th2 ratio was associated with poor outcome in Luminal A and basal-like breast cancer (p < 0.05). GSEA and KEGG analysis of DEGs obtained from comparing low and high Th1/Th2 ratios illuminated downregulation of immune-related gene sets and pathways affecting Th1/Th2 balance toward Th2 polarization (p < 0.05). Survival and Cox analyses of all the DEGs confirmed CCL1 and MYH6 were independent protective factors and IFNK and SOAT2 were independent risk factors for basal-like breast cancer (95%CI: 1.06-2.5, p = 0.026). Then a four-gene signature was constructed and achieved a promising prognostic value (C-index = 0.82; AUC = 0.826). CONCLUSIONS: Low Th1/Th2 ratio predicts poor outcome in Luminal A and Basal-like breast cancer, and downregulation of immune-related gene sets and pathways contribute to Th1/Th2 balance toward Th2 polarization. CCL1, MYH6, IFNK, and SOAT2 have an independent prognostic value of survival outcome and might be novel markers in basal-like breast cancer. CI - © 2023. The Author(s). FAU - Xiao, Yu AU - Xiao Y AD - Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi, China. AD - Department of Thyroid and Breast Surgery, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China. FAU - Huang, Yi AU - Huang Y AD - Department of Research, Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi, China. FAU - Jiang, Jianping AU - Jiang J AD - Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi, China. FAU - Chen, Yan AU - Chen Y AD - Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi, China. FAU - Wei, Changyuan AU - Wei C AD - Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi, China. changyuanwei@gxmu.edu.cn. LA - eng GR - 2020GXNSFAA297152/Natural Science Foundation of Guangxi Province/ PT - Journal Article DEP - 20230125 PL - England TA - Hereditas JT - Hereditas JID - 0374654 SB - IM MH - Humans MH - Female MH - *Th2 Cells/metabolism MH - Th1 Cells/metabolism MH - Prognosis MH - *Breast Neoplasms/genetics/metabolism PMC - PMC9875389 OTO - NOTNLM OT - Basal-like OT - Bioinformatic analysis OT - Breast cancer OT - Prognostic model OT - Th1/Th2 balance COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/25 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/24 23:38 PHST- 2022/07/18 00:00 [received] PHST- 2023/01/12 00:00 [accepted] PHST- 2023/01/24 23:38 [entrez] PHST- 2023/01/25 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.1186/s41065-023-00265-0 [pii] AID - 265 [pii] AID - 10.1186/s41065-023-00265-0 [doi] PST - epublish SO - Hereditas. 2023 Jan 25;160(1):2. doi: 10.1186/s41065-023-00265-0. PMID- 36678170 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 15 IP - 2 DP - 2023 Jan 6 TI - A Randomized Controlled Trial of Soy Isoflavone Intake on Mammographic Density among Malaysian Women. LID - 10.3390/nu15020299 [doi] LID - 299 AB - Soy intake is associated with lower breast cancer risk in observational studies concerning Asian women, however, no randomized controlled trials (RCT) have been conducted among Asian women living in Asia. This three-armed RCT assessed the effects of one-year soy isoflavone (ISF) intervention on mammographic density (MD) change among healthy peri- and postmenopausal Malaysian women. This study was registered at ClinicalTrials.gov (NCT03686098). Participants were randomized into the 100 mg/day ISF Supplement, 50 mg/day ISF Diet, or control arm, and assessed for change in absolute and relative dense area from digital mammograms conducted at enrolment and after 12 months, compared over time across study arms using Kruskal-Wallis tests. Out of 118 women enrolled, 91 women completed the intervention, while 27 women (23%) were lost in follow up. The ISF supplement arm participants observed a larger decline in dense area (-1.3 cm(2)), compared to the ISF diet (-0.5 cm(2)) and control arm (-0.8 cm(2)), though it was not statistically significant (p = 0.48). Notably, among women enrolled within 5 years of menopause; dense area declined by 6 cm(2) in the ISF supplement arm, compared to <1.0 cm(2) in the control arm (p = 0.13). This RCT demonstrates a possible causal association between soy ISF intake and MD, a biomarker of breast cancer risk, among Asian women around the time of menopause, but these findings require confirmation in a larger trial. FAU - Rajaram, Nadia AU - Rajaram N AD - Cancer Research Malaysia, Subang Jaya 47500, Malaysia. FAU - Yap, Beverley AU - Yap B AUID- ORCID: 0000-0001-8459-5969 AD - Cancer Research Malaysia, Subang Jaya 47500, Malaysia. FAU - Eriksson, Mikael AU - Eriksson M AUID- ORCID: 0000-0001-8135-4270 AD - Karolinska Institutet, 171 77 Stockholm, Sweden. FAU - Mariapun, Shivaani AU - Mariapun S AD - Cancer Research Malaysia, Subang Jaya 47500, Malaysia. FAU - Tan, Lee Mei AU - Tan LM AD - Cancer Research Malaysia, Subang Jaya 47500, Malaysia. FAU - Sa'at, Hamizah AU - Sa'at H AD - University of Malaya Cancer Research Institute, Kuala Lumpur 50603, Malaysia. FAU - Ho, Evelyn Lai Ming AU - Ho ELM AUID- ORCID: 0000-0002-4900-610X AD - ParkCity Medical Centre, Ramsay Sime Darby Healthcare, Kuala Lumpur 52200, Malaysia. FAU - Taib, Nur Aishah Mohd AU - Taib NAM AD - University of Malaya Cancer Research Institute, Kuala Lumpur 50603, Malaysia. FAU - Khor, Geok Lin AU - Khor GL AUID- ORCID: 0000-0002-4691-6319 AD - Department of Nutrition and Dietetics, Universiti Putra Malaysia, Serdang 43400, Malaysia. FAU - Yip, Cheng Har AU - Yip CH AD - Cancer Research Malaysia, Subang Jaya 47500, Malaysia. AD - Subang Jaya Medical Centre, Ramsay Sime Darby Healthcare, Subang Jaya 47500, Malaysia. FAU - Ho, Weang Kee AU - Ho WK AD - Cancer Research Malaysia, Subang Jaya 47500, Malaysia. AD - Department of Applied Mathematics, Faculty of Engineering, University of Nottingham Malaysia, Semenyih 43500, Malaysia. FAU - Hall, Per AU - Hall P AUID- ORCID: 0000-0002-5640-9126 AD - Karolinska Institutet, 171 77 Stockholm, Sweden. AD - Södersjukhuset, 118 83 Stockholm, Sweden. FAU - Teo, Soo Hwang AU - Teo SH AD - Cancer Research Malaysia, Subang Jaya 47500, Malaysia. AD - University of Malaya Cancer Research Institute, Kuala Lumpur 50603, Malaysia. LA - eng SI - ClinicalTrials.gov/NCT03686098 GR - Charitable Funds/Sime Darby Ladies Pro Golf Tournament/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20230106 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 RN - 0 (Isoflavones) SB - IM MH - Female MH - Humans MH - Breast Density MH - *Isoflavones/pharmacology MH - Breast/diagnostic imaging MH - *Breast Neoplasms/diagnostic imaging/prevention & control MH - Mammography PMC - PMC9862880 OTO - NOTNLM OT - Soy isoflavones OT - breast cancer OT - mammographic density OT - randomized controlled trial COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:46 PHST- 2022/11/21 00:00 [received] PHST- 2022/12/19 00:00 [revised] PHST- 2023/01/03 00:00 [accepted] PHST- 2023/01/21 01:46 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - nu15020299 [pii] AID - nutrients-15-00299 [pii] AID - 10.3390/nu15020299 [doi] PST - epublish SO - Nutrients. 2023 Jan 6;15(2):299. doi: 10.3390/nu15020299. PMID- 36674468 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 4 TI - Cpt1c Downregulation Causes Plasma Membrane Remodelling and Anthracycline Resistance in Breast Cancer. LID - 10.3390/ijms24020946 [doi] LID - 946 AB - Breast cancer (BC) is the most common malignancy in women worldwide. While the main systemic treatment option is anthracycline-containing chemotherapy, chemoresistance continues to be an obstacle to patient survival. Carnitine palmitoyltransferase 1C (CPT1C) has been described as a poor-prognosis marker for several tumour types, as it favours tumour growth and hinders cells from entering senescence. At the molecular level, CPT1C has been associated with lipid metabolism regulation and important lipidome changes. Since plasma membrane (PM) rigidity has been associated with reduced drug uptake, we explored whether CPT1C expression could be involved in PM remodelling and drug chemoresistance. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) lipid analysis of PM-enriched fractions of MDA-MB-231 BC cells showed that CPT1C silencing increased PM phospholipid saturation, suggesting a rise in PM rigidity. Moreover, CPT1C silencing increased cell survival against doxorubicin (DOX) treatment in different BC cells due to reduced drug uptake. These findings, further complemented by ROC plotter analysis correlating lower CPT1C expression with a lower pathological complete response to anthracyclines in patients with more aggressive types of BC, suggest CPT1C as a novel predictive biomarker for BC chemotherapy. FAU - Muley, Helena AU - Muley H AUID- ORCID: 0000-0003-0979-4815 AD - Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain. FAU - Valencia, Karmele AU - Valencia K AUID- ORCID: 0000-0002-2882-7427 AD - Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain. AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain. AD - Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31008 Pamplona, Spain. FAU - Casas, Josefina AU - Casas J AD - Research Unit on Bioactive Molecules (RUBAM), Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Spanish National Research Council (CSIC), 08034 Barcelona, Spain. AD - Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain. FAU - Moreno, Bea AU - Moreno B AD - Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain. FAU - Botella, Luis AU - Botella L AD - Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain. FAU - Lecanda, Fernando AU - Lecanda F AD - Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain. AD - Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain. AD - Department of Pathology, Anatomy and Physiology, University of Navarra, 31008 Pamplona, Spain. FAU - Fadó, Rut AU - Fadó R AUID- ORCID: 0000-0002-3293-2342 AD - Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain. AD - Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, 08193 Cerdanyola del Vallès, Spain. FAU - Casals, Núria AU - Casals N AUID- ORCID: 0000-0002-6719-4300 AD - Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain. AD - Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. LA - eng GR - PID2020-114953RB-C22/Spanish Ministry of Science and Innovation (MCIN)/ GR - CB06/03/0001/Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition/ PT - Journal Article DEP - 20230104 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Anthracyclines) RN - EC 2.3.1.21 (Carnitine O-Palmitoyltransferase) SB - IM MH - Female MH - Humans MH - Anthracyclines/therapeutic use MH - *Breast Neoplasms/drug therapy/pathology MH - *Carnitine O-Palmitoyltransferase/genetics/metabolism MH - Cell Membrane/metabolism MH - Down-Regulation MH - *Drug Resistance, Neoplasm PMC - PMC9864098 OTO - NOTNLM OT - CPT1C OT - breast cancer OT - chemoresistance OT - doxorubicin OT - drug uptake OT - fatty acid saturation OT - lipid remodelling OT - plasma membrane COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:24 PHST- 2022/11/13 00:00 [received] PHST- 2022/12/21 00:00 [revised] PHST- 2022/12/31 00:00 [accepted] PHST- 2023/01/21 01:24 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijms24020946 [pii] AID - ijms-24-00946 [pii] AID - 10.3390/ijms24020946 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 4;24(2):946. doi: 10.3390/ijms24020946. PMID- 36571376 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 2045-9912 (Electronic) IS - 2045-9912 (Linking) VI - 13 IP - 3 DP - 2023 Jul-Sep TI - A randomized controlled study to compare analgesic efficacy of sublingual buprenorphine and intravenous tramadol in patients undergoing mastectomy. PG - 118-122 LID - 10.4103/2045-9912.345170 [doi] AB - Sublingual (SL) buprenorphine is approved for managing acute postoperative pain, characterized by easy administration, good pain relief and good patient compliance. We hypothesized that SL buprenorphine would be a better perioperative analgesic compared to intravenous (IV) opioids like tramadol in patients undergoing mastectomy surgery for breast cancer. After institutional ethics committee approval, we randomized 60 patients with breast cancer into 2 groups. In buprenorphine group, patients received 200 μg of SL buprenorphine thrice daily and in tramadol group patients received 100 mg of IV tramadol thrice daily. The analgesic efficacy of SL buprenorphine was comparable to that of IV tramadol. Visual Analogue Scale scores had no significant difference between the two groups at various time frames (0, 1, 3, 6, 12, 18 and 24 hours) at rest and movement except at 0 and 3 hours during movement when the score was lower in the tramadol group than the buprenorphine group. Four patients in the buprenorphine group received rescue analgesic (IV morphine 3 mg). Analgesic efficacy of SL buprenorphine appears comparable to IV tramadol for managing postoperative pain after mastectomy. SL buprenorphine can be administered sublingually, which is an advantage. FAU - Dokku, Krishna Sumanth AU - Dokku KS AD - Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India. FAU - Nair, Abhijit Sukumaran AU - Nair AS AD - Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India. FAU - Prasad Mantha, Srinivasa Shyam AU - Prasad Mantha SS AD - Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India. FAU - Naik, Vibhavari Milind AU - Naik VM AD - Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India. FAU - Saifuddin, Mohammed Salman AU - Saifuddin MS AD - Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India. FAU - Rayani, Basanth Kumar AU - Rayani BK AD - Department of Anaesthesiology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - Australia TA - Med Gas Res JT - Medical gas research JID - 101564536 RN - 39J1LGJ30J (Tramadol) RN - 40D3SCR4GZ (Buprenorphine) RN - 0 (Analgesics, Opioid) SB - IM MH - Humans MH - Female MH - *Tramadol/therapeutic use MH - *Buprenorphine/therapeutic use MH - *Breast Neoplasms/drug therapy/surgery MH - Mastectomy/adverse effects MH - Analgesics, Opioid/therapeutic use MH - Pain, Postoperative/drug therapy OTO - NOTNLM OT - acute pain OT - analgesia OT - anesthesia OT - buprenorphine OT - mastectomy OT - opioids OT - perioperative care OT - postoperative pain OT - sublingual OT - tramadol COIS- None EDAT- 2022/12/27 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/12/26 07:35 PHST- 2022/12/26 07:35 [entrez] PHST- 2022/12/27 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] AID - MedGasRes_2023_13_3_118_345170 [pii] AID - 10.4103/2045-9912.345170 [doi] PST - ppublish SO - Med Gas Res. 2023 Jul-Sep;13(3):118-122. doi: 10.4103/2045-9912.345170. PMID- 36342625 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 1559-0291 (Electronic) IS - 0273-2289 (Linking) VI - 195 IP - 2 DP - 2023 Feb TI - Phytocompounds From Edible Oil Seeds Target Hub Genes To Control Breast Cancer. PG - 1231-1254 LID - 10.1007/s12010-022-04224-9 [doi] AB - Breast cancer is one of the most commonly diagnosed cancers in woman which accounts for more than 1 in 10 new cancers in the entire world. The recently found four new potential hub genes that show a strong expression in breast cancer are CCNA2, CCNB1, MAD2L1, and RAD51. Nowadays, food habits and lifestyle of an individual are one of the factors for causing cancers. Consumption of seeds on a regular basis is the key factor for leading a good health. Sesame seeds and Sunflower seeds are few examples of cancer fighting seeds. Sesame (Sesamum indicum) is one of the earliest oil seed plant with various phytocompounds present which include lignans, tocopherols, phenolics, polyunsaturated fatty acids, and phytosterols. Sunflower (Helianthus annuus L.) is primarily harvested as an oil seed plant with various phytocompounds present which include flavonoids, phenolic acids, tocopherols, and vitamin B3. These are the few seeds that help women to prevent and also to fight against Breast cancer with its potential anti-cancer activity. The main objective of the current study is to identify the potential phytocompounds present in the cancer fighting seeds using molecular docking and dynamic simulation approach which can further help pharmaceuticals industries in producing targeted drugs against breast cancer hub genes as well as food industries in producing products combining the potential phytocompounds present in the seeds. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Kumar, Soniya Ashok AU - Kumar SA AD - School of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science & Technology, Tamil Nadu, Vandalur, Chennai, 600048, India. FAU - Mohaideen, Noorul Samsoon Maharifa Haja AU - Mohaideen NSMH AD - School of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science & Technology, Tamil Nadu, Vandalur, Chennai, 600048, India. FAU - S, Hemalatha AU - S H AUID- ORCID: 0000-0002-8150-7721 AD - School of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science & Technology, Tamil Nadu, Vandalur, Chennai, 600048, India. hemalatha.sls@bsauniv.ac.in. LA - eng PT - Journal Article DEP - 20221107 PL - United States TA - Appl Biochem Biotechnol JT - Applied biochemistry and biotechnology JID - 8208561 RN - R0ZB2556P8 (Tocopherols) RN - 0 (Phenols) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/genetics MH - Molecular Docking Simulation MH - Tocopherols/metabolism MH - Seeds/chemistry MH - Phenols/metabolism MH - *Sesamum OTO - NOTNLM OT - Anti-cancer activity OT - Breast cancer OT - Hub genes OT - Sesame seeds OT - Sunflower seeds EDAT- 2022/11/08 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/11/07 11:18 PHST- 2022/10/21 00:00 [accepted] PHST- 2022/11/08 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/11/07 11:18 [entrez] AID - 10.1007/s12010-022-04224-9 [pii] AID - 10.1007/s12010-022-04224-9 [doi] PST - ppublish SO - Appl Biochem Biotechnol. 2023 Feb;195(2):1231-1254. doi: 10.1007/s12010-022-04224-9. Epub 2022 Nov 7. PMID- 36685105 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1532-2807 (Electronic) IS - 1219-4956 (Print) IS - 1219-4956 (Linking) VI - 28 DP - 2022 TI - Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy. PG - 1610598 LID - 10.3389/pore.2022.1610598 [doi] LID - 1610598 AB - Background: The therapeutic strategy of invasive breast cancer is based on routine histopathological markers (estrogen-, progesterone receptor, HER2, Ki67) routinely evaluated in tumor cells. However, the assessment of cancer stroma could influence therapeutic strategies. Studies have shown that stromal expression of CD10, a zinc-dependent metalloproteinase, is associated with biological aggressiveness of the tumor. In the present retrospective study, we aimed to evaluate stromal CD10 expression and association between CD10 expression and response to neoadjuvant chemotherapy in invasive breast cancer. Methods: CD10 immunohistochemistry was performed on core biopsies taken before the neoadjuvant therapy. Stromal CD10 expression was determined and compared with well-known predictive and prognostic tissue markers as well as with the following groups defined according to the degree of tumor response: no regression, partial regression, and complete regression. Results: A total of 60 locally advanced invasive breast carcinomas of "no special type" were included. The proportion of CD10 positive tumors was significantly higher in the "no regression" group compared to "complete regression" group (p = 0.000). Stromal CD10 expression was found to be significantly associated with decrease in response to neoadjuvant chemotherapy. According to CD10 expression we did not find any difference in hormone receptor status, Ki67, tumor grade or neostromal area. Conclusion: Our data suggest that CD10 expression can serve as a predictive marker of the effect of neoadjuvant chemotherapy in breast cancer patients. Therefore, its inclusion into the routine assessment of biopsies to tailor tumor-specific therapeutic strategies merits consideration. CI - Copyright © 2023 Olah, Majlat, Koszo, Vereb and Voros. FAU - Olah, Orsolya AU - Olah O AD - Department of Pathology, School of Medicine, University of Szeged, Szeged, Hungary. FAU - Majlat, Edit AU - Majlat E AD - Department of Pathology, School of Medicine, University of Szeged, Szeged, Hungary. FAU - Koszo, Renata AU - Koszo R AD - Department of Oncotherapy, School of Medicine, University of Szeged, Szeged, Hungary. FAU - Vereb, Zoltan AU - Vereb Z AD - Department of Dermatology and Allergology, School of Medicine, University of Szeged, Szeged, Hungary. FAU - Voros, Andras AU - Voros A AD - Department of Pathology, School of Medicine, University of Szeged, Szeged, Hungary. LA - eng PT - Journal Article DEP - 20230105 PL - Switzerland TA - Pathol Oncol Res JT - Pathology oncology research : POR JID - 9706087 RN - 0 (Ki-67 Antigen) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Progesterone) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Neoadjuvant Therapy MH - Ki-67 Antigen/metabolism MH - Retrospective Studies MH - Prognosis MH - Receptor, ErbB-2/metabolism MH - Biomarkers, Tumor/metabolism MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Receptors, Progesterone/metabolism PMC - PMC9849231 OTO - NOTNLM OT - CD10 OT - advanced breast cancer OT - neoadjuvant therapy OT - neostroma OT - predictive factors COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/24 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/23 04:32 PHST- 2022/05/16 00:00 [received] PHST- 2022/12/16 00:00 [accepted] PHST- 2023/01/23 04:32 [entrez] PHST- 2023/01/24 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 1610598 [pii] AID - 10.3389/pore.2022.1610598 [doi] PST - epublish SO - Pathol Oncol Res. 2023 Jan 5;28:1610598. doi: 10.3389/pore.2022.1610598. eCollection 2022. PMID- 36163601 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Print) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - The feasibility of pelvic floor training to treat urinary incontinence in women with breast cancer: a telehealth intervention trial. PG - 121-130 LID - 10.1007/s12282-022-01405-6 [doi] AB - PURPOSE: To investigate the feasibility of recruiting into a pelvic floor muscle training (PFMT) program delivered via telehealth to treat urinary incontinence (UI) in women with breast cancer on aromatase inhibitors. METHODS: We conducted a pre-post single cohort clinical trial with 54 women with breast cancer. Participants underwent a 12-week PFMT program using an intra-vaginal pressure biofeedback device: femfit(®). The intervention included eight supervised individual PFMT sessions over Zoom(™) and a 12-week home exercise program. The primary outcome of this study was feasibility, specifically consent rate. Secondary outcomes which included prevalence and burden of UI measured using the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF), and pelvic floor muscle (PFM) strength measured as intravaginal squeeze pressure were compared using McNemar's and paired t tests. RESULTS: The mean age of participants was 50 years (SD ± 7.3). All women who were eligible to participate in this study consented (n = 55/55, 100%). All participants reported that the program was beneficial and tailored to their needs. The results showed a statistically significant decline in the prevalence (percentage difference 42%, 95% CI 28, 57%) and burden (ICIQ-UI SF score mean change 9.4, 95% CI 8.5, 10.4) of UI post intervention. A significant increase in PFM strength was observed post-intervention (mean change 4.8 mmHg, 95% CI 3.9, 5.5). CONCLUSION: This study indicated that PFMT delivered via telehealth may be feasible and potentially beneficial in treating stress UI in women with breast cancer. Further studies such as randomized controlled trials are required to confirm these results. CI - © 2022. The Author(s). FAU - Colombage, Udari N AU - Colombage UN AUID- ORCID: 0000-0003-0662-9363 AD - Department of Physiotherapy, Faculty of Medicine, Dentistry and Health Sciences, Melbourne School of Health Sciences, The University of Melbourne, 161 Barry St, Carlton, VIC, 3053, Australia. ucolombage@student.unimelb.edu.au. AD - Institute of Health and Wellbeing, Federation University, Churchill, VIC, Australia. ucolombage@student.unimelb.edu.au. AD - Department of Physiotherapy, Monash University, Melbourne, VIC, Australia. ucolombage@student.unimelb.edu.au. FAU - Soh, Sze-Ee AU - Soh SE AD - Department of Physiotherapy, Monash University, Melbourne, VIC, Australia. AD - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia. FAU - Lin, Kuan-Yin AU - Lin KY AD - Department of Physical Therapy, National Cheng Kung University, Tainan, Taiwan. AD - Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. FAU - Kruger, Jennifer AU - Kruger J AD - Auckland Bioengineering Institute, The University of Auckland, Auckland, New Zealand. AD - Junofem, Auckland, New Zealand. FAU - Frawley, Helena C AU - Frawley HC AD - Department of Physiotherapy, Faculty of Medicine, Dentistry and Health Sciences, Melbourne School of Health Sciences, The University of Melbourne, 161 Barry St, Carlton, VIC, 3053, Australia. AD - Allied Health Research, Mercy Hospital for Women, Melbourne, VIC, Australia. AD - Allied Health Research, Royal Women's Hospital, Melbourne, VIC, Australia. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20220926 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 SB - IM MH - Female MH - Humans MH - Middle Aged MH - *Breast Neoplasms/complications/therapy MH - Exercise Therapy/methods MH - Feasibility Studies MH - Pelvic Floor/physiology MH - Quality of Life MH - *Telemedicine MH - Treatment Outcome MH - *Urinary Incontinence/epidemiology/etiology/therapy PMC - PMC9512983 OTO - NOTNLM OT - Breast cancer OT - Pelvic floor muscle training OT - Telehealth OT - Urinary incontinence COIS- Jennifer Kruger is the CEO of JUNOFEM, the company responsible for the development of the intra-vaginal pressure biofeedback device, femfit(®), used in this study. This author was not involved in the recruitment and data collection process, and did not have any contact with study participants. EDAT- 2022/09/28 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/09/27 00:21 PHST- 2022/06/08 00:00 [received] PHST- 2022/09/14 00:00 [accepted] PHST- 2022/09/28 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/09/27 00:21 [entrez] AID - 10.1007/s12282-022-01405-6 [pii] AID - 1405 [pii] AID - 10.1007/s12282-022-01405-6 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):121-130. doi: 10.1007/s12282-022-01405-6. Epub 2022 Sep 26. PMID- 36634299 OWN - NLM STAT- MEDLINE DCOM- 20230116 LR - 20230116 IS - 2473-4284 (Electronic) IS - 2473-4284 (Linking) VI - 7 DP - 2023 Jan TI - Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing. PG - e2200415 LID - 10.1200/PO.22.00415 [doi] AB - PURPOSE: PTEN-associated clinical syndromes such as Cowden syndrome (CS) increase cancer risk and have historically been diagnosed based upon phenotypic criteria. Because not all patients clinically diagnosed with CS have PTEN pathogenic variants (PVs), and not all patients with PTEN PVs have been clinically diagnosed with CS, the cancer risk conferred by PTEN PVs calculated from cohorts of patients with clinical diagnoses of CS/CS-like phenotypes may be inaccurate. METHODS: We assessed a consecutive cohort of 727,091 individuals tested clinically for hereditary cancer risk, with a multigene panel between September 2013 and February 2022. Multivariable logistic regression models accounting for personal and family cancer history, age, sex, and ancestry were used to quantify disease risks associated with PTEN PVs. RESULTS: PTEN PVs were detected in 0.027% (193/727,091) of the study population, and were associated with a high risk of female breast cancer (odds ratio [OR], 7.88; 95% CI, 5.57 to 11.16; P = 2.3 × 10(-31)), endometrial cancer (OR, 13.51; 95% CI, 8.77 to 20.83; P = 4.2 × 10(-32)), thyroid cancer (OR, 4.88; 95% CI, 2.64 to 9.01; P = 4.0 × 10(-7)), and colon polyposis (OR, 31.60; CI, 15.60 to 64.02; P = 9.0 × 10(-22)). We observed modest evidence suggesting that PTEN PVs may be associated with ovarian cancer risk (OR, 3.77; 95% CI, 1.71 to 8.32; P = 9.9 × 10(-4)). Among patients with similar personal/family history and ancestry, every 5-year increase in age of diagnosis decreased the likelihood of detecting a PTEN PV by roughly 60%. CONCLUSION: We demonstrate that PTEN PVs are associated with significantly increased risk for a range of cancers. Together with the observation that PTEN PV carriers had earlier disease onset relative to otherwise comparable noncarriers, our results may guide screening protocols, inform risk-management strategies, and warrant enhanced surveillance approaches that improve clinical outcomes for PTEN PV carriers, regardless of their clinical presentation. FAU - Cummings, Shelly AU - Cummings S AUID- ORCID: 0000-0001-6901-9664 AD - Myriad Genetics Inc, Salt Lake City, UT. FAU - Alfonso, Andrew AU - Alfonso A AUID- ORCID: 0000-0001-6421-9720 AD - Myriad Genetics Inc, Salt Lake City, UT. FAU - Hughes, Elisha AU - Hughes E AUID- ORCID: 0000-0002-3145-3913 AD - Myriad Genetics Inc, Salt Lake City, UT. FAU - Kucera, Matt AU - Kucera M AD - Myriad Genetics Inc, Salt Lake City, UT. FAU - Mabey, Brent AU - Mabey B AD - Myriad Genetics Inc, Salt Lake City, UT. FAU - Singh, Nanda AU - Singh N AD - Myriad Genetics Inc, Salt Lake City, UT. FAU - Eng, Charis AU - Eng C AUID- ORCID: 0000-0002-3693-5145 AD - Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH. AD - Center for Personalized Genetic Healthcare, Cleveland Clinic Community Care, Cleveland, OH. AD - Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. AD - Department of Genetics and Genome Sciences, and CASE Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH. LA - eng PT - Journal Article PL - United States TA - JCO Precis Oncol JT - JCO precision oncology JID - 101705370 RN - EC 3.1.3.67 (PTEN protein, human) RN - EC 3.1.3.67 (PTEN Phosphohydrolase) SB - IM MH - Humans MH - Female MH - Genetic Predisposition to Disease/genetics MH - *Hamartoma Syndrome, Multiple/diagnosis/genetics MH - *Breast Neoplasms/genetics MH - Phenotype MH - *Thyroid Neoplasms MH - PTEN Phosphohydrolase/genetics EDAT- 2023/01/13 06:00 MHDA- 2023/01/17 06:00 CRDT- 2023/01/12 16:03 PHST- 2023/01/12 16:03 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] AID - 10.1200/PO.22.00415 [doi] PST - ppublish SO - JCO Precis Oncol. 2023 Jan;7:e2200415. doi: 10.1200/PO.22.00415. PMID- 36681070 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1980-5322 (Electronic) IS - 1807-5932 (Linking) VI - 78 DP - 2023 TI - Could be FOXO3a, miR-96-5p and miR-182-5p useful for Brazilian women with luminal A and triple negative breast cancers prognosis and target therapy? PG - 100155 LID - S1807-5932(22)03356-7 [pii] LID - 10.1016/j.clinsp.2022.100155 [doi] AB - FOXO3a dysregulation is frequently implicated in tumorigenesis, and its inhibition can occur by several molecular mechanisms. Among these, post-transcriptional suppression by miRNAs has been associated with various cancers initiation. Here, we assessed the expression profiles of the most relevant miRNAs for breast tumorigenesis, using Luminal A (LA) and Triple-Negative (TN) breast cancer from Brazilian patients, by the quantitative real time-PCR method. Their potential prognostic role for the patients was also evaluated. We identified the miRNAs miR-96-5p and miR-182-5p, de-scribed as negative regulators of FOXO3A, with differential expression both in LA and TN tumors when compared to normal tissue. The miR-96-5p and miR-182-5p miRNAs were upregulated in LA (7.82 times, p < 0.005; 6.12 times, p < 0.005, respectively) and TN breast cancer samples (9.42 times, p < 0.0001; 8.51 times, p < 0.0001) compared to normal tissues. The samples with higher miR-96-5p and miR-182-5p expression (FR ≥ 4) were submitted for FOXO3a immunostaining. Reduced protein detection was observed in all of the tumors compared to normal tissues. The most prominent miRNA expression and FOXO3a protein suppression were observed in TN samples (p < 0.001), indicating the relevant role of these molecules in this tumor biology and clinical behavior. Our results corroborate the literature regarding to the relevance of FOXO3a in the breast cancer, and they open new perspectives for alternative target therapy options for Brazilian patients expressing both FOXO3a and its regulatory miRNAs. CI - Copyright © 2022 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved. FAU - Mendes, Daniele Carvalho Calvano AU - Mendes DCC AD - Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, HCFMUSP, São Paulo, SP, Brazil. FAU - Filho, Carlos Marino Cabral Calvano AU - Filho CMCC AD - Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, HCFMUSP, São Paulo, SP, Brazil; Setor de Mastologia, Disciplina de Ginecologia, Universidade de Brasília, Brasília, DF, Brazil. FAU - Garcia, Natália AU - Garcia N AD - Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, HCFMUSP, São Paulo, SP, Brazil. FAU - Ricci, Marcos Desidério AU - Ricci MD AD - Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, HCFMUSP, São Paulo, SP, Brazil. FAU - Soares, José Maria Júnior AU - Soares JM Júnior AD - Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, HCFMUSP, São Paulo, SP, Brazil. FAU - Carvalho, Katia Candido AU - Carvalho KC AD - Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, HCFMUSP, São Paulo, SP, Brazil. Electronic address: carvalhokc@gmail.com. FAU - Baracat, Edmund Chada AU - Baracat EC AD - Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, HCFMUSP, São Paulo, SP, Brazil. LA - eng PT - Journal Article DEP - 20230119 PL - United States TA - Clinics (Sao Paulo) JT - Clinics (Sao Paulo, Brazil) JID - 101244734 RN - 0 (Biomarkers, Tumor) RN - 0 (MicroRNAs) RN - 0 (Mirn182 microRNA, human) RN - 0 (MIRN96 microRNA, human) SB - IM MH - Humans MH - Female MH - *Triple Negative Breast Neoplasms/genetics/pathology MH - *Breast Neoplasms/genetics/pathology MH - Brazil MH - Biomarkers, Tumor/genetics MH - *MicroRNAs/genetics/metabolism MH - Prognosis MH - Carcinogenesis MH - Gene Expression Regulation, Neoplastic MH - Gene Expression Profiling OTO - NOTNLM OT - Breast cancer OT - FOXO3a OT - IHC OT - miRNAs OT - qRT-PCR COIS- Declaration of Competing Interest The authors declare no conflicts of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/22 06:00 CRDT- 2023/01/21 18:23 PHST- 2022/07/18 00:00 [received] PHST- 2022/11/12 00:00 [revised] PHST- 2022/12/07 00:00 [accepted] PHST- 2023/01/21 18:23 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/22 06:00 [medline] AID - S1807-5932(22)03356-7 [pii] AID - 10.1016/j.clinsp.2022.100155 [doi] PST - epublish SO - Clinics (Sao Paulo). 2023 Jan 19;78:100155. doi: 10.1016/j.clinsp.2022.100155. eCollection 2023. PMID- 35508427 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1878-7541 (Electronic) IS - 1550-8307 (Linking) VI - 19 IP - 1 DP - 2023 Jan-Feb TI - Effectiveness of mandala coloring in reducing anxiety in women with early-stage breast cancer receiving chemotherapy for the first time. PG - 42-47 LID - S1550-8307(22)00070-2 [pii] LID - 10.1016/j.explore.2022.04.007 [doi] AB - CONTEXT: Many people with cancer experience fear or anxiety when starting chemotherapy for the first time. Mandala coloring is an art therapy approach commonly used for anti-stress therapy. OBJECTIVE: To assess whether mandala coloring reduces the anxiety experienced by women with early-stage breast cancer during their first chemotherapy session. DESIGN: A quasi-experimental controlled study with pretest/posttest design. SETTING: The study was conducted in the outpatient chemotherapy unit of the Istanbul University Institute of Oncology between March 2017 and May 2018. PARTICIPANTS: Eight-four women with early-stage breast cancer who presented for their first session of chemotherapy were included, 41 in the intervention group and 43 in the control group. INTERVENTION: Patients in the intervention group were asked to color a mandala for 30 min while receiving premedication prior to chemotherapy. No intervention was applied to the control group. MAIN OUTCOME MEASURES: Levels of distress and anxiety were assessed before and after premedication using the distress thermometer and State-Trait Anxiety Inventory. RESULTS: The sample group consisted primarily of women who had primary school education, were married, and were homemakers. Average distress levels were low in both the intervention and control group before premedication, and state anxiety scores did not differ statistically between the groups before or after premedication. However, patients in the intervention group who had high distress levels before premedication showed a significant decrease in state anxiety score after premedication, while patients in the control group showed no decrease. CI - Copyright © 2022. Published by Elsevier Inc. FAU - Akbulak, Fatma AU - Akbulak F AD - Istanbul Health and Technology University, Güngören, İstanbul, Turkey. Electronic address: fatma.akbulak@istun.edu.tr. FAU - Can, Gülbeyaz AU - Can G AD - Istanbul University-Cerrahpaşa Florence Nightingale School of Nursing, Çağlayan, İstanbul/Turkey. Electronic address: gulbeyaz@istanbul.edu.tr. LA - eng PT - Journal Article DEP - 20220428 PL - United States TA - Explore (NY) JT - Explore (New York, N.Y.) JID - 101233160 RN - Phobia, Specific SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Anxiety/drug therapy MH - Anxiety Disorders MH - *Phobic Disorders OTO - NOTNLM OT - Anxiety OT - Chemotherapy OT - Distress OT - Early-stage breast cancer OT - Mandala coloring EDAT- 2022/05/05 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/05/04 23:32 PHST- 2021/10/14 00:00 [received] PHST- 2022/04/11 00:00 [revised] PHST- 2022/04/18 00:00 [accepted] PHST- 2022/05/05 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/05/04 23:32 [entrez] AID - S1550-8307(22)00070-2 [pii] AID - 10.1016/j.explore.2022.04.007 [doi] PST - ppublish SO - Explore (NY). 2023 Jan-Feb;19(1):42-47. doi: 10.1016/j.explore.2022.04.007. Epub 2022 Apr 28. PMID- 36652284 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 1438-8871 (Electronic) IS - 1438-8871 (Linking) VI - 25 DP - 2023 Jan 18 TI - Web-Based Asynchronous Tool to Facilitate Communication Between Primary Care Providers and Cancer Specialists: Pragmatic Randomized Controlled Trial. PG - e40725 LID - 10.2196/40725 [doi] AB - BACKGROUND: Cancer poses a significant global health burden. With advances in screening and treatment, there are now a growing number of cancer survivors with complex needs, requiring the involvement of multiple health care providers. Previous studies have identified problems related to communication and care coordination between primary care providers (PCPs) and cancer specialists. OBJECTIVE: This study aimed to examine whether a web- and text-based asynchronous system (eOncoNote) could facilitate communication between PCPs and cancer specialists (oncologists and oncology nurses) to improve patient-reported continuity of care among patients receiving treatment or posttreatment survivorship care. METHODS: In this pragmatic randomized controlled trial, a total of 173 patients were randomly assigned to either the intervention group (eOncoNote plus usual methods of communication between PCPs and cancer specialists) or a control group (usual communication only), including 104 (60.1%) patients in the survivorship phase (breast and colorectal cancer) and 69 (39.9%) patients in the treatment phase (breast and prostate cancer). The primary outcome was patient-reported team and cross-boundary continuity (Nijmegen Continuity Questionnaire). Secondary outcome measures included the Generalized Anxiety Disorder Screener (GAD-7), Patient Health Questionnaire on Major Depression, and Picker Patient Experience Questionnaire. Patients completed the questionnaires at baseline and at 2 points following randomization. Patients in the treatment phase completed follow-up questionnaires at 1 month and at either 4 months (patients with prostate cancer) or 6 months following randomization (patients with breast cancer). Patients in the survivorship phase completed follow-up questionnaires at 6 months and at 12 months following randomization. RESULTS: The results did not show an intervention effect on the primary outcome of team and cross-boundary continuity of care or on the secondary outcomes of depression and patient experience with their health care. However, there was an intervention effect on anxiety. In the treatment phase, there was a statistically significant difference in the change score from baseline to the 1-month follow-up for GAD-7 (mean difference -2.3; P=.03). In the survivorship phase, there was a statistically significant difference in the change score for GAD-7 between baseline and the 6-month follow-up (mean difference -1.7; P=.03) and between baseline and the 12-month follow-up (mean difference -2.4; P=.004). CONCLUSIONS: PCPs' and cancer specialists' access to eOncoNote is not significantly associated with patient-reported continuity of care. However, PCPs' and cancer specialists' access to the eOncoNote intervention may be a factor in reducing patient anxiety. TRIAL REGISTRATION: ClinicalTrials.gov NCT03333785; https://clinicaltrials.gov/ct2/show/NCT03333785. CI - ©Bojana Petrovic, Jim A Julian, Clare Liddy, Amir Afkham, Sharon F McGee, Scott C Morgan, Roanne Segal, Jonathan Sussman, Gregory R Pond, Mary Ann O'Brien, Jacqueline L Bender, Eva Grunfeld. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 18.01.2023. FAU - Petrovic, Bojana AU - Petrovic B AUID- ORCID: 0000-0001-8172-1966 AD - Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. FAU - Julian, Jim A AU - Julian JA AUID- ORCID: 0000-0003-0476-5396 AD - Department of Oncology, McMaster University, Hamilton, ON, Canada. FAU - Liddy, Clare AU - Liddy C AUID- ORCID: 0000-0003-0699-5494 AD - Bruyère Research Institute, Ottawa, ON, Canada. AD - Department of Family Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Afkham, Amir AU - Afkham A AUID- ORCID: 0000-0001-7563-636X AD - Ontario Health East, Ottawa, ON, Canada. FAU - McGee, Sharon F AU - McGee SF AUID- ORCID: 0000-0002-0323-6372 AD - The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada. FAU - Morgan, Scott C AU - Morgan SC AUID- ORCID: 0000-0002-6568-3346 AD - The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada. AD - Department of Radiology, Radiation Oncology and Medical Physics, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Segal, Roanne AU - Segal R AUID- ORCID: 0000-0002-2055-2596 AD - The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada. FAU - Sussman, Jonathan AU - Sussman J AUID- ORCID: 0000-0002-7702-8816 AD - Department of Oncology, McMaster University, Hamilton, ON, Canada. FAU - Pond, Gregory R AU - Pond GR AUID- ORCID: 0000-0003-1033-0882 AD - Department of Oncology, McMaster University, Hamilton, ON, Canada. FAU - O'Brien, Mary Ann AU - O'Brien MA AUID- ORCID: 0000-0001-6093-1040 AD - Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. FAU - Bender, Jacqueline L AU - Bender JL AUID- ORCID: 0000-0003-1501-335X AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. AD - Cancer Rehabilitation and Survivorship, Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. FAU - Grunfeld, Eva AU - Grunfeld E AUID- ORCID: 0000-0001-9695-2118 AD - Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. AD - Ontario Institute for Cancer Research, Toronto, ON, Canada. LA - eng SI - ClinicalTrials.gov/NCT03333785 PT - Journal Article PT - Randomized Controlled Trial DEP - 20230118 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - Male MH - Humans MH - *Breast Neoplasms/therapy MH - Continuity of Patient Care MH - *Prostatic Neoplasms MH - Communication MH - Internet OTO - NOTNLM OT - cancer OT - coordination of care OT - electronic communication OT - primary care EDAT- 2023/01/19 06:00 MHDA- 2023/01/21 06:00 CRDT- 2023/01/18 11:52 PHST- 2022/07/02 00:00 [received] PHST- 2022/11/13 00:00 [accepted] PHST- 2022/10/28 00:00 [revised] PHST- 2023/01/18 11:52 [entrez] PHST- 2023/01/19 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] AID - v25i1e40725 [pii] AID - 10.2196/40725 [doi] PST - epublish SO - J Med Internet Res. 2023 Jan 18;25:e40725. doi: 10.2196/40725. PMID- 36609396 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1756-9966 (Electronic) IS - 0392-9078 (Print) IS - 0392-9078 (Linking) VI - 42 IP - 1 DP - 2023 Jan 7 TI - The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer. PG - 10 LID - 10.1186/s13046-022-02581-1 [doi] LID - 10 AB - BACKGROUND: Posttranscriptional modification of tumor-associated factors plays a pivotal role in breast cancer progression. However, the underlying mechanism remains unknown. M6A modifications in cancer cells are dynamic and reversible and have been found to impact tumor initiation and progression through various mechanisms. In this study, we explored the regulatory mechanism of breast cancer cell proliferation and metabolism through m6A methylation in the Hippo pathway.  METHODS: A combination of MeRIP-seq, RNA-seq and metabolomics-seq was utilized to reveal a map of m6A modifications in breast cancer tissues and cells. We conducted RNA pull-down assays, RIP-qPCR, MeRIP-qPCR, and RNA stability analysis to identify the relationship between m6A proteins and LATS1 in m6A regulation in breast cancer cells. The expression and biological functions of m6A proteins were confirmed in breast cancer cells in vitro and in vivo. Furthermore, we investigated the phosphorylation levels and localization of YAP/TAZ to reveal that the activity of the Hippo pathway was affected by m6A regulation of LATS1 in breast cancer cells.  RESULTS: We demonstrated that m6A regulation plays an important role in proliferation and glycolytic metabolism in breast cancer through the Hippo pathway factor, LATS1. METTL3 was identified as the m6A writer, with YTHDF2 as the reader protein of LATS1 mRNA, which plays a positive role in promoting both tumorigenesis and glycolysis in breast cancer. High levels of m6A modification were induced by METTL3 in LATS1 mRNA. YTHDF2 identified m6A sites in LATS1 mRNA and reduced its stability. Knockout of the protein expression of METTL3 or YTHDF2 increased the expression of LATS1 mRNA and suppressed breast cancer tumorigenesis by activating YAP/TAZ in the Hippo pathway. CONCLUSIONS: In summary, we discovered that the METTL3-LATS1-YTHDF2 pathway plays an important role in the progression of breast cancer by activating YAP/TAZ in the Hippo pathway. CI - © 2023. The Author(s). FAU - Xu, Youqin AU - Xu Y AD - Department of Thyroid and Breast Surgery, The Seventh Affiliated Hospital, Southern Medical University, Foshan, 528200, China. AD - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. AD - Institute of Oncology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. FAU - Song, Mu AU - Song M AD - Department of Thyroid and Breast Surgery, The Seventh Affiliated Hospital, Southern Medical University, Foshan, 528200, China. FAU - Hong, Ziyang AU - Hong Z AD - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Chen, Wancheng AU - Chen W AD - Department of Radiotherapy, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. FAU - Zhang, Qianbing AU - Zhang Q AD - Institute of Oncology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. FAU - Zhou, Jianlong AU - Zhou J AD - Department of Oncology, Guangxi International Zhuang Medicine Hospital, Nanning, 530021, China. FAU - Yang, Chao AU - Yang C AD - Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - He, Zilong AU - He Z AD - Department of Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Yu, Juanjuan AU - Yu J AD - Department of Thyroid and Breast Surgery, The Seventh Affiliated Hospital, Southern Medical University, Foshan, 528200, China. FAU - Peng, Xiaolin AU - Peng X AD - Department of Thyroid and Breast Surgery, The Seventh Affiliated Hospital, Southern Medical University, Foshan, 528200, China. FAU - Zhu, Qiuhong AU - Zhu Q AD - Department of Thyroid and Breast Surgery, The Seventh Affiliated Hospital, Southern Medical University, Foshan, 528200, China. FAU - Li, Shaotian AU - Li S AD - Department of Thyroid and Breast Surgery, The Seventh Affiliated Hospital, Southern Medical University, Foshan, 528200, China. FAU - Ji, Kaiyuan AU - Ji K AD - Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510620, China. 369027938@qq.com. FAU - Liu, Minfeng AU - Liu M AD - Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. matthewliu007@163.com. FAU - Zuo, Qiang AU - Zuo Q AUID- ORCID: 0000-0002-2492-3489 AD - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. nfyyzq@126.com. LA - eng GR - 81902865/Young Scientists Fund/ GR - 82002938/Young Scientists Fund/ GR - 82103378/Young Scientists Fund/ GR - 81872009/National Natural Science Foundation of China/ GR - 2021M690073/Postdoctoral Research Foundation of China/ GR - 15-A2020510/Medical Science and Technology Foundation of Guangdong Province/ GR - 2019C017/President's Fund of Nanfang Hospital/ PT - Journal Article DEP - 20230107 PL - England TA - J Exp Clin Cancer Res JT - Journal of experimental & clinical cancer research : CR JID - 8308647 RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - 0 (Transcription Factors) RN - 0 (RNA, Messenger) RN - EC 2.1.1.62 (METTL3 protein, human) RN - EC 2.1.1.- (Methyltransferases) RN - EC 2.7.1.- (LATS1 protein, human) SB - IM MH - Humans MH - Female MH - Methylation MH - *Breast Neoplasms/genetics/pathology MH - Protein Serine-Threonine Kinases/genetics/metabolism MH - Cell Transformation, Neoplastic/genetics MH - Carcinogenesis/genetics MH - Transcription Factors/metabolism MH - RNA, Messenger/genetics/metabolism MH - Methyltransferases/genetics/metabolism PMC - PMC9824909 OTO - NOTNLM OT - Breast cancer OT - Hippo-YAP/TAZ signaling pathway OT - LATS1 OT - METTL3 COIS- Youqin Xu, Mu Song, Ziyang Hong, Wancheng Chen, Qianbing Zhang, Jianlong Zhou, Chao Yang, Zilong He, Juanjuan Yu, Xiaolin Peng, Qiuhong Zhu, Shaotian Li, Kaiyuan Ji, Minfeng Liu and Qiang Zuo declare that they have no conflict of interest. EDAT- 2023/01/08 06:00 MHDA- 2023/01/11 06:00 CRDT- 2023/01/07 16:29 PHST- 2022/08/23 00:00 [received] PHST- 2022/12/23 00:00 [accepted] PHST- 2023/01/07 16:29 [entrez] PHST- 2023/01/08 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] AID - 10.1186/s13046-022-02581-1 [pii] AID - 2581 [pii] AID - 10.1186/s13046-022-02581-1 [doi] PST - epublish SO - J Exp Clin Cancer Res. 2023 Jan 7;42(1):10. doi: 10.1186/s13046-022-02581-1. PMID- 36063308 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - Sarcopenia detected with bioelectrical impedance versus CT scan and chemotherapy tolerance in patients with early breast cancer. PG - 101-109 LID - 10.1007/s12282-022-01401-w [doi] AB - BACKGROUND: Early breast cancer (EBC) is a potentially curable disease. Some patients with EBC require chemotherapy, exposing patients to undesirable side effects. Loss of muscle mass, or sarcopenia, has been associated with worse outcomes in patients with EBC and worse treatment-related toxicity in patients with advanced breast cancer. CT scans can identify sarcopenia; however, most patients with EBC do not require routine CT scans. Bioelectrical impedance spectrometry (BIS) is another method to detect sarcopenia and can be performed quickly in the office without radiation exposure. We sought to investigate whether sarcopenia measurements by CT scan versus BIS correlated with each other and whether sarcopenia identified by each method is associated with chemotherapy toxicity and adherence in patients with EBC. METHODS: This is a retrospective study; eligible patients received chemotherapy treatment for EBC and had undergone BIS. A subset of patients had also had a CT abdomen with a Lumbar L3 level. Measures of sarcopenia were obtained from the BIS and CT data. In addition, patient characteristics, treatment, and toxicity-related outcomes were obtained from medical records. Multivariate logistic regression models were used to associate sarcopenia status with toxicity endpoints, adjusted for other patient characteristics. RESULTS: There was a moderate correlation between sarcopenia detected by CT scan and BIS (r = 0.64 p < 0.0001). Patients with sarcopenia detected by BIS had more chemotherapy toxicity (OR = 2.56; CI 1.72-3.84), dose reductions or dose delays (OR = 1.58; CI 1.06-2.38), and hospitalizations (OR = 2.38; CI 1.33-4.16) due to side effects than patients without sarcopenia. CONCLUSION: The presence of sarcopenia in patients with EBC is associated with worse chemotherapy tolerance. BIS represents a high-value alternative to CT scans for sarcopenia assessment. CI - © 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society. FAU - Aleixo, Gabriel F P AU - Aleixo GFP AUID- ORCID: 0000-0002-9329-6044 AD - Department of Internal Medicine, Cleveland Clinic Main Campus, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. Francig3@ccf.org. FAU - Valente, Stephanie A AU - Valente SA AD - Department of Surgery, Cleveland Clinic, Cleveland, OH, USA. FAU - Wei, Wei AU - Wei W AD - Department of Biostatistics, Cleveland Clinic, Cleveland, OH, USA. FAU - Chen, Po-Hao AU - Chen PH AD - Department of Imaging and Diagnostic Medicine, Cleveland Clinic, Cleveland, OH, USA. FAU - Moore, Halle C F AU - Moore HCF AD - Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA. LA - eng PT - Journal Article DEP - 20220905 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 SB - IM MH - Humans MH - Female MH - *Sarcopenia/diagnosis/diagnostic imaging MH - *Breast Neoplasms/diagnostic imaging/drug therapy/complications MH - Retrospective Studies MH - Electric Impedance MH - Tomography, X-Ray Computed/methods MH - Muscle, Skeletal/pathology OTO - NOTNLM OT - Bioelectrical impedance OT - Chemotherapy OT - Early breast cancer OT - Sarcopenia EDAT- 2022/09/06 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/09/05 11:19 PHST- 2022/07/05 00:00 [received] PHST- 2022/08/26 00:00 [accepted] PHST- 2022/09/06 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/09/05 11:19 [entrez] AID - 10.1007/s12282-022-01401-w [pii] AID - 10.1007/s12282-022-01401-w [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):101-109. doi: 10.1007/s12282-022-01401-w. Epub 2022 Sep 5. PMID- 36595552 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1553-7404 (Electronic) IS - 1553-7390 (Print) IS - 1553-7390 (Linking) VI - 19 IP - 1 DP - 2023 Jan TI - ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PG - e1010563 LID - 10.1371/journal.pgen.1010563 [doi] LID - e1010563 AB - BACKGROUND: Previous studies have provided a comprehensive picture of genomic alterations in primary and metastatic Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer (HR+ HER2- BC). However, the evolution of the genomic landscape of HR+ HER2- BC during adjuvant endocrine therapies (ETs) remains poorly investigated. METHODS AND FINDINGS: We performed a genomic characterization of surgically resected HR+ HER2- BC patients relapsing during or at the completion of adjuvant ET. Using a customized panel, we comprehensively evaluated gene mutations and copy number variation (CNV) in paired primary and metastatic specimens. After retrieval and quality/quantity check of tumor specimens from an original cohort of 204 cases, 74 matched tumor samples were successfully evaluated for DNA mutations and CNV analysis. Along with previously reported genomic alterations, including PIK3CA, TP53, CDH1, GATA3 and ESR1 mutations/deletions, we found that ESR1 gene amplification (confirmed by FISH) and MAP3K mutations were enriched in metastatic lesions as compared to matched primary tumors. These alterations were exclusively found in patients treated with adjuvant aromatase inhibitors or LHRH analogs plus tamoxifen, but not in patients treated with tamoxifen alone. Patients with tumors bearing MAP3K mutations in metastatic lesions had significantly worse distant relapse-free survival (hazard ratio [HR] 3.4, 95% CI 1.52-7.70, p value 0.003) and worse overall survival (HR 5.2, 95% CI 2.10-12.8, p-value < 0.001) independently of other clinically relevant patient- and tumor-related variables. CONCLUSIONS: ESR1 amplification and activating MAP3K mutations are potential drivers of acquired resistance to adjuvant ETs employing estrogen deprivation in HR+ HER2- BC. MAP3K mutations are associated with worse prognosis in patients with metastatic disease. CI - Copyright: © 2023 Ferrando et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Ferrando, Lorenzo AU - Ferrando L AUID- ORCID: 0000-0002-4025-7930 AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Vingiani, Andrea AU - Vingiani A AUID- ORCID: 0000-0002-9827-3976 AD - Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Garuti, Anna AU - Garuti A AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. FAU - Vernieri, Claudio AU - Vernieri C AD - Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. AD - IFOM, The FIRC Institute of Molecular Oncology, Milan, Italy. FAU - Belfiore, Antonino AU - Belfiore A AD - Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Agnelli, Luca AU - Agnelli L AUID- ORCID: 0000-0003-0582-6170 AD - Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Dagrada, Gianpaolo AU - Dagrada G AD - Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. FAU - Ivanoiu, Diana AU - Ivanoiu D AD - Department of Surgery and Cancer, Imperial College London, London, United Kingdom. FAU - Bonizzi, Giuseppina AU - Bonizzi G AD - Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Munzone, Elisabetta AU - Munzone E AD - Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Lippolis, Luana AU - Lippolis L AD - Division of Pathology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy. FAU - Dameri, Martina AU - Dameri M AD - Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy. FAU - Ravera, Francesco AU - Ravera F AUID- ORCID: 0000-0002-1619-1708 AD - Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy. FAU - Colleoni, Marco AU - Colleoni M AD - Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Viale, Giuseppe AU - Viale G AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. AD - Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy. FAU - Magnani, Luca AU - Magnani L AD - Department of Surgery and Cancer, Imperial College London, London, United Kingdom. FAU - Ballestrero, Alberto AU - Ballestrero A AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. AD - Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy. FAU - Zoppoli, Gabriele AU - Zoppoli G AD - IRCCS Ospedale Policlinico San Martino, Genova, Italy. AD - Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy. FAU - Pruneri, Giancarlo AU - Pruneri G AUID- ORCID: 0000-0002-7963-7172 AD - Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. LA - eng PT - Journal Article DEP - 20230103 PL - United States TA - PLoS Genet JT - PLoS genetics JID - 101239074 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 094ZI81Y45 (Tamoxifen) RN - 0 (ESR1 protein, human) RN - EC 2.3.1.256 (NAA30 protein, human) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - DNA Copy Number Variations/genetics MH - Gene Amplification MH - Mutation MH - Neoplasm Recurrence, Local/drug therapy/genetics MH - Receptor, ErbB-2/genetics MH - Tamoxifen PMC - PMC9839248 COIS- I have read the journal’s policy and the authors of this manuscript have the following competing interests: Giancarlo Pruneri reports honoraria from Novartis, Roche, Lilly and Exact Science. Gabriele Zoppoli reports travel grants from Novartis and Pfizer, and reagents for research from Citiva and ThermoFisher Scientific. Andrea Vingiani reports honoraria from Roche and Lilly. Marco Colleoni reports Research Grant from Roche. Elisabtta Munzone reports travel grants from Roche, Pfizer, Lilly and Novartis and reports receiving consultancy fees from Eisai, Exact Sciences, MSD Oncology, Daiichi Sankyo/Astra Zeneca, Pfizer and Seagen. Giuseppe Viale has received grants from Roche/Genentech and Astra Zeneca for his institution; consulting fees from Roche/Genentech, Astra Zeneca, MDS Oncology and Daiichi Sanyko; honoraria for lectures from Roche/Genentech, Astra Zeneca and Daiichi Sanyko; support for attending meetings from Roche/Genentech; and has served on Advisory Boards for Roche/Genentech, Astra Zeneca, Pfizer, MDS Oncology and Novartis. Lorenzo Ferrando, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Luana Lippolis, Martina Dameri, Francesco Ravera, Luca Magnani and Alberto Ballestrero have no conflict of interest to disclose. EDAT- 2023/01/04 06:00 MHDA- 2023/01/18 06:00 CRDT- 2023/01/03 13:44 PHST- 2022/07/11 00:00 [received] PHST- 2022/12/08 00:00 [accepted] PHST- 2023/01/13 00:00 [revised] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2023/01/03 13:44 [entrez] AID - PGENETICS-D-22-00807 [pii] AID - 10.1371/journal.pgen.1010563 [doi] PST - epublish SO - PLoS Genet. 2023 Jan 3;19(1):e1010563. doi: 10.1371/journal.pgen.1010563. eCollection 2023 Jan. PMID- 36094631 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1432-1459 (Electronic) IS - 0340-5354 (Linking) VI - 270 IP - 1 DP - 2023 Jan TI - Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity. PG - 531-537 LID - 10.1007/s00415-022-11377-4 [doi] AB - INTRODUCTION: Paclitaxel-induced peripheral neurotoxicity (PIPN) typically manifests as a predominantly sensory axonopathy. Nerve conduction studies (NCS) represent the gold standard method to quantify axonal impairment in PIPN. Serum neurofilament light chain (sNfL) levels are emerging biomarkers for quantifying axonal damage in peripheral neuropathies. To date, the association between NCS abnormalities and sNfL levels during paclitaxel-based chemotherapy has not been specifically addressed. METHODS: We prospectively conducted longitudinal measurement of sNfL levels in 27 chemotherapy-naïve breast cancer patients and correlated conventional NCS recordings with sNfL in 22 of them, before (T0) and after (T1) 12 cycles of weekly paclitaxel-based therapy. RESULTS: PIPN was diagnosed in 24/27 patients (88%) after completion of the 12-week paclitaxel-based chemotherapy regimen. Serum NfL levels (pg/mL) were significantly higher at T1 compared to T0 (T0: 18.50 ± 12.88 vs T1: 255.80 ± 194.16; p < 0.001). The increase of sNfL levels at T1 significantly correlated with the decrease or abolishment of amplitudes recorded from the sural nerve (r = 0.620; p = 0.0035), sensory radial (r = 0.613; p = 0.005), sensory ulnar (r = 0.630; p = 0.005), and peroneal motor (r = 0.568; p = 0.024) nerves. CONCLUSION: sNfL levels proportionally increase during chemotherapy administration and significantly correlate with NCS axonal abnormalities in patients with PIPN. A multimodal testing approach employing both sNfL and NCS might improve the PIPN diagnostic accuracy. CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. FAU - Velasco, R AU - Velasco R AUID- ORCID: 0000-0003-3194-9406 AD - Unit of Neuro-Oncology, Hospital Universitari de Bellvitge. Catalan Institute of Oncology-L'Hospitalet, Carrer de La Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. rvelascof@bellvitgehospital.cat. AD - Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Universitat Autònoma de Barcelona, Bellaterra, Spain. rvelascof@bellvitgehospital.cat. FAU - Argyriou, A A AU - Argyriou AA AD - Neurology Department, Agios Andreas General Hospital of Patras, Patras, Greece. FAU - Marco, C AU - Marco C AD - Unit of Neuro-Oncology, Hospital Universitari de Bellvitge. Catalan Institute of Oncology-L'Hospitalet, Carrer de La Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Mariotto, S AU - Mariotto S AD - Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. FAU - Stradella, A AU - Stradella A AD - Department of Medical Oncology, Breast Cancer Unit, ICO L'Hospitalet (IDIBELL), Barcelona, Spain. FAU - Hernández, J AU - Hernández J AD - Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Universitat Autònoma de Barcelona, Bellaterra, Spain. FAU - Pernas, S AU - Pernas S AD - Department of Medical Oncology, Breast Cancer Unit, ICO L'Hospitalet (IDIBELL), Barcelona, Spain. FAU - Ferrari, S AU - Ferrari S AD - Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. FAU - Bruna, J AU - Bruna J AD - Unit of Neuro-Oncology, Hospital Universitari de Bellvitge. Catalan Institute of Oncology-L'Hospitalet, Carrer de La Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. AD - Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Universitat Autònoma de Barcelona, Bellaterra, Spain. LA - eng GR - PI20/00283/Instituto de Salud Carlos III/ GR - PI21/00181/Instituto de Salud Carlos III/ GR - PI20/00544/Instituto de Salud Carlos III/ GR - SLT008/18/00028/Agència de Gestió d'Ajuts Universitaris i de Recerca/ PT - Journal Article DEP - 20220912 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - P88XT4IS4D (Paclitaxel) RN - 0 (Biomarkers) RN - 0 (Neurofilament Proteins) SB - IM MH - Humans MH - Female MH - Paclitaxel/adverse effects MH - *Peripheral Nervous System Diseases/chemically induced/diagnosis MH - Intermediate Filaments MH - *Breast Neoplasms/drug therapy MH - Biomarkers MH - Neurofilament Proteins OTO - NOTNLM OT - Chemotherapy-induced peripheral neuropathy OT - Nerve conduction studies OT - Neurofilament light chain OT - Neurotoxicity OT - Paclitaxel EDAT- 2022/09/13 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/09/12 11:48 PHST- 2022/08/13 00:00 [received] PHST- 2022/09/07 00:00 [accepted] PHST- 2022/09/06 00:00 [revised] PHST- 2022/09/13 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/09/12 11:48 [entrez] AID - 10.1007/s00415-022-11377-4 [pii] AID - 10.1007/s00415-022-11377-4 [doi] PST - ppublish SO - J Neurol. 2023 Jan;270(1):531-537. doi: 10.1007/s00415-022-11377-4. Epub 2022 Sep 12. PMID- 36334189 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis. PG - 71-82 LID - 10.1007/s10549-022-06788-w [doi] AB - BACKGROUND: Approximately 30% of patients with oestrogen receptor (ER)-positive breast cancer (BC) exhibit intrinsic or recurrent resistance to tamoxifen (TAM) adjuvant endocrine therapy. The androgen receptor (AR) is expressed in about 90% of ER-positive patients. Our previous studies found that BC patients with an AR:ER expression ratio ≥ 2.0 are more susceptible to TAM resistance. However, the specific mechanism by which a high AR:ER ratio promotes TAM resistance remains unknown. METHODS: RNA sequencing was performed on 10 cases of BC tissues with AR:ER ratios ≥ 2.0 and 3 cases with AR:ER ratios < 2.0. We then compared our data with the screened TAM-resistant and TAM-sensitive cases from the TCGA BC database. Bioinformatics methods were used to screen differentially expressed genes (DEGs) and to perform gene enrichment analysis. Weighted correlation network analysis (WGCNA) was used to screen hub genes in the AR-induced TAM resistance process. RESULTS: PAM50 analysis showed that the molecular phenotype of BC patients with AR:ER ratios ≥ 2.0 was similar to that of triple-negative breast cancer (TNBC), whereas the BC samples with AR:ER ratios < 2.0 were classified as the luminal subtype. Among the AR:ER ratio ≥ 2.0 and AR:ER < 2.0 BC tumours, 1855 DEGs were identified. Gene enrichment analysis showed that DEGs were enriched mainly in proliferation-related molecular pathways, such as the cell cycle, necroptosis, metabolic pathways and DNA replication. WGCNA analysis showed that SEC14L2, RIIAD1, STC2 and MAGEA6 served as hub genes in AR-induced TAM resistance and were associated with BC survival prognosis in the TCGA cohort. CONCLUSIONS: A high AR:ER expression ratio is a biomarker for patients who might develop TAM resistance, and AR expression seems to be a possible mechanism of resistance to endocrine therapy. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Lu, Cao AU - Lu C AD - Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. FAU - Yang, Yang AU - Yang Y AD - Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. FAU - Lingmei, Li AU - Lingmei L AD - Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. FAU - Qiujuan, Huang AU - Qiujuan H AD - Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. FAU - Qianru, Guo AU - Qianru G AD - Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. FAU - Lisha, Qi AU - Lisha Q AD - Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. FAU - Wenfeng, Cao AU - Wenfeng C AD - Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. FAU - Yun, Niu AU - Yun N AD - Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. FAU - Peisen, Zhang AU - Peisen Z AUID- ORCID: 0000-0003-1675-9700 AD - Tianjin University of Science and Technology, Tianjin, 300222, China. zpsbit@foxmail.com. LA - eng GR - 82002813/National Natural Science Foundation of China/ GR - TJWJ2021QN010/Tianjin Municipal Health Commission/ PT - Journal Article DEP - 20221105 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 094ZI81Y45 (Tamoxifen) RN - 0 (Receptors, Androgen) RN - 0 (Receptors, Estrogen) RN - 0 (MAGEA6 protein, human) RN - 0 (Antigens, Neoplasm) RN - 0 (Neoplasm Proteins) SB - IM MH - Humans MH - Female MH - *Tamoxifen/pharmacology/therapeutic use MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - Receptors, Androgen/genetics/metabolism MH - Receptors, Estrogen/genetics/metabolism MH - Prognosis MH - Drug Resistance, Neoplasm/genetics MH - Gene Expression Regulation, Neoplastic MH - Antigens, Neoplasm MH - Neoplasm Proteins/genetics OTO - NOTNLM OT - Androgen receptor OT - Breast cancer OT - Estrogen receptor OT - RNA sequencing OT - Tamoxifen EDAT- 2022/11/06 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/05 12:26 PHST- 2022/08/09 00:00 [received] PHST- 2022/10/25 00:00 [accepted] PHST- 2022/11/06 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/05 12:26 [entrez] AID - 10.1007/s10549-022-06788-w [pii] AID - 10.1007/s10549-022-06788-w [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):71-82. doi: 10.1007/s10549-022-06788-w. Epub 2022 Nov 5. PMID- 36674656 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 2 DP - 2023 Jan 6 TI - Functional Relationships between Long Non-Coding RNAs and Estrogen Receptor Alpha: A New Frontier in Hormone-Responsive Breast Cancer Management. LID - 10.3390/ijms24021145 [doi] LID - 1145 AB - In the complex and articulated machinery of the human genome, less than 2% of the transcriptome encodes for proteins, while at least 75% is actively transcribed into non-coding RNAs (ncRNAs). Among the non-coding transcripts, those ≥200 nucleotides long (lncRNAs) are receiving growing attention for their involvement in human diseases, particularly cancer. Genomic studies have revealed the multiplicity of processes, including neoplastic transformation and tumor progression, in which lncRNAs are involved by regulating gene expression at epigenetic, transcriptional, and post-transcriptional levels by mechanism(s) that still need to be clarified. In breast cancer, several lncRNAs were identified and demonstrated to have either oncogenic or tumor-suppressive roles. The functional understanding of the mechanisms of lncRNA action in this disease could represent a potential for translational applications, as these molecules may serve as novel biomarkers of clinical use and potential therapeutic targets. This review highlights the relationship between lncRNAs and the principal hallmark of the luminal breast cancer phenotype, estrogen receptor α (ERα), providing an overview of new potential ways to inhibit estrogenic signaling via this nuclear receptor toward escaping resistance to endocrine therapy. FAU - Melone, Viola AU - Melone V AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. FAU - Salvati, Annamaria AU - Salvati A AUID- ORCID: 0000-0002-9601-2975 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. AD - Medical Genomics Program and Division of Oncology, AOU 'S. Giovanni di Dio e Ruggi d'Aragona', University of Salerno, Rete Oncologica Campana, 84131 Salerno, Italy. FAU - Brusco, Noemi AU - Brusco N AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. FAU - Alexandrova, Elena AU - Alexandrova E AUID- ORCID: 0000-0002-6220-6229 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. FAU - D'Agostino, Ylenia AU - D'Agostino Y AUID- ORCID: 0000-0002-1890-6682 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. AD - Medical Genomics Program and Division of Oncology, AOU 'S. Giovanni di Dio e Ruggi d'Aragona', University of Salerno, Rete Oncologica Campana, 84131 Salerno, Italy. FAU - Palumbo, Domenico AU - Palumbo D AUID- ORCID: 0000-0001-5878-9428 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. FAU - Palo, Luigi AU - Palo L AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. AD - CRGS-Genome Research Center for Health, University of Salerno Campus of Medicine, 84081 Baronissi, Italy. FAU - Terenzi, Ilaria AU - Terenzi I AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. FAU - Nassa, Giovanni AU - Nassa G AUID- ORCID: 0000-0001-7453-1240 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. FAU - Rizzo, Francesca AU - Rizzo F AUID- ORCID: 0000-0003-1783-5015 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. FAU - Giurato, Giorgio AU - Giurato G AUID- ORCID: 0000-0002-0538-8978 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. FAU - Weisz, Alessandro AU - Weisz A AUID- ORCID: 0000-0003-0455-2083 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. AD - Medical Genomics Program and Division of Oncology, AOU 'S. Giovanni di Dio e Ruggi d'Aragona', University of Salerno, Rete Oncologica Campana, 84131 Salerno, Italy. AD - CRGS-Genome Research Center for Health, University of Salerno Campus of Medicine, 84081 Baronissi, Italy. FAU - Tarallo, Roberta AU - Tarallo R AUID- ORCID: 0000-0001-9668-3632 AD - Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy. LA - eng GR - IG-23068/Italian Association for Cancer Research/ GR - ORSA223095/University of Salerno/ GR - GR-2018-12366312/Ministero della Salute/ PT - Journal Article PT - Review DEP - 20230106 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (RNA, Long Noncoding) RN - 0 (Estrogen Receptor alpha) RN - 0 (Hormones) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics MH - *RNA, Long Noncoding/genetics/metabolism MH - Estrogen Receptor alpha/genetics/metabolism MH - Transcriptome MH - Hormones MH - Gene Expression Regulation, Neoplastic PMC - PMC9863308 OTO - NOTNLM OT - breast cancer biomarkers OT - estrogen receptor alpha OT - estrogen signaling OT - lncRNAs COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:25 PHST- 2022/12/22 00:00 [received] PHST- 2023/01/03 00:00 [revised] PHST- 2023/01/05 00:00 [accepted] PHST- 2023/01/21 01:25 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijms24021145 [pii] AID - ijms-24-01145 [pii] AID - 10.3390/ijms24021145 [doi] PST - epublish SO - Int J Mol Sci. 2023 Jan 6;24(2):1145. doi: 10.3390/ijms24021145. PMID- 36334188 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 1 DP - 2023 Jan TI - Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. PG - 161-175 LID - 10.1007/s10549-022-06732-y [doi] AB - PURPOSE: We aimed to compare (1) treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and (2) the number of treatments started during and before the pandemic. METHODS: Women were selected from the Netherlands Cancer Registry. For aim one, odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the treatment of women diagnosed within four periods of 2020: pre-COVID (weeks 1-8), transition (weeks 9-12), lockdown (weeks 13-17), and care restart (weeks 18-26), with data from 2018/2019 as reference. Wilcoxon rank-sums test was used to compare treatment intervals, using a two-sided p-value < 0.05. For aim two, number of treatments started per week in 2020 was compared with 2018/2019. RESULTS: We selected 34,097 women for aim one. Compared to 2018/2019, neo-adjuvant chemotherapy was less likely for stage I (OR 0.24, 95%CI 0.11-0.53), stage II (OR 0.63, 95%CI 0.47-0.86), and hormone receptor+/HER2- tumors (OR 0.55, 95%CI 0.41-0.75) diagnosed during transition. Time between diagnosis and first treatment decreased for patients diagnosed during lockdown with a stage I (p < 0.01), II (p < 0.01) or III tumor (p = 0.01). We selected 30,002 women for aim two. The number of neo-adjuvant endocrine therapies and surgeries starting in week 14, 2020, increased by 339% and 18%, respectively. The number of adjuvant chemotherapies decreased by 42% in week 15 and increased by 44% in week 22. CONCLUSION: The pandemic and subsequently altered treatment recommendations affected multiple aspects of the breast cancer treatment strategy and the number of treatments started per week. CI - © 2022. The Author(s). FAU - Eijkelboom, Anouk H AU - Eijkelboom AH AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. AD - Department of Health Technology and Services Research, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands. FAU - de Munck, Linda AU - de Munck L AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. FAU - Menke-van der Houven van Oordt, C Willemien AU - Menke-van der Houven van Oordt CW AD - Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands. FAU - Broeders, Mireille J M AU - Broeders MJM AD - Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. AD - Dutch Expert Centre for Screening, Nijmegen, The Netherlands. FAU - van den Bongard, Desiree H J G AU - van den Bongard DHJG AD - Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands. FAU - Strobbe, Luc J A AU - Strobbe LJA AD - Department of Surgical Oncology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. FAU - Mureau, Marc A M AU - Mureau MAM AD - Department of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Lobbes, Marc B I AU - Lobbes MBI AD - Department of Medical Imaging, Zuyderland Medical Center Sittard-Geleen, Geleen, The Netherlands. AD - Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands. AD - School for Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands. FAU - Westenend, Pieter J AU - Westenend PJ AD - Laboratory of Pathology, Dordrecht, The Netherlands. FAU - Koppert, Linetta B AU - Koppert LB AD - Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Jager, Agnes AU - Jager A AD - Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. FAU - Siemerink, Ester J M AU - Siemerink EJM AD - Department of Internal Medicine, Ziekenhuis Groep Twente, Hengelo, The Netherlands. FAU - Wesseling, Jelle AU - Wesseling J AD - Division of Diagnostic Oncology and Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. AD - Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. FAU - Verkooijen, Helena M AU - Verkooijen HM AD - Division of Imaging and Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands. FAU - Vrancken Peeters, Marie-Jeanne T F D AU - Vrancken Peeters MTFD AD - Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands. AD - Department of Surgery, Amsterdam UMC, Amsterdam, The Netherlands. FAU - Smidt, Marjolein L AU - Smidt ML AD - Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Tjan-Heijnen, Vivianne C G AU - Tjan-Heijnen VCG AD - Department of Medical Oncology, School for Oncology and Developmental Biology (GROW), Maastricht University Medical Centre, Maastricht, The Netherlands. FAU - Siesling, Sabine AU - Siesling S AUID- ORCID: 0000-0002-0273-824X AD - Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. s.siesling@utwente.nl. AD - Department of Health Technology and Services Research, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands. s.siesling@utwente.nl. CN - NABON-COVID-19 Consortium CN - COVID and Cancer Care-NL Consortium LA - eng GR - 10430022010014/ZONMW_/ZonMw/Netherlands PT - Journal Article DEP - 20221105 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/therapy/drug therapy MH - Pandemics MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Registries PMC - PMC9638417 OTO - NOTNLM OT - Breast cancer OT - Breast cancer care OT - COVID-19 OT - Treatment COIS- Financial interests: HMV received funding by the Dutch Cancer Foundation, European Commission, ZonMw. MLS received grants from Servier Pharma and Nutricia. JW received funding from the Cancer Research UK KWF Dutch Cancer Society ZonMW and the Antoni van Leeuwenhoek Foundation. Non-financial interests: JW is a member of the Scientific Advisory Board Dutch Expert Centre for Screening. All other authors have no relevant financial or non-financial interests to disclose. FIR - van Hoeve, J C IR - van Hoeve JC FIR - Merkx, M A W IR - Merkx MAW FIR - de Wit, N J IR - de Wit NJ FIR - Dingemans, I IR - Dingemans I FIR - Nagtegaal, I D IR - Nagtegaal ID EDAT- 2022/11/06 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/05 12:26 PHST- 2022/04/26 00:00 [received] PHST- 2022/08/28 00:00 [accepted] PHST- 2022/11/06 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/05 12:26 [entrez] AID - 10.1007/s10549-022-06732-y [pii] AID - 6732 [pii] AID - 10.1007/s10549-022-06732-y [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(1):161-175. doi: 10.1007/s10549-022-06732-y. Epub 2022 Nov 5. PMID- 36379436 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1559-2030 (Electronic) IS - 1551-7144 (Print) IS - 1551-7144 (Linking) VI - 124 DP - 2023 Jan TI - Testing the effects of the Strong Together self-advocacy serious game among women with advanced cancer: Protocol for the STRONG randomized clinical trial. PG - 107003 LID - S1551-7144(22)00329-9 [pii] LID - 10.1016/j.cct.2022.107003 [doi] AB - BACKGROUND: Women with advanced cancer experience significant barriers to achieving high-quality care and maximizing their physical and emotional health. Our novel serious game, Strong Together, aims to teach women with advanced cancer self-advocacy skills needed to improve their symptom burden, quality of life, and patient-centered care. METHODS: This is a single-center, multi-site randomized clinical trial of the Strong Together intervention among 336 women within three months of an advanced breast or gynecologic cancer diagnosis. Randomization occurs to the 3-month Strong Together serious game or enhanced care as usual group. The aims are to: (1) evaluate the effects of the intervention on patient self-advocacy (primary outcome); (2) evaluate the effects of the intervention on quality of life, symptom burden, and patient-centered care (secondary outcomes); and (3) evaluate the behavioral and game mechanisms that influence the efficacy of the intervention. ELIGIBILITY CRITERIA: female, age ≥ 18 years; diagnosis of advanced breast or gynecologic cancer within the past 3 months; Eastern Cooperative Oncology Group score of 0-2; English literacy; and ≥ 6-month life expectancy. Patient-reported outcome measures are collected at baseline, 3-months, and 6-months. CONCLUSION: This protocol is the first large-scale intervention aimed at promoting self-advocacy in women with advanced cancer. Understanding the ability of serious games to impact patient outcomes provides critical information for researchers, clinicians, and stakeholders aiming to improve patient-centered care. TRIAL REGISTRATION: NCT04813276. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Thomas, Teresa H AU - Thomas TH AD - University of Pittsburgh School of Nursing, University of Pittsburgh, 3500 Victoria Street, Pittsburgh 15261, PA, USA; Palliative Research Center (PaRC), University of Pittsburgh, 230 McKee Place, Suite 600, Pittsburgh 15213, PA, USA. Electronic address: t.thomas@pitt.edu. FAU - Bender, Catherine AU - Bender C AD - University of Pittsburgh School of Nursing, University of Pittsburgh, 3500 Victoria Street, Pittsburgh 15261, PA, USA. Electronic address: cbe100@pitt.edu. FAU - Rosenzweig, Margaret AU - Rosenzweig M AD - University of Pittsburgh School of Nursing, University of Pittsburgh, 3500 Victoria Street, Pittsburgh 15261, PA, USA; Palliative Research Center (PaRC), University of Pittsburgh, 230 McKee Place, Suite 600, Pittsburgh 15213, PA, USA; University of Pittsburgh Medical Center Magee-Womens Hospital, 300 Halket Street, Pittsburgh 15213, PA, USA. Electronic address: mros@pitt.edu. FAU - Taylor, Sarah AU - Taylor S AD - University of Pittsburgh Medical Center Magee-Womens Hospital, 300 Halket Street, Pittsburgh 15213, PA, USA. Electronic address: taylorse2@upmc.edu. FAU - Sereika, Susan M AU - Sereika SM AD - University of Pittsburgh School of Nursing, University of Pittsburgh, 3500 Victoria Street, Pittsburgh 15261, PA, USA. Electronic address: ssereika@pitt.edu. FAU - Babichenko, Dmitriy AU - Babichenko D AD - University of Pittsburgh School of Computing and Information, 135 North Bellefield Avenue, Pittsburgh 15213, PA, USA. Electronic address: Dmitriy.b@pitt.edu. FAU - You, Kai-Lin AU - You KL AD - University of Pittsburgh School of Nursing, University of Pittsburgh, 3500 Victoria Street, Pittsburgh 15261, PA, USA. Electronic address: kailinyou@pitt.edu. FAU - Terry, Martha Ann AU - Terry MA AD - University of Pittsburgh School of Public Health, 130 De Soto Street, Pittsburgh 15261, PA, USA. Electronic address: materry@pitt.edu. FAU - Sabik, Lindsay M AU - Sabik LM AD - University of Pittsburgh School of Public Health, 130 De Soto Street, Pittsburgh 15261, PA, USA. Electronic address: lsabik@pitt.edu. FAU - Schenker, Yael AU - Schenker Y AD - Palliative Research Center (PaRC), University of Pittsburgh, 230 McKee Place, Suite 600, Pittsburgh 15213, PA, USA; University of Pittsburgh School of Medicine, Division of General Internal Medicine, 200 Lothrop Street, Pittsburgh 15213, PA, USA. Electronic address: yas28@pitt.edu. LA - eng SI - ClinicalTrials.gov/NCT04813276 GR - R37 CA262025/CA/NCI NIH HHS/United States PT - Clinical Trial Protocol PT - Journal Article DEP - 20221113 PL - United States TA - Contemp Clin Trials JT - Contemporary clinical trials JID - 101242342 SB - IM MH - Adolescent MH - Female MH - Humans MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - Adult MH - *Games, Experimental MH - *Breast Neoplasms/pathology/therapy MH - *Genital Neoplasms, Female/pathology/therapy MH - Treatment Outcome MH - *Self Care PMC - PMC9839496 MID - NIHMS1852207 OTO - NOTNLM OT - Communication OT - Decision-making OT - Health games OT - Patient self-advocacy OT - Videogames OT - Virtual systems COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/16 06:00 MHDA- 2023/01/17 06:00 PMCR- 2024/01/01 CRDT- 2022/11/15 19:27 PHST- 2022/07/15 00:00 [received] PHST- 2022/10/27 00:00 [revised] PHST- 2022/11/09 00:00 [accepted] PHST- 2024/01/01 00:00 [pmc-release] PHST- 2022/11/16 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/11/15 19:27 [entrez] AID - S1551-7144(22)00329-9 [pii] AID - 10.1016/j.cct.2022.107003 [doi] PST - ppublish SO - Contemp Clin Trials. 2023 Jan;124:107003. doi: 10.1016/j.cct.2022.107003. Epub 2022 Nov 13. PMID- 36484412 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1364-5528 (Electronic) IS - 0003-2654 (Linking) VI - 148 IP - 2 DP - 2023 Jan 16 TI - A highly specific and flexible detection assay using collaborated actions of DNA-processing enzymes for identifying multiple gene expression signatures in breast cancer. PG - 316-327 LID - 10.1039/d2an01672a [doi] AB - Most nucleic acid biosensors employ nucleic acid-processing enzymes to bind, degrade, splice, synthesize, and modify nucleic acids. Utilizing their unique substrate preference, binding mode, and catalytic activity is of great importance in designing nucleic acid biosensors. Combination with DNA-processing enzymes enables them to transform into a new generation of molecular diagnostics tools with enhanced selectivity and sensitivity and reduced reaction time. Here, we report an isothermal amplification strategy by coemploying a structure-specific endonuclease (flap endonuclease 1, FEN1) and a strand-displacing DNA polymerase (Bst DNA polymerase) to detect long RNA targets. This approach couples the FEN1-driven invasive cleavage reaction with toehold-mediated rolling circle amplification (iFEN-tRCA), enabling the highly selective and rapid detection of long RNA targets and offering a detection limit below 10 pM within 1 h. We used two targets, such as human epidermal growth factor receptor 2 (HER2, encoded by ERBB2) and dopamine- and cyclic AMP-regulated phosphoprotein (DARPP, encoded by PPP1R1B), associated with prognosis or response to anticancer therapy. We demonstrated the feasibility and quantitative capability of the iFEN-tRCA assay by assessing the expression of two RNA transcripts (ERBB2 and PPP1R1B) with total RNA extracts purified from human breast cancer cells. Therefore, we envision that the developed assay will provide a suitable prognostic and diagnostic tool for identifying appropriate patients for HER2-targeted therapy and predicting the clinical outcome and occurrence of metastasis relapse in breast cancer. FAU - Kim, Dain AU - Kim D AD - Department of Bioengineering & Nano-bioengineering, Research Center for Bio Materials and Process Development, Incheon National University, Incheon 22012, Republic of Korea. e.kim@inu.ac.kr. FAU - Lee, Jiyoung AU - Lee J AD - Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea. FAU - Han, Jueun AU - Han J AD - Department of Chemistry, Incheon National University, Incheon 22012, Republic of Korea. FAU - Lim, Jaewoo AU - Lim J AD - BioNanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea. eklim1112@kribb.re.kr. FAU - Lim, Eun-Kyung AU - Lim EK AUID- ORCID: 0000-0003-2793-3700 AD - BioNanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea. eklim1112@kribb.re.kr. AD - Department of Nanobiotechnology, KRIBB School of Biotechnology, UST, Daejeon 34113, Republic of Korea. AD - School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea. FAU - Kim, Eunjung AU - Kim E AUID- ORCID: 0000-0001-9579-9414 AD - Department of Bioengineering & Nano-bioengineering, Research Center for Bio Materials and Process Development, Incheon National University, Incheon 22012, Republic of Korea. e.kim@inu.ac.kr. AD - Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea. LA - eng PT - Journal Article DEP - 20230116 PL - England TA - Analyst JT - The Analyst JID - 0372652 RN - 9007-49-2 (DNA) RN - EC 2.7.7.7 (DNA-Directed DNA Polymerase) RN - 63231-63-0 (RNA) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/genetics MH - Transcriptome MH - Nucleic Acid Amplification Techniques MH - DNA/genetics/metabolism MH - DNA-Directed DNA Polymerase/chemistry MH - RNA EDAT- 2022/12/10 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/12/09 06:43 PHST- 2022/12/10 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/12/09 06:43 [entrez] AID - 10.1039/d2an01672a [doi] PST - epublish SO - Analyst. 2023 Jan 16;148(2):316-327. doi: 10.1039/d2an01672a. PMID- 36409396 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. PG - 369-376 LID - 10.1007/s10549-022-06798-8 [doi] AB - PURPOSE: SOLAR-1 investigated alpelisib-fulvestrant (ALP + FLV) in patients with HR + /HER2-, PIK3CA-mutated advanced breast cancer and demonstrated a clinically significant increase in all-grade and grade (G) 3-4 hyperglycemia (HG) compared to placebo-fulvestrant. Given high rates of HG, a preventative protocol and identification of associated risk factors was implemented. METHODS: This single-center, retrospective study included patients receiving ALP + FLV. One week before ALP initiation, patients started an insulin-sensitizer. Patients had fasting plasma glucose (FPG) levels drawn day 8, 15, 28, then monthly. Primary outcome was incidence of G2-4 HG by day 28. Risk factors assessed included age, BMI, FPG, and HbA1c. Number of risk factors were compared between patients with and without HG. RESULTS: Sixteen women were included with median age of 59 years. The cohort was 69% White, 25% Black, 75% with BMI ≥ 25 kg/m(2), and 50% with history of diabetes. By day 28, 9 patients (56%) had G2-4 HG, with only 3 (19%) G3 and zero G4. Patients with G2-4 HG had a median of 2 risk factors compared to only 1 if no HG (p = 0.03). 5 patients (31%) required a temporary hold of ALP and 3 (19%) required dose reduction due to HG. 13 patients permanently discontinued ALP-9 due to disease progression and 4 from an adverse event (only 1 HG). CONCLUSION: Implementation of a HG prophylaxis protocol with ALP in a single-center study demonstrated fewer G3-4 HG events compared to that seen in SOLAR-1 (19% vs 36.6%). An increase in HG-associated risk factors correlated with a higher incidence of G2-4 HG. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Burnette, Sarah E AU - Burnette SE AUID- ORCID: 0000-0003-3264-1163 AD - Department of Pharmacy, Atrium Health Wake Forest Baptist, 1 Medical Center Blvd, Winston Salem, NC, 27157, USA. FAU - Poehlein, Emily AU - Poehlein E AUID- ORCID: 0000-0003-1358-0086 AD - Department of Biostatistics and Bioinformatics, Duke University, 2424 Erwin Road, Hock Plaza Suite 1102, Durham, NC, 27710, USA. FAU - Lee, Hui-Jie AU - Lee HJ AUID- ORCID: 0000-0002-6060-8443 AD - Department of Biostatistics and Bioinformatics, Duke University, 2424 Erwin Road, Hock Plaza Suite 1102, Durham, NC, 27710, USA. FAU - Force, Jeremy AU - Force J AUID- ORCID: 0000-0002-3326-2715 AD - Department of Breast Oncology, Duke University Cancer Institute, Durham, NC, USA. FAU - Westbrook, Kelly AU - Westbrook K AD - Department of Breast Oncology, Duke University Cancer Institute, Durham, NC, USA. FAU - Moore, Heather N AU - Moore HN AUID- ORCID: 0000-0002-0619-3267 AD - Department of Pharmacy, Duke University Medical Center, 20 Duke Medicine Circle, Clinic 2-1, Durham, NC, 27710, USA. heather.n.moore@duke.edu. LA - eng PT - Journal Article DEP - 20221121 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 22X328QOC4 (Fulvestrant) RN - 08W5N2C97Q (Alpelisib) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) RN - 0 (EGF Family of Proteins) RN - EC 2.7.1.137 (PIK3CA protein, human) SB - IM MH - Humans MH - Female MH - Middle Aged MH - *Breast Neoplasms/drug therapy/genetics/chemically induced MH - Fulvestrant/therapeutic use MH - Retrospective Studies MH - Receptor, ErbB-2/genetics MH - *Hyperglycemia/prevention & control/chemically induced/drug therapy MH - Risk Factors MH - Class I Phosphatidylinositol 3-Kinases/genetics MH - EGF Family of Proteins/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use OTO - NOTNLM OT - Alpelisib OT - Hormone-receptor positive OT - Hyperglycemia OT - Metastatic breast cancer OT - PIK3CA OT - Rash EDAT- 2022/11/22 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/21 11:17 PHST- 2022/06/23 00:00 [received] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/22 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/21 11:17 [entrez] AID - 10.1007/s10549-022-06798-8 [pii] AID - 10.1007/s10549-022-06798-8 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):369-376. doi: 10.1007/s10549-022-06798-8. Epub 2022 Nov 21. PMID- 35794206 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1439-099X (Electronic) IS - 0179-7158 (Linking) VI - 199 IP - 1 DP - 2023 Jan TI - Near-maximum rib dose is the most relevant risk factor for ipsilateral spontaneous rib fracture: a dosimetric analysis of breast cancer patients after radiotherapy. PG - 38-47 LID - 10.1007/s00066-022-01972-9 [doi] AB - PURPOSE: Spontaneous rib fracture (SRF) is a common late complication in treated breast cancer patients. This study evaluated the incidence and risk factors of ipsilateral SRF after radiotherapy (RT) in breast cancer patients. In addition, we identified dosimetric parameters that were significantly associated with ipsilateral SRF. METHODS: We retrospectively reviewed 2204 patients with breast cancer who underwent RT between 2014 and 2016, and were followed up with bone scans. We evaluated clinical risk factors for ipsilateral SRF. Dose-volume histogram analysis was also performed for patients (n = 538) whose dosimetric data were available. All ipsilateral ribs were manually delineated, and dosimetric parameters of the ribs were converted into the equivalent dose in 2 Gy fractions (EQD2). RESULTS: Most of the patients with SRF (87.3%) were asymptomatic, and the remaining symptomatic patients complained of mild tenderness or chest wall discomfort; these symptoms all resolved within 6 months without any treatment. Ipsilateral SRF occurred in 14.5% of patients 3 years after RT. The median time to develop ipsilateral SRF was 15 months. In dosimetric analysis, near-maximum rib dose (D2cc) best predicted ipsilateral SRF. The cut-off value of D2cc was EQD2 52 Gy, as determined by receiver operating characteristic analysis. In multivariate analysis including dosimetric variables, D2cc EQD2 ≥ 52 Gy was the only significant risk factor for ipsilateral SRF. CONCLUSION: Our data demonstrated that near-maximum rib dose was the best dosimetric parameter to predict ipsilateral SRF in RT-treated breast cancer patients. In addition, our results suggest that patients who received RT with exceeding rib dose cut-off value and had ipsilateral SRF on bone scan be recommended routine follow-up without additional imaging tests. CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. FAU - Kim, Dowook AU - Kim D AUID- ORCID: 0000-0002-6620-7085 AD - Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea (Republic of). FAU - Kim, Kyubo AU - Kim K AUID- ORCID: 0000-0001-6093-1294 AD - Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Korea (Republic of). FAU - Kim, Jae Sik AU - Kim JS AUID- ORCID: 0000-0002-0039-8667 AD - Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea (Republic of). AD - Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong, Seoul, Korea (Republic of). FAU - Kang, Seonghee AU - Kang S AUID- ORCID: 0000-0002-1153-6842 AD - Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea (Republic of). AD - Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea (Republic of). FAU - Park, Jong Min AU - Park JM AUID- ORCID: 0000-0003-3617-3870 AD - Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea (Republic of). AD - Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea (Republic of). AD - Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea (Republic of). FAU - Shin, Kyung Hwan AU - Shin KH AUID- ORCID: 0000-0002-5852-7644 AD - Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea (Republic of). radiat@snu.ac.kr. AD - Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea (Republic of). radiat@snu.ac.kr. AD - Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea (Republic of). radiat@snu.ac.kr. LA - eng PT - Journal Article DEP - 20220706 PL - Germany TA - Strahlenther Onkol JT - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] JID - 8603469 SB - IM MH - Humans MH - Female MH - *Rib Fractures/etiology/epidemiology MH - *Breast Neoplasms/radiotherapy/complications MH - Retrospective Studies MH - Ribs MH - *Fractures, Spontaneous/etiology MH - Risk Factors MH - Radiotherapy Dosage OTO - NOTNLM OT - Adverse effect OT - Breast neoplasm OT - Maximum tolerated doses OT - Radiation-induced rib fracture OT - Radiotherapy EDAT- 2022/07/07 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/07/06 23:25 PHST- 2022/02/23 00:00 [received] PHST- 2022/06/13 00:00 [accepted] PHST- 2022/07/07 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/07/06 23:25 [entrez] AID - 10.1007/s00066-022-01972-9 [pii] AID - 10.1007/s00066-022-01972-9 [doi] PST - ppublish SO - Strahlenther Onkol. 2023 Jan;199(1):38-47. doi: 10.1007/s00066-022-01972-9. Epub 2022 Jul 6. PMID- 36326735 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 2374-2445 (Electronic) IS - 2374-2437 (Print) IS - 2374-2437 (Linking) VI - 9 IP - 1 DP - 2023 Jan 1 TI - Receipt of Bilateral Mastectomy Among Women With Hereditary Breast Cancer. PG - 143-145 LID - 10.1001/jamaoncol.2022.5162 [doi] FAU - Reid, Sonya AU - Reid S AD - Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. AD - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Roberson, Mya L AU - Roberson ML AD - Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. AD - Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee. FAU - Koehler, Kenna AU - Koehler K AD - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Shah, Tiana AU - Shah T AD - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Weidner, Anne AU - Weidner A AD - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Whisenant, Jennifer G AU - Whisenant JG AD - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. FAU - Pal, Tuya AU - Pal T AD - Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. AD - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. LA - eng GR - K12 CA090625/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - JAMA Oncol JT - JAMA oncology JID - 101652861 RN - Breast Cancer, Familial SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/genetics/surgery MH - Mastectomy MH - Genetic Predisposition to Disease PMC - PMC9634589 MID - NIHMS1847510 OAB - This case series study examines differences in surgical treatment among adult females with invasive breast cancer who have pathogenic or likely pathogenic variants in genes with high vs moderate breast cancer penetrance. OABL- eng COIS- Conflict of Interest Disclosures: Dr Reid reported being a consultant for Novartis, AstraZeneca, and Daiichi Sankyo outside the submitted work. No other disclosures were reported. EDAT- 2022/11/04 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/11/03 11:33 PHST- 2022/11/04 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/11/03 11:33 [entrez] AID - 2797978 [pii] AID - 10.1001/jamaoncol.2022.5162 [doi] PST - ppublish SO - JAMA Oncol. 2023 Jan 1;9(1):143-145. doi: 10.1001/jamaoncol.2022.5162. PMID- 35858154 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221229 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 41 IP - 1 DP - 2023 Jan 1 TI - Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. PG - 65-74 LID - 10.1200/JCO.21.02953 [doi] AB - PURPOSE: Intravenous paclitaxel (IVpac) is complicated by neuropathy and requires premedication to prevent hypersensitivity-type reactions. Paclitaxel is poorly absorbed orally; encequidar (E), a novel P-glycoprotein pump inhibitor, allows oral absorption. METHODS: A phase III open-label study comparing oral paclitaxel plus E (oPac + E) 205 mg/m(2) paclitaxel plus 15 mg E methanesulfonate monohydrate 3 consecutive days per week versus IVpac 175 mg/m(2) once every 3 weeks was performed. Women with metastatic breast cancer and adequate organ function, at least 1 year from last taxane, were randomly assigned 2:1 to oPac + E versus IVpac. The primary end point was confirmed radiographic response using RECIST 1.1, assessed by blinded independent central review. Secondary end points included progression-free survival (PFS) and overall survival (OS). RESULTS: Four hundred two patients from Latin America were enrolled (265 oPac + E, 137 IVpac); demographics and prior therapies were balanced. The confirmed response (intent-to-treat) was 36% for oPac + E versus 23% for IVpac (P = .01). The PFS was 8.4 versus 7.4 months, respectively (hazard ratio, 0.768; 95.5% CI, 0.584 to 1.01; P = .046), and the OS was 22.7 versus 16.5 months, respectively (hazard ratio, 0.794; 95.5% CI, 0.607 to 1.037; P = .08). Grade 3-4 adverse reactions were 55% with oPac + E and 53% with IVpac. oPac + E had lower incidence and severity of neuropathy (2% v 15% > grade 2) and alopecia (49% v 62% all grades) than IVpac but more nausea, vomiting, diarrhea, and neutropenic complications, particularly in patients with elevated liver enzymes. On-study deaths (8% oPac + E v 9% IVpac) were treatment-related in 3% and 0%, respectively. CONCLUSION: oPac + E increased the confirmed tumor response versus IVpac, with trends in PFS and OS. Neuropathy was less frequent and severe with oPac + E; neutropenic serious infections were increased. Elevated liver enzymes at baseline predispose oPac + E patients to early neutropenia and serious infections (funded by Athenex, Inc; ClinicalTrials.gov identifier: NCT02594371). FAU - Rugo, Hope S AU - Rugo HS AUID- ORCID: 0000-0001-6710-4814 AD - University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. FAU - Umanzor, Gerardo A AU - Umanzor GA AUID- ORCID: 0000-0002-0298-706X AD - Centro Oncológico Integral with DEMEDICA, San Pedro Sula, Honduras. FAU - Barrios, Francisco J AU - Barrios FJ AD - American Cancer Center, Guatemala City, Guatemala. FAU - Vasallo, Rosa H AU - Vasallo RH AUID- ORCID: 0000-0002-9964-5778 AD - Clinical Research RD, Santo Domingo, Dominican Republic. FAU - Chivalan, Marco A AU - Chivalan MA AD - CELAN Clínica Médica, Guatemala City, Guatemala. FAU - Bejarano, Suyapa AU - Bejarano S AUID- ORCID: 0000-0002-2894-1342 AD - Excel Medica, San Pedro Sula, Honduras. FAU - Ramírez, Julio R AU - Ramírez JR AD - Sanatorio Centro Regional de Sub-Especialidades Médicas (CRESEM), Quetzaltenango, Guatemala. FAU - Fein, Luis AU - Fein L AUID- ORCID: 0000-0003-2627-1346 AD - Instituto de Oncología de Rosario, Rosario, Argentina. FAU - Kowalyszyn, Ruben D AU - Kowalyszyn RD AD - Centro de Investigaciones Clínicas, Clínica Viedma, Viedma, Argentina. FAU - Kramer, E Douglas AU - Kramer ED AD - Athenex, Inc, Buffalo, NY. FAU - Wang, Hui AU - Wang H AD - Athenex, Inc, Buffalo, NY. FAU - Kwan, Min-Fun R AU - Kwan MR AD - Athenex, Inc, Buffalo, NY. FAU - Cutler, David L AU - Cutler DL AUID- ORCID: 0000-0002-8164-1082 AD - Athenex, Inc, Buffalo, NY. CN - Oraxol Study Consortium Investigators LA - eng SI - ClinicalTrials.gov/NCT02594371 PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20220720 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - P88XT4IS4D (Paclitaxel) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/pathology MH - Paclitaxel/adverse effects MH - Progression-Free Survival MH - Proportional Hazards Models MH - Administration, Intravenous MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9788977 COIS- David L. Cutler Employment: Athenex Stock and Other Ownership Interests: Merck Sharp & Dohme, Athenex No other potential conflicts of interest were reported. EDAT- 2022/07/21 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/07/20 16:03 PHST- 2022/07/21 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/07/20 16:03 [entrez] AID - JCO.21.02953 [pii] AID - 10.1200/JCO.21.02953 [doi] PST - ppublish SO - J Clin Oncol. 2023 Jan 1;41(1):65-74. doi: 10.1200/JCO.21.02953. Epub 2022 Jul 20. PMID- 36332179 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230118 IS - 1527-7755 (Electronic) IS - 0732-183X (Print) IS - 0732-183X (Linking) VI - 41 IP - 2 DP - 2023 Jan 10 TI - Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. PG - 198-205 LID - 10.1200/JCO.21.02937 [doi] AB - Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711), a study of margetuximab versus trastuzumab, both with chemotherapy, in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer, is reported with updated safety. Overall, 536 patients in the intention-to-treat population were randomly assigned to margetuximab (15 mg/kg intravenously once every 3 weeks; n = 266) plus chemotherapy or trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg; n = 270) plus chemotherapy. Primary end points were progression-free survival, previously reported, and OS. Final OS analysis was triggered by 385 prespecified events. The median OS was 21.6 months (95% CI, 18.89 to 25.07) with margetuximab versus 21.9 months (95% CI, 18.69 to 24.18) with trastuzumab (hazard ratio [HR], 0.95; 95% CI, 0.77 to 1.17; P = .620). Preplanned, exploratory analysis of CD16A genotyping suggested a possible improvement in OS for margetuximab in CD16A-158FF patients versus trastuzumab (median OS, 23.6 v 19.2 months; HR, 0.72; 95% CI, 0.52 to 1.00) and a possible improvement in OS for trastuzumab in CD16A-158VV patients versus margetuximab (median OS, 31.1 v 22.0 months; HR, 1.77; 95% CI, 1.01 to 3.12). Margetuximab safety was comparable with trastuzumab. Final overall OS analysis did not demonstrate margetuximab advantage over trastuzumab. Margetuximab studies in patients with human epidermal growth factor receptor 2-positive breast cancer with different CD16A allelic variants are warranted. FAU - Rugo, Hope S AU - Rugo HS AUID- ORCID: 0000-0001-6710-4814 AD - University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. FAU - Im, Seock-Ah AU - Im SA AUID- ORCID: 0000-0002-5396-6533 AD - Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea. FAU - Cardoso, Fatima AU - Cardoso F AUID- ORCID: 0000-0002-6692-2249 AD - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. FAU - Cortes, Javier AU - Cortes J AUID- ORCID: 0000-0001-7623-1583 AD - Quironsalud Group, International Breast Cancer Center (IBCC), Madrid and Barcelona, Spain. AD - Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain. FAU - Curigliano, Giuseppe AU - Curigliano G AD - Istituto Europeo di Oncologia, IRCCS, University of Milano, Milan, Italy. FAU - Musolino, Antonino AU - Musolino A AD - Department of Medicine and Surgery, University of Parma, Parma, Italy. AD - Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. AD - Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy. FAU - Pegram, Mark D AU - Pegram MD AUID- ORCID: 0000-0002-9743-8118 AD - Stanford Comprehensive Cancer Institute, Stanford University School of Medicine, Stanford, CA. FAU - Bachelot, Thomas AU - Bachelot T AUID- ORCID: 0000-0002-0866-9484 AD - Medical Oncology Department, Centre Leon Berard, Lyon, France. FAU - Wright, Gail S AU - Wright GS AD - Florida Cancer Specialists & Research Institute, New Port Richey, FL. FAU - Saura, Cristina AU - Saura C AUID- ORCID: 0000-0001-8296-5065 AD - Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. FAU - Escrivá-de-Romaní, Santiago AU - Escrivá-de-Romaní S AD - Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. FAU - De Laurentiis, Michelino AU - De Laurentiis M AUID- ORCID: 0000-0001-9009-1572 AD - Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione Pascale," Naples, Italy. FAU - Schwartz, Gary N AU - Schwartz GN AUID- ORCID: 0000-0003-2537-9531 AD - Division of Medical Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH. FAU - Pluard, Timothy J AU - Pluard TJ AD - Saint Luke's Cancer Institute, Kansas City, MO. FAU - Ricci, Francesco AU - Ricci F AD - Institut Curie, Paris, France. FAU - Gwin, William R 3rd AU - Gwin WR 3rd AD - Division of Medical Oncology/Seattle Cancer Care Alliance, University of Washington, Seattle, WA. FAU - Levy, Christelle AU - Levy C AD - Centre François Baclesse, Institut Normand du Sein, Caen, France. FAU - Brown-Glaberman, Ursa AU - Brown-Glaberman U AD - Division of Hematology/Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM. FAU - Ferrero, Jean-Marc AU - Ferrero JM AD - Department of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France. FAU - de Boer, Maaike AU - de Boer M AD - Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, GROW-School of Oncology and Developmental Biology, Maastricht, the Netherlands. FAU - Kim, Sung-Bae AU - Kim SB AUID- ORCID: 0000-0001-5588-8332 AD - Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. FAU - Petráková, Katarína AU - Petráková K AD - Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. FAU - Yardley, Denise A AU - Yardley DA AD - Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN. FAU - Freedman, Orit AU - Freedman O AD - RS McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, ON, Canada. FAU - Jakobsen, Erik H AU - Jakobsen EH AD - Department of Oncology, Vejle Hospital, Vejle, Denmark. FAU - Gal-Yam, Einav Nili AU - Gal-Yam EN AD - Chaim Sheba Medical Center, Breast Oncology Institute, Ramat Gan, Israel. FAU - Yerushalmi, Rinat AU - Yerushalmi R AD - Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. FAU - Fasching, Peter A AU - Fasching PA AUID- ORCID: 0000-0003-4885-8471 AD - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Kaufman, Peter A AU - Kaufman PA AUID- ORCID: 0000-0003-3677-6807 AD - Breast Oncology, Division of Hematology/Oncology, University of Vermont Cancer Center, Burlington, VT. FAU - Ashley, Emily J AU - Ashley EJ AD - MacroGenics, Inc, Rockville, MD. FAU - Perez-Olle, Raul AU - Perez-Olle R AUID- ORCID: 0000-0001-9313-3694 AD - MacroGenics, Inc, Rockville, MD. AD - Former Employees of MacroGenics, Inc, Rockville, MD. FAU - Hong, Shengyan AU - Hong S AD - MacroGenics, Inc, Rockville, MD. FAU - Rosales, Minori Koshiji AU - Rosales MK AD - MacroGenics, Inc, Rockville, MD. AD - Former Employees of MacroGenics, Inc, Rockville, MD. FAU - Gradishar, William J AU - Gradishar WJ AUID- ORCID: 0000-0002-2772-3140 AD - Division of Hematology/Oncology, Northwestern University, Chicago, IL. CN - SOPHIA Study Group LA - eng SI - ClinicalTrials.gov/NCT02492711 PT - Clinical Trial, Phase III PT - Journal Article PT - Randomized Controlled Trial DEP - 20221104 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 RN - P188ANX8CK (Trastuzumab) RN - K911R84KEW (margetuximab) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM MH - Humans MH - Female MH - Trastuzumab/adverse effects MH - *Breast Neoplasms/drug therapy/genetics MH - Receptor, ErbB-2 MH - Antibodies, Monoclonal, Humanized/adverse effects MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9839304 COIS- Shengyan Hong Employment: MacroGenics Stock and Other Ownership Interests: MacroGenics No other potential conflicts of interest were reported. EDAT- 2022/11/05 06:00 MHDA- 2023/01/10 06:00 CRDT- 2022/11/04 16:03 PHST- 2022/11/05 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/11/04 16:03 [entrez] AID - JCO.21.02937 [pii] AID - 10.1200/JCO.21.02937 [doi] PST - ppublish SO - J Clin Oncol. 2023 Jan 10;41(2):198-205. doi: 10.1200/JCO.21.02937. Epub 2022 Nov 4. PMID- 35039446 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1468-6244 (Electronic) IS - 0022-2593 (Linking) VI - 60 IP - 1 DP - 2023 Jan TI - Long-term tumour dormancy in a BRCA1 heterozygote. PG - 33-35 LID - 10.1136/jmedgenet-2021-108269 [doi] FAU - Amuzu, Setor AU - Amuzu S AUID- ORCID: 0000-0003-3244-7475 AD - Genome Sciences, McGill Genome Centre, Montreal, Quebec, Canada. AD - Department of Human Genetics, McGill University, Montreal, Quebec, Canada. FAU - Fu, Lili AU - Fu L AD - Department of Pathology, McGill University, Montreal, Quebec, Canada. FAU - Demko, Nadine AU - Demko N AD - Department of Pathology, McGill University, Montreal, Quebec, Canada. FAU - Rivera, Barbara AU - Rivera B AD - Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. AD - Program in Molecular Mechanisms and Experimental Therapy in Oncology (ONCOBELL), and Hereditary Cancer Program at ICO-IDIBELL, Bellvitge Biomedical Research Institut (IDIBELL), Barcelona, Spain. FAU - Domecq, Celine AU - Domecq C AD - Cancer Research Program, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. FAU - de Kock, Leanne AU - de Kock L AD - Department of Human Genetics, McGill University, Montreal, Quebec, Canada. AD - Department of Pediatrics, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada. FAU - Hamel, Nancy AU - Hamel N AD - Cancer Research Program, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. FAU - Gilbert, Lucy AU - Gilbert L AD - Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. AD - Cancer Research Program, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. AD - Departments of Obstetrics & Gynaecology, McGill University, Montreal, Quebec, Canada. FAU - Polak, Paz AU - Polak P AD - Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. AD - Department of Oncological Sciences, and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Ragoussis, Jiannis AU - Ragoussis J AD - Genome Sciences, McGill Genome Centre, Montreal, Quebec, Canada. AD - Department of Human Genetics, McGill University, Montreal, Quebec, Canada. FAU - Foulkes, William D AU - Foulkes WD AUID- ORCID: 0000-0001-7427-4651 AD - Department of Human Genetics, McGill University, Montreal, Quebec, Canada william.foulkes@mcgill.ca. AD - Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. AD - Cancer Research Program, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. AD - Department of Medicine, McGill University, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20220117 PL - England TA - J Med Genet JT - Journal of medical genetics JID - 2985087R RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) SB - IM MH - Humans MH - Female MH - Heterozygote MH - BRCA1 Protein/genetics MH - *Neoplasms MH - Mutation MH - *Breast Neoplasms/genetics OTO - NOTNLM OT - genomic instability OT - genomics OT - gynecology OT - mutation OT - peritoneal diseases COIS- Competing interests: None declared. EDAT- 2022/01/19 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/01/18 05:46 PHST- 2021/10/13 00:00 [received] PHST- 2021/12/10 00:00 [accepted] PHST- 2022/01/19 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/01/18 05:46 [entrez] AID - jmedgenet-2021-108269 [pii] AID - 10.1136/jmedgenet-2021-108269 [doi] PST - ppublish SO - J Med Genet. 2023 Jan;60(1):33-35. doi: 10.1136/jmedgenet-2021-108269. Epub 2022 Jan 17. PMID- 35833600 OWN - NLM STAT- MEDLINE DCOM- 20230118 LR - 20230118 IS - 1365-277X (Electronic) IS - 0952-3871 (Linking) VI - 36 IP - 1 DP - 2023 Feb TI - Response to a novel, weight self-awareness plan used in a multi-component lifestyle intervention programme to reduce breast cancer risk factors in older women-Secondary analysis from the ActWELL trial. PG - 266-276 LID - 10.1111/jhn.13062 [doi] AB - BACKGROUND: The ActWELL randomised controlled trial assessed the effectiveness of a weight management programme delivered by volunteer lifestyle coaches (LCs) in women attending breast clinics. The intervention focused on caloric intake and physical activity, utilising behavioural change techniques including a weight awareness plan (WAP). The current work is a secondary analysis of the ActWELL data and aims to examine the response to the weight self-awareness plan (used as part of the intervention programme). METHODS: The LCs invited participants (n = 279) to undertake an implementation intention discussion to formulate a self-weighing (SW) plan. Bodyweight scales were offered, and recording books provided. The physical activity component of the intervention focused on a walking plan assessed by accelerometers. The LCs contacted participants by telephone monthly and provided personalised feedback. Mann-Whitney tests and chi-squared analysis were used to examine the effect of SW on weight change. A qualitative evaluation utilising semi-structured interviews was also undertaken. RESULTS: Most participants (96.4%) agreed to set a weekly SW goal and 76 (27%) requested scales. At 12 months, 226 (81%) returned for follow up. The median (interquartile range) weight change for those who self- reported at least one weight (n = 211) was -2.3 kg (-5.0 to 0.0) compared to -1.2 kg (-5.0 to 0.03) in those who did not (n = 14). Participants who reported weights on more than eight occasions (39%) were significantly more likely (p = 0.012) to achieve 5% weight loss compared to those who weighed less often. Low numbers of accelerometers were returned that did not allow for significance testing. Qualitative data (n = 24) indicated that many participants found the WAP helpful and motivating. CONCLUSIONS: Greater adherence to the WAP initiated by volunteer coaches is associated with achieving 5% weight loss. CI - © 2022 The Authors. Journal of Human Nutrition and Dietetics published by John Wiley & Sons Ltd on behalf of British Dietetic Association. FAU - Zaremba, Suzanne M M AU - Zaremba SMM AUID- ORCID: 0000-0003-1479-9653 AD - Division of Population Health & Genomics, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK. FAU - Stead, Martine AU - Stead M AUID- ORCID: 0000-0002-3066-4604 AD - Faculty of Health Sciences and Sport, Institute for Social Marketing and Health, University of Stirling, Stirling, UK. FAU - McKell, Jennifer AU - McKell J AUID- ORCID: 0000-0002-2912-0837 AD - Faculty of Health Sciences and Sport, Institute for Social Marketing and Health, University of Stirling, Stirling, UK. FAU - O'Carroll, Ronan E AU - O'Carroll RE AUID- ORCID: 0000-0001-7090-3414 AD - Division of Psychology, School of Natural Sciences, University of Stirling, Stirling, UK. FAU - Mutrie, Nanette AU - Mutrie N AUID- ORCID: 0000-0002-5018-6398 AD - Physical Activity for Health Research Centre, University of Edinburgh, Edinburgh, UK. FAU - Treweek, Shaun AU - Treweek S AUID- ORCID: 0000-0002-7239-7241 AD - Health Services Research Unit, University of Aberdeen, Aberdeen, UK. FAU - Anderson, Annie S AU - Anderson AS AUID- ORCID: 0000-0002-0047-4500 AD - Division of Population Health & Genomics, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK. CN - ActWELL team LA - eng GR - Scottish Government/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20220802 PL - England TA - J Hum Nutr Diet JT - Journal of human nutrition and dietetics : the official journal of the British Dietetic Association JID - 8904840 SB - IM MH - Humans MH - Female MH - Aged MH - *Breast Neoplasms/prevention & control MH - Life Style MH - Exercise MH - Weight Loss MH - Risk Factors OTO - NOTNLM OT - breast-cancer OT - self-monitoring OT - weight EDAT- 2022/07/15 06:00 MHDA- 2023/01/19 06:00 CRDT- 2022/07/14 07:34 PHST- 2022/03/30 00:00 [received] PHST- 2022/06/13 00:00 [accepted] PHST- 2022/07/15 06:00 [pubmed] PHST- 2023/01/19 06:00 [medline] PHST- 2022/07/14 07:34 [entrez] AID - 10.1111/jhn.13062 [doi] PST - ppublish SO - J Hum Nutr Diet. 2023 Feb;36(1):266-276. doi: 10.1111/jhn.13062. Epub 2022 Aug 2. PMID- 36510353 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230115 IS - 1098-2825 (Electronic) IS - 0887-8013 (Print) IS - 0887-8013 (Linking) VI - 37 IP - 1 DP - 2023 Jan TI - Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population. PG - e24806 LID - 10.1002/jcla.24806 [doi] LID - e24806 AB - OBJECTIVE: The KRAS gene has a pathophysiological role in the development of many cancers. This study aims to investigate the relationship between KRAS polymorphisms and genetic susceptibility to breast cancer. METHOD: The rs712, rs12587 and rs9266 gene loci in the KRAS gene of 421 subjects (141 breast cancer patients, 141 benign breast tumours and 139 healthy controls) were analysed by the polymerase chain reaction and SNaPshot sequencing. Transcriptomic information on KRAS and corresponding clinical information was downloaded from the TCGA and GTEx databases. Differences in KRAS expression between breast cancer tissues and control tissues were analysed. RESULTS: We found no significant association between KRAS rs712 and rs12587 locus gene polymorphisms and an increased risk of developing benign breast tumours and breast cancer (p > 0.05). The KRAS rs9266 locus mutation heterozygous model CT and dominant model CT + TT were significantly associated with an increased risk of breast cancer (both p < 0.05). In addition, the TAT haplotype was expressed at an increased frequency, and the GAC haplotype was expressed at a reduced frequency in breast cancer compared with controls (both p < 0.05). We found that KRAS was over expressed in breast cancer tumour tissues compared with the control tissues (p < 0.0001). CONCLUSION: The KRAS rs9266 gene polymorphism and the TAT haplotype may be associated with an increased risk of breast cancer in Chinese women. The GAC haplotype may be a protective factor against breast cancer. CI - © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. FAU - Jin, Min AU - Jin M AD - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Lu, Fengke AU - Lu F AUID- ORCID: 0000-0001-5976-3772 AD - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Department of Clinical Laboratory, Liuzhou Maternity and Child Healthcare Hospital, Affiliated Maternity Hospital and Affiliated Children's Hospital of Guangxi University of Science and Technology, Liuzhou, China. FAU - Li, Xi AU - Li X AUID- ORCID: 0000-0002-1981-9273 AD - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Zhou, Wei AU - Zhou W AD - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Li, Sihui AU - Li S AUID- ORCID: 0000-0002-3524-676X AD - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Jiang, Yanting AU - Jiang Y AUID- ORCID: 0000-0002-6578-4788 AD - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Wu, Huiling AU - Wu H AD - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Wang, Jian AU - Wang J AUID- ORCID: 0000-0001-9174-6219 AD - Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. LA - eng GR - 81660275/National Natural Science Foundation of China/ GR - S2017022/Scientific Research Project of Health and Health Committee of Guangxi Zhuang Autonomous Region/ PT - Journal Article DEP - 20221212 PL - United States TA - J Clin Lab Anal JT - Journal of clinical laboratory analysis JID - 8801384 RN - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) RN - 0 (KRAS protein, human) SB - IM MH - Humans MH - Female MH - *Genetic Predisposition to Disease/genetics MH - *Breast Neoplasms/epidemiology/genetics MH - Proto-Oncogene Proteins p21(ras)/genetics MH - East Asian People MH - Gene Frequency MH - Polymorphism, Single Nucleotide/genetics MH - Case-Control Studies MH - Genotype PMC - PMC9833971 OTO - NOTNLM OT - KRAS OT - Chinese population OT - breast cancer OT - single-nucleotide polymorphism COIS- The authors declare that there is no conflict of interest regarding the publication of this article. EDAT- 2022/12/14 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/12/13 00:02 PHST- 2022/10/30 00:00 [revised] PHST- 2022/08/31 00:00 [received] PHST- 2022/11/22 00:00 [accepted] PHST- 2022/12/14 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/12/13 00:02 [entrez] AID - JCLA24806 [pii] AID - 10.1002/jcla.24806 [doi] PST - ppublish SO - J Clin Lab Anal. 2023 Jan;37(1):e24806. doi: 10.1002/jcla.24806. Epub 2022 Dec 12. PMID- 36223556 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230125 IS - 2688-1535 (Electronic) IS - 2688-1527 (Print) IS - 2688-1527 (Linking) VI - 19 IP - 1 DP - 2023 Jan TI - IMPACT the Brain: A Team-Based Approach to Management of Metastatic Breast Cancer With CNS Metastases. PG - e67-e77 LID - 10.1200/OP.22.00291 [doi] AB - PURPOSE: CNS metastases are associated with decreased survival and quality of life for patients with metastatic breast cancer (MBC). Team-based care can optimize outcomes. IMPACT the Brain is a care coordination program that aims to improve access to team-based care for patients with MBC and CNS metastases. MATERIALS AND METHODS: Patients with MBC and CNS metastases were eligible for enrollment in this care coordination program. A team of specialists supported a dedicated program coordinator who provided navigation, education, specialty referral, and clinical trial screening. A unique intake form developed for the program created personalized, coordinated, and expedited specialty referrals. Patient-reported outcomes and caregiver burden assessments were collected on a voluntary basis throughout enrollment. Data were analyzed using descriptive statistics. RESULTS: Sixty patients were referred, and 53 were enrolled (88%). The median time to program enrollment was 1 day (range, 0-11) and to first visit was 5 days (range, 0-25). On the basis of the program intake form, 47 referrals were made across six specialties, most commonly physical medicine and rehabilitation (n = 10), radiation oncology (n = 10), and neuropsychology (n = 10). Nineteen patients (36%) consented to enroll in clinical trials. CONCLUSION: A tailored team-based care coordination program for patients with MBC and CNS metastases is feasible. Use of a unique intake screening form by a dedicated program coordinator resulted in faster time to first patient visit, enabled access to subspecialist care, and supported enrollment in clinical trials. Future research should focus on intervention development using PRO data collected in this care coordination program. FAU - Fleege, Nicole M Grogan AU - Fleege NMG AUID- ORCID: 0000-0001-6214-2790 AD - University of Michigan Health System, Ann Arbor, MI. FAU - Pierce-Gjeldum, Donna AU - Pierce-Gjeldum D AD - University of Michigan Health System, Ann Arbor, MI. FAU - Swartz, Leigh K AU - Swartz LK AD - Hunter Holmes McGuire VAMC, Richmond, VA. FAU - Verbal, Kait AU - Verbal K AD - University of Michigan Health System, Ann Arbor, MI. FAU - Merajver, Sofia AU - Merajver S AUID- ORCID: 0000-0002-6823-7130 AD - University of Michigan Health System, Ann Arbor, MI. FAU - Friese, Christopher R AU - Friese CR AUID- ORCID: 0000-0002-2281-2056 AD - University of Michigan Health System, Ann Arbor, MI. FAU - Kiyota, Ayano AU - Kiyota A AD - University of Michigan Health System, Ann Arbor, MI. FAU - Heth, Jason AU - Heth J AD - University of Michigan Health System, Ann Arbor, MI. FAU - Leung, Denise AU - Leung D AUID- ORCID: 0000-0003-4302-0098 AD - University of Michigan Health System, Ann Arbor, MI. FAU - Smith, Sean R AU - Smith SR AUID- ORCID: 0000-0001-9936-8750 AD - University of Michigan Health System, Ann Arbor, MI. FAU - Gabel, Nicolette AU - Gabel N AUID- ORCID: 0000-0002-0239-6403 AD - University of Michigan Health System, Ann Arbor, MI. FAU - Kim, Michelle M AU - Kim MM AUID- ORCID: 0000-0001-7566-6411 AD - University of Michigan Health System, Ann Arbor, MI. FAU - Morikawa, Aki AU - Morikawa A AUID- ORCID: 0000-0002-4764-4896 AD - University of Michigan Health System, Ann Arbor, MI. LA - eng PT - Journal Article DEP - 20221012 PL - United States TA - JCO Oncol Pract JT - JCO oncology practice JID - 101758685 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Quality of Life MH - *Central Nervous System Neoplasms MH - Brain/pathology PMC - PMC9870235 COIS- Leigh K. Swartz Employment: TriMed, Integra LifeSciences Consulting or Advisory Role: LEK Sofia Merajver Employment: Inheret, LLC Leadership: Inheret, LLC Stock and Other Ownership Interests: Inheret, LLC Christopher R. Friese Research Funding: Merck (Inst), NCCN/Pfizer (Inst) Other Relationship: Patient-Centered Outcomes Research Institute (PCORI), National Cancer Institute Michelle M. Kim Consulting or Advisory Role: Blue Earth Diagnostics (Inst) Research Funding: EpicentRx (Inst), Blue Earth Diagnostics (Inst) Travel, Accommodations, Expenses: Capital Health Aki Morikawa Consulting or Advisory Role: Eisai, Lilly, Seattle Genetics Research Funding: Lilly (Inst), Merrimack (Inst), Novartis (Inst), Genentech/Roche (Inst), Millenium Pharamceuticals (Inst), Eisai (Inst), Seattle Genetics (Inst), Pfizer (Inst), Tempus (Inst), Molecular Templates (Inst), Dantari Pharmaceuticals (Inst), Suzhou Zanrong Pharma Limited (Inst), Merck Sharp & Dohme Corp (Inst), F. Hoffmann-La Roche Ltd, (Inst) Other Relationship: Taiho Pharmaceutical Uncompensated Relationships: Puma Biotechnology No other potential conflicts of interest were reported. EDAT- 2022/10/13 06:00 MHDA- 2023/01/14 06:00 CRDT- 2022/10/12 16:02 PHST- 2022/10/13 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2022/10/12 16:02 [entrez] AID - OP.22.00291 [pii] AID - 10.1200/OP.22.00291 [doi] PST - ppublish SO - JCO Oncol Pract. 2023 Jan;19(1):e67-e77. doi: 10.1200/OP.22.00291. Epub 2022 Oct 12. PMID- 36658289 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Jan 19 TI - Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan. PG - 1018 LID - 10.1038/s41598-023-28304-w [doi] LID - 1018 AB - To determine the impact of the coverage of risk-reducing salpingo-oophorectomy (RRSO) and mastectomy (RRM) as well as genetic testing for BRCA pathogenic variants by the national insurance system in Japan. We compared the clinical background of women who underwent RRSO at our institution before and after its coverage by the national insurance system. Those who underwent RRSO between January 2017 and December 2019 and between April 2020 and March 2022 were classified as Period. A and B, respectively. Overall, 134 women underwent RRSO during the study period. In Period A and B, 45 and 89 women underwent RRSO for the study period was 36 and 24 months, respectively. Compared with Period A, the number of women who underwent RRSO per month increased by threefold in Period B (p < 0.01). In addition, the number of women who underwent surgery for breast cancer along with RRSO increased in Period B (p < 0.01). Although the number of women who underwent concurrent RRM with RRSO in Period B increased, the difference was not statistically significant. Compared with Period A, the number of women diagnosed with BRCA pathogenic variant increased by 3.9-fold, and the proportion of women who underwent concurrent hysterectomy at the time of RRSO decreased from 66 to 7.9% in Period B (p < 0.01). Owing to the introduction of the national insurance system, the number of women who underwent RRSO and concurrent surgery for breast cancer at the time of RRSO increased in Japan. CI - © 2023. The Author(s). FAU - Nomura, Hidetaka AU - Nomura H AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. hidetaka.nomura@jfcr.or.jp. FAU - Abe, Akiko AU - Abe A AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Fusegi, Atsushi AU - Fusegi A AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Yoshimitsu, Teruyuki AU - Yoshimitsu T AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Misaka, Satoki AU - Misaka S AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Murakami, Atsushi AU - Murakami A AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Matsumoto, Tsuyoshi AU - Matsumoto T AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Tsumura, Shiho AU - Tsumura S AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Kanno, Motoko AU - Kanno M AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Aoki, Yoichi AU - Aoki Y AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Netsu, Sachiho AU - Netsu S AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Omi, Makiko AU - Omi M AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Tanigawa, Terumi AU - Tanigawa T AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Okamoto, Sanshiro AU - Okamoto S AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Omatsu, Kohei AU - Omatsu K AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Yunokawa, Mayu AU - Yunokawa M AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Kanao, Hiroyuki AU - Kanao H AD - Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-8-31, Koto-Ku, Tokyo, 135-8550, Japan. FAU - Habano, Eri AU - Habano E AD - Department of Clinical Genetics, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Arakawa, Hiromi AU - Arakawa H AD - Department of Clinical Genetics, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Kaneko, Keika AU - Kaneko K AD - Department of Clinical Genetics, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Ueki, Arisa AU - Ueki A AD - Department of Clinical Genetics, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Haruyama, Yurie AU - Haruyama Y AD - Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Inari, Hitoshi AU - Inari H AD - Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. FAU - Ueno, Takayuki AU - Ueno T AD - Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20230119 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (BRCA1 Protein) RN - 0 (BRCA2 Protein) SB - IM MH - Humans MH - Female MH - Salpingo-oophorectomy MH - *Breast Neoplasms/genetics/surgery/pathology MH - Mastectomy MH - Ovariectomy MH - Japan MH - Mutation MH - *Ovarian Neoplasms/genetics/prevention & control/surgery MH - Genetic Predisposition to Disease MH - BRCA1 Protein/genetics MH - BRCA2 Protein/genetics PMC - PMC9852267 COIS- Dr. Takayuki Ueno received an honoraria for a lecture fees from Astra Zeneca, Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K. K. The other authors declare no conflicts of interest for this manuscript. EDAT- 2023/01/20 06:00 MHDA- 2023/01/24 06:00 CRDT- 2023/01/19 23:22 PHST- 2022/10/12 00:00 [received] PHST- 2023/01/17 00:00 [accepted] PHST- 2023/01/19 23:22 [entrez] PHST- 2023/01/20 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] AID - 10.1038/s41598-023-28304-w [pii] AID - 28304 [pii] AID - 10.1038/s41598-023-28304-w [doi] PST - epublish SO - Sci Rep. 2023 Jan 19;13(1):1018. doi: 10.1038/s41598-023-28304-w. PMID- 36327124 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 2374-2445 (Electronic) IS - 2374-2437 (Linking) VI - 9 IP - 1 DP - 2023 Jan 1 TI - Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer-Reply. PG - 147-148 LID - 10.1001/jamaoncol.2022.5094 [doi] FAU - Tarantino, Paolo AU - Tarantino P AD - Dana-Farber Cancer Institute, Boston, Massachusetts. AD - Harvard Medical School, Boston, Massachusetts. AD - Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. FAU - Tayob, Nabihah AU - Tayob N AD - Dana-Farber Cancer Institute, Boston, Massachusetts. AD - Harvard Medical School, Boston, Massachusetts. FAU - Tolaney, Sara M AU - Tolaney SM AD - Dana-Farber Cancer Institute, Boston, Massachusetts. AD - Harvard Medical School, Boston, Massachusetts. LA - eng PT - Journal Article PL - United States TA - JAMA Oncol JT - JAMA oncology JID - 101652861 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Hormones) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Receptor, ErbB-2 MH - Hormones EDAT- 2022/11/04 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/11/03 12:33 PHST- 2022/11/04 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/11/03 12:33 [entrez] AID - 2797976 [pii] AID - 10.1001/jamaoncol.2022.5094 [doi] PST - ppublish SO - JAMA Oncol. 2023 Jan 1;9(1):147-148. doi: 10.1001/jamaoncol.2022.5094. PMID- 36326737 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 2374-2445 (Electronic) IS - 2374-2437 (Linking) VI - 9 IP - 1 DP - 2023 Jan 1 TI - Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer. PG - 146-147 LID - 10.1001/jamaoncol.2022.5091 [doi] FAU - Cappelletti, Vera AU - Cappelletti V AD - Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Di Cosimo, Serena AU - Di Cosimo S AD - Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. FAU - Pruneri, Giancarlo AU - Pruneri G AD - Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. LA - eng PT - Journal Article PL - United States TA - JAMA Oncol JT - JAMA oncology JID - 101652861 RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Hormones) RN - EC 2.7.10.1 (ERBB2 protein, human) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Receptor, ErbB-2 MH - Hormones EDAT- 2022/11/04 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/11/03 11:33 PHST- 2022/11/04 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/11/03 11:33 [entrez] AID - 2797977 [pii] AID - 10.1001/jamaoncol.2022.5091 [doi] PST - ppublish SO - JAMA Oncol. 2023 Jan 1;9(1):146-147. doi: 10.1001/jamaoncol.2022.5091. PMID- 36671478 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 2218-273X (Electronic) IS - 2218-273X (Linking) VI - 13 IP - 1 DP - 2023 Jan 2 TI - PI3K-AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. LID - 10.3390/biom13010093 [doi] LID - 93 AB - Breast cancer is the most commonly diagnosed cancer in women. The high incidence of breast cancer, which is continuing to rise, makes treatment a significant challenge. The PI3K-AKT pathway and its downstream targets influence various cellular processes. In recent years, mounting evidence has shown that natural products and synthetic drugs targeting PI3K-AKT signaling have the potential to treat breast cancer. In this review, we discuss the role of the PI3K-AKT signaling pathway in the occurrence and development of breast cancer and highlight PI3K-AKT-targeting natural products and drugs in clinical trials for the treatment of breast cancer. FAU - Yuan, Yeqin AU - Yuan Y AD - Medical Research Center, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China. FAU - Long, Huizhi AU - Long H AD - School of Pharmacy, Hengyang Medical School, University of South China, Hengyang 421001, China. FAU - Zhou, Ziwei AU - Zhou Z AD - School of Pharmacy, Hengyang Medical School, University of South China, Hengyang 421001, China. FAU - Fu, Yuting AU - Fu Y AD - Medical Research Center, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China. FAU - Jiang, Binyuan AU - Jiang B AD - Medical Research Center, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China. AD - Department of Clinical Laboratory, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China. LA - eng GR - 81802952/National Natural Science Foundation of China/ GR - 2020JJ5608/Natural Science Foundation of Hunan Province/ GR - 21B0411/Scientific Research Project of the Education Department of Hunan Province/ GR - YNKY202201/Scientific Research Project of Changsha Central Hospital/ PT - Journal Article PT - Review DEP - 20230102 PL - Switzerland TA - Biomolecules JT - Biomolecules JID - 101596414 RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 0 (Biological Products) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/metabolism MH - Proto-Oncogene Proteins c-akt/metabolism MH - Phosphatidylinositol 3-Kinases/metabolism MH - TOR Serine-Threonine Kinases/metabolism MH - *Biological Products/pharmacology/therapeutic use PMC - PMC9856042 OTO - NOTNLM OT - PI3K–AKT pathway OT - breast cancer OT - clinical trial drugs OT - natural products COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:07 PHST- 2022/11/21 00:00 [received] PHST- 2022/12/16 00:00 [revised] PHST- 2022/12/30 00:00 [accepted] PHST- 2023/01/21 01:07 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - biom13010093 [pii] AID - biomolecules-13-00093 [pii] AID - 10.3390/biom13010093 [doi] PST - epublish SO - Biomolecules. 2023 Jan 2;13(1):93. doi: 10.3390/biom13010093. PMID- 36194057 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230124 IS - 1529-4242 (Electronic) IS - 0032-1052 (Linking) VI - 151 IP - 1 DP - 2023 Jan 1 TI - The BREASTrial Stage III: Acellular Dermal Matrix Breast Reconstruction Outcomes from 3 Months to 2 Years Postoperatively. PG - 17-24 LID - 10.1097/PRS.0000000000009768 [doi] AB - BACKGROUND: The Breast Reconstruction Evaluation of Acellular Dermal Matrix as a Sling Trial (BREASTrial) is a blinded, randomized trial comparing the outcomes of tissue expander breast reconstruction using AlloDerm or DermaMatrix. In this final stage of the trial, outcomes 3 months to 2 years after definitive reconstruction are reported along with patient satisfaction data. METHODS: A randomized trial was conducted to compare complication rates between groups of patients who underwent reconstruction with AlloDerm and DermaMatrix. Regression models were used to analyze the impact of matrix type, age, chemotherapy, radiation therapy, and reconstructive type on complication rates. Premastectomy and postmastectomy questionnaires were used to assess patient satisfaction and were also analyzed using regression models. RESULTS: Of the 128 patients (199 breasts) who were randomized in the trial, 108 patients (167 breasts) were available for analysis in stage III. There was no difference in the overall complication rates between the AlloDerm and DermaMatrix groups (6% versus 13.2%; P = 0.3) or the severity of those complications ( P = 0.7). Obesity was a positive predictor for complications, regardless of reconstruction group ( P = 0.02). Patient satisfaction was positive overall and did not grossly vary between AlloDerm and DermaMatrix groups. CONCLUSIONS: Findings from the BREASTrial conclude that AlloDerm and DermaMatrix exhibit similar histologic and clinical outcomes. Patient satisfaction is also similar between matrices. Obesity is a predictor of complications, and acellular dermal matrices should be used with caution in these patients. As the largest head-to-head trial comparing two acellular dermal matrices, the BREASTrial contributes to the fund of knowledge regarding acellular dermal matrix supplementation in breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II. CI - Copyright © 2022 by the American Society of Plastic Surgeons. FAU - Mendenhall, Shaun D AU - Mendenhall SD AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery. FAU - Moss, Whitney D AU - Moss WD AD - University of Utah School of Medicine. FAU - Graham, Emily M AU - Graham EM AD - University of Utah School of Medicine. FAU - Carter, Gentry AU - Carter G AD - Department of Population Health Sciences. FAU - Agarwal, Jayant P AU - Agarwal JP AD - From the Division of Plastic and Reconstructive Surgery, Department of Surgery. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20221004 PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 SB - IM MH - Humans MH - Female MH - *Acellular Dermis MH - Mastectomy/adverse effects MH - *Breast Neoplasms/surgery/complications MH - Postoperative Complications/epidemiology/etiology MH - *Mammaplasty/adverse effects MH - Retrospective Studies MH - Obesity/complications MH - *Breast Implants/adverse effects MH - *Breast Implantation/adverse effects COIS- Disclosure : The BREASTrial is an investigator-initiated study funded by grants from the University of Utah, Lifecell, Synthes, and the Musculoskeletal Transplant Foundation to Author Dr. Agarwal. Dr. Mendenhall is an educational consultant for PolyNovo and receives research funding from CoNextions Medical. No funding was received for this article. The remaining authors have no other financial conflicts of interest to declare in relation to this study . EDAT- 2022/10/05 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/10/04 09:23 PHST- 2022/10/05 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/10/04 09:23 [entrez] AID - 00006534-202301000-00004 [pii] AID - 10.1097/PRS.0000000000009768 [doi] PST - ppublish SO - Plast Reconstr Surg. 2023 Jan 1;151(1):17-24. doi: 10.1097/PRS.0000000000009768. Epub 2022 Oct 4. PMID- 36634296 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 2473-4284 (Electronic) IS - 2473-4284 (Linking) VI - 7 DP - 2023 Jan TI - Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. PG - e2200372 LID - 10.1200/PO.22.00372 [doi] AB - PURPOSE: Circulating tumor cells (CTCs) are strongly prognostic for overall survival (OS) in metastatic breast cancer although additional prognostic biomarkers are needed. We evaluated the complementary prognostic value of tumor-derived extracellular vesicles (tdEVs) next to CTCs. METHODS: We applied the open-source ACCEPT software to archived CellSearch images from the prospective clinical trial SWOG0500 to enumerate CTCs and tumor-derived extracellular vesicles (tdEVs) before and after one cycle of chemotherapy. RESULTS: CTCs enumerated by ACCEPT were strongly correlated with classical ocular enumeration (correlation r = 0.98). OS was worse with elevated tdEVs (median OS for high/medium/low groups: 17.1 v 29.0 v 43.3 months; P < .0001). In patients with longer OS by CTC counts (< 5 CTC/7.5 mL blood), elevated tdEV levels were independently associated with poorer OS (multivariable analysis P < .001). OS was also longer for patients with low tdEVs after one cycle of chemotherapy (median OS for high/medium/low group: 10.8 v 17.8 v 26.7; P < .0001). CONCLUSION: This study highlights the complementary prognostic significance of tdEVs in metastatic breast cancer before and after one cycle of chemotherapy. FAU - Nanou, Afroditi AU - Nanou A AUID- ORCID: 0000-0002-8682-3133 AD - Department of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands. FAU - Miao, Jieling AU - Miao J AD - SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Coumans, Frank A W AU - Coumans FAW AD - Department of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands. FAU - Dolce, Emily M AU - Dolce EM AUID- ORCID: 0000-0001-7212-8116 AD - University of Michigan Rogel Cancer Center, Ann Arbor, MI. FAU - Darga, Elizabeth AU - Darga E AD - University of Michigan Rogel Cancer Center, Ann Arbor, MI. FAU - Barlow, William AU - Barlow W AUID- ORCID: 0000-0003-4651-2282 AD - SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA. FAU - Smerage, Jeffrey B AU - Smerage JB AUID- ORCID: 0000-0001-9130-9342 AD - University of Michigan Rogel Cancer Center, Ann Arbor, MI. FAU - Paoletti, Costanza AU - Paoletti C AD - University of Michigan Rogel Cancer Center, Ann Arbor, MI. FAU - Godwin, Andrew K AU - Godwin AK AD - University of Kansas Medical Center, Kansas City, KS. FAU - Pusztai, Lajos AU - Pusztai L AUID- ORCID: 0000-0001-9632-6686 AD - Yale School of Medicine, New Haven, CT. FAU - Sharma, Priyanka AU - Sharma P AUID- ORCID: 0000-0001-8592-2239 AD - University of Kansas Medical Center, Kansas City, KS. FAU - Thompson, Alastair AU - Thompson A AD - Baylor College of Medicine, Houston, TX. FAU - Hortobagyi, Gabriel N AU - Hortobagyi GN AUID- ORCID: 0000-0002-4873-4412 AD - The University of Texas MD Anderson Cancer Center, Houston, TX. FAU - Terstappen, Leon W M M AU - Terstappen LWMM AUID- ORCID: 0000-0001-5944-3787 AD - Department of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands. FAU - Hayes, Daniel F AU - Hayes DF AUID- ORCID: 0000-0003-3620-7575 AD - University of Michigan Rogel Cancer Center, Ann Arbor, MI. LA - eng PT - Journal Article PL - United States TA - JCO Precis Oncol JT - JCO precision oncology JID - 101705370 RN - 0 (Biomarkers, Tumor) SB - IM MH - Female MH - Humans MH - Biomarkers, Tumor MH - *Breast Neoplasms/pathology MH - *Neoplastic Cells, Circulating MH - Prognosis MH - Prospective Studies MH - Clinical Trials as Topic EDAT- 2023/01/13 06:00 MHDA- 2023/01/17 06:00 CRDT- 2023/01/12 16:03 PHST- 2023/01/12 16:03 [entrez] PHST- 2023/01/13 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] AID - 10.1200/PO.22.00372 [doi] PST - ppublish SO - JCO Precis Oncol. 2023 Jan;7:e2200372. doi: 10.1200/PO.22.00372. PMID- 36165912 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1557-3265 (Electronic) IS - 1078-0432 (Linking) VI - 29 IP - 1 DP - 2023 Jan 4 TI - Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. PG - 67-80 LID - 10.1158/1078-0432.CCR-22-1281 [doi] AB - PURPOSE: To assess the efficacy and exploratory biomarkers of continuing palbociclib plus endocrine therapy (ET) beyond progression on prior palbociclib-based regimen in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC). PATIENTS AND METHODS: The multicenter, open-label, phase II BioPER trial included women who had experienced a progressive disease (PD) after having achieved clinical benefit on the immediately prior palbociclib plus ET regimen. Palbociclib (125 mg, 100 mg, or 75 mg daily orally for 3 weeks and 1 week off as per prior palbociclib-based regimen) plus ET of physician's choice were administered in 4-week cycles until PD or unacceptable toxicity. Coprimary endpoints were clinical benefit rate (CBR) and percentage of tumors with baseline loss of retinoblastoma (Rb) protein expression. Additional endpoints included safety and biomarker analysis. RESULTS: Among 33 patients enrolled, CBR was 34.4% [95% confidence interval (CI), 18.6-53.2; P < 0.001] and 13.0% of tumors (95% CI, 5.2-27.5) showed loss of Rb protein expression, meeting both coprimary endpoints. Median progression-free survival was 2.6 months (95% CI, 1.8-6.7). No new safety signals were reported. A signature that included baseline mediators of therapeutic resistance to palbociclib and ET (low Rb score, high cyclin E1 score, ESR1 mutation) was independently associated with shorter median progression-free survival (HR, 22.0; 95% CI, 1.71-282.9; P = 0.018). CONCLUSIONS: Maintaining palbociclib after progression on prior palbociclib-based regimen seems to be a reasonable, investigational approach for selected patients. A composite biomarker signature predicts a subset of patients who may not derive a greater benefit from palbociclib rechallenge, warranting further validation in larger randomized controlled trials. CI - ©2022 The Authors; Published by the American Association for Cancer Research. FAU - Albanell, Joan AU - Albanell J AUID- ORCID: 0000-0003-1239-4580 AD - Medical Oncology Department, Hospital del Mar, Barcelona, Spain. AD - Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain. AD - Universitat Pompeu Fabra, Barcelona, Spain. AD - GEICAM, Spain. FAU - Pérez-García, José Manuel AU - Pérez-García JM AUID- ORCID: 0000-0003-4238-2046 AD - International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. FAU - Gil-Gil, Miguel AU - Gil-Gil M AUID- ORCID: 0000-0003-1380-2718 AD - GEICAM, Spain. AD - Catalan Institute of Oncology, Breast Cancer Unit, Medical Oncology Department, IDIBELL, Barcelona, Spain. FAU - Curigliano, Giuseppe AU - Curigliano G AUID- ORCID: 0000-0003-1781-2518 AD - Istituto Europeo di Oncologia, IRCCS, Milano, Italy. AD - University of Milano, Department of Oncology and Hemato-Oncology, Milano, Italy. FAU - Ruíz-Borrego, Manuel AU - Ruíz-Borrego M AUID- ORCID: 0000-0002-1181-5622 AD - GEICAM, Spain. AD - Hospital Universitario Virgen del Rocío, Sevilla, Spain. FAU - Comerma, Laura AU - Comerma L AUID- ORCID: 0000-0002-0249-4636 AD - Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Pathology Department, Hospital del Mar, Barcelona, Spain. FAU - Gibert, Joan AU - Gibert J AUID- ORCID: 0000-0002-0742-0759 AD - Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Pathology Department, Hospital del Mar, Barcelona, Spain. FAU - Bellet, Meritxell AU - Bellet M AUID- ORCID: 0000-0001-8859-8307 AD - Vall d´Hebrón University Hospital, Barcelona, Spain. AD - Vall d´Hebrón Institute of Oncology (VHIO), Barcelona, Spain. FAU - Bermejo, Begoña AU - Bermejo B AUID- ORCID: 0000-0001-7773-5994 AD - Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain. AD - GEICAM, Spain. AD - Medical Oncology, Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia; Medicine Department, Universidad de Valencia, Valencia, Spain. FAU - Calvo, Lourdes AU - Calvo L AUID- ORCID: 0000-0001-8314-0241 AD - GEICAM, Spain. AD - Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain. FAU - de la Haba, Juan AU - de la Haba J AUID- ORCID: 0000-0001-5111-1702 AD - Hospital Universitario Reina Sofía, Córdoba, Spain. FAU - Espinosa, Enrique AU - Espinosa E AUID- ORCID: 0000-0001-6562-7902 AD - Hospital Universitario La Paz, Madrid, Spain. FAU - Minisini, Alessandro Marco AU - Minisini AM AUID- ORCID: 0000-0001-7712-7286 AD - Department of Oncology, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy. FAU - Quiroga, Vanesa AU - Quiroga V AUID- ORCID: 0000-0002-7852-474X AD - Badalona-Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Badalona, Barcelona, Spain. FAU - Santaballa Bertran, Ana AU - Santaballa Bertran A AUID- ORCID: 0000-0001-7763-320X AD - Hospital Universitari i Politècnic La Fe, Valencia, Spain. FAU - Mina, Leonardo AU - Mina L AUID- ORCID: 0000-0002-2289-4936 AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. FAU - Bellosillo, Beatriz AU - Bellosillo B AUID- ORCID: 0000-0002-5335-2726 AD - Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. AD - Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain. AD - Universitat Pompeu Fabra, Barcelona, Spain. AD - Pathology Department, Hospital del Mar, Barcelona, Spain. FAU - Rojo, Federico AU - Rojo F AUID- ORCID: 0000-0001-9989-0290 AD - Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain. AD - GEICAM, Spain. AD - IIS-Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. FAU - Menéndez, Silvia AU - Menéndez S AUID- ORCID: 0000-0002-9116-8743 AD - Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. FAU - Sampayo-Cordero, Miguel AU - Sampayo-Cordero M AUID- ORCID: 0000-0003-1469-3410 AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. FAU - Popa, Crina AU - Popa C AUID- ORCID: 0000-0002-4294-9949 AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. FAU - Malfettone, Andrea AU - Malfettone A AUID- ORCID: 0000-0003-3467-2334 AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. FAU - Cortés, Javier AU - Cortés J AUID- ORCID: 0000-0001-7623-1583 AD - International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. AD - Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. FAU - Llombart-Cussac, Antonio AU - Llombart-Cussac A AUID- ORCID: 0000-0003-4515-8293 AD - Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. AD - Hospital Arnau de Vilanova, Valencia, Spain. AD - Universidad Catolica, Valencia, Spain. LA - eng GR - na/Pfizer Foundation/ PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - G9ZF61LE7G (palbociclib) RN - 0 (Piperazines) SB - IM MH - Female MH - Humans MH - *Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Piperazines/therapeutic use EDAT- 2022/09/28 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/09/27 11:41 PHST- 2022/04/21 00:00 [received] PHST- 2022/06/27 00:00 [revised] PHST- 2022/09/21 00:00 [accepted] PHST- 2022/09/28 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/09/27 11:41 [entrez] AID - 709486 [pii] AID - 10.1158/1078-0432.CCR-22-1281 [doi] PST - ppublish SO - Clin Cancer Res. 2023 Jan 4;29(1):67-80. doi: 10.1158/1078-0432.CCR-22-1281. PMID- 36354182 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 2701-0198 (Electronic) IS - 2701-0198 (Linking) VI - 7 IP - 1 DP - 2023 Jan TI - A Biomimetic Hyaluronic Acid Hydrogel Models Mass Dormancy in Brain Metastatic Breast Cancer Spheroids. PG - e2200114 LID - 10.1002/adbi.202200114 [doi] AB - Approximately 90% of breast cancer related mortalities are due to metastasis to distant organs. At the metastatic sites, cancer cells are capable of evading death by exhibiting cellular or mass dormancy. However, the mechanisms involved in attaining dormancy at the metastatic site are not well understood. This is partly due to the lack of experimental models to study metastatic site-specific interactions, particularly in the context of brain metastatic breast cancer (BMBC). Herein, an in vitro hyaluronic acid (HA) hydrogel-based model is developed to study mass dormancy in BMBC. HA hydrogels with a stiffness of ≈0.4 kPa are utilized to mimic the brain extracellular matrix. MDA-MB-231Br or BT474Br3 BMBC spheroids are prepared and cultured on top of HA hydrogels or in suspension for 7 days. HA hydrogel induced a near mass dormant state in spheroids by achieving a balance between proliferating and dead cells. In contrast, these spheroids displayed growth in suspension cultures. The ratio of %p-ERK to %p-p38 positive cells is significantly lower in HA hydrogels compared to suspension cultures. Further, it is demonstrated that hydrogel induced mass dormant state is reversible. Overall, such models provide useful tools to study dormancy in BMBC and could be employed for drug screening. CI - © 2022 Wiley-VCH GmbH. FAU - Kondapaneni, Raghu Vamsi AU - Kondapaneni RV AD - Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL, 35487, USA. FAU - Shevde, Lalita A AU - Shevde LA AD - Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35233, USA. FAU - Rao, Shreyas S AU - Rao SS AUID- ORCID: 0000-0001-7649-0171 AD - Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL, 35487, USA. LA - eng GR - CBET 1749837/National Science Foundation/ GR - METAvivor/ PT - Journal Article DEP - 20221110 PL - Germany TA - Adv Biol (Weinh) JT - Advanced biology JID - 101775319 RN - 0 (Hydrogels) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Humans MH - Female MH - Hydrogels MH - Hyaluronic Acid/pharmacology MH - *Breast Neoplasms/drug therapy/pathology MH - Biomimetics MH - Brain/pathology MH - *Brain Neoplasms/drug therapy OTO - NOTNLM OT - hyaluronic acid OT - hydrogel OT - mass dormancy OT - metastasis OT - spheroids EDAT- 2022/11/11 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/11/10 07:32 PHST- 2022/08/15 00:00 [revised] PHST- 2022/04/19 00:00 [received] PHST- 2022/11/11 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/11/10 07:32 [entrez] AID - 10.1002/adbi.202200114 [doi] PST - ppublish SO - Adv Biol (Weinh). 2023 Jan;7(1):e2200114. doi: 10.1002/adbi.202200114. Epub 2022 Nov 10. PMID- 36694240 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1479-5876 (Electronic) IS - 1479-5876 (Linking) VI - 21 IP - 1 DP - 2023 Jan 24 TI - Radiogenomic analysis of prediction HER2 status in breast cancer by linking ultrasound radiomic feature module with biological functions. PG - 44 LID - 10.1186/s12967-022-03840-7 [doi] LID - 44 AB - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpressed associated with poor prognosis in breast cancer and HER2 has been defined as a therapeutic target for breast cancer treatment. We aimed to explore the molecular biological information in ultrasound radiomic features (URFs) of HER2-positive breast cancer using radiogenomic analysis. Moreover, a radiomics model was developed to predict the status of HER2 in breast cancer. METHODS: This retrospective study included 489 patients who were diagnosed with breast cancer. URFs were extracted from a radiomics analysis set using PyRadiomics. The correlations between differential URFs and HER2-related genes were calculated using Pearson correlation analysis. Functional enrichment of the identified URFs-correlated HER2 positive-specific genes was performed. Lastly, the radiomics model was developed based on the URF-module mined from auxiliary differential URFs to assess the HER2 status of breast cancer. RESULTS: Eight differential URFs (p < 0.05) were identified among the 86 URFs extracted by Pyradiomics. 25 genes that were found to be the most closely associated with URFs. Then, the relevant biological functions of each differential URF were obtained through functional enrichment analysis. Among them, Zone Entropy is related to immune cell activity, which regulate the generation of calcification in breast cancer. The radiomics model based on the Logistic classifier and URF-module showed good discriminative ability (AUC = 0.80, 95% CI). CONCLUSION: We searched for the URFs of HER2-positive breast cancer, and explored the underlying genes and biological functions of these URFs. Furthermore, the radiomics model based on the Logistic classifier and URF-module relatively accurately predicted the HER2 status in breast cancer. CI - © 2023. The Author(s). FAU - Cui, Hao AU - Cui H AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Sun, Yue AU - Sun Y AD - College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. FAU - Zhao, Dantong AU - Zhao D AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Zhang, Xudong AU - Zhang X AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Kong, Hanqing AU - Kong H AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Hu, Nana AU - Hu N AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Wang, Panting AU - Wang P AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Zuo, Xiaoxuan AU - Zuo X AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Fan, Wei AU - Fan W AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Yao, Yuan AU - Yao Y AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Fu, Baiyang AU - Fu B AD - Department of Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Tian, Jiawei AU - Tian J AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. FAU - Wu, Meixin AU - Wu M AD - Department of Clinical Medicine, The Second Affiliated Hospital of Harbin Medical University, Heilongjiang, 150086, China. FAU - Gao, Yue AU - Gao Y AD - College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. FAU - Ning, Shangwei AU - Ning S AD - College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. FAU - Zhang, Lei AU - Zhang L AUID- ORCID: 0000-0003-4143-668X AD - Department of Ultrasound Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. zhanglei6@hrbmu.edu.cn. LA - eng GR - 82102072/The National Natural Science Foundation of China/ GR - 81701705/The National Natural Science Foundation of China/ GR - 82272001/The National Natural Science Foundation of China/ GR - 81974265/The National Natural Science Foundation of China/ GR - 202210226004/College Students' Innovative Entrepreneurial Training Plan Program/ GR - YQ2022148/Outstanding Youth Program of Heilongjiang Natural Science Foundation/ PT - Journal Article DEP - 20230124 PL - England TA - J Transl Med JT - Journal of translational medicine JID - 101190741 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnostic imaging/genetics/metabolism MH - Retrospective Studies MH - Magnetic Resonance Imaging PMC - PMC9875533 OTO - NOTNLM OT - Breast cancer OT - HER2 OT - Radiogenomics OT - Radiomics OT - Ultrasound COIS- The authors declare that they have no competing interests. EDAT- 2023/01/25 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/24 23:39 PHST- 2022/05/26 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/24 23:39 [entrez] PHST- 2023/01/25 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - 10.1186/s12967-022-03840-7 [pii] AID - 3840 [pii] AID - 10.1186/s12967-022-03840-7 [doi] PST - epublish SO - J Transl Med. 2023 Jan 24;21(1):44. doi: 10.1186/s12967-022-03840-7. PMID- 34813048 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1543-0154 (Electronic) IS - 0885-8195 (Print) IS - 0885-8195 (Linking) VI - 38 IP - 1 DP - 2023 Feb TI - Using Protection Motivation Theory to Predict Intentions for Breast Cancer Risk Management: Intervention Mechanisms from a Randomized Controlled Trial. PG - 292-300 LID - 10.1007/s13187-021-02114-y [doi] AB - The purpose of this study is to evaluate the direct and indirect effects of a web-based, Protection Motivation Theory (PMT)-informed breast cancer education and decision support tool on intentions for risk-reducing medication and breast MRI among high-risk women. Women with ≥ 1.67% 5-year breast cancer risk (N = 995) were randomized to (1) control or (2) the PMT-informed intervention. Six weeks post-intervention, 924 (93% retention) self-reported PMT constructs and behavioral intentions. Bootstrapped mediations evaluated the direct effect of the intervention on behavioral intentions and the mediating role of PMT constructs. There was no direct intervention effect on intentions for risk-reducing medication or MRI (p's ≥ 0.12). There were significant indirect effects on risk-reducing medication intentions via perceived risk, self-efficacy, and response efficacy, and on MRI intentions via perceived risk and response efficacy (p's ≤ 0.04). The PMT-informed intervention effected behavioral intentions via perceived breast cancer risk, self-efficacy, and response efficacy. Future research should extend these findings from intentions to behavior. ClinicalTrials.gov Identifier: NCT03029286 (date of registration: January 24, 2017). CI - © 2021. The Author(s). FAU - Conley, Claire C AU - Conley CC AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 2115 Wisconsin Avenue NW, Suite 300, Washington, DC, 20007, USA. FAU - Wernli, Karen J AU - Wernli KJ AD - Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. FAU - Knerr, Sarah AU - Knerr S AD - Department of Health Services, University of Washington, Seattle, WA, USA. FAU - Li, Tengfei AU - Li T AD - Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA. FAU - Leppig, Kathleen AU - Leppig K AD - Washington Permanente Medical Group, Seattle, WA, USA. FAU - Ehrlich, Kelly AU - Ehrlich K AD - Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. FAU - Farrell, David AU - Farrell D AD - PeopleDesigns, Raleigh-Durham, NC, USA. FAU - Gao, Hongyuan AU - Gao H AD - Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. FAU - Bowles, Erin J A AU - Bowles EJA AD - Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. FAU - Graham, Amanda L AU - Graham AL AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 2115 Wisconsin Avenue NW, Suite 300, Washington, DC, 20007, USA. AD - Truth Initiative, Washington, DC, USA. FAU - Luta, George AU - Luta G AD - Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA. FAU - Jayasekera, Jinani AU - Jayasekera J AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 2115 Wisconsin Avenue NW, Suite 300, Washington, DC, 20007, USA. FAU - Mandelblatt, Jeanne S AU - Mandelblatt JS AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 2115 Wisconsin Avenue NW, Suite 300, Washington, DC, 20007, USA. FAU - Schwartz, Marc D AU - Schwartz MD AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 2115 Wisconsin Avenue NW, Suite 300, Washington, DC, 20007, USA. FAU - O'Neill, Suzanne C AU - O'Neill SC AD - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 2115 Wisconsin Avenue NW, Suite 300, Washington, DC, 20007, USA. Suzanne.ONeill@georgetown.edu. LA - eng SI - ClinicalTrials.gov/NCT03029286 GR - U01CA152958/national cancer institute (us)/ GR - U54 CA163303/CA/NCI NIH HHS/United States GR - K08 HG010488/HG/NHGRI NIH HHS/United States GR - P30 CA051008/CA/NCI NIH HHS/United States GR - R35 CA197289/CA/NCI NIH HHS/United States GR - HHSN261201100031C/CA/NCI NIH HHS/United States GR - ASPO-19-001/breast cancer research foundation (us)/ GR - U01 CA152958/CA/NCI NIH HHS/United States GR - R03CA259896/national cancer institute (us)/ GR - K12 HS022982/HS/AHRQ HHS/United States GR - P01 CA154292/CA/NCI NIH HHS/United States GR - R01CA190221/national cancer institute (us)/ GR - ACS IRG 17-177-23/american cancer society/ GR - K99 CA241397/CA/NCI NIH HHS/United States GR - R35CA197289/national cancer institute (us)/ GR - R50CA211115/national cancer institute (us)/ GR - R50 CA211115/CA/NCI NIH HHS/United States GR - K08HG010488/HG/NHGRI NIH HHS/United States GR - R03 CA259896/CA/NCI NIH HHS/United States GR - R01 CA190221/CA/NCI NIH HHS/United States GR - K99CA241397/national cancer institute (us)/ GR - K08HG010488/HG/NHGRI NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial DEP - 20211123 PL - England TA - J Cancer Educ JT - Journal of cancer education : the official journal of the American Association for Cancer Education JID - 8610343 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/diagnostic imaging/drug therapy MH - *Health Education/methods MH - *Intention MH - Motivation MH - Surveys and Questionnaires MH - Psychological Theory MH - *Internet-Based Intervention MH - Magnetic Resonance Imaging/psychology MH - Risk Assessment MH - Treatment Outcome PMC - PMC9124715 MID - NIHMS1776207 OTO - NOTNLM OT - Breast cancer OT - Magnetic resonance imaging (MRI) OT - Prevention OT - Protection Motivation Theory OT - Risk management OT - Risk-reducing medication COIS- The authors have no conflicts of interest to report. EDAT- 2021/11/24 06:00 MHDA- 2023/01/24 06:00 CRDT- 2021/11/23 12:27 PHST- 2021/11/01 00:00 [accepted] PHST- 2021/11/24 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2021/11/23 12:27 [entrez] AID - 10.1007/s13187-021-02114-y [pii] AID - 2114 [pii] AID - 10.1007/s13187-021-02114-y [doi] PST - ppublish SO - J Cancer Educ. 2023 Feb;38(1):292-300. doi: 10.1007/s13187-021-02114-y. Epub 2021 Nov 23. PMID- 36289041 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230105 IS - 1938-0666 (Electronic) IS - 1526-8209 (Linking) VI - 23 IP - 1 DP - 2023 Jan TI - Circ_0001667 Promotes Adriamycin Resistance and Malignant Progression via Targeting the miR-193a-5p/Rap2A Molecular Axis in Breast Cancer. PG - 71-83 LID - S1526-8209(22)00222-1 [pii] LID - 10.1016/j.clbc.2022.09.008 [doi] AB - BACKGROUND: The therapeutic effect of adriamycin (ADM) has been limited by chemoresistance in breast cancer (BC). Circular RNAs are involved in resistance regulation by mediating the miRNA/mRNA axis. Circ_0001667 enhanced ADM resistance via the miR-4458/NCOA3 axis in BC. This study was to investigate the other miRNA/mRNA network for circ_0001667. METHODS: The level detection of circ_0001667, microRNA-193a-5p (miR-193a-5p) or Ras-Related Protein 2a (Rap2A) was conducted by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Half inhibitory concentration (IC(50)) of ADM was detected through cell counting kit-8 (CCK-8) assay. The proliferation analysis was performed by colony formation assay and EdU assay. Flow cytometry was used for assessing apoptosis. Transwell assay was applied for examining cell migration and invasion. The protein detection was carried out by western blot. In vivo assay was performed using xenograft tumor model. Dual-luciferase reporter and RNA immunoprecipitation (RIP) assays were implemented to validate the target interaction. RESULTS: Circ_0001667 was highly expressed in ADM-resistant BC tissues and cells. Downregulation of circ_0001667 reduced ADM resistance and inhibited proliferation, migration, invasion in ADM-resistant BC cells. Tumor growth was repressed by circ_0001667 knockdown in ADM-resistant xenograft model. Circ_0001667 has induced the sponge effect on miR-193a-5p. The circ_0001667 function was partly achieved by targeting miR-193a-5p. Rap2A expression was positively regulated by circ_0001667 through sponging miR-193a-5p. The miR-193a-5p upregulation restrained chemoresistance and BC progression by the downregulation of Rap2A. CONCLUSION: All results unraveled that circ_0001667 contributed to ADM resistance and tumor development in BC via the miR-193a-5p-mediated Rap2A expression change, providing a novel regulatory mechanism for circ_0001667. CI - Copyright © 2022. Published by Elsevier Inc. FAU - Xu, Shilin AU - Xu S AD - Department of Oncology, Xichang People's Hospital, XiChang City, China. FAU - Luo, Wen AU - Luo W AD - Department of Oncology, Xichang People's Hospital, XiChang City, China. FAU - Li, Mengxin AU - Li M AD - Department of Oncology, Xichang People's Hospital, XiChang City, China. FAU - Li, Quanchao AU - Li Q AD - Department of Oncology, Xichang People's Hospital, XiChang City, China. FAU - Hong, Wanxin AU - Hong W AD - Department of Oncology, Xichang People's Hospital, XiChang City, China. FAU - Gao, Yun AU - Gao Y AD - Department of Oncology, Panzhihua Central Hospital, Pzhihua, Yunnan, China. FAU - Yang, Jin AU - Yang J AD - Department of Oncology, Panzhihua Central Hospital, Pzhihua, Yunnan, China. FAU - Song, Hongchang AU - Song H AD - Department of Oncology, Xichang People's Hospital, XiChang City, China. FAU - Chen, Li AU - Chen L AD - Department of Oncology, Xichang People's Hospital, XiChang City, China. FAU - Yang, Yuanxia AU - Yang Y AD - Department of Oncology, Xichang People's Hospital, XiChang City, China. FAU - Yang, Chao AU - Yang C AD - Department of Oncology, Xichang People's Hospital, XiChang City, China.. Electronic address: yangchao20210702@163.com. LA - eng PT - Journal Article DEP - 20221001 PL - United States TA - Clin Breast Cancer JT - Clinical breast cancer JID - 100898731 RN - 80168379AG (Doxorubicin) RN - 0 (MicroRNAs) RN - 0 (MIRN-4458 microRNA, human) RN - EC 3.6.5.2 (rap GTP-Binding Proteins) RN - EC 3.6.1.- (RAP2A protein, human) RN - 0 (RNA, Circular) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/drug therapy/genetics MH - Cell Proliferation MH - Down-Regulation MH - Doxorubicin/pharmacology/therapeutic use MH - *MicroRNAs/genetics MH - *rap GTP-Binding Proteins MH - Up-Regulation MH - *RNA, Circular/genetics OTO - NOTNLM OT - Adriamycin resistance OT - Breast cancer OT - Rap2A OT - circ_0001667 OT - miR-193a-5p COIS- Declaration of Competing Interest The authors declare that they have no competing interests. EDAT- 2022/10/27 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/10/26 22:03 PHST- 2022/05/26 00:00 [received] PHST- 2022/09/19 00:00 [revised] PHST- 2022/09/27 00:00 [accepted] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/10/26 22:03 [entrez] AID - S1526-8209(22)00222-1 [pii] AID - 10.1016/j.clbc.2022.09.008 [doi] PST - ppublish SO - Clin Breast Cancer. 2023 Jan;23(1):71-83. doi: 10.1016/j.clbc.2022.09.008. Epub 2022 Oct 1. PMID- 36434952 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 1090-2120 (Electronic) IS - 0045-2068 (Linking) VI - 131 DP - 2023 Feb TI - Discovery of dioxo-benzo[b]thiophene derivatives as potent YAP-TEAD interaction inhibitors for treating breast cancer. PG - 106274 LID - S0045-2068(22)00680-0 [pii] LID - 10.1016/j.bioorg.2022.106274 [doi] AB - Disruption of protein-protein interaction between transcriptional enhancer factor (TEA)-domain (TEAD; a transcription factor) and its co-activator Yes-associated protein (YAP)/ transcriptional co-activator with PDZ-binding motif (TAZ) is a potential therapeutic strategy against various types of solid tumors. Based on hit compound 8 and 9a, hydrazone derivatives with dioxo-benzo[d]isothiazole (9b-n) and oxime ester (10a-s) or amide derivatives (11a-r) with dioxo-benzo[b]thiophene were designed and synthesized as novel TEAD-YAP interaction inhibitors. Amide derivative 11q exhibited a higher potency in inhibiting TEAD-YAP reporter expression activity (IC(50) = 12.7 μM), endogenous target gene (e.g., CTGF and CYR61) expression, breast cancer cell growth (GI(50) = 3.2 μM), and anchorage-independent growth in soft agar. Molecular docking analysis suggested that the newly synthesized compounds bound to interface 2 of TEAD had lower docking scores compared to the compounds that bind to interface 3; moreover, they were predicted to overlap with YAP. Therefore, we identified 11q as an attractive therapeutic agent for treating solid tumors overexpressing YAP/TAZ. CI - Copyright © 2022 Elsevier Inc. All rights reserved. FAU - Son, Youngchai AU - Son Y AD - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, South Korea; Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, South Korea. FAU - Kim, Jaeyeal AU - Kim J AD - Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, South Korea; Department of Life Sciences, Korea University, Seoul 02841, South Korea. FAU - Kim, Yongchan AU - Kim Y AD - Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, South Korea. FAU - Chi, Sung-Gil AU - Chi SG AD - Department of Life Sciences, Korea University, Seoul 02841, South Korea. FAU - Kim, Tackhoon AU - Kim T AD - Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, South Korea; Department of Life Sciences, Korea University, Seoul 02841, South Korea; Division of Bio-medical science and technology, KIST school, University of Science and Technology, Daejeon 34113, South Korea. Electronic address: tackhoon@kist.re.kr. FAU - Yu, Jinha AU - Yu J AD - College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, South Korea. Electronic address: jhyu@ewha.ac.kr. LA - eng PT - Journal Article DEP - 20221116 PL - United States TA - Bioorg Chem JT - Bioorganic chemistry JID - 1303703 RN - 0 (Transcription Factors) RN - 0 (Amides) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - Molecular Docking Simulation MH - Transcription Factors/metabolism MH - Amides OTO - NOTNLM OT - Anticancer OT - Dioxo-benzo[b]thiophene scaffold OT - Protein-protein interaction inhibitor OT - YAP/TAZ-TEAD COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/27 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/11/26 18:23 PHST- 2022/09/27 00:00 [received] PHST- 2022/11/08 00:00 [revised] PHST- 2022/11/10 00:00 [accepted] PHST- 2022/11/27 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/11/26 18:23 [entrez] AID - S0045-2068(22)00680-0 [pii] AID - 10.1016/j.bioorg.2022.106274 [doi] PST - ppublish SO - Bioorg Chem. 2023 Feb;131:106274. doi: 10.1016/j.bioorg.2022.106274. Epub 2022 Nov 16. PMID- 36223443 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230103 IS - 1932-751X (Electronic) IS - 1932-7501 (Linking) VI - 43 IP - 1 DP - 2023 Jan 1 TI - Exercise Leg Blood Flow Is Preserved in Long-term Breast Cancer Survivors Previously Treated With Anthracycline Chemotherapy. PG - 61-65 LID - 10.1097/HCR.0000000000000718 [doi] AB - PURPOSE: The objective of this investigation was to compare the acute hemodynamic responses during single-leg knee extension (SLKE) exercise between female breast cancer (BC) survivors previously treated with anthracycline chemotherapy and age- and sex-matched control (CON) subjects. METHODS: Fourteen BC survivors (age: 61 ± 7 yr; time post-anthracycline therapy: 12 ± 6 yr) and nine CON subjects (age: 59 ± 7 yr) performed SLKE exercise at 25%, 50%, and 75% of peak power output during which heart rate, blood pressure (BP), leg blood flow (Doppler ultrasonography), and vascular conductance (leg blood flow/mean BP) were measured. Quadriceps mass was estimated from thigh volume and skinfold measures. RESULTS: Breast cancer survivors had lower quadriceps mass compared with CON subjects (1803 ± 607 vs 2601 ± 1102 g, P = .04). No difference was found between groups for maximal SLKE power output (28 ± 11 vs 34 ± 17 W, P = .35), heart rate (109 ± 14 vs 103 ± 13 bpm, P = .36), or mean arterial BP (122 ± 18 vs 119 ± 26 mm Hg, P = .33). Rest and submaximal exercise mean arterial BP, leg blood flow (indexed to quadriceps muscle mass), and leg vascular conductance were not significantly different between BC survivors and CON subjects. CONCLUSION: Leg blood flow during submaximal SLKE exercise is preserved in long-term BC survivors previously treated with anthracycline chemotherapy. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Beaudry, Rhys I AU - Beaudry RI AD - Department of Kinesiology, College of Nursing and Health Innovation, University of Texas Arlington (Drs Beaudry, Brothers, Nelson, and Haykowsky, Mr Akins, and Ms Richey); University of North Texas Health Science Center, Fort Worth (Ms Richey); Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital, Dallas (Dr Sarma); Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas (Dr Sarma); and Department of Nutrition and Food Sciences, Texas Woman's University, Houston (Dr Tucker). FAU - Akins, John D AU - Akins JD FAU - Richey, Rauchelle E AU - Richey RE FAU - Brothers, R Matthew AU - Brothers RM FAU - Nelson, Michael D AU - Nelson MD FAU - Sarma, Satyam AU - Sarma S FAU - Tucker, Wesley J AU - Tucker WJ FAU - Haykowsky, Mark J AU - Haykowsky MJ LA - eng PT - Journal Article DEP - 20221010 PL - United States TA - J Cardiopulm Rehabil Prev JT - Journal of cardiopulmonary rehabilitation and prevention JID - 101291247 RN - 0 (Anthracyclines) SB - IM MH - Humans MH - Female MH - Middle Aged MH - Aged MH - Leg/blood supply/physiology MH - *Breast Neoplasms/drug therapy MH - *Cancer Survivors MH - Anthracyclines/adverse effects MH - Hemodynamics MH - Muscle, Skeletal COIS- The authors declare no conflicts of interest. EDAT- 2022/10/13 06:00 MHDA- 2022/12/31 06:00 CRDT- 2022/10/12 14:21 PHST- 2022/10/13 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/10/12 14:21 [entrez] AID - 01273116-202301000-00009 [pii] AID - 10.1097/HCR.0000000000000718 [doi] PST - ppublish SO - J Cardiopulm Rehabil Prev. 2023 Jan 1;43(1):61-65. doi: 10.1097/HCR.0000000000000718. Epub 2022 Oct 10. PMID- 36585209 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230103 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 43 IP - 1 DP - 2023 Jan TI - (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer. PG - 127-136 LID - 10.21873/anticanres.16141 [doi] AB - BACKGROUND/AIM: The maximum standardized uptake value (SUVmax) obtained using (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is presumed to indicate tumor and active immune cells in the tumor immune microenvironment (TIME) based on their glycolysis activity. Therefore, this study investigated whether the metabolic parameter SUVmax could provide information regarding TIME in triple-negative breast cancer (TNBC) patients. PATIENTS AND METHODS: Fifty-four patients with TNBC underwent FDG PET/CT before neoadjuvant chemotherapy. Pretreatment biopsy specimens were pathologically evaluated. Expression statuses of CD8, forkhead box P3 (FOXP3), programmed cell death-1 (PD-1), and programmed cell death-ligand 1 (PD-L1) were assessed by immunohistochemistry. The relationships between immunological factors, including the tumor-infiltrating lymphocyte (TIL) grade and SUVmax or pathological complete response (pCR), were investigated. RESULTS: CD8, FOXP3, PD-1, and PD-L1 were high in 15 (27.8%), 39 (72.2%), 18 (33.3%), and 26 (48.2%) patients, respectively. SUVmax was significantly correlated with tumor size, Ki-67 labeling index, and CD8/FOXP3 ratio. Multiple linear regression analysis indicated that tumor size and the CD8/FOXP3 ratio predicted SUVmax. Seventeen patients (31.5%) achieved a pCR; TILs, the CD8/FOXP3 ratio, PD-1, and PD-L1 were significantly correlated with pCR rate. Multivariate analysis indicated that the CD8/FOXP3 ratio was the only independent predictive factor for pCR. CONCLUSION: SUVmax could provide metabolic information regarding TIME for TNBC patients and might be beneficial for formulating a treatment strategy and predicting pCR after neoadjuvant chemotherapy. CI - Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Kimura, Yuri AU - Kimura Y AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. FAU - Sasada, Shinsuke AU - Sasada S AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; shsasada@hiroshima-u.ac.jp. FAU - Emi, Akiko AU - Emi A AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. FAU - Masumoto, Norio AU - Masumoto N AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. FAU - Kadoya, Takayuki AU - Kadoya T AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. FAU - Arihiro, Koji AU - Arihiro K AD - Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan. FAU - Okada, Morihito AU - Okada M AD - Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 0 (B7-H1 Antigen) RN - 0 (Programmed Cell Death 1 Receptor) RN - 0 (Forkhead Transcription Factors) SB - IM MH - Humans MH - *Positron Emission Tomography Computed Tomography MH - Fluorodeoxyglucose F18/metabolism MH - *Triple Negative Breast Neoplasms/drug therapy MH - Prognosis MH - B7-H1 Antigen/metabolism MH - Programmed Cell Death 1 Receptor MH - Forkhead Transcription Factors/metabolism MH - Tumor Microenvironment MH - Positron-Emission Tomography/methods OTO - NOTNLM OT - CD8/forkhead box P3 ratio OT - Triple-negative breast cancer OT - neoadjuvant chemotherapy OT - positron emission tomography OT - tumor-infiltrating lymphocyte EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 CRDT- 2022/12/30 21:03 PHST- 2022/10/30 00:00 [received] PHST- 2022/11/16 00:00 [revised] PHST- 2022/11/17 00:00 [accepted] PHST- 2022/12/30 21:03 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 43/1/127 [pii] AID - 10.21873/anticanres.16141 [doi] PST - ppublish SO - Anticancer Res. 2023 Jan;43(1):127-136. doi: 10.21873/anticanres.16141. PMID- 36650603 OWN - NLM STAT- MEDLINE DCOM- 20230119 LR - 20230119 IS - 1536-5409 (Electronic) IS - 0749-8047 (Linking) VI - 39 IP - 2 DP - 2023 Feb 1 TI - Perioperative Sleep Disturbance Following Mastectomy: A Longitudinal Investigation of the Relationship to Pain, Opioid Use, Treatment, and Psychosocial Symptoms. PG - 76-84 LID - 10.1097/AJP.0000000000001090 [doi] AB - OBJECTIVES: Sleep disturbance negatively impacts the quality of life and recovery. Our objective was to evaluate the relationship between the individual patient and surgical factors with greater sleep disturbance following breast surgery. METHODS: In this prospective longitudinal study, patients completed validated measures regarding sleep disturbance, pain, opioid use, and psychological symptoms preoperatively and then 2 weeks, 6 and 12 months postoperatively. Univariable and multivariable generalized estimating equations evaluated demographic, surgical, pain, and psychological predictors of sleep disturbance during the first year after breast surgery. RESULTS: Female patients (n=259) reported varying degrees of sleep disturbance, which were longitudinally associated with pain and psychosocial factors (eg, anxiety, depression, and affect). Independent preoperative predictors of worse sleep disturbance included younger age (B=-0.09, P =0.006), opioid use (B=3.09, P =0.02), and higher pain (B=0.19, P =<0.001) and anxiety (B=0.45, P =<0.001) at baseline. In addition, higher baseline positive affect (B=-0.14, P =<0.012) and the surgical category total mastectomy without reconstruction (B=-2.81, P =<0.006) were independently associated with lower sleep disturbance. Those with worse baseline sleep required more opioid analgesics during surgical recovery, and continued use of opioids at 2 weeks postsurgery was associated with disturbed sleep. DISCUSSION: Certain patient characteristics, including younger age and baseline anxiety, positive affect, pain, and opioid use, were associated with greater sleep disturbance in the first year after breast surgery. Sleep disturbance was also associated with the greater perioperative and postoperative opioid requirements. Preoperative interventions (eg, anxiety management, cultivating positive affect, and multimodal pain management) in high-risk individuals may enhance sleep and recovery postoperatively, and allow more moderate and less prolonged opioid use. CI - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Azizoddin, Desiree R AU - Azizoddin DR AUID- ORCID: 0000-0001-6993-1776 AD - Department of Emergency Medicine. AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA. FAU - Soens, Mieke A AU - Soens MA AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital. FAU - Beck, Meghan R AU - Beck MR AD - Department of Emergency Medicine. FAU - Flowers, K Mikayla AU - Flowers KM AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital. FAU - Edwards, Robert R AU - Edwards RR AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital. FAU - Schreiber, Kristin L AU - Schreiber KL AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital. LA - eng PT - Journal Article DEP - 20230201 PL - United States TA - Clin J Pain JT - The Clinical journal of pain JID - 8507389 RN - 0 (Analgesics, Opioid) SB - IM MH - Humans MH - Female MH - Analgesics, Opioid/therapeutic use MH - Mastectomy/adverse effects MH - Longitudinal Studies MH - Prospective Studies MH - Quality of Life MH - *Breast Neoplasms/complications/surgery MH - Pain/drug therapy MH - *Opioid-Related Disorders/epidemiology/drug therapy MH - Sleep MH - Pain, Postoperative/diagnosis COIS- The authors declare no conflict of interest. EDAT- 2023/01/18 06:00 MHDA- 2023/01/20 06:00 CRDT- 2023/01/17 23:35 PHST- 2021/06/02 00:00 [received] PHST- 2022/10/04 00:00 [accepted] PHST- 2023/01/18 06:00 [pubmed] PHST- 2023/01/20 06:00 [medline] PHST- 2023/01/17 23:35 [entrez] AID - 00002508-202302000-00004 [pii] AID - 10.1097/AJP.0000000000001090 [doi] PST - epublish SO - Clin J Pain. 2023 Feb 1;39(2):76-84. doi: 10.1097/AJP.0000000000001090. PMID- 36481204 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230112 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 131 DP - 2023 Jan TI - Further predictive value of lymphovascular invasion explored via supervised deep learning for lymph node metastases in breast cancer. PG - 26-37 LID - S0046-8177(22)00273-8 [pii] LID - 10.1016/j.humpath.2022.11.007 [doi] AB - Lymphovascular invasion, specifically lymph-blood vessel invasion (LBVI), is a risk factor for metastases in breast invasive ductal carcinoma (IDC) and is routinely screened using hematoxylin-eosin histopathological images. However, routine reports only describe whether LBVI is present and does not provide other potential prognostic information of LBVI. This study aims to evaluate the clinical significance of LBVI in 685 IDC cases and explore the added predictive value of LBVI on lymph node metastases (LNM) via supervised deep learning (DL), an expert-experience embedded knowledge transfer learning (EEKT) model in 40 LBVI-positive cases signed by the routine report. Multivariate logistic regression and propensity score matching analysis demonstrated that LBVI (OR 4.203, 95% CI 2.809-6.290, P < 0.001) was a significant risk factor for LNM. Then, the EEKT model trained on 5780 image patches automatically segmented LBVI with a patch-wise Dice similarity coefficient of 0.930 in the test set and output counts, location, and morphometric features of the LBVIs. Some morphometric features were beneficial for further stratification within the 40 LBVI-positive cases. The results showed that LBVI in cases with LNM had a higher short-to-long side ratio of the minimum rectangle (MR) (0.686 vs. 0.480, P = 0.001), LBVI-to-MR area ratio (0.774 vs. 0.702, P = 0.002), and solidity (0.983 vs. 0.934, P = 0.029) compared to LBVI in cases without LNM. The results highlight the potential of DL to assist pathologists in quantifying LBVI and, more importantly, in exploring added prognostic information from LBVI. CI - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Chen, Jiamei AU - Chen J AD - Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. FAU - Yang, Yang AU - Yang Y AD - School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200000, China. FAU - Luo, Bo AU - Luo B AD - Department of Pathology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China. FAU - Wen, Yaofeng AU - Wen Y AD - School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200000, China. FAU - Chen, Qingzhong AU - Chen Q AD - School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200000, China. FAU - Ma, Ru AU - Ma R AD - Department of Peritoneal Cancer Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China. FAU - Huang, Zhen AU - Huang Z AD - Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. FAU - Zhu, Hangjia AU - Zhu H AD - Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. FAU - Li, Yan AU - Li Y AD - Department of Peritoneal Cancer Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China; Department of Pathology, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China. Electronic address: liyansd2@mail.ccmu.edu.cn. FAU - Chen, Yongshun AU - Chen Y AD - Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. Electronic address: cyszlsk@163.com. FAU - Qian, Dahong AU - Qian D AD - School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200000, China. Electronic address: dahong.qian@sjtu.edu.cn. LA - eng PT - Journal Article DEP - 20221205 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 SB - IM MH - Humans MH - Female MH - Lymphatic Metastasis/pathology MH - *Breast Neoplasms/pathology MH - *Deep Learning MH - Breast MH - Prognosis MH - *Lymphoma/pathology MH - Lymph Nodes/pathology MH - Retrospective Studies OTO - NOTNLM OT - Breast cancer OT - Deep learning OT - HE histopathology image OT - Knowledge transfer learning OT - Lymph node metastases OT - Lymphovascular invasion EDAT- 2022/12/09 06:00 MHDA- 2023/01/13 06:00 CRDT- 2022/12/08 23:25 PHST- 2022/10/04 00:00 [received] PHST- 2022/11/22 00:00 [revised] PHST- 2022/11/27 00:00 [accepted] PHST- 2022/12/09 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] PHST- 2022/12/08 23:25 [entrez] AID - S0046-8177(22)00273-8 [pii] AID - 10.1016/j.humpath.2022.11.007 [doi] PST - ppublish SO - Hum Pathol. 2023 Jan;131:26-37. doi: 10.1016/j.humpath.2022.11.007. Epub 2022 Dec 5. PMID- 36408723 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1097-0258 (Electronic) IS - 0277-6715 (Linking) VI - 42 IP - 2 DP - 2023 Jan 30 TI - Double robust estimation of optimal partially adaptive treatment strategies: An application to breast cancer treatment using hormonal therapy. PG - 178-192 LID - 10.1002/sim.9608 [doi] AB - Precision medicine aims to tailor treatment decisions according to patients' characteristics. G-estimation and dynamic weighted ordinary least squares are double robust methods to identify optimal adaptive treatment strategies. It is underappreciated that they require modeling all existing treatment-confounder interactions to be consistent. Identifying optimal partially adaptive treatment strategies that tailor treatments according to only a few covariates, ignoring some interactions, may be preferable in practice. Building on G-estimation and dWOLS, we propose estimators of such partially adaptive strategies and demonstrate their double robustness. We investigate these estimators in a simulation study. Using data maintained by the Centre des Maladies du Sein, we estimate a partially adaptive treatment strategy for tailoring hormonal therapy use in breast cancer patients. R software implementing our estimators is provided. CI - © 2022 John Wiley & Sons Ltd. FAU - Talbot, Denis AU - Talbot D AUID- ORCID: 0000-0003-0431-3314 AD - Département de médecine sociale et préventive, Université Laval, Québec, Canada. AD - Axe santé des Populations et Pratiques Optimales en Santé, Centre de Recherche du CHU de Québec - Université Laval, Québec, Canada. FAU - Moodie, Erica E M AU - Moodie EEM AUID- ORCID: 0000-0002-7225-3977 AD - Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Québec, Canada. FAU - Diorio, Caroline AU - Diorio C AD - Département de médecine sociale et préventive, Université Laval, Québec, Canada. AD - Axe oncologie, Centre de recherche du CHU de Québec - Université Laval, Québec, Canada. LA - eng GR - 265385/Fonds de Recherche du Québec - Santé/ GR - #2016-06295/Natural Sciences and Engineering Research Council of Canada/ PT - Journal Article DEP - 20221121 PL - England TA - Stat Med JT - Statistics in medicine JID - 8215016 SB - IM MH - Humans MH - Female MH - *Models, Statistical MH - *Breast Neoplasms/drug therapy MH - Computer Simulation MH - Precision Medicine/methods MH - Software OTO - NOTNLM OT - causal inference OT - double robustness OT - dynamic treatment regimens OT - inverse probability weighting OT - personalized medicine OT - precision medicine EDAT- 2022/11/22 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/21 05:13 PHST- 2022/09/17 00:00 [revised] PHST- 2022/05/18 00:00 [received] PHST- 2022/11/05 00:00 [accepted] PHST- 2022/11/22 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/21 05:13 [entrez] AID - 10.1002/sim.9608 [doi] PST - ppublish SO - Stat Med. 2023 Jan 30;42(2):178-192. doi: 10.1002/sim.9608. Epub 2022 Nov 21. PMID- 36372800 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1435-232X (Electronic) IS - 1434-5161 (Linking) VI - 68 IP - 1 DP - 2023 Jan TI - DOK7 CpG hypermethylation in blood leukocytes as an epigenetic biomarker for acquired tamoxifen resistant in breast cancer. PG - 33-38 LID - 10.1038/s10038-022-01092-3 [doi] AB - BACKGROUND: Breast cancer (BC) is among the most common cause of cancer 10.4% and one of the leading causes of death among 20-50 years old women in the world. Tamoxifen drug is the first line therapy for BC however tamoxifen resistance (TR) has shown in 30-50% of cases that may face BC recurrence. Hence, TR early detection reduces BC recurrence and fatalities. The epigenetic alteration that happens by hypermethylation of tumor suppressor genes and hypomethylation of oncogenes has been suggested to be useful in early cancer or drug resistance diagnosis. METHODS: This is the first study to investigate DOK7 CpG hypermethylation in blood leukocytes of 31 TR (ER+) BC compared to 29 tamoxifen sensitive BC to evaluate DOK7 as a potential TR biomarker. DNA was extracted from blood samples of all participants and MSRE-PCR and real-time PCR were used for quantification of CpG methylation alterations. RESULTS: The means of DOK7 CpG hypermethylation were obtained as 85.03%, 29.1% and 57.34% in TR, TS and normal control respectively. Significant hypermethylation were found among TR vs. TS (p < 0.001), TS vs. normal (p < 0.001) and TR vs. normal controls (p < 0.03). Online databases expression and survival analysis of DOK7 showed increasing expression in TS groups vs. TR groups which have consistency with our methylation alteration results. The sensitivity and specificity of the TR epigenetic test were determined using ROC analysis showed 89.66% and 96.77% respectively and showed that 37.5% above hypermethylation is at risk for TR and breast cancer recurrence. CONCLUSION: There is a significant difference in the methylation ratio of DOK7 between tamoxifen resistant and tamoxifen sensitive groups that may be useful in the early diagnosis of tamoxifen resistance in BC cases and cancer recurrence prevention. CI - © 2022. The Author(s), under exclusive licence to The Japan Society of Human Genetics. FAU - Gowdini, Erfan AU - Gowdini E AUID- ORCID: 0000-0001-5371-9121 AD - Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. FAU - Aleyasin, Seyed Ahmad AU - Aleyasin SA AUID- ORCID: 0000-0003-0224-9726 AD - Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. sogand@nigeb.ac.ir. FAU - Ramezani, Newsha AU - Ramezani N AD - Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. FAU - Nafisi, Nahid AU - Nafisi N AD - Department of General Surgery, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Tutuni, Mahdieh AU - Tutuni M AD - Medical Physics Department, Iran University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article DEP - 20221114 PL - England TA - J Hum Genet JT - Journal of human genetics JID - 9808008 RN - 094ZI81Y45 (Tamoxifen) RN - 0 (Biomarkers) RN - 0 (DOK7 protein, human) RN - 0 (Muscle Proteins) SB - IM MH - Female MH - Humans MH - Young Adult MH - Adult MH - Middle Aged MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Tamoxifen/therapeutic use MH - Neoplasm Recurrence, Local/genetics/drug therapy MH - DNA Methylation/genetics MH - Biomarkers/metabolism MH - Epigenesis, Genetic MH - Leukocytes/metabolism MH - CpG Islands/genetics MH - Muscle Proteins/genetics EDAT- 2022/11/14 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/11/13 23:35 PHST- 2022/05/13 00:00 [received] PHST- 2022/10/05 00:00 [accepted] PHST- 2022/09/28 00:00 [revised] PHST- 2022/11/14 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/11/13 23:35 [entrez] AID - 10.1038/s10038-022-01092-3 [pii] AID - 10.1038/s10038-022-01092-3 [doi] PST - ppublish SO - J Hum Genet. 2023 Jan;68(1):33-38. doi: 10.1038/s10038-022-01092-3. Epub 2022 Nov 14. PMID- 36394849 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20230123 IS - 2374-2445 (Electronic) IS - 2374-2437 (Print) IS - 2374-2437 (Linking) VI - 9 IP - 1 DP - 2023 Jan 1 TI - Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. PG - 40-50 LID - 10.1001/jamaoncol.2022.5228 [doi] AB - IMPORTANCE: Preclinical data suggest that poly(ADP-ribose) polymerase (PARP) inhibitors have synergistic activity when combined with immune checkpoint inhibitors (ICIs); however, it is unknown which tumor types or molecular subtypes may benefit from this combination. OBJECTIVE: To investigate responses associated with the combination of avelumab and talazoparib in different tumor types and/or molecular subtypes. DESIGN, SETTING, AND PARTICIPANTS: In this phase 1b and 2 basket nonrandomized controlled trial, patients with advanced solid tumors were enrolled in the following cohorts: non-small cell lung cancer (NSCLC); DNA damage response (DDR)-positive NSCLC; triple-negative breast cancer (TNBC); hormone receptor-positive, human epidermal growth factor receptor 2 (ERBB2)-negative, DDR-positive breast cancer; recurrent, platinum-sensitive ovarian cancer (OC); recurrent, platinum-sensitive, BRCA1/2-altered OC; urothelial cancer; metastatic castration-resistant prostate cancer (mCRPC); DDR-positive mCRPC; and BRCA1/2- or ATM-altered solid tumors. Data were analyzed between June 17, 2021, and August 6, 2021. INTERVENTIONS: All patients in phases 1b and 2 received avelumab plus talazoparib. MAIN OUTCOMES AND MEASURES: The phase 1b primary end point was dose-limiting toxic effects. The phase 2 primary end point was objective response, measured as objective response rate (ORR). Secondary end points included safety, time to response, duration of response (DOR), progression-free survival, time to prostate-specific antigen progression and PSA response of 50% or greater (for mCRPC), cancer antigen 125 response (for OC), pharmacokinetics, immunogenicity, and biomarkers. RESULTS: A total of 223 patients (mean [SD] age, 63.2 [11.0] years; 117 [52.5%] men) were treated, including 12 patients in phase 1b and 211 patients in phase 2. The recommended phase 2 dose was avelumab 800 mg every 2 weeks plus talazoparib 1 mg once daily. In phase 2, the ORR was 18.2% (95% CI, 5.2%-40.3%) in patients with TNBC; 34.8% (95% CI, 16.4%-57.3%) in patients with HR-positive, ERBB2-negative, and DDR-positive BC; and 63.6% (95% CI, 30.8%-89.1%) in patients with platinum-sensitive, BRCA1/2-altered OC. Responses occurred more frequently in patients with BRCA1/2-altered tumors. Durable responses were observed in patients with TNBC (median [range] DOR, 11.1 [3.4-20.4] months); HR-positive, ERBB2-negative, and DDR-positive BC (median [range] DOR, 15.7 [3.9 to ≥20.6] months); and BRCA1/2-altered OC (median DOR not reached; range, 5.6 to ≥18.4 months). The most common grade 3 or greater treatment-related adverse events were anemia (75 patients [33.6%]), thrombocytopenia (48 patients [21.5%]), and neutropenia (31 patients [13.9%]). CONCLUSIONS AND RELEVANCE: This nonrandomized controlled trial found that ORRs for avelumab plus talazoparib were comparable with those with PARP inhibitor or ICI monotherapy. Prolonged DOR in patients with TNBC; HR-positive, ERBB2-negative, and DDR-positive BC; and BRCA1/2-altered OC warrant further investigation in randomized clinical trials. These data highlight the importance of prospective patient selection in future studies of ICI and PARP-inhibitor combinations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03330405. FAU - Yap, Timothy A AU - Yap TA AD - The University of Texas MD Anderson Cancer Center, Houston. FAU - Bardia, Aditya AU - Bardia A AD - Massachusetts General Hospital, Boston. FAU - Dvorkin, Michael AU - Dvorkin M AD - Clinical Oncology Dispensary, Budget Healthcare Institution of Omsk Region, Omsk, Russian Federation. FAU - Galsky, Matthew D AU - Galsky MD AD - Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Beck, J Thaddeus AU - Beck JT AD - Highlands Oncology Group, Springdale, Arkansas. FAU - Wise, David R AU - Wise DR AD - NYU Laura and Isaac Perlmutter Cancer Center, New York, New York. FAU - Karyakin, Oleg AU - Karyakin O AD - Medical Radiological Research Center, Kaluga, Russian Federation. FAU - Rubovszky, Gábor AU - Rubovszky G AD - National Institute of Oncology, Budapest, Hungary. FAU - Kislov, Nikolay AU - Kislov N AD - Yaroslavl Regional Cancer Hospital, Yaroslavl, Russian Federation. FAU - Rohrberg, Kristoffer AU - Rohrberg K AD - Department of Oncology, Phase I Unit, Rigshospitalet, Copenhagen, Denmark. FAU - Joy, Anil Abraham AU - Joy AA AD - Cross Cancer Institute, Department of Oncology, University of Alberta, Edmonton, Canada. FAU - Telli, Melinda L AU - Telli ML AD - Stanford University School of Medicine, Stanford, California. FAU - Schram, Alison M AU - Schram AM AD - Memorial Sloan Kettering Cancer Center, New York, New York. FAU - Conte, Umberto AU - Conte U AD - Pfizer, New York, New York. FAU - Chappey, Colombe AU - Chappey C AD - Pfizer, San Francisco, California. FAU - Stewart, Ross AU - Stewart R AD - Now with Translational Medicine, Oncology at AstraZeneca, Cambridge, United Kingdom. AD - Pfizer, San Diego, California. FAU - Stypinski, Daria AU - Stypinski D AD - Pfizer, San Diego, California. FAU - Michelon, Elisabete AU - Michelon E AD - Pfizer, New York, New York. FAU - Cesari, Rossano AU - Cesari R AD - Pfizer, Milan, Italy. FAU - Konstantinopoulos, Panagiotis A AU - Konstantinopoulos PA AD - Dana-Farber Cancer Institute, Boston, Massachusetts. LA - eng SI - ClinicalTrials.gov/NCT03330405 PT - Comment PT - Journal Article PL - United States TA - JAMA Oncol JT - JAMA oncology JID - 101652861 RN - KXG2PJ551I (avelumab) RN - 0 (Poly(ADP-ribose) Polymerase Inhibitors) RN - 9QHX048FRV (talazoparib) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antineoplastic Agents) SB - IM CON - JAMA Oncol. 2023 Jan 1;9(1):25-27. PMID: 36394835 MH - Male MH - Humans MH - Middle Aged MH - Female MH - Poly(ADP-ribose) Polymerase Inhibitors/adverse effects MH - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics MH - Antibodies, Monoclonal/adverse effects/administration & dosage MH - *Triple Negative Breast Neoplasms/drug therapy MH - Prospective Studies MH - *Prostatic Neoplasms, Castration-Resistant/drug therapy MH - *Lung Neoplasms/drug therapy MH - *Antineoplastic Agents/therapeutic use MH - Immunotherapy PMC - PMC9673022 COIS- Conflict of Interest Disclosures: Dr Yap reported being employed as the Medical Director of the Institute for Applied Cancer Science (IACS), which has a commercial interest in DDR and other inhibitors, receiving research support and personal fees from Merck and Pfizer during the conduct of the study; research support from Artios, AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, Forbius, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Novartis, Ribon Therapeutics, Regeneron, Repare, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, and Vertex and serving as a consultant for Almac Consultancy, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, F-Star, Guidepoint, Ignyta, I-Mab, Janssen, Repare, Roche, Rubius, Schrodinger, Seattle Genetics, Varian, and Zai Lab outside the submitted work. Dr Bardia reported receiving personal fees from Pfizer, Novartis, Genentech, Merck, Radius Health, Gilead Sciences, Sanofi, Daiichi Pharma, AstraZeneca, Phillips, Eli Lilly, and Foundation Medicine and grants from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Gilead Sciences, Daiichi Pharma, Astra Zeneca, and Eli Lilly during the conduct of the study. Dr Galsky reported receiving personal fees from BioMotiv, Janssen, Merck, GlaxoSmithKline, Eli Lily, from Astellas, Genentech, Bristol Myers Squibb, Pfizer, EMD Serono, AstraZeneca, Seagen, Numab, and Gilead Sciences outside the submitted work. Dr Beck reported receiving grants from Pfizer during the conduct of the study. Dr Wise reported serving as a consultant for and receiving grants from Pfizer during the conduct of the study and serving as a consultant for Janssen, Leap Therapeutics, and Foundation Medicine outside the submitted work. Dr Rubovszky reported receiving research support from Pfizer during the conduct of the study and personal fees from Pfizer, Eli Lilly, and Novartis outside the submitted work. Dr Kislov reported receiving grants from Pfizer during the conduct of the study and grants from Pfizer outside the submitted work. Dr Rohrberg reported receiving grants from Pfizer during the conduct of the study and grants from Eli Lilly, Roche/Genentech, Bristol Myers Squibb, Symphogen, Novartis, Loxo, Bayer, Alligator Bioscience, Incyte, Genmab, Monta BioScience, Bioinvent, Orion, Cantargia and personal fees from Bayer and Amgen outside the submitted work. Dr Joy reported receiving personal fees from Pfizer, AstraZeneca, Novartis, Bristol Myers Squibb, Roche, Seagen, and Gilead Sciences outside the submitted work. Dr Telli reported receiving grants and personal fees from Pfizer during the conduct of the study; personal fees from AstraZeneca, Merck, Genentech, Gilead Sciences, Blueprint Medicine, Novartis, RefleXion, G1 Therapeutics, Immunomedics, Guardant, Natera, Sanofi,OncoSec, Celgene, Eli Lilly, AbbVie, Daiichi Sankyo, and Aduro and grants from Bayer, Vertex, EMD Serono, Merck, Genentech, GlaxoSmithKline, OncoSec, AbbVie, Hummingbird, and Biothera outside the submitted work. Dr Schram reported receiving research support from AstraZeneca, ArQule, BeiGene, Black Diamond Therapeutics, Eli Lilly, Merus, Northern Biologics, Pfizer, Relay, Elevation Oncology, Kura Oncology, PMV Pharma, Revolution Medicine, Repare, and Surface Oncology and personal fees from Relay and Mersana outside the submitted work. Dr Conte reported being employed by Pfizer during the conduct of the study. Dr Chappey reported being employed by Pfizer during the conduct of the study. Dr Stewart reported being employed by Pfizer during the conduct of the study; owning stock in Pfizer and AstraZeneca and being employed by AstraZeneca outside the submitted work. Dr Michelon reported being employed by and owning stock in Pfizer during the conduct of the study. Dr Cesari reported being employed by Pfizer during the conduct of the study. Dr Konstantinopoulos reported receiving grants from Pfizer during the conduct of the study; serving as a consultant for Alkermes, Bayer, Merck, Merck, Eli Lilly, Repare, Kadmon, Mersan, AstraZeneca, from Bristol Myers Squibb, GlaxoSmithKline, and IMV outside the submitted work. No other disclosures were reported. EDAT- 2022/11/18 06:00 MHDA- 2023/01/24 06:00 CRDT- 2022/11/17 14:02 PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/11/17 14:02 [entrez] AID - 2798848 [pii] AID - coi220064 [pii] AID - 10.1001/jamaoncol.2022.5228 [doi] PST - ppublish SO - JAMA Oncol. 2023 Jan 1;9(1):40-50. doi: 10.1001/jamaoncol.2022.5228. PMID- 36495878 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 401 IP - 10371 DP - 2023 Jan 14 TI - A second-generation antibody-drug conjugate to treat HER2-positive breast cancer. PG - 80-81 LID - S0140-6736(22)02534-X [pii] LID - 10.1016/S0140-6736(22)02534-X [doi] FAU - Rassy, Elie AU - Rassy E AD - Department of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, 94 805, France; Surgical Research Laboratory, Faculty of Medicine, Saint Joseph University, Beyrouth, Lebanon. FAU - Delaloge, Suzette AU - Delaloge S AD - Department of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, 94 805, France. Electronic address: suzette.delaloge@gustaveroussy.fr. LA - eng PT - Comment PT - Journal Article DEP - 20221207 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R RN - 0 (Immunoconjugates) RN - P188ANX8CK (Trastuzumab) RN - SE2KH7T06F (Ado-Trastuzumab Emtansine) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM CON - Lancet. 2023 Jan 14;401(10371):105-117. PMID: 36495879 MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy MH - *Immunoconjugates/therapeutic use MH - Trastuzumab/therapeutic use MH - Ado-Trastuzumab Emtansine/therapeutic use MH - Receptor, ErbB-2 COIS- SD reports grants and non-financial support from Pfizer and AstraZeneca; and grants from Novartis, Roche Genentech, Lilly, Orion, Amgen, Sanofi, Genomic Health, Servier, MSD, BMS, Pierre Fabre, Exact Sciences, Besins, European Commission, French Government, Fondation ARC, Taiho, and Elsan, all of them in relation to clinical or translational research in the breast cancer early detection, prognostication, or treatment fields, all of them to their institution. ER reports no competing interests. EDAT- 2022/12/11 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/12/10 19:06 PHST- 2022/11/25 00:00 [received] PHST- 2022/12/01 00:00 [accepted] PHST- 2022/12/11 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/12/10 19:06 [entrez] AID - S0140-6736(22)02534-X [pii] AID - 10.1016/S0140-6736(22)02534-X [doi] PST - ppublish SO - Lancet. 2023 Jan 14;401(10371):80-81. doi: 10.1016/S0140-6736(22)02534-X. Epub 2022 Dec 7. PMID- 35982377 OWN - NLM STAT- MEDLINE DCOM- 20230111 LR - 20230111 IS - 1869-1889 (Electronic) IS - 1674-7305 (Linking) VI - 66 IP - 1 DP - 2023 Jan TI - Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. PG - 94-109 LID - 10.1007/s11427-021-2140-8 [doi] AB - CDK4/6 inhibitors are the standard treatment in advanced HR+/HER2- breast cancer patients. Nevertheless, the resistance to CDK4/6 inhibitors is inevitable and the strategies to overcome resistance are of great interest. Here, we show that the palbociclib-resistant breast cancer cells expressed significantly higher levels of Cyclin D1 and CDK4 proteins because of upregulated protein synthesis. Silencing Cyclin D1 or CDK4 led to cell cycle arrest while silencing Cyclin E1 or CDK2 restored the sensitivity to palbociclib. Furthermore, PI3K/mTOR pathway was hyper-activated in palbociclib-resistant cells, leading to more phosphorylated 4E-BP1 and higher levels of Cyclin D1 and CDK4 translation. Targeting PI3K/mTOR pathway with a specific PI3Kα inhibitor (BYL719) or an mTOR inhibitor (everolimus) reduced the protein levels of Cyclin D1 and CDK4, and restored the sensitivity to palbociclib. The tumor samples expressed significantly higher levels of Cyclin D1, CDK4, p-AKT and p-4E-BP1 after progression on palbociclib treatment. In conclusion, our findings suggest that overexpressed Cyclin D1 and CDK4 proteins lead to the resistance to CDK4/6 inhibitor and PI3K/mTOR inhibitors are able to restore the sensitivity to CDK4/6 inhibitors, which provides the biomarker and rationale for the combinational use of CDK4/6 inhibitors and PI3K/mTOR inhibitors after CDK4/6 inhibitor resistance in breast cancer. CI - © 2022. Science China Press and Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Cai, Zijie AU - Cai Z AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Wang, Jingru AU - Wang J AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Li, Yudong AU - Li Y AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Shi, Qianfeng AU - Shi Q AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Jin, Liang AU - Jin L AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Li, Shunying AU - Li S AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Zhu, Mengdi AU - Zhu M AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Wang, Qi AU - Wang Q AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Wong, Lok Lam AU - Wong LL AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Yang, Wang AU - Yang W AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Lai, Hongna AU - Lai H AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Gong, Chang AU - Gong C AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Yao, Yandan AU - Yao Y AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Liu, Yujie AU - Liu Y AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Zhang, Jun AU - Zhang J AD - Department of Thyroid and Breast Surgery, Shenzhen Nanshan District Shekou People's Hospital, Shenzhen, 518067, China. FAU - Yao, Herui AU - Yao H AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. FAU - Liu, Qiang AU - Liu Q AD - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. liuq77@mail.sysu.edu.cn. AD - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. liuq77@mail.sysu.edu.cn. LA - eng PT - Journal Article DEP - 20220811 PL - China TA - Sci China Life Sci JT - Science China. Life sciences JID - 101529880 RN - 136601-57-5 (Cyclin D1) RN - 0 (MTOR Inhibitors) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.22 (CDK4 protein, human) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 4) SB - IM MH - Humans MH - Female MH - *Cyclin D1/genetics/metabolism/therapeutic use MH - MTOR Inhibitors MH - Phosphatidylinositol 3-Kinases/metabolism MH - *Breast Neoplasms/drug therapy/genetics/metabolism MH - TOR Serine-Threonine Kinases/metabolism MH - Protein Kinase Inhibitors/pharmacology/therapeutic use MH - Cyclin-Dependent Kinase 4/therapeutic use OTO - NOTNLM OT - CDK4 OT - CDK4/6 inhibitor OT - Cyclin D1 OT - PI3K/mTOR inhibitor OT - resistance EDAT- 2022/08/19 06:00 MHDA- 2023/01/12 06:00 CRDT- 2022/08/18 23:36 PHST- 2022/05/07 00:00 [received] PHST- 2022/06/30 00:00 [accepted] PHST- 2022/08/19 06:00 [pubmed] PHST- 2023/01/12 06:00 [medline] PHST- 2022/08/18 23:36 [entrez] AID - 10.1007/s11427-021-2140-8 [pii] AID - 10.1007/s11427-021-2140-8 [doi] PST - ppublish SO - Sci China Life Sci. 2023 Jan;66(1):94-109. doi: 10.1007/s11427-021-2140-8. Epub 2022 Aug 11. PMID- 36183017 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - ASO Visual Abstract: The Role of Cryoablation in Breast Cancer Beyond the Oncologic Control: COST and Breast-Q Patient Reported Outcomes. PG - 1040-1041 LID - 10.1245/s10434-022-12610-0 [doi] FAU - Khan, Sonia Y AU - Khan SY AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. AD - Texas Tech University Health Sciences Center, Breast Center of Excellence, Lubbock, TX, USA. FAU - Snitman, Annie AU - Snitman A AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. FAU - Habrawi, Zaina AU - Habrawi Z AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. AD - Texas Tech University Health Sciences Center, Breast Center of Excellence, Lubbock, TX, USA. FAU - Crawford, Sybil AU - Crawford S AD - Division of Preventive and Behavioral Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA. FAU - Melkus, Michael W AU - Melkus MW AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. AD - Texas Tech University Health Sciences Center, Breast Center of Excellence, Lubbock, TX, USA. FAU - Layeequr Rahman, Rakhshanda AU - Layeequr Rahman R AD - Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. rakhshanda.rahman@ttuhsc.edu. AD - Texas Tech University Health Sciences Center, Breast Center of Excellence, Lubbock, TX, USA. rakhshanda.rahman@ttuhsc.edu. LA - eng PT - Journal Article PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery MH - *Cryosurgery MH - *Carcinoma, Renal Cell/surgery MH - *Kidney Neoplasms/surgery MH - Treatment Outcome EDAT- 2022/10/02 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/10/01 23:32 PHST- 2022/10/02 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/10/01 23:32 [entrez] AID - 10.1245/s10434-022-12610-0 [pii] AID - 10.1245/s10434-022-12610-0 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1040-1041. doi: 10.1245/s10434-022-12610-0. PMID- 36401732 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer. PG - 319-331 LID - 10.1007/s10549-022-06797-9 [doi] AB - PURPOSE: GDC-0810 (ARN-810) is a novel, non-steroidal, orally bioavailable, selective estrogen receptor degrader (SERD) that potentially inhibits ligand-dependent and ligand-independent estrogen receptor (ER)-mediated signaling. METHODS: A phase Ia/Ib/IIa dose escalation, combination treatment with palbociclib or a luteinizing hormone-releasing hormone, and expansion study determined the safety, pharmacokinetics, and recommended phase 2 dose (RP2D) of GDC-0810 in postmenopausal women with ER + (HER2 -) locally advanced or metastatic breast cancer (MBC). Baseline plasma ctDNA samples were analyzed to determine the ESR1 mutation status. RESULTS: Patients (N = 152) received GDC-0810 100-800 mg once daily (QD) or 300-400 mg twice daily, in dose escalation, expansion, as single agent or combination treatment. Common adverse events regardless of attribution to study drug were diarrhea, nausea, fatigue, vomiting, and constipation. There was one dose-limiting toxicity during dose escalation. The maximum tolerated dose was not reached. GDC-0810 600 mg QD taken with food was the RP2D. Pharmacokinetics were predictable. FES reduction (> 90%) highlighting pharmacodynamic engagement of ER was observed. Outcomes for the overall population and for patients with tumors harboring ESR1 mutations included partial responses (4% overall; 4% ESR1), stable disease (39% overall; 42% ESR1), non-complete response/non-progressive disease (13% overall; 12% ESR1), progressive disease (40% overall; 38% ESR1), and missing/unevaluable (5% overall; 5% ESR1). Clinical benefit (responses or SD, lasting ≥ 24 weeks) was observed in patients in dose escalation (n = 16, 39%) and expansion (n = 24, 22%). CONCLUSION: GDC-0810 was safe and tolerable with preliminary anti-tumor activity in heavily pretreated patients with ER + advanced/MBC, with/without ESR1 mutations, highlighting the potential for oral SERDs. Clinical Trial and registration date April 4, 2013. NCT01823835 . CI - © 2022. The Author(s). FAU - Bardia, Aditya AU - Bardia A AUID- ORCID: 0000-0003-4885-1157 AD - Massachusetts General Hospital Cancer Center, Harvard Medical School, Bartlett Hall Extension 237, 55 Fruit St, Boston, MA, 02114, USA. bardia.aditya@mgh.harvard.edu. FAU - Mayer, Ingrid AU - Mayer I AD - Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. AD - AstraZeneca, Gaithersburg, MD, USA. FAU - Winer, Eric AU - Winer E AD - Dana-Farber Cancer Institute, Boston, MA, USA. AD - Yale Cancer Center, New Haven, CT, USA. FAU - Linden, Hannah M AU - Linden HM AD - University of Washington, Seattle, WA, USA. FAU - Ma, Cynthia X AU - Ma CX AD - Washington University School of Medicine, St. Louis, MO, USA. FAU - Parker, Barbara A AU - Parker BA AD - University of California San Diego Moores Cancer Center, San Diego, CA, USA. FAU - Bellet, Meritxell AU - Bellet M AD - Vall d'Hebron Institute of Oncology, Barcelona, Spain. FAU - Arteaga, Carlos L AU - Arteaga CL AD - UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA. FAU - Cheeti, Sravanthi AU - Cheeti S AD - Genentech, Inc, South San Francisco, CA, USA. FAU - Gates, Mary AU - Gates M AD - Genentech, Inc, South San Francisco, CA, USA. FAU - Chang, Ching-Wei AU - Chang CW AD - Genentech, Inc, South San Francisco, CA, USA. FAU - Fredrickson, Jill AU - Fredrickson J AD - Genentech, Inc, South San Francisco, CA, USA. FAU - Spoerke, Jill M AU - Spoerke JM AD - Genentech, Inc, South San Francisco, CA, USA. FAU - Moore, Heather M AU - Moore HM AD - Genentech, Inc, South San Francisco, CA, USA. FAU - Giltnane, Jennifer AU - Giltnane J AD - Genentech, Inc, South San Francisco, CA, USA. FAU - Friedman, Lori S AU - Friedman LS AD - Genentech, Inc, South San Francisco, CA, USA. AD - ORIC Pharmaceuticals, South San Francisco, CA, USA. FAU - Chow Maneval, Edna AU - Chow Maneval E AD - ORIC Pharmaceuticals, South San Francisco, CA, USA. FAU - Chan, Iris AU - Chan I AD - Genentech, Inc, South San Francisco, CA, USA. FAU - Jhaveri, Komal AU - Jhaveri K AD - Memorial Sloan Kettering Cancer Center, New York, Weill Cornell Medical College, New York, NY, USA. LA - eng SI - ClinicalTrials.gov/NCT01823835 GR - P30 CA008748/CA/NCI NIH HHS/United States GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20221119 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid) RN - 0 (Receptors, Estrogen) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - 0 (Ligands) RN - 0 (Estrogen Antagonists) SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/drug therapy/genetics/pathology MH - Receptors, Estrogen/genetics MH - Receptor, ErbB-2/genetics MH - Ligands MH - Postmenopause MH - Estrogen Antagonists/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9823088 OTO - NOTNLM OT - GDC-0810; HR +  OT - HER2 −  OT - Metastatic breast cancer OT - Phase 1 OT - Postmenopausal OT - Selective estrogen receptor degrader COIS- A.B. held consulting/advisory board positions at Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/AstraZeneca, Phillips, Eli Lilly, Foundation Medicine, and received contracted research/grant to institution from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/AstraZeneca, and Eli Lilly. I.M. received consulting fees/ research support from Genentech and is an employee of AstraZeneca. E.W. and H.M.L. received consulting fees and research support from Genentech. C.X.M. held consulting/advisory board positions at Gilead, AstraZeneca, Sanofi-Genzyme, Jacobio, Natera, Novartis, Inivata, Biovica, Athenex, Bayer, Esai, and OncoSignal and received funding from Pfizer and Puma. B.A.P. received contracted research support to the institution from Pfizer, Novartis, Glaxo Smith Kline, Genentech/Roche, and Oncternal Therapeutics Inc., consulting fees from Dare Bioscience, Bioatla Inc. (spouse), EMD Serona (spouse), and Samumed LLC (spouse), and has stock ownership in Merck. M.B. held advisory board positions at Pfizer, Novartis, and Lilly and received speakers bureau fees from Pfizer, Novartis, and Lilly and travel expenses from Pfizer and Roche. C.L.A. held advisory board positions at Novartis, Lilly, Merck, TAIHO Oncology, Immunomedics, Daiichi Sankyo, AstraZeneca, Sanofi, OrigiMed, and Susan G. Komen Foundation, received research grant support from Pfizer, Lilly, and Takeda, and has stock ownership in Provista. S.C., M.G., C.-W.C., J.F., H.M.M., J.G., and I.C. are employees and stockholders of Roche/Genentech. J.M.S. and L.S.F. are former employees and stockholders of Roche/Genentech. E.C.M. is a former employee of Seragon. K.J. received consulting fees from AbbVie, AstraZeneca, Blueprint Medicines, Biotheranostics, BMS, Genentech, Jounce Therapeutics, Lilly Pharmaceuticals, Novartis, Pfizer, Seattle Genetics, SunPharma Pvt Ltd, and Taiho Oncology and contracted research grants to institution from ADC Therapeutics, AstraZeneca, Clovis Oncology, Debio Pharmaceuticals, Genentech, Immunomedics, Novartis, Lilly Pharmaceuticals, Merck/VelosBio, Novartis, Novita Pharmaceuticals, Pfizer, Puma Biotechnology, and Zymeworks. EDAT- 2022/11/20 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/19 11:17 PHST- 2022/08/16 00:00 [received] PHST- 2022/10/30 00:00 [accepted] PHST- 2022/11/20 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/19 11:17 [entrez] AID - 10.1007/s10549-022-06797-9 [pii] AID - 6797 [pii] AID - 10.1007/s10549-022-06797-9 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):319-331. doi: 10.1007/s10549-022-06797-9. Epub 2022 Nov 19. PMID- 36245054 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - ASO Author Reflections: The Evolution of Axillary Management in Breast Cancer. PG - 1014-1015 LID - 10.1245/s10434-022-12677-9 [doi] FAU - Schwartz, Theresa AU - Schwartz T AD - Department of Surgery, Henry Ford Cancer Institute, Detroit, MI, USA. FAU - Marumoto, Ashley D AU - Marumoto AD AD - Department of Surgery, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA. FAU - Giuliano, Armando E AU - Giuliano AE AD - Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Armando.Giuliano@cshs.org. LA - eng PT - Comment PT - Journal Article DEP - 20221016 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CON - Ann Surg Oncol. 2023 Feb;30(2):1008-1013. PMID: 36194309 MH - Humans MH - Female MH - *Breast Neoplasms/surgery MH - Axilla MH - Neoadjuvant Therapy EDAT- 2022/10/17 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/10/16 23:19 PHST- 2022/10/04 00:00 [received] PHST- 2022/10/04 00:00 [accepted] PHST- 2022/10/17 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/10/16 23:19 [entrez] AID - 10.1245/s10434-022-12677-9 [pii] AID - 10.1245/s10434-022-12677-9 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1014-1015. doi: 10.1245/s10434-022-12677-9. Epub 2022 Oct 16. PMID- 36496487 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - ASO Visual Abstract: Association of Fat Graft in Implant-Based Reconstruction with Breast Cancer Recurrence: Does the Timing Matter? PG - 1098 LID - 10.1245/s10434-022-12602-0 [doi] FAU - Lee, Kyeong-Tae AU - Lee KT AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Kim, Ju Hee AU - Kim JH AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Jeon, Byung-Joon AU - Jeon BJ AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Pyon, Jai Kyong AU - Pyon JK AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Mun, Goo-Hyun AU - Mun GH AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Lee, Se Kyung AU - Lee SK AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Yu, Jonghan AU - Yu J AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Kim, Seok Won AU - Kim SW AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Lee, Jeong Eon AU - Lee JE AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Ryu, Jai Min AU - Ryu JM AD - Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. jaimin.ryu@samsung.com. FAU - Bang, Sa Ik AU - Bang SI AD - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. si55.bang@samsung.com. LA - eng PT - Journal Article PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/surgery MH - *Breast Implantation MH - Neoplasm Recurrence, Local/surgery MH - Breast/surgery MH - Mastectomy MH - *Mammaplasty MH - *Breast Implants MH - Retrospective Studies EDAT- 2022/12/11 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/12/10 23:39 PHST- 2022/12/11 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/12/10 23:39 [entrez] AID - 10.1245/s10434-022-12602-0 [pii] AID - 10.1245/s10434-022-12602-0 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1098. doi: 10.1245/s10434-022-12602-0. PMID- 36449205 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - ASO Visual Abstract: Postmastectomy Tissue Expander Placement Followed by Radiation Therapy-A Cost-Effectiveness Analysis of Staged Autologous versus Implant-Based Unilateral Reconstruction. PG - 1086 LID - 10.1245/s10434-022-12680-0 [doi] FAU - Bloom, Joshua A AU - Bloom JA AD - Department of Surgery, Tufts Medical Center, Boston, MA, USA. FAU - Shah, Shivani A AU - Shah SA AD - Harvard Medical School, Boston, MA, USA. FAU - Long, Emily A AU - Long EA AD - Division of Plastic and Reconstructive Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. FAU - Chatterjee, Abhishek AU - Chatterjee A AD - Division of Plastic and Reconstructive Surgery, Tufts Medical Center, Boston, MA, USA. FAU - Lee, Bernard T AU - Lee BT AD - Division of Plastic and Reconstructive Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. blee3@bidmc.harvard.edu. LA - eng PT - Journal Article PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - Female MH - Tissue Expansion Devices MH - Mastectomy MH - Cost-Effectiveness Analysis MH - *Breast Neoplasms/radiotherapy/surgery MH - *Mammaplasty MH - *Breast Implantation MH - *Breast Implants MH - Retrospective Studies MH - Tissue Expansion MH - Postoperative Complications EDAT- 2022/12/01 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/11/30 11:22 PHST- 2022/12/01 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/11/30 11:22 [entrez] AID - 10.1245/s10434-022-12680-0 [pii] AID - 10.1245/s10434-022-12680-0 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1086. doi: 10.1245/s10434-022-12680-0. PMID- 36673662 OWN - NLM STAT- MEDLINE DCOM- 20230126 LR - 20230126 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 20 IP - 2 DP - 2023 Jan 4 TI - Recommending Breast Cancer Screening to My Mum: Examining the Interplay of Threat, Efficacy, and Virality on Recommendation Intention in the Chinese Context. LID - 10.3390/ijerph20020907 [doi] LID - 907 AB - The burgeoning eHealth campaigns and the emerging daughter-to-mother health communication necessitate a close examination of the intricate mechanism behind recommending preventive behaviors in online settings. The present study addresses existing gaps by investigating how message characteristics and platform-generated virality cues jointly influence younger females' intention to recommend breast cancer screening to their mothers. Drawing on the extended parallel process model (EPPM) as the theoretical basis, a 2 (threat: low vs. high) × 2 (efficacy: low vs. high) × 2 (virality: low vs. high) randomized between-subjects experiment (n = 269) was performed. Results revealed a three-way interaction effect between threat, efficacy, and virality on message involvement. Message involvement was positively associated with recommendation intention and mediated the three-way interaction effect on recommendation intention. This study demonstrates that a high threat can initiate message involvement but fail to trigger recommendation intention. In contrast, a low-threat, high-efficacy, high-virality combination would yield a salutary outcome. Besides, the indispensable role of message involvement in the underlying psychological mechanism behind recommending preventive behaviors was reaffirmed. Theoretical and practical implications are further discussed. FAU - Luo, Chen AU - Luo C AUID- ORCID: 0000-0002-9736-0533 AD - School of Journalism and Communication, Wuhan University, Wuhan 430072, China. FAU - Zhang, Zizhong AU - Zhang Z AD - School of Journalism and Communication, Tsinghua University, Beijing 100084, China. FAU - Jin, Jing AU - Jin J AD - School of Journalism and Communication, Tsinghua University, Beijing 100084, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20230104 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/prevention & control MH - Cues MH - Early Detection of Cancer MH - Fear/psychology MH - *Intention PMC - PMC9858677 OTO - NOTNLM OT - Chinese women OT - breast cancer screening OT - eHealth OT - extended parallel process model (EPPM) OT - message involvement OT - recommendation intention OT - virality metrics COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 CRDT- 2023/01/21 01:19 PHST- 2022/12/03 00:00 [received] PHST- 2022/12/22 00:00 [revised] PHST- 2022/12/31 00:00 [accepted] PHST- 2023/01/21 01:19 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] AID - ijerph20020907 [pii] AID - ijerph-20-00907 [pii] AID - 10.3390/ijerph20020907 [doi] PST - epublish SO - Int J Environ Res Public Health. 2023 Jan 4;20(2):907. doi: 10.3390/ijerph20020907. PMID- 36319870 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - ASO Visual Abstract: Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients. PG - 1028 LID - 10.1245/s10434-022-12712-9 [doi] FAU - Culver, Julie O AU - Culver JO AUID- ORCID: 0000-0001-8658-3507 AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. jculver@med.usc.edu. FAU - Freiberg, Yael AU - Freiberg Y AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Ricker, Charité AU - Ricker C AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Comeaux, Jacob G AU - Comeaux JG AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Chang, Emmeline Y AU - Chang EY AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Banerjee, Victoria AU - Banerjee V AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Sturgeon, Duveen AU - Sturgeon D AD - Center for Precision Medicine, City of Hope, Duarte, CA, USA. FAU - Solomon, Ilana AU - Solomon I AD - Center for Precision Medicine, City of Hope, Duarte, CA, USA. FAU - Kagey, Josie AU - Kagey J AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Dobre, Mariana G AU - Dobre MG AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Carey, Joseph AU - Carey J AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Carr, Azadeh AU - Carr A AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Cho, Stephanie AU - Cho S AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Lu, Janice AU - Lu J AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Kang, Irene M AU - Kang IM AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Patel, Ketan AU - Patel K AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Terando, Alicia AU - Terando A AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Ye, Jason C AU - Ye JC AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Li, Ming AU - Li M AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Lerman, Caryn AU - Lerman C AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Spicer, Darcy AU - Spicer D AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. FAU - Nelson, Maria AU - Nelson M AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. LA - eng PT - Journal Article PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/genetics MH - Genetic Testing MH - Genetic Predisposition to Disease MH - Germ Cells MH - Germ-Line Mutation EDAT- 2022/11/03 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/11/02 00:38 PHST- 2022/11/03 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/11/02 00:38 [entrez] AID - 10.1245/s10434-022-12712-9 [pii] AID - 10.1245/s10434-022-12712-9 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1028. doi: 10.1245/s10434-022-12712-9. PMID- 36625774 OWN - NLM STAT- MEDLINE DCOM- 20230112 LR - 20230112 IS - 1552-4833 (Electronic) IS - 1552-4825 (Linking) VI - 191 IP - 2 DP - 2023 Feb TI - Evidence Grows for Universal Germline Genetic Testing for Patients with Breast Cancer. PG - 319-320 LID - 10.1002/ajmg.a.62791 [doi] LA - eng PT - Journal Article PL - United States TA - Am J Med Genet A JT - American journal of medical genetics. Part A JID - 101235741 SB - IM MH - Humans MH - Female MH - *Breast Neoplasms/diagnosis/genetics MH - Genetic Testing MH - Genetic Predisposition to Disease MH - Germ-Line Mutation/genetics EDAT- 2023/01/11 06:00 MHDA- 2023/01/13 06:00 CRDT- 2023/01/10 10:33 PHST- 2023/01/10 10:33 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] AID - 10.1002/ajmg.a.62791 [doi] PST - ppublish SO - Am J Med Genet A. 2023 Feb;191(2):319-320. doi: 10.1002/ajmg.a.62791. PMID- 36241948 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230111 IS - 1534-4681 (Electronic) IS - 1068-9265 (Linking) VI - 30 IP - 2 DP - 2023 Feb TI - ASO Author Reflections: A Green Light for Genetic Testing in All Patients with Breast Cancer. PG - 1026-1027 LID - 10.1245/s10434-022-12671-1 [doi] FAU - Culver, Julie O AU - Culver JO AUID- ORCID: 0000-0001-8658-3507 AD - Division of Medical Oncology, USC Norris Comprehensive Cancer Center and Keck School of Medicine, University of Southern California, 1450 Biggy Street. #2509L, Los Angeles, CA, 90033, USA. jculver@med.usc.edu. LA - eng PT - Comment PT - Journal Article DEP - 20221014 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM CON - Ann Surg Oncol. 2023 Feb;30(2):1017-1025. PMID: 36161375 MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - Breast MH - Genetic Testing MH - Light MH - Patients EDAT- 2022/10/15 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/10/14 23:41 PHST- 2022/09/26 00:00 [received] PHST- 2022/10/04 00:00 [accepted] PHST- 2022/10/15 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/10/14 23:41 [entrez] AID - 10.1245/s10434-022-12671-1 [pii] AID - 10.1245/s10434-022-12671-1 [doi] PST - ppublish SO - Ann Surg Oncol. 2023 Feb;30(2):1026-1027. doi: 10.1245/s10434-022-12671-1. Epub 2022 Oct 14. PMID- 36427680 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20221230 IS - 1879-0038 (Electronic) IS - 0378-1119 (Linking) VI - 852 DP - 2023 Feb 5 TI - Identification of novel exonic variants contributing to hereditary breast and ovarian cancer in west Indian population. PG - 147070 LID - S0378-1119(22)00890-3 [pii] LID - 10.1016/j.gene.2022.147070 [doi] AB - Breast and ovarian cancers are the most common cancer types in females worldwide and in India. Patients with these cancers require an early diagnosis which is essential for better prognosis, treatment and improved patient survival. Recently, the utilization of next-generation sequencing (NGS)-based screening has accelerated molecular diagnosis of various cancers. In the present study, we performed whole-exome sequencing (WES) of 30 patients who had a first or second-degree relative with breast or ovarian cancer and are tested negative for BRCA1/2 or other high and moderate-risk genes reported for HBOC. WES data from patients were analyzed and variants were called using bcftools. Functional annotation of variants and variant prioritization was performed by Exomiser. The clinical significance of variants was determined as per ACMG classification using Varsome tool. The functional analysis of genes was determined by STRING analysis and disease association was determined by open target tool. We found novel variants and gene candidates having significant association with HBOC conditions. The genes identified by exomiser (phenotype score > 0.75) are associated with various biological processes such as DNA integrity maintenance, transcription regulation, cell cycle regulation, and apoptosis. Our findings provide novel and prevalent gene variants associated with the HBOC condition in the West Indian population which could be further studied for early diagnosis and better prognosis of HBOC. CI - Copyright © 2022. Published by Elsevier B.V. FAU - Waghela, Bhargav N AU - Waghela BN AD - Gujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, Gujarat 382011, India. FAU - Pandit, Ramesh J AU - Pandit RJ AD - Gujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, Gujarat 382011, India. FAU - Puvar, Apurvasinh AU - Puvar A AD - Gujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, Gujarat 382011, India. FAU - Shah, Franky D AU - Shah FD AD - Gujarat Cancer Research Institute, Civil Hospital, Ahmedabad, Gujarat 380016, India. FAU - Patel, Prabhudas S AU - Patel PS AD - Gujarat Cancer Research Institute, Civil Hospital, Ahmedabad, Gujarat 380016, India. FAU - Vora, Hemangini AU - Vora H AD - Gujarat Cancer Research Institute, Civil Hospital, Ahmedabad, Gujarat 380016, India. FAU - Sheth, Harsh AU - Sheth H AD - Frige House, Jodhpur Gam Rd, Satellite, Ahmedabad, Gujarat 380015, India. FAU - Tarapara, Bhoomi AU - Tarapara B AD - Gujarat Cancer Research Institute, Civil Hospital, Ahmedabad, Gujarat 380016, India. FAU - Pandya, Shashank AU - Pandya S AD - Gujarat Cancer Research Institute, Civil Hospital, Ahmedabad, Gujarat 380016, India. FAU - Joshi, Chaitanya G AU - Joshi CG AD - Gujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, Gujarat 382011, India. FAU - Joshi, Madhvi N AU - Joshi MN AD - Gujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, Gujarat 382011, India. Electronic address: madhvimicrobio@gmail.com. LA - eng PT - Journal Article DEP - 20221124 PL - Netherlands TA - Gene JT - Gene JID - 7706761 RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - Female MH - *Ovarian Neoplasms/genetics MH - BRCA1 Protein/genetics MH - Exons MH - India MH - *Breast Neoplasms/genetics MH - Genetic Predisposition to Disease OTO - NOTNLM OT - Autosomal dominant diseases OT - HBOC OT - Next-generation sequencing OT - Non-BRCA genes OT - Whole-exome sequencing COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/26 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/11/25 19:25 PHST- 2022/05/25 00:00 [received] PHST- 2022/10/21 00:00 [revised] PHST- 2022/11/18 00:00 [accepted] PHST- 2022/11/26 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/11/25 19:25 [entrez] AID - S0378-1119(22)00890-3 [pii] AID - 10.1016/j.gene.2022.147070 [doi] PST - ppublish SO - Gene. 2023 Feb 5;852:147070. doi: 10.1016/j.gene.2022.147070. Epub 2022 Nov 24. PMID- 36385461 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20230124 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 152 IP - 6 DP - 2023 Mar 15 TI - Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population. PG - 1159-1173 LID - 10.1002/ijc.34359 [doi] AB - Pathogenic variation in BRCA1 and BRCA2 (BRCA) causes high risk of breast and ovarian cancer, and BRCA variation data are important markers for BRCA-related clinical cancer applications. However, comprehensive BRCA variation data are lacking from the Asian population despite its large population size, heterogenous genetic background and diversified living environment across the Asia continent. We performed a systematic study on BRCA variation in Asian population including extensive data mining, standardization, annotation and characterization. We identified 7587 BRCA variants from 685 592 Asian individuals in 40 Asia countries and regions, including 1762 clinically actionable pathogenic variants and 4915 functionally unknown variants (https://genemutation.fhs.um.edu.mo/Asian-BRCA/). We observed the highly ethnic-specific nature of Asian BRCA variants between Asian and non-Asian populations and within Asian populations, highlighting that the current European descendant population-based BRCA data is inadequate to reflect BRCA variation in the Asian population. We also provided archeological evidence for the evolutionary origin and arising time of Asian BRCA variation. We further provided structural-based evidence for the deleterious variants enriched within the functionally unknown Asian BRCA variants. The data from our study provide a current view of BRCA variation in the Asian population and a rich resource to guide clinical applications of BRCA-related cancer for the Asian population. CI - © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. FAU - Qin, Zixin AU - Qin Z AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Li, Jiaheng AU - Li J AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Tam, Benjamin AU - Tam B AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Sinha, Siddharth AU - Sinha S AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Zhao, Bojin AU - Zhao B AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Bhaskaran, Shanmuga Priya AU - Bhaskaran SP AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Huang, Teng AU - Huang T AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Wu, Xiaobing AU - Wu X AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Chian, Jia Sheng AU - Chian JS AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Guo, Maoni AU - Guo M AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Kou, Si Hoi AU - Kou SH AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Lei, Huijun AU - Lei H AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Zhang, Li AU - Zhang L AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Wang, Xiaoyu AU - Wang X AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Lagniton, Philip Naderev P AU - Lagniton PNP AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Xiao, Fengxia AU - Xiao F AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Jiang, Xinyang AU - Jiang X AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. FAU - Wang, San Ming AU - Wang SM AUID- ORCID: 0000-0002-2172-1320 AD - Ministry of Education Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Department of Public Health and Medical Administration, Faculty of Health Sciences, University of Macau, Macao SAR, China. LA - eng GR - 085/2017/A2/Macau Science and Technology Development Fund/ GR - 0077/2019/AMJ/Macau Science and Technology Development Fund/ GR - 0032/2022/A1/Macau Science and Technology Development Fund/ GR - FHSIG/SW/0007/2020P/The Faculty of Health Sciences, University of Macau/ GR - MoE Frontier Center for Precision Oncology pilot grant, startup grant/ GR - SRG2017-00097-FHS/The University of Macau/ GR - MYRG2019-00018-FHS/The University of Macau/ GR - MYRG2020-00094-FHS/The University of Macau/ PT - Journal Article DEP - 20221130 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA2 protein, human) SB - IM MH - Female MH - Humans MH - Asia/epidemiology MH - Asian MH - Asian People/genetics MH - BRCA1 Protein/genetics MH - *Breast Neoplasms/genetics MH - Genetic Predisposition to Disease MH - Germ-Line Mutation MH - *Ovarian Neoplasms/genetics OTO - NOTNLM OT - Asian OT - BRCA1 OT - BRCA2 OT - cancer OT - database OT - evolution OT - germline variation OT - population OT - structure OT - variation EDAT- 2022/11/18 06:00 MHDA- 2023/01/21 06:00 CRDT- 2022/11/17 11:04 PHST- 2022/10/23 00:00 [revised] PHST- 2022/09/22 00:00 [received] PHST- 2022/11/08 00:00 [accepted] PHST- 2022/11/18 06:00 [pubmed] PHST- 2023/01/21 06:00 [medline] PHST- 2022/11/17 11:04 [entrez] AID - 10.1002/ijc.34359 [doi] PST - ppublish SO - Int J Cancer. 2023 Mar 15;152(6):1159-1173. doi: 10.1002/ijc.34359. Epub 2022 Nov 30. PMID- 35681111 OWN - NLM STAT- MEDLINE DCOM- 20230120 LR - 20230120 IS - 2005-9256 (Electronic) IS - 1598-2998 (Linking) VI - 55 IP - 1 DP - 2023 Jan TI - Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation. PG - 155-166 LID - 10.4143/crt.2021.1567 [doi] AB - PURPOSE: BRCA1 and BRCA2 are among the most important genes involved in DNA repair via homologous recombination (HR). Germline BRCA1/2 (gBRCA1/2)-related cancers have specific characteristics and treatment options but conducting gBRCA1/2 testing and interpreting the genetic imprint are sometimes complicated. Here, we describe the concordance of gBRCA1/2 derived from a panel of clinical tumor tissues using next-generation sequencing (NGS) and genetic aspects of tumors harboring gBRCA1/2 pathogenic variants. MATERIALS AND METHODS: Targeted sequencing was performed using available tumor tissue from patients who underwent gBRCA1/2 testing. Comparative genomic analysis was performed according to gBRCA1/2 pathogenicity. RESULTS: A total of 321 patients who underwent gBRCA1/2 testing were screened, and 26 patients with gBRCA1/2 pathogenic (gBRCA1/2p) variants, eight patients with gBRCA1/2 variants of uncertain significance (VUS; gBRCA1/2v), and 43 patients with gBRCA1/2 wild-type (gBRCA1/2w) were included in analysis. Mutations in TP53 (49.4%) and PIK3CA (23.4%) were frequently detected in all samples. The number of single-nucleotide variants (SNVs) per tumor tissue was higher in the gBRCA1/2w group than that in the gBRCA1/2p group (14.81 vs. 18.86, p=0.278). Tumor mutation burden (TMB) was significantly higher in the gBRCA1/2w group than in the gBRCA1/2p group (10.21 vs. 13.47, p=0.017). Except for BRCA1/2, other HR-related genes were frequently mutated in patients with gBRCA1/2w. CONCLUSION: We demonstrated high sensitivity of gBRCA1/2 in tumors analyzed by NGS using a panel of tumor tissues. TMB value and aberration of non-BRCA1/2 HR-related genes differed significantly according to gBRCA1/2 pathogenicity in patients with breast cancer. FAU - Kim, Ju Won AU - Kim JW AD - Division of Medical Oncology and Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea. FAU - Kang, Hyo Eun AU - Kang HE AD - K-MASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise, Korea University Medical Center, Seoul, Korea. FAU - Choi, Jimi AU - Choi J AD - Division of Endocrinology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea. FAU - Yun, Seung Gyu AU - Yun SG AD - Department of Laboratory Medicine, Korea University Anam Hospital, Seoul, Korea. FAU - Jung, Seung Pil AU - Jung SP AD - Department of Breast Surgery, Korea University Anam Hospital, Seoul, Korea. FAU - Bae, Soo Yeon AU - Bae SY AD - Department of Breast Surgery, Korea University Anam Hospital, Seoul, Korea. FAU - You, Ji Young AU - You JY AD - Department of Breast Surgery, Korea University Anam Hospital, Seoul, Korea. FAU - Choi, Yoon-Ji AU - Choi YJ AD - Division of Medical Oncology and Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea. FAU - Kim, Yeul Hong AU - Kim YH AD - Division of Medical Oncology and Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea. FAU - Park, Kyong Hwa AU - Park KH AD - Division of Medical Oncology and Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea. LA - eng GR - Korea Health Industry Development Institute/ GR - HI17C2206/Ministry of Health & Welfare/ GR - 2016R1A5A1010148/National Research Foundation of Korea/ PT - Journal Article DEP - 20220608 PL - Korea (South) TA - Cancer Res Treat JT - Cancer research and treatment JID - 101155137 RN - 0 (Biomarkers, Tumor) RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA2 protein, human) SB - IM MH - Female MH - Humans MH - Biomarkers, Tumor/genetics MH - BRCA1 Protein/genetics MH - *Breast Neoplasms/genetics/pathology MH - Genes, BRCA2 MH - Genomics MH - Germ-Line Mutation MH - High-Throughput Nucleotide Sequencing MH - Mutation MH - *Ovarian Neoplasms/genetics OTO - NOTNLM OT - BRCA OT - Breast neoplasms OT - Genomic landscape OT - Germ-line mutation OT - NGS OT - TMB EDAT- 2022/06/11 06:00 MHDA- 2023/01/17 06:00 CRDT- 2022/06/10 00:32 PHST- 2021/12/07 00:00 [received] PHST- 2022/06/06 00:00 [accepted] PHST- 2022/06/11 06:00 [pubmed] PHST- 2023/01/17 06:00 [medline] PHST- 2022/06/10 00:32 [entrez] AID - crt.2021.1567 [pii] AID - 10.4143/crt.2021.1567 [doi] PST - ppublish SO - Cancer Res Treat. 2023 Jan;55(1):155-166. doi: 10.4143/crt.2021.1567. Epub 2022 Jun 8. PMID- 36161580 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230111 IS - 1880-4233 (Electronic) IS - 1340-6868 (Linking) VI - 30 IP - 1 DP - 2023 Jan TI - Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants. PG - 110-120 LID - 10.1007/s12282-022-01404-7 [doi] AB - BACKGROUND: Recent advances in human genome research have provided evidence for genotype-phenotype associations, pathogenicity, and clinical actionability of variants and genomic risk prediction of disease. However, the return of individual genomic results to healthy individuals is fraught with ethical and practical complexity. METHODS: Individual genomic results were returned to BRCA1/2 pathogenic variant (PV) carriers of the Tohoku Medical Megabank cohort study participants with an information on hereditary breast and ovarian cancer syndrome (HBOC). One hundred and eighty participants, including 9 BRCA1/2 PV carriers, were asked about their willingness to receive individual genomic results, without revealing the gene name and related disorders, prior to the study. Of the 142 participants who responded, 103 showed willingness to know their genomic information. Each of the six BRCA1/2 PV carriers who consented to participate in the study received information about HBOC in person and underwent validation testing with blood resampling. RESULTS: All participants were in their 60s or 70s; of the four females and two males, two had a history of breast cancer and five had a family history of HBOC-related cancers. All participants appreciated the information, without remarkable negative psychological impact of the return, and intended to undergo clinical risk surveillance. Five participants were accompanied by family members while receiving the results, and three first-degree female relatives wished to undergo genomic testing at the hospital. CONCLUSIONS: Our results suggest that returning actionable genomic information to participants in a population-based genome cohort study is beneficial for preventing or providing early-stage intervention for associated diseases. CI - © 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society. FAU - Ohneda, Kinuko AU - Ohneda K AUID- ORCID: 0000-0002-6919-6529 AD - Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan. kohneda@megabank.tohoku.ac.jp. FAU - Hamanaka, Yohei AU - Hamanaka Y AD - Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan. AD - Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. FAU - Kawame, Hiroshi AU - Kawame H AD - Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan. AD - Department of Clinical Genetics, Jikei University Hospital, Tokyo, Japan. FAU - Fuse, Nobuo AU - Fuse N AD - Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan. AD - Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Miyagi, Japan. FAU - Nagami, Fuji AU - Nagami F AD - Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan. AD - Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Miyagi, Japan. FAU - Suzuki, Yoichi AU - Suzuki Y AD - Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan. AD - Department of Clinical Genetics, Ageo Central General Hospital, Ageo, Saitama, Japan. FAU - Yamaguchi-Kabata, Yumi AU - Yamaguchi-Kabata Y AD - Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan. FAU - Shimada, Muneaki AU - Shimada M AD - Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Miyagi, Japan. AD - Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. FAU - Masamune, Atsushi AU - Masamune A AD - Department of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. FAU - Aoki, Yoko AU - Aoki Y AD - Department of Medical Genetics, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. FAU - Ishida, Takanori AU - Ishida T AD - Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. FAU - Yamamoto, Masayuki AU - Yamamoto M AD - Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8573, Japan. masiyamamoto@med.tohoku.ac.jp. AD - Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Miyagi, Japan. masiyamamoto@med.tohoku.ac.jp. LA - eng GR - JP 17 km0105001/Ministry of Education, Culture, Sports, Science and Technology-Japan and the Japan Agency of Medical Research Development/ GR - JP 21tm0124005/Ministry of Education, Culture, Sports, Science and Technology-Japan and the Japan Agency of Medical Research Development/ PT - Journal Article DEP - 20220926 PL - Japan TA - Breast Cancer JT - Breast cancer (Tokyo, Japan) JID - 100888201 RN - 0 (BRCA1 Protein) RN - 0 (BRCA2 Protein) RN - 0 (BRCA1 protein, human) SB - IM MH - Male MH - Humans MH - Female MH - *Breast Neoplasms/genetics MH - Cohort Studies MH - BRCA1 Protein/genetics MH - *Hereditary Breast and Ovarian Cancer Syndrome/genetics MH - Genomics MH - *Ovarian Neoplasms/genetics/prevention & control MH - Genetic Predisposition to Disease MH - BRCA2 Protein/genetics OTO - NOTNLM OT - Hereditary breast and ovarian cancer syndrome OT - Population-based genome cohort study OT - Return of individual genomic results EDAT- 2022/09/27 06:00 MHDA- 2023/01/07 06:00 CRDT- 2022/09/26 18:19 PHST- 2022/05/04 00:00 [received] PHST- 2022/09/14 00:00 [accepted] PHST- 2022/09/27 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2022/09/26 18:19 [entrez] AID - 10.1007/s12282-022-01404-7 [pii] AID - 10.1007/s12282-022-01404-7 [doi] PST - ppublish SO - Breast Cancer. 2023 Jan;30(1):110-120. doi: 10.1007/s12282-022-01404-7. Epub 2022 Sep 26. PMID- 36121189 OWN - NLM STAT- MEDLINE DCOM- 20230105 LR - 20230112 IS - 1745-4514 (Electronic) IS - 0145-8884 (Linking) VI - 46 IP - 12 DP - 2022 Dec TI - Preparation of Black pepper (Piper nigrum L.) essential oil nanoparticles and its antitumor activity on triple negative breast cancer in vitro. PG - e14406 LID - 10.1111/jfbc.14406 [doi] AB - The active compounds isolated from Black pepper have anticancer effects, but the bioactivity of Black pepper essential oil (BP-EO) is rarely studied. BP-EO has poor stability and a suitable dose form should be prepared for in vivo delivery. Triple negative breast cancer (TNBC) has attracted more and more attention due to its high mitotic index, high metastasis rate and poor prognosis. In this study, the composition of BP-EO was analyzed by gas chromatography-mass spectrometry (GC-MS), and nanoparticles (NPs) loaded with BP-EO were prepared by nanoprecipitation method using Eudragit L100 as a carrier. We investigated the preparation, characterization, stability and in vitro release of nanoparticles. MTT assay, cell wound healing, Transwell invasion assay and Western blot were used to study the anti-tumor effect and mechanism of MDA-MB-231 cells. The GC-MS analysis identified a total of 33 compounds among which alkenes account for 63.55%. The prepared BP-EO NPs exhibited nanoscale morphology, good stability and pH-responsive and sustained release character which is suitable for in vivo delivery. BP-EO NPs significantly inhibited the proliferation, migration and invasion of MDA-MB-231 cells. Furthermore, BP-EO NPs significantly inhibited the expressions of Wnt and β-catenin and significantly activated the expression of GSK-3β in MDA-MB-231 cells. Therefore, BP-EO NPs prepared in this study provide a new effective strategy for the treatment of TNBC. PRACTICAL APPLICATIONS: Black pepper is rich in essential oil and has excellent antioxidant and antibacterial activities. However, the anti-tumor activity of BP-EO has not been studied. In this study, we found that BP-EO has excellent anticancer activity. To achieve effective encapsulation of black pepper essential oil and an excellent anti-triple negative breast cancer activity, nanoparticles loaded with BP-EO were prepared using Eudragit L100 as the carrier by the nanoprecipitation method. The in vitro study revealed that BP-EO NPs inhibited proliferation, migration and invasion of MDA-MB-231 cells via inhibiting the Wnt/β-Catenin signaling pathway. This study provides new ideas and innovations for the treatment of invasive triple negative breast cancer in the future. At the same time, we will further reveal the application potential, pharmacokinetic characteristics and precise mechanism of BP-EO NPs in vivo in subsequent studies. CI - © 2022 Wiley Periodicals LLC. FAU - Zhang, Mengying AU - Zhang M AD - Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China. FAU - Qiu, Beibei AU - Qiu B AD - Department of Pathology, Feicheng Hospital affiliated to Shandong First Medical University, Feicheng, China. FAU - Sun, Mengjia AU - Sun M AD - Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China. FAU - Wang, Yunfei AU - Wang Y AD - Quality Assurance Department, Shandong Xinhua Pharmaceutical Company Limited, Zibo, China. FAU - Wei, Meijiao AU - Wei M AD - Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China. FAU - Gong, Yanling AU - Gong Y AUID- ORCID: 0000-0002-2394-8772 AD - Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China. FAU - Yan, Meixing AU - Yan M AD - Department of Pharmacy, Qingdao Women and Children's Hospital, Qingdao, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220919 PL - United States TA - J Food Biochem JT - Journal of food biochemistry JID - 7706045 RN - 0 (Oils, Volatile) RN - 25086-15-1 (methylmethacrylate-methacrylic acid copolymer) RN - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta) SB - IM MH - Humans MH - *Oils, Volatile/pharmacology/chemistry MH - *Piper nigrum/chemistry MH - *Triple Negative Breast Neoplasms/drug therapy/metabolism/pathology MH - Glycogen Synthase Kinase 3 beta MH - *Nanoparticles OTO - NOTNLM OT - Black pepper OT - essential oil OT - nanoparticles OT - triple negative breast cancer EDAT- 2022/09/20 06:00 MHDA- 2023/01/06 06:00 CRDT- 2022/09/19 08:32 PHST- 2022/07/19 00:00 [revised] PHST- 2022/06/13 00:00 [received] PHST- 2022/08/13 00:00 [accepted] PHST- 2022/09/20 06:00 [pubmed] PHST- 2023/01/06 06:00 [medline] PHST- 2022/09/19 08:32 [entrez] AID - 10.1111/jfbc.14406 [doi] PST - ppublish SO - J Food Biochem. 2022 Dec;46(12):e14406. doi: 10.1111/jfbc.14406. Epub 2022 Sep 19. PMID- 36555509 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230104 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 24 DP - 2022 Dec 14 TI - PKR-Mediated Phosphorylation of eIF2a and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells. LID - 10.3390/ijms232415872 [doi] LID - 15872 AB - Triple-negative breast cancer is more aggressive than other types of breast cancer. Protein kinase R (PKR), which is activated by dsRNA, is known to play a role in doxorubicin-mediated apoptosis; however, its role in DNA damage-mediated apoptosis is not well understood. In this study, we investigated the roles of PKR and its downstream players in doxorubicin-treated HCC1143 triple-negative breast cancer cells. Doxorubicin treatment induces DNA damage and apoptosis. Interestingly, doxorubicin treatment induced the phosphorylation of eukaryotic initiation factor 2 alpha (eIF2α) via PKR, whereas the inhibition of PKR with inhibitor C16 reduced eIF2α phosphorylation. Under these conditions, doxorubicin-mediated DNA fragmentation, cell death, and poly(ADP ribose) polymerase and caspase 7 levels were recovered. In addition, phosphorylation of checkpoint kinase 1 (CHK1), which is known to be involved in doxorubicin-mediated DNA damage, was increased by doxorubicin treatment, but blocked by PKR inhibition. Protein translation was downregulated by doxorubicin treatment and upregulated by blocking PKR phosphorylation. These results suggest that PKR activation induces apoptosis by increasing the phosphorylation of eIF2α and CHK1 and decreasing the global protein translation in doxorubicin-treated HCC1143 triple-negative breast cancer cells. FAU - Lee, Sol AU - Lee S AUID- ORCID: 0000-0002-6655-2188 AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. FAU - Jee, Ha-Yeon AU - Jee HY AUID- ORCID: 0000-0001-9136-8748 AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. FAU - Lee, Yoon-Gyeong AU - Lee YG AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. FAU - Shin, Jong-Il AU - Shin JI AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. FAU - Jeon, Yong-Joon AU - Jeon YJ AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. FAU - Kim, Ji-Beom AU - Kim JB AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. FAU - Seo, Hye-Eun AU - Seo HE AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. FAU - Lee, Ji-Yeon AU - Lee JY AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. FAU - Lee, Kyungho AU - Lee K AUID- ORCID: 0000-0002-5220-1387 AD - Department of Biological Sciences, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. AD - Korea Hemp Institute, Konkuk University, 120 Neungdong-ro, Gwangin-gu, Seoul 05029, Republic of Korea. LA - eng GR - 2017R1D1A1B03031743/National Research Foundation of Korea/ GR - 2017M3A9G7072745/National Research Foundation of Korea/ GR - 2022R1F1A1074572/National Research Foundation of Korea/ PT - Journal Article DEP - 20221214 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - EC 2.7.11.1 (Checkpoint Kinase 1) RN - 80168379AG (Doxorubicin) RN - 0 (Eukaryotic Initiation Factor-2) RN - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases) RN - 0 (EIF2S1 protein, human) RN - EC 2.7.11.1 (CHEK1 protein, human) SB - IM MH - Humans MH - Apoptosis MH - *Checkpoint Kinase 1/metabolism MH - *Doxorubicin/pharmacology MH - *Eukaryotic Initiation Factor-2/metabolism MH - Phosphorylation MH - Poly(ADP-ribose) Polymerases/metabolism MH - *Triple Negative Breast Neoplasms/drug therapy PMC - PMC9779813 OTO - NOTNLM OT - CHK1 OT - ER OT - PKR OT - apoptosis OT - doxorubicin OT - eIF2α OT - triple-negative breast cancer COIS- All authors declare no competing interests. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:34 PHST- 2022/11/06 00:00 [received] PHST- 2022/12/11 00:00 [revised] PHST- 2022/12/11 00:00 [accepted] PHST- 2022/12/23 01:34 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - ijms232415872 [pii] AID - ijms-23-15872 [pii] AID - 10.3390/ijms232415872 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 14;23(24):15872. doi: 10.3390/ijms232415872. PMID- 36436516 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20230117 IS - 1474-5488 (Electronic) IS - 1470-2045 (Print) IS - 1470-2045 (Linking) VI - 24 IP - 1 DP - 2023 Jan TI - Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes. PG - 91-106 LID - S1470-2045(22)00643-X [pii] LID - 10.1016/S1470-2045(22)00643-X [doi] AB - BACKGROUND: Truncating pathogenic or likely pathogenic variants of CDH1 cause hereditary diffuse gastric cancer (HDGC), a tumour risk syndrome that predisposes carrier individuals to diffuse gastric and lobular breast cancer. Rare CDH1 missense variants are often classified as variants of unknown significance. We conducted a genotype-phenotype analysis in families carrying rare CDH1 variants, comparing cancer spectrum in carriers of pathogenic or likely pathogenic variants (PV/LPV; analysed jointly) or missense variants of unknown significance, assessing the frequency of families with lobular breast cancer among PV/LPV carrier families, and testing the performance of lobular breast cancer-expanded criteria for CDH1 testing. METHODS: This genotype-first study used retrospective diagnostic and clinical data from 854 carriers of 398 rare CDH1 variants and 1021 relatives, irrespective of HDGC clinical criteria, from 29 institutions in ten member-countries of the European Reference Network on Tumour Risk Syndromes (ERN GENTURIS). Data were collected from Oct 1, 2018, to Sept 20, 2022. Variants were classified by molecular type and clinical actionability with the American College of Medical Genetics and Association for Molecular Pathology CDH1 guidelines (version 2). Families were categorised by whether they fulfilled the 2015 and 2020 HDGC clinical criteria. Genotype-phenotype associations were analysed by Student's t test, Kruskal-Wallis, χ(2), and multivariable logistic regression models. Performance of HDGC clinical criteria sets were assessed with an equivalence test and Youden index, and the areas under the receiver operating characteristic curves were compared by Z test. FINDINGS: From 1971 phenotypes (contributed by 854 probands and 1021 relatives aged 1-93 years), 460 had gastric and breast cancer histology available. CDH1 truncating PV/LPVs occurred in 176 (21%) of 854 families and missense variants of unknown significance in 169 (20%) families. Multivariable logistic regression comparing phenotypes occurring in families carrying PV/LPVs or missense variants of unknown significance showed that lobular breast cancer had the greatest positive association with the presence of PV/LPVs (odds ratio 12·39 [95% CI 2·66-57·74], p=0·0014), followed by diffuse gastric cancer (8·00 [2·18-29·39], p=0·0017) and gastric cancer (7·81 [2·03-29·96], p=0·0027). 136 (77%) of 176 families carrying PV/LPVs fulfilled the 2015 HDGC criteria. Of the remaining 40 (23%) families, who did not fulfil the 2015 criteria, 11 fulfilled the 2020 HDGC criteria, and 18 had lobular breast cancer only or lobular breast cancer and gastric cancer, but did not meet the 2020 criteria. No specific CDH1 variant was found to predispose individuals specifically to lobular breast cancer, although 12 (7%) of 176 PV/LPV carrier families had lobular breast cancer only. Addition of three new lobular breast cancer-centred criteria improved testing sensitivity while retaining high specificity. The probability of finding CDH1 PV/LPVs in patients fulfilling the lobular breast cancer-expanded criteria, compared with the 2020 criteria, increased significantly (AUC 0·92 vs 0·88; Z score 3·54; p=0·0004). INTERPRETATION: CDH1 PV/LPVs were positively associated with HDGC-related phenotypes (lobular breast cancer, diffuse gastric cancer, and gastric cancer), and no evidence for a positive association with these phenotypes was found for CDH1 missense variants of unknown significance. CDH1 PV/LPVs occurred often in families with lobular breast cancer who did not fulfil the 2020 HDGC criteria, supporting the expansion of lobular breast cancer-centred criteria. FUNDING: European Reference Network on Genetic Tumour Risk Syndromes, European Regional Development Fund, Fundação para a Ciência e a Tecnologia (Portugal), Cancer Research UK, and European Union's Horizon 2020 research and innovation programme. CI - Copyright © 2023 Elsevier Ltd. All rights reserved. FAU - Garcia-Pelaez, José AU - Garcia-Pelaez J AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Barbosa-Matos, Rita AU - Barbosa-Matos R AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Lobo, Silvana AU - Lobo S AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Dias, Alexandre AU - Dias A AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Garrido, Luzia AU - Garrido L AD - Centro Hospitalar Universitário São João, Porto, Portugal. FAU - Castedo, Sérgio AU - Castedo S AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Centro Hospitalar Universitário São João, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal. FAU - Sousa, Sónia AU - Sousa S AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Pinheiro, Hugo AU - Pinheiro H AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Serviço de Medicina Interna, Centro Hospitalar Tâmega e Sousa, Penafiel, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Sousa, Liliana AU - Sousa L AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Escola de Economia e Gestão, Universidade do Minho, Braga, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Monteiro, Rita AU - Monteiro R AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal. FAU - Maqueda, Joaquin J AU - Maqueda JJ AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Bioinf2Bio, Porto, Portugal. FAU - Fernandes, Susana AU - Fernandes S AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal. FAU - Carneiro, Fátima AU - Carneiro F AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Centro Hospitalar Universitário São João, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal. FAU - Pinto, Nádia AU - Pinto N AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Center of Mathematics, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Lemos, Carolina AU - Lemos C AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Pinto, Carla AU - Pinto C AD - Department of Laboratory Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal. FAU - Teixeira, Manuel R AU - Teixeira MR AD - Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Department of Laboratory Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal. FAU - Aretz, Stefan AU - Aretz S AD - Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany; National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; ERN GENTURIS, Bonn, Germany. FAU - Bajalica-Lagercrantz, Svetlana AU - Bajalica-Lagercrantz S AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Genetics, Cancer Genetic Unit, Karolinska University Hospital Solna, Stockholm, Sweden; Cancer Theme, Karolinska University Hospital Solna, Stockholm, Sweden; ERN GENTURIS, Stockholm, Sweden. FAU - Balmaña, Judith AU - Balmaña J AD - Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; ERN GENTURIS, Barcelona, Spain. FAU - Blatnik, Ana AU - Blatnik A AD - Department of Clinical Cancer Genetics, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ERN GENTURIS, Ljubljana, Slovenia. FAU - Benusiglio, Patrick R AU - Benusiglio PR AD - Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France. FAU - Blanluet, Maud AU - Blanluet M AD - Service de Génétique Oncologique, Institut Curie, Paris, France. FAU - Bours, Vincent AU - Bours V AD - Laboratory of Human Genetics, GIGA Institute, University of Liège, Liège, Belgium; Center of Genetics, University Hospital, Liège, Belgium; ERN GENTURIS, Liège, Belgium. FAU - Brems, Hilde AU - Brems H AD - Department of Human Genetics, University of Leuven, Leuven, Belgium. FAU - Brunet, Joan AU - Brunet J AD - Hereditary Cancer Programme, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research and Girona Biomedical Research Institute, Barcelona-Girona, Spain; ERN GENTURIS, Barcelona, Spain. FAU - Calistri, Daniele AU - Calistri D AD - Laboratorio di Bioscienze, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Capellá, Gabriel AU - Capellá G AD - Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; ERN GENTURIS, Barcelona, Spain. FAU - Carrera, Sergio AU - Carrera S AD - Oncology Service, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Cruces-Barakaldo, Bizkaia, Spain. FAU - Colas, Chrystelle AU - Colas C AD - Service de Génétique Oncologique, Institut Curie, Paris, France; ERN GENTURIS, Paris, France. FAU - Dahan, Karin AU - Dahan K AD - Center of Human Genetics, IPG, Gosselies, Belgium. FAU - de Putter, Robin AU - de Putter R AD - Clinical Genetics Department, University Hospital of Ghent, Ghent, Belgium; ERN GENTURIS, Ghent, Belgium. FAU - Desseignés, Camille AU - Desseignés C AD - Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France. FAU - Domínguez-Garrido, Elena AU - Domínguez-Garrido E AD - Molecular Diagnostics Laboratory, Fundación Rioja Salud, Logroño, Spain. FAU - Egas, Conceição AU - Egas C AD - CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. FAU - Evans, D Gareth AU - Evans DG AD - Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK; Manchester Centre for Genomic Medicine, Manchester, UK. FAU - Feret, Damien AU - Feret D AD - Center of Human Genetics, IPG, Gosselies, Belgium. FAU - Fewings, Eleanor AU - Fewings E AD - Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK. FAU - Fitzgerald, Rebecca C AU - Fitzgerald RC AD - Early Cancer Institute, University of Cambridge, Cambridge, UK. FAU - Coulet, Florence AU - Coulet F AD - Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France. FAU - Garcia-Barcina, María AU - Garcia-Barcina M AD - Genetics Unit, Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Bilbao, Bizkaia, Spain. FAU - Genuardi, Maurizio AU - Genuardi M AD - Sezione di Medicina Genomica, Dipartimento di Scienze della Vita e Salute Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy; UOC Genetica Medica, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy; ERN GENTURIS, Rome, Italy. FAU - Golmard, Lisa AU - Golmard L AD - Service de Génétique Oncologique, Institut Curie, Paris, France. FAU - Hackmann, Karl AU - Hackmann K AD - Institute for Clinical Genetics, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; National Center for Tumor Diseases, Dresden, Germany: German Cancer Research Center, Heidelberg, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; German Cancer Consortium, Dresden, Germany. FAU - Hanson, Helen AU - Hanson H AD - SouthWest Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, UK. FAU - Holinski-Feder, Elke AU - Holinski-Feder E AD - Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany; Medizinisch Genetisches Zentrum, Munich, Germany; ERN GENTURIS, Munich, Germany. FAU - Hüneburg, Robert AU - Hüneburg R AD - Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany; National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; ERN GENTURIS, Bonn, Germany. FAU - Krajc, Mateja AU - Krajc M AD - Department of Clinical Cancer Genetics, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ERN GENTURIS, Ljubljana, Slovenia. FAU - Lagerstedt-Robinson, Kristina AU - Lagerstedt-Robinson K AD - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Genetics, Cancer Genetic Unit, Karolinska University Hospital Solna, Stockholm, Sweden; ERN GENTURIS, Stockholm, Sweden. FAU - Lázaro, Conxi AU - Lázaro C AD - Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; ERN GENTURIS, Barcelona, Spain. FAU - Ligtenberg, Marjolijn J L AU - Ligtenberg MJL AD - Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands; Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands; Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands; ERN GENTURIS, Nijmegen, Netherlands. FAU - Martínez-Bouzas, Cristina AU - Martínez-Bouzas C AD - Genetics Service, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Cruces-Barakaldo, Bizkaia, Spain. FAU - Merino, Sonia AU - Merino S AD - Genetics Unit, Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Bilbao, Bizkaia, Spain. FAU - Michils, Geneviève AU - Michils G AD - Department of Human Genetics, University of Leuven, Leuven, Belgium. FAU - Novaković, Srdjan AU - Novaković S AD - Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia. FAU - Patiño-García, Ana AU - Patiño-García A AD - Unidad de Medicina Genómica y Pediatría, Clínica Universidad de Navarra, Programa de Tumores Sólidos, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Navarra, Spain. FAU - Ranzani, Guglielmina Nadia AU - Ranzani GN AD - Department of Biology and Biotechnology, University of Pavia, Pavia, Italy. FAU - Schröck, Evelin AU - Schröck E AD - Institute for Clinical Genetics, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; National Center for Tumor Diseases, Dresden, Germany: German Cancer Research Center, Heidelberg, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; German Cancer Consortium, Dresden, Germany; Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany; ERN GENTURIS, Dresden, Germany. FAU - Silva, Inês AU - Silva I AD - GenoMed-Diagnósticos de Medicina Molecular, Lisbon, Portugal. FAU - Silveira, Catarina AU - Silveira C AD - GenoMed-Diagnósticos de Medicina Molecular, Lisbon, Portugal. FAU - Soto, José L AU - Soto JL AD - Molecular Genetics Laboratory, Elche University Hospital, Elche, Spain. FAU - Spier, Isabel AU - Spier I AD - Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany; National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; ERN GENTURIS, Bonn, Germany. FAU - Steinke-Lange, Verena AU - Steinke-Lange V AD - Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany; Medizinisch Genetisches Zentrum, Munich, Germany; ERN GENTURIS, Munich, Germany. FAU - Tedaldi, Gianluca AU - Tedaldi G AD - Laboratorio di Bioscienze, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. FAU - Tejada, María-Isabel AU - Tejada MI AD - Genetics Service, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Cruces-Barakaldo, Bizkaia, Spain. FAU - Woodward, Emma R AU - Woodward ER AD - Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK; Manchester Centre for Genomic Medicine, Manchester, UK. FAU - Tischkowitz, Marc AU - Tischkowitz M AD - Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK. FAU - Hoogerbrugge, Nicoline AU - Hoogerbrugge N AD - Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands; Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands; ERN GENTURIS, Nijmegen, Netherlands. FAU - Oliveira, Carla AU - Oliveira C AD - Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal. Electronic address: carlaol@i3s.up.pt. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20221124 PL - England TA - Lancet Oncol JT - The Lancet. Oncology JID - 100957246 RN - 0 (Antigens, CD) RN - 0 (Cadherins) RN - 0 (CDH1 protein, human) SB - IM EIN - Lancet Oncol. 2023 Jan;24(1):e10. PMID: 36603924 MH - Female MH - Humans MH - Antigens, CD/genetics MH - *Breast Neoplasms/epidemiology/genetics/pathology MH - Cadherins/genetics MH - *Carcinoma, Lobular MH - Genetic Predisposition to Disease MH - Genotype MH - Germ Cells/pathology MH - Germ-Line Mutation MH - Pedigree MH - Phenotype MH - Retrospective Studies MH - *Stomach Neoplasms/epidemiology/genetics MH - Mutation, Missense PMC - PMC9810541 COIS- Declaration of interests DGE declares fees from Astrazeneca and Recursion. ERW declares grants from International Alliance for Cancer Early Detection, for which they are codirector of the research domain. GNR declares receipt of funding for study materials, medical writing, and article processing charges from Italian Ministry of Education (GNR). MJLL declares consulting fees (via the Radboud University Medical Center) from Merck Sharp & Dohme (MSD), AstraZeneca, Lilly, Janssen-Cilag, Illumina, GlaxoSmithKline. PRB declares fees from AstraZeneca, MSD, and Bristol Myers Squibb; and is a scientific committee member for the Geneticancer patients association. JBa declares fees from AstraZeneca, Lilly, and Pfizer. SA is a member of APC subVCEP of the InSiGHT/ClinGen Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel; is an unpaid member of the German Gene Diagnostics Commission and speaker of the Centre for Hereditary Tumour Syndromes of the University of Bonn. RH declares grants from SLA Pharma and Janssen Pharmaceuticals; consulting fees from Janssen and One Two Therapeutics; equipment from Fujifilm; is the head of German Consortium for Familial Gastrointestinal Cancer; and is an unpaid advisory board member of the Lynch Syndrome advocacy Group and the Familial Polyposis Group. ES declares grants from NCT/DKTK Master. ES declares honoraria for presentations from AstraZeneca, Georg Thieme Verlag KG, and payment for expert testimony from Illumina; is a member of the board of directors of Deutsche Gesellschaft für HumanGenetik; an advisor for Dresden-concept Genome Center; and is board of directors president (paid) for LNS laboratoire National de Santé. RdP declares support for presentations (via his institution) from MSD and AstraZeneca. GC declares to receive funding for study materials, medical writing, article processing charges from the Spanish Ministry of Science and Innovation, the Instituto de Salud Carlos III CIBERONC, and the Government of Catalonia.; consulting fees from VCN Biosciences Synthetic Biologics; is the chair of the Council of the International Society of Hereditary Gastrointestinal Tumours and the FUREGA Fundació Recerca en Gastroenterologia; and stock in Synthetic Biologics. CLa declares consulting fees and honoraria from AstraZeneca and MSD, and is a paid advisory board member for Illumina. EDAT- 2022/11/28 06:00 MHDA- 2023/01/10 06:00 CRDT- 2022/11/27 19:02 PHST- 2022/07/17 00:00 [received] PHST- 2022/10/11 00:00 [revised] PHST- 2022/10/12 00:00 [accepted] PHST- 2022/11/28 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2022/11/27 19:02 [entrez] AID - S1470-2045(22)00643-X [pii] AID - 10.1016/S1470-2045(22)00643-X [doi] PST - ppublish SO - Lancet Oncol. 2023 Jan;24(1):91-106. doi: 10.1016/S1470-2045(22)00643-X. Epub 2022 Nov 24. PMID- 36214786 OWN - NLM STAT- MEDLINE DCOM- 20221227 LR - 20230103 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 152 IP - 4 DP - 2023 Feb 15 TI - Proteomic signature for detection of high-grade ovarian cancer in germline BRCA mutation carriers. PG - 781-793 LID - 10.1002/ijc.34318 [doi] AB - No current screening methods for high-grade ovarian cancer (HGOC) guarantee effective early detection for high-risk women such as germline BRCA mutation carriers. Therefore, the standard-of-care remains risk-reducing salpingo-oophorectomy (RRSO) around age 40. Proximal liquid biopsy is a promising source of biomarkers, but sensitivity has not yet qualified for clinical implementation. We aimed to develop a proteomic assay based on proximal liquid biopsy, as a decision support tool for monitoring high-risk population. Ninety Israeli BRCA1 or BRCA2 mutation carriers were included in the training set (17 HGOC patients and 73 asymptomatic women), (BEDOCA trial; ClinicalTrials.gov Identifier: NCT03150121). The proteome of the microvesicle fraction of the samples was profiled by mass spectrometry and a classifier was developed using logistic regression. An independent cohort of 98 BRCA mutation carriers was used for validation. Safety information was collected for all women who opted for uterine lavage in a clinic setting. We present a 7-protein diagnostic signature, with AUC >0.97 and a negative predictive value (NPV) of 100% for detecting HGOC. The AUC of the biomarker in the independent validation set was >0.94 and the NPV >99%. The sampling procedure was clinically acceptable, with favorable pain scores and safety. We conclude that the acquisition of Müllerian tract proximal liquid biopsies in women at high-risk for HGOC and the application of the BRCA-specific diagnostic assay demonstrates high sensitivity, specificity, technical feasibility and safety. Similar classifier for an average-risk population is warranted. CI - © 2022 UICC. FAU - Bahar-Shany, Keren AU - Bahar-Shany K AD - Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Barnabas, Georgina D AU - Barnabas GD AD - Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. FAU - Deutsch, Lisa AU - Deutsch L AD - BioStats, Statistical Consulting Ltd, Modiin, Israel. FAU - Deutsch, Netanel AU - Deutsch N AD - BioStats, Statistical Consulting Ltd, Modiin, Israel. FAU - Glick-Saar, Efrat AU - Glick-Saar E AD - Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Dominissini, Dan AU - Dominissini D AD - Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. FAU - Sapoznik, Stav AU - Sapoznik S AD - Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Helpman, Limor AU - Helpman L AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Perri, Tamar AU - Perri T AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Blecher, Anna AU - Blecher A AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Katz, Guy AU - Katz G AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Yagel, Itai AU - Yagel I AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Rosenblatt, Orgad AU - Rosenblatt O AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Shai, Daniel AU - Shai D AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Brandt, Benny AU - Brandt B AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Meyer, Raanan AU - Meyer R AD - Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Mohr-Sasson, Aya AU - Mohr-Sasson A AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Volodarsky-Perel, Alexander AU - Volodarsky-Perel A AD - Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Zilberman, Itamar AU - Zilberman I AD - Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Armon, Shunit AU - Armon S AD - Department of Obstetrics & Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel. FAU - Jakobson-Setton, Ariella AU - Jakobson-Setton A AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Department of Gynecologic Oncology, Rabin Medical Center, Petah Tikva, Israel. FAU - Eitan, Ram AU - Eitan R AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Department of Gynecologic Oncology, Rabin Medical Center, Petah Tikva, Israel. FAU - Kadan, Yfat AU - Kadan Y AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Division of Gynecologic Oncology, Meir Medical Center, Kfar Saba, Israel. FAU - Beiner, Mario AU - Beiner M AD - Division of Gynecologic Oncology, Meir Medical Center, Kfar Saba, Israel. FAU - Josephy, Dana AU - Josephy D AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Division of Gynecologic Oncology, Meir Medical Center, Kfar Saba, Israel. FAU - Brodsky, Malka AU - Brodsky M AD - Meirav Breast Health Center, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Friedman, Eitan AU - Friedman E AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - The Susanne-Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Anafi, Liat AU - Anafi L AD - Department of Pathology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Molchanov, Yossef AU - Molchanov Y AD - Department of Pathology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Korach, Jacob AU - Korach J AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. AD - Department of Gynecologic Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel. FAU - Geiger, Tamar AU - Geiger T AD - Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. AD - Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. FAU - Levanon, Keren AU - Levanon K AUID- ORCID: 0000-0002-5122-064X AD - Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel. LA - eng SI - ClinicalTrials.gov/NCT03150121 GR - Israel Cancer Association, Research Grant and Early Detection Grant/ GR - Israel Cancer Research Fund, Len & Susan Mark Initiative for Ovarian and Uterin/ GR - Israel Innovation Authority of the Israeli Ministry of Finance, Nofar Program/ GR - 1104/17/Israel Science Foundation/ GR - SPARK-Tel Aviv Program/ PT - Journal Article DEP - 20221023 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (BRCA1 Protein) SB - IM MH - Humans MH - Female MH - Adult MH - Genes, BRCA2 MH - Mutation MH - Proteomics MH - Salpingo-oophorectomy MH - BRCA1 Protein/genetics MH - *Ovarian Neoplasms/diagnosis/genetics/pathology MH - Ovariectomy MH - Germ-Line Mutation MH - *Breast Neoplasms/genetics MH - Genetic Predisposition to Disease OTO - NOTNLM OT - BRCA OT - early detection biomarker OT - ovarian cancer OT - utero-tubal lavage EDAT- 2022/10/11 06:00 MHDA- 2022/12/28 06:00 CRDT- 2022/10/10 10:53 PHST- 2022/08/21 00:00 [revised] PHST- 2022/03/15 00:00 [received] PHST- 2022/09/05 00:00 [accepted] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/12/28 06:00 [medline] PHST- 2022/10/10 10:53 [entrez] AID - 10.1002/ijc.34318 [doi] PST - ppublish SO - Int J Cancer. 2023 Feb 15;152(4):781-793. doi: 10.1002/ijc.34318. Epub 2022 Oct 23. PMID- 36555323 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230104 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 24 DP - 2022 Dec 10 TI - Obesity as a Risk Factor for Breast Cancer-The Role of miRNA. LID - 10.3390/ijms232415683 [doi] LID - 15683 AB - Breast cancer (BC) is the most common cancer diagnosed among women in the world, with an ever-increasing incidence rate. Due to the dynamic increase in the occurrence of risk factors, including obesity and related metabolic disorders, the search for new regulatory mechanisms is necessary. This will help a complete understanding of the pathogenesis of breast cancer. The review presents the mechanisms of obesity as a factor that increases the risk of developing breast cancer and that even initiates the cancer process in the female population. The mechanisms presented in the paper relate to the inflammatory process resulting from current or progressive obesity leading to cell metabolism disorders and disturbed hormonal metabolism. All these processes are widely regulated by the action of microRNAs (miRNAs), which may constitute potential biomarkers influencing the pathogenesis of breast cancer and may be a promising target of anti-cancer therapies. FAU - Hanusek, Karolina AU - Hanusek K AUID- ORCID: 0000-0002-8052-0086 AD - Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, ul. Marymoncka 99/103, 01-813 Warsaw, Poland. FAU - Karczmarski, Jakub AU - Karczmarski J AD - Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland. FAU - Litwiniuk, Anna AU - Litwiniuk A AUID- ORCID: 0000-0003-1115-733X AD - Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland. FAU - Urbańska, Katarzyna AU - Urbańska K AD - Department of General, Oncological, Metabolic and Thoracic Surgery, Military Institute of Medicine, 128 Szaserów St, 04-141 Warsaw, Poland. FAU - Ambrozkiewicz, Filip AU - Ambrozkiewicz F AUID- ORCID: 0000-0001-6850-780X AD - Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1665/76, 32300 Pilsen, Czech Republic. FAU - Kwiatkowski, Andrzej AU - Kwiatkowski A AD - Department of General, Oncological, Metabolic and Thoracic Surgery, Military Institute of Medicine, 128 Szaserów St, 04-141 Warsaw, Poland. FAU - Martyńska, Lidia AU - Martyńska L AD - Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland. FAU - Domańska, Anita AU - Domańska A AD - Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland. FAU - Bik, Wojciech AU - Bik W AD - Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland. FAU - Paziewska, Agnieszka AU - Paziewska A AUID- ORCID: 0000-0002-6644-1509 AD - Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland. AD - Faculty of Medical and Health Sciences, Institute of Health Sciences, Siedlce University of Natural Sciences and Humanities, 08-110 Siedlce, Poland. LA - eng GR - N°856620/European Union's Horizon 2020 research and innovation programme/ GR - Centre of Postgraduate Medical Education/Centre of Postgraduate Medical Education/ PT - Journal Article PT - Review DEP - 20221210 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (MicroRNAs) SB - IM MH - Female MH - Humans MH - *Breast Neoplasms/genetics/pathology MH - Gene Expression Regulation, Neoplastic MH - *Metabolic Diseases/genetics MH - *MicroRNAs/genetics MH - *Obesity/complications/genetics/pathology MH - Risk Factors PMC - PMC9779381 OTO - NOTNLM OT - breast cancer OT - estrogens OT - hypoxia OT - inflammation OT - metabolites OT - miRNA OT - obesity COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:33 PHST- 2022/11/15 00:00 [received] PHST- 2022/12/03 00:00 [revised] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/23 01:33 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - ijms232415683 [pii] AID - ijms-23-15683 [pii] AID - 10.3390/ijms232415683 [doi] PST - epublish SO - Int J Mol Sci. 2022 Dec 10;23(24):15683. doi: 10.3390/ijms232415683. PMID- 36367610 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230111 IS - 1573-7217 (Electronic) IS - 0167-6806 (Linking) VI - 197 IP - 2 DP - 2023 Jan TI - A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia. PG - 387-395 LID - 10.1007/s10549-022-06782-2 [doi] AB - PURPOSE: Pathogenic variants (PVs) in BRCA1 and BRCA2 genes are essential biomarkers of an increased breast and ovarian cancer risk and tumor sensitivity to poly ADP ribose polymerase inhibitors. In Russia, eight PVs were thought to be the most common, among which BRCA1 c.5266dup is the most frequently identified one. METHODS: We show the distribution of BRCA1/2 PVs identified with quantitative PCR and targeted next-generation sequencing in 1399 ovarian cancer patients recruited into the study from 72 Russian regions in 2015-2021. RESULTS: The most abundant PVs were c.5266dup (41.0%), c.4035del (7.0%), c.1961del (6.3%), c.181 T > G (5.2%), c.3756_3759del (1.8%), c.3700_3704del (1.5%), and c.68_69del (1.5%), all found in BRCA1 and known to be recurrent in Russia. Several other frequent PVs were identified: c.5152 + 1G > T (1.2%), c.1687C > T (1.0%), c.4689C > G (0.9%), c.1510del (0.6%), c.2285_2286del (0.6%) in the BRCA1 gene; and c.5286 T > G (1.2%), c.2808_2811del (0.8%), c.3847_3848del (0.8%), c.658_659del (0.7%), c.7879A > T (0.6%), in the BRCA2 gene. For the most common PV in the BRCA2 gene c.5286 T > G, we suggested that it arose about 700 years ago and is a new founder mutation. CONCLUSION: This study extends our knowledge about the BRCA1 and BRCA2 pathogenic variants variability. CI - © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Kechin, Andrey AU - Kechin A AUID- ORCID: 0000-0002-4822-0251 AD - Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia. aa_kechin@niboch.nsc.ru. AD - Novosibirsk State University, Novosibirsk, 630090, Russia. aa_kechin@niboch.nsc.ru. FAU - Boyarskikh, Ulyana AU - Boyarskikh U AD - Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia. FAU - Barinov, Alexey AU - Barinov A AD - Moscow City Oncology Hospital No 62 of the Moscow Health Department, Istra, 143423, Russia. FAU - Tanas, Alexander AU - Tanas A AD - Research Centre for Medical Genetics, Moscow, 115522, Russia. FAU - Kazakova, Svetlana AU - Kazakova S AD - Research Centre for Medical Genetics, Moscow, 115522, Russia. FAU - Zhevlova, Anastasia AU - Zhevlova A AD - Research Centre for Medical Genetics, Moscow, 115522, Russia. FAU - Khrapov, Evgeniy AU - Khrapov E AD - Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia. FAU - Subbotin, Sergey AU - Subbotin S AD - Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia. FAU - Mishukova, Olga AU - Mishukova O AD - Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia. FAU - Kekeeva, Tatiana AU - Kekeeva T AD - Research Centre for Medical Genetics, Moscow, 115522, Russia. FAU - Demidova, Irina AU - Demidova I AD - Moscow City Oncology Hospital No 62 of the Moscow Health Department, Istra, 143423, Russia. FAU - Filipenko, Maxim AU - Filipenko M AD - Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090, Russia. AD - Novosibirsk State University, Novosibirsk, 630090, Russia. LA - eng GR - 0245-2021-0006/Russian State-funded budget project/ PT - Journal Article DEP - 20221111 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (BRCA1 Protein) RN - 0 (BRCA2 Protein) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA2 protein, human) SB - IM MH - Humans MH - Female MH - Genes, BRCA2 MH - Genetic Predisposition to Disease MH - *Breast Neoplasms/genetics MH - BRCA1 Protein/genetics MH - BRCA2 Protein/genetics MH - Germ-Line Mutation MH - *Ovarian Neoplasms/epidemiology/genetics/pathology MH - Russia/epidemiology MH - Germ Cells OTO - NOTNLM OT - BRCA1/2 OT - Germline mutations OT - Hotspot OT - NGS OT - Ovarian cancer EDAT- 2022/11/12 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/11/11 11:16 PHST- 2022/04/27 00:00 [received] PHST- 2022/10/23 00:00 [accepted] PHST- 2022/11/12 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/11/11 11:16 [entrez] AID - 10.1007/s10549-022-06782-2 [pii] AID - 10.1007/s10549-022-06782-2 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2023 Jan;197(2):387-395. doi: 10.1007/s10549-022-06782-2. Epub 2022 Nov 11. PMID- 36558416 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20221227 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 14 IP - 24 DP - 2022 Dec 9 TI - Obesity, Fat Distribution and Risk of Cancer in Women and Men: A Mendelian Randomisation Study. LID - 10.3390/nu14245259 [doi] LID - 5259 AB - Obesity and upper-body fat distribution are independent, cardiometabolic risk factors but whether they also display comparable associations with cancer risk is unknown. We investigated the causal relationships between body mass index (BMI) and BMI-adjusted waist-to-hip ratio (WHRadjBMI) and cancer risk and searched for potential drivers linking these traits to carcinogenesis using two-sample and multivariable Mendelian randomisation. In women, genetically instrumented higher BMI was associated with lower breast (OR = 0.87, 95% CI 0.81-0.93) and higher endometrial (OR = 1.75, 95% CI 1.55-1.96) cancer risk whilst WHRadjBMI was associated with higher colon cancer risk (OR = 1.22, 95% CI 1.07-1.42). In men, elevated BMI was associated with lower prostate cancer risk (OR = 0.91, 95% CI 0.85-0.98). Mechanistically, testosterone and insulin mediated 21% and 35%, respectively of the total, genetically determined association of BMI with endometrial cancer risk whilst HDL cholesterol and IGF-1 mediated 40% and 22%, respectively of the association between BMI and breast cancer risk. In men, testosterone mediated 21% of the association between BMI and prostate cancer risk. Colon cancer aside, the total amount of body fat might be more important than its location in modulating cancer susceptibility due to differential effects of obesity and fat distribution on adiposity-associated cancer drivers. FAU - Loh, Nellie Y AU - Loh NY AUID- ORCID: 0000-0002-5979-9019 AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. FAU - Wang, Wenyi AU - Wang W AD - Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. FAU - Noordam, Raymond AU - Noordam R AUID- ORCID: 0000-0001-7801-809X AD - Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. FAU - Christodoulides, Constantinos AU - Christodoulides C AUID- ORCID: 0000-0001-5154-0785 AD - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. AD - NIHR Oxford Biomedical Research Centre, OUH Foundation Trust, Oxford OX3 7LE, UK. LA - eng GR - FS/16/45/32359/BHF_/British Heart Foundation/United Kingdom PT - Journal Article DEP - 20221209 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 RN - 3XMK78S47O (Testosterone) SB - IM MH - Male MH - Humans MH - Female MH - Risk Factors MH - Obesity/complications/epidemiology/genetics MH - Adiposity/genetics MH - *Breast Neoplasms/etiology/genetics MH - Adipose Tissue MH - Body Mass Index MH - *Prostatic Neoplasms/etiology/genetics MH - *Colonic Neoplasms/etiology/genetics MH - Testosterone PMC - PMC9784937 OTO - NOTNLM OT - GWAS OT - Mendelian randomisation OT - cancer OT - fat distribution OT - obesity COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 CRDT- 2022/12/23 01:52 PHST- 2022/10/18 00:00 [received] PHST- 2022/12/04 00:00 [revised] PHST- 2022/12/07 00:00 [accepted] PHST- 2022/12/23 01:52 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] AID - nu14245259 [pii] AID - nutrients-14-05259 [pii] AID - 10.3390/nu14245259 [doi] PST - epublish SO - Nutrients. 2022 Dec 9;14(24):5259. doi: 10.3390/nu14245259.